PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	WE	SC	GA	UT	PM	OA	HC	HP	DA	WOS
J	Koh, SH; Park, Y; Song, CW; Kim, JG; Kim, K; Kim, J; Kim, MH; Lee, SR; Kim, DW; Yu, HJ; Chang, DI; Hwang, SJ; Kim, SH				Koh, SH; Park, Y; Song, CW; Kim, JG; Kim, K; Kim, J; Kim, MH; Lee, SR; Kim, DW; Yu, HJ; Chang, DI; Hwang, SJ; Kim, SH			The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						neuroinflammation; neuronal cell death; PARP; stroke; survival factors	TRAUMATIC BRAIN-INJURY; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; INTERCELLULAR-ADHESION MOLECULE-1; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE; RAT-BRAIN; SYNTHETASE ACTIVATION; ENDOTHELIAL-CELLS; ADP-RIBOSYLATION; DNA-DAMAGE	Poly(ADP-ribose) polymerase (PARP) plays an important role in ischaemic cell death, and 3-aminobenzamide (3-AB), one of the PARP inhibitors, has a protective effect on ischaemic stroke. We investigated the neuroprotective mechanisms of 3-AB in ischaemic stroke. The occlusion of middle cerebral artery (MCA) was made in 170 Sprague-Dawley rats, and reperfusion was performed 2 h after the occlusion. Another 10 Sprague-Dawley rats were used for sham operation. 3-AB was administered to 85 rats 10 min before the occlusion [3-AB group (n = 85) vs. control group without 3-AB (n = 85)]. Infarct volume and water content were measured, brain magnetic resonance imaging, terminal deoxynucleotidyltransferase (TdT)-mediated dUTP-biotin nick end-labelling (TUNEL) and Cresyl violet staining were performed, and immunoreactivities (IRs) of poly(ADP-ribose) polymer (PAR), cleaved caspase-3, CD11b, intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2), phospho-Akt (pAkt) and phospho-glycogen synthase kinase-3 (pGSK-3) were compared in the peri-infarcted region of the 3-AB group and its corresponding ischaemic region of the control group at 2, 8, 24 and 72 h after the occlusion. In the 3-AB group, the infarct volume and the water content were decreased (about 45% and 3.6%, respectively, at 24 h), the number of TUNEL-positive cells was decreased (about 36% at 24 h), and the IRs of PAR, cleaved caspase-3, CD11b, ICAM-1 and COX-2 were significantly reduced, while the IRs of pAkt and pGSK-3 were increased. These results suggest that 3-AB treatment could reduce the infarct volume by reducing ischaemic cell death, its related inflammation and increasing survival signals. The inhibition of PARP could be another potential neuroprotective strategy in ischaemic stroke.	Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea; KFDA, Natl Inst Toxicol Res, Div Neurotoxicol, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Radiol, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Dept Anaesthesiol, Seoul 133791, South Korea; Bundang Jesaeng Hosp, Dept Neurol, Gyeonggi Do, South Korea; Kyung Hee Univ, Coll Med, Dept Neurol, Seoul, South Korea; Hanyang Univ, Coll Med, Dept Anat, Seoul 133791, South Korea; Hanyang Univ, Coll Med, Inst Mental Hlth, Seoul 133791, South Korea		Kim, SH (corresponding author), Hanyang Univ, Coll Med, Dept Neurol, Seoul 133791, South Korea.	kimsh1@hanyang.ac.kr	Kim, Seung Hyun/T-5133-2017; Chang, Dae-il/AAJ-5290-2020; Park, Yongsoon/E-6968-2017	Kim, Seung Hyun/0000-0001-9644-9598; Park, Yongsoon/0000-0001-5110-5716			AALTO TK, 1993, PEDIATR RES, V34, P572, DOI 10.1203/00006450-199311000-00004; Abdelkarim GE, 2001, INT J MOL MED, V7, P255; Augustin A, 2003, J CELL SCI, V116, P1551, DOI 10.1242/jcs.00341; BARNETT HJM, 1998, STROKE; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Besson VC, 2003, BRAIN RES, V989, P58, DOI 10.1016/S0006-8993(03)03362-6; Brecht S, 2003, NEUROSCIENCE, V120, P1037, DOI 10.1016/S0306-4522(03)00404-4; COSI C, 1994, J NEUROSCI RES, V39, P38, DOI 10.1002/jnr.490390106; Couturier JY, 2003, EXP NEUROL, V184, P973, DOI 10.1016/S0014-4886(03)00367-4; Czapski GA, 2004, NEUROSCI LETT, V356, P45, DOI 10.1016/j.neulet.2003.11.022; Diez J, 1998, CURR OPIN CARDIOL, V13, P317, DOI 10.1097/00001573-199809000-00005; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122, DOI 10.1152/ajplegacy.1949.157.1.122; Endres M, 1998, EUR J PHARMACOL, V351, P377, DOI 10.1016/S0014-2999(98)00381-1; Endres M, 1998, NEUROSCI LETT, V248, P41, DOI 10.1016/S0304-3940(98)00224-9; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; He JL, 2001, J PHARMACOL EXP THER, V298, P180; HIROMATSU Y, 1993, IMMUNOLOGY, V80, P330; IKAI K, 1980, J HISTOCHEM CYTOCHEM, V28, P670, DOI 10.1177/28.7.6993553; Kametsu Y, 2003, J CEREBR BLOOD F MET, V23, P416, DOI 10.1097/01.WCB.0000052281.23292.7C; Kim SH, 2004, NEUROLOGY, V62, P319, DOI 10.1212/01.WNL.0000103291.04985.DC; Kim SH, 2003, J NEUROPATH EXP NEUR, V62, P88, DOI 10.1093/jnen/62.1.88; Koh SH, 2003, MOL BRAIN RES, V118, P72, DOI 10.1016/j.molbrainres.2003.07.003; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lo EH, 1998, STROKE, V29, P830, DOI 10.1161/01.STR.29.4.830; Love S, 1999, BRAIN, V122, P247, DOI 10.1093/brain/122.2.247; Love S, 1999, NEUROPATH APPL NEURO, V25, P98; Love S, 1998, NEUROREPORT, V9, P955, DOI 10.1097/00001756-199804200-00001; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mazzon E, 2002, BIOCHEM PHARMACOL, V64, P327, DOI 10.1016/S0006-2952(02)01075-4; OGURA T, 1990, BIOCHEM BIOPH RES CO, V172, P377, DOI 10.1016/0006-291X(90)90683-E; Paschen W, 2000, J NEUROCHEM, V75, P1675, DOI 10.1046/j.1471-4159.2000.0751675.x; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCHRAUFSTATTER IU, 1986, J CLIN INVEST, V77, P1312, DOI 10.1172/JCI112436; Skaper SD, 2003, ANN NY ACAD SCI, V993, P217, DOI 10.1111/j.1749-6632.2003.tb07532.x; Smith S, 2001, TRENDS BIOCHEM SCI, V26, P174, DOI 10.1016/S0968-0004(00)01780-1; Strosznajder RP, 2003, J MOL NEUROSCI, V20, P61, DOI 10.1385/JMN:20:1:61; Takahashi K, 1997, J CEREBR BLOOD F MET, V17, P1137, DOI 10.1097/00004647-199711000-00001; Veres B, 2003, BIOCHEM PHARMACOL, V65, P1373, DOI 10.1016/S0006-2952(03)00077-7; Virag L, 1998, J IMMUNOL, V161, P3753; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; WALLIS RA, 1993, NEUROREPORT, V5, P245; Welch K.M., 1997, PRIMER CEREBROVASCUL; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; ZHANG J, 1995, J NEUROCHEM, V65, P1411; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zingarelli B, 1998, CIRC RES, V83, P85, DOI 10.1161/01.RES.83.1.85	52	73	74	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	SEP	2004	20	6					1461	1472		10.1111/j.1460-9568.2004.03632.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	852GV	WOS:000223744600004	15355313				2022-02-06	
J	Prins, ML; Lee, SM; Fujima, LS; Hovda, DA				Prins, ML; Lee, SM; Fujima, LS; Hovda, DA			Increased cerebral uptake and oxidation of exogenous beta HB improves ATP following traumatic brain injury in adult rats	JOURNAL OF NEUROCHEMISTRY			English	Article						alternative substrates; beta-hydroxybutyrate; metabolism; traumatic brain injury	KETONE-BODIES; MONOCARBOXYLATE TRANSPORTER; MITOCHONDRIAL DYSFUNCTION; ENERGY-METABOLISM; CORTICAL CONTUSION; GLUCOSE; NEURONS; ASTROCYTES; HYDROXYBUTYRATE; (CO2)-C-14	There is growing evidence of the brain's ability to increase its reliance on alternative metabolic substrates under conditions of energy stress such as starvation, hypoxia and ischemia. We hypothesized that following traumatic brain injury (TBI), which results in immediate changes in energy metabolism, the adult brain increases uptake and oxidation of the alternative substrate beta-hydroxybutyrate (betaHB). Arterio-venous differences were used to determine global cerebral uptake of betaHB and production of (CO2)-C-14 from [C-14]3-betaHB 3 h after controlled cortical impact (CCI) injury. Quantitative bioluminescence was used to assess regional changes in ATP concentration. As expected, adult sham and CCI animals with only endogenously available betaHB showed no significant increase in cerebral uptake of betaHB or (CO2)-C-14 production. Increasing arterial betaHB concentrations 2.9-fold with 3 h of betaHB infusion failed to increase cerebral uptake of betaHB or (CO2)-C-14 production in adult sham animals. Only CCI animals that received a 3-h betaHB infusion showed an 8.5-fold increase in cerebral uptake of betaHB and greater than 10.7-fold increase in (CO2)-C-14 production relative to sham betaHB-infused animals. The TBI-induced 20% decrease in ipsilateral cortical ATP concentration was alleviated by 3 h of betaHB infusion beginning immediately after CCI injury.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA		Prins, ML (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Room NPI 18-228,Box 957039, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS037363, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308, NS37363] Funding Source: Medline		Alberti K G, 1978, Biochem Soc Symp, P163; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BEAVEN MA, 1978, ANAL BIOCHEM, V84, P638, DOI 10.1016/0003-2697(78)90089-1; BRANDT RB, 1984, P SOC EXP BIOL MED, V175, P328; CASADO FJ, 1988, ANAL BIOCHEM, V172, P509, DOI 10.1016/0003-2697(88)90476-9; Chen T, 2000, ACT NEUR S, V76, P359; Cuff MA, 2002, J PHYSIOL-LONDON, V539, P361, DOI 10.1113/jphysiol.2001.014241; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EDMOND J, 1987, J NEUROSCI RES, V18, P551, DOI 10.1002/jnr.490180407; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; HAWKINS RA, 1971, BIOCHEM J, V122, P13, DOI 10.1042/bj1220013; HAWKINS RA, 1985, AM J PHYSIOL, V248, pC170, DOI 10.1152/ajpcell.1985.248.1.C170; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KAWAMATA Y, 1990, J NEUROSURG, V73, P889; KREIS R, 1992, RADIOLOGY, V184, P123, DOI 10.1148/radiology.184.1.1319074; KROGURE K, 1978, BRAIN RES, V154, P273; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Leino RL, 1999, DEV BRAIN RES, V113, P47, DOI 10.1016/S0165-3806(98)00188-6; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; LOPESCARDOZO M, 1986, J NEUROCHEM, V46, P773, DOI 10.1111/j.1471-4159.1986.tb13039.x; MCKENNA MC, 1990, NEUROCHEM RES, V15, P1211, DOI 10.1007/BF01208582; MCKENNA MC, 1986, BIOCHEM J, V237, P47, DOI 10.1042/bj2370047; MCKENNA MC, 1994, DEV NEUROSCI-BASEL, V16, P291, DOI 10.1159/000112122; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; POLLAY M, 1980, J NEUROSCI RES, V5, P163, DOI 10.1002/jnr.490050208; Ritter AM, 1996, J NEUROTRAUM, V13, P473, DOI 10.1089/neu.1996.13.473; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; RUDERMAN NB, 1974, BIOCHEM J, V138, P1; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; SHAND JH, 1987, COMP BIOCHEM PHYS A, V87, P583, DOI 10.1016/0300-9629(87)90365-3; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vannucci RC, 2000, SEMIN PERINATOL, V24, P107, DOI 10.1053/sp.2000.6361; Veech RL, 2001, IUBMB LIFE, V51, P241; Waniewski RA, 1998, J NEUROSCI, V18, P5225, DOI 10.1523/JNEUROSCI.18-14-05225.1998; WESTERGAARD N, 1994, J NEUROCHEM, V62, P1727; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YU ACH, 1984, J NEUROSCI RES, V11, P351, DOI 10.1002/jnr.490110403; ZWEIER JL, 1987, J BIOL CHEM, V262, P8015	51	73	74	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	AUG	2004	90	3					666	672		10.1111/j.1471-4159.2004.02542.x			7	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	838NQ	WOS:000222720500017	15255945	Bronze			2022-02-06	
J	Conti, A; Sanchez-Ruiz, Y; Bachi, A; Beretta, L; Grandi, E; Beltramo, M; Alessio, M				Conti, A; Sanchez-Ruiz, Y; Bachi, A; Beretta, L; Grandi, E; Beltramo, M; Alessio, M			Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; fibrinogen; proteomics; traumatic brain injury; two-dimensional gel electrophoresis	FIBRINOLYTIC-ACTIVITY; GEL-ELECTROPHORESIS; HEAD-INJURY; CSF; LUMBAR; INTERLEUKIN-6; FIBRINOGEN; PROTEINS; DISEASE; DAMAGE	Traumatic brain injury (TBI), like other central nervous system pathologies, causes changes in the composition of cerebrospinal fluid (CSF). Consequently analysis of the CSF components is important to better understand the pathological processes involved in such diseases. The aim of this work was to identify specific markers of severe TBI. Proteomic analysis including two-dimensional gel electrophoresis combined with mass spectrometry analysis was used to compare the CSF protein profile of severe TBI patients and controls. Proteins (alpha 1 antitrypsin, haptoglobin 1 alpha1, alpha2, and beta) belonging to the acute phase response showed an increased expression in severe TBI patients. Two other proteins, identified as proteolytic degradation products of the carboxyl-terminal portion of the fibrinogen beta, were present only in TBI patients. The presence of these markers could correlate with a post-traumatic local increase in fibrinolysis as well as to an inflammatory event following CNS tissue injury.	Ist Sci San Raffaele, DIBIT, Proteom Lab, Proteom Unit, I-20132 Milan, Italy; Ist Sci San Raffaele, Mass Spectrometry Unit, I-20132 Milan, Italy; Ist Sci San Raffaele, Intens Care Neurosurg Dept, I-20132 Milan, Italy; Schering Plough Res Inst, Milan, Italy		Alessio, M (corresponding author), Ist Sci San Raffaele, DIBIT, Proteom Lab, Proteom Unit, Via Olgettina 58, I-20132 Milan, Italy.	m.alessio@hsr.it	bachi, angela/B-3527-2015; Alessio, Massimo/L-4518-2019; Conti, Antonio/AAN-7161-2020; Alessio, Massimo/K-7028-2014	bachi, angela/0000-0003-4842-6556; Conti, Antonio/0000-0001-9150-5271; Alessio, Massimo/0000-0002-4133-3472			Balasingam V, 1996, J NEUROSCI, V16, P2945; Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Beaulieu JM, 2002, BRAIN RES, V946, P153, DOI 10.1016/S0006-8993(02)02830-5; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; BRUETON MJ, 1974, J CLIN PATHOL, V27, P402, DOI 10.1136/jcp.27.5.402; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Gajjar A, 1999, J CLIN ONCOL, V17, P1825, DOI 10.1200/JCO.1999.17.6.1825; Gerber J, 1998, NEUROLOGY, V51, P1710, DOI 10.1212/WNL.51.6.1710; Hochstrasser DF, 2002, PROTEOMICS, V2, P807, DOI 10.1002/1615-9861(200207)2:7<807::AID-PROT807>3.0.CO;2-4; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HUNTER R, 1974, J NEUROL NEUROSUR PS, V37, P249, DOI 10.1136/jnnp.37.3.249; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; JENNETT B, 1975, LANCET, V1, P480; KALSHEKER N, 1989, NUCLEIC ACIDS RES, V17, P10518, DOI 10.1093/nar/17.24.10518; Kasuya H, 1998, ACTA NEUROCHIR, V140, P579, DOI 10.1007/s007010050143; Kay AD, 2003, J NEUROTRAUM, V20, P243, DOI 10.1089/089771503321532824; Korschenhausen DA, 1996, SCHIZOPHR RES, V19, P103, DOI 10.1016/0920-9964(95)00073-9; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lemke R, 1999, GLIA, V27, P75, DOI 10.1002/(SICI)1098-1136(199907)27:1<75::AID-GLIA8>3.0.CO;2-J; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; NOWACKI P, 1990, Neuropatologia Polska, V28, P257; Okamoto S, 1991, Rinsho Byori, V39, P651; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Raby CA, 1998, J NEUROCHEM, V71, P2505; Reiber H, 2001, CLIN CHIM ACTA, V310, P173, DOI 10.1016/S0009-8981(01)00573-3; RINK A, 1995, AM J PATHOL, V147, P1575; RUBALCAVA MA, 1995, NEUROSURGERY, V37, P668, DOI 10.1227/00006123-199510000-00009; Shaw PJ, 2002, BRAIN, V125, P693, DOI 10.1093/brain/awf138; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Suzuki M, 1997, ACTA NEUROCHIR, V139, P1152, DOI 10.1007/BF01410975; Takahashi H, 1997, J NEUROSURG, V86, P768, DOI 10.3171/jns.1997.86.5.0768; TEASDALE G, 1974, LANCET, V2, P81; TOVI D, 1972, ACTA NEUROL SCAND, V48, P403, DOI 10.1111/j.1600-0404.1972.tb07562.x; Vejda S, 2002, MOL CELL PROTEOMICS, V1, P387, DOI 10.1074/mcp.M200004-MCP200; VERMEULEN M, 1985, J NEUROSURG, V63, P573, DOI 10.3171/jns.1985.63.4.0573; Wassell J, 2000, Clin Lab, V46, P547; WEISNER B, 1978, J NEUROL SCI, V37, P205, DOI 10.1016/0022-510X(78)90204-6; WIEDERKEHR F, 1987, J NEUROCHEM, V49, P363, DOI 10.1111/j.1471-4159.1987.tb02874.x; WILDENAUER DB, 1991, ELECTROPHORESIS, V12, P487, DOI 10.1002/elps.1150120706; Wood P. L., 1998, NEUROINFLAMMATION ME, P1; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	55	73	78	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					854	863		10.1089/0897715041526212			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800003	15307898				2022-02-06	
J	van den Broek, M; Beghi, E				van den Broek, M; Beghi, E		RESt-1 Grp	Accidents in patients with epilepsy: Types, circumstances, and complications: A European cohort study	EPILEPSIA			English	Article						epilepsy; accidents; injuries	MOTOR-VEHICLE CRASHES; RISK-FACTORS; INJURY; BURNS; FREQUENCY; FRACTURES; MORBIDITY; SEIZURES; CHILDREN	Purpose: To investigate the risk of accidents in a cohort of patients with epilepsy and in matched nonepilepsy controls. by type, circumstances, and complications. Methods: A total of 95 1 children and adults with idiopathic, cryptogenic, or remote symptomatic epilepsy and 904 matched controls seen in secondary and tertiary centers in eight European Countries (England. Estonia, Germany, Italy, the Netherlands, Portugal. Russia. and Slovenia) were followed Lip prospectively for 17,484 and 17.206 person-months and asked to report any accident requiring medical attention. its site, and complications. Risk assessment was done by using actuarial methods, relative risks (RRs). and 95% confidence intervals (CIs). Results: During the study period, 199 (21%) patients and 123 (14%) controls reported all accident (p < 0.0001); 24% were seizure related. The Cumulative probability of accidents at 12 and 24 months was 17 and 27% in the cases and 12 and 17% in the controls. The risk was highest for concussions (RR, 2.6; 95% Cl, 1.2-5.8), abrasions (RR, 2.1; 95% Cl, 1.1-4.0), and Wounds (RR, 1.9; Cl, 1.2-3.1). Domestic accidents prevailed in both groups, followed by street and work accidents, and were more common among cases. Compared with controls, patients with epilepsy reported more hospitalization, complications, and medical action. Disease characteristics associated with an increased risk of accidents included generalized epilepsy (conclusions), active epilepsy, and at least monthly seizures (abrasions). Most risks decreased, becoming nonsignificant after excluding, seizure-related events. Conclusions: Patients with epilepsy are at higher risk of accidents and their complications. However, the risk was substantially lower after exclusion of seizure-related events.	Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy		Beghi, E (corresponding author), Mario Negri Inst Pharmacol Res, Via Eritrea 62, I-20157 Milan, Italy.	beghi@marionegri.it	Gambardella, Antonio/F-5295-2012; Cavestro, Cinzia/S-1115-2019; Zarrelli, Michele/K-2210-2016; Beghi, Ettore/AAA-7426-2020; Cosottini, Mirco/K-7991-2016	Gambardella, Antonio/0000-0001-7384-3074; Cavestro, Cinzia/0000-0003-1172-1009; Zarrelli, Michele/0000-0001-7768-1762; Beghi, Ettore/0000-0003-2542-0469; Cosottini, Mirco/0000-0001-9400-6574; SPECCHIO, NICOLA/0000-0002-8120-0287; Belousova, Elena Dmitrievna/0000-0003-3594-6974; AGUGLIA, Umberto/0000-0002-4574-2951			ANNEGERS JF, 1989, EPILEPSIA, V30, P348, DOI 10.1111/j.1528-1157.1989.tb05308.x; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Beaussart M, 1997, Med Law, V16, P295; Beghi E, 2002, EPILEPSIA, V43, P1076, DOI 10.1046/j.1528-1157.2002.18701.x; Beghi E, 1997, NEUROEPIDEMIOLOGY, V16, P207, DOI 10.1159/000109689; BEGHI E, 2002, MED RISKS EPILEPSY, P7; Begley CE, 2002, EPILEPSIA, V43, P3, DOI 10.1046/j.1528-1157.43.s.4.2.x; Buck D, 1997, EPILEPSIA, V38, P439, DOI 10.1111/j.1528-1157.1997.tb01733.x; COX DR, 1972, J R STAT SOC B, V34, P187; Drazkowski JF, 2003, MAYO CLIN PROC, V78, P819, DOI 10.4065/78.7.819; Gislason T, 1997, J INTERN MED, V241, P213; HAMPTON KK, 1988, BRIT MED J, V296, P1659, DOI 10.1136/bmj.296.6637.1659; HANSOTIA P, 1991, NEW ENGL J MED, V324, P22, DOI 10.1056/NEJM199101033240105; Josty IC, 2000, EPILEPSIA, V41, P453, DOI 10.1111/j.1528-1157.2000.tb00188.x; Kirsch R, 2001, J CHILD NEUROL, V16, P100, DOI 10.2310/7010.2001.6916; Krauss GL, 1999, NEUROLOGY, V52, P1324, DOI 10.1212/WNL.52.7.1324; Lassouw G, 1997, SEIZURE-EUR J EPILEP, V6, P95, DOI 10.1016/S1059-1311(97)80061-1; Lings S, 2001, NEUROLOGY, V57, P435, DOI 10.1212/WNL.57.3.435; NAKKEN KO, 1993, EPILEPSIA, V34, P836, DOI 10.1111/j.1528-1157.1993.tb02099.x; Neufeld MY, 2000, SEIZURE-EUR J EPILEP, V9, P595, DOI 10.1053/seiz.2000.0469; Neufeld MY, 1999, EPILEPSY RES, V34, P123, DOI 10.1016/S0920-1211(98)00105-3; Persson HBI, 2002, EPILEPSIA, V43, P768, DOI 10.1046/j.1528-1157.2002.15801.x; RUSSELLJONES DL, 1989, J NEUROL NEUROSUR PS, V52, P659, DOI 10.1136/jnnp.52.5.659; SPITZ MC, 1994, EPILEPSIA, V35, P764, DOI 10.1111/j.1528-1157.1994.tb02508.x; Taylor J, 1996, J NEUROL NEUROSUR PS, V60, P621, DOI 10.1136/jnnp.60.6.621; van den Broek M, 2004, EPILEPSIA, V45, P71, DOI 10.1111/j.0013-9580.2004.33803.x; Vestergaard P, 1999, ACTA NEUROL SCAND, V99, P269, DOI 10.1111/j.1600-0404.1999.tb00675.x; Wirrell EC, 1996, ARCH NEUROL-CHICAGO, V53, P929, DOI 10.1001/archneur.1996.00550090141020; Zwimpfer TJ, 1997, J NEUROSURG, V86, P433, DOI 10.3171/jns.1997.86.3.0433	30	73	73	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	JUN	2004	45	6					667	672		10.1111/j.0013-9580.2004.33903.x			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	828SI	WOS:000221992900013	15144432				2022-02-06	
J	Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Ewing-Cobbs, L; Dennis, M; Barnes, MA; Max, J; Schachar, R; Chapman, SB; Hunter, JV				Levin, HS; Hanten, G; Zhang, LF; Swank, PR; Ewing-Cobbs, L; Dennis, M; Barnes, MA; Max, J; Schachar, R; Chapman, SB; Hunter, JV			Changes in working memory after traumatic brain injury in children	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; PREFRONTAL CORTEX; WHITE-MATTER; CHILDHOOD; DAMAGE; SUBVOCALIZATION; INFORMATION; MATURATION; SEVERITY; BEHAVIOR	The impact of traumatic brain injury (TBI) on working memory (WM) was studied in 144 children (79 with mild, 23 with moderate, and 42 with severe injuries) who underwent magnetic resonance imaging (MRI) at 3 months and were tested at baseline and at 3, 6, 12, and 24 months postinjury. An n-back WM task for letter identity was administered with memory load ranging from 1- to 3-back and a 0-back condition. A TBI Severity X Quadratic Time interaction showed that net percentage correct (correct detections of targets minus false alarms) was significantly lower in severe than in mild TBI groups. The Left Frontal Lesions X Age interaction approached significance. Mechanisms mediating late decline in WM and the effects of left frontal lesions are discussed.	Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77225 USA; Hosp Sick Children, Res Inst, Dept Psychol Brain & Behav Program, Toronto, ON, Canada; Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; Childrens Hosp, San Diego, CA USA; Ctr Hlth, San Diego, CA USA		Levin, HS (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Dept Neurosurg, 6560 Fannin St,Suite 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Schachar, Russell/0000-0002-2015-4395	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K08MH001800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5K-08MH01800-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; BADDELEY A, 1981, Q J EXP PSYCHOL-A, V33, P439, DOI 10.1080/14640748108400802; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; CASEY BJ, 1995, NEUROIMAGE, V2, P221, DOI 10.1006/nimg.1995.1029; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DANEMAN M, 1983, J EXP PSYCHOL LEARN, V9, P561, DOI 10.1037/0278-7393.9.4.561; deJonge P, 1996, PERS INDIV DIFFER, V21, P1007, DOI 10.1016/S0191-8869(96)00161-4; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Dennis M, 2000, APHASIOLOGY, V14, P391, DOI 10.1080/026870300401423; Diamond A., 2002, PRINCIPLES FRONTAL L, P466, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0029; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Ewing-Cobbs L, 1998, J CLIN EXP NEUROPSYC, V20, P769, DOI 10.1076/jcen.20.6.769.1109; Gaillard WD, 2000, NEUROLOGY, V54, P180, DOI 10.1212/WNL.54.1.180; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Gathercole SE, 1997, J EXP CHILD PSYCHOL, V67, P290, DOI 10.1006/jecp.1997.2391; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Goldman P S, 1974, Neurosci Res Program Bull, V12, P217; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1977, NATURE, V267, P613, DOI 10.1038/267613a0; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Klingberg T, 1999, NEUROREPORT, V10, P2817, DOI 10.1097/00001756-199909090-00022; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; LEVY BA, 1977, J VERB LEARN VERB BE, V16, P623, DOI 10.1016/S0022-5371(77)80024-8; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Littell R.C., 1996, SAS SYSTEM MIXED MOD; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; McCauley SR, 2004, DEV NEUROPSYCHOL, V25, P5, DOI 10.1207/s15326942dn2501&2_2; Mehta MA, 2000, J NEUROSCI, V20; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; MORRIS N, 1990, BRIT J PSYCHOL, V81, P111, DOI 10.1111/j.2044-8295.1990.tb02349.x; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; SLOWIACZEK ML, 1980, J VERB LEARN VERB BE, V19, P573, DOI 10.1016/S0022-5371(80)90628-3; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; Swanson HL, 2001, J EXP CHILD PSYCHOL, V79, P294, DOI 10.1006/jecp.2000.2587; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; TEASDALE G, 1974, LANCET, V2, P81; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P181	51	73	74	0	21	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	2004	18	2					240	247		10.1037/0894-4105.18.2.240			8	Psychology, Clinical; Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	810SX	WOS:000220725100005	15099146				2022-02-06	
J	Weinstock, M; Shoham, S				Weinstock, M; Shoham, S			Rat models of dementia based on reductions in regional glucose metabolism, cerebral blood flow and cytochrome oxidase activity	JOURNAL OF NEURAL TRANSMISSION			English	Article						bilateral carotid occlusion; cerebral blood flow; cerebral glucose metabolism; cytochrome oxidase; streptozotocin	CHOLINE-ACETYLTRANSFERASE ACTIVITY; NERVE GROWTH-FACTOR; ACETYL-L-CARNITINE; FIMBRIA-FORNIX TRANSECTION; SPATIAL-LEARNING DEFICIT; COMMON CAROTID ARTERIES; CLOSED-HEAD INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; PERMANENT OCCLUSION	Three models are described in rats which attempt to mimic morphological and behavioural pathology of Alzheimer's dementia; intracerebroventricular injection of streptozotocin (STZ), permanent bilateral carotid artery occlusion (2VO) and brain mitochondrial cytochrome oxidase inhibition by sodium azide. Learning and memory are impaired within 4 weeks in all models. This probably involves a reduction in cortical and/or hippocampal cholinergic neurotransmission. STZ causes microglial activation and specific damage to myelinated tracts in the fornix through generation of oxidative stress, thereby disrupting connections between the septum and hippocampus. 2VO results in damage to myelin and CA1 cells in hippocampus and in abnormal processing of APP to beta-amyloid. It is not known if microglial activation and neuronal damage occur after sodium azide administration. Memory and learning can be improved in the STZ and 2VO models by estradiol, melatonin and cholinesterase inhibitors. Antioxidants and neuroprotective agents may also decrease memory deficits by preventing inflammation and neurodegeneration.	Hebrew Univ Jerusalem, Med Ctr, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Herzog Hosp, Dept Res, Jerusalem, Israel		Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Med Ctr, Sch Pharm, Dept Pharmacol, Ein Kerem, IL-91120 Jerusalem, Israel.	martar@cc.huji.ac.il					ARANGO M, 1999, FREE RADICAL BIO MED, V11, P1467; Arnaiz E, 2001, NEUROREPORT, V12, P851, DOI 10.1097/00001756-200103260-00045; Bastar I, 1998, RES COMMUN MOL PATH, V102, P265; Bennett M C, 1992, J Geriatr Psychiatry Neurol, V5, P93; Bennett MC, 1996, J NEUROCHEM, V66, P2606; Bennett MC, 1996, P NATL ACAD SCI USA, V93, P1330, DOI 10.1073/pnas.93.3.1330; Bennett SAL, 2000, NEUROBIOL AGING, V21, P207, DOI 10.1016/S0197-4580(00)00131-7; BLOKLAND A, 1993, PHARMACOL BIOCHEM BE, V44, P491, DOI 10.1016/0091-3057(93)90497-H; BONAVITA E, 1986, INT J CLIN PHARM TH, V24, P511; Braak H, 2000, ANN NY ACAD SCI, V924, P53; Carter J., 2001, Current Molecular Medicine (Hilversum), V1, P733, DOI 10.2174/1566524013363177; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Cholerton B, 2002, DRUG AGING, V19, P405, DOI 10.2165/00002512-200219060-00002; COLTON CA, 1993, ADV NEUROL, V59, P321; de la Torre JC, 2000, BRAIN RES REV, V34, P119, DOI 10.1016/S0165-0173(00)00043-6; delaTorre JC, 1997, NEUROSCI LETT, V223, P165, DOI 10.1016/S0304-3940(97)13421-8; DELATORRE JC, 1993, BRAIN RES, V623, P6, DOI 10.1016/0006-8993(93)90003-6; DELATORRE JC, 1992, BRAIN RES, V582, P186, DOI 10.1016/0006-8993(92)90132-S; DELEON MJ, 1983, J CEREBR BLOOD F MET, V3, P391, DOI 10.1038/jcbfm.1983.57; DUFFY PE, 1980, NEUROLOGY, V30, P778, DOI 10.1212/WNL.30.7.778; FOLLI F, 1994, J NEUROSCI, V14, P6412; FROLICH F, 1998, PROGR ALZHEIMERS PAR, P287; Galani R, 2002, NEUROBIOL LEARN MEM, V77, P1, DOI 10.1006/nlme.2000.3998; Gibbs RB, 1998, HORM BEHAV, V34, P98, DOI 10.1006/hbeh.1998.1451; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Grammas P, 2000, NEUROBIOL AGING, V21, P199, DOI 10.1016/S0197-4580(00)00102-0; HAGG T, 1989, BRAIN RES, V505, P29, DOI 10.1016/0006-8993(89)90112-1; HARRELL LE, 1985, NEUROSCIENCE, V15, P359, DOI 10.1016/0306-4522(85)90218-0; HELLWEG R, 1992, J NEUROSCI RES, V31, P479, DOI 10.1002/jnr.490310310; Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001; Hollerbach EH, 1998, J COMP NEUROL, V390, P481; HORWOOD N, 1994, VIRCHOWS ARCH, V425, P69; Hoyer S, 1990, Aging (Milano), V2, P245; HOYER S, 1993, PROG NEURO-PSYCHOPH, V17, P199, DOI 10.1016/0278-5846(93)90043-R; Hoyer S, 1996, ANN NY ACAD SCI, V777, P374, DOI 10.1111/j.1749-6632.1996.tb34448.x; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; Jellinger KA, 2002, J NEURAL TRANSM, V109, P813, DOI 10.1007/s007020200068; KALARIA RN, 1992, ANN NEUROL, V32, P583, DOI 10.1002/ana.410320417; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; KIYOSAWA M, 1989, BRAIN, V112, P435, DOI 10.1093/brain/112.2.435; Konrad RJ, 2001, BIOCHEM J, V356, P31, DOI 10.1042/0264-6021:3560031; Lannert H, 1998, J NEURAL TRANSM, V105, P1045, DOI 10.1007/s007020050111; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Li X, 1997, NEUROENDOCRINOLOGY, V66, P63, DOI 10.1159/000127221; MASLIAH E, 1994, NEUROSCI LETT, V174, P67, DOI 10.1016/0304-3940(94)90121-X; MAYER G, 1990, BRAIN RES, V532, P95, DOI 10.1016/0006-8993(90)91747-5; McEwen BS, 2001, J APPL PHYSIOL, V91, P2785, DOI 10.1152/jappl.2001.91.6.2785; Murakami Y, 1997, JPN J PHARMACOL, V75, P443, DOI 10.1254/jjp.75.443; MUTISYA EM, 1994, J NEUROCHEM, V63, P2179; NI JW, 1995, BRAIN RES, V673, P290, DOI 10.1016/0006-8993(94)01436-L; NI JW, 1994, BRAIN RES, V653, P231, DOI 10.1016/0006-8993(94)90394-8; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Ohta H, 1997, NEUROSCIENCE, V79, P1039, DOI 10.1016/S0306-4522(97)00037-7; Ouchi Y, 1998, J NUCL MED, V39, P198; Pappas BA, 1996, BRAIN RES, V708, P50, DOI 10.1016/0006-8993(95)01267-2; PIOVESAN P, 1995, INT J DEV NEUROSCI, V13, P13, DOI 10.1016/0736-5748(94)00070-J; PLASCHKE K, 1993, INT J DEV NEUROSCI, V11, P477, DOI 10.1016/0736-5748(93)90021-5; Potkin SG, 2001, INT J NEUROPSYCHOPH, V4, P223, DOI 10.1017/S1461145701002528; Prickaerts J, 1999, BEHAV BRAIN RES, V102, P73, DOI 10.1016/S0166-4328(98)00158-2; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Salmon E, 1996, J CEREBR BLOOD F MET, V16, P399, DOI 10.1097/00004647-199605000-00006; SCREMIN OU, 1993, J CEREBR BLOOD F MET, V13, P702, DOI 10.1038/jcbfm.1993.89; Selkirk AB, 1998, PHARM SCI TECHNOL TO, V1, P8, DOI 10.1016/S1461-5347(98)00009-1; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; Sharma M, 2001, PHARMACOL BIOCHEM BE, V70, P325, DOI 10.1016/S0091-3057(01)00611-6; Shi J, 2000, NEUROBIOL AGING, V21, P357, DOI 10.1016/S0197-4580(00)00119-6; SIMPSON IA, 1994, ANN NEUROL, V35, P546, DOI 10.1002/ana.410350507; SINGH M, 1995, ENDOCRINOLOGY, V136, P2320, DOI 10.1210/en.136.5.2320; Small GW, 2000, P NATL ACAD SCI USA, V97, P6037, DOI 10.1073/pnas.090106797; Smith KJ, 1999, BRAIN PATHOL, V9, P69; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; Svendsen O, 1998, SCAND J LAB ANIM SCI, V25, P9; Svensson AL, 1999, NEUROREPORT, V10, P3485, DOI 10.1097/00001756-199911260-00004; TAGLIALATELA G, 1994, EXP GERONTOL, V29, P55, DOI 10.1016/0531-5565(94)90062-0; TAKASU N, 1991, DIABETES, V40, P1141, DOI 10.2337/diabetes.40.9.1141; Tanaka K, 1996, BRAIN RES, V729, P55, DOI 10.1016/S0006-8993(96)00400-3; TERWEL D, 1995, EUR J PHARMACOL, V287, P65, DOI 10.1016/0014-2999(95)00475-4; TSUCHIYA M, 1993, EXP BRAIN RES, V95, P1; TSUJIMOTO K, 1995, NEUROSCI LETT, V188, P105, DOI 10.1016/0304-3940(95)11409-P; Ueno M, 2002, J CEREBR BLOOD F MET, V22, P97, DOI 10.1097/00004647-200201000-00012; Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001; Wakita H, 2002, BRAIN RES, V924, P63, DOI 10.1016/S0006-8993(01)03223-1; Wang LM, 2000, EUR J PHARMACOL, V398, P65, DOI 10.1016/S0014-2999(00)00291-0; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; Weinstock M, 2001, ANN NY ACAD SCI, V939, P148; WILSON GL, 1984, DIABETOLOGIA, V27, P587, DOI 10.1007/BF00276973; Wong TP, 1999, J NEUROSCI, V19, P2706; Xiao XQ, 2000, NEUROSCI LETT, V286, P155, DOI 10.1016/S0304-3940(00)01088-0; Xiao XQ, 1999, NEUROSCI LETT, V275, P73, DOI 10.1016/S0304-3940(99)00695-3; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649	92	73	76	1	10	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	MAR	2004	111	3					347	366		10.1007/s00702-003-0058-y			20	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	803SZ	WOS:000220252100009	14991459				2022-02-06	
J	Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P				Coimbra, R; Hoyt, DB; Potenza, BM; Fortlage, D; Hollingsworth-Fridlund, P			Does sexual dimorphism influence outcome of traumatic brain injury patients? The answer is no!	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	61st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 26-28, 2002	ORLANDO, FL	Amer Assoc Surg Trauma		blunt trauma; sexual dimorphism; gender differences; traumatic brain injury; shock; complications; mortality	GENDER-DIFFERENCES; RISK-FACTORS; HEAD-INJURY; ESTROGEN; COMPLICATIONS; MORTALITY	Background. The protective effect of female gender on posttraumatic mortality or acute complications after traumatic brain injury (TBI) has been postulated. This effect might be seen if TBIs were analyzed by severity. To assess potential gender effects, we performed a retrospective case-controlled study matching female patients to male counterparts for overall injury severity; hemodynamic status at admission; and head, chest, and abdomen Abbreviated Injury Scale score. Methods: All female patients sustaining TBI admitted over 6.5 years were reviewed. An overall comparison between women (n = 914) and their male matched counterparts (n = 916) was performed. Patients were then stratified according to the severity of head injury on the basis of admission Glasgow Coma Scale (GCS) score into three groups: group 1, GCS score of 13 to 15 (788 female patients, 769 male patients); group 2, GCS score of 9 to 12 (40 female patients, 42 male patients); and group 3, GCS score < 9 (63 female patients, 87 male patients). Cohorts were compared for mortality or the development of acute respiratory distress syndrome, pneumonia, and systemic sepsis using standard definitions. A subset analysis was performed excluding patients with age above 50 years (789 women, 811 men) to exclude the effects of menopause on the results. Results: There was no statistically significant difference in outcome overall or in subset analysis of mild (group 1), moderate (group 2), or severe (group 3) TBI. The exclusion of patients older than 50 years showed no protective effect of female gender on outcome. Conclusion: Gender does not play a role in posttraumatic mortality or in the incidence of acute complications after any degree of TBI.	Univ Calif San Diego, Dept Surg, Div Trauma, Med Ctr, San Diego, CA 92103 USA		Coimbra, R (corresponding author), Univ Calif San Diego, Dept Surg, Div Trauma, Med Ctr, 200 W Arbor Dr, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851			AHMED SA, 1989, J IMMUNOL, V142, P2647; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; Angele MK, 1997, ARCH SURG-CHICAGO, V132, P1207; ANGELE MK, 1998, SURG FORUM, V49, P43; ANGELE MK, 2000, EUR J TRAUMA, V6, P267; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clerici E, 1991, J Clin Lab Immunol, V34, P71; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; FARACE E, 2002, NEUROSURG FOCUS, V8; Gannon CJ, 2002, J AM COLL SURGEONS, V195, P11, DOI 10.1016/S1072-7515(02)01187-0; Garner JS, 1996, APIC INFECT CONTROL, pA1; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HOYT DB, 1992, J TRAUMA, V33, P586, DOI 10.1097/00005373-199210000-00016; KRAUS JF, 2000, NEUROSURG FOCUS, V8; Moss M, 2002, CRIT CARE MED, V30, P1679, DOI 10.1097/00003246-200208000-00001; Mostafa G, 2002, J TRAUMA, V53, P430, DOI 10.1097/00005373-200209000-00006; Napolitano LM, 2001, J TRAUMA, V50, P274, DOI 10.1097/00005373-200102000-00013; O'Keefe GE, 2001, J AM COLL SURGEONS, V192, P153, DOI 10.1016/S1072-7515(00)00785-7; Oberholzer A, 2000, J TRAUMA, V48, P932, DOI 10.1097/00005373-200005000-00019; Rappold JF, 2002, J TRAUMA, V53, P436, DOI 10.1097/00005373-200209000-00007; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wichmann MW, 1997, AM J PHYSIOL-CELL PH, V273, pC1335, DOI 10.1152/ajpcell.1997.273.4.C1335; Wohltmann CD, 2001, AM J SURG, V181, P297, DOI 10.1016/S0002-9610(01)00582-7	27	73	75	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2003	54	4					689	700		10.1097/01.TA.0000058314.31655.5F			12	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	675AT	WOS:000182671400014	12707530				2022-02-06	
J	Watson, DJ; Longhi, L; Lee, EB; Fulp, CT; Fujimoto, S; Royo, NC; Passini, MA; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Wolfe, JH				Watson, DJ; Longhi, L; Lee, EB; Fulp, CT; Fujimoto, S; Royo, NC; Passini, MA; Trojanowski, JQ; Lee, VMY; McIntosh, TK; Wolfe, JH			Genetically modified NT2N human neuronal cells mediate long-term gene expression as CNS grafts in vivo and improve functional cognitive outcome following experimental traumatic brain injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						lentiviral vectors; nerve growth factor (NGF); neural progenitor cells; transplantation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SEPTAL CHOLINERGIC NEURONS; EMBRYONAL CARCINOMA-CELLS; RETINOIC ACID; HNT NEURONS; NTERA-2 CELLS; HEAD-INJURY; LINE; TRANSPLANTATION; DIFFERENTIATION	Human Ntera-2 (NT2) cells can be differentiated in vitro into well-characterized Populations of NT2N neurons that engraft and mature when transplanted into the adult CNS of rodents and humans. Them ha e shown promise as treatments for neurologic disease, trauma, and ischemic stroke. Although these features suggest that NT2N neurons would be an excellent platform for ex vivo gene therapy in the CNS, stable gene expression has been surprisingly difficult to achieve in these cells. In this report we demonstrate stable, efficient. and nontoxic gene transfer into undifferentiated NT2 cells using a pseudotyped lentiviral vector encoding the human elongation factor 1-alpha promoter and the reporter gene eGFP, Expression of eGFP was maintained when the NT2 cells were differentiated into NT2N neurons after treatment with retinoic acid, When transplanted into the striatum of adult nude mice, transduced NT2N neurons survived, engrafted, and continued to express the reporter gene for long-term time points in vivo. Furthermore. transplantation of NT2N neurons genetically modified to express nerve growth factor significantly attenuated cognitive dysfunction following traumatic brain injure in mice. These results demonstrate that defined populations of genetically modified human NT2N neurons are a practical and effective platform for stable ex vivo gene delivery into the CNS.	Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Vet Med, Ctr Comparat Med Genet, Philadelphia, PA 19104 USA; Osped Maggiore, Policlin IRCCS, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA		Wolfe, JH (corresponding author), Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, 502 Abramson Res Ctr,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	jhwolfe@vet.upenn.edu	Lee, Edward/AAU-8436-2021; Longhi, Luca/AAF-9903-2021	Longhi, Luca/0000-0001-9894-8788	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00255, AG09215] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK42707, DK07748] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH17168] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07810, NS11024, NS38690, NS40978, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T32DK007748, R01DK042707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH017168] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, F32NS011024, P01NS008803, P50NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG009215] Funding Source: NIH RePORTER		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Baker KA, 2000, EXP NEUROL, V162, P350, DOI 10.1006/exnr.1999.7337; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Blesch A, 1998, PROG BRAIN RES, V117, P473; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Cook DG, 1996, J COMP NEUROL, V374, P481; COOK DG, 1994, METHOD CELL BIOL, V43, P289; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gao ZY, 1998, BIOCHEM BIOPH RES CO, V247, P407, DOI 10.1006/bbrc.1998.8826; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; GREENE LA, 1998, CULTURING NERVE CELL; Guillemain I, 2000, J COMP NEUROL, V422, P380, DOI 10.1002/1096-9861(20000703)422:3<380::AID-CNE5>3.0.CO;2-C; Halene S, 2000, HUM GENE THER, V11, P1259, DOI 10.1089/10430340050032366; Hartley RS, 1999, J COMP NEUROL, V407, P1, DOI 10.1002/(SICI)1096-9861(19990428)407:1<1::AID-CNE1>3.0.CO;2-Z; Hartley RS, 1999, J COMP NEUROL, V415, P404, DOI 10.1002/(SICI)1096-9861(19991220)415:3<404::AID-CNE6>3.0.CO;2-R; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hsu WL, 2001, J VIROL, V75, P3819, DOI 10.1128/JVI.75.8.3819-3831.2001; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Hynes M, 2000, NEURON, V28, P11, DOI 10.1016/S0896-6273(00)00079-9; Iwakuma T, 1999, VIROLOGY, V261, P120, DOI 10.1006/viro.1999.9850; KESARI S, 1995, LAB INVEST, V73, P636; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; LEE VMY, 1986, J NEUROSCI, V6, P514; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Llanes C, 1995, J NEUROSCI RES, V42, P791, DOI 10.1002/jnr.490420608; Meier JL, 2001, J VIROL, V75, P1581, DOI 10.1128/JVI.75.4.1581-1593.2001; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; Miyazono M, 1996, J COMP NEUROL, V376, P603, DOI 10.1002/(SICI)1096-9861(19961223)376:4<603::AID-CNE8>3.0.CO;2-5; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Mukhtar M, 2000, HUM GENE THER, V11, P347, DOI 10.1089/10430340050016076; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Neelands TR, 1999, J NEUROSCI, V19, P7057, DOI 10.1523/JNEUROSCI.19-16-07057.1999; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; Passini MA, 2001, J VIROL, V75, P12382, DOI 10.1128/JVI.75.24.12382-12392.2001; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SNYDER EY, 1995, NATURE, V374, P367, DOI 10.1038/374367a0; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Watson Deborah J, 2003, Methods Mol Med, V76, P383; WERTKIN AM, 1993, P NATL ACAD SCI USA, V90, P9513, DOI 10.1073/pnas.90.20.9513; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu P, 1996, GENE THER, V3, P246; ZELLER M, 1995, INT J DEV NEUROSCI, V13, P437, DOI 10.1016/0736-5748(95)00025-C; Zigova T, 2000, EXP NEUROL, V163, P31, DOI 10.1006/exnr.2000.7344	61	73	75	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	2003	62	4					368	380		10.1093/jnen/62.4.368			13	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	664YH	WOS:000182092100005	12722829	Bronze, Green Published			2022-02-06	
J	Ponsford, J				Ponsford, J			Sexual changes associated with traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SEVERE HEAD-INJURY; SOCIAL-ADJUSTMENT; FOLLOW-UP; REHABILITATION	Findings from numerous outcome studies have suggested that people with traumatic brain injuries (TBI) experience relationship difficulties and changes in sexuality. However, there have been few investigations of these problems. This paper reports the results of a study of sexuality following TBI, which aimed to identify changes in sexual behaviour, affect, self-esteem, and relationship quality, and their inter-relationships. Two hundred and eight participants with moderate-to-severe TBI (69% males) completed a questionnaire 1-5 years post-injury. Their responses were compared with those of 150 controls, matched for age, gender, and education. Of TBI participants 36-54% reported: (1) A decrease in the importance of sexuality, opportunities, and frequency of engaging in sexual activities; (2) reduced sex drive; (3) a decline in their ability to give their partner sexual satisfaction and to engage in sexual intercourse; and (4) decreased enjoyment of sexual activity and ability to stay aroused and to climax. The frequencies of such negative changes were significantly higher than those reported by controls and far outweighed the frequency of increases on these dimensions. A significant proportion of TBI participants also reported decreased self-confidence, sex appeal, higher levels of depression, and decreased communication levels and relationship quality with their sexual partner. Factors associated with sexual problems in the TBI group are explored and implications of all findings discussed.	Monash Univ, Melbourne, Vic 3004, Australia; Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia		Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 30 Erin St, Richmond, Vic 3121, Australia.						ANDERSON DW, 1980, J NEUROSURGERY S, V53; Blackerby WF., 1990, J HEAD TRAUMA REHAB, V5, P73, DOI [10.1097/00001199-199005020-00012, DOI 10.1097/00001199-199005020-00012]; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Fryer J, 1989, TRAUMATIC BRAIN INJU, P255; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Gill K.M, 1990, J HEAD TRAUMA REHAB, V5, P38, DOI [DOI 10.1097/00001199-199005020-00007, 10.1097/00001199-199005020-00007]; *HLTH DEP VICT, 1991, REP HEAD INJ IMP STU; Horn LJ, 1990, J HEAD TRAUMA REHAB, V5, P1; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; Miller L., 1994, J COGNITIVE REHABILI, V12, P12; *NHIF, 1984, SIL EP; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 1999, NEUROPSYCHOL REHABIL, V9, P517, DOI 10.1080/096020199389563; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; Simpson F, 2001, TRAFFIC, V2, P2, DOI 10.1034/j.1600-0854.2001.020102.x; SIMPSON GK, 1999, YOU ME ED PROGR SEX; SNAITH RP, 1994, HOSPITAL ANXIETY DEP; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P117; THORNGRAY BE, 1983, REHABIL LIT, V44, P138; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZASLER ND, 1990, J HEAD TRAUMA REHAB, V5, P14, DOI DOI 10.1097/00001199-199005020-00004	31	73	74	0	9	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2003	13	1-2			SI		275	289		10.1080/09602010244000363			15	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	665EK	WOS:000182106500015	21854338				2022-02-06	
J	Larrabee, GJ				Larrabee, GJ			Detection of symptom exaggeration with the MMPI-2 in litigants with malingered neurocognitive dysfunction	CLINICAL NEUROPSYCHOLOGIST			English	Article							FAKE BAD SCALE; VALIDITY SCALES; BASE RATES; INJURY; MEMORY; SUBTLE	MMPI-2 scores of 26 persons identified as meeting criteria for definite malingered neurocognitive dysfunction (MND), were contrasted with the MMPI-2 scores of 29 persons who had suffered moderate or severe closed head injury. The Lees-Haley Fake Bad Scale (FBS) was the most sensitive MMPI-2 scale in discriminating the malingerers from the head-injured persons, with additional significant differences obtained on standard MMPI-2 clinical scales including Scales 1 (Hs), 2 (D), 3 (Hy), 7 (Pt), and 8 (Sc). Correlational analyses on a larger sample combining additional subjects with evidence of possible or probable MND, with the original sample and the head injured subjects, demonstrated the concurrent validity of the FBS, which correlated with the Portland Digit Recognition Test (PDRT), and with Scales 1 (Hs), 2 (D), 3 (Hy), and 7 (Pt) of the MMPI-2.			Larrabee, GJ (corresponding author), 630 S Orange Ave,S-202, Sarasota, FL 34236 USA.	glarrabee@aol.com					Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Arbisi PA, 1998, PSYCHOL ASSESSMENT, V10, P221, DOI 10.1037/1040-3590.10.3.221; Benton A., 1994, CONTRIBUTIONS NEUROP; BERRY DTR, 1991, CLIN PSYCHOL REV, V11, P585, DOI 10.1016/0272-7358(91)90005-F; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P461, DOI 10.1076/clin.15.4.461.1890; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; BINDER LM, 1996, ASSESSMENT, V3, P403, DOI DOI 10.1177/107319119600300405; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Butcher JN, 1992, ESSENTIALS MMPI 2 MM; BUTCHER JN, 1989, MANUAL ADM SCORING M, V2; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gass CS, 2001, ASSESSMENT, V8, P425, DOI 10.1177/107319110100800407; Gough H.G., 1950, J CONSULT PSYCHOL, V14, P408, DOI [10.1037/h0054506, DOI 10.1037/H0054506]; Gough HG, 1957, CALIFORNIA PSYCHOL I; GOUGH HG, 1954, J CONSULT PSYCHOL, V18, P287; Gouvier WD, 1999, STUD NEUROPSYCHOL DE, P27; GRAHAM JR, 2000, MMPI 2 ASSESSING PER; Greene RL, 2000, MMPI 2 INTERPRETIVE; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEATON RK, 1978, J CONSULT CLIN PSYCH, V46, P892, DOI 10.1037/0022-006X.46.5.892; Heaton RK, 1991, COMPREHENSIVE NORMS; KELLER LS, 1992, ASSESSMENT CHRONIC P; Lanyon R.I, 1993, PSYCHOL ASSESSMENT, V5, P324, DOI DOI 10.1037/1040-3590.5.3.324; Lanyon RI, 2001, J PERS ASSESS, V76, P169, DOI 10.1207/S15327752JPA7601_10; Larrabee G.J., 1988, PROFESSIONAL MANUAL; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P139, DOI 10.1076/1385-4046(200002)14:1;1-8;FT139; LARRABEE GJ, 2002, UNPUB DETECTION MALI; LARRABEE GJ, IN PRESS ARCH CLIN N; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEESHALEY PR, 1992, J CLIN PSYCHOL, V48, P681, DOI 10.1002/1097-4679(199209)48:5<681::AID-JCLP2270480516>3.0.CO;2-Q; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Meyers JE, 2002, ARCH CLIN NEUROPSYCH, V17, P157, DOI 10.1016/S0887-6177(00)00107-4; MILLER JS, 1995, CHEM ENG NEWS, V73, P30, DOI 10.1021/cen-v073n040.p030; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Pampel F.C., 2000, LOGISTIC REGRESSION; Paulhus D.L., 1991, MEASURES PERSONALITY, P17, DOI 10.1016/B978-0-12-590241-0.50006-X; PUTNAM SH, 1998, ANN M AM PSYCH ASS S; Rogers R., 1995, ASSESSMENT, V2, P81, DOI DOI 10.1177/1073191195002001008; Rogers R., 1994, ASSESSMENT, V1, P227, DOI DOI 10.1177/107319119400100302; ROSS SR, IN PRESS J CLIN EXPT; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; Tsushima WT, 2001, ASSESSMENT, V8, P205, DOI 10.1177/107319110100800208; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; Wechsler, 1997, WECHSLER ADULT INTEL; WIENER DN, 1948, J CONSULT PSYCHOL, V12, P164, DOI 10.1037/h0055594; [No title captured]; [No title captured]	56	73	73	0	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2003	17	1					54	68		10.1076/clin.17.1.54.15627			15	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	707XM	WOS:000184535300005	12854011				2022-02-06	
J	Feeney, TJ; Ylvisaker, M				Feeney, TJ; Ylvisaker, M			Context-sensitive behavioral supports for young children with TBI - Short-term effects and long-term outcome	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						behavior disorders; cognitive-bebavioral intervention; ecological validity; functional assessment; multicomponent intervention; pediatric rehabilitation; positive behavior support; school-based treatment; traumatic brain injury	TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE INJURY; CLOSED-HEAD INJURY; ADOLESCENTS; FAMILY; PREDICTORS; SEVERITY; RECOVERY; REHABILITATION; DISABILITY	Objective: To investigate the effects of a multicomponent cognitive-behavioral intervention on the challenging behavior of two young children with growing behavioral concerns after traumatic brain injury. Design. Single-subject reversal designs were used to document the effects of the intervention on the specific dependent variables. In addition, qualitative data were collected to determine the children's long-term outcome and staff evaluations of the intervention. Participants: Both children were normally developing before injury at age 5 years. Both experienced increasing behavior problems as expectations in school escalated. Main Outcome Measures: Quantitative data included frequency and intensity of,aggression and amount of work completed. Qualitative data included children's general engagement in school work and peer interaction and staff evaluations of the intervention. Intervention: The intervention-included components of positive behavior supports, cognitive supports, and an executive function routine. Results: The targeted challenging behaviors were reduced to near zero with decreased intensity. Long-term outcome was positive. Conclusions: These results illustrate the potential for successfully treating behavior disorders in young children With traumatic brain injury using a support-oriented intervention that combines behavioral and cognitive components.	Wildwood Inst, Schenectady, NY 12305 USA; Coll St Rose, Sch Educ, Albany, NY USA		Feeney, TJ (corresponding author), Wildwood Inst, 219 Liberty, Schenectady, NY 12305 USA.		Berger, Emily/N-7268-2017	Berger, Emily/0000-0001-5550-807X			Aman MG., 1994, ABERRANT BEHAV CHECK; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Barlow DH, 1984, SINGLE CASE EXPT DES; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; BIJOU SW, 1968, J APPL BEHAV ANAL, V1, P175, DOI 10.1901/jaba.1968.1-175; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BRAGA LW, UNPUB REHABIL PSYCHO; BRAGA LW, 2000, INT HDB NEUROPSYCHOL; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Carr EG, 2002, J POSIT BEHAV INTERV, V4, P4, DOI 10.1177/109830070200400102; CARR EG, 1994, COMMUNICATION BASED; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; COSTEFF H, 1985, SCAND J REHABIL MED, P10; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Detterman DL, 1993, TRANSFER TRIAL INTEL; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; DURAND M, 1992, MOTIVATION ASSESSMEN; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; FEENEY T, 1997, STUDENTS ACQUIRED BR, P229; FEENEY TJ, 1995, J HEAD TRAUMA REHAB, V10, P67; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Glesne C., 1992, BECOMING QUALITATIVE; Hanten G, 2000, DEV NEUROPSYCHOL, V18, P383, DOI 10.1207/S1532694206Hanten; Harchik A E, 1993, Ann Clin Psychiatry, V5, P151, DOI 10.3109/10401239309148979; Hebb DO, 1947, AM PSYCHOL, V2, P737; KEPPEL G, 1991, DESIGN ANAL INVESTIG; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kolb B., 1995, BRAIN PLASTICITY BEH; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; MACE FC, 1990, J EXP ANAL BEHAV, V54, P163, DOI 10.1901/jeab.1990.54-163; Mace FC, 1997, J APPL BEHAV ANAL, V30, P1, DOI 10.1901/jaba.1997.30-1; MARLOWE WB, 1990, J CLIN EXP NEUROPSYC, V12, P105; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1595, DOI 10.1016/S0890-8567(09)66570-9; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; REICHLE J, 1993, COMMUNICATIVE ALTERN; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; SCHWARTZ L, 2002, IN PRESS J PEDIAT PS; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 2002, IN PRESS NEUROPSYCHO, V16; TAYLOR HG, IN PRES J INT NEUROP; Taylor S.J., 1984, INTRO QUALITATIVE RE, V2nd ed.; Varney NR., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI [10.1097/00001199-199303000-00005, DOI 10.1097/00001199-199303000-00005]; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson, 1993, APPL PREV PSYCHOL, V2, P209, DOI DOI 10.1016/S0962-1849(05)80091-5; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; YLVISAKER M, 1994, TOP LANG DISORD, V15, P37, DOI 10.1097/00011363-199411000-00005; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU, Vxiv; Ylvisaker M., 1998, COLLABORATIVE BRAIN; YLVISAKER M, IN PRESS BRAIN DISOR; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P271; Ylvisaker Mark, 2002, Pediatr Rehabil, V5, P51, DOI 10.1080/1363849021000041891; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	82	73	73	1	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2003	18	1					33	51		10.1097/00001199-200301000-00006			19	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	641RR	WOS:000180760200006	12802236				2022-02-06	
J	Hofstetter, HH; Sewell, DL; Liu, F; Sandor, M; Forsthuber, T; Lehmann, PV; Fabry, Z				Hofstetter, HH; Sewell, DL; Liu, F; Sandor, M; Forsthuber, T; Lehmann, PV; Fabry, Z			Autoreactive T cells promote post-traumatic healing in the central nervous system	JOURNAL OF NEUROIMMUNOLOGY			English	Article						experimental allergic encephalomyelitis; myelin oligodendrocyte antigen; Cytokines; Th1/Th2; central nervous system; post-traumatic healing	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INFLAMMATORY BRAIN-LESIONS; PERTUSSIS TOXIN; BASIC-PROTEIN; IN-VITRO; BORDETELLA-PERTUSSIS; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS	In general, autoimmune responses are considered harmful to the host. In the best-defined model of autoimmune disease, murine experimental allergic encephalomyelitis (EAE), for example, brain-protein-specific autoimmune responses of both major classes, type-1 and type-2, have been implicated in causing brain pathology. We induced type-1 and type-2 autoimmunity to myelin oligodendrocyte protein (MOG) in C57.BL/6 mice. Instead of using pertussis toxin (PTX) to open the blood-brain barrier (131313), which is the classic procedure, we set an aseptic cerebral injury (ACI) to see what the consequences of pre-primed, autoreactive type-1 and type-2 memory T cells gaining access to the brain in the course of sterile tissue injury would be. Neither of these autoimmune response types induced pathology; on the contrary, both accelerated re-vascularization and post-traumatic healing. The data suggest that induction of either type-1 or type-2 autoimmune responses is not inherently noxious to the host, but can have beneficial effects on tissue repair. Autoimmune pathology may develop only if molecules of microbial origin such as pertussis toxin additionally induce the "infectious nonself/danger" reaction in the antigen-presenting cells (APC) of the target organ itself. (C) 2002 Elsevier Science B.V. All rights reserved.	Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA; Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA		Lehmann, PV (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pathol, 10900 Euclid Ave,BRB 929, Cleveland, OH 44106 USA.			/0000-0003-0692-7125	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R21AI042635, R21AI044484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R29DK048799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS037570, R01NS037570] Funding Source: NIH RePORTER; NIAID NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [AI-42635, AI/DK 44484] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK-48799] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37570-01A2] Funding Source: Medline		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abdul-Majid KB, 2000, J NEUROIMMUNOL, V111, P23, DOI 10.1016/S0165-5728(00)00360-X; Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; Arimoto H, 2000, J NEUROIMMUNOL, V104, P15, DOI 10.1016/S0165-5728(99)00242-8; Bauer J, 1998, AM J PATHOL, V153, P715, DOI 10.1016/S0002-9440(10)65615-5; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Blankenhorn EP, 2000, J IMMUNOL, V164, P3420, DOI 10.4049/jimmunol.164.6.3420; Brabb T, 1997, J IMMUNOL, V159, P497; Brocke S, 1998, NATURE, V392, P630, DOI 10.1038/33465; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; BROSNAN CF, 1981, J IMMUNOL, V126, P614; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1979, LAB INVEST, V40, P74; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; DEROSBO NK, 1995, EUR J IMMUNOL, V25, P985, DOI 10.1002/eji.1830250419; EFRON JE, 1990, J SURG RES, V48, P460, DOI 10.1016/0022-4804(90)90013-R; Ehrlich P., 1900, P R SOC LOND, V66, P424, DOI DOI 10.1098/RSPL.1899.0121; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Ferber IA, 1996, J IMMUNOL, V156, P5; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Fukushi J, 1998, BIOCHEM BIOPH RES CO, V250, P444, DOI 10.1006/bbrc.1998.9334; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GRENIERBROSSETTE N, 1991, IMMUNOPHARMACOLOGY, V21, P109, DOI 10.1016/0162-3109(91)90014-P; Hancock WW, 1998, NAT MED, V4, P1392, DOI 10.1038/3982; Heeger PS, 2000, J IMMUNOL, V164, P5771, DOI 10.4049/jimmunol.164.11.5771; HINRICHS DJ, 1987, J EXP MED, V166, P1906, DOI 10.1084/jem.166.6.1906; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Karulin AY, 2000, J IMMUNOL, V164, P1862, DOI 10.4049/jimmunol.164.4.1862; KELSO A, 1995, IMMUNOL TODAY, V16, P374, DOI 10.1016/0167-5699(95)80004-2; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; KHORUTS A, 1995, J IMMUNOL, V155, P5011; Krakowski M, 1996, EUR J IMMUNOL, V26, P1641, DOI 10.1002/eji.1830260735; Kumar R, 1998, INT J ONCOL, V12, P749; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LEE JM, 1955, P SOC EXP BIOL MED, V89, P263; Lehmann PV, 1998, IMMUNOL REV, V164, P53, DOI 10.1111/j.1600-065X.1998.tb01207.x; Limmer A, 1998, EUR J IMMUNOL, V28, P2395, DOI 10.1002/(SICI)1521-4141(199808)28:08<2395::AID-IMMU2395>3.0.CO;2-D; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Mendel I, 1996, EUR J IMMUNOL, V26, P2470, DOI 10.1002/eji.1830261030; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MOTRO B, 1990, P NATL ACAD SCI USA, V87, P3092, DOI 10.1073/pnas.87.8.3092; OURY TD, 1993, J BIOL CHEM, V268, P15394; Pakala SV, 1997, J EXP MED, V186, P299, DOI 10.1084/jem.186.2.299; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rocken M, 1996, IMMUNOL TODAY, V17, P225, DOI 10.1016/0167-5699(96)80556-1; Ryan M, 1998, INT IMMUNOL, V10, P651, DOI 10.1093/intimm/10.5.651; STEINMAN L, 1995, CELL, V80, P7, DOI 10.1016/0092-8674(95)90443-3; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; SUDWEEKS JD, 1993, P NATL ACAD SCI USA, V90, P3700, DOI 10.1073/pnas.90.8.3700; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Targoni OS, 1998, J EXP MED, V187, P2055, DOI 10.1084/jem.187.12.2055; Torre D, 1996, FEMS IMMUNOL MED MIC, V13, P95; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Yip HC, 1999, J IMMUNOL, V162, P3942	58	73	77	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	JAN	2003	134	1-2					25	34	PII S0165-5728(02)00358-2	10.1016/S0165-5728(02)00358-2			10	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	637JV	WOS:000180508700003	12507769				2022-02-06	
J	Kim, J; Gearhart, MM; Zurick, A; Zuccarello, M; James, L; Luchette, FA				Kim, J; Gearhart, MM; Zurick, A; Zuccarello, M; James, L; Luchette, FA			Preliminary report on the safety of heparin for deep venous thrombosis prophylaxis after severe head injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						heparin; deep venous thrombosis; head injury; venous thromboembolism; trauma; prophylaxis	LOW-DOSE HEPARIN; MOLECULAR-WEIGHT HEPARIN; TRAUMA PATIENTS; MAJOR TRAUMA; NEUROSURGICAL PATIENTS; VEIN THROMBOSIS; THROMBOEMBOLISM; PREVENTION; RISK; ENOXAPARIN	Background: Prophylaxis for venous thromboembolism (VTE) in head injured patients has avoided heparin products because of concern for exacerbating intracranial bleeding. The purpose of this study was to evaluate the safety of unfractionated heparin (UFH) for VTE prophylaxis after traumatic brain injury. Methods: We retrospectively evaluated the early use of UFH in patients sustaining a severe closed head injury (Abbreviated Injury Scale score > 3) from January 1, 2000, through December 31, 2000. Two groups were formed on the basis of the timing of UFH administration: within 72 hours of admission (Early group), or after the third day of hospitalization (Late group), if at all. Intracranial bleeding related to UFH administration was assessed by computed tomographic scan of the head and/or clinical examination. Results: Sixty-four of 76 patients with intracranial blood on admission head computed tomographic scan fulfilled study criteria. Seventy-three percent (n = 47) were in the Early group and 27% (n = 17) were in the Late group. None of the Early group had an increase in intracranial bleeding or deterioration on neurologic examination as a result of UFH administration. However, there was no statistical difference in VTE events between the two groups. Conclusion: Early use of UFH in the severe head injured patient does not increase bleeding complications.	Loyola Univ, Stritch Sch Med, Dept Surg, Div Trauma Crit Care & Burns, Maywood, IL 60153 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Pharm Serv, Cincinnati, OH USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH USA		Luchette, FA (corresponding author), Loyola Univ, Stritch Sch Med, Dept Surg, Div Trauma Crit Care & Burns, 2160 S 1st Ave, Maywood, IL 60153 USA.		Luchette, Fred/ABF-1710-2020	Luchette, Fred/0000-0002-8857-9111			Agnelli G, 1998, NEW ENGL J MED, V339, P80, DOI 10.1056/NEJM199807093390204; *AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARNETT HG, 1977, J NEUROSURG, V47, P27, DOI 10.3171/jns.1977.47.1.0027; BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; CERRATO D, 1978, J NEUROSURG, V49, P378, DOI 10.3171/jns.1978.49.3.0378; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; Gearhart MM, 2000, SURGERY, V128, P631, DOI 10.1067/msy.2000.108224; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; Greenfield LJ, 1997, J TRAUMA, V42, P100, DOI 10.1097/00005373-199701000-00017; HAMILTON MG, 1994, NEUROSURGERY, V34, P280, DOI 10.1227/00006123-199402000-00012; Iorio A, 2000, ARCH INTERN MED, V160, P2327, DOI 10.1001/archinte.160.15.2327; Knudson MM, 1996, J TRAUMA, V41, P446, DOI 10.1097/00005373-199609000-00010; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; Macdonald RL, 1999, NEUROSURGERY, V45, P245, DOI 10.1097/00006123-199908000-00008; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; Norwood SH, 2001, J AM COLL SURGEONS, V192, P161, DOI 10.1016/S1072-7515(00)00802-4; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; SHACKFORD SR, 1990, AM J SURG, V159, P365, DOI 10.1016/S0002-9610(05)81272-3; Velmahos GC, 1998, J AM COLL SURGEONS, V187, P529, DOI 10.1016/S1072-7515(98)00223-3; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Wen DY, 1998, SURG NEUROL, V50, P521, DOI 10.1016/S0090-3019(98)00083-4	24	73	76	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2002	53	1					38	42		10.1097/00005373-200207000-00008			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	573BR	WOS:000176809900012	12131387				2022-02-06	
J	Fann, JR; Leonetti, A; Jaffe, K; Katon, WJ; Cummings, P; Thompson, RS				Fann, JR; Leonetti, A; Jaffe, K; Katon, WJ; Cummings, P; Thompson, RS			Psychiatric illness and subsequent traumatic brain injury: a case control study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							HEALTH MAINTENANCE ORGANIZATION; COGNITIVE DYSFUNCTION; BENZODIAZEPINE USE; DEPRESSED-PATIENTS; TRAFFIC ACCIDENTS; POPULATION; IMPAIRMENT; DISORDERS; SYMPTOMS; RISK	Objective: To determine whether psychiatric illness is a risk factor for subsequent traumatic brain injury (TBI). Methods: Case control study in a large staff model health maintenance organisation in western Washington State. Patients with TBI, determined by International classification of diseases, 9th revision, clinical modification (ICD-9-CM) diagnoses, were 1440 health plan members who had TBI diagnosed in 1993 and who had been enrolled in the previous year, during which no TBI was ascertained. Three health plan members were randomly selected as control subjects, matched by age, sex, and reference date. Psychiatric illness in the year before the TBI reference date was determined by using computerised records of ICD-9-CM diagnoses, psychiatric medication prescriptions, and utilisation of a psychiatric service. Results: For those with a psychiatric diagnosis in the year before the reference date, the adjusted relative risk for TBI was 1.7 (95% confidence interval (Cl) 1.4 to 2.0) compared with those without a psychiatric diagnosis. Patients who had filled a psychiatric medication prescription had an adjusted relative risk for TBI of 1.6 (95% Cl 1.2 to 2.1) compared with those who had not filled a psychiatric medication prescription. Patients who had utilised psychiatric services had an adjusted relative risk for TBI of 1.3 (95% Cl 1.0 to 1.6) compared with those who had not utilised psychiatric services. The adjusted relative risk for TBI for patients with psychiatric illness determined by any of the three psychiatric indicators was 1.6 (95% Cl 1.4 to 1.9) compared with those without any psychiatric indicator. Conclusion: Psychiatric illness appears to be associated with an increased risk for TBI.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Harborview Injury Prevent & Res Ctr, Seattle, WA USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA		Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.						American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Barbone F, 1998, LANCET, V352, P1331, DOI 10.1016/S0140-6736(98)04087-2; BEITMAN BD, 1982, J FAM PRACTICE, V15, P1119; Breslow N.E., 1980, STAT METHODS CANC RE, P192; BRODY EM, 1984, J AM GERIATR SOC, V32, P877, DOI 10.1111/j.1532-5415.1984.tb00886.x; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cornblatt B, 1997, PSYCHIAT QUART, V68, P343, DOI 10.1023/A:1025495030997; CORNELL DG, 1984, J ABNORM PSYCHOL, V93, P150; CRANCER A, 1969, AM J PSYCHIAT, V126, P807, DOI 10.1176/ajp.126.6.807; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; DICKER BG, 1992, J HEAD TRAUMA REHAB, V7, P83; EELKEMA RC, 1970, AM J PUBLIC HEALTH N, V60, P459, DOI 10.2105/AJPH.60.3.459; ELANDER J, 1993, PSYCHOL BULL, V113, P279, DOI 10.1037/0033-2909.113.2.279; Fann JR, 1997, J PSYCHOSOM RES, V43, P335, DOI 10.1016/S0022-3999(97)00130-X; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; FOY A, 1995, J GERONTOL A-BIOL, V50, pM99, DOI 10.1093/gerona/50A.2.M99; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GOLINKOFF M, 1989, J AFFECT DISORDERS, V17, P105, DOI 10.1016/0165-0327(89)90032-3; Henk HJ, 1996, ARCH GEN PSYCHIAT, V53, P899; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; KATON W, 1981, J FAM PRACTICE, V13, P47; KATON W, 1990, GEN HOSP PSYCHIAT, V12, P355, DOI 10.1016/0163-8343(90)90002-T; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KUNY S, 1995, PSYCHOPATHOLOGY, V28, P190, DOI 10.1159/000284922; LEVEILLE SG, 1994, EPIDEMIOLOGY, V5, P591, DOI 10.1097/00001648-199411000-00006; LEWIN I, 1982, ERGONOMICS, V25, P917, DOI 10.1080/00140138208925051; MacKenzie E J, 1989, Md Med J, V38, P725; Manheimer D I, 1997, Inj Prev, V3, P135, DOI 10.1136/ip.3.2.135; *NAT CTR HLTH STAT, 1991, DHHS PUBL; Oxman TE, 1996, J CLIN PSYCHIAT, V57, P38; PELCO L, 1992, Brain Injury, V6, P29, DOI 10.3109/02699059209008119; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAY WA, 1992, AM J EPIDEMIOL, V136, P873, DOI 10.1093/aje/136.7.873; RUSSO J, 1994, PSYCHOSOMATICS, V35, P546, DOI 10.1016/S0033-3182(94)71723-0; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Schatz J, 1998, SCHIZOPHR RES, V30, P41, DOI 10.1016/S0920-9964(97)00125-4; SELZER ML, 1967, Q J STUD ALCOHOL, V28, P505; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Stergachis AS, 1991, PHARMACOPEIDEMIOLOGY, P222; SULLIVAN M, 1993, APS J, V2, P141, DOI 10.1016/S1058-9139(05)80078-6; Teasdale TW, 1997, BRIT MED J, V315, P569; Thurman DJ, 1996, WESTERN J MED, V165, P192; Thurman DJ., 1996, P ANN M AM PUBL HLTH; Thurman DJ., 1995, GUIDELINES SURVEILLA; Trzepacz PT, 1996, PSYCHIAT CLIN N AM, V19, P429, DOI 10.1016/S0193-953X(05)70299-9; TSUANG MT, 1985, AM J PSYCHIAT, V142, P538; van den Bosch RJ, 1998, J NERV MENT DIS, V186, P364, DOI 10.1097/00005053-199806000-00007; Vinson D C, 1995, Arch Fam Med, V4, P505, DOI 10.1001/archfami.4.6.505; WALKER EA, 1993, J GEN INTERN MED, V8, P436, DOI 10.1007/BF02599621; WALLER JA, 1965, NEW ENGL J MED, V273, P1413, DOI 10.1056/NEJM196512232732605; Weinberger DR, 1997, INT CLIN PSYCHOPHARM, V12, pS29, DOI 10.1097/00004850-199709004-00006; Weiner DK, 1998, GERONTOLOGY, V44, P217, DOI 10.1159/000022013; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 2000, PHYSICIANS DESK REFE; 1998, J HOPKINS U ACG CASE	60	73	73	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2002	72	5					615	620		10.1136/jnnp.72.5.615			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	547QX	WOS:000175344200016	11971048	Green Published, Bronze			2022-02-06	
J	Cuny, E; Richer, E; Castel, JP				Cuny, E; Richer, E; Castel, JP			Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal Baclofen therapy	BRAIN INJURY			English	Article							ALLEVIATES AUTONOMIC DYSFUNCTION; DIENCEPHALIC SEIZURES	In the initial phase of severe head injury, dysautonomic abnormalities are frequent. Within the framework of a prospective study, evaluating the efficacy of continuous intrathecal Baclofen therapy (CIBT) on hypertonia during the initial recovery phase of severe head injury, the authors report on the preliminary results of this treatment on paroxysmal dysautonomia about four patients. Continuous intrathecal Baclofen infusion was first delivered, for a test period, continuously for 6 days. If a relapse of dysautonomia occurred at the end of the test period, an implantation of a continuous intrathecal infusion pump delivering Baclofen was performed. Results were assessed with four continuous variables; duration (days), dose of Baclofen per day (mug/d), number of dysautonomic paroxysmal episodes per day, and initial recovery evaluated by a scale of the first initial stages of head injury coma recovery. For three patients: (1) the number of dysautonomic paroxysmal episodes per day and the doses of Baclofen during the follow-up period were correlated (p=0.02, p<0.001, p=0.008, respectively, distribution-free test of Spearman), (2) during the test period and the relapse after the test period, the number of paroxysmal episodes and the Baclofen dose are correlated to p<0.05, p=0.03, p=0.04, respectively (distribution-free test of Spearman). The second statistical test was used to prove that Baclofen doses and number of paroxysmal dysautonomic episodes are correlated independently of the duration of follow-up. The fourth patient improved with CIBT without any recurrence at the end of the treatment test period. For the four patients, recovery score increased during the overall follow-up. In the authors' experience CIBT is very efficient to control paroxysmal dysautonomia during the initial recovery phase in severe head injury, and seems to facilitate recovery.	CHU Bordeaux, Hop Pellegrin, Clin Univ Neurochirurg, F-33076 Bordeaux, France; Ctr Reeduc, Cenac, France		Cuny, E (corresponding author), CHU Bordeaux, Hop Pellegrin, Clin Univ Neurochirurg, Pl Amelie Raba Leon, F-33076 Bordeaux, France.						Baguley IJ, 1999, J NEUROL NEUROSUR PS, V67, P39, DOI 10.1136/jnnp.67.1.39; Becker R, 1999, J NEUROL NEUROSUR PS, V66, P114, DOI 10.1136/jnnp.66.1.114; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; COHADON F, 1993, NEUROCHIRURGIE, V39, P281; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; PRANZATELLI MR, 1991, J CHILD NEUROL, V6, P115, DOI 10.1177/088307389100600204	8	73	76	1	1	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	OCT	2001	15	10					917	925		10.1080/02699050110065277			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	483HF	WOS:000171627000008	11595088				2022-02-06	
J	Bate, AJ; Mathias, JL; Crawford, JR				Bate, AJ; Mathias, JL; Crawford, JR			Performance on the test of everyday attention and standard tests of attention following severe traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							CLOSED-HEAD-INJURY; DEFICITS; RECOVERY; TASK; VALIDITY; SYSTEMS	The Test of Everyday Attention (TEA) was designed to address some of the limitations of established measures of attention. However, very few studies have examined its clinical utility. A group of 35 patients who had sustained a severe TBI were compared with 35 age- and education-matched controls on the TEA, Stroop, SDMT, WMS-R Digit Span, Ruff 2s and 7s Selective Attention Test, and PASAT. Of the TEA subtests, only the Map and Telephone Search subtests of the TEA produced significant differences between the two groups, suggesting a deficit in visual selective attention following TBI. Principal components analysis revealed a four-component/factor structure of attention, largely consistent with previous studies. A logistic regression found that the TEA Map Search and Modified Colour-Word subtest of the Stroop were best able to discriminate between the TBI and control groups. When the TBI group was divided into Early (<1 year post injury) and Late (>2 years post injury) groups, there was an additional deficit on the Lottery (sustained attention) subtest in the Early TBI group, indicating that there is some recovery in attentional function beyond 1 year post injury.	Community Rehabil Program, Julia Farr Serv, Adelaide, SA 5070, Australia; Univ Adelaide, Dept Psychol, Adelaide, SA 5001, Australia; Univ Aberdeen, Kings Coll, Dept Psychol, Aberdeen, Scotland		Bate, AJ (corresponding author), Community Rehabil Program, Julia Farr Serv, 8 Briar Rd, Adelaide, SA 5070, Australia.		Mathias, J L/L-6295-2013; Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428; Mathias, Jane/0000-0001-8957-8594			Barth JT, 1989, MILD HEAD INJURY; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bohnen N, 1992, Clin Neuropsychol, V6, P178, DOI 10.1080/13854049208401854; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Chan RCK, 1999, ARCH CLIN NEUROPSYCH, V14, P715, DOI 10.1016/S0887-6177(99)80187-5; Crawford J. R., 1992, HDB NEUROPSYCHOLOGIC; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; Crawford JR, 1997, BRIT J CLIN PSYCHOL, V36, P609, DOI 10.1111/j.2044-8260.1997.tb01265.x; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Golden CJ., 1978, STROOP COLOUR WORD T; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; Ishihara S., 1972, TESTS COLOUR BLINDNE; KERNS KA, 1998, ECOLOGICAL VALIDITY, P147; Kinsella GJ, 1998, NEUROPSYCHOL REHABIL, V8, P351, DOI 10.1080/713755576; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOKEN WJ, 1995, NEUROPSYCHOLOGY, V9, P592, DOI 10.1037/0894-4105.9.4.592; LOWE DG, 1982, CAN J PSYCHOL, V36, P684, DOI 10.1037/h0080661; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nelson H.E., 1982, NATL ADULT READING T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1982, PHILOS T ROY SOC B, V298, P187, DOI 10.1098/rstb.1982.0081; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; POSNER MI, 1987, PSYCHOBIOLOGY, V15, P107; Rimel RW, 1990, REHABILITATION ADULT, P8; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; ROBERTSON IH, 1995, INS ASSBI C CAIRNS A; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Sbordone R. J., 1998, ECOLOGICAL VALIDITY, P15; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schmitter-Edgecombe M, 1998, J INT NEUROPSYCH SOC, V4, P144, DOI 10.1017/S1355617798001441; Shum DHK, 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; SLOAN S, 1995, TRAUMATIC BRAIN INJU, P65; SMITH A, 1973, SYBMOL DIGIT MODALIT; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; TEASDALE G, 1974, LANCET, V2, P81; UZZELL BP, 1987, SURG NEUROL, V27, P419, DOI 10.1016/0090-3019(87)90247-3; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1987, NEUROBEHAVIORAL RECO; Wechsler D, 1987, MEMORY SCALE REVISED; WEINBERG J, 1972, J CLIN PSYCHOL, V28, P361, DOI 10.1002/1097-4679(197207)28:3+<361::AID-JCLP2270280315>3.0.CO;2-5; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; Zoccolotti P, 2000, CORTEX, V36, P93, DOI 10.1016/S0010-9452(08)70839-6; [No title captured]	56	73	76	0	11	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2001	15	3					405	422		10.1076/clin.15.3.405.10279			18	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	482NA	WOS:000171581200014	11778779				2022-02-06	
J	Kondratyev, A; Sahibzada, N; Gale, K				Kondratyev, A; Sahibzada, N; Gale, K			Electroconvulsive shock exposure prevents neuronal apoptosis after kainic acid-evoked status epilepticus	MOLECULAR BRAIN RESEARCH			English	Article						epilepsy; seizure; electroconvulsive shock; neuroprotection; apoptosis; gene induction	FIBROBLAST GROWTH-FACTOR; TRAUMATIC BRAIN INJURY; PROGRAMMED CELL-DEATH; KAINATE-INDUCED APOPTOSIS; DEEP PREPIRIFORM CORTEX; INDUCED SEIZURES; MESSENGER-RNA; BCL-X; DNA FRAGMENTATION; UP-REGULATION	In the aftermath of prolonged continuous seizure activity (status epilepticus. SE), neuronal cell death occurs in the brain regions through which the seizure propagates. The vulnerability to adrenalectomy-induced apoptotic neuronal death was recently reported to be reduced by prior exposure to repeated daily noninjurious electroconvulsive shock (ECS). The present studies identified apoptosis and apoptosis-associated gene products in the neurodegenerative response to experimentally controlled periods (1 or 2 h) of SE in the rat, and determined whether exposure to ECS can interrupt these apoptotic responses mechanisms. Internucleosomal DNA fragmentation and the presence of apoptotic-like neurons (as assessed by in situ double labeling technique) was detected in hippocampus and rhinal cortex at 24 h after SE. Under these conditions, levels of both mRNA and protein encoded by the 'death promoting' bcl-X-s gene were increased in the same brain areas. Pretreatment of animals for 7 days with low intensity (minimal) ECS conferred resistance to SE-evoked neurodegeneration, as assessed histopathologically by silver staining. Associated with this neuroprotective action was a reduction in the incidence of apoptosis-like neuronal morphology and DNA fragmentation, and a prevention of the increase in Bcl-X-s protein and mRNA in hippocampus and rhinal cortex. These data suggest that pre-exposure to controlled, brief noninjurious seizures decreases vulnerability to programmed neuronal cell death, that this neuroprotective action occurs upstream from Bcl-X-s, and that increases in bcl-X-s gene expression may serve as a sensitive indicator of neurodegeneration following SE. (C) 2001 Elsevier Science B.V. All rights reserved.	Georgetown Univ, Med Ctr, Dept Pharmacol, Washington, DC 20007 USA		Kondratyev, A (corresponding author), Georgetown Univ, Med Ctr, Dept Pharmacol, Res Bldg,Room W217,3970 Reservoir Rd NW, Washington, DC 20007 USA.	kondrata@georgetown.edu		Sahibzada, Niaz/0000-0002-4169-370X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [S11NS036035, R01NS020576] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM 08005] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20576, NS 36035] Funding Source: Medline		Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Ferrer I, 1998, EXP BRAIN RES, V121, P167, DOI 10.1007/s002210050448; FILIPKOWSKI RK, 1994, NEUROREPORT, V5, P1538, DOI 10.1097/00001756-199407000-00032; FOLLESA P, 1994, EXP NEUROL, V127, P37, DOI 10.1006/exnr.1994.1077; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Giardina SF, 1998, J NEUROCHEM, V71, P1325; GILLARDON F, 1995, NEUROSCI LETT, V192, P85, DOI 10.1016/0304-3940(95)11619-8; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; Guegan C, 1998, EXP NEUROL, V154, P371, DOI 10.1006/exnr.1998.6913; Katoh S, 1997, NEUROSCI LETT, V232, P71, DOI 10.1016/S0304-3940(97)00582-X; KELLY ME, 1994, BRAIN RES, V634, P245, DOI 10.1016/0006-8993(94)91927-5; Kitamura Y, 1998, NEUROSCI LETT, V255, P57, DOI 10.1016/S0304-3940(98)00714-9; Kondratyev A, 2000, MOL BRAIN RES, V75, P216, DOI 10.1016/S0169-328X(99)00292-2; LIU Z, 1993, BRAIN RES, V626, P335, DOI 10.1016/0006-8993(93)90598-H; MAGGIO R, 1993, EXP NEUROL, V119, P11, DOI 10.1006/exnr.1993.1002; Masco D, 1999, NEUROSCIENCE, V91, P1315, DOI 10.1016/S0306-4522(98)00636-8; MASCO D, 1995, P SOC NEUROSCI, V21; MONTPIED P, 1993, BIOCHEM BIOPH RES CO, V195, P623, DOI 10.1006/bbrc.1993.2091; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POLLARD H, 1994, NEUROREPORT, V5, P1053, DOI 10.1097/00001756-199405000-00009; Pretel S, 1997, ACTA HISTOCHEM, V99, P71, DOI 10.1016/S0065-1281(97)80010-4; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Sakhi S, 1996, NEUROREPORT, V7, P493, DOI 10.1097/00001756-199601310-00028; Sankar R, 1998, J NEUROSCI, V18, P8382; SASAHIRA M, 1995, NEUROSCI LETT, V185, P95, DOI 10.1016/0304-3940(94)11233-9; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SCHWOB JE, 1980, NEUROSCIENCE, V5, P991, DOI 10.1016/0306-4522(80)90181-5; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; SHIMOSAKA S, 1994, NEUROSCIENCE, V61, P817, DOI 10.1016/0306-4522(94)90404-9; SPERK G, 1983, NEUROSCIENCE, V10, P1301, DOI 10.1016/0306-4522(83)90113-6; Tamatani M, 1998, MOL BRAIN RES, V58, P27, DOI 10.1016/S0169-328X(98)00095-3; Wang Q, 1998, EXP CELL RES, V238, P177, DOI 10.1006/excr.1997.3820; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zhang LX, 1998, MOL BRAIN RES, V55, P198, DOI 10.1016/S0169-328X(97)00316-1; [No title captured]	45	73	73	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	JUL 13	2001	91	1-2					1	13		10.1016/S0169-328X(01)00099-7			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	455ZA	WOS:000170056600001	11457487				2022-02-06	
J	Boake, C; Millis, SR; High, WM; Delmonico, RL; Kreutzer, JS; Rosenthal, M; Sherer, M; Ivanhoe, CB				Boake, C; Millis, SR; High, WM; Delmonico, RL; Kreutzer, JS; Rosenthal, M; Sherer, M; Ivanhoe, CB			Using early neuropsychologic testing to predict long-term productivity outcome from traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; craniocerebral trauma; neuropsychologic tests; prognosis; rehabilitation	COMA-DATA-BANK; HEAD-INJURY; AMNESIA; RETURN; WORK	Objective: To evaluate whether early neuropsychologic testing is useful in predicting long-term productivity outcome after traumatic brain injury (TBI). Design: Validation cohort prediction study. Setting: Four inpatient brain injury rehabilitation programs participating in the Traumatic Brain Injury Model Systems project. Participants: A total or 293 adults with nonpenetrating TBI. Main Outcome Measures: Fifteen neuropsychologic tests were administered to patients who emerged from posttraumatic amnesia before rehabilitation discharge. Test scores were classified in the normal range or impaired range, using objective criteria. Outcome was defined as productive if the patient was competitively employed or enrolled full time in regular education. Results: Productivity at follow-up was predicted by completion of at least 1 neuropsychologic test before discharge, by an injury-test interval of less than 2 months, and by normal range scores on 10 of the 15 neuropsychologic tests, Normal range scores on these tests increased the probability of a productive outcome by 40% to 130%. Conclusions: Neuropsychologic testing can help predict long-term productivity even when performed before discharge from inpatient rehabilitation and at variable injury-test intervals. Early testing should be interpreted in relation to injury-test interval. Because tests of multiple neuropsychologic domains predicted outcome, comprehensive evaluations might be more useful in predicting outcome. (C) 2001 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	TIRR, Houston, TX 77030 USA; Univ Texas, Dept Phys Med, Baylor Coll Med, Sch Med, Houston, TX USA; Univ Texas, Dept Rehabil Alliance, Baylor Coll Med, Sch Med, Houston, TX USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; Kaiser Fdn, Rehabil Ctr, Vallejo, CA USA; Univ Calif Davis, Sch Med, Davis, CA 95616 USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Mississippi Methodist Rehabil Ctr, Jackson, MS USA		Boake, C (corresponding author), TIRR, 1333 Moursund, Houston, TX 77030 USA.						Benton A., 1976, MULTILINGUAL APHASIA; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Caplan B, 1996, J HEAD TRAUMA REHAB, V11, P1; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CRIPE LI, 1989, REHABIL PSYCHOL, V34, P93; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; HEATON RK, 1993, PSYCHOLOGICAL ASSESS; Heaton RK, 1991, COMPREHENSIVE NORMS; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Kraus J. F., 1999, REHABILITATION ADULT, P3; KREUTZER JS, 1993, J HEAD TRAUMA REHAB, V8, P47; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Millis S R, 1994, Int J Neurosci, V79, P165; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; Reitan R, 1985, HALSTEAD REITAN NEUR; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Smith, 1973, SYMBOL DIGIT MODALIT; Spreen O, 1991, COMPENDIUM NEUROPSYC; Stuss D. T., 1992, J HEAD TRAUMA REHAB, V7, P40; *TRAUM BRAIN INJ M, 1998, TRAUM BRAIN INJ MOD; Walsh K., 1987, NEUROPSYCHOLOGY CLIN; Wechsler D, 1987, MEMORY SCALE REVISED; WECHSLER D, 1981, WEEHSLER ADULT INTEL; 1999, J HEAD TRAUMA REHABI, V14, P189	30	73	74	0	14	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2001	82	6					761	768		10.1053/apmr.2001.23753			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	439KK	WOS:000169115900008	11387580				2022-02-06	
J	Lewen, A; Sugawara, T; Gasche, Y; Fujimura, M; Chan, PH				Lewen, A; Sugawara, T; Gasche, Y; Fujimura, M; Chan, PH			Oxidative cellular damage and the reduction of APE/Ref-1 expression after experimental traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						traumatic brain injury; mice; cellular injury; oxidative stress; DNA repair; DNA oxidation; DNA fragmentation; outcome	FOCAL CEREBRAL-ISCHEMIA; SUPEROXIDE-DISMUTASE PREVENTS; HYDROXYL RADICAL GENERATION; DNA STRAND SCISSION; APURINIC/APYRIMIDINIC ENDONUCLEASE; EARLY DECREASE; EDEMA FORMATION; RAT-BRAIN; REPAIR; FRAGMENTATION	The DNA repair enzyme, apurinic/apyrimidinic endonuclease (or redox effector factor-1, APE/Ref-1), is involved in base excision repair of apurinic/apyrimidinic sites after oxidative DNA damage. We investigated the expression of APE/Ref-1 and its relationship to oxidative stress after severe traumatic brain injury produced by controlled cortical impact in normal mice, and in mice over- or underexpressing copper-zinc superoxide dismutase (SOD1TG and SOD1KO, respectively). Oxygen free radical-mediated cellular injury was visualized with 8-hydroxyguanine immunoreactivity as a marker for DNA oxidation, and in situ hydroethidine oxidation as a marker for superoxide production. After trauma there was a reduced expression of APE/Ref-1 in the ipsilateral cortex and hippocampus that correlated with the gene dosage levels of cytosolic superoxide dismutase. The decrease in APE/Ref-1 expression preceded DNA fragmentation. There was also a close correlation between APE/Ref-1 protein levels 4 h after trauma and the volume of the lesion 1 week after injury. Our data have demonstrated that reduction of APE/Ref-1 protein levels correlates closely with the level of oxidative stress after traumatic brain injury. We suggest that APE/Ref-1 immunoreactivity is a sensitive marker for oxidative cellular injury. (C) 2001 Academic Press.	Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Neurosci Program, Stanford, CA 94305 USA		Lewen, A (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA.		Lewen, Anders/A-5156-2013	Lewen, Anders/0000-0003-4925-1348	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038653, P01NS014543, N01NS082386, P50NS014543, R01NS036147, R01NS025372] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 82386, NS 14543, NS 25372, NS 38653, NS 36147] Funding Source: Medline		ALTHAUS JS, 1993, MOL CHEM NEUROPATHOL, V20, P147, DOI 10.1007/BF02815368; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BRAWN K, 1981, ARCH BIOCHEM BIOPHYS, V206, P414, DOI 10.1016/0003-9861(81)90108-9; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Carey DC, 1999, BIOCHEMISTRY-US, V38, P16553, DOI 10.1021/bi9907429; Chen J, 1997, J NEUROCHEM, V69, P232; Chopp M, 1996, STROKE, V27, P363, DOI 10.1161/01.STR.27.3.363; Cui JK, 2000, FASEB J, V14, P955; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOETSCH PW, 1986, BIOCHEMISTRY-US, V25, P2212, DOI 10.1021/bi00356a054; Edwards M, 1998, NEUROREPORT, V9, P4015, DOI 10.1097/00001756-199812210-00005; EPSTEIN CJ, 1987, P NATL ACAD SCI USA, V84, P8044, DOI 10.1073/pnas.84.22.8044; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fabian RH, 1998, J NEUROTRAUM, V15, P433, DOI 10.1089/neu.1998.15.433; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; Fujimura M, 1999, STROKE, V30, P2408, DOI 10.1161/01.STR.30.11.2408; Fujimura M, 2000, J NEUROSCI, V20, P2817; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HAMANA K, 1985, BIOCHEM INT, V10, P301; Hayashi T, 1999, BRAIN RES, V832, P159, DOI 10.1016/S0006-8993(99)01409-2; Huang DY, 2000, FASEB J, V14, P407, DOI 10.1096/fasebj.14.2.407; Kawamata T, 1997, ACT NEUR S, V70, P191; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P119, DOI 10.1097/00004647-200001000-00016; Kondo T, 1997, J NEUROSCI, V17, P4180; Lan J, 2000, J NEUROCHEM, V74, P302, DOI 10.1046/j.1471-4159.2000.0740302.x; Laval J, 1998, MUTAT RES-FUND MOL M, V402, P93, DOI 10.1016/S0027-5107(97)00286-8; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lin LH, 2000, J NEUROCHEM, V74, P1098; Maeda M, 1998, NEUROSCI LETT, V240, P69, DOI 10.1016/S0304-3940(97)00901-4; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Morita-Fujimura Y, 1999, NEUROSCIENCE, V93, P1465, DOI 10.1016/S0306-4522(99)00231-6; Murakami K, 1998, J NEUROSCI, V18, P205; Nakamura J, 2000, J BIOL CHEM, V275, P5323, DOI 10.1074/jbc.275.8.5323; Namura S, 1998, J NEUROSCI, V18, P3659; Nunomura A, 1999, J NEUROSCI, V19, P1959; PARK EM, 1992, P NATL ACAD SCI USA, V89, P3375, DOI 10.1073/pnas.89.8.3375; Povlishock J T, 1992, Hum Cell, V5, P345; Povlishock J.T., 1994, NEUROBIOLOGY CENTRAL, P109; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; SATCHELL M, 1999, SOC NEUR ABSTR, V29; SEN S, 1993, FREE RADICAL RES COM, V19, P255, DOI 10.3109/10715769309056513; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5	50	73	79	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	JUN	2001	8	3					380	390		10.1006/nbdi.2001.0396			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	445LM	WOS:000169459000002	11447995				2022-02-06	
J	Fineman, I; Giza, CC; Nahed, BV; Lee, SM; Hovda, DA				Fineman, I; Giza, CC; Nahed, BV; Lee, SM; Hovda, DA			Inhibition of neocortical plasticity during development by a moderate concussive brain injury	JOURNAL OF NEUROTRAUMA			English	Article						concussive brain injury; cortex; development; enriched environment; Morris water maze; plasticity	PEDIATRIC HEAD-INJURY; ENVIRONMENTAL ENRICHMENT; DEVELOPING RAT; AMINO-ACIDS; CORTEX; MEMORY; ADULT; EXPERIENCE; ASPARTATE; RECEPTORS	To determine if a moderate traumatic brain injury (TBI) sustained early in life alters the capacity for developmental plasticity, 17-20-day-old rat pups received a lateral fluid percussion and then reared in an enriched environment for 17 days. Compared to sham-injured controls, this moderate TBI prevented the increase in cortical thickness (1.48 vs. 1.68 mm, p < 0.01) as well as the corresponding enhancement in cognitive performance in the Morris Water Maze (39 vs. 25 trials to criterion, p < 0.05), These injured animals exhibited no significant neuronal degeneration and no evidence of neurologic or motor deficits, These findings strongly support the conclusion that a diffuse brain injury is capable of inhibiting both anatomical and cognitive manifestations of experience-dependent developmental plasticity.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA		Fineman, I (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Brain Injury Res Ctr, 18-228 NPI,Box 957039, Los Angeles, CA 90095 USA.		Nahed, Brian/E-4239-2014	Nahed, Brian/0000-0001-8537-106X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308, NS37363, NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308, R01NS037363] Funding Source: NIH RePORTER		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BENNETT EL, 1964, SCIENCE, V146, P610, DOI 10.1126/science.146.3644.610; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DIAMOND MC, 1972, J NEUROBIOL, V3, P47, DOI 10.1002/neu.480030105; DIAMOND MC, 1964, J COMP NEUROL, V123, P111, DOI 10.1002/cne.901230110; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GORMAN LK, 1995, J NEUROTRAUM, V12, P120; GREENOUGH WT, 1973, EXP NEUROL, V40, P491, DOI 10.1016/0014-4886(73)90090-3; GREENOUGH WT, 1972, PSYCHON SCI, V27, P279; GREENSPAN AI, 1994, PEDIATRICS, V94, P425; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEBB DO, 1976, J ABNORM CHILD PSYCH, V4, P309, DOI 10.1007/BF00922529; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; JURASKA JM, 1984, DEV PSYCHOBIOL, V17, P209, DOI 10.1002/dev.420170302; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KOLB B, 1987, BEHAV BRAIN RES, V26, P119, DOI 10.1016/0166-4328(87)90161-6; KRAUS JF, 1987, PEDIATRICS, V79, P501; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MOSS ML, 1972, ACTA ANAT, V81, P161; NAHED BV, 1998, J NEUROTRAUM, V15, P887; NIETOSAMPEDRO M, 1985, SYNAPTIC PLASTICITY, P407; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rosenzweig MR, 1996, ANNU REV PSYCHOL, V47, P1, DOI 10.1146/annurev.psych.47.1.1; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SIREVAAG AM, 1988, BRAIN RES, V441, P386, DOI 10.1016/0006-8993(88)91420-5; TEES RC, 1990, DEV PSYCHOBIOL, V23, P427, DOI 10.1002/dev.420230505; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; VENABLE N, 1988, BEHAV BRAIN RES, V31, P89, DOI 10.1016/0166-4328(88)90162-3; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	38	73	73	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2000	17	9					739	749		10.1089/neu.2000.17.739			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	356LM	WOS:000089444800002	11011814				2022-02-06	
J	Daviss, WB; Racusin, R; Fleischer, A; Mooney, D; Ford, JD; McHugo, GJ				Daviss, WB; Racusin, R; Fleischer, A; Mooney, D; Ford, JD; McHugo, GJ			Acute stress disorder symptomatology during hospitalization for pediatric injury	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						acute stress disorder; injury	TRAUMATIC BRAIN INJURY; CHILDREN; SYMPTOMS; VICTIMIZATION; CONSEQUENCES; SEQUELAE; ATTACK	Objective: To examine and identity predictors of acute stress disorder (ASD) and ASD symptomatology (ASDS) in children hospitalized for injuries. Method: Fifty-four youths were assessed while hospitalized for injuries. Dependent variables were parent and nurse ratings of children's ASDS. Independent variables included children's prior trauma exposure and behavior problems, injury severity and permanence, brain injury, injury or death to family/friend(s), parental distress, and child reports of the injury/hospitalization experience as meeting criterion A for ASD. Results: A total of 92.6% of children felt the current experience met criterion A, compared with 64.8% of parents. According to parent questionnaires, 4 subjects (7.4%) met DSM-IV criteria for ASD while another 12 (22.2%) had clinically significant but subsyndromal ASDS. Children's ASDS, as reported by parents, correlated highly with parental distress and ratings of children's prior psychopathology, and modestly with injury severity and family/friend(s) injured or killed. Nurses' ratings of children's ASDS correlated strictly with injury- and accident-related variables, and not with parent ratings of children's ASDS. Conclusions: Children perceive injuries and hospitalizations as stressful. ASDS is widely though divergently reported by parents and nurses in children hospitalized for injury. Parental distress, children's prior psychopathology, and injury-related factors may be useful predictors of children's postinjury ASDS.	Dartmouth Med Sch, Psychiat Res Ctr, Lebanon, NH USA; Natl Ctr PTSD, White River Junction, VT USA		Daviss, WB (corresponding author), Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.						ACHENBACH TM, 1991, PROGRAM MANUAL 1991; Achenbach TM, 1991, MANUAL CHILD BEHAV C; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BoneyMcCoy S, 1996, J CONSULT CLIN PSYCH, V64, P1406, DOI 10.1037/0022-006X.64.6.1406; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037/0022-006X.63.5.726; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P610, DOI 10.1097/00004583-199705000-00011; Classen C, 1998, AM J PSYCHIAT, V155, P620, DOI 10.1176/ajp.155.5.620; Daviss WB, 2000, J AM ACAD CHILD PSY, V39, P576, DOI 10.1097/00004583-200005000-00011; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; EARLS F, 1988, J AM ACAD CHILD PSY, V27, P90, DOI 10.1097/00004583-198801000-00014; ENGEL NA, 1994, PSYCHOL REP, V75, P1251, DOI 10.2466/pr0.1994.75.3.1251; Ford JD, 1997, P INT SOC TRAUM STRE; Foy DW, 1996, J SCHOOL PSYCHOL, V34, P133, DOI 10.1016/0022-4405(96)00003-9; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; KOOPMAN C, 1994, AM J PSYCHIAT, V151, P888; MARTINI DR, 1990, J AM ACAD CHILD PSY, V29, P70, DOI 10.1097/00004583-199001000-00012; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; MCKELVEY RS, 1999, SCI P 46 ANN M AM AC; NADER K, 1990, AM J PSYCHIAT, V147, P1526; Peterson L G, 1986, Adv Psychosom Med, V16, P84; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; Rossman BBR, 1997, J AM ACAD CHILD PSY, V36, P1089; SANCHEZ R, 1998, SCI P 45 ANN M AM AC; SAXE G, 1997, P INT SOC TRAUM STRE; *SPSS, 1994, SPSS 6 1 BAS SYST 1; Suhr M A, 1986, Adv Psychosom Med, V16, P31	29	73	74	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	MAY	2000	39	5					569	575		10.1097/00004583-200005000-00010			7	Psychology, Developmental; Pediatrics; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics; Psychiatry	308DC	WOS:000086694400010	10802974				2022-02-06	
J	Lewis, DW; Qureshi, F				Lewis, DW; Qureshi, F			Acute headache in children and adolescents presenting to the emergency department	HEADACHE			English	Article						acute headache; children; adolescents; occipital		Objectives.-Our goals were (1) to investigate the causes of acute headache in childhood from the emergency department perspective and (2) to search for clinical clues that might distinguish headache associated with serious underlying disease. Background.-The clinical presentation of headache in children and adolescents can be separated into 5 temporal patterns: acute, acute-recurrent, chronic progressive, chronic nonprogressive, and mixed. Few data exist regarding acute headache in children. Methods.-Consecutive children who presented to our emergency department with the abrupt onset of severe headache were prospectively evaluated. The headache character, location, severity, and associated symptoms, as well as underlying causes, were recorded using a standardized survey. Results.-One hundred fifty children, aged from 2 to 18 years, 87 boys and 63 girls, were enrolled over a 10-month period. Upper respiratory tract infection with fever (viral upper respiratory tract infection 39%, sinusitis 9%, streptococcal pharyngitis 9%) was the most frequently identified cause of acute headache (57%). Other causes included migraine (18%), viral meningitis (9%), posterior fossa tumors (2.6%), ventriculoperitoneal shunt malfunction (2%), epileptic seizure (postictal headache) (1.3%), concussion (postconcussive headache) (1.3%), intracranial hemorrhage (1.3%), and undetermined (7%). Two clinical features were found to have statistically significant associations with serious underlying disease: occipital location of headache anti an inability of the patient to describe the quality of the head pain. All children with surgically remediable conditions had clear and objective neurological signs. Conclusions.-In children and adolescents, the abrupt onset of severe headache is most frequently caused by upper respiratory tract infection with fever, sinusitis, or migraine. Special attention is warranted if the acute headache is occipital in location and if the affected patient is unable to describe the quality of the pain. Serious underlying processes such as brain tumor or intracranial hemorrhage are uncommon and, when present, are accompanied by multiple neurological signs (ataxia, hemiparesis, papilledema).	Childrens Hosp Kings Daughters, Eastern Virginia Med Sch, Dept Pediat, Norfolk, VA USA		Lewis, DW (corresponding author), Child & Adolescent Neurol, 850 Southampton Ave, Norfolk, VA 23510 USA.						Burton LJ, 1997, PEDIATR EMERG CARE, V13, P1, DOI 10.1097/00006565-199702000-00001; GILLES FH, 1991, J NEURO-ONCOL, V10, P31; KANDT RS, 1987, J CHILD NEUROL, V2, P22, DOI 10.1177/088307388700200104; ROTHNER AD, 1986, CONSULTANT, V26, P113	4	73	75	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	MAR	2000	40	3					200	203		10.1046/j.1526-4610.2000.00029.x			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	296BB	WOS:000086002200003	10759922				2022-02-06	
J	Herskovits, EH; Megalooikonomou, V; Davatzikos, C; Chen, A; Bryan, RN; Gerring, JP				Herskovits, EH; Megalooikonomou, V; Davatzikos, C; Chen, A; Bryan, RN; Gerring, JP			Is the spatial distribution of brain lesions associated with closed-head injury predictive of subsequent development of attention-deficit/hyperactivity disorder? Analysis with brain-image database?	RADIOLOGY			English	Article						attention-deficit/hyperactivity disorder; brain, injuries; brain, MR; children, central nervous system; images, analysis; images, display	BEHAVIOR; SCALE; ADHD	PURPOSE: To determine whether there is an association between the spatial distribution of lesions detected at magnetic resonance (MR) imaging of the brain in children after closed-head injury and the development of secondary attention-deficit/hyperactivity disorder (ADHD). MATERIALS AND METHODS: Data obtained from 76 children without prior history of ADHD were analyzed. MR images were obtained 3 months after closed-head injury. After manual delineation of lesions, images were registered to the Talairach coordinate system. For each subject, registered images and secondary ADHD status were integrated into a brain-image database, which contains depiction (visualization) and statistical analysis software. Using this database, we assessed visually the spatial distributions of lesions and performed statistical analysis of image and clinical variables. RESULTS: Of the 76 children, 15 developed secondary ADHD. Depiction of the data suggested that children who developed secondary ADHD had more lesions in the right putamen than children who did not develop secondary ADHD; this impression was confirmed statistically. After Bonferroni correction, we could not demonstrate significant differences between secondary ADHD status and lesion burdens for the right caudate nucleus or the right globus pallidus. CONCLUSION: Closed-head injury-induced lesions in the right putamen in children are associated with subsequent development of secondary ADHD. Depiction software is useful in guiding statistical analysis of image data.	Johns Hopkins Med Inst, Div Neuroradiol, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Sch Publ Hlth, Dept Biostat, Baltimore, MD 21287 USA; Johns Hopkins Med Inst, Bayview Med Ctr, Dept Psychiat, Baltimore, MD 21287 USA; NIH, Dept Diagnost Radiol, Bethesda, MD 20892 USA		Herskovits, EH (corresponding author), Johns Hopkins Med Inst, Div Neuroradiol, 600 N Wolfe St, Baltimore, MD 21287 USA.		Bryan, R. Nick/P-1661-2014; Davatzikos, Christos/ABE-2057-2021	Davatzikos, Christos/0000-0002-1025-8561	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG13743-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG013743] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; Andres AM, 1997, BIOMETRICAL J, V39, P935; Brodmann K ., 1909, VERGLEICHENDE LOKALI; Castellanos FX, 1997, CHILD ADOL PSYCH CL, V6, P383, DOI 10.1016/S1056-4993(18)30310-9; CHAMBERLIN DD, 1976, IBM J RES DEV, V20, P560, DOI 10.1147/rd.206.0560; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Davatzikos C, 1997, COMPUT VIS IMAGE UND, V66, P207, DOI 10.1006/cviu.1997.0605; Fisher LD., 1993, BIOSTATISTICS METHOD; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Letovsky SI, 1998, AM J NEURORADIOL, V19, P1869; Nowinski WL., 1997, ELECT CLIN BRAIN ATL; RICHTERS JE, 1995, J AM ACAD CHILD PSY, V34, P987, DOI 10.1097/00004583-199508000-00008; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; WILSON J T L, 1990, Brain Injury, V4, P349	19	73	74	0	4	RADIOLOGICAL SOC NORTH AMER	EASTON	20TH AND NORTHAMPTON STS, EASTON, PA 18042 USA	0033-8419			RADIOLOGY	Radiology	NOV	1999	213	2					389	394		10.1148/radiology.213.2.r99nv45389			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Radiology, Nuclear Medicine & Medical Imaging	249AE	WOS:000083308900013	10551217				2022-02-06	
J	Eachempati, SR; Vaslef, SN; Sebastian, MW; Reed, RL				Eachempati, SR; Vaslef, SN; Sebastian, MW; Reed, RL			Blunt vascular injuries of the head and neck: Is heparinization necessary?	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							CAROTID-ARTERY DISSECTION; EARLY DIAGNOSIS; TRAUMA; ARTERIOGRAPHY; ANGIOGRAPHY; THERAPY	Background: Blunt vascular injuries to the head and neck (BHVI) represent some of the most devastating and morbid injuries seen by a trauma surgeon. This series reviewed the experience of a single institution to determine if diagnostic and therapeutic guidelines can be established for these uncommon injuries. In particular, the utility of anticoagulation in the treatment of these injuries is examined. Methods: The institutional trauma registry of a single state-designated Level I trauma center was examined for patients with BHVI, Patients were identified and their charts reviewed individually with regard to multiple data points including the type of injury, its presentation, the treatment of the injury, and the functional outcome of the patient. Results: Twenty-nine BHVI in 23 patients were reviewed from 1989 to 1997, No mortalities were noted. Among the injuries noted were 14 internal carotid artery dissections and 8 carotid artery tears. Thirteen patients had accompanying closed head injuries. Ten patients were diagnosed after an abnormal neurologic examination, and eight others were diagnosed after having carotid canal fractures. Heparin was started within 48 hours of injury in 4 patients (17%) and was used in a total of 12 patients (52%), No patient worsened neurologically after diagnosis independent of the use of heparin, Thirteen patients (57%) had no or minimal deficits upon discharge. Conclusion: BHVI represent a serious cause of morbidity in the patient with multiple injuries. Patients with closed head injuries and carotid canal fractures appear most at risk, A multicenter, randomized trial involving antiplatelet therapy, full systemic anticoagulation, or observation with a long-term functional assessment is indicated to determine the optimal management of these injuries.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Cornell Univ, Med Ctr, Dept Surg, New York, NY 10021 USA; Loyola Univ, Med Ctr, Dept Surg, Chicago, IL 60611 USA		Eachempati, SR (corresponding author), New York Hosp, Dept Surg, 525 E 68th St, New York, NY 10021 USA.	seachempati@cornell.surgery.med.edu	Reed, Robert/AAJ-2575-2020				Bilbao R, 1997, AM J OPHTHALMOL, V123, P562, DOI 10.1016/S0002-9394(14)70191-6; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; Carter DA, 1998, J TRAUMA, V44, P230, DOI 10.1097/00005373-199801000-00039; COGBILL TH, 1994, J TRAUMA, V37, P473, DOI 10.1097/00005373-199409000-00024; Colella JJ, 1996, AM SURGEON, V62, P212; DAlise MD, 1996, J TRAUMA, V40, P452, DOI 10.1097/00005373-199603000-00023; DAVIS JW, 1990, J TRAUMA, V30, P1514, DOI 10.1097/00005373-199012000-00013; DUKE BJ, 1997, 57 ANN M AM ASS SURG; Englund R, 1988, Ann Vasc Surg, V2, P362, DOI 10.1016/S0890-5096(06)60817-0; Fabian TC, 1996, ANN SURG, V223, P513, DOI 10.1097/00000658-199605000-00007; FAKHRY SM, 1988, J VASC SURG, V8, P501; FRY WR, 1994, AM J SURG, V168, P693, DOI 10.1016/S0002-9610(05)80147-3; GaskillShipley MF, 1996, NEUROIMAG CLIN N AM, V6, P607; GOUAZE A, 1969, NEURO-CHIR, V15, P234; Laitt RD, 1996, CLIN RADIOL, V51, P117, DOI 10.1016/S0009-9260(96)80268-6; LANNUZEL A, 1994, NEUROPEDIATRICS, V25, P106, DOI 10.1055/s-2008-1071595; LEE KP, 1995, NEUROLOGY, V45, P1213, DOI 10.1212/WNL.45.6.1213; Lewis AI, 1996, J NEUROSURG, V84, P400, DOI 10.3171/jns.1996.84.3.0400; PALMER SH, 1995, INJURY, V26, P555, DOI 10.1016/0020-1383(95)00114-O; PANETTA TF, 1992, J TRAUMA, V33, P627, DOI 10.1097/00005373-199210000-00019; Parikh AA, 1997, J AM COLL SURGEONS, V185, P80, DOI 10.1016/S1072-7515(97)00002-1; PERRY MO, 1980, ANN SURG, V192, P74, DOI 10.1097/00000658-198007000-00013; PRETRE R, 1995, J TRAUMA, V39, P1012, DOI 10.1097/00005373-199511000-00036; PRETRE R, 1994, SURGERY, V115, P375; RICHARDSON JD, 1988, SURGERY, V104, P673; ROGERS FB, 1998, 28 ANN M W TRAUM ASS; ROMNER B, 1994, ACTA NEUROCHIR, V126, P815; Urwin RW, 1996, NEUROIMAG CLIN N AM, V6, P957; WELLING RE, 1987, J TRAUMA, V27, P1221; YAMADA S, 1967, J TRAUM, V7, P333, DOI 10.1097/00005373-196705000-00001	30	73	74	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1998	45	6					997	1004		10.1097/00005373-199812000-00004			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	151DF	WOS:000077704900004	9867039				2022-02-06	
J	Trudel, TM; Tryon, WW; Purdum, CM				Trudel, TM; Tryon, WW; Purdum, CM			Awareness of disability and long-term outcome after traumatic brain injury	REHABILITATION PSYCHOLOGY			English	Article							BLUNT HEAD-INJURY; FOLLOW-UP; SOCIAL-ADJUSTMENT; RELATIVES VIEW; REHABILITATION; PERSONALITY; IMPAIRMENT; DEFICITS; RECOVERY; ADULTS	The degree of long-term (7.41 years postinjury) impairment of disability awareness was quantified in 63 adults with closed-head injuries as the difference between self-ratings and staff ratings on the Scales of Independent Behavior. Impaired awareness was significantly associated with lower vocational and residential status, maladaptive behavior, greater distractibility, and increased perseveration. Impaired awareness is directly proportional to duration of posttraumatic amnesia and general memory. Impaired awareness of disability appears to be a consequence of a general cognitive impairment rather than a specific deficit.	Lakeview NeuroRehabil Ctr, Effingham Falls, NH 03814 USA		Trudel, TM (corresponding author), Lakeview NeuroRehabil Ctr, 101 Highwatch Rd, Effingham Falls, NH 03814 USA.						ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Benson D.F., 1986, FRONTAL LOBES; Bisiach E., 1991, AWARENESS DEFICIT BR, P17; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P124; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BRUININKS R, 1988, AM J MENT RETARD, V93, P265; Bruininks R. H., 1984, SCALES INDEPENDENT B; CAVALLO MM, 1993, BRAIN INJURY, V6, P327; Chittum WR, 1996, BRAIN INJURY, V10, P763; DREWE E A, 1974, Cortex, V10, P159; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Farmer J E, 1988, Brain Inj, V2, P323, DOI 10.3109/02699058809150903; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; FRALISH KB, 1992, INNOVATIONS HEAD INJ, P100; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K.M., 1991, AWARENESS DEFICIT BR, P53; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hill B., 1985, DEV STANDARDIZATION; Hillier SL, 1997, BRAIN INJURY, V11, P525, DOI 10.1080/713802189; KREUZER JS, 1990, VOCATIONAL REHABILIT, P35; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEZAK M, 1995, NEUROLOGICAL ASSESSM; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Mesulam M., 1985, PRINCIPLES BEHAV NEU; MIDDLETON HA, 1990, AM J MENT RETARD, V94, P669; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PARKER K, 1983, J CONSULT CLIN PSYCH, V51, P302, DOI 10.1037/0022-006X.51.2.302; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1987, NEUROPSYCHOL REHABIL, P355; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sattler J. M., 1988, ASSESSMENT CHILDREN; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Stuss D., 1991, AWARENESS DEFICIT BR, P63; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wechsler D, 1987, MANUAL WECHSLER MEMO; Wechsler D, 1981, WECHSLER ADULT INTEL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WEHMAN P, 1990, VOCATIONAL REHABILIT; Willer B, 1994, BRAIN INJURY REHABIL, P355; [No title captured], DOI DOI 10.1097/00001199-198812000-00004	63	73	73	0	7	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	WIN	1998	43	4					267	281		10.1037/0090-5550.43.4.267			15	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	158FL	WOS:000078105300001					2022-02-06	
J	Zafonte, RD; Watanabe, T; Mann, NR				Zafonte, RD; Watanabe, T; Mann, NR			Amantadine: a potential treatment for the minimally conscious state	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURY; ATTENTION; AROUSAL	Pharmacologic strategies have been advocated to enhance the: neurorehabilitation of persons with severe traumatic brain injury. Dopaminergic pathways have been felt to play a significant role in arousal. Employing single case design methodology we present the case of a survivor of severe traumatic brain injury who appeared to have a dose dependent response to the pro-dopaminergic medication amantadine. Further research is necessary to clarify the role of pharmacotherapy in the improvement of functional outcome.	Wayne State Univ, Rehabil Inst Michigan, Detroit, MI USA		Zafonte, RD (corresponding author), 261 Mack Blvd, Detroit, MI 48201 USA.						HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KELLEY J, 1996, P ASP NEUR I; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; NICKELS J, 1994, BRAIN INJURY, V8, P809; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WHYTE J, 1992, ARCH PHYS MED REHAB, V73, P940	10	73	79	1	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1998	12	7					617	621					5	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	ZX249	WOS:000074495200008	9653525				2022-02-06	
J	Busch, CR; Alpern, HP				Busch, CR; Alpern, HP			Depression after mild traumatic brain injury: A review of current research	NEUROPSYCHOLOGY REVIEW			English	Article						mild traumatic brain injury; depression; postconcussion syndrome; head injury	CLOSED-HEAD-INJURY; POSTCONCUSSION SYMPTOMS; PSYCHIATRIC-DISORDERS; CEREBRAL CONCUSSION; SEQUELAE; ANTIDEPRESSANTS; DEMOGRAPHICS; PERFORMANCE; MANAGEMENT; DISABILITY	Research pertaining to the occurrence of depression and/or depression symptomatology after a Mild Traumatic Brain Injury (MTBI) was reviewed. We found that methodological differences such as the criteria used to assess MTBI and depression, time that elapsed since brain injury, and control group variations confounded comparisons across studies. Nevertheless, the studies are consistent with at least a 35% prevalence of, and left frontal damage with depression after MTBI, an overlap of symptoms of depression and Postconcussion Syndrome (PCS), and indicate that depression can continue for many years following the injury. Our conclusion is that MTBI is the triggering event for a set of pathophysiological changes and a concomitant depressive episode in a vulnerable subset of the population. Due to a paucity of research, it cannot be definitively concluded that the underlying substrates of depression seen after MTBI and clinical depression are the same. Implications for future investigations are discussed.	Univ Colorado, Dept Psychol, Behav Neurosci Program, Boulder, CO 80309 USA		Alpern, HP (corresponding author), Univ Colorado, Dept Psychol, Behav Neurosci Program, Campus Box 345, Boulder, CO 80309 USA.						ALEXANDER MP, 1992, J HED TRAUMA REHABIL, V1, P50; ALOIA MS, 1995, BRAIN INJURY, V9, P575, DOI 10.3109/02699059509008216; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; BARNAT MR, 1986, HEADACHE, V26, P271, DOI 10.1111/j.1526-4610.1986.hed2606271.x; BERROL S, 1992, PHYSICAL MED REHABIL, V6, P1; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1989, ASSESSMENT BEHAV CON, P37; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; BOND M, 1984, CLOSED HEAD INJURY P, P44; BUSCH CR, 1995, UNPUB BASAL SALIVARY; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; COYNE JC, 1994, PSYCHOL BULL, V116, P29, DOI 10.1037/0033-2909.116.1.29; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; DOWNHILL JE, 1994, J NERV MENT DIS, V182, P425, DOI 10.1097/00005053-199408000-00001; ETTLIN TM, 1992, J NEUROL NEUROSUR PS, V55, P943, DOI 10.1136/jnnp.55.10.943; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GASPARRINI WG, 1978, J NEUROL NEUROSUR PS, V41, P470, DOI 10.1136/jnnp.41.5.470; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1985, GC SNIV MEM LECT WAS; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; GLAZER HI, 1981, DEPRESSION BEHAV DIR; Gotlib I.H., 1992, PSYCHOL ASPECTS DEPR; GOTLIB IH, 1984, J PERS SOC PSYCHOL, V47, P427, DOI 10.1037/0022-3514.47.2.427; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HAMM RJ, 1995, EXP NEUROL, V136, P143, DOI 10.1006/exnr.1995.1091; HARRINGTON KT, 1993, J HEAD TRAUMA REHAB, V8, P86; HELLER W, 1993, J AFFECT DISORDERS, V29, P129, DOI 10.1016/0165-0327(93)90028-I; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1981, MANAGEMENTS HEAD INJ; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Levin Harvey S, 1987, NEUROBEHAVIORAL RECO; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levin HS., 1982, NEUROBEHAVIORAL CONS; LEWINSOHN PM, 1982, J CONSULT CLIN PSYCH, V50, P590, DOI 10.1037/0022-006X.50.4.590; LEZAK MD, 1978, AM J PHYS MED REHAB, V57, P9; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISTER RG, 1985, NEUROSCI BIOBEHAV R, V9, P87, DOI 10.1016/0149-7634(85)90034-X; MACNIVEN E, 1993, BRAIN INJURY, V7, P241, DOI 10.3109/02699059309029676; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCBEATH JG, 1994, HEADACHE, V34, P148, DOI 10.1111/j.1526-4610.1994.hed3403148.x; MERSKEY H, 1996, NEUROLOGY TRAUMA; Mialet JP, 1996, PSYCHOL MED, V26, P1009, DOI 10.1017/S0033291700035339; MILLER L, 1993, PSYCHOTHERAPY BRAIN; Mittenberg W, 1993, PSYCHOTHERAPY PRIVAT, V12, P37, DOI DOI 10.1300/1294V12N02_03; MOBAYED M, 1990, J AFFECT DISORDERS, V19, P237, DOI 10.1016/0165-0327(90)90100-M; NOCKLEBY DM, 1984, J NEUROL NEUROSUR PS, V47, P260; NOLENHOEKSMA S, 1990, SEX DIFFERENCES DEPR; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; POST RM, 1984, NEUROBIOLOGY MOOD DI; POVLSHOCK JT, 1983, J NEUROSURG, V62, P96; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON R G, 1989, Journal of Geriatric Psychiatry, V22, P1; ROBINSON RG, 1986, HOSP PRACT, V21, P83; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SCHOENHUBER R, 1988, J NEUROSURG, V68, P742, DOI 10.3171/jns.1988.68.5.0742; SEKINO H, 1981, Neurologia Medico-Chirurgica, V21, P677; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; STAUSS I, 1934, ARCH NEUROLOGICAL PS, V31, P893; STEIN SC, 1996, NEUROTRAMA; STRICH SJ, 1961, LANCET, V2, P443; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; SYZMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357; TUCKER GJ, 1994, J NEUROPSYCH CLIN N, V6, P58; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; VANWOERKOM TCAM, 1977, LANCET, V1, P812; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; World Health Organization, 1978, MENT DIS GLOSS GUID; [No title captured]	97	73	75	1	11	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013 USA	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	JUN	1998	8	2					95	108		10.1023/A:1025661200911			14	Psychology, Clinical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	ZX490	WOS:000074521400003	9658412				2022-02-06	
J	Kreuter, M; Dahllof, AG; Gudjonsson, G; Sullivan, M; Siosteen, A				Kreuter, M; Dahllof, AG; Gudjonsson, G; Sullivan, M; Siosteen, A			Sexual adjustment and its predictors after traumatic brain injury	BRAIN INJURY			English	Article							GLASGOW OUTCOME SCALE; CLOSED HEAD-INJURY; SOCIAL RECOVERY; ATTITUDES; HEALTH	The aim of this study was to investigate the impact of traumatic brain injury (TBI) on sexual ability, activity and satisfaction and to relate the findings to neurological status, functioning and well-being. A total of 92 TBI persons (65 men, 27 women) participated. Their ages ranged from 20-70 years (median 40 years); the median age at injury was 32 years, ranging from 16-56 years. The elapsed time since injury ranged from 1-20 years (median 9 years). The participants were examined according to a procedure including neurological examination, self-assessment of general health status and functioning and mooed, and collection of data on social conditions. A structured study-specific questionnaire was developed to assess various aspects of sexuality before and after the injury. Fifty-three of the participants had a stable partner relationship at the time of the investigation. This study showed that a TBI commonly alters sexual functioning as well as desire. Many of the respondents reported decreased ability to achieve an erection, decreased ability to experience orgasm, decreased sexual desire and diminished frequency of intercourse. A high degree of physical independence and maintained sexual ability were the most important predictors for sexual adjustment. Considering that many TBI persons in this study reported physiological sexual disturbances and decreased sexual ability, it is important to inform. patients about possibilities of optimizing their sexual ability. Organized programmes of sexuality education should be an integral component of TBI rehabilitation.	Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Rehabil Med, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Hlth Care Res Unit, S-41345 Gothenburg, Sweden		Kreuter, M (corresponding author), Sahlgrens Univ Hosp, Spinal Injuries Unit, Dept 12, S-41345 Gothenburg, Sweden.						AHLMEN EM, 1990, SCAND J RHEUMATOL, V19, P413, DOI 10.3109/03009749009097630; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; BANCROFT J, 1991, ARCH SEX BEHAV, V20, P105, DOI 10.1007/BF01541938; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLACKBURN BK, 1989, STEREOCHEMISTRY ORGA, V3, P143; Bradley J. V., 1968, DISTRIBUTION FREE ST; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Cole TM, 1990, KRUSENS HDB PHYSICAL, P988; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; DIKMEN S, 1983, ARCH NEUROL-CHICAGO, V40, P333, DOI 10.1001/archneur.1983.04050060033004; ELASS L, 1987, PSYCHOL MED, V17, P67; Elliott ML, 1996, BRAIN INJURY, V10, P703, DOI 10.1080/026990596123972; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Granger C. V., 1986, TOP GERIATR REHABIL, V1, P59, DOI DOI 10.1097/00013614-198604000-00007; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAMILTON BB, 1987, ARCH PHYS MED REHAB, V68, P583; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; KEITH RA, 1987, ADV CLIN REHABILITAT, P10; KENNETT B, 1975, LANCET, V1, P480; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P169; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LEVIN HS, 1987, HEAD INJURY; LUNDQVIST C, 1991, SPINE, V16, P78, DOI 10.1097/00007632-199101000-00014; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141, DOI 10.1192/bjp.153.2.141; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Medlar T. M., 1993, SEX DISABIL, V11, P57, DOI DOI 10.1007/BF01102309; MEYER JE, 1971, J NEUROVIS REL S10, P519; Nunnally J.C., 1994, PSYCHOMETRIC THEORY, V3; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRIGATANO GP, 1987, BNI Q, V3, P2; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; SILVERBAGE GC, 1986, THESIS U GOTEBORG GO; SIOSTEEN A, 1990, PARAPLEGIA, V28, P285; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WOLF AL, 1989, EMERGENCY MED SERVIC, V18, P35; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; [No title captured]; [No title captured]	53	73	74	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	1998	12	5					349	368		10.1080/026990598122494			20	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	ZL444	WOS:000073433500001	9591141				2022-02-06	
J	Zhang, C; Raghupathi, R; Saatman, KE; Smith, DH; Stutzmann, JM; Wahl, F; McIntosh, TK				Zhang, C; Raghupathi, R; Saatman, KE; Smith, DH; Stutzmann, JM; Wahl, F; McIntosh, TK			Riluzole attenuates cortical lesion size, but not hippocampal neuronal loss, following traumatic brain injury in the rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						excitotoxicity; fluid-percussion; glutamate antagonist; lesion volume; neuroprotection	FOCAL CEREBRAL-ISCHEMIA; AMINO-ACID NEUROTRANSMISSION; SODIUM-CHANNEL BLOCKER; GLUTAMATE RELEASE; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; POSSIBLE ANTAGONIST; DAMAGE; HYPOTHERMIA; EXCITOTOXICITY; NEUROTOXICITY	The neuroprotective effects of Riluzole, a compound with several mechanisms of action including the inhibition of sodium channel activity and glutamate release, were evaluated in a rat model of parasagittal fluid-percussion (FP) brain injury. Male Sprague-Dawley rats (350-400 g, n = 17) were anesthetized with sodium pentobarbital (60 mg/kg i.p.) and subjected to parasagittal FP brain injury of moderate severity (2.3-2.5 atm), Fifteen min following injury, animals randomly received an i,v, bolus of either Riluzole (8 mg/kg, n = 8) or vehicle (n = 9), followed by subcutaneous injections (identical dose) at 6 hr and 24 hr, Two weeks after injury and drug treatment, animals were sacrificed and a series of brain sections, stained with Hematoxylin and Eosin (H&E) or cresyl violet, were evaluated for quantitative cortical lesion volume and cell counts of hippocampal CA3 neurons, respectively, using a computerized image analysis system. Administration of Riluzole significantly reduced FP-induced tissue loss in the temporal/occipital cortices ipsilateral to the site of impact by 46%, compared to vehicle-treated, brain-injured animals (P = 0.01), In contrast, the selective neuronal loss observed in the CA3 region of the ipsilateral hippocampus was unaffected by Riluzole treatment. The present study demonstrates that Riluzole can attenuate cortical lesion size following brain trauma. These neuroprotective effects may be related to the synergy of the different mechanisms of action of Riluzole. (C) 1998 Wiley-Liss, Inc.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Rhone Poulenc Rorer, Pharmaceut Discovery, Neurodegenerat Dis Dept, Vitry Sur Seine, France		McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Raghupathi, Ramesh/AAX-5538-2021; smith, douglas/A-1321-2007		NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; FADEN AI, 1989, SCIENCE, V244, P789; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM SH, 1994, J PHARMACOL EXP THER, V269, P854; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOVDA DA, 1992, J NEUROTRAUMA, V9, P547; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; Mary V, 1995, NEUROSCI LETT, V201, P92, DOI 10.1016/0304-3940(95)12137-S; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1996, LAB INVEST, V74, P315; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Miller RG, 1996, NEUROLOGY, V47, pS86, DOI 10.1212/WNL.47.4_Suppl_2.86S; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1971, J NEUROPATH EXP NEUR, V30, P75, DOI 10.1097/00005072-197101000-00008; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PELUFFO H, 1997, NEUROSCI LETT, V228, P1; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Smith DH, 1997, NEUROSCI LETT, V231, P135, DOI 10.1016/S0304-3940(97)00551-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; Stutzmann JM, 1996, NEUROREPORT, V7, P387, DOI 10.1097/00001756-199601310-00003; STUTZMANN JM, 1991, EUR J PHARMACOL, V193, P223, DOI 10.1016/0014-2999(91)90040-W; STUTZMANN JM, 1995, NEURODEGENERATIVE DI, P205; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1993, EUR J PHARMACOL, V230, P209, DOI 10.1016/0014-2999(93)90804-Q; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117	65	73	75	0	1	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 1	1998	52	3					342	349		10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	ZM121	WOS:000073506800010	9590442				2022-02-06	
J	Heard, SO; Fink, MP; Gamelli, RL; Solomkin, JS; Joshi, M; Trask, AL; Fabian, TC; Hudson, LD; Gerold, KB; Logan, ED				Heard, SO; Fink, MP; Gamelli, RL; Solomkin, JS; Joshi, M; Trask, AL; Fabian, TC; Hudson, LD; Gerold, KB; Logan, ED		Filgrastim Study Grp	Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage	CRITICAL CARE MEDICINE			English	Article						nosocomial pneumonia; granulocyte colony-stimulating factor; infection; bacteremia; brain injury; cerebral hemorrhage	FACTOR G-CSF; RESPIRATORY-DISTRESS-SYNDROME; BLOOD-STREAM INFECTIONS; ACUTE LUNG INJURY; HEAD-INJURY; VENTILATED PATIENTS; IMMUNE FUNCTION; SECULAR TRENDS; PNEUMONIA; ENDOTOXIN	Objective: To determine whether the use of prophylactic recombinant human granulocyte colony-stimulating factor (filgrastim) reduces the frequency of nosocomial infections in patients with either acute traumatic brain injury or cerebral hemorrhage. Design: Randomized, placebo-controlled, double-blind, multicenter phase II study. Setting: Intensive cave units of seven medical centers. Patients: Patients with either acute traumatic brain injury or cerebral hemorrhage who were intubated within 6 hrs of admission and who were expected to be ventilated for >72 hrs. Interventions: Patients were randomized to receive daily subcutaneous injections of placebo (n = 21) or one of two doses of filgrastim (75 mu g [n = 20] or 300 mu g [n = 20]) for 10 days or until the absolute neutrophil count was >75,000 cells/mm(3) or until extubation. Measurements and Main Results: End points included increase in absolute neutrophil count, safety of filgrastim, and frequency of nosocomial infections (pneumonia, bacteremia, and urinary tract infection). Filgrastim caused a dose-dependent increase in absolute neutrophil count. There were no differences in the frequency of pneumonia or urinary tract infection; however, there was a dose dependent decrease in the frequency of bacteremias (p < .05). Adverse events were similar among the three groups. There was one case of acute respiratory distress syndrome in the placebo group. Conclusion: In this patient population, use of filgrastim was safe and the agent appeared to reduce the risk of primary bacteremias but had no beneficial effects on mortality, length of stay, or other nosocomial infections.	Univ Massachusetts, Med Ctr, Dept Anesthesiol, Worcester, MA 01655 USA; Univ Massachusetts, Med Ctr, Dept Surg, Worcester, MA 01655 USA		Heard, SO (corresponding author), Univ Massachusetts, Med Ctr, Dept Anesthesiol, 55 Lake Ave N, Worcester, MA 01655 USA.			Solomkin, Joseph/0000-0001-6382-4902			*AMG INC, 1995, FILGR INV BROCH; BANERJEE SN, 1991, AM J MED, V91, pS86, DOI 10.1016/0002-9343(91)90349-3; BEGLEY CG, 1986, BLOOD, V68, P162; BONTEN MJM, 1994, CRIT CARE MED, V22, P1683; CHASTRE J, 1995, AM J RESP CRIT CARE, V152, P231, DOI 10.1164/ajrccm.152.1.7599829; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Colton T, 1974, STAT MED; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DEMUYNCK H, 1995, ANN HEMATOL, V70, P143, DOI 10.1007/s002770050047; DIXON WJ, 1990, BMDP STAT SOFTWARE M, V1, P1385; DIXON WJ, 1990, BMDP STAT SOFTWARE M, V2; DONOWITZ LG, 1982, CRIT CARE MED, V10, P355, DOI 10.1097/00003246-198206000-00001; FINK MP, 1990, CHEST, V97, P132, DOI 10.1378/chest.97.1.132; FINK MP, 1993, J TRAUMA, V34, P571, DOI 10.1097/00005373-199304000-00015; Freeman BD, 1996, J APPL PHYSIOL, V80, P2066, DOI 10.1152/jappl.1996.80.6.2066; GLASPY JA, 1988, ANN INTERN MED, V109, P789, DOI 10.7326/0003-4819-109-10-789; GORGEN I, 1992, J IMMUNOL, V149, P918; HEBERT JC, 1990, ARCH SURG-CHICAGO, V125, P1075; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; KANAZAWA M, 1992, AM REV RESPIR DIS, V145, P1030, DOI 10.1164/ajrccm/145.5.1030; KING J, 1995, AM J RESP CRIT CARE, V151, P302, DOI 10.1164/ajrccm.151.2.7531097; KOIZUMI T, 1993, AM REV RESPIR DIS, V148, P132, DOI 10.1164/ajrccm/148.1.132; LEIBOVICI L, 1995, JAMA-J AM MED ASSOC, V274, P807, DOI 10.1001/jama.274.10.807; LUNDBLAD R, 1995, SHOCK, V4, P68, DOI 10.1097/00024382-199507000-00011; MACGREGOR RR, 1972, ARCH INTERN MED, V130, P84, DOI 10.1001/archinte.130.1.84; MARQUETTE CH, 1995, AM J RESP CRIT CARE, V151, P1878, DOI 10.1164/ajrccm.151.6.7767535; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; MOONEY DP, 1988, ARCH SURG-CHICAGO, V123, P1353; OREILLY M, 1992, J TRAUMA, V33, P679, DOI 10.1097/00005373-199211000-00014; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; PITTET D, 1995, ARCH INTERN MED, V155, P1177, DOI 10.1001/archinte.155.11.1177; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; SCARFFE JH, 1990, CANCER SURV, V9, P115; SCHILERO GJ, 1995, CHEST, V107, P276, DOI 10.1378/chest.107.1.276; SILVER GM, 1989, SURGERY, V106, P452; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; STARK RP, 1984, NEW ENGL J MED, V311, P560, DOI 10.1056/NEJM198408303110903; WANG JM, 1988, BLOOD, V72, P1456; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218; WHITE K, 1995, LANCET, V345, P1022, DOI 10.1016/S0140-6736(95)90759-9; WOLACH B, 1993, BRAIN INJURY, V7, P401, DOI 10.3109/02699059309029683	42	73	78	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	1998	26	4					748	754		10.1097/00003246-199804000-00027			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZH472	WOS:000073113900024	9559614				2022-02-06	
J	Kelly, DF; Lee, SM; Pinanong, PA; Hovda, DA				Kelly, DF; Lee, SM; Pinanong, PA; Hovda, DA			Paradoxical effects of acute ethanolism in experimental brain injury	JOURNAL OF NEUROSURGERY			English	Article						ethanol; excitotoxicity; traumatic brain injury; N-methyl-D-aspartate receptor; rat	CORTICAL IMPACT MODEL; BLOOD-ALCOHOL LEVELS; HEAD-INJURY; RAT; TRAUMA; CALCIUM; EXCITOTOXICITY; INTOXICATION; MICRODIALYSIS; ABNORMALITIES	Acute ethanol intoxication is a frequent complicating factor in human head injury, yet its impact on neurological outcome remains poorly defined. This study was undertaken to assess the effect of varying levels of preinjury ethanol on early postinjury mortality, recovery of motor function, and degree of neural degeneration after cortical contusion injury in the rat. Adult rats were pretrained on a beam-walking task, then randomized to one of five groups: low-dose ethanol and injury (1 g/kg, 16 animals); moderate-dose ethanol and injury (2.5 g/kg, 11 animals); high-dose ethanol and injury (3 g/kg, 17 animals); no ethanol and injury (nine animals); or ethanol and sham injury (seven animals). Forty minutes after intraperitoneal injection of ethanol or saline, the rats received a pneumatic piston-induced contusion injury of the left primary motor cortex. Their beam-walking ability was assessed daily for the next 7 days. At 4 weeks postinjury, the brains were sectioned and the dimensions of the cortical lesions were determined. Preinjury ethanol administration was associated with an acute postinjury mortality rate of 29.5% (p <0.05); the highest mortality rate (47.1%) occurred in the high-dose ethanol group, whereas no deaths occurred in the animals in the no ethanol or sham-injured groups (p <0.01). However, injured animals receiving low- and moderate-dose ethanol had significantly less severe beam-walking impairment initially, and a more rapid return to normal beam-walking ability, compared to the no and high-dose ethanol groups (p <0.05). Additionally, the mean lesion volumes were significantly smaller in the low- and moderate-dose ethanol treatment groups compared to the no and high-dose ethanol groups (23.2+/-8 mm(3) and 29+/-6.7 mm(3) vs. 52+/-8.8 mm(3) and 53.7+/-10.9 mm(3), respectively, p <0.01). In this cortical contusion model, the presence of ethanol before injury appears to exert a potent neuroprotective effect when administered in low or moderate doses. This action is postulated to result from ethanol-induced inhibition of N-methyl-D-aspartate receptor-mediated excitotoxicity. The loss of neuroprotection and increased mortality rates observed with high-dose ethanol may be related to ethanol-induced hemodynamic and respiratory depression.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MOL & MED PHARMACOL,LOS ANGELES,CA 90095		Kelly, DF (corresponding author), UNIV CALIF LOS ANGELES,DIV NEUROSURG,BRAIN INJURY RES CTR,INST BRAIN RES,ROOM 18-218A NPI,LOS ANGELES,CA 90095, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30308, NS 27544] Funding Source: Medline		ABEL EL, 1979, PHYSIOL PSYCHOL, V7, P391; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BENGMARK S, 1980, THROMB HAEMOSTASIS, V43, P203; BLOOM F, 1982, BRIT J PHARMACOL, V75, P251, DOI 10.1111/j.1476-5381.1982.tb08780.x; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; DECRESCITO V, 1994, SURG FORUM, V25, P438; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DILDYMAYFIELD JE, 1991, J NEUROCHEM, V56, P1536, DOI 10.1111/j.1471-4159.1991.tb02048.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ELMER O, 1984, HAEMOSTASIS, V14, P223; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HOFSTEDE DJ, 1995, J NEUROTRAUM, V12, P974; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; INGLIS FM, 1990, ACT NEUR S, V51, P277; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; KELLY DF, 1995, CRIT CARE MED, V23, pA245; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kraus JF, 1993, HEAD INJURY, P1; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LEE SM, 1995, J CEREB BLOOD FLO S1, V15, pS722; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; McQueen J D, 1975, Surg Neurol, V4, P375; MODELL JG, 1990, NEW ENGL J MED, V323, P455, DOI 10.1056/NEJM199008163230706; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; OTT JF, 1985, ALCOHOL CLIN EXP RES, V9, P59, DOI 10.1111/j.1530-0277.1985.tb05051.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROINE RP, 1991, ALCOHOL CLIN EXP RES, V15, P734, DOI 10.1111/j.1530-0277.1991.tb00589.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Smith D H, 1995, New Horiz, V3, P562; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; *US DEP TRANSP, 1994, TRAFFIC SAFETY FACTS; VOGEL WH, 1986, BIOCHEM PHARMACOL, V35, P3983, DOI 10.1016/0006-2952(86)90015-8; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275	59	73	76	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1997	86	5					876	882		10.3171/jns.1997.86.5.0876			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	WV756	WOS:A1997WV75600020	9126906				2022-02-06	
J	Adelson, PD; Robichaud, P; Hamilton, RL; Kochanek, PM				Adelson, PD; Robichaud, P; Hamilton, RL; Kochanek, PM			A model of diffuse traumatic brain injury in the immature rat	JOURNAL OF NEUROSURGERY			English	Article						head injury; immature model; brain swelling; pathophysiology; rat	FLUID-PERCUSSION MODEL; HEAD-INJURY; AXONAL INJURY; CHILDREN; RESPONSES; COMA; CAT	Diffuse cerebral swelling after severe traumatic brain injury (TBI) develops more commonly in children than adults; however, models of diffuse brain injury in immature animals are lacking. The authors developed a new model of diffuse severe TBI in immature rats by modifying a recently described closed head injury model for adult rats. A total of 105 Sprague-Dawley immature rats (17 days old; average weight 38.5 +/- 5.46 g) were subjected to he:td impact using variable weights (0 g (sham), 75 g, 100 g, or 125 g) delivered from a height of 2 m onto a metal disk cemented to the intact cranium. Mortality, physiological and neurological parameters (from early reflex recovery to escape), and early histopathological changes were assessed. During the acute period after severe injury (SI) (100 g delivered from a height of 2 m; 50 rats), apnea was frequently observed and the mortality rate was 38%. Neurological recovery was complete in the sham-injured animals (11 rats) by 4.1 +/- 0.23 minutes (mean +/- standard error of the mean), but was delayed in both moderately injured (MI) (75 g/2 m; Il rats) (14.97 +/- 3.99 minutes) and ST (20.57 +/- 1.31 minutes (p < 0.05)) rats. In the first 24 hours, the sham-injured animals were more active than the injured ones as reflected by a greater net weight gain: 2.9 +/- 1.0 g, 1.2 +/- 1.6 g, and -0.6 +/- 2.1 g in sham-injured, MI, and SI animals, respectively. Immediately after injury, transient hypertension (lasting < 15 seconds) was followed by hypotension (lasting < 3 minutes) and loss of temperature regulation. Both injuries also induced apnea (0.75 +/- 0.7 minutes and 1.27 +/- 0.53 minutes in MI and SI groups, respectively), which either resolved or deteriorated to death. Intubation and assisted ventilation in animals with SI for 9.57 +/- 3.27 minutes in the peritrauma period eliminated mortality (p < 0.05, intubated vs. nonintubated). Histologically, after SI, there was diffuse edema throughout the corpus callosum below the region of injury and in the thalami. Other injuries included neuronal death in the deep nuclei, bilateral disruption of CA3, diffuse subarachnoid hemorrhage, and, in some, ventriculomegaly. Following a diffuse TBI in immature rats, SI produced a mortality rate, neurological deficit, and histological changes similar to those previously reported for an injury resulting from a 450-g weight dropped from 2 m in adult rats. A graded insult was achieved by maintaining the height of the weight drop but varying the weights. Weight loss, acute physiological instability, and acute neurological deficits were also indicative of an SI. Mortality was eliminated when ventilatory support was used during the peritrauma period. This model should be useful in studying the response of the immature rat to diffuse severe TBI.	CHILDRENS HOSP PITTSBURGH,DEPT NEUROPATHOL,PITTSBURGH,PA 15213; CHILDRENS HOSP PITTSBURGH,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA 15213; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,PITTSBURGH,PA		Adelson, PD (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT NEUROSURG,3705 5TH AVE,PITTSBURGH,PA 15213, USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADELSON PD, 1995, J NEUROTRAUM, V412, P9970; ADELSON PD, 1995, J NEUROTRAUM, V12, P984; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BELL RS, 1971, NEW ENGL J MED, V284, P236, DOI 10.1056/NEJM197102042840504; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRAHAM DI, 1988, J CLIN PATHOL, V42, P18; GRUBB RL, 1970, J NEUROSURG, V32, P320, DOI 10.3171/jns.1970.32.3.0320; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HARWOODNASH DC, 1971, RADIOLOGY, V101, P151, DOI 10.1148/101.1.151; HENDRICK EB, 1965, CLIN NEUROSURG, V11, P46; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; LEONIDAS JC, 1982, PEDIATRICS, V69, P139; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SMITH ML, 1995, J NEUROTRAUM, V12, P143; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Yuan XQ, 1991, J NEUROTRAUM, V8, P219, DOI 10.1089/neu.1991.8.219; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	38	73	74	0	8	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	1996	85	5					877	884		10.3171/jns.1996.85.5.0877			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	VP489	WOS:A1996VP48900019	8893727				2022-02-06	
J	Biddle, KR; McCabe, A; Bliss, LS				Biddle, KR; McCabe, A; Bliss, LS			Narrative skills following traumatic brain injury in children and adults	JOURNAL OF COMMUNICATION DISORDERS			English	Article							CLOSED HEAD-INJURY; DISCOURSE; CHILDHOOD; LANGUAGE; ADOLESCENTS; DAMAGE	Personal narratives serve an important function in virtually all societies (Peterson & McCabe, 1991). Through narratives individuals make sense of their experiences and represent themselves to others (Bruner, 1990). The ability to produce narratives has been linked to academic success (Feagans, 1982). Persons who have sustained a traumatic brain injury (TBI) are at risk for impaired narrative ability (Dennis, 1991). However, a paucity of information exists on the discourse abilities of persons with TBI. This is partly due to a lack of reliable tools with which to assess narrative discourse. The present study utilized dependency analysis (Deese, 1984) to document and describe the narrative discourse impairments of children and adults with TBI. Ten children (mean age 12;0) and 10 adults (mean age 35;2) were compared with matched controls. Dependency analysis reliably differentiated the discourse of the individuals with TBI from their controls. Individuals with TBI were significantly more dysfluent than their matched controls. Furthermore, their performance on the narrative task revealed a striking listener burden. (C) 1996 Elsevier Science Inc.	UNIV LOWELL,DEPT PSYCHOL,LOWELL,MA 01854; TUFTS UNIV,ELIOT PEARSON DEPT CHILD STUDY,MEDFORD,MA 02155; HARVARD UNIV,GRAD SCH EDUC,CAMBRIDGE,MA 02138; WAYNE STATE UNIV,DEPT COMMUN SCI & DISORDERS,DETROIT,MI 48202						EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007415] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HDO 7415] Funding Source: Medline		ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Benton A. L., 1987, NEUROBEHAVIORAL RECO, P111; BROOKS DN, 1987, NEUROBEHAVIORAL RECO, P57; Bruner Jerome S., 1990, ACTS MEANING; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; DEESE J, 1984, THOUGHT INTO SPEECH; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DENNIS M, 1990, DISCOURSE ABILITY BR, P199; ERLICH JS, 1988, J COMMUN DISORD, V21, P1; EWINGCOBBS L, 1987, J LEARN DISABIL, V20, P526, DOI 10.1177/002221948702000904; Feagans L, 1982, LANGUAGE CHILDREN RE; FINGER S, 1991, DEV NEUROPSYCHOL, V7, P261, DOI 10.1080/87565649109540494; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; Glosser G., 1990, BRAIN LANG, V40, P67; GRATTAN LM, 1991, DEV NEUROPSYCHOL, V7, P283, DOI 10.1080/87565649109540496; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; JORDAN F M, 1990, Brain Injury, V4, P147, DOI 10.3109/02699059009026159; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Katz D, 1992, J HEAD TRAUMA REHAB, V72, P1, DOI [10.1097/00001199-200501000-00008, DOI 10.1097/00001199-200501000-00008]; Labov W., 1972, LANGUAGE INNER CITY; Levin HS., 1982, NEUROBEHAVIORAL CONS; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1993, J SPEECH HEAR RES, V36, P868, DOI 10.1044/jshr.3605.868; MARSH NV, 1991, J CLIN EXP NEUROPSYC, V13, P729, DOI 10.1080/01688639108401086; MATEER CA, 1991, DEV NEUROPSYCHOL, V7, P359, DOI 10.1080/87565649109540498; MCCABE A, 1991, DEV NARRATIVE STRUCT; MCCABE A, 1990, 5 INT C STUD CHILD L; MCDONALD S, 1992, Brain Injury, V6, P283, DOI 10.3109/02699059209029670; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Peterson C., 1991, DEVELOPING NARRATIVE, P29; Peterson C., 1983, DEV PSYCHOLINGUISTIC; PREECE A, 1987, J CHILD LANG, V14, P353, DOI 10.1017/S0305000900012976; TEASDALE G, 1974, LANCET, V2, P81; WYCKOFF LH, 1984, THESIS U FLORIDA; YLVISAKER M, 1989, TOP LANG DISORD, V9, P34, DOI 10.1097/00011363-198903000-00005; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447; Ylvisaker M., 1986, J HEAD TRAUMA REHAB, V1, P48	43	73	74	1	8	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010	0021-9924			J COMMUN DISORD	J. Commun. Disord.	NOV-DEC	1996	29	6					447	469		10.1016/0021-9924(95)00038-0			23	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	VW284	WOS:A1996VW28400002	8956102				2022-02-06	
J	Ohry, A; Rattok, J; Solomon, Z				Ohry, A; Rattok, J; Solomon, Z			Post-traumatic stress disorder in brain injury patients	BRAIN INJURY			English	Article							EVENT SCALE; COMBAT; VALIDATION; SOLDIERS; IMPACT; PTSD; WAR	In the absence of the recognition of the emotional sequelae following traumatic brain injury (TBI), many patients are deprived of adequate treatment. The purpose of the current study is to evaluate the prevalence of post-traumatic stress disorder (PTSD) and explore the clinical picture among TBI patients. Twenty-four outpatients with diagnosed head injuries following various traumas filled out standardized questionnaires, assessing post-traumatic residuals. Thirty-three per cent of these patients met criteria for PTSD diagnosis. The clinical picture of PTSD following TBI is somewhat distinguished from those following other traumatic events. Issues concerning the specific nature of the syndrome following TBI, and the difficulties in differentiating between PTSD and postconcussive syndrome, are discussed.	TEL AVIV UNIV,BOB SHAPELL SCH SOCIAL WORK,IL-69978 TEL AVIV,ISRAEL; LONG ISL JEWISH MED CTR,NEW YORK,NY								American Psychiatric Association, 1987, DIAGN STAT MAN MENT, V3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; BRACKSTONE MJ, 1995, INT J REHABILITATION, V1, P37; COLLINS A, 1985, SEX ROLES, V12, P1219, DOI 10.1007/BF00287831; Epstein Richard S., 1994, P285; HARTMAN CR, 1993, INT HDB TRAUMATIC ST, P507; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Kraus Jess F., 1994, P3; McAllister Thomas W., 1994, P357; OSHANICK GJ, 1994, NEUROPSYCHIATRY TRAU, P163; RATTOK J, 1993, J CLIN EXPT NEUROPSY, V16, P243; Rattok Jack, 1994, P703; Robinson Robert G., 1994, P219; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SCHWARZWALD J, 1987, J CONSULT CLIN PSYCH, V55, P251, DOI 10.1037/0022-006X.55.2.251; SELTZER DJ, 1994, NEUROPSYCHIATRY TRAU, P251; Silver Jonathan M., 1994, P313; Smith E. M., 1993, INT HDB TRAUMATIC ST, P405; SOLOMON Z, 1993, ISRAEL J PSYCHIAT, V30, P110; SOLOMON Z, 1987, AM J PSYCHIAT, V144, P448; SOLOMON Z, 1994, AM J PSYCHIAT, V151, P554; SOLOMON Z, 1986, AM J PSYCHIAT, V143, P613; Solomon Z., 1993, COMBAT STRESS REACTI; Solomon Z., 1995, COPING WAR INDUCED S; Taylor Craig A., 1994, P81	25	73	73	0	1	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	SEP	1996	10	9					687	695		10.1080/026990596124106			9	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	VB635	WOS:A1996VB63500006	8853871				2022-02-06	
J	Rutledge, R; Lentz, CW; Fakhry, S; Hunt, J				Rutledge, R; Lentz, CW; Fakhry, S; Hunt, J			Appropriate use of the Glasgow Coma Scale in intubated patients: A linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							HEAD-INJURED PATIENTS; TRAUMATIC BRAIN INJURY; INTENSIVE-CARE UNIT; INTRACRANIAL HYPERTENSION; COMPUTERIZED-TOMOGRAPHY; ACUTE PHYSIOLOGY; RISK-FACTORS; APACHE-II; SEVERITY; RELIABILITY	The Glasgow Coma Scale (GCS) has been shown to be a valuable tool in assessing the neurologic and physiologic status of critically ill patients. Unfortunately, the GCS requires assessment of the verbal response of the patient and this can be blocked by intubation. The purpose of this study was to assess the ability of a regression model based upon the eye and motor components of the GCS to accurately predict the verbal response of the GCS. The primary hypothesis was that the verbal response could be derived from the motor and eye responses of the GCS. Methods: Data were collected prospectively in an intensive care unit computer data base, Patients were divided into training and test data sets. Linear regression was used to derive a model of verbal score from the motor and eye scores of the GCS in the training data set. Correlation between the actual and the predicted verbal scores was calculated. Results: A total of 2,521 GCS assessments were available for analysis. The second order multiple regression model was an accurate predictor of the verbal score (Pearson's Correlation r = 0.9, R(2) = 0.8,p = 0.0001) in 1,463 observations in the training data set. Second Order Multiple Regression Model: Estimated GCS Verbal = (2.3976) + [GCS Motor x (-0.9253)] + [GCS Eye x (-0.9214)] + [(GCS Motor)(2) x (0.2208)] + [(GCS Eye)(2) x (0.2318)] where r = 0.91, R(2) = 0.83, and p = 0.0001. The accuracy of this model was confirmed by comparing the predicted verbal score to the actual verbal score in the test data set (n = 736, r = 0.92, R(2) = 0.85, p = 0.0001) Conclusions: The GCS is a useful tool in the intensive care unit and a critical part of the APACHE II assessment of patient acuity. GCS has been shown to be a useful tool in its own right as a predictor of outcome in the critically ill. Its use is limited with intubation. (See Segatore M, Way C: Heart Lung 21:548, 1992; and Lieh-Lai MW, Theodorou AA, Sarnaik AP, et al: J Pediatr 120:195,1992.) The present study demonstrates that a relatively simple regression model can use the eve and motor components of the GCS to predict the expected verbal component of the GCS, thus allowing the calculation of the GCS sum score in intubated patients.			Rutledge, R (corresponding author), UNIV N CAROLINA,DEPT SURG,CAMPUS BOX 7210,BURNETT WOMACK,CHAPEL HILL,NC 27599, USA.						ANTONELLI M, 1994, CHEST, V105, P224, DOI 10.1378/chest.105.1.224; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; BENESCH CG, 1993, ARCH NEUROL-CHICAGO, V50, P1309, DOI 10.1001/archneur.1993.00540120024008; BRATTON SL, 1994, ARCH PEDIAT ADOL MED, V148, P167, DOI 10.1001/archpedi.1994.02170020053008; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chan Betty, 1993, Journal of Emergency Medicine, V11, P579, DOI 10.1016/0736-4679(93)90312-U; ELLIS A, 1992, INTENSIVE CRIT CARE, V8, P4; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; GENSEMER IB, 1989, ANN EMERG MED, V18, P9, DOI 10.1016/S0196-0644(89)80303-8; GIACINO JT, 1991, ARCH PHYS MED REHAB, V72, P897, DOI 10.1016/0003-9993(91)90008-7; GOTT PS, 1991, ARCH NEUROL-CHICAGO, V48, P1267, DOI 10.1001/archneur.1991.00530240071024; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JOHNSON SB, 1992, J TRAUMA, V33, P95, DOI 10.1097/00005373-199207000-00018; KARKELA J, 1992, CRIT CARE MED, V20, P378; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLAUBER MR, 1984, J NEUROSURG, V61, P695, DOI 10.3171/jns.1984.61.4.0695; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LANGFITT TW, 1983, J NEUROSURG, V48, P673; LANZA DC, 1990, ANN OTO RHINOL LARYN, V99, P38, DOI 10.1177/000348949009900106; LEE H, 1992, CRIT CARE MED, V20, P1555, DOI 10.1097/00003246-199211000-00013; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MARGULIES DR, 1994, AM SURGEON, V60, P387; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MENEGAZZI JJ, 1993, J TRAUMA, V34, P46, DOI 10.1097/00005373-199301000-00008; METZ CA, 1993, CRIT CARE MED, V21, P1844, DOI 10.1097/00003246-199312000-00010; NISKANEN M, 1991, CRIT CARE MED, V19, P1465, DOI 10.1097/00003246-199112000-00005; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; ROCCA B, 1989, J TRAUMA, V29, P299, DOI 10.1097/00005373-198903000-00004; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SANO K, 1994, NEUROL RES, V16, P23; SCHWARTZ ML, 1991, J TRAUMA, V31, P962, DOI 10.1097/00005373-199107000-00013; SEGATORE M, 1992, HEART LUNG, V21, P548; STARMARK JE, 1988, J NEUROSURG, V69, P692, DOI 10.3171/jns.1988.69.5.0692; TEASDALE G, 1974, LANCET, V2, P81; TERES D, 1982, CRIT CARE MED, V10, P86, DOI 10.1097/00003246-198202000-00004; TUHRIM S, 1991, ANN NEUROL, V29, P658, DOI 10.1002/ana.410290614; TURAZZI S, 1984, ACTA NEUROCHIR, V72, P167, DOI 10.1007/BF01406869; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WOLFGOULD C, 1991, J TROP PEDIATRICS, V38, P290; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; ZIMMERMAN JE, 1989, CRIT CARE MED S, V17, pS169	47	73	75	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1996	41	3					514	522		10.1097/00005373-199609000-00022			9	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	VH571	WOS:A1996VH57100026	8810973				2022-02-06	
J	Hetherington, CR; Stuss, DT; Finlayson, MAJ				Hetherington, CR; Stuss, DT; Finlayson, MAJ			Reaction time and variability 5 and 10 years after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; LONG; CONSISTENCY; PERFORMANCE	Improvement in performance can occur up to 10 years after traumatic brain injury (TBI). Few previous studies have examined the long-term effects of TBI on information processing. This study used reaction time (RT) tasks of increasing complexity with 10-year post-injury, 5-year post-injury, and control groups to assess any such effects. There were no significant group differences in mean RT; however, in the groups of persons with head injury only, response latency was related to age and to task demands. Older members of the groups of persons with head injury were slower than controls. The variability in performance was significantly higher in the 5-year post-injury group than in both the 10-year group and the control group. There were no significant differences among the groups in their ability to inhibit the processing of redundant information. There were no correlations between any dependent measure and severity of injury. Speed of processing is more sensitive to task complexity in individuals with head injury, but only when age at injury is considered. Most importantly, for rehabilitation purposes, recovery of consistency in performance can be expected more than 5 years after a TBI.	UNIV TORONTO, DEPT PSYCHOL, TORONTO, ON M5S 1A1, CANADA; UNIV TORONTO, DEPT MED NEUROL, TORONTO, ON M5S 1A1, CANADA; CHEDOKE MCMASTER HOSP, HAMILTON, ON, CANADA; MCMASTER UNIV, DEPT PSYCHIAT, HAMILTON, ON L8S 4L8, CANADA		Hetherington, CR (corresponding author), HOSP SICK CHILDREN, DEPT PATHOL, 555 UNIV AVE, TORONTO, ON M5G 1X8, CANADA.						ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ALFANO DP, 1993, NEUROPSY NEUROPSY BE, V6, P117; Allport A., 1989, FDN COGNITIVE SCI, P631; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; Dyer-Smith M. B., 1995, CONT ERGONOMICS, P56; ESON ME, 1978, J NEUROL NEUROSUR PS, V41, P1036, DOI 10.1136/jnnp.41.11.1036; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HALE S, 1988, PSYCHOL AGING, V3, P407, DOI 10.1037/0882-7974.3.4.407; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1976, LANCET, V1, P1031; Kolb B, 1985, FUNDAMENTALS HUMAN N; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1988, SCAND J REHABIL MED, P33; Luria A.R., 1966, HIGHER CORTICAL FUNC; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MIRSKY AF, 1995, J PSYCHIATR RES, V29, P23, DOI 10.1016/0022-3956(94)00041-O; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; SEGALOWITZ NS, 1993, APPL PSYCHOLINGUIST, V14, P369, DOI 10.1017/S0142716400010845; SEGALOWITZ S, 1992, J CLIN EXPT NEUROPSY, V14, P73; SHUM DHK, 1994, J CLIN EXP NEUROPSYC, V16, P547, DOI 10.1080/01688639408402666; Spreen O., 1989, CLIN NEUROPSYCHOL, V3, P129, DOI [10.1080/13854048908403285, DOI 10.1080/13854048908403285]; STREISSGUTH AP, 1994, ALCOHOL CLIN EXP RES, V18, P202, DOI 10.1111/j.1530-0277.1994.tb00904.x; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; STUSS DT, 1989, CAN J NEUROL SCI, V16, P161, DOI 10.1017/S0317167100028833; STUSS DT, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P157; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003; WOOD RL, 1988, J LEARN DISABIL, V21, P327, DOI 10.1177/002221948802100603	39	73	73	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	1996	10	7					473	486		10.1080/026990596124197			14	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	UU819	WOS:A1996UU81900001	8806008				2022-02-06	
J	Dietrich, WD; Alonso, O; Busto, R; Prado, R; Dewanjee, S; Dewanjee, MK; Ginsberg, MD				Dietrich, WD; Alonso, O; Busto, R; Prado, R; Dewanjee, S; Dewanjee, MK; Ginsberg, MD			Widespread hemodynamic depression and focal platelet accumulation after fluid percussion brain injury: A double-label autoradiographic study in rats	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; platelets; cerebral blood flow; vasoactive substances	CEREBRAL BLOOD-FLOW; CAROTID-ARTERY THROMBOSIS; HEAD-INJURIES; COMMON; METABOLISM; ISCHEMIA; BARRIER	Cerebrovascular damage leading to subsequent reductions in local cerebral blood flow (ICBF) may represent an important secondary injury mechanism following traumatic brain injury (TBI). We determined whether patterns of (111)indium-labeled platelet accumulation were spatially related to alterations in ICBF determined autoradiographically 30 min after TBI. Sprague-Dawley rats (n = 8), anesthetized with halothane and maintained on a 70:30 (vol/vol) mixture of nitrous oxide/oxygen and 0.5% halothane, underwent parasagittal fluid percussion brain injury (1.7-2.2 atm). (111)Indium-tropolone-labeled platelets were injected 30 min prior to TBI while [C-14]-iodoantipyrine was infused 30 min after trauma. Sham-operated animals (n = 7) underwent similar surgical procedures but were not injured, In autoradiographic images of the indium-labeled platelets, focal sites of platelet accumulation within the traumatized hemisphere were restricted to the pial surface (five of eight rats), the external capsule underlying the lateral parietal cortex (five of eight rats), and within cerebrospinal fluid (CSF) compartments (six of eight rats). In contrast, mild-to-moderate reductions in lCBF, not restricted to sites of platelet accumulation, were seen throughout the traumatized hemisphere. Flow reductions were most severe in coronal sections underlying the impact site, For example, within the lateral parietal cortex and hippocampus, 1CBF was significantly reduced [p < 0.01; analysis of variance (ANOVA)] from 1.71 +/- 0.34 (mean +/- SD) and 0.78 +/- 0.12 ml/g/min, respectively, versus 0.72 +/- 0.17 and 0.41 +/- 0.06 ml/g/min within the traumatized hemisphere. Significant flow reductions were also seen in remote cortical and subcortical areas, including the right frontal cortex and striatum. These results indicate that focal platelet accumulation and widespread hemodynamic depression are both early consequences of TBI, Therapeutic strategies directed at these early microvascular consequences of TBI may be neuroprotective by attenuating secondary ischemic processes.	UNIV MIAMI, SCH MED, DEPT RADIOL, MIAMI, FL 33101 USA		Dietrich, WD (corresponding author), UNIV MIAMI, SCH MED, DEPT NEUROL D45, NEUROTRAUMA CLIN RES CTR, POB 016960, MIAMI, FL 33101 USA.						Adams JH, 1982, RECENT ADV NEUROPATH, P165; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWANJEE MK, 1983, MAYO CLIN PROC, V58, P307; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1991, J CEREBR BLOOD F MET, V11, P957, DOI 10.1038/jcbfm.1991.161; DIETRICH WD, 1993, STROKE, V24, P1534, DOI 10.1161/01.STR.24.10.1534; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1977, STROKE, V8, P480, DOI 10.1161/01.STR.8.4.480; FIESCHI C, 1974, J NEUROL NEUROSUR PS, V37, P1378, DOI 10.1136/jnnp.37.12.1378; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HEKMATPANAH J, 1985, J NEUROSURG, V62, P888, DOI 10.3171/jns.1985.62.6.0888; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JONSSON BA, 1992, J NUCL MED, V33, P1825; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MUIR JK, 1992, J NEUROTRAUM, V9, P355, DOI 10.1089/neu.1992.9.355; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1983, INTRACRANIAL PRESSUR, P491; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Reivich M, 1974, Res Publ Assoc Res Nerv Ment Dis, V53, P125; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; Roy C S, 1890, J Physiol, V11, P85; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; THOMPSON JA, 1984, STROKE, V15, P1021, DOI 10.1161/01.STR.15.6.1021; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Young W, 1988, J Neurotrauma, V5, P219, DOI 10.1089/neu.1988.5.219; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZILLES L, 1985, CORTEX RAT STEREOTAX	48	73	74	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1996	16	3					481	489		10.1097/00004647-199605000-00015			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	UF710	WOS:A1996UF71000015	8621753	Bronze			2022-02-06	
J	WHITLOCK, JA; HAMILTON, BB				WHITLOCK, JA; HAMILTON, BB			FUNCTIONAL OUTCOME AFTER REHABILITATION FOR SEVERE TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article								Objective: (1) Define functional status at rehabilitation discharge and follow-up for patients admitted with Functional Independence Measure (FIM) of 18 after traumatic brain injury; (2) describe patterns of function measured at discharge, rehabilitation lengths of stay and costs, and disposition. Design: Retrospective, descriptive study using data from the Uniform Data System for Medical Rehabilitation (UDSMR) dataset. Setting: Acute rehabilitation hospitals and, for follow-up data, variety of settings, from community to long-term care. Patients: 328 patients with rehabilitation admission FIM of 18 (principal impairment group ''Brain Dysfunction, Traumatic'') drawn from 5,430 TBI patients entered into the data set during 1989-1991. Excluded were 22 persons readmitted to rehab, 5 deaths, 1 case without recorded disposition, and 49 cases without 1CD-9 code consistent with brain trauma. Main Outcome Measures: FIM scores at rehab discharge and follow-up; disposition; length of stay; cost. Results: (1) Mean FIM score at discharge for the group overall (n = 328) was 53 (median = 42 with interquartile range of 18 to 87); (2) 7.6% had functional scores consistent with independence in motor areas measured by FIM; (3) 2.7% had functional scores consistent with independence in cognitive areas measured by FIM; (4)26.1% showed no change in FIM score between admission and discharge; (5) 53% were discharged to community settings, 25% to long-term care, 11% to acute facilities, and 11% to other rehab facilities; (6) average length of stay in acute rehab was 110 days (SD = 70.9, median = 99 days, interquartile range = 57 to 153 days); (7) average rehabilitation charges (n = 322) were $110,891; (8) for those with follow-up data (n = 59), average FIM score was 79 (median, 90); 24% were in school and 5% worked in sheltered workshops. Conclusions: (1) Even the most severely disabled persons admitted to acute rehabilitation after traumatic brain injury can show a large degree of measurable functional improvement; (2) while about 25% of patients showed no measured FIM change, some showed dramatic degrees of functional recovery; (3) most common discharge setting was home (and community). (C) 1995 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	SUNY BUFFALO,BUFFALO,NY		WHITLOCK, JA (corresponding author), NE REHABIL HOSP,70 BUTLER ST,SALEM,NH 03079, USA.			Whitlock, James/0000-0002-6150-1111			ARONOW HU, 1987, J HEAD INJURY REHABI, V2, P24; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Bontke C. F., 1993, J HEAD TRAUMA REHAB, V8, P34; BRICOLO A, 1988, J NEUROSURG, V52, P625; COPE D N, 1991, Brain Injury, V5, P127, DOI 10.3109/02699059109008084; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; COPE DN, 1982, ARCH PHYS MED REHAB, V63, P433; Data Management Service of the Uniform Data System for Medical Rehabilitation and the Center for Functional Assessment Research, 1990, GUIDE USE UNIFORM DA; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; FIEDLER R, 1993, PROGR MED REHABILITA, V7, P1; FOULKES MA, 1991, J NEUROSURG, V75, pS11; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GROSWASSER Z, 1990, J NEUROSURG, V72, P75; HAFFEY WJ, 1989, TRAUMATIC BRAIN INJU, P203; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HAMILTON B B, 1991, Archives of Physical Medicine and Rehabilitation, V72, P790; HAMILTON BB, 1994, PHYS THER, V74, P499; Hamilton BB, 1987, REHABILITATION OUTCO, P137; HEIDEN JS, 1979, SEMINARS NEUROLOGICA, P181; HEINEMANN AW, 1992, REHABILITATION EFFIC; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1975, LANCET, V1, P480; KARAFFA MC, 1992, INT CLASSIFICATION D; Kraus JF, 1993, HEAD INJURY, P1; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MACK A, 1989, TBI STAR PM R, P13; Malec James F., 1993, Brain Injury, V7, P15, DOI 10.3109/02699059309008153; Rasch Georg, 1980, PROBABILISTIC MODELS; SANDEL ME, 1990, COMA EMERGING PATIEN, P409; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; Timmons M, 1987, J HEAD TRAUMA REHAB, V2, P64; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; VOLLMER DG, 1993, HEAD INJURY, P553; WHITLOCK J A JR, 1992, Brain Injury, V6, P447, DOI 10.3109/02699059209008140; WRIGHT BD, 1989, ARCH PHYS MED REHAB, V70, P857; 1990, PARADOX RELATIONAL D; 1995, STATA VERSION 3 1 CO; 1993, QUATTRO PRO VERSION	40	73	75	0	7	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1995	76	12					1103	1112		10.1016/S0003-9993(95)80117-0			10	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	TJ667	WOS:A1995TJ66700003	8540785				2022-02-06	
J	HUNKIN, NM; PARKIN, AJ; BRADLEY, VA; BURROWS, EH; ALDRICH, FK; JANSARI, A; BURDONCOOPER, C				HUNKIN, NM; PARKIN, AJ; BRADLEY, VA; BURROWS, EH; ALDRICH, FK; JANSARI, A; BURDONCOOPER, C			FOCAL RETROGRADE-AMNESIA FOLLOWING CLOSED-HEAD INJURY - A CASE-STUDY AND THEORETICAL ACCOUNT	NEUROPSYCHOLOGIA			English	Article						MEMORY; AMNESIA; RETROGRADE	AUTOBIOGRAPHICAL MEMORY; ENCEPHALITIS; ANTEROGRADE; IMPAIRMENT	In this paper we present data from a closed head injury patient who presents a striking example of what Kapur (Cortex 29, 217-234, 1993) has termed ''focal retrograde amnesia''. The patient, D.H., is unable to recollect any autobiographical incidents from the pre-morbid period, although he is able to provide personal and public information from this period. The data are discussed in relation to other reported instances of focal retrograde amnesia and a preliminary theoretical account is offered.	HURSTWOOD PK NEUROL CTR,HAYWARDS HEATH RH17 7SJ,W SUSSEX,ENGLAND; KING EDWARD VII HOSP,MIDHURST GU29 0BL,W SUSSEX,ENGLAND		HUNKIN, NM (corresponding author), UNIV SUSSEX,EXPTL PSYCHOL LAB,BRIGHTON BN1 9QG,E SUSSEX,ENGLAND.				Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		ANDREWS E, 1982, CORTEX, V18, P441, DOI 10.1016/S0010-9452(82)80041-5; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DERENZI E, 1993, CORTEX, V29, P449, DOI 10.1016/S0010-9452(13)80253-5; ESLINGER PJ, 1993, BRAIN COGNITION, V21, P140, DOI 10.1006/brcg.1993.1011; EVANS J, 1993, J NEUROL NEUROSUR PS, V56, P1227, DOI 10.1136/jnnp.56.11.1227; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; HODGES JR, 1993, BRAIN, V116, P921, DOI 10.1093/brain/116.4.921; HUNKIN NM, 1994, NEUROPSYCHOLOGIA, V32, P819, DOI 10.1016/0028-3932(94)90020-5; KAPUR N, 1994, NEUROPSYCHOLOGIA, V32, P23, DOI 10.1016/0028-3932(94)90066-3; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; KAPUR N, 1993, CORTEX, V29, P217, DOI 10.1016/S0010-9452(13)80177-3; KAPUR N, 1992, BRAIN, V115, P73, DOI 10.1093/brain/115.1.73; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; MARKOWITSCH HJ, 1993, J NEUROL NEUROSUR PS, V56, P988, DOI 10.1136/jnnp.56.9.988; Nelson H. E., 1991, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OCONNOR M, 1992, J CLIN EXP NEUROPSYC, V14, P159, DOI 10.1080/01688639208402821; OGDEN JA, 1993, NEUROPSYCHOLOGIA, V31, P571, DOI 10.1016/0028-3932(93)90053-3; Parkin A. J., 1993, NEUROPSYCHOLOGY AMNE; PARKIN AJ, 1991, PSYCHOL MED, V21, P11, DOI 10.1017/S0033291700014598; PARKIN AJ, 1990, Q J EXP PSYCHOL-A, V42, P585, DOI 10.1080/14640749008401238; PARKIN AJ, 1991, BRIT J CLIN PSYCHOL, V30, P349, DOI 10.1111/j.2044-8260.1991.tb00955.x; PERNER J, 1992, HUM DEV, V35, P146, DOI 10.1159/000277146; ROBINSON JA, 1976, COGNITIVE PSYCHOL, V8, P578, DOI 10.1016/0010-0285(76)90020-7; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; Squire LR., 1987, MEMORY BRAIN; STRACCIARI A, 1994, CORTEX, V30, P459, DOI 10.1016/S0010-9452(13)80341-3; Warrington E, 1984, RECOGNITION MEMORY T, V1; Wechsler, 1997, WECHSLER ADULT INTEL; Wechsler D, 1987, MEMORY SCALE REVISED; YONEDA Y, 1992, EUR NEUROL, V32, P340, DOI 10.1159/000116857; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	33	73	73	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	APR	1995	33	4					509	523		10.1016/0028-3932(94)00136-D			15	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	QV067	WOS:A1995QV06700008	7617158				2022-02-06	
J	ALLEN, K; LINN, RT; GUTIERREZ, H; WILLER, BS				ALLEN, K; LINN, RT; GUTIERREZ, H; WILLER, BS			FAMILY BURDEN FOLLOWING TRAUMATIC BRAIN INJURY	REHABILITATION PSYCHOLOGY			English	Article							GENDER DIFFERENCES; COPING STRATEGIES; HEAD-INJURY; CAREGIVERS; RELATIVES; DEMENTIA; STRESS; SYMPTOMS; IMPACT; WIVES	This study investigated burden experienced by 60 spouses and 71 parents who served as primary caregivers to individuals with traumatic brain injury. Burden levels, as assessed by the Questionnaire on Resources and Stress (QRS-SF), were compared for spouses and parents. Overall, both parents and spouses of individuals with traumatic brain injury exhibited high levels of burden. Relative to spouses, parents reported significantly greater burden related to lifespan care. Spouses reported significantly less personal reward than did parents. The presence of social aggression and cognitive disability in the individual with brain injury was found to have a greater association with subjective burden of caregivers than was the presence of physical disability or injury severity. Comparisons were made between QRS-SF scores for relatives of individuals with brain injury and QRS-SF scores reported in previous investigations focused on caregivers to individuals with other disabling conditions. It was found that the responsibility assumed by spouses and parents of individuals with brain injury was as great as that experienced by families of people with severe chronic physical disabilities.			ALLEN, K (corresponding author), SUNY BUFFALO, CTR STUDY BIOBEHAV & SOCIAL ASPECTS HLTH, 316 PK HALL, BUFFALO, NY 14260 USA.						BARUSCH AS, 1989, GERONTOLOGIST, V29, P667, DOI 10.1093/geront/29.5.667; BOUMA R, 1990, J CLIN PSYCHOL, V46, P722, DOI 10.1002/1097-4679(199011)46:6<722::AID-JCLP2270460605>3.0.CO;2-6; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CHENOWETH B, 1986, GERONTOLOGIST, V26, P267, DOI 10.1093/geront/26.3.267; CHWALISZ K, 1992, REHABIL PSYCHOL, V37, P189, DOI 10.1037/h0079103; Cohen J., 1983, APPL MULTIPLE REGRES, V2nd ed.; DAY AM, 1988, REHABIL PSYCHOL, V33, P113; DEIMLING GT, 1986, J GERONTOL, V41, P778, DOI 10.1093/geronj/41.6.778; HAYS WL, 1988, STATISTICS; HOLROYD J, 1976, AM J MENT DEF, V80, P431; HOLROYD J, 1986, J CLIN PSYCHOL, V42, P552, DOI 10.1002/1097-4679(198607)42:4<552::AID-JCLP2270420403>3.0.CO;2-8; Holroyd J., 1987, MANUAL QUESTIONNAIRE; HOLROYD J, 1985, QUESTIONNAIRE RESOUR; Holroyd J., 1974, J COMMUNITY PSYCHOL, V2, P92, DOI [10.1002/1520-6629(197401)2:1, DOI 10.1002/1520-6629(197401)2:1]; *HOUGHT MIFFL CO, 1985, AM HER DICT; INANAMI M, 1980, JAPANESE J SPECIAL E, V18, P33; Kuder GF, 1937, PSYCHOMETRIKA, V2, P151, DOI 10.1007/BF02288391; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1988, J HEAD TRAUMA REHAB, V2, P6; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCDOWELL J, 1988, DISABILITY SCORE HLT; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORRIS RG, 1991, BRIT J PSYCHIAT, V158, P69, DOI 10.1192/S0007125000292027; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Panting A, 1972, REHABILITATION, V38, P33; PRATT CC, 1985, FAM RELAT, V34, P27, DOI 10.2307/583754; RABINS PV, 1982, JAMA-J AM MED ASSOC, V248, P333, DOI 10.1001/jama.248.3.333; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; SCHARLACH AE, 1989, RES AGING, V11, P225, DOI 10.1177/0164027589112005; *STAT CAN, 1989, HLTH ACT LIM SURV DA; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLER B, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P18; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Wood R. L., 1987, BRAIN INJURY REHABIL	36	73	73	0	3	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	SPR	1994	39	1					29	48		10.1037/0090-5550.39.1.29			20	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	NQ432	WOS:A1994NQ43200003					2022-02-06	
J	GOLDENBERG, G; ODER, W; SPATT, J; PODREKA, I				GOLDENBERG, G; ODER, W; SPATT, J; PODREKA, I			CEREBRAL CORRELATES OF DISTURBED EXECUTIVE FUNCTION AND MEMORY IN SURVIVORS OF SEVERE CLOSED HEAD-INJURY - A SPECT STUDY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							BRAIN-LESIONS; DISEASE; TOMOGRAPHY; TASKS; MILD	Thirty six patients in the chronic stage after severe closed head injury were examined with tests of executive function, memory, intelligence, and functional capacities in daily living. Correlations were sought between test results and Tc-99m-HMPAO uptake of frontal, temporal, and thalamic regions assessed by SPECT. Neither the number of significant correlation coefficients between memory tests and regional uptake nor that between temporal uptake and tests exceeded chance. For the remaining tests, correlations to thalamic regions were stronger than those to the frontal regions, and those to right brain regions stronger than those to homologous left brain regions. Relationships of thalamic isotope uptake to neuropsychological performance may reflect the impact of diffuse brain damage and particularly of diffuse axonal injury on mental capacities.	UNIV VIENNA,NEUROL KLIN,A-1010 VIENNA,AUSTRIA								ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Adams JH, 1975, HDB CLIN NEUROLOGY, V23, P35; Baddeley A.D., 1986, WORKING MEMORY; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P746; Brooks N., 1990, TRAUMATIC BRAIN INJU, P77; BROWNELL HH, 1983, BRAIN LANG, V18, P20, DOI 10.1016/0093-934X(83)90002-0; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DIEM K, 1968, WISSENSCHAFTLICHE TA; Gainotti G, 1972, Cortex, V8, P41; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GOLDENBERG G, 1990, J NEUROL, V237, P191, DOI 10.1007/BF00314593; GOLDENBERG G, 1989, NEUROPSYCHOLOGIA, V27, P1315, DOI 10.1016/0028-3932(89)90127-9; GOLDENBERG G, 1989, BEHAV NEUROL, V2, P79; HECAEN H, 1978, CEREBRAL CORRELATES, P119; HEILMAN KM, 1978, NEUROLOGY, V28, P229, DOI 10.1212/WNL.28.3.229; HEISS WD, 1990, J CEREBR BLOOD F MET, V10, P687, DOI 10.1038/jcbfm.1990.122; HOLM S, 1979, SCAND J STAT, V6, P65; JENKINS A, 1986, LANCET, V2, P445; LASSEN NA, 1987, J CEREB BLOOD FLOW S, V7, P535; Lehrl S., 1977, MEHRFACHWAHL WORTSCH; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; METTER EJ, 1981, ANN NEUROL, V10, P173, DOI 10.1002/ana.410100208; OSTROVE JM, 1990, BRAIN COGNITION, V12, P144, DOI 10.1016/0278-2626(90)90010-L; PODREKA I, 1987, J NUCL MED, V28, P1657; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; Raven J., 1965, COLOURED PROGR MATRI; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SHOULSON I, 1981, NEUROLOGY, V31, P1333, DOI 10.1212/WNL.31.10.1333; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; UZZELL BP, 1986, CLIN NEUROPSYCHOLOGY, P3; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wiedmann KD, 1989, NEUROPSYCHOLOGY, V3, P267, DOI 10.1037//0894-4105.3.4.267; Wilson JTL, 1989, NEUROPSYCHOLOGY, V3, P255, DOI 10.1037//0894-4105.3.4.255; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	41	73	73	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	1992	55	5					362	368		10.1136/jnnp.55.5.362			7	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	HV661	WOS:A1992HV66100007	1602308	Green Published, Bronze			2022-02-06	
J	WARD, A				WARD, A			ATROPINE IN THE TREATMENT OF CLOSED HEAD INJURY	JOURNAL OF NEUROSURGERY			English	Article																	BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349, DOI 10.1152/jn.1946.9.5.349; DAVIS JE, 1946, J PHARMACOL EXP THER, V88, P246; de No RL, 1938, AM J PHYSIOL, V121, P331, DOI 10.1152/ajplegacy.1938.121.2.331; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296, DOI 10.1152/physrev.1945.25.2.296; GREIG ME, 1949, SCIENCE, V110, P237, DOI 10.1126/science.110.2853.237; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HENDERSON W. R., 1936, QUART JOUR EXP PHYSIOL, V26, P83; Kremer M, 1942, Q J EXP PHYSIOL CMS, V31, P337, DOI 10.1113/expphysiol.1942.sp000867; PARFITT DN, 1947, J NEUROL NEUROSUR PS, V10, P85, DOI 10.1136/jnnp.10.2.85; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; SCHEINKER IM, 1948, J NEUROPATH EXP NEUR, V7, P321, DOI 10.1097/00005072-194807000-00007; Scheinker IM, 1948, NEUROSURGICAL PATHOL; SCHEINKER JM, 1949, ARCH NEUROL CHIC, V61, P248; SEGERBERG LH, 1949, JAMA-J AM MED ASSOC, V141, P371, DOI 10.1001/jama.1949.02910060009003; TOWER DB, 1948, J CLIN INVEST, V27, P558; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WELBOURN R B, 1948, Lancet, V2, P211; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223	19	73	73	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1950	7	5					398	402		10.3171/jns.1950.7.5.0398			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	UN062	WOS:A1950UN06200004	14774757				2022-02-06	
J	Mamik, MK; Power, C				Mamik, Manmeet K.; Power, Christopher			Inflammasomes in neurological diseases: emerging pathogenic and therapeutic concepts	BRAIN			English	Article						inflammasome; interleukin-1beta; caspase-1; ASC; pyroptosis	CENTRAL-NERVOUS-SYSTEM; INHIBITS NLRP3 INFLAMMASOME; SMALL-MOLECULE INHIBITOR; TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; MULTIPLE-SCLEROSIS; INTERLEUKIN-1-BETA PRODUCTION; RECEPTOR ANTAGONIST; ALZHEIMERS-DISEASE; PERIPHERAL-BLOOD	Inflammasome activation in the central nervous system occurs in both health and disease. Inflammasomes are cytosolic protein complexes that sense specific infectious or host stimuli and initiate inflammatory responses through caspase activation. Assembly of inflammasomes results in caspase-1-mediated proteolytic cleavage and release of the pro-inflammatory cytokines, interleukin-1 beta and interleukin-18, with initiation of pyroptosis, an inflammatory programmed cell death. Recent developments in the inflammasome field have uncovered novel molecular mechanisms that contribute to a broad range of neurological disorders including those associated with specific mutations in inflammasome genes as well as diseases modulated by inflammasome activation. This update focuses on recent developments in the field of inflammasome biology highlighting different inflammasome activators and pathways discovered in the nervous system. We also discuss targeted therapies that regulate inflammasomes and improve neurological outcomes.	[Mamik, Manmeet K.; Power, Christopher] Univ Alberta, Dept Med, Div Nephrol, Edmonton, AB, Canada; [Power, Christopher] Univ Alberta, Neurosci & Mental Hlth Inst, Edmonton, AB, Canada		Power, C (corresponding author), Univ Alberta, Heritage Med Res Ctr 611, Dept Med, Edmonton, AB T6G 2S2, Canada.; Power, C (corresponding author), Univ Alberta, Heritage Med Res Ctr 611, Dept Med Microbiol & Immunol, Edmonton, AB T6G 2S2, Canada.	chris.power@ualberta.ca			Alberta Innovates-Health Solution; Campus Alberta Neuroscience; Canada Research Chair in Neurological Infection and ImmunityCanada Research Chairs; Alberta Innovates [201400453] Funding Source: researchfish	M.K.M. is supported by fellowships from Alberta Innovates-Health Solution and Campus Alberta Neuroscience. C.P. is supported by a Canada Research Chair in Neurological Infection and Immunity.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak S, 2012, J NEUROSURG, V117, P1119, DOI 10.3171/2012.9.JNS12815; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alcocer-Gomez E, 2014, BRAIN BEHAV IMMUN, V36, P111, DOI 10.1016/j.bbi.2013.10.017; Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069; Bandyopadhyay S, 2013, BIOCHEM BIOPH RES CO, V439, P407, DOI 10.1016/j.bbrc.2013.08.056; Barone FC, 2001, J PHARMACOL EXP THER, V296, P312; Bartlett R, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/271813; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Biragyn A, 2008, J LEUKOCYTE BIOL, V83, P998, DOI 10.1189/jlb.1007700; Blok DC, 2014, J INNATE IMMUN, V6, P542, DOI 10.1159/000358239; Branton WG, 2016, SCI REP-UK, V6, DOI 10.1038/srep37344; Bryant C, 2009, TRENDS CELL BIOL, V19, P455, DOI 10.1016/j.tcb.2009.06.002; Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013; Bulau AM, 2014, P NATL ACAD SCI USA, V111, P2650, DOI 10.1073/pnas.1324140111; Burm SM, 2015, J NEUROSCI, V35, P678, DOI 10.1523/JNEUROSCI.2510-14.2015; Capuron L, 2011, PHARMACOL THERAPEUT, V130, P226, DOI 10.1016/j.pharmthera.2011.01.014; Chakraborty A, 2013, J CLIN PHARMACOL, V53, P1240, DOI 10.1002/jcph.162; Chen LZ, 2014, BRAIN RES, V1566, P1, DOI 10.1016/j.brainres.2014.04.019; Cho MH, 2014, AUTOPHAGY, V10, P1761, DOI 10.4161/auto.29647; Claxton A, 2015, J ALZHEIMERS DIS, V44, P897, DOI 10.3233/JAD-141791; Codolo G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055375; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Coll RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029539; Couturier J, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0477-y; Curto-Reyes V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133707; Dagenais M, 2012, CELL DEATH DIFFER, V19, P5, DOI 10.1038/cdd.2011.159; Debye B, 2018, BRAIN PATHOL, V28, P14, DOI 10.1111/bpa.12467; Denes A, 2015, P NATL ACAD SCI USA, V112, P4050, DOI 10.1073/pnas.1419090112; Dinarello CA, 2007, EUR J IMMUNOL, V37, pS34, DOI 10.1002/eji.200737772; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Ellis A, 2013, BRIT J ANAESTH, V111, P26, DOI 10.1093/bja/aet128; Fann DYW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.326; Fann DYW, 2013, AGEING RES REV, V12, P941, DOI 10.1016/j.arr.2013.09.004; Farez MF, 2009, NAT IMMUNOL, V10, P958, DOI 10.1038/ni.1775; Festoff BW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0670-z; Frank MG, 2015, BRAIN BEHAV IMMUN, V48, P1, DOI 10.1016/j.bbi.2015.03.010; Freeman LC, 2016, J NEUROCHEM, V136, P29, DOI 10.1111/jnc.13217; Furlan R, 1999, J NEUROL NEUROSUR PS, V67, P785, DOI 10.1136/jnnp.67.6.785; Galea J, 2018, J NEUROSURG, V128, P515, DOI 10.3171/2016.9.JNS16615; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; Geng FY, 2016, NEUROIMMUNOMODULAT, V23, P122, DOI 10.1159/000445689; Gola H, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-40; Gong YN, 2010, CELL RES, V20, P1289, DOI 10.1038/cr.2010.135; Gougeon ML, 2017, J INTERN MED, V281, P433, DOI 10.1111/joim.12570; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Gustot A, 2015, BIOCHEM J, V471, P323, DOI 10.1042/BJ20150617; Hafner-Bratkovic I, 2012, CELL MOL LIFE SCI, V69, P4215, DOI 10.1007/s00018-012-1140-0; Hamel R, 2015, J VIROL, V89, P8880, DOI 10.1128/JVI.00354-15; Han S, 2008, ARCH PHARM RES, V31, P67, DOI 10.1007/s12272-008-1122-9; Hanamsagar R, 2014, J NEUROCHEM, V129, P704, DOI 10.1111/jnc.12669; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; He Y, 2014, J BIOL CHEM, V289, P1142, DOI 10.1074/jbc.M113.515080; Heidary M, 2014, J NEUROL SCI, V343, P41, DOI 10.1016/j.jns.2014.05.013; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hoogman M, 2007, J NEUROL NEUROSUR PS, V78, P1092, DOI 10.1136/jnnp.2006.110023; Howard C, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-94; Huang WX, 2004, MULT SCLER J, V10, P482, DOI 10.1191/1352458504ms1071oa; Inoue M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002767; Italiani P, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-94; Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev-med-061512-150641; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Jones G, 2005, VIROLOGY, V334, P178, DOI 10.1016/j.virol.2005.01.027; Juliana C, 2010, J BIOL CHEM, V285, P9792, DOI 10.1074/jbc.M109.082305; Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517; Kappos L, 2006, NEUROLOGY, V67, P944, DOI 10.1212/01.wnl.0000237994.95410.ce; Karatas H, 2013, SCIENCE, V339, P1092, DOI 10.1126/science.1231897; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Keystone EC, 2012, ANN RHEUM DIS, V71, P1630, DOI 10.1136/annrheumdis-2011-143578; Kim HK, 2016, J PSYCHIATR RES, V72, P43, DOI 10.1016/j.jpsychires.2015.10.015; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; Kita T, 2009, INT REV NEUROBIOL, V88, P43, DOI 10.1016/S0074-7742(09)88003-3; Kitley JL, 2010, NEUROLOGY, V74, P1267, DOI 10.1212/WNL.0b013e3181d9ed69; Kong XX, 2017, J NEUROSCI RES, V95, P1565, DOI 10.1002/jnr.24004; Kumar M, 2013, J VIROL, V87, P3655, DOI 10.1128/JVI.02667-12; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Li Q, 2013, NEUROSCIENCE, V254, P230, DOI 10.1016/j.neuroscience.2013.09.028; Liao KC, 2013, INFECT IMMUN, V81, P570, DOI 10.1128/IAI.01003-12; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu L, 2014, NEUROBIOL AGING, V35, P309, DOI 10.1016/j.neurobiolaging.2013.08.016; Liu W, 2013, BIOCHEM PHARMACOL, V85, P1504, DOI 10.1016/j.bcp.2013.03.008; Lu M, 2014, NEUROBIOL AGING, V35, P421, DOI 10.1016/j.neurobiolaging.2013.08.015; Maier NK, 2015, J IMMUNOL, V194, P2776, DOI 10.4049/jimmunol.1401611; Maier NK, 2014, J IMMUNOL, V192, P763, DOI 10.4049/jimmunol.1301434; Malhotra S, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0269-9; Mamik MK, 2017, J NEUROIMMUNE PHARM, V12, P233, DOI 10.1007/s11481-016-9708-3; Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053; Maroso M, 2011, NEUROTHERAPEUTICS, V8, P304, DOI 10.1007/s13311-011-0039-z; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; Meng XF, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0212-5; Ming X, 2002, J NEUROL SCI, V197, P9, DOI 10.1016/S0022-510X(02)00030-8; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Momeni M, 2016, NORD J PSYCHIAT, V70, P280, DOI 10.3109/08039488.2015.1100328; Moretti S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004462; Mortimer L, 2016, NAT IMMUNOL, V17, P1176, DOI 10.1038/ni.3538; Munoz LS, 2016, SEMIN REPROD MED, V34, P273, DOI 10.1055/s-0036-1592066; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Netea MG, 2006, NAT MED, V12, P650, DOI 10.1038/nm1415; Netea MG, 2015, ANNU REV IMMUNOL, V33, P49, DOI 10.1146/annurev-immunol-032414-112306; Nomura J, 2015, J IMMUNOL, V195, P5718, DOI 10.4049/jimmunol.1402512; Nowakowski TJ, 2016, CELL STEM CELL, V18, P591, DOI 10.1016/j.stem.2016.03.012; Pan Y, 2014, BRAIN BEHAV IMMUN, V41, P90, DOI 10.1016/j.bbi.2014.04.007; Qu Y, 2009, J IMMUNOL, V182, P5052, DOI 10.4049/jimmunol.0802968; Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254; Ramaswamy V, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-152; Ramos HJ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003039; Robaeys G, 2007, WORLD J GASTROENTERO, V13, P5736, DOI 10.3748/wjg.v13.i43.5736; Rogliani P, 2015, PULM PHARMACOL THER, V31, P15, DOI 10.1016/j.pupt.2015.01.005; Santoni G, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0239-2; Saresella M, 2016, BRAIN BEHAV IMMUN, V57, P125, DOI 10.1016/j.bbi.2016.03.009; Saresella M, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0088-1; Schrijver IA, 2001, BRAIN, V124, P1544, DOI 10.1093/brain/124.8.1544; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Sokolowska M, 2015, J IMMUNOL, V194, P5472, DOI 10.4049/jimmunol.1401343; Son MY, 2015, J PATHOL, V237, P98, DOI 10.1002/path.4551; Song LM, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00063; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Tan CC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0233-0; Tan MS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.348; Tan MS, 2013, MOL NEUROBIOL, V48, P875, DOI 10.1007/s12035-013-8475-x; Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432; Tricarico PM, 2017, BIOCHEM BIOPH RES CO, V492, P597, DOI 10.1016/j.bbrc.2017.01.158; TYOR WR, 1993, NEUROLOGY, V43, P1002, DOI 10.1212/WNL.43.5.1002; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Vaccari JPD, 2012, J NEUROSCI, V32, P3058, DOI 10.1523/JNEUROSCI.4930-11.2012; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Vasudeva K, 2015, J NEUROIMMUNOL, V283, P43, DOI 10.1016/j.jneuroim.2015.04.012; Vigano E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9761; Walsh JG, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-35; Wannamaker W, 2007, J PHARMACOL EXP THER, V321, P509, DOI 10.1124/jpet.106.111344; Weber MD, 2015, J NEUROSCI, V35, P316, DOI 10.1523/JNEUROSCI.3561-14.2015; Weber MD, 2013, BRAIN BEHAV IMMUN, V32, P112, DOI 10.1016/j.bbi.2013.03.004; Wesselingh SL, 1997, J NEUROIMMUNOL, V74, P1, DOI 10.1016/S0165-5728(96)00160-9; Wong ML, 2016, MOL PSYCHIATR, V21, P797, DOI 10.1038/mp.2016.46; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu PJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep32405; Xing HQ, 2009, NEUROPATHOLOGY, V29, P433, DOI 10.1111/j.1440-1789.2008.00996.x; Xiong XY, 2015, TRANSL STROKE RES, V6, P339, DOI 10.1007/s12975-015-0402-1; Yang Z, 2015, MOL IMMUNOL, V65, P267, DOI 10.1016/j.molimm.2014.12.018; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zhou Y, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0094-3; Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695; Zwijnenburg PJG, 2003, J IMMUNOL, V170, P4724, DOI 10.4049/jimmunol.170.9.4724; Zwijnenburg RJG, 2001, J INFECT DIS, V183, P1143, DOI 10.1086/319271	155	72	79	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2017	140		9				2273	2285		10.1093/brain/awx133			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	FF0PB	WOS:000408602500012	29050380	Bronze			2022-02-06	
J	Mac Donald, CL; Barber, J; Jordan, M; Johnson, AM; Dikmen, S; Fann, JR; Temkin, N				Mac Donald, Christine L.; Barber, Jason; Jordan, Mary; Johnson, Ann M.; Dikmen, Sureyya; Fann, Jesse R.; Temkin, Nancy			Early Clinical Predictors of 5-Year Outcome After Concussive Blast Traumatic Brain Injury	JAMA NEUROLOGY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; ADMINISTERED PTSD SCALE; POSTCONCUSSIVE SYMPTOMS; STRUCTURED INTERVIEWS; MILITARY PERSONNEL; OEF/OIF VETERANS; NATIONAL-GUARD; MENTAL-HEALTH; IRAQI FREEDOM	IMPORTANCE The long-term clinical effects of wartime traumatic brain injuries (TBIs), most of which are mild, remain incompletely described. Current medical disability cost estimates from world conflicts continually surpass projections. Additional information regarding long-term functional trajectory is needed to reduce this extensive public health burden. OBJECTIVES To examine 5-year clinical outcomes leveraging existing clinical data collected at 1 year after injury in the same patients and to identify early risk factors for long-term disability. DESIGN, SETTING, AND PARTICIPANTS This prospective, longitudinal study enrolled active-duty US military after concussive blast injury (n = 50) in the acute to subacute stage and combat-deployed control individuals (n = 44) in Afghanistan or after medical evacuation to Germany from November 1, 2008, through July 1, 2013. One-and 5-year clinical evaluations were completed in the United States. All concussive blast injuriesmet the Department of Defense definition of mild, uncomplicated TBI. In-person clinical evaluations included standardized evaluations for neurobehavior, neuropsychological performance, and mental health burden that were essentially identical to the evaluations completed at 1-year follow-up. Data were analyzed from October 1 through November 30, 2016. MAIN OUTCOMES AND MEASURES Changes in the in-person standardized evaluations for neurobehavior, neuropsychological performance, and mental health burden from the 1- to 5-year follow-up. Predictive modeling was used to identify early risk factors for long-term disability. RESULTS Among the 94 participants (87 men [93%] and 7 women [7%]; mean [SD] age, 34 [8] years), global disability, satisfaction with life, neurobehavioral symptom severity, psychiatric symptom severity, and sleep impairment were significantly worse in patients with concussive blast TBI compared with combat-deployed controls, whereas performance on cognitive measures was no different between groups at the 5-year evaluation. Logistic regression on the dichotomized Extended Glasgow Outcome Scale (GOS-E) at 5 years as a measure of overall disability identified brain injury diagnosis, preinjury intelligence, motor strength, verbal fluency, and neurobehavioral symptom severity at 1 year as risk factors for a poor outcome at 5 years, with an area under the curve of 0.92 indicating excellent prediction strength. Thirty-six of 50 patients with concussive blast TBI (72%) had a decline in the GOS-E from the 1- to 5-year evaluations, in contrast with only 5 of 44 combat-deployed controls (11%). Worsening of symptoms in concussive blast TBI was also observed on measures of posttraumatic stress disorder and depression. Service members with concussive blast TBI experienced evolution, not resolution, of symptoms from the 1- to 5-year outcomes. CONCLUSIONS AND RELEVANCE Considerable declinewas observed in military service members with concussive blast TBI when comparing 1- and 5-year clinical outcomes. These results advocate for new treatment strategies to combat the long-term and extremely costly effect of these wartime injuries.	[Mac Donald, Christine L.; Barber, Jason; Jordan, Mary; Temkin, Nancy] Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 359924, Seattle, WA 98104 USA; [Johnson, Ann M.] Washington Univ, Ctr Clin Studies, St Louis, MO USA; [Dikmen, Sureyya] Univ Washington, Dept Rehabil Med, Seattle, WA 98104 USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat, Seattle, WA 98104 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98104 USA		Mac Donald, CL (corresponding author), Univ Washington, Dept Neurol Surg, 352 9th Ave,Box 359924, Seattle, WA 98104 USA.	cmacd@uw.edu			Department of Defense grant through the Chronic Effects of Neurotrauma Consortium [W81XWH-13-2-0095]; National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health [1R01NS091618-01]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS091618] Funding Source: NIH RePORTER	This study was supported by Department of Defense grant W81XWH-13-2-0095 through the Chronic Effects of Neurotrauma Consortium and by grant 1R01NS091618-01 from the National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health.	Adam O, 2015, NEUROLOGY, V85, P219, DOI 10.1212/WNL.0000000000001758; Akaike H., 1973, P 2 INT S INF THEOR, V1973, P267, DOI 10.1007/978-1-4612-1694-0; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bell KR, 2017, J NEUROTRAUM, V34, P313, DOI 10.1089/neu.2016.4444; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Bilmes L, 2011, ELGAR HDB EC CONFLIC; Bilmes L, 2007, SOLDIERS RETURNING I; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Casscells S.W., 2007, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention (CDC) NCfIPaC, 2003, REP C MILD TRAUM BRA; Chapman JC, 2014, ALZHEIMERS DEMENT, V10, pS97, DOI 10.1016/j.jalz.2014.04.012; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Dams-O'Connor K, 2014, J HEAD TRAUMA REHAB, V29, P479, DOI 10.1097/HTR.0000000000000099; Defense and Veterans Brain Injury Center, 2016, DOD WORLDW TBI NUMB; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DVBIC, 2013, DOD NUMB TRAUM BRAIN; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Hamster K., 1983, MULTILINGUAL APHASIA; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Homaifar BY, 2009, ARCH PHYS MED REHAB, V90, P652, DOI 10.1016/j.apmr.2008.10.028; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Lannsjo M, 2013, J REHABIL MED, V45, P721, DOI 10.2340/16501977-1169; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lippa SM, 2010, J INT NEUROPSYCH SOC, V16, P856, DOI 10.1017/S1355617710000743; Mac Donald CL, 2015, BRAIN, V138, P1314, DOI 10.1093/brain/awv038; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mac Donald CL, 2016, J NEUROTRAUMA; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McCauley SR, 2010, J NEUROTRAUM, V27, P991, DOI 10.1089/neu.2009.1195; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Reid MW, 2014, J NEUROTRAUM, V31, P1899, DOI 10.1089/neu.2014.3455; Research IoMUCoSMa, 2006, SLEEP DISORDERS SLEE; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Stein MB, 2016, J NEUROTRAUM, V33, P2125, DOI 10.1089/neu.2015.4320; Stewart WF, 1999, NEUROLOGY, V53, P988, DOI 10.1212/WNL.53.5.988; Storzbach D, 2015, J INT NEUROPSYCH SOC, V21, P353, DOI 10.1017/S1355617715000326; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Taniellian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Truelle JL, 2010, BRAIN INJURY, V24, P1272, DOI 10.3109/02699052.2010.506865; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Verfaellie M, 2013, J INT NEUROPSYCH SOC, V19, P1, DOI 10.1017/S1355617712000902; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; Vuletic S, 2016, J HEAD TRAUMA REHAB, V31, P147, DOI 10.1097/HTR.0000000000000221; Walker WC, 2015, BRAIN INJURY, V29, P1581, DOI 10.3109/02699052.2015.1075151; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WechslerD, 2001, WECHSLER TEST ADULT; Wilde EA, 2010, J NEUROTRAUM, V27, P13551; Wilde EA, 2010, J NEUROTRAUM, V27, P975, DOI 10.1089/neu.2009.1193; Wilde EA, 2010, J NEUROTRAUM, V27, P983, DOI 10.1089/neu.2009.1194; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yeager DE, 2007, GEN HOSP PSYCHIAT, V29, P294, DOI 10.1016/j.genhosppsych.2007.03.004	72	72	72	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUL	2017	74	7					821	829		10.1001/jamaneurol.2017.0143			9	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	EZ9VB	WOS:000405077100014	28459953	Green Accepted, Bronze			2022-02-06	
J	Herman, DC; Jones, D; Harrison, A; Moser, M; Tillman, S; Farmer, K; Pass, A; Clugston, JR; Hernandez, J; Chmielewski, TL				Herman, Daniel C.; Jones, Debi; Harrison, Ashley; Moser, Michael; Tillman, Susan; Farmer, Kevin; Pass, Anthony; Clugston, James R.; Hernandez, Jorge; Chmielewski, Terese L.			Concussion May Increase the Risk of Subsequent Lower Extremity Musculoskeletal Injury in Collegiate Athletes	SPORTS MEDICINE			English	Article							CRUCIATE LIGAMENT RECONSTRUCTION; SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; NEUROMUSCULAR CONTROL; PERSISTENT INFLUENCE; COGNITIVE CONTROL; FOOTBALL PLAYERS; BALANCE CONTROL; GAIT; PREVENTION	Background Laboratory-based studies on neuromuscular control after concussion and epidemiological studies suggest that concussion may increase the risk of subsequent musculoskeletal injury. Objective The purpose of this study was to determine if athletes have an increased risk of lower extremity musculoskeletal injury after return to play from a concussion. Methods Injury data were collected from 2006 to 2013 for men's football and for women's basketball, soccer and lacrosse at a National Collegiate Athletic Association Division I university. Ninety cases of in-season concussion in 73 athletes (52 male, 21 female) with return to play at least 30 days prior to the end of the season were identified. A period of up to 90 days of in-season competition following return to play was reviewed for time-loss injury. The same period was studied in up to two control athletes who had no concussion within the prior year and were matched for sport, starting status and position. Results Lower extremity musculoskeletal injuries occurred at a higher rate in the concussed athletes (45/90 or 50 %) than in the non-concussed athletes (30/148 or 20 %; P < 0.01). The odds of sustaining a musculoskeletal injury were 3.39 times higher in the concussed athletes (95 % confidence interval 1.90-6.05; P < 0.01). Overall, the number of days lost because of injury was similar between concussed and non-concussed athletes (median 9 versus 15; P = 0.41). Conclusions The results of this study demonstrate a relationship between concussion and an increased risk of lower extremity musculoskeletal injury after return to play, and may have implications for current medical practice standards regarding evaluation and management of concussion injuries.	[Herman, Daniel C.; Moser, Michael; Farmer, Kevin] Univ Florida, Dept Orthopaed & Rehabil, POB 112727, Gainesville, FL 32611 USA; [Moser, Michael; Farmer, Kevin; Clugston, James R.] Univ Florida, Univ Florida Athlet Assoc, Gainesville, FL USA; [Jones, Debi; Tillman, Susan] Orthopaed & Sports Med Inst, UF Hlth Rehab Ctr, Gainesville, FL USA; [Harrison, Ashley] ProFormPT, Maitland, FL USA; [Pass, Anthony] Univ Texas Athlet, Austin, TX USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Student Hlth Care Ctr, Gainesville, FL USA; [Hernandez, Jorge] Univ Florida, Coll Vet Sci, Gainesville, FL USA; [Chmielewski, Terese L.] TRIA Orthoped Ctr, Bloomington, MN USA; [Chmielewski, Terese L.] Univ Florida, Dept Phys Therapy, Gainesville, FL USA		Herman, DC (corresponding author), Univ Florida, Dept Orthopaed & Rehabil, POB 112727, Gainesville, FL 32611 USA.	hermadc@ortho.ufl.edu		Clugston, James/0000-0002-2103-1039	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5K12HD001097-17]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER	This study was supported in part by National Institutes of Health Grant #5K12HD001097-17.	Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-25; Chiu SL, 2013, GAIT POSTURE, V38, P717, DOI 10.1016/j.gaitpost.2013.03.010; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Dai BY, 2012, RES SPORTS MED, V20, P198, DOI 10.1080/15438627.2012.680987; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Kuenze CM, 2015, J ATHL TRAINING, V50, P303, DOI 10.4085/1062-6050-49.5.06; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Livingston SC, 2010, BRAIN INJURY, V24, P904, DOI 10.3109/02699051003789245; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McGrath N, 2013, BRAIN INJURY, V27, P103, DOI 10.3109/02699052.2012.729282; Moore RD, 2015, BIOL PSYCHOL, V109, P93, DOI 10.1016/j.biopsycho.2015.04.008; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Pearce AJ, 2014, J NEUROTRAUM, V31, P1139, DOI 10.1089/neu.2013.3219; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pietrosimone BG, 2013, J SPORT REHABIL, V22, P1, DOI 10.1123/jsr.22.1.1; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Sadoghi P, 2012, J BONE JOINT SURG AM, V94A, P769, DOI 10.2106/JBJS.K.00467; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Tallus J, 2012, ACTA NEUROL SCAND, V126, P178, DOI 10.1111/j.1600-0404.2011.01623.x; Tsao H, 2008, BRAIN, V131, P2161, DOI 10.1093/brain/awn154; Tsushima WT, 2016, APPL NEUROPSYCH-CHIL, V5, P9, DOI 10.1080/21622965.2014.902762; Verhagen EALM, 2010, BRIT J SPORT MED, V44, P1082, DOI 10.1136/bjsm.2010.076406; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	37	72	72	0	27	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	MAY	2017	47	5					1003	1010		10.1007/s40279-016-0607-9			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	EV7HA	WOS:000401945300013	27544666	Green Accepted			2022-02-06	
J	Gu, S; Betzel, RF; Mattar, MG; Cieslak, M; Delio, PR; Grafton, ST; Pasqualetti, F; Bassett, DS				Gu, Shi; Betzel, Richard F.; Mattar, Marcelo G.; Cieslak, Matthew; Delio, Philip R.; Grafton, Scott T.; Pasqualetti, Fabio; Bassett, Danielle S.			Optimal trajectories of brain state transitions	NEUROIMAGE			English	Article						Network neuroscience; Control theory; Traumatic brain injury; Cognitive control; Diffusion imaging	INTERHEMISPHERIC FUNCTIONAL CONNECTIVITY; RESTING-STATE; DEFAULT-MODE; COGNITIVE IMPAIRMENT; DYNAMICAL-SYSTEMS; HUMAN CONNECTOME; MATTER; ORGANIZATION; NETWORKS; DISCONNECTION	The complexity of neural dynamics stems in part from the complexity of the underlying anatomy. Yet how white matter structure constrains how the brain transitions from one cognitive state to another remains unknown. Here we address this question by drawing on recent advances in network control theory to model the underlying mechanisms of brain state transitions as elicited by the collective control of region sets. We find that previously identified attention and executive control systems are poised to affect a broad array of state transitions that cannot easily be classified by traditional engineering-based notions of control. This theoretical versatility comes with a vulnerability to injury. In patients with mild traumatic brain injury, we observe a loss of specificity in putative control processes, suggesting greater susceptibility to neurophysiological noise. These results offer fundamental insights into the mechanisms driving brain state transitions in healthy cognition and their alteration following injury.	[Gu, Shi] Univ Penn, Appl Math & Computat Sci, Philadelphia, PA 19104 USA; [Gu, Shi; Betzel, Richard F.; Bassett, Danielle S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Mattar, Marcelo G.] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Cieslak, Matthew; Delio, Philip R.; Grafton, Scott T.] Univ Calif Santa Barbara, Dept Psychol & Brain Sci, Santa Barbara, CA 93106 USA; [Delio, Philip R.] Neurol Associates Santa Barbara, Santa Barbara, CA 93105 USA; [Pasqualetti, Fabio] Univ Calif Riverside, Dept Mech Engn, Riverside, CA 92521 USA; [Bassett, Danielle S.] Univ Penn, Dept Elect & Syst Engn, Philadelphia, PA 19104 USA		Bassett, DS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	dsb@seas.upenn.com	; Pasqualetti, Fabio/H-5807-2013	Mattar, Marcelo G/0000-0003-3303-2490; Pasqualetti, Fabio/0000-0002-8457-8656	John D. and Catherine T. MacArthur Foundation; Alfred P. Sloan FoundationAlfred P. Sloan Foundation; Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL); Army Research Office [W911NF-10-2-0022, W911NF-14-1-0679]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [2-R01-DC-009209-11]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1R01HD086888-01]; Office of Naval ResearchOffice of Naval Research; National Science FoundationNational Science Foundation (NSF) [BCS-1441502, BCS-1430087, PHY-1554488, BCS 1430280]; Head Health Challenge grant from General ElectricGeneral Electric; National Football League [SB140165]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD086888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH106799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS099348] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC009209] Funding Source: NIH RePORTER	D.S.B., S.G., and R.F.B. acknowledge support from the John D. and Catherine T. MacArthur Foundation, the Alfred P. Sloan Foundation, the Army Research Laboratory and the Army Research Office through Contract numbers W911NF-10-2-0022 and W911NF-14-1-0679, the National Institute of Mental Health (2-R01-DC-009209-11), the National Institute of Child Health and Human Development (1R01HD086888-01), the Office of Naval Research, and the National Science Foundation (BCS-1441502, BCS-1430087, and CAREER PHY-1554488). S.T.G. and P.R.D. acknowledge support from a Head Health Challenge grant from General Electric and the National Football League (SB140165). F.P. acknowledges support from the National Science Foundation award #BCS 1430280. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies.	Abdelnour F, 2014, NEUROIMAGE, V90, P335, DOI 10.1016/j.neuroimage.2013.12.039; Adachi Y, 2012, CEREB CORTEX, V22, P1586, DOI 10.1093/cercor/bhr234; Alavash M, 2015, HUM BRAIN MAPP, V36, P3542, DOI 10.1002/hbm.22861; Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001; Bassett DS, 2015, NAT NEUROSCI, V18, P744, DOI 10.1038/nn.3993; Bassett DS, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003171; Bassett DS, 2011, P NATL ACAD SCI USA, V108, P7641, DOI 10.1073/pnas.1018985108; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Bassett DS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000748; Betzel RF, 2016, SCI REP-UK, V6, DOI 10.1038/srep30770; Boltyanskii V. G., 1960, TECHNICAL REPORT; Braun U., 2015, ELS, P1, DOI DOI 10.1002/9780470015902.A0025783; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Bzdok D, 2013, NEUROIMAGE, V81, P381, DOI 10.1016/j.neuroimage.2013.05.046; Cammoun L, 2012, J NEUROSCI METH, V203, P386, DOI 10.1016/j.jneumeth.2011.09.031; Carter AR, 2012, NEUROREHAB NEURAL RE, V26, P7, DOI 10.1177/1545968311411054; Ching SN, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.021920; Cieslak M, 2014, BRAIN IMAGING BEHAV, V8, P292, DOI 10.1007/s11682-013-9254-z; Cima RFF, 2014, J AM ACAD AUDIOL, V25, P29, DOI 10.3766/jaaa.25.1.4; Cocchi L, 2013, TRENDS COGN SCI, V17, P493, DOI 10.1016/j.tics.2013.08.006; Collin G, 2016, SCHIZOPHR RES, V173, P166, DOI 10.1016/j.schres.2015.03.012; Collin G, 2013, NEUROSCIENTIST, V19, P616, DOI 10.1177/1073858413503712; Cools R, 2011, BIOL PSYCHIAT, V69, pE113, DOI 10.1016/j.biopsych.2011.03.028; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Crofts JJ, 2009, J R SOC INTERFACE, V6, P411, DOI 10.1098/rsif.2008.0484; Daducci A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048121; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Di Martino A, 2014, NEURON, V83, P1335, DOI 10.1016/j.neuron.2014.08.050; Durstewitz D, 2008, EUR J NEUROSCI, V27, P217, DOI 10.1111/j.1460-9568.2007.05976.x; Eisenreich B., 2016, CONTROL CONTROLLERS; Fagerholm ED, 2015, BRAIN, V138, P1696, DOI 10.1093/brain/awv075; Fiete IR, 2010, NEURON, V65, P563, DOI 10.1016/j.neuron.2010.02.003; Freeman Walter J., 1994, Integrative Physiological and Behavioral Science, V29, P294, DOI 10.1007/BF02691333; Galan RF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002148; Garrett DD, 2013, NEUROSCI BIOBEHAV R, V37, P610, DOI 10.1016/j.neubiorev.2013.02.015; Gazzaniga M., 2013, COGNITIVE NEUROSCIEN; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Gu S., 2016, ENERGY LANDSCA UNPUB; Gu S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9414; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hansen ECA, 2015, NEUROIMAGE, V105, P525, DOI 10.1016/j.neuroimage.2014.11.001; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hermundstad AM, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003591; Hermundstad AM, 2013, P NATL ACAD SCI USA, V110, P6169, DOI 10.1073/pnas.1219562110; Hermundstad AM, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002063; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Jbabdi S, 2013, CURR OPIN NEUROBIOL, V23, P207, DOI 10.1016/j.conb.2012.12.004; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnston JM, 2008, J NEUROSCI, V28, P6453, DOI 10.1523/JNEUROSCI.0573-08.2008; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Khambhati AN, 2016, NEURON, V91, P1170, DOI 10.1016/j.neuron.2016.07.039; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klimm F, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003491; Laughlin SB, 2001, NOVART FDN SYMP, V239, P177; Laughlin SB, 1998, NAT NEUROSCI, V1, P36, DOI 10.1038/236; Lee S, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.16; Lett TA, 2014, BIOL PSYCHIAT, V75, P361, DOI 10.1016/j.biopsych.2013.07.026; Levy N, 2001, NEURAL NETWORKS, V14, P815, DOI 10.1016/S0893-6080(01)00044-2; Liu YY, 2011, NATURE, V473, P167, DOI 10.1038/nature10011; Luenberger D.G., 1979, INTRO DYNAMIC SYSTEM; Medaglia JD, 2015, J COGNITIVE NEUROSCI, V27, P1471, DOI 10.1162/jocn_a_00810; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Misic B, 2015, NEURON, V86, P1518, DOI 10.1016/j.neuron.2015.05.035; Muller FJ, 2011, NATURE, V478, pE4, DOI 10.1038/nature10543; Muldoon SF, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005076; Muldoon SF, 2016, SCI REP-UK, V6, DOI 10.1038/srep22057; Nenadovic V, 2008, J NEUROTRAUM, V25, P615, DOI 10.1089/neu.2007.0474; Niven JE, 2008, J EXP BIOL, V211, P1792, DOI 10.1242/jeb.017574; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; O'Reilly JX, 2013, P NATL ACAD SCI USA, V110, P13982, DOI 10.1073/pnas.1305062110; Pasqualetti F, 2014, IEEE T CONTROL NETW, V1, P40, DOI 10.1109/TCNS.2014.2310254; Pestilli F, 2014, NAT METHODS, V11, P1058, DOI 10.1038/nmeth.3098; Posner M. I., 1989, DTIC DOCUMENT; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Radhu N, 2012, BRAIN STIMUL, V5, P44, DOI 10.1016/j.brs.2011.01.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Raja Beharelle A, 2012, NEUROIMAGE, V60, P1528, DOI 10.1016/j.neuroimage.2012.01.037; Rajan K, 2016, NEURON, V90, P128, DOI 10.1016/j.neuron.2016.02.009; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Reveley C, 2015, P NATL ACAD SCI USA, V112, pE2820, DOI 10.1073/pnas.1418198112; Rusconi E, 2009, ANN NEUROL, V66, P654, DOI 10.1002/ana.21776; Rushworth MFS, 2006, CEREB CORTEX, V16, P1418, DOI 10.1093/cercor/bhj079; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Shenoy KV, 2011, PROG BRAIN RES, V192, P33, DOI 10.1016/B978-0-444-53355-5.00003-8; Sidaros A., 2008, DIFFUSION TENSOR IMA; Sizemore A., 2015, CLASSIFICATION WEIGH; Sommer IEC, 2012, SCHIZOPHRENIA BULL, V38, P704, DOI 10.1093/schbul/sbs034; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stam CJ, 2014, NAT REV NEUROSCI, V15, P683, DOI 10.1038/nrn3801; Stephan KE, 2009, SCHIZOPHRENIA BULL, V35, P509, DOI 10.1093/schbul/sbn176; Szameitat AJ, 2011, NEUROIMAGE, V54, P1765, DOI 10.1016/j.neuroimage.2010.07.069; Thomas C, 2014, P NATL ACAD SCI USA, V111, P16574, DOI 10.1073/pnas.1405672111; Tortella G, 2014, CNS NEUROL DISORD-DR, V13, P1759; Weiss SA, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00081; Yan G, 2012, PHYS REV LETT, V108, DOI 10.1103/PhysRevLett.108.218703; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	100	72	73	4	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAR 1	2017	148						305	317		10.1016/j.neuroimage.2017.01.003			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	EO6LD	WOS:000396803100030	28088484	Green Accepted, hybrid, Green Submitted			2022-02-06	
J	Parsons, TD; Carlew, AR; Magtoto, J; Stonecipher, K				Parsons, Thomas D.; Carlew, Anne R.; Magtoto, Jonlih; Stonecipher, Kiefer			The potential of function-led virtual environments for ecologically valid measures of executive function in experimental and clinical neuropsychology	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Virtual environments; Neuropsychological assessment; Ecological validity; Executive function	MULTIPLE ERRANDS TEST; CONTINUOUS PERFORMANCE-TEST; TRAUMATIC BRAIN-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; SIMULATOR DRIVING PERFORMANCE; ACTION PLANNING-SUPERMARKET; COGNITIVE IMPAIRMENTS; INITIAL VALIDATION; SIMPLIFIED VERSION; PEDESTRIAN SAFETY	The assessment of executive functions is an integral task of neuropsychological assessment. Traditional measures of executive function are often based on hypothetical constructs that may have little relevance to real-world behaviours. In fact, some traditional tests utilised today were not originally developed for clinical use. Recently, researchers have been arguing for a new generation of function-led neuropsychological assessments that are developed from directly observable everyday behaviours. Although virtual environments (VEs) have been presented as potential aides in enhancing ecological validity, many were modelled on construct-driven approaches found in traditional assessments. In the current paper, we review construct-driven and function-led VE-based neuropsychological assessments of executive functions. Overall, function-led VEs best represent the sorts of tasks needed for enhanced ecological validity and prediction of real-world functioning.	[Parsons, Thomas D.; Carlew, Anne R.; Magtoto, Jonlih; Stonecipher, Kiefer] Univ North Texas, Dept Psychol, Computat Neuropsychol & Simulat, Denton, TX USA		Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, CNS Lab, Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.; Parsons, TD (corresponding author), Univ North Texas, Dept Psychol, CNS Lab, 1155 Union Circle 311280, Denton, TX 76203 USA.	Thomas.Parsons@unt.edu		Parsons, Thomas/0000-0003-0331-5019; Carlew, Anne/0000-0001-7980-3954			Adams R, 2009, CHILD NEUROPSYCHOL, V15, P120, DOI 10.1080/09297040802169077; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; Allen AJ, 2009, ALCOHOL CLIN EXP RES, V33, P617, DOI 10.1111/j.1530-0277.2008.00876.x; Armstrong CM, 2013, J CLIN EXP NEUROPSYC, V35, P113, DOI 10.1080/13803395.2012.740002; Asimakopulos J, 2012, AUST OCCUP THER J, V59, P402, DOI 10.1111/j.1440-1630.2011.00963.x; Attree E. A., 1996, ECDVRAT 1 EUR C DIS, V118; Avis KT, 2014, SLEEP, V37, P283, DOI 10.5665/sleep.3398; Bailey PE, 2010, Q J EXP PSYCHOL, V63, P646, DOI 10.1080/17470210903521797; Barkley RA, 2006, NEUROPSYCHOLOGY, V20, P77, DOI 10.1037/0894-4105.20.1.77; Barkley RA, 2005, J SAFETY RES, V36, P121, DOI 10.1016/j.jsr.2005.01.001; Barkley Russell A, 2007, J Atten Disord, V10, P306, DOI 10.1177/1087054706292122; Bauer RM, 2012, CLIN NEUROPSYCHOL, V26, P177, DOI 10.1080/13854046.2012.663001; Bedard M, 2010, AM J OCCUP THER, V64, P336, DOI 10.5014/ajot.64.2.336; Bioulac S, 2012, EUR J PAEDIATR NEURO, V16, P514, DOI 10.1016/j.ejpn.2012.01.006; Bohil CJ, 2011, NAT REV NEUROSCI, V12, P752, DOI 10.1038/nrn3122; Bottari C, 2009, BRAIN INJURY, V23, P322, DOI 10.1080/02699050902788436; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P.W., 2005, EFFECTIVENESS REHABI, P211, DOI DOI 10.1093/ACPROF:OSO/9780198526544.001.0001; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Buxbaum LJ, 2012, NEUROPSYCHOLOGY, V26, P430, DOI 10.1037/a0028674; Calhoun VD, 2012, NEUROIMAGE, V59, P25, DOI 10.1016/j.neuroimage.2011.06.037; Campbell Z, 2009, APPL NEUROPSYCHOL, V16, P295, DOI 10.1080/09084280903297891; Cao X, 2010, P 8 INT C DIS VIRT R, P71; Carelli L, 2008, 2008 VIRTUAL REHABILITATION, P99, DOI 10.1109/ICVR.2008.4625144; Chan RCK, 2008, ARCH CLIN NEUROPSYCH, V23, P201, DOI 10.1016/j.acn.2007.08.010; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cipresso P, 2013, EXP BRAIN RES, V229, P443, DOI 10.1007/s00221-013-3471-y; Clancy TA, 2006, J CLIN CHILD ADOLESC, V35, P203, DOI 10.1207/s15374424jccp3502_4; Cook LG, 2013, J INT NEUROPSYCH SOC, V19, P508, DOI 10.1017/S1355617712001452; Cox DJ, 2008, J CHILD ADOL PSYCHOP, V18, P1, DOI 10.1089/cap.2006.0141; Cuberos-Urbano G, 2013, J CLIN EXP NEUROPSYC, V35, P329, DOI 10.1080/13803395.2013.776011; Davis AL, 2013, J ADOLESCENT HEALTH, V53, P785, DOI 10.1016/j.jadohealth.2013.07.008; Dawson DR, 2009, ARCH PHYS MED REHAB, V90, pS41, DOI 10.1016/j.apmr.2009.07.012; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Diaz-Orueta U, 2014, CHILD NEUROPSYCHOL, V20, P328, DOI 10.1080/09297049.2013.792332; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; Fox J., 2009, J MEDIA PSYCHOL-GER, V21, P95; Franzen M.D., 1996, ECOLOGICAL VALIDITY, P91; Goldstein, 1996, ECOLOGICAL VALIDITY, P75; Henry M, 2012, J NEUROSCI METH, V210, P125, DOI 10.1016/j.jneumeth.2012.07.025; Iriarte Y, 2016, J ATTEN DISORD, V20, P542, DOI 10.1177/1087054712465335; Jansari AS, 2013, ADDICTION, V108, P977, DOI 10.1111/add.12082; Josman N, 2014, J STROKE CEREBROVASC, V23, P879, DOI 10.1016/j.jstrokecerebrovasdis.2013.07.013; Josman N, 2009, SCHIZOPHR RES, V115, P270, DOI 10.1016/j.schres.2009.09.015; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P207, DOI 10.1080/09084282.2011.643956; Jovanovski D, 2012, APPL NEUROPSYCH-ADUL, V19, P171, DOI 10.1080/09084282.2011.643955; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Knouse Laura E, 2005, J Atten Disord, V8, P221, DOI 10.1177/1087054705280159; Lalonde G, 2013, J NEUROSCI METH, V219, P76, DOI 10.1016/j.jneumeth.2013.07.005; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; Law AS, 2013, Q J EXP PSYCHOL, V66, P1241, DOI 10.1080/17470218.2012.748813; Lee HC, 2003, J SAFETY RES, V34, P453, DOI 10.1016/j.jsr.2003.09.007; Lee HC, 2003, ACCIDENT ANAL PREV, V35, P797, DOI 10.1016/S0001-4575(02)00083-0; Levine B, 2000, NEUROPSYCHOLOGY, V14, P491, DOI 10.1037/0894-4105.14.4.491; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; Logie RH, 2011, MEM COGNITION, V39, P1561, DOI 10.3758/s13421-011-0120-1; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; Miller KJ, 2014, AGE AGEING, V43, P188, DOI 10.1093/ageing/aft194; Milleville-Pennel I, 2010, BRAIN INJURY, V24, P678, DOI 10.3109/02699051003692159; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Moffat SD, 2009, NEUROPSYCHOL REV, V19, P478, DOI 10.1007/s11065-009-9120-3; Montgomery C, 2011, HUM PSYCHOPHARM CLIN, V26, P208, DOI 10.1002/hup.1194; Morris R. G., 2002, INT C DIS VIRT REAL, V4, P101; Nagamatsu LS, 2011, PSYCHOL AGING, V26, P253, DOI 10.1037/a0022929; Norman DA., 1986, CONSCIOUSNESS SELF R, P1, DOI [10.1007/978-1-4757-0629-1_1, DOI 10.1007/978-1-4757-0629-1_1]; Parsey CM, 2013, CLIN NEUROPSYCHOL, V27, P1328, DOI 10.1080/13854046.2013.834971; Parsons TD, 2008, J BEHAV THER EXP PSY, V39, P250, DOI 10.1016/j.jbtep.2007.07.007; Parsons TD, 2008, CYBERPSYCHOL BEHAV, V11, P17, DOI 10.1089/cpb.2007.9934; Parsons TD, 2007, CHILD NEUROPSYCHOL, V13, P363, DOI 10.1080/13825580600943473; Parsons TD, 2013, 2013 1ST WORKSHOP ON VIRTUAL AND AUGMENTED ASSISTIVE TECHNOLOGY (VAAT), P27, DOI 10.1109/VAAT.2013.6786190; Parsons TD, 2014, J NEUROSCI METH, V222, P15, DOI 10.1016/j.jneumeth.2013.10.006; Parsons TD, 2013, J CLIN EXP NEUROPSYC, V35, P812, DOI 10.1080/13803395.2013.824556; Parsons TD, 2011, STUD COMPUT INTELL, V337, P271; Patil I, 2014, SOC NEUROSCI-UK, V9, P94, DOI 10.1080/17470919.2013.870091; Pedroli E., 2013, ANN REV CYBERTHERAPY, V191, P48; Pollak Y, 2010, CNS SPECTRUMS, V15, P125, DOI 10.1017/S109285290002736X; Pollak Y, 2009, J DEV BEHAV PEDIATR, V30, P2, DOI 10.1097/DBP.0b013e3181969b22; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Pugnetti L., 1998, CYBERPSYCHOLOGY BEHA, V1, P151, DOI DOI 10.1089/CPB.1998.1.151; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Rand D, 2009, NEUROPSYCHOL REHABIL, V19, P583, DOI 10.1080/09602010802469074; Raspelli S, 2012, PRESENCE-TELEOP VIRT, V21, P31, DOI 10.1162/PRES_a_00077; Renison B, 2012, J INT NEUROPSYCH SOC, V18, P440, DOI 10.1017/S1355617711001883; Rizzo AS, 2002, STUD NEUROPSYCHOL DE, P243; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Saidel-Goley IN, 2012, CYBERPSYCH BEH SOC N, V15, P112, DOI 10.1089/cyber.2011.0302; Sauzeon H, 2016, J NEUROPSYCHOL, V10, P33, DOI 10.1111/jnp.12055; Sbordone R.J., 2008, NEUROPSYCHOLOGY HDB, P367; Schatz P, 2002, J HEAD TRAUMA REHAB, V17, P395, DOI 10.1097/00001199-200210000-00003; Schultheis MT, 2007, ASSIST TECHNOL, V19, P1, DOI 10.1080/10400435.2007.10131860; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P378, DOI 10.1097/00001199-200210000-00002; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; Sweeney S, 2010, NEUROPSYCHOL REHABIL, V20, P239, DOI 10.1080/09602010903080531; Toet A, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00883; Wald J, 2001, ST HEAL T, V81, P564; Wald JL, 2000, CYBERPSYCHOL BEHAV, V3, P643, DOI 10.1089/109493100420232; Weigl E., 1948, J ABNORM SOC PSYCHOL, V36, P3; Werner P, 2009, DEMENT GERIATR COGN, V27, P301, DOI 10.1159/000204915	107	72	73	1	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2017	27	5			SI		777	807		10.1080/09602011.2015.1109524			31	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	EU3IT	WOS:000400923300010	26558491				2022-02-06	
J	Alluri, H; Wilson, RL; Shaji, CA; Wiggins-Dohlvik, K; Patel, S; Liu, Y; Peng, X; Beeram, MR; Davis, ML; Huang, JH; Tharakan, B				Alluri, Himakarnika; Wilson, Rickesha L.; Shaji, Chinchusha Anasooya; Wiggins-Dohlvik, Katie; Patel, Savan; Liu, Yang; Peng, Xu; Beeram, Madhava R.; Davis, Matthew L.; Huang, Jason H.; Tharakan, Binu			Melatonin Preserves Blood-Brain Barrier Integrity and Permeability via Matrix Metalloproteinase-9 Inhibition	PLOS ONE			English	Article							ENDOTHELIAL-CELLS; CEREBROSPINAL-FLUID; IN-VITRO; INJURY; INTERLEUKIN-1; MICE; METALLOPROTEINASES; HYPERPERMEABILITY; DYSFUNCTION; OCCLUDIN	Microvascular hyperpermeability that occurs at the level of the blood-brain barrier (BBB) often leads to vasogenic brain edema and elevated intracranial pressure following traumatic brain injury (TBI). At a cellular level, tight junction proteins (TJPs) between neighboring endothelial cells maintain the integrity of the BBB via TJ associated proteins particularly, zonula occludens-1 (ZO-1) that binds to the transmembrane TJPs and actin cytoskeleton intracellularly. The pro-inflammatory cytokine, interleukin-1 beta (IL-1 beta) as well as the proteolytic enzymes, matrix metalloproteinase-9 (MMP-9) are key mediators of trauma-associated brain edema. Recent studies indicate that melatonin a pineal hormone directly binds to MMP-9 and also might act as its endogenous inhibitor. We hypothesized that melatonin treatment will provide protection against TBI-induced BBB hyperpermeability via MMP-9 inhibition. Rat brain microvascular endothelial cells grown as monolayers were used as an in vitro model of the BBB and a mouse model of TBI using a controlled cortical impactor was used for all in vivo studies. IL-1 beta (10 ng/mL; 2 hours)-induced endothelial monolayer hyperpermeability was significantly attenuated by melatonin (10 mu g/mL; 1 hour), GM6001 (broad spectrum MMP inhibitor; 10 mu M; 1 hour), MMP-9 inhibitor-1 (MMP-9 specific inhibitor; 5 nM; 1 hour) or MMP-9 siRNA transfection (48 hours) in vitro. Melatonin and MMP-9 inhibitor-1 pretreatment attenuated IL-1 beta-induced MMP-9 activity, loss of ZO-1 junctional integrity and f-actin stress fiber formation. IL-1 beta treatment neither affected ZO-1 protein or mRNA expression or cell viability. Acute melatonin treatment attenuated BBB hyperpermeability in a mouse controlled cortical impact model of TBI in vivo. In conclusion, one of the protective effects of melatonin against BBB hyperpermeability occurs due to enhanced BBB integrity via MMP-9 inhibition. In addition, acute melatonin treatment provides protection against BBB hyperpermeability in a mouse model of TBI indicating its potential as a therapeutic agent for brain edema when established in humans.	[Alluri, Himakarnika; Wilson, Rickesha L.; Shaji, Chinchusha Anasooya; Wiggins-Dohlvik, Katie; Patel, Savan; Tharakan, Binu] Texas A&M Univ, Coll Med, Dept Surg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Liu, Yang; Peng, Xu; Davis, Matthew L.] Texas A&M Univ, Coll Med, Dept Med Physiol, Hlth Sci Ctr, Temple, TX 76508 USA; [Beeram, Madhava R.] Texas A&M Univ, Coll Med, Dept Pediat, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Huang, Jason H.] Texas A&M Univ, Coll Med, Dept Neurosurg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA; [Wilson, Rickesha L.] Univ Connecticut, Sch Med, Dept Surg, Farmington, CT USA		Tharakan, B (corresponding author), Texas A&M Univ, Coll Med, Dept Surg, Baylor Scott & White Hlth,Hlth Sci Ctr, Temple, TX 76508 USA.	btharakan@medicine.tamhsc.edu	Huang, Jason H/J-4739-2019	Huang, Jason H/0000-0002-4426-0168	Baylor Scott and White Health Academic Operations	We acknowledge the Baylor Scott and White Health Academic Operations for financial Support and Texas A&M University Health Science Center Integrated Microscopy and Imaging Laboratory for the use of Olympus confocal laser microscope. We also acknowledge Mr. Glen Cryer for his help with manuscript preparation.	Adderley SP, 2015, AM J PHYSIOL-CELL PH, V309, pC51, DOI 10.1152/ajpcell.00096.2015; Alluri H, 2015, METAB BRAIN DIS, V30, P1093, DOI 10.1007/s11011-015-9651-7; Amin ARMR, 2003, GENES CELLS, V8, P515, DOI 10.1046/j.1365-2443.2003.00652.x; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Blamire AM, 2000, J NEUROSCI, V20, P8153; Bolton SJ, 1998, NEUROSCIENCE, V86, P1245, DOI 10.1016/S0306-4522(98)00058-X; Breslin JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117970; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Chen F, 2009, HEPATOLOGY, V50, P1914, DOI 10.1002/hep.23203; Chen YC, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00100; Coisne C, 2011, ANTIOXID REDOX SIGN, V15, P1285, DOI 10.1089/ars.2011.3929; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Didier N, 2003, J NEUROCHEM, V86, P246, DOI 10.1046/j.1471-4159.2003.01829.x; Dong LP, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/370804; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Rigor RR, 2012, AM J PHYSIOL-CELL PH, V302, pC1513, DOI 10.1152/ajpcell.00371.2011; Rudra DS, 2013, J PINEAL RES, V54, P398, DOI 10.1111/jpi.12034; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Simao F, 2012, J CEREBR BLOOD F MET, V32, P884, DOI 10.1038/jcbfm.2012.2; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Sozen T, 2009, STROKE, V40, P2519, DOI 10.1161/STROKEAHA.109.549592; Stagg HW, 2013, J TRAUMA ACUTE CARE, V75, P1040, DOI 10.1097/TA.0b013e3182aa9c79; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; Wiggins-Dohlvik K, 2014, AM J SURG, V208, P954, DOI 10.1016/j.amjsurg.2014.08.014; Wiggins-Dohlvik K, 2014, J TRAUMA ACUTE CARE, V77, P899, DOI 10.1097/TA.0000000000000346; Wu BH, 2010, TRANSL STROKE RES, V1, P57, DOI 10.1007/s12975-009-0002-z	28	72	76	2	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2016	11	5							e0154427	10.1371/journal.pone.0154427			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DL5KX	WOS:000375677000020	27152411	Green Published, Green Submitted, gold			2022-02-06	
J	Fischer, TD; Hylin, MJ; Zhao, J; Moore, AN; Waxharni, MN; Dash, PK				Fischer, Tara D.; Hylin, Michael J.; Zhao, Jing; Moore, Anthony N.; Waxharni, M. Neal; Dash, Pramod K.			Altered Mitochondria! Dynamics and TBI Pathophysiology	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						Drp1; mitochondrial dynamics; neurodegeneration; neurogenesis; TBI	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; ADULT HIPPOCAMPAL NEUROGENESIS; DEPENDENT PROTEIN-KINASE; NEWBORN NEURONS; WORKING-MEMORY; CYCLOSPORINE-A; GRANULE CELLS; MOUSE MODEL; FISSION	Mitochondrial function is intimately linked to cellular survival, growth, and death. Mitochondria not only generate ATP from oxidative phosphorylation, but also mediate intracellular calcium buffering, generation of reactive oxygen species (ROS), and apoptosis. Electron leakage from the electron transport chain, especially from damaged or depolarized mitochondria, can generate excess free radicals that damage cellular proteins. DNA, and lipids. Furthermore, Mitochondrial damage releases pro-apoptotic factors to initiate cell death. Previous studies have reported that traumatic brain injury (TBI) reduces Mitochondrial respiration, enhances production of ROS, and triggers apoptotic cell death, suggesting a prominent role of mitochondria in TBI pathophysiology. Mitochondria maintain cellular energy homeostasis and health via balanced processes of fusion and fission, continuously dividing and fusing to form an interconnected network throughout the cell. An imbalance of these processes, particularly an excess of fission, can be detrimental to Mitochondrial function, causing decreased respiration, ROS production, and apoptosis. Mitochondrial fission is regulated by the cytosolic GTPase, dynamin-related protein 1 (Drp1), which translocates to the Mitochondrial outer membrane (MOM) to initiate fission. Aberrant Drp1 activity has been linked to excessive Mitochondrial fission and neurodegeneration. Measurement of Drp1 levels in purified hippocampal mitochondria showed an increase in TBI animals as compared to sham controls. Analysis of cryo-electron micrographs of these mitochondria also showed that TBI caused an initial increase in the length of hippocampal mitochondria at 24 h post-injury, followed by a significant decrease in length at 72 h. Post-TBI administration of Mitochondrial division inhibitor-1 (Mdivi-1), a pharmacological inhibitor of Drp1, prevented this decrease in mitochondria length. Mdivi-1 treatment also reduced the loss of newborn neurons in the hippocampus and improved novel object recognition (NOR) memory and context-specific fear memory. Taken together, our results show that TBI increases Mitochondrial fission and that inhibition of fission improves hippocampal-dependent learning and memory, suggesting that strategies to reduce fission may have translational value after injury.	[Fischer, Tara D.; Zhao, Jing; Moore, Anthony N.; Waxharni, M. Neal; Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Hylin, Michael J.] So Illinois Univ, Dept Psychol, Carbondale, IL 62901 USA; [Dash, Pramod K.] Univ Texas Hlth Sci Ctr Houston, McGovern Pvled Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA		Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX 77030 USA.; Dash, PK (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Pvled Sch, Vivian L Smith Dept Neurosurg, Houston, TX 77030 USA.	p.dash@uth.tmc.edu	Hylin, Michael/U-2878-2019; Fischer, Tara/ABA-1727-2020	Waxham, M. Neal/0000-0003-4801-1190; Hylin, Michael/0000-0002-8600-3047; Fischer, Tara/0000-0002-6590-4401	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS086301, NS087149]; William Wheless III professorship; Structural Biology Imaging Center at UTHSC-Houston; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016279]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS101686, R01NS087149, R01NS086301] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD016279] Funding Source: NIH RePORTER	The authors would like to thank Kimberly Hood, John Redell for their assistance and suggestions. This work was supported by the Nina and Michael Zilkha endowment, grants from NIH (NS086301 and NS087149). MNW acknowledges the support of William Wheless III professorship. The Polara electron microscope was supported, in part, through the Structural Biology Imaging Center at UTHSC-Houston. The Gatan K2 Summit was funded by the National Institutes of Health-Award S10OD016279.	Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Burte F, 2015, NAT REV NEUROL, V11, P11, DOI 10.1038/nrneurol.2014.228; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cereghetti GM, 2008, P NATL ACAD SCI USA, V105, P15803, DOI 10.1073/pnas.0808249105; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Costa V, 2010, EMBO MOL MED, V2, P490, DOI 10.1002/emmm.201000102; Cribbs JT, 2007, EMBO REP, V8, P939, DOI 10.1038/sj.embor.7401062; Denny CA, 2012, HIPPOCAMPUS, V22, P1188, DOI 10.1002/hipo.20964; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drew MR, 2010, BEHAV NEUROSCI, V124, P446, DOI 10.1037/a0020081; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hernandez-Rabaza V, 2009, NEUROSCIENCE, V159, P59, DOI 10.1016/j.neuroscience.2008.11.054; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Jheng HF, 2012, MOL CELL BIOL, V32, P309, DOI 10.1128/MCB.05603-11; Kanamaru Yusuke, 2012, J Signal Transduct, V2012, P931215, DOI 10.1155/2012/931215; Kheirbek MA, 2012, J NEUROSCI, V32, P8696, DOI 10.1523/JNEUROSCI.1692-12.2012; Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Manczak M, 2012, HUM MOL GENET, V21, P2538, DOI 10.1093/hmg/dds072; Nakashiba T, 2012, CELL, V149, P188, DOI 10.1016/j.cell.2012.01.046; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Otera H, 2013, BBA-MOL CELL RES, V1833, P1256, DOI 10.1016/j.bbamcr.2013.02.002; Prins M, 2013, DIS MODEL MECH, V6, P1307, DOI 10.1242/dmm.011585; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rappold PM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6244; Reddy PH, 2011, BRAIN RES REV, V67, P103, DOI 10.1016/j.brainresrev.2010.11.004; Rintoul GL, 2003, J NEUROSCI, V23, P7881; Santel A, 2008, IUBMB LIFE, V60, P448, DOI 10.1002/iub.71; Sims NR, 2008, NAT PROTOC, V3, P1228, DOI 10.1038/nprot.2008.105; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Suarez-Pereira I, 2015, HIPPOCAMPUS, V25, P51, DOI 10.1002/hipo.22349; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Wang HX, 2011, J BIOL CHEM, V286, P11649, DOI 10.1074/jbc.M110.144238; Westermann B, 2012, BBA-BIOENERGETICS, V1817, P1833, DOI 10.1016/j.bbabio.2012.02.033; Wiltgen BJ, 2006, J NEUROSCI, V26, P5484, DOI 10.1523/JNEUROSCI.2685-05.2006; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Yu TZ, 2008, CARDIOVASC RES, V79, P341, DOI 10.1093/cvr/cvn104; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhao YX, 2014, CNS NEUROSCI THER, V20, P528, DOI 10.1111/cns.12266; Zhao YX, 2013, J NEUROCHEM, V127, P711, DOI 10.1111/jnc.12340	65	72	73	1	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	MAR 30	2016	10								20	10.3389/fnsys.2010.00020			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DH7IC	WOS:000372965600001	27065821	gold, Green Published			2022-02-06	
J	Johnstone, DM; Moro, C; Stone, J; Benabid, AL; Mitrofanis, J				Johnstone, Daniel M.; Moro, Cecile; Stone, Jonathan; Benabid, Alim-Louis; Mitrofanis, John			Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease	FRONTIERS IN NEUROSCIENCE			English	Article						disease-modifying; neuroprotection; photobiomodulation; amyloid plagues; tau protein	LEVEL LASER THERAPY; TRAUMATIC BRAIN-INJURY; DOPAMINERGIC CELL-SURVIVAL; TERM NEUROLOGICAL DEFICITS; TRANSGENIC MOUSE MODEL; ACUTE ISCHEMIC-STROKE; MPTP-TREATED MICE; MITOCHONDRIAL DYSFUNCTION; INDUCED NEUROTOXICITY; SENILE PLAQUES	Alzheimer's and Parkinson's disease are the two most common neurodegenerative disorders. They develop after a progressive death of many neurons in the brain. Although therapies are available to treat the signs and symptoms of both diseases, the progression of neuronal death remains relentless, and it has proved difficult to slow or stop. Hence, there is a need to develop neuroprotective or disease-modifying treatments that stabilize this degeneration. Red to infrared light therapy (lambda =600-1070 nm), and in particular light in the near infrared (NIr) range, is emerging as a safe and effective therapy that is capable of arresting neuronal death. Previous studies have used NIr to treat tissue stressed by hypoxia, toxic insult, genetic mutation and mitochondrial dysfunction with much success. Here we propose NIr therapy as a neuroprotective or disease-modifying treatment for Alzheimer's and Parkinson's patients.	[Johnstone, Daniel M.; Stone, Jonathan] Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; [Moro, Cecile; Benabid, Alim-Louis; Mitrofanis, John] Univ Grenoble Alpes, CEA, LETI, CLINATEC, Grenoble, France; Univ Sydney, Dept Anat, Sydney, NSW 2006, Australia		Mitrofanis, J (corresponding author), Univ Grenoble Alpes, CEA, LETI, CLINATEC, MINATEC Campus, Grenoble, France.	john.mitrofanis@sydney.edu.cn	Johnstone, Daniel/E-9929-2013	Johnstone, Daniel/0000-0003-2876-3299	Tenix corp; Salteri family; Fondation Philanthropique Edmond J. Safra, France Parkinson; Michael J. Fox Foundation; French National Research Agency (ANR Carnot Institute)French National Research Agency (ANR); Foote Foundation; Sir Zelman Cowen Universities Fund	We are forever grateful to Tenix corp, Salteri family, Fondation Philanthropique Edmond J. Safra, France Parkinson, Michael J. Fox Foundation, and the French National Research Agency (ANR Carnot Institute) for funding our work. DJ is an Early Career Fellow of the NHMRC Australia. JS was supported by the Foote Foundation and Sir Zelman Cowen Universities Fund; he is Director of CSCM Ply Ltd.	Abdo A, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.7.075001; Albarracin R, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-125; Alzheimer A, 1911, Z GESAMTE NEUROL PSY, V4, P356, DOI 10.1007/BF02866241; Alzheimer A., 1907, ALLG ZEITSCHR PSYCHI, V64, P146; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828; Benabid AL, 2009, LANCET NEUROL, V8, P67, DOI 10.1016/S1474-4422(08)70291-6; Bergman H, 2002, MOVEMENT DISORD, V17, pS28, DOI 10.1002/mds.10140; Bezard E, 2013, MOVEMENT DISORD, V28, P61, DOI 10.1002/mds.25108; Blanco NJ, 2017, J NEUROPSYCHOL, V11, P14, DOI 10.1111/jnp.12074; Blandini F, 2000, PROG NEUROBIOL, V62, P63, DOI 10.1016/S0301-0082(99)00067-2; Blesa J, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/845618; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; BRAVERMAN B, 1989, LASER SURG MED, V9, P50, DOI 10.1002/lsm.1900090111; Brettschneider J, 2015, NAT REV NEUROSCI, V16, P109, DOI 10.1038/nrn3887; Burchman M A, 2011, J LASER DENT, V19, P297; Byrnes KR, 2005, LASER SURG MED, V36, P171, DOI 10.1002/lsm.20143; Carvey PM, 2009, J NEUROCHEM, V111, P291, DOI 10.1111/j.1471-4159.2009.06319.x; Chaturvedi RK, 2008, ANN NY ACAD SCI, V1147, P395, DOI 10.1196/annals.1427.027; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Coppede F, 2015, MUTAT RES-FUND MOL M, V776, P84, DOI 10.1016/j.mrfmmm.2014.11.010; Corti O, 2013, CURR OPIN NEUROBIOL, V23, P100, DOI 10.1016/j.conb.2012.11.002; Cosgrove J, 2015, POSTGRAD MED J, V91, P212, DOI 10.1136/postgradmedj-2015-133247; Cullen KM, 2006, NEUROBIOL AGING, V27, P1786, DOI 10.1016/j.neurobiolaging.2005.10.016; Cullen KM, 2005, J CEREBR BLOOD F MET, V25, P1656, DOI 10.1038/sj.jcbfm.9600155; Darlot F, 2016, ANN NEUROL, V79, P59, DOI 10.1002/ana.24542; de la Torre JC, 2004, LANCET NEUROL, V3, P184, DOI 10.1016/S1474-4422(04)00683-0; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Del Tredici K, 2013, J NEUROL NEUROSUR PS, V84, P774, DOI 10.1136/jnnp-2011-301817; DeSmet K, 2009, PROC SPIE, V7165, DOI 10.1117/12.803964; Desmet KD, 2006, PHOTOMED LASER SURG, V24, P121, DOI 10.1089/pho.2006.24.121; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Durieux J, 2011, CELL, V144, P79, DOI 10.1016/j.cell.2010.12.016; Eells JT, 2004, MITOCHONDRION, V4, P559, DOI 10.1016/j.mito.2004.07.033; El Massri N, 2016, INT J NEUROSCI, V126, P76, DOI 10.3109/00207454.2014.994063; Exner N, 2012, EMBO J, V31, P3038, DOI 10.1038/emboj.2012.170; Farfara D, 2015, J MOL NEUROSCI, V55, P430, DOI 10.1007/s12031-014-0354-z; Farkas E, 2000, ACTA NEUROPATHOL, V100, P395, DOI 10.1007/s004010000195; Fitzgerald M, 2010, J NEUROTRAUM, V27, P2107, DOI 10.1089/neu.2010.1426; Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002; Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946; Garcia-Alloza M, 2006, NEUROBIOL DIS, V24, P516, DOI 10.1016/j.nbd.2006.08.017; Gitler AD, 2009, NAT GENET, V41, P308, DOI 10.1038/ng.300; Gkotsi D, 2014, EXP EYE RES, V122, P50, DOI 10.1016/j.exer.2014.02.023; Goedert M, 2006, SCIENCE, V314, P777, DOI 10.1126/science.1132814; Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Grammas P, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001918; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Hamblin M. R., 2006, P SPIE INT SOC OPTIC; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Haslinger B, 2001, BRAIN, V124, P558, DOI 10.1093/brain/124.3.558; Hausenloy DJ, 2008, CARDIOVASC RES, V79, P377, DOI 10.1093/cvr/cvn114; Herrup K, 2015, NAT NEUROSCI, V18, P794, DOI 10.1038/nn.4017; Hou ST, 2008, INT REV CEL MOL BIO, V267, P125, DOI 10.1016/S1937-6448(08)00603-5; Ilic S, 2006, PHOTOMED LASER SURG, V24, P458, DOI 10.1089/pho.2006.24.458; Jankovic J, 2012, CURR OPIN NEUROL, V25, P433, DOI 10.1097/WCO.0b013e3283542fc2; Johnstone D., 2014, CHRONOPHYSIOL THER, V4, P1, DOI DOI 10.2147/CPT.S57180; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Johnstone DM, 2015, NEURAL REGEN RES, V10, P349, DOI 10.4103/1673-5374.153673; Kortekaas R, 2005, ANN NEUROL, V57, P176, DOI 10.1002/ana.20369; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2010, ANN MED, V42, P576, DOI 10.3109/07853890.2010.532811; Liang HL, 2008, NEUROSCIENCE, V153, P963, DOI 10.1016/j.neuroscience.2008.03.042; Maloney R., 2010, AM SOC LASER MED SUR, V185; McCarthy TJ, 2010, PHOTOMED LASER SURG, V28, P663, DOI 10.1089/pho.2009.2581; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Moges H, 2009, LASER SURG MED, V41, P52, DOI 10.1002/lsm.20732; Moro C, 2014, J NEUROSURG, V120, P670, DOI 10.3171/2013.9.JNS13423; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Muili KA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030655; Naeser MA, 2014, J NEUROTRAUM, V31, P1008, DOI 10.1089/neu.2013.3244; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; Natoli R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072135; Natoli R, 2010, MOL VIS, V16, P1801; Nelson L, 2015, AGEING RES REV, V23, P193, DOI 10.1016/j.arr.2015.07.002; Olanow CW, 2008, ANN NEUROL, V64, pS101, DOI 10.1002/ana.21461; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Postow MA, 2012, NEW ENGL J MED, V366, P925, DOI 10.1056/NEJMoa1112824; Purushothuman S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt232; Purushothuman S, 2013, BRAIN RES, V1535, P61, DOI 10.1016/j.brainres.2013.08.047; Purushothurnan S, 2015, NEUROSCI LETT, V591, P155, DOI 10.1016/j.neulet.2015.02.037; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Quirk Brendan J, 2012, Front Biosci (Elite Ed), V4, P818; Recasens A, 2014, ANN NEUROL, V75, P351, DOI 10.1002/ana.24066; Reinhart F, 2016, J NEUROSURG, V124, P1829, DOI 10.3171/2015.5.JNS15735; Reinhart F, 2015, NEUROSCI RES, V92, P86, DOI 10.1016/j.neures.2014.11.005; Reyes S, 2012, INVEST OPHTH VIS SCI, V53, P2049; RINNE JO, 1993, MOVEMENT DISORD, V8, pS31, DOI 10.1002/mds.870080507; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Sabatini U, 2000, BRAIN, V123, P394, DOI 10.1093/brain/123.2.394; Samuel M, 1997, BRAIN, V120, P963, DOI 10.1093/brain/120.6.963; Schapira AHV, 2014, LANCET, V384, P545, DOI 10.1016/S0140-6736(14)61010-2; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Shaw VE, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/296875; Shaw VE, 2010, PARKINSONISM RELAT D, V16, P338, DOI 10.1016/j.parkreldis.2010.02.008; Sommer AP, 2012, PHOTOMED LASER SURG, V30, P54, DOI 10.1089/pho.2011.3073; Stone J, 2013, 9 WALT C GOLD COAST; Stone J, 2008, MED HYPOTHESES, V71, P347, DOI 10.1016/j.mehy.2008.04.007; Stone J, 2015, J ALZHEIMERS DIS, V44, P355, DOI 10.3233/JAD-141884; Swerdlow RH, 2004, MED HYPOTHESES, V63, P8, DOI 10.1016/j.mehy.2003.12.045; Tang XQ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00175; Tata DB, 2011, LASER PHOTONICS REV, V5, P1, DOI 10.1002/lpor.200900032; Taylor RC, 2014, NAT REV MOL CELL BIO, V15, P211, DOI 10.1038/nrm3752; Tierney Travis S, 2013, Front Biosci (Elite Ed), V5, P490; Trimmer PA, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-26; Tuby H, 2011, LASER SURG MED, V43, P401, DOI 10.1002/lsm.21063; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Vos M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078562; WHELAN HT, 2008, SPIE NEWSROOM, V24, P1, DOI DOI 10.1117/2.1200801.1014; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Xuan WJ, 2015, J BIOPHOTONICS, V8, P502, DOI 10.1002/jbio.201400069; Xuan WJ, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.10.108003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yetgin T, 2012, CARDIOL REV, V20, P279, DOI 10.1097/CRD.0b013e31826c15aa; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; ZHAO G, 2003, ACTA ACAD MED QINGDA, V39, P398; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	122	72	72	5	56	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	JAN 11	2016	9								500	10.3389/fninc.2015.00500			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DA5LF	WOS:000367843900001	26793049				2022-02-06	
J	Helmick, KM; Spells, CA; Malik, SZ; Davies, CA; Marion, DW; Hinds, SR				Helmick, Katherine M.; Spells, Cynthia A.; Malik, Saafan Z.; Davies, Cathleen A.; Marion, Donald W.; Hinds, Sidney R.			Traumatic brain injury in the US military: epidemiology and key clinical and research programs	BRAIN IMAGING AND BEHAVIOR			English	Article						Traumatic brain injury; Military; Department of Defense; Concussion; Surveillance; Clinical recommendations	OPERATION IRAQI FREEDOM	Traumatic brain injury (TBI), and particularly concussion, is a major concern for the U.S. Military because of the associated short term disability, long term cognitive and pain symptoms suffered by some, and risk of prolonged or permanent neurologic injury if the Service member incurs a second TBI before full recovery from the first. Concussions were seen more often during the recent conflicts in Afghanistan and Iraq than in prior conflicts, such as the Vietnam War, because of the use of improvised explosive devices that typically caused non-penetrating closed head injury. Since 2000 more than 300,000 Service members were diagnosed with TBI, of which more than 80 % were concussions. Improved TBI screening tools also have identified a higher than expected incidence of concussions occurring in garrison. In this review we summarize current epidemiologic data for TBI in the Military, and describe contemporary Military procedures and strategies for TBI prevention, identification, evaluation, and acute and chronic care. Key TBI clinical research priorities and programs are described, and innovative organizational plans to address future TBI needs are summarized.	[Helmick, Katherine M.; Spells, Cynthia A.; Malik, Saafan Z.; Davies, Cathleen A.; Marion, Donald W.; Hinds, Sidney R.] DVBIC DCoE Headquarters, Silver Spring, MD 20910 USA		Helmick, KM (corresponding author), DVBIC DCoE Headquarters, 1335 East West Hwy,Suite 605, Silver Spring, MD 20910 USA.	Katherine.m.helmick.civ@mail.mil; donald.w.marion.ctr@mail.mil	Marion, Donald/AAR-5749-2021				Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; French L., 2008, J SPECIAL OPERATIONS, V8, P68; French LM, 2010, ANN NY ACAD SCI, V1208, P38, DOI 10.1111/j.1749-6632.2010.05696.x; Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003; Institute of Medicine (IOM) & National Research Council (NRC), 2013, SPORTS REL CONC YOUT; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; MacFarlane MP, 2015, BRAIN INJURY, V29, P139, DOI 10.3109/02699052.2014.965208; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Maruta J, 2014, PROG NEUROL SURG, V28, P226, DOI 10.1159/000358786; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Regasa LE, 2015, J HEAT TRAU IN PRESS; Scholten JD, 2012, BRAIN INJURY, V26, P1177, DOI 10.3109/02699052.2012.661914; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	16	72	77	2	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	SEP	2015	9	3					358	366		10.1007/s11682-015-9399-z			9	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	CR8LQ	WOS:000361604300002	25972118				2022-02-06	
J	Spielberg, JM; McGlinchey, RE; Milberg, WP; Salat, DH				Spielberg, Jeffrey M.; McGlinchey, Regina E.; Milberg, William P.; Salat, David H.			Brain Network Disturbance Related to Posttraumatic Stress and Traumatic Brain Injury in Veterans	BIOLOGICAL PSYCHIATRY			English	Article						Posttraumatic stress disorder; Traumatic brain injury; Brain network; Graph theory; Hippocampus; fMRI	DISORDER; CONNECTIVITY; PTSD; METAANALYSIS	BACKGROUND: Understanding the neural causes and consequences of posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) is a high research priority, given the high rates of associated disability and suicide. Despite remarkable progress in elucidating the brain mechanisms of PTSD and mTBI, a comprehensive understanding of these conditions at the level of brain networks has yet to be achieved. The present study sought to identify functional brain networks and topological properties (measures of network organization and function) related to current PTSD severity and mTBI. METHODS: Graph theoretic tools were used to analyze resting-state functional magnetic resonance imaging data from 208 veterans of Operation Enduring Freedom, Operation Iraqi Freedom, and Operation New Dawn, all of whom had experienced a traumatic event qualifying for PTSD criterion A. Analyses identified brain networks and topological network properties linked to current PTSD symptom severity, mTBI, and the interaction between PTSD and mTBI. RESULTS: Two brain networks were identified in which weaker connectivity was linked to higher PTSD re-experiencing symptoms, one of which was present only in veterans with comorbid mTBI. Re-experiencing was also linked to worse functional segregation (necessary for specialized processing) and diminished influence of key regions on the network, including the hippocampus. CONCLUSIONS: Findings of this study demonstrate that PTSD re-experiencing symptoms are linked to weakened connectivity in a network involved in providing contextual information. A similar relationship was found in a separate network typically engaged in the gating of working memory, but only in veterans with mTBI.	[Spielberg, Jeffrey M.; Salat, David H.] Boston Univ, Sch Med, Neuroimaging Res Vet Ctr, Boston, MA 02215 USA; [McGlinchey, Regina E.; Milberg, William P.] Boston Univ, Sch Med, Geriatr Res Educ & Clin Ctr, Boston, MA 02115 USA; [McGlinchey, Regina E.; Milberg, William P.] Boston Univ, Sch Med, Translat Res Ctr TBI & Stress Disorders, Boston, MA 02115 USA; [Spielberg, Jeffrey M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [McGlinchey, Regina E.; Milberg, William P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Salat, David H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA		Spielberg, JM (corresponding author), VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, 150 South Huntington Ave 182 JP, Boston, MA 02130 USA.	jmsp@bu.edu	McGlinchey, Regina E/R-1971-2016; Spielberg, Jeffrey/D-1402-2014	Spielberg, Jeffrey/0000-0001-8348-7157	Translational Research Center for TBI and Stress Disorders; U.S. Department of Veterans Affairs Rehabilitation ResearchUS Department of Veterans Affairs; Development Traumatic Brain Injury Center of Excellence [B9254-C]	This work was supported by the Translational Research Center for TBI and Stress Disorders, a U.S. Department of Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (Grant No. B9254-C).	Badre D, 2012, CEREB CORTEX, V22, P527, DOI 10.1093/cercor/bhr117; Banich MT, 2009, CURR DIR PSYCHOL SCI, V18, P89, DOI 10.1111/j.1467-8721.2009.01615.x; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Brown AD, 2013, J BEHAV THER EXP PSY, V44, P129, DOI 10.1016/j.jbtep.2011.11.004; Castellanos FX, 2013, NEUROIMAGE, V80, P527, DOI 10.1016/j.neuroimage.2013.04.083; Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; FRIEDMAN MJ, 1994, PSYCHIAT CLIN N AM, V17, P265; Garfinkel SN, 2009, PSYCHIAT ANN, V39, P370, DOI 10.3928/00485713-20090527-01; Gates MA, 2012, PSYCHOL SERV, V9, P361, DOI 10.1037/a0027649; Insel Thomas R, 2010, Sci Am, V302, P44; Kloppel S, 2012, NEUROIMAGE, V61, P457, DOI 10.1016/j.neuroimage.2011.11.002; Konkel A, 2009, FRONT NEUROSCI-SWITZ, V3, P166, DOI 10.3389/neuro.01.023.2009; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Morris Sarah E, 2012, Dialogues Clin Neurosci, V14, P29; Obama B, 2012, IMPROVING ACCESS MEN; Panagioti M, 2012, COMPR PSYCHIAT, V53, P915, DOI 10.1016/j.comppsych.2012.02.009; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Rubinov M, 2013, TRENDS COGN SCI, V17, P641, DOI 10.1016/j.tics.2013.10.007; Sadeh N, 2014, CLIN PSYCHOL SCI, V2, P748, DOI 10.1177/2167702614530113; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Suvak MK, 2011, J TRAUMA STRESS, V24, P3, DOI 10.1002/jts.20618; Turk-Browne NB, 2013, SCIENCE, V342, P580, DOI 10.1126/science.1238409; van den Heuvel MP, 2013, TRENDS COGN SCI, V17, P683, DOI 10.1016/j.tics.2013.09.012; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Wisco BE, 2014, J TRAUMA STRESS, V27, P244, DOI 10.1002/jts.21900; Zalesky A, 2010, NEUROIMAGE, V53, P1197, DOI 10.1016/j.neuroimage.2010.06.041	29	72	73	3	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	AUG 1	2015	78	3					210	216		10.1016/j.biopsych.2015.02.013			7	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	CM2DC	WOS:000357489000011	25818631				2022-02-06	
J	Ge, XT; Han, ZL; Chen, FL; Wang, HC; Zhang, BL; Jiang, RC; Lei, P; Zhang, JN				Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Wang, Haichen; Zhang, Baoliang; Jiang, Rongcai; Lei, Ping; Zhang, Jianning			miR-21 alleviates secondary blood-brain barrier damage after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Traumatic brain injury; miR-21; Gene therapy; Blood-brain barrier; Secondary brain damage	ENDOTHELIAL GROWTH-FACTOR; VASCULAR STABILIZATION; EXPRESSION; ANGIOGENESIS; STROKE; MODEL; IMPROVES; ANGIOPOIETIN1/TIE2; MORPHOGENESIS; HIPPOCAMPUS	Our recent studies have identified increased expression of miR-21 in brain following traumatic brain injury (TBI), which alleviated brain edema that related to the blood-brain barrier (BBB) leakage. To analyze the potential effect of miR-21 on secondary BBB damage after TBI, we employed the fluid percussion injury rat model and manipulated the expression level of miR-21 in brain. We found that miR-21 level in brain microvascular endothelial cells (BMVECs) in lesioned cerebral cortex can be upregulated or downregulated by intracerebroventricular infusion of miR-21 agomir or antagomir. Upregulated miR-21 level conferred a better neurological outcome of TBI, and alleviated TBI-induced secondary BBB damage and loss of tight junction proteins. To explore the molecular mechanism underlying this protective effect, we detected the impact of miR-21 on the expression of Angiopoietin-1(Ang-1) and Tie-2, which can promote the expression of tight junction proteins and amplify BBB stabilization. We found that miR-21 exerts the protective effect on BBB by activating the Ang-1/Tie-2 axis in BMVECs. Thus, miR-21 could be a potential therapeutic target for interventions of secondary BBB damage after TBI. (C) 2015 Elsevier B.V. All rights reserved.	[Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin 300052, Peoples R China; [Ge, Xintong; Han, Zhaoli; Chen, Fanglian; Zhang, Baoliang; Jiang, Rongcai; Zhang, Jianning] Tianjin Neurol Inst, Lab Neurotrauma, Tianjin 300052, Peoples R China; [Ge, Xintong; Zhang, Baoliang; Jiang, Rongcai; Lei, Ping; Zhang, Jianning] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Med Univ, Gen Hosp, Dept Geriatr, Tianjin 300052, Peoples R China; [Han, Zhaoli; Lei, Ping] Tianjin Geriatr Inst, Lab Neurotrauma & Neurodegenerat Disorders, Tianjin 300052, Peoples R China; [Wang, Haichen] Duke Univ, Sch Med, Dept Neurol, Durham, NC 27710 USA		Lei, P (corresponding author), Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.	leiping1974@163.com; jianningzhang@hotmail.com	Ge, Xintong/X-4889-2019	Ge, Xintong/0000-0001-7153-952X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029, 81471252, 81271361]; Tianjin Municipal Science and Technology Commission natural fund project [13JCYBJC23700]; National Clinical Key Subject Construction Project of NHFPC Fund	This research was supported by grants from the National Natural Science Foundation of China (grant nos. 81330029, 81471252 and 81271361), Tianjin Municipal Science and Technology Commission natural fund project (grant no. 13JCYBJC23700) and National Clinical Key Subject Construction Project of NHFPC Fund. We express special acknowledgement to the senior professor Chunsheng Kang who contributes greatly on this research. The authors also appreciate Li Liu, Weiyun Cui, Ying Li, Lei Zhou, Zhifan Jia, and Guangxiu Wang from Tianjin Neurological Institute for their technical support.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen JL, 2009, J CELL MOL MED, V13, P1348, DOI 10.1111/j.1582-4934.2008.00380.x; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen X, 2013, CRIT CARE, V17, DOI 10.1186/cc13067; Cui X, 2012, NEUROSCIENCE, V227, P223, DOI 10.1016/j.neuroscience.2012.09.066; Davis B, 2010, INT J DEV NEUROSCI, V28, P423, DOI 10.1016/j.ijdevneu.2010.06.010; Edwards P, 2005, LANCET, V365, P1957; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Fukuhara S, 2010, HISTOL HISTOPATHOL, V25, P387, DOI 10.14670/HH-25.387; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Herbert SP, 2011, NAT REV MOL CELL BIO, V12, P551, DOI 10.1038/nrm3176; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Lei P, 2009, BRAIN RES, V1284, P191, DOI 10.1016/j.brainres.2009.05.074; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mustafa AG, 2013, NEUROSCIENCES, V18, P222; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; Qian XM, 2014, BIOMATERIALS, V35, P2322, DOI 10.1016/j.biomaterials.2013.11.039; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2009, J NEUROSCI RES, V87, P1435, DOI 10.1002/jnr.21945; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Senger DR, 2010, MOL BIOL CELL, V21, P377, DOI 10.1091/mbc.E09-07-0591; Sethi G, 2009, ADV EXP MED BIOL, V647, P207, DOI 10.1007/978-0-387-89520-8_15; Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280; Tchantchou F, 2013, J NEUROTRAUM, V30, P565, DOI 10.1089/neu.2012.2647; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; Yan EB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-147; Yang Y, 2011, STROKE, V42, P3323, DOI 10.1161/STROKEAHA.110.608257; Zacharek A, 2007, J CEREBR BLOOD F MET, V27, P1684, DOI 10.1038/sj.jcbfm.9600475; Zacharek A, 2006, NEUROSCI LETT, V404, P28, DOI 10.1016/j.neulet.2006.05.027; Zheng M., 2014, J MOL NEUROSCI; Zhou X, 2010, LAB INVEST, V90, P144, DOI 10.1038/labinvest.2009.126; Zhu Y, 2006, ACTA NEUROCHIR SUPPL, V96, P438; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	40	72	76	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 7	2015	1603						150	157		10.1016/j.brainres.2015.01.009			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CG2CL	WOS:000353082400015	25598202				2022-02-06	
J	Maekawa, T; Yamashita, S; Nagao, S; Hayashi, N; Ohashi, Y				Maekawa, Tsuyoshi; Yamashita, Susumu; Nagao, Seigo; Hayashi, Nariyuki; Ohashi, Yasuo		Brain-Hypothermia B-HYPO Study Grp	Prolonged Mild Therapeutic Hypothermia versus Fever Control with Tight Hemodynamic Monitoring and Slow Rewarming in Patients with Severe Traumatic Brain Injury: A Randomized Controlled Trial	JOURNAL OF NEUROTRAUMA			English	Article						cardiac output; cerebral perfusion; therapeutic hypothermia.; intracranial pressure	HOSPITAL CARDIAC-ARREST; MODERATE HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; EFFICACY; INDUCTION; OUTCOMES; SCALE	Although mild therapeutic hypothermia is an effective neuroprotective strategy for cardiac arrest/resuscitated patients, and asphyxic newborns, recent randomized controlled trials (RCTs) have equally shown good neurological outcome between targeted temperature management at 33 degrees C versus 36 degrees C, and have not shown consistent benefits in patients with traumatic brain injury (TBI). We aimed to determine the effect of therapeutic hypothermia, while avoiding some limitations of earlier studies, which included patient selection based on Glasgow coma scale (GCS), delayed initiation of cooling, short duration of cooling, inter-center variation in patient care, and relatively rapid rewarming. We conducted a multicenter RCT in patients with severe TBI (GCS 4-8). Patients were randomly assigned (2:1 allocation ratio) to either therapeutic hypothermia (32-34 degrees C, n=98) or fever control (35.5-37 degrees C, n=50). Patients with therapeutic hypothermia were cooled as soon as possible for >= 72 h and rewarmed at a rate of <1 degrees C/day. All patients received tight hemodynamic monitoring under intensive neurological care. The Glasgow Outcome Scale was assessed at 6 months by physicians who were blinded to the treatment allocation. The overall rates of poor neurological outcomes were 53% and 48% in the therapeutic hypothermia and fever control groups, respectively. There were no significant differences in the likelihood of poor neurological outcome (relative risk [RR] 1.24, 95% confidence interval [CI] 0.62-2.48, p=0.597) or mortality (RR 1.82, 95% CI 0.82-4.03, p=0.180) between the two groups. We concluded that tight hemodynamic management and slow rewarming, together with prolonged therapeutic hypothermia (32-34 degrees C) for severe TBI, did not improve the neurological outcomes or risk of mortality compared with strict temperature control (35.5-37 degrees C).	[Maekawa, Tsuyoshi] Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, Ube, Yamaguchi 7558505, Japan; [Maekawa, Tsuyoshi; Yamashita, Susumu] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan; [Nagao, Seigo] Kagawa Univ, Fac Med, Dept Neurol Surg, Takamatsu, Kagawa 760, Japan; [Hayashi, Nariyuki] Nihon Univ, Sch Med, Dept Acute Med, Div Emergency & Crit Care Med, Tokyo, Japan; [Ohashi, Yasuo] Univ Tokyo, Fac Med, Sch Integrated Hlth Sci, Tokyo 113, Japan		Maekawa, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Stress & Bioresponse Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.	maekawa.tsuyoshi@ymghp.jp	Oksengendler, Boris L/G-1329-2011; Oksengendler, Boris Leonidovich/E-4504-2012	Oksengendler, Boris L/0000-0001-8247-8996; Oksengendler, Boris Leonidovich/0000-0002-6771-293X; dohi, kenji/0000-0002-4451-0382	Japanese Ministry of Health, Labour and WelfareMinistry of Health, Labour and Welfare, Japan [H-14-shinkin-005, H-15-shinkin-001, H-16-shinkin-001]; Japanese Human Science Association	This study was supported by grants from Japanese Ministry of Health, Labour and Welfare (H-14-shinkin-005, H-15-shinkin-001, and H-16-shinkin-001), and the Japanese Human Science Association 2002-2004. We thank Takahiro Kiuchi (Director of the UMIN Centre) and Kiyoshi Ichihara (Yamaguchi University Graduate School of Medicine) for their support. We also thank Kees H Polderman (University of Pittsburgh Medical Center) for reviewing our manuscript and for his valuable suggestions.	Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Eddy VA, 2000, SURG CLIN N AM, V80, P845, DOI 10.1016/S0039-6109(05)70099-2; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Holzer M, 2002, NEW ENGL J MED, V346, P549; Holzer M, 2006, STROKE, V37, P1792, DOI 10.1161/01.STR.0000227265.52763.16; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Kasaoka S, 2006, MINIMALLY INVASIVE NEUROSURGERY AND MULTIDISCIPLINARY NEUROTRAUMATOLOGY, P335, DOI 10.1007/4-431-28576-8_50; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Nagao K, 2010, CIRC J, V74, P77, DOI 10.1253/circj.CJ-09-0502; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; The Japan Society of Neurotraumatology, 2001, GUID MAN SEV HEAD IN	30	72	74	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					422	429		10.1089/neu.2013.3197			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400002	25099730	Green Published			2022-02-06	
J	Grandhi, R; Harrison, G; Voronovich, Z; Bauer, J; Chen, SH; Nicholas, D; Alarcon, LH; Okonkwo, DO				Grandhi, Ramesh; Harrison, Gillian; Voronovich, Zoya; Bauer, Joshua; Chen, Stephanie H.; Nicholas, Dederia; Alarcon, Louis H.; Okonkwo, David O.			Preinjury warfarin, but not antiplatelet medications, increases mortality in elderly traumatic brain injury patients	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; aspirin; clopidogrel; warfarin; mortality	INTRACRANIAL HEMORRHAGE; HEAD-INJURY; ANTICOAGULATED PATIENTS; PLATELET TRANSFUSION; IMPACT; OUTCOMES; RISK; CLOPIDOGREL; ASPIRIN; AGENTS	BACKGROUND: Previous studies of traumatic brain injury ( TBI) outcomes in elderly patients on oral antithrombotic ( OAT) therapies have yielded conflicting results. Our objective was to examine the effect of premorbid OAT medications on outcomes among elderly TBI patients with intracranial hemorrhage. METHODS: We performed a retrospective analysis of elderly TBI patients ( >= 65 years) with closed head injury and evidence of brain hemorrhage on computed tomography scan from 2006 to 2010. Patient demographics, injury severity, clinical course, hospital and intensive care unit length of stay, and disposition were collected. Comparison of patients stratified by premorbid OAT use was performed using nonparametric Kruskal-Wallis and Fisher's exact tests. Multivariable logistic regression was used to compare groups and identify predictors of primary outcomes, including mortality, neurosurgical intervention, hemorrhage progression, complications, and infection. RESULTS: A total of 1,552 patients were identified: 543 on aspirin only, 97 on clopidogrel only, 218 on warfarin only, 193 on clopidogrel and aspirin, and 501 on no antithrombotic agent. Blood products were administered to reverse coagulopathy in 77.3% of patients on antithrombotic medications. After adjusting for covariates, including medication reversal, OAT use was associated with increased mortality ( p = 0.04). Warfarin use was identified as a key predictor ( odds ratio, 2.27; p = 0.05), in contrast to the preinjury use of antiplatelet medications, which was not associated with increased risk of in-hospital death. Rates of neurosurgical intervention differed between groups, with patients on warfarin undergoing intervention more frequently. Survivor subset analysis demonstrated that hemorrhage progression was not associated with preinjury antithrombotic therapy, nor were rates of complication or infection, hospital and intensive care unit lengths of stay, or ventilator days. CONCLUSION: Preinjury use of warfarin, but not antiplatelet medications, influences survival and need for neurosurgical intervention in elderly TBI patients with intracranial hemorrhage; hemorrhage progression and morbidity are not affected. The importance of antithrombotic therapy may lie in its impact on initial injury severity. (Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved.)	[Grandhi, Ramesh; Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15213 USA; [Nicholas, Dederia; Alarcon, Louis H.] Univ Pittsburgh, Med Ctr, Div Trauma & Gen Surg, Dept Surg, Pittsburgh, PA 15213 USA; [Bauer, Joshua; Chen, Stephanie H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Voronovich, Zoya] Univ New Mexico, Dept Neurosurg, Albuquerque, NM 87131 USA; [Harrison, Gillian] NYU Langone Med Ctr, Dept Neurosurg, New York, NY USA		Okonkwo, DO (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurol Surg, 200 Lothrop St,Suite B-400, Pittsburgh, PA 15213 USA.	okonkwodo@upmc.edu		Alarcon, Louis/0000-0001-6994-8412			Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; [Anonymous], 2005, J TRAUMA; [Anonymous], 2008, J TRAUMA; [Anonymous], 2008, SURGERY; Bonville DJ, 2011, SURGERY, V150, P861, DOI 10.1016/j.surg.2011.07.070; Centers for Disease Control and Prevention (CDC), 2012, MMWR-MORBID MORTAL W, V61, P11; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Depreitere B, 2012, Acta Neurochir Suppl, V114, P289, DOI 10.1007/978-3-7091-0956-4_56; Dossett LA, 2011, ARCH SURG-CHICAGO, V146, P565, DOI 10.1001/archsurg.2010.313; Downey DM, 2009, AM SURGEON, V75, P1100; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Fortuna GR, 2008, SURGERY, V144, P598, DOI 10.1016/j.surg.2008.06.009; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gangavati AS, 2009, J AM GERIATR SOC, V57, P1470, DOI 10.1111/j.1532-5415.2009.02344.x; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; Grandhi R, 2008, AM SURGEON, V74, P802; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Karni A, 2001, AM SURGEON, V67, P1098; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirley K, 2012, CIRC-CARDIOVASC QUAL, V5, P615, DOI 10.1161/CIRCOUTCOMES.112.967299; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Ott MM, 2010, J TRAUMA, V68, P560, DOI 10.1097/TA.0b013e3181ad6600; Peck KA, 2011, J TRAUMA, V71, P1600, DOI 10.1097/TA.0b013e31823b9ce1; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Spektor S, 2003, J NEUROSURG, V99, P661, DOI 10.3171/jns.2003.99.4.0661; Vincent GK, NEXT 4 DECADES OLDER; Wahl WL, 2001, J TRAUMA, V51, P1151; Warkentin AE, 2012, J THROMB HAEMOST, V10, P512, DOI 10.1111/j.1538-7836.2012.04635.x; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Werner C., 2010, OLDER POPULATION 201; Williams TM, 2008, J TRAUMA, V65, P772, DOI 10.1097/TA.0b013e3181877ff7; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	41	72	75	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAR	2015	78	3					614	621		10.1097/TA.0000000000000542			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	CE8DQ	WOS:000352072000030	25710435				2022-02-06	
J	Kumar, RG; Diamond, ML; Boles, JA; Berger, RP; Tisherman, SA; Kochanek, PM; Wagner, AK				Kumar, R. G.; Diamond, M. L.; Boles, J. A.; Berger, R. P.; Tisherman, S. A.; Kochanek, P. M.; Wagner, A. K.			Acute CSF interleukin-6 trajectories after TBI: Associations with neuroinflammation, polytrauma, and outcome	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Cytokines; Interleukin-6; Rehabilomics	TRAUMATIC BRAIN-INJURY; TRANSLATIONAL REHABILITATION RESEARCH; CEREBROSPINAL-FLUID; TRANSGENIC MICE; ANTIINFLAMMATORY MEDIATORS; INFLAMMATORY RESPONSE; PROGNOSTIC BIOMARKER; RHEUMATOID-ARTHRITIS; MULTIPLE INJURIES; HORMONE-LEVELS	Traumatic brain injury (TBI) results in a significant inflammatory burden that perpetuates the production of inflammatory mediators and biomarkers. Interleukin-6 (IL-6) is a pro-inflammatory cytokine known to be elevated after trauma, and a major contributor to the inflammatory response following TBI. Previous studies have investigated associations between IL-6 and outcome following TBI, but to date, studies have been inconsistent in their conclusions. We hypothesized that cohort heterogeneity, temporal inflammatory profiles, and concurrent inflammatory marker associations are critical to characterize when targeting subpopulations for anti-inflammatory therapies. Toward this objective, we used serial cerebrospinal fluid (CSF) samples to generate temporal acute IL-6 trajectory (TRAJ) profiles in a prospective cohort of adults with severe TBI (n = 114). We examined the impact of injury type on IL-6 profiles, and how IL-6 profiles impact sub-acute (2 weeks-3 months) serum inflammatory marker load and long-term global outcome 6-12 months post-injury. There were two distinct acute CSF IL-6 profiles, a high and low TRAJ group. Individuals in the high TRAJ had increased odds of unfavorable Glasgow Outcome Scale (GOS) scores at 6 months (adjusted OR = 3.436, 95% CI: 1.259, 9.380). Individuals in the high TRAJ also had higher mean acute CSF inflammatory load compared to individuals in the low TRAJ (p <= 0.05). The two groups did not differ with respect acute serum profiles; however, individuals in the high CSF IL-6 TRAJ also had higher mean sub-acute serum IL-beta and IL-6 levels compared with the low TRAJ group (p <= 0.05). Lastly, injury type (isolated TBI vs. TBI + polytrauma) was associated with IL-6 TRAJ group (chi(2) = 5.31, p = 0.02). Specifically, there was 70% concordance between those with TBI + polytrauma and the low TRAJ; in contrast, isolated TBI was similarly distributed between TRAJ groups. These data provide evidence that sustained, elevated levels of CSF IL-6 are associated with an increased inflammatory load, and these increases are associated with increased odds for unfavorable global outcomes in the first year following TBI. Future studies should explore additional factors contributing to IL-6 elevations, and therapies to mitigate its detrimental effects on outcome. (C) 2014 Elsevier Inc. All rights reserved.	[Kumar, R. G.; Diamond, M. L.; Boles, J. A.; Wagner, A. K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Wagner, A. K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Berger, R. P.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; [Berger, R. P.; Kochanek, P. M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Tisherman, S. A.] Univ Maryland, Med Ctr, Ctr Shock Trauma, Baltimore, MD 21201 USA; [Kochanek, P. M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15213 USA		Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	Wagnerak@upmc.edu	Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729	University of Pittsburgh Women's Studies Faculty Research Fund [CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR: H133A120087]	This work was supported in part by: CDC: R49 CCR 323155, DOD: W81XWH-071-0701, NIDRR: H133A120087, University of Pittsburgh Women's Studies Faculty Research Fund.	Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brand RE, 2011, CLIN CANCER RES, V17, P805, DOI 10.1158/1078-0432.CCR-10-0248; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chiaretti A, 2005, CHILD NERV SYST, V21, P185, DOI 10.1007/s00381-004-1032-1; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Dalla Libera AL, 2011, BRAIN INJURY, V25, P365, DOI 10.3109/02699052.2011.556107; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; DROST AC, 1993, J TRAUMA, V35, P335, DOI 10.1097/00005373-199309000-00001; Failla M.D., 2014, NEUROREHABIL NEURAL; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hirota H, 1996, J EXP MED, V183, P2627, DOI 10.1084/jem.183.6.2627; Hoh NZ, 2010, J NEUROTRAUM, V27, P1413, DOI 10.1089/neu.2009.1256; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Kalabalikis P, 1999, INTENS CARE MED, V25, P288, DOI 10.1007/s001340050837; Kesinger M.R., 2014, J TRAUMA IN PRESS; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kumar R., 2014, J HEAD TRAUMA REHABI; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Ley EJ, 2011, J SURG RES, V170, P253, DOI 10.1016/j.jss.2011.03.006; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Long J. S., 1997, REGRESSION MODELS CA; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Maegele M, 2007, INFLAMM RES, V56, P318, DOI 10.1007/s00011-007-6141-3; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Maier B, 2005, J NEUROTRAUM, V22, P822, DOI 10.1089/neu.2005.22.822; Maini RN, 2006, ARTHRITIS RHEUM-US, V54, P2817, DOI 10.1002/art.22033; Marz P, 1999, GLIA, V26, P191, DOI 10.1002/(SICI)1098-1136(199905)26:3<191::AID-GLIA1>3.0.CO;2-#; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; NIJSTEN MWN, 1991, SURGERY, V109, P761; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; Pavelko KD, 2003, J NEUROSCI, V23, P481, DOI 10.1523/JNEUROSCI.23-02-00481.2003; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 1999, GLIA, V25, P343; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Qi HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037858; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Santarsieri M, 2014, J NEUROTRAUM, V31, P699, DOI 10.1089/neu.2013.3177; Sarkar D, 2006, CANCER LETT, V236, P13, DOI 10.1016/j.canlet.2005.04.009; Shein SL, 2014, J NEUROTRAUM, V31, P1386, DOI 10.1089/neu.2013.2985; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140-6736(08)60453-5; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wagner AK, 2010, EUR J PHYS REHAB MED, V46, P549; Wagner AK, 2014, J SPINAL CORD MED, V37, P493, DOI 10.1179/2045772314Y.0000000248; Wagner Amy K, 2013, Pathophysiology, V20, P39, DOI 10.1016/j.pathophys.2012.02.007; Wagner AK, 2012, BRAIN INJURY, V26, P1658, DOI 10.3109/02699052.2012.700089; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Weaver S.M., 2012, BRAIN IMAGING BEHAV; Weckbach S, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/890816; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018	73	72	74	2	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	MAR	2015	45						253	262		10.1016/j.bbi.2014.12.021			10	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	CC7BX	WOS:000350523800026	25555531				2022-02-06	
J	Stanley, RM; Hoyle, JD; Dayan, PS; Atabaki, S; Lee, L; Lillis, K; Gorelick, MH; Holubkov, R; Miskin, M; Holmes, JF; Dean, JM; Kuppermann, N				Stanley, Rachel M.; Hoyle, John D., Jr.; Dayan, Peter S.; Atabaki, Shireen; Lee, Lois; Lillis, Kathy; Gorelick, Marc H.; Holubkov, Richard; Miskin, Michelle; Holmes, James F.; Dean, J. Michael; Kuppermann, Nathan		Pediat Emergency Care Appl Res	Emergency Department Practice Variation in Computed Tomography Use for Children with Minor Blunt Head Trauma	JOURNAL OF PEDIATRICS			English	Article							RADIATION-EXPOSURE; UNITED-STATES; PEDIATRIC CT; RISK; CANCER; SEDATION	Objective To describe factors associated with computed tomography (CT) use for children with minor blunt head trauma that are evaluated in emergency departments. Study design Planned secondary analysis of a prospective observational study of children <18 years with minor blunt head trauma between 2004 and 2006 at 25 emergency departments. CT scans were obtained at the discretion of treating clinicians. We risk-adjusted patients for clinically important traumatic brain injuries and performed multivariable regression analyses. Outcome measures were rates of CT use by hospital and by clinician training type. Results CT rates varied between 19.2% and 69.2% across hospitals. Risk adjustment had little effect on the differential rate of CT use. In low-and middle-risk patients, clinicians obtained CTs more frequently at suburban and nonfreestanding children's hospitals. Physicians with emergency medicine (EM) residency training obtained CTs at greater rates than physicians with pediatric residency or pediatric EM training. In multivariable analyses, compared with pediatric EM-trained physicians, theOR for CT use among EM-trained physicians in children <2 years was 1.24 (95% CI 1.04-1.46), and for children >2 years was 1.68 (95% CI 1.50-1.89). Physicians of all training backgrounds, however, overused CT scans in low-risk children. Conclusions Substantial variation exists in the use of CT for childrenwithminor blunt head trauma not explained by patient severityor rates of positive CT scans or clinically important traumaticbrain injuries.	[Stanley, Rachel M.] Univ Michigan, Dept Emergency Med & Pediat, Ann Arbor, MI 48109 USA; [Hoyle, John D., Jr.] Michigan State Univ, Coll Human Med, Helen DeVos Childrens Hosp, Div Emergency Med, Grand Rapids, MI USA; [Dayan, Peter S.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Atabaki, Shireen] George Washington Sch Med, Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC USA; [Lee, Lois] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Lillis, Kathy] SUNY Buffalo, Dept Pediat, Buffalo, NY 14260 USA; [Lillis, Kathy] Womens & Childrens Hosp, Buffalo, NY USA; [Gorelick, Marc H.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; [Holubkov, Richard; Miskin, Michelle; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Holubkov, Richard; Miskin, Michelle; Dean, J. Michael] PECARN Data Coordinating Ctr, Salt Lake City, UT USA; [Holmes, James F.; Kuppermann, Nathan] Univ Calif Davis, Davis Sch Med, Dept Emergency Med, Davis, CA 95616 USA		Stanley, RM (corresponding author), Univ Michigan, Dept Emergency Med, 1500 E Med Ctr Dr,TC B1 354,SPC 5303, Ann Arbor, MI 48109 USA.	stanleyr@umich.edu		Lee, Lois/0000-0002-3551-5050; Tsung, James/0000-0002-4718-8325; Holubkov, Richard/0000-0003-0431-3381	Health Resources and Services Administration (HRSA)United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); Maternal and Child Health Bureau (MCHB) [R40MC02461]; Emergency Medical Services of Children (EMSC) Program through the PECARN; PECARN [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, U03MC22685]	Supported in part by the Health Resources and Services Administration (HRSA), Maternal and Child Health Bureau (MCHB; R40MC02461), the Emergency Medical Services of Children (EMSC) Program through the PECARN. PECARN is supported by the following cooperative agreements: U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008, U03MC22684, and U03MC22685. The authors declare no conflicts of interest.	Alpern ER, 2006, PEDIATR EMERG CARE, V22, P689, DOI 10.1097/01.pec.0000236830.39194.c0; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Faul M, 2010, TRAUMATIC BRAIN INJU; FAULKNER K, 1987, ACTA RADIOL, V28, P483; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Levine MB, 2013, AM J EMERG MED, V31, P1437, DOI 10.1016/j.ajem.2013.07.003; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Malviya S, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.3.e42; Mannix R, 2012, J PEDIATR-US, V160, P136, DOI 10.1016/j.jpeds.2011.06.024; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Sanborn PA, 2005, RADIOLOGY, V237, P288, DOI 10.1148/radiol.2371041415	20	72	72	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2014	165	6					1201	+		10.1016/j.jpeds.2014.08.008			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AU3PS	WOS:000345526500027	25294604				2022-02-06	
J	Murugavel, M; Cubon, V; Putukian, M; Echemendia, R; Cabrera, J; Osherson, D; Dettwiler, A				Murugavel, Murali; Cubon, Valerie; Putukian, Margot; Echemendia, Ruben; Cabrera, Javier; Osherson, Daniel; Dettwiler, Annegret			A Longitudinal Diffusion Tensor Imaging Study Assessing White Matter Fiber Tracts after Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; longitudinal study; mTBI; radial diffusivity; sports-related concussion	TRAUMATIC BRAIN-INJURY; AXONAL INJURY; ACUTE MILD; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; CORPUS-CALLOSUM; ABNORMALITIES; DISABILITY; ANISOTROPY; PREDICTORS	The extent of structural injury in sports-related concussion (SRC) is central to the course of recovery, long-term effects, and the decision to return to play. In the present longitudinal study, we used diffusion tensor imaging (DTI) to assess white matter (WM) fiber tract integrity within 2 days, 2 weeks, and 2 months of concussive injury. Participants were right-handed male varsity contact-sport athletes (20.2 +/- 1.0 years of age) with a medically diagnosed SRC (no loss of consciousness). They were compared to right-handed male varsity non-contact-sport athletes serving as controls (19.9 +/- 1.7 years). We found significantly increased radial diffusivity (RD) in concussed athletes (n = 12; paired t-test, tract-based spatial statistics; p < 0.025) at 2 days, when compared to the 2-week postinjury time point. The increase was found in a cluster of right hemisphere voxels, spanning the posterior limb of the internal capsule (IC), the retrolenticular part of the IC, the inferior longitudinal fasciculus, the inferior fronto-occipital fasciculus (sagittal stratum), and the anterior thalamic radiation. Post-hoc, univariate, between-group (controls vs. concussed), mixed-effects analysis of the cluster showed significantly higher RD at 2 days (p = 0.002), as compared to the controls, with a trend in the same direction at 2 months (p = 0.11). Results for fractional anisotropy (FA) in the same cluster showed a similar, but inverted, pattern; FA was decreased at 2 days and at 2 months postinjury, when compared to healthy controls. At 2 weeks postinjury, no statistical differences between concussed and control athletes were found with regard to either RD or FA. These results support the hypothesis of increased RD and reduced FA within 72 h postinjury, followed by recovery that may extend beyond 2 weeks. RD appears to be a sensitive measure of concussive injury.	[Murugavel, Murali; Dettwiler, Annegret] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Cubon, Valerie] Kent State Univ, Dept Chem, Warren, OH USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Echemendia, Ruben] Psychol & Neurobehav Associates Inc, State Coll, PA USA; [Cabrera, Javier] Rutgers State Univ, Dept Stat, Piscataway, NJ USA; [Osherson, Daniel] Princeton Univ, Dept Psychol, Princeton, NJ 08544 USA; [Dettwiler, Annegret] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, New Brunswick, NJ USA		Dettwiler, A (corresponding author), Princeton Univ, Princeton Neurosci Inst, Washington Rd, Princeton, NJ 08544 USA.	adettwil@princeton.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	New Jersey Commission for Brain Injury Research [10-3217-BIR-E-0]; American Medical Society for Sports Medicine AMSSM Foundation [005548]; Goldstein Family Fund; Peter & Cynthia Kellogg Foundation	The authors acknowledge the athletic trainers of University Health Services for their assistance with subject recruitment and NP testing. This work was funded by the New Jersey Commission for Brain Injury Research (grant no.: 10-3217-BIR-E-0), the American Medical Society for Sports Medicine AMSSM Foundation (grant no.: 005548), the Goldstein Family Fund, and the Peter & Cynthia Kellogg Foundation.	Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Budde MD, 2011, BRAIN, V134, P2248, DOI 10.1093/brain/awr161; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Ding GL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061241; Efron B., 1993, INTRO BOOTSTRAP; Geary EK, 2010, J INT NEUROPSYCH SOC, V16, P506, DOI 10.1017/S135561771000010X; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Grossman EJ, 2012, J NEUROTRAUM, V29, P2318, DOI 10.1089/neu.2011.1763; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Horsfield MA, 1998, J NEUROL NEUROSUR PS, V64, pS80; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; JohansenBerg H, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P1; KIM J, 2010, CTS-CLIN TRANSL SCI, V3, pS45; Kim N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059382; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Langlois J. A., 2004, BIOL PSYCHIAT, V55, P21; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Leemans A, 2009, MAGN RESON MED, V61, P1336, DOI 10.1002/mrm.21890; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Ling J, 2012, HUM BRAIN MAPP, V33, P50, DOI 10.1002/hbm.21192; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lipton ML, 2012, BRAIN IMAGING BEHAV, V6, P329, DOI 10.1007/s11682-012-9175-2; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P., 2009, S AFR J SPORTS MED, V21; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S., 2007, INTRO DIFFUSION TENS; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Naismith RT, 2009, NEUROLOGY, V72, P589, DOI 10.1212/01.wnl.0000335766.22758.cd; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pinheiro J. C., 2000, MIXED EFFECTS MODELS; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shin W, 2014, AM J NEURORADIOL, V35, P285, DOI 10.3174/ajnr.A3676; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Smith S., 2007, TR07JA2 FMRIB U OXF; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Waters RJ, 2005, CURR OPIN CRIT CARE, V11, P105, DOI 10.1097/01.ccx.0000155354.78617.91; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhu T., 2010, P 18 ANN M INT SOC M, P4482	89	72	72	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 1	2014	31	22					1860	1871		10.1089/neu.2014.3368			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CB4ZO	WOS:000349637400005	24786666	Green Published			2022-02-06	
J	Xuan, WJ; Vatansever, F; Huang, LY; Hamblin, MR				Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.			Transcranial low-level laser therapy enhances learning, memory, and neuroprogenitor cells after traumatic brain injury in mice	JOURNAL OF BIOMEDICAL OPTICS			English	Article						traumatic brain injury; transcranial low level light therapy; Morris water maze; wire grip motion test; neurogenesis; BrdU; NeuN; double-cortin; TUJ-1; caspase-3; mitochondrial modulation	TERM NEUROLOGICAL DEFICITS; NEURON-SPECIFIC TUBULIN; ADULT NEUROGENESIS; LIGHT THERAPY; IMPACT; RAT; NEUROPROTECTION; DYSFUNCTION; EXPRESSION; DEPRESSION	The use of transcranial low-level laser (light) therapy (tLLLT) to treat stroke and traumatic brain injury (TBI) is attracting increasing attention. We previously showed that LLLT using an 810-nm laser 4 h after controlled cortical impact (CCI)-TBI in mice could significantly improve the neurological severity score, decrease lesion volume, and reduce Fluoro-Jade staining for degenerating neurons. We obtained some evidence for neurogenesis in the region of the lesion. We now tested the hypothesis that tLLLT can improve performance on the Morris water maze (MWM, learning, and memory) and increase neurogenesis in the hippocampus and subventricular zone (SVZ) after CCI-TBI in mice. One and (to a greater extent) three daily laser treatments commencing 4-h post-TBI improved neurological performance as measured by wire grip and motion test especially at 3 and 4 weeks post-TBI. Improvements in visible and hidden platform latency and probe tests in MWM were seen at 4 weeks. Caspase-3 expression was lower in the lesion region at 4 days post-TBI. Double-stained BrdU-NeuN (neuroprogenitor cells) was increased in the dentate gyrus and SVZ. Increases in double-cortin (DCX) and TUJ-1 were also seen. Our study results suggest that tLLLT may improve TBI both by reducing cell death in the lesion and by stimulating neurogenesis. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)	[Xuan, Weijun] Guangxi Univ Chinese Med, Ruikang Hosp, Dept Otolaryngol, Nanning 530021, Peoples R China; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Xuan, Weijun; Vatansever, Fatma; Huang, Liyi; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Liyi] Guangxi Med Univ, Affiliated Coll & Hosp 1, Dept Infect Dis, Nanning 530021, Peoples R China; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA		Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019	Hamblin, Michael R/0000-0001-6431-4605	US NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01AI050875]; Air Force Office of Scientific ResearchUnited States Department of DefenseAir Force Office of Scientific Research (AFOSR) [FA9550-13-1-0068]; US Army Medical Research Acquisition Activity Grant [W81XWH-09-1-0514]; US Army Medical Research and Materiel Command GrantU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-13-2-0067]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI050875] Funding Source: NIH RePORTER	This work was supported by US NIH Grant No. R01AI050875, by Air Force Office of Scientific Research Grant No. FA9550-13-1-0068, by US Army Medical Research Acquisition Activity Grant No. W81XWH-09-1-0514 and by US Army Medical Research and Materiel Command Grant No. W81XWH-13-2-0067.	Acosta S, 2010, REJUV RES, V13, P581, DOI 10.1089/rej.2009.1011; Ad N, 2001, INT J CARDIOL, V80, P109, DOI 10.1016/S0167-5273(01)00503-4; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; [Anonymous], 2011, REV NEUROSCI, V22, P457; Beukelaers P, 2012, CELL MOL LIFE SCI, V69, P1493, DOI 10.1007/s00018-011-0880-6; Bonfanti L, 2011, EUR J NEUROSCI, V34, P930, DOI 10.1111/j.1460-9568.2011.07832.x; Bovetti S, 2011, J CHEM NEUROANAT, V42, P304, DOI 10.1016/j.jchemneu.2011.05.006; Bromley-Brits K, 2011, JOVE-J VIS EXP, DOI 10.3791/2920; Brus M, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00135; Chu JR, 2010, CANCER LETT, V297, P207, DOI 10.1016/j.canlet.2010.05.013; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Dubourg J, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11182; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Hanson ND, 2011, NEUROPSYCHOPHARMACOL, V36, P2589, DOI 10.1038/npp.2011.220; Huang YY, 2014, J BIOPHOTONICS, V7, P656, DOI 10.1002/jbio.201300125; Huang YY, 2013, J BIOPHOTONICS, V6, P829, DOI 10.1002/jbio.201200157; Huang YY, 2009, DOSE-RESPONSE, V7, P358, DOI 10.2203/dose-response.09-027.Hamblin; Kaneko Y, 2012, CELL MED, V4, P55, DOI 10.3727/215517912X639306; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim EJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018472; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Masiulis I, 2011, MOL NEUROBIOL, V44, P287, DOI 10.1007/s12035-011-8207-z; MEMBERG SP, 1995, J NEUROBIOL, V27, P26, DOI 10.1002/neu.480270104; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Meyer KS, 2010, PSYCHIAT CLIN N AM, V33, P783, DOI 10.1016/j.psc.2010.08.007; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P443, DOI 10.1089/pho.2011.9908; Opreanu RC, 2010, J AM COLL SURGEONS, V210, P997, DOI 10.1016/j.jamcollsurg.2010.01.036; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Roozenbeek B, 2012, J NEUROTRAUM, V29, P1306, DOI 10.1089/neu.2011.1988; Salvesen GS, 2002, CELL DEATH DIFFER, V9, P3, DOI 10.1038/sj.cdd.4400963; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xiao XL, 2010, NEUROL RES, V32, P547, DOI 10.1179/174313209X414533; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Zhang L, 2013, INT J MOL MED, V32, P867, DOI 10.3892/ijmm.2013.1456	45	72	75	2	18	SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS	BELLINGHAM	1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA	1083-3668	1560-2281		J BIOMED OPT	J. Biomed. Opt.	OCT	2014	19	10							108003	10.1117/1.JBO.19.10.108003			15	Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging	AU8HM	WOS:000345837200036	25292167	Green Published			2022-02-06	
J	Cripton, PA; Dressler, DM; Stuart, CA; Dennison, CR; Richards, D				Cripton, Peter A.; Dressler, Daniel M.; Stuart, Cameron A.; Dennison, Christopher R.; Richards, Darrin			Bicycle helmets are highly effective at preventing head injury during head impact: Head-form accelerations and injury criteria for helmeted and unhelmeted impacts	ACCIDENT ANALYSIS AND PREVENTION			English	Article						Brain injury; Concussion; Helmet; Bicycle; Injury prevention	PROFESSIONAL FOOTBALL; HYBRID III; RISK; CONCUSSION; EFFICACY; TRAUMA	Cycling is a popular form of recreation and method of commuting with clear health benefits. However, cycling is not without risk. In Canada, cycling injuries are more common than in any other summer sport; and according to the US National Highway and Traffic Safety Administration, 52,000 cyclists were injured in the US in 2010. Head injuries account for approximately two-thirds of hospital admissions and three-quarters of fatal injuries among injured cyclists. In many jurisdictions and across all age levels, helmets have been adopted to mitigate risk of serious head injuries among cyclists and the majority of epidemiological literature suggests that helmets effectively reduce risk of injury. Critics have raised questions over the actual efficacy of helmets by pointing to weaknesses in existing helmet epidemiology including selection bias and lack of appropriate control for the type of impact sustained by the cyclist and the severity of the head impact. These criticisms demonstrate the difficulty in conducting epidemiology studies that will be regarded as definitive and the need for complementary biomechanical studies where confounding factors can be adequately controlled. In the bicycle helmet context, there is a paucity of biomechanical data comparing helmeted to unhelmeted head impacts and, to our knowledge, there is no data of this type available with contemporary helmets. In this research, our objective was to perform biomechanical testing of paired helmeted and unhelmeted head impacts using a validated anthropomorphic test headform and a range of drop heights between 0.5 m and 3.0 m, while measuring headform acceleration and Head Injury Criterion (HIC). In the 2 m (6.3 m/s) drops, the middle of our drop height range, the helmet reduced peak accelerations from 824 g (unhelmeted) to 181 g (helmeted) and HIC was reduced from 9667 (unhelmeted) to 1250 (helmeted). At realistic impact speeds of 5.4 m/s (1.5 m drop) and 6.3 m/s (2.0 m drop), bicycle helmets changed the probability of severe brain injury from extremely likely (99.9% risk at both 5.4 and 6.3 m/s) to unlikely (9.3% and 30.6% risk at 1.5 m and 2.0 m drops respectively). These biomechanical results for acceleration and HIC, and the corresponding results for reduced risk of severe brain injury show that contemporary bicycle helmets are highly effective at reducing head injury metrics and the risk for severe brain injury in head impacts characteristic of bicycle crashes. (C) 2014 Elsevier Ltd. All rights reserved.	[Cripton, Peter A.; Dressler, Daniel M.; Dennison, Christopher R.] Univ British Columbia, Dept Mech Engn, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.; Dressler, Daniel M.; Dennison, Christopher R.] Univ British Columbia, Int Collaborat Repair Discoveries, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.] Univ British Columbia, Ctr Hip Hlth & Mobil, Vancouver, BC V6T 1Z4, Canada; [Cripton, Peter A.; Dressler, Daniel M.] Univ British Columbia, Orthopaed & Injury Biomech Grp, Vancouver, BC V6T 1Z4, Canada; [Stuart, Cameron A.; Richards, Darrin] Synapt Anal Consulting Grp, Vancouver, BC, Canada		Cripton, PA (corresponding author), Univ British Columbia, Dept Mech Engn, 6250 Appl Sci Lane, Vancouver, BC V6T 1Z4, Canada.	cripton@mech.ubc.ca	Cripton, Peter Alec/AAC-8268-2020	Cripton, Peter Alec/0000-0002-5067-0833			Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; [Anonymous], 2010, BIC OTH CYCL; Bandak, 1999, DEV IMPROVED INJURY; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; BENZ G, 1993, EUR J PEDIATR SURG, V3, P259, DOI 10.1055/s-2008-1063555; Canadian Institute for Health Information, 2010, CYCL INJ HOSP CAN 20; Curnow WJ, 2006, ACCIDENT ANAL PREV, V38, P833, DOI 10.1016/j.aap.2006.04.007; Curnow WJ, 2003, ACCIDENT ANAL PREV, V35, P287, DOI 10.1016/S0001-4575(02)00012-X; DeMarco AL, 2010, ACCIDENT ANAL PREV, V42, P1778, DOI 10.1016/j.aap.2010.04.019; DeParle Min, 1998, FED REG, V63; Depreitere B, 2004, ACCIDENT ANAL PREV, V36, P561, DOI 10.1016/S0001-4575(03)00062-9; Elvik R, 2011, ACCIDENT ANAL PREV, V43, P1245, DOI 10.1016/j.aap.2011.01.007; Fahlstedt M., 2012, 2012 IRCOBI C P INT, P787, DOI DOI 10.1177/1753193412460139; Foster K.J., 1977, 770938 SAE; Gennarelli TA, 2005, ABBREVIATED INJURY S; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hagel BE, 2006, ACCIDENT ANAL PREV, V38, P277, DOI 10.1016/j.aap.2005.09.004; Hamer M, 2008, PREV MED, V46, P9, DOI 10.1016/j.ypmed.2007.03.006; Heng K. W. J., 2006, SMJ Singapore Medical Journal, V47, P367; Hodgson VR., 1990, IMPACT SKID RETENTIO; Kendall M, 2012, P I MECH ENG P-J SPO, V226, P260, DOI 10.1177/1754337112436901; MAIMARIS C, 1994, BRIT MED J, V308, P1537, DOI 10.1136/bmj.308.6943.1537; Mattei T.A., 2012, J NEUROSURG PEDIAT, V10, P1; Mertz Harold J, 2003, Stapp Car Crash J, V47, P155; Newman J. A., 2002, ACCIDENTAL INJURY BI, P303; Nightingale RW, 1997, SPINE, V22, P2380, DOI 10.1097/00007632-199710150-00012; Page JL, 2012, INJURY PREV, V18, P94, DOI 10.1136/injuryprev-2011-040029; Pang TY, 2011, INT J CRASHWORTHINES, V16, P297, DOI 10.1080/13588265.2011.559799; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Scher I., 2006, J ASTM INT, V3; Scher IS, 2009, 010248 SAE; Thompson D., 1999, COCHRANE DATABASE SY; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Viano DC, 2012, ANN BIOMED ENG, V40, P175, DOI 10.1007/s10439-011-0395-1; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; Wen LM, 2008, PREV MED, V46, P29, DOI 10.1016/j.ypmed.2007.08.009	37	72	74	1	104	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0001-4575	1879-2057		ACCIDENT ANAL PREV	Accid. Anal. Prev.	SEP	2014	70						1	7		10.1016/j.aap.2014.02.016			7	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Social Science Citation Index (SSCI)	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	AJ7CR	WOS:000337855300001	24686160				2022-02-06	
J	Almeida-Suhett, CP; Prager, EM; Pidoplichko, V; Figueiredo, TH; Marini, AM; Li, Z; Eiden, LE; Braga, MFM				Almeida-Suhett, Camila P.; Prager, Eric M.; Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.			Reduced GABAergic Inhibition in the Basolateral Amygdala and the Development of Anxiety-Like Behaviors after Mild Traumatic Brain Injury	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; NICOTINIC ACETYLCHOLINE-RECEPTORS; CONTROLLED CORTICAL IMPACT; BENZODIAZEPINE-RECEPTOR; SYNAPTIC-TRANSMISSION; PREFRONTAL CORTEX; PANIC DISORDER; BINDING; SENSITIVITY; MICE	Traumatic brain injury (TBI) is a major public health concern affecting a large number of athletes and military personnel. Individuals suffering from a TBI risk developing anxiety disorders, yet the pathophysiological alterations that result in the development of anxiety disorders have not yet been identified. One region often damaged by a TBI is the basolateral amygdala (BLA); hyperactivity within the BLA is associated with increased expression of anxiety and fear, yet the functional alterations that lead to BLA hyperexcitability after TBI have not been identified. We assessed the functional alterations in inhibitory synaptic transmission in the BLA and one mechanism that modulates excitatory synaptic transmission, the alpha(7) containing nicotinic acetylcholine receptor (alpha(7)-nAChR), after mTBI, to shed light on the mechanisms that contribute to increased anxiety-like behaviors. Seven and 30 days after a mild controlled cortical impact (CCI) injury, animals displayed significantly greater anxiety-like behavior. This was associated with a significant loss of GABAergic interneurons and significant reductions in the frequency and amplitude of spontaneous and miniature GABA(A)-receptor mediated inhibitory postsynaptic currents (IPSCs). Decreases in the mIPSC amplitude were associated with reduced surface expression of alpha 1, beta 2, and gamma 2 GABA(A) receptor subunits. However, significant increases in the surface expression and current mediated by alpha(7)-nAChR, were observed, signifying increases in the excitability of principal neurons within the BLA. These results suggest that mTBI causes not only a significant reduction in inhibition in the BLA, but also an increase in neuronal excitability, which may contribute to hyperexcitability and the development of anxiety disorders.	[Almeida-Suhett, Camila P.; Prager, Eric M.; Marini, Ann M.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA; [Pidoplichko, Volodymyr; Figueiredo, Taiza H.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marini, Ann M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Almeida-Suhett, Camila P.; Marini, Ann M.; Li, Zheng; Eiden, Lee E.; Braga, Maria F. M.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Li, Zheng] NIMH, Sect Clin Studies, Intramural Res Program, NIH, Bethesda, MD 20892 USA; [Eiden, Lee E.] NIMH, Mol Neurosci Sect, Intramural Res Program, NIH, Bethesda, MD 20892 USA		Braga, MFM (corresponding author), Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA.	maria.braga@usuhs.edu	Prager, Eric/O-1567-2015; Li, Zheng/I-8016-2014; Almeida-Suhett, Camila/I-8045-2016	Prager, Eric/0000-0002-3810-0985; Li, Zheng/0000-0002-2978-2531; Almeida-Suhett, Camila/0000-0002-7588-9487; Eiden, Lee/0000-0001-7524-944X	Department of Defense in the Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1702Z]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002386] Funding Source: NIH RePORTER	The authors acknowledge the Department of Defense in the Center for Neuroscience and Regenerative Medicine for financially supporting the present work. Grant# G1702Z. URL of funder's website: http://www.usuhs.mil/cnrm/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida-Suhett CP, 2014, J NEUROTRAUM, V31, P683, DOI 10.1089/neu.2013.3029; Aroniadou-Anderjaska V, 2012, NEUROSCIENCE, V221, P157, DOI 10.1016/j.neuroscience.2012.07.006; Bailey SJ, 2004, J NEUROSCI, V24, P6343, DOI 10.1523/JNEUROSCI.0563-04.2004; Barazangi N, 2001, J NEUROPHYSIOL, V86, P463, DOI 10.1152/jn.2001.86.1.463; Bay Esther H, 2009, Res Theory Nurs Pract, V23, P42; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bremner JD, 2000, AM J PSYCHIAT, V157, P1120, DOI 10.1176/appi.ajp.157.7.1120; Bremner JD, 2000, BIOL PSYCHIAT, V47, P96, DOI 10.1016/S0006-3223(99)00188-2; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Chen J, 2013, NEUROSCI LETT, V541, P275, DOI 10.1016/j.neulet.2013.02.005; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Cowley DS, 1997, J CLIN PSYCHIAT, V58, P555, DOI 10.4088/JCP.v58n1208; Crestani F, 1999, NAT NEUROSCI, V2, P833, DOI 10.1038/12207; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Faraday MM, 2001, PHARMACOL BIOCHEM BE, V70, P475, DOI 10.1016/S0091-3057(01)00642-6; Faul M, 2010, TRAUMATIC BRAIN INJU; Feuerbach D, 2009, NEUROPHARMACOLOGY, V56, P254, DOI 10.1016/j.neuropharm.2008.08.025; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; GLUE P, 1991, LANCET, V337, P563, DOI 10.1016/0140-6736(91)91359-3; Gundersen HJG, 1999, J MICROSC-OXFORD, V193, P199, DOI 10.1046/j.1365-2818.1999.00457.x; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holzschneider Kathrin, 2011, Dialogues Clin Neurosci, V13, P453; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Jiang L, 2008, J NEUROPHYSIOL, V99, P1988, DOI 10.1152/jn.00933.2007; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelso ML, 2012, CURR DRUG TARGETS, V13, P631, DOI 10.2174/138945012800398964; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Klein RC, 2006, J PHYSIOL-LONDON, V576, P865, DOI 10.1113/jphysiol.2006.118232; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Malizia AL, 1998, ARCH GEN PSYCHIAT, V55, P715, DOI 10.1001/archpsyc.55.8.715; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Meyer DL, 2012, EXP NEUROL, V235, P574, DOI 10.1016/j.expneurol.2012.03.012; Mohler H, 2006, CELL TISSUE RES, V326, P505, DOI 10.1007/s00441-006-0284-3; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Pandya AA, 2013, BIOCHEM PHARMACOL, V86, P1054, DOI 10.1016/j.bcp.2013.05.018; Pidoplichko VI, 2005, J NEUROSCI METH, V142, P55, DOI 10.1016/j.jneumeth.2004.07.012; Pidoplichko VI, 2013, J NEUROPHYSIOL, V110, P2358, DOI 10.1152/jn.01030.2012; Prager EM, 2011, FRONT BEHAV NEUROSCI, V5, DOI 10.3389/fnbeh.2011.00038; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; RoyByrne P, 1996, AM J PSYCHIAT, V153, P1444; Sah P, 2003, ANN NY ACAD SCI, V985, P67; Sah P, 2003, PHYSIOL REV, V83, P803, DOI 10.1152/physrev.00002.2003; Schmitz C, 2000, J CHEM NEUROANAT, V20, P93, DOI 10.1016/S0891-0618(00)00066-1; Shin LM, 2004, ARCH GEN PSYCHIAT, V61, P168, DOI 10.1001/archpsyc.61.2.168; Sibille E, 2000, J NEUROSCI, V20, P2758; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tiihonen J, 1997, MOL PSYCHIATR, V2, P463, DOI 10.1038/sj.mp.4000329; Truitt WA, 2009, NEUROSCIENCE, V160, P284, DOI 10.1016/j.neuroscience.2009.01.083; Turtzo LC, 2013, NMR BIOMED, V26, P468, DOI 10.1002/nbm.2886; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Villarreal G, 2001, Semin Clin Neuropsychiatry, V6, P131, DOI 10.1053/scnp.2001.21840; Wagner AK, 2007, J NEUROTRAUM, V24, P1308, DOI 10.1089/neu.2007.0274; Watson C., 2005, RAT BRAIN STEROTAXIC; WOMBLE MD, 1993, J NEUROPHYSIOL, V70, P2056, DOI 10.1152/jn.1993.70.5.2056; Wood RL, 2014, J HEAD TRAUMA REHAB, V29, pE9, DOI 10.1097/HTR.0b013e31827eabba; Zappala G, 2012, CORTEX, V48, P156, DOI 10.1016/j.cortex.2011.06.020; Zhang BL, 2011, CHINESE MED J-PEKING, V124, P740, DOI 10.3760/cma.j.issn.0366-6999.2011.05.020	72	72	72	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2014	9	7							e102627	10.1371/journal.pone.0102627			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AM0SW	WOS:000339558100054	25047645	Green Published, gold, Green Submitted			2022-02-06	
J	Chrisman, SPD; Richardson, LP				Chrisman, Sara P. D.; Richardson, Laura P.			Prevalence of Diagnosed Depression in Adolescents With History of Concussion	JOURNAL OF ADOLESCENT HEALTH			English	Article						Adolescents; Concussion; Depression; Traumatic brain injury	TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; MENTAL-DISORDERS; UNITED-STATES; ASSOCIATION; CHILDREN; SPORTS; RISK; PSYCHOPATHOLOGY; EPIDEMIOLOGY	Purpose: Previous studies in adults have suggested concussion and other brain injury presents a risk factor for depression. The goal of our study was to analyze the association between previous concussion and current depression diagnosis in a large nationally representative adolescent data set. Methods: Retrospective cohort study using the National Survey of Children's Health 2007-2008, a nationally representative survey conducted via random digit dialing. Data were obtained by parental report. We included youth 12-17 years old without a current concussion (N = 36,060), and evaluated the association between previous concussion (binary) and current depression diagnosis (binary) using multiple logistic regression to control for age, sex, parental mental health, and socioeconomic status. Results: After controlling for age, sex, parental mental health, and socioeconomic status, history of concussion was associated with a 3.3-fold greater risk for depression diagnosis (95% CI: 2.0-5.5). Other factors significantly associated with depression diagnosis included poor or fair parental mental health (OR: 3.7, 95% CI: 2.8-4.9), and older age (15-17 years vs. 12-14 years, OR: 1.4, 95% CI: 1.1-1.8). Sex of the subject was not significantly related to depression diagnosis. Being above 200% of the poverty level was associated with approximately a 50% decreased risk of depression diagnosis (95% CI: 35%-70%). Conclusions: History of concussion was associated with a higher prevalence of diagnosed depression in a large nationally representative adolescent data set. Clinicians should screen for depression in their adolescent patients with concussion. Future studies should confirm this association using prospective methodology and examine potential treatment approaches. (C) 2014 Society for Adolescent Health and Medicine. All rights reserved.	[Chrisman, Sara P. D.; Richardson, Laura P.] Univ Washington, Dept Pediat, Div Adolescent Med, Seattle, WA 98195 USA; [Chrisman, Sara P. D.; Richardson, Laura P.] Seattle Childrens Hosp, Ctr Child Hlth Behav & Dev, Seattle, WA 98104 USA		Chrisman, SPD (corresponding author), Seattle Childrens Hosp, Dept Anesthesiol & Pain Med, MB 11-500-3,Seattle 4800 Sandpoint Way NE, Seattle, WA 98104 USA.	sara.chrisman@seattlechildrens.org		Chrisman, Sara/0000-0001-5373-7223	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA	This research was supported by a National Institutes of Health Loan Repayment Grant.	Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Birmaher B, 1998, J AM ACAD CHILD PSY, V37, P1234, DOI 10.1097/00004583-199811000-00029; Blumberg Stephen J, 2012, Vital Health Stat 1, P1; Centers for Disease Control and Prevention (CDC), REP C MILD TRAUM BRA; Child and Adolescent Health Measurement Initiative (CAHMI), 2007, NAT SURV CHILDR HLTH; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fewell Z, 2007, AM J EPIDEMIOL, V166, P646, DOI 10.1093/aje/kwm165; Fletcher JM, 2008, HEALTH ECON, V17, P1215, DOI 10.1002/hec.1319; Fogelberg DJ, 2012, ARCH PHYS MED REHAB, V93, P1313, DOI 10.1016/j.apmr.2012.04.031; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Gureje O, 2011, MOL PSYCHIATR, V16, P1221, DOI 10.1038/mp.2010.111; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hirshfeld-Becker DR, 2012, AM J PSYCHIAT, V169, P1175, DOI 10.1176/appi.ajp.2012.11101514; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Ilie G, 2013, JAMA-J AM MED ASSOC, V309, P2550, DOI 10.1001/jama.2013.6750; Krystal AD, 2012, NEUROL CLIN, V30, P1389, DOI 10.1016/j.ncl.2012.08.018; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEWINSOHN PM, 1993, J ABNORM PSYCHOL, V102, P133, DOI 10.1037/0021-843X.102.1.133; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; MCGUINNESS TM, 2012, J PSYCHOSOC NURS MEN, V50, P17; McLaughlin KA, 2012, AM J PUBLIC HEALTH, V102, P1742, DOI 10.2105/AJPH.2011.300477; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Nordin JD, 2010, ANN FAM MED, V8, P511, DOI 10.1370/afm.1188; O'Connor SS, 2012, J TRAUMA STRESS, V25, P264, DOI 10.1002/jts.21704; Richardson LP, 2003, ARCH PEDIAT ADOL MED, V157, P739, DOI 10.1001/archpedi.157.8.739; Rushton JL, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e8; Saluja G, 2004, ARCH PEDIAT ADOL MED, V158, P760, DOI 10.1001/archpedi.158.8.760; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; StataCorp, 2011, STAT STAT SOFTW REL; Teychenne M, 2011, INT J BEHAV MED, V17, P246, DOI 10.1007/s12529-010-9075-z; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Witvliet M, 2010, J ABNORM CHILD PSYCH, V38, P1045, DOI 10.1007/s10802-010-9426-x; Zatzick DF, 2011, PSYCHIAT SERV, V62, P264, DOI 10.1176/ps.62.3.pss6203_0264	37	72	73	4	34	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	MAY	2014	54	5					582	586		10.1016/j.jadohealth.2013.10.006			5	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Public, Environmental & Occupational Health; Pediatrics	AF1XG	WOS:000334506600013	24355628	Green Accepted			2022-02-06	
J	Tollner, K; Brandt, C; Topfer, M; Brunhofer, G; Erker, T; Gabriel, M; Feit, PW; Lindfors, J; Kaila, K; Loscher, W				Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Brunhofer, Gerda; Erker, Thomas; Gabriel, Mario; Feit, Peter W.; Lindfors, Jenna; Kaila, Kai; Loescher, Wolfgang			A Novel Prodrug-Based Strategy to Increase Effects of Bumetanide in Epilepsy	ANNALS OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; CATION-CHLORIDE COTRANSPORTERS; RAT HIPPOCAMPUS; GABA UPTAKE; IN-VITRO; NKCC1; MODEL; TRANSPORTERS; DIURETICS; DRUGS	ObjectiveThere is considerable interest in using bumetanide, a chloride importer Na-K-Cl cotransporter antagonist, for treatment of neurological diseases, such as epilepsy or ischemic and traumatic brain injury, that may involve deranged cellular chloride homeostasis. However, bumetanide is heavily bound to plasma proteins (approximate to 98%) and highly ionized at physiological pH, so that it only poorly penetrates into the brain, and chronic treatment with bumetanide is compromised by its potent diuretic effect. MethodsTo overcome these problems, we designed lipophilic and uncharged prodrugs of bumetanide that should penetrate the blood-brain barrier more easily than the parent drug and are converted into bumetanide in the brain. The feasibility of this strategy was evaluated in mice and rats. ResultsAnalysis of bumetanide levels in plasma and brain showed that administration of 2 ester prodrugs of bumetanide, the pivaloyloxymethyl (BUM1) and N,N-dimethylaminoethylester (BUM5), resulted in significantly higher brain levels of bumetanide than administration of the parent drug. BUM5, but not BUM1, was less diuretic than bumetanide, so that BUM5 was further evaluated in chronic models of epilepsy in mice and rats. In the pilocarpine model in mice, BUM5, but not bumetanide, counteracted the alteration in seizure threshold during the latent period. In the kindling model in rats, BUM5 was more efficacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital. InterpretationOur data demonstrate that the goal of designing bumetanide prodrugs that specifically target the brain is feasible and that such drugs may resolve the problems associated with using bumetanide for treatment of neurological disorders. ANN NEUROL 2014;75:550-562	[Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Feit, Peter W.; Loescher, Wolfgang] Univ Vet Med, Dept Pharmacol Toxicol & Pharm, D-30559 Hannover, Germany; [Toellner, Kathrin; Brandt, Claudia; Toepfer, Manuel; Loescher, Wolfgang] Ctr Syst Neurosci, Hannover, Germany; [Brunhofer, Gerda; Erker, Thomas; Gabriel, Mario] Univ Vienna, Dept Med Chem, Vienna, Austria; [Lindfors, Jenna; Kaila, Kai] Univ Helsinki, Dept Biosci, Helsinki, Finland; [Lindfors, Jenna; Kaila, Kai] Univ Helsinki, Ctr Neurosci, Helsinki, Finland		Loscher, W (corresponding author), Univ Vet Med, Dept Pharmacol Toxicol & Pharm, Bunteweg 17, D-30559 Hannover, Germany.	wolfgang.loescher@tiho-hannover.de	Kaila, Kai K/R-8528-2016; Loscher, Wolfgang/G-9824-2016	Kaila, Kai K/0000-0003-0668-5955; Loscher, Wolfgang/0000-0002-9648-8973	Deutsche Forschungsgemeinschaft (Bonn, Germany)German Research Foundation (DFG) [Lo 274/11]; Akademie fur Tiergesundheit (Bonn, Germany)	The study was supported by a grant (Lo 274/11; for WL) from the Deutsche Forschungsgemeinschaft (Bonn, Germany) and a scholarship (for M. T.) from the Akademie fur Tiergesundheit (Bonn, Germany). Leo Pharma (Ballerup, Denmark) provided a sample of the methyl ester of bumetanide, and Roquette-Pharma (Frankfurt, Germany) provided hydroxypropyl-beta-cyclodextrin.	Ben-Ari Y, 2012, EPILEPSIA, V53, P394, DOI 10.1111/j.1528-1167.2011.03378.x; BENARI Y, 1989, J PHYSIOL-LONDON, V416, P303, DOI 10.1113/jphysiol.1989.sp017762; Brandt C, 2010, J NEUROSCI, V30, P8602, DOI 10.1523/JNEUROSCI.0633-10.2010; Cleary RT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057148; Cohen I, 2002, SCIENCE, V298, P1418, DOI 10.1126/science.1076510; COHEN MR, 1976, J PHARMACOL EXP THER, V197, P697; Dzhala VI, 2005, NAT MED, V11, P1205, DOI 10.1038/nm1301; Dzhala VI, 2008, ANN NEUROL, V63, P222, DOI 10.1002/ana.21229; FEIT PW, 1971, J MED CHEM, V14, P432, DOI 10.1021/jm00287a014; FREY HH, 1980, NEUROPHARMACOLOGY, V19, P217, DOI 10.1016/0028-3908(80)90141-0; FREY HH, 1979, NEUROPHARMACOLOGY, V18, P581, DOI 10.1016/0028-3908(79)90108-4; Hannaert P, 2002, N-S ARCH PHARMACOL, V365, P193, DOI 10.1007/s00210-001-0521-y; Hasannejad H, 2004, J PHARMACOL EXP THER, V308, P1021, DOI 10.1124/jpet.103.059139; Hochman D, 2009, AM EP SOC 63 ANN M D; Hochman DW, 2006, Methods and compositions for the treatment of neuropsychiatric disorders with bumetanide and furo-semide analogs, Patent No. [US20060089350A1, 20060089350]; Hochman DW, 2007, Methods and compositions using NKCC cotransporter inhibitors for the treatment of neuropsychiat-ric and addictive disorders, Patent No. [WO2007047698A2, 2007047698]; Huberfeld G, 2007, J NEUROSCI, V27, P9866, DOI 10.1523/JNEUROSCI.2761-07.2007; HUNTER R L, 1961, Ann Histochim, V6, P447; JAVAHERI S, 1993, J NEUROCHEM, V61, P1525, DOI 10.1111/j.1471-4159.1993.tb13648.x; Kahle KT, 2008, NAT CLIN PRACT NEURO, V4, P490, DOI 10.1038/ncpneuro0883; Kobayashi Y, 2005, EUR J PHARMACOL, V524, P44, DOI 10.1016/j.ejphar.2005.09.054; KOLIS SJ, 1976, DRUG METAB DISPOS, V4, P169; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Li XB, 2008, BRAIN RES, V1221, P141, DOI 10.1016/j.brainres.2008.04.047; Li YJ, 2011, J CHROMATOGR B, V879, P998, DOI 10.1016/j.jchromb.2011.02.018; Liu YQ, 2012, PEDIATR RES, V71, P559, DOI 10.1038/pr.2012.7; Loscher W, 2013, NEUROPHARMACOLOGY, V69, P62, DOI 10.1016/j.neuropharm.2012.05.045; LOSCHER W, 1983, J PHARMACOL EXP THER, V226, P839; LOSCHER W, 1986, EXP NEUROL, V93, P211, DOI 10.1016/0014-4886(86)90160-3; Loscher W, 1997, PROG NEUROBIOL, V53, P239, DOI 10.1016/S0301-0082(97)00035-X; LOSCHER W, 1985, EUR J PHARMACOL, V110, P103, DOI 10.1016/0014-2999(85)90034-2; Maa EH, 2011, EPILEPSIA, V52, P1559, DOI 10.1111/j.1528-1167.2011.03203.x; Mazarati A, 2009, EPILEPSIA, V50, P2117, DOI 10.1111/j.1528-1167.2009.02048.x; Munoz A, 2007, EPILEPSIA, V48, P663, DOI 10.1111/j.1528-1167.2007.00986.x; Nardou R, 2011, BRAIN, V134, P987, DOI 10.1093/brain/awr041; OGRADY SM, 1987, AM J PHYSIOL, V253, pC177, DOI 10.1152/ajpcell.1987.253.2.C177; Okabe A, 2002, NEUROSCI RES, V44, P225, DOI 10.1016/S0168-0102(02)00093-7; Okabe A, 2003, BRAIN RES, V990, P221, DOI 10.1016/S0006-8993(03)03528-5; OLSEN UB, 1977, ACTA PHARMACOL TOX, V41, P5; Palma E, 2006, P NATL ACAD SCI USA, V103, P8465, DOI 10.1073/pnas.0602979103; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Rattka M, 2012, EUR J NEUROSCI, V36, P2505, DOI 10.1111/j.1460-9568.2012.08143.x; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Rautio J, 2008, AAPS J, V10, P92, DOI 10.1208/s12248-008-9009-8; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Sipila ST, 2006, J PHYSIOL-LONDON, V573, P765, DOI 10.1113/jphysiol.2006.107086; Tollner K, 2011, EPILEPSIA, V52, P52; Tollner K, 2010, SOC NEUR ANN M NOV 1; Topfer M, 2011, AM EP SOC 65 ANN M D; Wanaski S, 2010, Preparation of bumetanide, furosemide, piretanide, azosemide, and torsemide analogs and therapeutic compositions containing same for treating disorders involving the Na + K+Cl-cotransporter and GABAA receptors, Patent No. [WO2010085352A2, 2010085352]; Wanaski S, 2012, Arylsulfonamide derivatives as sodium-#potassium-chloride cotransporter inhibitors and their preparation, compositions, and methods of use, Patent No. [WO2012018635A2, 2012018635]; Weindlmayr-Goettel M, 2002, BRIT J ANAESTH, V88, P555, DOI 10.1093/bja/88.4.555	53	72	72	0	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	APR	2014	75	4					550	562		10.1002/ana.24124			13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AG2GL	WOS:000335234200010	24615913				2022-02-06	
J	Ham, TE; Bonnelle, V; Hellyer, P; Jilka, S; Robertson, IH; Leech, R; Sharp, DJ				Ham, Timothy E.; Bonnelle, Valerie; Hellyer, Peter; Jilka, Sagar; Robertson, Ian H.; Leech, Robert; Sharp, David J.			The neural basis of impaired self-awareness after traumatic brain injury	BRAIN			English	Article						traumatic brain injury; fronto-parietal control network; salience network; self-awareness; functional connectivity	ANTERIOR CINGULATE CORTEX; RESPONSE-INHIBITION; FINANCIAL CAPACITY; SALIENCE NETWORK; SPATIAL NEGLECT; FRONTAL SYSTEMS; ERROR-DETECTION; CONNECTIVITY; PERFORMANCE; ATTENTION	Self-awareness is commonly impaired after traumatic brain injury. This is an important clinical issue as awareness affects long-term outcome and limits attempts at rehabilitation. It can be investigated by studying how patients respond to their errors and monitor their performance on tasks. As awareness is thought to be an emergent property of network activity, we tested the hypothesis that impaired self-awareness is associated with abnormal brain network function. We investigated a group of subjects with traumatic brain injury (n = 63) split into low and high performance-monitoring groups based on their ability to recognize and correct their own errors. Brain network function was assessed using resting-state and event-related functional magnetic resonance imaging. This allowed us to investigate baseline network function, as well as the evoked response of networks to specific events including errors. The low performance-monitoring group underestimated their disability and showed broad attentional deficits. Neural activity within what has been termed the fronto-parietal control network was abnormal in patients with impaired self-awareness. The dorsal anterior cingulate cortex is a key part of this network that is involved in performance-monitoring. This region showed reduced functional connectivity to the rest of the fronto-parietal control network at 'rest'. In addition, the anterior insulae, which are normally tightly linked to the dorsal anterior cingulate cortex, showed increased activity following errors in the impaired group. Interestingly, the traumatic brain injury patient group with normal performance-monitoring showed abnormally high activation of the right middle frontal gyrus, putamen and caudate in response to errors. The impairment of self-awareness was not explained either by the location of focal brain injury, or the amount of traumatic axonal injury as demonstrated by diffusion tensor imaging. The results suggest that impairments of self-awareness after traumatic brain injury result from breakdown of functional interactions between nodes within the fronto-parietal control network.	[Ham, Timothy E.; Hellyer, Peter; Jilka, Sagar; Leech, Robert; Sharp, David J.] Univ London Imperial Coll Sci Technol & Med, C3NL, Ctr Restorat Neurosci, Div Brain Sci,Dept Med, London W12 0NN, England; [Ham, Timothy E.] Univ Cambridge, Neurol Unit, Cambridge CB2 0SZ, England; [Bonnelle, Valerie] UCL, Inst Cognit Neurosci, London WC1N 3AR, England; [Jilka, Sagar] Univ London, Dept Psychol, London SE14 6NW, England; [Robertson, Ian H.] Trinity Coll Dublin, Trinity Coll, Inst Neurosci, Dublin 2, Ireland		Sharp, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Computat Cognit & Clin Neuroimaging Lab, Ctr Neurosci, Div Expt Med, Burlington Danes Bldg,Hammersmith Hosp Campus, London W12 0NN, England.	david.sharp@csc.mrc.ac.uk	Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013; Hellyer, Peter/F-7112-2013	Leech, Robert/0000-0002-5801-6318; Hellyer, Peter/0000-0002-5139-3401; Robertson, Ian H/0000-0001-8637-561X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; National Institute of Health ResearchNational Institute for Health Research (NIHR); Imperial College Healthcare Charity; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783, G0701951] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0701951] Funding Source: UKRI	This work was supported by grants from the Medical Research Council, the National Institute of Health Research and the Imperial College Healthcare Charity (to D.J.S).	BALTES PB, 1993, GERONTOLOGIST, V33, P580, DOI 10.1093/geront/33.5.580; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bekker EM, 2005, PSYCHOL MED, V35, P807, DOI 10.1017/S0033291704003459; Boly M, 2007, P NATL ACAD SCI USA, V104, P12187, DOI 10.1073/pnas.0611404104; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Botvinick MM, 2004, TRENDS COGN SCI, V8, P539, DOI 10.1016/j.tics.2004.10.003; Brett M, 2001, NEUROIMAGE, V14, P486, DOI 10.1006/nimg.2001.0845; Cabeza R, 2002, NEUROIMAGE, V17, P1394, DOI 10.1006/nimg.2002.1280; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; Corbetta M, 2011, ANNU REV NEUROSCI, V34, P569, DOI 10.1146/annurev-neuro-061010-113731; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; DEHAENE S, 1994, PSYCHOL SCI, V5, P303, DOI 10.1111/j.1467-9280.1994.tb00630.x; Dreer LE, 2012, REHABIL PSYCHOL, V57, P5, DOI 10.1037/a0025818; Filippini N, 2009, P NATL ACAD SCI USA, V106, P7209, DOI 10.1073/pnas.0811879106; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fox MD, 2006, NAT NEUROSCI, V9, P23, DOI 10.1038/nn1616; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; Ham T, 2013, J NEUROSCI, V33, P7091, DOI 10.1523/JNEUROSCI.4692-12.2013; Ham TE, 2013, CEREB CORTEX, V23, P703, DOI 10.1093/cercor/bhs056; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; He BJ, 2007, NEURON, V53, P905, DOI 10.1016/j.neuron.2007.02.013; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hesselmann G, 2008, P NATL ACAD SCI USA, V105, P10984, DOI 10.1073/pnas.0712043105; Husain M, 1997, NATURE, V385, P154, DOI 10.1038/385154a0; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Li CSR, 2008, J COGNITIVE NEUROSCI, V20, P1021, DOI 10.1162/jocn.2008.20071; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Martin RC, 2012, J HEAD TRAUMA REHAB, V27, pE81, DOI 10.1097/HTR.0b013e318273de49; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Modirrousta M, 2008, J NEUROSCI, V28, P14000, DOI 10.1523/JNEUROSCI.4450-08.2008; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; O'Keeffe FM, 2004, COGNITIVE BRAIN RES, V22, P101, DOI 10.1016/j.cogbrainres.2004.07.012; Oakes TR, 2007, NEUROIMAGE, V34, P500, DOI 10.1016/j.neuroimage.2006.10.007; Oliveira FTP, 2007, J COGNITIVE NEUROSCI, V19, P1994, DOI 10.1162/jocn.2007.19.12.1994; Ornstein TJ, 2009, J CHILD PSYCHOL PSYC, V50, P506, DOI 10.1111/j.1469-7610.2008.01997.x; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RABBITT PMA, 1968, Q J EXP PSYCHOL, V20, P179, DOI 10.1080/14640746808400146; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Robertson IH, 1998, NATURE, V395, P169, DOI 10.1038/25993; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2006, CEREB CORTEX, V16, P1739, DOI 10.1093/cercor/bhj109; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Soto D, 2009, P NATL ACAD SCI USA, V106, P6011, DOI 10.1073/pnas.0811681106; Spreng RN, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00145; Spreng RN, 2010, NEUROIMAGE, V53, P303, DOI 10.1016/j.neuroimage.2010.06.016; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Taylor JG, 1997, NEURAL NETWORKS, V10, P1207, DOI 10.1016/S0893-6080(97)00064-6; Thompson E, 2001, TRENDS COGN SCI, V5, P418, DOI 10.1016/S1364-6613(00)01750-2; Triebel KL, 2012, NEUROLOGY, V78, P1472, DOI 10.1212/WNL.0b013e3182553c38; Ullsperger M, 2004, CORTEX, V40, P593, DOI 10.1016/S0010-9452(08)70155-2; Ullsperger M, 2010, BRAIN STRUCT FUNCT, V214, P629, DOI 10.1007/s00429-010-0261-1; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; Verbruggen F, 2008, Q J EXP PSYCHOL, V61, P1151, DOI 10.1080/17470210801994971; Vincent JL, 2008, J NEUROPHYSIOL, V100, P3328, DOI 10.1152/jn.90355.2008; Ward NS, 2006, BRAIN, V129, P809, DOI 10.1093/brain/awl002; Zuo XN, 2010, NEUROIMAGE, V49, P2163, DOI 10.1016/j.neuroimage.2009.10.080	75	72	73	2	25	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2014	137		2				586	597		10.1093/brain/awt350			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AA7QB	WOS:000331290900024	24371217	Bronze, Green Published			2022-02-06	
J	West, TA; Marion, DW				West, Therese A.; Marion, Donald W.			Current Recommendations for the Diagnosis and Treatment of Concussion in Sport: A Comparison of Three New Guidelines	JOURNAL OF NEUROTRAUMA			English	Article						concussion; guidelines; mild traumatic brain injury; post-concussion syndrome; return to play	STATEMENT	Currently, there is considerable debate within the sports medicine community about the role of concussion and the risk of chronic neurological sequelae. This concern has led to significant confusion among primary care providers and athletic trainers about how to best identify those athletes at risk and how to treat those with concussion. During the first quarter of 2013, several new or updated clinical practice guidelines and position statements were published on the diagnosis, treatment, and management of mild traumatic brain injury/concussion in sports. Three of these guidelines were produced by the American Medical Society for Sports Medicine, The American Academy of Neurology, and the Zurich Consensus working group. The goal of each group was to clearly define current best practices for the definition, diagnosis, and acute and post-acute management of sports-related concussion, including specific recommendations for return to play. In this article, we compare the recommendations of each of the three groups, and highlight those topics for which there is consensus regarding the definition of concussion, diagnosis, and acute care of athletes suspected of having a concussion, as well as return-to-play recommendations.	[West, Therese A.; Marion, Donald W.] DVBIC, Silver Spring, MD 20910 USA		West, TA (corresponding author), DVBIC, 1335 East West Highway,Suite 605, Silver Spring, MD 20910 USA.	therese.a.west.ctr@mail.mil	Marion, Donald/AAR-5749-2021		CCSi; Henry Jackson Foundation	Defense and Veterans Brain Injury Center is a component center of The Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury; CCSi and Henry Jackson Foundation contracting support.	Centers for Disease Control and Prevention, 2013, INJ PREV CONTR; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Kelly JP, 1997, NEUROLOGY, V48, P581; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; National Institutes of Health, 2013, NIH CONS DEV PROGR	7	72	74	0	42	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					159	168		10.1089/neu.2013.3031			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600002	23879529	Green Published			2022-02-06	
J	Tanna, T; Sachan, V				Tanna, Tanmay; Sachan, Vatsal			Mesenchymal Stem Cells: Potential in Treatment of Neurodegenerative Diseases	CURRENT STEM CELL RESEARCH & THERAPY			English	Article						Alzheimer's disease (AD); Amyotrophic lateral sclerosis (ALS); Huntington's disease (HD); Mesenchymal stem cells; multiple sclerosis (MS); neurodegenerative diseases; Parkinson's disease (PD)	AMYOTROPHIC-LATERAL-SCLEROSIS; AMYLOID-BETA DEPOSITION; MARROW STROMAL CELLS; NEURON-LIKE CELLS; ALZHEIMERS-DISEASE; BONE-MARROW; HUNTINGTONS-DISEASE; MULTIPLE-SCLEROSIS; UMBILICAL-CORD; PARKINSONS-DISEASE	Mesenchymal Stem Cells or Marrow Stromal Cells (MSCs) have long been viewed as a potent tool for regenerative cell therapy. MSCs are easily accessible from both healthy donor and patient tissue and expandable in vitro on a therapeutic scale without posing significant ethical or procedural problems. MSC based therapies have proven to be effective in preclinical studies for graft versus host disease, stroke, myocardial infarction, pulmonary fibrosis, autoimmune disorders and many other conditions and are currently undergoing clinical trials at a number of centers all over the world. MSCs are also being extensively researched as a therapeutic tool against neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease (HD) and Multiple Sclerosis (MS). MSCs have been discussed with regard to two aspects in the context of neurodegenerative diseases: their ability to transdifferentiate into neural cells under specific conditions and their neuroprotective and immunomodulatory effects. When transplanted into the brain, MSCs produce neurotrophic and growth factors that protect and induce regeneration of damaged tissue. Additionally, MSCs have also been explored as gene delivery vehicles, for example being genetically engineered to over express glial-derived or brain-derived neurotrophic factor in the brain. Clinical trials involving MSCs are currently underway for MS, ALS, traumatic brain injuries, spinal cord injuries and stroke. In the present review, we explore the potential that MSCs hold with regard to the aforementioned neurodegenerative diseases and the current scenario with reference to the same.	[Tanna, Tanmay; Sachan, Vatsal] Natl Inst Technol, Dept Biotechnol, Warangal 506004, Andhra Pradesh, India		Sachan, V (corresponding author), Natl Inst Technol, Dept Biotechnol, Warangal 506004, Andhra Pradesh, India.	vatsalsac@gmail.com		Tanna, Tanmay/0000-0002-1150-0188			Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Ahmed H, 2014, HUM EXP TOXICOL; Amin EM, 2008, NEUROL RES, V30, P1086, DOI 10.1179/174313208X327955; Ardeshiry Lajimi Abdolreza, 2013, Int J Hematol Oncol Stem Cell Res, V7, P15; Arnold I, J ORTHOPAED RES; Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; Auletta JJ, 2012, IMMUNOTHERAPY-UK, V4, P529, DOI [10.2217/IMT.12.41, 10.2217/imt.12.41]; Babaei P, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/369417; Bachoud-Levi AC, 2006, LANCET NEUROL, V5, P303, DOI 10.1016/S1474-4422(06)70381-7; Bachurin SO, 2003, MED RES REV, V23, P48, DOI 10.1002/med.10026; Bae JS, 2013, CURR ALZHEIMER RES, V10, P524; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Baraniak PR, 2010, REGEN MED, V5, P121, DOI 10.2217/RME.09.74; Barker RA, 2012, REGEN MED, V7, P26, DOI [10.2217/RME.12.64, 10.2217/rme.12.64]; BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BECKER AJ, 1963, NATURE, V197, P452, DOI 10.1038/197452a0; Ben-Ami E, 2014, AUTOIMMUN REV, V13, P187, DOI 10.1016/j.autrev.2013.09.007; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Bobkova NV, 2013, B EXP BIOL MED+, V156, P119, DOI 10.1007/s10517-013-2293-z; Boillee S, 2006, NEURON, V52, P39, DOI 10.1016/j.neuron.2006.09.018; Bonab MM, 2013, ARCH MED RES, V44, P266, DOI 10.1016/j.arcmed.2013.03.007; Bonab MM, 2012, CURR STEM CELL RES T, V7, P407; Bouchez G, 2008, NEUROCHEM INT, V52, P1332, DOI 10.1016/j.neuint.2008.02.003; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brunt KR, 2012, CAN J PHYSIOL PHARM, V90, P327, DOI [10.1139/y2012-007, 10.1139/Y2012-007]; Burt RK, 2009, LANCET NEUROL, V8, P244, DOI 10.1016/S1474-4422(09)70017-1; Cattaneo E, 2005, NAT REV NEUROSCI, V6, P919, DOI 10.1038/nrn1806; Chang KA, 2014, NEURODEGENER DIS, V13, P99, DOI 10.1159/000355261; Chapuis S, 2005, MOVEMENT DISORD, V20, P224, DOI 10.1002/mds.20279; Chen Y, 2014, DRUG DISCOV TODAY; Chipman PH, 2012, PROG BRAIN RES, V201, P313, DOI 10.1016/B978-0-444-59544-7.00015-9; Choi CI, 2013, CELL TRANSPLANT, V22, P855, DOI 10.3727/096368912X637019; Chow VW, 2010, NEUROMOL MED, V12, P1, DOI 10.1007/s12017-009-8104-z; CLARKE DJ, 1988, PROG BRAIN RES, V78, P47; Cobo M, 2013, CELL TRANSPLANT, V22, P839, DOI 10.3727/096368912X657404; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Cova L, 2010, STEM CELLS CLONING, V3, P145, DOI 10.2147/SCCAA.S8662; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; Dantuma E, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt37; Darlington PJ, 2011, EXPERT REV NEUROTHER, V11, P1295, DOI [10.1586/ern.11.113, 10.1586/ERN.11.113]; Davie CA, 2008, BRIT MED BULL, V86, P109, DOI 10.1093/bmb/ldn013; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; de Munter Johannes P J M, 2014, Parkinsonism Relat Disord, V20 Suppl 1, pS150, DOI 10.1016/S1353-8020(13)70036-1; de Oliveira G., 2013, CELL TRANSPLANT; Deierborg T, 2014, NEURODEGENER DIS, V13, P99; Dey ND, 2010, BEHAV BRAIN RES, V214, P193, DOI 10.1016/j.bbr.2010.05.023; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Dezawa M, 2008, MED MOL MORPHOL, V41, P14, DOI 10.1007/s00795-007-0389-0; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Dyson SC, 2011, EXPERT REV NEUROTHER, V11, P831, DOI [10.1586/ern.11.33, 10.1586/ERN.11.33]; Ehnert S, 2009, LANGENBECK ARCH SURG, V394, P985, DOI 10.1007/s00423-009-0546-0; Erba P, 2010, CURR STEM CELL RES T, V5, P153, DOI 10.2174/157488810791268645; Fan XT, 2014, MED RES REV, V34, P957, DOI 10.1002/med.21309; Farge D, 2010, HAEMATOL-HEMATOL J, V95, P284, DOI 10.3324/haematol.2009.013458; Feng ZL, 2009, AM J ALZHEIMERS DIS, V24, P52, DOI 10.1177/1533317508327587; Garcia KO, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00030; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Glavaski-Joksimovic A, 2013, EXP NEUROL, V247, P25, DOI 10.1016/j.expneurol.2013.03.016; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Habisch HJ, 2010, STEM CELLS DEV, V19, P629, DOI 10.1089/scd.2009.0045; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Harris VK, 2012, STEM CELL TRANSL MED, V1, P536, DOI 10.5966/sctm.2012-0015; Harrison DM, 2009, ANN INDIAN ACAD NEUR, V12, P283, DOI 10.4103/0972-2327.58279; Hedayatpour A, 2013, CELL J, V15, P142; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Hou ZL, 2013, CELL ADHES MIGR, V7, P404, DOI 10.4161/cam.26941; Ikebe C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/951512; ISACSON O, 1984, NATURE, V311, P458, DOI 10.1038/311458a0; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Jin GZ, 2008, CELL BIOL INT, V32, P1433, DOI 10.1016/j.cellbi.2008.08.014; Joyce N, 2010, REGEN MED, V5, P933, DOI 10.2217/RME.10.72; Kanno Hiroshi, 2013, World J Stem Cells, V5, P163, DOI 10.4252/wjsc.v5.i4.163; Karussis D, 2013, EXPERT REV NEUROTHER, V13, P567, DOI [10.1586/ern.13.36, 10.1586/ERN.13.36]; Katsuda T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01197; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Keilhoff G, 2006, CELL MOL NEUROBIOL, V26, P1235, DOI 10.1007/s10571-006-9029-9; Khoo MLM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019025; Kim HJ, 2013, EXP BIOL MED, V238, P923, DOI 10.1177/1535370213497173; Kim S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045757; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kitada M, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/873706; Koh SH, 2012, EXP NEUROL, V233, P472, DOI 10.1016/j.expneurol.2011.11.021; Krakora D, 2013, MOL THER, V21, P1602, DOI 10.1038/mt.2013.108; Lanctot KL, 2003, CAN MED ASSOC J, V169, P557; Le Blanc K, 2006, CYTOTHERAPY, V8, P559, DOI 10.1080/14653240601045399; Lee H, 2007, STEM CELLS, V25, P1931, DOI 10.1634/stemcells.2007-0097; Lee HJ, 2012, NEUROBIOL AGING, V33, P588, DOI 10.1016/j.neurobiolaging.2010.03.024; Lee HJ, 2010, NEUROSCI LETT, V481, P30, DOI 10.1016/j.neulet.2010.06.045; Lee JK, 2009, NEUROSCI LETT, V450, P136, DOI 10.1016/j.neulet.2008.11.059; Lee ST, 2006, MECH AGEING DEV, V127, P432, DOI 10.1016/j.mad.2006.01.022; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lescaudron L, 2012, CURR MED CHEM, V19, P6018; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Li JY, 2008, NAT MED, V14, P501, DOI 10.1038/nm1746; Liang J, 2013, NEUROSCI LETT, V532, P59, DOI 10.1016/j.neulet.2012.11.014; LINDVALL O, 1990, SCIENCE, V247, P574, DOI 10.1126/science.2105529; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Lu GH, 2012, NEUROREPORT, V23, P513, DOI 10.1097/WNR.0b013e328353fbb4; Lundkvist J, 2001, TRENDS NEUROSCI, V24, P492, DOI 10.1016/S0166-2236(00)01888-9; Ma T, 2013, CELL TRANSPLANT, V22, pS113, DOI 10.3727/096368913X672181; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Mancardi G, 2008, LANCET NEUROL, V7, P626, DOI 10.1016/S1474-4422(08)70138-8; Mannon PJ, 2011, EXPERT OPIN BIOL TH, V11, P1249, DOI 10.1517/14712598.2011.602967; Marconi S, 2013, NEUROSCIENCE, V248, P333, DOI 10.1016/j.neuroscience.2013.05.034; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Maucksch C, 2013, J CELL BIOCHEM, V114, P754, DOI 10.1002/jcb.24432; Mazzini L, 2010, EXP NEUROL, V223, P229, DOI 10.1016/j.expneurol.2009.08.007; Mazzini L, 2008, J NEUROL SCI, V265, P78, DOI 10.1016/j.jns.2007.05.016; Mazzini L, 2012, PROG BRAIN RES, V201, P333, DOI 10.1016/B978-0-444-59544-7.00016-0; Mazzini L, 2012, CYTOTHERAPY, V14, P56, DOI 10.3109/14653249.2011.613929; Meamar R, 2013, J CLIN NEUROSCI, V20, P1659, DOI 10.1016/j.jocn.2013.04.024; Meininger V, 2000, J NEUROL, V247, P19; Meyerrose T, 2010, ADV DRUG DELIVER REV, V62, P1167, DOI 10.1016/j.addr.2010.09.013; Mitrecic D, 2009, ANAT REC, V292, P1962, DOI 10.1002/ar.20971; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Naganska E, 2011, FOLIA NEUROPATHOL, V49, P1; Nishimura K, 2013, BIOL PHARM BULL, V36, P171, DOI 10.1248/bpb.b12-00929; Oh SH, 2014, CELL TRANSPLANT; Olson SD, 2012, MOL CELL NEUROSCI, V49, P271, DOI 10.1016/j.mcn.2011.12.001; Park HK, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0032847, 10.1371/journal.pone.0039921]; Park HJ, 2008, J NEUROCHEM, V107, P141, DOI 10.1111/j.1471-4159.2008.05589.x; Pasquini MC, 2010, BIOL BLOOD MARROW TR, V16, P1076, DOI 10.1016/j.bbmt.2010.03.012; Paul G, 2013, BIOCHIMIE, V95, P2246, DOI 10.1016/j.biochi.2013.07.013; Payne NL, 2013, CELL TRANSPLANT, V22, P1409, DOI 10.3727/096368912X657620; Pereira MCL, 2011, STEM CELL REV REP, V7, P1006, DOI 10.1007/s12015-011-9256-4; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pluchino S, 2009, NEUROSCI LETT, V456, P101, DOI 10.1016/j.neulet.2008.03.097; Politis M, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-1; PURDON SE, 1994, J PSYCHIATR NEUROSCI, V19, P359; Reekmans K, 2012, REGEN MED, V7, P245, DOI [10.2217/RME.12.5, 10.2217/rme.12.5]; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Rice CM, 2013, LANCET, V382, P1204, DOI 10.1016/S0140-6736(13)61810-3; Rivera FJ, 2012, BIOL RES, V45, P257, DOI 10.4067/S0716-97602012000300007; Rivera FT, 2006, STEM CELLS, V24, P2209, DOI 10.1634/stemcells.2005-0614; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rossignol J, 2014, STEM CELLS, V32, P500, DOI 10.1002/stem.1508; Ryu CH, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/696738; Sadan O, 2012, EXP NEUROL, V234, P417, DOI 10.1016/j.expneurol.2011.12.045; Sadan O, 2008, STEM CELLS, V26, P2542, DOI 10.1634/stemcells.2008-0240; Sadan O, 2009, STEM CELLS DEV, V18, P1179, DOI 10.1089/scd.2008.0411; SANBERG PR, 1989, EXP NEUROL, V105, P45, DOI 10.1016/0014-4886(89)90170-2; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Selmani Z, 2008, STEM CELLS, V26, P212, DOI 10.1634/stemcells.2007-0554; Shetty P, 2013, CELL BIOL INT, V37, P167, DOI 10.1002/cbin.10029; Shin JY, 2014, AUTOPHAGY, V10, P32, DOI 10.4161/auto.26508; Siatskas C, 2010, STEM CELL REV REP, V6, P500, DOI 10.1007/s12015-010-9173-y; Silani V, 2004, LANCET, V364, P200, DOI 10.1016/S0140-6736(04)16634-8; SIMINOVITCH L, 1963, J CELL COMPAR PHYSL, V62, P327, DOI 10.1002/jcp.1030620313; Snyder BR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009347; Soldner F, 2009, CELL, V136, P964, DOI 10.1016/j.cell.2009.02.013; Sorrentino A, 2008, EXP HEMATOL, V36, P1035, DOI 10.1016/j.exphem.2008.03.004; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; Sugaya K, 2008, J ALZHEIMERS DIS, V15, P241; Sun H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072926; Suzuki M, 2008, MOL THER, V16, P2002, DOI 10.1038/mt.2008.197; Taran R, 2014, J BIOSCIENCES, V39, P157, DOI 10.1007/s12038-013-9409-5; Thomas MG, 2011, TRANSL RES, V157, P56, DOI 10.1016/j.trsl.2010.11.001; Thomsen GM, 2014, EXP NEUROL; Trapp BD, 2008, ANNU REV NEUROSCI, V31, P247, DOI 10.1146/annurev.neuro.30.051606.094313; Trounson A, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-52; Uccelli A, 2013, MULT SCLER J, V19, P515, DOI 10.1177/1352458512464686; Vercelli A, 2008, NEUROBIOL DIS, V31, P395, DOI 10.1016/j.nbd.2008.05.016; Volkmann J, 2009, MOVEMENT DISORD, V24, P1154, DOI 10.1002/mds.22496; Waldau B, 2008, CELL MOL LIFE SCI, V65, P2372, DOI 10.1007/s00018-008-8053-y; Wang MJ, 2006, AM J PHYSIOL-REG I, V291, pR880, DOI 10.1152/ajpregu.00280.2006; WHITEHOUSE PJ, 1983, PSYCHOPHARMACOL BULL, V19, P437; Wichterle H, 2002, CELL, V110, P385, DOI 10.1016/S0092-8674(02)00835-8; Wu S, 2008, PATHOBIOLOGY, V75, P186, DOI 10.1159/000124979; Xuan AG, 2009, NEUROSCI LETT, V450, P167, DOI 10.1016/j.neulet.2008.12.001; Yan MX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061056; Yang H, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt227; Yun HM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.490; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zavan B, 2010, DISCOV MED, V10, P37; Zhang L, 2012, INT J DEV NEUROSCI, V30, P471, DOI 10.1016/j.ijdevneu.2012.05.006; Zhao CP, 2007, CYTOTHERAPY, V9, P414, DOI 10.1080/14653240701376413; Zhao HB, 2014, CELL BIOL INT, V38, P462, DOI 10.1002/cbin.10217; Zhu JS, 2012, EXP CLIN TRANSPLANT, V10, P492, DOI 10.6002/ect.2011.0197; Zilka N, 2011, NEUROSCIENCE, V193, P330, DOI 10.1016/j.neuroscience.2011.06.088	186	72	75	0	50	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1574-888X	2212-3946		CURR STEM CELL RES T	Curr. Stem Cell Res. Ther.		2014	9	6					513	521		10.2174/1574888X09666140923101110			9	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	AQ9WV	WOS:000343209600009	25248677				2022-02-06	
J	Fukuda, AM; Adami, A; Pop, V; Bellone, JA; Coats, JS; Hartman, RE; Ashwal, S; Obenaus, A; Badaut, J				Fukuda, Andrew M.; Adami, Arash; Pop, Viorela; Bellone, John A.; Coats, Jacqueline S.; Hartman, Richard E.; Ashwal, Stephen; Obenaus, Andre; Badaut, Jerome			Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						aquaporin; astrocyte; juvenile traumatic brain injury; pediatric neurology; siRNA	TRAUMATIC BRAIN-INJURY; PROTECTIVE ROLE; INHIBITION; EXPRESSION; CHANNELS; ASTROCYTES; MICROGLIA; IMMATURE; ROLES; BETA	Traumatic brain injury (TBI) is common in young children and adolescents and is associated with long-term disability and mortality. The neuropathologic sequelae that result from juvenile TBI are a complex cascade of events that include edema formation and brain swelling. Brain aquaporin-4 (AQP4) has a key role in edema formation. Thus, development of novel treatments targeting AQP4 to reduce edema could lessen the neuropathologic sequelae. We hypothesized that inhibiting AQP4 expression by injection of small-interfering RNA (siRNA) targeting AQP4 (siAQP4) after juvenile TBI would decrease edema formation, neuroinflammation, neuronal cell death, and improve neurologic outcomes. The siAQP4 or a RNA-induced silencing complex (RISC)-free control siRNA (siGLO) was injected lateral to the trauma site after controlled cortical impact in postnatal day 17 rats. Magnetic resonance imaging, neurologic testing, and immunohistochemistry were performed to assess outcomes. Pups treated with siAQP4 showed acute (3 days after injury) improvements in motor function and in spatial memory at long term (60 days after injury) compared with siGLO-treated animals. These improvements were associated with decreased edema formation, increased microglial activation, decreased blood-brain barrier disruption, reduced astrogliosis and neuronal cell death. The effectiveness of our treatment paradigm was associated with a 30% decrease in AQP4 expression at the injection site.	[Fukuda, Andrew M.; Badaut, Jerome] Loma Linda Univ, Dept Physiol, Loma Linda, CA 92354 USA; [Fukuda, Andrew M.; Pop, Viorela; Coats, Jacqueline S.; Obenaus, Andre; Badaut, Jerome] Loma Linda Univ, Med Ctr, Dept Pediat, Loma Linda, CA 92354 USA; [Adami, Arash; Ashwal, Stephen; Obenaus, Andre] Univ Calif Riverside, Dept Neurosci, Riverside, CA 92521 USA; [Bellone, John A.; Hartman, Richard E.] Loma Linda Univ, Dept Psychol, Loma Linda, CA 92354 USA		Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu	Fukuda, Andrew/ABD-1038-2021	Fukuda, Andrew/0000-0002-7927-6602	National Institute of child disorders (NICHD) [R01HD061946]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure [0923559]; Loma Linda University School of Medicine; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	This study was supported by a grant from the National Institute of child disorders (NICHD) R01HD061946 and The Swiss National Science Foundation (Jerome Badaut). A portion of this material was performed in the Loma Linda University School of Medicine Advanced Imaging and Microscopy Core (LLUSM AIM) that is supported by the National Science Foundation under Major Research Instrumentation, Division of Biological Infrastructure Grant No. 0923559 (Sean M Wilson) and the Loma Linda University School of Medicine.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Badaut J, 2011, CEREBROVASC DIS, V31, P521, DOI 10.1159/000324328; Badaut J, 2007, METAB BRAIN DIS, V22, P251, DOI 10.1007/s11011-007-9057-2; Badaut J, 2007, PEDIATR RES, V62, P248, DOI 10.1203/PDR.0b013e3180db291b; Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Berezowski Vincent, 2012, Int J Cell Biol, V2012, P176287, DOI 10.1155/2012/176287; Brower V, 2010, J NATL CANCER I, V102, P1459, DOI 10.1093/jnci/djq405; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Eder C, 1998, J NEUROSCI, V18, P7127; Faul M, 2010, TRAUMATIC BRAIN INJU; Fukuda AM, 2012, NEUROSCIENCE, V222, P366, DOI 10.1016/j.neuroscience.2012.06.033; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Huber VJ, 2007, BIOORG MED CHEM LETT, V17, P1270, DOI 10.1016/j.bmcl.2006.12.010; Huber VJ, 2009, BIOORGAN MED CHEM, V17, P418, DOI 10.1016/j.bmc.2007.12.038; Igarashi H, 2011, NEUROL SCI, V32, P113, DOI 10.1007/s10072-010-0431-1; Kimura A, 2010, ANN NEUROL, V67, P794, DOI 10.1002/ana.22023; LEWIS RS, 1993, J GEN PHYSIOL, V101, P801, DOI 10.1085/jgp.101.6.801; Li LH, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-94; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lu DC, 2011, J NEUROTRAUM; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Migliati E, 2009, MOL PHARMACOL, V76, P105, DOI 10.1124/mol.108.053744; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; Saadoun S, 2008, BRAIN, V131, P1087, DOI 10.1093/brain/awn014; Shi WZ, 2012, NEUROSCI BULL, V28, P61, DOI 10.1007/s12264-012-1063-7; Tait MJ, 2010, NEUROSCIENCE, V167, P60, DOI 10.1016/j.neuroscience.2010.01.053; Tait MJ, 2008, TRENDS NEUROSCI, V31, P37, DOI 10.1016/j.tins.2007.11.003; Tanimura Y, 2009, J STRUCT BIOL, V166, P16, DOI 10.1016/j.jsb.2008.11.010; Thorne RG, 2008, NEUROSCIENCE, V152, P785, DOI 10.1016/j.neuroscience.2008.01.013; Tourdias T, 2009, NEUROIMAGE, V47, P659, DOI 10.1016/j.neuroimage.2009.04.070; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018	40	72	78	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2013	33	10					1621	1632		10.1038/jcbfm.2013.118			12	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	228PV	WOS:000325199600017	23899928	Green Published, Bronze			2022-02-06	
J	Rojas, JC; Gonzalez-Lima, F				Rojas, Julio C.; Gonzalez-Lima, F.			Neurological and psychological applications of transcranial lasers and LEDs	BIOCHEMICAL PHARMACOLOGY			English	Article						Cognitive enhancement; Cytochrome oxidase; Low-level light therapy; Methylene blue; Neuroprotection; Photobiomodulation	NEAR-INFRARED LIGHT; TRAUMATIC BRAIN-INJURY; MIDBRAIN DOPAMINERGIC CELLS; METHYLENE-BLUE; COGNITIVE DEFICITS; CYTOCHROME-OXIDASE; ALZHEIMERS-DISEASE; EMBOLIC STROKES; THERAPY; IRRADIATION	Transcranial brain stimulation with low-level light/laser therapy (LLLT) is the use of directional low-power and high-fluency monochromatic or quasimonochromatic light from lasers or LEDs in the red-to-near-infrared wavelengths to modulate a neurobiological function or induce a neurotherapeutic effect in a nondestructive and non-thermal manner. The mechanism of action of LLLT is based on photon energy absorption by cytochrome oxidase, the terminal enzyme in the mitochondrial respiratory chain. Cytochrome oxidase has a key role in neuronal physiology, as it serves as an interface between oxidative energy metabolism and cell survival signaling pathways. Cytochrome oxidase is an ideal target for cognitive enhancement, as its expression reflects the changes in metabolic capacity underlying higher-order brain functions. This review provides an update on new findings on the neurotherapeutic applications of LLLT. The photochemical mechanisms supporting its cognitive-enhancing and brain-stimulatory effects in animal models and humans are discussed. LLLT is a potential non-invasive treatment for cognitive impairment and other deficits associated with chronic neurological conditions, such as large vessel and lacunar hypoperfusion or neurodegeneration. Brain photobiomodulation with LLLT is paralleled by pharmacological effects of low-dose USP methylene blue, a non-photic electron donor with the ability to stimulate cytochrome oxidase activity, redox and free radical processes. Both interventions provide neuroprotection and cognitive enhancement by facilitating mitochondrial respiration, with hormetic dose-response effects and brain region activational specificity. This evidence supports enhancement of mitochondrial respiratory function as a generalizable therapeutic principle relevant to highly adaptable systems that are exquisitely sensitive to energy availability such as the nervous system. (C) 2013 Elsevier Inc. All rights reserved.	[Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Pharmacol, Austin, TX 78712 USA; [Rojas, Julio C.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Toxicol, Austin, TX 78712 USA; [Rojas, Julio C.] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75235 USA		Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Rojas, Julio/AAL-7973-2020	Gonzalez-Lima, Francisco/0000-0001-9856-0775			Ahmed NAEH, 2008, PHOTOMED LASER SURG, V26, P479, DOI 10.1089/pho.2007.2190; Ando T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026212; Arntzen KA, 2012, CEREBROVASC DIS, V33, P159, DOI 10.1159/000334182; Bangen KJ, 2012, J ALZHEIMERS DIS, V31, pS59, DOI 10.3233/JAD-2012-120292; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Bashkatov AN, 2006, P SOC PHOTO-OPT INS, V6163, P61630; Bruchey Aleksandra K, 2008, Am J Pharmacol Toxicol, V3, P72; Byrnes KR, 2005, LASER SURG MED, V37, P161, DOI 10.1002/lsm.20202; Calabrese EJ, 2008, AM J PHARM TOXICOL, V3, P59, DOI DOI 10.3844/AJPTSP.2008.59.71; Callaway NL, 2002, NEUROSCI LETT, V332, P83, DOI 10.1016/S0304-3940(02)00827-3; Chung H, 2012, ANN BIOMED ENG, V40, P516, DOI 10.1007/s10439-011-0454-7; de la Torre Jack C, 2012, Cardiovasc Psychiatry Neurol, V2012, P367516, DOI 10.1155/2012/367516; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Deiana S, 2009, PSYCHOPHARMACOLOGY, V202, P53, DOI 10.1007/s00213-008-1394-2; DeTaboada L, 2006, LASER SURG MED, V38, P70, DOI 10.1002/lsm.20256; Drummond SPA, 2005, SLEEP, V28, P1059; Furian AF, 2007, NEUROCHEM INT, V50, P164, DOI 10.1016/j.neuint.2006.07.012; Gabrielli D, 2004, PHOTOCHEM PHOTOBIOL, V79, P227, DOI 10.1562/BE-03-27.1; Hashmi JT, 2010, PM&R, V2, pS292, DOI 10.1016/j.pmrj.2010.10.013; Huang YY, 2011, DOSE-RESPONSE, V9, P602, DOI 10.2203/dose-response.11-009.Hamblin; Jang H, 2012, PHOTOMED LASER SURG, V30, P405, DOI 10.1089/pho.2012.3240; Jenkins PA, 2011, PHOTOMED LASER SURG, V29, P785, DOI 10.1089/pho.2011.9895; Johnson NA, 2005, RADIOLOGY, V234, P851, DOI 10.1148/radiol.2343040197; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 1996, LASER SURG MED, V18, P171, DOI 10.1002/(SICI)1096-9101(1996)18:2<171::AID-LSM7>3.0.CO;2-P; Karu TI, 2001, LASER SURG MED, V28, P227, DOI 10.1002/lsm.1043; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lampl Yair, 2007, Expert Rev Neurother, V7, P961, DOI 10.1586/14737175.7.8.961; Lapchak PA, 2007, NEUROSCIENCE, V148, P907, DOI 10.1016/j.neuroscience.2007.07.002; Lapchak PA, 2004, STROKE, V35, P1985, DOI 10.1161/01.STR.0000131808.69640.b7; Lapchak PA, 2008, STROKE, V39, P3073, DOI 10.1161/STROKEAHA.108.516393; Lapchak PA, 2010, BRAIN RES, V1306, P100, DOI 10.1016/j.brainres.2009.10.022; Lee RB, 2002, ARTHRITIS RHEUM, V46, P3190, DOI 10.1002/art.10686; Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047; Mak HKF, 2012, J ALZHEIMERS DIS, V31, P33, DOI 10.3233/JAD-2012-111877; Medina DX, 2011, BRAIN PATHOL, V21, P140, DOI 10.1111/j.1750-3639.2010.00430.x; Michalikova S, 2008, NEUROBIOL LEARN MEM, V89, P480, DOI 10.1016/j.nlm.2007.07.014; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Moreira MS, 2009, J PHOTOCH PHOTOBIO B, V97, P145, DOI 10.1016/j.jphotobiol.2009.09.002; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Naeser MA, 2011, PHOTOMED LASER SURG, V29, P351, DOI 10.1089/pho.2010.2814; National Institute of Aging, 2012, ALZH DIS PROGR REP I; National Institute of Neurological Disorders and Stroke, 2004, STROK HOP RES; Nieder A, 2004, P NATL ACAD SCI USA, V101, P7457, DOI 10.1073/pnas.0402239101; O'Leary JC, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-45; Ohlow MJ, 2011, DRUG DISCOV TODAY, V16, P119, DOI 10.1016/j.drudis.2011.01.001; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Oron A, 2012, J NEUROTRAUM, V29, P401, DOI 10.1089/neu.2011.2062; Pastore D, 2000, INT J RADIAT BIOL, V76, P863; Leal ECP, 2010, J ORTHOP SPORT PHYS, V40, P524, DOI 10.2519/jospt.2010.3294; Poyton RO, 2011, DISCOV MED, V11, P154; Poyton RO, 2009, ANN NY ACAD SCI, V1177, P48, DOI 10.1111/j.1749-6632.2009.05046.x; Quirk BJ, 2012, PHOTOMED LASER SURG, V30, P523, DOI 10.1089/pho.2012.3261; Riha PD, 2011, NEUROIMAGE, V54, P2623, DOI 10.1016/j.neuroimage.2010.11.023; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Rojas JC, 2012, PROG NEUROBIOL, V96, P32, DOI 10.1016/j.pneurobio.2011.10.007; Rojas JC, 2009, NEUROTOX RES, V15, P260, DOI 10.1007/s12640-009-9027-z; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Schirmer RH, 2011, NEUROBIOL AGING, V32, DOI 10.1016/j.neurobiolaging.2010.12.012; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Sokoloff L, 1989, CIRCULATION ENERGY M; Uozumi Y, 2010, LASER SURG MED, V42, P566, DOI 10.1002/lsm.20938; Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001; Wong-Riley MTT, 1998, CYTOCHROME OXIDASE IN NEURONAL METABOLISM AND ALZHEIMER'S DISEASE, P1; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057; Yip KK, 2011, NEUROSCIENCE, V190, P301, DOI 10.1016/j.neuroscience.2011.06.022; Zhang XA, 2006, NEUROTOX RES, V9, P47, DOI 10.1007/BF03033307; Zivin JA, 2009, STROKE, V40, P1359, DOI 10.1161/STROKEAHA.109.547547	75	72	75	0	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952	1873-2968		BIOCHEM PHARMACOL	Biochem. Pharmacol.	AUG 15	2013	86	4					447	457		10.1016/j.bcp.2013.06.012			11	Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Pharmacology & Pharmacy	203MK	WOS:000323297100001	23806754				2022-02-06	
J	Seichepine, DR; Stamm, JM; Daneshvar, DH; Riley, DO; Baugh, CM; Gavett, BE; Tripodis, Y; Martin, B; Chaisson, C; Mckee, AC; Cantu, RC; Nowinski, CJ; Stern, RA				Seichepine, Daniel R.; Stamm, Julie M.; Daneshvar, Daniel H.; Riley, David O.; Baugh, Christine M.; Gavett, Brandon E.; Tripodis, Yorghos; Martin, Brett; Chaisson, Christine; Mckee, Ann C.; Cantu, Robert C.; Nowinski, Christopher J.; Stern, Robert A.			Profile of Self-Reported Problems with Executive Functioning in College and Professional Football Players	JOURNAL OF NEUROTRAUMA			English	Article						chronic traumatic encephalopathy; executive function; football; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; BRAIN-FUNCTION; LEAGUE PLAYER; CONCUSSION; INJURY; EPIDEMIOLOGY; DISEASE; SPORTS; IMPACT	Repetitive mild traumatic brain injury (mTBI), such as that experienced by contact-sport athletes, has been associated with the development of chronic traumatic encephalopathy (CTE). Executive dysfunction is believed to be among the earliest symptoms of CTE, with these symptoms presenting in the fourth or fifth decade of life. The present study used a well-validated self-report measure to study executive functioning in football players, compared to healthy adults. Sixty-four college and professional football players were administered the Behavior Rating Inventory of Executive Function, adult version (BRIEF-A) to evaluate nine areas of executive functioning. Scores on the BRIEF-A were compared to published age-corrected normative scores for healthy adults Relative to healthy adults, the football players indicated significantly more problems overall and on seven of the nine clinical scales, including Inhibit, Shift, Emotional Control, Initiate, Working Memory, Plan/Organize, and Task Monitor. These symptoms were greater in athletes 40 and older, relative to younger players. In sum, football players reported more-frequent problems with executive functioning and these symptoms may develop or worsen in the fifth decade of life. The findings are in accord with a growing body of evidence that participation in football is associated with the development of cognitive changes and dementia as observed in CTE.	[Seichepine, Daniel R.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Seichepine, Daniel R.; Stamm, Julie M.; Daneshvar, Daniel H.; Riley, David O.; Baugh, Christine M.; Mckee, Ann C.; Cantu, Robert C.; Nowinski, Christopher J.; Stern, Robert A.] Boston Univ, Sch Med, Ctr Study Traumat Encephalopathy, Boston, MA 02118 USA; [Gavett, Brandon E.] Univ Colorado, Dept Psychol, Colorado Springs, CO 80933 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA; [Martin, Brett; Chaisson, Christine] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02118 USA; [Mckee, Ann C.] Vet Affairs Boston Healthcare Syst, Neurol Serv, Jamaica Plain, MA USA; [Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA		Stern, RA (corresponding author), Boston Univ, Ctr Study Traumat Encephalopathy, 72 East Concord St,Suite B7800, Boston, MA 02118 USA.	bobstern@bu.edu	Baugh, Christine/AAG-2324-2020; , Bob/ABA-8507-2020	Baugh, Christine/0000-0002-9340-6338; Stern, Robert/0000-0002-5008-077X; Tripodis, Yorghos/0000-0003-2190-7608; Chaisson, Christine/0000-0002-3207-9257; Seichepine, Daniel/0000-0002-2331-3072; Daneshvar, Daniel/0000-0003-3691-9513; Gavett, Brandon/0000-0003-1938-1854	Boston University Alzheimer's Disease Center [NIA P30 AG13846, 0572063345-5]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS078337]; National Operating Committee on Standards for Athletic Equipment; Sports Legacy Institute; Center for the Integration of Medicine and Innovative Technology; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER	This work was supported by the Boston University Alzheimer's Disease Center (NIA P30 AG13846, supplement 0572063345-5), the National Institutes of Health (R01NS078337), a grant from the National Operating Committee on Standards for Athletic Equipment, the Sports Legacy Institute, the Center for the Integration of Medicine and Innovative Technology, and an unrestricted gift from the National Football League. A portion of this research was presented at the 2012 Military Health System Research Symposium, in Fort Lauderdale, FL, August 13-16, 2012.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Control C.f.I.P.a, 2003, REP C MILD TRAUM BRA; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Council of Youth Sports, 2008, REP TRENDS PART ORG; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Promotion N.C.f.C.D.P.H, 2006, BEH RISK FACT SURV S; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Roth RM, 2005, BRIEF A BEHAV RATING; Weir DR, 2009, NATL FOOTBALL LEAGUE, P1	24	72	72	1	53	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1299	1304		10.1089/neu.2012.2690			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100010	23421745	Green Published			2022-02-06	
J	Turgeon, AF; Lauzier, F; Burns, KEA; Meade, MO; Scales, DC; Zarychanski, R; Moore, L; Zygun, DA; McIntyre, LA; Kanji, S; Hebert, PC; Murat, V; Pagliarello, G; Fergusson, DA				Turgeon, Alexis F.; Lauzier, Francois; Burns, Karen E. A.; Meade, Maureen O.; Scales, Damon C.; Zarychanski, Ryan; Moore, Lynne; Zygun, David A.; McIntyre, Lauralyn A.; Kanji, Salmaan; Hebert, Paul C.; Murat, Valerie; Pagliarello, Giuseppe; Fergusson, Dean A.		Canadian Critical Care Trials Grp	Determination of Neurologic Prognosis and Clinical Decision Making in Adult Patients With Severe Traumatic Brain Injury: A Survey of Canadian Intensivists, Neurosurgeons, and Neurologists	CRITICAL CARE MEDICINE			English	Article						critical care medicine; healthcare survey; traumatic brain injury; neurologic prognosis; withdrawal of life-sustaining therapies	OF-LIFE CARE; END; WITHDRAWAL; MORTALITY; CULTURE; SUPPORT; UNIT	Objectives: Accurate prognostic information in patients with severe traumatic brain injury remains limited, but mortality following the withdrawal of life-sustaining therapies is high and variable across centers. We designed a survey to understand attitudes of physicians caring for patients with severe traumatic brain injury toward the determination of prognosis and clinical decision making on the level of care. Design, Setting, and Participants: We conducted a cross-sectional study of intensivists, neurosurgeons, and neurologists that participate in the care of patients with severe traumatic brain injury at all Canadian level 1 and level 2 trauma centers. Intervention: None. Measurements: The main outcome measure was physicians' perceptions of prognosis and recommendations on the level of care. Main Results: Our response rate was 64% (455/712). Most respondents (65%) reported that an accurate prediction of prognosis would be most helpful during the first 7 days. Most respondents (>80%) identified bedside monitoring, clinical exam, and imaging to be useful for evaluating prognosis, whereas fewer considered electrophysiology tests (<60%) and biomarkers (<15%). In a case-based scenario, approximately one-third of respondents agreed, one-third were neutral, and one-third disagreed that the patient prognosis would be unfavorable at one year. About 10% were comfortable recommending withdrawal of life-sustaining therapies. Conclusions: A significant variation in perceptions of neurologic prognosis and in clinical decision making on the level of care was found among Canadian intensivists, neurosurgeons, and neurologists. Improved understanding of the factors that can accurately predict prognosis for patients with traumatic brain injury is urgently needed. (Crit Care Med 2013; 41:1087-1093)	[Turgeon, Alexis F.; Lauzier, Francois; Moore, Lynne; Murat, Valerie] Univ Laval, Trauma Emergency Crit Care Med Unit, Enfant Jesus Hosp, CHU Quebec,Res Ctr,Ctr Rech FRQ S, Quebec City, PQ, Canada; [Turgeon, Alexis F.; Lauzier, Francois] Univ Laval, Dept Anesthesiol, Div Crit Care Med, Quebec City, PQ, Canada; [Lauzier, Francois] Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; [Burns, Karen E. A.; Scales, Damon C.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada; [Meade, Maureen O.] McMaster Univ, Dept Crit Care Med, Hamilton, ON, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Crit Care Med, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Hematol, Winnipeg, MB, Canada; [Zarychanski, Ryan] Univ Manitoba, Dept Internal Med, Sect Med Oncol, Winnipeg, MB, Canada; [Moore, Lynne] Univ Laval, Dept Social & Prevent Med, Quebec City, PQ, Canada; [Zygun, David A.] Univ Calgary, Dept Crit Care Med, Calgary, AB, Canada; [McIntyre, Lauralyn A.; Kanji, Salmaan; Hebert, Paul C.; Fergusson, Dean A.] Univ Ottawa, Clin Epidemiol Program, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [McIntyre, Lauralyn A.; Hebert, Paul C.; Pagliarello, Giuseppe; Fergusson, Dean A.] Univ Ottawa, Dept Med, Div Crit Care Med, Ottawa, ON, Canada		Turgeon, AF (corresponding author), Univ Laval, Trauma Emergency Crit Care Med Unit, Enfant Jesus Hosp, CHU Quebec,Res Ctr,Ctr Rech FRQ S, Quebec City, PQ, Canada.	alexis.turgeon@fmed.ulaval.ca	McIntyre, Lauralyn/AAR-7710-2021; Zarychanski, Ryan/AAB-6369-2022; Lauzier, Francois/B-9237-2015	McIntyre, Lauralyn/0000-0001-7421-1407; Lauzier, Francois/0000-0002-6530-5513; Zarychanski, Ryan/0000-0001-9455-6138; Fergusson, Dean/0000-0002-3389-2485	Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation); Fonds de recherche du Quebec-Sante (FRQ-S); Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHRCanadian Institutes of Health Research (CIHR); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	Supported, in part, by the Fondation de l'Hopital de l'Enfant-Jesus (Enfant-Jesus Hospital Foundation) and by the Fonds de recherche du Quebec-Sante (FRQ-S) who had no role in any part of conduct of the study or preparation of the manuscript. Dr. Turgeon and Dr. Lauzier are recipients of a research career award from the Fonds de recherche du Quebec-Sante (FRQ-S). Dr. Fergusson, McIntyre, Moore, and Scales are recipients of New Investigator Awards from the Canadian Institutes of Health Research (CIHR). Dr Zarychanski is supported by a Randomized Controlled Trial Mentoring Award from the CIHR.; Dr. Scales received grant support from Canadian Institutes of Health Research and the New Investigator Award. The remaining authors have not disclosed any potential conflicts of interest	American Association for Public Opinion Research, 2011, STAND DEF FIN DISP C; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Ball CG, 2010, J TRAUMA, V69, P1323, DOI 10.1097/TA.0b013e3181f66878; Becker KJ, 2001, NEUROLOGY, V56, P766, DOI 10.1212/WNL.56.6.766; Burns KEA, 2008, CAN MED ASSOC J, V179, P245, DOI 10.1503/cmaj.080372; Cohen J, 2008, J MED ETHICS, V34, P247, DOI 10.1136/jme.2006.020297; Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC; Fergusson DA, 2007, AM J RESP CRIT CARE, V175, pA218; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Jacobs LM, 2010, J TRAUMA, V69, P1567, DOI 10.1097/TA.0b013e3181f65921; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lamontagne F, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2011.01.005; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Mayor SA, 1999, NEUROLOGY, V52, P1602, DOI 10.1212/WNL.52.8.1602; Mosenthal AC, 2008, J TRAUMA, V64, P1587, DOI 10.1097/TA.0b013e318174f112; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; National Scientific Advisory Committee, 2004, LIST DIR INJ FIN REP; Nelson JE, 2006, CRIT CARE MED, V34, P2547, DOI 10.1097/01.CCM.0000239233.63425.1D; OCALLAHAN JG, 1995, CRIT CARE MED, V23, P1567, DOI 10.1097/00003246-199509000-00018; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Ramondetta L, 2011, INT J GYNECOL CANCER, V21, P573, DOI 10.1097/IGC.0b013e31820ba507; Randolph AG, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.4.e46; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Scales DC, 2009, J CRIT CARE, V24, P176, DOI 10.1016/j.jcrc.2009.03.010; Schaller C, 2006, J MED ETHICS, V32, P65, DOI 10.1136/jme.2005.011767; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Truog RD, 2001, CRIT CARE MED, V29, P2332, DOI 10.1097/00003246-200112000-00017; Turgeon AF, 2006, CAN J ANAESTH, V53, P344, DOI 10.1007/BF03022497; Turgeon AF, 2011, CAN MED ASSOC J, V183, P1581, DOI 10.1503/cmaj.101786; Zygun DA, 2005, CAN J NEUROL SCI, V32, P87, DOI 10.1017/S0317167100016930	32	72	72	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2013	41	4					1086	1093		10.1097/CCM.0b013e318275d046			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114HN	WOS:000316731800027	23385104				2022-02-06	
J	Tanaka, Y; Matsuwaki, T; Yamanouchi, K; Nishihara, M				Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.			EXACERBATED INFLAMMATORY RESPONSES RELATED TO ACTIVATED MICROGLIA AFTER TRAUMATIC BRAIN INJURY IN PROGRANULIN-DEFICIENT MICE	NEUROSCIENCE			English	Article						progranulin; traumatic brain injury; neuroinflammation; microglia; CD68; TGF beta 1	AMYOTROPHIC-LATERAL-SCLEROSIS; GRANULIN-EPITHELIN PRECURSOR; GROWTH-FACTOR-BETA; FRONTOTEMPORAL LOBAR DEGENERATION; OLIGOMERIC MATRIX PROTEIN; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; NEURODEGENERATIVE DISEASE; GENETIC-VARIABILITY; SURFACE EXPRESSION	Progranulin (PGRN), a multifunctional growth factor, appears to play a role in neurodegenerative diseases accompanied by neuroinflammation. In this study, we investigated the role of PGRN in neuroinflammation, especially in the activation of microglia, by means of experimental traumatic brain injury (TBI) in the cerebral cortex of mice. The expression of GRN mRNA was increased in association with neuroinflammation after TBI. Double-immunohistochemical study showed that PGRN-immunoreactive (-IR) cells were mainly overlapped with CD68-IR cells, suggesting that the main source of PGRN was CD68-positive activated microglia. To investigate the role of PGRN in inflammatory responses related to activated microglia, we compared the immunoreactivity and expression of ionized calcium-binding adaptor molecule 1 (Iba1), CD68, and CD11b as markers for activated microglia between wild-type (WT) and GRN-deficient (KO) mice. The number of Iba1- and CD11b-IR cells and gene expression of Iba1 and CD11b were not significantly different between WT and KO mice, while the number of CD68-IR cells and CD68 expression in KO mice were significantly greater than those in WT mice. Double-immunohistochemical study showed that CD68-IR microglia were also IR for TGF beta 1, and TGF beta 1 expression and Smad3 phosphorylation in KO mice were elevated compared to WT mice. Moreover, double-immunostaining between phospho-Smad3 and glial fibrillary acidic protein suggested increased TGF beta 1-Smad3 signal mainly by astrocytes. The levels of protein carbonyl groups, which reflect protein oxidation, and laminin immunoreactivity, which is associated with angiogenesis, were also significantly increased in KO mice compared to WT mice. These results suggest that PGRN is produced in CD68-positive microglia and suppresses excessive inflammatory responses related to activated microglia after TBI in mice. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.	[Tanaka, Y.; Matsuwaki, T.; Yamanouchi, K.; Nishihara, M.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, Tokyo 1138657, Japan		Nishihara, M (corresponding author), Grad Sch Agr & Life Sci, Dept Vet Physiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amnishi@mail.ecc.u-tokyo.ac.jp	Yamanouchi, Keitaro/R-5003-2019		JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23228004, 24-7548]	This work was supported in part by JSPS KAKENHI Grant Number 23228004 to MN and 24-7548 to YT.	Ahmed Z, 2010, AM J PATHOL, V177, P311, DOI 10.2353/ajpath.2010.090915; Arai T, 2006, BIOCHEM BIOPH RES CO, V351, P602, DOI 10.1016/j.bbrc.2006.10.093; Asakura R, 2011, NEUROREPORT, V22, P881, DOI 10.1097/WNR.0b013e32834bf4ca; BABA T, 1993, FEBS LETT, V322, P89, DOI 10.1016/0014-5793(93)81544-A; Baker M, 2006, NATURE, V442, P916, DOI 10.1038/nature05016; Barreto G, 2009, ENDOCRINOLOGY, V150, P5010, DOI 10.1210/en.2009-0352; Bateman A, 2009, BIOESSAYS, V31, P1245, DOI 10.1002/bies.200900086; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brouwers N, 2008, NEUROLOGY, V71, P656, DOI 10.1212/01.wnl.0000319688.89790.7a; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Carecchio M, 2009, J NEUROL SCI, V287, P291, DOI 10.1016/j.jns.2009.07.011; Chiba S, 2007, J REPROD DEVELOP, V53, P297, DOI 10.1262/jrd.18108; Cortini F, 2008, EUR J NEUROL, V15, P1111, DOI 10.1111/j.1468-1331.2008.02266.x; Cruts M, 2006, NATURE, V442, P920, DOI 10.1038/nature05017; Daniel R, 2000, J HISTOCHEM CYTOCHEM, V48, P999, DOI 10.1177/002215540004800713; de Beer MC, 2003, J LIPID RES, V44, P674, DOI 10.1194/jlr.M200444-JLR200; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Doyle KP, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-62; Feng JAQ, 2010, FASEB J, V24, P1879, DOI 10.1096/fj.09-144659; Fenger C, 2006, GLIA, V54, P591, DOI 10.1002/glia.20405; Ghoshal N, 2012, NEUROBIOL DIS, V45, P395, DOI 10.1016/j.nbd.2011.08.029; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Guo FJ, 2010, ARTHRITIS RHEUM-US, V62, P2023, DOI 10.1002/art.27491; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; He ZH, 2003, J MOL MED-JMM, V81, P600, DOI 10.1007/s00109-003-0474-3; He ZH, 2003, NAT MED, V9, P225, DOI 10.1038/nm816; Jantaratnotai N, 2010, CURR ALZHEIMER RES, V7, P625, DOI 10.2174/156720510793499039; Kabashi E, 2008, NAT GENET, V40, P572, DOI 10.1038/ng.132; Kao AW, 2011, P NATL ACAD SCI USA, V108, P4441, DOI 10.1073/pnas.1100650108; Kayasuga Y, 2007, BEHAV BRAIN RES, V185, P110, DOI 10.1016/j.bbr.2007.07.020; Kessenbrock K, 2008, J CLIN INVEST, V118, P2438, DOI 10.1172/JCI34694; Kraft AD, 2009, NEUROTOXICOLOGY, V30, P785, DOI 10.1016/j.neuro.2009.07.001; Kurushima H, 2000, J LEUKOCYTE BIOL, V67, P104, DOI 10.1002/jlb.67.1.104; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Ling L, 2009, J CEREBR BLOOD F MET, V29, P1538, DOI 10.1038/jcbfm.2009.76; Liu CJ, 2009, NAT CLIN PRACT RHEUM, V5, P38, DOI 10.1038/ncprheum0961; Llaverias G, 2004, BIOCHEM BIOPH RES CO, V318, P265, DOI 10.1016/j.bbrc.2004.04.021; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Louboutin JP, 2010, EXP NEUROL, V221, P231, DOI 10.1016/j.expneurol.2009.11.004; Martens LH, 2012, J CLIN INVEST, V122, P3955, DOI 10.1172/JCI63113; McTigue DM, 2000, EXP NEUROL, V163, P220, DOI 10.1006/exnr.2000.7372; Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43; Naphade SB, 2010, ACTA NEUROPATHOL, V119, P123, DOI 10.1007/s00401-009-0616-y; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; Pereson S, 2009, J PATHOL, V219, P173, DOI 10.1002/path.2580; Ramprasad MP, 1996, P NATL ACAD SCI USA, V93, P14833, DOI 10.1073/pnas.93.25.14833; Robinson CE, 1999, ANAL BIOCHEM, V266, P48, DOI 10.1006/abio.1998.2932; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Sleegers K, 2008, NEUROLOGY, V71, P253, DOI 10.1212/01.wnl.0000289191.54852.75; Smith KR, 2012, AM J HUM GENET, V90, P1102, DOI 10.1016/j.ajhg.2012.04.021; Smith ME, 2000, J NEUROIMMUNOL, V102, P154, DOI 10.1016/S0165-5728(99)00218-0; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Sreedharan J, 2008, SCIENCE, V319, P1668, DOI 10.1126/science.1154584; Suzuki M, 1998, NEUROSCI LETT, V242, P127, DOI 10.1016/S0304-3940(98)00008-1; Tang W, 2011, SCIENCE, V332, P478, DOI 10.1126/science.1199214; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Wang WX, 2010, AM J PATHOL, V177, P334, DOI 10.2353/ajpath.2010.091202; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Wappler EA, 2011, MICROVASC RES, V81, P153, DOI 10.1016/j.mvr.2010.12.005; Welser JV, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-89; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321; Xu K, 2007, J BIOL CHEM, V282, P11347, DOI 10.1074/jbc.M608744200; Yin FF, 2010, J EXP MED, V207, P117, DOI 10.1084/jem.20091568; Zhang D, 2010, MOL NEUROBIOL, V41, P232, DOI 10.1007/s12035-010-8098-4; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8	68	72	73	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	FEB 12	2013	231						49	60		10.1016/j.neuroscience.2012.11.032			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	087EN	WOS:000314744200005	23201826				2022-02-06	
J	Beauchamp, MH; Beare, R; Ditchfield, M; Coleman, L; Babl, FE; Kean, M; Crossley, L; Catroppa, C; Yeates, KO; Anderson, V				Beauchamp, Miriam H.; Beare, Richard; Ditchfield, Michael; Coleman, Lee; Babl, Franz E.; Kean, Michael; Crossley, Louise; Catroppa, Cathy; Yeates, Keith O.; Anderson, Vicki			Susceptibility weighted imaging and its relationship to outcome after pediatric traumatic brain injury	CORTEX			English	Article						Traumatic brain injury; Children; Intellectual function; Magnetic resonance imaging; Susceptibility weighted imaging	DIFFUSE AXONAL INJURY; CHILDHOOD HEAD-INJURY; CHILDREN; PREDICTORS; LESIONS; PERFORMANCE; RECOVERY; MRI; SWI	Introduction: Traumatic brain injury (TBI) sustained during childhood can cause difficulties in a wide range of physical, neurological, cognitive, social and functional domains. However, the ability of health professionals and researchers to accurately predict the outcome of pediatric TBI remains limited. The advent of advanced neuroimaging techniques shows some promise in improving outcome prediction, as they contribute to greater sensitivity in characterizing intracranial lesions underlying many cognitive and functional deficits. In this study, the relationship between lesions identified on susceptibility weighted imaging (SWI) and cognitive and functional outcomes was investigated following childhood TBI. Method: Participants between 5 and 14 years of age with varying levels of TBI severity (mild, mild complicated, moderate, severe, n = 106) underwent susceptibility weighted scanning on average 1-month post-injury and completed an assessment of intellectual functioning, processing speed, and behavioral and adaptive skills 6-month post-injury. Results: More severe TBI was generally associated with poorer intellectual functioning, greater behavioral problems and lower adaptive functioning. Number and volume of SWI lesions were significantly correlated with clinical outcome variables including Glasgow Coma Score (GCS), surgical intervention, length of hospital stay and length of intubation, as well as with intellectual functioning. Together, SWI and GCS accounted for a significant, though small, proportion of the variance in intellectual quotient (IQ). Conclusions: SWI is a sensitive technique for detecting brain lesions at all TBI severity levels and shows promise in contributing to prediction of cognitive outcomes in the initial stages post-injury. (C) 2012 Elsevier Ltd. All rights reserved.	[Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, Miriam H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Beare, Richard; Coleman, Lee; Babl, Franz E.; Kean, Michael; Crossley, Louise; Catroppa, Cathy; Anderson, Vicki] Murdoch Childrens Res Inst, Melbourne, Australia; [Ditchfield, Michael] Monash Med Ctr, Melbourne, Australia; [Coleman, Lee; Babl, Franz E.; Kean, Michael; Catroppa, Cathy; Anderson, Vicki] Royal Childrens Hosp, Melbourne, Australia; [Catroppa, Cathy; Anderson, Vicki] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA		Anderson, V (corresponding author), Murdoch Childrens Res Inst, 4th Floor West,Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Catroppa, Cathy/AAX-9458-2021; Yeates, Keith/AAJ-4223-2020	Catroppa, Cathy/0000-0002-9750-0436; Yeates, Keith/0000-0001-7680-2892; Beare, Richard/0000-0002-7530-5664	Victoria Neurotrauma Initiative, Australia; Victorian Government Operational Infrastructure Support Program; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	This work was supported by a grant from the Victoria Neurotrauma Initiative, Australia; the Victorian Government Operational Infrastructure Support Program; and a fellowship from the Canadian Institutes of Health Research to MB. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Ashwal S, 2006, ARCH PHYS MED REHAB, V87, pS50, DOI 10.1016/j.apmr.2006.07.275; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Beauchamp MH, 2011, INT J DEV NEUROSCI, V29, P137, DOI 10.1016/j.ijdevneu.2010.12.003; Beauchamp MH, HDB CLIN PE IN PRESS; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Coffey CE, 1991, PSYCHOPATHOL BRAIN, P243; Colbert CA, 2010, RADIOLOGY, V256, P898, DOI 10.1148/radiol.10091842; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Haacke EM, 2011, J MAGN RESON, V32, P516; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Kurowski B, 2009, J PEDIATR REHAB MED, V2, P273, DOI 10.3233/PRM-2009-0093; McMillan J, 2009, J SOCIOL, V45, P123, DOI 10.1177/1440783309103342; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sigmund GA, 2007, PEDIATR NEUROL, V36, P217, DOI 10.1016/j.pediatrneurol.2007.01.003; Suskauer SJ, 2009, DEV DISABIL RES REV, V15, P117, DOI 10.1002/ddrr.62; Tong KA, 2008, AM J NEURORADIOL, V29, P9, DOI 10.3174/ajnr.A0786; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D., 2003, MANUAL WECHSLER INTE; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	36	72	75	0	14	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2013	49	2			SI		591	598		10.1016/j.cortex.2012.08.015			8	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychology	117BJ	WOS:000316926800022	23062584				2022-02-06	
J	O'Donnell, ML; Varker, T; Holmes, AC; Ellen, S; Wade, D; Creamer, M; Silove, D; McFarlane, A; Bryant, RA; Forbes, D				O'Donnell, Meaghan L.; Varker, Tracey; Holmes, Alexander C.; Ellen, Steven; Wade, Darryl; Creamer, Mark; Silove, Derrick; McFarlane, Alexander; Bryant, Richard A.; Forbes, David			Disability After Injury: The Cumulative Burden of Physical and Mental Health	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; CHRONIC PAIN; FUNCTIONAL OUTCOMES; HOSPITAL ANXIETY; DEPRESSION; PREVALENCE; SEVERITY; IMPACT; SCALE	Context: Injury is one of the leading contributors to the global burden of disease. The factors that drive long-term disability after injury are poorly understood. Objective: The main aim of the study was to model the direct and indirect pathways to long-term disability after injury. Specifically, the relationships between 3 groups of variables and long-term disability were examined over time. These included physical factors (including injury characteristics and premorbid disability), pain severity (including pain at 1 week and 12 months), and psychiatric symptoms (including psychiatric history and posttraumatic stress, depression, and anxiety symptoms at 1 week and 12 months). Design, Setting, and Participants: A multisite, longitudinal cohort study of 715 randomly selected injury patients (from April 2004 to February 2006). Participants were assessed just prior to discharge (mean = 7.0 days, SD = 7.8 days) and reassessed at 12 months postinjury. Injury patients who experienced moderate/severe traumatic brain injury and spinal cord injury were excluded from the study. Main Outcome Measure: The World Health Organization Disability Assessment Schedule 2.0 was used to assess disability at 12 months after injury. Results: Disability at 12 months was up to 4 times greater than community norms, across all age groups. The development and maintenance of long-term disability occurred through a complex interaction of physical factors, pain severity across time, and psychiatric symptoms across time. While both physical factors and pain severity contributed significantly to 12-month disability (pain at 1 week: total effect [TE] = 0.2, standard error [SE] < 0.1; pain at 12 months: TE = 0.3, SE < 0.1; injury characteristics: TE = 0.3, SE < 0.1), the total effects of psychiatric symptoms were substantial (psychiatric symptoms 1 week: TE = 0.30, SE < 0.1; psychiatric symptoms 12 months: TE = 0.71, SE < 0.1). Taken together, psychiatric symptoms accounted for the largest proportion of the variance in disability at 12 months. Conclusions: While the physical and pain consequences of injury contribute significantly to enduring disability after injury, psychiatric symptoms play a greater role. Early interventions targeting psychiatric symptoms may play an important role in improving functional outcomes after injury. (C) Copyright 2013 Physicians Postgraduate Press, Inc.	[O'Donnell, Meaghan L.; Varker, Tracey; Wade, Darryl; Forbes, David] Univ Melbourne, Australian Ctr Posttraumat Mental Hlth, Melbourne, Vic 3010, Australia; [O'Donnell, Meaghan L.; Varker, Tracey; Wade, Darryl; Forbes, David] Univ Melbourne, Dept Psychiat, Melbourne, Vic 3010, Australia; [Holmes, Alexander C.; Creamer, Mark] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Ellen, Steven] Alfred Hosp, Melbourne, Vic, Australia; [Ellen, Steven] Alfred Psychiat Res Ctr, Melbourne, Vic, Australia; [Silove, Derrick] Univ New S Wales, Sch Psychiat, Sydney, NSW 2052, Australia; [McFarlane, Alexander] Univ Adelaide, Ctr Traumat Stress, Adelaide, SA 5005, Australia; [Bryant, Richard A.] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		O'Donnell, ML (corresponding author), Level 1,340 Albert St, East Melbourne, Vic 3002, Australia.	mod@unimelb.edu.au	Varker, Tracey/T-5125-2019; Bryant, Richard/AAA-6479-2019	Varker, Tracey/0000-0002-7139-062X; Bryant, Richard/0000-0002-9607-819X; Wade, Darryl/0000-0002-8079-321X; Forbes, David/0000-0001-9145-1605; O'Donnell, Meaghan/0000-0003-4349-0022	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [568970]	This study was supported by a National Health and Medical Research Council of Australia program grant (568970).	Andrews G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008343; Aziz Mohamed A, 2004, J Psychiatr Pract, V10, P307, DOI 10.1097/00131746-200409000-00004; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bonne O, 2004, NEUROSCI BIOBEHAV R, V28, P65, DOI 10.1016/j.neubiorev.2003.12.001; Breivik H, 2006, EUR J PAIN, V10, P287, DOI 10.1016/j.ejpain.2005.06.009; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Collip D, 2008, SCHIZOPHRENIA BULL, V34, P220, DOI 10.1093/schbul/sbm163; Fabian ES, 2007, REHABIL COUNS BULL, V50, P130, DOI 10.1177/00343552070500030101; Furlan JC, 2011, J NEUROTRAUM, V28, P1413, DOI 10.1089/neu.2009.1148; Gabbe BJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025862; Geldman M, 2008, CLIN REHABIL, V22, P364, DOI 10.1177/0269215507081966; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; Kariuki M, 2011, DISABIL HEALTH J, V4, P91, DOI 10.1016/j.dhjo.2010.08.001; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Liedl A, 2010, PSYCHOL MED, V40, P1215, DOI 10.1017/S0033291709991310; Lopez AD, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-5; McFarlane AC, 2010, WORLD PSYCHIATRY, V9, P3; McFarlane AC, 2007, BEST PRACT RES CL RH, V21, P549, DOI 10.1016/j.berh.2007.03.008; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; O'Donnell ML, 2009, MED J AUSTRALIA, V190, pS71; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; Organization W.H, 2008, GLOBAL BURDEN DIS 20; Otis JD, 2003, J REHABIL RES DEV, V40, P397, DOI 10.1682/JRRD.2003.09.0397; Perini SJ, 2006, J AFFECT DISORDERS, V90, P123, DOI 10.1016/j.jad.2005.10.011; Ramchand R, 2008, J CONSULT CLIN PSYCH, V76, P668, DOI 10.1037/0022-006X.76.4.668; Richmond TS, 2003, AM J CRIT CARE, V12, P197, DOI 10.4037/ajcc2003.12.3.197; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Schnurr Paula P, 2004, Adv Mind Body Med, V20, P18; Schnurr PP, 2004, TRAUMA HLTH PHYS HLT, P3; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shih RA, 2010, J TRAUMA, V69, P1560, DOI 10.1097/TA.0b013e3181e59c05; Sterling M, 2005, PAIN, V114, P141, DOI 10.1016/j.pain.2004.12.005; Tatham, 1998, MULTIVARIATE DATA AN; TEASDALE G, 1974, LANCET, V2, P81; Tunks ER, 2008, CAN J PSYCHIAT, V53, P224, DOI 10.1177/070674370805300403; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; WHODAS Group, 2000, WHO DIS ASS SCHED 2; World Health Organisation, A29INFDOCI11976 WHO; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2002, ARCH SURG-CHICAGO, V137, P200, DOI 10.1001/archsurg.137.2.200; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	47	72	72	0	21	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 752870, MEMPHIS, TN 38175-2870 USA	0160-6689	1555-2101		J CLIN PSYCHIAT	J. Clin. Psychiatry	FEB	2013	74	2					E137	E143		10.4088/JCP.12m08011			7	Psychology, Clinical; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	AA4UN	WOS:000331091900004	23473359				2022-02-06	
J	Stein, NR; McArthur, DL; Etchepare, M; Vespa, PM				Stein, Nathan R.; McArthur, David L.; Etchepare, Maria; Vespa, Paul M.			Early Cerebral Metabolic Crisis After TBI Influences Outcome Despite Adequate Hemodynamic Resuscitation	NEUROCRITICAL CARE			English	Article						Brain trauma; Glucose; Lactate; Lactate/pyruvate ratio; Microdialysis; Resuscitation	TRAUMATIC BRAIN-INJURY; MICRODIALYSIS; SEIZURES; LACTATE; ATROPHY	Optimal resuscitation after traumatic brain injury (TBI) remains uncertain. We hypothesize that cerebral metabolic crisis is frequent despite adequate resuscitation of the TBI patient and that metabolic crisis negatively influences outcome. We assessed the effectiveness of a standardized trauma resuscitation protocol in 89 patients with moderate to severe TBI, and determined the frequency of adequate resuscitation. Prospective hourly values of heart rate, blood pressure, pulse oximetry, intracranial pressure (ICP), respiratory rate, jugular venous oximetry, and brain extracellular values of glucose, lactate, pyruvate, glycerol, and glutamate were obtained. The incidence during the initial 72 h after injury of low brain glucose < 0.8 mmol/L, elevated lactate/pyruvate ratio (LPR) > 25, and metabolic crisis, defined as the simultaneous occurrence of both low glucose and high LPR, were determined for the group. 5 patients were inadequately resuscitated and eight patients had intractable ICP. In patients with successful resuscitation and controlled ICP (n = 76), within 72 h of trauma, 76 % had low glucose, 93 % had elevated LPR, and 74 % were in metabolic crisis. The duration of metabolic crisis was longer in those patients with unfavorable (GOSe a parts per thousand currency sign 6) versus favorable (GOSe a parts per thousand yen 7) outcome at 6 months (P = 0.011). In four multivariate models the burden of metabolic crisis was a powerful independent predictor of poor outcome. Metabolic crisis occurs frequently after TBI despite adequate resuscitation and controlled ICP, and is a strong independent predictor of poor outcome at 6 months.	[Stein, Nathan R.; McArthur, David L.; Etchepare, Maria; Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Vespa, Paul M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA		Vespa, PM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, 757 Westwood Blvd,RR 6236A, Los Angeles, CA 90095 USA.	pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	 [NS-058489]	UCLA Brain Injury Research Center, supported by NS-058489.	Agostinelli C, 2010, WLE WEIGHTED LIKELIH; Bhardwaj A, 2011, HDB NEUROCRITICAL CA, DOI [10.1007/978-1-4419-6842-5_18, DOI 10.1007/978-1-4419-6842-5_18]; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Dries DJ, 2011, INITIAL EVALUATION T; Fletcher JJ, 2010, NEUROCRIT CARE, V13, P47, DOI 10.1007/s12028-010-9345-2; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sander A., 2002, EXTENDED GLASGOW OUT; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Ts L., 2006, HONG KONG J EMERG ME, V13, P24; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wilcox R, 2012, ROBUST STAT; Wilcox RR, 2005, INTRO ROBUST ESTIMAT; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263	27	72	73	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2012	17	1					49	57		10.1007/s12028-012-9708-y			9	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	976NG	WOS:000306591000007	22528283				2022-02-06	
J	Bressan, S; Romanato, S; Mion, T; Zanconato, S; Da Dalt, L				Bressan, Silvia; Romanato, Sabrina; Mion, Teresa; Zanconato, Stefania; Da Dalt, Liviana			Implementation of Adapted PECARN Decision Rule for Children With Minor Head Injury in the Pediatric Emergency Department	ACADEMIC EMERGENCY MEDICINE			English	Article							COMPUTED-TOMOGRAPHY; PREDICTION; IMPACT	ACADEMIC EMERGENCY MEDICINE 2012; 19:801807 (c) 2012 by the Society for Academic Emergency Medicine Abstract Objectives: Of the currently published clinical decision rules for the management of minor head injury (MHI) in children, the Pediatric Emergency Care Applied Research Network (PECARN) rule, derived and validated in a large multicenter prospective study cohort, with high methodologic standards, appears to be the best clinical decision rule to accurately identify children at very low risk of clinically important traumatic brain injuries (ciTBI) in the pediatric emergency department (PED). This study describes the implementation of an adapted version of the PECARN rule in a tertiary care academic PED in Italy and evaluates implementation success, in terms of medical staff adherence and satisfaction, as well as its effects on clinical practice. Methods: The adapted PECARN decision rule algorithms for children (one for those younger than 2 years and one for those older than 2 years) were actively implemented in the PED of Padova, Italy, for a 6-month testing period. Adherence and satisfaction of medical staff to the new rule were calculated. Data from 356 visits for MHI during PECARN rule implementation and those of 288 patients attending the PED for MHI in the previous 6 months were compared for changes in computed tomography (CT) scan rate, ciTBI rate (defined as death, neurosurgery, intubation for longer than 24 hours, or hospital admission at least for two nights associated with TBI) and return visits for symptoms or signs potentially related to MHI. The safety and efficacy of the adapted PECARN rule in clinical practice were also calculated. Results: Adherence to the adapted PECARN rule was 93.5%. The percentage of medical staff satisfied with the new rule, in terms of usefulness and ease of use for rapid decision-making, was significantly higher (96% vs. 51%, p < 0.0001) compared to the previous, more complex, internal guideline. CT scan was performed in 30 patients (8.4%, 95% confidence interval [CI] = 6% to 11.8%) in the implementation period versus 21 patients (7.3%, 95% CI = 4.8% to 10.9%) before implementation. A ciTBI occurred in three children (0.8%, 95% CI = 0.3 to 2.5) during the implementation period and in two children (0.7%, 95% CI = 0.2 to 2.5) in the prior 6 months. There were five return visits (1.4%) postimplementation and seven (2.4%) before implementation (p = 0.506). The safety of use of the adapted PECARN rule in clinical practice was 100% (95% CI = 36.8 to 100; three of three patients with ciTBI who received CT scan at first evaluation), while efficacy was 92.3% (95% CI = 89 to 95; 326 of 353 patients without ciTBI who did not receive a CT scan). Conclusions: The adapted PECARN rule was successfully implemented in an Italian tertiary care academic PED, achieving high adherence and satisfaction of medical staff. Its use determined a low CT scan rate that was unchanged compared to previous clinical practice and showed an optimal safety and high efficacy profile. Strict monitoring is mandatory to evaluate the long-lasting benefit in patient care and/or resource utilization.	[Bressan, Silvia; Romanato, Sabrina; Mion, Teresa; Zanconato, Stefania; Da Dalt, Liviana] Univ Padua, Dept Pediat, Padua, Italy		Bressan, S (corresponding author), Univ Padua, Dept Pediat, Padua, Italy.	silvia.bressan.1@unipd.it					Armon K, 2004, ARCH DIS CHILD, V89, P159, DOI 10.1136/adc.2002.024406; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Brenner David J., 2010, Reviews on Environmental Health, V25, P63; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Callegaro S, 2009, PEDIATR NEUROL, V40, P78, DOI 10.1016/j.pediatrneurol.2008.09.008; Da Dalt L, 2006, EUR J PEDIATR, V165, P142, DOI 10.1007/s00431-005-0019-6; Da Dalt L, 2007, J PEDIATR-US, V150, P274, DOI 10.1016/j.jpeds.2006.11.060; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Gilbert EH, 1996, ANN EMERG MED, V27, P305, DOI 10.1016/S0196-0644(96)70264-0; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Norton SP, 2007, ARCH DIS CHILD, V92, P60, DOI 10.1136/adc.2006.097287; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Parkin PC, 2009, LANCET, V374, P1127, DOI 10.1016/S0140-6736(09)61634-2; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009	18	72	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUL	2012	19	7					801	807		10.1111/j.1553-2712.2012.01384.x			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	974CL	WOS:000306407300005	22724450				2022-02-06	
J	Tang, CH; Fu, XJ; Xu, XL; Wei, XJ; Pan, HS				Tang, Chong-Hui; Fu, Xiao-Jun; Xu, Xin-Long; Wei, Xiao-Jie; Pan, Hong-Song			The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain	PEPTIDES			English	Article						Traumatic brain injury; Nesfatin-1; Inflammation; Neuronal cell apoptosis	SATIETY MOLECULE; KAPPA-B; INJURY; BARRIER; IMMUNOREACTIVITY	Nesfatin-1 has been demonstrated to possess anti-inflammatory and anti-apoptotic effects in the rat brain with subarachnoid hemorrhage. The study was designed to investigate the influence of nesfatin-1 on inflammatory responses and neuronal cell apoptosis after traumatic brain injury. Wistar rats were subjected to 5, 10 or 20 mu g/kg of nesfatin-1 at designed time points (0.5, 2, 4 or 8h after head trauma) intraperitoneally. Rats were sacrificed at hours 2, 6 and 12, as well as day 1, 2, 3 and 5 after head trauma. The administration of 10 or 20 mu g/kg of nesfatin-1 at hour 0.5 after head trauma could significantly suppress gene expressions of nuclear factor kappa-B, lessen concentrations of tumor necrosis factor-alpha, interleukin-1beta and interleukin-6, diminish caspase-3 activity as well as reduce number of apoptotic neuronal cells in traumatic rat brain tissues (P < 0.05), but the administration of 5 mu g/kg of nesfatin-1 not (P > 0.05). Moreover, 20 mu g/kg nesfatin-1 also significantly suppressed the inflammation and neuronal cell apoptosis when applied 2, 4 or 8 h after head trauma. However, a clear concentration-response or time-response relationship was not found. These findings suggest that nesfatin-1 may inhibit nuclear factor kappa-B-dependent inflammatory responses, and lessen caspase-3-mediated neuronal cell apoptosis after traumatic brain injury in rats. (C) 2012 Elsevier Inc. All rights reserved.	[Tang, Chong-Hui; Fu, Xiao-Jun; Xu, Xin-Long; Wei, Xiao-Jie; Pan, Hong-Song] Cixi Peoples Hosp, Wenzhou Med Coll, Dept Neurosurg, Hushan Dist 315300, Cixi, Peoples R China		Fu, XJ (corresponding author), Cixi Peoples Hosp, Wenzhou Med Coll, Dept Neurosurg, 999 Nanerhuan E Rd, Hushan Dist 315300, Cixi, Peoples R China.	chonghuitang@126.com			Ningbo Municipal Natural Science Foundation of China [2010A610065]; Cixi Municipal Science and Technology Bureau of China [CN2008032, CN2009022]	This work is financially supported by Ningbo Municipal Natural Science Foundation of China (Grant No. 2010A610065) and Cixi Municipal Science and Technology Bureau of China (Grant Nos. CN2008032, CN2009022).	Ballabh P, 2004, NEUROBIOL DIS, V16, P1, DOI 10.1016/j.nbd.2003.12.016; Begley DJ, 2003, PROG DRUG RES, V61, P39; Bonnet MS, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-27; Brailoiu GC, 2007, ENDOCRINOLOGY, V148, P5088, DOI 10.1210/en.2007-0701; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Foo KS, 2008, NEUROSCIENCE, V156, P563, DOI 10.1016/j.neuroscience.2008.07.054; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Goebel M, 2009, BRAIN RES, V1300, P114, DOI 10.1016/j.brainres.2009.08.082; Goebel M, 2009, NEUROSCI LETT, V452, P241, DOI 10.1016/j.neulet.2009.01.064; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Lu J, 2009, FRONT BIOSCI-LANDMRK, V14, P3795, DOI 10.2735/3489; Merali Z, 2008, PSYCHOPHARMACOLOGY, V201, P115, DOI 10.1007/s00213-008-1252-2; Oh-I S, 2006, NATURE, V443, P709, DOI 10.1038/nature05162; Ozsavci D, 2011, NEUROSURGERY, V68, P1699, DOI 10.1227/NEU.0b013e318210f258; Pan WH, 2007, PEPTIDES, V28, P2223, DOI 10.1016/j.peptides.2007.09.005; Price TO, 2007, PEPTIDES, V28, P2372, DOI 10.1016/j.peptides.2007.10.008; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Yosten GLC, 2009, AM J PHYSIOL-REG I, V297, pR330, DOI 10.1152/ajpregu.90867.2008	22	72	75	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0196-9781			PEPTIDES	Peptides	JUL	2012	36	1					39	45		10.1016/j.peptides.2012.04.014			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy	986EH	WOS:000307323400006	22561242				2022-02-06	
J	Helmy, A; Antoniades, CA; Guilfoyle, MR; Carpenter, KLH; Hutchinson, PJ				Helmy, Adel; Antoniades, Chrystalina A.; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Hutchinson, Peter J.			Principal Component Analysis of the Cytokine and Chemokine Response to Human Traumatic Brain Injury	PLOS ONE			English	Article							NECROSIS-FACTOR-ALPHA; INTENSIVE-CARE PATIENTS; HUMAN VENTRICULAR CSF; CLOSED-HEAD INJURY; PROGNOSTIC VALUE; INTRACEREBRAL MICRODIALYSIS; INNATE IMMUNITY; DUAL ROLE; INTERLEUKIN-6; IMPACT	There is a growing realisation that neuro-inflammation plays a fundamental role in the pathology of Traumatic Brain Injury (TBI). This has led to the search for biomarkers that reflect these underlying inflammatory processes using techniques such as cerebral microdialysis. The interpretation of such biomarker data has been limited by the statistical methods used. When analysing data of this sort the multiple putative interactions between mediators need to be considered as well as the timing of production and high degree of statistical co-variance in levels of these mediators. Here we present a cytokine and chemokine dataset from human brain following human traumatic brain injury and use principal component analysis and partial least squares discriminant analysis to demonstrate the pattern of production following TBI, distinct phases of the humoral inflammatory response and the differing patterns of response in brain and in peripheral blood. This technique has the added advantage of making no assumptions about the Relative Recovery (RR) of microdialysis derived parameters. Taken together these techniques can be used in complex microdialysis datasets to summarise the data succinctly and generate hypotheses for future study.	[Helmy, Adel; Guilfoyle, Mathew R.; Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Antoniades, Chrystalina A.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Dept Clin Neurol, Oxford OX1 2JD, England; [Carpenter, Keri L. H.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England		Helmy, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 2QQ, England.	adelhelmy@cantab.net	Viani, Rafael/V-1196-2018; Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727; Antoniades, Chrystalina/0000-0002-1192-3834	Medical Research Council/Royal College of Surgeons of England Clinical Research Training FellowshipUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Raymond and Beverly Sackler Fellowship; Royal College of Surgeons of England; National Institute of Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research Council (Acute Brain Injury Programme Grant)UK Research & Innovation (UKRI)Medical Research Council UK (MRC); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, ID 65883, G0600986, ID 79068]; National Institute of Health Research (NIHR) Oxford Biomedical Research CentreNational Institute for Health Research (NIHR); Thames Valley Dementia and Neurodegenerative Disease Research Network (DeNDRoN); MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0600986, G0802251, G9439390, G1002277] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G1002277, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004] Funding Source: researchfish	AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship and a Raymond and Beverly Sackler Fellowship. MRG is supported by the Royal College of Surgeons of England and a Raymond and Beverly Sackler Fellowship. KLHC is supported by the National Institute of Health Research Biomedical Research Centre, Cambridge and by the Medical Research Council (Acute Brain Injury Programme Grant). PJAH is supported by the Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. Study support was provided by the Medical Research Council (Grant numbers G9439390 ID 65883 and G0600986 ID 79068). CAA is funded by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre and by the Thames Valley Dementia and Neurodegenerative Disease Research Network (DeNDRoN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andre R, 2005, NEUROREPORT, V16, P153, DOI 10.1097/00001756-200502080-00017; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Boulesteix AL, 2007, BRIEF BIOINFORM, V8, P32, DOI 10.1093/bib/bb1016; Ceulemans AG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-74; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Downen M, 1999, GLIA, V28, P114, DOI 10.1002/(SICI)1098-1136(199911)28:2<114::AID-GLIA3>3.0.CO;2-O; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Eriksson L., 2001, MULTI MEGAVARIATE DA; Eriksson L, 2006, MULTI MEGAVARIATE DA; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gasteiger J, 2006, ANAL BIOANAL CHEM, V384, P57, DOI 10.1007/s00216-005-0065-y; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; Helmy A, 2011, PROG NEUROBIOL; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Helmy A, 2010, ACTA NEUROCHIR, V152, P953, DOI 10.1007/s00701-009-0584-y; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Hillman J, 2007, J NEUROSURG, V106, P820, DOI 10.3171/jns.2007.106.5.820; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kirchhoff C, 2008, EUR J MED RES, V13, P464; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Marcus HJ, 2010, J NEURO-ONCOL, V97, P11, DOI 10.1007/s11060-009-9990-5; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Ramon J, 2007, ADV ENG INFORM, V21, P243, DOI 10.1016/j.aei.2006.12.002; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Semple BD, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-67; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Simi A, 2007, BIOCHEM SOC T, V35, P1122, DOI 10.1042/BST0351122; Singhal A, 2002, J NEUROTRAUM, V19, P929, DOI 10.1089/089771502320317087; Stein DM, 2011, J TRAUMA, V70, P1096, DOI 10.1097/TA.0b013e318216930d; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stenken JA, 2010, AAPS J, V12, P73, DOI 10.1208/s12248-009-9163-7; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Yao HH, 2010, J NEUROIMMUNE PHARM, V5, P489, DOI 10.1007/s11481-010-9211-1	61	72	72	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2012	7	6							e39677	10.1371/journal.pone.0039677			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	964XV	WOS:000305730900097	22745809	gold, Green Published			2022-02-06	
J	Campbell, M; Hanrahan, F; Gobbo, OL; Kelly, ME; Kiang, AS; Humphries, MM; Nguyen, ATH; Ozaki, E; Keaney, J; Blau, CW; Kerskens, CM; Cahalan, SD; Callanan, JJ; Wallace, E; Grant, GA; Doherty, CP; Humphries, P				Campbell, Matthew; Hanrahan, Finnian; Gobbo, Oliviero L.; Kelly, Michael E.; Kiang, Anna-Sophia; Humphries, Marian M.; Nguyen, Anh T. H.; Ozaki, Ema; Keaney, James; Blau, Christoph W.; Kerskens, Christian M.; Cahalan, Stephen D.; Callanan, John J.; Wallace, Eugene; Grant, Gerald A.; Doherty, Colin P.; Humphries, Peter			Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury	NATURE COMMUNICATIONS			English	Article							DRUG-DELIVERY; BARRIER; ALTERNATION; MODEL	Traumatic brain injury is the leading cause of death in children and young adults globally. Malignant cerebral oedema has a major role in the pathophysiology that evolves after severe traumatic brain injury. Added to this is the significant morbidity and mortality from cerebral oedema associated with acute stroke, hypoxic ischemic coma, neurological cancers and brain infection. Therapeutic strategies to prevent cerebral oedema are limited and, if brain swelling persists, the risks of permanent brain damage or mortality are greatly exacerbated. Here we show that a temporary and size-selective modulation of the blood-brain barrier allows enhanced movement of water from the brain to the blood and significantly impacts on brain swelling. We also show cognitive improvement in mice with focal cerebral oedema following administration in these animals of short interfering RNA directed against claudin-5. These observations may have profound consequences for early intervention in cases of traumatic brain injury, or indeed any neurological condition where cerebral oedema is the hallmark pathology.	[Campbell, Matthew; Hanrahan, Finnian; Kiang, Anna-Sophia; Humphries, Marian M.; Nguyen, Anh T. H.; Ozaki, Ema; Keaney, James; Blau, Christoph W.; Humphries, Peter] Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland; [Gobbo, Oliviero L.] Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin 2, Ireland; [Kelly, Michael E.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Neurosci, FMRIB Ctr, Oxford OX3 9DU, England; [Kerskens, Christian M.] Trinity Coll Dublin, Trinity Coll Inst Neurosci, Dublin 2, Ireland; [Cahalan, Stephen D.; Callanan, John J.] Univ Coll Dublin, UCD Sch Vet Med, Dublin 4, Ireland; [Cahalan, Stephen D.; Callanan, John J.] Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; [Wallace, Eugene; Doherty, Colin P.] St James Hosp, Hosp 5, Hlth Care Ctr, Dept Neurol, Dublin 8, Ireland; [Grant, Gerald A.] Duke Univ, Med Ctr, Dept Surg, Div Neurosurg, Durham, NC 27710 USA		Campbell, M (corresponding author), Trinity Coll Dublin, Smurfit Inst Genet, Dublin 2, Ireland.	matthew.campbell@tcd.ie	Gobbo, Oliviero L/R-1763-2016; Gobbo, Oliviero/S-2043-2019; Kerskens, Christian/AAJ-6202-2020; Cahalan, Stephen/P-9149-2016	Gobbo, Oliviero L/0000-0003-4629-9485; Gobbo, Oliviero/0000-0003-4629-9485; Kerskens, Christian/0000-0003-0823-4648; Cahalan, Stephen/0000-0003-2287-1416; Callanan, John/0000-0003-4356-1783; Doherty, Colin/0000-0002-8869-8567	US Department of Defense (US-DoD)United States Department of Defense; Telemedicine and Advanced Technology Research Center (TATRC); Enterprise Ireland (EI)	This work was supported by the US Department of Defense (US-DoD), Telemedicine and Advanced Technology Research Center (TATRC) and Enterprise Ireland (EI). Aspects of research involving neuronal barrier modulation are also supported by Science Foundation Ireland (SFI), the Health Research Board of Ireland (HRB) and Fighting Blindness-Ireland. We thank Prof. John Kelly and Dr Gemma Keegan for their assistance with the Zeta-sizer hardware. We also thank Dr Thomas Connor for assistance and advice relating to RT-PCR analyses and Rustam Rakhmatullin for technical assistance with MRI studies. We also thank Caroline Woods, Charles Murray, David Flynn, and Rebecca Robertson for animal husbandry, Brian Cloak for post-mortem technical assistance and photo-microscopy, and Joe Brady for processing brain samples.	Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Callans DJ, 2004, NEW ENGL J MED, V351, P632, DOI 10.1056/NEJMp048174; Campbell M, 2008, J GENE MED, V10, P930, DOI 10.1002/jgm.1211; Campbell M, 2011, EMBO MOL MED, V3, P235, DOI 10.1002/emmm.201100126; Campbell M, 2009, P NATL ACAD SCI USA, V106, P17817, DOI 10.1073/pnas.0908561106; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Daneman R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013741; Davies DC, 2002, J ANAT, V200, P639, DOI 10.1046/j.1469-7580.2002.00065.x; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; DOUGLAS RJ, 1975, HIPPOCAMPUS, V2, P327; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jinnouchi Y, 2007, BRAIN RES, V1167, P92, DOI 10.1016/j.brainres.2007.04.088; Kanasty RL, 2012, MOL THER, V20, P513, DOI 10.1038/mt.2011.294; Kelly ME, 2009, PHYS MED BIOL, V54, P1235, DOI 10.1088/0031-9155/54/5/009; Kelly ME, 2010, J CEREBR BLOOD F MET, V30, P913, DOI 10.1038/jcbfm.2009.284; Klohs J, 2009, J NEUROSCI METH, V180, P126, DOI 10.1016/j.jneumeth.2009.03.002; Kroll RA, 1998, NEUROSURGERY, V43, P879, DOI 10.1097/00006123-199810000-00090; Lukaszewicz AC, 2011, CURR OPIN ANESTHESIO, V24, P138, DOI 10.1097/ACO.0b013e32834458af; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; MOULIN DE, 1985, STROKE, V16, P282, DOI 10.1161/01.STR.16.2.282; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Nitta T, 2003, J CELL BIOL, V161, P653, DOI 10.1083/jcb.200302070; Robbins M, 2007, MOL THER, V15, P1663, DOI 10.1038/sj.mt.6300240; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; ROBERTS WW, 1962, J COMP PHYSIOL PSYCH, V55, P695, DOI 10.1037/h0045168; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; Shih RH, 2010, J NEUROTRAUM, V27, P1477, DOI 10.1089/neu.2009.1201; Sorani MD, 2008, J NEUROTRAUM, V25, P291, DOI 10.1089/neu.2007.0411; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Weiss C, 1998, NEUROSCI RES COMMUN, V23, P77, DOI 10.1002/(SICI)1520-6769(199809/10)23:2<77::AID-NRC2>3.0.CO;2-Y; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212	41	72	74	5	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	MAY	2012	3								849	10.1038/ncomms1852			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	949XP	WOS:000304611400044	22617289	hybrid			2022-02-06	
J	Oliva, AA; Kang, Y; Sanchez-Molano, J; Furones, C; Atkins, CM				Oliva, Anthony A., Jr.; Kang, Yuan; Sanchez-Molano, Juliana; Furones, Concepcion; Atkins, Coleen M.			STAT3 signaling after traumatic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						astrocyte; inflammation; signal transducer and activation of transcription-3; traumatic brain injury	NITRIC-OXIDE SYNTHASE; COLONY-STIMULATING FACTOR; FOCAL CEREBRAL-ISCHEMIA; LEUKEMIA INHIBITORY FACTOR; SPINAL-CORD-INJURY; HUMAN HEAD-INJURY; REACTIVE ASTROCYTES; ONCOSTATIN-M; GROWTH-FACTOR; UP-REGULATION	Astrocytes respond to trauma by stimulating inflammatory signaling. In studies of cerebral ischemia and spinal cord injury, astrocytic signaling is mediated by the cytokine receptor glycoprotein 130 (gp130) and Janus kinase (Jak) which phosphorylates the transcription factor signal transducer and activator of transcription-3 (STAT3). To determine if STAT3 is activated after traumatic brain injury (TBI), adult male SpragueDawley rats received moderate parasagittal fluid-percussion brain injury or sham surgery, and then the ipsilateral cortex and hippocampus were analyzed at various post-traumatic time periods for up to 7 days. Western blot analyses indicated that STAT3 phosphorylation significantly increased at 30 min and lasted for 24 h post-TBI. A significant increase in gp130 and Jak2 phosphorylation was also observed. Confocal microscopy revealed that STAT3 was localized primarily within astrocytic nuclei. At 6 and 24 h post-TBI, there was also an increased expression of STAT3 pathway-related genes: suppressor of cytokine signaling 3, nitric oxide synthase 2, colony stimulating factor 2 receptor beta, oncostatin M, matrix metalloproteinase 3, cyclin-dependent kinase inhibitor 1A, CCAAT/enhancer-binding protein beta, interleukin-2 receptor gamma, interleukin-4 receptor a, and a-2-macroglobulin. These results clarify some of the signaling pathways operative in astrocytes after TBI and demonstrate that the gp130-Jak2-STAT3 signaling pathway is activated after TBI in astrocytes.	[Oliva, Anthony A., Jr.; Kang, Yuan; Sanchez-Molano, Juliana; Furones, Concepcion; Atkins, Coleen M.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA		Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	Miami Project to Cure Paralysis; Buoniconti Fund to Cure Paralysis	This work was supported by The Miami Project to Cure Paralysis and The Buoniconti Fund to Cure Paralysis. The authors declare no conflict of interest. We thank Drs Ina Wanner, Valerie Bracchi-Ricard, W. Dalton Dietrich and Michael Norenberg for critical reading of the manuscript.	Banner LR, 1997, EXP NEUROL, V147, P1, DOI 10.1006/exnr.1997.6536; Beurel E, 2008, J BIOL CHEM, V283, P21934, DOI 10.1074/jbc.M802481200; Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Choi JS, 2003, GLIA, V41, P237, DOI 10.1002/glia.10186; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Dawn B, 2004, CARDIOVASC RES, V64, P61, DOI 10.1016/j.cardiores.2004.05.011; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DiNapoli VA, 2010, NEUROSCIENCE, V170, P633, DOI 10.1016/j.neuroscience.2010.07.011; Dziennis S, 2007, J NEUROSCI, V27, P7268, DOI 10.1523/JNEUROSCI.1558-07.2007; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fischer P, 2004, BIOCHEM J, V378, P449, DOI 10.1042/BJ20030893; Gahm C, 2000, NEUROSURGERY, V46, P169, DOI 10.1093/neurosurgery/46.1.169; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Glezer I, 2010, BRAIN BEHAV IMMUN, V24, P695, DOI 10.1016/j.bbi.2010.01.005; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Gurney KJ, 2006, NEUROBIOL DIS, V23, P87, DOI 10.1016/j.nbd.2006.02.006; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Ishikawa K, 1999, J TRAUMA, V46, P999, DOI 10.1097/00005373-199906000-00004; Jung JE, 2009, J NEUROSCI, V29, P7003, DOI 10.1523/JNEUROSCI.1110-09.2009; Justicia C, 2000, GLIA, V30, P253, DOI 10.1002/(SICI)1098-1136(200005)30:3<253::AID-GLIA5>3.0.CO;2-O; Kim EJ, 2008, J CEREBR BLOOD F MET, V28, P1329, DOI 10.1038/jcbfm.2008.26; Kim HJ, 2005, EXP NEUROL, V192, P60, DOI 10.1016/j.expneurol.2004.10.014; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kordula T, 1998, J BIOL CHEM, V273, P4112, DOI 10.1074/jbc.273.7.4112; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Laird AD, 2003, MOL CANCER THER, V2, P461; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Leibinger M, 2009, J NEUROSCI, V29, P14334, DOI 10.1523/JNEUROSCI.2770-09.2009; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Morikawa Yoshihiro, 2005, Anatomical Science International, V80, P53, DOI 10.1111/j.1447-073x.2005.00100.x; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Na YJ, 2007, J NEUROCHEM, V103, P637, DOI 10.1111/j.1471-4159.2007.04769.x; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Petrov T, 2001, NEUROL RES, V23, P139, DOI 10.1179/016164101101198479; Planas AM, 1996, EUR J NEUROSCI, V8, P2612, DOI 10.1111/j.1460-9568.1996.tb01556.x; Qin HW, 2008, J IMMUNOL, V181, P3167, DOI 10.4049/jimmunol.181.5.3167; Qiu J, 2005, J NEUROSCI, V25, P1645, DOI 10.1523/JNEUROSCI.3269-04.2005; Rao VLR, 2003, J NEUROSCI RES, V71, P208, DOI 10.1002/jnr.10486; Rimaniol AC, 1995, NEUROREPORT, V7, P133, DOI 10.1097/00001756-199512290-00032; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; Rychli K, 2010, J THROMB HAEMOST, V8, P596, DOI 10.1111/j.1538-7836.2010.03741.x; Satriotomo I, 2006, J NEUROCHEM, V98, P1353, DOI 10.1111/j.1471-4159.2006.04051.x; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2008, J CLIN INVEST, V118, P133, DOI 10.1172/JCI32723; Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209; Suzuki S, 2005, J CEREBR BLOOD F MET, V25, P685, DOI 10.1038/sj.jcbfm.9600061; Suzuki S, 2001, EXP NEUROL, V170, P63, DOI 10.1006/exnr.2001.7701; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Weiss TW, 2006, FASEB J, V20, P2369, DOI 10.1096/fj.06-5850fje; Wen TC, 2001, NEUROSCI LETT, V303, P153, DOI 10.1016/S0304-3940(01)01711-6; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Xia X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018282; Yamashita T, 2005, J NEUROCHEM, V94, P459, DOI 10.1111/j.1471-4159.2005.03227.x; Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yi JH, 2007, NEUROCHEM INT, V50, P1014, DOI 10.1016/j.neuint.2007.04.019; Yu JH, 2006, BIOCHEM PHARMACOL, V72, P1555, DOI 10.1016/j.bcp.2006.07.008; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	78	72	73	0	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2012	120	5					710	720		10.1111/j.1471-4159.2011.07610.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	895NQ	WOS:000300503400007	22145815	Bronze			2022-02-06	
J	Marini, A; Galetto, V; Zampieri, E; Vorano, L; Zettin, M; Carlomagno, S				Marini, Andrea; Galetto, Valentina; Zampieri, Elisa; Vorano, Lorenza; Zettin, Marina; Carlomagno, Sergio			Narrative language in traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						Traumatic brain injury; Narrative analysis; Neurolinguistics; Neuropsychology	CLOSED-HEAD-INJURY; CONNECTED SPEECH; FOLLOW-UP; DISCOURSE; ADULTS; APHASIA; ADOLESCENTS; IMPAIRMENT; ABILITIES; COHESION	Persons with traumatic brain injury (TBI) often show impaired linguistic and/or narrative abilities. The present study aimed to document the features of narrative discourse impairment in a group of adults with TBI. 14 severe TBI non-aphasic speakers (GCS < 8) in the phase of neurological stability and 14 neurologically intact participants were recruited for the experiment. Their cognitive, linguistic and narrative skills were thoroughly assessed. The group of non-aphasic individuals with TBI had normal lexical and grammatical skills. However, they produced narratives with increased errors of cohesion and coherence due to the frequent interruption of ongoing utterances, derailments and extraneous utterances that made their discourse vague and ambiguous. They produced a normal amount of thematic units (i.e. concepts) in their narratives. However, this information was not correctly organized at micro- and macrolinguistic levels of processing. A Principal Component Analysis showed that a single factor accounted for the production of global coherence errors, and the reduction of both propositional density at the utterance level and proportion of words that conveyed information. It is hypothesized that the linguistic deficits observed in the participants with TBI may reflect a deficit at the interface between cognitive and linguistic processing rather than a specific linguistic disturbance. (C) 2011 Elsevier Ltd. All rights reserved.	[Marini, Andrea] Univ Udine, Dipartimento Sci Umane, I-33100 Udine, Italy; [Galetto, Valentina; Zettin, Marina] Ctr Puzzle, Turin, Italy; [Galetto, Valentina; Zettin, Marina] Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy; [Vorano, Lorenza] IMFR Gervasutta, Udine, Italy; [Carlomagno, Sergio] Univ Trieste, Dipartimento Psicol, I-34127 Trieste, Italy; [Marini, Andrea; Zampieri, Elisa] IRCCS E Medea Nostra Famiglia, San Vito Al Tagliamento, Pn, Italy		Marini, A (corresponding author), Univ Udine, Dipartimento Sci Umane, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	Marini, Andrea/A-1206-2012	Marini, Andrea/0000-0002-6058-3864	IRCCS "E. Medea"	Funding for this study was provided by IRCCS "E. Medea". The IRCCS "E. Medea" had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Caplan D., 1992, LANGUAGE STRUCTURE P; Carlomagno S., 2008, 46 ANN M AC APH TURK; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Coelho CA, 2005, BRAIN INJURY, V19, P1139, DOI 10.1080/02699050500110678; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; EHRLICH JS, 1988, J COMMUN DISORD, V21, P1, DOI 10.1016/0021-9924(88)90006-8; Ellis C, 2009, NEUROREHABILITATION, V24, P255, DOI 10.3233/NRE-2009-0476; GLOSSER G, 1993, NARRATIVE DISCOURSE; Glosser G., 1990, BRAIN LANG, V40, P67; Haravon A., 1994, DISCOURSE ANAL APPL, P47; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Kertesz A., 1982, W APHASIA BATTERY; Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, J PSYCHOLINGUIST RES, V34, P439, DOI 10.1007/s10936-005-6203-z; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Marionnet C, 2011, EXP DERMATOL, V20, P477, DOI 10.1111/j.1600-0625.2011.01265.x; McDonald S, 1998, BRAIN LANG, V61, P88, DOI 10.1006/brln.1997.1846; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Peach R. K., 1986, ANN CONV AM SPEECH L; Raven, 1938, PROGR MATRICES PERCE; Reitan RM, 1992, TRAIL MAKING TEST; SAFFRAN EM, 1989, BRAIN LANG, V37, P440, DOI 10.1016/0093-934X(89)90030-8; SHEWAN CM, 1988, J COMMUN DISORD, V21, P103, DOI 10.1016/0021-9924(88)90001-9; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 2000, BRAIN INJURY, V14, P397; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Thompson CK, 1996, BRAIN LANG, V52, P175, DOI 10.1006/brln.1996.0009; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	40	72	74	0	29	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	AUG	2011	49	10					2904	2910		10.1016/j.neuropsychologia.2011.06.017			7	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	820XX	WOS:000294940500012	21723304				2022-02-06	
J	Iverson, KM; Hendricks, AM; Kimerling, R; Krengel, M; Meterko, M; Stolzmann, KL; Baker, E; Pogoda, TK; Vasterling, JJ; Lew, HL				Iverson, Katherine M.; Hendricks, Ann M.; Kimerling, Rachel; Krengel, Maxine; Meterko, Mark; Stolzmann, Kelly L.; Baker, Errol; Pogoda, Terri K.; Vasterling, Jennifer J.; Lew, Henry L.			Psychiatric Diagnoses and Neurobehavioral Symptom Severity among OEF/OIF VA Patients with Deployment-Related Traumatic Brain Injury: A Gender Comparison	WOMENS HEALTH ISSUES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; HEALTH-CARE; VETERANS; IRAQ; AFGHANISTAN; WAR; WOMEN; ORGANIZATION; DEPRESSION; OUTCOMES	Background: Traumatic brain injury (TBI) has substantial negative implications for the post-deployment adjustment of veterans who served in Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OIF); however, most research on veterans has focused on males. This study investigated gender differences in psychiatric diagnoses and neurobehavioral symptom severity among OEF/OIF veterans with deployment-related TBI. Methods: This population-based study examined psychiatric diagnoses and self-reported neurobehavioral symptom severity from administrative records for 12,605 United States OEF/OIF veterans evaluated as having deployment-related TBI. Men (n = 11,951) and women (n = 654) who were evaluated to have deployment-related TBI during a standardized comprehensive TBI evaluation in Department of Veterans Affairs facilities were compared on the presence of psychiatric diagnoses and severity of neurobehavioral symptoms. Findings: Posttraumatic stress disorder (PTSD) was the most common psychiatric condition for both genders, although women were less likely than men to have a PTSD diagnosis. In contrast, relative to men, women were 2 times more likely to have a depression diagnosis, 1.3 times more likely to have a non-PTSD anxiety disorder, and 1.5 times more likely to have PTSD with comorbid depression. Multivariate analyses indicated that blast exposure during deployment may account for some of these differences. Additionally, women reported significantly more severe symptoms across a range of neurobehavioral domains. Conclusion: Although PTSD was the most common condition for both men and women, it is also critical for providers to identify and treat other conditions, especially depression and neurobehavioral symptoms, among women veterans with deployment-related TBI. Published by Elsevier Inc.	[Iverson, Katherine M.; Vasterling, Jennifer J.] VA Boston Healthcare Syst, Psychol Serv, WHSD NCPTSD 116B 3, Boston, MA 02130 USA; [Iverson, Katherine M.] Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA; [Iverson, Katherine M.; Meterko, Mark; Stolzmann, Kelly L.; Baker, Errol; Pogoda, Terri K.] Ctr Org Leadership & Management Res, Boston, MA USA; [Iverson, Katherine M.; Krengel, Maxine; Vasterling, Jennifer J.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Hendricks, Ann M.; Meterko, Mark; Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Kimerling, Rachel] VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA; [Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA; [Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Univ Richmond, Sch Med, Dept PM&R, Richmond, VA 23173 USA		Iverson, KM (corresponding author), VA Boston Healthcare Syst, Psychol Serv, WHSD NCPTSD 116B 3, 150 S Huntington Ave, Boston, MA 02130 USA.	Katherine.lverson@va.gov	; Pogoda, Terri/F-6243-2012	Kimerling, Rachel/0000-0003-0996-4212; Krengel, Maxine/0000-0001-7632-590X; Pogoda, Terri/0000-0003-1397-8780	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019836] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019836-14, T32MH019836, T32 MH019836] Funding Source: Medline		Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; CHARD KM, J TRAUMATIC IN PRESS; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Department of Veterans Affairs Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FARACE E, 2000, NEUROSURGICAL FOCUS, V0008, P00001, DOI [DOI 10.3171/F0C.2000.8.1.152, DOI 10.3171/foc.2000.8.1.152]; French LM, 2011, CLIN MANUAL MANAGEME, P383; HENDRICKS A, 2011, NAT HSR D C WASH DC; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, INT J EPIDEMIOL, V36, P327, DOI 10.1093/ije/dym013; Iverson K. M, 2011, CLIN MANUAL MANAGEME, P157; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kimerling R., 2007, HDB PTSD, P207; Kimerling R, 2010, AM J PUBLIC HEALTH, V100, P1409, DOI 10.2105/AJPH.2009.171793; Maguen S, 2010, AM J PUBLIC HEALTH, V100, P2450, DOI 10.2105/AJPH.2009.166165; Marino SE, 2009, EPILEPSY BEHAV, V14, P459, DOI 10.1016/j.yebeh.2008.12.007; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; METERKO M, 2011, PSYCHOMETRIC A UNPUB; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murdoch M, 2006, J GEN INTERN MED, V21, pS5, DOI 10.1111/j.1525-1497.2006.00368.x; National Center for Mental Health Statistics and the Centers for Medicare & Medicaid Services, 2008, INT CLASS DIS 9 REV; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Resick PA, 2010, COGNITIVE PROCESSING; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Street AE, 2009, CLIN PSYCHOL REV, V29, P685, DOI 10.1016/j.cpr.2009.08.007; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Yano EM, 2010, J GEN INTERN MED, V25, P56, DOI 10.1007/s11606-009-1116-4; Yano EM, 2003, WOMEN HEALTH ISS, V13, P55, DOI 10.1016/S1049-3867(02)00198-6	35	72	72	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1049-3867			WOMEN HEALTH ISS	Womens Health Iss.	JUL-AUG	2011	21	4		S	SI		S210	S217		10.1016/j.whi.2011.04.019			8	Public, Environmental & Occupational Health; Women's Studies	Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Women's Studies	792YA	WOS:000292785100022	21724143	Green Accepted			2022-02-06	
J	Cloots, RJH; van Dommelen, JAW; Nyberg, T; Kleiven, S; Geers, MGD				Cloots, R. J. H.; van Dommelen, J. A. W.; Nyberg, T.; Kleiven, S.; Geers, M. G. D.			Micromechanics of diffuse axonal injury: influence of axonal orientation and anisotropy	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Traumatic brain injury (TBI); Diffuse axonal injury (DAI); Brain tissue; Finite element model; Cellular mechanics; Axons; Neurons	PREFRONTAL CORTEX; PYRAMIDAL NEURONS; SIMPLE ELONGATION; LARGE-DEFORMATION; WHITE-MATTER; BRAIN-INJURY; HEAD-INJURY; SOMAL SIZE; MODEL; SCHIZOPHRENIA	Multiple length scales are involved in the development of traumatic brain injury, where the global mechanics of the head level are responsible for local physiological impairment of brain cells. In this study, a relation between the mechanical state at the tissue level and the cellular level is established. A model has been developed that is based on pathological observations of local axonal injury. The model contains axons surrounding an obstacle (e.g., a blood vessel or a brain soma). The axons, which are described by an anisotropic fiber-reinforced material model, have several physically different orientations. The results of the simulations reveal axonal strains being higher than the applied maximum principal tissue strain. For anisotropic brain tissue with a relatively stiff inclusion, the relative logarithmic strain increase is above 60%. Furthermore, it is concluded that individual axons oriented away from the main axonal direction at a specific site can be subjected to even higher axonal strains in a stress-driven process, e.g., invoked by inertial forces in the brain. These axons can have a logarithmic strain of about 2.5 times the maximum logarithmic strain of the axons in the main axonal direction over the complete range of loading directions. The results indicate that cellular level heterogeneities have an important influence on the axonal strain, leading to an orientation and location-dependent sensitivity of the tissue to mechanical loads. Therefore, these effects should be accounted for in injury assessments relying on finite element head models.	[Cloots, R. J. H.; van Dommelen, J. A. W.; Geers, M. G. D.] Eindhoven Univ Technol, Mat Technol Inst, NL-5600 MB Eindhoven, Netherlands; [Nyberg, T.; Kleiven, S.] Royal Inst Technol, Sch Technol & Hlth, Div Neuron Engn, S-14152 Huddinge, Sweden		van Dommelen, JAW (corresponding author), Eindhoven Univ Technol, Mat Technol Inst, POB 513, NL-5600 MB Eindhoven, Netherlands.	j.a.w.v.dommelen@tue.nl	Geers, Marc G.D./E-4385-2014	Geers, Marc G.D./0000-0002-0009-6351	Dutch Technology Foundation STW, applied science division of NWOTechnologiestichting STWNetherlands Organization for Scientific Research (NWO); Ministry of Economic Affairs	This work has been supported by the Dutch Technology Foundation STW, applied science division of NWO and the Technology Program of the Ministry of Economic Affairs.	Abolfathi N, 2009, COMPUT METHOD BIOMEC, V12, P249, DOI [10.1080/10255840802430587, 10.1080/10255840903097871]; Alberts B., 1994, MOL BIOL CELL, V3rd ed; ALBSHARAT AS, 1999, STAPP CAR CRASH C P, V43; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bain AC, 2003, J BIOMECH ENG-T ASME, V125, P798, DOI 10.1115/1.1632627; Bain AC, 2001, J NEUROTRAUM, V18, P499, DOI 10.1089/089771501300227305; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Braitenberg V., 1998, CORTEX STAT GEOMETRY; BRANDS DWA, 2002, STAPP CAR CRASH C P, V46; Chklovskii DB, 2002, NEURON, V34, P341, DOI 10.1016/S0896-6273(02)00679-7; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cotter D, 2002, CEREB CORTEX, V12, P386, DOI 10.1093/cercor/12.4.386; ETOH A, 1994, JPN J APPL PHYS 1, V33, P2874, DOI 10.1143/JJAP.33.2874; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOLDMAN DE, 1956, J ACOUST SOC AM, V28, P35, DOI 10.1121/1.1908216; Highley JR, 2003, BRIT J PSYCHIAT, V183, P414, DOI 10.1192/bjp.183.5.414; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Hutsler JJ, 2003, BRAIN LANG, V86, P226, DOI 10.1016/S0093-934X(02)00531-X; Karami G, 2009, J MECH BEHAV BIOMED, V2, P243, DOI 10.1016/j.jmbbm.2008.08.003; Khoshgoftar Mehdi, 2007, American Journal of Applied Sciences, V4, P918, DOI 10.3844/ajassp.2007.918.924; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kouznetsova V, 2001, COMPUT MECH, V27, P37, DOI 10.1007/s004660000212; Lauret C, 2009, MED ENG PHYS, V31, P392, DOI 10.1016/j.medengphy.2008.05.004; LIN S, 1997, P CTR DIS CONTR WAYN, P27; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Ning XG, 2006, J BIOMECH ENG-T ASME, V128, P925, DOI 10.1115/1.2354208; Nolte J., 2002, HUMAN BRAIN INTRO IT; Pierri JN, 2001, ARCH GEN PSYCHIAT, V58, P466, DOI 10.1001/archpsyc.58.5.466; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2000, STAPP CAR CRASH C P, V44; RAJKOWSKA G, 1995, CEREB CORTEX, V5, P307, DOI 10.1093/cercor/5.4.307; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; Raul JS, 2006, INT J LEGAL MED, V120, P212, DOI 10.1007/s00414-005-0018-1; Roberts VL, 1976, HDB HUMAN TOLERANCE; *SIM, 2008, AB 6 8 MAN; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Snook L, 2005, NEUROIMAGE, V26, P1164, DOI 10.1016/j.neuroimage.2005.03.016; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TAKHOUNTS EG, 2003, STAPP CAR CRASH C P, V47; Ventura R, 1999, J NEUROSCI, V19, P6897, DOI 10.1523/JNEUROSCI.19-16-06897.1999; VERSACE J, 1971, STAPP CAR CRASH C P, V15; [No title captured]	47	72	75	0	23	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959			BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	JUN	2011	10	3					413	422		10.1007/s10237-010-0243-5			10	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	762NP	WOS:000290486600011	20635116	hybrid			2022-02-06	
J	Jin, KL; Xie, L; Mao, XO; Greenberg, MB; Moore, A; Peng, BT; Greenberg, RB; Greenberg, DA				Jin, Kunlin; Xie, Lin; Mao, XiaoOu; Greenberg, Maeve B.; Moore, Alexander; Peng, Botao; Greenberg, Rose B.; Greenberg, David A.			Effect of human neural precursor cell transplantation on endogenous neurogenesis after focal cerebral ischemia in the rat	BRAIN RESEARCH			English	Article						Ischemia; Stroke; Transplantation; Neurogenesis; Subventricular zone	TRAUMATIC BRAIN-INJURY; STEM-CELLS; SUBVENTRICULAR ZONE; FOREBRAIN NEUROGENESIS; PROMOTE PROLIFERATION; ADULT NEUROGENESIS; DENTATE GYRUS; AGED RATS; STROKE; MODEL	Little is known about the relationship between neuronal cell transplantation and endogenous neurogenesis after experimental stroke. We found previously that transplantation of neuronal precursors derived from BG01 human embryonic stem cells reduced infarct volume and improved behavioral outcome after distal middle cerebral artery occlusion (MCAO) in rats. In this study, transplantation was performed 14 days after distal MCAO and doublecortin (Dcx)-expressing cells in the subventricular zone (SVZ) and subgranular zone of dentate gyrus (SGZ) were counted 60 days post-transplant. Transplantation increased neurogenesis (Dcx expression) in ipsilateral SVZ, but not in contralateral SVZ or either SGZ, in both young adult (3-month-old) and aged (24-month-old) rats. These findings suggest that cell-based therapy for stroke may be associated with changes in endogenous adaptive processes, including neurogenesis. (C) 2010 Elsevier B.V. All rights reserved.	[Jin, Kunlin; Xie, Lin; Mao, XiaoOu; Greenberg, Maeve B.; Moore, Alexander; Peng, Botao; Greenberg, Rose B.; Greenberg, David A.] Buck Inst Age Res, Novato, CA 94945 USA		Greenberg, DA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dgreenberg@buckinstitute.org			USPHSUnited States Department of Health & Human ServicesUnited States Public Health Service [NS44921, AG21980, NS057186]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057186, R01NS044921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021980] Funding Source: NIH RePORTER	Supported by USPHS grants NS44921 (to D.A.G) and AG21980 and NS057186 (to K.J.).	Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bath KG, 2010, DEV NEUROBIOL, V70, P339, DOI 10.1002/dneu.20781; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Carbonaro DA, 2008, BLOOD, V111, P5745, DOI 10.1182/blood-2007-08-103663; Chen JL, 2004, BRAIN RES, V1005, P21, DOI 10.1016/j.brainres.2003.11.080; Esneault E, 2008, J CEREBR BLOOD F MET, V28, P1552, DOI 10.1038/jcbfm.2008.40; Gould E, 1997, NEUROSCIENCE, V80, P427, DOI 10.1016/S0306-4522(97)00127-9; Hattiangady B, 2007, STEM CELLS, V25, P2104, DOI 10.1634/stemcells.2006-0726; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2003, AGING CELL, V2, P175, DOI 10.1046/j.1474-9728.2003.00046.x; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2010, AGING CELL, V9, P1076, DOI 10.1111/j.1474-9726.2010.00638.x; Jin KL, 2010, P NATL ACAD SCI USA, V107, P7993, DOI 10.1073/pnas.1000154107; Jin KL, 2010, J CEREBR BLOOD F MET, V30, P534, DOI 10.1038/jcbfm.2009.219; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Locatelli F, 2009, CELL MOL LIFE SCI, V66, P757, DOI 10.1007/s00018-008-8346-1; Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Park DH, 2010, STEM CELLS DEV, V19, P175, DOI 10.1089/scd.2009.0172; Shin SJ, 2006, STEM CELLS, V24, P125, DOI 10.1634/stemcells.2004-0150; Stroemer P, 2009, NEUROREHAB NEURAL RE, V23, P895, DOI 10.1177/1545968309335978; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Urban VS, 2008, STEM CELLS, V26, P244, DOI 10.1634/stemcells.2007-0267; Whitney NP, 2009, J NEUROCHEM, V108, P1343, DOI 10.1111/j.1471-4159.2009.05886.x; Won SJ, 2006, BRAIN RES, V1123, P237, DOI 10.1016/j.brainres.2006.09.055; Yoo SW, 2008, EXP MOL MED, V40, P387, DOI 10.3858/emm.2008.40.4.387; Yoshioka T, 2005, STEM CELLS, V23, P355, DOI 10.1634/stemcells.2004-0200; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	29	72	76	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	FEB 16	2011	1374						56	62		10.1016/j.brainres.2010.12.037			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	725DA	WOS:000287624200007	21167824	Green Accepted, Green Published			2022-02-06	
J	Rosenthal, G; Sanchez-Mejia, RO; Phan, N; Hemphill, JC; Martin, C; Manley, GT				Rosenthal, Guy; Sanchez-Mejia, Rene O.; Phan, Nicolas; Hemphill, J. Claude, III; Martin, Christine; Manley, Geoffrey T.			Incorporating a parenchymal thermal diffusion cerebral blood flow probe in bedside assessment of cerebral autoregulation and vasoreactivity in patients with severe traumatic brain injury Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral autoregulation; thermal diffusion probe; advanced neuromonitoring; MAP challenge; hyperventilation challenge	CARBON-DIOXIDE REACTIVITY; SEVERE HEAD-INJURY; PRESSURE AUTOREGULATION; INDUCED HYPERTENSION	Object. Cerebral autoregulation may be altered after traumatic brain injury (TBI). Recent evidence suggests that patients' autoregulatory status following severe TBI may influence cerebral perfusion pressure management. The authors evaluated the utility of incorporating a recently upgraded parenchymal thermal diffusion probe for the measurement of cerebral blood flow (CBF) in the neurointensive care unit for assessing cerebral autoregulation and vasoreactivity at bedside. Methods. The authors evaluated 20 patients with severe TBI admitted to San Francisco General Hospital who underwent advanced neuromonitoring. Patients had a parenchymal thermal diffusion probe placed for continuous bedside monitoring of local CBF (locCBF) in addition to the standard intracranial pressure and brain tissue oxygen tension (PbtO2) monitoring. The CBF probes were placed in the white matter using a separate cranial bolt. A pressure challenge, whereby mean arterial pressure (MAP) was increased by about 10 mm Hg, was performed in all patients to assess autoregulation. Cerebral CO2 vasoreactivity was assessed with a hyperventilation challenge. Local cerebral vascular resistance (locCVR) was calculated by dividing cerebral perfusion pressure by locCBF. Local cerebral vascular resistance normalized to baseline (locCVRnormalized) was also calculated for the MAP and hyperventilation challenges. Results. In all cases, bedside measurement of locCBF using a cranial bolt in patients with severe TBI resulted in correct placement in the white matter with a low rate of complications. Mean locCBF decreased substantially with hyperventilation challenge (-7 +/- 8 ml/100 g/min, p = 0.0002) and increased slightly with MAP challenge (1 +/- 7 ml/100 g/min, p = 0.17). Measurements of locCBF following MAP and hyperventilation challenges can be used to calculate locCVR. In 83% of cases locCVR increased during a hyperventilation challenge (mean change +3.5 +/- 3.8 mm Hg/ml/100 g/min, p = 0.0002), indicating preserved cerebral CO2 vasoreactivity. In contrast, we observed a more variable response of locCVR to MAP challenge, with increased locCVR in only 53% of cases during a MAP challenge (mean change -0.17 +/- 3.9 mm Hg/ml/100 g/min, p = 0.64) indicating that in many cases autoregulation was impaired following severe TBI. Conclusions. Use of the Hemedex thermal diffusion probe appears to be a safe and feasible method that enables continuous monitoring of CBF at the bedside. Cerebral autoregulation and CO, vasoreactivity can be assessed in patients with severe TBI using the CBF probe by calculating locCVR in response to MAP and hyperventilation challenges. Determining whether CVR increases or decreases with a MAP challenge (locCVRnormalized) may be a simple provocative test to determine patients' autoregulatory status following severe TBI and helping to optimize CPP management. (DOI: 10.3171/2010.6.JNS091360)	[Rosenthal, Guy; Sanchez-Mejia, Rene O.; Phan, Nicolas; Martin, Christine; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; [Hemphill, J. Claude, III] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Rosenthal, Guy] Hadassah Hebrew Univ Med Ctr, Dept Neurosurg, Jerusalem, Israel		Manley, GT (corresponding author), San Francisco Gen Hosp, 1001 Potrero Ave, San Francisco, CA 94110 USA.	manley@itsa.ucsf.edu	Hemphill, Claude/AAY-5630-2021; Demchuk, Andrew M/E-1103-2012	Hemphill, Claude/0000-0003-4019-7525; Demchuk, Andrew M/0000-0002-4930-7789	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS050173]; University of California, San Francisco Brain and Spinal Cord Injury CenterUniversity of California System; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173] Funding Source: NIH RePORTER	This study was supported by National Institutes of Health Grant R01 NS050173 and the University of California, San Francisco Brain and Spinal Cord Injury Center.	ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brain Trauma F, 2008, J NEUROTRAUM, V25, P276; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS26; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; De Georgia MA, 2005, NEUROLOGIST, V11, P45, DOI 10.1097/01.nrl.0000149993.99956.09; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Hlatky R, 2005, NEUROSURGERY, V57, P917, DOI 10.1227/01.NEU.0000180025.43747.fc; Hlatky R, 2007, NEUROSURGERY, V61, P249, DOI [10.1227/01.NEU.0000143029.42638.2c, 10.1227/01.neu.0000279220.30633.45]; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; SIOUTOS PJ, 1995, NEUROSURGERY, V36, P943, DOI 10.1227/00006123-199505000-00009; Soukup J, 2008, J NEUROSURG ANESTH, V20, P249, DOI 10.1097/ANA.0b013e31817ef487; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Thome C, 2001, J NEUROSURG, V95, P402, DOI 10.3171/jns.2001.95.3.0402; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Vajkoczy P, 2001, STROKE, V32, P498, DOI 10.1161/01.STR.32.2.498; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	23	72	75	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					62	70		10.3171/2010.6.JNS091360			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500015	20707619				2022-02-06	
J	Echlin, PS; Tator, CH; Cusimano, MD; Cantu, RC; Taunton, JE; Upshur, REG; Hall, CR; Johnson, AM; Forwell, LA; Skopelja, EN				Echlin, Paul Sean; Tator, Charles H.; Cusimano, Michael D.; Cantu, Robert C.; Taunton, Jack E.; Upshur, Ross E. G.; Hall, Craig R.; Johnson, Andrew M.; Forwell, Lorie A.; Skopelja, Elaine N.			A prospective study of physician-observed concussions during junior ice hockey: implications for incidence rates	NEUROSURGICAL FOCUS			English	Article						concussion; ice hockey; incidence; Canada	PROFESSIONAL FOOTBALL PLAYERS; INJURY SURVEILLANCE SYSTEM; RECURRENT CONCUSSION; SPORTS CONCUSSION; DESCRIPTIVE EPIDEMIOLOGY; COLLEGIATE; RISK; ASSOCIATION; SEASON; STATEMENT	Object. The objective of this study was to measure the incidence of concussion (scaled relative to number of athlete exposures) and recurrent concussion within 2 teams of fourth-tier junior ice hockey players (16-21 years old) during 1 regular season. Methods. A prospective cohort study called the Hockey Concussion Education Project was conducted during 1 junior ice hockey regular season (2009-2010) involving 67 male fourth-tier ice hockey players (mean age 18.2 +/- 1.2 years, range 16-21 years) from 2 teams. Prior to the start of the season, every player underwent baseline assessments using the Sideline Concussion Assessment Tool 2 (SCAT2) and the Immediate Post-Concussion Assessment and Cognitive Test (ImPACT). The study protocol also required players who entered the study during the season to complete baseline SCAT2 and ImPACT testing. If the protocol was not followed, the postinjury test results of a player without true baseline test results would be compared against previously established age and gender group normative levels. Each regular season game was observed by a qualified physician and at least 1 other neutral nonphysician observer. Players who suffered a suspected concussion were evaluated at the game. If a concussion diagnosis was made, the player was subsequently examined in the physician's office for a full clinical evaluation and the SCAT2 and ImPACT were repeated. Based on these evaluations, players were counseled on the decision of when to return to play. Athlete exposure was defined as 1 game played by 1 athlete. Results. Twenty-one concussions occurred during the 52 physician-observed games (incidence 21.5 concussions per 1000 athlete exposures). Five players experienced repeat concussions. No concussions were reported during practice sessions. A concussion was diagnosed by the physician in 19 (36.5%) of the 52 observed games. One of the 5 individuals who suffered a repeat concussion sustained his initial concussion in a regular season game that was not observed by a physician, and as a result this single case was not included in the total of 21 total concussions. This initial concussion of the player was identified during baseline testing 2 days after the injury and was subsequently medically diagnosed and treated. Conclusions. The incidence of game-related concussions (per 1000 athlete exposures) in these fourth-tier ice hockey players was 3.3 times higher than the highest rate previously reported in the literature. This difference may be the result of the use of standardized direct physician observation, diagnosis, and subsequent treatment. The results of this study demonstrate the need for follow-up studies involving larger and more diverse sample groups to reflect generalizability of the findings. These follow-up studies should involve other contact sports (for example football and rugby) and also include the full spectrum of gender, age, and skill levels. (DOI: 10.3171/2010.9.FOCUS10186)	[Echlin, Paul Sean] AIM Hlth Grp Family Med, London, ON, Canada; [Tator, Charles H.; Cusimano, Michael D.] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Cantu, Robert C.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Taunton, Jack E.] Univ British Columbia, Fac Med, Div Sports Med, Vancouver, BC V5Z 1M9, Canada; [Taunton, Jack E.] Univ British Columbia, Sch Human Kinet, Vancouver, BC V5Z 1M9, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Family, Toronto, ON M5S 1A1, Canada; [Upshur, Ross E. G.] Univ Toronto, Dept Community Med, Toronto, ON M5S 1A1, Canada; [Hall, Craig R.] Univ Western Ontario, Sch Kinesiol, London, ON, Canada; [Johnson, Andrew M.] Univ Western Ontario, Fac Hlth Sci, London, ON, Canada; [Forwell, Lorie A.] Univ Western Ontario, Dept Physiotherapy, London, ON, Canada; [Skopelja, Elaine N.] Indiana Univ, Sch Med Lib, Indianapolis, IN 46204 USA		Echlin, PS (corresponding author), 320 Adelaide St, S London, ON N5Z 3L2, Canada.	p_echlinfp@hotmail.com	Johnson, Andrew M/B-2048-2012; Cusimano, Michael/X-4059-2019	Upshur, Ross/0000-0003-1128-0557; Cusimano, Michael/0000-0002-9989-0650; Johnson, Andrew M./0000-0002-7269-3016	Ontario Trillium Foundation; Dr. Tom Pashby Safety Fund; Dave Irwin Foundation for Brain Injury; Canadian Institutes of Health Strategic Teams in Applied Injury Research	This work was funded by the Ontario Trillium Foundation, the Dr. Tom Pashby Safety Fund, and the Dave Irwin Foundation for Brain Injury. The Ontario Neurotrauma Foundation made administrative and facilitative contributions. Dr. Cusimano is funded by the Canadian Institutes of Health Strategic Teams in Applied Injury Research.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Keating P, ESPN MAGAZINE; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; Schick DM, 2003, AM J SPORT MED, V31, P47, DOI 10.1177/03635465030310011901; Schwarz A, 2009, NY TIMES        1217; SCHWARZ A, 2010, NY TIMES        0628; Shuttleworth-Edwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P479, DOI 10.1016/j.acn.2008.07.002; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	72	72	2	17	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	NOV	2010	29	5							E4	10.3171/2010.9.FOCUS10186			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	675CE	WOS:000283801900005	21039138				2022-02-06	
J	Acosta-Escribano, J; Fernandez-Vivas, M; Carmona, TG; Caturla-Such, J; Garcia-Martinez, M; Menendez-Mainer, A; Solera-Suarez, M; Sanchez-Paya, J				Acosta-Escribano, Jose; Fernandez-Vivas, Miguel; Grau Carmona, Teodoro; Caturla-Such, Juan; Garcia-Martinez, Miguel; Menendez-Mainer, Ainhoa; Solera-Suarez, Manuel; Sanchez-Paya, Jose			Gastric versus transpyloric feeding in severe traumatic brain injury: a prospective, randomized trial	INTENSIVE CARE MEDICINE			English	Article						Nutrition; Neurotrauma; Mechanical ventilation; Complications	CRITICALLY-ILL PATIENTS; VENTILATOR-ASSOCIATED PNEUMONIA; ENTERAL NUTRITION; GASTROINTESTINAL COMPLICATIONS; CARE; HYPERGLYCEMIA; DEFINITIONS; GUIDELINES; MORTALITY; INFECTION	To evaluate the efficacy of transpyloric feeding (TPF) compared with gastric feeding (GF) with regard to the incidence of ventilator-associated pneumonia in severe traumatic brain injury patients (TBI). Prospective, open-label, randomized study in an intensive care unit of a university hospital. One hundred and four CHI adult patients admitted for TBI between April 2007 and December 2008. Patients were included within the first 24 h after ICU admission and were followed until discharge or 30 days after admission. Patients were randomized to TPF or GF groups. They received the same diet, with 25 kcal kg(-1) day(-1) of calculated energy requirements and a nitrogen intake of 0.2 g N kg(-1) day(-1). Primary outcome was the incidence of early and ventilatory-associated pneumonia. Secondary outcomes were enteral nutrition-related gastrointestinal complications (GIC), days on mechanical ventilation, length of ICU stay and hospital stay, and sequential organ failure assessment score (SOFA). The TPF group had a lower incidence of pneumonia, OR 0.3 (95% CI 0.1-0.7, P = 0.01). There were no significant differences in other nosocomial infections. The TPF group received higher amounts of diet compared to the GF group (92 vs. 84%, P < 0.01) and had lesser incidence of increased gastric residuals, OR 0.2 (95% CI 0.04-0.6, P = 0.003). Enteral nutrition delivered through the transpyloric route reduces the incidence of overall and late pneumonia and improves nutritional efficacy in severe TBI patients.	[Acosta-Escribano, Jose; Caturla-Such, Juan; Garcia-Martinez, Miguel; Menendez-Mainer, Ainhoa; Solera-Suarez, Manuel] Hosp Gen Univ Alicante, Intens Care Unit, Alicante 03010, Spain; [Fernandez-Vivas, Miguel] Hosp Univ Virgen Arrixaca, Intens Care Unit, Murcia, Spain; [Grau Carmona, Teodoro] Hosp Univ Doce Octubre, Intens Care Unit, Madrid, Spain; [Sanchez-Paya, Jose] Hosp Gen Univ Alicante, Epidemiol Unit, Alicante 03010, Spain		Acosta-Escribano, J (corresponding author), Hosp Gen Univ Alicante, Intens Care Unit, Pintor Baeza 12, Alicante 03010, Spain.	acosta_jos@telefonica.net	Grau, Teodoro/J-5127-2019	Grau, Teodoro/0000-0002-6243-6323			ACOSTA JA, 2001, NUTR HOSP, V6, P262; *AM THOR SOC, 1995, AM J RESP CRIT CARE, V153, P1711; Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; APELGREN KN, 1982, CRIT CARE MED, V10, P305, DOI 10.1097/00003246-198205000-00003; BLOM M, 1975, CLIN CHEM, V21, P195; Bochicchio GV, 2006, JPEN-PARENTER ENTER, V30, P503, DOI 10.1177/0148607106030006503; BRATTON S, 2005, J NEUROTRAUM, V24, pS1; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; CHANDRA RK, 1983, LANCET, V1, P688; DeMeo Mark T., 2002, Journal of Parenteral and Enteral Nutrition, V26, pS9, DOI 10.1177/014860710202600603; DEMPSEY DT, 1988, AM J CLIN NUTR, V47, P352, DOI 10.1093/ajcn/47.2.352; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; Grau T., 2005, Nutr. Hosp., V20, P278; HADLEY MN, 1986, NEUROSURGERY, V19, P367, DOI 10.1097/00006123-198609000-00006; Heyland DK, 2001, CRIT CARE MED, V29, P1495, DOI 10.1097/00003246-200108000-00001; HEYLAND DK, 2003, JPEN, V27, P255; Ho KM, 2006, INTENS CARE MED, V32, P639, DOI 10.1007/s00134-006-0128-3; Hubmayr R D, 2002, Intensive Care Med, V28, P1521; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Kaye AH, 2000, LANCET, V356, P1540, DOI 10.1016/S0140-6736(00)03121-4; Kearns PJ, 2000, CRIT CARE MED, V28, P1742, DOI 10.1097/00003246-200006000-00007; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; Marik PE, 2003, CRIT CARE, V7, pR46, DOI 10.1186/cc2190; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Montejo JC, 2010, INTENS CARE MED, V36, P1386, DOI 10.1007/s00134-010-1856-y; Montejo JC, 1999, CRIT CARE MED, V27, P1447, DOI 10.1097/00003246-199908000-00006; Montejo JC, 2002, CRIT CARE MED, V30, P796, DOI 10.1097/00003246-200204000-00013; MOYLAN JA, 1976, J TRAUMA, V16, P517, DOI 10.1097/00005373-197607000-00001; Nguyen NQ, 2008, INTENS CARE MED, V34, P454, DOI 10.1007/s00134-007-0942-2; NORTON JA, 1988, J NEUROSURG, V68, P62, DOI 10.3171/jns.1988.68.1.0062; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Ravasco Paula, 2003, Nutr Clin Pract, V18, P427, DOI 10.1177/0115426503018005427; STRONG RM, 1992, JPEN-PARENTER ENTER, V16, P59, DOI 10.1177/014860719201600159; Tarling MM, 1997, INTENS CARE MED, V23, P256, DOI 10.1007/s001340050325; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Valles J, 2007, INTENS CARE MED, V33, P1363, DOI 10.1007/s00134-007-0721-0; Vincent JL, 2000, CRIT CARE CLIN, V16, P353, DOI 10.1016/S0749-0704(05)70114-7; Yavagal DR, 2000, CRIT CARE MED, V28, P1408, DOI 10.1097/00003246-200005000-00025	40	72	90	2	17	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	SEP	2010	36	9					1532	1539		10.1007/s00134-010-1908-3			8	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	638PV	WOS:000280908000012	20495781				2022-02-06	
J	Lew, HL; Pogoda, TK; Hsu, PT; Cohen, S; Amick, MM; Baker, E; Meterko, M; Vanderploeg, RD				Lew, Henry L.; Pogoda, Terri K.; Hsu, Pei-Te; Cohen, Sara; Amick, Melissa M.; Baker, Errol; Meterko, Mark; Vanderploeg, Rodney D.			Impact of the "Polytrauma Clinical Triad" on Sleep Disturbance in a Department of Veterans Affairs Outpatient Rehabilitation Setting	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Traumatic Brain Injury; Post Traumatic Stress Disorder; Pain; Sleep	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; HEAD-INJURY; IRAQ-WAR; MANAGEMENT; COMPLAINTS; SYMPTOMS; PREVALENCE; HEADACHES; INSOMNIA	Objective: There is a high prevalence of Operation Enduring Freedom/Operation Iraqi Freedom veterans returning with the "polytrauma clinical triad" of pain, posttraumatic stress disorder, and traumatic brain injury. This study examined the effect of the polytrauma clinical triad on sleep disturbance, defined as difficulty falling or staying asleep, a common problem in Operation Enduring Freedom/Operation Iraqi Freedom veterans. Design: A chart review was conducted for 200 Operation Enduring Freedom/Operation Iraqi Freedom veterans evaluated at a polytrauma outpatient clinic. Data that were abstracted included a sleep disturbance severity index, diagnoses of posttraumatic stress disorder and traumatic brain injury, and reported problems of pain. Results: Sleep disturbance was highly prevalent (93.5%) in this sample, in which the majority of traumatic brain injury diagnoses were mild. In the multiple regression analysis, posttraumatic stress disorder, pain, the interaction of traumatic brain injury and posttraumatic stress disorder, and the interaction of posttraumatic stress disorder and pain significantly accounted for sleep disturbance. As a separate independent variable, traumatic brain injury was not associated with sleep disturbance. Conclusions: Our preliminary results showed that posttraumatic stress disorder and pain significantly contributed to sleep disturbance. When traumatic brain injury or pain coexisted with posttraumatic stress disorder, sleep problems worsened. In this clinical population, where the majority of traumatic brain injury diagnoses tend to be in the mild category, traumatic brain injury alone did not predict sleep disturbance. Through increased awareness of pain, posttraumatic stress disorder, and traumatic brain injury, clinicians can work collaboratively to maximize rehabilitation outcomes.	[Lew, Henry L.] DVBIC, Richmond, VA USA; [Lew, Henry L.] Virginia Commonwealth Univ, Dept PM&R, Sch Med, Richmond, VA USA; [Lew, Henry L.; Hsu, Pei-Te; Cohen, Sara] Harvard Univ, Sch Med, Dept PM&R, Boston, MA USA; [Pogoda, Terri K.; Cohen, Sara; Amick, Melissa M.] VA Boston Healthcare Syst, Polytrauma & Traumat Brain Injury Ctr, Boston, MA USA; [Pogoda, Terri K.; Baker, Errol; Meterko, Mark] VA Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; [Pogoda, Terri K.; Meterko, Mark] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA; [Hsu, Pei-Te] Kaohsiung Vet Gen Hosp, Dept Rehabil, Kaohsiung, Taiwan; [Vanderploeg, Rodney D.] James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Vanderploeg, Rodney D.] Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; [Vanderploeg, Rodney D.] Univ S Florida, Dept Psychol, Tampa, FL USA		Lew, HL (corresponding author), DVBIC, Richmond, VA USA.		Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780			American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Atkinson MP, 2009, MANAGE SCI, V55, P1454, DOI 10.1287/mnsc.1090.1042; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Maher MJ, 2006, CNS DRUGS, V20, P567, DOI 10.2165/00023210-200620070-00003; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Neylan TC, 1998, AM J PSYCHIAT, V155, P929, DOI 10.1176/ajp.155.7.929; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Singareddy Ravi Kumar, 2002, Ann Clin Psychiatry, V14, P183, DOI 10.1023/A:1021190620773; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; *US GAO, 2008, GAO08276; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	37	72	72	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115			AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JUN	2010	89	6					437	445		10.1097/PHM.0b013e3181ddd301			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	605GY	WOS:000278337100001	20489391				2022-02-06	
J	Tanriverdi, F; Unluhizarci, K; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin			Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy	PITUITARY			English	Article						Traumatic brain injury; Mild TBI; Pituitary; Hypopituitarism; Growth hormone; Boxing; Sports	ANEURYSMAL SUBARACHNOID HEMORRHAGE; INSULIN TOLERANCE-TEST; ADRENAL INSUFFICIENCY; PROFESSIONAL BOXERS; ACUTE-PHASE; HIGH-RISK; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; CONCUSSION	Traumatic brain injury (TBI) is an important public health problem all over the world. The level of consciousness of the patients and the severity of the brain injury is commonly evaluated by the Glascow Coma Scale as mild, moderate and severe TBI. When we consider the high frequency of mild TBI (MTBI) among the all TBI patients the burden of the pituitary dysfunction problem in this group could not be ignored. However, one of the most important and still unresolved questions is which patients with MTBI should be screened for hypopituitarism? Another type of head trauma which could be considered as the subgroup of MTBI is sports related chronic repetitive head trauma. Therefore, in this review we will discuss the frequency, characteristics and current management of pituitary dysfunction in patients with MTBI including the subjects exposed to sports related chronic mild head trauma.	[Tanriverdi, Fatih; Unluhizarci, Kursad; Kelestimur, Fahrettin] Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr	kelestimur, f/ABE-9873-2021				Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2007, NAT CLIN PRACT ENDOC, V3, P318, DOI 10.1038/ncpendmet0460; [Anonymous], 1999, JAMA, V282, P974; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Hillier SL, 1997, BRAIN INJURY, V11, P649; Ives JC, 2007, J ATHL TRAINING, V42, P431; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Popovic V, 2005, GROWTH HORM IGF RES, V15, P177, DOI 10.1016/j.ghir.2005.02.003; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powell JW, 2001, J ATHL TRAINING, V36, P307; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schmidt IL, 2003, J CLIN ENDOCR METAB, V88, P4193, DOI 10.1210/jc.2002-021897; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2008, J NEUROTRAUM, V25, P1071, DOI 10.1089/neu.2007.0456; Tanriverdi F, 2008, EUR J ENDOCRINOL, V159, P7, DOI 10.1530/EJE-08-0050; Tanriverdi F, 2008, ANN INTERN MED, V148, P827, DOI 10.7326/0003-4819-148-11-200806030-00005; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2007, BRAIN INJURY, V21, P433, DOI 10.1080/02699050701311083; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	42	72	73	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1386-341X	1573-7403		PITUITARY	Pituitary	JUN	2010	13	2					146	153		10.1007/s11102-009-0215-x			8	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	584RS	WOS:000276770900008	20037793				2022-02-06	
J	Dijkers, MP; Harrison-Felix, C; Marwitz, JH				Dijkers, Marcel P.; Harrison-Felix, Cynthia; Marwitz, Jennifer H.			The Traumatic Brain Injury Model Systems: History and Contributions to Clinical Service and Research	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						care systems; government support; history; traumatic brain injuries; rehabilitation; research	GLASGOW OUTCOME SCALE; DISABILITY RATING-SCALE; HEAD-INJURY; COMA	The model systems (MSs) of care for traumatic brain injury (TBI) is a demonstration program started by the National Institute on Disability and Rehabilitation Research in 1987 to improve care and outcomes for individuals with TBI, from emergency services through life-long follow-up. Over the next 20 years, the program increased in size, and the emphasis shifted from demonstration to research. The focal point of that research is the National Data Base, a longitudinal database including nearly 9000 individuals who were admitted for inpatient acute TBI rehabilitation. In addition to preinjury, injury, acute care, and rehabilitation information, the database includes reports of outcomes at 1, 2, 5, 10, 15, etc, years postinjury. The National Data Base criteria, main contents, and mechanisms used to improve data quantity and quality are described. The MSs' other research is described: local (site-specific), module, and collaborative, with illustrative glimpses of the content. The impact of the TBI MSs program, through dissemination, knowledge translation, training of clinicians and researchers, as well as consulting with policy makers, administrators, clinicians, and researchers is discussed.	[Dijkers, Marcel P.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; [Harrison-Felix, Cynthia] Craig Hosp, Englewood, CO USA; [Harrison-Felix, Cynthia] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA		Dijkers, MP (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 5 E 98th St, New York, NY 10029 USA.	marcel.dijkers@mssm.edu		Dijkers, Marcel/0000-0002-8362-5596	National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of EducationUS Department of Education [H133A070036, H133A070033, H133A070022, H133A060038]	This study was supported in part by the National Institute on Disability and Rehabilitation Research, Office of Special Education and Rehabilitative Services, US Department of Education (grants H133A070036, H133A070033, H133A070022, and H133A060038).	Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; *CESSI, 2006, DESCR TRAUM BRAIN IN; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers M, 2009, ARCH PHYS MED REHAB, V90, pe39, DOI DOI 10.1016/j.apmr.2009.08.123; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Ragnarsson KT, 1993, J HEAD TRAUMA REHAB, V8, P1, DOI DOI 10.1097/00001199-199308020-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sanchez Gonzalo Moreno, 2007, Neurosurg Focus, V23, pE5; TEASDALE G, 1974, LANCET, V2, P81; *TRAUM BRAIN INJ M, STAND OP PROC A, V101; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; 1987, FED REG, V52, P15448; 2002, FED REG, V67, P39571; 2003, FED REG, V68, P44752; [No title captured]; 1999, J HEAD TRAUMA REHABI, V14, P189; 1998, FED REG, V62, P25759; 2008, FED REG, V73, P6132; 2007, FED REG, V72, P7287; 1999, FED REG, V63, P40155	26	72	72	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2010	25	2					81	91		10.1097/HTR.0b013e3181cd3528			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	578EJ	WOS:000276276000003	20134334				2022-02-06	
J	Andelic, N; Sigurdardottir, S; Schanke, AK; Sandvik, L; Sveen, U; Roe, C				Andelic, Nada; Sigurdardottir, Solrun; Schanke, Anne-Kristine; Sandvik, Leiv; Sveen, Unni; Roe, Cecilie			Disability, physical health and mental health 1 year after traumatic brain injury	DISABILITY AND REHABILITATION			English	Article						Traumatic brain injury; disability; SF-36; ICF; FIM; CIQ	QUALITY-OF-LIFE; SF-36; OUTCOMES; MODERATE; ADULTS; QUESTIONNAIRE; SATISFACTION; INDIVIDUALS; SCALES; MODEL	Purpose. The purpose of this study was to assess disability and the physical and mental health status 1 year after traumatic brain injury (TBI), using the International Classification of Functioning, Disability and Health (ICF) as a conceptual model for understanding TBI disability. Methods. A prospective study of 85 patients with moderate-to-severe TBI (aged 16-55 years) due to injury occurring from May 2005 to May 2007 and hospitalised at the Trauma Referral Centre in Eastern Norway were included. The severity of structural brain damage and overall trauma were used as indices of body structure impairments. Activity limitations were measured by the Functional Independence Measure, and participation restrictions were assessed via the Community Integration Questionnaire. Physical and mental health dimensions as reported on the Medical Outcome Survey Short-Form were chosen as outcome measures. Results. Roughly one quarter of the patients reported disability requiring personal assistance. One third had major problems with social integration, and 42% were not working. Nearly half of the patients reported poor physical health, and 37% reported poor mental health. Regression models, including demographics, impairments, activity limitations and participation restrictions, accounted for 50% of the variance in physical health and 35% of the variance in mental health. More severe impairments, fewer activity limitations and fewer participation restrictions equated to better overall health. Conclusions. The results demonstrated that a significant proportion of TBI survivors face substantial disability and impaired overall health 1 year after injury. To optimise health and well-being outcomes, clinicians need to ensure that health needs of patients with less severe TBI are identified and treated during the post-acute period.	[Andelic, Nada; Sveen, Unni; Roe, Cecilie] Oslo Univ Hosp, Dept Phys Med & Rehabil, Ulleval, Norway; [Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Nesoddtangen, Norway; [Sandvik, Leiv] Oslo Univ Hosp, Clin Res Ctr, Ulleval, Norway; [Sandvik, Leiv] Univ Oslo, Fac Dent, N-0316 Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, N-0316 Oslo, Norway		Andelic, N (corresponding author), Oslo Univ Hosp, Dept Phys Med & Rehabil, N-0407 Oslo, Norway.	nada.andelic@ulleval.no		Andelic, Nada/0000-0002-3719-4406	Norwegian Health South-East Authority	The authors want to thank all of the subjects for their participation. Special thanks are given to Tone Jerstad (neuroradiologist, Oslo University Hospital, Ulleval) for the CT assessment, Morten Hestnes (Trauma Register, Oslo University Hospital, Ulleval) for the extraction of trauma scores and Nini Hammergren for assistance with patient registrations. This study was supported by grants from the Norwegian Health South-East Authority.	Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cohen ME, 2000, ARCH PHYS MED REHAB, V81, pS21, DOI 10.1053/apmr.2000.20620; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Farivar SS, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-54; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Hann M, 2008, QUAL LIFE RES, V17, P413, DOI 10.1007/s11136-008-9310-0; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lasa L, 2000, J AFFECT DISORDERS, V57, P261, DOI 10.1016/S0165-0327(99)00088-9; Loge JH, 1998, SCAND J SOC MED, V26, P250; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; Novack TA, 2000, BRAIN INJURY, V14, P987; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; TEASDALE G, 1974, LANCET, V2, P81; Uniform Data System for Medical Rehabilitation, 1996, GUID UN DAT SET MED; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; World Health Organization, 2007, INT CLASS FUNCT DIS	41	72	75	3	17	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32	13					1122	1131		10.3109/09638280903410722			10	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	608OE	WOS:000278592800007	20113311				2022-02-06	
J	Kimberley, TJ; Samargia, S; Moore, LG; Shakya, JK; Lang, CE				Kimberley, Teresa Jacobson; Samargia, Sharyl; Moore, Lisa G.; Shakya, Josefin K.; Lang, Catherine E.			Comparison of amounts and types of practice during rehabilitation for traumatic brain injury and stroke	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cortical reorganization; CVA; neuroplasticity; observation; occupational therapy; physical therapy; rehabilitation; repetitions; stroke; TBI	INDUCED MOVEMENT THERAPY; ADULT SQUIRREL-MONKEYS; MOTOR CORTEX; CONTROLLED-TRIAL; FINGER TRACKING; RECOVERY; REPRESENTATIONS; REORGANIZATION; PLASTICITY; SESSIONS	Patients with acquired neurological deficits may capitalize on cortical reorganization to recover functional skills that have been lost. Research in neuroplasticity proposes that a high number of repetitions may lead to cortical reorganization. The purposes of this study were to quantify the number and type of activities performed by patients with traumatic brain injury (TBI) and stroke in physical and occupational therapy sessions to determine whether (1) the number of repetitions approaches the numbers in neuroplasticity research, (2) there were differences based on patient diagnosis, and (3) patient or therapist characteristics affected the type or amount of activities performed. Forty-eight patient and forty provider subjects participated. One hundred seven therapy sessions were observed. Data from therapy sessions were counted and categorized. Neither patient group approached the total number of repetitions neuroplasticity research suggests may be required for neuroplastic change. Repetitions per session did not differ between groups. Subjects with TBI performed more repetitions per minute in three categories (total upper-limb repetitions, gait steps, and transfers) than subjects with stroke. Therapists with <1 year or >15 years of neurological therapy experience instructed patients in fewer functional repetitions per minute than did therapists with 5 to 15 years of experience.	[Kimberley, Teresa Jacobson; Moore, Lisa G.; Shakya, Josefin K.] Univ Minnesota, Program Phys Therapy, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA; [Kimberley, Teresa Jacobson; Samargia, Sharyl] Univ Minnesota, Program Rehabil Sci, Minneapolis, MN 55455 USA; [Lang, Catherine E.] Washington Univ, Dept Neurol, Program Occupat Therapy, Program Phys Therapy, St Louis, MO USA		Kimberley, TJ (corresponding author), Univ Minnesota, Program Phys Therapy, Dept Phys Med & Rehabil, MMC 388,420 Church St SE, Minneapolis, MN 55455 USA.	tjk@umn.edu	Kimberley, Teresa/AAL-1893-2020	Kimberley, Teresa/0000-0001-6397-4054; Lang, Catherine/0000-0002-7120-0136	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD047669]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD047669] Funding Source: NIH RePORTER	This material was unfunded at the time of manuscript preparation. Salary support for Dr. Lang was provided by the National Institutes of Health (grant HD047669).	Birkenmeier RL, 2010, NEUROREHAB NEURAL RE, V24, P620, DOI 10.1177/1545968310361957; BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Canning CG, 2003, CLIN REHABIL, V17, P355, DOI 10.1191/0269215503cr620oa; Carey JR, 2007, NEUROREHAB NEURAL RE, V21, P216, DOI 10.1177/1545968306292381; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Cha J, 2007, J NEUROTRAUM, V24, P1000, DOI 10.1089/neu.2006.0233; Chau C, 1998, J NEUROPHYSIOL, V79, P392, DOI 10.1152/jn.1998.79.1.392; Classen J, 1998, J NEUROPHYSIOL, V79, P1117, DOI 10.1152/jn.1998.79.2.1117; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; Elson T, 2009, INT J THER REHABIL, V16, P78, DOI 10.12968/ijtr.2009.16.2.38893; English CK, 2007, ARCH PHYS MED REHAB, V88, P955, DOI 10.1016/j.apmr.2007.04.010; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kimberley TJ, 2004, EXP BRAIN RES, V154, P450, DOI 10.1007/s00221-003-1695-y; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321, DOI 10.1152/jn.1998.80.6.3321; Kuys S, 2006, PHYSIOTHER RES INT, V11, P219, DOI 10.1002/pri.344; Kwakkel G, 2008, NEUROREHAB NEURAL RE, V22, P111, DOI 10.1177/1545968307305457; Lang Catherine E, 2007, J Neurol Phys Ther, V31, P3; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; LANG CE, 2006, TXB NEURAL REPAIR RE, V2; Liepert J, 1998, NEUROSCI LETT, V250, P5, DOI 10.1016/S0304-3940(98)00386-3; Liepert J, 2000, ACTA NEUROL SCAND, V101, P321, DOI 10.1034/j.1600-0404.2000.90337a.x; Lin KC, 2009, NEUROREHAB NEURAL RE, V23, P336, DOI 10.1177/1545968308321773; NATHAN PW, 1982, BRAIN, V105, P223, DOI 10.1093/brain/105.2.223; Nudo RJ, 2003, J REHABIL MED, V35, P7, DOI 10.1080/16501960310010070; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; NUDO RJ, 1988, J COMP NEUROL, V277, P53, DOI 10.1002/cne.902770105; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Shaw SE, 2005, J REHABIL RES DEV, V42, P769, DOI 10.1682/JRRD.2005.06.0094; Van Peppen RPS, 2004, CLIN REHABIL, V18, P833, DOI 10.1191/0269215504cr843oa; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	34	72	73	1	31	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2010	47	9					851	861		10.1682/JRRD.2010.02.0019			11	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	707PX	WOS:000286299600006	21174250	Green Submitted, Bronze			2022-02-06	
J	McKinlay, A; Grace, RC; Horwood, LJ; Fergusson, DM; MacFarlane, MR				McKinlay, A.; Grace, R. C.; Horwood, L. J.; Fergusson, D. M.; MacFarlane, M. R.			Long-term behavioural outcomes of pre-school mild traumatic brain injury	CHILD CARE HEALTH AND DEVELOPMENT			English	Article						children; cohort; longitudinal; mild traumatic brain injury; psychiatric disorders	HEAD-INJURY; NEUROPSYCHOLOGICAL FUNCTION; MENTAL-DISORDERS; CHILDREN; ADOLESCENTS; RECOVERY	Background Mild traumatic brain injury (MTBI) is a leading cause of injury for children during their pre-school years. However, there is little information regarding the long-term outcomes of these injuries. Method We used fully prospective data from an epidemiological study of a birth cohort to examine behavioural effects associated with MTBI during the pre-school years. Cases of confirmed MTBI were divided into two groups, those that had received outpatient medical attention, and those that had been admitted to hospital for a brief period of observation (inpatient cases). The remainder of the cohort served as a reference control group. Results Mother/teacher ratings for behaviours associated with attention deficit/hyperactivity disorder and oppositional defiant/conduct disorder, obtained yearly from age 7 to 13, revealed evidence of deficits after inpatient MTBI (n = 21), relative to more minor outpatient injury MTBI (n = 55) and the reference control group (n = 852). For the inpatient group there was evidence of increasing deficits over years 7-13. Conclusions More severe pre-school MTBI may be associated with persistent negative effects in terms of psychosocial development. The vulnerability of pre-school children to MTBI signals a pressing need to identify high-risk cases that may benefit from monitoring and early intervention.	[McKinlay, A.; Grace, R. C.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Horwood, L. J.; Fergusson, D. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [MacFarlane, M. R.] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand		McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	audrey.mckinlay@canterbury.ac.nz		McKinlay, Audrey/0000-0001-9846-8514; Horwood, L./0000-0003-4881-1956; Grace, Randolph/0000-0003-1115-6089; Fergusson, David/0000-0002-8117-017X	Health Research Council of New ZealandHealth Research Council of New Zealand; National Child Health Research Foundation; Canterbury Medical Research Foundation; New Zealand Lottery Grants Board; New Zealand Foundation for Research Science and TechnologyNew Zealand Foundation for Research, Science and Technology; Todd Foundation; Neurological Foundation	The Christchurch Health and Development Study has been funded by grants from the Health Research Council of New Zealand, the National Child Health Research Foundation, the Canterbury Medical Research Foundation and the New Zealand Lottery Grants Board. Audrey McKinlay was sponsored by a scholarship from the New Zealand Foundation for Research Science and Technology, a Todd Foundation award for research excellence and a Neurological Foundation grant.	ACHENBACH TM, 1978, PSYCHOL BULL, V85, P1275, DOI 10.1037/0033-2909.85.6.1275; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bergman DA, 1999, PEDIATRICS, V104, P1407; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CASEY R, 1986, PEDIATRICS, V78, P497; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; COSTEFF H, 1988, BRAIN DEV-JPN, V10, P371, DOI 10.1016/S0387-7604(88)80095-0; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; FERGUSSON DM, 1991, J CHILD PSYCHOL PSYC, V32, P257, DOI 10.1111/j.1469-7610.1991.tb00305.x; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Goodman SH, 1997, J ABNORM PSYCHOL, V106, P3, DOI 10.1037/0021-843X.106.1.3; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hessen E, 2006, SCAND J PSYCHOL, V47, P245, DOI 10.1111/j.1467-9450.2006.00514.x; Horowitz I, 1983, Int Rehabil Med, V5, P32; Jacobs R, 2007, CORTEX, V43, P792, DOI 10.1016/S0010-9452(08)70507-0; JORDAN F M, 1992, Brain Injury, V6, P39, DOI 10.3109/02699059209008120; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MICHAUD LJ, 1993, ARCH PHYS MED REHAB, V74, P368; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; TOMPKINS CA, 1990, BRAIN COGNITION, V13, P86, DOI 10.1016/0278-2626(90)90042-M	35	72	72	1	14	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1862	1365-2214		CHILD CARE HLTH DEV	Child Care Health Dev.	JAN	2010	36	1					22	30		10.1111/j.1365-2214.2009.00947.x			9	Psychology, Developmental; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Pediatrics	536BF	WOS:000273016400003	19250251				2022-02-06	
J	Heile, AMB; Wallrapp, C; Klinge, PM; Samii, A; Kassem, M; Silverberg, G; Brinker, T				Heile, Anna M. B.; Wallrapp, Christine; Klinge, Petra M.; Samii, Amir; Kassem, Moustapha; Silverberg, Gerald; Brinker, Thomas			Cerebral transplantation of encapsulated mesenchymal stem cells improves cellular pathology after experimental traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						Brain injury; Human mesenchymal stem cells; Cell encapsulation; Cell transplantation	GLUCAGON-LIKE PEPTIDE-1; MARROW STROMAL CELLS; HIPPOCAMPAL-NEURONS; PARKINSONS-DISEASE; EXPRESSION; RECEPTOR; THERAPY; STROKE; RAT; NEUROPROTECTION	Purpose: "Naked" human mesenchymal stem cells (MSC)are neuro-protective in experimental brain injury (TBI). In a controlled cortical impact (CCI) rat model, we investigated whether encapsulated MSC (eMSC) act similarly, and whether efficacy is augmented using cells transfected to produce the neuro-protective substance glucagon-like peptide-1 (GLP-1). Methods: Thirty two Sprague-Dawley rats were randomized to five groups: controls (no CCI), CCI-only, CCI + eMSC, CCI + GLP-1 eMSC, and CCI + empty capsules. On day 14, cisternal cerebro-spinal fluid (CSF) was sampled for measurement of GLP-1 concentration. Brains were immuno-histochemically assessed using specific antibody staining for NeuN, MAP-2 and GFAR In another nine healthy rats, in vitro Results: GLP-1 production rates were measured from cells explanted after 2, 7 and 14 days. GLP-1 production rate in transfected cells, before implantation, was 7.03 fmol/capsule/h. Cells were still secreting GLP-1 at a rate of 3.68 +/- 0.49, 2.85 +/- 0.45 and 3.53 +/- 0.55 after 2, 7 and 14 days, respectively. In both of the stem cell treated CCI groups, hippocampal cell loss was reduced, along with an attenuation of cortical neuronal and glial abnormalities, as measured by MAP-2 and GFAP expression. The effects were more pronounced in animals treated with GLP-1 secreting eMSC. This group displayed an increased CSF level of GLP-1 (17.3 +/- 3.4 pM). Conclusions: Hippocampal neuronal cell loss, and cortical glial and neuronal cyto-skeletal abnormalities, after CCI are reduced following transplantation of encapsulated eMSC. These effects were augmented by GLP-1 transfected eMSC. (C) 2009 Elsevier Ireland Ltd. All rights reserved.	[Heile, Anna M. B.; Klinge, Petra M.; Samii, Amir; Brinker, Thomas] Int Neurosci Inst GmbH, D-30625 Hannover, Germany; [Wallrapp, Christine] CellMed AG, D-63755 Alzenau, Germany; [Kassem, Moustapha] Odense Univ Hosp, Dept Endocrinol & Metab, DK-5000 Odense, Denmark; [Silverberg, Gerald] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci, Providence, RI 02912 USA		Brinker, T (corresponding author), Int Neurosci Inst GmbH, Rudolf Pichlmayr Str 4, D-30625 Hannover, Germany.	thbrinker@gmail.com	Kassem, Moustapha/J-7688-2013; Kassem, Moustapha/O-3819-2019	Kassem, Moustapha/0000-0003-1557-0869; Kassem, Moustapha/0000-0003-1557-0869	German Federal Ministry of Education and ResearchFederal Ministry of Education & Research (BMBF); Neurobionics Foundation, Hannover, Germany; Saunders Family Fund at the Neurosurgical Foundation; Warren Alpert Medical School, Brown University, R.I., U.S.A.	This study was supported by the German Federal Ministry of Education and Research; the Neurobionics Foundation, Hannover, Germany; and the Saunders Family Fund at the Neurosurgical Foundation, the Warren Alpert Medical School, Brown University, R.I., U.S.A.	Beak SA, 1998, J CLIN INVEST, V101, P1334, DOI 10.1172/JCI610; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bliss T, 2007, STROKE, V38, P817, DOI 10.1161/01.STR.0000247888.25985.62; Boockvar JA, 2005, NEUROSURGERY, V56, P163, DOI 10.1227/01.NEU.0000145866.25433.FF; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Brandt C, 2004, EPILEPSY RES, V62, P135, DOI 10.1016/j.eplepsyres.2004.08.008; CAMPOS RV, 1994, ENDOCRINOLOGY, V134, P2156, DOI 10.1210/en.134.5.2156; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chowen JA, 1999, NEUROPEPTIDES, V33, P212, DOI 10.1054/npep.1999.0757; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drucker DJ, 2002, GUT, V50, P428, DOI 10.1136/gut.50.3.428; During MJ, 2003, NAT MED, V9, P1173, DOI 10.1038/nm919; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gilman CP, 2003, J NEUROCHEM, V87, P1137, DOI 10.1046/j.1471-4159.2003.02073.x; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Holst JJ, 2006, DIABETOLOGIA, V49, P253, DOI 10.1007/s00125-005-0107-1; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lindvall O, 2008, EXP NEUROL, V209, P82, DOI 10.1016/j.expneurol.2007.08.019; Longhi L, 2005, TRANSPL IMMUNOL, V15, P143, DOI 10.1016/j.trim.2005.09.003; Murua A, 2008, J CONTROL RELEASE, V132, P76, DOI 10.1016/j.jconrel.2008.08.010; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2002, J PHARMACOL EXP THER, V300, P958, DOI 10.1124/jpet.300.3.958; Sarnowska A, 2009, EXP NEUROL, V215, P317, DOI 10.1016/j.expneurol.2008.10.023; Savitz SI, 2009, STROKE, V40, pS141, DOI 10.1161/STROKEAHA.108.535864; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Tseng J L, 2000, Prog Brain Res, V127, P189	29	72	74	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	OCT 9	2009	463	3					176	181		10.1016/j.neulet.2009.07.071			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	496JT	WOS:000269968200003	19638295				2022-02-06	
J	Gao, X; Enikolopov, G; Chen, JH				Gao, Xiang; Enikolopov, Grigori; Chen, Jinhui			Moderate traumatic brain injury promotes proliferation of quiescent neural progenitors in the adult hippocampus	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Neural stem/progenitor; Proliferation; Transgenic mice	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; STEM-CELLS; NEURONAL DIFFERENTIATION; INTERMEDIATE PROGENITORS; COGNITIVE DEFICITS; MOUSE HIPPOCAMPUS; GRANULE CELLS; NEUROGENESIS	Recent evidence shows that traumatic brain injury (TBI) regulates proliferation of neural stem/progenitor cells in the dentate gyrus (DG) of adult hippocampus. There are distinct classes of neural stem/progenitor cells in the adult DG, including quiescent neural progenitors (QNPs), which carry stem cell properties, and their progeny, amplifying neural progenitors (ANPs). The response of each class of progenitors to TBI is not clear. We here used a transgenic reporter Nestin-GFP mouse line, in which QNP and ANP cells are easily visualized and quantified, to determine the targets of the TBI in the DG. We examined changes in proliferation of QNPs and ANPs in the acute phase following TBI and found that QNPs were induced by TBI insult to enter the cell cycle whereas proliferation of ANPs was not significantly affected. These results indicate that different subtypes of neural stem/progenitor cells respond differently to TBI insult. Stem cell activation by the TBI may reflect the induction of innate repair and plasticity mechanisms by the injured brain. (C) 2009 Elsevier Inc. All rights reserved.	[Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA; [Gao, Xiang; Chen, Jinhui] Indiana Univ, Sch Med, Stark Neurosci Res Inst, Spinal Cord & Brain Injury Res Grp, Indianapolis, IN 46202 USA; [Chen, Jinhui] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40236 USA; [Enikolopov, Grigori] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA		Chen, JH (corresponding author), 950 W Walnut St, Indianapolis, IN 46202 USA.	chen204@iupui.edu	Enikolopov, Grigori/P-5731-2019; Chen, Jinhui/A-7138-2009	Enikolopov, Grigori/0000-0001-8178-8917; Chen, Jinhui/0000-0002-6864-7121	Indiana University School of Medicine; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS072631, R21NS075733] Funding Source: NIH RePORTER	This work was supported by a startup funding to J. Chen from Indiana University School of Medicine.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Chua HC, 2001, ANN ACAD MED SINGAP, V30, P134; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; Encinas JM, 2008, EXP NEUROL, V210, P274, DOI 10.1016/j.expneurol.2007.10.021; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Encinas JM, 2008, METHOD CELL BIOL, V85, P243, DOI 10.1016/S0091-679X(08)85011-X; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Filippov V, 2003, MOL CELL NEUROSCI, V23, P373, DOI 10.1016/S1044-7431(03)00060-5; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAO X, J NEUROTRAU IN PRESS; Gao X, 2008, J NEUROTRAUM, V25, P985, DOI 10.1089/neu.2008.0460; Gao X, 2008, J NEUROSCI RES, V86, P2258, DOI 10.1002/jnr.21677; Gao X, 2009, EXP NEUROL, V215, P178, DOI 10.1016/j.expneurol.2008.10.009; Gupta Y K, 2006, Indian J Physiol Pharmacol, V50, P7; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Isoniemi H, 2006, NEUROLOGY, V67, P756, DOI 10.1212/01.wnl.0000234140.64954.12; Kelly Kevin M, 2004, Epilepsy Curr, V4, P160, DOI 10.1111/j.1535-7597.2004.44015.x; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Kronenberg G, 2003, J COMP NEUROL, V467, P455, DOI 10.1002/cne.10945; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Mignone JL, 2004, J COMP NEUROL, V469, P311, DOI 10.1002/cne.10964; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Prigatano GP, 2005, ACT NEUR S, V93, P39; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Salmond CH, 2005, CURR OPIN CRIT CARE, V11, P111, DOI 10.1097/01.ccx.0000155358.31983.37; Sandhir R, 2008, EXP NEUROL, V213, P372, DOI 10.1016/j.expneurol.2008.06.013; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Seaberg RM, 2002, J NEUROSCI, V22, P1784, DOI 10.1523/JNEUROSCI.22-05-01784.2002; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shapiro LA, 2005, BRAIN RES REV, V48, P43, DOI 10.1016/j.brainresrev.2004.08.003; Statler KD, 2006, DEV NEUROSCI-BASEL, V28, P354, DOI 10.1159/000094162; Stiles J, 2005, TRENDS COGN SCI, V9, P136, DOI 10.1016/j.tics.2005.01.002; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun D, 2005, J NEUROTRAUM, V22, P95, DOI 10.1089/neu.2005.22.95; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Tran LD, 2006, J NEUROTRAUM, V23, P1330, DOI 10.1089/neu.2006.23.1330; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; YAVUZ BB, 2006, INT PSYCHOGERIATR, P1; Yoon KJ, 2008, NEURON, V58, P519, DOI 10.1016/j.neuron.2008.03.018; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang TY, 2007, PSYCHOPHARMACOLOGY, V191, P171, DOI 10.1007/s00213-006-0548-3; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	63	72	79	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2009	219	2					516	523		10.1016/j.expneurol.2009.07.007			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	498QN	WOS:000270157300017	19615997	Green Accepted			2022-02-06	
J	Manesh, KM; Halamek, J; Pita, M; Zhou, J; Tam, TK; Santhosh, P; Chuang, MC; Windmiller, JR; Abidin, D; Katz, E; Wang, J				Manesh, Kalayil Manian; Halamek, Jan; Pita, Marcos; Zhou, Jian; Tam, Tsz Kin; Santhosh, Padmanabhan; Chuang, Min-Chieh; Windmiller, Joshua R.; Abidin, Dewi; Katz, Evgeny; Wang, Joseph			Enzyme logic gates for the digital analysis of physiological level upon injury	BIOSENSORS & BIOELECTRONICS			English	Article						Enzyme logic; Biomarker; Injury; Digital sensor; Optical biosensor; Amperometric biosensor	BIOCHEMICAL LOGIC; HEMORRHAGIC-SHOCK; BRAIN-INJURY; REAL-TIME; NOREPINEPHRINE; DIAGNOSTICS; OPERATIONS; BIOSENSORS; LACTATE; SYSTEM	A biocomputing system composed of a combination of AND/IDENTITY logic gates based on the concerted operation of three enzymes: lactate oxidase, horseradish peroxidase and glucose dehydrogenase was designed to process biochemical information related to pathophysiological conditions originating from various injuries. Three biochemical markers: lactate, norepinephrine and glucose were applied as input signals to activate the enzyme logic system. Physiologically normal concentrations of the markers were selected as logic 0 values of the input signals, while their abnormally increased concentrations, indicative of various injury conditions were defined as logic 1 input. Biochemical processing of different patterns of the biomarkers resulted in the formation of norepi-quinone and NADH defined as the output signals. Optical and electrochemical means were used to follow the formation of the output signals for eight different combinations of three input signals. The enzymatically processed biochemical information presented in the form of a logic truth table allowed distinguishing the difference between normal physiological conditions, pathophysiological conditions corresponding to traumatic brain injury and hemorrhagic shock, and abnormal situations (not corresponding to injury). The developed system represents a biocomputing logic system applied for the analysis of biomedical conditions related to various injuries. We anticipate that such biochemical logic gates will facilitate decision-making in connection to an integrated therapeutic feedback-loop system and hence will revolutionize the monitoring and treatment of injured civilians and soldiers. (C) 2009 Elsevier B.V. All rights reserved.	[Halamek, Jan; Pita, Marcos; Zhou, Jian; Tam, Tsz Kin; Katz, Evgeny] Clarkson Univ, Dept Chem & Biomol Sci, Potsdam, NY 13699 USA; [Manesh, Kalayil Manian; Santhosh, Padmanabhan; Chuang, Min-Chieh; Windmiller, Joshua R.; Abidin, Dewi; Wang, Joseph] Univ Calif San Diego, Dept Nanoengn, La Jolla, CA 92093 USA		Katz, E (corresponding author), Clarkson Univ, Dept Chem & Biomol Sci, 8 Clarkson Ave, Potsdam, NY 13699 USA.	ekatz@clarkson.edu; josephwang@ucsd.edu	Pita, Marcos/F-3547-2015; Pita, Marcos/AAB-9772-2020; Wang, Joseph/C-6175-2011; Tam, Tsz Kin/F-9794-2011; Manesh, KM/A-6877-2010; Padmanabhan, Santhosh/A-6930-2009	Pita, Marcos/0000-0002-6714-3669; Pita, Marcos/0000-0002-6714-3669; Padmanabhan, Santhosh/0000-0003-2418-5284	Office of Naval Research (ONR)Office of Naval Research [N00014-08-1-1202]	This work was supported by Office of Naval Research (ONR Award #N00014-08-1-1202).	ALTURA BM, 1983, HDB SHOCK TRAUMA; Amir L, 2009, J AM CHEM SOC, V131, P826, DOI 10.1021/ja8076704; Astaras A, 2008, HIPPOKRATIA, V12, P10; Baker SP, 1992, THE INJURY FACT BOOK, VSecond; Baron R, 2006, ANGEW CHEM INT EDIT, V45, P1572, DOI 10.1002/anie.200503314; Credi A, 2007, ANGEW CHEM INT EDIT, V46, P5472, DOI 10.1002/anie.200700879; Curreli M, 2008, IEEE T NANOTECHNOL, V7, P651, DOI 10.1109/TNANO.2008.2006165; de Silva AP, 2007, NAT NANOTECHNOL, V2, P399, DOI 10.1038/nnano.2007.188; Feliciano DV, 2007, TRAUMA; Kline JA, 1997, J MOL CELL CARDIOL, V29, P2465, DOI 10.1006/jmcc.1997.0483; LeonCarrion J, 2006, STUD NEUROPSYCH DEV, P1; Mascini M, 2008, BIOMARKERS, V13, P637, DOI [10.1080/13547500802645905, 10.1080/13547500802645905 ]; Pita M, 2009, SENSOR ACTUAT B-CHEM, V139, P631, DOI 10.1016/j.snb.2009.03.001; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; Privman V, 2008, J PHYS CHEM B, V112, P11777, DOI 10.1021/jp802673q; ROSENBERG J, 1961, ANN SURG, V154, P611, DOI 10.1097/00000658-196110000-00011; Shao XG, 2002, PROG CHEM, V14, P37; Simpson ML, 2001, TRENDS BIOTECHNOL, V19, P317, DOI 10.1016/S0167-7799(01)01691-2; Sivan S, 2003, BIOSYSTEMS, V70, P21, DOI 10.1016/S0303-2647(03)00039-X; Stojanovic MN, 2005, BIOELECTRONICS: FROM THEORY TO APPLICATIONS, P427, DOI 10.1002/352760376X.ch14; Strack G, 2008, CHEMBIOCHEM, V9, P1260, DOI 10.1002/cbic.200700762; Strack G, 2008, J AM CHEM SOC, V130, P4234, DOI 10.1021/ja7114713; Tokarev I, 2009, ACS APPL MATER INTER, V1, P532, DOI 10.1021/am800251a; Tomizaki KY, 2007, J AM CHEM SOC, V129, P8345, DOI 10.1021/ja0703067; Unger R, 2006, PROTEINS, V63, P53, DOI 10.1002/prot.20886; Wang J, 2006, BIOSENS BIOELECTRON, V21, P1887, DOI 10.1016/j.bios.2005.10.027; Zhou J, 2009, ACS APPL MATER INTER, V1, P144, DOI 10.1021/am800088d; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	28	72	72	1	38	ELSEVIER ADVANCED TECHNOLOGY	OXFORD	OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0956-5663			BIOSENS BIOELECTRON	Biosens. Bioelectron.	AUG 15	2009	24	12					3569	3574		10.1016/j.bios.2009.05.019			6	Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical; Electrochemistry; Nanoscience & Nanotechnology	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Biotechnology & Applied Microbiology; Chemistry; Electrochemistry; Science & Technology - Other Topics	487MI	WOS:000269278300027	19523809				2022-02-06	
J	Kerwin, AJ; Schinco, MA; Tepas, JJ; Renfro, WH; Vitarbo, EA; Muehlberger, M				Kerwin, Andrew J.; Schinco, Miren A.; Tepas, Joseph J., III; Renfro, William H.; Vitarbo, Elizabeth A.; Muehlberger, Michael			The Use of 23.4% Hypertonic Saline for the Management of Elevated Intracranial Pressure in Patients With Severe Traumatic Brain Injury: A Pilot Study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	66th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 27-29, 2007	Las Vegas, NV	Amer Assoc Surg Trauma		Hypertonic saline; Severe traumatic brain injury; Intracranial pressure; Mannitol	CEREBRAL OXYGEN DELIVERY; HEAD-INJURY; FLUID RESUSCITATION; HYPERTENSION; MANNITOL; EPIDEMIOLOGY; REDUCTION; HEMORRHAGE; DEXTRAN; UREA	Background: Oncotic agents are a therapeutic mainstay for the management of intracranial hypertension. Both mannitol and varied concentrations of hypertonic saline (HTS) have been shown to be effective at reducing elevated intracranial pressure (ICP). We compared the safety and efficacy of 23.4% HTS to mannitol for acute management of elevated ICP after traumatic brain injury (TBI). Methods: After approval from our institutional review board, the records of patients admitted with severe TBI who received mannitol or HTS were reviewed. Demographic and physiologic data were recorded. ICP, cerebral perfusion pressure, reduction of ICP after dose administration, serum sodium, osmolality, and magnitude of dose response during the subsequent 60 minutes were analyzed. Efficacy was determined by comparison of proportion of patients with any response and mean change in ICP after dosing with either agent. Safety was determined by recording any new postinfusion electrolyte or neurologic anomalies. Data were compared using chi(2) test, accepting p < 0.05 as significant. Results: Twenty-two patients with severe TBI received 210 doses of either mannitol or HTS. All patients suffered severe blunt injury (mean Injury Severity Score 28 +/- 11). HTS patients had a significantly higher ICP at the initiation of therapy than that of mannitol group (30.7 +/- 7.94 mm Hg vs. 28.3 +/- 8.07 mm Hg, respectively). There was no difference in initial cerebral perfusion pressure. Mean ICP reduction in the hour after administration of 102 doses of mannitol and 108 doses of HTS was greater for patients receiving HTS (9.3 +/- 7.37 mm Hg vs. 6.4 +/- 6.57 mm Hg, respectively; p = 0.0028, chi(2)). More patients responded to HTS (92.6% HTS vs. 74% mannitol; p = 0.0002, chi(2)). There was no significant difference between groups in the duration of ICP reduction after dose administration (4.1 hours vs. 3.8 hours, respectively). No adverse events after administration of either agent were identified. Conclusion: Based on this retrospective analysis, 23.4% HTS is more efficacious than mannitol in reducing ICP. If these results are confirmed in a prospective, randomized study, 23.4% HTS may become the agent of choice for the management of elevated ICP after TBI.	[Kerwin, Andrew J.; Schinco, Miren A.; Tepas, Joseph J., III; Muehlberger, Michael] Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA; [Vitarbo, Elizabeth A.] Univ Florida, Hlth Sci Ctr, Dept Neurosurg, Jacksonville, FL 32209 USA; [Renfro, William H.] Univ Florida, Shands Jacksonville Med Ctr, Dept Pharm, Jacksonville, FL 32209 USA		Kerwin, AJ (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 655 W 8th St, Jacksonville, FL 32209 USA.	andy.kerwin@jax.ufl.edu					BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; *BRAIN TRAUM FDN I, 2000, MAN PROGN SEV TRAUM; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Ciesla DJ, 2001, SURGERY, V129, P567, DOI 10.1067/msy.2001.113286; Coimbra R, 2005, J TRAUMA, V59, P257, DOI 10.1097/01.ta.0000174678.12523.9f; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; DeWitt DS, 1996, CRIT CARE MED, V24, P109, DOI 10.1097/00003246-199601000-00019; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Fremont-Smith F, 1927, ARCH NEURO PSYCHIATR, V18, P550, DOI 10.1001/archneurpsyc.1927.02210040057002; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Hughes J, 1938, ARCH NEURO PSYCHIATR, V39, P1277, DOI 10.1001/archneurpsyc.1938.02270060167009; JAVID M, 1956, JAMA-J AM MED ASSOC, V160, P943, DOI 10.1001/jama.1956.02960460021006; JAVID M, 1961, J NEUROSURG, V18, P51, DOI 10.3171/jns.1961.18.1.0051; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kolsen-Petersen JA, 2004, ACTA ANAESTH SCAND, V48, P667, DOI 10.1111/j.1399-6576.2004.00396.x; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Munar F, 2000, J NEUROTRAUM, V17, P41, DOI 10.1089/neu.2000.17.41; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Rangel-Castillo L, 2006, CRIT CARE CLIN, V22, P713, DOI 10.1016/j.ccc.2006.06.003; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; SHENKIN HA, 1962, J NEUROSURG, V19, P897, DOI 10.3171/jns.1962.19.10.0897; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TODD MM, 1985, J NEUROSURG, V63, P944, DOI 10.3171/jns.1985.63.6.0944; TOKYAY R, 1992, J TRAUMA, V32, P704, DOI 10.1097/00005373-199206000-00006; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Weed LH, 1919, AM J PHYSIOL, V48, P531, DOI 10.1152/ajplegacy.1919.48.4.531; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Zausinger S, 2004, NEUROSURGERY, V55, P679, DOI 10.1227/01.NEU.0000134558.28977.EE	42	72	77	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2					277	282		10.1097/TA.0b013e3181acc726			6	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	482OL	WOS:000268898500013	19667879				2022-02-06	
J	Bombardier, CH; Bell, KR; Temkin, NR; Fann, JR; Hoffman, J; Dikmen, S				Bombardier, Charles H.; Bell, Kathleen R.; Temkin, Nancy R.; Fann, Jesse R.; Hoffman, Jeanne; Dikmen, Sureyya			The Efficacy of a Scheduled Telephone Intervention for Ameliorating Depressive Symptoms During the First Year After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						depression; motivational interviewing; problem solving; telephone intervention	RANDOMIZED CONTROLLED-TRIAL; HEAD-INJURY; PSYCHIATRIC-DISORDERS; BEHAVIORAL TREATMENT; CARE MANAGEMENT; MILD; MODERATE; PSYCHOTHERAPY; INDIVIDUALS; IMPAIRMENT	Objective: To determine whether an designed to improve functioning after traumatic brain injury (TBI) also ameliorates depressive symptoms. Design: Single-blinded, randomized controlled trial comparing a scheduled telephone intervention to usual care. Participants: One hundred seventy-one persons with TBI discharged from an inpatient rehabilitation unit. Methods: The treatment group received up to 7 scheduled telephone sessions over 9 months designed to elicit current concerns, provide information, and facilitate problem solving in domains relevant to TBI recovery. Outcome Measures: Brief Symptom Inventory-Depression (BSI-D) subscale, Neurobehavioral Functioning Inventory-Depression subscale, and Mental Health Index-5 from the Short-Form-36 Health Survey. Results: Baseline BSI-D subscale and outcome data were available on 126 (74%) participants. Randomization was effective except for greater severity of depressive symptoms in the usual care (control) group at baseline. Outcome analyses were adjusted for these differences. Overall, control participants developed greater depressive symptom severity from baseline to 1 year than did the treatment group. The treated group reported significantly lower depression symptom severity on all outcome measures. For those more depressed at baseline, the treated group demonstrated greater improvement in symptoms than did the controls. Conclusions: Telephone-based interventions using problem-solving and behavioral activation approaches may be effective in ameliorating depressive symptoms following TBI. Proactive telephone calls, motivational interviewing, and including significant others in the intervention may have contributed to its effectiveness.	[Bombardier, Charles H.] Univ Washington, Sch Med, Dept Rehabil Med, Harborview Med Ctr, Seattle, WA 98104 USA; [Temkin, Nancy R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Sch Med, Dept Biostat, Seattle, WA 98104 USA; [Fann, Jesse R.; Dikmen, Sureyya] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98104 USA		Bombardier, CH (corresponding author), Univ Washington, Sch Med, Dept Rehabil Med, Harborview Med Ctr, Box 359740,325 9th Ave, Seattle, WA 98104 USA.	chb@u.washington.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Bell, Kathleen/0000-0002-0928-2046	National Institute on Disability and Rehabilitation Research [H133A020508]	This research was supported by the National Institute on Disability and Rehabilitation Research, grant number H133A020508, Traumatic Brain Injuly Model Systems. The authors express their gratitude to Jason Barber, MS, for his assistance with data analysis and to the Issue Editor Dr Tessa Hartfor her expert guidance.	Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bell KR, 2004, J HEAD TRAUMA REHAB, V19, P502, DOI 10.1097/00001199-200411000-00007; BERWICK DM, 1991, MED CARE, V29, P169, DOI 10.1097/00005650-199102000-00008; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Ciechanowski P, 2004, JAMA-J AM MED ASSOC, V291, P1569, DOI 10.1001/jama.291.13.1569; Cuijpers P, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-36; Derogatis L. R., 1994, SCL 90 R ADM SCORING, VThird; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; Fann JR, 2003, PSYCHOSOMATICS, V44, P161; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; Hart T, 2008, NEUROPSYCHOL REHABIL, V18, P1, DOI 10.1080/09602010601082359; Hettema J, 2005, ANNU REV CLIN PSYCHO, V1, P91, DOI 10.1146/annurev.clinpsy.1.102803.143833; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Jakupcak M, 2006, J TRAUMA STRESS, V19, P387, DOI 10.1002/jts.20125; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; Miller WR, 1991, MOTIVATIONAL INTERVI; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; Mohr DC, 2000, J CONSULT CLIN PSYCH, V68, P356, DOI 10.1037//0022-006X.68.2.356; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; NEZU AM, 1986, J CONSULT CLIN PSYCH, V54, P196, DOI 10.1037/0022-006X.54.2.196; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2006, AM J GERIAT PSYCHIAT, V14, P456, DOI 10.1097/01.JGP.0000199339.79689.8a; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Strong V, 2008, LANCET, V372, P40, DOI 10.1016/S0140-6736(08)60991-5; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teri L, 1997, J GERONTOL B-PSYCHOL, V52, pP159, DOI 10.1093/geronb/52B.4.P159; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836	48	72	72	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2009	24	4					230	238		10.1097/HTR.0b013e3181ad65f0			9	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	506SK	WOS:000270796000002	19625862				2022-02-06	
J	Kilbride, RD; Costello, DJ; Chiappa, KH				Kilbride, Ronan D.; Costello, Daniel J.; Chiappa, Keith H.			How Seizure Detection by Continuous Electroencephalographic Monitoring Affects the Prescribing of Antiepileptic Medications	ARCHIVES OF NEUROLOGY			English	Article							NONCONVULSIVE STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; INTRACEREBRAL HEMORRHAGE; ELECTROGRAPHIC SEIZURES; MORTALITY; DAMAGE	Objectives: To assess the effect of continuous electroencephalographic monitoring on the decision to treat seizures in the inpatient setting, particularly in the intensive care unit. Design: Retrospective cohort study. Setting: Medical and neuroscience intensive care units and neurological wards. Patients: Three hundred consecutive nonelective continuous electroencephalographic monitoring studies, performed on 287 individual inpatients over a 27-month period. Main Outcome Measures: Epileptiform electroencephalographic abnormalities and changes in antiepileptic drug (AED) therapy based on the electroencephalographic findings. Results: The findings from the continuous electroencephalographic monitoring led to a change in AED prescribing in 52% of all studies with initiation of an AED therapy in 14%, modification of AED therapy in 33%, and discontinuation of AED therapy in 5% of all studies. Specifically, the detection of electrographic seizures led to a change in AED therapy in 28% of all studies. Conclusions: The findings of continuous electroencephalographic monitoring resulted in a change in AED prescribing during or after half of the studies performed. Most AED changes were made as a result of the detection of electrographic seizures. Arch Neurol. 2009;66(6):723-728	[Kilbride, Ronan D.] Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Clin Neurophysiol Serv, Boston, MA 02114 USA		Kilbride, RD (corresponding author), Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, ACC 7,15 Parkman St, Boston, MA 02114 USA.	rkilbride@partners.org		Costello, Daniel/0000-0001-6023-8246			Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DeLorenzo RJ, 1999, EPILEPSIA, V40, P164, DOI 10.1111/j.1528-1157.1999.tb02070.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Drislane FW, 1999, J CLIN NEUROPHYSIOL, V16, P323, DOI 10.1097/00004691-199907000-00004; Fountain NB, 2007, NEUROLOGY, V69, P1312, DOI 10.1212/01.wnl.0000285495.12791.62; Fountain NB, 2000, EPILEPSIA, V41, pS23, DOI 10.1111/j.1528-1157.2000.tb01521.x; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Jordan KG, 2006, EPILEPSIA, V47, P2211; Knake S, 2006, EPILEPSIA, V47, P2020, DOI 10.1111/j.1528-1167.2006.00845.x; Kull LL, 2005, J CLIN NEUROPHYSIOL, V22, P107, DOI 10.1097/01.WNP.0000158361.24544.2D; Rossetti AO, 2007, NEUROLOGY, V69, P255, DOI 10.1212/01.wnl.0000265819.36639.e0; Sutula TP, 2003, CURR OPIN NEUROL, V16, P189, DOI 10.1097/00019052-200304000-00012; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; Wittman JJ, 2005, NEUROCRIT CARE, V2, P330, DOI 10.1385/NCC:2:3:330; Young GB, 1996, NEUROLOGY, V47, P83	21	72	74	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JUN	2009	66	6					723	728		10.1001/archneurol.2009.100			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	455OQ	WOS:000266772200005	19506131	Bronze			2022-02-06	
J	Kim, YH; Yoo, WK; Ko, MH; Park, CH; Kim, ST; Na, DL				Kim, Yun-Hee; Yoo, Woo-Kyoung; Ko, Myoung-Hwan; Park, Chang-hyun; Kim, Sung Tae; Na, Duk L.			Plasticity of the Attentional Network After Brain Injury and Cognitive Rehabilitation	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						Traumatic brain injury; Cognitive training; Plasticity; Attentional network; Functional MRI	VISUAL-ATTENTION; SPATIAL ATTENTION; ANTERIOR CINGULATE; FUNCTIONAL-ANATOMY; CORTICAL NETWORK; PARAMETRIC FMRI; NEURAL-NETWORKS; ACTIVATION; DEFICITS; MILD	Background. This study aimed to delineate the cerebral attentional network in patients with traumatic brain injury (TBI) and assess for adaptations in this network in response to a rehabilitation intervention. Methods. Seventeen patients with TBI and 15 healthy subjects underwent functional magnetic resonance imaging (fMRI) using a visuospatial attention task. Ten TBI patients who successfully completed attentional training had a follow-up fMRI. Results. In the TBI patients, fMRI analysis showed more activation in the frontal and temporoparietal lobes, as well as less activation in the anterior cingulated gyrus, SMA, and temporooccipital regions compared to the healthy subjects. Following cognitive training, the TBI patients improved performance of attention tasks accompanied by changes in attentional network activation; the activity of the frontal lobe decreased, whereas activation of the anterior cingulate cortices and precuneus increased. Conclusions. These findings demonstrate the plasticity and training induced redistribution of the visuospatial attentional network in TBI patients.	[Kim, Yun-Hee; Park, Chang-hyun] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Phys Med & Rehabil,Div Neurorehabil,Stroke &, Seoul 135710, South Korea; [Kim, Sung Tae] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Ctr Imaging Sci,Dept Radiol, Seoul 135710, South Korea; [Na, Duk L.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul 135710, South Korea; [Yoo, Woo-Kyoung] Hallym Univ, Sacred Heart Hosp, Dept Phys & Rehabil Med, Anyang, South Korea; [Ko, Myoung-Hwan] Chonbuk Natl Univ, Sch Med, Res Inst Clin Med, Dept Phys Med & Rehabil, Jeonju, South Korea; [Park, Chang-hyun] Korea Adv Inst Sci & Technol, Dept Phys, Taejon 305701, South Korea		Kim, YH (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Phys Med & Rehabil,Div Neurorehabil,Stroke &, 50 Irwon Dong, Seoul 135710, South Korea.	yunkim@skku.edu	Na, Duk Lyul/C-9598-2011; Yoo, Woo-Kyoung/B-6356-2013; Kim, Yun Hee/F-4600-2014; Park, Chang-hyun/I-2217-2016	Yoo, Woo-Kyoung/0000-0002-1273-0647; Ko, Myoung-Hwan/0000-0002-0566-3677	Korean government (MOST)Ministry of Science and Technology (MOST) KoreaKorean Government [M10644000022-06N440002210]; Korean Health 21 RD Project [A0550079]	This study was supported by a KOSEF grant funded by the Korean government (MOST; Number M10644000022-06N440002210) and a grant of the Korean Health 21 R&D Project (A0550079).	Arrington CM, 2000, J COGNITIVE NEUROSCI, V12, P106, DOI 10.1162/089892900563975; Aston-Jones G, 2005, ANNU REV NEUROSCI, V28, P403, DOI 10.1146/annurev.neuro.28.061604.135709; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Beauchamp MS, 2001, NEUROIMAGE, V14, P310, DOI 10.1006/nimg.2001.0788; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Buckner RL, 1998, P NATL ACAD SCI USA, V95, P891, DOI 10.1073/pnas.95.3.891; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen AJW, 2006, J HEAD TRAUMA REHAB, V21, P107, DOI 10.1097/00001199-200603000-00004; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; COHEN JD, 1992, AM J PSYCHOL, V105, P239, DOI 10.2307/1423029; Corbetta M, 2002, J COGNITIVE NEUROSCI, V14, P508, DOI 10.1162/089892902317362029; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; CORBETTA M, 1993, J NEUROSCI, V13, P1202; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; Donovan NJ, 2008, NEUROREHAB NEURAL RE, V22, P122, DOI 10.1177/1545968307306239; Downar J, 2000, NAT NEUROSCI, V3, P277, DOI 10.1038/72991; Fletcher PC, 1996, BRAIN, V119, P1587, DOI 10.1093/brain/119.5.1587; Gerardin E, 2000, CEREB CORTEX, V10, P1093, DOI 10.1093/cercor/10.11.1093; Ghajar J, 2008, NEUROREHAB NEURAL RE, V22, P217, DOI 10.1177/1545968308315600; Gitelman DR, 1999, BRAIN, V122, P1093, DOI 10.1093/brain/122.6.1093; Goldstein RZ, 2007, NEUROIMAGE, V35, P194, DOI 10.1016/j.neuroimage.2006.12.004; Habekost T, 2003, NEUROPSYCHOLOGIA, V41, P1171, DOI 10.1016/S0028-3932(03)00018-6; Habekost T, 2007, NEUROPSYCHOLOGIA, V45, P1474, DOI 10.1016/j.neuropsychologia.2006.11.006; Hahn B, 2006, NEUROIMAGE, V32, P842, DOI 10.1016/j.neuroimage.2006.04.177; Hillis AE, 2005, J NEUROSCI, V25, P3161, DOI 10.1523/JNEUROSCI.4468-04.2005; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim YH, 1999, NEUROIMAGE, V9, P269, DOI 10.1006/nimg.1999.0408; Kincade JM, 2005, J NEUROSCI, V25, P4593, DOI 10.1523/JNEUROSCI.0236-05.2005; Kircher TTJ, 2000, COGNITIVE BRAIN RES, V10, P133, DOI 10.1016/S0926-6410(00)00036-7; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Marois R, 2000, NEURON, V25, P717, DOI 10.1016/S0896-6273(00)81073-9; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; Michel J A, 2006, Eura Medicophys, V42, P59; Milham MP, 2003, NEUROIMAGE, V18, P483, DOI 10.1016/S1053-8119(02)00050-2; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Nobre AC, 1997, BRAIN, V120, P515, DOI 10.1093/brain/120.3.515; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Robertson IH, 1999, PSYCHOL BULL, V125, P544, DOI 10.1037/0033-2909.125.5.544; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Tomasi D, 2004, NEUROIMAGE, V23, P1414, DOI 10.1016/j.neuroimage.2004.07.065; Weissman DH, 2002, NEUROIMAGE, V17, P1266, DOI 10.1006/nimg.2002.1284	55	72	73	1	19	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	JUN	2009	23	5					468	477		10.1177/1545968308328728			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	450JP	WOS:000266397100008	19118131				2022-02-06	
J	Kellinghaus, C; Berning, S; Besselmann, M				Kellinghaus, Christoph; Berning, Sascha; Besselmann, Michael			Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy	EPILEPSY & BEHAVIOR			English	Article						Nonconvulsive status epilepticus; Anticonvulsant therapy; Lacosamide	TRAUMATIC BRAIN-INJURY; PARTIAL-ONSET SEIZURES; ORAL LACOSAMIDE; MORTALITY; VALPROATE; DAMAGE	Treatment of status epilepticus usually requires intravenous anticonvulsant therapy. Lacosamide is a novel anticonvulsant drug that is available as infusion solution. We describe a patient with nonconvulsive status epilepticus who was Successfully treated with intravenous lacosamide. (C) 2008 Elsevier Inc. All rights reserved.	[Kellinghaus, Christoph; Berning, Sascha; Besselmann, Michael] Klin Osnabruck, Dept Neurol, D-49076 Osnabruck, Germany		Kellinghaus, C (corresponding author), Klin Osnabruck, Dept Neurol, Finkenhugel 1, D-49076 Osnabruck, Germany.	christoph.kellinghaus@klinikum-os.de					Aminoff MJ, 1998, ARCH NEUROL-CHICAGO, V55, P119, DOI 10.1001/archneur.55.1.119; Ben-Menachem E, 2007, EPILEPSIA, V48, P1308, DOI 10.1111/j.1528-1167.2007.01188.x; Biton V, 2008, EPILEPSIA, V49, P418, DOI 10.1111/j.1528-1167.2007.01317.x; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Doty P, 2007, NEUROTHERAPEUTICS, V4, P145, DOI 10.1016/j.nurt.2006.10.002; Garnett WR, 2002, ANTIEPILEPTIC DRUGS, P380; Jordan KG, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00659.x; Knake S, 2008, J NEUROL NEUROSUR PS, V79, P588, DOI 10.1136/jnnp.2007.130260; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; Lowenstein DH, 1998, NEW ENGL J MED, V338, P970, DOI 10.1056/NEJM199804023381407; Misra UK, 2006, NEUROLOGY, V67, P340, DOI 10.1212/01.wnl.0000224880.35053.26; NAGLER J, 1981, AM J GASTROENTEROL, V76, P495; Peters CNA, 2005, SEIZURE-EUR J EPILEP, V14, P164, DOI 10.1016/j.seizure.2005.01.002; SACHDEO R, 2003, ANN M EFNS HELS; Shneker BF, 2003, NEUROLOGY, V61, P1066, DOI 10.1212/01.WNL.0000082653.40257.0B; Shorvon S, 2008, EPILEPSIA, V49, P1277, DOI 10.1111/j.1528-1167.2008.01706_3.x; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Waterhouse EJ, 1998, EPILEPSY RES, V29, P175, DOI 10.1016/S0920-1211(97)00071-5; YAFFE K, 1993, NEUROLOGY, V43, P895, DOI 10.1212/WNL.43.5.895; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	22	72	76	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050			EPILEPSY BEHAV	Epilepsy Behav.	FEB	2009	14	2					429	431		10.1016/j.yebeh.2008.12.009			3	Behavioral Sciences; Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	412ZB	WOS:000263761600027	19130901				2022-02-06	
J	Ring, H; Treger, I; Gruendlinger, L; Hausdorff, JM				Ring, Haim; Treger, Iuly; Gruendlinger, Leor; Hausdorff, Jeffrey M.			Neuroprosthesis for Footdrop Compared with an Ankle-Foot Orthosis: Effects on Postural Control during Walking	JOURNAL OF STROKE & CEREBROVASCULAR DISEASES			English	Article; Proceedings Paper	EvoWorkshops 2007	APR 11-13, 2007	Valencia, SPAIN	Univ Politecn Valencia, Inst Tecnol Informat, Minist Educ & Ciencia, Napier Univ, Ctr Emergent Comp		Neuroprosthesis; functional electrical stimulation; ankle-foot orthosis; postural control; gait	FUNCTIONAL ELECTRICAL-STIMULATION; PERONEAL NERVE STIMULATOR; DROPPED FOOT; EXECUTIVE FUNCTION; GAIT VARIABILITY; STROKE; HEMIPLEGIA; COORDINATION; HEMIPARESIS; PERFORMANCE	Objectives: We sought to compare the effects of a radio frequency-controlled neuroprosthesis on gait stability and symmetry to the effects obtained with a standard ankle-foot orthosis (AFO). Methods: A total of 15 patients (mean age: 52.2 +/- 3.6 years) with prior chronic hemiparesis resulting from stroke or traumatic brain injury (5.9 +/- 1.5 year) whose walking was impaired by footdrop and regularly used an AFO participated in the study. There was a 4-week adaptation period during which participants increased their daily use of the neuroprosthesis, while using the AFO for the rest of the day. Gait was then assessed in a 6-minute walk while wearing force-sensitive insoles, by using the neuroprosthesis and the AFO in a randomized order. An additional gait assessment was conducted after using the neuroprosthesis for a further 4 weeks. Gait speed and stride time (inverse of cadence) were determined, as were gait asymmetry index and swing time variability. Results: After the 4-week adaptation period, there were no differences between walking with the neuroprosthesis and walking with the AFO (P >.05). After 8 weeks, there was no significant difference in gait speed, whereas stride time improved from 1.48 +/- 0.21 seconds with the AFO to 1.41 +/- 0.16 seconds with the neuroprosthesis (P < .02). Swing time variability decreased from 5.3 +/- 1.6% with the AFO to 4.3 +/- 1.4% with the neuroprosthesis (P = .01). A gait asymmetry index improved by 15% from 0.20 +/- 0.09 with the AFO to 0.17 +/- 0.08 with the neuroprothesis (P < .05). Conclusions: Compared with AFO, the studied neuroprosthesis appears to enhance balance control during walking and, thus, more effectively manage footdrop.	[Gruendlinger, Leor; Hausdorff, Jeffrey M.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, IL-69978 Tel Aviv, Israel; [Ring, Haim; Treger, Iuly] Loewenstein Hosp & Rehabil Ctr, Neurol Rehabil Dept, Ranana, Israel; [Ring, Haim; Treger, Iuly] Tel Aviv Univ, Sackler Fac Med, Dept Rehabil Med, IL-69978 Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Tel Aviv Univ, Sackler Fac Med, Dept Phys Therapy, IL-69978 Tel Aviv, Israel; [Hausdorff, Jeffrey M.] Harvard Univ, Sch Med, Div Aging, Boston, MA 02115 USA		Hausdorff, JM (corresponding author), Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Neurol, Movement Disorders Unit, Weizmann 6, IL-69978 Tel Aviv, Israel.	jhausdorff@alum.mit.edu	Treger, Iuly/H-6791-2015				Alfieri V, 2001, NEUROMODULATION, V4, P85, DOI 10.1046/j.1525-1403.2001.00085.x; BUNNELL KL, 1994, J ORTHOP SPORT PHYS, V20, P287; Burridge J., 1997, PHYSIOTHERAPY, V83, P82, DOI [10.1016/S0031-9406(05)65582-4, DOI 10.1016/S0031-9406(05)65582-4]; Donker SF, 2002, ACTA PSYCHOL, V110, P265, DOI 10.1016/S0001-6918(02)00037-9; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; Fatone S, 2007, J REHABIL RES DEV, V44, P11, DOI 10.1682/JRRD.2006.08.0090; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Geboers JFM, 2002, J REHABIL MED, V34, P80, DOI 10.1080/165019702753557872; Granat MH, 1996, ARCH PHYS MED REHAB, V77, P19, DOI 10.1016/S0003-9993(96)90214-2; Harris-Love ML, 2001, NEUROREHAB NEURAL RE, V15, P105, DOI 10.1177/154596830101500204; Hausdorff JM, 2008, AM J PHYS MED REHAB, V87, P4, DOI 10.1097/PHM.0b013e31815e6680; Hausnerova B, 2005, INT POLYM PROC, V20, P19, DOI 10.3139/217.1853; HILL KD, 1994, ARCH PHYS MED REHAB, V75, P577; Kottink AIR, 2004, ARTIF ORGANS, V28, P577, DOI 10.1111/j.1525-1594.2004.07310.x; Kottink AI, 2007, ARCH PHYS MED REHAB, V88, P971, DOI 10.1016/j.apmr.2007.05.002; LIBERSON W T, 1961, Arch Phys Med Rehabil, V42, P101; Lyons GM, 2002, IEEE T NEUR SYS REH, V10, P260, DOI 10.1109/TNSRE.2002.806832; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Peckham PH, 2005, ANNU REV BIOMED ENG, V7, P327, DOI 10.1146/annurev.bioeng.6.040803.140103; Pohl PS, 2002, J REHABIL RES DEV, V39, P439; SACKLEY C M, 1990, Physiotherapy Theory and Practice, V6, P179, DOI 10.3109/09593989009048293; Sheffler LR, 2006, NEUROREHAB NEURAL RE, V20, P355, DOI 10.1177/1545968306287925; Sheridan PL, 2003, J AM GERIATR SOC, V51, P1633, DOI 10.1046/j.1532-5415.2003.51516.x; Shimada Y, 2006, NEUROMODULATION, V9, P320, DOI 10.1111/j.1525-1403.2006.00074.x; Springer S, 2006, MOVEMENT DISORD, V21, P950, DOI 10.1002/mds.20848; Stein RB, 2006, NEUROREHAB NEURAL RE, V20, P371, DOI 10.1177/1545968306289292; Taylor PN, 1999, ARCH PHYS MED REHAB, V80, P1577, DOI 10.1016/S0003-9993(99)90333-7; Taylor PN, 1999, CLIN REHABIL, V13, P439, DOI 10.1191/026921599677086409; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; Wang RY, 2005, CLIN REHABIL, V19, P37, DOI 10.1191/0269215505cr797oa; WOLLY SM, 2001, TOP STROKE REHABIL, V7, P1; WRIGHT A, 2002, 1 ANN C FESNET SEPT; Yogev G, 2007, EXP BRAIN RES, V177, P336, DOI 10.1007/s00221-006-0676-3	33	72	80	0	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1052-3057	1532-8511		J STROKE CEREBROVASC	J. Stroke Cerebrovasc. Dis.	JAN	2009	18	1					41	47		10.1016/j.jstrokecerebrovasdis.2008.08.006			7	Neurosciences; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Cardiovascular System & Cardiology	410EJ	WOS:000263560000008	19110144				2022-02-06	
J	Ruff, RL; Ruff, SS; Wang, XF				Ruff, Robert L.; Ruff, Suzanne S.; Wang, Xiao-Feng			Improving sleep: Initial headache treatment in OIF/OEF veterans with blast-induced mild traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						combat; concussion; explosion; headache; mild traumatic brain injury; OIF/OEF; pain; prazosin; PTSD; sleep	ENDURING FREEDOM; PAIN; PRAZOSIN; CLASSIFICATION; NIGHTMARES; MANAGEMENT; SCALE	This was an observational study of a cohort of 126 veterans with mild traumatic brain injury caused by an explosion during deployment in Operation Iraqi Freedom or Operation Enduring Freedom (OIF/OEF); 74 of the 126 veterans had comorbidities including frequent, severe headaches and residual deficits on neurological examination, neuropsychological testing, or both. Of these veterans, 71 had posttraumatic stress disorder and only 5 had restful sleep. We examined whether treatment with sleep hygiene counseling and oral prazosin would improve sleep, headaches, and cognitive performance. Nine weeks after providing sleep counseling and initiating an increasing dosage schedule of prazosin at bedtime, 65 veterans reported restful sleep. Peak headache pain (0-10 scale) decreased from 7.28 +/- 0.27 to 4.08 +/- 0.19 (values presented as mean +/- standard deviation). The number of headaches per month decreased from 12.40 +/- 0.94 to 4.77 +/- 0.34. Montreal Cognitive Assessment scores improved from 24.50 +/- 0.49 to 28.60 +/- 0.59. We found these gains maintained 6 months later. This pilot study suggests that addressing sleep is a good first step in treating posttraumatic headaches in OIF/OEF veterans.	[Ruff, Robert L.] Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Neurol Serv, Cleveland, OH USA; [Ruff, Robert L.] Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; [Ruff, Suzanne S.] LSCVAMC, Psychol Serv, Cleveland, OH USA; [Wang, Xiao-Feng] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH 44106 USA		Ruff, RL (corresponding author), Louis Stokes Cleveland VA Med Ctr, Neurol Serv, 127W,10701 E Blvd, Cleveland, OH 44106 USA.	robert.ruffl@va.gov	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604	Patient Care Services of the VA	This material was based on work supported by the Patient Care Services of the VA.	Agresti A., 2019, INTRO CATEGORICAL DA; Alberti A, 2006, SLEEP MED REV, V10, P431, DOI 10.1016/j.smrv.2006.03.003; Ballester E, 1999, AM J RESP CRIT CARE, V159, P495, DOI 10.1164/ajrccm.159.2.9804061; Boehnlein James K, 2007, J Psychiatr Pract, V13, P72, DOI 10.1097/01.pra.0000265763.79753.c1; Breivik EK, 2000, CLIN J PAIN, V16, P22, DOI 10.1097/00002508-200003000-00005; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; COGGON D, 2002, STAT CLIN PRACTICE; *COMB STRESS CTR C, 2009, W REED ARM I RES PSY; DeLoach LJ, 1998, ANESTH ANALG, V86, P102, DOI 10.1097/00000539-199801000-00020; Dick BD, 2007, ANESTH ANALG, V104, P1223, DOI 10.1213/01.ane.0000263280.49786.f5; Dierks MR, 2007, ANN PHARMACOTHER, V41, P1013, DOI 10.1345/aph.1H588; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; *FORC HLTH PROT RE, POST DEPL HLTH REASS; FRY JM, 1987, MED CLIN N AM, V71, P95, DOI 10.1016/S0025-7125(16)30885-9; Hans G, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-170; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holroyd KA, 2001, JAMA-J AM MED ASSOC, V285, P2208, DOI 10.1001/jama.285.17.2208; Holroyd KA, 2009, PAIN, V143, P213, DOI 10.1016/j.pain.2009.02.019; Johns MW, 2000, J SLEEP RES, V9, P5, DOI 10.1046/j.1365-2869.2000.00177.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KREMER E, 1981, PAIN, V10, P241, DOI 10.1016/0304-3959(81)90199-8; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Linder Steven L, 2007, Curr Pain Headache Rep, V11, P396, DOI 10.1007/s11916-007-0223-3; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Mastin DF, 2006, J BEHAV MED, V29, P223, DOI 10.1007/s10865-006-9047-6; McCrea M., 2008, MILD TRAUMATIC BRAIN; Molenberghs G., 2000, LINEAR MIXED MODELS; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; PROYINI F, 2006, NEUROL SCI, V27, pS149, DOI DOI 10.1007/S10072-006-0591-1; Rains JC, 2008, CURR NEUROL NEUROSCI, V8, P167, DOI 10.1007/s11910-008-0027-9; Raskind MA, 2007, BIOL PSYCHIAT, V61, P928, DOI 10.1016/j.biopsych.2006.06.032; Redline S, 1998, AM J RESP CRIT CARE, V157, P858, DOI 10.1164/ajrccm.157.3.9709042; Roberts RJ, 2008, SCI AM MIND, V19, P51, DOI DOI 10.1038/SCIENTIFICAMERICANMIND1208-50; Roth T, 2007, CNS SPECTRUMS, V12, P1; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schmader KE, 2007, CLIN J PAIN, V23, P490, DOI 10.1097/AJP.0b013e318065b6c9; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Slone L. B., 2008, WAR ZONE PRACTICAL G; Smith MT, 2007, SLEEP, V30, P494, DOI 10.1093/sleep/30.4.494; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor FB, 2008, BIOL PSYCHIAT, V63, P629, DOI 10.1016/j.biopsych.2007.07.001; Vgontzas AN, 1999, ANNU REV MED, V50, P387; *W REED ARM I RES, 2009, BATTL TRAIN, V2; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WHEALIN JM, 2008, CLIN GUIDE TREATING; Wright KP, 2006, J COGNITIVE NEUROSCI, V18, P508, DOI 10.1162/jocn.2006.18.4.508; Young James A, 2007, Phys Med Rehabil Clin N Am, V18, P145, DOI 10.1016/j.pmr.2006.11.008; ZADIKOFF C, 2007, MOVEMENT DISORD, V23, P297, DOI DOI 10.1002/MDS.21837; Zalewski, 1994, Assessment, V1, P133, DOI 10.1177/1073191194001002003; Zelman DC, 2006, CLIN J PAIN, V22, P681, DOI 10.1097/01.ajp.0000210910.49923.09	54	72	72	0	10	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	9					1071	1084		10.1682/JRRD.2009.05.0062			14	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	580JJ	WOS:000276444000002	20437313	Bronze			2022-02-06	
J	Bowman, SM; Bird, TM; Aitken, ME; Tilford, JM				Bowman, Stephen M.; Bird, Tommy M.; Aitken, Mary E.; Tilford, John M.			Trends in Hospitalizations Associated With Pediatric Traumatic Brain Injuries	PEDIATRICS			English	Article						traumatic brain injury; hospitalizations; incidence; trends	UNITED-STATES; CARE	OBJECTIVES. The goals were to describe trends in pediatric traumatic brain injury hospitalizations in the United States and to provide national benchmarks for state and regional comparisons. METHODS. Analysis of existing data (1991-2005) from the Nationwide Inpatient Sample, the largest longitudinal, all-payer, inpatient care database in the United States, was performed. Children 0 to 19 years of age were included. Annual rates of traumatic brain injury-related hospitalizations, stratified according to age, gender, severity of traumatic brain injury, and outcome, were determined. RESULTS. From 1991 to 2005, the estimated annual incidence rate of pediatric hospitalizations associated with traumatic brain injury decreased 39%, from 119.4 to 72.7 hospitalizations per 100 000. The rates decreased for all age groups and for both boys and girls, although the rate for boys remained consistently higher at each time point. Fatal hospitalization rates decreased from 3.5 deaths per 100 000 in 1991-1993 to 2.8 deaths per 100 000 in 2003-2005. The rate of mild traumatic brain injury hospitalizations accounted for most of the overall decrease, whereas nonfatal hospitalization rates for moderate and severe traumatic brain injuries remained relatively unchanged. CONCLUSIONS. Although pediatric hospitalization rates for mild traumatic brain injuries have decreased over the past 15 years, rates for moderate and severe traumatic brain injuries are relatively unchanged. Our study provides national estimates of pediatric traumatic brain injury hospitalizations that can be used as benchmarks to increase injury prevention effectiveness through targeting of effective strategies. Pediatrics 2008; 122: 988-993	[Bowman, Stephen M.; Bird, Tommy M.; Aitken, Mary E.; Tilford, John M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA		Bowman, SM (corresponding author), Arkansas Childrens Hosp, Dept Pediat, CARE Peds Slot 512-26,800 Marshall St, Little Rock, AR 72202 USA.	bowmanstephenm@uams.edu	Aitken, Mary/ABG-6119-2021; Bowman, Stephen/AAF-2154-2019	Aitken, Mary/0000-0002-8318-9755	Arkansas Biosciences Institute; Arkansas Children's Hospital, Arkansas State University, the University of Arkansas Division of Agriculture, the University of Arkansas, Fayetteville; University of Arkansas for Medical Sciences. The Arkansas Biosciences Institute	Support for Dr Bowman was provided in part by the Arkansas Biosciences Institute, a partnership of scientists from Arkansas Children's Hospital, Arkansas State University, the University of Arkansas Division of Agriculture, the University of Arkansas, Fayetteville, and the University of Arkansas for Medical Sciences. The Arkansas Biosciences Institute is the major research component of the Tobacco Settlement Proceeds Act of 2000.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; American College of Surgeons, 2006, RES OPT CAR INJ PAT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRETT M, 2006, HCUP METHODS SERIES; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Finkelstein E., 2006, INCIDENCE EC BURDEN; Langlois JA, 2006, TRAUMATIC BRAIN INJU; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Moore E. E., 2004, TRAUMA; *NAT CTR HLTH STAT, FRAM PRES NAT INJ DA; *NAT HIGHW TRAFF S, 2006, PUBL DOT HS NAT HIGH; *NAT HIGHW TRAFF S, 2005, TRAFF SAF FACTS MOT; *NAT HIGHW TRAFF S, 2007, PUBL DOT HS NAT HIGH; National Center for Injury Prevention and Control Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Rivara FP, 1999, AM J PREV MED, V16, P1, DOI 10.1016/S0749-3797(98)00111-1; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Westfall JM, 2001, MED CARE, V39, P459, DOI 10.1097/00005650-200105000-00006; Youth Risk Behavior Surveillance System (YRBSS), YOUTH RISK BEH SURV	22	72	75	0	8	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	NOV	2008	122	5					988	993		10.1542/peds.2007-3511			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	367HG	WOS:000260542500010	18977977				2022-02-06	
J	Merkley, TL; Bigler, ED; Wilde, EA; McCauley, SR; Hunter, JV; Levin, HS				Merkley, Tricia L.; Bigler, Erin D.; Wilde, Elisabeth A.; McCauley, Stephen R.; Hunter, Jill V.; Levin, Harvey S.			Diffuse Changes in Cortical Thickness in Pediatric Moderate-to-Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						MRI; neural injury; other tools of modern imaging; pediatric brain injury; traumatic brain injury	SURFACE-BASED ANALYSIS; WORKING-MEMORY; ANTERIOR; ATROPHY; MRI	Generalized whole brain volume loss has been well documented in moderate-to-severe traumatic brain injury (TBI), as has diffuse cerebral atrophy based on magnetic resonance imaging (MRI) volumetric methods where white matter may be more selectively affected than gray matter. However, specific regional differences in gray matter thickness of the cortical mantle have not been previously examined. As such, cortical thickness was assessed using FreeSurfer (R) software to identify regions of significant gray matter cortical thinning in MRI scans of 16 young TBI subjects (age range, 9-16 years) compared to 16 demographically matched controls. Significant cortical thinning was observed globally in the TBI group compared to the cohort of typically developing children. Reduced cortical thickness was related to reported deficits in working memory. TBI-induced cortical thickness reductions are probably due to a combination of focal and diffuse effects and have implications for the neurobehavioral sequelae of TBI.	[Merkley, Tricia L.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Wilde, Elisabeth A.; McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Levin, Harvey S.] Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Hunter, Jill V.] Texas Childrens Hosp, EB Singleton Dept Diagnost Imaging, Houston, TX 77030 USA		Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Kimball Tower, Provo, UT 84602 USA.	erin_bigler@byu.edu	Merkley, Tricia L./AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	Ira Fulton Foundation [NS-21889, NIH R01 HD048946]; Home and Social Science, Brigham Young University; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048946] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER	This research was supported by grants NS-21889 and NIH R01 HD048946, by the Ira Fulton Foundation, and a grant from the College of Family, Home and Social Science, Brigham Young University. The technical assistance of Tracy J. Abildskov and the editorial assistance of Jo Ann Petrie are gratefully acknowledged.	ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; JENNETT B, 1975, LANCET, V1, P480; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Postle BR, 2006, NEUROIMAGE, V30, P950, DOI 10.1016/j.neuroimage.2005.10.018; Postle BR, 2006, NEUROSCIENCE, V139, P23, DOI 10.1016/j.neuroscience.2005.06.005; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	17	72	72	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2008	25	11					1343	1345		10.1089/neu.2008.0615			3	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	384BP	WOS:000261718900006	19061377	Green Published, Green Accepted			2022-02-06	
J	Norwood, SH; Berne, JD; Rowe, SA; Villarreal, DH; Ledlie, JT				Norwood, Scott H.; Berne, John D.; Rowe, Stephen A.; Villarreal, David H.; Ledlie, Jon T.			Early Venous Thromhoembolism Prophylaxis With Enoxaparin in Patients With Blunt Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	21st Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2008	Jacksonville, FL	Eastern Assoc Surg Trauma		DVT prophylaxis in traumatic brain injury; Enoxaparin; DVT prophylaxis complications	VENA-CAVA FILTERS; DEEP-VEIN THROMBOSIS; PULMONARY-EMBOLISM; THROMBOEMBOLISM PROPHYLAXIS; FOLLOW-UP; PREVENTION	Objective: To determine the safety of early enoxaparin for venous thromboembolism (VTE) prophylaxis in patients with blunt traumatic brain injury (TBI). Methods: Prospective observational study of patients with TBI who received enoxaparin within 48 hours after admission. Brain computed tomography (0) scans were obtained at the time of admission, at 24 hours, and at variable intervals thereafter based on clinical course. Patients were excluded from the study for intracerebral contusions >= 2 cm. multiple contusions within one brain region, subdural or epidural hematomas >= 8 mm, increased size or number of lesions on follow-up CT, persistent intracranial pressure >20 mm Hg, or neurosurgeon or trauma surgeon reluctance to initiate early pharmacologic VTE prophylaxis. Bleeding complications were defined as CT progression of hemorrhage by Marshall CT Classification or radiologists' report, regardless of any neurologic deterioration. Main outcomes measured were intracranial bleeding complications, discharge Glasgow Outcome Score, and hospital mortality. Results: Five hundred twenty-five patients were studied. Eighteen patients (3.4%) had progressive hemorrhagic CT changes after receiving enoxaparin, 12 of whom had no change in treatment, neurologic status, or outcome. Six patients (1.1%) had a change in treatment or potential outcome, including three who required subsequent craniotomy. Twenty-one patients (4.0%) died, and pharmacologic prophylaxis may have contributed to one death (0.2%). Discharge Glasgow Outcome Scores were 445 (84.8%) good recovery, 19 (3.6%) moderate disability, 36 (6.8%) severe disability, 4 (0.8%) persistent vegetative state, and 21 (4.0%) dead. Conclusion: Enoxaparin should be considered as an option for early VTE prophylaxis in selected patients with blunt TBI. Early enoxaparin should be strongly considered in those patients with TBI with additional high risk traumatic injuries.	[Norwood, Scott H.; Berne, John D.; Rowe, Stephen A.; Villarreal, David H.] E Texas Med Ctr, Trauma Serv, Dept Surg, Tyler, TX 75701 USA; [Ledlie, Jon T.] E Texas Med Ctr, Dept Neurosurg, Tyler, TX 75701 USA		Norwood, SH (corresponding author), E Texas Med Ctr, Trauma Serv, Dept Surg, 1020 E Idel St, Tyler, TX 75701 USA.	snorwo01@msn.com					Aito S, 2002, SPINAL CORD, V40, P300, DOI 10.1038/sj.sc.3101298; Borer DS, 2005, J ORTHOP TRAUMA, V19, P92, DOI 10.1097/00005131-200502000-00004; Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons, 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2007.9991; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GEERTS WH, 1999, THROMB HAEMOST S, V82, P650; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; HUK M, 1998, CRIT CARE MED S, V26, pA47; Imberti D, 2005, J THROMB HAEMOST, V3, P1370, DOI 10.1111/j.1538-7836.2005.01448.x; Kaufman JA, 2007, WORLD J SURG, V31, P251, DOI 10.1007/s00268-006-0292-1; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Nathens AB, 2007, J TRAUMA, V62, P557, DOI 10.1097/TA.0b013e318031b5f5; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Rogers FB, 1998, ARCH SURG-CHICAGO, V133, P406, DOI 10.1001/archsurg.133.4.406; Rosenthal D, 2004, J VASC SURG, V40, P958, DOI 10.1016/j.jvs.2004.07.048; Schellong SM, 2007, J THROMB HAEMOST, V5, P1431, DOI 10.1111/j.1538-7836.2007.02570.x; Slavik RS, 2007, J TRAUMA, V62, P1075, DOI 10.1097/TA.0b013e31804fa177; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Velmahos GC, 2000, J TRAUMA, V49, P132, DOI 10.1097/00005373-200007000-00020; Velmahos GC, 2000, J TRAUMA, V49, P140, DOI 10.1097/00005373-200007000-00021	24	72	74	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2008	65	5					1021	1027		10.1097/TA.0b013e31818a0e74			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	372DD	WOS:000260881000010	19001969				2022-02-06	
J	Wijdicks, EFM; Rabinstein, AA; Manno, EM; Atkinson, JD				Wijdicks, Eelco F. M.; Rabinstein, Alejandro A.; Manno, Edward M.; Atkinson, John D.			Pronouncing brain death - Contemporary practice and safety of the apnea test	NEUROLOGY			English	Article							ORGAN; IDENTIFICATION; COMA	Background: Little is known of hospital practice in brain death determination, specialty involvement, and followed procedures, including the apnea test. Methods: We reviewed 228 patients pronounced brain dead at Mayo Clinic from 1996 to 2007. We performed a detailed review of clinical determination of brain death, intensive care support, apnea test procedure, and complications. Results: There were 228 patients who were pronounced brain dead, mostly after traumatic brain injury, cerebral hematoma, or aneurysmal subarachnoid hemorrhage. Brain death was declared within 24 hours of ictus in 30% of the patients and within 3 days in 62%. All patients were using one or more vasopressors, and 61% of the patients received vasopressin for diabetes insipidus. An apnea test could not be performed in 7% of the patients because of hemodynamic instability or poor oxygenation at baseline. In 3% of the patients, the apnea test procedure was aborted because of hypoxemia or hypotension. No major complications (cardiac arrest or pneumothorax) occurred during the apnea test. Polytrauma resulting in brain death was significantly more common in patients with aborted or not attempted apnea tests than in patients with completed apnea tests (p = 0.0004). During the study epoch, we found a shift toward determination of the tests by neurointensivists, pediatric neurologists, and neurosurgeons. Conclusions: Brain death declaration is frequent within the first 3 days of admission. It is usually performed in hemodynamically unstable patients requiring vasopressors and vasopressin. If preconditions are met, apnea testing using an oxygen-diffusion technique is safe. However, in 1 of 10 patients, an apnea test could not be completed and confirmatory tests were needed.	[Wijdicks, Eelco F. M.] Mayo Clin, Coll Med, Dept Neurol, Div Crit Care Neurol, Rochester, MN 55905 USA; [Atkinson, John D.] Mayo Clin, Dept Neurosurg, Rochester, MN 55905 USA		Wijdicks, EFM (corresponding author), Mayo Clin, Coll Med, Dept Neurol, Div Crit Care Neurol, 200 1st St SW, Rochester, MN 55905 USA.	wijde@mayo.edu					[Anonymous], 1995, Neurology, V45, P1012; Bustos JL, 2006, TRANSPLANT P, V38, P3697, DOI 10.1016/j.transproceed.2006.10.046; de Freitas GR, 2005, J NEUROL, V252, P106, DOI 10.1007/s00415-005-0605-6; Goudreau JL, 2000, NEUROLOGY, V55, P1045, DOI 10.1212/WNL.55.7.1045; Greer DM, 2008, NEUROLOGY, V70, P284, DOI 10.1212/01.wnl.0000296278.59487.c2; Helms AK, 2004, NEUROLOGY, V63, P1955, DOI 10.1212/01.WNL.0000144197.06562.24; Kompanje EJO, 2006, INTENS CARE MED, V32, P217, DOI 10.1007/s00134-005-0001-9; Rodrigue JR, 2006, AM J TRANSPLANT, V6, P190, DOI 10.1111/j.1600-6143.2005.01130.x; Ruiz-Garcia M, 2000, CHILD NERV SYST, V16, P40, DOI 10.1007/s003810050010; SASPOSNIK G, 2005, AM J MED, V118, P311; Senouci K, 2004, INTENS CARE MED, V30, P38, DOI 10.1007/s00134-003-1923-8; Wijdicks EFM, 2001, NEW ENGL J MED, V344, P1215, DOI 10.1056/NEJM200104193441606; Wijdicks EFM, 2002, NEUROLOGY, V58, P20, DOI 10.1212/WNL.58.1.20	13	72	79	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 14	2008	71	16					1240	1244		10.1212/01.wnl.0000327612.69106.4c			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	359KT	WOS:000259986300006	18852438				2022-02-06	
J	Hatton, J; Rosbolt, B; Empey, P; Kryscio, R; Young, B				Hatton, Jimmi; Rosbolt, Bonnie; Empey, Philip; Kryscio, Richard; Young, Byron			Dosing and safety of cyclosporine in patients with severe brain injury	JOURNAL OF NEUROSURGERY			English	Article						cyclosporine; neuroprotection; traumatic brain injury	MITOCHONDRIAL PERMEABILITY TRANSITION; GROWTH-FACTOR-I; CLINICAL-TRIALS; HEAD-INJURY; PHARMACOLOGICAL-TREATMENT; NEUROPROTECTIVE AGENTS; LIPID-PEROXIDATION; OXIDATIVE DAMAGE; DOSE-RESPONSE; MOUSE MODEL	Object. Cyclosporine neuroprotection has been reported in brain injury models but safety and dosing guidelines have not been determined in humans with severe traumatic brain injury (TBI). The purpose of this investigation was to establish the safety of cyclosporine using 4 clinically relevant closing schemes. Methods. The authors performed a prospective, blinded, placebo-control led, randomized, dose-escalation trial of cyclosporine administration initiated within 8 hours of TBI (Glasgow Coma Scale score range 4-9; motor score range 2-5). Four dosing cohorts (8 patients treated with cyclosporine and 2 receiving placebo treatment per cohort) received cyclosporine (1.25-5 mg/kg/day) or placebo in 2 divided doses (Cohorts I-III) or Continuous infusion (Cohort IV) over 72 hours, Adverse events and outcome were monitored for 6 months. Results. Forty patients were enrolled over 3 years (cyclosporine cohorts, 24 male and 8 female patients placebo group, 8 male patients). Systemic trough concentrations were below 250 ng/ml during intermittent doses. Higher blood concentrations were observed in Cohorts III and IV. There was no significant difference in immunological effects, adverse events, infection, renal dysfunction, or seizures. Mortality rate was not affected by cyclosporine administration, independent of dose, compared with placebo (6 of 32 patients receiving cyclosporine and 2 of 8 receiving placebo died, p > 0.05). At 6 months, a dose-related improvement in favorable Outcome was observed in cyclosporine-treated patients (p < 0.05). Conclusions. In patients with acute TBI who received cyclosporine at doses Lip to 5 mg/kg/day, administered intravenously, with treatment initiated within 8 hours of injury, the rate of mortality or other adverse events was not significantly different from that of the placebo group.	[Hatton, Jimmi] Univ Kentucky, Dept Pharm Practice & Sci, Lexington, KY 40536 USA; [Hatton, Jimmi; Young, Byron] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Empey, Philip] Univ Kentucky, Dept Pharmaceut Sci, Coll Pharm, Lexington, KY 40536 USA; [Hatton, Jimmi; Rosbolt, Bonnie; Young, Byron] Univ Kentucky, Coll Med, Dept Neurosurg, Lexington, KY 40536 USA; [Kryscio, Richard] Univ Kentucky, Coll Publ Hlth, Dept Biostat, Lexington, KY 40536 USA		Hatton, J (corresponding author), Univ Kentucky, Dept Pharm Practice & Sci, 725 Rose St, Lexington, KY 40536 USA.	jhatt1@uky.edu	Empey, Philip/L-9604-2019	Empey, Philip/0000-0001-7474-2339	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR02602, M01 RR002602] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS041239-02, R01 NS41239-02, 1R01NS 41239-01, R01 NS041239] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041239] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Avramut M, 2003, CURR TOP MED CHEM, V3, P1376, DOI 10.2174/1568026033451871; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Borlongan CV, 2002, BRAIN RES, V956, P211, DOI 10.1016/S0006-8993(02)03474-1; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Domanska-Janik K, 2004, MOL BRAIN RES, V121, P50, DOI 10.1016/j.molbrainres.2003.11.006; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; Farin A, 2004, ACT NEUR S, V89, P101; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Gogarten W, 1998, J NEUROSURG ANESTH, V10, P101, DOI 10.1097/00008506-199804000-00006; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hatton J, 1997, J NEUROSURG, V86, P779, DOI 10.3171/jns.1997.86.5.0779; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hatton J, 2006, J NEUROSURG, V105, P843, DOI 10.3171/jns.2006.105.6.843; Kagawa Y, 2003, BIOL PHARM BULL, V26, P1115; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kaminska B, 2004, J CELL MOL MED, V8, P45, DOI 10.1111/j.1582-4934.2004.tb00259.x; Kristal BS, 2004, J BIOENERG BIOMEMBR, V36, P309, DOI 10.1023/B:JOBB.0000041759.35731.70; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lenzlinger PM, 2004, RESTOR NEUROL NEUROS, V22, P73; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2004, ACT NEUR S, V89, P113; MacGregor DG, 2003, J NEUROCHEM, V85, P1402, DOI 10.1046/j.1471-4159.2003.01772.x; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marciano PG, 2002, NEUROCHEM RES, V27, P1147, DOI 10.1023/A:1020973308941; Marciano PG, 2001, RESTOR NEUROL NEUROS, V18, P105; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Marmarou A, 2005, J NEUROTRAUM, V22, P1444, DOI 10.1089/neu.2005.22.1444; MARR AL, 2001, CENTRAL NERVOUS SYST; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Okonkwo DO, 2003, NEUROREPORT, V14, P463, DOI 10.1097/01.wnr.0000058958.85541.d3; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thurman D, 1999, TRAUMATIC BRAIN INJU, DOI http://www.cdc.gov/ncipc/tbi/tbi_congress/TBI_in_the_US.PDF; TOLER SM, 1993, DRUG METAB DISPOS, V21, P1064; Uchino H, 2003, ACTA NEUROCHIR SUPPL, V86, P105; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Van den Heuvel C, 2004, J NEUROTRAUM, V21, P1562, DOI 10.1089/0897715042441783; Zieminska E, 2000, Acta Pol Pharm, V57 Suppl, P129	68	72	73	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2008	109	4					699	707		10.3171/JNS/2008/109/10/0699			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	353EO	WOS:000259549100016	18826358	Green Accepted			2022-02-06	
J	Xiong, Y; Lu, DY; Qu, CS; Goussev, A; Schallert, T; Mahmood, A; Chopp, M				Xiong, Ye; Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Schallert, Timothy; Mahmood, Asim; Chopp, Michael			Effects of erythropoietin on reducing brain damage and improving functional outcome after traumatic brain injury in mice - Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						erythropoietin; mouse; sensorimotor function; spatial learning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SPATIAL MEMORY PERFORMANCE; SUBVENTRICULAR ZONE; NEURONAL APOPTOSIS; MITOCHONDRIAL DYSFUNCTION; ENHANCES NEUROGENESIS; CEREBRAL-ISCHEMIA; PROTECTS NEURONS; RATS; HIPPOCAMPAL	Object. This study was designed to investigate the beneficial effects of recombinant human erythropoietin (rhEPO) treatment of traumatic brain injury (TBI) in mice. Methods. Adult male C57BL/6 mice were divided into 3 groups: 1) the saline group (TBI and saline [13 mice]); 2) EPO group (TBI and rhEPO [12]); and 3) sham group (sham and rhEPO [8]). Traumatic brain injury was induced by controlled cortical impact. Bromodeoxyuridine (100 mg/kg) was injected daily for 10 days, starting 1 day after injury, for labeling proliferating cells. Recombinant human erythropoietin was administered intraperitoneally at 6 hours and at 3 and 7 days post-TBI (5000 U/kg body weight, total dosage 15,000 U/kg). Neurological function was assessed using the Morris water maze and footfault tests. Animals were killed 35 days after injury, and brain sections were stained for immunohistochemical evaluation. Results. Traumatic brain injury caused tissue loss in the cortex and cell loss in the dentate gyrus (DG) as well as impairment of sensorimotor function (footfault testing) and spatial teaming (Morris water maze). Traumatic brain injury alone stimulated cell proliferation and angiogenesis. Compared with saline treatment, rhEPO significantly reduced lesion Volume in the cortex and cell loss in the DG after TBI and substantially improved recovery of sensorimotor function and spatial learning performance. It enhanced neurogenesis in the injured cortex and the DG. Conclusions. Recombinant human erythropoietin initiated 6 hours post-TBI provided neuroprotection by decreasing lesion volume and cell loss as well as neurorestoration by enhancing neurogenesis, subsequently improving sensorimotor and spatial learning function. It is a promising neuroprotective and neurorestorative agent for TBI and warrants further investigation.	[Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Xiong, Ye; Qu, Changsheng; Goussev, Anton; Mahmood, Asim] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Schallert, Timothy] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Schallert, Timothy] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA		Chopp, M (corresponding author), Henry Ford Hlth Syst, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS52280, P01 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS052280] Funding Source: NIH RePORTER	Support for this research was provided by NINDS grants R01 NS52280 (D.L.) and P01 NS42345 (A.M. and M.C.).	Arlotta P, 2003, EXP GERONTOL, V38, P173, DOI 10.1016/S0531-5565(02)00156-0; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Hasselblatt M, 2006, J NEUROSURG ANESTH, V18, P132, DOI 10.1097/00008506-200604000-00007; Itoh T, 2005, NEUROREPORT, V16, P1687, DOI 10.1097/01.wnr.0000183330.44112.ab; Iwai M, 2007, STROKE, V38, P2795, DOI 10.1161/STROKEAHA.107.483008; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/neu.2004.21.1756; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; Miskowiak K, 2007, J NEUROSCI, V27, P2788, DOI 10.1523/JNEUROSCI.5013-06.2007; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Ramaswamy S, 2005, BRAIN RES, V1053, P38, DOI 10.1016/j.brainres.2005.06.042; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Sundholm-Peters NL, 2005, J NEUROPATH EXP NEUR, V64, P1089, DOI 10.1097/01.jnen.0000190066.13312.8f; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wen TC, 2002, J NEUROSCI RES, V67, P795, DOI 10.1002/jnr.10166; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8; Zhang RL, 2007, J NEUROSCI, V27, P3157, DOI 10.1523/JNEUROSCI.4969-06.2007; Zhong LC, 2007, INVEST OPHTH VIS SCI, V48, P1212, DOI 10.1167/iovs.06-0757	72	72	78	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	SEP	2008	109	3					510	521		10.3171/JNS/2008/109/9/0510			12	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	344CX	WOS:000258904400024	18759585	Green Accepted			2022-02-06	
J	Rao, V; Spiro, J; Vaishnavi, S; Rastogi, P; Mielke, M; Noll, K; Cornwell, E; Schretlen, D; Makley, M				Rao, Vani; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Mielke, Michelle; Noll, Kathy; Cornwell, Edward; Schretlen, David; Makley, Michael			Prevalence and types of sleep disturbances acutely after traumatic brain injury	BRAIN INJURY			English	Article						trauma; mood disorder; sleep	HEAD-INJURY; GENDER-DIFFERENCES; INSOMNIA; COMPLAINTS; DISORDERS; SYMPTOMS; PATTERNS; PAIN; SEX	Primary objective: To assess the prevalence of and risk factors for sleep disturbances in the acute post-traumatic brain injury (TBI) period. Research design: Longitudinal, observational study. Methods and procedures: Fifty-four first time closed-head injury patients were recruited and evaluated within 3 months after injury. Pre-injury and post-injury sleep disturbances were compared on the Medical Outcome Scale for Sleep. The subjects were also assessed on anxiety, depression, medical comorbidity and severity of TBI. Main outcomes and results: Subjects were worse on most sleep measures after TBI compared to before TBI. Anxiety disorder secondary to TBI was the most consistent significant risk factor to be associated with worsening sleep status. Conclusions: Anxiety is associated with sleep disturbances after TBI. Further studies need to be done to evaluate if this is a causal relationship.	[Rao, Vani; Spiro, Jennifer; Vaishnavi, Sandeep; Rastogi, Pramit; Mielke, Michelle] Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat, Baltimore, MD USA; [Noll, Kathy; Cornwell, Edward] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA; [Schretlen, David] Johns Hopkins Sch Med, Dept Psychiat, Div Med Psychol, Baltimore, MD USA; [Makley, Michael] Univ Maryland, Kernan Hosp, Baltimore, MD 21201 USA		Rao, V (corresponding author), 550 N Broadway, Baltimore, MD 21205 USA.	vrao@jhmi.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604; Mielke, Michelle/0000-0001-7177-1185	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23MH066894] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K23 MH 066894, K23 MH066894-03, K23 MH066894] Funding Source: Medline		BARTLETT DJ, 2007, SLEEP MED       1031; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Evans BM, 2002, J ROY SOC MED, V95, P591, DOI 10.1258/jrsm.95.12.591; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; First M., 1997, STRUCTURED CLIN INTE; Foley DJ, 1999, SLEEP, V22, pS366; GIILBAY BE, 2007, RESPIRATION     0627; Hays RD, 2005, SLEEP MED, V6, P41, DOI 10.1016/j.sleep.2004.07.006; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; Kapur VK, 2002, SLEEP, V25, P289; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Kroenke K, 1998, PSYCHOSOM MED, V60, P150, DOI 10.1097/00006842-199803000-00006; Lyketsos CG, 1999, J AM GERIATR SOC, V47, P487, DOI 10.1111/j.1532-5415.1999.tb07245.x; Neau JP, 2002, SLEEP MED REV, V6, P457, DOI 10.1053/smrv.2002.0207; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; PARSONS LC, 1982, NURS RES, V31, P260; Resta O, 2001, INT J OBESITY, V25, P669, DOI 10.1038/sj.ijo.0801603; RICHTER KJ, 1995, J HEAD TRAUMA REHAB, V10, P7, DOI 10.1097/00001199-199512000-00004; TEASDALE G, 1974, LANCET, V2, P81; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; VanWijk CMTG, 1997, SOC SCI MED, V45, P231, DOI 10.1016/S0277-9536(96)00340-1; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WOOL CA, 1994, PSYCHOSOMATICS, V35, P445, DOI 10.1016/S0033-3182(94)71738-2; YJINK ME, 1992, ARCH INTERN MED, V152, P1634	30	72	75	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2008	22	5					381	386		10.1080/02699050801935260			6	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	302RH	WOS:000255986500003	18415718	Green Accepted			2022-02-06	
J	Ellingson, KD; Leventhal, JM; Weiss, HB				Ellingson, Katherine D.; Leventhal, John M.; Weiss, Harold B.			Using hospital discharge data to track inflicted traumatic brain injury	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							INFANTS; SHAKE; BABY	Background: Inflicted traumatic brain injury (inflicted TBI) in infants has been the subject of recent preventive interventions, yet the burden of this problem is poorly defined. This article estimates the national incidence of hospitalizations due to inflicted TBI in infants aged <1 year using hospital discharge databases (HDDs) over 3 years, compares findings to previous infant inflicted TBI studies, and assesses differences in case composition and coding over time. Methods: The Kids' Inpatient Databases (KIDs) for 1997, 2000, and 2003 were used to estimate the incidence of inflicted TBI hospitalizations in infants. Cases were identified by the presence of ICD-9-CM codes indicating both TBI and abuse. Incidence estimates were generated by dividing the weighted number of inflicted TBI cases identified by the year-specific infant population. Changes over time were evaluated using Cochran-Armitage and ANOVA statistical tests. Results: The 1997, 2000, and 2003 KIDs yielded infant inflicted TBI incidence estimates of 27.5 (95% CI=20.8-34.0), 27.5 (95% 6=22.6-32.3), and 32.2 (95% CI=26.9-37.4) cases per 100,000 infants per year, respectively. KIDs estimates were within the range of previous inflicted TBI incidence studies that used active surveillance. Over time, the proportion of cases covered by Medicaid increased (p<0.0001). Conclusions: The KIDs call be used to generate incidence estimates of infant inflicted TBI hospitalizations that are consistent with previously published active surveillance estimates. HDDs call be used to assess the scope of infant inflicted TBI as well as trends in case composition and coding practices. Such assessments may be useful for the evaluation of prevention programs.	[Leventhal, John M.] Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06520 USA; [Ellingson, Katherine D.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; [Weiss, Harold B.] Univ Pittsburgh, Ctr Injury Prevent & Control, Pittsburgh, PA USA		Leventhal, JM (corresponding author), Yale Univ, Sch Med, Dept Pediat, POB 208064,333 Cedar St, New Haven, CT 06520 USA.	john.leventhal@yale.edu	Weiss, Hank/D-1052-2010	Ellingson, Katherine/0000-0001-7624-312X	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR323155] Funding Source: Medline		Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; *COUNC STAT TERR I, 2005, STAT COLL US CAUS IN; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; *HCUP, KID DAT DOC; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Langlois JA, 2006, TRAUMATIC BRAIN INJU; National Center for Health Statistics, INT CLASS DIS 9 REV; SHOWERS J, 1992, CHILD ABUSE NEGLECT, V16, P11, DOI 10.1016/0145-2134(92)90004-B; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; Thurman DJ., 1995, GUIDELINES SURVEILLA; *USDHHS, ICD9CM OFF GUID COD; WINN DG, 1995, PUBLIC HEALTH REP, V110, P277	18	72	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0749-3797	1873-2607		AM J PREV MED	Am. J. Prev. Med.	APR	2008	34	4		S			S157	S162		10.1016/j.amepre.2007.12.021			6	Public, Environmental & Occupational Health; Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; General & Internal Medicine	279TT	WOS:000254378300012	18374268				2022-02-06	
J	Andelic, N; Sigurdardottir, S; Brunborg, C; Roe, C				Andelic, Nada; Sigurdardottir, Solrun; Brunborg, Cathrine; Roe, Cecilie			Incidence of hospital-treated traumatic brain injury in the Oslo population	NEUROEPIDEMIOLOGY			English	Article						traumatic brain injury; epidemiology; incidence; case fatality rate	HEAD-INJURY; EPIDEMIOLOGY; MANAGEMENT; NORWAY; MILD; REHABILITATION; MORTALITY; IMPACT	Background: The aim of this prospective, population-based study is to present the incidence of hospital-treated traumatic brain injury (TBI) in Oslo, Norway, and to describe the severity of brain injuries and outcome of the patients' acute medical care. Methods: Data were obtained from hospital admission registers and medical records from May 2005 to May 2006. The initial severity of TBI was measured by the Glasgow Coma Scale. The region is urban with a population of 534,129. Results: The 445 patients identified represent an annual incidence of 83.3/100,000. The median age was 29 years. The male: female ratio was 1.8:1.0. The highest incidence of TBI hospitalizations was found in the elderly males and the youngest children. The most common causes of TBI were falls (51%) and transport accidents (29.7%). Intracranial lesions were found more often in the elderly. The case fatality rate was 2.0/100 hospitalized patients and was highest in the elderly. Conclusions: The incidence of hospital-treated TBI in this study is considerably lower than that found in previous studies from Norway and Scandinavia. Despite the apparent decline in TBI hospitalization rates, our findings should also draw attention to the need for more effective preventive programmes related to falls. Studies that assess long-term consequences of TBI in elderly patients are also needed. Copyright (C) 2008 S. Karger AG, Basel.	[Andelic, Nada; Roe, Cecilie] Ullevaal Univ Hosp, Dept Phys Med & Rehabil, NO-0407 Oslo, Norway; [Brunborg, Cathrine] Ullevaal Univ Hosp, Clin Res Ctr, NO-0407 Oslo, Norway; [Sigurdardottir, Solrun] Sunnaas Rehabil Hosp, Nesoddtangen, Norway		Andelic, N (corresponding author), Ullevaal Univ Hosp, Dept Phys Med & Rehabil, NO-0407 Oslo, Norway.	nada.andelic@ulleval.no		Andelic, Nada/0000-0002-3719-4406			Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P199; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Flanagan Steven R, 2005, Phys Med Rehabil Clin N Am, V16, P163, DOI 10.1016/j.pmr.2004.06.012; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Javouhey E, 2006, ACCIDENT ANAL PREV, V38, P225, DOI 10.1016/j.aap.2005.08.001; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kelly DF, 2001, WORLD J SURG, V25, P1179; Kennedy RE, 2006, J HEAD TRAUMA REHAB, V21, P260, DOI 10.1097/00001199-200605000-00006; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; *NORW PUBL ROAD AD, KEY FIG ANN REP 2005; Ragnarsson KT, 2006, J HEAD TRAUMA REHAB, V21, P379, DOI 10.1097/00001199-200609000-00002; Stella J, 2001, ANZ J SURG, V71, P665, DOI 10.1046/j.1445-1433.2001.02229.x; Steudel WI, 2005, ACTA NEUROCHIR, V147, P231, DOI 10.1007/s00701-004-0441-y; Sundstrom Terje, 2005, Tidsskr Nor Laegeforen, V125, P1310; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; TEASDALE G, 1974, LANCET, V2, P81; Tieves Kelly S, 2005, WMJ, V104, P22; Tieves KS, 2005, WMJ, V104, P54; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 2006, MMWR MORB MORTAL WKL, V55, P201; 2005, NORWEGIAN SAFETY FOR	32	72	72	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology		2008	30	2					120	128		10.1159/000120025			9	Public, Environmental & Occupational Health; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health; Neurosciences & Neurology	280HV	WOS:000254417700008	18334828	Bronze, Green Published			2022-02-06	
J	Ehlhardt, LA; Sohlberg, MM; Kennedy, M; Coelho, C; Ylvisaker, M; Turkstra, L; Yorkston, K				Ehlhardt, Laurie A.; Sohlberg, Mckay Moore; Kennedy, Mary; Coelho, Carl; Ylvisaker, Mark; Turkstra, Lyn; Yorkston, Kathryn			Evidence-based practice guidelines for instructing individuals with neurogenic memory impairments: What have we learned in the past 20 years?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						evidence based practice guidelines; memory impairment; cognitive rehabilitation; instruction; errorless learning	FACE-NAME ASSOCIATIONS; TRAUMATIC BRAIN-INJURY; IMPAIRED PATIENTS; VANISHING CUES; COGNITIVE REHABILITATION; INTERVENTION RESEARCH; ORGANIC AMNESIA; ERRORLESS; ACQUISITION; IMPLICIT	This article examines the instructional research literature pertinent to teaching procedures or information to individuals with acquired memory impairments due to brain injury or related conditions. The purpose is to evaluate the available evidence in order to generate practice guidelines for clinicians working in the field of cognitive rehabilitation. A systematic review of the instructional literature from 1986 to 2006 revealed 51 studies meeting search criteria. Studies were analysed and coded within the following four key domains: Population Sample, Intervention, Study Design, and Treatment Outcomes. Coding included 17 characteristics of the population sample; seven intervention parameters; five study design features; and five treatment outcome parameters. Interventions that were evaluated included systematic instructional techniques such as method of vanishing cues and errorless learning. The majority of the studies reported positive outcomes in favour of systematic instruction. However, issues related to the design and execution of effective instruction lack clarity and require further study. The interaction between the target learning objective and the individual learner profile is not well understood. The evidence review concludes with clinical recommendations based on the instructional literature and a call to clinicians to incorporate these methods into their practice to maximise patient outcomes.	[Ehlhardt, Laurie A.] Western Oregon Univ, Teaching Res Inst Eugene, Monmouth, OR USA; [Sohlberg, Mckay Moore] Univ Oregon, Eugene, OR 97403 USA; [Kennedy, Mary] Univ Minnesota, Minneapolis, MN USA; [Coelho, Carl] Univ Connecticut, Storrs, CT USA; [Ylvisaker, Mark] Coll St Rose, Albany, NY USA; [Turkstra, Lyn] Univ Wisconsin, Madison, WI 53706 USA; [Yorkston, Kathryn] Univ Washington, Seattle, WA 98195 USA		Sohlberg, MM (corresponding author), 5285 Univ Oregon Eugene, Eugene, OR 97403 USA.	mckay@uoregon.edu	Turkstra, Lyn/ABC-5831-2021	Turkstra, Lyn/0000-0002-6948-6921			Adams G. L., 1996, RES DIRECT INSTRUCTI; Andrewes D, 1999, NEUROPSYCHOL REHABIL, V9, P77, DOI 10.1080/713755591; BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; BRADLEY VA, 2003, EFFECTIVENESS REHABI, P115; BUTTERS MA, 1993, J CLIN EXP NEUROPSYC, V15, P219, DOI 10.1080/01688639308402559; Clare L, 2002, NEUROPSYCHOLOGY, V16, P538, DOI 10.1037//0894-4105.16.4.538; Clare L, 2000, J CLIN EXP NEUROPSYC, V22, P132, DOI 10.1076/1380-3395(200002)22:1;1-8;FT132; Donovan JJ, 1999, J APPL PSYCHOL, V84, P795, DOI 10.1037/0021-9010.84.5.795; Dou ZL, 2006, BRAIN INJURY, V20, P219, DOI 10.1080/02699050500488215; Ducharme JM, 2001, BRAIN INJURY, V15, P333, DOI 10.1080/02699050010005869; Dunn J, 2007, NEUROPSYCHOL REHABIL, V17, P735, DOI 10.1080/09602010701218317; Ehlhardt LA, 2005, BRAIN INJURY, V19, P569, DOI 10.1080/002699050400013550; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Franklin G., 2004, CLIN PRACTICE GUIDEL; GLANG A, 1992, J HEAD TRAUMA REHAB, V7, P93; GLISKY EL, 1989, NEUROPSYCHOLOGIA, V27, P107, DOI 10.1016/0028-3932(89)90093-6; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1987, NEUROPSYCHOLOGIA, V25, P893, DOI 10.1016/0028-3932(87)90094-7; GLISKY EL, 1992, NEUROPSYCHOLOGIA, V30, P899, DOI 10.1016/0028-3932(92)90034-J; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GONZALEZROTHI L, 2006, FED INT C TBI MARCH; Graham S., 2003, HDB LEARNING DISABIL, P323; Haslam C, 2006, NEUROPSYCHOL REHABIL, V16, P505, DOI 10.1080/09602010500231867; Hillary FG, 2003, J CLIN EXP NEUROPSYC, V25, P49, DOI 10.1076/jcen.25.1.49.13631; Hopper T, 2005, J MED SPEECH-LANG PA, V13, pXXVII; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; Hunkin NM, 1998, NEUROPSYCHOL REHABIL, V8, P433, DOI 10.1080/713755581; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P1255, DOI 10.1016/0028-3932(95)00061-7; Kalla T, 2001, NEUROPSYCHOL REHABIL, V11, P1; Kavale KA, 2000, J LEARN DISABIL-US, V33, P239, DOI 10.1177/002221940003300303; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kennedy MRT, 2002, J MED SPEECH-LANG PA, V10, pIX; Kern RS, 2002, AM J PSYCHIAT, V159, P1921, DOI 10.1176/appi.ajp.159.11.1921; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 1996, J PSYCHIATR RES, V30, P283, DOI 10.1016/0022-3956(96)00028-3; Kessels RPC, 2003, J CLIN EXP NEUROPSYC, V25, P805, DOI 10.1076/jcen.25.6.805.16474; Kim AH, 2004, J LEARN DISABIL-US, V37, P105, DOI 10.1177/00222194040370020201; Komatsu S, 2000, NEUROPSYCHOL REHABIL, V10, P113, DOI 10.1080/096020100389200; Laatsch LK, 2004, BRAIN INJURY, V18, P957, DOI 10.1080/02699050410001672369; Landis J, 2006, ARCH PHYS MED REHAB, V87, P799, DOI 10.1016/j.apmr.2006.02.017; LEMONCELLO R, 2005, ANN CONV AM SPEECH L; LENG NRC, 1991, BEHAV PSYCHOTHER, V19, P173, DOI 10.1017/S0141347300012209; MASTROPIERI MA, 1996, ADV LEARNING BEHAV D, P277; MCKENNA P, 1995, HDB MEMORY DISORDERS; Melton AK, 2005, APHASIOLOGY, V19, P353, DOI 10.1080/02687030444000804; Metzler-Baddeley C, 2005, J CLIN EXP NEUROPSYC, V27, P1070, DOI 10.1080/13803390490919164; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; O'Carroll RE, 1999, PSYCHOL MED, V29, P105, DOI 10.1017/S0033291798007673; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Page M, 2006, NEUROPSYCHOLOGIA, V44, P90, DOI 10.1016/j.neuropsychologia.2005.04.004; Parkin AJ, 1998, COGNITIVE NEUROPSYCH, V15, P361, DOI 10.1080/026432998381131; Pope JW, 2006, J CLIN EXP NEUROPSYC, V28, P101, DOI 10.1080/13803390490918138; Riley GA, 2004, NEUROPSYCHOL REHABIL, V14, P257, DOI 10.1080/09602010343000057; Riley GA, 2000, NEUROPSYCHOL REHABIL, V10, P133, DOI 10.1080/096020100389219; Rothi LJG, 2001, J MED SPEECH-LANG PA, V9, P117; Ruis C, 2005, AGING CLIN EXP RES, V17, P514, DOI 10.1007/BF03327420; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; SOHLBERG M, 2007, J MED SPEECH PATHOLO, V15; Sohlberg M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 2006, REV NEUROPSICOLOGIA, V1, P14; Sohlberg McKay Moore, 2005, Seminars in Speech and Language, V26, P268, DOI 10.1055/s-2005-922105; Sohlberg MM, 2003, J MED SPEECH-LANG PA, V11, pXIX; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; Stark C, 2005, NEUROPSYCHOLOGY, V19, P139, DOI 10.1037/0894-4105.19.2.139; Swanson HL, 2001, FOCUS EXCEPT CHILD, V34, P1; Swanson HL, 1998, REV EDUC RES, V68, P277, DOI 10.3102/00346543068003277; Swanson HL, 1996, SCHOOL PSYCHOL REV, V25, P370; SWANSON HL, 1999, LEARN DISABIL RES PR, V14, P129, DOI DOI 10.1207/SLDRP1403_; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Turkstra LS, 2005, J MED SPEECH-LANG PA, V13, P205; VANDERLINDEN M, 1994, CORTEX, V30, P305, DOI 10.1016/S0010-9452(13)80201-8; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Wilson FC, 2003, NEUROPSYCHOL REHABIL, V13, P537, DOI 10.1080/09602010343000200; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Ylvisaker M, 2002, J MED SPEECH-LANG PA, V10, pXXV; Ylvisaker M, 2003, ASHA S, V23, P59; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470; Young B, 2002, AQUAT CONSERV, V12, P3, DOI 10.1002/aqc.470	84	72	74	0	16	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2008	18	3					300	342		10.1080/09602010701733190			43	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychology	318CB	WOS:000257068100002	18569746				2022-02-06	
J	Hart, T; Fann, JR; Novack, TA				Hart, Tessa; Fann, Jesse R.; Novack, Thomas A.			The dilemma of the control condition in experience-based cognitive and behavioural treatment research	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							TRAUMATIC BRAIN-INJURY; INDUCED MOVEMENT THERAPY; CONTROLLED-TRIAL; REHABILITATION; INTERVENTIONS; PLACEBO; DEPRESSION; PSYCHOTHERAPY; APPROPRIATE; ALLIANCE	Rehabilitation using cognitive and behavioural treatment methods (i.e., experience-based interventions) faces particular challenges in improving its evidence base through rigorous studies such as randomised controlled trials (RCTs). Experience-based treatments are often complex, with multiple "active ingredients" that may be difficult to characterise. In addition to the difficulty in specifying treatment ingredients, experience-based rehabilitation researchers face challenges in designing or selecting appropriate control or comparison conditions to test the efficacy of complex treatments. Based on lessons learned in designing a cognitive-behavioural intervention for anger self-management for people with traumatic brain injury (TBI) for the National Institutes of Health (NIH)-funded TBI Clinical Trials Network, we review the advantages, disadvantages and applications of a variety of control conditions for experience-based interventions. We discuss controls in which active treatments are withheld (no-treatment controls, waitlist controls, and placebo-analogue designs); controls that involve comparison to naturally occurring or devised usual care treatments; and conditions that compare active treatments (dismantling designs, dose controls, and equivalence trials). Recommendations for selecting and developing control groups that maximise both equipoise and participant enrolment/retention are discussed.	[Hart, Tessa] Jefferson Med Coll, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; [Hart, Tessa] Jefferson Med Coll, Dept Rehabil Med, Philadelphia, PA USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Novack, Thomas A.] Univ Alabama, Dept Rehabil Med, Birmingham, AL USA		Hart, T (corresponding author), Jefferson Med Coll, Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD050836, U01 HD042738] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042738, R24HD050836] Funding Source: NIH RePORTER		Barkauskas VH, 2005, WESTERN J NURS RES, V27, P346, DOI 10.1177/0193945904271446; Baskin TW, 2003, J CONSULT CLIN PSYCH, V71, P973, DOI 10.1037/0022-006X.71.6.973; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Benda M, 1999, VACUUM, V55, P171, DOI 10.1016/S0042-207X(99)00145-1; BORKOVEC TD, 1996, PSYCHOTHERAPY REHABI, V5, P14; BUTLER G, 1991, J CONSULT CLIN PSYCH, V59, P167, DOI 10.1037/0022-006X.59.1.167; Carnevale GJ, 2002, J HEAD TRAUMA REHAB, V17, P83, DOI 10.1097/00001199-200204000-00002; Carroll KM, 1997, J CONSULT CLIN PSYCH, V65, P510, DOI 10.1037/0022-006X.65.3.510; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DEFFENBACHER JL, 1992, J COUNS PSYCHOL, V39, P158, DOI 10.1037/0022-0167.39.2.158; DEVINE E, 2005, ISSUES CHALLENGES CO; Dijkers M, 2002, AM J PHYS MED REHAB, V81, P21, DOI 10.1097/00002060-200201000-00005; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; GESUGENS C, 2006, NEUROPSYCHOL REHABIL, V16, P213; Joyce AS, 2003, J CONSULT CLIN PSYCH, V71, P672, DOI 10.1037/0022-006X.71.4.672; Karlawish JHT, 1998, ARCH NEUROL-CHICAGO, V55, P1420, DOI 10.1001/archneur.55.11.1420; Kupfer DJ, 2002, JAMA-J AM MED ASSOC, V287, P1853, DOI 10.1001/jama.287.14.1853; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; McMillan T, 2002, NEUROPSYCHOL REHABIL, V12, P117, DOI 10.1080/09602010143000202; Miller SS, 2000, EMERG MED CLIN N AM, V18, P233, DOI 10.1016/S0733-8627(05)70120-6; Mohr DC, 2005, ARCH GEN PSYCHIAT, V62, P1007, DOI 10.1001/archpsyc.62.9.1007; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Olsen DP, 2000, J ADV NURS, V31, P267, DOI 10.1046/j.1365-2648.2000.01301.x; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pyne JM, 2005, PSYCHOL MED, V35, P839, DOI 10.1017/S0033291704003332; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Saks ER, 2002, ETHICS BEHAV, V12, P87, DOI 10.1207/S15327019EB1201_6; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Silverman HJ, 2004, CRIT CARE MED, V32, P852, DOI 10.1097/01.CCM.0000114814.62759.06; Smeets RJEM, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-5; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; Sterr A, 2002, ARCH PHYS MED REHAB, V83, P1374, DOI 10.1053/apmr.2002.35108; Strasser DC, 2005, ARCH PHYS MED REHAB, V86, P403, DOI 10.1016/j.apmr.2004.04.046; Taub E, 2006, STROKE, V37, P1045, DOI 10.1161/01.STR.0000206463.66461.97; Whitehead WE, 2004, GASTROENTEROLOGY, V126, pS159, DOI 10.1053/j.gastro.2003.10.038; Whyte J, 2003, AM J PHYS MED REHAB, V82, P639, DOI 10.1097/01.PHM.0000078200.61840.2D; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477	39	72	72	0	17	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2008	18	1					1	21		10.1080/09602010601082359			21	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	249HD	WOS:000252218000001	17852761				2022-02-06	
J	Mbye, LH; Singh, IN; Sullivan, PG; Springer, JE; Hall, ED				Mbye, L. H.; Singh, I. N.; Sullivan, P. G.; Springer, J. E.; Hall, E. D.			Attenuation of acute mitochondrial dysfunction after traumatic brain injury in mice by NIM811, a non-immunosuppressive cyclosporin A analog	EXPERIMENTAL NEUROLOGY			English	Article						cyclosporin A; mitochondrial permeability transition; NIM811; oxidative damage; respiratory control ratio; traumatic brain injury	PERMEABILITY TRANSITION; CELL-DEATH; NITRIC-OXIDE; LIPID-PEROXIDATION; OXIDATIVE STRESS; DAMAGE; NEUROPROTECTION; INHIBITION; RATS; AMELIORATION	Following traumatic brain injury (TBI), mitochondrial function becomes compromised. Mitochondrial dysfunction is characterized by intra-mitochondrial Ca2+ accumulation, induction of oxidative damage, and mitochondrial permeability transition (mPT). Experimental studies show that cyclosporin A (CsA) inhibits mPT. However, CsA also inhibits calcineurin. In the present study, we conducted a dose-response analysis of NIM811, a non-calcineurin inhibitory CsA analog, on mitochondrial dysfunction following TBI in mice, and compared the effects of the optimal dose of NIM811 (10 mg/kg i.p.) against an optimized dose of CsA (20 mg/kg i.p.). Male CF-1 mice were subjected to severe TBI utilizing the controlled cortical impact model. Mitochondrial respiration was assessed from animals treated with either NIM811, CsA, or vehicle 15 min post-injury. The respiratory control ratio (RCR) of mitochondria from vehicle-treated animals was significantly (p < 0.01) lower at 3 or 12 h post-TBI, relative to shams. Treatment of animals with either NIM811 or CsA significantly (p < 0.03) attenuated this reduction. Consistent with this finding, both NIM811 and CsA significantly reduced lipid peroxidative and protein nitrative damage to mitochondria at 12 h post-TBI. These results showing the ability of NIM811 to fully duplicate the mitochondrial protective efficacy of CsA supports the conclusion that inhibition of the mPT may be sufficient to explain CsA's protective effects. (C) 2007 Elsevier Inc. All rights reserved.	[Mbye, L. H.; Singh, I. N.; Sullivan, P. G.; Springer, J. E.; Hall, E. D.] Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA		Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,Room B383 BBSRB, Lexington, KY 40536 USA.	edhall@uky.edu	springer, joe/B-2581-2014; Hall, Edward D/F-8930-2013	springer, joe/0000-0001-9611-8107; 	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS46566, NS048191] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566, R01NS048191] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; Floyd RA, 1992, ANN NEUROL, V32, P22; Fonagy A, 1999, COMP BIOCHEM PHYS B, V124, P51, DOI 10.1016/S0305-0491(99)00096-6; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Friberg H, 1998, J NEUROSCI, V18, P5151, DOI 10.1523/JNEUROSCI.18-14-05151.1998; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; HADDAD IY, 1993, AM J PHYSIOL, V265, P555; HALL ED, 1993, RES P ARNMD, V71, P81; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; HALLIWELL B, 1993, AM J CLIN NUTR, V57, pS724; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S; Hansson MJ, 2004, J BIOENERG BIOMEMBR, V36, P407, DOI 10.1023/B:JOBB.0000041776.31885.45; Hansson MJ, 2003, BRAIN RES, V960, P99, DOI 10.1016/S0006-8993(02)03798-8; Jiang H H, 2001, Sheng Li Ke Xue Jin Zhan, V32, P359; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Muramoto M, 2003, NEUROPHARMACOLOGY, V45, P394, DOI 10.1016/S0028-3908(03)00168-0; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Reed JC, 2000, CELL DEATH DIFFER, V7, P1145, DOI 10.1038/sj.cdd.4400777; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Waldmeier PC, 2003, CURR MED CHEM, V10, P1485, DOI 10.2174/0929867033457160; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	48	72	75	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	JAN	2008	209	1					243	253		10.1016/j.expneurol.2007.09.025			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	253EG	WOS:000252500900030	18022160				2022-02-06	
J	Ellemberg, D; Leclerc, S; Couture, S; Daigle, C				Ellemberg, Dave; Leclerc, Suzanne; Couture, Sandra; Daigle, Chantal			Prolonged neuropsychological impairments following a first concussion in female university soccer athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; women; soccer; neuropsychology; sports	TRAUMATIC BRAIN-INJURY; CONCUSSION HISTORY; SEX-DIFFERENCES; HEAD	Objective: Although research is accumulating on the cognitive sequelae from sports-related concussions in men, little to nothing is known about the prolonged cognitive outcome after a concussion 'm women. This point is important because recent evidence suggests th at female athletes are at greater risk of sustaining a concussion. Design: We assessed cognitive functioning after a first concussion n female soccer players, 6 to 8 months after their injury. The first-time concussed athletes were compared with a group of age-matched teammates who had never experienced a concussion. Setting and Participants: A total of 22 female university-level soccer players participated in the study. Main Outcome Measurements: Paper-and-pencil and computcrized tasks were used to assess different neuropsycliological functions. Results: Short- and long-term verbal memory, attention, and simrle reaction time were non-nal. In contrast, compared with the contiol group, the concussed athletes were significantly slower on tasks ttat required decision making (complex reaction time), inhibition and flexibility (Stroop), and planning (Tour of London task). Conclusions: The results of this study suggest that cognitive functions related to cognitive processing speed are most vulnerable to a sports-related concussion and are still impaired for a half year afcr injury in university-level female soccer players.	Univ Montreal, Dept Kinesiol, Montreal, PQ H3T 1J4, Canada; Ctr Rech En Neuropsychol Et Cognition, Montreal, PQ, Canada		Ellemberg, D (corresponding author), Univ Montreal, Dept Kinesiol, 2100 Edouard Montpetit, Montreal, PQ H3T 1J4, Canada.	dave.ellemberg@umontreal.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Covassin T, 2003, J ATHL TRAINING, V38, P238; CULBERTSON W, 2001, TOWER LONDON; Culbertson WC, 1998, ASSESSMENT, V5, P215, DOI 10.1177/107319119800500302; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Elwood RW, 1995, NEUROPSYCHOL REV, V5, P173, DOI 10.1007/BF02214761; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kelly JP, 1997, NEUROLOGY, V48, P581; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MASTER EJ, 1999, JAMA-J AM MED ASSOC, V282, P971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; *NAT COLL ATHL ASS, 2000, INJ SURV SYST AC YEA; PARKS RW, 1988, J CLIN EXP NEUROPSYC, V10, P565, DOI 10.1080/01688638808402795; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUFF RM, 1986, PERCEPT MOTOR SKILL, V62, P407, DOI 10.2466/pms.1986.62.2.407; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; Smith A., 1982, SYMBOL DIGIT MODALIT; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuss DT, 2005, NEUROPSYCHOLOGIA, V43, P396, DOI 10.1016/j.neuropsychologia.2004.06.010; THALHEIMER W, HOW CALCULATE EFFECT; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P204; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	47	72	72	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2007	17	5					369	374		10.1097/JSM.0b013e31814c3e3e			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	208GP	WOS:000249308100006	17873549				2022-02-06	
J	Zhou, ML; Shi, JX; Hang, CH; Cheng, HL; Qi, XP; Mao, L; Chen, KF; Yin, HX				Zhou, Men-Liang; Shi, Ji-Xin; Hang, Chun-Hua; Cheng, Hui-Lin; Qi, Xiao-Ping; Mao, Lei; Chen, Ke-Fei; Yin, Hong-Xia			Potential contribution of nuclear factor-kappa B to cerebral vasospasm after experimental subarachnoid hemorrhage in rabbits	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral vasospasm; inflammation; NF-kappa B; subarachnoid hemorrhage	SMOOTH-MUSCLE-CELLS; TRAUMATIC BRAIN-INJURY; PYRROLIDINE DITHIOCARBAMATE; OXIDATIVE STRESS; BASILAR ARTERY; TNF-ALPHA; ISCHEMIA; ACTIVATION; RATS; INFLAMMATION	Nuclear factor-kappa B (NF-kappa B) plays a key role in inflammation, which is involved in the development of cerebral vasospasm after subarachnoid hemorrhage (SAH). In the present study, we assessed the potential role of NF-kappa B in regulation of cerebral vasospasm. Nuclear factor-kappa B DNA-binding activity was measured in cultured vascular smooth muscle cells (VSMCs) treated with hemolysate and pyrrolidine dithiocarbamate (PDTC, 80 mu mol/L), an inhibitor of NF-kappa B. Forty-two rabbits were divided into three groups: control, SAH, and PDTC groups (n= 14 for each group). The caliber of the basilar artery was evaluated. Nuclear factor-kappa B DNA-binding activity and the gene expression levels of cytokines and adhesion molecules in the basilar artery were measured. Immunohistochernical study was performed to assess the expression and localization of tumor necrosis factor (TNF)-alpha, intercellular adhesion molecule (ICAM)-1, and myeloperoxidase (MPO). It was observed that NF-kappa B DNA-binding activity was significantly increased by treatment with hemolysate in cultured VSCMs, but this increase was suppressed by pretreatment with PDTC. Severe vasospasm was observed in the SAH group, which was attenuated in the PDTC group. Subarachnoid hemorrhage could induce increases of NF-KB DNA-binding activity and the gene expression levels of TNF-alpha, interleukin (IL)-1 beta, ICAM-1, and vascular cell adhesion molecule (VCAM)-1 which were reduced in the PDTC group. Immunohistochemical study demonstrated that the expression levels of TNF-alpha, ICAM-1, and MPO were all increased in the SAH group, but these increases were attenuated in the PDTC group. Our results suggest that NF-KB is activated in the arterial wall after SAH, which potentially leads to vasospasm development through induction of inflammatory response.	Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing 210002, Peoples R China; Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing 210008, Jiangsu, Peoples R China		Shi, JX (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.	shiix52@hotmail.com	Yin, Hong/AAC-5784-2020	Zhou, Meng-liang/0000-0002-1165-5489			Aihara Y, 2001, STROKE, V32, P212, DOI 10.1161/01.STR.32.1.212; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E; El Eter E, 2005, CAN J PHYSIOL PHARM, V83, P483, DOI 10.1139/Y05-034; Fassbender K, 2001, J NEUROL NEUROSUR PS, V70, P534, DOI 10.1136/jnnp.70.4.534; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HANDA Y, 1995, ACTA NEUROCHIR, V132, P92, DOI 10.1007/BF01404854; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2004, BRAIN RES, V1026, P23, DOI 10.1016/j.brainres.2004.07.090; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Iseki A, 2000, BIOCHEM BIOPH RES CO, V276, P88, DOI 10.1006/bbrc.2000.3452; KAHN SE, 1981, ANN CLIN LAB SCI, V11, P126; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kawanabe Y, 2002, J CARDIOVASC PHARM, V40, P438, DOI 10.1097/00005344-200209000-00013; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Lau D, 2006, PHARMACOL THERAPEUT, V111, P16, DOI 10.1016/j.pharmthera.2005.06.023; Li CF, 1999, AM J PHYSIOL-HEART C, V276, pH543, DOI 10.1152/ajpheart.1999.276.2.H543; Liu SF, 1999, MOL PHARMACOL, V55, P658; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; Moellering D, 1999, FREE RADICAL BIO MED, V26, P1138, DOI 10.1016/S0891-5849(98)00300-1; Monaco C, 2004, CARDIOVASC RES, V61, P671, DOI 10.1016/j.cardiores.2003.11.038; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nurmi A, 2004, J NEUROCHEM, V91, P755, DOI 10.1111/j.1471-4159.2004.02756.x; Nurmi A, 2004, STROKE, V35, P987, DOI 10.1161/01.STR.0000120732.45951.26; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; Shi XZ, 2003, GASTROENTEROLOGY, V124, P1369, DOI 10.1016/S0016-5085(03)00263-4; Song YS, 2005, J CEREBR BLOOD F MET, V25, P1301, DOI 10.1038/sj.jcbfm.9600123; STEELE JA, 1991, CIRC RES, V68, P416, DOI 10.1161/01.RES.68.2.416; Stephenson D, 2000, J CEREBR BLOOD F MET, V20, P592, DOI 10.1097/00004647-200003000-00017; Treggiari-Venzi MM, 2001, NEUROSURGERY, V48, P249, DOI 10.1097/00006123-200102000-00001; VARSOS VG, 1983, J NEUROSURG, V58, P11, DOI 10.3171/jns.1983.58.1.0011; Zeiffer U, 2004, CIRC RES, V94, P776, DOI 10.1161/01.RES.0000121105.72718.5C; Zhang W, 2005, J CEREBR BLOOD F MET, V25, P30, DOI 10.1038/sj.jcbfm.9600004; Zhou ML, 2007, J NEUROSCI METH, V159, P318, DOI 10.1016/j.jneumeth.2006.07.026; Zingarelli B, 2005, CRIT CARE MED, V33, pS414, DOI 10.1097/01.CCM.0000186079.88909.94; Zubkov AY, 1999, J NEUROSURG, V90, P1091, DOI 10.3171/jns.1999.90.6.1091	39	72	80	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2007	27	9					1583	1592		10.1038/sj.jcbfm.9600456			10	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	202ZY	WOS:000248946100006	17293842	Bronze			2022-02-06	
J	Robertson, CL; Saraswati, M; Fiskum, G				Robertson, Courtney L.; Saraswati, Manda; Fiskum, Gary			Mitochondrial dysfunction early after traumatic brain injury in immature rats	JOURNAL OF NEUROCHEMISTRY			English	Article						brain mitochondria; cerebral metabolism; cytochrome c; development; oxidative stress	PYRUVATE-DEHYDROGENASE COMPLEX; CYTOCHROME-C RELEASE; ALPHA-KETOGLUTARATE DEHYDROGENASE; TERM FOREBRAIN ISCHEMIA; OXIDATIVE STRESS; CELL-DEATH; CEREBROSPINAL-FLUID; HYPOXIA-ISCHEMIA; LIPID-PEROXIDATION; CASPASE ACTIVATION	Mitochondria play central roles in acute brain injury; however, little is known about mitochondrial function following traumatic brain injury (TBI) to the immature brain. We hypothesized that TBI would cause mitochondrial dysfunction early (< 4 h) after injury. Immature rats underwent controlled cortical impact (CCI) or sham injury to the left cortex, and mitochondria were isolated from both hemispheres at 1 and 4 h after TBI. Rates of phosphorylating (State 3) and resting (State 4) respiration were measured with and without bovine serum albumin. The respiratory control ratio was calculated (State 3/State 4). Rates of mitochondrial H2O2 production, pyruvate dehydrogenase complex enzyme activity, and cytochrome c content were measured. Mitochondrial State 4 rates (ipsilateral/contralateral ratios) were higher after TBI at 1 h, which was reversed with bovine serum albumin. Four hours after TBI, pyruvate dehydrogenase complex activity and cytochrome c content (ipsilateral/contralateral ratios) were lower in TBI mitochondria. These data demonstrate abnormal mitochondrial function early (<= 4 h) after TBI in the developing brain. Future studies directed at reversing mitochondrial abnormalities could guide neuroprotective interventions after pediatric TBI.	Univ Maryland, Dept Pediat, Sch Med, Baltimore, MD 21201 USA; Univ Maryland, Dept Anesthesiol, Sch Med, Baltimore, MD 21201 USA		Robertson, CL (corresponding author), Univ Maryland, Dept Pediat, Sch Med, 22 S Greene St,N5E13, Baltimore, MD 21201 USA.	croberts@peds.umaryland.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS42805] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS042805] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; ALLEN KL, 1995, J NEUROCHEM, V64, P2222; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Bayir H, 2006, BBA-BIOENERGETICS, V1757, P648, DOI 10.1016/j.bbabio.2006.03.002; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; BOOTH RFG, 1980, J NEUROCHEM, V34, P17, DOI 10.1111/j.1471-4159.1980.tb04616.x; Buki A, 2000, J NEUROSCI, V20, P2825; CARDELL M, 1989, J CEREBR BLOOD F MET, V9, P350, DOI 10.1038/jcbfm.1989.53; CLARK JB, 1993, DEV NEUROSCI-BASEL, V15, P174, DOI 10.1159/000111333; CULLINGFORD TE, 1994, J NEUROCHEM, V62, P1682; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200; ELNAGEH KM, 1988, J NEUROCHEM, V51, P1482, DOI 10.1111/j.1471-4159.1988.tb01115.x; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2004, J BIOENERG BIOMEMBR, V36, P347, DOI 10.1023/B:JOBB.0000041766.71376.81; Hagberg H, 2004, J BIOENERG BIOMEMBR, V36, P369, DOI 10.1023/B:JOBB.0000041770.00567.4f; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HILLERED L, 1988, J NEUROSCI RES, V20, P451, DOI 10.1002/jnr.490200407; HINMAN LM, 1981, J BIOL CHEM, V256, P6583; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; HOLTZMAN D, 1975, J NEUROCHEM, V24, P1011, DOI 10.1111/j.1471-4159.1975.tb03670.x; HOLTZMAN D, 1973, BIOL NEONATE, V22, P230; JOPE R, 1975, BIOCHEM J, V150, P397, DOI 10.1042/bj1500397; Kagan VE, 2006, CHEM-BIOL INTERACT, V163, P15, DOI 10.1016/j.cbi.2006.04.019; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lyeth BG, 1996, BRAIN RES, V742, P63, DOI 10.1016/S0006-8993(96)01002-5; MALLOCH GDA, 1986, BIOCHEM J, V238, P729, DOI 10.1042/bj2380729; Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Nakajima W, 2000, J NEUROSCI, V20, P7994; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Petrosillo G, 2003, FASEB J, V17, P2202, DOI 10.1096/fj.03-0012com; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Polster BM, 2003, CELL DEATH DIFFER, V10, P365, DOI 10.1038/sj.cdd.4401158; Richards EM, 2006, FREE RADICAL BIO MED, V40, P1960, DOI 10.1016/j.freeradbiomed.2006.01.022; Robertson CL, 2004, DEV BRAIN RES, V151, P141, DOI 10.1016/j.devbrainres.2004.04.007; Robertson CL, 2006, EXP NEUROL, V197, P235, DOI 10.1016/j.expneurol.2005.09.014; Robertson CL, 2006, DEV NEUROSCI-BASEL, V28, P432, DOI 10.1159/000094169; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Schuh RA, 2005, TOXICOL SCI, V88, P495, DOI 10.1093/toxsci/kfi334; SEVANIAN A, 1988, BIOCHIM BIOPHYS ACTA, V961, P316, DOI 10.1016/0005-2760(88)90079-3; SHINOHARA Y, 1995, BBA-BIOENERGETICS, V1228, P229, DOI 10.1016/0005-2728(94)00179-9; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2004, J NEUROSCI, V24, P7779, DOI 10.1523/JNEUROSCI.1899-04.2004; Starner TE, 2003, IEEE PERVAS COMPUT, V2, P86, DOI 10.1109/MPRV.2003.1251172; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tretter L, 2004, J NEUROSCI, V24, P7771, DOI 10.1523/JNEUROSCI.1842-04.2004; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vannucci SJ, 2004, J EXP BIOL, V207, P3149, DOI 10.1242/jeb.01064; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Zaidan E, 1998, J NEUROCHEM, V70, P233; Zaidan E, 1997, BRAIN RES, V772, P23, DOI 10.1016/S0006-8993(97)00833-0; ZAIDAN E, 1993, J CEREBR BLOOD F MET, V13, P98, DOI 10.1038/jcbfm.1993.12; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	68	72	72	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JUN	2007	101	5					1248	1257		10.1111/j.1471-4159.2007.04489.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	166GF	WOS:000246365600010	17403141	Bronze			2022-02-06	
J	Rees, L; Marshall, S; Hartridge, C; Mackie, D; Weiser, M				Rees, Laura; Marshall, Shawn; Hartridge, Cheryl; Mackie, David; Weiser, Margaret		ERABI Grp	Cognitive interventions post acquired brain injury	BRAIN INJURY			English	Article						attention; brain; brain injuries; craniocerebral trauma; cognition; cognition disorders; cognitive therapy; drug therapy; evidence-based medicine; memory; rehabilitation	CLOSED-HEAD-INJURY; METHYLPHENIDATE TREATMENT; POSTTRAUMATIC AMNESIA; MEMORY REMEDIATION; ATTENTION DEFICITS; TRAINING-PROGRAM; POCKET-COMPUTER; REHABILITATION; EFFICACY; PERFORMANCE	Objective: Cognitive rehabilitation represents a substantial portion of rehabilitative efforts put forth in increasing independence following an acquired brain injury. Main outcomes and results: This review examined four major areas of cognitive therapy including: attention/concentration, learning and memory, executive functioning, and general cognitive rehabilitation approaches. In total, 64 studies were evaluated throughout the four major areas, which provided the evidence-base for 18 conclusions. The majority of the conclusions were based on moderate and limited evidence, however three strong and one conflicting conclusions were made. Conclusions: Future research should explore functional outcome measures and long-term effects of treatment interventions through follow-up.	Univ Western Ontario, Ottawa Rehabil Ctr, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, St Josephs Hlth Care London, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, Div Phy Med, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Western Ontario, Div Rehabil, Schulich Sch Med & Dent, London, ON N6A 3K7, Canada; Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Sch Psychol, Ottawa, ON K1N 6N5, Canada		Marshall, S (corresponding author), Ottawa Hosp, Rehabil Ctr, Ottawa, ON, Canada.	smarshall@ottawahospital.on.ca					Alvarez XA, 2003, INT CLIN PSYCHOPHARM, V18, P271, DOI 10.1097/07.yic.0000085765.24936.9a; Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Berg IJ, 1991, NEUROPSYCHOL REHABIL, V1, P97, DOI DOI 10.1080/09602019108401384; Brett A W, 1998, Pediatr Rehabil, V2, P27; Burke DT, 2001, J HEAD TRAUMA REHAB, V16, P284, DOI 10.1097/00001199-200106000-00007; Chen SHA, 1997, BRAIN INJURY, V11, P197; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; CONSTANTINIDOU F, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199508000-00009; Dirette DK, 1999, J HEAD TRAUMA REHAB, V14, P595, DOI 10.1097/00001199-199912000-00008; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377, DOI 10.1136/jech.52.6.377; ESLINGER P, 2002, NEUROPSYCHOLOGICAL I; Evans J, 1992, CLIN REHABIL, V6, P75, DOI DOI 10.1177/026921559200600110; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Fasotti L, 2000, NEUROPSYCHOL REHABIL, V10, P47, DOI 10.1080/096020100389291; Gansler D A, 1991, Arch Clin Neuropsychol, V6, P335, DOI 10.1016/0887-6177(91)90010-7; Glisky EL, 1996, J HEAD TRAUMA REHAB, V11, P31, DOI 10.1097/00001199-199604000-00004; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Goldstein G, 1996, CLIN NEUROPSYCHOL, V10, P66, DOI 10.1080/13854049608406664; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Harrington D E, 1987, Brain Inj, V1, P65, DOI 10.3109/02699058709034447; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; Hux K, 2000, BRAIN INJURY, V14, P907; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MIDDLETON DK, 1991, PERCEPT MOTOR SKILL, V72, P527, DOI 10.2466/PMS.72.2.527-530; Milders M, 1998, MEMORY, V6, P21, DOI 10.1080/741941597; MILDERS MV, 1995, NEUROPSYCHOL REHABIL, V5, P223, DOI 10.1080/09602019508401468; Miller MA, 2003, ARCH PHYS MED REHAB, V84, pS12, DOI 10.1053/apmr.2003.50053; Moseley AM, 2002, AUST J PHYSIOTHER, V48, P43, DOI 10.1016/S0004-9514(14)60281-6; NIEMANN H, 1990, J CONSULT CLIN PSYCH, V58, P811, DOI 10.1037/0022-006X.58.6.811; Novack TA, 1996, J HEAD TRAUMA REHAB, V11, P52, DOI 10.1097/00001199-199606000-00008; Ownsworth TL, 1999, BRAIN INJURY, V13, P605, DOI 10.1080/026990599121340; Ownsworth TL, 2000, NEUROPSYCHOL REHABIL, V10, P465, DOI 10.1080/09602010050143559; Parente R, 1999, NEUROREHABILITATION, V13, P13; Parente R, 1999, NEUROREHABILITATION, V13, P157; Park NW, 1999, NEUROPSYCHOL REHABIL, V9, P135, DOI 10.1080/713755595; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Quemada JI, 2003, J HEAD TRAUMA REHAB, V18, P532, DOI 10.1097/00001199-200311000-00007; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RATTOK J, 1992, NEUROPSYCHOLOGIA, V6, P395, DOI DOI 10.1037/0894-4105.6.4.395; RUFF R, 1994, BRAIN INJURY, V8, P3, DOI 10.3109/02699059409150954; Ruff R. M., 1989, J HEAD TRAUMA REHAB, V4, P20, DOI [10.1097/00001199-198909000-00006, DOI 10.1097/00001199-198909000-00006]; Ryan T V, 1988, Arch Clin Neuropsychol, V3, P165, DOI 10.1016/0887-6177(88)90061-3; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; SCHMITTEREDGECOMBE M, 1995, J CONSULT CLIN PSYCH, V63, P484; Schneider WN, 1999, BRAIN INJURY, V13, P863; SOHLBERG MM, 1987, J CLIN EXP NEUROPSYC, V9, P117, DOI 10.1080/01688638708405352; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Stablum F, 2000, PSYCHOL RES-PSYCH FO, V63, P265, DOI 10.1007/s004269900002; Tailby R, 2003, NEUROPSYCHOLOGIA, V41, P1230, DOI 10.1016/S0028-3932(03)00036-8; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TWUM M, 1994, J CLIN EXP NEUROPSYC, V16, P630, DOI 10.1080/01688639408402674; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; Watanabe TK, 1998, BRAIN INJURY, V12, P81; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2001, INT J REHABIL RES, V24, P299, DOI 10.1097/00004356-200112000-00006; ZENCIUS A, 1991, Brain Injury, V5, P321, DOI 10.3109/02699059109008102; ZENCIUS A, 1990, Brain Injury, V4, P33, DOI 10.3109/02699059009026146; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014; [No title captured]; 2005, DEFINITION ACQUIRED	72	72	72	0	21	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2007	21	2					161	200		10.1080/02699050701201813			40	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	162SQ	WOS:000246110200005	17364530				2022-02-06	
J	Beers, SR; Berger, RP; Adelson, PD				Beers, Sue R.; Berger, Rachel P.; Adelson, P. David			Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children	JOURNAL OF NEUROTRAUMA			English	Article						calcium binding protein; myelin-basic protein; neuron-specific enolase	NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; SEVERE HEAD-INJURY; PROTEIN; S-100B; AGE; PREDICTOR; SEVERITY; DAMAGE; ABUSE	Traumatic brain injury (TBI) in infants and toddlers is frequently explained by child abuse. This study compared 6-month outcome in children with inflicted TBI (iTBI) or non-inflicted TBI (nTBI) who were injured before 3 years of age, and assessed the relationship between outcome and serum concentrations of neuron-specific enolase (NSE), S100B, and myelin-basic protein (MBP). Children with iTBI (n = 15) or nTBI (n = 15) of varying severity were assessed 6 months after injury using the Glasgow Outcome Scale (GOS), Vineland Adaptive Behavior Scale (VABS), and an intelligence quotient (IQ) measure. Serum concentrations of NSE, S100B, and MBP were measured soon after injury and every 12 h, for up to 5 days. Groups were matched by ethnicity, gender, socioeconomic status, and injury severity. Student's t-tests, analysis of covariance, or nonparametric tests assessed between-group differences for GOS, IQ, and biomarkers; correlation coefficients assessed relationships between outcome and biochemical markers. Functional and cognitive tests showed significant between-group differences (p <= 0.05); the iTBI group performed more poorly (GOS, 2.00 +/- 1.00 vs. 1.23 +/- 0.60; VABS, 95.92 +/- 14.05 vs. 115.80 +/- 20.02; IQ, 69.00 +/- 20.85 vs. 97.33 +/- 23.66). Significant between-group differences (iTBI vs. nTBI) were found for time to peak NSE (66.48 +/- 53.56 vs. 8.11 +/- 11.58), S100B (43.30 +/- 51.41 vs. 8.21 +/- 8.29), and MBP (77.66 +/- 56.77 vs. 21.63 +/- 28.39). Time to peak concentrations were significantly correlated with outcome measures. Children with iTBI are at risk for poorer outcome. Acute measurement of NSE, S100B, and MBP serum concentrations may provide a quantitative predictor of outcome after TBI in young children. Outcome may be due to the mechanism of iTBI, cumulative effects of unreported TBI, and/or other unidentified risk factors.	Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Pediat Neurosurg, Pittsburgh, PA 15261 USA		Beers, SR (corresponding author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA.	beerssr@upmc.edu	Adelson, David/W-2083-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 00084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23 HD 43843-01] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 38448-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038448] Funding Source: NIH RePORTER		Alexander R. C, 2001, CHILD ABUSE MED DIAG, P47; American College of Surgeons, 1997, ADV TRAUM LIF SUPP P, V6th; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Bandyopadhyay S, 2005, ACAD EMERG MED, V12, P732, DOI 10.1197/j.aem.2005.02.017; BARLOW L, 2004, PEDIAT REHABIL, V7, P195; BAYLEY N, 1993, BAYLEY SCALE INFANT; Beers SR, 2002, AM J PSYCHIAT, V159, P483, DOI 10.1176/appi.ajp.159.3.483; Berger RP, 2006, DEV NEUROSCI-BASEL, V28, P327, DOI 10.1159/000094158; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Ciccetti D., 1984, VINELAND ADAPTIVE BE; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Huck S. W., 1974, READING STAT RES; IRAZUZTA JE, 1997, CHILD ABUSE NEGL, V21, P69; JENNETT B, 1975, LANCET, V1, P480; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Lange N, 1997, J R STAT SOC C-APPL, V46, P1, DOI 10.1111/1467-9876.00046; Langlois JA, 2001, TRAUMATIC BRAIN INJU; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; MARKOFF KL, 2003, DEV MED CHILD NEUROL, V45, P497; Perez-Arjona E, 2003, CHILD NERV SYST, V19, P69, DOI 10.1007/s00381-002-0686-9; Rao P, 1999, CLIN RADIOL, V54, P495, DOI 10.1016/S0009-9260(99)90845-0; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Soares HD, 2003, J NEUROTRAUM, V20, P1080; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; *SPSS INC, 1989, SPSS WIND 11 5 0; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; THOMAS DJ, 1984, J NEUROL NEUROSUR PS, V47, P421; Thorndike R. L., 1986, STANFORD BINET INTEL; Thurman DJ, 2001, HEAD TRAUMA, P327; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	45	72	72	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					97	105		10.1089/neu.2006.0055			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100009	17263673				2022-02-06	
J	Ownsworth, T; Fleming, J; Strong, J; Radel, M; Chan, W; Clare, L				Ownsworth, Tamara; Fleming, Jenny; Strong, Jenny; Radel, Michael; Chan, Wilbur; Clare, Linda			Awareness typologies, long-term emotional adjustment and psychosocial outcomes following acquired brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							CLOSED-HEAD INJURY; SELF-AWARENESS; IMPAIRED AWARENESS; EXECUTIVE FUNCTION; DEFICITS; REHABILITATION; ANOSOGNOSIA; UNAWARENESS; SCALE; QUESTIONNAIRE	Previous research suggests considerable heterogeneity within groups of individuals identified as having low self-awareness or good self-awareness following acquired brain injury (ABI). The present study aimed to identify typologies of individuals according to neuropsychological and psychological factors related to awareness deficits and compare emotional adjustment and psychosocial outcomes at the initial assessment and 12-month follow-up. Eighty-four participants with ABI (mean time since injury 3.9 years) were assessed on the Self-Awareness of Deficits Interview, Awareness Questionnaire, Symptom Expectancy Checklist, Marlowe-Crowne Social Desirability Scale, Hospital Anxiety Depression Scale, Sydney Psychosocial Reintegration Scale, and an error self-regulation index. A 12-month follow-up assessment of emotional adjustment and psychosocial outcomes was conducted. A hierarchical cluster analysis distinguished four awareness typologies, namely, "poor self-awareness" (n = 12), "high defensiveness" (n = 13), "high symptom reporting" (n = 15), and "good self-awareness" (n = 44). An overall comparison of outcomes indicated that the poor self-awareness and high symptom reporting typologies experienced poorer outcomes than the high defensiveness and good self-awareness typologies. The findings confirm that there are different awareness typologies and highlight the need to tailor interventions according to the nature of awareness deficits.	Univ Queensland, Div Occupat Therapy, Brisbane, Qld, Australia; Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; Prince Charles Hosp, Rehabil Day Hosp, Div Geriatr & Rehabil Med, Brisbane, Qld 4032, Australia; Univ Wales, Sch Psychol, Bangor, Gwynedd, Wales		Ownsworth, T (corresponding author), Griffith Univ, Sch Psychol, Mt Gravatt Campus, Nathan, Qld 4111, Australia.	t.ownsworth@griffith.edu.au	Ownsworth, Tamara/ABB-6961-2021; Strong, Jenny/F-1211-2010; Fleming, Jennifer M/B-4436-2011	Ownsworth, Tamara/0000-0003-1835-7094; Strong, Jenny/0000-0002-9367-8755; Clare, Linda/0000-0003-3989-5318			Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cramer P, 1998, J PERS, V66, P919, DOI 10.1111/1467-6494.00037; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; CROWNE DP, 1960, J CONSULT PSYCHOL, V24, P349, DOI 10.1037/h0047358; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hartman-Maeir A, 2002, J REHABIL MED, V34, P158, DOI 10.1080/16501970213236; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; Katz Noomi, 2002, Can J Occup Ther, V69, P281; LANE RD, 1990, AM J PSYCHIAT, V147, P573; Langer KG., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [DOI 10.1080/09602019208401395, 10.1080/09602019208401395]; Lee GP, 1997, CLIN NEUROPSYCHOL, V11, P59, DOI 10.1080/13854049708407030; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth T., 2005, NEUROPSYCHOANALYSIS, V7, P83; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; Pepping M, 1991, NEUROPSYCHOLOGY EVER, P215; Pia L, 2004, CORTEX, V40, P367, DOI 10.1016/S0010-9452(08)70131-X; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1996, NEUROPSYCHOL REHABIL, V6, P305, DOI 10.1080/713755515; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; REYNOLDS WM, 1982, J CLIN PSYCHOL, V38, P119, DOI 10.1002/1097-4679(198201)38:1<119::AID-JCLP2270380118>3.0.CO;2-I; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Sherer M, 2005, J HEAD TRAUMA REHAB, V20, P287, DOI 10.1097/00001199-200507000-00002; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Vuilleumier P, 2004, CORTEX, V40, P9, DOI 10.1016/S0010-9452(08)70918-3; [No title captured]	44	72	72	0	14	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	2					129	150		10.1080/09602010600615506			22	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	165IP	WOS:000246298400001	17454690				2022-02-06	
J	Leaver, SG; Cui, Q; Bernard, O; Harvey, AR				Leaver, Simone G.; Cui, Qi; Bernard, Ora; Harvey, Alan R.			Cooperative effects of bcl-2 and AAV-mediated expression of CNTF on retinal ganglion cell survival and axonal regeneration in adult transgenic mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						anti-apoptosis; gene therapy; neurotrauma; optic nerve injury	CILIARY NEUROTROPHIC FACTOR; AXOTOMY-INDUCED APOPTOSIS; OPTIC-NERVE REGENERATION; LONG-TERM SURVIVAL; SPINAL-CORD-INJURY; IN-VIVO; GENE-TRANSFER; NEURONAL SURVIVAL; VIRAL VECTORS; CNS NEURONS	We used a gene therapy approach in transgenic mice to assess the cooperative effects of combining anti-apoptotic and growth-promoting stimuli on adult retinal ganglion cell (RGC) survival and axonal regeneration following intraorbital optic nerve injury. Bi-cistronic adeno-associated viral vectors encoding a secretable form of ciliary neurotrophic factor and green fluorescent protein (AAV-CNTF-GFP) were injected into eyes of mice that had been engineered to over-express the anti-apoptotic protein bcl-2. For comparison this vector was also injected into wildtype (wt) mice, and both mouse strains were injected with control AAV encoding GFP. Five weeks after optic nerve injury we confirmed that bcl-2 over-expression by itself promoted the survival of axotomized RGCs, but in contrast to previous reports we also saw regeneration of some mature RGC axons beyond the optic nerve crush. AAV-mediated expression of CNTF in adult retinas significantly increased the survival and axonal regeneration of RGCs following axotomy in wt and bcl-2 transgenic mice; however, the effects were greatest in the transgenic strain. Compared with AAV-GFP-injected bcl-2 mice, RGC viability was increased by about 50% (mean, 36 738 RGCs per retina), and over 1000 axons per optic nerve regenerated 1-1.5 mm beyond the crush. These findings exemplify the importance of using a multifactorial therapeutic approach that enhances both neuroprotection and regeneration after central nervous system injury.	Univ Western Australia, Sch Anat & Human Biol, Nedlands, WA 6009, Australia; Univ Western Australia, Sch Anim Biol, Nedlands, WA 6009, Australia; St Vincent Inst Med Res, Melbourne, Vic, Australia		Harvey, AR (corresponding author), Univ Western Australia, Sch Anat & Human Biol, 35 Stirling Hwy, Nedlands, WA 6009, Australia.	arharvey@anhb.uwa.edu.au	Harvey, Alan R/A-4911-2008	, Alan/0000-0002-2590-831X			Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Bahr M, 2000, TRENDS NEUROSCI, V23, P483, DOI 10.1016/S0166-2236(00)01637-4; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bernard R, 1997, DEV NEUROSCI-BASEL, V19, P79, DOI 10.1159/000111188; Bonfanti L, 1996, J NEUROSCI, V16, P4186; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chen J, 1996, P NATL ACAD SCI USA, V93, P7042, DOI 10.1073/pnas.93.14.7042; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Chierzi S, 1999, J NEUROSCI, V19, P8367; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cui Q, 2004, J NEUROTRAUM, V21, P617, DOI 10.1089/089771504774129946; Dietz GPH, 2001, NEUROREPORT, V12, P3353, DOI 10.1097/00001756-200110290-00041; Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Harvey AR, 2006, PROG RETIN EYE RES, V25, P449, DOI 10.1016/j.preteyeres.2006.07.002; Harvey AR, 2002, MOL CELL NEUROSCI, V21, P141, DOI 10.1006/mcne.2002.1168; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; Hermens WTJMC, 1998, PROG NEUROBIOL, V55, P399, DOI 10.1016/S0301-0082(98)00007-0; Hermens WTJMC, 1999, HUM GENE THER, V10, P1885, DOI 10.1089/10430349950017563; Inoue T, 2002, J NEUROSCI, V22, P4468, DOI 10.1523/JNEUROSCI.22-11-04468.2002; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Jiao JW, 2005, EMBO J, V24, P1068, DOI 10.1038/sj.emboj.7600589; Ju WK, 2000, NEUROREPORT, V11, P3893, DOI 10.1097/00001756-200011270-00057; Kretz A, 2004, MOL CELL NEUROSCI, V26, P63, DOI 10.1016/j.mcn.2004.01.007; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Liang FQ, 2001, MOL THER, V3, P241, DOI 10.1006/mthe.2000.0252; Lodovichi C, 2001, EUR J NEUROSCI, V13, P833, DOI 10.1046/j.1460-9568.2001.01440.x; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; MacLennan AJ, 2000, NEUROSCIENCE, V99, P761, DOI 10.1016/S0306-4522(00)90236-7; Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Park K, 2004, J NEUROSCI, V24, P10806, DOI 10.1523/JNEUROSCI.3532-04.2004; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Simon PD, 1999, HUM GENE THER, V10, P1715, DOI 10.1089/10430349950017716; Straten G, 2002, NEUROBIOL DIS, V11, P123, DOI 10.1006/nbdi.2002.0543; THANOS S, 1993, J NEUROSCI, V13, P455; van Adel BA, 2005, J NEUROBIOL, V63, P215, DOI 10.1002/neu.20117; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Whitmore AV, 2005, PROG RETIN EYE RES, V24, P639, DOI 10.1016/j.preteyeres.2005.04.004; Yin YQ, 2003, J NEUROSCI, V23, P2284; You SW, 2000, INVEST OPHTH VIS SCI, V41, P3165; ZENG BY, 1995, J ANAT, V186, P495; Zhi Y, 2005, BRAIN RES, V1047, P224, DOI 10.1016/j.brainres.2005.04.037	54	72	74	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2006	24	12					3323	3332		10.1111/j.1460-9568.2006.05230.x			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	116DR	WOS:000242783200001	17229081				2022-02-06	
J	Hardingham, GE				Hardingham, G. E.			Pro-survival signalling from the NMDA receptor	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article						apoptosis; calcium signalling; cAMP-response element (CRE)-binding protein (CREB); excitotoxicity; neuroprotection; N-methyl-D-aspartate receptor (NMDA receptor)	TRAUMATIC BRAIN-INJURY; NEURODEGENERATION; NEUROPROTECTION; PATHWAYS	Ca2+ influx through the NMDA (N-methyl-D-aspartate) subtype of ionotropic glutamate receptors plays a Jekyll and Hyde role in the mammalian central nervous system. While it mediates excitotoxic death triggered by stroke and other acute trauma, there is growing evidence that physiological levels of NMDA receptor activity promote survival. Understanding the mechanisms that underlie these opposing effects may lead to strategies to selectively block pro-death signalling, which could have considerable clinical benefits.	Univ Edinburgh, Ctr Neurosci Res, Edinburgh EH9 1QH, Midlothian, Scotland		Hardingham, GE (corresponding author), Univ Edinburgh, Ctr Neurosci Res, Summerhall Sq, Edinburgh EH9 1QH, Midlothian, Scotland.	Giles.Hardingham@ed.ac.uk		Hardingham, Giles/0000-0002-7629-5314	Wellcome TrustWellcome TrustEuropean Commission [078178] Funding Source: Medline		Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hardingham GE, 2001, NAT NEUROSCI, V4, P565, DOI 10.1038/88380; Hardingham GE, 2003, TRENDS NEUROSCI, V26, P81, DOI 10.1016/S0166-2236(02)00040-1; Hetman M, 2006, CURR TOP MED CHEM, V6, P787, DOI 10.2174/156802606777057553; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Ivanov A, 2006, J PHYSIOL-LONDON, V572, P789, DOI 10.1113/jphysiol.2006.105510; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Olney JW, 2002, BRAIN PATHOL, V12, P488, DOI 10.1111/j.1750-3639.2002.tb00467.x; Papadia S, 2005, J NEUROSCI, V25, P4279, DOI 10.1523/JNEUROSCI.5019-04.2005; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577	14	72	74	0	3	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0300-5127			BIOCHEM SOC T	Biochem. Soc. Trans.	NOV	2006	34		5				936	938		10.1042/BST0340936			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	109EE	WOS:000242289900065	17052231	Green Accepted, Green Submitted			2022-02-06	
J	McGrath, JC; Linley, PA				McGrath, Joanna Collicutt; Linley, P. Alex			Post-traumatic growth in acquired brain injury: A preliminary small scale study	BRAIN INJURY			English	Article						trauma; adversity; post-traumatic; growth; thriving; stroke; brain injury; benefit	STRESS-DISORDER; BREAST-CANCER; DEPRESSION; ANXIETY; TRAUMA; STROKE; SENSE	Primary objective: To examine the nature, degree and time course of positive psychological change in people with severe acquired brain injury. Research design: This preliminary exploratory study employed a cross-sectional design, comparing two matched samples, one early post-brain injury (M = 7 months) and one late post-brain injury (M = 10 years). Methods and procedures: The Posttraumatic Growth Inventory (PTGI), Sense of Coherence Scale-13 (SOC-13) and Hospital Anxiety and Depression Scale ( HADS) were administered. Main outcomes and results: The samples differed significantly with respect to reported post-traumatic growth, with the late sample reporting higher levels. HADS anxiety was significantly associated with post-traumatic growth. Both samples achieved high scores on the SOC-13. Conclusions: The participants showed evidence of substantial positive psychological change, demonstrating that it is not precluded by severe brain injury. The results suggest that this develops slowly over time and requires a degree of emotional engagement.	Oxford Ctr Enablement, Oxford, England; Univ Leicester, Leicester LE1 7RH, Leics, England		McGrath, JC (corresponding author), Univ Oxford, Wycliffe Hall,54 Banbury Rd, Oxford OX2 6PW, England.	jcollicutt@aol.co.uk	McGrath, John C/G-6485-2012	McGrath, John C/0000-0002-5276-0381			ADAMS N, 1996, AUSTR NZ J FAMILY TH, V17, P75; ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; BROOKS DN, 1984, CLOSED HEAD INJURY P; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Calhoun LG, 1998, LEA SER PER CLIN PSY, P215; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P155, DOI 10.1348/014466504323088033; Collin C, 1988, Int Disabil Stud, V10, P61; Cordova MJ, 2001, HEALTH PSYCHOL, V20, P176, DOI 10.1037//0278-6133.20.3.176; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HOUSE A, 1992, OX MED PUBL, P51; JOHNSON G, 1995, ACTA PSYCHIAT SCAND, V91, P252, DOI 10.1111/j.1600-0447.1995.tb09778.x; King LA, 2000, J RES PERS, V34, P509, DOI 10.1006/jrpe.2000.2285; Kneebone II, 2000, BRIT J CLIN PSYCHOL, V39, P53, DOI 10.1348/014466500163103; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Linley PA, 2003, J TRAUMA STRESS, V16, P601, DOI 10.1023/B:JOTS.0000004086.64509.09; Lyon Brenda L, 2002, Top Stroke Rehabil, V9, P1; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; McGrath J, 2004, CLIN REHABIL, V18, P767, DOI 10.1191/0269215504cr802oa; McGrath J, 2000, BEHAV NEUROL, V12, P201, DOI 10.1155/2000/612185; McGrath J., 2004, OXFORD GUIDE BEHAV E, P331; McMillan TM, 2003, NEUROPSYCHOL REHABIL, V13, P149, DOI 10.1080/09602010244000453; ODDY M, 1995, TRAUMATIC BRAIN INJU, P167; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Polatinsky S, 2000, J TRAUMA STRESS, V13, P709, DOI 10.1023/A:1007870419116; PRIGATANO G, 1999, PRINCIPLES NEUROPSYC, P89; Sampson MJ, 2003, INT J GERIATR PSYCH, V18, P23, DOI 10.1002/gps.763; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SNAPE MC, 1997, PSYCHOL HEALTH MED, V2, P237, DOI DOI 10.1080/13548509708400581; Snekkevik H, 2003, CLIN REHABIL, V17, P443, DOI 10.1191/0269215503cr630oa; Tedeschi RG, 2004, PSYCHOL INQ, V15, P1, DOI 10.1207/s15327965pli1501_01; Tedeschi RG, 1996, J TRAUMA STRESS, V9, P455, DOI 10.1007/BF02103658; TYERMAN A, 1984, INT J REHABILITATION, P11; Weiss T, 2002, J PSYCHOSOC ONCOL, V20, P65, DOI 10.1300/J077v20n02_04; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	72	74	0	20	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2006	20	7					767	773		10.1080/02699050600664566			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	062LV	WOS:000238947200011	16809209				2022-02-06	
J	Zhong, C; Zhao, XR; Van, KC; Bzdega, T; Smyth, A; Zhou, J; Kozikowski, AP; Jiang, JY; O'Connor, WT; Berman, RF; Neale, JH; Lyeth, BG				Zhong, C; Zhao, XR; Van, KC; Bzdega, T; Smyth, A; Zhou, J; Kozikowski, AP; Jiang, JY; O'Connor, WT; Berman, RF; Neale, JH; Lyeth, BG			NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat	JOURNAL OF NEUROCHEMISTRY			English	Article						gamma-aminobutyric acid; glutamate; metabotropic glutamate receptor; microdialysis; N-acetylaspartylglutamate; traumatic brain injury	TRAUMATIC BRAIN-INJURY; ENERGY-RELATED METABOLITES; GAMMA-AMINOBUTYRIC-ACID; UREA-BASED INHIBITORS; N-ACETYLASPARTYLGLUTAMATE; GROUP-II; CARBOXYPEPTIDASE-II; NEURONAL INJURY; AMINO-ACIDS; EXTRACELLULAR LEVELS	Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate that induces excitotoxic brain cell death. The peptide neurotransmitter N-acetyl-aspartylglutamate (NAAG) is reported to suppress neurotransmitter release through selective activation of presynaptic group II metabotropic glutamate receptors. Therefore, strategies to elevate levels of NAAG following brain injury could reduce excessive glutamate release associated with TBI. We hypothesized that the NAAG peptidase inhibitor, ZJ-43 would elevate extracellular NAAG levels and reduce extracellular levels of amino acid neurotransmitters following TBI by a group II metabotropic glutamate receptor (mGluR)-mediated mechanism. Dialysate levels of NAAG, glutamate, aspartate and GABA from the dorsal hippocampus were elevated after TBI as measured by in vivo microdialysis. Dialysate levels of NAAG were higher and remained elevated in the ZJ-43 treated group (50 mg/kg, i.p.) compared with control. ZJ-43 treatment also reduced the rise of dialysate glutamate, aspartate, and GABA levels. Co-administration of the group II mGluR antagonist, LY341495 (1 mg/kg, i.p.) partially blocked the effects of ZJ-43 on dialysate glutamate and GABA, suggesting that NAAG effects are mediated through mGluR activation. The results are consistent with the hypothesis that inhibition of NAAG peptidase may reduce excitotoxic events associated with TBI.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Neurosurg, Shanghai 200030, Peoples R China; Georgetown Univ, Dept Biol, Washington, DC 20057 USA; Univ Coll Dublin, Conway Inst, Appl Neurotherapeut Res Grp, Dublin 2, Ireland; Acenta Discovery Inc, Tucson, AZ USA; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu	O'Connor, William T./I-7459-2015	O'Connor, William/0000-0003-0082-1119; Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS45136, NS42672, NS38080, NS29995] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045136, R01NS042672, R01NS038080, R01NS029995] Funding Source: NIH RePORTER		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Alves OL, 2005, J NEUROTRAUM, V22, P733, DOI 10.1089/neu.2005.22.733; Aronica E, 2003, EUR J NEUROSCI, V17, P2106, DOI 10.1046/j.1460-9568.2003.02657.x; Bentzer P, 2000, J NEUROTRAUM, V17, P441, DOI 10.1089/neu.2000.17.441; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bischofberger J, 1996, J NEUROPHYSIOL, V76, P2089, DOI 10.1152/jn.1996.76.3.2089; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Coyle JT, 1997, NEUROBIOL DIS, V4, P231, DOI 10.1006/nbdi.1997.0153; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ferraguti F, 2001, EXP BRAIN RES, V137, P1, DOI 10.1007/s002210000633; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; GLOBUS MYT, 1991, J NEUROCHEM, V57, P470, DOI 10.1111/j.1471-4159.1991.tb03775.x; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; HSIAO JK, 1990, J NEUROCHEM, V54, P1449, DOI 10.1111/j.1471-4159.1990.tb01982.x; Jackson PF, 2001, CURR MED CHEM, V8, P949, DOI 10.2174/0929867013372797; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Jones CK, 2005, NEUROPHARMACOLOGY, V49, P206, DOI 10.1016/j.neuropharm.2005.05.008; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Koura SS, 1998, ACT NEUR S, V71, P244; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Kozikowski AP, 2001, J MED CHEM, V44, P298, DOI 10.1021/jm000406m; Luthi-Carter R, 1998, P NATL ACAD SCI USA, V95, P3215, DOI 10.1073/pnas.95.6.3215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Monn JA, 1999, J MED CHEM, V42, P1027, DOI 10.1021/jm980616n; MORARI M, 1994, EUR J PHARMACOL, V256, P23, DOI 10.1016/0014-2999(94)90611-4; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PARSONS LH, 1994, CRIT REV NEUROBIOL, V8, P189; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; PINHEIRO JC, 2000, MIXED EFFECTS MODELS, P11; R Core Team, 2019, R LANG ENV STAT COMP; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rong SB, 2002, J MED CHEM, V45, P4140, DOI 10.1021/jm010561g; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; SMYTH A, 2005, ACTA NEUROBIOL EXP, V65, P90; SMYTH A, 2005, P MOL MECH NEUR JOIN, P25; Smyth GK, 1996, J ROY STAT SOC B MET, V58, P565; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; Xi ZX, 2002, J PHARMACOL EXP THER, V300, P162, DOI 10.1124/jpet.300.1.162; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, BRAIN RES, V909, P138, DOI 10.1016/S0006-8993(01)02650-6; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zauner A, 1996, ACT NEUR S, V67, P40; ZEEVALK GD, 1993, J NEUROCHEM, V61, P1445, DOI 10.1111/j.1471-4159.1993.tb13639.x; Zhang W, 2002, J NEUROL SCI, V194, P21, DOI 10.1016/S0022-510X(01)00670-0; Zhao ZX, 2001, SOLID STATE SCI, V3, P339, DOI 10.1016/S1293-2558(00)01087-6; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; Zhou J, 2005, NAT REV DRUG DISCOV, V4, P1015, DOI 10.1038/nrd1903; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	70	72	77	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2006	97	4					1015	1025		10.1111/j.1471-4159.2006.03786.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	036HW	WOS:000237063200010	16606367	Green Submitted			2022-02-06	
J	Trokel, M; Wadimmba, A; Griffith, J; Sege, R				Trokel, M; Wadimmba, A; Griffith, J; Sege, R			Variation in the diagnosis of child abuse in severely injured infants	PEDIATRICS			English	Article						medical error; hospital discharge data; child abuse; femur fracture; traumatic brain injury; medical error	YOUNG-CHILDREN; HEALTH-CARE; HEAD-INJURY; FRACTURES; PHYSICIAN	OBJECTIVE. Diagnosis of child abuse is difficult and may reflect patient, practitioner, and system factors. Previous studies have demonstrated potential lethal consequences if cases of abuse are missed and suggested a role for continuing medical education in improving the accuracy of diagnosis of suspected abuse. Although the majority of injured American children are treated at general hospitals, most published studies of severe injury resulting from child abuse have been conducted at children's hospitals. The objective of this study was to evaluate the role of hospital type in observed variations in the frequency of diagnosis of child physical abuse among children with high-risk injuries. METHODS. Hospital discharge data were evaluated, and adjusted rates of abuse diagnosis were reported according to hospital type. A regression model estimated the number of cases of abuse that would have been diagnosed if all hospitals identified abuse as frequently as observed at pediatric specialty hospitals. This study consisted of children who were < 1 year old and admitted to US hospitals in 1997 for treatment of traumatic brain injury or femur fracture, excluding penetrating trauma or motor-vehicle-related injury. A total of 2253 weighted cases were analyzed. RESULTS. The proportion of patients with a medical diagnosis of child abuse varied widely between hospital types: 29% of the cases were diagnosed as abuse at children's hospitals compared with 13% at general hospitals. An estimated 178 infants (39% of total) with these specific injuries would have been identified as abused had they been treated at children's rather than general hospitals. CONCLUSIONS. Hospital type was associated with large variations in the frequency of diagnosis of child abuse. This variation was not related to observed differences in the patients or their injuries and may result from systematic underdiagnosis in general hospitals. This result has implications for quality-improvement programs at general hospitals, where the majority of injured children in the United States receive emergent medical care.	Boston Univ, Dept Publ Hlth, Boston, MA 02215 USA; Boston Med Ctr, Dept Pediat, Boston, MA USA; Tufts Univ, New England Med Ctr, Floating Hosp Children, Biostat Res Ctr, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Floating Hosp Children, Pediat & Adolescent Hlth Res Ctr, Boston, MA 02111 USA		Sege, R (corresponding author), NEMC, Box 351,750 Washington St, Boston, MA 02111 USA.	rsege@tufts-nemc.org		Sege, Robert/0000-0003-1260-4787; Waddimba, Anthony/0000-0002-5377-0864	AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS000060] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW001083] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32 HS00060] Funding Source: Medline; FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [D43TW001083-04] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49/CCR1186-03] Funding Source: Medline		ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; BADGER LW, 1989, SOUTHERN MED J, V82, P281, DOI 10.1097/00007611-198903000-00002; BEALS RK, 1983, J PEDIATR ORTHOPED, V3, P583, DOI 10.1097/01241398-198311000-00004; BENZEL EC, 1989, SOUTHERN MED J, V82, P1347, DOI 10.1097/00007611-198911000-00005; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; CANIANO DA, 1986, ANN SURG, V203, P219, DOI 10.1097/00000658-198602000-00017; DALTON HJ, 1990, AM J DIS CHILD, V144, P875, DOI 10.1001/archpedi.1990.02150320039022; DIAMOND P, 1994, PEDIATR EMERG CARE, V10, P83, DOI 10.1097/00006565-199404000-00005; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Flaherty EG, 2002, AMBUL PEDIATR, V2, P120, DOI 10.1367/1539-4409(2002)002<0120:AOSOAI>2.0.CO;2; Flaherty EG, 2000, ARCH PEDIAT ADOL MED, V154, P489, DOI 10.1001/archpedi.154.5.489; GROSS RH, 1983, J PEDIATR ORTHOPED, V3, P341, DOI 10.1097/01241398-198307000-00012; *HEALTHC COST UT P, 1997, KIDS INP DAT; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; JACKSON G, 1972, BRIT MED J, V2, P756, DOI 10.1136/bmj.2.5816.756; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Lane WG, 2002, JAMA-J AM MED ASSOC, V288, P1603, DOI 10.1001/jama.288.13.1603; Lawrence LL, 2000, MIL MED, V165, P607, DOI 10.1093/milmed/165.8.607; McCormick MC, 2000, PEDIATRICS, V105, P219; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; *US DEP HHS, 2003, CHILD MALTR 2001	22	72	72	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2006	117	3					722	728		10.1542/peds.2004-2731			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	017QV	WOS:000235709000043	16510652				2022-02-06	
J	Dohi, K; Satoh, K; Ohtaki, H; Shioda, S; Miyake, Y; Shindo, M; Aruga, T				Dohi, K; Satoh, K; Ohtaki, H; Shioda, S; Miyake, Y; Shindo, M; Aruga, T			Elevated plasma levels of bilirubin in patients with neurotrauma reflect its pathophysiological role in free radical scavenging	IN VIVO			English	Article						bilirubin; heme oxygenase; traumatic brain injury; antioxidant; bioantioxidant potential (BAP); electron spin resonance; ESR; hydroxyl radical	HEME OXYGENASE-1; OXIDATIVE STRESS; SERUM BILIRUBIN; CARBON-MONOXIDE; BRAIN-INJURY; RAT-BRAIN; RISK; ANTIOXIDANT; PEROXYNITRITE; ASSOCIATION	Bilirubin, a powerful endogenous antioxidant, is one of the catabolites of heme oxygenases (HOs). In this study, the plasma bilirubin concentration was measured to establish bilirubin kinesis after traumatic brain injury (TBI). Furthermore, in in vitro studies, the free radical scavenging activity and antioxidant potency of bilirubin was also investigated at various concentrations, including physiological ones. Indirect plasma bilirubin was measured in 25 patients on days 1, 2, 3 and 4 after presentation with TBI, The ability of bilirubin to scavenge the hydroxyl (OH.) and 1,1-diphenyl-2-picrylhyrazyl (DPPH) radicals, and its antioxidant potency, were also analyzed using electron spin resonance (ESR) and the bioantioxidant power (BAP) methods, respectively. Plasma bilirubin levels were significantly higher on days 2, 3 and 4 than on patient admission (day 1; p < 0.05). ESR and BAP results revealed that bilirubin has direct OH. and DPPH radical scavenging activities and potent antioxidant effects in vitro at physiological concentrations. These data indicate that physiological concentrations of bilirubin have antioxidant properties and that it constitutes one of the biological defense mechanisms in neurotrauma patients.	Showa Univ, Sch Med, Dept Crit Care & Emergency Med, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Anat, Tokyo 1428555, Japan		Dohi, K (corresponding author), Showa Univ, Sch Med, Dept Crit Care & Emergency Med, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	kdop@med.showa-u.ac.jp		dohi, kenji/0000-0002-4451-0382			Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; BREIMER LH, 1995, CLIN CHEM, V41, P1504; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chin K, 2001, SLEEP, V24, P218, DOI 10.1093/sleep/24.2.218; Clark JE, 2000, BIOCHEM J, V348, P615, DOI 10.1042/0264-6021:3480615; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; Dani C, 2003, ARCH DIS CHILD-FETAL, V88, pF119, DOI 10.1136/fn.88.2.F119; Dohi K, 2003, ACT NEUR S, V86, P247; Dohi K, 2003, ACT NEUR S, V86, P87; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; Hansen TWR, 1999, MOL GENET METAB, V68, P404, DOI 10.1006/mgme.1999.2899; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; HOUKIN K, 2003, CEREBROVASC DIS, V15, P222; Imaizumi Y, 2003, ACT NEUR S, V86, P101; Iwashita A, 2003, J PHARMACOL EXP THER, V307, P961, DOI 10.1124/jpet.103.056572; Kapitulnik J, 2004, MOL PHARMACOL, V66, P773, DOI 10.1124/mol.104.002832; Leinonen JS, 2000, STROKE, V31, P33, DOI 10.1161/01.STR.31.1.33; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; MAINES MD, 1986, J BIOL CHEM, V261, P411; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Mayer M, 2000, CLIN CHEM, V46, P1723; McCoubrey WK, 1997, EUR J BIOCHEM, V247, P725, DOI 10.1111/j.1432-1033.1997.00725.x; Mihara Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P94; Minetti M, 1998, ARCH BIOCHEM BIOPHYS, V352, P165, DOI 10.1006/abbi.1998.0584; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; OTSUJI S, 1988, CLIN BIOCHEM, V21, P33, DOI 10.1016/S0009-9120(88)80109-7; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; Siow RCM, 1999, CARDIOVASC RES, V41, P385, DOI 10.1016/S0008-6363(98)00278-8; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suzuki H, 1999, J CLIN INVEST, V104, P59, DOI 10.1172/JCI5357; Temme EHM, 2001, CANCER CAUSE CONTROL, V12, P887, DOI 10.1023/A:1013794407325; Tomaro ML, 2002, INT J BIOCHEM CELL B, V34, P216, DOI 10.1016/S1357-2725(01)00130-3; Van Hoydonck PGA, 2001, INT J EPIDEMIOL, V30, P1465; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165	44	72	75	0	0	INT INST ANTICANCER RESEARCH	ATHENS	EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22, ATHENS 19014, GREECE	0258-851X	1791-7549		IN VIVO	In Vivo	SEP-OCT	2005	19	5					855	860					6	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	951AU	WOS:000230901900007	16097438				2022-02-06	
J	Williams, GP; Robertson, V; Greenwood, KM; Goldie, PA; Morris, ME				Williams, GP; Robertson, V; Greenwood, KM; Goldie, PA; Morris, ME			The high-level mobility assessment tool (HiMAT) for traumatic brain injury. Part 2: Content validity and discriminability	BRAIN INJURY			English	Article; Proceedings Paper	1st Neurological Physiotherapy Conference of the National-Neurology-Group-of-Australian-Physiotherapy-Association	NOV, 2003	Sydney, AUSTRALIA	Natl Neurol Grp Australian Physiotherapy Assoc		brain injuries; rehabilitation; gait disorders; neurologic; outcome assessment	FUNCTIONAL MOBILITY; OBSTACLE COURSE; RASCH ANALYSIS; OLDER-ADULTS; STROKE; BALANCE; MOTOR; STABILITY; OUTCOMES; PROFILE	Primary objectives: (i) To assess the measurement properties of the high-level mobility assessment tool (HiMAT) for people with traumatic brain injury (TBI), (ii) to measure the extent to which the HiMAT is a uni-dimensional, discriminative hierarchical outcome scale. Research design: The content validity was assessed using a three-stage process of investigating internal consistency, factor analysis and Rasch analysis. The uni-dimensionality of the HiMAT items was also tested. Discriminability was investigated by correlating raw and logit scores obtained from Rasch analysis. The study was conducted at a major rehabilitation facility using a convenience sample of 103 adults with TBI. Main outcomes and results: The internal consistency for the high-level items was very high (Cronbach's alpha = 0.99). Principal axis factoring identified several balance items as belonging to a second factor not related to high-level mobility, hence these items were excluded. Rasch analysis identified several misfitting items, such as walking around a figure of eight and stopping from a run, which were also excluded. Logit scores were used to exclude clustered and, therefore, redundant items. Raw scores correlated very highly (r = 0.98) with logit scores, indicating that raw scores provided good discriminability and were suitable for use by clinicians. Conclusion: The HiMAT, which assesses higher-level mobility requirements of people with TBI for return to pre-accident social, leisure and sporting activities, is a uni-dimensional and discriminative scale for quantifying therapy outcomes.	Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; Univ Newcastle, Newcastle, NSW 2308, Australia; La Trobe Univ, Bundoora, Vic 3083, Australia		Williams, GP (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavinw@epworth.org.au	Greenwood, Kenneth M/J-8993-2015	Greenwood, Kenneth M/0000-0002-8420-6588; Williams, Gavin/0000-0003-2758-7473; Morris, Meg/0000-0002-0114-4175			Badke Mary Beth, 1993, Physiotherapy Canada, V45, P15; Baer HR, 2001, STROKE, V32, P973, DOI 10.1161/01.STR.32.4.973; BERG K, 1989, Physiotherapy Canada, V41, P304; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Brauer S, 1999, Physiother Res Int, V4, P81, DOI 10.1002/pri.155; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; CHANG WC, 1995, ARCH PHYS MED REHAB, V76, P934, DOI 10.1016/S0003-9993(95)80070-0; Collen F M, 1991, Int Disabil Stud, V13, P50; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; GOWLAND C, 1993, STROKE, V24, P58, DOI 10.1161/01.STR.24.1.58; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; KORNERBITENSKY N, 1989, ARCH PHYS MED REHAB, V70, P95; Linacre J M, 1999, J Outcome Meas, V3, P103; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Lincoln N, 1979, Physiotherapy, V65, P48; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Means KM, 1996, J REHABIL RES DEV, V33, P413; Means KM, 1996, AM J PHYS MED REHAB, V75, P88, DOI 10.1097/00002060-199603000-00003; Newton RA, 2001, J GERONTOL A-BIOL, V56, pM248, DOI 10.1093/gerona/56.4.M248; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PASTOR MA, 1993, BRAIN, V116, P1177, DOI 10.1093/brain/116.5.1177; PFEIFFER E, 1981, J AM GERIATR SOC, V29, P433, DOI 10.1111/j.1532-5415.1981.tb01744.x; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; ROTHSTEIN JM, 1991, PHYS THER, V71, P589, DOI 10.1093/ptj/71.8.589; SEABY L, 1989, Physiotherapy Canada, V41, P264; Sosin DM, 1996, BRAIN INJURY, V10, P47; Tang PF, 1998, J GERONTOL A-BIOL, V53, pM140, DOI 10.1093/gerona/53A.2.M140; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Williams G, 2001, BRAIN INJURY, V15, P831; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	36	72	72	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2005	19	10					833	843		10.1080/02699050500058711			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800009	16175843				2022-02-06	
J	Fehlings, MG; Baptiste, DC				Fehlings, MG; Baptiste, DC			Current status of clinical trials for acute spinal cord injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						clinical trials; acute spinal cord injury; neurotrauma; neuroprotection; pharmacological; apoptosis	THYROTROPIN-RELEASING-HORMONE; METHYLPREDNISOLONE SODIUM SUCCINATE; NEUROPROTECTIVE AGENT; DOSE-RESPONSE; RECOVERY; NIMODIPINE; GACYCLIDINE; MACROPHAGES; MULTICENTER; NALOXONE	Acute spinal cord injury (ASCI) occurs as a result of physical disruption of spinal cord axons through the epicenter of injury leading to deficits in motor, sensory, and autonomic function. This is a debilitating neurological disorder common in young adults that often requires life-long therapy and rehabilitative care, placing a significant burden on our healthcare system. While no cure exists, research has identified various pharmacological compounds that specifically antagonize primary and secondary mechanisms contributing to the etiology of ASCI. Several compounds including methylprednisotone (MPSS), GM-1 ganglioside, thyrotropin releasing hormone (TRH), nimodipine, and gacyclidine have been tested in prospective randomized clinical trials of ASCI. MPSS and GM-1 ganglioside have shown evidence of modest benefits. Clearly trials of improved neuroprotective agents are required. Promising potential therapies for ASCI include riluzole, minocycline, erythropoietin, and the fusogen polyethylene glycol, as well as mild hypothermia.	Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Toronto Western Res Inst, Div Neurosurg, 4th Floor,W Wing,Room 449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; BOSE B, 1986, NEUROSCI LETT, V63, P165, DOI 10.1016/0304-3940(86)90055-8; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.1984.03340250025015; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; Dergham P, 2002, J NEUROSCI, V22, P6570; Drian MJ, 1999, J NEUROSCI RES, V57, P927, DOI 10.1002/(SICI)1097-4547(19990915)57:6<927::AID-JNR18>3.0.CO;2-C; Dubreuil CI, 2003, J CELL BIOL, V162, P233, DOI 10.1083/jcb.200301080; DUCKER TB, 1994, SPINE, V19, P2281, DOI 10.1097/00007632-199410150-00006; FADEN AI, 1989, ANN NY ACAD SCI, V553, P380; FADEN AI, 1984, J NEUROSURG, V60, P796, DOI 10.3171/jns.1984.60.4.0796; FADEN AI, 1984, NEUROLOGY, V34, P1280, DOI 10.1212/WNL.34.10.1280; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; Feldblum S, 2000, J NEUROTRAUM, V17, P1079, DOI 10.1089/neu.2000.17.1079; FERRARI G, 1983, DEV BRAIN RES, V8, P215, DOI 10.1016/0165-3806(83)90006-8; FEUERSTEIN G, 1984, Neuroscience Research, V2, P121, DOI 10.1016/0168-0102(84)90010-5; FEUERSTEIN G, 1984, CIRC SHOCK, V13, P255; Ford R W, 1985, Cent Nerv Syst Trauma, V2, P9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS58, DOI 10.1097/00007632-200112151-00013; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Geisler FH, 2001, SPINE, V26, pS68, DOI 10.1097/00007632-200112151-00014; GUHA A, 1987, J NEUROSURG, V66, P423, DOI 10.3171/jns.1987.66.3.0423; Hadley MN, 2002, NEUROSURGERY, V50, pS63; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; Hall ED, 1989, J NEUROTRAUM, V6, P227, DOI 10.1089/neu.1989.6.227; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hirbec H, 2002, J NEUROSCI RES, V68, P305, DOI 10.1002/jnr.10203; Hirbec H, 2001, CNS DRUG REV, V7, P172; Hurlbert RJ, 2000, J NEUROSURG, V93, P1, DOI 10.3171/spi.2000.93.1.0001; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kadoya, 1994, SEKITSUI SEKIZUI J, V7, P633; KALIA M, 1982, NEUROSCI LETT, V34, P1, DOI 10.1016/0304-3940(82)90083-0; Karpiak S E, 1984, Adv Exp Med Biol, V174, P489; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KAZDA S, 1982, ARZNEIMITTEL-FORSCH, V32-1, P331; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; LAINETTI RD, 1993, BRAZ J MED BIOL RES, V26, P841; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; LAZAREWICZ JW, 1990, STROKE, V21, P108; Lazarov-Spiegler O, 1998, MOL MED TODAY, V4, P337, DOI 10.1016/S1357-4310(98)01298-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296, DOI 10.1096/fasebj.10.11.8836043; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; Lepeintre JF, 2004, NEUROCHIRURGIE, V50, P83; Luo J, 2004, NEUROSCI LETT, V359, P167, DOI 10.1016/j.neulet.2004.02.027; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P373, DOI 10.1089/neu.1993.10.373; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mitha A P, 2001, Curr Opin Investig Drugs, V2, P814; Monnier PP, 2003, MOL CELL NEUROSCI, V22, P319, DOI 10.1016/S1044-7431(02)00035-0; NAFTCHI NE, 1982, PEPTIDES, V3, P235, DOI 10.1016/0196-9781(82)90084-5; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Petitjean ME, 1998, ANN FR ANESTH, V17, P114, DOI 10.1016/S0750-7658(98)80058-0; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Ross IB, 1991, J NEUROTRAUM, V8, P229, DOI 10.1089/neu.1991.8.229; ROSS IB, 1993, SURG NEUROL, V40, P461, DOI 10.1016/0090-3019(93)90048-6; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shi R, 1999, J NEUROPHYSIOL, V81, P2406, DOI 10.1152/jn.1999.81.5.2406; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727; STEEN PA, 1983, J CEREBR BLOOD F MET, V3, P38, DOI 10.1038/jcbfm.1983.4; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Sung JK, 2003, BRAIN RES, V959, P29, DOI 10.1016/S0006-8993(02)03717-4; TADIE M, 1999, SOCN EUR ABSTR, P1090; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; WINKLER T, 1994, ACTA NEUROCHIR, P511	74	72	74	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JUL	2005	36			2			113	122		10.1016/j.injury.2005.06.022			10	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	951DA	WOS:000230908000014					2022-02-06	
J	Horner, MD; Ferguson, PL; Selassie, AW; Labbate, LA; Kniele, K; Corrigan, JD				Horner, MD; Ferguson, PL; Selassie, AW; Labbate, LA; Kniele, K; Corrigan, JD			Patterns of alcohol use 1 year after traumatic brain injury: A population-based, epidemiological study	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						alcohol abuse; alcohol drinking; alcoholism; epidemiological studies; follow-up studies; substance abuse; traumatic brain injury	NATIONAL PROBABILITY SAMPLE; AMERICAN DRINKING PRACTICES; SUBSTANCE-ABUSE; PSYCHIATRIC-DISORDERS; DRUG-USE; AXIS-I; EXTENT	This study delineated patterns of alcohol use 1 year after traumatic brain injury (TBI) in a large, population-based, epidemiological, nonclinical sample, and identified predictors of heavy alcohol use in these individuals. Participants were 1,606 adults identified by review of a South Carolina statewide hospital discharge data set, on the basis of satisfying the Centers for Disease Control case definition of TBI, and were interviewed by telephone 1 year after TBI-related discharge. Alcohol use in the month prior to interview was classified according to categories from the Quantity-Frequency-Variability Index; heavy drinking was defined as nearly daily use with >= 5 drinks at least occasionally, or at least three occasions with >= 5 drinks. A polychotomous logistic regression with 3 response levels (heavy, moderate, and abstinent/infrequent/light drinking) was used to identify predictors of heavy drinking. Heavy drinking in the month prior to interview was reported by 15.4% of participants, while 14.3% reported moderate drinking and 70.3% reported abstinence or light/infrequent drinking. Risk factors for heavy drinking included male gender, younger age, history of substance abuse prior to TBI, diagnosis of depression since TBI, fair/moderate mental health, and better physical functioning. There was no association between drinking patterns and TBI severity.	Ralph H Johnson Dept VA Med Ctr, Mental Hlth Serv, Charleston, SC USA; Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH USA		Horner, MD (corresponding author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv, 109 Bee St, Charleston, SC 29401 USA.	hornermd@musc.edu	Cusco, Xavier Garcia/S-7576-2019	Cusco, Xavier Garcia/0000-0001-7199-6931			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bombardier CH, 2002, ARCH PHYS MED REHAB, V83, P1765, DOI 10.1053/apmr.2002.36085; Burnett DM, 2000, BRAIN INJURY, V14, P713; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; *CDC, 2003, BEH RISK FACT SURV S; Corrigan J. D., 1999, REHABILITATION ADULT; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; *CTR INJ RES POL J, 1997, ICMAP90 SOFTW; DARLINGTON GA, 1998, ENCY BIOSTATISTICS, P788; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; ELLERD DA, 1992, J APPL REHABILITATIO, V23, P48; Findler RB, 2001, ACM SIGPLAN NOTICES, V36, P1, DOI 10.1145/504311.504283; Gentilello LM, 1999, ANN SURG, V230, P473, DOI 10.1097/00000658-199910000-00003; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MASSAGLI TL, 1996, ARCH PHYS MED REHAB, V77, P25; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P174; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; *SAS I, 2001, STAT AN SOFTW VERS 8; Sherer M, 1999, BRAIN INJURY, V13, P973; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stokes ME, 1995, CATEGORICAL DATA ANA, P217; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Ware JE., 1993, SF36 HLTH SURVEY MAN	38	72	72	0	5	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2005	11	3					322	330		10.1017/S135561770505037X			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	924UL	WOS:000229005900011	15892908				2022-02-06	
J	Mailhan, L; Azouvi, P; Dazord, A				Mailhan, L; Azouvi, P; Dazord, A			Life satisfaction and disability after severe traumatic brain injury	BRAIN INJURY			English	Article; Proceedings Paper	3rd World Congress in Neurological Rehabilitation	APR 02-06, 2002	VENICE, ITALY				QUALITY-OF-LIFE; BLUNT HEAD-INJURY; RATING-SCALE; REHABILITATION; EMPLOYMENT; RELATIVES; OUTCOMES; PROFILE; SAMPLE; COMA	Objective: To assess the relationships between life satisfaction and disability after a severe traumatic brain injury (TBI). Design: Cross-sectional study, including 75 patients 2 years or more after a severe TBI. Methods: Life satisfaction was assessed with the Subjective Quality of Life Profile. Impairments, activities and participation were assessed with standardized tests. Results: The satisfaction profile was flat, i.e. the majority of items obtained mean satisfaction scores close to 0, suggesting that participants felt indifferent to these items or in other words that they were neither satisfied nor unsatisfied. Patients were on average slightly dissatisfied with their cognitive functions, physical abilities and self-esteem. A factor analysis revealed three underlying factors. The main finding was that the relationships between life satisfaction and disability were not linear: the lowest satisfaction scores were reported by participants with moderate disability rated by the Glasgow Outcome Scale, while individuals with severe disability did not significantly differ from the good recovery group. Conclusion: Life satisfaction is not linearly related to disability after severe TBI.	Univ Versailles, Hop Raymond Poincare, Dept Neurol Rehabil,Serv Reeduc Neurol, Format Rech Associee Claude Bernard, F-92380 Garches, France; Univ Versailles, Hop Raymond Poincare, Fac Med Paris Ile France Ouest, INSERM,U483, F-92380 Garches, France; Hop St Jean de Dieu, Script Inserm, Lyon, France		Azouvi, P (corresponding author), Univ Versailles, Hop Raymond Poincare, Dept Neurol Rehabil,Serv Reeduc Neurol, Format Rech Associee Claude Bernard, F-92380 Garches, France.	philippe.azouvi@rpc.aphp.fr					Andresen EM, 2000, ARCH PHYS MED REHAB, V81, pS30, DOI 10.1053/apmr.2000.20621; AZOUVI P, UNPUB LIFE SATISFACT; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Bonomi AE, 2000, J CLIN EPIDEMIOL, V53, P1, DOI 10.1016/S0895-4356(99)00123-7; Bonomi AE, 2000, J CLIN EPIDEMIOL, V53, P19, DOI 10.1016/S0895-4356(99)00121-3; Bradley C, 2001, LANCET, V357, P7, DOI 10.1016/S0140-6736(00)03562-5; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P93; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dazord A, 1996, EUR PSYCHIAT, V11, P277, DOI 10.1016/S0924-9338(96)89895-6; Dazord A, 1998, EUR PSYCHIAT, V13, P235, DOI 10.1016/S0924-9338(98)80011-4; Dazord A, 1998, COMMUNITY MENT HLT J, V34, P525, DOI 10.1023/A:1018746614552; Dazord A., 1994, QUALITY LIFE ASSESSM, P185; DAZORD A, 1997, QUALITY LIFE NEWSLET, V18, P7; Dehail P., 1998, Annales de Readaptation et de Medecine Physique, V41, P133, DOI 10.1016/S0168-6054(98)80011-1; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; GERIN P, 1992, FUNDAM CLIN PHARM, V6, P263, DOI 10.1111/j.1472-8206.1992.tb00120.x; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LORHANDICAP GDR, 2000, REV SCI HUMAINES SOC, V88, P1; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCleary C, 1998, J CLIN EXP NEUROPSYC, V20, P270, DOI 10.1076/jcen.20.2.270.1172; Morton RP, 2003, LARYNGOSCOPE, V113, P1091, DOI 10.1097/00005537-200307000-00001; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Riegel B, 2003, QUAL LIFE RES, V12, P689, DOI 10.1023/A:1025132623647; SARTORIUS N, 1993, ARCH GEN PSYCHIAT, V50, P819; SmithKnapp K, 1996, BRAIN INJURY, V10, P651, DOI 10.1080/026990596124070; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1989, MED CARE, V27, pS44, DOI 10.1097/00005650-198903001-00004; Truelle J L, 1990, Brain Inj, V4, P305, DOI 10.3109/02699059009026181; Vanier M, 2000, ARCH PHYS MED REHAB, V81, P796, DOI 10.1016/S0003-9993(00)90114-X; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 2001, BRAIN DAM B, P3	56	72	74	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					227	238		10.1080/02699050410001720149			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400001	15832869				2022-02-06	
J	Germano, C; Kinsella, GJ				Germano, C; Kinsella, GJ			Working memory and learning in early Alzheimer's disease	NEUROPSYCHOLOGY REVIEW			English	Article						early Alzheimer's disease; working memory; learning; acquisition	TRAUMATIC BRAIN INJURY; MINI-MENTAL-STATE; FRONTOTEMPORAL DEMENTIA; NEUROPSYCHOLOGICAL MEASURES; EXECUTIVE FUNCTION; DIVIDED ATTENTION; RETRIEVAL; IMPAIRMENT; PATTERNS; DEFICITS	Cognitive deficits associated with early Alzheimer's disease (AD) have been recently operationalised in terms of an acquisition deficit and the research supporting this view is presented. However, there is still debate concerning the nature of this deficit and how underlying cognitive processes may be detrimentally affecting the ability to acquire new information in early AD. This review argues that the pattern of cognitive deficits contributing to the acquisition impairment in early AD patients may be readily interpreted within the context of a working memory model. Isolating the component processes of working memory that underlie the acquisition deficit in early AD patients will aid in the design of clinical applications that are focussed at enhancing the ability to acquire new information in everyday life.	La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia		Kinsella, GJ (corresponding author), La Trobe Univ, Sch Psychol Sci, Bundoora, Vic 3086, Australia.	g.kinsella@latrobe.edu.au	Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			Albert MS, 2001, J INT NEUROPSYCH SOC, V7, P631, DOI 10.1017/S1355617701755105; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Backman L, 1998, PSYCHOL AGING, V13, P267; BADDELEY A, 1992, SCIENCE, V255, P556, DOI 10.1126/science.1736359; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; BADDELEY A, 1984, J EXP PSYCHOL GEN, V113, P518, DOI 10.1037/0096-3445.113.4.518; Baddeley A, 2002, NEUROPSYCHOLOGIA, V40, P1737, DOI 10.1016/S0028-3932(01)00146-4; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; BADDELEY A, 1997, COGNITIVE MODELS MEM, P61; Baddeley AD, 2000, J EXP PSYCHOL GEN, V129, P126, DOI 10.1037//0096-3445.129.1.126; Baddeley AD, 2001, BRAIN, V124, P1492, DOI 10.1093/brain/124.8.1492; Baddeley AD, 2001, AM PSYCHOL, V56, P851, DOI 10.1037/0003-066X.56.11.851; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; Baddeley AD, 2000, J EXP CHILD PSYCHOL, V77, P128, DOI 10.1006/jecp.2000.2592; BADDELEY AD, 1974, PSYCHOL LEARNING MOT; BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9; Belleville S, 1996, NEUROPSYCHOLOGIA, V34, P195, DOI 10.1016/0028-3932(95)00097-6; Bird M, 2001, NEUROPSYCHOL REHABIL, V11, P357, DOI 10.1080/09602010042000042; Brown S.C., 2000, OXFORD HDB MEMORY, P93, DOI DOI 10.1016/J.ADOLESCENCE.2017.05.018; Cahn D A, 1997, J Int Neuropsychol Soc, V3, P387; Cannata AP, 2002, DEMENT GERIATR COGN, V13, P101, DOI 10.1159/000048641; Carlesimo GA, 1998, J CLIN EXP NEUROPSYC, V20, P14, DOI 10.1076/jcen.20.1.14.1482; Cherry K.E., 1999, J CLIN GEROPSYCHOLOG, V5, P159, DOI DOI 10.1023/A:1022983131186; Collette F, 1999, NEUROPSYCHOLOGIA, V37, P905, DOI 10.1016/S0028-3932(98)00148-1; Collette F, 1999, CORTEX, V35, P57, DOI 10.1016/S0010-9452(08)70785-8; CRONINGOLOMB A, 1992, PSYCHOL AGING, V7, P359, DOI 10.1037/0882-7974.7.3.359; Crowell TA, 2002, AGING NEUROPSYCHOL C, V9, P288, DOI 10.1076/anec.9.4.288.8772; Curtiss G, 2001, J INT NEUROPSYCH SOC, V7, P574, DOI 10.1017/S1355617701755051; Dorrego MF, 1999, J NEUROPSYCH CLIN N, V11, P490, DOI 10.1176/jnp.11.4.490; Engle RW, 2002, CURR DIR PSYCHOL SCI, V11, P19, DOI 10.1111/1467-8721.00160; Fernandes MA, 2000, J EXP PSYCHOL GEN, V129, P155, DOI 10.1037/0096-3445.129.2.155; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox N C, 1999, Rev Neurol (Paris), V155 Suppl 4, pS33; Gathercole S., 1994, NEUROPSYCHOLOGY, V8, P494, DOI DOI 10.1037/0894-4105.8.4.494; Glosser G, 2002, NEUROPSYCHOLOGY, V16, P190, DOI 10.1037//0894-4105.16.2.190; GRANHOLM E, 1988, BRAIN COGNITION, V7, P335, DOI 10.1016/0278-2626(88)90007-3; Greene JDW, 1996, NEUROPSYCHOLOGIA, V34, P537, DOI 10.1016/0028-3932(95)00151-4; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; GROBER E, 1991, J CLIN EXP NEUROPSYC, V13, P667, DOI 10.1080/01688639108401081; Grober E, 1997, PSYCHOL AGING, V12, P183, DOI 10.1037/0882-7974.12.1.183; GROBER E, 1985, BRAIN LANG, V26, P276, DOI 10.1016/0093-934X(85)90043-4; HAXBY JV, 1988, NEUROLOGY, V38, P1853, DOI 10.1212/WNL.38.12.1853; HILL RD, 2000, COGNITIVE REHABILITA, P23; Kellogg RT, 1996, AM J PSYCHOL, V109, P205, DOI 10.2307/1423273; KOPELMAN MD, 1985, NEUROPSYCHOLOGIA, V23, P623, DOI 10.1016/0028-3932(85)90064-8; LAFLECHE G, 1995, NEUROPSYCHOLOGY, V9, P313, DOI 10.1037/0894-4105.9.3.313; Lipinska B, 1997, BRAIN COGNITION, V34, P274, DOI 10.1006/brcg.1997.0916; Logie RH, 1996, WORKING MEMORY HUMAN, P31, DOI DOI 10.1093/ACPROF:OSO/9780195100990.003.0002; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P336, DOI 10.1037/0278-7393.24.2.336; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Miyake A, 2001, J EXP PSYCHOL GEN, V130, P621, DOI 10.1037/0096-3445.130.4.621; MORRIS RG, 1984, COGNITIVE NEUROPSYCH, V1, P143, DOI 10.1080/02643298408252019; MOSCOVITCH M, 1992, J COGNITIVE NEUROSCI, V4, P257, DOI 10.1162/jocn.1992.4.3.257; MOSCOVITCH M, 1991, PERSPECTIVES COGNITI, P229; Moscovitch M., 1994, NEUROPSYCHOLOGY, V8, P524; Naveh-Benjamin M, 2000, Q J EXP PSYCHOL-A, V53, P609, DOI 10.1080/027249800410454; O'Hara R, 2000, WESTERN J MED, V172, P115, DOI 10.1136/ewjm.172.2.115; PARASURAMAN R, 1992, BRAIN, V115, P711, DOI 10.1093/brain/115.3.711; PARKIN AJ, 1997, MEMORY AMNESIA INTRO, P124; Pasquier F, 2001, NEUROCASE, V7, P161, DOI 10.1076/neur.7.2.161.16263; Perry RJ, 1999, BRAIN, V122, P383, DOI 10.1093/brain/122.3.383; Perry RJ, 2000, NEUROLOGY, V54, P2277, DOI 10.1212/WNL.54.12.2277; Perry RJ, 2000, NEUROPSYCHOLOGIA, V38, P252, DOI 10.1016/S0028-3932(99)00079-2; Reid W, 1996, ARCH NEUROL-CHICAGO, V53, P1056, DOI 10.1001/archneur.1996.00550100142023; Rochon E, 2000, J SPEECH LANG HEAR R, V43, P395, DOI 10.1044/jslhr.4302.395; Rosen VM, 2002, NEUROPSYCHOLOGIA, V40, P2226, DOI 10.1016/S0028-3932(02)00132-X; Schmitter-Edgecombe M, 1999, MEM COGNITION, V27, P512, DOI 10.3758/BF03211545; SGARAMELLA TM, 2001, TENNET, V11, P264; Shah, 1999, MODELS WORKING MEMOR, DOI DOI 10.1017/CBO9781139174909.005; SIMON E, 1994, J CLIN EXP NEUROPSYC, V16, P414, DOI 10.1080/01688639408402652; SPINNLER H, 1988, COGNITIVE NEUROPSYCH, V5, P193, DOI 10.1080/02643298808252933; Storey E, 2002, FRONT BIOSCI-LANDMRK, V7, pE155, DOI 10.2741/storey; Storey E, 2001, J ALZHEIMERS DIS, V3, P261, DOI 10.3233/JAD-2001-3302; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922, DOI 10.1111/j.1532-5415.1992.tb01992.x; Tulving E., 2000, OXFORD HDB MEMORY, P441; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; WEINGARTNER H, 1981, J ABNORM PSYCHOL, V90, P187, DOI 10.1037/0021-843X.90.3.187; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; WENGER JL, 1995, J EXP PSYCHOL HUMAN, V21, P170; WILSON RS, 1983, J CLIN NEUROPSYCHOL, V5, P337, DOI 10.1080/01688638308401181	82	72	75	0	12	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1040-7308	1573-6660		NEUROPSYCHOL REV	Neuropsychol. Rev.	MAR	2005	15	1					1	10		10.1007/s11065-005-3583-7			10	Psychology, Clinical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	920EZ	WOS:000228673500001	15929495				2022-02-06	
J	Creeley, CE; Wozniak, DF; Bayly, PV; Olney, JW; Lewis, LM				Creeley, CE; Wozniak, DF; Bayly, PV; Olney, JW; Lewis, LM			Multiple episodes of mild traumatic brain injury result in impaired cognitive performance in mice	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine	MAY 29-JUN 01, 2003	BOSTON, MA	Soc Acad Emergency Med		traumatic brain injury; concussion; memory; cognition; mice	COLLEGIATE FOOTBALL PLAYERS; ALZHEIMERS-DISEASE; HEAD-INJURY; SOCCER INJURIES; RISK; MODEL; CONCUSSION; PROTEIN; SPORTS; TIME	Objectives: Results from recent studies on animal models of concussion suggest that multiple, rather than single, episodes of mild traumatic brain injury result in impaired cognitive performance in mice. The objective of the present study was to administer multiple impacts to the heads of mice while directly measuring the force of the impacts to determine how these parameters are related to transient loss of consciousness, cognitive deficits, and potential neuropathologic effects. Methods: Seven-week-old male C57BL/6 mice were randomly assigned to experimental conditions involving three impacts (weight-drop method) to the head to induce mild traumatic brain injury or to sham control procedures. Some impacted (n = 10) and sham control (n = 10) mice were evaluated behaviorally and tested for spatial learning using the Morris water maze (MWM), whereas other impacted (n = 10) and sham control (n = 5) mice were used for histopathologic analysis. Results: The mean (+/-SD) force of impact was 19 (+/-3.5) N. Impacted mice took longer to regain consciousness compared with sham control mice (p < 0.0005). Behavioral test results showed that the groups did not differ on activity or sensorimotor tests or during cued trials in the MWM. Impacted mice exhibited impaired spatial learning performance during place trials in the MWM (p < 0.05). Silver staining revealed a contra-coup type of injury involving ventral brain structures in contact with or in close proximity to the skull. Conclusions: This multiple-impact model, delivered within a specifiable force range, results in transient, reversible loss of consciousness, a contra-coup brain injury, and cognitive impairment.	Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mech Engn, St Louis, MO 63110 USA		Lewis, LM (corresponding author), Washington Univ, Sch Med, Div Emergency Med, Box 8072,600 S Euclid Ave, St Louis, MO 63110 USA.	lewisl@msnotes.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005681, P01AG011355] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG11355, P50AG05681] Funding Source: Medline		ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fratiglioni L, 1993, Acta Neurol Scand Suppl, V145, P1; GRONWALL D, 1975, LANCET, V2, P995; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ross J, 2000, HAEMOPHILIA, V6, P41; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Wozniak DF, 1996, BRAIN RES, V707, P165, DOI 10.1016/0006-8993(95)01230-3	31	72	73	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2004	11	8					809	819		10.1197/j.aem.2004.03.006			11	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	843NP	WOS:000223090900001	15289185	Bronze			2022-02-06	
J	Oquendo, MA; Friedman, JH; Grunebaum, MF; Burke, A; Silver, JM; Mann, JJ				Oquendo, MA; Friedman, JH; Grunebaum, MF; Burke, A; Silver, JM; Mann, JJ			Suicidal behavior and mild traumatic brain injury in major depression	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						suicidal behavior; traumatic brain injury; major depression; aggression; cluster B personality disorder	PSYCHIATRIC-DISORDERS; AXIS-I; SCALE; IDEATION; RISK; PSYCHOPATHOLOGY; INDIVIDUALS; INVENTORY; CHILDREN; ILLNESS	Traumatic brain injury (TBI) is associated with psychiatric illness, suicidal ideation, suicide attempts, and completed suicide. We investigated the relationship between mild TBI and other risk factors for suicidal behavior in major depressive episode. We hypothesized that mild TBI would be associated with suicidal behavior at least partly because of shared risk factors that contribute to the diathesis for suicidal acts. Depressed patients (N = 325) presenting for treatment were evaluated for psychopathology, traumatic history, and suicidal behavior. Data were analyzed using Student t-test, chi-square statistic, or Fisher exact test. A backward stepwise logistic regression model (N = 255) examined the relationship between attempter status and variables that differed in the TBI and non-TBI patients. Forty-four percent of all subjects reported mild TBI. Subjects with TBI were more likely to be male, have a history of substance abuse, have cluster B personality disorder, and be more aggressive and hostile compared with subjects without TBI. They were also more likely to be suicide attempters, although their suicidal behavior was not different from that of suicide attempters without TBI. Attempt status was mostly predicted by aggression and hostility, but not the presence of TBI. Of note, for males, a history of TBI increased the likelihood of being a suicide attempter, whereas the risk was elevated for females regardless of TBI history. Our data suggest that suicidal behavior and TBI share antecedent risk factors: hostility and aggression. Future studies may yield confirmation using a prospective design.	Columbia Univ, New York State Psychiat Inst, Dept Neurosci, New York, NY 10032 USA; Lenox Hill Hosp, New York, NY 10021 USA; NYU, Sch Med, New York, NY USA		Oquendo, MA (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Neurosci, 1051 Riverside Dr,Unit 41, New York, NY 10032 USA.		Oquendo, Maria/AAC-6237-2019		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH062185, R01MH048514] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH62185, MH48514-09] Funding Source: Medline		*AM PSYCH ASS TASK, 1987, DIAGN STAT MAN MENT; Anderson, 1998, Semin Clin Neuropsychiatry, V3, P232; BARRATT ES, 1965, PSYCHOL REP, V16, P547, DOI 10.2466/pr0.1965.16.2.547; BECK AT, 1979, J CONSULT CLIN PSYCH, V47, P343, DOI 10.1037/0022-006X.47.2.343; BECK AT, 1975, AM J PSYCHIAT, V132, P285; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BIJUR P, 1988, AM J DIS CHILD, V142, P1307, DOI 10.1001/archpedi.1988.02150120061041; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; BUSS AH, 1957, J CONSULT PSYCHOL, V21, P343, DOI 10.1037/h0046900; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Deb S, 1999, AM J PSYCHIAT, V156, P374; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; First M.B., 1996, STRUCTURED CLIN INTE; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Leon-Carrion J, 2001, BRAIN INJURY, V15, P175, DOI 10.1080/026990501458407; LINEHAN MM, 1983, J CONSULT CLIN PSYCH, V51, P276, DOI 10.1037/0022-006X.51.2.276; Loranger A.W., 1987, J PERSONALITY DISORD, V1, P1, DOI [DOI 10.1521/PEDI.1987.1.1.1, 10.1521/pedi.1987.1.1.1]; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1998, BRAIN INJURY, V12, P41; Oquendo M. A., 2003, STANDARDIZED EVALUAT, P103; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Sorenson SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI [10.1097/00001199-199106000-00003, DOI 10.1097/00001199-199106000-00003]; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; [No title captured], DOI DOI 10.1001/ARCHPSYC.1961.01710120031004	35	72	72	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	JUN	2004	192	6					430	434		10.1097/01.nmd.0000126706.53615.7b			5	Clinical Neurology; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	828BB	WOS:000221946400006	15167407				2022-02-06	
J	Johnston, AJ; Steiner, LA; Chatfield, DA; Coles, JP; Hutchinson, PJ; Al-Rawi, PG; Menon, DK; Gupta, AK				Johnston, AJ; Steiner, LA; Chatfield, DA; Coles, JP; Hutchinson, PJ; Al-Rawi, PG; Menon, DK; Gupta, AK			Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury	INTENSIVE CARE MEDICINE			English	Article						norepinephrine; dopamine; brain tissue oxygen; cerebral microdialysis; head injury; cerebral oxygenation	BLOOD-FLOW; CORTICAL PERFUSION; METABOLISM; BARRIER; EDEMA	Objective. To compare the effects of a cerebral perfusion pressure (CPP) intervention achieved with dopamine and norepinephrine after severe head injury. Design. Prospective, controlled, trial. Setting. Neurosciences critical care unit. Patients. Eleven patients with a head injury, requiring dopamine or norepinephrine infusions to support CPP. Intervention. Cerebral tissue gas measurements were recorded using a multimodal sensor, and regional chemistry was assessed using microdialysis. Patients received in, randomised order, either dopamine or norepinephrine to achieve and maintain a CPP of 65 mmHg, and then, following a 30-min period of stable haemodynamics, a CPP of 85 mmHg. Data were then acquired using the second agent. Haemodynamic measurements and measurements of cerebral physiology were made during each period. Measurements and results. The CPP augmentation with norepinephrine, but not with dopamine, resulted in a significant reduction in arterial-venous oxygen difference (37+/-11 vs 33+/-12 ml/l) and a significant increase in brain tissue oxygen (2.6+/-1.1 vs 3.0+/-1.1 kPa). The CPP intervention did not significantly affect intracranial pressure. There were no significant differences between norepinephrine and dopamine on cerebral oxygenation or metabolism either at baseline or following a CPP intervention; however, the response to a CPP intervention with dopamine seemed to be more variable than the response achieved with norepinephrine. Conclusions. If CPP is to be raised to a level higher than 65-70 mmHg, then it is important to recognise that the response to the intervention may be unpredictable and that the vasoactive agent used may be of importance.	Univ Cambridge, Addenbrookes Hosp, Dept Anaesthet, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England		Johnston, AJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anaesthet, Box 93, Cambridge CB2 2QQ, England.	ajj29@cam.ac.uk	Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Coles, Jonathan/0000-0003-4013-679X	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI		ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; EDVINSSON L, 1978, J PHYSIOL-LONDON, V274, P149, DOI 10.1113/jphysiol.1978.sp012140; Edvinsson L, 2002, CEREBRAL BLOOD FLOW; Grande PO, 2000, ACTA ANAESTH SCAND, V44, P886, DOI 10.1034/j.1399-6576.2000.440718.x; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Haitsma Iain K, 2002, Curr Opin Crit Care, V8, P115, DOI 10.1097/00075198-200204000-00005; Hutchinson PJA, 2000, BRIT J NEUROSURG, V14, P46; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; MCCALDEN TA, 1977, AM J PHYSIOL, V233, pH458, DOI 10.1152/ajpheart.1977.233.4.H458; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Myburgh JA, 1998, ACT NEUR S, V71, P19; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stocchetti N, 1998, ACT NEUR S, V71, P162; TUOR UI, 1986, AM J PHYSIOL, V251, pH824, DOI 10.1152/ajpheart.1986.251.4.H824; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	26	72	74	0	2	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAY	2004	30	5					791	797		10.1007/s00134-003-2155-7			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	817BW	WOS:000221154000010	15048550				2022-02-06	
J	Steiner, LA; Johnston, AJ; Czosnyka, M; Chatfield, DA; Salvador, R; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK				Steiner, LA; Johnston, AJ; Czosnyka, M; Chatfield, DA; Salvador, R; Coles, JP; Gupta, AK; Pickard, JD; Menon, DK			Direct comparison of cerebrovascular effects of norepinephrine and dopamine in head-injured patients	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; cerebral perfusion; cerebral blood flow; norepinephrine; dopamine; transcranial Doppler	CEREBRAL-BLOOD-FLOW; CORTICAL IMPACT INJURY; TRANSCRANIAL DOPPLER; PERFUSION; HYPERTENSION; AUTOREGULATION; EPINEPHRINE; CIRCULATION; RATS	Objective: To directly compare the cerebrovascular effects of norepinephrine and dopamine in patients with acute traumatic brain injury. Design. Prospective randomized crossover trial. Setting. Neurosciences critical care unit of a university hospital. Patients: Ten acutely head-injured patients requiring vasoactive drugs to maintain a cerebral perfusion pressure of 65 mm Hg. Interventions: Patients were randomized to start the protocol with either norepinephrine or dopamine. Using an infusion of the allocated drug, cerebral perfusion pressure was adjusted to 65 mm Hg. After 20 mins of data collection, cerebral perfusion pressure was increased to 75 mm Hg by increasing the infusion rate of the vasoactive agent. After 20 mins of data collection, cerebral perfusion pressure was increased to 85 mm Hg and again data were collected for 20 mins. Subsequently, the infusion rate of the vasoactive drug was reduced until a cerebral perfusion pressure of 65 mm Hg was reached and the drug was exchanged against the other agent. The protocol was then repeated. Measurements and Main Results. Mean arterial pressure and intracranial pressure were monitored and cerebral blood flow was estimated with transcranial Doppler. Norepinephrine led to predictable and significant increases in flow velocity for each step increase in cerebral perfusion pressure (57.5 +/- 19.9 cm(.)sec(-1), 61.3 +/- 22.3 cm(.)sec(-1), and 68.4 +/- 24.8 cm-sec(-1) at 65, 75, and 85 mm Hg, respectively; p < .05 for all three comparisons), but changes with dopamine were variable and inconsistent. There were no differences between absolute values of flow velocity or intracranial pressure between the two drugs at any cerebral perfusion pressure level. Conclusions. Norepinephrine may be more predictable and efficient to augment cerebral perfusion in patients with traumatic brain injury.	Univ Cambridge, Wolfson Brain Imaging Ctr, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Anesthesia, Cambridge CB2 2QQ, England		Steiner, LA (corresponding author), Univ Basel, Dept Anaesthesia, Kantonsspital, CH-4031 Basel, Switzerland.	lsteiner@uhbs.ch	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Salvador, Raymond/0000-0001-5557-1562; Coles, Jonathan/0000-0003-4013-679X	MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G9439390] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		COLEMAN MR, 2002, J NEUROSURG ANESTHES, V14, P91; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; EDVINSSON L, 1978, ACTA PHYSIOL SCAND, V104, P349, DOI 10.1111/j.1748-1716.1978.tb06286.x; Fukushima U, 1999, J VET MED SCI, V61, P1293, DOI 10.1292/jvms.61.1293; Kroppenstedt SN, 2002, ACT NEUR S, V81, P225; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; LAM AM, 1995, ANESTHESIOLOGY, V82, P1536, DOI 10.1097/00000542-199506000-00035; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; MacGregor DA, 2000, ANESTHESIOLOGY, V92, P338, DOI 10.1097/00000542-200002000-00013; MACKENZIE ET, 1976, AM J PHYSIOL, V231, P483, DOI 10.1152/ajplegacy.1976.231.2.483; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Myburgh JA, 1998, ACT NEUR S, V71, P19; Myburgh JA, 2001, INTENS CARE MED, V27, P276, DOI 10.1007/s001340000793; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Prielipp RC, 2001, ANESTH ANALG, V93, P45; Ract C, 2001, INTENS CARE MED, V27, P101, DOI 10.1007/s001340000754; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012; TUOR UI, 1986, NEUROSCI LETT, V63, P253, DOI 10.1016/0304-3940(86)90365-4; TUOR UI, 1986, AM J PHYSIOL, V251, pH824, DOI 10.1152/ajpheart.1986.251.4.H824; VandenBerghe G, 1996, CRIT CARE MED, V24, P1580, DOI 10.1097/00003246-199609000-00024; ZABLOTNY W, 1994, INTRACRANIAL PRESSUR, V9, P439	27	72	75	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	2004	32	4					1049	1054		10.1097/01.CCM.0000120054.32845.A6			6	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	812XR	WOS:000220872700022	15071400				2022-02-06	
J	Hoane, MR; Becerra, GD; Shank, JE; Tatko, L; Pak, ES; Smith, M; Murashov, AK				Hoane, MR; Becerra, GD; Shank, JE; Tatko, L; Pak, ES; Smith, M; Murashov, AK			Transplantation of neuronal and glial precursors dramatically improves sensorimotor function but not cognitive function in the traumatically injured brain	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain injury; embryonic stem cells; neural stem cells; rat; recovery of function; transplantation	FACILITATE RECOVERY; MAGNESIUM THERAPY; NMDA ANTAGONISTS; CORTEX LESIONS; RAT; DEFICITS; SURVIVAL; ATROPHY; MODEL	Embryonic stem (ES) cells have been investigated in various animal models of neurodegenerative disease; however, few studies have examined the ability of ES cells to improve functional outcome following traumatic brain injury (TBI). The purpose of the present study was to examine the ability of pre-differentiated murine ES cells (neuronal and glial precursors) to improve functional outcome. Rats were prepared with a unilateral controlled cortical impact injury or sham and then transplanted 7 days later with 100K ES cells (WW6G) (similar to30% neurons) or media. Two days following transplantation rats were tested on a battery of behavioral tests. It was found that transplantation of ES cells improved behavioral outcome by reducing the initial magnitude of the deficit on the bilateral tactile removal and locomotor placing tests. ES cells also induced almost complete recovery on the vibrissae (-->) forelimb placing test, whereas, media-transplanted rats failed to show recovery. Acquisition of a reference memory task in the Morris water maze was not improved by transplantation of ES cells. Histological analysis revealed a large number of surviving ES cells in the lesion cavity and showed migration of ES cells into subcortical structures. It was found that transplantation of ES cells prevented the occurrence of multiple small necrotic cavities that were seen in the cortex adjacent to the lesion cavity in media transplanted rats. Additionally, ES cells transplants also significantly reduced lesion size. Results of this study suggest that ES cells that have been pre-differentiated into neuronal precursors prior to transplantation have therapeutic potential.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Brody Sch Med, Greenville, NC 27858 USA; E Carolina Univ, Brody Sch Med, Neurosci Program, Greenville, NC USA; E Carolina Univ, Brody Sch Med, Dept Physiol, Greenville, NC USA		Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Brody Sch Med, Greenville, NC 27858 USA.	hoanem@mail.ecu.edu	Murashov, Alexander/ABB-2151-2020; Murashov, Alexander K/F-2241-2011	Murashov, Alexander/0000-0002-8912-5891; Murashov, Alexander K/0000-0002-8912-5891; Hoane, Michael/0000-0001-7779-2657			BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARTH TM, 1990, STROKE, V21, P153; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Grossman KJ, 2000, BEHAV BRAIN RES, V116, P141, DOI 10.1016/S0166-4328(00)00275-8; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 2003, BRAIN RES BULL, V60, P105, DOI 10.1016/S0361-9230(03)00022-4; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; Kerr DA, 2003, J NEUROSCI, V23, P5131; LEVIN JR, 1994, PSYCHOL BULL, V115, P153, DOI 10.1037/0033-2909.115.1.153; Lindner MD, 1998, J NEUROTRAUM, V15, P199, DOI 10.1089/neu.1998.15.199; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Murashov AK, 2001, MOL BRAIN RES, V93, P199, DOI 10.1016/S0169-328X(01)00212-1; OHANE MR, 2002, J NEUROTRAUM, V19, P1328; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Wilkins A, 2003, J NEUROSCI, V23, P4967, DOI 10.1523/jneurosci.23-12-04967.2003	32	72	77	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2004	21	2					163	174		10.1089/089771504322778622			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	774WB	WOS:000189008200004	15000757				2022-02-06	
J	Letenneur, L				Letenneur, L			Risk of dementia and alcohol and wine consumption: A review of recent results	BIOLOGICAL RESEARCH			English	Article; Proceedings Paper	Vinsalud Chile 2002 Wine and Health International Congress	OCT, 2002	Santiago, CHILE			Alcohol; Alzheimer's disease; dementia; wine	ALZHEIMERS-DISEASE; COMMUNITY	The term dementia refers to a clinical syndrome of acquired intellectual disturbances produced by brain dysfunction. Dementia may result from a wide variety of disorders, including degenerative (e.g. Alzheimer's disease, AD), vascular (e.g. multi-infarct dementia), and traumatic (e.g. head injury). Long-term abuse of alcohol is related to the development of the Wernicke-Korsakoff's syndrome or alcohol dementia. However. light to moderate alcohol intake might also reduce the risk of dementia and AD. In Bordeaux (France), a population-based prospective study found that subjects drinking 3 to 4 standard glasses of wine per day (>250 and up to 500 ml), categorized as moderate drinkers, the Crude odds ratio (OR) was 0.18 for incident dementia (p<0.01) and 0.25 for Alzheimer's disease (p<0.03), as compared to the non-drinkers. After adjusting for age, sex, education, occupation, baseline cognitive performances and other possible confounders, the ORs were respectively 0.19 (p<0.01) and 0.28 (p<0.05). In the 922 mild drinkers (<1 to 2 classes per day) there was a negative association only with AD, after adjustment (OR = 0.55 p<0.05). The inverse relationship between moderate wine drinking and incident dementia was explained neither by known predictors of dementia nor by medical, psychological or socio-familial factors. These results were confirmed from data of the Rotterdam study. Light-to-moderate drinking (one to three drinks per day) was significantly associated with a lower risk of any dementia (hazard ratio 0.58 [95% CI 0.38-0.90]) and vascular dementia (hazard ratio 0.29 [0.09-0.93]). No evidence that the relation between alcohol and dementia varied by type of alcoholic beverage was found. Stroke constitutes one of the most common causes of serious functional impairment in developed countries. Ischaemic strokes represent about 80% of all strokes, Several Studies have been published and the overall conclusion is that heavy drinking is a risk factor for most stroke subtypes. Regular light to moderate drinking seemed to be associated with a decreased risk for ischaemic stroke.	Univ Victor Segalen Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France		Letenneur, L (corresponding author), Univ Victor Segalen Bordeaux 2, INSERM, U593, Case 11,146 Rue Leo Saignat, F-33076 Bordeaux, France.	luc.letenneur@isped.u.bordeaux2.fr	LETENNEUR, Luc/T-4424-2019	LETENNEUR, Luc/0000-0002-3274-937X			Commenges D, 2000, EUR J EPIDEMIOL, V16, P357, DOI 10.1023/A:1007614613771; Huang WY, 2002, J CLIN EPIDEMIOL, V55, P959, DOI 10.1016/S0895-4356(02)00462-6; Lemeshow S, 1998, AM J EPIDEMIOL, V148, P298; Letenneur L, 1999, J NEUROL NEUROSUR PS, V66, P177, DOI 10.1136/jnnp.66.2.177; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Lobo A, 2000, NEUROLOGY, V54, pS4; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Ruitenberg A, 2002, LANCET, V359, P281, DOI 10.1016/S0140-6736(02)07493-7; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; Truelsen T, 2002, NEUROLOGY, V59, P1313, DOI 10.1212/01.WNL.0000031421.50369.E7	10	72	77	1	16	SOC BIOLGIA CHILE	SANTIAGO	CASILLA 16164, SANTIAGO 9, CHILE	0716-9760	0717-6287		BIOL RES	Biol. Res.		2004	37	2					189	193					5	Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Life Sciences & Biomedicine - Other Topics	857JJ	WOS:000224112200003	15455646	gold, Green Submitted			2022-02-06	
J	Lu, M; Chen, JL; Lu, DY; Yi, L; Mahmood, A; Chopp, M				Lu, M; Chen, JL; Lu, DY; Yi, L; Mahmood, A; Chopp, M			Global test statistics for treatment effect of stroke and traumatic brain injury in rats with administration of bone marrow stromal cells	JOURNAL OF NEUROSCIENCE METHODS			English	Article						stroke; traumatic brain injury; rat; data analysis; global test	LONGITUDINAL DATA-ANALYSIS; GENERALIZED LINEAR-MODELS; MIDDLE CEREBRAL-ARTERY; CLINICAL-TRIALS; ODDS RATIO; OUTCOMES; OCCLUSION; ISCHEMIA	Because no single test measures disability in rats with middle cerebral artery occlusion/traumatic brain injury (MCAo/TBI), multiple tests are needed to assess the effect of bone marrow stromal cell (MSC) on functional recovery. Testing the treatment effect on each outcome at the 0.05 level without adjusting for multiple outcomes can increase type I error. Therefore, we applied the global test to evaluate a common MSC dose effect on multiple outcomes in two applications: (i) MCAo rats with the MSC dose of zero (BPS), 1 x 10(6) and 3 x 10(6), and (ii) TBI rats with the MSC dose of zero, 1 x 10(6), 2 x 10(6) and 4 x 10(6), administered intravenously at I day after injury. For the MCAo rats, 3 x 10(6) MSCs improved the 14 day functional recovery (P < 0.05) compared to the controls. TBI rats with the MSC dose 4 x 10(6) were improved significantly at I month compared to controls, rats with 1 x 10(6) or 2 x 10(6) MSCs (P < 0.05). The global test on multiple outcomes is more efficient than a single outcome when treatment effects are consistent. The less correlation among the outcomes, the more power and, therefore, the higher efficiency of the global test. We demonstrated that the global test for continuous outcomes could be implemented under careful statistical modeling and proper data transformation. (C) 2003 Elsevier B.V. All rights reserved.	Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; Oakland Univ, Dept Phys, Rochester, MI 48309 USA		Lu, M (corresponding author), Henry Ford Hlth Sci Ctr, Dept Biostat & Res Epidemiol, 1 Ford Pl,3E, Detroit, MI 48202 USA.				NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01 HL64766] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38292, P01 NS23393, R01 NS33627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL064766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033627, R01NS038292, P01NS023393] Funding Source: NIH RePORTER		CHEN H, 1992, J CEREBR BLOOD F MET, V12, P621, DOI 10.1038/jcbfm.1992.86; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Cohen J., 2013, STAT POWER ANAL BEHA; Cohen J., 1983, APPL MULTIPLE REGRES; Diggle PJ, 1994, ANAL LONGITUDINAL DA; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Lehmann E. L., 1986, TESTING STAT HYPOTHE; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIPSITZ SR, 1991, BIOMETRIKA, V78, P153; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu M, 2001, STAT MED, V20, P1891, DOI 10.1002/sim.841.abs; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; PARK T, 1993, STAT MED, V12, P1723, DOI 10.1002/sim.4780121807; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; *SAS I, 1999, SAS STAT SOFTW; Schallert T, 2000, NEUROPHARMACOLOGY, V39, P777, DOI 10.1016/S0028-3908(00)00005-8; Tilley BC, 1996, STROKE, V27, P2136, DOI 10.1161/01.STR.27.11.2136; WEDDERBURN RWM, 1974, BIOMETRIKA, V61, P439, DOI 10.1093/biomet/61.3.439; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zhang L, 2002, J NEUROSCI METH, V117, P207, DOI 10.1016/S0165-0270(02)00114-0	24	72	92	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2003	128	1-2					183	190		10.1016/S0165-0270(03)00188-2			8	Biochemical Research Methods; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	721GD	WOS:000185307900019	12948561				2022-02-06	
J	Lang, EW; Czosnyka, M; Mehdorn, HM				Lang, EW; Czosnyka, M; Mehdorn, HM			Tissue oxygen reactivity and cerebral autoregulation after severe traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						arterial blood pressure; cerebral blood flow velocity; static cerebral pressure autoregulation; transcranial Doppler ultrasound; severe head injury; cerebrovascular circulation; cerebral perfusion pressure; tissue oxygen reactivity; cerebral oxygenation	BLOOD-FLOW VELOCITY; PERFUSION-PRESSURE; TRANSCRANIAL DOPPLER; PHASE RELATIONSHIP; HEAD-INJURY; SATURATION; PO2	Objective. To study the relationship between arterial blood pressure, intracranial pressure, directly measured brain tissue oxygenation (Ptio(2)), and middle cerebral artery blood flow velocity in severely head-injured patients. Design: Prospective study. Setting: Neurosurgical intensive care unit. Patients. A total of 14 patients with severe head injury. Interventions. Pharmacologic blood pressure manipulations using norepinephrine. Measurements and Main Results., We assessed the magnitude Of Ptio(2) related to changes in cerebral perfusion pressure in 12 of the patients. We calculated in all the static rate of regulation, which is an index to describe the change of cerebrovascular resistance, using cerebral artery blood flow velocity in relation to changing cerebral perfusion pressure. Finally, we calculated the rate of change in Ptio(2), which quantifies the percentage of change in Ptio(2) divided by the percentage of change in cerebral perfusion pressure. It is a new marker for cerebral tissue oxygen regulation based on direct measurement of Ptio(2). There was a plateau phase for the cerebral perfusion pressure-Ptio(2) relation that was similar to the autoregulatory plateau seen in the relationship between cerebral perfusion pressure and cerebral artery blood flow velocity. The rate of change in Ptio(2) demonstrated a significant correlation with the static rate of regulation (R = -.61, p <.05). A decrease in intracranial pressure when arterial blood pressure increased from 70 to 90 mm Hg was strongly correlated with static rate of regulation (R =.79, p <.001). Conclusions. Cerebral tissue Po-2 demonstrates a plateau phase similar to what is known about cerebral blood flow velocity, which suggests a close link between cerebral blood flow and oxygenation. Static cerebral autoregulation is significantly correlated with cerebral tissue oxygen reactivity.	Univ Kiel, Dept Neurosurg, Kiel, Germany; Univ Cambridge, Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England		Lang, EW (corresponding author), Westmead Hosp, Dept Neurosurg, Level 5, Westmead, NSW 2145, Australia.	keeflang@optusnet.com.au	Mehdorn, Maximilian/D-2495-2010				AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; BOUMA GJ, 1992, J NEUROTRAUM, V9, pS333; BULLOCK R, 1996, GUIDELINES MANAGEMEN; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Dawson SL, 2000, CEREBROVASC DIS, V10, P126, DOI 10.1159/000016041; DIEHL RR, 1995, STROKE, V26, P1801, DOI 10.1161/01.STR.26.10.1801; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Fandino J, 1999, ACTA NEUROCHIR, V141, P825, DOI 10.1007/s007010050383; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kiening KL, 1998, ACT NEUR S, V71, P172; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang EW, 2001, CRIT CARE MED, V29, P158, DOI 10.1097/00003246-200101000-00031; LARSEN FS, 1994, STROKE, V25, P1985, DOI 10.1161/01.STR.25.10.1985; LASSEN NA, 1974, CIRC RES, V34, P749, DOI 10.1161/01.RES.34.6.749; MARMAROU A, 1993, ACTA NEUROCHIR, P18; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUIZELAAR JP, 1986, STROKE, V17, P44, DOI 10.1161/01.STR.17.1.44; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; Schneider GH, 1998, ACT NEUR S, V71, P62; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; Stocchetti N, 1998, ACT NEUR S, V71, P162; STREBEL S, 1995, ANESTHESIOLOGY, V83, P66, DOI 10.1097/00000542-199507000-00008; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007	34	72	73	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2003	31	1					267	271		10.1097/00003246-200301000-00042			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	640XU	WOS:000180714800042	12545027				2022-02-06	
J	Weismer, G; Laures, JS				Weismer, G; Laures, JS			Direct magnitude estimates of speech intelligibility in dysarthria: Effects of a chosen standard	JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH			English	Article						speech intelligibility; perceptual scaling; dysarthria	VOWEL ROUGHNESS; QUALITY	Direct magnitude estimation (DME) has been used frequently as a perceptual scaling technique in studies of the speech intelligibility of persons with speech disorders. The technique is typically used with a standard, or reference stimulus, chosen as a good exemplar of "midrange" intelligibility. In several published studies, the standard has been chosen subjectively, usually on the basis of the fixed set expertise of the investigators. The current experiment demonstrates that a of sentence-level utterances, obtained from 4 individuals with dysarthria (2 with Parkinson disease, 2 with traumatic brain injury) as well as 3 neurologically normal speakers, is scaled differently depending on the identity of the standard. Four different standards were used in the main experiment, three of which were judged qualitatively in two independent evaluations to be good exemplars of midrange intelligibility. Acoustic analyses did not reveal obvious differences between these four standards but suggested that the standard with the worst-scaled intelligibility had much poorer voice source characteristics compared to the other three standards. Results are discussed in terms of possible standardization of midrange intelligibility exemplars for DME experiments.	Univ Wisconsin, Dept Commun Disorders, Madison, WI 53706 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Georgia State Univ, Program Commun Disorders, Atlanta, GA 30303 USA		Weismer, G (corresponding author), Univ Wisconsin, Dept Commun Disorders, 1975 Willow Dr, Madison, WI 53706 USA.	weismer@waisman.wisc.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC01409, DC00319] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [P60DC001409] Funding Source: NIH RePORTER		BECK J, 1965, PERCEPT MOTOR SKILL, V21, P151, DOI 10.2466/pms.1965.21.1.151; BECK J, 1961, AM J PSYCHOL, V74, P242, DOI 10.2307/1419409; CHEN MY, 1995, J ACOUST SOC AM, V98, P2443, DOI 10.1121/1.414399; CULLINAN WL, 1963, J SPEECH HEAR RES, V6, P187, DOI 10.1044/jshr.0602.187; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P462, DOI 10.1044/jshr.1203.462; DARLEY FL, 1969, J SPEECH HEAR RES, V12, P246, DOI 10.1044/jshr.1202.246; Forrest K., 1997, CLIN MANAGEMENT SENS, P63; Gescheider G.A, 1976, PSYCHOPHYSICS METHOD; HILLENBRAND J, 1994, J SPEECH HEAR RES, V37, P769, DOI 10.1044/jshr.3704.769; KENT RD, 1989, J SPEECH HEAR DISORD, V54, P482, DOI 10.1044/jshd.5404.482; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; Milenkovic P., 1994, CSPEECH COMPUTER PRO; MONSEN RB, 1983, J SPEECH HEAR DISORD, V48, P286, DOI 10.1044/jshd.4803.286; Poulton E. C., 1989, BIAS QUANTIFYING JUD; POULTON EC, 1968, PSYCHOL BULL, V69, P1, DOI 10.1037/h0025267; Ramig L.O., 1992, INTELLIGIBILITY SPEE, P119, DOI DOI 10.1075/SSPCL.1.05RAM; SCHIAVETTI N, 1983, J SPEECH HEAR RES, V26, P568, DOI 10.1044/jshr.2604.568; SCHIAVETTI N, 1981, J SPEECH HEAR RES, V24, P441, DOI 10.1044/jshr.2403.441; Schiavetti N., 1992, INTELLIGIBILITY SPEE, P11; SCHIFF ER, 1994, GASTROINTEST DIS TOD, V3, P7; SCHLIESSER HF, 1985, PERCEPT MOTOR SKILL, V61, P1299, DOI 10.2466/pms.1985.61.3f.1299; Southwood M., 1993, J MED SPEECH-LANG PA, V1, P151; Southwood M., 1996, J MED SPEECH-LANG PA, V4, P13; Stevens S. S., 1975, PSYCHOPHYSICS INTRO; STEVENS SS, 1956, AM J PSYCHOL, V69, P1, DOI 10.2307/1418112; TONER MA, 1989, J SPEECH HEAR RES, V32, P78, DOI 10.1044/jshr.3201.78; TONER MA, 1990, J SPEECH HEAR RES, V33, P238, DOI 10.1044/jshr.3302.238; TURNER GS, 1995, J SPEECH HEAR RES, V38, P1001, DOI 10.1044/jshr.3805.1001; Weismer, 1995, AM J SPEECH-LANG PAT, V4, P9, DOI 10.1044/1058-0360.0402.09; WEISMER G, 1988, J ACOUST SOC AM, V84, P1281, DOI 10.1121/1.396627; Weismer G, 2001, FOLIA PHONIATR LOGO, V53, P1, DOI 10.1159/000052649; Weismer G., 1992, INTELLIGIBILITY SPEE, V1, DOI [10.1075/sspcl.1.04wei, DOI 10.1075/SSPCL.1.04WEI]; Zraick RI, 2000, J SPEECH LANG HEAR R, V43, P979, DOI 10.1044/jslhr.4304.979; [No title captured]	34	72	73	0	5	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1092-4388	1558-9102		J SPEECH LANG HEAR R	J. Speech Lang. Hear. Res.	JUN	2002	45	3					421	433		10.1044/1092-4388(2002/033)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	561MH	WOS:000176144200001	12068996				2022-02-06	
J	Schwab, JM; Beschorner, R; Meyermann, R; Gozalan, F; Schluesener, HJ				Schwab, JM; Beschorner, R; Meyermann, R; Gozalan, F; Schluesener, HJ			Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury	JOURNAL OF NEUROSURGERY			English	Article						prostaglandin; oxidative stress; inflammation; tissue viability	ALZHEIMERS-DISEASE; INDUCIBLE CYCLOOXYGENASE; GENE DISRUPTION; HEAD-INJURY; EXPRESSION; INFLAMMATION; PROTEINS; NEURONS; COX-1; INDOMETHACIN	Object. Secondary damage after central nervous system (CNS) injury is driven in part by oxidative stress and CNS inflammation and is substantially mediated by cyclooxygenases (COXs). To date, the rapidly inducible COX-2 isoform has been primarily linked to inflammatory processes, whereas expression of COX-1 is confined to physiological functions. The authors report the differential localization of COX-1 in human traumatic brain injury (TBI). Methods. Differential cellular COX-1 protein expression profiles were analyzed following TBI in 31 patients and compared with neuropathologically unaltered control brains by using immunohistochemistry. In these patients with TBI, a significant increase of COX-1 protein expression by vessel endothelial and smooth-muscle cells and CD68(+) microglia/macrophages was observed to be strictly confined to the lesion. Accumulation of COX-1(+) microglia/macrophages in the lesion was already evident 6 hours postinjury, reaching maximal levels after several weeks and remaining elevated at submaximal levels for several months after injury. Furthermore, COX-1(+) cell clusters were located in the Virchow-Robin space during the leukocyte infiltration period from Days 4 to 8 after TBI. Double-labeling experiments confirmed coexpression of COX-1 by CD68(-) microglia/macrophages. The numbers of COX-1(+) vessel endothelial and smooth-muscle cells increased from Day 1, remaining at submaximal levels for months after injury. Conclusions. The prolonged accumulation of COX-1(-) microglia/macrophages that were restricted to perilesional areas affected by the acute inflammatory response points to a role of COX-1 in secondary injury. The authors have identified localized, accumulated COX-1 expression as a potential pharmacological target following TBI. Their results challenge the current paradigms of a selective COX-2 role in the postinjury inflammatory, response.	Univ Tubingen, Brain Res Inst, Sch Med, D-72076 Tubingen, Germany		Schwab, JM (corresponding author), Univ Tubingen, Brain Res Inst, Sch Med, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de	Beschorner, Rudi/M-6397-2014	Schwab, Jan/0000-0001-6784-4919; Beschorner, Rudi/0000-0003-1109-915X			Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Becher B, 1996, GLIA, V18, P1; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; BRUGG B, 1995, P NATL ACAD SCI USA, V92, P3032, DOI 10.1073/pnas.92.7.3032; Crofford LJ, 1997, J RHEUMATOL, V24, P15; Deininger MH, 1999, J NEUROIMMUNOL, V95, P202, DOI 10.1016/S0165-5728(98)00257-4; Deininger MH, 1999, ACTA NEUROPATHOL, V98, P240, DOI 10.1007/s004010051075; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Graham E M, 1997, J Matern Fetal Med, V6, P1; HALL ED, 1996, NEUROTRAUMA, P1405; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; HOFF T, 1993, FEBS LETT, V320, P38, DOI 10.1016/0014-5793(93)81653-H; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hsu CY, 1996, NEUROTRAUMA, P1433; Iadecola C, 1999, ACTA NEUROPATHOL, V98, P9, DOI 10.1007/s004010051045; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kennedy DW, 1998, P NATL ACAD SCI USA, V95, P14944, DOI 10.1073/pnas.95.25.14944; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; MALLAT M, 1994, J LEUKOCYTE BIOL, V56, P416, DOI 10.1002/jlb.56.3.416; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; Mattson MP, 1998, TRENDS NEUROSCI, V21, P53, DOI 10.1016/S0166-2236(97)01188-0; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Nogawa S, 1997, J NEUROSCI, V17, P2746; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; ROGERS J, 1993, NEUROLOGY, V43, P1609, DOI 10.1212/WNL.43.8.1609; Roller A, 1999, BIOCHEM BIOPH RES CO, V259, P600, DOI 10.1006/bbrc.1999.0825; Sairanen T, 1998, ANN NEUROL, V43, P738, DOI 10.1002/ana.410430608; SANDERS K, 1987, AM J PHYSIOL, V234, pE209; Schwab JM, 2000, ACTA NEUROPATHOL, V99, P609, DOI 10.1007/s004010051170; Shillabeer G, 1998, METABOLISM, V47, P461, DOI 10.1016/S0026-0495(98)90060-9; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Willoughby DA, 2000, LANCET, V355, P646, DOI 10.1016/S0140-6736(99)12031-2; Wyss-Coray T, 2000, NAT MED, V6, P973, DOI 10.1038/79661; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Yasojima K, 1999, BRAIN RES, V830, P226, DOI 10.1016/S0006-8993(99)01389-X; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003	55	72	73	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2002	96	5					892	899		10.3171/jns.2002.96.5.0892			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	547VT	WOS:000175353700011	12005397				2022-02-06	
J	Stone, JR; Okonkwo, DO; Singleton, RH; Mutlu, LK; Helm, GA; Povlishock, JT				Stone, JR; Okonkwo, DO; Singleton, RH; Mutlu, LK; Helm, GA; Povlishock, JT			Caspase-3-mediated cleavage of amyloid precursor protein and formation of amyloid beta peptide in traumatic axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						A beta peptide; Alzheimer's Disease; apoptosis; APP; caspase; traumatic axonal injury; traumatic brain injury	DIFFUSE BRAIN-INJURY; SEVERE HEAD-INJURY; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CYCLOSPORINE-A; WHITE MATTER; DAMAGE; APP; APOPTOSIS; SECRETASE	Immunohistochemical studies demonstrate accumulation of the beta-amyloid precursor protein (APP) within injured axons following traumatic brain injury (TBI). Despite such descriptions, little is known about the ultimate fate of accumulating APP at sites of traumatic axonal injury (TAI). Recently, caspase-3-mediated cleavage of APP and subsequent Abeta deposition was linked to apoptotic neuronal death pathways in hippocampal neurons following ischemic and excitotoxic brain injury. Given that (1) APP is known to accumulate within traumatically injured axons, (2) caspase-3 activation has been demonstrated in traumatic axonal injury (TAI), and (3) recent studies have identified a caspase-3 cleavage site within APP, we initiated the current investigation to determine whether caspase-3-mediated cleavage of APP occurs in TAL We further assessed whether these events were found in relation to Abeta peptide formation. To this end, we employed antibodies targeting APP, the caspase-3-mediated breakdown product of APP proteolysis, and the Abeta peptide. Rats were subjected to impact acceleration TBI (6 h to 10 days survival), and their brains were processed for single-label bright field and multiple double-label immunofluorescent paradigms using the above antibodies. By 12 h postinjury, caspase-3-mediated APP proteolysis (CMAP) was demonstrated within the medial lemniscus (ML) and medial longitudinal fasciculus (MLF) in axons undergoing TAI, identified by their concomitant APP accumulation. Immunoreactivity for CMAP persisted up to 48 h postinjury in the ML and MLF, but was notably reduced by 10 days following injury. Further, CMAP was colocalized with Abeta formation in foci of TAL The current study demonstrates that caspase-3 cleavage of APP occurs in TAI and is associated with formation of Abeta peptide. These findings are of interest given recent epidemiological studies supporting an association between TBI and later risk for AD development.	Univ Virginia, Dept Neurosurg, Charlottesville, VA 22903 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA USA		Stone, JR (corresponding author), Univ Virginia, Dept Neurosurg, Charlottesville, VA 22903 USA.	jrs7r@virginia.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline		Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; Barnes NY, 1998, J NEUROSCI, V18, P5869; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; BRAMLETT HM, J NEUROPATHOL EXP NE, V596, P1132; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Dumanchin-Njock C, 2001, J NEUROCHEM, V78, P1153, DOI 10.1046/j.1471-4159.2001.00513.x; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jordan J, 1997, J NEUROCHEM, V68, P1612; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; LeBlanc A, 1995, J NEUROSCI, V15, P7837; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAHUQUILLO J, 1989, ACTA NEUROCHIR, V101, P149, DOI 10.1007/BF01410531; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Soriano S, 2001, J BIOL CHEM, V276, P29045, DOI 10.1074/jbc.M102456200; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Teramoto N, 1998, J VIROL METHODS, V73, P89, DOI 10.1016/S0166-0934(98)00048-2; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Troy CM, 2000, J NEUROSCI, V20, P1386; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; VONBERNHARDI R, 1989, BRAIN RES, V478, P301, DOI 10.1016/0006-8993(89)91510-2; Wang GJ, 1999, METHODS, V18, P459, DOI 10.1006/meth.1999.0813; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Zhang L, 1997, BIOCHEM BIOPH RES CO, V235, P845, DOI 10.1006/bbrc.1997.6698	73	72	73	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2002	19	5					601	614		10.1089/089771502753754073			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	557PA	WOS:000175915900005	12042095				2022-02-06	
J	Miranda, FE; Dennis, JW; Veldenz, HC; Dovgan, PS; Frykberg, ER				Miranda, FE; Dennis, JW; Veldenz, HC; Dovgan, PS; Frykberg, ER			Confirmation of the safety and accuracy of physical examination in the evaluation of knee dislocation for injury of the popliteal artery: A prospective study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	60th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	OCT 11-15, 2000	SAN ANTONIO, TX	Amer Assoc Surg Trauma			ARTERIOGRAPHY; TRAUMA; FRACTURES; PATIENT	Background: Knee dislocation, which poses a significant risk for injury of the popliteal artery, prompts many surgeons to evaluate these patients with arteriography routinely. Our hypothesis was that physical examination alone (without arteriography) accurately confirms or excludes surgically significant vascular injuries associated with knee dislocation. Methods: All patients diagnosed with a knee dislocation by an attending orthopedic surgeon between January 1990 and January 2000 were prospectively managed by protocol at our Level I trauma center according to their physical examination. Those with hard signs (active hemorrhage, expanding hematoma, absent pulse, distal ischemia, bruit/thrill) underwent arteriography followed immediately by surgical repair if indicated. Patients with no hard signs (negative physical examination) were admitted for 23 hours, underwent serial physical examination, and then followed as outpatients. Results: There were 35 knee dislocations in 35 patients during this 10-year period. The average age was 31 years; 18 dislocations were on the right knee and 17 were on the left. Two patients died from closed head injuries and multisystem trauma. Eight patients were found to have hard signs (positive physical examination) either at presentation (six patients) or during their hospitalization after reduction of their dislocation (two patients). All eight patients demonstrated a loss of pulses only. Six of these patients showed occlusion of the popliteal artery on arteriography and underwent surgical repair without complication (five vein grafts, one primary repair), one demonstrated spasm of the popliteal artery, and one showed a normal artery that required no treatment. None of the 27 patients with negative physical examination during their hospitalization ever developed limb ischemia, needed an operation for vascular injury, or experienced limb loss. Sixteen patients were available for follow-up (46%). Twelve patients with negative physical examination (44%) were contacted (mean, 13 months; range, 2-35 months), and four of the eight patients with positive physical examination (50%) and surgical repair were contacted (mean, 19 months; range, 6-49 months). None of the patients in either group developed any vascular-related symptoms or suffered from a vascular repair complication over the follow-up interval. Conclusion: This limited series suggests that the presence or absence of an injury of the popliteal artery after knee dislocation can be safely and reliably predicted, with a 94.3% positive predictive value and 100% negative predictive value. Arteriography appears to be unnecessary when physical examination is negative but may avert negative vascular exploration when physical examination is positive. This approach substantially reduces cost and resource use without adverse impact on the patient.	Univ Florida, Hlth Sci Ctr, Dept Surg, Jacksonville, FL 32209 USA		Dennis, JW (corresponding author), Univ Florida, Hlth Sci Ctr, Dept Surg, 653-2 W 8th St, Jacksonville, FL 32209 USA.	james.dennis@jax.ufl.edu					APPLEBAUM R, 1990, AM J SURG, V160, P221, DOI 10.1016/S0002-9610(05)80311-3; Atteberry LR, 1996, J AM COLL SURGEONS, V183, P377; BISHARA RA, 1986, J VASC SURG, V3, P707, DOI 10.1067/mva.1986.avs0030707; Bryan T, 1991, Orthop Rev, V20, P525; BYNOE RP, 1991, J VASC SURG, V14, P346, DOI 10.1016/0741-5214(91)90087-B; DEBAKEY ME, 1946, ANN SURG, V123, P534, DOI 10.1097/00000658-194604000-00005; DENNIS JW, 1990, J VASC SURG, V11, P85; DENNIS JW, 1993, J TRAUMA, V35, P692, DOI 10.1097/00005373-199311000-00007; DOWNS AR, 1986, J VASC SURG, V4, P55; FRYKBERG ER, 1989, J TRAUMA, V29, P577, DOI 10.1097/00005373-198905000-00006; FRYKBERG ER, 1991, SURGERY, V109, P85; Gable DR, 1997, J TRAUMA, V43, P541, DOI 10.1097/00005373-199709000-00029; GOMES AS, 1985, AM J ROENTGENOL, V145, P1249, DOI 10.2214/ajr.145.6.1249; HUGHES CW, 1958, ANN SURG, V147, P555; KAUFMAN SL, 1992, RADIOLOGY, V184, P153, DOI 10.1148/radiology.184.1.1609074; KENDALL RW, 1993, J TRAUMA, V35, P875, DOI 10.1097/00005373-199312000-00013; Melton SM, 1997, ANN SURG, V225, P518, DOI 10.1097/00000658-199705000-00009; Roman P D, 1987, Orthop Rev, V16, P917; ROSE SC, 1988, J TRAUMA, V28, P240, DOI 10.1097/00005373-198802000-00022; SCLAFANI SJA, 1986, RADIOLOGY, V161, P165, DOI 10.1148/radiology.161.1.3763860; TREIMAN GS, 1992, ARCH SURG-CHICAGO, V127, P1056	21	72	76	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2002	52	2					247	251		10.1097/00005373-200202000-00008			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	522XQ	WOS:000173922600012	11834983				2022-02-06	
J	Schmeer, C; Straten, G; Kugler, S; Gravel, C; Bahr, M; Isenmann, S				Schmeer, C; Straten, G; Kugler, S; Gravel, C; Bahr, M; Isenmann, S			Dose-dependent rescue of axotomized rat retinal ganglion cells by adenovirus-mediated expression of glial cell-line derived neurotrophic factor in vivo	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; GDNF; gene transfer; neurodegeneration; neurotrophic factors; regeneration	OPTIC-NERVE LESION; NEURONS IN-VIVO; ADULT-RATS; GENE-TRANSFER; FACTOR GDNF; DOPAMINERGIC-NEURONS; RET PROTOONCOGENE; MESSENGER-RNA; BRAIN; SURVIVAL	Adult rat retinal ganglion cells undergo degeneration after optic nerve transection. Repeated intraocular injection of glial cell-line derived neurotrophic factor (GDNF) has been shown to be efficient in enhancing retinal ganglion cell survival following optic nerve axotomy. In the present study we evaluated the potential survival-promoting effect of adenovirally administered GDNF on axotomized retinal ganglion cells. A single intravitreal injection [7 x 10(7) plaque-forming units (pfu) or 7 x 10(8) pfu] of an adenoviral vector expressing the rat GDNF gene from a cytomegalovirus promoter enhanced retinal ganglion cell survival 14 days after axotomy by 67 and 125%, respectively, when compared to control animals. Intraocular administration of the vector rescued 12.6 and 23%, respectively, of the retinal ganglion cells which would otherwise have died after axotomy. An increase in retinal GDNF protein and specific virally transduced GDNF mRNA expression was detected following intraocular vector application. Our data support previous findings showing that adenoviral delivery of neurotrophic factors to the vitreous body is a feasible approach for the prevention of axotomy-induced retinal ganglion cell death in vivo and may constitute a relevant strategy for future treatment in traumatic brain injury and ensuing neurodegeneration.	Univ Tubingen, Dept Neurol, Neuroregenerat Lab, D-72076 Tubingen, Germany; Inst Venezolano Invest Cient, Lab Neuroquim, Caracas 1020A, Venezuela; Univ Laval Robert Giffard, Ctr Rech, Beauport, PQ, Canada		Isenmann, S (corresponding author), Univ Tubingen, Dept Neurol, Neuroregenerat Lab, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.		Isenmann, Stefan/AAJ-3788-2020; Baehr, Mathias/K-2188-2014	Schmeer, Christian/0000-0002-2289-0126			BAHR M, 1991, NEUROREPORT, V2, P581; BECK KD, 1995, NATURE, V373, P339, DOI 10.1038/373339a0; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CUI Q, 1994, NEUROREPORT, V5, P1882, DOI 10.1097/00001756-199410000-00010; Di Polo A, 1998, P NATL ACAD SCI USA, V95, P3978, DOI 10.1073/pnas.95.7.3978; Eberhardt O, 2000, J NEUROSCI, V20, P9126; Encinas M, 2001, J NEUROSCI, V21, P1464, DOI 10.1523/JNEUROSCI.21-05-01464.2001; ESCHWEILER GW, 1993, J NEUROL SCI, V116, P34, DOI 10.1016/0022-510X(93)90086-E; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRAHAM FL, 1991, GENE TRANSFER EXPRES, P109, DOI DOI 10.1385/0-89603-178-0:109; Gravel C, 1997, NAT MED, V3, P765, DOI 10.1038/nm0797-765; Isenmann S, 1998, EUR J NEUROSCI, V10, P2751, DOI 10.1046/j.1460-9568.1998.00325.x; Isenmann S, 1997, EUR J NEUROSCI, V9, P1763, DOI 10.1111/j.1460-9568.1997.tb01534.x; Isenmann S, 1997, EXP NEUROL, V147, P28, DOI 10.1006/exnr.1997.6585; Isenmann S, 2001, BRAIN RES, V892, P229, DOI 10.1016/S0006-8993(00)02957-7; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; Knusel B, 1997, NEUROSCIENCE, V78, P851, DOI 10.1016/S0306-4522(96)00616-1; Koeberle PD, 1998, VISION RES, V38, P1505, DOI 10.1016/S0042-6989(97)00364-7; Kugler S, 2001, MOL CELL NEUROSCI, V17, P78, DOI 10.1006/mcne.2000.0929; Kugler S, 2000, CELL DEATH DIFFER, V7, P815, DOI 10.1038/sj.cdd.4400712; LE GLS, 1993, SCIENCE, V259, P988; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LORENZO MJ, 1995, ONCOGENE, V10, P1377; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; Mason I, 1996, MOL CELL NEUROSCI, V8, P112, DOI 10.1006/mcne.1996.0050; Matheson CR, 1997, J NEUROBIOL, V32, P22, DOI 10.1002/(SICI)1097-4695(199701)32:1<22::AID-NEU3>3.3.CO;2-B; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; Slack RS, 1996, J CELL BIOL, V135, P1085, DOI 10.1083/jcb.135.4.1085; Trupp M, 1997, J NEUROSCI, V17, P3554; VIDALSANZ M, 1988, EXP NEUROL, V102, P92, DOI 10.1016/0014-4886(88)90081-7; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Williams LR, 1996, J PHARMACOL EXP THER, V277, P1140; Yan Q, 1999, J NEUROBIOL, V38, P382, DOI 10.1002/(SICI)1097-4695(19990215)38:3<382::AID-NEU7>3.0.CO;2-5	41	72	73	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2002	15	4					637	643		10.1046/j.1460-9568.2002.01893.x			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	536HB	WOS:000174693700005	11886444				2022-02-06	
J	Matsushita, Y; Bramlett, HM; Alonso, O; Dietrich, WD				Matsushita, Y; Bramlett, HM; Alonso, O; Dietrich, WD			Posttraumatic hypothermia is neuroprotective in a model of traumatic brain injury complicated by a secondary hypoxic insult	CRITICAL CARE MEDICINE			English	Article						hypothermia; traumatic brain injury; hypoxia; histopathology; rat	CONTROLLED CORTICAL IMPACT; MODERATE HYPOTHERMIA; CEREBRAL-ISCHEMIA; HEAD-INJURY; DAMAGE; MILD; RATS; VULNERABILITY; HYPERTHERMIA; EXPRESSION	Objective: Human traumatic brain injury frequently results in secondary complications, including hypoxia. In previous studies, we have reported that posttraumatic hypothermia is neuroprotective and that secondary hypoxia exacerbates histopathologic outcome after fluid-percussion brain injury. The purpose of this study was to assess the therapeutic effects of mild (33 degreesC) hypothermia after fluid-percussion injury combined with secondary hypoxia. In addition, the importance of the rewarming period on histopathologic outcome was investigated. Design: Prospective experimental study in rats. Setting. Experimental laboratory in a university teaching hospital. Intervention: Intubated, anesthetized rats underwent normothermic parasagittal fluid-percussion brain injury (1.8-2.1 atmospheres) followed by either 30 mins of normoxia (n = 6) or hypoxic (n = 6) gas levels and by 4 hrs of normothermia (37 degreesC). In hypothermic rats, brain temperature was reduced immediately after the 30-min hypoxic insult and maintained for 4 hrs. After hypothermia, brain temperature was either rapidly (n = 6) or slowly (n = 5) increased to normothermic levels. Rats were killed 3 days after traumatic brain injury, and contusion volumes were quantitatively assessed. Measurements and Main Results: As previously shown, posttraumatic hypoxia significantly increased contusion volume compared with traumatic brain injury-normoxic animals (p < .02). Importantly, although posttraumatic hypothermia followed by rapid rewarming (15 mins) failed to decrease contusion volume, those animals undergoing a slow rewarming period (120 mins) demonstrated significantly (p < .03) reduced contusion volumes, compared with hypoxic normothermic rats. Conclusions: These data emphasize the beneficial effects of posttraumatic hypothermia in a traumatic brain injury model complicated by secondary hypoxia and stress the importance of the rewarming period in this therapeutic intervention.	Univ Miami, Sch Med, Dept Neurol, Miami Project Cure Paralysis,Neurotrauma Res Ctr, Miami, FL 33101 USA		Dietrich, WD (corresponding author), Univ Miami, Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis,Neurotrauma Res Ctr, POB 016960 R-48, Miami, FL 33101 USA.	ddietrich@miami.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Chatzipanteli K, 1999, J NEUROCHEM, V72, P2047, DOI 10.1046/j.1471-4159.1999.0722047.x; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Chesnut R M, 1995, New Horiz, V3, P366; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dave JR, 1997, NEUROREPORT, V8, P395, DOI 10.1097/00001756-199701200-00002; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; Dietrich WD, 1996, NEUROTRAUMA, P1491; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Huh PW, 2000, J NEUROSURG, V92, P91, DOI 10.3171/jns.2000.92.1.0091; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; NAWASHIRO H, 1995, NEUROL RES, V17, P455, DOI 10.1080/01616412.1995.11740363; *NIH, 1985, PUBL NIH; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PHILLIS JW, 1993, REGULATION CEREBRAL, P249; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; STATLER KD, IN PRESS NEUROTRAUMA; SUEHIRO E, IN PRESS J NEUROTRAU; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; Zhao WZ, 1999, J NEUROSURG, V90, P510, DOI 10.3171/jns.1999.90.3.0510; ZILLES L, 1985, CORTEX RAT STEREOTAX	50	72	75	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2001	29	11					2060	2066		10.1097/00003246-200111000-00004			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490WL	WOS:000172076700004	11700395				2022-02-06	
J	Weber, JT; Rzigalinski, BA; Ellis, EF				Weber, JT; Rzigalinski, BA; Ellis, EF			Traumatic injury of cortical neurons causes changes in intracellular calcium stores and capacitative calcium influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; OPERATED HTRP3 CHANNELS; STRETCH-INDUCED INJURY; CENTRAL-NERVOUS-SYSTEM; BRAIN INJURY; DELAYED DEPOLARIZATION; ENDOPLASMIC-RETICULUM; GLUTAMATE RECEPTORS; TRANSMITTER RELEASE; ARACHIDONIC-ACID	Using an in vitro traumatic injury model, we examined the effects of mechanical (stretch) injury on intracellular Ca2+ store-mediated signaling in cultured cortical neurons using fura-2. We previously found that elevation of [Ca2+](i) by the endoplasmic reticulum Ca2+-ATPase inhibitor, thapsigargin, was abolished 15 min post-injury. In the current studies, pre-injury inhibition of phospholipase C with neomycin sulfate maintained Ca2+-replete stores 15 min post-injury, suggesting that the initial injury-induced store depletion may be due to increased inositol trisphosphate production. Thapsigargin-stimulated elevation of [Ca2+], returned with time after injury and was potentiated at 3 h. Stimulation with thapsigargin in Ca2+-free media revealed that the size of the Ca2+ stores was normal at 3 h post-injury, However, Ca2+ influx triggered by depletion of intracellular Ca2+ stores (capacitative Ca2+ influx) was enhanced 3 h after injury. Enhancement was blocked by inhibitors of cytosolic phospholipase A, and cytochrome P450 epoxygenase. Since intracellular Ca2+ store-mediated signaling plays an important role in neuronal function, the observed changes may contribute to dysfunction produced by traumatic brain injury. Additionally, our results suggest that capacitative Ca2+ influx may be mediated by both conformational coupling and a diffusible messenger synthesized by the combined action of cytosolic PLA, and P450.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA		Rzigalinski, BA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Box 980613, Richmond, VA 23298 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL057869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL57869] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27214] Funding Source: Medline		AbdulGhani MA, 1996, J NEUROPHYSIOL, V76, P2691, DOI 10.1152/jn.1996.76.4.2691; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BRORSON JR, 1991, J NEUROSCI, V11, P4024; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; Budd SL, 1996, J NEUROCHEM, V67, P2282; Choi S, 1996, J NEUROSCI, V16, P36; DELAHUNTY TM, 1992, BRAIN RES, V594, P507; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Doutheil J, 1997, BRAIN RES, V775, P43, DOI 10.1016/S0006-8993(97)00899-8; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Fomina AF, 1999, J NEUROSCI, V19, P3711; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; Garaschuk O, 1997, J PHYSIOL-LONDON, V502, P13, DOI 10.1111/j.1469-7793.1997.013bl.x; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Jonas S, 1997, ANN NY ACAD SCI, V825, P389, DOI 10.1111/j.1749-6632.1997.tb48449.x; Kaftan EJ, 1997, J GEN PHYSIOL, V110, P529, DOI 10.1085/jgp.110.5.529; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kohn EC, 1996, CANCER RES, V56, P569; KOSTYUK P, 1994, NEUROSCIENCE, V63, P381, DOI 10.1016/0306-4522(94)90537-1; Lamb RG, 1997, J NEUROCHEM, V68, P1904; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; Ma L, 1998, J NEUROPHYSIOL, V79, P1183, DOI 10.1152/jn.1998.79.3.1183; McConkey DJ, 1996, J LEUKOCYTE BIOL, V59, P775, DOI 10.1002/jlb.59.6.775; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; McIntosh TK, 1996, LAB INVEST, V74, P315; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; Paschen W, 1999, J CEREBR BLOOD F MET, V19, P1, DOI 10.1097/00004647-199901000-00001; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Picard L, 1998, CELL CALCIUM, V23, P339, DOI 10.1016/S0143-4160(98)90029-X; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROBITAILLE R, 1993, NEURON, V11, P645, DOI 10.1016/0896-6273(93)90076-4; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sakaki Y, 1997, J NEUROBIOL, V32, P62, DOI 10.1002/(SICI)1097-4695(199701)32:1<62::AID-NEU6>3.0.CO;2-C; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHLAEPFER WW, 1985, PROG BRAIN RES, V63, P185; Scholz WK, 1998, J NEUROCHEM, V71, P580; SCHREIBER D, 1995, P 1995 INT RES C BIO; Tavalin SJ, 1997, J NEUROPHYSIOL, V77, P632, DOI 10.1152/jn.1997.77.2.632; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767, DOI 10.1152/jn.1995.74.6.2767; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; TRIFARO JM, 1993, TRENDS NEUROSCI, V16, P466, DOI 10.1016/0166-2236(93)90079-2; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang MH, 1998, J PHARMACOL EXP THER, V284, P966; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; White RJ, 1996, J NEUROSCI, V16, P5688; WILLIAMS DA, 1990, CELL CALCIUM, V11, P75, DOI 10.1016/0143-4160(90)90061-X; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; YOUNG W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	70	72	76	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1800	1807		10.1074/jbc.M009209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	WOS:000166528000022	11050103	hybrid			2022-02-06	
J	Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J				Anderson, V; Catroppa, C; Morse, S; Haritou, F; Rosenfeld, J			Outcome from mild head injury in young children: A prospective study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; BEHAVIORAL SEQUELAE; ADOLESCENTS; TOMOGRAPHY	There is a lack of agreement regarding the long-term consequences of mild head injury (HI) at any age, with such effects rarely studied in early childhood. Given the rapid development occurring within the brain during this period, any disruption may have the potential to cause transient or permanent damage to brain structure and function. The present study sought to investigate the behavioral implications of such potential disruptions using a prospective, longitudinal design. Children aged 3-7 years at the time of injury, and suffering from mild HI, were evaluated acutely and at 6 and 30 months post-injury. Pre-injury data were collected with respect to communication, social skills, daily living skills and behavioral function. Results were compared to those from a non-injured control sample matched for age, gender, socioeconomic status, and pre-injury function. Findings showed few group differences. Children with mild HI performed similarly to controls on measures of intellectual ability, receptive language, and both everyday and spatial memory capacity. Group differences were identified for verbal fluency and story recall, with HI children failing to recover over time.	Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia; Royal Childrens Hosp, Melbourne, Vic, Australia; Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Anderson, V (corresponding author), Univ Melbourne, Dept Psychol, Melbourne, Vic 3010, Australia.	v.anderson@psych.unimelb.edu.au	Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436			ALVES W, 1992, STATE ARTS REV, V6, P21; Anderson V, 1997, J Int Neuropsychol Soc, V3, P147; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V., 1995, NEUROPSYCHOLOGICAL A; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; BIJUR PE, 1990, PEDIATRICS, V86, P337; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; CARROWWOOLFOLK E, 1985, EXAMINERS MANUAL TES; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Ciccetti D., 1984, VINELAND ADAPTIVE BE; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; Daniel A., 1983, POWER PRIVILEGE PRES; Dennis M, 1989, CLIN NEUROPSYCHOLOGY, P89; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dunn LM., 1981, PEABODY PICTURE VOCA; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1985, HEAD INJURY REHABILI, P71; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; GARDNER M, 1979, MANUAL EXPRESSIVE 1; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HAYES R, 1994, BRAIN, V109, P251; HAYES RL, 1992, PHYS MED REHAB STATE, V6, P9; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Klonoff P., 1996, CLIN NEUROPSYCHOL, V12, P31; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Lachar D., 1992, PERSONALITY INVENT S; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; McCarthy D., 1972, MANUAL MCCARTHY SCAL; Miller L, 1996, J COGNITIVE REHABILI, V15, P8; MOYES CD, 1980, CHILD CARE HLTH DEV, V6, P1, DOI 10.1111/j.1365-2214.1980.tb00791.x; PAPERO PH, 1993, NEUROPSYCHOL REHABIL, V3, P321, DOI 10.1080/09602019308401445; PENTLAND L, 2000, CHILD NEUROPSYCHOLOG; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 1987, MANUAL PRESCHOOL PRI; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; YEATES K, 1999, PEDIAT NEUROPSYCHOLO, P192; [No title captured]	53	72	72	0	11	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					705	717		10.1076/jcen.23.6.705.1015			13	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200001	11910538				2022-02-06	
J	Bryant, RA				Bryant, RA			Posttraumatic stress disorder and mild brain injury: controversies, causes and consequences	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; COGNITIVE-BEHAVIORAL THERAPY; MOTOR-VEHICLE ACCIDENTS; ROAD TRAFFIC ACCIDENTS; CONTROLLED TRIAL; ANXIETY; HYPOCHONDRIASIS; SYMPTOMS; MODEL; PTSD	Posttraumatic stress disorder (PTSD) is an anxiety condition that often arises following a traumatic experience. It has commonly been argued that impaired consciousness associated with mild brain injury (MBI) precludes encoding of the traumatic experience, and this prevents PTSD development. This review considers the available evidence on PTSD following MBI and indicates the distinctive nature of PTSD after MBI. The review then discusses the possible mechanisms that may mediate PTSD in this population. The interaction of PTSD and postconcussive symptoms is discussed within a cognitive model that emphasizes the role of catastrophic interpretations of postconcussive symptoms. Finally, the implications of PTSD after MBI for assessment and treatment are reviewed.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Brewin CR, 1996, PSYCHOL REV, V103, P670, DOI 10.1037/0033-295X.103.4.670; Brewin CR, 1999, AM J PSYCHIAT, V156, P360; Bryant RA, 1995, INT J PSYCHOPHYSIOL, V20, P209, DOI 10.1016/0167-8760(95)00036-4; BRYANT RA, 1995, J ABNORM PSYCHOL, V104, P537, DOI 10.1037/0021-843X.104.3.537; Bryant RA, 1999, AM J PSYCHIAT, V156, P1780; Bryant RA, 1998, J CONSULT CLIN PSYCH, V66, P862, DOI 10.1037/0022-006X.66.5.862; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1998, APPL COGNITIVE PSYCH, V12, P81, DOI 10.1002/(SICI)1099-0720(199802)12:1<81::AID-ACP507>3.0.CO;2-8; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2000, AGGRESS VIOLENT BEH, V5, P79, DOI 10.1016/S1359-1789(98)00021-4; BRYANT RA, IN PRESS CLIN PSYCHO; Bryant RA., 2000, ACUTE STRESS DISORDE; CARR DB, 1984, J CLIN PSYCHIAT, V45, P323; Clark D. M., 1988, PANIC PSYCHOL PERSPE, P71; Clark DM, 1998, BRIT J PSYCHIAT, V173, P218, DOI 10.1192/bjp.173.3.218; DEITZ J, 1992, J AM ACAD PSYCHOAN, V20, P277, DOI 10.1521/jaap.1.1992.20.2.277; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EIFERT GH, 1992, BEHAV RES THER, V30, P329, DOI 10.1016/0005-7967(92)90045-I; Eifert GH, 2000, BEHAV RES THER, V38, P1039, DOI 10.1016/S0005-7967(99)00132-1; FLEMINGER S, 1993, BIOL PSYCHIAT, V33, P22, DOI 10.1016/0006-3223(93)90274-H; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1996, COGNITIVE THER RES, V20, P613, DOI 10.1007/BF02227964; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P500, DOI 10.1037/0022-006X.66.3.500; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HARVEY AG, IN PRESS J TRAUMATIC; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; KOLB LC, 1987, AM J PSYCHIAT, V144, P989; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; KRYSTAL JH, 1989, BEHAV THER, V20, P177, DOI 10.1016/S0005-7894(89)80068-1; Ledoux J E, 1989, J Cogn Neurosci, V1, P238, DOI 10.1162/jocn.1989.1.3.238; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Marcus DK, 1999, J PSYCHOSOM RES, V47, P79, DOI 10.1016/S0022-3999(99)00008-2; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; MCNALLY RJ, 1990, PSYCHOL BULL, V108, P403, DOI 10.1037/0033-2909.108.3.403; Middelboe T., 1992, European Psychiatry, V7, P183; MILLER L, 1993, J COGNITIVE REHABILI, V11, P18; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; Pitman RK, 1997, ANN NY ACAD SCI, V821, P1, DOI 10.1111/j.1749-6632.1997.tb48264.x; Price K. P., 1994, DEF LAW J, V43, P113; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Reiss S., 1985, THEORETICAL ISSUES B, P107; RUTHERFORD WH, 1989, NEUROBEHAVIORAL RECO, P217; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SBORDONE RJ, 1992, NEUROLAW LETT   0503; SCHACTER DL, 1993, ANNU REV NEUROSCI, V16, P159, DOI 10.1146/annurev.ne.16.030193.001111; Schmidt NB, 1999, J ABNORM PSYCHOL, V108, P532, DOI 10.1037/0021-843X.108.3.532; SIVEC HJ, 1995, CLIN PSYCHOL REV, V15, P297, DOI 10.1016/0272-7358(95)00012-E; Smith K, 2000, BEHAV RES THER, V38, P709, DOI 10.1016/S0005-7967(99)00096-0; SOLOMON SD, 1990, COMPR PSYCHIAT, V31, P227, DOI 10.1016/0010-440X(90)90006-E; Speckens A. E. M., 1997, BEHAV COGN PSYCHOTH, V25, P291; Tarrier N, 1999, J CONSULT CLIN PSYCH, V67, P13, DOI 10.1037/0022-006X.67.1.13; Van Der Kolk Bessel A., 1996, P214; Warda G, 1998, BEHAV RES THER, V36, P1171, DOI 10.1016/S0005-7967(98)00082-5; Warwick HMC, 1996, BRIT J PSYCHIAT, V169, P189, DOI 10.1192/bjp.169.2.189; YERAGANI V, 1989, ACTA PSYCHIAT SCAND, V79, P421	79	72	73	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2001	23	6					718	728		10.1076/jcen.23.6.718.1024			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	535QL	WOS:000174655200002	11910539				2022-02-06	
J	Aibiki, M; Maekawa, S; Yokono, S				Aibiki, M; Maekawa, S; Yokono, S			Moderate hypothermia improves imbalances of thromboxane A(2) and prostaglandin I-2 production after traumatic brain injury in humans	CRITICAL CARE MEDICINE			English	Article						arterial-jugular bulb difference; moderate hypothermia; normothermia; prostaglandins; traumatic brain injury	CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; RAT; INTERLEUKIN-1; PROSTACYCLIN; EICOSANOIDS; ASTROCYTES; RELEASE; EDEMA	Objective: To examine the levels of thromboxane B-2 (TXB2) and 6-keto prostaglandin F-1 alpha (6-keto PGF(1 alpha)) production in arterial and internal jugular bulb sera in patients with traumatic brain injury (TBI). TBI is associated with arachidonate release and may be associated with an imbalance of vasoconstricting and vasodilating cyclooxygenase metabolites. Design: A prospective, randomized study. Setting: The intensive care unit of a medical university hospital. Interventions: Twenty-six ventilated TBI patents (Glasgow Coma Scale score on admission, less than or equal to8 points) were divided randomly into two groups: a hypothermic group (n = 15), in which the patients were cooled to 32 to 33 degreesC after being giving vecuronium, midazolam, and buprenorphine; and a normothermic group (n = 11), in which the patients' body temperature was controlled at 36 to 37 degreesC by surface cooling using the same treatment as the hypothermic group. Body temperature control including normothermia was started 3 to 4 hrs after injury. The duration of hypothermia usually lasted for 3 to 4 days, after which the patients were rewarmed at a Fate of approximately 1 degreesC per day. Measurements and Main Results: Blood sampling for TXB2 and 6-keto PGF(1 alpha) was started shortly after admission in both groups. Arterial TXB2 levels on admission in both groups were elevated remarkably, but not 6-keto PGF(1 alpha), thereby causing an imbalance of the prostanoids after injury. In the normothermic group, TXB2 decreased transiently, but this prostanoid increased again 3 days after the injury. In the hypothermic group, such prostanoid differences disappeared shortly after therapy, and the condition was sustained for 10 days. Hypothermia attenuated differences in TXB2 levels between arterial and Internal jugular bulb sera, which may reflect reduced cerebral prostanoid production. The Glasgow Outcome Scale score 6 months after the insult in the hypothermic group was significantly higher than that in the normothermic group (p = .04). Conclusion: The current results from a limited number of patients suggest that moderate hypothermia may reduce prostanoid production after TBI, thereby attenuating an imbalance of thromboxane A(2) and prostaglandin I-2. However, it must be clarified whether the changes in the prostanoid after moderate hypothermia are a secondary effect of other mediator changes or whether they simply represent an epiphenomenon that is mechanistically unrelated to damage in TBI.	Kagawa Med Univ Hosp, Intens Care Unit, Kita Ku, Kagawa 7610793, Japan; Ehime Univ, Sch Med, Dept Emergency Med, Matsuyama, Ehime, Japan		Aibiki, M (corresponding author), Kagawa Med Univ Hosp, Intens Care Unit, Kita Ku, 1750-1 Ikenode, Kagawa 7610793, Japan.						Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; ASAGA T, 1997, ICU CCU JAP J INTENS, V21, P967; BOULLIN DJ, 1979, BRIT J CLIN PHARMACO, V7, P139, DOI 10.1111/j.1365-2125.1979.tb00914.x; COOK JA, 1993, PATHOPHYSIOLOGY SHOC, P518; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; DEMPSEY RJ, 1986, J NEUROSURG, V64, P118, DOI 10.3171/jns.1986.64.1.0118; DEVRIES HE, 1995, J NEUROIMMUNOL, V59, P1, DOI 10.1016/0165-5728(95)00009-Q; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KENT KC, 1993, CIRC RES, V72, P958, DOI 10.1161/01.RES.72.5.958; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Leffler CW, 1997, NEWS PHYSIOL SCI, V12, P72; MAEKAWA S, 1997, IMMUNE CONSEQUENCES, P135; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MURPHY S, 1985, NEUROSCI LETT, V61, P61, DOI 10.1016/0304-3940(85)90401-X; PICKARD JD, 1994, ACTA NEUROCHIR, V129, P152, DOI 10.1007/BF01406495; SAEEDABDELHALIM M, 1980, J NEUROCHEM, V34, P1331, DOI 10.1111/j.1471-4159.1980.tb09980.x; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Stella N, 1997, J NEUROSCI, V17, P2939; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2	29	72	74	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2000	28	12					3902	3906		10.1097/00003246-200012000-00029			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	388NB	WOS:000166186200020	11153633				2022-02-06	
J	Rothstein, TL				Rothstein, TL			The role of evoked potentials in anoxic-ischemic coma and severe brain trauma	JOURNAL OF CLINICAL NEUROPHYSIOLOGY			English	Article						anoxic-ischemic coma; cardiac arrest; traumatic brain injury; somatosensory evoked potentials; cortical evoked potentials; central conduction time; brainstem auditory evoked potentials; persistent vegetative state; outcome prediction	SEVERE HEAD-INJURY; HOSPITAL CARDIAC-ARREST; PERSISTENT VEGETATIVE STATE; PREDICTIVE VALUE; CARDIOPULMONARY-RESUSCITATION; PROGNOSTIC VALUE; CEREBRAL TRAUMA; RECOVERY; DEATH; MANAGEMENT	The early recognition of comatose patients with a hopeless prognosis-regardless of how aggressively they rue managed-is of utmost importance. Median somatosensory evoked potentials supplement and enhance neurologic examination findings in anoxic-ischemic coma and severe brain trauma, and are useful as an early guide to outcome. The key finding is that bilateral absence of cortical evoked potentials, generated by thalamocortical tracts, reliably predicts unfavorable outcome in comatose patients after cardiac arrest, and correlates strongly with death or persistent vegetative state in severe brain trauma. The author studied 50 comatose patients with preserved brainstem function after cardiac arrest. All 23 patients with bilateral absence of cortical evoked potentials died without awakening. Neuropathologic study in seven patients disclosed widespread ischemic changes or frank cortical laminar necrosis. The remaining 27 patients with normal or delayed central conduction times had an uncertain prognosis because some died without awakening or entered a persistent vegetative state. The majority of patients with normal central conduction times had a good outcome, whereas a delay in central conduction times increased the likelihood of neurologic deficit or death. This report includes a systematic review of the literature concerning adults in anoxic-ischemic coma and severe brain trauma, in which somatosensory evoked potentials were used as an early guide to predict clinical outcome. Greater use of somatosensory evoked potentials in anoxic-ischemic coma and severe brain trauma would identify those patients unlikely to recover and would avoid costly medical care that is to no avail.	NW Neurosci Inst, Seattle, WA 98133 USA		Rothstein, TL (corresponding author), NW Neurosci Inst, 10330 Meridan Ave N,Suite 300, Seattle, WA 98133 USA.						AHMED I, 1988, CLIN ELECTROENCEPHAL, V19, P78, DOI 10.1177/155005948801900209; ANDERSON DC, 1984, ARCH NEUROL-CHICAGO, V41, P369, DOI 10.1001/archneur.1984.04050160031011; Attia J, 1998, CRIT CARE CLIN, V14, P497, DOI 10.1016/S0749-0704(05)70013-0; BARELLI A, 1991, CRIT CARE MED, V19, P1374, DOI 10.1097/00003246-199111000-00013; Bassetti C, 1996, J NEUROL NEUROSUR PS, V61, P610, DOI 10.1136/jnnp.61.6.610; Berek K, 1997, EUR NEUROL, V37, P135, DOI 10.1159/000117426; Bernat JL, 1998, HASTINGS CENT REP, V28, P14, DOI 10.2307/3527567; BINIEK R, 1989, INTENS CARE MED, V15, P212, DOI 10.1007/BF01058577; BRENDLER SJ, 1970, BRAIN, V93, P381, DOI 10.1093/brain/93.2.381; BRIERLEY JB, 1971, LANCET, V2, P560; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; CANT BR, 1986, ELECTROEN CLIN NEURO, V65, P188, DOI 10.1016/0168-5597(86)90053-5; Chatrian GE, 1996, ELECTROEN CLIN NEURO, V99, P103, DOI 10.1016/0013-4694(96)96059-9; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Chen R, 1996, CRIT CARE MED, V24, P672, DOI 10.1097/00003246-199604000-00020; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; COBB LA, 1976, MED CLIN N AM, V60, P283, DOI 10.1016/S0025-7125(16)31909-5; DANZE F, 1989, Neurosurgical Review, V12, P477, DOI 10.1007/BF01790694; DELECLUSE F, 1987, ANN NEUROL, V22, P142; DEMEIRLEIR LJ, 1987, PEDIATR NEUROL, V3, P78, DOI 10.1016/0887-8994(87)90031-2; DEWEERD AW, 1985, ACTA NEUROL SCAND, V72, P489; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; Edgren E, 1988, Acta Anaesthesiol Belg, V39, P121; EDGREN E, 1989, RESUSCITATION, V17, pS131, DOI 10.1016/0300-9572(89)90097-X; FACCO E, 1990, ELECTROEN CLIN NEURO, P330; FACCO E, 1994, MINERVA ANESTESIOL, V60, P595; GANJI S, 1988, CLIN ELECTROENCEPHAL, V19, P55, DOI 10.1177/155005948801900206; GENARELLI TA, 1982, HEAD INJURY BASIC CL, P129; GOLBY A, 1995, NEUROLOGY, V45, P1629, DOI 10.1212/WNL.45.8.1629; GOODWIN SR, 1991, CRIT CARE MED, V19, P518, DOI 10.1097/00003246-199104000-00011; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit J M, 1992, Eur J Med, V1, P233; GUTLING E, 1993, ELECTROEN CLIN NEURO, V88, P369, DOI 10.1016/0168-5597(93)90013-F; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEYMANS C, 1950, PHYSIOL REV, V30, P375, DOI 10.1152/physrev.1950.30.3.375; HOULDEN DA, 1990, NEUROSURGERY, V27, P701, DOI 10.1227/00006123-199011000-00006; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JACOBS P, 1990, CRIT CARE MED, V18, P1282, DOI 10.1097/00003246-199011000-00020; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jennett B, 1981, MANAGEMENT HEAD INJU; JORGENSEN EO, 1978, RESUSCITATION, V6, P217, DOI 10.1016/0300-9572(78)90001-1; JUDSON JA, 1990, CRIT CARE MED, V18, P363, DOI 10.1097/00003246-199004000-00003; KANE NM, 1993, LANCET, V341, P688, DOI 10.1016/0140-6736(93)90453-N; KANO T, 1992, RESUSCITATION, V23, P235, DOI 10.1016/0300-9572(92)90007-Y; KAPLAN PW, 2000, IN PRESS J CLIN NEUR; Kraus J F, 1978, Adv Neurol, V19, P261; Krieger DW, 1998, LANCET, V352, P1796, DOI 10.1016/S0140-6736(98)00081-6; LEVY DE, 1981, ANN INTERN MED, V94, P293, DOI 10.7326/0003-4819-94-3-293; LEVY DE, 1985, JAMA-J AM MED ASSOC, V253, P1420, DOI 10.1001/jama.253.10.1420; LINDSAY K, 1990, NEUROSURGERY, V26, P278, DOI 10.1227/00006123-199002000-00015; Longstreth Jr WT, 1994, NEUROLOGY GEN MED, P166; LONGSTRETH WT, 1983, ANN INTERN MED, V98, P588, DOI 10.7326/0003-4819-98-5-588; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; LOWN B, 1979, AM J CARDIOL, V43, P313, DOI 10.1016/S0002-9149(79)80021-1; Madl C, 1996, ARCH NEUROL-CHICAGO, V53, P512, DOI 10.1001/archneur.1996.00550060054017; MADL C, 1993, LANCET, V341, P855, DOI 10.1016/0140-6736(93)93061-5; Mahapatra A K, 1990, J Indian Med Assoc, V88, P217; Marcus EM, 1984, EVOKED POTENTIAL, VII, P609; MULLIE A, 1989, RESUSCITATION, V17, pS23, DOI 10.1016/0300-9572(89)90088-9; MULLIE A, 1988, LANCET, V1, P137; NEWLON PG, 1982, J NEUROSURG, V57, P168, DOI 10.3171/jns.1982.57.2.0168; NUWER MR, 1994, ELECTROENCEPHALOGR C, V9, P6; PLUM F, 1982, DIAGNOSIS STUPOR COM, P846; PohlmannEden B, 1997, INTENS CARE MED, V23, P301, DOI 10.1007/s001340050332; Ragazzoni A, 1999, CLIN NEUROPHYSIOL, V110, pS245; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROTHSTEIN TL, 1991, ELECTROEN CLIN NEURO, V79, P101, DOI 10.1016/0013-4694(91)90046-7; RUMPL E, 1988, J CLIN NEUROPHYSIOL, V5, P237, DOI 10.1097/00004691-198807000-00002; Sherman AL, 2000, NEUROLOGY, V54, P889, DOI 10.1212/WNL.54.4.889; SHEWMON DA, 1989, NEUROL CLIN, V7, P823, DOI 10.1016/S0733-8619(18)30392-X; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; SNYDER BD, 1981, NEUROLOGY, V31, P1092, DOI 10.1212/WNL.31.9.1092; *SOC CRIT CAR MED, 1988, CRIT CARE MED, V16, P807; SOHMER H, 1986, ELECTROEN CLIN NEURO, V64, P334, DOI 10.1016/0013-4694(86)90157-4; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; YING Z, 1992, J NEUROL NEUROSUR PS, V55, P470, DOI 10.1136/jnnp.55.6.470; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8; [No title captured]	82	72	74	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0736-0258	1537-1603		J CLIN NEUROPHYSIOL	J. Clin. Neurophysiol.	SEP	2000	17	5					486	497		10.1097/00004691-200009000-00007			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	371MQ	WOS:000165183100007	11085552				2022-02-06	
J	Nayak, S; Wheeler, BL; Shiflett, SC; Agostinelli, S				Nayak, S; Wheeler, BL; Shiflett, SC; Agostinelli, S			Effect of music therapy on mood and social interaction among individuals with acute traumatic brain injury and stroke	REHABILITATION PSYCHOLOGY			English	Article							SICKNESS IMPACT PROFILE	Objective: To investigate the efficacy of music therapy techniques as an aid in improving mood and social interaction after traumatic brain injury or stroke. Design: Eighteen individuals with traumatic brain injury or stroke were assigned either standard rehabilitation alone or standard rehabilitation along with music therapy (3 treatments per week for up to 10 treatments). Measures: Pretreatment and posttreatment assessments of participant self-rating of mood, family ratings of mood and social interaction, and therapist rating of mood and participation in therapy. Results: There was a significant improvement in family members' assessment of participants' social interaction in the music therapy group relative to the control group. The staff rated participants in the music therapy group as more actively involved and cooperative in therapy than those in the control group. There was a trend suggesting that self-ratings and family ratings of mood showed greater improvement in the music group than in the control group. Conclusions: Results lend preliminary support to the efficacy of music therapy as a complementary therapy for social functioning and participation in rehabilitation with a trend toward improvement in mood during acute rehabilitation.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, Newark, NJ 07107 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Montclair State Univ, Dept Mus, Upper Montclair, NJ 07043 USA		Nayak, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Psychiat, ADMC 1404,30 Bergen St, Newark, NJ 07107 USA.						Behrens G. A., 1988, MUSIC THERAPY PERSPE, V5, P16; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CASSITY MD, 1976, J MUSIC THER, V13, P66, DOI 10.1093/jmt/13.2.66; Clair AA, 1997, J MUSIC THER, V34, P148, DOI 10.1093/jmt/34.3.148; DEBRUIN AF, 1992, SOC SCI MED, V35, P1003, DOI 10.1016/0277-9536(92)90240-Q; ESLINGER P, 1993, MUSIC THERAPY BRAIN; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hanser SB, 1998, J GERONTOL, V49, P265, DOI 10.1093/geronj/49.6.P265; Hodges D. A., 1980, HDB MUSIC PSYCHOL; MACRAE A, 1992, AM J OCCUP THER, V46, P275, DOI 10.5014/ajot.46.3.275; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P267, DOI 10.1001/jama.275.4.267; McDowell I., 1996, MEASURING HLTH GUIDE, P194; MCKINNEY CH, 1990, J MUSIC THER, V27, P34, DOI 10.1093/jmt/27.1.34; POLLACK NJ, 1992, J MUSIC THER, V29, P54, DOI 10.1093/jmt/29.1.54; STANDLEY JM, 1994, RES MUSIC THERAPY TR; Steckler M A, 1998, J Long Term Home Health Care, V17, P42; THAUT MH, 1989, J MUSIC THER, V26, P155, DOI 10.1093/jmt/26.3.155	17	72	74	3	52	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2000	45	3					274	283		10.1037/0090-5550.45.3.274			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	338BZ	WOS:000088399400004					2022-02-06	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Video analysis of acute motor and convulsive manifestations in sport-related concussion	NEUROLOGY			English	Article						concussion; traumatic brain injury; head injury; video analysis	MEMORY; AMNESIA; INJURY	Objectives: To describe the motor and convulsive manifestations in acute sports-related head injury. Methods: A total of 234 cases of concussive injuries during the 1995 through 1997 football seasons were obtained from the Australian Football League Medical Officers Association injury survey. Of these, 102 cases were recorded adequately on television videotape and were analyzed by two independent observers using a standardized recording form detailing injury mechanics and clinical features of the episodes. Motor and convulsive features were correlated with mechanical variables and with duration of loss of consciousness using linear modeling techniques. Results: Tonic posturing occurred in 25 subjects, clonic movements in 6, righting movement in 40, and gait unsteadiness in 42. In one subject the tonic and clonic features were sufficiently prolonged to be deemed a concussive convulsion. The only risk factor for tonic posturing using logistic regression was the presence of loss of consciousness (p = 0.0001). There was a trend toward facial impact being an independent predictor of tonic posturing but this did not reach significance. No other independent variable predicted the development of clonic movements, righting movements, or gait unsteadiness. Conclusions: Subtle motor manifestations such as tonic posturing and clonic movements commonly occur in concussion; the main predictive factor for tonic posturing is the presence of loss of consciousness. The authors speculate that these clinical features are due to brainstem dysfunction secondary to biomechanical forces inducing a transient functional decerebration.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Neurol, Heidelberg, Germany		McCrory, PR (corresponding author), 31 Grosvenor Parade, Balwyn, Vic 3108, Australia.	pmccrory@compuserve.com	McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			Barth JT, 1989, MILD HEAD INJURY, P257; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GOLDBERG E, 1982, CORTEX, V18, P459, DOI 10.1016/S0010-9452(82)80042-7; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; JACKSON J, 1895, LANCET, V1, P274; Jackson J., 1871, BMJ-BRIT MED J, Vii, p[242, 528]; JACKSON J, 1871, BMJ-BRIT MED J, V2, P528; JACKSON JH, 1863, MED TIMES GAZ, V2, P65; JANE JA, 1985, TRAUMA CENTRAL NERVO, P27; LETCHER FS, 1973, J NEUROSURG, V39, P167, DOI 10.3171/jns.1973.39.2.0167; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrory PR, 1997, MED SCI SPORT EXER, V29, pS207; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1999, NEUROLOGY, V52, P1888, DOI 10.1212/WNL.52.9.1888; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; MCMILLIAN MK, 1994, TRENDS NEUROSCI, V17, P138, DOI 10.1016/0166-2236(94)90086-8; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; Orchard J, 1998, J Sci Med Sport, V1, P83, DOI 10.1016/S1440-2440(98)80016-9; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; WESTPHAL CFO, 1871, BERLINER FKLIN WOCHE, V1, P39; WESTPHAL CFO, 1872, BRIT MED J, V1, P399; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863	30	72	73	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	APR 11	2000	54	7					1488	1491		10.1212/WNL.54.7.1488			4	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	304AT	WOS:000086460900019	10751264				2022-02-06	
J	Matz, PG; Fujimura, M; Chan, PH				Matz, PG; Fujimura, M; Chan, PH			Subarachnoid hemolysate produces DNA fragmentation in a pattern similar to apoptosis in mouse brain	BRAIN RESEARCH			English	Article						apoptosis; hemoglobin; oxidative injury; stroke; subarachnoid hemorrhage	LIPID-PEROXIDATION; HEMOGLOBIN; INDUCTION; RAT; HEMORRHAGE; ISCHEMIA; DAMAGE; STRESS; INJURY; GLIA	Stroke and traumatic brain/spinal cord injuries are often associated with hemorrhage. Despite the relative frequency of hemorrhage in the central nervous system (CNS), little is known about what role blood and hemoglobin (Hb) play in mediating cellular injury. Since Hb and hemolysate have been associated with generation of oxidative stress and cell injury, we examined whether apoptosis was present after cortical exposure to subarachnoid hemolysate. Subarachnoid hemorrhage (SAH) was induced in CD-1 mice (n = 25) by injection of 50 mu l of autologous hemolysate over the right parietal cortex. Saline-injected mice (n. = 13) were used as controls. Subjects were sacrificed at 24 h. Transcardiac perfusion fixation was performed on a subgroup of hemolysate- (n. = 15) and saline-injected (n = 9) animals. Sections were stained for DNA fragmentation using the terminal deoxyuridine nick end-labeling (TUNEL) method and also immunostained for the hemeoxygenase-1 (HO-1) protein to assess blood distribution In the remaining animals (n = 6 SAH, n = 4 saline), DNA was extracted and precipitated from 40 mg of tissue and subjected to electrophoresis on a 1.5% agarose gel. DNA fragmentation was evident on TUNEL staining in 10/15 subjects injected with hemolysate as compared to 0/9 subjects injected with saline (p < 0.01, Fisher exact test). TUNEL-positive cells were most abundant closest to the site of cortical SAH, as evidenced by HO-1 immunoreactivity. TUNEL-positive cells were also seen remotely in the hippocampus and basal forebrain. The presence of apoptosis was suggested by DNA laddering on electrophoresis in the hemolysate-injected subjects (4/6 animals). No laddering was evident in saline-injected subjects (rt = 4). These results provide evidence that the presence of subarachnoid blood products is associated with DNA fragmentation and apoptotic cell death. (C) 2000 Elsevier Science B.V. All rights reserved.	Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Palo Alto Vet Affairs Hlth Care Syst, Surg Serv, Palo Alto, CA 94304 USA; Stanford Univ, Dept Neurol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA		Matz, PG (corresponding author), Vet Adm Med Ctr, Surg Serv 112N, 3801 Miranda Ave, Palo Alto, CA 94304 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS25372, NS36144, NS14543] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS014543, R01NS025372, P50NS014543] Funding Source: NIH RePORTER		BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BONITA R, 1985, STROKE, V16, P591, DOI 10.1161/01.STR.16.4.591; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; DELGADO TJ, 1985, STROKE, V16, P595, DOI 10.1161/01.STR.16.4.595; Dreier JP, 1998, J CEREBR BLOOD F MET, V18, P978, DOI 10.1097/00004647-199809000-00007; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; GUTTERIDGE JMC, 1987, BIOCHIM BIOPHYS ACTA, V917, P219, DOI 10.1016/0005-2760(87)90125-1; IMLAY JA, 1988, SCIENCE, V240, P640, DOI 10.1126/science.2834821; Kondo T, 1997, J NEUROSCI, V17, P4180; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; MACDONALD RL, 1991, STROKE, V22, P971, DOI 10.1161/01.STR.22.8.971; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1996, J NEUROSURG, V85, P892, DOI 10.3171/jns.1996.85.5.0892; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; REGAN RF, 1993, NEUROSCI LETT, V153, P219, DOI 10.1016/0304-3940(93)90326-G; ROSEN AD, 1979, EXP NEUROL, V66, P277, DOI 10.1016/0014-4886(79)90080-3; Turner CP, 1999, MOL BRAIN RES, V65, P87, DOI 10.1016/S0169-328X(98)00340-4; Turner CP, 1998, J CEREBR BLOOD F MET, V18, P257, DOI 10.1097/00004647-199803000-00004	24	72	76	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAR 10	2000	858	2					312	319		10.1016/S0006-8993(99)02454-3			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	292VB	WOS:000085814800009	10708682				2022-02-06	
J	Langan, EM; Miller, RS; Casey, WJ; Carsten, CG; Graham, RM; Taylor, SM				Langan, EM; Miller, RS; Casey, WJ; Carsten, CG; Graham, RM; Taylor, SM			Prophylactic inferior vena cava filters in trauma patients at high risk: Follow-up examination and risk/benefit assessment	JOURNAL OF VASCULAR SURGERY			English	Article; Proceedings Paper	23rd Annual Meeting of the Southern-Association-for-Vascular-Surgery	JAN 27-30, 1999	NAPLES, FLORIDA	So Assoc Vasc Surg			PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; PLACEMENT; PREVENTION	Purpose: The efficacy of prophylactic inferior vena cava filters in selected trauma patients at high risk has come into question in relation to risk/benefit assessment. To evaluate the usefulness of prophylactic inferior vena cava filters, we reviewed our experience and overall complication rate. Methods: From February 1991 to April 1998, the trauma registry identified 7333 admissions. One hundred eighty-seven prophylactic inferior vena cava filters were inserted. After the exclusion of 27 trauma-related deaths (none caused by thromboembolism), 160 patients were eligible for the study. The eligible patients were contacted and asked to complete a survey and return for a follow-up examination to include physical examination, Doppler scan study, vena cava duplex scanning, and fluoroscopic examination. The patients' hospital charts were reviewed in detail. The indications for prophylactic inferior vena cava filter insertion included prolonged immobilization with multiple injuries, closed head injury, pelvic fracture, spine fracture, multiple long bone fracture, and attending discretion. Results: Of the 160 eligible patients, 127 were men, the mean age was 40.3 years, and the mean injury severity score was 26.1. The mean day of insertion was hospital day 6. Seventy-five patients (47%) returned for evaluation, with a mean follow-up period of 19.4 months after implantation (range, 7 to 60 months). On survey, patients had leg swelling (n = 27), lower extremity numbness (n = 14), shortness of breath (n = 9), chest pain (n = 7), and skin changes (n = 4). All the survey symptoms appeared to be attributable to patient injuries and not related to prophylactic inferior vena cava filter Physical examination results revealed edema (n = 12) and skin changes (n = 2). Tell Doppler scan studies had results that were suggestive of venous insufficiency, nine of which had histories of deep vein thrombosis. With duplex scanning, 93% (70 of 75) of the vena cavas were visualized, and all were patent. Only 52% (39 of 75) of the prophylactic inferior vena cava filters were visualized with duplex scanning. ALL the prophylactic inferior vena cava filters were visualized with fluoroscopy, with no evidence of filter migration. Of the total 187 patients, 24 (12.8%) had deep vein thrombosis develop after prophylactic inferior vena cava filter insertion, including 10 of 75 (13.3%) in the follow-up, group, and one patient had a nonfatal pulmonary embolism despite filter placement. Filter insertion complications occurred in 1.6% (three of 187) of patients and included one groin hematoma, one arteriovenous fistula, and one misplacement in the common iliac vein. Conclusion: This study's results show that prophylactic inferior vena cava filters can be placed safely with low morbidity and no attributable long-term disabilities. In this patient population with a high risk of pulmonary embolism, prophylactic inferior vena cava filters offered a 99.5% protection rate, with only one of 187 patients having a nonfatal pulmonary embolism.	Greenville Hosp Syst, Dept Surg Educ, Greenville, SC 29605 USA; Greenville Hosp Syst, Dept Res, Greenville, SC 29605 USA		Langan, EM (corresponding author), Greenville Hosp Syst, Dept Surg Educ, 701 Grove Rd, Greenville, SC 29605 USA.						BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; Brasel KJ, 1997, J TRAUMA, V42, P456, DOI 10.1097/00005373-199703000-00013; COON WW, 1976, SURG GYNECOL OBSTET, V143, P385; ENDERSON BL, 1991, J TRAUMA, V31, P1230; Erstad BL, 1998, PHARMACOTHERAPY, V18, P1011; FITTS WT, 1964, SURGERY, V56, P663; Gosin JS, 1997, ANN VASC SURG, V11, P100, DOI 10.1007/s100169900017; GREENFIELD LJ, 1995, J AM COLL SURGEONS, V180, P725; GREENFIELD LJ, 1998, PERSPECTIVES VASCULA, P41; KHANSARINIA S, 1995, J VASC SURG, V22, P231, DOI 10.1016/S0741-5214(95)70135-4; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; LEACH TA, 1994, AM SURGEON, V60, P292; McCartney JS, 1935, SURG GYNECOL OBSTET, V61, P369; MONTREY JS, 1985, J TRAUMA, V25, P534, DOI 10.1097/00005373-198506000-00011; Patton JH, 1996, J TRAUMA, V41, P231, DOI 10.1097/00005373-199608000-00006; Quirke TE, 1997, J TRAUMA, V43, P333, DOI 10.1097/00005373-199708000-00020; Rodriguez JL, 1996, J TRAUMA, V40, P797, DOI 10.1097/00005373-199605000-00020; ROGERS FB, 1995, J AM COLL SURGEONS, V180, P641; Rosenthal D, 1994, Cardiovasc Surg, V2, P52; RUIZ AJ, 1991, AM J SURG, V162, P159, DOI 10.1016/0002-9610(91)90180-L; SEVITT S, 1961, BRIT J SURG, V48, P475, DOI 10.1002/bjs.18004821103; SUE LP, 1995, J TRAUMA, V39, P693, DOI 10.1097/00005373-199510000-00014; Webb L X, 1992, J Orthop Trauma, V6, P139, DOI 10.1097/00005131-199206000-00002; WINCHELL RJ, 1994, J TRAUMA, V37, P600, DOI 10.1097/00005373-199410000-00013	24	72	73	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	SEP	1999	30	3					484	488		10.1016/S0741-5214(99)70075-3			5	Surgery; Peripheral Vascular Disease	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Surgery; Cardiovascular System & Cardiology	234YP	WOS:000082512200020	10477641	Bronze			2022-02-06	
J	LaPlaca, MC; Thibault, LE				LaPlaca, MC; Thibault, LE			An in vitro traumatic injury model to examine the response of neurons to a hydrodynamically-induced deformation	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						cellular calcium; in vitro modeling; mechanical loading; shear stress; strain rate	FLUID SHEAR-STRESS; ENDOTHELIAL-CELL; BRAIN INJURY; INVITRO; DEPENDENCE; DAMAGE; SYSTEM; DEATH	A novel in vitro system was developed to examine the effects of traumatic mechanical loading on individual cells. The cell shearing injury device (CSID) is a parallel disk viscometer that applies fluid shear stress with variable onset rate. The CSID was used in conjunction with microscopy and biochemical techniques to obtain a quantitative expression of the deformation and functional response of neurons to injury. Analytical and numerical approximations of the shear stress at the bottom disk were compared to determine the contribution of secondary flows. A significant portion of the shear stress was directed in the r-direction during start-up, and therefore the full Navier-Stokes equation was necessary to accurately describe the transient shear stress. When shear stress was applied at a high rate (800 dyne cm(-2) sec(-1)) to cultured neurons, a range of cell membrane strains (0.01 to 0.53) was obtained, suggesting inhomogeneity in cellular response. Functionally, cytosolic calcium and extracellular lactate dehydrogenase levels increased in response to high strain rate (>1 sec(-1)) loading, compared with quasistatic (<1 sec(-1)) loading. In addition, a subpopulation of the culture subjected to rapid deformation subsequently died, These strain rates are relevant to those shown to occur in traumatic injury, and, as such, the CSID is an appropriate model for studying the biomechanics and pathophysiology of neuronal injury.	UNIV PENN, DEPT BIOENGN, PHILADELPHIA, PA 19104 USA; ALLEGHENY UNIV HLTH SCI, DEPT NEUROSURG, DIV BIOENGN, PHILADELPHIA, PA 19102 USA						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R491CCR304684] Funding Source: Medline		BARBEE KA, 1994, ANN BIOMED ENG, V22, P14, DOI 10.1007/BF02368218; Cargill RS, 1996, J NEUROTRAUM, V13, P395, DOI 10.1089/neu.1996.13.395; DAVIES PF, 1984, J CLIN INVEST, V73, P1121, DOI 10.1172/JCI111298; DEWEY CF, 1981, J BIOMECH ENG-T ASME, V103, P177, DOI 10.1115/1.3138276; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; EVANS E, 1984, BLOOD, V64, P1028; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; GANOT G, 1981, BIOCHIM BIOPHYS ACTA, V649, P487, DOI 10.1016/0005-2736(81)90440-5; GENNARELLI TA, 1984, CENTRAL NERVOUS SYST; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GUILAK F, 1994, J MICROSC-OXFORD, V173, P245, DOI 10.1111/j.1365-2818.1994.tb03447.x; HYMAN WA, 1972, J BIOMECH, V5, P45, DOI 10.1016/0021-9290(72)90018-8; LANDSMAN AS, 1995, J AM PODIAT MED ASSN, V85, P519, DOI 10.7547/87507315-85-10-519; LEAL G, 1992, LAMINAR FLOW CONVECT; Levich V.G., 1962, PHYSICOCHEM HYDRODYN; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; NOMURA H, 1988, BIORHEOLOGY, V25, P461; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; RAND RP, 1964, BIOPHYS J, V4, P115, DOI 10.1016/S0006-3495(64)86773-4; SAATMAN KE, 1994, J NEUROTRAUMA, V11, P125; SATO M, 1990, J BIOMECH ENG-T ASME, V112, P263, DOI 10.1115/1.2891183; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; THIBAULT LE, 1993, ACCIDENTAL INJURY BI, P512; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; WATSON PA, 1991, FASEB J, V5, P2013, DOI 10.1096/fasebj.5.7.1707019; WINSTON FK, 1989, J APPL PHYSIOL, V67, P397, DOI 10.1152/jappl.1989.67.1.397; ZIMMERMANN U, 1980, J MEMBRANE BIOL, V54, P103, DOI 10.1007/BF01940564	33	72	76	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JUL-AUG	1997	25	4					665	677		10.1007/BF02684844			13	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	XK197	WOS:A1997XK19700007	9236979				2022-02-06	
J	Gourin, CG; Shackford, SR				Gourin, CG; Shackford, SR			Production of tumor necrosis factor-alpha and interleukin-1 beta by human cerebral microvascular endothelium after percussive trauma	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							SECONDARY BRAIN INJURY; PLATELET-ACTIVATING-FACTOR; SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; NEUTROPHIL FUNCTION; ICAM-1 EXPRESSION; RAT-BRAIN; CELLS; ADHESION; LIPOPOLYSACCHARIDE	Intracerebral cytokine production is thought to be partially responsible for the brain edema and increased leukocyte adhesion seen after head injury by both a direct effect on vascular permeability and by causing leukocyte activation, Cerebrospinal fluid concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and IL-6 are elevated after traumatic brain injury, The cerebral endothelium has not been investigated as a de novo source of cytokines after injury, We have found that conditioned media from cultured human cerebral microvascular endothelium (HCME) subjected to percussion trauma increases neutrophil chemotaxis, To test the hypothesis that percussive trauma increases the production of TNF-alpha and IL-1 beta by HCME, serial supernatant samples from passage 2 HCME were collected for 24 hours and analyzed for TNF-alpha and IL-beta concentration by enzyme-linked immunosorbent assay after trauma, HCME subjected to percussion injury secreted significantly more TNF-alpha at 8 and 24 hours end significantly more IL-1 beta at 4 and 24 hours compared with uninjured controls (p < 0.05, Student's t test), These data suggest that HCME production of inflammatory cytokines occurs after traumatic brain injury independent of systemic influences. In situ cytokine production by HCME after percussion trauma may mediate the increased cerebral leukocyte accumulation and cerebrovascular dysfunction observed after focal brain injury.	UNIV VERMONT,COLL MED,DEPT SURG,BURLINGTON,VT 05401						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030324] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20-NS30324-03] Funding Source: Medline		BIFFL WL, 1994, ARCH SURG-CHICAGO, V129, P1131; BOTHA AJ, 1995, J TRAUMA, V39, P411; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CINAT M, 1995, J TRAUMA, V39, P112, DOI 10.1097/00005373-199507000-00015; CLARK WM, 1994, STROKE, V25, P115; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FAN L, 1993, SOC NEUR ABSTR, V76, P9; FRESHNEY RI, 1994, CULTURE ANIMAL CELLS, P161; FRIESE RS, 1994, SHOCK, V1, P388, DOI 10.1097/00024382-199405000-00013; Gourin CG, 1996, J TRAUMA, V41, P129, DOI 10.1097/00005373-199607000-00021; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HAUSER SL, 1990, NEUROLOGY, V40, P1735, DOI 10.1212/WNL.40.11.1735; HESS DC, 1994, NEUROSCI LETT, V168, P201, DOI 10.1016/0304-3940(94)90450-2; HIRAFUJI M, 1991, BRIT J PHARMACOL, V103, P1333, DOI 10.1111/j.1476-5381.1991.tb09789.x; HOCH RC, 1993, CRIT CARE MED, V21, P839, DOI 10.1097/00003246-199306000-00010; HUGHES CCW, 1988, IMMUNOLOGY, V64, P677; ISHII E, 1991, LEUKEMIA RES, V15, P143, DOI 10.1016/0145-2126(91)90095-B; LUSCINSKAS FW, 1992, J IMMUNOL, V149, P2163; MARUO N, 1992, ENDOCRINOLOGY, V131, P710, DOI 10.1210/en.131.2.710; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MOSER R, 1989, J CLIN INVEST, V83, P444, DOI 10.1172/JCI113903; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ORFEO T, 1994, J TRAUMA, V37, P347, DOI 10.1097/00005373-199409000-00003; PRICE TH, 1987, J IMMUNOL, V139, P4174; READ RA, 1994, J TRAUMA, V37, P13, DOI 10.1097/00005373-199407000-00004; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Schmoker Joseph D., 1993, Surgical Forum, V44, P568; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHARIF SF, 1993, NEUROL RES, V15, P109; SHEPARD SR, 1990, ACT NEUR S, V51, P58; SHEPARD SR, 1991, J SURG RES, V51, P417, DOI 10.1016/0022-4804(91)90144-B; SIMPSON R, 1993, ANN SURG, V218, P444, DOI 10.1097/00000658-199310000-00005; SOMERSALO K, 1990, ANAL BIOCHEM, V185, P238, DOI 10.1016/0003-2697(90)90286-I; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WATANABE M, 1991, BRIT J PHARMACOL, V102, P239, DOI 10.1111/j.1476-5381.1991.tb12160.x; WONG D, 1992, J NEUROIMMUNOL, V39, P11, DOI 10.1016/0165-5728(92)90170-P; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; WOODROOFE MN, 1995, NEUROLOGY, V45, pS6, DOI 10.1212/WNL.45.6_Suppl_6.S6; YEE J, 1994, ARCH SURG-CHICAGO, V129, P1249; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	47	72	82	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1997	42	6					1101	1107		10.1097/00005373-199706000-00020			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	XH700	WOS:A1997XH70000027	9210549				2022-02-06	
J	Schagen, S; Schmand, B; deSterke, S; Lindeboom, J				Schagen, S; Schmand, B; deSterke, S; Lindeboom, J			Amsterdam short-term memory test: A new procedure for the detection of feigned memory deficits	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MILD HEAD-INJURY; IMPAIRMENT; AMNESIA; MOTIVATION; VALIDITY	The validity of two malingering tests, the newly developed Amsterdam Short-Term Memory (ASTM) test and the Distraction test (Baker, Hanley, Jackson, Kimmance, & Slade, 1993) was examined in a group of patients with closed-head injury (CHI), a normal control group, and a control group with instruction to feign memory deficits. Both control groups consisted of first-degree relatives of the patients. The ASTM test is a forced-choice verbal memory test, based on the technique of symptom validity testing. Stimulus material was chosen from category norms, and chance level is not transparent. The CHI and normal control groups scored near ceiling on the ASTM test, whereas the feigned deficit group scored significantly worse. The ASTM test classified all subjects correctly. Contrary to expectation, the Distraction test appeared to be invalid. The score profiles of the CHI and feigning groups on conventional memory and concentration tests were indistinguishable from each other. Thus, the ASTM test may be very useful for the detection of malingering and other kinds of less than optimal performance. The test may readily be constructed in any language for which category norms are available.	UNIV AMSTERDAM,AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,AMSTERDAM,NETHERLANDS		Schagen, S (corresponding author), SLOTERVAARTZIEKENHUIS,DEPT PSYCHOL,LOUWESWEG 6,NL-1066 EC AMSTERDAM,NETHERLANDS.						BAKER GA, 1993, J CLIN EXP NEUROPSYC, V15, P668, DOI 10.1080/01688639308402588; BATTIG WF, 1969, J EXP PSYCHOL, V80, P1, DOI 10.1037/h0027577; Benton AL, 1963, REVISED VISUAL RETEN; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Bouma A., 1996, NEUROPSYCHOLOGISCHE; CLIFFE MJ, 1992, BRIT J CLIN PSYCHOL, V31, P207, DOI 10.1111/j.2044-8260.1992.tb00985.x; DESTERKE SH, 1993, THESIS U AMSTERDAM; GUILMETTE TJ, 1994, PERCEPT MOTOR SKILL, V78, P1179, DOI 10.2466/pms.1994.78.3c.1179; Hammes J., 1978, STROOP KLEUR WOORD T; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HORTON KD, 1992, J EXP PSYCHOL GEN, V121, P326, DOI 10.1037/0096-3445.121.3.326; HUDSON PTW, 1982, 82FU05 CATH U NIJM D; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LUTEIJN F, 1983, GRONINGER INTELLIGEN; MARTIN RC, 1993, J CLIN EXP NEUROPSYC, V15, P867, DOI 10.1080/01688639308402604; MILLIS SR, 1994, J CLIN PSYCHOL, V50, P601, DOI 10.1002/1097-4679(199407)50:4<601::AID-JCLP2270500417>3.0.CO;2-9; MILLIS SR, 1994, PERCEPT MOTOR SKILL, V79, P384, DOI 10.2466/pms.1994.79.1.384; Morse P, 1992, CLIN SYNDROMES ADULT, P85; Nelson H. E, 1982, NATIONAL ADULT READI; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; RAWLING P J, 1992, Brain Injury, V6, P381, DOI 10.3109/02699059209034953; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A., 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROGERS R, 1993, CLIN PSYCHOL REV, V13, P255, DOI 10.1016/0272-7358(93)90023-F; SCHMAND B, AMSTERDAM SHORT TERM; Schmand BL., 1992, NEDERLANDSE LEESLIJS NEDERLANDSE LEESTEST; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Stinissen J, 1970, HANDLEIDING BIJ NEDE; STROOP JR, 1935, J EXP PSYCHOL, V12, P242; TEADALE G, 1974, LANCET, V2, P81; TRUEBLOOD W, 1994, J CLIN EXP NEUROPSYC, V16, P597, DOI 10.1080/01688639408402671; Van Balen HGG, 1987, RIVERMEAD BEHAV MEMO; Van den Burg W., 1985, 15 WOORDENTEST PROVI; Wechsler D, 1987, MEMORY SCALE REVISED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th Edn; WIGGINS EC, 1988, LAW HUMAN BEHAV, V12, P57, DOI 10.1007/BF01064274; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO	40	72	72	0	5	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	FEB	1997	19	1					43	51		10.1080/01688639708403835			9	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	WN019	WOS:A1997WN01900005	9071640				2022-02-06	
J	Owings, JT; Bagley, M; Gosselin, R; Romac, D; Disbrow, E				Owings, JT; Bagley, M; Gosselin, R; Romac, D; Disbrow, E			Effect of critical injury on plasma antithrombin activity: Low antithrombin levels are associated with thromboembolic complications	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						antithrombin; deep venous thrombosis; disseminated intravascular coagulation; heparin; thromboembolism prophylaxis; trauma; adult respiratory distress syndrome	DISSEMINATED INTRAVASCULAR COAGULATION; RESPIRATORY-DISTRESS SYNDROME; DEEP VENOUS THROMBOSIS; SEVERE HEAD-INJURY; TRAUMA PATIENTS; III DEFICIENCY; MAJOR TRAUMA; SEPTIC SHOCK; DOUBLE-BLIND; EFFICACY	Objective: Determine whether severe injury results in decreased plasma antithrombin (AT) activity and whether this decreased AT activity is associated with thromboembolic complications. Design: Prospective observational. Subjects: A total of 157 critically injured trauma patients. Methods: Each patient underwent laboratory analysis on arrival to the emergency room at hours 8, 16, 24, and 45, and days 3, 4, 5, and 6. Laboratory analyses included AT, tissue factor pathway inhibitor, protein C, prothrombin fragment 1.2, thrombin-antithrombin complex, and D-dimer, Patients were followed for thromboembolic complications including: deep venous thrombosis (DVT), pulmonary embolus, disseminated intravascular coagulation (DIG) and adult respiratory distress syndrome (ARDS). Results: Mean Injury Severity Score was 23 (+/-11), AT activity fell below normal in 95 (61%) patients; AT activity rose to greater than normal in 51 (32%) patients, Nine (6%) patients developed DVT, two (1%) pulmonary embolus, 13 (8%) DIC and 26 (17%) ARDS. Using logistic regression analysis, low AT levels were a significant predictor of DVT, DIG, and ARDS (p < 0.05). Supranormal AT levels mere associated with closed head injury (p < 0.05), D-dimer levels were inversely correlated with AT (p < 0.05). Conclusions: AT activity was depressed in critically injured patients, Patients with head injury developed supranormal AT activity, The risk factors for AT deficiency mimicked those for thromboembolism. Patients with decreased AT activity were at increased risk for thromboembolic complications. Given heparin's dependence on AT, these data call into question the use of unmonitored heparin thromboembolism prophylaxis.			Owings, JT (corresponding author), UNIV CALIF DAVIS,MED CTR,DEPT SURG,4301 X ST,SACRAMENTO,CA 95817, USA.			Gosselin, Robert/0000-0002-5669-8722			BAUER KA, 1985, J CLIN INVEST, V76, P826, DOI 10.1172/JCI112040; BELL WR, 1994, SEMIN HEMATOL, V31, P19; BLAUHUT B, 1985, THROMB RES, V39, P81, DOI 10.1016/0049-3848(85)90123-9; CAFFERATA HT, 1969, AM J SURG, V118, P221; COLMAN RW, 1994, HEMOSTASIS THROMBOSI, P3; DEMERS C, 1993, THROMB HAEMOSTASIS, V69, P231; DENNIS JW, 1993, J TRAUMA, V35, P132, DOI 10.1097/00005373-199307000-00021; DIAZCREMADES JM, 1994, INTENS CARE MED, V20, P577, DOI 10.1007/BF01705725; ENDERSON BL, 1991, J TRAUMA, V31, P1240, DOI 10.1097/00005373-199109000-00007; FOURRIER F, 1992, CHEST, V101, P816, DOI 10.1378/chest.101.3.816; FOURRIER F, 1993, CHEST, V104, P882, DOI 10.1378/chest.104.3.882; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; GEERTS WH, 1995, THROMB HAEMOSTASIS, V73, P973; GERSIN K, 1994, J TRAUMA, V37, P205, DOI 10.1097/00005373-199408000-00009; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; HIRSH J, 1989, AM J MED, V87, pS34, DOI 10.1016/0002-9343(89)80529-7; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; KILLEWICH LA, 1993, J VASC SURG, V17, P934, DOI 10.1016/0741-5214(93)90043-L; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; LUTERMAN A, 1977, SURGERY, V82, P703; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MODIG J, 1983, ACTA ANAESTH SCAND, V27, P369, DOI 10.1111/j.1399-6576.1983.tb01970.x; Moser, 1988, J INTENSIVE CARE MED, V3, P87, DOI DOI 10.1177/088506668800300205; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; RAPAPORT SI, 1993, WESTERN J MED, V158, P153; RUIZ AJ, 1991, AM J SURG, V162, P159, DOI 10.1016/0002-9610(91)90180-L; SCHMIDT U, 1992, J TRAUMA, V33, P312, DOI 10.1097/00005373-199208000-00023; SEVITT S, 1986, BRIT J SURG, V256, P744; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; TAYLOR FB, 1988, CIRC SHOCK, V26, P227; VASSAR MJ, 1992, J TRAUMA, V32, P490, DOI 10.1097/00005373-199204000-00014; WESSLER S, 1977, FED PROC, V36, P66; WILLEJORGENSEN P, 1990, SURG GYNECOL OBSTET, V171, P126	34	72	73	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	1996	41	3					396	405		10.1097/00005373-199609000-00004			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	VH571	WOS:A1996VH57100006	8810955				2022-02-06	
J	Azouvi, P; Jokic, C; VanDerLinden, M; Marlier, N; Bussel, B				Azouvi, P; Jokic, C; VanDerLinden, M; Marlier, N; Bussel, B			Working memory and supervisory control after severe closed-head injury. A study of dual task performance and random generation	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	17th European Conference of the International-Neuropsychological-Society	JUN, 1994	ANGERS, FRANCE	Int Neuropsychol Soc			RANDOM NUMBER GENERATION; REACTION-TIME; BRAIN-DAMAGE; DEFICITS; ATTENTION; SCALE; RECOVERY	Survivors of severe closed-head injury (CHI) frequently suffer from slowed information processing. Whether supervisory strategies are additionally impaired remains a point of debate. The first part of this study employed a self-paced dual task; the second part, a random generation task, performed at a paced rate, under single and dual task conditions. A measure of information processing speed was used as a covariate in statistical analysis. In the first experiment, in addition to slow processing, patients performed slightly poorer than controls on each task. In the second experiment, patients' performance (one randomness index in single task condition, and processing of dual task) was impaired even after statistical control of slow processing. These results suggest that there is at least some degree of impairment in supervisory strategies in addition to, but independent of, slowed processing. The clinical significance of this finding is discussed.	DEPT NEUROL REHABIL,GARCHES,FRANCE; UNIV LIEGE,DEPT NEUROPSYCHOL,B-4000 LIEGE,BELGIUM		Azouvi, P (corresponding author), UNIV PARIS 05,HOP RAYMOND POINCARE,SERV REEDUCAT NEUROL,F-92380 GARCHES,FRANCE.						ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ATTNEAVE F, 1959, APPLICATIONS INFORMA; Baddeley A.D., 1986, WORKING MEMORY; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1976, J NEUROL NEUROSUR PS, V39, P593, DOI 10.1136/jnnp.39.6.593; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; BROWN RG, 1991, BRAIN, V114, P215; CALICIS F, 1991, UNPUB ADAPTATION LAN; Cicerone K., 1987, ARCH PHYSICAL MED RE, V68, P11; Crossman ERFW, 1953, Q J EXP PSYCHOL, V5, P41, DOI 10.1080/17470215308416625; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HORNE RL, 1982, ARCH GEN PSYCHIAT, V39, P680; Kendall MG, 1973, TIME SERIES; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; NORMAN DA, 1975, COGNITIVE PSYCHOL, V7, P44, DOI 10.1016/0010-0285(75)90004-3; NORMAN DA, 1980, 99 CHIP U CAL; PETERSON LR, 1959, J EXP PSYCHOL, V58, P193, DOI 10.1037/h0049234; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SPATT J, 1993, BRAIN COGNITION, V23, P231, DOI 10.1006/brcg.1993.1057; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stevens J.P., 1992, APPL MULTIVARIATE ST, V2nd; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; TULVING E, 1962, PSYCHOL REV, V69, P344, DOI 10.1037/h0043150; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; van Zomeren AH, 1984, CLOSED HEAD INJURY P, P74; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; VANDERLINDEN M, 1994, WORK MEM C CAMBR UK; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; VELTMAN JC, IN PRESS NEUROPSYCHO; VILKKI J, 1994, 17 ANN EUR C INT NEU; VONCRAMON DY, 1994, NEUROPSYCHOLOGICAL R, V14, P399; WAGENAAR WA, 1972, PSYCHOL BULL, V77, P65, DOI 10.1037/h0032060; [No title captured]; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1	50	72	73	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1996	18	3					317	337		10.1080/01688639608408990			21	Psychology, Clinical; Clinical Neurology; Psychology	Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	VF466	WOS:A1996VF46600001	8877617				2022-02-06	
J	KATAYAMA, Y; MAEDA, T; KOSHINAGA, M; KAWAMATA, T; TSUBOKAWA, T				KATAYAMA, Y; MAEDA, T; KOSHINAGA, M; KAWAMATA, T; TSUBOKAWA, T			ROLE OF EXCITATORY AMINO ACID-MEDIATED IONIC FLUXES IN TRAUMATIC BRAIN INJURY	BRAIN PATHOLOGY			English	Article							CORTICAL SPREADING DEPRESSION; EXTRACELLULAR POTASSIUM CONCENTRATION; DIFFUSE CEREBRAL-ISCHEMIA; EXPERIMENTAL HEAD-INJURY; RAT-BRAIN; GLUTAMATE NEUROTOXICITY; GLUCOSE-UTILIZATION; BLOOD-FLOW; METABOLIC-ACTIVITY; REGIONAL CHANGES	One major event taking place at the moment of traumatic brain injury in neuronal cells is the occurrence of massive ionic fluxes across the plasma membrane, which can be referred to as traumatic depolarization (TD). Unlike spreading depression, TD can occur over wide brain areas simultaneously. Furthermore, recovery from TD often takes far longer than recovery from ionic perturbation elicited by the passage of a single wave of spreading depression. Neuronal cell damage caused by ischemic brain injury is also initiated by massive ionic fluxes, termed anoxic depolarization. The occurrence of similar ionic events in these two forms of brain injury may account for the genesis of diffuse ischemia-like damage without actual episodes of hypoxia or ischemia in traumatic brain injury. We review the data indicating that excitatory amino acids (EAA) may play a vital role in producing TD, and that such EAA-mediated ionic perturbation is responsible for a number of posttraumatic events including subcellular metabolic dysfunction and cellular responses such as microglial activation and astrocytic transformation. TD may represent one of the most important mechanisms of diffuse neuronal cell dysfunction and damage associated with traumatic brain injury.			KATAYAMA, Y (corresponding author), NIHON UNIV,SCH MED,DEPT NEUROL SURG,TOKYO 173,JAPAN.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		AQUINO DA, 1988, J NEUROCHEM, V51, P1085, DOI 10.1111/j.1471-4159.1988.tb03072.x; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J CEREB BLOOD FLOW M, V9, pS46; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CSIBA L, 1985, BRAIN RES, V336, P167, DOI 10.1016/0006-8993(85)90430-5; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GANONG AH, 1986, J PHARMACOL EXP THER, V236, P293; GINSBERG MD, 1980, STROKE, V11, P347, DOI 10.1161/01.STR.11.4.347; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORELOVA NA, 1987, ELECTROEN CLIN NEURO, V66, P440, DOI 10.1016/0013-4694(87)90213-6; GRAHAM DI, 1988, J CLIN PATHOL, V41, P34, DOI 10.1136/jcp.41.1.34; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HANSEN AJ, 1980, ACTA PHYSIOL SCAND, V108, P355, DOI 10.1111/j.1748-1716.1980.tb06544.x; HANSEN AJ, 1977, ACTA PHYSIOL SCAND, V99, P412, DOI 10.1111/j.1748-1716.1977.tb10394.x; HANSEN AJ, 1985, PHYIOL REV, V165, P101; HANSEN AJ, 1988, RECENT ADV EXCITATOR; HARRIS RJ, 1987, J CEREBR BLOOD F MET, V7, P599, DOI 10.1038/jcbfm.1987.111; HAYES RL, 1991, J NEUROTRAUMA S1, V9, pS157; HERNANDEZCACERE.J, 1987, BRAIN RES, V437, P360; HOVDA DA, 1991, J NEUROTRAUMA S1, V9, pS47; HOWSE DC, 1975, J NEUROCHEM, V24, P935, DOI 10.1111/j.1471-4159.1975.tb03658.x; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KALIMO H, 1981, J CEREBR BLOOD F MET, V1, P313, DOI 10.1038/jcbfm.1981.35; KATAYAMA Y, 1991, BRAIN RES, V567, P57, DOI 10.1016/0006-8993(91)91435-4; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KATAYAMA Y, 1990, ACT NEUR S, V51, P183; KATAYAMA Y, 1992, BRAIN RES, V584, P329, DOI 10.1016/0006-8993(92)90916-W; KATAYAMA Y, 1994, BRAIN RES, V635, P331, DOI 10.1016/0006-8993(94)91457-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1990, ACT NEUR S, V51, P271; KATAYAMA Y, 1992, BRAIN RES, V568, P294; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KATAYAMA Y, 1993, INTRACRANIAL PRESSUR, V8, P484; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; KETTENMANN H, 1990, J NEUROSCI RES, V26, P278, DOI 10.1002/jnr.490260303; Koshinaga Morimichi, 1995, Journal of Neurotrauma, V12, P401; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MAEDA T, 1995, IN PRESS J NEUROTRAU, V12; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MARRANNES R, 1988, MECHANISMS CEREBRAL, P303; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; MOGHADDAM B, 1987, CAN J PHYSL PHARM, V54, P1105; MUTCH WAC, 1984, J CEREBR BLOOD F MET, V4, P17, DOI 10.1038/jcbfm.1984.3; Nelson S, 1966, HEAD INJURY, P444; NICHOLSON C, 1979, BRAIN RES, V169, P580, DOI 10.1016/0006-8993(79)90408-6; Nicholson C, 1981, APPLICATION ION SELE, P217; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; PASCHEN W, 1987, J NEUROCHEM, V48, P154, DOI 10.1111/j.1471-4159.1987.tb13140.x; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PETITO CK, 1990, J CEREBR BLOOD F MET, V10, P850, DOI 10.1038/jcbfm.1990.141; PHILLIPS JM, 1979, BRAIN RES, V173, P567, DOI 10.1016/0006-8993(79)90254-3; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; REICHENBACH A, 1989, GLIA, V2, P71, DOI 10.1002/glia.440020202; ROSENTHAL M, 1973, J NEUROPHYSIOL, V36, P739, DOI 10.1152/jn.1973.36.4.739; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; SIESJO BK, 1985, CEREBROVASC DIS, P187; SOMJEN GG, 1984, BRAIN RES, V311, P186, DOI 10.1016/0006-8993(84)91416-1; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tsubokawa T, 1983, No Shinkei Geka, V11, P563; VANHARREVELD A, 1978, J NEUROBIOL, V9, P419, DOI 10.1002/neu.480090602; VANHARREVELD A, 1956, AM J PHYSIOL, V187, P180, DOI 10.1152/ajplegacy.1956.187.1.180; WEISEND M P, 1989, Society for Neuroscience Abstracts, V15, P69; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	86	72	74	0	3	INT SOC NEUROPATHOLOGY	ZURICH	ISN JOURNAL PO BOX, CH-8033 ZURICH, SWITZERLAND	1015-6305			BRAIN PATHOL	Brain Pathol.	OCT	1995	5	4					427	435		10.1111/j.1750-3639.1995.tb00621.x			9	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	TK374	WOS:A1995TK37400009	8974625				2022-02-06	
J	FINSET, A; DYRNES, S; KROGSTAD, JM; BERSTAD, J				FINSET, A; DYRNES, S; KROGSTAD, JM; BERSTAD, J			SELF-REPORTED SOCIAL NETWORKS AND INTERPERSONAL SUPPORT 2 YEARS AFTER SEVERE TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; REHABILITATION; ADJUSTMENT; RECOVERY	Fifty-four patients with traumatic brain injury (TBI) consecutively admitted to a rehabilitation hospital were examined 2 years post-injury. Social interaction and support, subjective complaints, and functional status were assessed. A large variability in social interaction and support patterns was found. Most patients had more interaction and received more support from family members than from friends and neighbours. Thirty-one patients (57.4%) reported that their social networks had markedly declined subsequent to injury. Relatively short duration of coma (<1 week) and severe sequelae in terms of low functional status and poor emotional adjustment at follow-up, especially in terms of deficits in initiating behaviour, were found to be related to little interaction and support. The importance of both provider and patient initiative in order to establish and preserve a social support network is suggested, and clinical implications briefly discussed.	BERG GARD,CENT INST HABIL,OSLO,NORWAY; SUNNASS REHABIL HOSP,NESODDTANGEN,NORWAY		FINSET, A (corresponding author), UNIV OSLO,DEPT BEHAV SCI MED,POB 1111 BLINDERN,N-0317 OSLO,NORWAY.						Benson D.F., 1986, FRONTAL LOBES; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FINSET A, UNPUB FUNKSJONSBEDRI; FINSET A, 1993, 12TH WORLD C PSYCH M; FINSET A, 1993, FORSCHRITTE NEUROTRA, V1, P153; FINSET A, 1990, COGNITIVE REHABILITA, P99; FYRAND L, 1994, SOSIALE NETTVERK TEO; GODFREY HPD, 1989, PSYCHOL MED, V19, P175, DOI 10.1017/S0033291700011120; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kozloff R., 1987, J HEAD TRAUMA REHAB, V2, P14, DOI [DOI 10.1097/00001199-198709000-00004, 10.1097/00001199-198709000-00004]; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; RUFF R M, 1990, Brain Injury, V4, P339, DOI 10.3109/02699059009026187; SARASON IG, 1983, J PERS SOC PSYCHOL, V44, P127, DOI 10.1037/0022-3514.44.1.127; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VOLPE BT, 1990, ARCH NEUROL-CHICAGO, V47, P220, DOI 10.1001/archneur.1990.00530020128026; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; [No title captured]; [No title captured]; [No title captured]	28	72	72	0	9	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	FEB-MAR	1995	9	2					141	150		10.3109/02699059509008187			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	QN628	WOS:A1995QN62800003	7787834				2022-02-06	
J	ROSS, DT; GRAHAM, DI; ADAMS, JH				ROSS, DT; GRAHAM, DI; ADAMS, JH			SELECTIVE LOSS OF NEURONS FROM THE THALAMIC RETICULAR NUCLEUS FOLLOWING SEVERE HUMAN HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article							FOREBRAIN ISCHEMIA; BRAIN INJURY; RAT; DAMAGE; COLLATERALS; COMPLEX; DEATH; MODEL; CAT	The GABAergic neurons of the thalamic reticular nucleus, or nucleus reticularis thalami (RT), have been implicated as important components in attentional processing systems. Neurons in the RT are exquisitely sensitive to degeneration following kainic and domoic acid toxicity, experimental global ischemia, human cardiac arrest, and experimental closed head injury in nonhuman primates. The present study was performed to establish whether the selective loss of human RT neurons occurred following severe head injury. Brains from 37 human nonsurvivors of head injury were examined for evidence of RT neuronal loss. RT lesions in were found in 36 of 37 cases, representing 65 of 73 (89%) of the reticular nuclei examined. The incidence of RT lesions was similar in all age groups: 13 of 14 cases (92.9%) in the pediatric (less-than-or-equal-to 16 years) group, 33 of 37 (89.2%) in the young adult (18-45 years) group, and 19 of 22 (86.4%) in the older adult (>45 years) group. RT lesions were characterized by loss of one fourth to three fourths of the neurons from the region of the nucleus associated with the frontal cortex and thalamic mediodorsal (MD) and ventrolateral (VL) nuclei. Sparing of RT neurons correlated highly with the presence of extensive frontal cortical lesions, suggesting that an intact corticothalamic projection was necessary for RT degeneration following head injury. A pathologic cascade with a prominent excitotoxic component is proposed. The loss of these inhibitory thalamic reticular neurons and the resultant thalamic and neocortical neuronal dysfunctions may underlie some forms of attentional deficits that persist following head injury.	SO GEN HOSP,INST NEUROSCI,DEPT NEUROPATHOL,GLASGOW G51 4TF,SCOTLAND		ROSS, DT (corresponding author), UNIV PENN,CTR HEAD INJURY,DIV NEUROSURG,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS028852, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NINDS NS-08803-22, NINDS NS-28852-02] Funding Source: Medline		Adams J. H., 1982, HEAD INJURY BASIC CL, P141; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; ADAMS JH, 1982, RECENT ADV NEUROPATH, P165; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BRIERLEY JB, 1971, BRAIN RES, V25, P483, DOI 10.1016/0006-8993(71)90456-2; Brierly J, 1984, GREENFIELDS NEUROPAT, P125; CARMAN JB, 1964, J ANAT, V98, P587; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOW KL, 1952, J COMP NEUROL, V97, P37, DOI 10.1002/cne.900970105; COOK J, 1990, REHABILITATION ADULT, P493; CRICK F, 1984, P NATL ACAD SCI-BIOL, V81, P4586, DOI 10.1073/pnas.81.14.4586; DECURTIS M, 1989, NEUROSCIENCE, V33, P275, DOI 10.1016/0306-4522(89)90207-8; DESCHENES M, 1990, EUR J NEUROSCI, V2, P140, DOI 10.1111/j.1460-9568.1990.tb00406.x; FRIEDBERG EB, 1993, IN PRESS NEUROSCI LE; Fuster JM, 1989, PREFRONTAL CORTEX, V2nd; Gennarelli T, 1982, HEAD INJURY BASIC CL, V1982, P129; GENNARELLI TA, 1980, INTRACRANIAL PRESSUR, V4, P28; Goldman-Rakic P.S., 2011, COMPR PHYSIOL, P373, DOI DOI 10.1002/CPHY.CP010509; Gronwall D, 1989, MILD HEAD INJURY, P153; Grunthal E, 1942, MON PSYCHIATR NEUROL, V106, P114; HARRINGTON DE, 1990, REHABILITATION ADULT, P493; HARRIS RM, 1987, J COMP NEUROL, V258, P397, DOI 10.1002/cne.902580308; HAYES RL, 1989, MILD HEAD INJURY, P54; HEILMAN KM, 1987, HDB PHYSL 1, V5, P461; HOUSER CR, 1980, BRAIN RES, V200, P341, DOI 10.1016/0006-8993(80)90925-7; Jasper H.H., 1954, BRAIN MECHANISMS CON, P374; Jones E.G., 1985, THALAMUS; JONES EG, 1975, J COMP NEUROL, V162, P285, DOI 10.1002/cne.901620302; JORGENSEN MB, 1987, ACTA NEUROPATHOL, V73, P189, DOI 10.1007/BF00693788; KAWAI K, 1991, J CEREB BLOOD FLO S2, V11, pS532; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; Levin HS., 1982, NEUROBEHAVIORAL CONS; MARTIN JJ, 1975, HDB CLIN NEUROLOGY, V21, P469; MARTIN JJ, 1969, HDB CLIN NEUROLOGY, V2; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; OHARA PT, 1985, J NEUROCYTOL, V14, P365, DOI 10.1007/BF01217752; ONODERA H, 1986, NEUROSCI LETT, V68, P169, DOI 10.1016/0304-3940(86)90136-9; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RINVIK E, 1988, CELLULAR THALAMIC ME, P321; ROSS D T, 1987, Society for Neuroscience Abstracts, V13, P762; ROSS DT, 1989, BRAIN RES, V501, P129, DOI 10.1016/0006-8993(89)91034-2; ROSS DT, 1993, IN PRESS J CEREB BLO; ROSS DT, 1990, SOC NEUR ABSTR, V20, P476; ROSS DT, 1993, UNPUB J NEUROSCI; ROSS DT, 1992, J NEUROTRAUM, V9, P399; SCHEIBEL MADGE E., 1966, BRAIN RES, V1, P43, DOI 10.1016/0006-8993(66)90104-1; SCHEIBEL ME, 1967, NEUROSCIENCES STUDY, P577; SHOSAKU A, 1986, J NEUROPHYSIOL, V55, P1030, DOI 10.1152/jn.1986.55.5.1030; SKINNER JE, 1976, ELECTROEN CLIN NEURO, V40, P288, DOI 10.1016/0013-4694(76)90152-8; SKINNER JF, 1977, PROGR CLIN NEUROPHYS, P30; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; STERIADE M, 1986, DYNAMIC ASPECTS NEOC, P107; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TOURTELLOTTE WG, 1990, BRAIN RES, V515, P227, DOI 10.1016/0006-8993(90)90600-G; van Zomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VONHARTMANMONAK.N, 1972, SCHWEIZ ARCH NEUROL, V110, P13; YEN CT, 1983, BRAIN RES, V280, P148, DOI 10.1016/0006-8993(83)91183-6; YINGLING CD, 1976, ELECTROEN CLIN NEURO, V41, P476, DOI 10.1016/0013-4694(76)90059-6; YOON M S, 1989, Anatomical Record, V223, p125A	61	72	72	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SUM	1993	10	2					151	165		10.1089/neu.1993.10.151			15	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	LM056	WOS:A1993LM05600006	8411218				2022-02-06	
J	TAHA, JM; SABA, MI; BROWN, JA				TAHA, JM; SABA, MI; BROWN, JA			MISSILE INJURIES TO THE BRAIN TREATED BY SIMPLE WOUND CLOSURE - RESULTS OF A PROTOCOL DURING THE LEBANESE CONFLICT	NEUROSURGERY			English	Article						BRAIN ABSCESS; HEAD INJURY; INTRACRANIAL HEMORRHAGE	CRANIOCEREBRAL GUNSHOT WOUNDS; INTRACRANIAL BONE FRAGMENTS; INTRACEREBRAL HEMORRHAGE; CIVILIAN PRACTICE; MANAGEMENT; EXPERIENCE; PROGNOSIS; VIETNAM; HEAD	This is a prospective study of the treatment of penetrating missile injuries to the brain without intracranial surgery carried out at the American University of Beirut Medical Center between 1981 and 1988. Of 600 patients treated for missile injuries to the head, 32 satisfied the study criteria. There were 27 shrapnel and 5 bullet injuries. The mean patient age was 23 years (range, 3-51 years). Twenty patients had intracranial indriven bone fragments. Six patients had exposed brain tissue. The mean follow-up was 3.5 years (range, 1-7.5 years). The superficial entry wound was debrided and closed without drainage in the Emergency Room within a mean of 3 hours (range, 0.5-6 hours), and the patient received methicillin for 14 days. All patients survived and had no or improved neurological deficits. No leakage of the cerebrospinal fluid, infection, or seizures occurred in 31 patients. One patient with indriven bone fragments had leakage of the cerebrospinal fluid and developed seizures and a brain abscess 20 days after the injury. The management of penetrating missile injuries to the brain without intracranial surgery in a select patient population is a reasonable option. This treatment becomes important for a surgeon facing large numbers of casualties, or when operative personnel or resources are limited or unavailable.	AMER UNIV BEIRUT, MED CTR, DIV NEUROL SURG, BEIRUT, LEBANON; MED COLL OHIO, DEPT NEUROL SURG, TOLEDO, OH 43699 USA		TAHA, JM (corresponding author), UNIV CINCINNATI, MED CTR, DEPT NEUROL SURG, 231 BETHESDA AVE 515, CINCINNATI, OH 45267 USA.						AARABI B, 1989, NEUROSURGERY, V25, P923, DOI 10.1227/00006123-198912000-00011; Ascroft PB, 1943, LANCET, V2, P211; ASCROFT PB, 1947, BR J SURG S, V1, P183; BARNETT JC, 1955, J NEUROSURG, V12, P34, DOI 10.3171/jns.1955.12.1.0034; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BYRNES DP, 1974, BRIT J SURG, V61, P169, DOI 10.1002/bjs.1800610302; CAIRNS H, 1947, BR J SURG WAR SURG S, V1, P198; CAREY ME, 1971, J NEUROSURG, V34, P145, DOI 10.3171/jns.1971.34.2part1.0145; CAREY ME, 1970, MIL MED, V135, P1161, DOI 10.1093/milmed/135.12.1161; CAREY ME, 1974, J NEUROSURG, V41, P542, DOI 10.3171/jns.1974.41.5.0542; CAREY ME, 1989, J NEUROSURG, V71, P754, DOI 10.3171/jns.1989.71.5.0754; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; CLIFTON GL, 1983, CLIN NEUROSCIENCES, P1269; COOPER P, 1985, NEUROSURGERY, P1510; COOPER P, 1982, HEAD INJURY, P257; COURVILLE C B, 1956, Bull Los Angel Neuro Soc, V21, P49; CROCKARD HA, 1975, J TRAUMA, V15, P339, DOI 10.1097/00005373-197504000-00011; Cushing H, 1918, BRIT J SURG, V5, P558; Cushing H, 1918, Br Med J, V1, P221; DUCKER T, 1985, NEUROSURGERY, P1510; ECKER AD, 1946, J NEUROSURG, V3, P1, DOI 10.3171/jns.1946.3.1.0001; FISCHER G, 1957, P STAFF M MAYO CLIN, V32, P14; FREYTAG E, 1963, ARCH PATHOL, V76, P215; FURLOW LT, 1947, J NEUROSURG, V4, P380, DOI 10.3171/jns.1947.4.4.0380; GALBRAITH S, 1981, J NEUROSURG, V55, P75, DOI 10.3171/jns.1981.55.1.0075; GOLDSMITH W, 1966, HEAD INJURY C P, P350; GREENWOOD J, 1950, J NEUROSURG, V7, P169, DOI 10.3171/jns.1950.7.2.0169; GURDJIAN ES, 1973, HEAD INJURY ANTIQUIT, P111; HAGAN RE, 1971, J NEUROSURG, V34, P132, DOI 10.3171/jns.1971.34.2part1.0132; HAMMON WM, 1971, J NEUROSURG, V34, P142, DOI 10.3171/jns.1971.34.2part1.0142; HAMMON WM, 1971, J NEUROSURG, V34, P127, DOI 10.3171/jns.1971.34.2part1.0127; HARSH GR, 1965, NEUROLOGICAL SURGERY, P135; HAYES GJ, 1967, CLIN NEUROSURG, V14, P380; HEEVER CMV, 1989, J NEUROSURG, V71, P186; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; LILLARD PL, 1978, SURG NEUROL, V9, P79; MALTBY GL, 1946, J NEUROSURG, V3, P239, DOI 10.3171/jns.1946.3.3.0239; MARTIN J, 1946, J NEUROSURG, V3, P58, DOI 10.3171/jns.1946.3.1.0058; MASDEU JC, 1984, NEUROLOGY, V34, P381, DOI 10.1212/WNL.34.3.381; MATHEWS WE, 1972, J TRAUM, V12, P939, DOI 10.1097/00005373-197211000-00004; MATSON DD, 1946, J NEUROSURG, V3, P46, DOI 10.3171/jns.1946.3.1.0046; MATSON DD, 1948, TREATMENT ACUTE CRAN, P34; Meirowsky A., 1965, NEUROLOGICAL SURGERY, P103; MEIROWSKY AM, 1954, JAMA-J AM MED ASSOC, V154, P666, DOI 10.1001/jama.1954.02940420028008; MEIROWSKY AM, 1981, J NEUROSURG, V54, P44, DOI 10.3171/jns.1981.54.1.0044; MEIROWSKY AM, 1968, MIL MED, V133, P887, DOI 10.1093/milmed/133.11.887; MEIROWSKY AM, 1953, J NEUROSURG, V10, P373, DOI 10.3171/jns.1953.10.4.0373; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; OMMAYA AK, 1966, HEAD INJURY, P260; PITLYK PJ, 1970, J NEUROSURG, V33, P19, DOI 10.3171/jns.1970.33.1.0019; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RISH BL, 1981, NEUROSURGERY, V9, P535, DOI 10.1227/00006123-198111000-00008; SCHEIBERT CD, 1965, NEUROLOGICAL SURGERY, P216; SCHWARTZ HG, 1945, ANN SURG, V121, P129; SCHWARTZ HG, 1948, ANN SURG, V127, P58, DOI 10.1097/00000658-194801000-00006; SHOUNG HM, 1985, ACTA NEUROCHIR, V74, P27, DOI 10.1007/BF01413272; TEASDALE G, 1974, LANCET, V2, P81; TEDESCHI G, 1975, J NEUROSURG, V43, P590, DOI 10.3171/jns.1975.43.5.0590; WALKER E, 1961, FOLLOW UP STUDY HEAD, P119; WALLACE PB, 1960, ANN SURG, V151, P174, DOI 10.1097/00000658-196002000-00004; WANNAMAKER GT, 1958, J NEUROSURG, V15, P512, DOI 10.3171/jns.1958.15.5.0512; WANNAMAKER GT, 1954, J NEUROSURG, V11, P151, DOI 10.3171/jns.1954.11.2.0151; WEBSTER JE, 1946, J NEUROSURG, V3, P7, DOI 10.3171/jns.1946.3.1.0007; YASHON D, 1972, American Surgeon, V38, P346	65	72	75	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1991	29	3					380	384		10.1227/00006123-199109000-00007			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	GB934	WOS:A1991GB93400007	1922705				2022-02-06	
J	CERVOSNAVARRO, J; LAFUENTE, JV				CERVOSNAVARRO, J; LAFUENTE, JV			TRAUMATIC BRAIN INJURIES - STRUCTURAL-CHANGES	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL			LESION-INDUCED SYNAPTOGENESIS; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; SPINAL-CORD; VASCULAR-PERMEABILITY; DEVELOPING RAT; DENTATE GYRUS; AGED RATS; CONTUSION; LAMININ	A host of complications and consequences may follow a contusion or other brain injury of any sort. An appreciation of the temporal evolution of the contusion from a microscopic standpoint is useful to a full understanding of the process by which physical force damages the brain and how the brain reacts to this damage. Some disruptions of the blood brain barrier quite early will result in extracellular edema. The microscopic appearance of an edematous area is usually spongy with numerous vacuoles. The neuropil may appear bubbly, and glial cells may be swollen. If edema has been long standing, the vacuoles may be larger and in fact a small cyst may appear in the white matter. If focal cerebral edema is not present for long periods of time and the underlying cause has been corrected, residual fluid and electrolytes are eventually removed, restoring the neuropil to a normal state, leaving no sign of its presence. However, in longer standing lesions, myelin pallor and some reactive gliosis may remain indefinitely. Neurons may show swelling very early and for a short period of time, which gives way to shrinkage, eosinophilia, and nuclear pyknosis. These changes may be observed at the periphery of lesions for as long as 5 or 6 months after the initial event. Before dissolution, nuclear pyknosis may remain in the tissue for many days and possibly longer, and may even become mineralized in situ (ferruginated neurons) to remain for years. In a traumatic lesion, swollen and ballooned axons may be found in and around the contusion but also at great distances from it (diffuse axonal injury). Axonal ballooning may be observed between 24 and 48 h postinjury and may persist wherever found for many years. Selective axonal calcification has been observed in humans as well as in experimental trauma. At about 7-10 days postinjury increased numbers of astroglia probably are present. Over the ensuing weeks and months, and probably years, astrocytes increase in number and in fibrillary appearance, eventually resulting in a glial scar in and about the injured area. It is thought that this reactive gliosis results in restoration of the blood-brain barrier in the damaged area.	UNIV BASKE COUNTRY,DEPT NEUROSCI,LEIOA,SPAIN		CERVOSNAVARRO, J (corresponding author), FREE UNIV BERLIN,INST NEUROPATHOL,W-1000 BERLIN 33,GERMANY.		Lafuente, Jose-Vicente/O-6395-2014	Lafuente, Jose-Vicente/0000-0001-7246-0987			ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1986, NATO ASI SERIES A, V115, P2; ADLER R, 1981, DEV BIOL, V86, P69, DOI 10.1016/0012-1606(81)90316-X; BALENTINE JD, 1983, SURV SYN PATHOL RES, V2, P184; BALENTINE JD, 1986, J NEUROPATH EXP NEUR, V45, P363, DOI 10.1097/00005072-198605000-00148; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1982, HEAD INJURY; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COTMAN CW, 1984, SCIENCE, V225, P1287, DOI 10.1126/science.6382610; CRACCO RQ, 1985, CENTRAL NERVOUS SYST, V31, P331; DELATORRE JC, 1982, BRAIN RES BULL, V9, P545, DOI 10.1016/0361-9230(82)90162-9; EISENMENGER W, 1978, BEITR GERICHTL MED, V26, P281; EVANS JP, 1945, J NEUROSURG, V2, P306, DOI 10.3171/jns.1945.2.4.0306; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GO KG, 1986, NATO ASI SER, V115, P127; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; GRONWALL D, 1974, LANCET, V2, P605; GUTH L, 1981, J COMP NEUROL, V203, P297, DOI 10.1002/cne.902030209; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HOFF SF, 1982, J COMP NEUROL, V205, P246, DOI 10.1002/cne.902050304; HOFF SF, 1982, J COMP NEUROL, V205, P253, DOI 10.1002/cne.902050305; JELLINGER K, 1977, PATHOLOGY PATHOGENES, V1; JENNETT B, 1982, MANAGEMENT HEAD INJU; KATO T, 1981, BRAIN RES, V212, P393, DOI 10.1016/0006-8993(81)90471-6; KENNADY JC, 1967, PAC MED SURG, V75, P163; Kirkpatrick J B, 1984, Semin Diagn Pathol, V1, P98; KIRKPATRICK JB, 1985, J NEUROPATH EXP NEUR, V44, P268, DOI 10.1097/00005072-198505000-00005; KISHORE PRS, 1982, HEAD INJURY; Kobrine A I, 1975, Surg Neurol, V3, P261; KOBRINE AI, 1977, J NEUROSURG, V46, P489; KRAULAND W, 1982, VERLETZUNGEN INTRAKR; LANGFITT TW, 1966, HEAD INJURY, P172; LIESI P, 1984, EMBO J, V3, P683, DOI 10.1002/j.1460-2075.1984.tb01867.x; LIESI P, 1984, J NEUROSCI RES, V11, P241, DOI 10.1002/jnr.490110304; LINDENBERG R, 1973, GUIDELINES APPLICATI, P420; MANTHORPE M, 1983, BRAIN RES, V267, P47, DOI 10.1016/0006-8993(83)91038-7; MCHEDLISHVILI G, 1986, NATO ASI SERIES A, V115, P295; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NIETOSAMPEDRO M, 1984, P NATL ACAD SCI-BIOL, V81, P6250, DOI 10.1073/pnas.81.19.6250; NIETOSAMPEDRO M, 1989, SYNAPTIC PLASTICITY, P407; OEHMICHEN M, 1980, Z RECHTSMED, V84, P79, DOI 10.1007/BF02114577; Oehmichen M, 1978, Beitr Gerichtl Med, V36, P291; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; OVERGAARD J, 1974, J NEUROSURG, V41, P532; PETERS G, 1955, HDB SPEZIELLEN PATHO, V13, P363; PETERS G, 1977, APALLIC SYNDROME; PETITO CK, 1982, J NEUROPATH EXP NEUR, V41, P423, DOI 10.1097/00005072-198207000-00005; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; PRUSS RM, 1982, DEV BRAIN RES, V2, P19; Ramon y Cajal, 1928, DEGENERATION REGENER; Reier P., 1983, SPINAL CORD RECONSTR, P163; ROGERS SL, 1983, DEV BIOL, V98, P212, DOI 10.1016/0012-1606(83)90350-0; SCHLAEPFER WW, 1979, PROGR NEUROPATHOLOGY, V4, P101; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STURROCK RR, 1982, ADV CELL NEUROBIOL, V3, P3; WE EP, 1980, CIRC RES, V46, P37; WILMES F, 1979, ACTA NEUROPATHOL, V45, P47, DOI 10.1007/BF00691804; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; [No title captured]	68	72	73	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S3	S14					12	Clinical Neurology; Neurosciences	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	GF379	WOS:A1991GF37900002	1940963				2022-02-06	
J	BIGLER, ED; ROSA, L; SCHULTZ, F; HALL, S; HARRIS, J				BIGLER, ED; ROSA, L; SCHULTZ, F; HALL, S; HARRIS, J			REY-AUDITORY VERBAL-LEARNING AND REY-OSTERRIETH COMPLEX FIGURE DESIGN PERFORMANCE IN ALZHEIMERS-DISEASE AND CLOSED HEAD-INJURY	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article									UNIV TEXAS,AUSTIN,TX 78712		BIGLER, ED (corresponding author), AUSTIN NEUROL CLIN,BLDG F MED SCI CTR,711 W 38TH ST,AUSTIN,TX 78705, USA.						BIGLER ED, 1985, J NERV MENT DIS, V173, P347, DOI 10.1097/00005053-198506000-00004; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; Denman S. B., 1984, MANUAL DENMAN NEUROP; Jennett B, 1981, MANAGEMENT HEAD INJU; LEZAK MD, 1985, NEUROPSYCHOLOGICAL A; MARTIN A, 1987, J CLIN EXP NEUROPSYC, V9, P191, DOI 10.1080/01688638708405361; MUNGAS D, 1983, J CONSULT CLIN PSYCH, V51, P848, DOI 10.1037/0022-006X.51.6.848; Osterrieth P., 1944, ARCH PSYCHOLOGIE, V30, P206; QUERY WT, 1983, J CLIN PSYCHOL, V39, P136, DOI 10.1002/1097-4679(198301)39:1<136::AID-JCLP2270390125>3.0.CO;2-Q; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4	12	72	73	0	8	CLINICAL PSYCHOLOGY PUBL CO	BRANDON	4 CONANT SQUARE, BRANDON, VT 05733	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	MAR	1989	45	2					277	280		10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M			4	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	U2824	WOS:A1989U282400014	2723084				2022-02-06	
J	LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; EISENBERG, HM				LEVIN, HS; GOLDSTEIN, FC; HIGH, WM; EISENBERG, HM			DISPROPORTIONATELY SEVERE MEMORY DEFICIT IN RELATION TO NORMAL INTELLECTUAL-FUNCTIONING AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DEPT NEUROL,GALVESTON,TX 77550		LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG D73,GALVESTON,TX 77550, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline		ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BADDELEY A, 1987, NEUROBEHAVIORAL RECO; Benton A., 1978, MULTILINGUAL APHASIA; BROOKS D N, 1974, Cortex, V10, P224; BROOKS D N, 1975, Cortex, V11, P329; BROOKS DN, 1974, J NEUROL NEUROSUR PS, V37, P794, DOI 10.1136/jnnp.37.7.794; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BUTTERS N, 1985, J CLIN EXP NEUROPSYC, V7, P181, DOI 10.1080/01688638508401252; Butters N., 1980, ALCOHOLIC KORSAKOFFS; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GREEN DM, 1966, SIGNAL DETECTION THE; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HANNAY HJ, 1985, J CLIN EXP NEUROPSYC, V7, P251, DOI 10.1080/01688638508401258; JACOBSON RR, 1987, PSYCHOL MED, V17, P649, DOI 10.1017/S0033291700025885; KOPELMAN MD, 1987, BRIT J PSYCHIAT, V150, P428, DOI 10.1192/bjp.150.4.428; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1985, ARCH NEUROL-CHICAGO, V42, P963, DOI 10.1001/archneur.1985.04060090045012; Levin HS., 1982, NEUROBEHAVIORAL CONS; Siegel S., 1956, NONPARAMETRIC STAT B; SQUIRE LR, 1986, BEHAV NEUROSCI, V100, P866, DOI 10.1037/0735-7044.100.6.866; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; WARRINGT.EK, 1970, NATURE, V228, P628, DOI 10.1038/228628a0; WARRINGTON EK, 1978, NEUROPSYCHOLOGIA, V16, P169, DOI 10.1016/0028-3932(78)90104-5; Wechsler D., 1955, MANUAL WECHSLER ADUL; WHITTY CWM, 1977, AMNESIA CLIN PSYCHOL; WILSON RS, 1978, J CONSULT CLIN PSYCH, V46, P1554, DOI 10.1037/0022-006X.46.6.1554; [No title captured]	31	72	73	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	1988	51	10					1294	1301		10.1136/jnnp.51.10.1294			8	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Surgery	Q4621	WOS:A1988Q462100008	3225586	Bronze, Green Published			2022-02-06	
J	LEZAK, MD; OBRIEN, KP				LEZAK, MD; OBRIEN, KP			LONGITUDINAL-STUDY OF EMOTIONAL, SOCIAL, AND PHYSICAL CHANGES AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF LEARNING DISABILITIES			English	Article									OREGON HLTH SCI UNIV,DEPT NEUROL L226,PORTLAND,OR 97201; BARROW NEUROL INST,PORTLAND,OR; ADULT DAY HOSP NEUROL REHABIL,PORTLAND,OR								ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P239; Bond M R, 1975, Ciba Found Symp, P141; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1984, CLOSED HEAD INJURY P, P123; CRAWFORD C, 1983, NEW ZEAL MED J, V96, P972; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSASS L, 1987, PSYCHOL MED, V17, P67, DOI 10.1017/S003329170001299X; Goldstein K., 1942, AFTEREFFECTS BRAIN I; Harlow J.M., 1993, PUBLICATIONS MASSACH, V4, P274, DOI [DOI 10.1177/0957154X9300401407, https://doi.org/10.1177/0957154X9300401407]; HEILMAN KM, 1983, NEUROPSYCHOLOGY HUMA; LEIGH D, 1979, PSYCHIAT DIG, V40, P21; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P172; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; Luria A.R., 1966, HIGHER CORTICAL FUNC; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; OBRIEN KP, 1982, 4TH EUR M INT NEUR S; OBRIEN KP, 1986, THESIS U VICTORIA VI; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, IN PRESS CLIN MANAGE; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VIGOUROUX RP, 1971, P INT S HEAD INJURIE, P335; [No title captured]	30	72	73	1	4	PRO-ED INC	AUSTIN	8700 SHOAL CREEK BLVD, AUSTIN, TX 78757-6897	0022-2194			J LEARN DISABIL	J. Learn. Disabil.	OCT	1988	21	8					456	463		10.1177/002221948802100802			8	Education, Special; Rehabilitation	Social Science Citation Index (SSCI)	Education & Educational Research; Rehabilitation	Q4889	WOS:A1988Q488900010	2972786				2022-02-06	
J	Kempuraj, D; Selvakumar, GP; Ahmed, ME; Raikwar, SP; Thangavel, R; Khan, A; Zaheer, SA; Iyer, SS; Burton, C; James, D; Zaheer, A				Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Burton, Casey; James, Donald; Zaheer, Asgar			COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation	NEUROSCIENTIST			English	Article						angiotensin-converting enzyme 2; COVID-19; cytokine storm; mast cells; neuroinflammation; severe acute respiratory syndrome coronavirus 2; traumatic brain injury	ALZHEIMERS-DISEASE; BRAIN; INFLAMMATION; INVOLVEMENT; INFECTIONS; DISRUPTION; MICROGLIA; RELEASE; RISK; GLIA	Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China. COVID-19 is a global public health emergency of international concern. COVID-19 causes mild to severe illness with high morbidity and mortality, especially in preexisting risk groups. Therapeutic options are now limited to COVID-19. The hallmark of COVID-19 pathogenesis is the cytokine storm with elevated levels of interleukin-6 (IL-6), IL-1 beta, tumor necrosis factor-alpha (TNF-alpha), chemokine (C-C-motif) ligand 2 (CCL2), and granulocyte-macrophage colony-stimulating factor (GM-CSF). COVID-19 can cause severe pneumonia, and neurological disorders, including stroke, the damage to the neurovascular unit, blood-brain barrier disruption, high intracranial proinflammatory cytokines, and endothelial cell damage in the brain. Mast cells are innate immune cells and also implicated in adaptive immune response, systemic inflammatory diseases, neuroinflammatory diseases, traumatic brain injury and stroke, and stress disorders. SARS-CoV-2 can activate monocytes/macrophages, dendritic cells, T cells, mast cells, neutrophils, and induce cytokine storm in the lung. COVID-19 can activate mast cells, neurons, glial cells, and endothelial cells. SARS-CoV-2 infection can cause psychological stress and neuroinflammation. In conclusion, COVID-19 can induce mast cell activation, psychological stress, cytokine storm, and neuroinflammation.	[Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Zaheer, Asgar] Univ Missouri, Sch Med, Dept Neurol, 1 Hosp Dr, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Khan, Asher; Zaheer, Smita A.; Iyer, Shankar S.; Zaheer, Asgar] Univ Missouri, Sch Med, Ctr Translat Neurosci, 1 Hosp Dr, Columbia, MO 65211 USA; [Kempuraj, Duraisamy; Selvakumar, Govindhasamy Pushpavathi; Ahmed, Mohammad Ejaz; Raikwar, Sudhanshu P.; Thangavel, Ramasamy; Iyer, Shankar S.; Zaheer, Asgar] US Dept Vet Affairs, Harry S Truman Mem Vet Hosp, Columbia, MO USA; [Burton, Casey; James, Donald] Phelps Hlth, Rolla, MO USA		Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Sch Med, Dept Neurol, 1 Hosp Dr, Columbia, MO 65211 USA.; Kempuraj, D; Zaheer, A (corresponding author), Univ Missouri, Sch Med, Ctr Translat Neurosci, 1 Hosp Dr, Columbia, MO 65211 USA.	duraisamyk@health.missouri.edu; Zaheera@health.missouri.edu	Raikwar, Sudhanshu/AAT-5128-2021	Khan, Asher/0000-0001-6314-240X; Raikwar, Sudhanshu/0000-0001-8549-8570	Leonard Wood Institute; US Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL) [W911NF-14-2-0034]; VA Research Career Scientist Award	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Research was sponsored by the Leonard Wood Institute in cooperation with the US Army Research Laboratory and was accomplished under Cooperative Agreement Number W911NF-14-2-0034. The views and conclusions contained in this article are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the Leonard Wood Institute, the Army Research Laboratory, or the US government. The US government is authorized to reproduce and distribute reprints for government purposes, not-withstanding any copyright notation heron. The authors express their gratitude for the Acute Effects of Neurotrauma Consortium in assisting and coordinating the conduct of this project at Fort Leonard Wood. This research was also supported by VA Research Career Scientist Award to Asgar Zaheer.	Acharya A, 2020, J NEUROIMMUNE PHARM, V15, P167, DOI 10.1007/s11481-020-09924-9; [Anonymous], 2020, LANCET, V395, P922, DOI 10.1016/S0140-6736(20)30644-9; Arac A, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00126; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Baig AM, 2020, ACS CHEM NEUROSCI, V11, P995, DOI 10.1021/acschemneuro.0c00122; Barlow A, 2020, PHARMACOTHERAPY, V40, P416, DOI 10.1002/phar.2398; Berger JR, 2020, J NEUROVIROL, V26, P143, DOI 10.1007/s13365-020-00840-5; Bisht K, 2018, NEUROBIOL STRESS, V9, P9, DOI 10.1016/j.ynstr.2018.05.003; Blanco-Melo D, 2020, CELL, V181, P1036, DOI 10.1016/j.cell.2020.04.026; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Bostanciklioglu M, 2020, INFLAMM BOWEL DIS, V26, pE89, DOI 10.1093/ibd/izaa131; Cabrera-Pastor A, 2019, ACTA PHYSIOL, V226, DOI 10.1111/apha.13270; Calcia MA, 2016, PSYCHOPHARMACOLOGY, V233, P1637, DOI 10.1007/s00213-016-4218-9; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Chary MA, 2020, J MED TOXICOL, V16, P284, DOI 10.1007/s13181-020-00777-5; Ciotti M, 2020, CHEMOTHERAPY, V64, P215, DOI 10.1159/000507423; Connell NT, 2020, J THROMB HAEMOST, DOI 10.1111/jth.14893; Connors JM, 2020, BLOOD, V135, P2033, DOI 10.1182/blood.2020006000; Conti P, 2020, J BIOL REG HOMEOS AG, V34, P327, DOI 10.23812/CONTI-E; Coperchini F, 2020, CYTOKINE GROWTH F R, V53, P25, DOI 10.1016/j.cytogfr.2020.05.003; Crisci CD, 2020, CURR TREAT OPTION AL, V7, P422, DOI 10.1007/s40521-020-00258-8; Cure E, 2020, DIABETES METAB SYND, V14, P349, DOI 10.1016/j.dsx.2020.04.019; De Felice FG, 2020, TRENDS NEUROSCI, V43, P355, DOI 10.1016/j.tins.2020.04.004; Debuc B, 2021, STEM CELL REV REP, V17, P4, DOI 10.1007/s12015-020-09987-4; Dinet V, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01178; Dixon L, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000789; Dong HQ, 2014, MED SCI MONIT BASIC, V20, P200, DOI 10.12659/MSMBR.893093; Felsenstein S, 2020, CLIN IMMUNOL, V215, DOI 10.1016/j.clim.2020.108448; Finsterer J, 2020, J MED VIROL, V92, P2316, DOI 10.1002/jmv.26000; Gasparyan AY, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e176; Gigante A, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109856; Gilfillan AM, 2011, ADV EXP MED BIOL, V716, P2, DOI 10.1007/978-1-4419-9533-9_1; Golpanian RS, 2020, CLIN THER, V42, P745, DOI 10.1016/j.clinthera.2020.01.025; Hasegawa T, 2007, MED HYPOTHESES, V69, P1135, DOI 10.1016/j.mehy.2007.02.034; Heneka MT, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00640-3; Hotez PJ, 2020, MICROBES INFECT, V22, P165, DOI 10.1016/j.micinf.2020.04.005; Johnson VE, 2018, ACTA NEUROPATHOL, V135, P711, DOI 10.1007/s00401-018-1824-0; Jones MK, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00171; Karamloo F, 2020, ALLERGY, V75, P1822, DOI 10.1111/all.14360; Kempuraj D., 2016, J NEUROL NEUROSURG S, V1, P1003; Kempuraj D, 2020, NEUROSCIENTIST, V26, P134, DOI 10.1177/1073858419848293; Kempuraj D, 2020, CLIN THER, V42, P974, DOI 10.1016/j.clinthera.2020.02.018; Kempuraj D, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00054; Kempuraj D, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00216; Khalili N, 2020, ACAD RADIOL, V27, P1051, DOI 10.1016/j.acra.2020.04.035; Khalsaa DS, 2015, J ALZHEIMERS DIS, V48, P1, DOI 10.3233/JAD-142766; Kim YK, 2017, BEHAV BRAIN RES, V329, P6, DOI 10.1016/j.bbr.2017.04.020; Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P342, DOI 10.1007/s12016-019-08769-2; Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Kustrimovic N, 2019, CURR MED CHEM, V26, P3719, DOI 10.2174/0929867325666181009161048; Leonardi M, 2020, J NEUROL, V267, P1573, DOI 10.1007/s00415-020-09896-z; Li H, 2020, NEUROTOX RES, V38, P1, DOI 10.1007/s12640-020-00219-8; Li L, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00661-z; Li MY, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00662-x; Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001; Li YW, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104833; Li Y, 2020, BRIT J HAEMATOL, V190, pE24, DOI 10.1111/bjh.16811; Logsdon AF, 2015, COMPR PHYSIOL, V5, P1147, DOI 10.1002/cphy.c140057; Long B, 2020, AM J EMERG MED, V38, P1504, DOI 10.1016/j.ajem.2020.04.048; Magrone T, 2020, ENDOCR METAB IMMUNE, V20, P1391, DOI 10.2174/1871530320666200406123734; Manjili RH, 2020, J IMMUNOL, V205, P12, DOI 10.4049/jimmunol.2000413; Mankad K, 2020, NEURORADIOLOGY, V62, P647, DOI 10.1007/s00234-020-02437-5; Markus HS, 2020, INT J STROKE, V15, P361, DOI 10.1177/1747493020923472; McCreary EK, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz538; McKee DL, 2020, PHARMACOL RES, V157, DOI 10.1016/j.phrs.2020.104859; McKittrick CM, 2015, J CEREBR BLOOD F MET, V35, P638, DOI 10.1038/jcbfm.2014.239; Mehra MR, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMoa2007621; Minihan E, 2020, IRISH J PSYCHOL MED, V37, P259, DOI 10.1017/ipm.2020.41; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Mravec B, 2018, CELL MOL NEUROBIOL, V38, P73, DOI 10.1007/s10571-017-0521-1; Mukai K, 2018, IMMUNOL REV, V282, P121, DOI 10.1111/imr.12634; Natoli S, 2020, EUR J NEUROL, V27, P1764, DOI 10.1111/ene.14277; Nile SH, 2020, CYTOKINE GROWTH F R, V53, P66, DOI 10.1016/j.cytogfr.2020.05.002; Ogier Michael, 2020, Brain Behav Immun Health, V5, P100081, DOI 10.1016/j.bbih.2020.100081; Ou XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15562-9; Park CL, 2020, J GEN INTERN MED, V35, P2296, DOI 10.1007/s11606-020-05898-9; Parrella E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050437; Pedersen SF, 2020, J CLIN INVEST, V130, P2202, DOI 10.1172/JCI137647; Piirainen S, 2017, NEUROSCI BIOBEHAV R, V77, P148, DOI 10.1016/j.neubiorev.2017.01.046; de Chambrun MP, 2021, J INTERN MED, V289, P422, DOI 10.1111/joim.13126; Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5; Ritchie AI, 2020, LANCET, V395, P1111, DOI 10.1016/S0140-6736(20)30691-7; Rogers JP, 2020, LANCET PSYCHIAT, V7, P611, DOI 10.1016/S2215-0366(20)30203-0; Ronconi G, 2020, J Biol Regul Homeost Agents, V34, P767, DOI 10.23812/EDITORIAL-RONCONI-E-59; Saavedra JM, 2020, CELL MOL NEUROBIOL, V40, P667, DOI 10.1007/s10571-020-00861-y; Saleki K, 2020, REV NEUROSCIENCE, V31, P453, DOI 10.1515/revneuro-2020-0026; Serrano-Castro PJ, 2020, NEUROLOGIA, V35, P245, DOI 10.1016/j.nrl.2020.04.002; Sheraton M, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.8192; Singh AK, 2020, DIABETES METAB SYND, V14, P303, DOI 10.1016/j.dsx.2020.04.004; Skaper SD, 2017, NEUROSCIENTIST, V23, P478, DOI 10.1177/1073858416687249; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Steenblock C, 2020, MOL PSYCHIATR, V25, P1611, DOI 10.1038/s41380-020-0758-9; Stefaniak AA, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13477; Stuve O, 2014, CLIN EXP IMMUNOL, V175, P333, DOI 10.1111/cei.12260; Sun XJ, 2020, CYTOKINE GROWTH F R, V53, P38, DOI 10.1016/j.cytogfr.2020.04.002; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Theoharides TC, 2020, CLIN THER, V42, P1007, DOI 10.1016/j.clinthera.2020.05.002; Theoharides TC, 2020, BIOFACTORS, V46, P306, DOI 10.1002/biof.1633; Theoharides TC, 2012, BBA-MOL BASIS DIS, V1822, P21, DOI 10.1016/j.bbadis.2010.12.014; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Varricchi G, 2019, INT ARCH ALLERGY IMM, V179, P247, DOI 10.1159/000500088; Verdecchia P, 2020, EUR J INTERN MED, V76, P14, DOI 10.1016/j.ejim.2020.04.037; Vinciguerra M, 2020, INFECT GENET EVOL, V84, DOI 10.1016/j.meegid.2020.104361; Vinkers CH, 2020, EUR NEUROPSYCHOPHARM, V35, P12, DOI 10.1016/j.euroneuro.2020.05.003; Wang CY, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072459; Wilson MP, 2020, CLIN NEUROL NEUROSUR, V193, DOI 10.1016/j.clineuro.2020.105866; Wu DD, 2020, J MICROBIOL IMMUNOL, V53, P368, DOI 10.1016/j.jmii.2020.03.005; Wu WZ, 2020, J MED VIROL, V92, P1962, DOI 10.1002/jmv.25914; Xia HJ, 2008, J NEUROCHEM, V107, P1482, DOI 10.1111/j.1471-4159.2008.05723.x; Xiao H, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923921; Xu XL, 2020, P NATL ACAD SCI USA, V117, P10970, DOI 10.1073/pnas.2005615117; Ye Q, 2020, J INFECTION, V80, P607, DOI 10.1016/j.jinf.2020.03.037; Yeung D, 2008, ACTA NEUROPATHOL, V115, P635, DOI 10.1007/s00401-008-0364-4; Zhang JC, 2020, BRAIN BEHAV IMMUN, V87, P59, DOI 10.1016/j.bbi.2020.04.046; Zhang LT, 2020, J THROMB HAEMOST, V18, P1324, DOI 10.1111/jth.14859; Zhang Y, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2007575; Zheng YY, 2020, NAT REV CARDIOL, V17, P259, DOI 10.1038/s41569-020-0360-5	119	71	75	7	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584	1089-4098		NEUROSCIENTIST	Neuroscientist	OCT	2020	26	5-6					402	414	1073858420941476	10.1177/1073858420941476		JUL 2020	13	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	NX6QK	WOS:000549920700001	32684080		Y	N	2022-02-06	
J	Tiedt, S; Duering, M; Barro, C; Kaya, AG; Boeck, J; Bode, FJ; Klein, M; Dorn, F; Gesierich, B; Kellert, L; Ertl-Wagner, B; Goertler, MW; Petzold, GC; Kuhle, J; Wollenweber, FA; Peters, N; Dichgans, M				Tiedt, Steffen; Duering, Marco; Barro, Christian; Kaya, Asli Gizem; Boeck, Julia; Bode, Felix J.; Klein, Matthias; Dorn, Franziska; Gesierich, Benno; Kellert, Lars; Ertl-Wagner, Birgit; Goertler, Michael W.; Petzold, Gabor C.; Kuhle, Jens; Wollenweber, Frank A.; Peters, Nils; Dichgans, Martin			Serum neurofilament light A biomarker of neuroaxonal injury after ischemic stroke	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; INFARCT VOLUME; MARKER; REMOTE; BLOOD; DIAGNOSIS; LESION; CHAIN; NEURODEGENERATION; RECURRENCE	Objective To explore the utility of serum neurofilament light chain (NfL) as a biomarker for primary and secondary neuroaxonal injury after ischemic stroke (IS) and study its value for the prediction of clinical outcome. Methods We used an ultrasensitive single-molecule array assay to measure serum NfL levels in healthy controls (n = 30) and 2 independent cohorts of patients with IS: (1) with serial serum sampling at hospital arrival (n = 196), at days 2, 3, and 7 (n = 89), and up to 6 months post stroke; and (2) with standardized MRI at baseline and at 6 months post stroke, and with cross-sectional serum sampling at 6 months (n = 95). We determined the temporal profile of serum NfL levels, their association with imaging markers of neuroaxonal injury, and with clinical outcome. Results Patients with IS had higher serum NfL levels compared with healthy controls starting from admission until 6 months post stroke. Serum NfL levels peaked at day 7 (211.2 pg/mL [104.7-442.6], median [IQR]) and correlated with infarct volumes (day 7: partial r = 0.736, p = 1.5 x 10(-15)). Six months post stroke, patients with recurrent ischemic lesions on MRI (n = 19) had higher serum NfL levels compared to those without new lesions (n = 76, p = 0.002). Serum NfL levels 6 months post stroke further correlated with a quantitative measure of secondary neurodegeneration obtained from diffusion tensor imaging MRI (r = 0.361, p = 0.001). Serum NfL levels 7 days post stroke independently predicted modified Rankin Scale scores 3 months post stroke (cumulative odds ratio [95% confidence interval] = 2.35 [1.60-3.45]; p = 1.24 x 10(-05)). Conclusion Serum NfL holds promise as a biomarker for monitoring primary and secondary neuroaxonal injury after IS and for predicting functional outcome.	[Tiedt, Steffen; Duering, Marco; Kaya, Asli Gizem; Boeck, Julia; Gesierich, Benno; Wollenweber, Frank A.; Dichgans, Martin] Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Univ Hosp, Munich, Germany; [Tiedt, Steffen] Ludwig Maximilians Univ Munchen, Grad Sch Syst Neurosci, Munich, Germany; [Tiedt, Steffen; Dichgans, Martin] Munich Cluster Syst Neurol SyNergy, Munich, Germany; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Med, Univ Hosp Basel, Basel, Switzerland; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Biomed, Univ Hosp Basel, Basel, Switzerland; [Barro, Christian; Kuhle, Jens] Univ Basel, Neurol Clin & Policlin, Dept Clin Res, Univ Hosp Basel, Basel, Switzerland; [Bode, Felix J.; Petzold, Gabor C.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Bode, Felix J.; Petzold, Gabor C.] Univ Hosp Bonn, Dept Neurol, Bonn, Germany; [Klein, Matthias; Kellert, Lars] Ludwig Maximilians Univ Munchen, Dept Neurol, Univ Hosp, Munich, Germany; [Dorn, Franziska] Ludwig Maximilians Univ Munchen, Dept Neuroradiol, Univ Hosp, Munich, Germany; [Ertl-Wagner, Birgit] Ludwig Maximilians Univ Munchen, Dept Radiol, Univ Hosp, Munich, Germany; [Goertler, Michael W.] Univ Magdeburg, Univ Hosp, Dept Neurol, Magdeburg, Germany; [Goertler, Michael W.] German Ctr Neurodegenerat Dis DZNE, Magdeburg, Germany; [Peters, Nils] Univ Hosp Basel, Stroke Ctr, Basel, Switzerland; [Peters, Nils] Univ Hosp Basel, Dept Neurol, Basel, Switzerland; [Dichgans, Martin] German Ctr Neurodegenerat Dis DZNE, Munich, Germany		Dichgans, M (corresponding author), Ludwig Maximilians Univ Munchen, Inst Stroke & Dementia Res, Univ Hosp, Munich, Germany.; Dichgans, M (corresponding author), Munich Cluster Syst Neurol SyNergy, Munich, Germany.; Dichgans, M (corresponding author), German Ctr Neurodegenerat Dis DZNE, Munich, Germany.	martin.dichgans@med.uni-muenchen.de	Dorn, Franziska/AAA-7754-2020; Klein, Matthias/F-4118-2017; Ertl-Wagner, Birgit/AAD-5708-2020; Barro, Christian/AAO-3567-2021; Duering, Marco/AAE-6949-2021	Dorn, Franziska/0000-0001-9093-8307; Klein, Matthias/0000-0001-9064-6865; Barro, Christian/0000-0002-7795-7383; Duering, Marco/0000-0003-2302-3136; Ertl-Wagner, Birgit/0000-0002-7896-7049; Wollenweber, Frank Arne/0000-0002-9375-405X	Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [CRC 1123]; German Federal Ministry of Education and Research (BMBF)Federal Ministry of Education & Research (BMBF); European UnionEuropean Commission [66688, 667375, Health-F2-2013-601456]; Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain)Leducq Foundation; Vascular Dementia Research Foundation; Jackstaedt Foundation; Josef-Hackl-Stiftung; Swiss National Research FoundationSwiss National Science Foundation (SNSF) [320030_160221]; Alzheimer Forschung Initiative e.V. [16018CB]; German Research FoundationGerman Research Foundation (DFG) [DFG DU1626/1-1]; Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology [SyNergy]); Neurology Research Pool (University Hospital Basel)	M. Dichgans was supported by grants from the Deutsche Forschungsgemeinschaft (CRC 1123 [B3] and Munich Cluster for Systems Neurology [SyNergy]), the German Federal Ministry of Education and Research (BMBF, e:Med programme e: AtheroSysMed), the FP7/2007-2103 European Union project CVgenes@target (grant agreement no. Health-F2-2013-601456), the European Union Horizon2020 projects SVDs@target (grant agreement no. 66688) and CoSTREAM (grant agreement no. 667375), the Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain), the Vascular Dementia Research Foundation, and the Jackstaedt Foundation. S.T. was supported by the Josef-Hackl-Stiftung and by a grant from the Deutsche Forschungsgemeinschaft (Munich Cluster for Systems Neurology [SyNergy]). J.K. was supported by the Swiss National Research Foundation (320030_160221). N.P. was supported by the Neurology Research Pool (University Hospital Basel). M. Duering was supported by grants from the Alzheimer Forschung Initiative e.V. (#16018CB) and the German Research Foundation (DFG DU1626/1-1).	Ahmad O, 2012, CEREBROVASC DIS, V33, P47, DOI 10.1159/000332810; Avants BB, 2008, MED IMAGE ANAL, V12, P26, DOI 10.1016/j.media.2007.06.004; Baird AE, 2001, LANCET, V357, P2095, DOI 10.1016/S0140-6736(00)05183-7; Baykara E, 2016, ANN NEUROL, V80, P581, DOI 10.1002/ana.24758; BRANT R, 1990, BIOMETRICS, V46, P1171, DOI 10.2307/2532457; Byrne LM, 2017, LANCET NEUROL, V16, P601, DOI 10.1016/S1474-4422(17)30124-2; Christensen R. H. B, 2015, ORDINAL REGRESSION M, P6; Conklin J, 2014, ANN NEUROL, V76, P899, DOI 10.1002/ana.24285; De Marchis GM, 2018, EUR J NEUROL, V25, P562, DOI 10.1111/ene.13554; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Duering M, 2017, BRAIN, V140, P1818, DOI 10.1093/brain/awx135; Duering M, 2015, NEUROLOGY, V84, P1685, DOI 10.1212/WNL.0000000000001502; Duering M, 2012, NEUROLOGY, V79, P2025, DOI 10.1212/WNL.0b013e3182749f39; Eastwood JD, 2003, AM J NEURORADIOL, V24, P680; Foerch C, 2005, ARCH NEUROL-CHICAGO, V62, P1130, DOI 10.1001/archneur.62.7.1130; Gattringer T, 2017, NEUROLOGY, V89, P2108, DOI 10.1212/WNL.0000000000004645; Hansson O, 2017, NEUROLOGY, V88, P930, DOI 10.1212/WNL.0000000000003680; Hopyan J, 2010, RADIOLOGY, V255, P142, DOI 10.1148/radiol.09091021; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Kang DW, 2009, STROKE, V40, P1653, DOI 10.1161/STROKEAHA.108.539429; Kang DW, 2003, ANN NEUROL, V54, P66, DOI 10.1002/ana.10592; Kang DW, 2004, NEUROLOGY, V63, P2261, DOI 10.1212/01.WNL.0000147295.50029.67; Katan M, 2009, ANN NEUROL, V66, P799, DOI 10.1002/ana.21783; Kellner E, 2016, MAGN RESON MED, V76, P1574, DOI 10.1002/mrm.26054; Kluge MG, 2017, GLIA, V65, P1885, DOI 10.1002/glia.23201; Kuchcinski G, 2017, BRAIN, V140, P1932, DOI 10.1093/brain/awx114; Kuhle J, 2017, NEUROLOGY, V88, P826, DOI 10.1212/WNL.0000000000003653; Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195; Kuhle J, 2015, NEUROLOGY, V84, P1639, DOI 10.1212/WNL.0000000000001491; R Core Team, 2017, R LANG ENV STAT COMP; Rost NS, 2012, STROKE, V43, P441, DOI 10.1161/STROKEAHA.111.629212; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schulz UGR, 2007, J NEUROL, V254, P375, DOI 10.1007/s00415-006-0381-y; Shahim P, 2017, NEUROLOGY, V88, P1788, DOI 10.1212/WNL.0000000000003912; Singh P, 2011, J NEUROL SCI, V304, P117, DOI 10.1016/j.jns.2011.01.025; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Steinacker P, 2017, NEUROLOGY, V88, P961, DOI 10.1212/WNL.0000000000003688; Strobl C, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-307; Tiedt S, 2017, CIRC RES, V121, P970, DOI 10.1161/CIRCRESAHA.117.311572; Traenka C, 2015, CEREBROVASC DIS, V40, P222, DOI 10.1159/000440774; Tustison NJ, 2010, IEEE T MED IMAGING, V29, P1310, DOI 10.1109/TMI.2010.2046908; Veraart J, 2016, NEUROIMAGE, V142, P384, DOI 10.1016/j.neuroimage.2016.08.016; Veraart J, 2016, MAGN RESON MED, V76, P1582, DOI 10.1002/mrm.26059; Vogt G, 2012, STROKE, V43, P1266, DOI 10.1161/STROKEAHA.111.646570; Winbeck K, 2002, STROKE, V33, P2459, DOI 10.1161/01.STR.0000029828.51413.82; Wollenweber FA, 2014, INT J STROKE, V9, P387, DOI 10.1111/ijs.12092; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zhang J, 2012, STROKE, V43, P1700, DOI 10.1161/STROKEAHA.111.632448; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zhang ZX, 2002, J COMP NEUROL, V450, P144, DOI 10.1002/cne.10306	50	71	73	4	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	OCT 2	2018	91	14					E1338	E1347		10.1212/WNL.0000000000006282			10	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	HD4LD	WOS:000452498100008	30217937	Green Published			2022-02-06	
J	Vella, MA; Crandall, ML; Patel, MB				Vella, Michael A.; Crandall, Marie L.; Patel, Mayur B.			Acute Management of Traumatic Brain Injury	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; Intracranial hypertension; Secondary injury; Hyperosmolar therapy; Barbiturate coma; Decompressive craniectomy	CEREBRAL PERFUSION-PRESSURE; REFRACTORY INTRACRANIAL HYPERTENSION; PROTHROMBIN COMPLEX CONCENTRATE; ACUTE SUBDURAL-HEMATOMA; SEVERE HEAD-INJURY; DECOMPRESSIVE CRANIECTOMY; CONTROLLED-TRIAL; BLOOD-FLOW; EASTERN ASSOCIATION; ENTERAL NUTRITION	Traumatic brain injury (TBI) is a leading cause of death and disability in patients with trauma. Management strategies must focus on preventing secondary injury by avoiding hypotension and hypoxia and maintaining appropriate cerebral perfusion pressure (CPP), which is a surrogate for cerebral blood flow. CPP can be maintained by increasing mean arterial pressure, decreasing intracranial pressure, or both. The goal should be euvolemia and avoidance of hypotension. Other factors that deserve important consideration in the acute management of patients with TBI are venous thromboembolism, stress ulcer, and seizure prophylaxis, as well as nutritional and metabolic optimization.	[Vella, Michael A.] Vanderbilt Univ, Med Ctr, Dept Surg, Sect Surg Sci,Med Ctr North, CCC-4312,1161 21st Ave South, Nashville, TN 37232 USA; [Vella, Michael A.] Univ Penn, Dept Surg, Div Traumatol Surg Crit Care & Emergency Surg, Philadelphia, PA 19104 USA; [Crandall, Marie L.] Univ Florida, Dept Surg, Div Acute Care Surg, 655 West 8th St, Jacksonville, FL 32209 USA; [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Brain Inst,Ctr Hlth Serv Res, Dept Surg,Sect Surg Sci,Div Trauma Surg Crit Care, 1211 21st Ave South,Med Arts Bldg,Suite 404, Nashville, TN 37212 USA; [Patel, Mayur B.] Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Surg Serv, 1310 24th Ave South, Nashville, TN 37212 USA		Patel, MB (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Brain Inst,Ctr Hlth Serv Res, Dept Surg,Sect Surg Sci,Div Trauma Surg Crit Care, 1211 21st Ave South,Med Arts Bldg,Suite 404, Nashville, TN 37212 USA.; Patel, MB (corresponding author), Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Surg Serv, 1310 24th Ave South, Nashville, TN 37212 USA.	mayur.b.patel@vanderbilt.edu	Crandall, Marie/L-9066-2019	Crandall, Marie/0000-0002-6536-3123	National Institutes of Health (Bethesda, MD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NHLBI R01 HL111111, NIGMS R01 GM120484]; REDCap from NCATS/NIH [UL1 TR000445]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	M.B. Patel is supported by National Institutes of Health (Bethesda, MD) NHLBI R01 HL111111 and NIGMS R01 GM120484. This work was also supported by REDCap UL1 TR000445 from NCATS/NIH. The authors have no other disclosures relevant to this article.	Acosta-Escribano J, 2010, INTENS CARE MED, V36, P1532, DOI 10.1007/s00134-010-1908-3; Alali AS, 2017, ANN SURG; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; [Anonymous], 2012, HEAD TRAUM ATLS ADV, P148; Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Bilotta F, 2008, NEUROCRIT CARE, V9, P159, DOI 10.1007/s12028-008-9084-9; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Bouzat P, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-23; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Bullock M Ross, 2006, Neurosurgery, V58, pS7; Calland JF, 2012, J TRAUMA ACUTE CARE, V73, pS345, DOI 10.1097/TA.0b013e318270191f; Cameron John L, 2017, MANAGEMENT TRAUMATIC; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Chiang YH, 2012, J NEUROTRAUM, V29, P75, DOI 10.1089/neu.2011.1801; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cotte J, 2014, NEW ENGL J MED, V371, P971, DOI 10.1056/NEJMc1407775; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Crandall M, 2014, BRAIN INJURY, V28, P1359, DOI 10.3109/02699052.2014.919533; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Dorfman JD, 2011, NEUROCRIT CARE, V15, P516, DOI 10.1007/s12028-011-9549-0; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; HALLORAN LG, 1980, AM J SURG, V139, P44, DOI 10.1016/0002-9610(80)90228-7; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Imberti R, 2002, J NEUROSURG, V96, P97, DOI 10.3171/jns.2002.96.1.0097; Inaba K, 2013, J TRAUMA ACUTE CARE, V74, P766, DOI 10.1097/TA.0b013e3182826e84; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Jones KE, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E3; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P102, DOI 10.1097/TA.0b013e3182946667; Joseph B, 2013, J TRAUMA ACUTE CARE, V74, P248, DOI 10.1097/TA.0b013e3182788a40; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lasky MR, 1998, J TRAUMA, V44, P527, DOI 10.1097/00005373-199803000-00020; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; MacLaren R, 2014, JAMA INTERN MED, V174, P564, DOI 10.1001/jamainternmed.2013.14673; Mangat HS, 2015, J NEUROSURG, V122, P202, DOI 10.3171/2014.10.JNS132545; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 2002, CRIT CARE MED, V30, P2619, DOI 10.1097/00003246-200212000-00001; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; Matsushima K, 2015, AM J SURG, V209, P413, DOI 10.1016/j.amjsurg.2014.08.019; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; McMillian WD, 2009, J TRAUMA, V66, P942, DOI 10.1097/TA.0b013e3181978e7b; Mendelow AD, 2015, J NEUROTRAUM, V32, P1312, DOI 10.1089/neu.2014.3644; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nwachuku EL, 2014, NEUROCRIT CARE, V20, P49, DOI 10.1007/s12028-013-9885-3; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Patel MB, 2015, ENCY TRAUMA CARE, P1711; Phelan HA, 2012, J NEUROTRAUM, V29, P1821, DOI 10.1089/neu.2012.2459; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Pollack Jr CV, 2015, NEW ENGL J MED, V373, P511, DOI 10.1056/NEJMoa1502000; Prabhakar Hemanshu, 2014, J Anaesthesiol Clin Pharmacol, V30, P318, DOI 10.4103/0970-9185.137260; Roberts I, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000033.pub2; ROBERTSON C, 1993, ACTA NEUROCHIR, P98; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Schirmer CM, 2012, NEUROCRIT CARE, V16, P184, DOI 10.1007/s12028-011-9580-1; Scudday T, 2011, J AM COLL SURGEONS, V213, P148, DOI 10.1016/j.jamcollsurg.2011.02.027; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Siegal DM, 2013, J THROMB THROMBOLYS, V35, P391, DOI 10.1007/s11239-013-0885-0; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stocchetti N, 2004, ANESTH ANALG, V99, P230, DOI 10.1213/01.ane.0000130393.08355.d4; SYDENHAM E, 2009, COCHRANE DATABASE SY; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Weiner GM, 2010, NEUROSURGERY, V66, P1111, DOI 10.1227/01.NEU.0000369607.71913.3E; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Zeiler FA, 2014, NEUROCRIT CARE, V21, P163, DOI 10.1007/s12028-013-9950-y	96	71	80	8	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	OCT	2017	97	5					1015	+		10.1016/j.suc.2017.06.003			17	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	FL0EV	WOS:000413885300007	28958355	Green Accepted			2022-02-06	
J	Llinas-Regla, J; Vilalta-Franch, J; Lopez-Pousa, S; Calvo-Perxas, L; Torrents Rodas, D; Garre-Olmo, J				Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Calvo-Perxas, Laia; Torrents Rodas, David; Garre-Olmo, Josep			The Trail Making Test: Association With Other Neuropsychological Measures and Normative Values for Adults Aged 55 Years and Older From a Spanish-Speaking Population-Based Sample	ASSESSMENT			English	Article						Trail Making Test; psychometrics; neuropsychological tests; executive function; reference standards; cognition	TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; ORAL WORD-ASSOCIATION; ALZHEIMERS-DISEASE; EXECUTIVE FUNCTIONS; CONSTRUCT-VALIDITY; ELDERLY-PEOPLE; VISUAL-SEARCH; STROOP TEST; PART-B	The Trail Making Test (TMT) is used as an indicator of visual scanning, graphomotor speed, and executive function. The aim of this study was to examine the TMT relationships with several neuropsychological measures and to provide normative data in community-dwelling participants of 55 years and older. A population-based Spanish-speaking sample of 2,564 participants was used. The TMT, Symbol Digit Test, Stroop Color-Word Test, Digit Span Test, Verbal Fluency tests, and the MacQuarrie Test for Mechanical Ability tapping subtest were administered. Exploratory factor analyses and regression lineal models were used. Normative data for the TMT scores were obtained. A total of 1,923 participants (76.3%) participated, 52.4% were women, and the mean age was 66.5 years (Digit Span = 8.0). The Symbol Digit Test, MacQuarrie Test for Mechanical Ability tapping subtest, Stroop Color-Word Test, and Digit Span Test scores were associated in the performance of most TMT scores, but the contribution of each measure was different depending on the TMT score. Normative tables according to significant factors such as age, education level, and sex were created. Measures of visual scanning, graphomotor speed, and visuomotor processing speed were more related to the performance of the TMT-A score, while working memory and inhibition control were mainly associated with the TMT-B and derived TMT scores..	[Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino] Hosp Santa Caterina, Memory Clin, Salt, Spain; [Llinas-Regla, Jordi; Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Garre-Olmo, Josep] Univ Girona, Dept Med Sci, Girona, Spain; [Vilalta-Franch, Joan; Lopez-Pousa, Secundino; Calvo-Perxas, Laia; Garre-Olmo, Josep] Girona Biomed Res Inst IDIBGI, Salt, Spain; [Torrents Rodas, David] Univ Autonoma Barcelona, Dept Psychiat & Forens Med, Barcelona, Spain		Garre-Olmo, J (corresponding author), Girona Biomed Res Inst, Edifici Mancomunitat 1,Parc Hosp Marti & Julia, Girona 17190, Catalonia, Spain.	josep.garre@ias.scs.es	Garre-Olmo, Josep/D-8460-2011; Garre-Olmo, Josep/AAA-2349-2022; Calvo-Perxas, Laia/H-9931-2013	Garre-Olmo, Josep/0000-0002-7817-0814; Calvo-Perxas, Laia/0000-0001-8618-504X; Lopez-Pousa, Secundino/0000-0002-2818-3473; Vilalta-Franch, Joan/0000-0002-5306-437X; Torrents-Rodas, David/0000-0003-0222-7770	Instituto de Salud Carlos IIIInstituto de Salud Carlos IIIEuropean Commission [PI09/02591]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Instituto de Salud Carlos III under Grant number PI09/02591.	Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Armitage SG, 1946, PSYCHOL MONOGR, V60, P1; Army Individual Tests Battery, 1944, MAN DIR SCOR; Ashendorf L, 2008, ARCH CLIN NEUROPSYCH, V23, P129, DOI 10.1016/j.acn.2007.11.005; Bell-McGinty S, 2002, INT J GERIATR PSYCH, V17, P828, DOI 10.1002/gps.646; Belsley DA., 1980, REGRESSION DIAGNOSTI, DOI 10.1002/0471725153; Bezdicek O, 2012, ARCH CLIN NEUROPSYCH, V27, P906, DOI 10.1093/arclin/acs084; BORNSTEIN RA, 1988, DEV NEUROPSYCHOL, V4, P17, DOI 10.1080/87565648809540386; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Cangoz B, 2009, J NEUROL SCI, V283, P73, DOI 10.1016/j.jns.2009.02.313; Cavaco S, 2013, ARCH CLIN NEUROPSYCH, V28, P189, DOI 10.1093/arclin/acs115; Chapman RM, 2011, J CLIN EXP NEUROPSYC, V33, P187, DOI 10.1080/13803395.2010.499356; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; Cook RD, 1982, RESIDUALS INFLUENCE; CORRIGAN JD, 1987, J CLIN PSYCHOL, V43, P402, DOI 10.1002/1097-4679(198707)43:4<402::AID-JCLP2270430411>3.0.CO;2-E; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.3.CO;2-M; Dawson JD, 2009, NEUROLOGY, V72, P521, DOI 10.1212/01.wnl.0000341931.35870.49; EHRENSTEIN WH, 1982, ARCH PSYCHIAT NERVEN, V231, P333, DOI 10.1007/BF00345589; Emerson JL, 2012, PSYCHOL AGING, V27, P550, DOI 10.1037/a0026359; Ernst J, 1987, Arch Clin Neuropsychol, V2, P1, DOI 10.1016/0887-6177(87)90030-8; Ewers M, 2012, NEUROBIOL AGING, V33, P1203, DOI 10.1016/j.neurobiolaging.2010.10.019; Ferman TJ, 2006, CLIN NEUROPSYCHOL, V20, P623, DOI 10.1080/13854040500376831; Fernandez AL, 2008, SCAND J PSYCHOL, V49, P239, DOI 10.1111/j.1467-9450.2008.00637.x; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Golden C.J., 1994, STROOP TEST COLORES; Gomar JJ, 2011, ARCH GEN PSYCHIAT, V68, P961, DOI 10.1001/archgenpsychiatry.2011.96; Grau M, 2007, EUR J CARDIOV PREV R, V14, P653, DOI 10.1097/HJR.0b013e3281764429; Guilford J. P., 1973, FUNDAMENTAL STAT PSY; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hashimoto R, 2006, PSYCHIAT CLIN NEUROS, V60, P422, DOI 10.1111/j.1440-1819.2006.01526.x; Heled E, 2012, J CLIN EXP NEUROPSYC, V34, P151, DOI 10.1080/13803395.2011.625351; Hester RL, 2005, CLIN NEUROPSYCHOL, V19, P45, DOI 10.1080/13854040490524137; Horton A. M., 2003, ARCH CLIN NEUROPSYCH, V18, P310; Ivnik RJ, 1996, CLIN NEUROPSYCHOL, V10, P262, DOI 10.1080/13854049608406689; Jacobson SC, 2011, BRAIN COGNITION, V77, P60, DOI 10.1016/j.bandc.2011.06.001; Jurado MB, 2007, NEUROPSYCHOL REV, V17, P213, DOI 10.1007/s11065-007-9040-z; Koziol L.F., 2014, MYTH EXECUTIVE FUNCT; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P813, DOI 10.1080/13854040701625846; Leiter RG., 1949, PSYCHOL SERVICE CTR, V1, P11; Lemiere J, 2004, J NEUROL, V251, P935, DOI 10.1007/s00415-004-0461-9; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; Lopez-Pousa S, 2004, NEUROEPIDEMIOLOGY, V23, P170, DOI 10.1159/000078502; Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P243, DOI 10.1080/13854040590945337; MacQuarrie TW, 1925, MACQUARRIE TEST MECH; Manea L, 2015, GEN HOSP PSYCHIAT, V37, P67, DOI 10.1016/j.genhosppsych.2014.09.009; MATARAZZO JD, 1974, J NERV MENT DIS, V158, P37, DOI 10.1097/00005053-197401000-00006; McCurry SM, 2001, ARCH CLIN NEUROPSYCH, V16, P447, DOI 10.1016/S0887-6177(00)00056-1; Misdraji EL, 2010, J CLIN EXP NEUROPSYC, V32, P159, DOI 10.1080/13803390902881942; Mitrushina M., 2005, HDB NORMATIVE DATA N, V2nd; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; O'Rourke JJF, 2011, J CLIN EXP NEUROPSYC, V33, P567, DOI 10.1080/13803395.2010.541228; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; Oosterman JM, 2010, CLIN NEUROPSYCHOL, V24, P203, DOI 10.1080/13854040903482848; PAUKER JD, 1988, J CLIN PSYCHOL, V44, P930, DOI 10.1002/1097-4679(198811)44:6<930::AID-JCLP2270440613>3.0.CO;2-H; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P321, DOI 10.1093/arclin/acp038; Pena-Casanova J, 2009, ARCH CLIN NEUROPSYCH, V24, P307, DOI 10.1093/arclin/acp027; Perianez JA, 2007, ARCH CLIN NEUROPSYCH, V22, P433, DOI 10.1016/j.acn.2007.01.022; Potter GG, 2013, AM J GERIAT PSYCHIAT, V21, P297, DOI 10.1016/j.jagp.2012.12.009; Quijano TD, 2004, MED CLIN-BARCELONA, V122, P727, DOI 10.1157/13062190; Rabbitt P., 1997, METHODOLOGY FRONTAL, P1; Rasmusson DX, 1998, CLIN NEUROPSYCHOL, V12, P169, DOI 10.1076/clin.12.2.169.2005; Reitan R.M., 1955, NEUROPSYCHOLOGICAL T; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; REITAN RM, 1959, J CLIN PSYCHOL, V15, P281, DOI 10.1002/1097-4679(195907)15:3<281::AID-JCLP2270150314>3.0.CO;2-D; Rios M, 2004, BRAIN INJURY, V18, P257, DOI 10.1080/02699050310001617442; Salthouse TA, 2005, NEUROPSYCHOLOGY, V19, P532, DOI 10.1037/0894-4105.19.4.532; Salthouse TA, 2000, NEUROPSYCHOLOGY, V14, P102, DOI 10.1037/0894-4105.14.1.102; Salthouse TA, 2011, INTELLIGENCE, V39, P222, DOI 10.1016/j.intell.2011.03.001; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Seo EH, 2006, INT J GERIATR PSYCH, V21, P844, DOI 10.1002/gps.1570; Soukup V M, 1998, Appl Neuropsychol, V5, P65, DOI 10.1207/s15324826an0502_2; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Steinberg BA, 2005, CLIN NEUROPSYCHOL, V19, P329, DOI 10.1080/13854040590945210; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Stuss D.T., 1987, CLIN NEUROPSYCHOL, V1, P139, DOI [DOI 10.1080/13854048708520046, 10.1080/13854048708520046]; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; Terada S, 2013, PSYCHIAT RES-NEUROIM, V213, P249, DOI 10.1016/j.pscychresns.2013.03.006; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; Van Breukelen GJP, 2005, PSYCHOL ASSESSMENT, V17, P336, DOI 10.1037/1040-3590.17.3.336; Van der Elst W, 2006, ASSESSMENT, V13, P62, DOI 10.1177/1073191105283427; Vazzana R, 2010, J AM GERIATR SOC, V58, P719, DOI 10.1111/j.1532-5415.2010.02780.x; Wasserman T, 2013, APPL NEUROPSYCH-CHIL, V2, P88, DOI 10.1080/21622965.2013.748394; Wechsler D., 1999, WECHSLER ADULT INTEL; Wecker NS, 2000, NEUROPSYCHOLOGY, V14, P409, DOI 10.1037//0894-4105.14.3.409; Weiskrantz L., 1992, NEUROPSYCHOLOGY CONS, P1; Wiberg B, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000458; WIEDERHOLT WC, 1993, J AM GERIATR SOC, V41, P639, DOI 10.1111/j.1532-5415.1993.tb06738.x; Wolfson, 1993, HALSTEAD REITAN NEUR; ZACHARY RA, 1985, J CLIN PSYCHOL, V41, P86, DOI 10.1002/1097-4679(198501)41:1<86::AID-JCLP2270410115>3.0.CO;2-W; Zalonis I., 2010, ANN GEN PSYCHIAT S, V9, pS145; [No title captured]	93	71	73	0	12	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-1911	1552-3489		ASSESSMENT	Assessment	MAR	2017	24	2					183	196		10.1177/1073191115602552			14	Psychology, Clinical	Social Science Citation Index (SSCI)	Psychology	EL9SF	WOS:000394959700004	26318386				2022-02-06	
J	Yip, PK; Carrillo-Jimenez, A; King, P; Vilalta, A; Nomura, K; Chau, CC; Egerton, AMS; Liu, ZH; Shetty, AJ; Tremoleda, JL; Davies, M; Deierborg, T; Priestley, JV; Brown, GC; Michael-Titus, AT; Venero, JL; Burguillos, MA				Yip, Ping Kei; Carrillo-Jimenez, Alejandro; King, Paul; Vilalta, Anna; Nomura, Koji; Chau, Chi Cheng; Egerton, Alexander Michael Scott; Liu, Zhuo-Hao; Shetty, Ashray Jayaram; Tremoleda, Jordi L.; Davies, Meirion; Deierborg, Tomas; Priestley, John V.; Brown, Guy Charles; Michael-Titus, Adina Teodora; Luis Venero, Jose; Burguillos, Miguel Angel			Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration	SCIENTIFIC REPORTS			English	Article							SPINAL-CORD-INJURY; RECEPTOR 4; INFLAMMATORY RESPONSE; GENE-EXPRESSION; MESSENGER-RNA; MICROGLIA; ACTIVATION; NEURONS; MICE; NEUROINFLAMMATION	Traumatic brain injury (TBI) is currently a major cause of morbidity and poor quality of life in Western society, with an estimate of 2.5 million people affected per year in Europe, indicating the need for advances in TBI treatment. Within the first 24 h after TBI, several inflammatory response factors become upregulated, including the lectin galectin-3. In this study, using a controlled cortical impact (CCI) model of head injury, we show a large increase in the expression of galectin-3 in microglia and also an increase in the released form of galectin-3 in the cerebrospinal fluid (CSF) 24 h after head injury. We report that galectin-3 can bind to TLR-4, and that administration of a neutralizing antibody against galectin-3 decreases the expression of IL-1 beta, IL-6, TNF alpha and NOS2 and promotes neuroprotection in the cortical and hippocampal cell populations after head injury. Long-term analysis demonstrated a significant neuroprotection in the cortical region in the galectin-3 knockout animals in response to TBI. These results suggest that following head trauma, released galectin-3 may act as an alarmin, binding, among other proteins, to TLR-4 and promoting inflammation and neuronal loss. Taking all together, galectin-3 emerges as a clinically relevant target for TBI therapy.	[Yip, Ping Kei; King, Paul; Chau, Chi Cheng; Egerton, Alexander Michael Scott; Liu, Zhuo-Hao; Shetty, Ashray Jayaram; Tremoleda, Jordi L.; Davies, Meirion; Priestley, John V.; Michael-Titus, Adina Teodora; Burguillos, Miguel Angel] Queen Mary Univ London, Blizard Inst, Ctr Neurosci & Trauma, London E1 2AT, England; [Carrillo-Jimenez, Alejandro] Univ Seville, Fac Farm, Dept Bioquim & Biol Mol, E-41012 Seville, Spain; [Carrillo-Jimenez, Alejandro] Univ Seville, CSIC, Hosp Univ Virgen Rocio, Inst Biomed Sevilla, E-41012 Seville, Spain; [Vilalta, Anna; Nomura, Koji; Brown, Guy Charles] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Liu, Zhuo-Hao] Chang Gung Med Coll & Univ, Chang Gung Mem Hosp, Dept Neurosurg, 5 Fu Shin St, Linkou, Taiwan; [Deierborg, Tomas] Lund Univ, Dept Expt Med Sci, Expt Neuroinflammat Lab, BMC B11, S-22184 Lund, Sweden; [Burguillos, Miguel Angel] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England		Burguillos, MA (corresponding author), Queen Mary Univ London, Blizard Inst, Ctr Neurosci & Trauma, London E1 2AT, England.; Burguillos, MA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.	m.burguillos@qmul.ac.uk	Garcia, Miguel Angel Burguillos/N-4806-2019; Liu, Zhuo-Hao/C-6758-2011; CARRILLO JIMENEZ, ALEJANDRO/H-9351-2015	Burguillos, Miguel Angel/0000-0002-3165-9997; Nomura, Koji/0000-0002-5912-074X; Liu, Zhuo-Hao/0000-0003-4079-8697; Chau, Chi Cheng/0000-0002-3134-6798; CARRILLO JIMENEZ, ALEJANDRO/0000-0002-3023-4268; Brown, Guy/0000-0002-3610-1730; Vilalta, Anna/0000-0002-2183-072X	Spanish Ministerio de Educacion, Cultura y DeporteSpanish Government; Spanish Ministerio (MINECO/FEDER, UE), Blizard Research Theme grants, Blizard Institute, Queen Mary University of London [SAF2015-64171R]; Barts Charity Centre for Trauma Sciences (C4TS); Wellcome Trust Institutional Strategic Support Fund (ISSF)Wellcome Trust; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MR/L010593/1] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/L010593/1] Funding Source: researchfish	We thank Drs B. Joseph, D. Sheer and M. Branco for providing us with reagents. A.C.-J. is supported by a pre-doctoral fellowship from Spanish Ministerio de Educacion, Cultura y Deporte. This work has been supported by grants from the Spanish Ministerio SAF2015-64171R (MINECO/FEDER, UE), Blizard Research Theme grants, Blizard Institute, Queen Mary University of London. M. A. B has been funded by the Barts Charity Centre for Trauma Sciences (C4TS) and the Wellcome Trust Institutional Strategic Support Fund (ISSF).	Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113; Bergold PJ, 2016, EXP NEUROL, V275, P367, DOI 10.1016/j.expneurol.2015.05.024; Boza-Serrano A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0156-0; Brazinova A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0133-z; Brown GC, 2014, NAT REV NEUROSCI, V15, P209, DOI 10.1038/nrn3710; Burguillos MA, 2015, CELL REP, V10, P1626, DOI 10.1016/j.celrep.2015.02.012; Butenschon J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-015-0268-x; Byrnes KR, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-130; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Chen L, 2015, J NEUROPATH EXP NEUR, V74, P557, DOI 10.1097/NEN.0000000000000199; Colnot C, 1998, DEV DYNAM, V211, P306, DOI 10.1002/(SICI)1097-0177(199804)211:4<306::AID-AJA2>3.0.CO;2-L; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Didangelos A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21607; DODD J, 1986, J EXP BIOL, V124, P225; Doverhag C, 2010, NEUROBIOL DIS, V38, P36, DOI 10.1016/j.nbd.2009.12.024; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Ferrini F, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/429815; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Funasaka T, 2014, GLYCOBIOLOGY, V24, P886, DOI 10.1093/glycob/cwu086; Hanamsagar R, 2012, TRENDS IMMUNOL, V33, P333, DOI 10.1016/j.it.2012.03.001; Hayward Jin Hee, 2014, Exp Neurobiol, V23, P138, DOI 10.5607/en.2014.23.2.138; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Jeon SB, 2010, J IMMUNOL, V185, P7037, DOI 10.4049/jimmunol.1000154; Jha MK, 2016, BIOCHEM PHARMACOL, V103, P1, DOI 10.1016/j.bcp.2015.11.003; Ji XC, 2015, CELL MOL NEUROBIOL, V35, P881, DOI 10.1007/s10571-015-0182-x; Kim CC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0581-z; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Leffler H, 2002, GLYCOCONJUGATE J, V19, P433, DOI 10.1023/B:GLYC.0000014072.34840.04; Li Y, 2008, J IMMUNOL, V181, P2781, DOI 10.4049/jimmunol.181.4.2781; Liu ZH, 2015, J NEUROSCI, V35, P12733, DOI 10.1523/JNEUROSCI.0605-15.2015; MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650; Massa SM, 2010, J CLIN INVEST, V120, P1774, DOI 10.1172/JCI41356; Morganti JM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148001; Mostacada K, 2015, EXP NEUROL, V271, P390, DOI 10.1016/j.expneurol.2015.07.006; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Neher JJ, 2013, P NATL ACAD SCI USA, V110, pE4098, DOI 10.1073/pnas.1308679110; Newlaczyl AU, 2011, CANCER LETT, V313, P123, DOI 10.1016/j.canlet.2011.09.003; Pajoohesh-Ganji A, 2012, BRAIN RES, V1475, P96, DOI 10.1016/j.brainres.2012.07.058; Park C, 2008, NEUROSCI LETT, V431, P123, DOI 10.1016/j.neulet.2007.11.057; Parpura V, 2010, BRAIN RES REV, V63, P83, DOI 10.1016/j.brainresrev.2009.11.008; Pearce N, 2015, NEUROBIOL AGING, V36, P1383, DOI 10.1016/j.neurobiolaging.2014.12.024; Pesheva P, 2000, NEUROSCI LETT, V293, P37, DOI 10.1016/S0304-3940(00)01499-3; Santos D, 2016, BRAIN RES, V1636, P93, DOI 10.1016/j.brainres.2016.01.051; Shan RZ, 2016, J NEUROTRAUM, V33, P49, DOI 10.1089/neu.2014.3811; Shen YF, 2016, CLIN CHIM ACTA, V456, P75, DOI 10.1016/j.cca.2016.02.029; Shin T, 2013, ACTA HISTOCHEM, V115, P407, DOI 10.1016/j.acthis.2012.11.010; Sirko S, 2015, GLIA, V63, P2340, DOI 10.1002/glia.22898; Sundblad V, 2011, HISTOL HISTOPATHOL, V26, P247, DOI 10.14670/HH-26.247; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; Yu ZQ, 2012, ANN CLIN LAB SCI, V42, P26; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247	61	71	71	4	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JAN 27	2017	7								41689	10.1038/srep41689			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	EJ2DM	WOS:000393020100001	28128358	Green Published, Green Accepted, gold			2022-02-06	
J	Spaite, DW; Hu, CC; Bobrow, BJ; Chikani, V; Barnhart, B; Gaither, JB; Denninghoff, KR; Adelson, PD; Keim, SM; Viscusi, C; Mullins, T; Sherrill, D				Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Adelson, P. David; Keim, Samuel M.; Viscusi, Chad; Mullins, Terry; Sherrill, Duane			The Effect of Combined Out-of-Hospital Hypotension and Hypoxia on Mortality in Major Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Scientific Sessions of the American-Heart-Association and American-Stroke-Association / Resuscitation Science Symposium	NOV 15-19, 2014	Chicago, IL	Amer Heart Assoc, Amer Stroke Assoc			SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; SECONDARY INSULTS; PROGNOSTIC VALUE; MANAGEMENT; HYPOXEMIA; CHILDREN; IMPACT; DEATH	Study objective: Survival is significantly reduced by either hypotension or hypoxia during the out-of-hospital management of major traumatic brain injury. However, only a handful of small studies have investigated the influence of the combination of both hypotension and hypoxia occurring together. In patients with major traumatic brain injury, we evaluate the associations between mortality and out-of-hospital hypotension and hypoxia separately and in combination. Methods: All moderate or severe traumatic brain injury cases in the preimplementation cohort of the Excellence in Prehospital Injury Care study (a statewide, before/after, controlled study of the effect of implementing the out-of-hospital traumatic brain injury treatment guidelines) from January 1, 2007, to March 31, 2014, were evaluated (exclusions: <10 years, out-of-hospital oxygen saturation <= 10%, and out-of-hospital systolic blood pressure <40 or >200 mm Hg). The relationship between mortality and hypotension (systolic blood pressure <90 mm Hg) or hypoxia (saturation <90%) was assessed with multivariable logistic regression, controlling for Injury Severity Score, head region severity, injury type (blunt versus penetrating), age, sex, race, ethnicity, payer, interhospital transfer, and trauma center. Results: Among the 13,151 patients who met inclusion criteria (median age 45 years; 68.6% men), 11,545 (87.8%) had neither hypotension nor hypoxia, 604 (4.6%) had hypotension only, 790 (6.0%) had hypoxia only, and 212 (1.6%) had both hypotension and hypoxia. Mortality for the 4 study cohorts was 5.6%, 20.7%, 28.1%, and 43.9%, respectively. The crude and adjusted odds ratios for death within the cohorts, using the patients with neither hypotension nor hypoxia as the reference, were 4.4 and 2.5, 6.6 and 3.0, and 13.2 and 6.1, respectively. Evaluation for an interaction between hypotension and hypoxia revealed that the effects were additive on the log odds of death. Conclusion: In this statewide analysis of major traumatic brain injury, combined out-of-hospital hypotension and hypoxia were associated with significantly increased mortality. This effect on survival persisted even after controlling for multiple potential confounders. In fact, the adjusted odds of death for patients with both hypotension and hypoxia were more than 2 times greater than for those with either hypotension or hypoxia alone. These findings seem supportive of the emphasis on aggressive prevention and treatment of hypotension and hypoxia reflected in the current emergency medical services traumatic brain injury treatment guidelines but clearly reveal the need for further study to determine their influence on outcome.	[Spaite, Daniel W.; Hu, Chengcheng; Bobrow, Bentley J.; Chikani, Vatsal; Barnhart, Bruce; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad] Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA; [Adelson, P. David] Univ Arizona, Coll Med, Barrow Neurol Inst, Phoenix Childrens Hosp, Phoenix, AZ USA; [Adelson, P. David] Univ Arizona, Coll Med, Dept Child Hlth Neurosurg, Phoenix, AZ USA; [Spaite, Daniel W.; Bobrow, Bentley J.; Gaither, Joshua B.; Denninghoff, Kurt R.; Keim, Samuel M.; Viscusi, Chad] Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85721 USA; [Hu, Chengcheng; Sherrill, Duane] Univ Arizona, Coll Publ Hlth, Tucson, AZ USA; [Bobrow, Bentley J.; Chikani, Vatsal; Mullins, Terry] Arizona Dept Hlth Serv, Bur EMS & Trauma Syst, Phoenix, AZ USA		Spaite, DW (corresponding author), Univ Arizona, Coll Med, Arizona Emergency Med Res Ctr, Phoenix, AZ 85004 USA.; Spaite, DW (corresponding author), Univ Arizona, Coll Med, Dept Emergency Med, Tucson, AZ 85721 USA.	dan@aemrc.arizona.edu	Adelson, David/W-2083-2019	Chikani, Vatsal/0000-0003-0904-7887; Spaite, Daniel/0000-0003-2601-6476	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS071049] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071049] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P199; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; COOKE RS, 1995, INJURY, V26, P395, DOI 10.1016/0020-1383(95)00003-R; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Finkelstein E., 2006, INCIDENCE EC BURDEN; Frieden T.R., 2015, CDC NIH REP C, P1, DOI [10.3171/2009.10.JNS091500, DOI 10.3171/2009.10.JNS091500]; GENTLEMAN D, 1992, INT SURG, V77, P297; Glance LG, 2001, J TRAUMA, V51, P725, DOI 10.1097/00005373-200110000-00017; Haddad Samir, 2005, Middle East Journal of Anesthesiology, V18, P45; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; JEFFREYS RV, 1981, LANCET, V2, P459; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MacKenzie EJ, 2010, J TRAUMA, V69, P1, DOI 10.1097/TA.0b013e3181e03a21; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MAYER TA, 1985, ANN EMERG MED, V14, P1178, DOI 10.1016/S0196-0644(85)81025-8; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; McSwain NE, 2004, J TRAUMA, V57, P8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; R Foundation, R LANG ENV STAT COMP; Ringdal KG, 2007, SCAND J SURG, V96, P325, DOI 10.1177/145749690709600412; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1986, INTRACRANIAL PRESSUR, P675; Shutter LA, 2008, ANN EMERG MED, V51, pS37, DOI 10.1016/j.annemergmed.2007.11.013; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Spaite DW, 2014, ACAD EMERG MED, V21, P818, DOI 10.1111/acem.12411; Spaite DW, 1993, PREHOSP DISASTER MED, V8, pS35; Stassen W, 2014, SAMJ S AFR MED J, V104, P424, DOI [10.7196/SAMJ.7494, 10.7196/samj.7494]; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WARDROPE J, 1992, BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016; Wood S.N., 2017, GEN ADDITIVE MODELS, DOI [10.1201/978131537027, DOI 10.1201/9781315370279]; Wood SN, 2013, BIOMETRIKA, V100, P221, DOI 10.1093/biomet/ass048; Wood SN, 2011, J R STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x	58	71	71	0	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2017	69	1					62	72		10.1016/j.annemergmed.2016.08.007			11	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	EG3XQ	WOS:000390978400014	27692683	Green Accepted, Bronze			2022-02-06	
J	Shi, W; Huang, CJ; Xu, XD; Jin, GH; Huang, RQ; Huang, JF; Chen, YN; Ju, SQ; Wang, Y; Shi, YW; Qin, JB; Zhang, YQ; Liu, QQ; Wang, XB; Zhang, XH; Chen, J				Shi, W.; Huang, C. J.; Xu, X. D.; Jin, G. H.; Huang, R. Q.; Huang, J. F.; Chen, Y. N.; Ju, S. Q.; Wang, Y.; Shi, Y. W.; Qin, J. B.; Zhang, Y. Q.; Liu, Q. Q.; Wang, X. B.; Zhang, X. H.; Chen, J.			Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury	ACTA BIOMATERIALIA			English	Article						Traumatic brain injury; Transplantation; hUC-MSCs; Astrocytes; CXCR4/SDF-1axis; Neuronal differentiation; Peptide hydrogel	BONE-MARROW; IN-VITRO; REACTIVE ASTROCYTES; ADULT BRAIN; THERAPY; BDNF; RECOVERY; MODEL; DIFFERENTIATION; PROLIFERATION	Due to the poor self-regeneration of brain tissue, stem cell transplantation therapy is purported to enable the replacement of lost neurons after traumatic brain injury (TBI). The main challenge of brain regeneration is whether the transplanted cells can survive and carry out neuronal functions in the lesion area. The brain is a complex neuronal network consisting of various types of cells that significantly influence on each other, and the survival of the implanted stem cells in brain is critically influenced by the surrounding cells. Although stem cell-based therapy is developing rapidly, most previous studies just focus on apply single type of stem cells as cell source. Here, we found that co-culturing human umbilical cord mesenchymal stem cells (hUC-MSCs) directly with the activated astrocytes benefited to the proliferation and neuron differentiation of hUC-MSCs in vitro. In this study, hUC-MSCs and the activated astrocytes were seeded in RADA16-BDNF peptide scaffold (R-B-SPH scaffold), a specifical self-assembling peptide hydrogel, in which the environment promoted the differentiation of typical neuron-like cells with neurites extending in three-dimensional directions. Moreover, the results showed co-culture of hUC-MSCs and activated astrocytes promoted more BDNF secretion which may benefit to both neural differentiation of ectogenic hUC-MSCs and endogenic neurogenesis. In order to promote migration of the transplanted hUC-MSCs to the host brain, the hUC-MSCs were forced with CXC chemokine receptor 4 (CXCR4). We found that the moderate-sized lesion cavity, but not the large cavity caused by TBI was repaired via the transplantation of hUC-MSCscxcR4 and activated astrocytes embedded in R-B-SPH scaffolds. The functional neural repair for TBI demonstrated in this study is mainly due to the transplantation system of double cells, hUC-MSCs and activated astrocytes. We believe that this novel cell transplantation system offers a promising treatment option for cell replacement therapy for TBI. Statement of Significance In this reach, we specifically linked RGIDKRHWNSQ a functional peptide derived from BDNF, to the C-terminal of RADARADARADARADA (RADA16) to structure a functional self-assembling peptide hydro gel scaffold, RADA16-BDNF (R-B-SPH scaffold) for the better transplantation of the double cell unit. Also, the novel scaffold was used as cell-carrier for transplantation double cell unit (hUC-MSCs/astrocyte) for treating traumatic brain injury. The results of this study showing that R-B-SPH scaffold was pliancy and flexibility to fit the brain lesion cavity and promotes the outgrowth of axons and dendrites of the neurons derived from hUC-MSCs in vitro and in vivo, indicating the 3D R-B-SPH scaffold provided a suitable microenvironment for hUC-MSC survival, proliferation and differentiation. Also, our results showing the double-cells transplantation system (hUC-MSC5/astrocyte) may be a novel cell-based therapeutic strategy for neuroregeneration after TBI with potential value for clinical application. (C) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Shi, W.; Xu, X. D.; Chen, Y. N.; Liu, Q. Q.; Chen, J.] Nantong Univ, Dept Neurosurg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China; [Jin, G. H.; Qin, J. B.; Zhang, X. H.] Nantong Univ, Sch Med, Dept Anat & Neurobiol, Nantong 226001, Peoples R China; [Huang, C. J.] First Peoples Hosp Wujiang, Dept Neurosurg, Suzhou 215200, Peoples R China; [Shi, W.] Xinhua Hosp Kazak Autonomous Prefecture Ili, Dept Neurosurg, Sinkiang 835000, Peoples R China; [Shi, W.; Huang, C. J.; Ju, S. Q.] Nantong Univ, Dept Lab Surg, Affiliated Hosp, Nantong 226001, Peoples R China; [Huang, R. Q.] Fudan Univ, Minist Educ, Key Lab Smart Drug Delivery, Shanghai 201203, Peoples R China; [Huang, R. Q.] Fudan Univ, Sch Pharm, Dept Pharmaceut, PLA, Shanghai 201203, Peoples R China; [Wang, Y.] Fudan Univ, Ctr Anal & Measurement, Shanghai 200433, Peoples R China; [Huang, J. F.] Nantong Univ, Affiliated Hosp, Dept Pathol & Clin Biobank, Nantong 226001, Peoples R China; [Shi, Y. W.] Nantong Univ, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Peoples R China; [Zhang, Y. Q.] Nantong Univ, Affiliated Hosp, Dept Obstet & Gynecol, Nantong 226001, Peoples R China; [Wang, X. B.] Nantong Univ, Affiliated Hosp, Med Image Ctr, Nantong 226001, Peoples R China		Chen, J (corresponding author), Nantong Univ, Dept Neurosurg, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.; Zhang, XH (corresponding author), Nantong Univ, Dept Anat & Neurobiol, Nantong 226001, Jiangsu, Peoples R China.	zhangxinhua@ntu.edu.cn; ntfychenjian@126.com	Huang, Rongqin/C-4165-2014	Zhang, Xin-hua/0000-0002-5702-6733	National Natural Science Foundation of China - ChinaNational Natural Science Foundation of China (NSFC) [81271368]; Chinese Projects for Postdoctoral Science Funds - China [2014M561698]; Chinese Special Projects for Postdoctoral Science Funds - China [2015T80573]; Natural Science Foundation of Jiangsu Province - ChinaNatural Science Foundation of Jiangsu Province [BK2012654]; Jiangsu Planned Projects for Postdoctoral Research Funds - China [1401085B]; Application Research Project of Nantong City - China [HS12030]; Grand of Nantong University for innovation talent - China [CXZR201308]	The authors thank the Surgical Comprehensive Laboratory of the Affiliated Hospital of Nantong University for technical assistance and equipment support. This work was supported by the National Natural Science Foundation of China - China (grant no. 81271368); Chinese Projects for Postdoctoral Science Funds - China (No. 2014M561698); Chinese Special Projects for Postdoctoral Science Funds - China (No. 2015T80573); the Natural Science Foundation of Jiangsu Province - China (grant no. BK2012654); Jiangsu Planned Projects for Postdoctoral Research Funds - China (No. 1401085B); Application Research Project of Nantong City - China (Grant No. HS12030) and The Grand of Nantong University for innovation talent - China (Grant No. CXZR201308).	Bara JJ, 2014, STEM CELLS, V32, P1713, DOI 10.1002/stem.1649; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Bjorklund A, 2000, NATURE, V405, P892, DOI 10.1038/35016175; Boccazzi M, 2014, GLIA, V62, P428, DOI 10.1002/glia.22614; Bonilla C, 2009, BRAIN INJURY, V23, P760, DOI 10.1080/02699050903133970; Buffo A, 2010, BIOCHEM PHARMACOL, V79, P77, DOI 10.1016/j.bcp.2009.09.014; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chen LW, 2005, CURR DRUG TARGETS, V6, P821, DOI 10.2174/138945005774574506; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Conti L, 2006, BRAIN PATHOL, V16, P143, DOI 10.1111/j.1750-3639.2006.00009.x; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Delcroix GJR, 2010, BIOMATERIALS, V31, P2105, DOI 10.1016/j.biomaterials.2009.11.084; Dimmeler S, 2014, NAT MED, V20, P814, DOI 10.1038/nm.3627; Du JL, 2004, NATURE, V429, P878, DOI 10.1038/nature02618; England T, 2009, INT J STROKE, V4, P101, DOI 10.1111/j.1747-4949.2009.00253.x; Filous AR, 2010, DEV NEUROBIOL, V70, P826, DOI 10.1002/dneu.20820; Fobian K, 2010, J NEUROSCI RES, V88, P1170, DOI 10.1002/jnr.22285; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Gonfiotti A, 2014, LANCET, V383, P238, DOI 10.1016/S0140-6736(13)62033-4; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guzman R, 2008, STROKE, V39, P1300, DOI 10.1161/STROKEAHA.107.500470; Ihrie RA, 2011, NEURON, V70, P674, DOI 10.1016/j.neuron.2011.05.004; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Kim DK, 2016, P NATL ACAD SCI USA, V113, P170, DOI 10.1073/pnas.1522297113; Kim SS, 2008, STEM CELLS, V26, P2217, DOI 10.1634/stemcells.2008-0108; Lee J, 2008, TISSUE ENG PART B-RE, V14, P61, DOI 10.1089/teb.2007.0150; Li JY, 2015, J CRANIOFAC SURG, V26, P548, DOI 10.1097/SCS.0000000000001348; Luo ZL, 2012, CHEM SOC REV, V41, P4736, DOI 10.1039/c2cs15360b; Mojsilovic S, 2011, CELL TISSUE RES, V346, P305, DOI 10.1007/s00441-011-1284-5; Nakano M, 2016, SCI REP-UK, V6, DOI 10.1038/srep24805; Park HJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0180-4; Patel K, 2016, BRAIN RES, V1640, P104, DOI 10.1016/j.brainres.2016.01.055; Pelizzoni I, 2013, BBA-MOL BASIS DIS, V1832, P1326, DOI 10.1016/j.bbadis.2013.04.007; Raynald, 2016, BRAIN RES, V1634, P21, DOI 10.1016/j.brainres.2015.10.038; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Saracino GAA, 2013, CHEM SOC REV, V42, P225, DOI 10.1039/c2cs35065c; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Son BR, 2006, STEM CELLS, V24, P1254, DOI 10.1634/stemcells.2005-0271; Srikanth M, 2012, NAT REV NEUROL, V8, P307, DOI 10.1038/nrneurol.2012.76; Thomaidou D, 2014, METHODS MOL BIOL, V1210, P9, DOI 10.1007/978-1-4939-1435-7_2; Vazey EM, 2006, EXP NEUROL, V199, P384, DOI 10.1016/j.expneurol.2006.01.034; Wang FW, 2011, STEM CELL RES, V7, P41, DOI 10.1016/j.scr.2011.03.004; Yang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6627; Zhu J, 2005, CURR DRUG TARGETS, V6, P97, DOI 10.2174/1389450053345055	45	71	72	1	63	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	NOV	2016	45						247	261		10.1016/j.actbio.2016.09.001			15	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	EB3VZ	WOS:000387298300018	27592818				2022-02-06	
J	Bhomia, M; Balakathiresan, NS; Wang, KK; Papa, L; Maheshwari, RK				Bhomia, Manish; Balakathiresan, Nagaraja S.; Wang, Kevin K.; Papa, Linda; Maheshwari, Radha K.			A Panel of Serum MiRNA Biomarkers for the Diagnosis of Severe to Mild Traumatic Brain Injury in Humans	SCIENTIFIC REPORTS			English	Article							FIBRILLARY ACIDIC PROTEIN; INTRACRANIAL LESIONS; NEUROSURGICAL INTERVENTION; POTENTIAL BIOMARKERS; MICRORNAS; DISEASES; MODERATE; PLASMA	MicroRNAs (MiRNAs) are small endogenous RNA molecules and have emerged as novel serum diagnostic biomarkers for several diseases due to their stability and detection at minute quantities. In this study, we have identified a serum miRNA signature in human serum samples of mild to severe TBI, which can be used for diagnosis of mild and moderate TBI (MMTBI). Human serum samples of MMTBI, severe TBI (STBI), orthopedic injury and healthy controls were used and miRNA profiling was done using taqman real time PCR. The real time PCR data for the MMTBI, STBI and orthopedic injury was normalized to the control samples which showed upregulation of 39, 37 and 33 miRNAs in MMTBI, STBI and orthopedic injury groups respectively. TBI groups were compared to orthopedic injury group and an up-regulation of 18 and 20 miRNAs in MMTBI and STBI groups was observed. Among these, a signature of 10 miRNAs was found to be present in both MMTBI and STBI groups. These 10 miRNAs were validated in cerebrospinal fluid (CSF) from STBI and four miRNAs were found to be upregulated in CSF. In conclusion, we identified a subset of 10 unique miRNAs which can be used for diagnosis of MMTBI and STBI.	[Bhomia, Manish; Balakathiresan, Nagaraja S.; Maheshwari, Radha K.] Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Wang, Kevin K.] Univ Florida, McKnight Brain Inst, Dept Psychiat, Program Neurotrauma Neuroprote & Biomarker Res, Gainesville, FL 32611 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL 32806 USA		Bhomia, M (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	manish.bhomia.ctr@usuhs.edu	Bhomia, Manish/C-7683-2015; Balakathiresan, Nagaraja Sethuraman/O-3213-2019	Bhomia, Manish/0000-0003-2808-9927; Balakathiresan, Nagaraja Sethuraman/0000-0001-5756-6070; Wang, Kevin/0000-0002-9343-6473	defense medical research and development program (DMRDP)	The authors will like to thank Dr Claudia S. Robertson for her help in providing the STBI serum samples for this study. The authors also acknowledge Dr. Barbara Knollmann-Ritschel for her input into this study and careful review of the manuscript. The study was supported by a grant from defense medical research and development program (DMRDP) to Radha K. Maheshwari (Principal Investigator). The opinions expressed herein are those of authors and are not necessarily representative of those of the Uniformed Services University of the Health Sciences, Department of Defense or, the United States Army, Navy, or Air Force and DMRDP. The authors wish to dedicate this manuscript to Dr Radha K. Maheshwari, who passed away after the manuscript was submitted for review. He read and approved the initial version of the manuscript which was submitted for review.	Alevizos I, 2010, NAT REV RHEUMATOL, V6, P391, DOI 10.1038/nrrheum.2010.81; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; Balakathiresan NS, 2014, J PSYCHIATR RES, V57, P65, DOI 10.1016/j.jpsychires.2014.05.020; Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015; Burda JE, 2016, EXP NEUROL, V275, P305, DOI 10.1016/j.expneurol.2015.03.020; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Faul Mark, 2015, Handb Clin Neurol, V127, P3, DOI 10.1016/B978-0-444-52892-6.00001-5; Herring SA, 2011, MED SCI SPORTS EXERC, V43, P2412; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jin XF, 2013, CELL MOL NEUROBIOL, V33, P601, DOI 10.1007/s10571-013-9940-9; Kelly JP, 1997, NEUROLOGY, V48, P581; Liu L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103948; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Meissner L, 2016, J NEUROTRAUM, V33, P713, DOI 10.1089/neu.2015.4077; Mercier E, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1757; Nam JW, 2014, MOL CELL, V53, P1031, DOI 10.1016/j.molcel.2014.02.013; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2015, NEUROCRIT CARE, V22, P52, DOI 10.1007/s12028-014-0028-2; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Powers CJ, 2016, PHYSIOL GENOMICS, V48, P361, DOI 10.1152/physiolgenomics.00052.2015; Rao V, 2013, PSYCHOSOMATICS, V54, P403, DOI 10.1016/j.psym.2013.01.001; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rockhill CM, 2012, J NEUROTRAUM, V29, P1038, DOI 10.1089/neu.2010.1562; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112019; Siddeek B, 2014, MUTAT RES-GEN TOX EN, V764, P46, DOI 10.1016/j.mrgentox.2014.01.010; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018	30	71	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUN 24	2016	6								28148	10.1038/srep28148			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DP4RK	WOS:000378483300001	27338832	Green Published, gold			2022-02-06	
J	Raina, GB; Cersosimo, MG; Folgar, SS; Giugni, JC; Calandra, C; Paviolo, JP; Tkachuk, VA; Ramirez, CZ; Tschopp, AL; Calvo, DS; Pellene, LA; Roca, MCU; Velez, M; Giannaula, RJ; Pardal, MMF; Micheli, FE				Raina, Gabriela B.; Cersosimo, Maria G.; Folgar, Silvia S.; Giugni, Juan C.; Calandra, Cristian; Paviolo, Juan P.; Tkachuk, Veronica A.; Zuniga Ramirez, Carlos; Tschopp, Andrea L.; Calvo, Daniela S.; Pellene, Luis A.; Uribe Roca, Marcela C.; Velez, Miriam; Giannaula, Rolando J.; Fernandez Pardal, Manuel M.; Micheli, Federico E.			Holmes tremor Clinical description, lesion localization, and treatment in a series of 29 cases	NEUROLOGY			English	Article							HYPERTROPHIC OLIVARY DEGENERATION; MIDBRAIN TOXOPLASMA ABSCESS; BRAIN-STEM HEMORRHAGE; RUBRAL TREMOR; LEVODOPA; STIMULATION; SUPPRESSION; PET; CAVERNOMA; PATIENT	Objective:To describe the clinical features, etiology, findings from neuroimaging, and treatment results in a series of 29 patients with Holmes tremor (HT).Methods:A retrospective study was performed based on review of medical records and videos of patients with HT diagnosis.Results:A total of 16 women and 13 men were included. The mean age at the moment of CNS insult was 33.9 20.1 years (range 8-76 years). The most common causes were vascular (48.3%), ischemic, or hemorrhagic. Traumatic brain injury only represented 17.24%; other causes represented 34.5%. The median latency from lesion to tremor onset was 2 months (range 7 days-228 months). The most common symptoms/signs associated with HT were hemiparesis (62%), ataxia (51.7%), hypoesthesia (27.58%), dystonia (24.1%), cranial nerve involvement (24.1%), and dysarthria (24.1%). Other symptoms/signs were vertical gaze disorders (6.8%), bradykinesia/rigidity (6.8%), myoclonus (3.4%), and seizures (3.4%). Most of the patients had lesions involving more than one area. MRI showed lesions in thalamus or midbrain or cerebellum in 82.7% of the patients. Levodopa treatment was effective in 13 out of 24 treated patients (54.16%) and in 3 patients unilateral thalamotomy provided excellent results.Conclusions:The most common causes of HT in our series were vascular lesions. The most common lesion topography was mesencephalic, thalamic, or both. Treatment with levodopa and thalamic stereotactic lesional surgery seems to be effective.	[Raina, Gabriela B.; Cersosimo, Maria G.; Folgar, Silvia S.; Giugni, Juan C.; Calandra, Cristian; Paviolo, Juan P.; Tkachuk, Veronica A.; Tschopp, Andrea L.; Calvo, Daniela S.; Pellene, Luis A.; Micheli, Federico E.] Hosp Clin Jose San Martin, Caba, Buenos Aires, Argentina; [Uribe Roca, Marcela C.; Fernandez Pardal, Manuel M.] Hosp Britan, Caba, Buenos Aires, Argentina; [Giannaula, Rolando J.] Hosp Espanol, Caba, Buenos Aires, Argentina; [Zuniga Ramirez, Carlos] Hosp Civil Guadalajara Fray Antonio Alcalde, Movement Disorders & Neurodegenerat Dis Unit, Guadalajara, Jalisco, Mexico; [Velez, Miriam] Inst Ciencias Neurol Luis Trelles Montes, Lima, Peru		Micheli, FE (corresponding author), Hosp Clin Jose San Martin, Caba, Buenos Aires, Argentina.	fmicheli@fibertel.com.ar		Tschopp, Andrea Lorena/0000-0003-0838-8188; Zuniga-Ramirez, Carlos/0000-0003-4319-5875			ANDREW J, 1982, J NEUROL NEUROSUR PS, V45, P815, DOI 10.1136/jnnp.45.9.815; Aydin S, 2013, J NEUROL SURG PART A, V74, P271, DOI 10.1055/s-0032-1322549; Benedikt M., 1889, B MED, V3, P547; BIARY N, 1989, NEUROLOGY, V39, P103, DOI 10.1212/WNL.39.1.103; Boelmans K, 2012, MOVEMENT DISORD, V27, P1097, DOI 10.1002/mds.24005; Bolen RD, 2014, J NEUROL SCI, V347, P411, DOI 10.1016/j.jns.2014.10.039; Castrop F, 2013, MOVEMENT DISORD, V28, P1456, DOI 10.1002/mds.25398; Coumou AD, 2012, MOVEMENT DISORD, V27, P964, DOI 10.1002/mds.25039; de Mattos JP, 2002, ARQ NEURO-PSIQUIAT, V60, P525, DOI 10.1590/S0004-282X2002000400002; DEFER GL, 1994, J NEUROL NEUROSUR PS, V57, P987, DOI 10.1136/jnnp.57.8.987; DERECONDO A, 1993, REV NEUROL, V149, P46; Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303; Fahn S, 1986, MOVEMENT DISORD, V1, P299; FINDLEY LJ, 1980, BRIT MED J, V281, P1043, DOI 10.1136/bmj.281.6247.1043; Follett MA, 2014, NEUROMODULATION, V17, P289, DOI 10.1111/ner.12096; FUJIEDA T, 1974, BMJ-BRIT MED J, V1, P456, DOI 10.1136/bmj.1.5905.456-b; Gajos A, 2010, ACTA NEUROL SCAND, V122, P360, DOI 10.1111/j.1600-0404.2009.01319.x; HARMON R L, 1991, Brain Injury, V5, P213, DOI 10.3109/02699059109008092; Holmes G, 1904, BRAIN, V27, P327, DOI 10.1093/brain/27.3.327; Kim DG, 2009, MOVEMENT DISORD, V24, P463, DOI 10.1002/mds.22394; Kipfer S, 2013, MOVEMENT DISORD, V28, P1347, DOI 10.1002/mds.25621; KOPPEL BS, 1990, MOVEMENT DISORD, V5, P254, DOI 10.1002/mds.870050314; KREMER M, 1947, J NEUROL NEUROSUR PS, V10, P49, DOI 10.1136/jnnp.10.2.49; Lekoubou A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-37; Menon B, 2014, J MOV DISORD, V7, P22, DOI 10.14802/jmd.14005; MOSSUTOAGATIELLO L, 1993, J NEUROL, V241, P27, DOI 10.1007/BF00870668; Paviour DC, 2006, MOVEMENT DISORD, V21, P2260, DOI 10.1002/mds.20981; Pezzini A, 2002, PARKINSONISM RELAT D, V8, P177, DOI 10.1016/S1353-8020(01)00013-X; Raina GB, 2007, CLIN NEUROPHARMACOL, V30, P95, DOI 10.1097/01.WNF.0000240957.56939.E6; REMY P, 1995, NEUROLOGY, V45, P472, DOI 10.1212/WNL.45.3.472; Rieder CRM, 2003, ARQ NEURO-PSIQUIAT, V61, P473, DOI 10.1590/S0004-282X2003000300028; SAMIE MR, 1990, NEUROLOGY, V40, P62, DOI 10.1212/WNL.40.1.62; Shepherd GMG, 1997, MOVEMENT DISORD, V12, P432, DOI 10.1002/mds.870120327; Strecker K, 2007, EUR J NEUROL, V14, pE9, DOI 10.1111/j.1468-1331.2006.01665.x; Velez Miriam, 2002, Mov Disord, V17, P741, DOI 10.1002/mds.10224; Vidailhet M, 1998, MOVEMENT DISORD, V13, P49; Walker M, 2007, MOVEMENT DISORD, V22, P272, DOI 10.1002/mds.21271; Woo JH, 2013, ANN REHABIL MED-ARM, V37, P591, DOI 10.5535/arm.2013.37.4.591; YUILL GM, 1980, BRIT MED J, V281, P1428, DOI 10.1136/bmj.281.6252.1428-b; Zhong J, 2007, CHINESE MED J-PEKING, V120, P2059, DOI 10.1097/00029330-200711020-00025	40	71	78	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	MAR 8	2016	86	10					931	938		10.1212/WNL.0000000000002440			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DG1NA	WOS:000371833600009	26865524	Green Published			2022-02-06	
J	LaRoche, AA; Nelson, LD; Connelly, PK; Walter, KD; McCrea, MA				LaRoche, Ashley A.; Nelson, Lindsay D.; Connelly, Peter K.; Walter, Kevin D.; McCrea, Michael A.			Sport-Related Concussion Reporting and State Legislative Effects	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						sport concussion; head injury; mild traumatic brain injury; legislation; reporting	HIGH-SCHOOL; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; HEAD-INJURY; EPIDEMIOLOGY; COLLEGIATE; KNOWLEDGE; RECOVERY; RECOMMENDATIONS	Objective:To investigate concussion rates and reporting frequencies in high school and collegiate athletes in 2013, compare results to those obtained from 1999 to 2002, and examine to what extent the 2012 Wisconsin state concussion law affected reporting in 2013.Design:Retrospective 2013 survey compared with prior survey.Setting:High schools and colleges in the Milwaukee, Wisconsin, area.Participants:Athletes (N = 784) from multiple sports were surveyed in 2013. Football players (N = 1532) from 1999 to 2002 completed the same measure.Main Outcome Measures:Both surveys assessed concussion history, concussion incidence during the current season, whether incident concussions were reported, who concussions were reported to, and reasons for not reporting. The 2013 survey also assessed awareness of the Wisconsin state law and its effect on reporting.Results:Rates of concussion in the surveyed season were comparable to previous findings from 1999 to 2002 (16.6% vs 15.3%, P = 0.558). Notably, athletes were significantly more likely to report their concussions in 2013 (70.6% vs 47.3% previously, P = 0.011). Among high school athletes surveyed, 59.5% were aware of the Wisconsin state law, with 55.1% stating it would make them more likely to report a concussion.Conclusions:Rates of concussion for 1 sport season have not changed significantly over the past 14 years. The percentage of concussions that are reported to someone has increased significantly. Awareness of the Wisconsin state law does not fully account for the increase in concussion reporting.	[LaRoche, Ashley A.; Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Nelson, Lindsay D.; McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [Connelly, Peter K.] Med Coll Wisconsin, Phys Med & Rehabil, Milwaukee, WI 53226 USA; [Walter, Kevin D.] Childrens Hosp Wisconsin, Dept Orthoped Surg, Milwaukee, WI 53201 USA		LaRoche, AA (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 8701 W Watertown Plank Rd, Milwaukee, WI 53226 USA.	alaroche@mcw.edu		LaRoche, Ashley/0000-0003-0197-0853	US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-12-1-0004]; Clinical and Translational Science Institute [1UL1-RR031973 (-01)]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000055] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR031973] Funding Source: NIH RePORTER	Supported by the US Army Medical Research and Materiel Command under Award No. W81XWH-12-1-0004 and the Clinical and Translational Science Institute Grant No. 1UL1-RR031973 (-01). Opinions, interpretations, conclusions, and recommendations are those of the author and are not necessarily endorsed by the US Army. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant No. 8UL1TR000055. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.	Armstrong C, 2014, AM FAM PHYSICIAN, V89, P585; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Clay MB, 2013, J CHIROPR MED, V12, P230, DOI 10.1016/j.jcm.2012.11.005; Converse PD, 2008, AM J EVAL, V29, P99, DOI 10.1177/1098214007313228; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; LaRoche A., 2014, END OF SEASON SURVEY; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Nelson LD, 2013, NEUROPSYCHOL REV, V23, P285, DOI 10.1007/s11065-013-9240-7; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; WIAA, 2011, WIAA CONCUSSION POLI	36	71	71	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2016	26	1					33	39		10.1097/JSM.0000000000000192			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	DA2JB	WOS:000367620000005	25894530	Green Accepted			2022-02-06	
J	Al Nimer, F; Thelin, E; Nystrom, H; Dring, AM; Svenningsson, A; Piehl, F; Nelson, DW; Bellander, BM				Al Nimer, Faiez; Thelin, Eric; Nystrom, Harriet; Dring, Ann M.; Svenningsson, Anders; Piehl, Fredrik; Nelson, David W.; Bellander, Bo-Michael			Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light	PLOS ONE			English	Article							NEURON-SPECIFIC ENOLASE; AMYOTROPHIC-LATERAL-SCLEROSIS; GLASGOW COMA SCALE; HEAD-INJURY; PREDICTIVE-VALUE; BARRIER CHANGES; SEVERITY SCORE; AXONAL INJURY; S100B LEVELS; BLOOD	Traumatic brain injury (TBI) is a common cause of death and disability, worldwide. Early determination of injury severity is essential to improve care. Neurofilament light (NF-L) has been introduced as a marker of neuroaxonal injury in neuroinflammatory/-degenerative diseases. In this study we determined the predictive power of serum (s-) and cerebrospinal fluid (CSF-) NF-L levels towards outcome, and explored their potential correlation to diffuse axonal injury (DAI). A total of 182 patients suffering from TBI admitted to the neurointensive care unit at a level 1 trauma center were included. S-NF-L levels were acquired, together with S100B and neuron-specific enolase (NSE). CSF-NF-L was measured in a subcohort (n = 84) with ventriculostomies. Clinical and neuro-radiological parameters, including computerized tomography (CT) and magnetic resonance imaging, were included in the analyses. Outcome was assessed 6 to 12 months after injury using the Glasgow Outcome Score (1-5). In univariate proportional odds analyses mean s-NF-L, -S100B and -NSE levels presented a pseudo-R-2 Nagelkerke of 0.062, 0.214 and 0.074 in correlation to outcome, respectively. In a multivariate analysis, in addition to a model including core parameters (pseudo-R-2 0.33 towards outcome; Age, Glasgow Coma Scale, pupil response, Stockholm CT score, abbreviated injury severity score, S100B), S-NF-L yielded an extra 0.023 pseudo-R-2 and a significantly better model (p = 0.006) No correlation between DAI or CT assessed-intracranial damage and NF-L was found. Our study thus demonstrates that SNF-L correlates to TBI outcome, even if used in models with S100B, indicating an independent contribution to the prediction, perhaps by reflecting different pathophysiological processes, not possible to monitor using conventional neuroradiology. Although we did not find a predictive value of NF-L for DAI, this cannot be completely excluded. We suggest further	[Al Nimer, Faiez; Piehl, Fredrik] Karolinska Inst, Dept Clin Neurosci, Neuroimmunol Unit, Stockholm, Sweden; [Thelin, Eric; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden; [Nystrom, Harriet] Karolinska Inst, Dept Clin Neurosci, Neuroradiol Sect, Stockholm, Sweden; [Dring, Ann M.; Svenningsson, Anders] Umea Univ, Dept Pharmacol & Clin Neurosci, Umea, Sweden; [Nelson, David W.] Karolinska Inst, Dept Physiol & Pharmacol, Sect Anesthesiol & Intens Care, Stockholm, Sweden		Thelin, E (corresponding author), Karolinska Inst, Dept Clin Neurosci, Neurosurg Sect, Stockholm, Sweden.	eric.thelin@ki.se	Nimer, Faiez Al/ABB-9465-2020; Thelin, Eric Peter/K-2144-2012	Thelin, Eric Peter/0000-0002-2338-4364; Nelson, David/0000-0003-2530-8207; Al Nimer, Faiez/0000-0003-0937-5995; Svenningsson, Anders/0000-0003-0663-2220; Piehl, Fredrik/0000-0001-8329-5219	Roche Diagnostics	The authors have read the journal's policy and have the following competing interests: BM and ET received funds from Roche Diagnostics as compensation for lectures concerning other procedures/products in the past. However, the authors certify that this did not in any way influence their objectivity in the current study. Concerning the funding, authors ET and BM wish to declare that this did not alter the authors' adherence to PLOS ONE policies on sharing data and materials.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Al Nimer F, 2013, BRAIN BEHAV IMMUN, V27, P109, DOI 10.1016/j.bbi.2012.10.002; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Barry DM, 2007, EXP CELL RES, V313, P2110, DOI 10.1016/j.yexcr.2007.03.011; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bergman AS, 2009, VERIFICATIO IN PRESS; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Cheng F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106680; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Disanto G, 2016, J NEUROL NEUROSUR PS, V87, P126, DOI 10.1136/jnnp-2014-309690; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Ghanem G, 2001, INT J CANCER, V94, P586, DOI 10.1002/ijc.1504; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; JENNETT B, 1975, LANCET, V1, P480; Khademi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063172; Kleindienst Andrea, 2010, Cardiovasc Psychiatry Neurol, V2010, P801295, DOI 10.1155/2010/801295; Kuhle J, 2015, J NEUROL NEUROSUR PS, V86, P273, DOI 10.1136/jnnp-2013-307454; Kuhle J, 2013, MULT SCLER J, V19, P1597, DOI 10.1177/1352458513482374; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Magnoni S, 2012, BRAIN, V135, P1268, DOI 10.1093/brain/awr286; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Raj R, 2014, J NEUROTRAUM, V31, P1721, DOI 10.1089/neu.2014.3361; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schmidt FM, 2015, WORLD J BIOL PSYCHIA, V16, P106, DOI 10.3109/15622975.2014.952776; Sharma R, 2012, CURR NEUROL NEUROSCI, V12, P560, DOI 10.1007/s11910-012-0301-8; Shin SS, 2012, J NEUROSURG, V116, P1062, DOI 10.3171/2012.1.JNS111282; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smit LHM, 2005, INT J BIOL MARKER, V20, P34, DOI 10.1177/172460080502000106; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; SMITH ME, 1984, NEUROCHEM RES, V9, P1493, DOI 10.1007/BF00964675; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Strathmann FG, 2014, CLIN BIOCHEM, V47, P876, DOI 10.1016/j.clinbiochem.2014.01.028; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Teunissen CE, 2012, MULT SCLER J, V18, P552, DOI 10.1177/1352458512443092; Thelin EP, 2012, S100B IS IMPORTANT O; Thelin EP, 2014, NEUROCRIT CARE, V20, P217, DOI 10.1007/s12028-013-9916-0; Thelin EP, 2013, J NEUROTRAUM, V30, P519, DOI 10.1089/neu.2012.2553; Tortelli R, 2012, EUR J NEUROL, V19, P1561, DOI 10.1111/j.1468-1331.2012.03777.x; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Vajtr D, 2012, Soud Lek, V57, P7; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wolf H, 2015, J NEUROTRAUM, V32, P23, DOI 10.1089/neu.2013.3202; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277	70	71	71	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2015	10	7							e0132177	10.1371/journal.pone.0132177			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	CN1CS	WOS:000358154400103	26136237	Green Published, Green Submitted, gold			2022-02-06	
J	Phang, I; Werndle, MC; Saadoun, S; Varsos, G; Czosnyka, M; Zoumprouli, A; Papadopoulos, MC				Phang, Isaac; Werndle, Melissa C.; Saadoun, Samira; Varsos, Georgios; Czosnyka, Marek; Zoumprouli, Argyro; Papadopoulos, Marios C.			Expansion Duroplasty Improves Intraspinal Pressure, Spinal Cord Perfusion Pressure, and Vascular Pressure Reactivity Index in Patients with Traumatic Spinal Cord Injury: Injured Spinal Cord Pressure Evaluation Study	JOURNAL OF NEUROTRAUMA			English	Article						decompression; duroplasty; perfusion pressure; spinal cord injury	BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; INTRACRANIAL-PRESSURE; ANIMAL-MODEL; COMPENSATION; MULTICENTER; REPAIR	We recently showed that, after traumatic spinal cord injury (TSCI), laminectomy does not improve intraspinal pressure (ISP), spinal cord perfusion pressure (SCPP), or the vascular pressure reactivity index (sPRx) at the injury site sufficiently because of dural compression. This is an open label, prospective trial comparing combined bony and dural decompression versus laminectomy. Twenty-one patients with acute severe TSCI had re-alignment of the fracture and surgical fixation; 11 had laminectomy alone (laminectomy group) and 10 had laminectomy and duroplasty (laminectomy+duroplasty group). Primary outcomes were magnetic resonance imaging evidence of spinal cord decompression (increase in intradural space, cerebrospinal fluid around the injured cord) and spinal cord physiology (ISP, SCPP, sPRx). The laminectomy and laminectomy+duroplasty groups were well matched. Compared with the laminectomy group, the laminectomy+duroplasty group had greater increase in intradural space at the injury site and more effective decompression of the injured cord. In the laminectomy+duroplasty group, ISP was lower, SCPP higher, and sPRx lower, (i.e., improved vascular pressure reactivity), compared with the laminectomy group. Laminectomy+duroplasty caused cerebrospinal fluid leak that settled with lumbar drain in one patient and pseudomeningocele that resolved completely in five patients. We conclude that, after TSCI, laminectomy+duroplasty improves spinal cord radiological and physiological parameters more effectively than laminectomy alone.	[Phang, Isaac; Werndle, Melissa C.; Saadoun, Samira; Papadopoulos, Marios C.] St Georges Univ London, Acad Neurosurg Unit, London SW17 0RE, England; [Varsos, Georgios; Czosnyka, Marek] Univ Cambridge, Dept Clin Neurosci, Cambridge, England; [Zoumprouli, Argyro] St George Hosp, Dept Anaesthesia, London, England		Papadopoulos, MC (corresponding author), St Georges Univ London, Dept Neurosurg, Room 0-136 Jenner Wing,Cranmer Terrace, London SW17 0RE, England.	mpapadop@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176; Zoumprouli, Argyro/0000-0003-0890-690X; Saadoun, Samira/0000-0002-5480-5678; czosnyka, marek/0000-0003-2446-8006	Neurosciences Research Foundation; London Deanery; Royal College of Surgeons of England; Housham Fund; Fletcher Fund; Guthy Jackson Foundation; Wings for Life Spinal Cord Research Foundation; A. G. Leventis Foundation Scholarship; Charter Studentship from St. Edmund's College, Cambridge	Financial support was provided by the Neurosciences Research Foundation (MCP, MCW, IP), London Deanery (IP, MCW), the Royal College of Surgeons of England (MCW), the Housham Fund (MCW), and the Fletcher Fund (MCP). MCP is supported by the Guthy Jackson Foundation and by the Wings for Life Spinal Cord Research Foundation. MC is National Institute for Health Research principal investigator on cerebrospinal dynamics. GV is supported by an A. G. Leventis Foundation Scholarship and a Charter Studentship from St. Edmund's College, Cambridge. The funders had no input at any stage of this research.	Ackerman P, 2010, SPINAL CORD, V48, P380, DOI 10.1038/sc.2009.140; Awwad Waleed, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS261, DOI 10.1007/s00590-013-1409-5; Cao Y., 2011, TOPICS SPINAL CORD I, V16, P10, DOI DOI 10.1310/SCI1604-10; Cripps RA, 2011, SPINAL CORD, V49, P493, DOI 10.1038/sc.2010.146; Curt A, 2008, J NEUROTRAUM, V25, P677, DOI 10.1089/neu.2007.0468; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Ditunno JF, 2000, SPINAL CORD, V38, P234, DOI 10.1038/sj.sc.3100993; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Fehlings MG, 2010, SPINE, V35, pS166, DOI 10.1097/BRS.0b013e3181f386f6; FERNANDEZ E, 1985, ACTA NEUROCHIR, V76, P145, DOI 10.1007/BF01418478; Huang X, 2010, INT J MED SCI, V7, P385; Iannotti C, 2006, J NEUROTRAUM, V23, P853, DOI 10.1089/neu.2006.23.853; Jones CF, 2012, SPINE, V37, pE1422, DOI 10.1097/BRS.0b013e31826ba7cd; Kirshblum SC, 2011, J SPINAL CORD MED, V34, P547, DOI 10.1179/107902611X13186000420242; Kornblith LZ, 2013, J TRAUMA ACUTE CARE, V75, P1060, DOI 10.1097/TA.0b013e3182a74a5b; Martirosyan NL, 2011, J NEUROSURG-SPINE, V15, P238, DOI 10.3171/2011.4.SPINE10543; Papadopoulos MC, 2012, LANCET NEUROL, V11, P535, DOI 10.1016/S1474-4422(12)70133-3; Perkins P., 1998, INJURY, V19, P397; Ropper Allan H, 2014, Pract Neurol, V14, P152, DOI 10.1136/practneurol-2014-000811; Rowland JW, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.11.E2; Smith JS, 2010, J BONE JOINT SURG AM, V92A, P1206, DOI 10.2106/JBJS.I.00740; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Walters B, 2013, SIGHT SOUND, V23, P82; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	27	71	74	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 15	2015	32	12					865	874		10.1089/neu.2014.3668			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	CV0NZ	WOS:000363948800001	25705999	Green Published, Green Accepted, Green Submitted			2022-02-06	
J	Daneshvar, DH; Goldstein, LE; Kiernan, PT; Stein, TD; McKee, AC				Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.			Post-traumatic neurodegeneration and chronic traumatic encephalopathy	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Traumatic brain injury; Chronic traumatic encephalopathy; Axonal injury; Brain trauma; Posttraumatic neurodegeneration; Motor neuron disease; Tau protein; Concussion; Blast and impact neurotrauma	AMYOTROPHIC-LATERAL-SCLEROSIS; REPETITIVE HEAD-INJURY; BRAIN-INJURY; ALZHEIMERS-DISEASE; AMYLOID-BETA; SUBDURAL-HEMATOMA; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; DEPRESSIVE SYMPTOMS	Traumatic brain injury (TBI) is a leading cause of mortality and morbidity around the world. Concussive and subconcussive forms of closed-head injury due to impact or blast neurotrauma represent the most common types of TBI in civilian and military settings. It is becoming increasingly evident that TBI can lead to persistent, long-term debilitating effects, and in some cases, progressive neurodegeneration and chronic traumatic encephalopathy (CTE). The epidemiological literature suggests that a single moderate-to-severe TBI may be associated with accelerated neurodegeneration and increased risk of Alzheimer's disease, Parkinson's disease, or motor neuron disease. However, the pathologic phenotype of these post-traumatic neurodegenerations is largely unknown and there may be pathobiological differences between post-traumatic disease and the corresponding sporadic disorder. By contrast, the pathology of CTE is increasingly well known and is characterized by a distinctive pattern of progressive brain atrophy and accumulation of hyperphosphorylated tau neurofibrillary and glial tangles, dystrophic neurites, 43 kDa TAR DNA-binding protein (TDP-43) neuronal and glial aggregates, microvasculopathy, myelinated axonopathy, neuroinflammation, and white matter degeneration. Clinically, CTE is associated with behavioral changes, executive dysfunction, memory deficits, and cognitive impairments that begin insidiously and most often progress slowly over decades. Although research on the long-term effects of TBI is advancing quickly, the incidence and prevalence of post-traumatic neurodegeneration and CTE are unknown. Critical knowledge gaps include elucidation of pathogenic mechanisms, identification of genetic risk factors, and clarification of relevant variables-including age at exposure to trauma, history of prior and subsequent head trauma, substance use, gender, stress, and comorbidities-all of which may contribute to risk profiles and the development of post-traumatic neurodegeneration and CTE. This article is part of a Special Issue entitled 'Traumatic Brain Injury'. Published by Elsevier Inc.	[Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Chron Traumat Encephalopathy Program, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Daneshvar, Daniel H.; Goldstein, Lee E.; Kiernan, Patrick T.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Goldstein, Lee E.; Stein, Thor D.; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Goldstein, Lee E.] Boston Univ, Photon Ctr, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Biomed Engn, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Elect & Comp Engn, Boston, MA 02115 USA; [Goldstein, Lee E.] Boston Univ, Dept Mech Engn, Boston, MA 02115 USA; [Stein, Thor D.; McKee, Ann C.] VA Boston Healthcare Syst, Jamaica Plain, MA 02130 USA		McKee, AC (corresponding author), Boston Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02118 USA.			Daneshvar, Daniel/0000-0003-3691-9513; Stein, Thor/0000-0001-6954-4477	Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Neurological Diseases and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1U01NS086659-01]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [R01 [AG1649]]; Sports Legacy Institute; National Operating Committee on Standards for Athletic Equipment; National Football League; Andlinger Foundation; WWE; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	We gratefully acknowledge the use of resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA). We also gratefully acknowledge the help of all members of the Boston University and the Boston VA, and the individuals and families whose participation and contributions made this work possible. This work was supported by the Department of Veterans Affairs; Veterans Affairs Biorepository (CSP 501); Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS) Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C); National Institute of Neurological Diseases and Stroke 1U01NS086659-01, National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846; supplement 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study R01 [AG1649]; Sports Legacy Institute; and National Operating Committee on Standards for Athletic Equipment. This work was also supported by an unrestricted gift from the National Football League, the Andlinger Foundation and the WWE.	Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Baker M, 1999, HUM MOL GENET, V8, P711, DOI 10.1093/hmg/8.4.711; Barnes DE, 2014, NEUROLOGY, V83, P312, DOI 10.1212/WNL.0000000000000616; Bekris LM, 2010, J GERIATR PSYCH NEUR, V23, P228, DOI 10.1177/0891988710383572; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; Bennett RE, 2013, J NEUROPATH EXP NEUR, V72, P396, DOI 10.1097/NEN.0b013e31828e24ab; Binazzi A, 2009, AMYOTROPH LATERAL SC, V10, P361, DOI 10.3109/17482960802382313; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; >Centers for Disease Control and Prevention (CDC) the National Institutes of Health (NIH) the Department of Defense (DoD) & the Department of Veterans Affairs (VA) Leadership Panel, 2013, C TRAUM BRAIN INJ US; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Czell D, 2013, NEURODEGENER DIS, V12, P150, DOI 10.1159/000345835; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; Di Maria E, 2000, ANN NEUROL, V47, P374, DOI 10.1002/1531-8249(200003)47:3<374::AID-ANA15>3.3.CO;2-#; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Ford JH, 2013, J NEUROTRAUM, V30, P1683, DOI 10.1089/neu.2012.2535; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; Gasparini L, 2007, NEURODEGENER DIS, V4, P236, DOI 10.1159/000101848; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Gentleman SM, 1997, NEUROREPORT, V8, P1519, DOI 10.1097/00001756-199704140-00039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GORELL JM, 1994, NEUROLOGY, V44, P1865, DOI 10.1212/WNL.44.10.1865; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Horsburgh K, 2000, NEUROPATH APPL NEURO, V26, P124, DOI 10.1046/j.1365-2990.2000.026002124.x; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Institute of Medicine (US) Committee on Gulf War and Health, 2008, GULF WAR AND HLTH, V7; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Jicha GA, 2010, J ALZHEIMERS DIS, V19, P253, DOI 10.3233/JAD-2010-1237; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Kenney K., 2014, ALZHEIMERS DEMENT, V10, pP843; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lee SE, 2013, ALZ DIS ASSOC DIS, V27, P302, DOI 10.1097/WAD.0b013e31828cc357; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Logan SM, 2001, J ATHL TRAINING, V36, P433; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McKee A., 2013, ALZHEIMERS DEMENT, V9, P438, DOI [10.1016/j.jalz.2013.05.868, DOI 10.1016/JJALZ.2013.05.868]; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Miele VJ, 2004, MED SCI SPORT EXER, V36, P1852, DOI 10.1249/01.MSS.0000145470.16938.7A; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morales R, 2009, CNS NEUROL DISORD-DR, V8, P363, DOI 10.2174/187152709789541998; Mori T, 2006, ACTA NEUROCHIR SUPPL, V96, P40; Mott F. W., 1919, WAR NEUROSES SHELL S; Mott FW, 1916, LANCET, V1, P331; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Randolph C, 2013, J INT NEUROPSYCH SOC, V19, P873, DOI 10.1017/S1355617713000805; Rosenbohm A, 2014, J NEUROL, V261, P283, DOI 10.1007/s00415-013-7185-7; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, NEUROLOGY, V49, P30, DOI 10.1212/WNL.49.1.30; Sephton C.F., 2012, TDP 43 CENTRAL NERVO; Sephton CF, 2011, J BIOL CHEM, V286, P1204, DOI 10.1074/jbc.M110.190884; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Strickland D, 1996, ACTA NEUROL SCAND, V94, P45, DOI 10.1111/j.1600-0404.1996.tb00038.x; Strong MJ, 2011, J MOL NEUROSCI, V45, P648, DOI 10.1007/s12031-011-9609-0; Sullivan S, 2013, J NEUROTRAUM, V30, P538, DOI 10.1089/neu.2012.2594; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tremblay S., 2014, BRAIN, V236; Uryu K, 2006, AM J PATHOL, V168, P947, DOI 10.2353/ajpath.2006.050770; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; Vandrovcova J, 2010, CURR ALZHEIMER RES, V7, P726, DOI 10.2174/156720510793611619; Waite LM, 1997, MED J AUSTRALIA, V167, P429, DOI 10.5694/j.1326-5377.1997.tb126655.x; Yang ZH, 2014, J CEREBR BLOOD F MET, V34, P1444, DOI 10.1038/jcbfm.2014.105; Zeng S, 2014, GENET TEST MOL BIOMA, V18, P202, DOI 10.1089/gtmb.2013.0421; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029	120	71	71	5	76	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		81	90		10.1016/j.mcn.2015.03.007			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CK7FT	WOS:000356398900003	25758552				2022-02-06	
J	Gavvala, J; Abend, N; LaRoche, S; Hahn, C; Herman, ST; Claassen, J; Macken, M; Schuele, S; Gerard, E				Gavvala, Jay; Abend, Nicholas; LaRoche, Suzette; Hahn, Cecil; Herman, Susan T.; Claassen, Jan; Macken, Micheal; Schuele, Stephan; Gerard, Elizabeth		Critical Care EEG Monitoring Res	Continuous EEG monitoring: A survey of neurophysiologists and neurointensivists	EPILEPSIA			English	Article						Continuous video-EEG monitoring; Nonconvulsive seizures; Quantitative EEG	NONCONVULSIVE STATUS EPILEPTICUS; CRITICALLY-ILL PATIENTS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; QUANTITATIVE EEG; CONTINUOUS ELECTROENCEPHALOGRAPHY; ELECTROGRAPHIC SEIZURES; ICU; IDENTIFICATION; HEMORRHAGE	ObjectiveContinuous EEG monitoring (cEEG) of critically ill adults is being used with increasing frequency, and practice guidelines on indications for cEEG monitoring have recently been published. However, data describing the current practice of cEEG in critically ill adults is limited. We aimed to describe the current practice of cEEG monitoring in adults in the United States. MethodsA survey assessing cEEG indications and procedures was sent to one intensivist and one neurophysiologist responsible for intensive care unit (ICU) cEEG at 151 institutions in the United States. At some institutions only one physician could be identified. ResultsOne hundred thirty-seven physicians from 97 institutions completed the survey. Continuous EEG is utilized by nearly all respondents to detect nonconvulsive seizures (NCS) in patients with altered mental status following clinical seizures, intra cerebral hemorrhage (ICH), traumatic brain injury, and cardiac arrest, as well as to characterize abnormal movements suspected to be seizures. The majority of physicians monitor comatose patients for 24-48h. In an ideal situation with unlimited resources, 18% of respondents would increase cEEG duration. Eighty-six percent of institutions have an on-call EEG technologist available 24/7 for new patient hookups, but only 26% have technologists available 24/7 in-house. There is substantial variability in who reviews EEG and how frequently it is reviewed as well as use of quantitative EEG. SignificanceAlthough there is general agreement regarding the indications for ICU cEEG, there is substantial interinstitutional variability in how the procedure is performed.	[Gavvala, Jay; Macken, Micheal; Schuele, Stephan; Gerard, Elizabeth] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA; [Abend, Nicholas] Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Abend, Nicholas] Univ Penn, Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; [Abend, Nicholas] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [LaRoche, Suzette] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Hahn, Cecil] Hosp Sick Children, Div Neurol, Toronto, ON M5G 1X8, Canada; [Hahn, Cecil] Univ Toronto, Toronto, ON, Canada; [Herman, Susan T.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Claassen, Jan] Columbia Univ Coll Phys & Surg, Dept Neurol, Neurol Inst, New York, NY 10032 USA		Gerard, E (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Neurol, 710 North Lake Shore Dr 1114, Chicago, IL 60611 USA.	e-gerard@northwestern.edu	Gavvala, Jay/ABF-5040-2021; Hahn, Cecil/J-3372-2016; Hahn, Cecil D./F-6218-2011; Claassen, Jan/AAA-5451-2020	Gavvala, Jay/0000-0002-9392-6608; Hahn, Cecil/0000-0002-0887-8761; Hahn, Cecil D./0000-0002-0887-8761; gerard, elizabeth/0000-0003-3062-8360; Herman, Susan/0000-0002-6556-083X	UCB PharmaUCB Pharma SA; Lundbeck, IncLundbeck Corporation; National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Fidelity Biosciences Research Initiative; Epilepsy Therapy Development Project	Dr. Schuele is on the speakers' bureau for GlaxoSmithKline and Lundbeck. Dr. Herman is on the advisory board for Eisai, Inc., consults for Biotie, Inc., and provides research support for UCB Pharma, Lundbeck, Inc, National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS), Fidelity Biosciences Research Initiative, and Epilepsy Therapy Development Project. Dr. Macken is a consultant and on the speakers bureau for Cyberonics, Lundbeck, and UCB Pharma. None of the other authors have any conflicts of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.	Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Akman CI, 2011, EPILEPSY RES, V93, P66, DOI 10.1016/j.eplepsyres.2010.10.018; Baruch Y, 1999, HUM RELAT, V52, P421, DOI 10.1177/001872679905200401; Brophy GM, 2012, NEUROCRIT CARE, V17, P3, DOI 10.1007/s12028-012-9695-z; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Claassen J, 2004, CLIN NEUROPHYSIOL, V115, P2699, DOI 10.1016/j.clinph.2004.06.017; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; Diedler J, 2009, NEUROCRIT CARE, V11, P210, DOI 10.1007/s12028-009-9236-6; Finnigan S, 2013, CLIN NEUROPHYSIOL, V124, P10, DOI 10.1016/j.clinph.2012.07.003; Finnigan SP, 2007, CLIN NEUROPHYSIOL, V118, P2525, DOI 10.1016/j.clinph.2007.07.021; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Huang ZC, 2002, CLIN NEUROPHYSIOL, V113, P446, DOI 10.1016/S1388-2457(02)00012-3; Jordan KG, 2004, J CLIN NEUROPHYSIOL, V21, P341; Kennedy JD, 2012, CURR NEUROL NEUROSCI, V12, P419, DOI 10.1007/s11910-012-0289-0; Kurtz P, 2014, INTENS CARE MED, V40, P228, DOI 10.1007/s00134-013-3149-8; Kurtz P, 2009, CURR OPIN CRIT CARE, V15, P99, DOI 10.1097/MCC.0b013e3283294947; LABAR DR, 1991, ELECTROEN CLIN NEURO, V78, P325, DOI 10.1016/0013-4694(91)90094-K; Newey CR, 2013, NEUROCRIT CARE, V18, P261, DOI 10.1007/s12028-011-9650-4; Ney JP, 2013, NEUROLOGY, V81, P2002, DOI 10.1212/01.wnl.0000436948.93399.2a; Nulty DD, 2008, ASSESS EVAL HIGH EDU, V33, P301, DOI 10.1080/02602930701293231; Oddo M, 2009, CRIT CARE MED, V37, P2051, DOI 10.1097/CCM.0b013e3181a00604; Pensirikul AD, 2013, J CLIN NEUROPHYSIOL, V30, P371, DOI 10.1097/WNP.0b013e31829de01c; Rathakrishnan R, 2011, NEUROCRIT CARE, V14, P152, DOI 10.1007/s12028-010-9495-2; Richardson JohnT.E., 2005, ASSESS EVAL HIGH EDU, V30, DOI [10.1080/02602930500099193, DOI 10.1080/02602930500099193]; Riviello JJ, 2013, NEUROCRIT CARE, V18, P193, DOI 10.1007/s12028-012-9790-1; Scheuer ML, 2004, J CLIN NEUROPHYSIOL, V21, P353; Stewart CP, 2010, NEUROLOGY, V75, P1501, DOI 10.1212/WNL.0b013e3181f9619e; Tichauer KM, 2009, J APPL PHYSIOL, V106, P1506, DOI 10.1152/japplphysiol.91156.2008; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; U. S. News Best Hospitals: Neurology & Neurosurgery, US NEWS WORLD REP 20; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; WINER JW, 1991, NEUROSURGERY, V29, P739, DOI 10.1227/00006123-199111000-00016; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117; Young GB, 1996, NEUROLOGY, V47, P83	40	71	72	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	NOV	2014	55	11					1864	1871		10.1111/epi.12809			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AT9DE	WOS:000345227400029	25266728				2022-02-06	
J	Castellino, FJ; Chapman, MP; Donahue, DL; Thomas, S; Moore, EE; Wohlauer, MV; Fritz, B; Yount, R; Ploplis, V; Davis, P; Evans, E; Walsh, M				Castellino, Francis J.; Chapman, Michael P.; Donahue, Deborah L.; Thomas, Scott; Moore, Ernest E.; Wohlauer, Max V.; Fritz, Braxton; Yount, Robert; Ploplis, Victoria; Davis, Patrick; Evans, Edward; Walsh, Mark			Traumatic brain injury causes platelet adenosine diphosphate and arachidonic acid receptor inhibition independent of hemorrhagic shock in humans and rats	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; coagulopathy; platelet; thrombelastography; ADP receptor	ACUTE COAGULOPATHY; DYSFUNCTION; ACTIVATION; THROMBELASTOGRAPHY; HYPOPERFUSION; REPLACE; TISSUE	BACKGROUND: Coagulopathy in traumatic brain injury (CTBI) is a well established phenomenon, but its mechanism is poorly understood. Various studies implicate protein C activation related to the global insult of hemorrhagic shock or brain tissue factor release with resultant platelet dysfunction and depletion of coagulation factors. We hypothesized that the platelet dysfunction of CTBI is a distinct phenomenon from the coagulopathy following hemorrhagic shock. METHODS: We used thrombelastography with platelet mapping as a measure of platelet function, assessing the degree of inhibition of the adenosine diphosphate (ADP) and arachidonic acid (AA) receptor pathways. First, we studied the early effect of TBI on platelet inhibition by performing thrombelastography with platelet mapping on rats. We then conducted an analysis of admission blood samples from trauma patients with isolated head injury (n = 70). Patients in shock or on clopidogrel or aspirin were excluded. RESULTS: In rats, ADP receptor inhibition at 15 minutes after injury was 77.6% +/- 6.7% versus 39.0% +/- 5.3% for controls (p < 0.0001). Humans with severe TBI (Glasgow Coma Scale [GCS] score <= 8) showed an increase in ADP receptor inhibition at 93.1% (interquartile range [IQR], 44.8-98.3%; n = 29) compared with 56.5% (IQR, 35-79.1%; n = 41) in milder TBI and 15.5% (IQR, 13.2-29.1%) in controls (p = 0.0014 and p < 0.0001, respectively). No patient had significant hypotension or acidosis. Parallel trends were noted in AA receptor inhibition. CONCLUSION: Platelet ADP and AA receptor inhibition is a prominent early feature of CTBI in humans and rats and is linked to the severity of brain injury in patients with isolated head trauma. This phenomenon is observed in the absence of hemorrhagic shock or multisystem injury. Thus, TBI alone is shown to be sufficient to induce a profound platelet dysfunction. (J Trauma Acute Care Surg. 2014; 76: 1169-1176. Copyright (C) 2014 by Lippincott Williams & Wilkins)	[Castellino, Francis J.; Donahue, Deborah L.; Ploplis, Victoria; Davis, Patrick; Walsh, Mark] Univ Notre Dame, WM Keck Ctr Transgene Res, Notre Dame, IN 46556 USA; [Thomas, Scott; Yount, Robert; Evans, Edward; Walsh, Mark] Mem Hosp South Bend, Emergency Trauma Ctr, South Bend, IN 46601 USA; [Fritz, Braxton; Davis, Patrick; Walsh, Mark] Indiana Univ Sch Med, South Bend, IN USA; [Chapman, Michael P.; Moore, Ernest E.; Wohlauer, Max V.] Univ Colorado, Dept Surg, Boulder, CO 80309 USA; [Chapman, Michael P.; Moore, Ernest E.; Wohlauer, Max V.] Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; [Chapman, Michael P.] Georgia Hlth Sci Univ, Dept Surg, Augusta, GA USA		Chapman, MP (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St, Denver, CO 80204 USA.	michael.chapman@ucdenver.edu; ernest.moore@dhha.org		Walsh, Mark/0000-0002-5795-1144	Haemonetics Corporation, Niles, Illinois; NIH(NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL019982]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL019982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM049222, T32GM008315] Funding Source: NIH RePORTER	This study received research support from the Haemonetics Corporation, Niles, Illinois. The animal portion of this study was funded in part by NIH(NHLBI) grant #HL019982.	Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Bochsen Louise, 2007, Thromb J, V5, P3, DOI 10.1186/1477-9560-5-3; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Chen LQ, 2004, J THORAC CARDIOV SUR, V128, P425, DOI 10.1016/j.jtcvs.2004.02.019; Cohan MJ, 2007, J TRAUMA, V63, P1254, DOI 10.1097/TA.0b013e318156ee4c; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Eachempati Soumitra R, 2003, Surg Infect (Larchmt), V4, P193, DOI 10.1089/109629603766956988; FitzSullivan E, 2005, AM J SURG, V190, P941, DOI 10.1016/j.amjusrg.2005.08.024; Gonzalez E, 2010, SEMIN THROMB HEMOST, V36, P723, DOI 10.1055/s-0030-1265289; Hoffman M, 2009, STROKE, V40, P2882, DOI 10.1161/STROKEAHA.109.555433; Holcomb JB, 2012, ANN SURG, V256, P476, DOI 10.1097/SLA.0b013e3182658180; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Johansson PI, 2012, J THROMB HAEMOST, V10, P207, DOI 10.1111/j.1538-7836.2011.04589.x; Kutcher ME, 2013, J TRAUMA, V73, P13; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, J TRAUMA, V69, P1410, DOI 10.1097/TA.0b013e3181cdae81; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maeda T, 1997, ACT NEUR S, V70, P102; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Ostrowski SR, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-64; PARETI FI, 1980, AM J MED, V69, P235, DOI 10.1016/0002-9343(80)90383-6; Schrieber M, 2007, J TRAUMA, V63, P1261; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Spinella PC, 2011, J TRAUMA, V71, pS343, DOI 10.1097/TA.0b013e318227ef2d; Stein SC, 2012, NEUROSURGERY, V70, P1345; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050	28	71	78	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2014	76	5					1169	1175		10.1097/TA.0000000000000216			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	AG6YA	WOS:000335563800001	24747445	Green Accepted			2022-02-06	
J	Dougan, BK; Horswill, MS; Geffen, GM				Dougan, Brooke K.; Horswill, Mark S.; Geffen, Gina M.			Athletes' Age, Sex, and Years of Education Moderate the Acute Neuropsychological Impact of Sports-Related Concussion: A Meta-analysis	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article							TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; HIGH-SCHOOL; NEUROCOGNITIVE PERFORMANCE; PROFESSIONAL FOOTBALL; POSTURAL STABILITY; CEREBRAL CONCUSSION; SYMPTOMS; RECOVERY; COLLEGIATE		[Dougan, Brooke K.; Horswill, Mark S.; Geffen, Gina M.] Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia		Dougan, BK (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	brooke.dougan@uqconnect.edu.au	Horswill, Mark/J-9029-2019	Horswill, Mark/0000-0002-0286-6292	Australian Postgraduate AwardAustralian Government	This research forms part of the doctoral thesis of the first author, submitted to the University of Queensland, and was supported by an Australian Postgraduate Award. This research received no specific grant from any other funding agency, commercial or not-for-profit sectors. We confirm that the information in this manuscript and the manuscript itself has never been published either electronically or in print and that none of the authors has any financial or other conflict of interest affecting this manuscript. We acknowledge the help of John Guimelli in checking the data for accuracy.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Baillargeon A, 2012, BRAIN INJURY, V26, P211, DOI 10.3109/02699052.2012.654590; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Bruce JM, 2004, NEUROLOGY, V63, P1516; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cohen J., 2013, STAT POWER ANAL BEHA; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Ferguson RJ, 1999, NEUROPSYCHOLOGY, V13, P582, DOI 10.1037/0894-4105.13.4.582; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hedges L.V., 1985, STAT METHODS META AN; Higgins, 2005, COMPREHENSIVE META A; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnson PD, 2002, CLIN J SPORT MED, V12, P12, DOI 10.1097/00042752-200201000-00006; Kaplan RF, 2009, J CLIN EXP NEUROPSYC, V31, P868, DOI 10.1080/13803390802635174; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kontos AP, 2011, BRAIN INJURY, V25, P1234, DOI 10.3109/02699052.2011.608209; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lipsey M.W., 2001, PRACTICAL META ANAL; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Nassiri JD, 2002, MIL MED, V167, P873, DOI 10.1093/milmed/167.10.873; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/S0165-3806(96)00098-3; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Ratcliff JJ, 2007, BRAIN INJURY, V21, P1023, DOI 10.1080/02699050701633072; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, CYBERPSYCHOL BEHAV, V9, P188, DOI 10.1089/cpb.2006.9.188; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Sosnoff JJ, 2008, EXP BRAIN RES, V187, P563, DOI 10.1007/s00221-008-1324-x; Sosnoff JJ, 2007, NEUROPSYCHOLOGY, V21, P796, DOI 10.1037/0894-4105.21.6.796; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Tsushima WT, 2009, BRAIN INJURY, V23, P809, DOI 10.1080/02699050903200530; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	125	71	71	0	31	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2014	20	1					64	80		10.1017/S1355617712001464			17	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	AC2VC	WOS:000332373400009	23375058	Green Submitted			2022-02-06	
J	McIntosh, AS; Patton, DA; Frechede, B; Pierre, PA; Ferry, E; Barthels, T				McIntosh, Andrew S.; Patton, Declan A.; Frechede, Bertrand; Pierre, Paul-Andre; Ferry, Edouard; Barthels, Tobias			The biomechanics of concussion in unhelmeted football players in Australia: a case-control study	BMJ OPEN			English	Article							TRAUMATIC BRAIN-INJURY; HEAD IMPACTS; RECONSTRUCTION; SPORT; RUGBY	Objective: Concussion is a prevalent brain injury in sport and the wider community. Despite this, little research has been conducted investigating the dynamics of impacts to the unprotected human head and injury causation in vivo, in particular the roles of linear and angular head acceleration. Setting: Professional contact football in Australia. Participants: Adult male professional Australian rules football players participating in 30 games randomly selected from 103 games. Cases selected based on an observable head impact, no observable symptoms (eg, loss-of-consciousness and convulsions), no on-field medical management and no injury recorded at the time. Primary and secondary outcome measures: A data set for no-injury head impact cases comprising head impact locations and head impact dynamic parameters estimated through rigid body simulations using the MAthematical DYnamic MOdels (MADYMO) human facet model. This data set was compared to previously reported concussion case data. Results: Qualitative analysis showed that the head was more vulnerable to lateral impacts. Logistic regression analyses of head acceleration and velocity components revealed that angular acceleration of the head in the coronal plane had the strongest association with concussion; tentative tolerance levels of 1747 rad/s(2) and 2296 rad/s(2) were reported for a 50% and 75% likelihood of concussion, respectively. The mean maximum resultant angular accelerations for the concussion and no-injury cases were 7951 rad/s(2) (SD 3562 rad/s(2)) and 4300 rad/s(2) (SD 3657 rad/s(2)), respectively. Linear acceleration is currently used in the assessment of helmets and padded headgear. The 50% and 75% likelihood of concussion values for resultant linear head acceleration in this study were 65.1 and 88.5 g, respectively. Conclusions: As hypothesised by Holbourn over 70 years ago, angular acceleration plays an important role in the pathomechanics of concussion, which has major ramifications in terms of helmet design and other efforts to prevent and manage concussion.	[McIntosh, Andrew S.] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia; [McIntosh, Andrew S.] Monash Univ, Monash Injury Res Inst, Melbourne, Vic 3004, Australia; [Patton, Declan A.] Univ New S Wales, Fac Sci, Sydney, NSW, Australia; [Frechede, Bertrand] Univ Lyon, F-69622 Villeurbanne, France; [Frechede, Bertrand] Univ Lyon 1, F-69622 Villeurbanne, France; [Frechede, Bertrand] LBMC, UMR T9406, IFSTTAR, F-69675 Bron, France; [Pierre, Paul-Andre] Techspace Aero, Safran Grp Milmort, Liege, Belgium; [Ferry, Edouard] Ecoparc Affaires Sologne, CEDREM, Neung Sur Beuvron, France; [Barthels, Tobias] Stryker GmbH & Co, Duisburg, Germany		McIntosh, AS (corresponding author), Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia.	as.mcintosh@bigpond.com	FRECHEDE, Bertrand/H-3091-2018	FRECHEDE, Bertrand/0000-0002-9292-3544			[Anonymous], 2009, PASW STAT; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Beusenberg MC., 2000, P INT RES C BIOM IMP; Bewick V, 2005, CRIT CARE, V9, P112, DOI 10.1186/cc3045; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cheng HM, 1996, PROCEEDINGS OF THE 1996 FIFTEENTH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE, P251, DOI 10.1109/SBEC.1996.493162; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Frechede B, 2007, 20 INT TECHN C ENH S, P1; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Funk JR, 2006, INT BIOM RES P 34 IN, P1; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hardy WN, STAPP CAR CRASH J; Holbourn AHS., LANCET; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McIntosh AS, 2009, MED SCI SPORT EXER, V41, P306, DOI 10.1249/MSS.0b013e3181864bee; McIntosh AS, 2011, BRIT J SPORT MED, V45, P1258, DOI 10.1136/bjsports-2011-090509; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 1993, 37 STAPP CAR CRASH C, P43; Menard S.W., 1995, APPL LOGISTIC REGRES; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Neale M, 2004, INT RES COUNC BIOM I; Newman J., 1986, INT IRCOBI C BIOM IM, V14, P121; Newman J., 1999, INT RES COUNC BIOM I, P17; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peng CYJ, 2002, J EDUC RES, V96, P3, DOI 10.1080/00220670209598786; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schmitt K-U, 2007, TRAUMA BIOMECHANICS, P55; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	45	71	72	0	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2014	4	5							e005078	10.1136/bmjopen-2014-005078			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AI6IQ	WOS:000336976900050	24844272	Green Submitted, gold, Green Published			2022-02-06	
J	Zuckerman, SL; Apple, RP; Odom, MJ; Lee, YM; Solomon, GS; Sills, AK				Zuckerman, Scott L.; Apple, Rachel P.; Odom, Mitchell J.; Lee, Young M.; Solomon, Gary S.; Sills, Allen K.			Effect of sex on symptoms and return to baseline in sport-related concussion Clinical article	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						concussion; sports; sex; mild traumatic brain injury; symptoms; return to baseline; trauma	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; NEUROPSYCHOLOGICAL FUNCTION; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; GENDER; SPECIFICITY; SENSITIVITY; PERFORMANCE; ZURICH	Object. Sport-related concussions (SRCs) among youth athletes represent a significant public health concern. Prior research suggests that females fare worse symptomatically after an SRC. The authors aimed to assess sex differences in number, severity, and resolution of postconcussive symptoms using reliable change index (RCI) methodology applied to days to return to symptom baseline. Methods. Between 2009 and 2011, 740 youth athletes completed valid neurocognitive and symptom testing before and after an SRC using Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT). A total of 122 female and 122 male athletes were matched on number of prior concussions, age, and number of days to first postconcussion test. At baseline and postconcussion, the authors compared each of the individual 22 symptoms on ImPACT to calculate individual symptom severity and aggregate symptom severity, or the Total Symptom Score (TSS). When comparing individual symptoms, the significance level for the comparison of each symptom was set at 0.05/22 = 0.0023. When comparing aggregate symptom severity, or TSS, a single value was compared, requiring an alpha set to 0.05. The number of days to return to baseline TSS was compared using RCI methods set at the 80% confidence interval, equal to a raw score point value of 9.18 on the TSS. Results. At baseline, females reported a greater severity for the symptom, "sleeping less than usual," compared with males (0.88 +/- 1.49 vs 0.31 +/- 0.86, p < 0.001). However, no other individual symptom severity differences were noted before or after SRC. At baseline, females exhibited a statistically significant greater aggregate symptom severity than males (7.24 +/- 10.22 vs 4.10 +/- 6.52, p = 0.005). Greater aggregate symptom severity for females was also found postconcussion (21.38 +/- 19.02 vs 16.80 +/- 17.07, p = 0.049). Females took longer to return to baseline TSS (9.1 +/- 7.1 days vs 7.0 +/- 5.1 days, p = 0.013). Conclusions. The results of this retrospective study indicate that females endorse a greater severity of symptoms at baseline and postconcussion than males without significantly different symptom profiles. Furthermore, after suffering an SRC, females take longer to return to their baseline symptom level.	[Zuckerman, Scott L.; Solomon, Gary S.; Sills, Allen K.] Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN USA; [Apple, Rachel P.] Vanderbilt Univ, Sch Med, Dept Med & Pediat, Nashville, TN 37232 USA; [Odom, Mitchell J.; Lee, Young M.] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA		Zuckerman, SL (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurol Surg, T-4224 Med Ctr N, Nashville, TN 37232 USA.	scott.zuckerman@vanderbilt.edu	Solomon, Gary/K-9011-2019; Meijer, Anna/K-5118-2016				ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BROSHEK DK, 2012, J CHILD NEUROL; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2011, PM&R, V3, pS440, DOI 10.1016/j.pmrj.2011.07.013; Cantu RC, 2010, PM&R, V2, P1088, DOI 10.1016/j.pmrj.2010.07.483; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M, 2010, TRAUMATIC BRAIN INJU; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Granito V.J., 2002, J SPORT BEHAV, V25, P243; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; RUTHERFORD WH, 1977, LANCET, V1, P1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Weiss E, 2003, NEUROSCI LETT, V344, P169, DOI 10.1016/S0304-3940(03)00406-3; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139; [No title captured]	44	71	71	0	21	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JAN	2014	13	1					72	81		10.3171/2013.9.PEDS13257			10	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pediatrics; Surgery	281GM	WOS:000329088000013	24206343				2022-02-06	
J	Burke, JF; Stulc, JL; Skolarus, LE; Sears, ED; Zahuranec, DB; Morgenstern, LB				Burke, James F.; Stulc, Jessica L.; Skolarus, Lesli E.; Sears, Erika D.; Zahuranec, Darin B.; Morgenstern, Lewis B.			Traumatic brain injury may be an independent risk factor for stroke	NEUROLOGY			English	Article							ISCHEMIC-STROKE; SPONTANEOUS DISSECTION; ADMINISTRATIVE DATA; UNITED-STATES; YOUNG-ADULTS; ALGORITHMS; ACCURACY; EPILEPSY; CHILDREN; ARTERIES	Objective: To explore whether traumatic brain injury (TBI) may be a risk factor for subsequent ischemic stroke. Methods: Patients with any emergency department visit or hospitalization for TBI (exposed group) or non-TBI trauma (control) based on statewide emergency department and inpatient databases in California from 2005 to 2009 were included in a retrospective cohort. TBI was defined using the Centers for Disease Control definition. Our primary outcome was subsequent hospitalization for acute ischemic stroke. The association between TBI and stroke was estimated using Cox proportional hazards modeling adjusting for demographics, vascular risk factors, comorbidities, trauma severity, and trauma mechanism. Results: The cohort included a total of 1,173,353 trauma subjects, 436,630 (37%) with TBI. The patients with TBI were slightly younger than the controls (mean age 49.2 vs 50.3 years), less likely to be female (46.8% vs 49.3%), and had a higher mean injury severity score (4.6 vs 4.1). Subsequent stroke was identified in 1.1% of the TBI group and 0.9% of the control group over a median follow-up period of 28 months (interquartile range 14-44). After adjustment, TBI was independently associated with subsequent ischemic stroke (hazard ratio 1.31, 95% confidence interval 1.25-1.36). Conclusions: In this large cohort, TBI is associated with ischemic stroke, independent of other major predictors.	[Burke, James F.] Univ Michigan, Dept Vet Affairs, VA Ctr Clin Management & Res, Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA; [Stulc, Jessica L.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Burke, James F.; Skolarus, Lesli E.; Zahuranec, Darin B.; Morgenstern, Lewis B.] Univ Michigan, Stroke Program, Ann Arbor, MI 48109 USA; [Sears, Erika D.] Univ Michigan, Dept Surg, Sect Plast Surg, Ann Arbor, MI 48109 USA; [Morgenstern, Lewis B.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA		Burke, JF (corresponding author), Univ Michigan, Dept Vet Affairs, VA Ctr Clin Management & Res, Ann Arbor VA Healthcare Syst, Ann Arbor, MI 48109 USA.	jamesbur@umich.edu			VA Advanced Fellowship; NIH from the National Institute of Neurological Diseases and Stroke [K23NS073685]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG038731]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS38916, R01NS062675, U01NS056975, U01NS062835, R18HS017690, R01NS073595, R01HL098065]; St. Jude MedicalSt. Jude Medical; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS073685] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG038731] Funding Source: NIH RePORTER	J. Burke is supported by a VA Advanced Fellowship. J. Stulc reports no disclosures relevant to the manuscript. L. Skolarus is supported by NIH K23NS073685 from the National Institute of Neurological Diseases and Stroke. E. Sears reports no disclosures relevant to the manuscript. D. Zahuranec is supported by grant K23AG038731 from the National Institute on Aging. L. Morgenstern receives NIH funding (significant) from grants R01NS38916, R01NS062675, U01NS056975, U01NS062835, R18HS017690, R01NS073595, and R01HL098065. He receives significant research support from St. Jude Medical. Go to Neurology.org for full disclosures.	Agency for Healthcare Research and Quality (AHRQ), 2012, HCUP CLINICAL CLASSI; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; [Anonymous], 1997, MMWR Recomm Rep, V46, P1; Association for the Advancement of Automotive Medicine, THE ABBREVIATED INJU; Baracchini C, 2010, NEUROLOGY, V75, P1864, DOI 10.1212/WNL.0b013e3181feae5e; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Brown DL, 2006, NEUROLOGY, V67, P1390, DOI 10.1212/01.wnl.0000237024.16438.20; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; CAPLAN LR, 1985, STROKE, V16, P1030, DOI 10.1161/01.STR.16.6.1030; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.2307/2335362; DAGOSTINO RB, 1994, STROKE, V25, P40, DOI 10.1161/01.STR.25.1.40; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein EA, 2006, INCIDENCE AND ECONOM; FISHER CM, 1978, CAN J NEUROL SCI, V5, P9, DOI 10.1017/S0317167100024690; Fullerton HJ, 2001, NEUROLOGY, V57, P1155, DOI 10.1212/WNL.57.7.1155; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Goldstein LB, 1998, STROKE, V29, P1602, DOI 10.1161/01.STR.29.8.1602; Haas B, 2012, CAN J SURG, V55, P21, DOI 10.1503/cjs.017510; Hand PJ, 2006, STROKE, V37, P769, DOI 10.1161/01.STR.0000204041.13466.4c; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Ji RJ, 2013, JAMA NEUROL, V70, P51, DOI 10.1001/jamaneurol.2013.575; Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; National Center for Injury Prevention, 2003, REPORT TO CON GRESS; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Rector TS, 2004, HEALTH SERV RES, V39, P1839, DOI 10.1111/j.1475-6773.2004.00321.x; Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046; Sniezek JE, 1995, GUIDELINES FOR SURVE; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD; Touze E, 2003, NEUROLOGY, V61, P1347, DOI 10.1212/01.WNL.0000094325.95097.86; Williams LS, 1997, NEUROLOGY, V49, P1541, DOI 10.1212/WNL.49.6.1541	36	71	71	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JUL 2	2013	81	1					33	39		10.1212/WNL.0b013e318297eecf			7	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	304JC	WOS:000330741900010	23803315	Green Published			2022-02-06	
J	DeWitt, DS; Perez-Polo, R; Hulsebosch, CE; Dash, PK; Robertson, CS				DeWitt, Douglas S.; Perez-Polo, Regino; Hulsebosch, Claire E.; Dash, Pramod K.; Robertson, Claudia S.			Challenges in the Development of Rodent Models of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						animal models; brain injury; head injury; mild traumatic brain injury; traumatic brain injury	MINOR HEAD-INJURY; LATERAL FLUID PERCUSSION; CONTROLLED CORTICAL IMPACT; FOOTBALL-LEAGUE PLAYER; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RETROGRADE-AMNESIA; HIPPOCAMPAL-LESIONS; RIGHTING REFLEX; RAT MODEL	Approximately 75% of traumatic brain injuries (TBI) are classified mild (mTBI). Despite the high frequency of mTBI, it is the least well studied. The prevalence of mTBI among service personnel returning from Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF) and the recent reports of an association between repeated mTBI and the early onset of Alzheimer's and other types of dementias in retired athletes has focused much attention on mTBI. The study of mTBI requires the development and validation of experimental models and one of the most basic requirements for an experimental model is that it replicates important features of the injury or disease in humans. mTBI in humans is associated with acute symptoms such as loss of consciousness and pre-and/or posttraumatic amnesia. In addition, many mTBI patients experience long-term effects of mTBI, including deficits in speed of information processing, attention and concentration, memory acquisition, retention and retrieval, and reasoning and decision-making. Although methods for the diagnosis and evaluation of the acute and chronic effects of mTBI in humans are well established, the same is not the case for rodents, the most widely used animal for TBI studies. Despite the magnitude of the difficulties associated with adapting these methods for experimental mTBI research, they must be surmounted. The identification and testing of treatments for mTBI depends of the development, characterization and validation of reproducible, clinically relevant models of mTBI.	[DeWitt, Douglas S.] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA; [Perez-Polo, Regino] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Hulsebosch, Claire E.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; [Dash, Pramod K.] Univ Texas Hlth Sci Ctr, Dept Neurosci, Houston, TX USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		DeWitt, DS (corresponding author), Univ Texas Med Branch, Dept Anesthesiol, 301 Univ Blvd, Galveston, TX 77555 USA.	ddewitt@utmb.edu		Dash, Pramod/0000-0001-6746-1002	U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0132]	This work was supported by the U.S. Army Medical Research and Materiel Command award number W81XWH-08-2-0132. The authors are grateful to Emmy Miller, RN, PhD, for her coordination of the research of the Mission Connect Mild Traumatic Brain Injury Translational Research Consortium.	Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bay Esther, 2007, J Neurosci Nurs, V39, P43; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; BIGNALL KE, 1974, EXP NEUROL, V42, P566, DOI 10.1016/0014-4886(74)90079-X; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2011, J NEUROTRAUM, V28, P2061, DOI 10.1089/neu.2011.1905; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Brown AW, 2004, NEUROREHABILITATION, V19, P37; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention (CDC), 2003, REP C MILD TRAUM BRA, P1; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chavko M, 2006, J TRAUMA, V61, P933, DOI 10.1097/01.ta.0000233742.75450.47; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Cicerone KD, 2002, CLIN NEUROPSYCHOL, V16, P280, DOI 10.1076/clin.16.3.280.13849; Colgan NC, 2010, J NEUROTRAUM, V27, P1265, DOI 10.1089/neu.2009.1267; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RC, 2002, ANESTHESIOLOGY, V96, P1223, DOI 10.1097/00000542-200205000-00027; Eckner JT, 2011, J NEUROTRAUM, V28, P2079, DOI 10.1089/neu.2011.1910; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Epstein D, 2010, SPORTS ILLUSTRATED, V113, P42; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fijalkowski RJ, 2007, J NEUROTRAUM, V24, P1387, DOI 10.1089/neu.2007.0268; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gaskin S, 2003, HIPPOCAMPUS, V13, P962, DOI 10.1002/hipo.10154; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457, DOI 10.1152/ajpheart.1999.277.4.H1457; Golding EM, 2001, J NEUROTRAUM, V18, P691, DOI 10.1089/089771501750357636; Griesbach GS, 2011, NEUROSCIENCE, V178, P147, DOI 10.1016/j.neuroscience.2011.01.028; Griesbach GS, 2002, J NEUROTRAUM, V19, P803, DOI 10.1089/08977150260190401; [Group M.o.C.M.T.W. Affairs/Defense V], 2009, CLIN PRACT GUID MAN, P1; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Haijima A, 2008, LEARN MEMORY, V15, P477, DOI 10.1101/lm.862308; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hamberger A, 2009, NEUROSURGERY, V64, P1174, DOI 10.1227/01.NEU.0000316855.40986.2A; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Jacobs A, 1996, J NUCL MED, V37, P1605; Jacobs A, 1994, J NUCL MED, V35; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jonasson Z, 2004, HIPPOCAMPUS, V14, P28, DOI 10.1002/hipo.10146; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; King P., 2010, SPORTS ILLUSTRATED, P34; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kuehn R, 2011, J NEUROTRAUM, V28, P2155, DOI 10.1089/neu.2010.1532; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Lifshitz J, 2007, BEHAV BRAIN RES, V177, P347, DOI 10.1016/j.bbr.2006.11.014; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory P, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2003.006338; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Millspaugh JA, 1937, US NAVAL MED B, V35, P297; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Mumby DG, 2000, BEHAV BRAIN RES, V114, P119, DOI 10.1016/S0166-4328(00)00217-5; Navarro JC, 2012, J NEUROTRAUM, V29, P1; Nguyen HT, 2009, ANESTHESIOLOGY, V110, P326, DOI 10.1097/ALN.0b013e3181942b5b; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Park E, 2011, J NEUROTRAUM, V28, P343, DOI 10.1089/neu.2009.1050; Parsley M, 2007, J NEUROTRAUM, V24, P1277; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Raskin SA, 1998, CLIN NEUROPSYCHOL, V12, P21, DOI 10.1076/clin.12.1.21.1724; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Schwarz Alan, 2007, NY TIMES; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Sukhotinsky I, 2007, EUR J NEUROSCI, V25, P1417, DOI 10.1111/j.1460-9568.2007.05399.x; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Tanielian T. L., 2008, INVISIBLE WOUNDS WAR, P1; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Whiting MD, 2008, BRAIN RES, V1213, P69, DOI 10.1016/j.brainres.2008.01.107; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winocur G, 1999, J NEUROSCI, V19, P9611; Winocur G, 2001, HIPPOCAMPUS, V11, P18, DOI 10.1002/1098-1063(2001)11:1<18::AID-HIPO1016>3.0.CO;2-5; Young JW, 2009, PHARMACOL THERAPEUT, V122, P150, DOI 10.1016/j.pharmthera.2009.02.004; ZHOU YL, 1995, PHYSIOL BEHAV, V57, P1107, DOI 10.1016/0031-9384(95)00019-F	136	71	71	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2013	30	9			SI		688	701		10.1089/neu.2012.2349			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	145BJ	WOS:000318987600002	23286417				2022-02-06	
J	Furtado, MD; Rossetti, F; Chanda, S; Yourick, D				Furtado, Marcio de Araujo; Rossetti, Franco; Chanda, Soma; Yourick, Debra			Exposure to nerve agents: From status epilepticus to neuroinflammation, brain damage, neurogenesis and epilepsy	NEUROTOXICOLOGY			English	Article						Nerve agents; Status epilepticus; Spontaneous recurrent seizures; Epileptogenesis; Neurogenesis	SOMAN-INDUCED SEIZURES; SPONTANEOUS RECURRENT SEIZURES; CONVULSIVE STATUS EPILEPTICUS; SARIN-INDUCED SEIZURES; CYCLOOXYGENASE-2 INHIBITOR; KAINIC ACID; HIPPOCAMPAL NEUROGENESIS; PILOCARPINE MODEL; INDUCED NEUROPATHOLOGY; ADULT NEUROGENESIS	Epilepsy is a common neurological disorder characterized by an initial injury due to stroke, traumatic brain injury, brain infection, or febrile seizures causing status epilepticus (SE). This phenomenon precedes recurrent (secondary) seizures, the latent period (period without seizures) and downstream appearance of spontaneous recurrent seizures (SRS). Epilepsy inducers include the organophosphorous (OP) compounds modified as chemical warfare nerve agents, such as soman. SE induced by soman is a result of cholinergic system hyperactivity caused by the irreversible inhibition of acetylcholinesterase, and the subsequent increase in the amount of the neurotransmitter acetylcholine at central and peripheral sites. SE leads to profound, permanent, complex and widespread brain damage and associated cognitive and behavioral deficits, accompanied by impaired neurogenesis. Several anticonvulsant and neuroprotective strategies have been studied in order to avoid the epileptogenesis which occurs after SE caused by soman exposure. In recent studies, we showed that SRS occur post-soman exposure and neuropathology can be reduced with diazepam (DZP) and valproic acid (VPA) when administered in combination treatment. These effects are accompanied by neurogenesis seen 15 days post-exposure in the hippocampal dentate gyrus (DG). This review discusses several findings about epilepsy induced by soman exposure such as behavioral changes, EEG anomalies, neuropathology, neuroinflammation, neurogenesis, possible circuitry changes and current strategies for treatment. The soman seizure model is an important model of temporal lobe epilepsy (TLE) and comparable in certain respects with well studied models in the literature such as pilocarpine and kainic acid. All these models together allow for a greater understanding of the different mechanisms of seizure induction, propagation and options for treatment. These studies are very necessary for current military and civilian treatment regimens, against OP nerve agent exposure, which fail to prevent SE resulting in severe neuropathology and epilepsy. Published by Elsevier Inc.	[Yourick, Debra] Walter Reed Army Inst Res, US Army Garrison Forest Glen, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, Silver Spring, MD 20910 USA		Yourick, D (corresponding author), Walter Reed Army Inst Res, US Army Garrison Forest Glen, Ctr Mil Psychiat & Neurosci, Blast Induced Neurotrauma Branch, 2460 Linden Lane,Bldg 503, Silver Spring, MD 20910 USA.	debra.yourick@us.army.mil	Yourick, Debra/A-2121-2011		National Research Council; Defense Threat Reduction AgencyUnited States Department of DefenseDefense Threat Reduction Agency [I.E0042-08-WR-C]	Dr. Marcio de Araujo Furtado is currently employed by Clinical RM, Inc., and under contract to the Walter Reed Army Institute of Research. Dr. Franco Rossetti is supported administratively by a National Research Council fellowship. The present study was supported financially by the Defense Threat Reduction Agency (Grant I.E0042-08-WR-C, Principal Investigator: Dr. Debra Yourick).	Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Albuquerquet EX, 2006, P NATL ACAD SCI USA, V103, P13220, DOI 10.1073/pnas.0605370103; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Angoa-Perez M, 2010, NEUROTOXICOLOGY, V31, P738, DOI 10.1016/j.neuro.2010.06.007; Apland JP, 2009, NEUROSCIENCE, V159, P380, DOI 10.1016/j.neuroscience.2008.11.053; Apland JP, 2010, NEUROTOXICOLOGY, V31, P485, DOI 10.1016/j.neuro.2010.05.014; ASHANI Y, 1981, BIOCHEM PHARMACOL, V30, P2593, DOI 10.1016/0006-2952(81)90587-6; Auta J, 2004, NEUROPHARMACOLOGY, V46, P397, DOI 10.1016/j.neuropharm.2003.09.010; Awni W M, 1995, Clin Pharmacokinet, V29 Suppl 2, P112; BABB TL, 1992, EPILEPSY RES, P193; Baille V, 2005, TOXICOLOGY, V215, P1, DOI 10.1016/j.tox.2005.05.028; BailleLeCrom V, 1995, NEUROREPORT, V7, P365; Barelli A, 2011, MINERVA ANESTESIOL, V77, P1197; BENARI Y, 1979, BRAIN RES, V163, P176, DOI 10.1016/0006-8993(79)90163-X; Berger C, 2008, EXP NEUROL, V210, P543, DOI 10.1016/j.expneurol.2007.12.002; Bhagat YA, 2005, NEUROTOXICOLOGY, V26, P1001, DOI 10.1016/j.neuro.2005.04.006; Bradman A, 2007, J EXPO SCI ENV EPID, V17, P331, DOI 10.1038/sj.jes.7500507; Britt JO, 2000, COMPARATIVE MED, V50, P133; Candelario-Jalil E, 2008, PHARMACOL RES, V57, P266, DOI 10.1016/j.phrs.2008.03.003; Candelario-Jalil E, 2007, J NEUROCHEM, V100, P1108, DOI 10.1111/j.1471-4159.2006.04280.x; CAPACIO BR, 1991, EPILEPSIA, V32, P604, DOI 10.1111/j.1528-1157.1991.tb04699.x; CARPENTIER P, 1990, NEUROTOXICOLOGY, V11, P493; CARPENTIER P, 1991, BRAIN RES, V541, P293, DOI 10.1016/0006-8993(91)91030-5; Carpentier P, 2001, NEUROTOXICOLOGY, V22, P299, DOI 10.1016/S0161-813X(01)00019-5; CARPENTIER P, 1994, NEUROTOXICOLOGY, V15, P837; Castro OW, 2011, BRAIN RES, V1374, P43, DOI 10.1016/j.brainres.2010.12.012; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Chapman S, 2006, NEUROTOXICOLOGY, V27, P277, DOI 10.1016/j.neuro.2005.11.009; CHEN J, 1995, NEUROREPORT, V6, P245; Chen JWY, 2006, LANCET NEUROL, V5, P246, DOI 10.1016/S1474-4422(06)70374-X; Choi EK, 2004, EUR J PHARMACOL, V505, P83, DOI 10.1016/j.ejphar.2004.10.034; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; Collombet JM, 2006, NEUROTOXICOLOGY, V27, P201, DOI 10.1016/j.neuro.2005.10.002; CRONIN J, 1988, BRAIN RES, V474, P181, DOI 10.1016/0006-8993(88)90681-6; Curtin BF, 2005, J CELL BIOCHEM, V96, P839, DOI 10.1002/jcb.20591; Dabisch PA, 2010, NEUROCHEMICAL CONSEQ, P185; Dabisch PA, 2007, TOXICOL SCI, V100, P281, DOI 10.1093/toxsci/kfm213; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; Demar JC, 2010, CHEM-BIOL INTERACT, V187, P191, DOI 10.1016/j.cbi.2010.02.015; Despain KE, 2007, TOXICOL MECH METHOD, V17, P255, DOI 10.1080/15376510600972733; Dhir A., 2008, Inflammopharmacology, V16, P83, DOI 10.1007/s10787-007-7007-6; Dhote F, 2012, TOXICOL APPL PHARM, V259, P195, DOI 10.1016/j.taap.2011.12.024; Dillman JF, 2009, CHEM RES TOXICOL, V22, P633, DOI 10.1021/tx800466v; Ding GD, 2012, ENVIRON SCI TECHNOL, V46, P2911, DOI 10.1021/es202583d; Doctor BP, 2005, CHEM-BIOL INTERACT, V157, P167, DOI 10.1016/j.cbi.2005.10.024; Dorandeu F, 2005, BRAIN RES, V1051, P164, DOI 10.1016/j.brainres.2005.06.013; Dorandeu F, 2007, TOXICOLOGY, V234, P185, DOI 10.1016/j.tox.2007.02.012; Doretto MC, 1998, NEUROREPORT, V9, P2415, DOI 10.1097/00001756-199807130-00048; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; DUDEK FE, 1994, HIPPOCAMPUS, V4, P259, DOI 10.1002/hipo.450040306; Dudek FE, 2012, JASPERS BASIC MECH E; Duman RS, 2001, NEUROPSYCHOPHARMACOL, V25, P836, DOI 10.1016/S0893-133X(01)00358-X; Elmer E, 1997, NEUROREPORT, V8, P1193, DOI 10.1097/00001756-199703240-00027; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409, DOI 10.1289/ehp.99107s3409; Eskenazi B, 2008, BASIC CLIN PHARMACOL, V102, P228, DOI 10.1111/j.1742-7843.2007.00171.x; Faraco G, 2006, MOL PHARMACOL, V70, P1876, DOI 10.1124/mol.106.027912; Figueiredo TH, 2011, BRIT J PHARMACOL, V164, P1495, DOI 10.1111/j.1476-5381.2011.01427.x; Figueiredo TH, 2011, J PHARMACOL EXP THER, V336, P303, DOI 10.1124/jpet.110.171835; Filliat P, 2007, NEUROTOXICOLOGY, V28, P508, DOI 10.1016/j.neuro.2006.11.004; Furtado M, 2008, TOXICOLOGIST S, V102, P469; Furtado M, 2011, MODERN TELEMETRY, P199; Furtado MA, 2011, EPILEPSY BEHAV, V20, P257, DOI 10.1016/j.yebeh.2010.11.024; Furtado MA, 2002, EPILEPSIA, V43, P37; Furtado MD, 2010, EPILEPSIA, V51, P1503, DOI 10.1111/j.1528-1167.2009.02478.x; Furtado MD, 2009, J NEUROSCI METH, V184, P176, DOI 10.1016/j.jneumeth.2009.07.020; GALE K, 1980, SCIENCE, V208, P288, DOI 10.1126/science.6768130; Gannon RL, 2011, BEHAV BRAIN RES, V218, P8, DOI 10.1016/j.bbr.2010.11.029; GAUSE EM, 1985, PHARMACOL BIOCHEM BE, V23, P1003, DOI 10.1016/0091-3057(85)90107-8; Gilat E, 2005, TOXICOL APPL PHARM, V209, P74, DOI 10.1016/j.taap.2005.03.007; Gobbo OL, 2004, NEUROSCIENCE, V125, P317, DOI 10.1016/j.neuroscience.2004.01.045; Goodkin HP, 2007, EPILEPSIA, V48, P14, DOI 10.1111/j.1528-1167.2007.01337.x; HAGGERTY GC, 1986, NEUROTOXICOL TERATOL, V8, P695; HARRIS LW, 1994, DRUG CHEM TOXICOL, V17, P35, DOI 10.3109/01480549409064045; HARRIS LW, 1984, DRUG CHEM TOXICOL, V7, P605, DOI 10.3109/01480548409042823; Haug KH, 2007, TOXICOL APPL PHARM, V220, P156, DOI 10.1016/j.taap.2006.12.023; HAYES SG, 1989, J CLIN PSYCHIAT, V50, P35; Hellier JL, 1999, EPILEPSY RES, V35, P47, DOI 10.1016/S0920-1211(98)00127-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Jacobsson SOP, 1997, NEUROSCI LETT, V231, P155; Jakubs K, 2006, NEURON, V52, P1047, DOI 10.1016/j.neuron.2006.11.004; Jett DA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000752; Jiang JX, 2012, P NATL ACAD SCI USA, V109, P3149, DOI 10.1073/pnas.1120195109; JOHNSON DD, 1974, EUR J PHARMACOL, V28, P245, DOI 10.1016/0014-2999(74)90276-3; Joosen MJA, 2011, TOXICOL LETT, V206, P67, DOI 10.1016/j.toxlet.2011.05.231; Joosen MJA, 2009, NEUROTOXICOLOGY, V30, P72, DOI 10.1016/j.neuro.2008.11.010; JOPE RS, 1986, EXP NEUROL, V93, P404, DOI 10.1016/0014-4886(86)90200-1; JOPE RS, 1986, EXP NEUROL, V91, P471, DOI 10.1016/0014-4886(86)90045-2; Jung KH, 2006, NEUROBIOL DIS, V23, P237, DOI 10.1016/j.nbd.2006.02.016; Jung KH, 2004, EUR J NEUROSCI, V19, P3219, DOI 10.1111/j.0953-816X.2004.03412.x; Jutila L, 2002, ADV TECH STAND NEUR, V27, P3; Kalviainen R, 1998, NEUROLOGY, V50, P1377, DOI 10.1212/WNL.50.5.1377; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Klegeris A, 2002, NEUROBIOL AGING, V23, P787, DOI 10.1016/S0197-4580(02)00021-0; Koplovitz I, 1998, EPILEPSY RES, V30, P159, DOI 10.1016/S0920-1211(97)00100-9; Kozhemyakin M, 2010, J NEUROPHYSIOL, V103, P1748, DOI 10.1152/jn.00949.2009; Kunz T, 2001, EUR J NEUROSCI, V13, P569, DOI 10.1046/j.1460-9568.2001.01420.x; Laeng P, 2004, J NEUROCHEM, V91, P238, DOI 10.1111/j.1471-4159.2004.02725.x; LALLEMENT G, 1994, NEUROREPORT, V5, P2265, DOI 10.1097/00001756-199411000-00015; LALLEMENT G, 1991, BRAIN RES, V563, P234, DOI 10.1016/0006-8993(91)91539-D; Lallement G, 1998, ARCH TOXICOL, V72, P84; Lallement G, 1998, J PHYSIOLOGY-PARIS, V92, P369, DOI 10.1016/S0928-4257(99)80007-2; LANDAUER MR, 1984, NEUROBEH TOXICOL TER, V6, P239; LEITE JP, 1990, NEUROSCI BIOBEHAV R, V14, P511, DOI 10.1016/S0149-7634(05)80076-4; Liu H, 2003, EXP NEUROL, V184, P196, DOI 10.1016/S0014-4886(03)00207-3; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; LOTHMAN EW, 1989, EPILEPSY RES, V3, P107, DOI 10.1016/0920-1211(89)90038-7; Marrs Timothy C, 2006, Toxicol Rev, V25, P297, DOI 10.2165/00139709-200625040-00009; Marrs Timothy C, 2004, Toxicol Rev, V23, P145, DOI 10.2165/00139709-200423030-00002; Mathern GW, 1996, NEUROREPORT, V7, P1029, DOI 10.1097/00001756-199604100-00015; MAXWELL DM, 1988, J PHARMACOL EXP THER, V246, P986; Mazarati AM, 1998, BRAIN RES, V801, P251, DOI 10.1016/S0006-8993(98)00606-4; McDonnall D, 2009, IEEE ENG MED BIO, P5291, DOI 10.1109/IEMBS.2009.5333515; McDonough JH, 1998, NEUROTOXICOLOGY, V19, P381; MCDONOUGH JH, 1989, FUND APPL TOXICOL, V13, P256, DOI 10.1016/0272-0590(89)90262-5; MCDONOUGH JH, 1995, NEUROTOXICOLOGY, V16, P123; MCDONOUGH JH, 1986, NEUROBEH TOXICOL TER, V8, P179; McDonough JH, 1997, NEUROSCI BIOBEHAV R, V21, P559, DOI 10.1016/S0149-7634(96)00050-4; McDonough JH, 1999, ARCH TOXICOL, V73, P473, DOI 10.1007/s002040050637; MCDONOUGH JH, 1993, NEUROSCI BIOBEHAV R, V17, P203, DOI 10.1016/S0149-7634(05)80151-4; McDonough JH, 2000, EPILEPSY RES, V38, P1; McDonough JH, 2009, BASIC CLIN PHARMACOL, V104, P27, DOI 10.1111/j.1742-7843.2008.00326.x; MELDRUM BS, 1973, ARCH NEUROL-CHICAGO, V28, P1; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Mirsattari SM, 2011, CAN J NEUROL SCI, V38, P487, DOI 10.1017/S0317167100011914; Moffett MC, 2011, PHARMACOL BIOCHEM BE, V98, P120, DOI 10.1016/j.pbb.2010.11.022; MOLLACE V, 1995, BIOCHEM BIOPH RES CO, V215, P793, DOI 10.1006/bbrc.1995.2533; Mora GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005759; Murata K, 1997, J NEUROL, V244, P601, DOI 10.1007/s004150050153; Murphy BL, 2011, J NEUROSCI, V31, P105, DOI 10.1523/JNEUROSCI.2728-10.2011; Myhrer T, 2003, NEUROTOXICOLOGY, V24, P357, DOI 10.1016/S0161-813X(03)00040-8; Myhrer T, 2011, NEUROTOXICOLOGY; Myhrer T, 2007, TOXICOLOGY, V239, P1, DOI 10.1016/j.tox.2007.06.099; Nguyen N, 2007, NEUROTOXICOLOGY, V28, P13, DOI 10.1016/j.neuro.2006.09.007; Nielsen SS, 2010, ENVIRON HEALTH PERSP, V118, P144, DOI 10.1289/ehp.0901226; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; O'Donnell JC, 2011, ARCH TOXICOL, V85, P1607, DOI 10.1007/s00204-011-0724-z; Parent JM, 2007, PROG BRAIN RES, V163, P529, DOI 10.1016/S0079-6123(07)63028-3; Parent JM, 2006, HIPPOCAMPUS, V16, P321, DOI 10.1002/hipo.20166; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, EPILEPSY RES, V50, P179, DOI 10.1016/S0920-1211(02)00078-5; Park EM, 2005, NEUROSCIENCE, V132, P625, DOI 10.1016/j.neuroscience.2005.01.021; Pazdernik TL, 2001, J APPL TOXICOL, V21, pS87, DOI 10.1002/jat.818; Pereira EFR, 2010, J MOL NEUROSCI, V40, P196, DOI 10.1007/s12031-009-9234-3; Pernot F, 2009, NEUROSCIENCE, V162, P1351, DOI 10.1016/j.neuroscience.2009.05.068; Persinger MA, 2004, EPILEPSY BEHAV, V5, P440, DOI 10.1016/j.yebeh.2004.03.007; Peterson SL, 2005, NEUROTOXICOLOGY, V26, P969, DOI 10.1016/j.neuro.2005.04.002; PETRAS JM, 1994, J EXP ANAL BEHAV, V61, P319, DOI 10.1901/jeab.1994.61-319; PHILIPPENS IHCHM, 1992, PHARMACOL BIOCHEM BE, V42, P711, DOI 10.1016/0091-3057(92)90019-C; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Pierre SC, 2007, BRIT J PHARMACOL, V151, P494, DOI 10.1038/sj.bjp.0707239; PISA M, 1980, BRAIN RES, V200, P481, DOI 10.1016/0006-8993(80)90938-5; Pitkanen A, 2005, EPILEPSY RES, V63, P27, DOI 10.1016/j.eplepsyres.2004.10.003; Pizarro JM, 2012, TOXICOL SCI, V126, P497, DOI 10.1093/toxsci/kfr353; RAFFAELE K, 1987, PHARMACOL BIOCHEM BE, V27, P407, DOI 10.1016/0091-3057(87)90341-8; Rauh VA, 2006, PEDIATRICS, V118, pE1845, DOI 10.1542/peds.2006-0338; Romano J, 2001, CHEM WARFARE AGENT T; Rossetti F, 2012, NEUROTOXICOLOGY; Rotenberg JS, 2003, PEDIATRICS, V112, P648, DOI 10.1542/peds.112.3.648; SALVEMINI D, 1993, P NATL ACAD SCI USA, V90, P7240, DOI 10.1073/pnas.90.15.7240; SAMSON FE, 1984, FUND APPL TOXICOL, V4, pS173, DOI 10.1016/0272-0590(84)90150-7; Saxena A, 2011, BIOCHEM PHARMACOL, V82, P1984, DOI 10.1016/j.bcp.2011.09.019; Scali C, 2003, NEUROSCIENCE, V117, P909, DOI 10.1016/S0306-4522(02)00839-4; Scharfman HE, 2000, J NEUROSCI, V20, P6144, DOI 10.1523/JNEUROSCI.20-16-06144.2000; Scharfman HE, 2001, NEUROSCIENCE, V104, P741, DOI 10.1016/S0306-4522(01)00132-4; Schlichtiger J, 2010, BRIT J PHARMACOL, V160, P1062, DOI 10.1111/j.1476-5381.2010.00765.x; Schultz MK, 2012, TOXICOL APPL PHARM, V259, P376, DOI 10.1016/j.taap.2012.01.017; Scremin OU, 1998, BRAIN RES BULL, V45, P167, DOI 10.1016/S0361-9230(97)00334-1; Sekijima Y, 1995, Rinsho Shinkeigaku, V35, P1241; SHIH TM, 1990, EPILEPSY RES, V7, P105, DOI 10.1016/0920-1211(90)90095-D; Shih TM, 1997, J APPL TOXICOL, V17, P255, DOI 10.1002/(SICI)1099-1263(199707)17:4<255::AID-JAT441>3.0.CO;2-D; Shih TM, 1999, PHARMACOL BIOCHEM BE, V64, P147, DOI 10.1016/S0091-3057(99)00114-8; Shih TM, 2003, TOXICOL APPL PHARM, V188, P69, DOI 10.1016/S0041-008X(03)00019-X; Shih TM, 2011, TOXICOL MECH METHOD, V21, P53, DOI 10.3109/15376516.2010.529190; Shih TM, 2010, J MOL NEUROSCI, V40, P63, DOI 10.1007/s12031-009-9259-7; Shorvon SD, 2000, HDB EPILEPSY TREATME; Silakova JM, 2004, J PHARMACOL EXP THER, V309, P1060, DOI 10.1124/jpet.103.063867; Silbergleit R, 2012, NEW ENGL J MED, V366, P591, DOI 10.1056/NEJMoa1107494; Sit RK, 2011, J BIOL CHEM, V286, P19422, DOI 10.1074/jbc.M111.230656; Skovira JW, 2012, NEUROTOXICOLOGY, V33, P463, DOI 10.1016/j.neuro.2012.03.006; Skovira JW, 2010, J MOL NEUROSCI, V40, P56, DOI 10.1007/s12031-009-9253-0; Sloviter RS, 1999, EPILEPSIA, V40, pS34, DOI 10.1111/j.1528-1157.1999.tb00876.x; Sloviter RS, 2003, J COMP NEUROL, V459, P44, DOI 10.1002/cne.10630; SPARENBORG S, 1993, EPILEPSY RES, V14, P95, DOI 10.1016/0920-1211(93)90014-X; Spradling KD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-83; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Testylier G, 1999, ACTA BIOTHEOR, V47, P191, DOI 10.1023/A:1002626318172; Tetz LM, 2006, TOXICOL IND HEALTH, V22, P255, DOI 10.1191/0748233706th268oa; TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092; Tocco G, 1997, EXP NEUROL, V144, P339, DOI 10.1006/exnr.1997.6429; Tonduli LS, 2001, NEUROTOXICOLOGY, V22, P29, DOI 10.1016/S0161-813X(00)00015-2; TREIMAN DM, 1990, EPILEPSY RES, V5, P49, DOI 10.1016/0920-1211(90)90065-4; TRYPHONAS L, 1995, TOXICOL PATHOL, V23, P393, DOI 10.1177/019262339502300316; Tryphonas L, 1996, TOXICOL PATHOL, V24, P190, DOI 10.1177/019262339602400207; Tu XK, 2009, NEUROL RES, V31, P848, DOI 10.1179/174313209X403913; TURSKI WA, 1983, BEHAV BRAIN RES, V9, P315, DOI 10.1016/0166-4328(83)90136-5; Vartiainen N, 2001, J NEUROCHEM, V76, P480, DOI 10.1046/j.1471-4159.2001.00065.x; Vezzani A, 2011, NAT REV NEUROL, V7, P31, DOI 10.1038/nrneurol.2010.178; VIOLAN JS, 1985, MED CLIN-BARCELONA, V85, P217; Voutsinos-Porche B, 2004, NEUROBIOL DIS, V17, P385, DOI 10.1016/j.nbd.2004.07.023; Wang Y, 2007, CURR NEUROVASC RES, V4, P176; Wang Yan-Ling, 2004, Zhonghua Er Ke Za Zhi, V42, P621; WASTERLAIN CG, 1994, BRAIN DEV-JPN, V16, P279, DOI 10.1016/0387-7604(94)90025-6; Wasterlain G, 2009, J NEUROSCI, V50, P16; White HS, 2011, ESILEPSIA; Williams PA, 2002, J NEUROPHYSIOL, V88, P2075, DOI 10.1152/jn.2002.88.4.2075; Williams PA, 2007, EPILEPSIA, V48, P157, DOI 10.1111/j.1528-1167.2007.01304.x; Wiltrout C, 2007, NEUROCHEM INT, V50, P1028, DOI 10.1016/j.neuint.2007.04.011; Xu B, 2004, EUR J NEUROSCI, V20, P403, DOI 10.1111/j.1460-9568.2004.03489.x; Yamada A, 2009, NUCL MED BIOL, V36, P949, DOI 10.1016/j.nucmedbio.2009.06.008; Young JG, 2005, NEUROTOXICOLOGY, V26, P199, DOI 10.1016/j.neuro.2004.10.004; Yourick DL, 2007, RTOMPHFM149; Zandieh A, 2010, ACTA NEUROBIOL EXP, V70, P390; Zhang HJ, 2008, J ZHEJIANG UNIV-SC B, V9, P903, DOI 10.1631/jzus.B0820018; Zheng Z, 2007, BRAIN RES, V1186, P275, DOI 10.1016/j.brainres.2007.10.029; Zimmer LA, 1998, J NEUROSCI, V18, P3897	219	71	75	0	119	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0161-813X	1872-9711		NEUROTOXICOLOGY	Neurotoxicology	DEC	2012	33	6			SI		1476	1490		10.1016/j.neuro.2012.09.001			15	Neurosciences; Pharmacology & Pharmacy; Toxicology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Toxicology	063UI	WOS:000313027100011	23000013				2022-02-06	
J	Lee, PC; Bordelon, Y; Bronstein, J; Ritz, B				Lee, Pei-Chen; Bordelon, Yvette; Bronstein, Jeff; Ritz, Beate			Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease	NEUROLOGY			English	Article							ENVIRONMENTAL RISK-FACTORS; ALPHA-SYNUCLEIN; HEAD-INJURY; INFLAMMATORY RESPONSE; PESTICIDE EXPOSURE; POPULATION; CALIFORNIA; ACCUMULATION; HISTORY	Objectives: Traumatic brain injury (TBI) increased risk of Parkinson disease (PD) in many but not all epidemiologic studies, giving rise to speculations about modifying factors. A recent animal study suggested that the combination of TBI with subthreshold paraquat exposure increases dopaminergic neurodegeneration. The objective of our study was to investigate PD risk due to both TBI and paraquat exposure in humans. Methods: From 2001 to 2011, we enrolled 357 incident idiopathic PD cases and 754 population controls in central California. Study participants were asked to report all head injuries with loss of consciousness for >5 minutes. Paraquat exposure was assessed via a validated geographic information system (GIS) based on records of pesticide applications to agricultural crops in California since 1974. This GIS tool assesses ambient pesticide exposure within 500 m of residences and workplaces. Results: In logistic regression analyses, we observed a 2-fold increase in risk of PD for subjects who reported a TBI (adjusted odds ratio [AOR] 2.00, 95% confidence interval [CI] 1.28-3.14) and a weaker association for paraquat exposures (AOR 1.36, 95% CI 1.02-1.81). However, the risk of developing PD was 3-fold higher (AOR 3.01, 95% CI 1.51-6.01) in study participants with a TBI and exposure to paraquat than those exposed to neither risk factor. Conclusions: While TBI and paraquat exposure each increase the risk of PD moderately, exposure to both factors almost tripled PD risk. These environmental factors seem to act together to increase PD risk in a more than additive manner. Neurology (R) 2012; 79: 2061-2066	[Lee, Pei-Chen; Ritz, Beate] Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Bordelon, Yvette; Bronstein, Jeff; Ritz, Beate] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA		Lee, PC (corresponding author), Univ Calif Los Angeles, Dept Epidemiol, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.	pel27@ucla.edu	Ritz, Beate R/E-3043-2015	, Pei-Chen/0000-0001-7813-0823	National Institute of Environmental Health ScienceUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES010544, U54ES012078]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS038367]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30ES007048]; American Parkinson Disease Association; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [P30ES007048, R01ES010544, U54ES012078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS038367] Funding Source: NIH RePORTER	This work was supported by the National Institute of Environmental Health Science (grant numbers R01ES010544 and U54ES012078) and the National Institute of Neurological Disorders and Stroke (grant number P50NS038367); in addition, initial pilot funding was provided from NIH P30ES007048 and a pilot grant by the American Parkinson Disease Association.	Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dinis-Oliveira RJ, 2006, NEUROTOXICOLOGY, V27, P1110, DOI 10.1016/j.neuro.2006.05.012; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Frantseva M, 2002, PROG BRAIN RES, V137, P171; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldberg DW, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-60; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012; HUGHES AJ, 1992, NEUROLOGY, V42, P1142, DOI 10.1212/WNL.42.6.1142; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Kang GA, 2005, MOVEMENT DISORD, V20, P1133, DOI 10.1002/mds.20513; Kay DM, 2008, AM J MED GENET B, V147B, P1222, DOI 10.1002/ajmg.b.30758; Kuter K, 2010, NEUROCHEM RES, V35, P1121, DOI 10.1007/s11064-010-0163-x; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manthripragada AD, 2010, EPIDEMIOLOGY, V21, P87, DOI 10.1097/EDE.0b013e3181c15ec6; Maraganore DM, 2006, JAMA-J AM MED ASSOC, V296, P661, DOI 10.1001/jama.296.6.661; McCann SJ, 1998, NEUROEPIDEMIOLOGY, V17, P310, DOI 10.1159/000026185; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Ritz B, 2006, ANN NY ACAD SCI, V1076, P378, DOI 10.1196/annals.1371.074; Ritz B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036199; Ritz BR, 2009, ENVIRON HEALTH PERSP, V117, P964, DOI 10.1289/ehp.0800277; Rothman KJ., 2002, EPIDEMIOLOGY INTRO; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Rull RA, 2003, ENVIRON HEALTH PERSP, V111, P1582, DOI 10.1289/ehp.6118; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Sulzer D, 2007, TRENDS NEUROSCI, V30, P244, DOI 10.1016/j.tins.2007.03.009; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Taylor CA, 1999, AM J MED GENET, V88, P742, DOI 10.1002/(SICI)1096-8628(19991215)88:6<742::AID-AJMG29>3.0.CO;2-#; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang A, 2011, EUR J EPIDEMIOL, V26, P547, DOI 10.1007/s10654-011-9574-5	40	71	73	0	30	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	NOV	2012	79	20					2061	2066		10.1212/WNL.0b013e3182749f28			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	036NC	WOS:000311032100013	23150532	Green Published			2022-02-06	
J	Zhao, SF; Fu, JD; Liu, XR; Wang, T; Zhang, JL; Zhao, YL				Zhao, Shangfeng; Fu, Jidi; Liu, Xiangrong; Wang, Tony; Zhang, Jialiang; Zhao, Yuanli			Activation of Akt/GSK-3beta/beta-catenin signaling pathway is involved in survival of neurons after traumatic brain injury in rats	NEUROLOGICAL RESEARCH			English	Article						Akt; GSK-3beta; Beta-catenin; Traumatic brain injury	GLYCOGEN-SYNTHASE KINASE-3-BETA; CEREBRAL-ARTERY OCCLUSION; BETA-CATENIN; KINASE-B; APOPTOSIS; ISCHEMIA; CELL; AKT; DEATH; PHOSPHORYLATION	Objective: Apoptotic cell death is an important factor influencing the prognosis after traumatic brain injury (TBI). Akt/GSK-3beta/beta-catenin signaling plays a critical role in the apoptosis of neurons in several models of neurodegeneration. The goal of this study was to determine if the mechanism of cell survival mediated by the Akt/GSK-3beta/beta-catenin pathway is involved in a rat model of TBI. Methods: TBI was performed by a controlled cortical impact device. Expression of Akt, phospho-Akt, GSK-3beta, phospho-GSK-3beta, beta-catenin, phospho-beta-catenin were examined by immunohistochemistry and Western blot analysis. Double immunofluorenscent staining was used to observe the neuronal expression of the aforementioned subtrates. Terminal deoxynucleotidyl transferase-mediated uridine 5'-triphosphate-biotin nick end-labeling (TUNEL) staining was performed to identify apoptosis. Results: Western blot analysis showed that phospho-Akt significantly increased at 4 hours post-TBI, but decreased after 72 hours post-TBI. Phospho-GSK-3beta - phosphorylated by phospho-Akt - slightly increased at 4 hours post-TBI and peaked at 72 hours post-TBI. These changes in Phospho-GSK-3beta expression were accompanied by a marked increase in expression of phospho-beta-catenin at 4 hours post-TBI which was sustained until 7 days post-TBI. Double staining of phospho-Akt and NeuN revealed the colocalization of phospho-Akt positive cells and neuronal cells. In addition, double staining of phospho-Akt and TUNEL showed no colocalization of phospho-Akt cells and TUNEL-positive cells. Conclusion: Phosphorylation of Akt (Ser473) and GSK3beta (Ser9) was accelerated in the injured cortex, and involved in the neuronal survival after TBI. Moreover, neuroprotection of beta-catenin against ischemia was partly mediated by enhanced and persistent activation of the Akt/GSK3beta signaling pathway.	[Zhao, Yuanli] Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Zhao, Shangfeng; Fu, Jidi; Zhang, Jialiang] Capital Univ Med Sci, Beijing Tongren Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Liu, Xiangrong] Capital Univ Med Sci, Xuanwu Hosp, Key Lab Neurodegenerat Dis, Cerebrovasc Dis Res Inst,Minist Educ, Beijing 100050, Peoples R China; [Wang, Tony] Wayne State Univ, Detroit, MI USA		Zhao, YL (corresponding author), Capital Univ Med Sci, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	zhaolang88@hotmail.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81000504]	This project was supported by the Natural Science Foundation of China (Grant No. 81000504).	Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chan PH, 2004, STROKE, V35, P2748, DOI 10.1161/01.STR.0000143325.25610.ac; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROSCI, V17, P9172; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Endo H, 2006, J CEREBR BLOOD F MET, V26, P1479, DOI 10.1038/sj.jcbfm.9600303; Endo H, 2006, STROKE, V37, P2140, DOI 10.1161/01.STR.0000229888.55078.72; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Friguls B, 2002, NEUROBIOL DIS, V11, P443, DOI 10.1006/nbdi.2002.0553; Geiger B, 1995, ACTA ANAT, V154, P46; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Jin G, 2003, NEUROL RES, V25, P249, DOI 10.1179/016164103101201454; Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5; Kelly S, 2004, EXP NEUROL, V188, P378, DOI 10.1016/j.expneurol.2004.04.004; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Lei ZN, 2008, NEUROSCI LETT, V435, P108, DOI 10.1016/j.neulet.2008.02.031; Li Q, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.33; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010; Sanderson TH, 2009, NEUROL RES, V31, P947, DOI 10.1179/174313209X382449; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007; Wang JM, 2000, BRAIN RES, V859, P381, DOI 10.1016/S0006-8993(00)02008-4; Wang SJ, 2002, NEUROL RES, V24, P719, DOI 10.1179/016164102101200645; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Xia Y, 2010, NEUROPHARMACOLOGY, V58, P330, DOI 10.1016/j.neuropharm.2009.10.009; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang HF, 2008, BRAIN RES, V1198, P182, DOI 10.1016/j.brainres.2008.01.007; Zhao H, 2005, J NEUROSCI, V25, P9794, DOI 10.1523/JNEUROSCI.3163-05.2005; Zhu D, 2009, NEUROL RES, V31, P200, DOI 10.1179/174313209X393915	39	71	74	1	15	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	MAY	2012	34	4					400	407		10.1179/1743132812Y.0000000025			8	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	948XJ	WOS:000304536600012	22643085				2022-02-06	
J	Diaz, AP; Schwarzbold, ML; Thais, ME; Hohl, A; Bertotti, MM; Schmoeller, R; Nunes, JC; Prediger, R; Linhares, MN; Guarnieri, R; Walz, R				Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Thais, Maria Emilia; Hohl, Alexandre; Bertotti, Melina More; Schmoeller, Roseli; Nunes, Jean Costa; Prediger, Rui; Linhares, Marcelo Neves; Guarnieri, Ricardo; Walz, Roger			Psychiatric Disorders and Health-Related Quality of Life after Severe Traumatic Brain Injury: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						major depressive disorder; personality changes; quality of life; severe traumatic brain injury	DEPRESSION; RELIABILITY; INTERVIEW; VALIDITY; IMPACT; APATHY	Traumatic brain injury (TBI) is a major cause of death and disability and impairs health-related quality of life (HRQOL). Psychiatric disorders have been recognized as major components of TBI morbidity, yet few studies have addressed the relationship between these outcomes. Sample size, selection bias, and retrospective design, are methodological limitations for TBI-related psychiatric studies. For this study, 33 patients with severe TBI were evaluated prospectively regarding demographic, clinical, radiological, neurosurgical, laboratory, and psychosocial characteristics, as well as psychiatric manifestations and HRQOL, 18 months after hospitalization. Psychiatric manifestations were assessed using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), the Hospital Anxiety and Depression Scale (HADS), the Brief Psychiatric Rating Scale (BPRS), and the Apathy Evaluation Scale (AES). HRQOL was determined using the Medical Outcomes Study's 36-item Short-Form Health Survey (SF-36). Following TBI, a significant increase in the prevalence of major depressive disorder (MDD) and generalized anxiety disorder (p = 0.02), and a significant decrease in the prevalence of alcohol and cannabinoid abuse (p = 0.001) were observed. The most frequent psychiatric disorders following severe TBI were found to be MDD (30.3%), and personality changes (33.3%). In comparison to patients without personality changes, patients with personality changes experienced a decline in general health and impairments in physical and social functioning. Patients with MDD showed impairment in all SF-36 domains compared to non-depressed patients. This prospective TBI-related psychiatric study is the first to demonstrate a significant association between MDD, personality changes, and HRQOL, following severe TBI in a well-defined sample of patients.	[Diaz, Alexandre Paim] Inst Psiquiatria Estado Santa Catarina IPQ, Sao Jose, SC, Brazil; [Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Thais, Maria Emilia; Hohl, Alexandre; Schmoeller, Roseli; Nunes, Jean Costa; Prediger, Rui; Linhares, Marcelo Neves; Walz, Roger] Univ Fed Santa Catarina, Ctr Neurociencias Aplicadas CeNAp, Univ Hosp, Florianopolis, SC, Brazil; [Diaz, Alexandre Paim; Schwarzbold, Marcelo Liborio; Guarnieri, Ricardo] Univ Fed Santa Catarina, Ambulatorio Transtornos Psiquiatr Resistentes Tra, Univ Hosp, Florianopolis, SC, Brazil; [Hohl, Alexandre; Walz, Roger] Univ Fed Santa Catarina, Dept Clin Med, Univ Hosp, Florianopolis, SC, Brazil; [Linhares, Marcelo Neves; Guarnieri, Ricardo] Univ Fed Santa Catarina, Dept Cirurgia, Univ Hosp, Florianopolis, SC, Brazil; [Prediger, Rui] Univ Fed Santa Catarina, Lab Expt Doencas Neurodegenerat, Dept Farmacol, Ctr Ciencias Biol, Florianopolis, SC, Brazil; [Thais, Maria Emilia; Linhares, Marcelo Neves] Hosp Governador Celso Ramos, Serv Neurocirurgia, Florianopolis, SC, Brazil		Walz, R (corresponding author), Univ Fed Santa Trindade, Univ Hosp, Dept Clin Med, 3 Andar, BR-88040970 Florianopolis, SC, Brazil.	rogerwalz@hotmail.com	Hohl, Alexandre/R-9269-2019; Prediger, Rui D/C-4036-2013; Schwarzbold, Marcelo Liborio/J-8960-2014; Diaz, Alexandre Paim/AAD-8323-2019; Walz, Roger/K-9096-2013; Prediger, Rui Daniel/AAV-3419-2020; Neurociencia, Inct/I-1011-2013; Diaz, Alexandre Paim/J-9042-2014	Hohl, Alexandre/0000-0002-8073-5837; Prediger, Rui D/0000-0002-7547-6463; Diaz, Alexandre Paim/0000-0002-6591-6648; Walz, Roger/0000-0002-9875-6687; Prediger, Rui Daniel/0000-0002-7547-6463; 	Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC); CNPqConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)	This research was supported by Fundacao de Amparo a Pesquisa e Inovacao do Estado de Santa Catarina (FAPESC) and CNPq (Dr. Walz). Dr. Schwarzbold is a post-graduate fellow from CNPq (Brazil).	Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Botega NJ, 1998, J BRAS PSIQUIAT, V47, P285; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Ciconelli R.M., 1999, REV BRAS REUMATOL, V39, P143, DOI DOI 10.1590/S0482-50042010000300005; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Crippa JAS, 2001, ACTA PSYCHIAT SCAND, V103, P465, DOI 10.1034/j.1600-0447.2001.00185.x; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; First M.B., 1996, STRUCTURED CLIN INTE; Giacino JT, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199810000-00003; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Gullo J.D., 2010, HOSP MORTALITY PATIE; Hawthorne G, 2011, J CLIN NEUROSCI, V18, P197, DOI 10.1016/j.jocn.2010.06.015; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARKLUND N, 2010, BR J PHARM; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Pelegrin-Valero C, 2001, REV NEUROLOGIA, V32, P681, DOI 10.33588/rn.3207.2000180; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Rao V, 2008, J NEUROPSYCH CLIN N, V20, P118, DOI 10.1176/jnp.2008.20.1.118; RHOADES HM, 1988, PSYCHOPHARMACOL BULL, V24, P101; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Strawbridge WJ, 1998, GROWTH HORM IGF RES, V8, P59, DOI 10.1016/S1096-6374(98)80011-7; Tavares M, 1996, ENTREVISTA CLIN ESTR; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	41	71	71	1	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1029	1037		10.1089/neu.2011.2089			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100001	22111890				2022-02-06	
J	Kabadi, SV; Stoica, BA; Byrnes, KR; Hanscom, M; Loane, DJ; Faden, AI				Kabadi, Shruti V.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Hanscom, Marie; Loane, David J.; Faden, Alan I.			Selective CDK inhibitor limits neuroinflammation and progressive neurodegeneration after brain trauma	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; cell cycle; cyclin-dependent kinases; microglial activation; neurodegeneration	CONTROLLED CORTICAL IMPACT; CELL-CYCLE ACTIVATION; ALZHEIMERS-DISEASE; SPATIAL MEMORY; INJURY; ROSCOVITINE; DAMAGE; NEURONS; DEATH; MICROGLIA	Traumatic brain injury (TBI) induces secondary injury mechanisms, including cell-cycle activation (CCA), which lead to neuronal cell death, microglial activation, and neurologic dysfunction. Here, we show progressive neurodegeneration associated with microglial activation after TBI induced by controlled cortical impact (CCI), and also show that delayed treatment with the selective cyclin-dependent kinase inhibitor roscovitine attenuates posttraumatic neurodegeneration and neuroinflammation. CCI resulted in increased cyclin A and D1 expressions and fodrin cleavage in the injured cortex at 6 hours after injury and significant neurodegeneration by 24 hours after injury. Progressive neuronal loss occurred in the injured hippocampus through 21 days after injury and correlated with a decline in cognitive function. Microglial activation associated with a reactive microglial phenotype peaked at 7 days after injury with sustained increases at 21 days. Central administration of roscovitine at 3 hours after CCI reduced subsequent cyclin A and D1 expressions and fodrin cleavage, improved functional recovery, decreased lesion volume, and attenuated hippocampal and cortical neuronal cell loss and cortical microglial activation. Furthermore, delayed systemic administration of roscovitine improved motor recovery and attenuated microglial activation after CCI. These findings suggest that CCA contributes to progressive neurodegeneration and related neurologic dysfunction after TBI, likely in part related to its induction of microglial activation. Journal of Cerebral Blood Flow & Metabolism (2012) 32, 137-149; doi:10.1038/jcbfm.2011.117; published online 10 August 2011	[Kabadi, Shruti V.; Stoica, Bogdan A.; Hanscom, Marie; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Dept Anesthesiol, Baltimore, MD 21201 USA; [Kabadi, Shruti V.; Stoica, Bogdan A.; Byrnes, Kimberly R.; Loane, David J.; Faden, Alan I.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Faden, AI (corresponding author), Univ Maryland, Sch Med, STAR Organized Res Ctr, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	afaden@anes.umm.edu	Loane, David/ABD-5177-2021; STOICA, BOGDAN/H-9782-2013	Loane, David/0000-0003-0393-3503; STOICA, BOGDAN/0000-0002-2501-6434; Byrnes, Kimberly/0000-0002-7501-7734; Hanscom, Marie/0000-0001-8308-135X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS052568]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052568] Funding Source: NIH RePORTER	This work was supported by a grant from the National Institutes of Health, R01 NS052568.	Arendt T, 2003, PROG NEUROBIOL, V71, P83, DOI 10.1016/j.pneurobio.2003.09.007; Bach S, 2005, J BIOL CHEM, V280, P31208, DOI 10.1074/jbc.M500806200; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2007, BRAIN, V130, P2977, DOI 10.1093/brain/awm179; Byrnes KR, 2007, NEUROCHEM RES, V32, P1799, DOI 10.1007/s11064-007-9312-2; Cernak I, 2005, CELL CYCLE, V4, P1286, DOI 10.4161/cc.4.9.1996; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; DAVIS EJ, 1994, BRAIN RES BULL, V34, P73, DOI 10.1016/0361-9230(94)90189-9; Di Giovanni S, 2005, P NATL ACAD SCI USA, V102, P8333, DOI 10.1073/pnas.0500989102; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M, 2010, TRAUMATIC BRAIN INJU; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Gilbert PE, 2009, PROG NEURO-PSYCHOPH, V33, P774, DOI 10.1016/j.pnpbp.2009.03.037; Goldstein LB, 2003, ILAR J, V44, P125, DOI 10.1093/ilar.44.2.125; Greene LA, 2004, CELL DEATH DIFFER, V11, P49, DOI 10.1038/sj.cdd.4401341; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrup K, 2007, NAT REV NEUROSCI, V8, P368, DOI 10.1038/nrn2124; Hilton GD, 2008, J CEREBR BLOOD F MET, V28, P1845, DOI 10.1038/jcbfm.2008.75; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lee I, 2005, BEHAV NEUROSCI, V119, P145, DOI 10.1037/0735-7044.119.1.145; Lee I, 2004, HIPPOCAMPUS, V14, P66, DOI 10.1002/hipo.10167; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; LUNDBERG A, 1998, MOL CELL BIOL, V23, P1044; MARTIN JH, 1996, NEUROANATOMY TEXT AT; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Menn B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012117; Mori T, 1998, ACT NEUR S, V71, P120; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nauta WJH, 1986, FUNDAMENTAL NEUROANA; Nguyen MD, 2003, J NEUROSCI, V23, P2131; Nutley BP, 2005, MOL CANCER THER, V4, P125; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Redish AD, 1998, NEURAL COMPUT, V10, P73, DOI 10.1162/089976698300017908; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Soltys Z, 2001, J NEUROSCI RES, V63, P90, DOI 10.1002/1097-4547(20010101)63:1<90::AID-JNR11>3.0.CO;2-9; Stoica BA, 2009, NEUROTOX RES, V16, P221, DOI 10.1007/s12640-009-9050-0; Zhan XH, 2008, BRAIN RES, V1234, P183, DOI 10.1016/j.brainres.2008.07.094	47	71	73	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2012	32	1					137	149		10.1038/jcbfm.2011.117			13	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	875DG	WOS:000299010000016	21829212	Bronze, Green Published			2022-02-06	
J	Shultz, SR; MacFabe, DF; Foley, KA; Taylor, R; Cain, DP				Shultz, Sandy R.; MacFabe, Derrick F.; Foley, Kelly A.; Taylor, Roy; Cain, Donald P.			A single mild fluid percussion injury induces short-term behavioral and neuropathological changes in the Long-Evans rat: Support for an animal model of concussion	BEHAVIOURAL BRAIN RESEARCH			English	Article						Fluid percussion injury; Concussion; Neuroinflammation; Axonal injury; Learning and memory; Animal model; Anxiety-like behavior	TRAUMATIC BRAIN-INJURY; ELEVATED PLUS-MAZE; AXONAL INJURY; HEAD-INJURY; WATER MAZE; SYNAPTIC PLASTICITY; SPATIAL NAVIGATION; PERIRHINAL CORTEX; SEX-DIFFERENCES; PROPIONIC-ACID	Brain concussion is a serious public health concern and is associated with short-term cognitive impairments and behavioral disturbances that typically occur in the absence of significant brain damage. The current study addresses the need to better understand the effects of a mild lateral fluid percussion injury on rat behavior and neuropathology in an animal model of concussion. Male Long-Evans rats received either a single mild fluid percussion injury or a sham-injury, and either a short (24 h) or long (4 weeks) post-injury recovery period. After recovery, rats underwent a detailed behavioral analysis consisting of tests for rodent anxiety, cognition, social behavior, sensorimotor function, and depression-like behavior. After testing all rats were sacrificed and brains were examined immunohistochemically with markers for microglia/macrophage activation, reactive astrocytosis, and axonal injury. Injured rats (mean injury force: 1.20 +/- .03 atm) displayed significant short-term cognitive impairments in the water maze and significantly more anxiolytic-like behavior in the elevated-plus maze compared to sham controls. Neuropathological analysis of the brains of injured rats showed an acute increase in reactive astrogliosis and activated microglia in cortex and evidence of axonal injury in the corpus callosum. There were no significant long-term effects on any behavioral or neuropathological measure 4 weeks after injury. These short-term behavioral and neuropathological changes are consistent with findings in human patients suffering a brain concussion, and provide further evidence for the use of a single mild lateral fluid percussion injury to study concussion in the rat. (C) 2011 Elsevier B.V. All rights reserved.	[MacFabe, Derrick F.; Taylor, Roy] Univ Western Ontario, Dept Psychol, Kilee Patchell Evans Autism Res Grp, London, ON, Canada; [Shultz, Sandy R.; Foley, Kelly A.; Cain, Donald P.] Univ Western Ontario, Grad Program Neurosci, London, ON, Canada		Shultz, SR (corresponding author), Univ Melbourne, Royal Melbourne Hosp, 1-52 Thompson St, Williamtown, Vic 3016, Australia.	sshultz@unimelb.edu.au		Shultz, Sandy/0000-0002-2525-8775	Natural Science and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by a grant from the Natural Science and Engineering Research Council (NSERC) to Dr. Donald P. Cain, a scholarship from NSERC to Sandy R. Shultz, and contributions from GoodLife Childrens's Foundation and Round for a Reason Charities to Derrick F. MacFabe. We thank Dr. Richard Sutton and Dr. David Hovda from the UCLA Brain Injury Research Center for their help in LFP training. Additional thanks go to Lisa Tichenoff and Francis Boon for their assistance in the research project.	AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Amagdei A, 2010, INT J DEV NEUROSCI, V28, P105, DOI 10.1016/j.ijdevneu.2009.08.017; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Beiko J, 1997, BEHAV BRAIN RES, V88, P201, DOI 10.1016/S0166-4328(97)02298-5; Beiko J, 2004, BEHAV BRAIN RES, V151, P239, DOI 10.1016/j.bbr.2003.08.019; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bortolato M, 2009, NEUROPSYCHOPHARMACOL, V34, P2746, DOI 10.1038/npp.2009.118; Cain DP, 2006, BEHAV BRAIN RES, V170, P241, DOI 10.1016/j.bbr.2006.02.023; Cain DP, 2003, BRAIN RES, V972, P64, DOI 10.1016/S0006-8993(03)02486-7; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Dringen R, 2005, ANTIOXID REDOX SIGN, V7, P1223, DOI 10.1089/ars.2005.7.1223; Fan LW, 2008, EUR J NEUROSCI, V27, P1475, DOI 10.1111/j.1460-9568.2008.06121.x; Gerber J, 2009, CLIN NEUROPATHOL, V28, P33; Giza CC, 2001, J ATHL TRAINING, V36, P228; Griesbach GS, 2009, BRAIN RES, V1288, P105, DOI 10.1016/j.brainres.2009.06.045; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hasenohrl RU, 1998, PHARMACOL BIOCHEM BE, V59, P527, DOI 10.1016/S0091-3057(97)00406-1; Hein AM, 2009, MOL NEUROBIOL, V40, P15, DOI 10.1007/s12035-009-8066-z; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jones NC, 2008, J NEUROTRAUM, V25, P1367, DOI 10.1089/neu.2008.0641; Kaut KP, 2001, COGN AFFECT BEHAV NE, V1, P270, DOI 10.3758/CABN.1.3.270; Kim E, 2002, NEUROREHABILITATION, V17, P297; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laurer HL., 2000, EUR J TRAUMA, V26, P95, DOI [10.1007/s000680050007, DOI 10.1007/S000680050007]; Lee YB, 2002, J NEUROSCI RES, V69, P94, DOI 10.1002/jnr.10253; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lindemann S, 2008, PHYSIOL BEHAV, V93, P415, DOI 10.1016/j.physbeh.2007.11.038; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meyer JS, 2008, ANN NY ACAD SCI, V1139, P151, DOI 10.1196/annals.1432.029; Miu AC, 2006, BEHAV BRAIN RES, V172, P135, DOI 10.1016/j.bbr.2006.05.007; Mochizuki A, 1996, EXP NEUROL, V142, P89, DOI 10.1006/exnr.1996.0181; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; Mumby DG, 2000, BEHAV BRAIN RES, V114, P119, DOI 10.1016/S0166-4328(00)00217-5; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Saucier DM, 2008, ANIM COGN, V11, P129, DOI 10.1007/s10071-007-0096-1; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; Shultz SR, 2008, NEUROPHARMACOLOGY, V54, P901, DOI 10.1016/j.neuropharm.2008.01.013; Shultz SR, 2009, BEHAV BRAIN RES, V200, P33, DOI 10.1016/j.bbr.2008.12.023; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44; Wiig KA, 1996, LEARN MEMORY, V3, P313, DOI 10.1101/lm.3.4.313; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2010, NEUROREHAB NEURAL RE, V24, P290, DOI 10.1177/1545968309348318; Young GB, 2009, ANN NY ACAD SCI, V1157, P32, DOI 10.1111/j.1749-6632.2009.04471.x; Zilka N, 2006, Bratisl Lek Listy, V107, P374	63	71	71	2	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	OCT 31	2011	224	2					326	335		10.1016/j.bbr.2011.06.012			10	Behavioral Sciences; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Behavioral Sciences; Neurosciences & Neurology	818ZQ	WOS:000294795600014	21704658				2022-02-06	
J	Bolander, R; Mathie, B; Bir, C; Ritzel, D; Vandevord, P				Bolander, Richard; Mathie, Blake; Bir, Cynthia; Ritzel, David; Vandevord, Pamela			Skull Flexure as a Contributing Factor in the Mechanism of Injury in the Rat when Exposed to a Shock Wave	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Blast; Injury; Mechanism; Explosion	TRAUMATIC BRAIN-INJURY; BLAST; MODEL	The manner in which energy from an explosion is transmitted into the brain is currently a highly debated topic within the blast injury community. This study was conducted to investigate the injury biomechanics causing blast-related neurotrauma in the rat. Biomechanical responses of the rat head under shock wave loading were measured using strain gauges on the skull surface and a fiber optic pressure sensor placed within the cortex. MicroCT imaging techniques were applied to quantify skull bone thickness. The strain gauge results indicated that the response of the rat skull is dependent on the intensity of the incident shock wave; greater intensity shock waves cause greater deflections of the skull. The intracranial pressure (ICP) sensors indicated that the peak pressure developed within the brain was greater than the peak side-on external pressure and correlated with surface strain. The bone plates between the lambda, bregma, and midline sutures are probable regions for the greatest flexure to occur. The data provides evidence that skull flexure is a likely candidate for the development of ICP gradients within the rat brain. This dependency of transmitted stress on particular skull dynamics for a given species should be considered by those investigating blast-related neurotrauma using animal models.	[Bolander, Richard; Mathie, Blake; Bir, Cynthia; Vandevord, Pamela] Wayne State Univ, Dept Biomed Engn, Detroit, MI 48201 USA; [Ritzel, David] Dyn FX Consulting Ltd, Amherstburg, ON N9V 2T5, Canada; [Vandevord, Pamela] John D Dingell VAMC, Detroit, MI 48201 USA		Vandevord, P (corresponding author), Wayne State Univ, Dept Biomed Engn, 818 W Hancock, Detroit, MI 48201 USA.	dt8583@wayne.edu; blakemathie@gmail.com; cbir@wayne.edu; dritz@dyn-fx.com; pvord@wayne.edu	VandeVord, Pamela/B-4606-2012	Bir, Cynthia/0000-0002-0777-0951	DODUnited States Department of Defense [W81XWH-08-2-0207]; Thomas J. Rumble Fellowship	We would like to thank the WSU Bioengineering Center staff and students for assisting with this project. We would also like thank Dr. Amanda Esquivel for obtaining the CT images. This project was partially funded by DOD Award Number W81XWH-08-2-0207 and the Thomas J. Rumble Fellowship.	Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; CERNAK I, 2005, RESTORATIVE NEUROLOG, V23, P139; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; CLEMEDSON CJ, 1955, AM J PHYSIOL, V181, P471, DOI 10.1152/ajplegacy.1955.181.3.471; Courtney MW, 2011, NEUROIMAGE, V54, pS55, DOI 10.1016/j.neuroimage.2010.05.025; Finkel MF, 2006, J NEUROL SCI, V249, P63, DOI 10.1016/j.jns.2006.06.005; Henshall B, 1954, J ROYAL AERONAUT SOC, V58, P541; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kluger Yoram, 2007, Am J Disaster Med, V2, P21; Lechner R, 2010, UNFALLCHIRURG, V113, P106, DOI 10.1007/s00113-009-1732-9; Leonardi AD, 2011, J NEUROTRAUM, V28, P85, DOI 10.1089/neu.2010.1324; Ling GSF, 2011, CURR OPIN ANESTHESIO, V24, P124, DOI 10.1097/ACO.0b013e32834458da; Luks FI, 2010, ACTA CHIR BELG, V110, P517, DOI 10.1080/00015458.2010.11680667; Moss WC, 2009, PHYS REV LETT, V103, DOI 10.1103/PhysRevLett.103.108702; Mott FW, 1916, LANCET, V1, P331; Risling Marten, 2010, Front Neurol, V1, P1, DOI 10.3389/fneur.2010.00001; Romba J., 1961, US ARMY ORDINANCE HU, P17; Stuhmiller JH, 1996, J BIOMECH, V29, P227, DOI 10.1016/0021-9290(95)00039-9; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765	22	71	72	0	19	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2011	39	10					2550	2559		10.1007/s10439-011-0343-0			10	Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Engineering	841JE	WOS:000296507800008	21735320				2022-02-06	
J	Windmiller, JR; Valdes-Ramirez, G; Zhou, N; Zhou, M; Miller, PR; Jin, CM; Brozik, SM; Polsky, R; Katz, E; Narayan, R; Wang, J				Windmiller, Joshua Ray; Valdes-Ramirez, Gabriela; Zhou, Nandi; Zhou, Ming; Miller, Philip R.; Jin, Chunming; Brozik, Susan M.; Polsky, Ronen; Katz, Evgeny; Narayan, Roger; Wang, Joseph			Bicomponent Microneedle Array Biosensor for Minimally-Invasive Glutamate Monitoring	ELECTROANALYSIS			English	Article						Amperometry; Biosensors; Glutamate; Microneedle; Poly(o-phenylenediamine)	TRAUMATIC BRAIN-INJURY; MODIFIED POLY(PHENYLENEDIAMINE)-COATED ELECTRODES; O-PHENYLENEDIAMINE FILM; EXCITATORY AMINO-ACIDS; GLUCOSE-OXIDASE; LACTATE BIOSENSOR; IN-VITRO; BLOOD; INTERFERENCE; EXTRACTION	This article describes the design of a new and attractive minimally-invasive bicomponent microneedle sensing device for the electrochemical monitoring of the excitatory neurotransmitter glutamate and glucose. The new device architecture relies on the close integration of solid and hollow microneedles into a single biosensor array device containing multiple microcavities. Such microcavities facilitate the electropolymeric entrapment of the recognition enzyme within each microrecess. The resulting microneedle biosensor array can be employed as a minimally-invasive on-body transdermal patch, obviating the extraction/sampling of the biological fluid, thereby simplifying device requirements. The new concept is demonstrated for the electropolymeric entrapment of glutamate oxidase and glucose oxidase within a poly(o-phenylenediamine) (PPD) thin film. The PPD-based enzyme entrapment methodology enables the effective rejection of coexisting electroactive interferents without compromising the sensitivity or response time of the device. The resulting microneedle-based glutamate and glucose biosensors thus exhibit high selectivity, sensitivity, speed, and stability in both buffer and undiluted human serum. High-fidelity glutamate measurements down to the 10 mu M level are obtained in serum. The attractive recess design also serves to protect the enzyme layer upon insertion into the skin. This simple, yet robust microneedle design is well-suited for diverse biosensing applications in which real-time metabolite monitoring is a core requirement.	[Miller, Philip R.; Jin, Chunming; Narayan, Roger] Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27695 USA; [Windmiller, Joshua Ray; Valdes-Ramirez, Gabriela; Zhou, Nandi; Zhou, Ming; Wang, Joseph] Univ Calif San Diego, Dept Nano Engn, La Jolla, CA 92093 USA; [Brozik, Susan M.; Polsky, Ronen] Sandia Natl Labs, Dept Biosensors & Nanomat, Albuquerque, NM 87185 USA; [Katz, Evgeny] Clarkson Univ, Dept Chem, Potsdam, NY 13699 USA		Narayan, R (corresponding author), Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27695 USA.	roger_narayan@unc.edu; josephwang@ucsd.edu	Zhou, Nandi/C-5111-2011; Valdes-Ramirez, Gabriela/D-2053-2012; Wang, Joseph/C-6175-2011; Zhou, Ming/B-7451-2009	Zhou, Nandi/0000-0002-2906-7781; Zhou, Ming/0000-0003-2239-9342; Valdes Ramirez, Gabriela/0000-0002-9566-930X	Office of Naval ResearchOffice of Naval Research [N00014-08-1-1202]; National Science FoundationNational Science Foundation (NSF) [0547491]; Sandia National LaboratoriesUnited States Department of Energy (DOE); United States Department of Energy's National Nuclear Security AdministrationNational Nuclear Security Administration [DE-SC0004937, DE-AC04-94AL85000]; Mexican government; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [20805020]; Chinese Ministry of EducationMinistry of Education, China [109079]	This work was supported by the Office of Naval Research (Award No. N00014-08-1-1202), the National Science Foundation (Award No. 0547491), the Laboratory Directed Research and Development program at Sandia National Laboratories, and the United States Department of Energy's National Nuclear Security Administration (Grant Number DE-SC0004937) under Contract DE-AC04-94AL85000. G. V. R. acknowledges a CONACyT post-doctoral fellowship from the Mexican government. N. Z. acknowledges support from the National Natural Science Foundation of China (Award No. 20805020) and the Key Project of the Chinese Ministry of Education (Award No. 109079).	BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BERNERS MOM, 1994, ANAL CHEM, V66, P2017, DOI 10.1021/ac00085a016; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; Cosnier S, 2003, ANAL BIOANAL CHEM, V377, P507, DOI 10.1007/s00216-003-2131-7; DeBenedetto GE, 1996, BIOSENS BIOELECTRON, V11, P1001, DOI 10.1016/0956-5663(96)87659-7; DEMPSEY E, 1993, TALANTA, V40, P445, DOI 10.1016/0039-9140(93)80257-R; Gittard Shaun D., 2009, Biotechnology Journal, V4, P129, DOI 10.1002/biot.200800233; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GRIFFITHS T, 1984, J NEUROTRAUM, V15, P253; Henry C, 1998, ANAL CHEM, V70, p594A; Iijima T, 1998, NEUROSCI RES, V32, P201, DOI 10.1016/S0168-0102(98)00090-X; Kratz A, 2004, NEW ENGL J MED, V351, P1548, DOI 10.1056/NEJMcpc049016; LEUCHTNER RE, 1992, SURF COAT TECH, V51, P476, DOI 10.1016/0257-8972(92)90285-I; LOWRY JP, 1994, ELECTROANAL, V6, P369, DOI 10.1002/elan.1140060504; LOWRY JP, 1994, ANAL CHEM, V66, P1754, DOI 10.1021/ac00082a025; MALITESTA C, 1990, ANAL CHEM, V62, P2735, DOI 10.1021/ac00223a016; McAteer K, 1996, ANALYST, V121, P773, DOI 10.1039/an9962100773; McMahon CP, 2006, ANAL CHEM, V78, P2352, DOI 10.1021/ac0518194; Miller PR, 2011, BIOMICROFLUIDICS, V5, DOI 10.1063/1.3569945; Mukerjee E, 2004, SENSOR ACTUAT A-PHYS, V114, P267, DOI 10.1016/j.sna.2003.11.008; Opitz T, 1994, NEUROPSYCHOPHARMACOL, V11, P278; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMISANO F, 1994, BIOSENS BIOELECTRON, V9, P471, DOI 10.1016/0956-5663(94)90009-4; Prausnitz MR, 2008, NAT BIOTECHNOL, V26, P1261, DOI 10.1038/nbt.1504; Ryan MR, 1997, ANALYST, V122, P1419, DOI 10.1039/a704508e; Suzuki M, 2002, J NEUROTRAUM, V19, P285, DOI 10.1089/08977150252807027; SWAIN MS, 1992, HEPATOLOGY, V16, P1028, DOI 10.1002/hep.1840160428; Tsuchiya K, 2005, BIOMED MICRODEVICES, V7, P347, DOI 10.1007/s10544-005-6077-8; Valencia E, 2002, NUTRITION, V18, P367, DOI 10.1016/S0899-9007(02)00774-8; Wang J, 2008, CHEM REV, V108, P814, DOI 10.1021/cr068123a; Windmiller JR, 2011, ANALYST, V136, P1846, DOI 10.1039/c1an00012h; Yang QL, 1999, BIOSENS BIOELECTRON, V14, P203, DOI 10.1016/S0956-5663(98)00109-2; ZILKHA E, 1995, J NEUROSCI METH, V40, P1	35	71	72	15	117	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1040-0397			ELECTROANAL	Electroanalysis	OCT	2011	23	10					2302	2309		10.1002/elan.201100361			8	Chemistry, Analytical; Electrochemistry	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Electrochemistry	839WC	WOS:000296399200007					2022-02-06	
J	Andrews, PJD; Sinclair, HL; Battison, CG; Polderman, KH; Citerio, G; Mascia, L; Harris, BA; Murray, GD; Stocchetti, N; Menon, DK; Shakur, H; De Backer, D				Andrews, Peter J. D.; Sinclair, Helen Louise; Battison, Claire G.; Polderman, Kees H.; Citerio, Giuseppe; Mascia, Luciana; Harris, Bridget A.; Murray, Gordon D.; Stocchetti, Nino; Menon, David K.; Shakur, Haleema; De Backer, Daniel			European society of intensive care medicine study of therapeutic hypothermia (32-35 degrees C) for intracranial pressure reduction after traumatic brain injury (the Eurotherm3235Trial)	TRIALS			English	Article							TERM MILD HYPOTHERMIA; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; GUIDELINES; EXPERIENCE; MANAGEMENT; INDUCTION	Background: Traumatic brain injury is a major cause of death and severe disability worldwide with 1,000,000 hospital admissions per annum throughout the European Union. Therapeutic hypothermia to reduce intracranial hypertension may improve patient outcome but key issues are length of hypothermia treatment and speed of re-warming. A recent meta-analysis showed improved outcome when hypothermia was continued for between 48 hours and 5 days and patients were re-warmed slowly (1 degrees C/4 hours). Previous experience with cooling also appears to be important if complications, which may outweigh the benefits of hypothermia, are to be avoided. Methods/design: This is a pragmatic, multi-centre randomised controlled trial examining the effects of hypothermia 32-35 degrees C, titrated to reduce intracranial pressure <20 mmHg, on morbidity and mortality 6 months after traumatic brain injury. The study aims to recruit 1800 patients over 41 months. Enrolment started in April 2010. Participants are randomised to either standard care or standard care with titrated therapeutic hypothermia. Hypothermia is initiated with 20-30 ml/kg of intravenous, refrigerated 0.9% saline and maintained using each centre's usual cooling technique. There is a guideline for detection and treatment of shivering in the intervention group. Hypothermia is maintained for at least 48 hours in the treatment group and continued for as long as is necessary to maintain intracranial pressure <20 mmHg. Intracranial hypertension is defined as an intracranial pressure >20 mmHg in accordance with the Brain Trauma Foundation Guidelines, 2007. Discussion: The Eurotherm3235Trial is the most important clinical trial in critical care ever conceived by European intensive care medicine, because it was launched and funded by the European Society of Intensive Care Medicine and will be the largest non-commercial randomised controlled trial due to the substantial number of centres required to deliver the target number of patients. It represents a new and fundamental step for intensive care medicine in Europe. Recruitment will continue until January 2013 and interested clinicians from intensive care units worldwide can still join this important collaboration by contacting the Trial Coordinating Team via the trial website http://www.eurotherm3235trial.eu.	[Andrews, Peter J. D.; Sinclair, Helen Louise; Battison, Claire G.; Harris, Bridget A.] Univ Edinburgh, Dept Anaesthesia, Crit Care & Pain Management, Edinburgh EH8 9YL, Midlothian, Scotland; [Polderman, Kees H.] Crit Care Med, Pittsburgh, PA 15261 USA; [Citerio, Giuseppe] Nuovo Osped S Gerardo, Dipartimento Anestesia & Rianimaz, I-20052 Monza, MI, Italy; [Mascia, Luciana] Univ Turin, Osped S Giovanni Battista, Dipartimento Anestesiol & Rianimaz, Turin, Italy; [Murray, Gordon D.] Univ Edinburgh, Sch Med, Publ Hlth Sci Sect, Div Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Stocchetti, Nino] Osped Maggiore, Policlin IRCCS, Terapia Intens Neurosci, I-3520122 Milan, Italy; [Menon, David K.] Univ Cambridge, Dept Anaesthesia, Div Anaesthesia, Cambridge CB2 1TN, England; [Shakur, Haleema] London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England; [De Backer, Daniel] Free Univ Brussels, Erasme Univ Hosp, B-1070 Brussels, Belgium		Andrews, PJD (corresponding author), Univ Edinburgh, Dept Anaesthesia, Crit Care & Pain Management, Edinburgh EH8 9YL, Midlothian, Scotland.	p.andrews@ed.ac.uk	De Backer, Daniel/AAF-4177-2020; mascia, Luciana/L-3039-2018; Polderman, Kees H/K-3623-2012; Citerio, Giuseppe/B-1839-2015; Stocchetti, Nino/O-7444-2017; Forbes, John F/L-2558-2013	De Backer, Daniel/0000-0001-9841-5762; Citerio, Giuseppe/0000-0002-5374-3161; Stocchetti, Nino/0000-0003-3250-6834; Forbes, John F/0000-0002-8255-3762; Shakur-Still, Haleema/0000-0002-6511-109X; Murray, Gordon/0000-0001-9866-4734	European Society of Intensive Care Medicine; University of Edinburgh; NHS Lothian; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803, G9439390, G0600986, G0001237] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0800803, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Funded by: The European Society of Intensive Care Mediciner Sponsored by: The University of Edinburgh and NHS Lothian	Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Alderson P, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001048.pub2, DOI 10.1002/14651858.CD001048.PUB2]; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Badjatia N, 2008, STROKE, V39, P3242, DOI 10.1161/STROKEAHA.108.523654; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; *BRAIN TRAUM FDN A, 2007, GUID MAN SEV TRAUM B, V3; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; Dixon SR, 2005, HEART, V91, pIII2, DOI 10.1136/hrt.2005.060251; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Grant A. M., 2005, ISSUES DATA MONITORI; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; National Patient Safety Agency, 2007, INF SHEETS CONS FORM; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2005, CRIT CARE MED, V33, P2744, DOI 10.1097/01.CCM.0000190427.88735.19; Polderman KH, 2002, INTENS CARE MED, V28, pS103; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; POLDERMAN KH, 2003, INTENS CARE MED, V29, P1637; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yan Y, 2001, Chin J Traumatol, V4, P8; Zhang K, 2000, INNER MONGOLIA MED J, V32, P4; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4	47	71	75	0	8	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1745-6215		TRIALS	Trials	JAN 12	2011	12								8	10.1186/1745-6215-12-8			12	Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine	711KX	WOS:000286591500001	21226939	Green Published, gold, Green Accepted			2022-02-06	
J	Lester, P; Mogil, C; Saltzman, W; Woodward, K; Nash, W; Leskin, G; Bursch, B; Green, S; Pynoos, R; Beardslee, W				Lester, Patricia; Mogil, Catherine; Saltzman, William; Woodward, Kirsten; Nash, William; Leskin, Gregoty; Bursch, Brenda; Green, Sara; Pynoos, Robert; Beardslee, William			Families Overcoming Under Stress: Implementing Family-Centered Prevention for Military Families Facing Wartime Deployments and Combat Operational Stress	MILITARY MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; CHILD MALTREATMENT; MENTAL-HEALTH; LOW-INCOME; PARENTS; INTERVENTION; VETERANS; RISK; WAR; ADOLESCENTS	The toll of multiple and prolonged deployments on families has become clearer in recent years as military families have seen an increase in childhood anxiety, parental psychological distress, and marital discord. Families overcoming under stress (FOCUS), a family-centered evidence-informed resiliency training program developed at University of California, Los Angeles and Harvard Medical School, is being implemented at military installations through an initiative from Navy Bureau of Medicine and Surgery. The research foundation for FOCUS includes evidence-based preventive interventions that were adapted to meet the specific needs of military families facing combat operational stress associated with wartime deployments. Using a family narrative approach, FOCUS includes a customized approach utilizing core intervention components, including psychoeducation, emotional regulation skills, goal setting and problem solving skills, traumatic stress reminder management techniques, and family communication skills. The purpose of this study is to describe the development and implementation of FOCUS for military families. A case example is also presented.	[Lester, Patricia; Mogil, Catherine; Saltzman, William; Leskin, Gregoty; Bursch, Brenda; Green, Sara; Pynoos, Robert] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA; [Woodward, Kirsten] US Bur Navy Med & Surg, Washington, DC 20372 USA; [Nash, William] UCSD, VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; [Beardslee, William] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02215 USA		Lester, P (corresponding author), Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, 760 Westwood Plaza,Room A8-159, Los Angeles, CA 90024 USA.				Unites States Department of Navy Bureau Medicine and Surgery (BUMED) [N00189-09-C-Z057]; Frederick R. Weisman Philanthropic Foundation and Discretionary Trust	FOCUS has been supported by resources from the Unites States Department of Navy Bureau Medicine and Surgery (BUMED; contract no. N00189-09-C-Z057) and the Frederick R. Weisman Philanthropic Foundation and Discretionary Trust.	[Anonymous], 2006, DEV PSYCHOPATHOLOGY; Baker DG, 2009, MIL MED, V174, P773; Beardslee WR, 2007, J FAM PSYCHOL, V21, P703, DOI 10.1037/0893-3200.21.4.703; Beardslee WR, 2003, PEDIATRICS, V112, pE119, DOI 10.1542/peds.112.2.e119; Beardslee WR, 2009, ZERO 3, V29, P34; CHANDRA A, 2008, UNDERSTANDING IMPACT; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Chartrand MM, 2008, ARCH PEDIAT ADOL MED, V162, P1009, DOI 10.1001/archpedi.162.11.1009; Compas BE, 1989, PRIMARY PREVENTION P, P60; D'Angelo EJ, 2009, FAM PROCESS, V48, P269, DOI 10.1111/j.1545-5300.2009.01281.x; Department of Defense Task Force on Mental Health, 2007, ARCH VIS REP DEP DEF; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Faber AJ, 2008, J FAM PSYCHOL, V22, P222, DOI 10.1037/0893-3200.22.2.222; Flake EM, 2009, J DEV BEHAV PEDIATR, V30, P271, DOI 10.1097/DBP.0b013e3181aac6e4; Galovski T, 2004, AGGRESS VIOLENT BEH, V9, P477, DOI 10.1016/S1359-1789(03)00045-4; Gibbs DA, 2007, JAMA-J AM MED ASSOC, V298, P528, DOI 10.1001/jama.298.5.528; Hoge CQ, 2004, NEW ENGL J MED, V351, P2471; Huebner AJ, 2007, FAM RELAT, V56, P112, DOI 10.1111/j.1741-3729.2007.00445.x; Jensen PS, 1996, J AM ACAD CHILD PSY, V35, P433, DOI 10.1097/00004583-199604000-00009; Layne CM, 2008, J AM ACAD CHILD PSY, V47, P1048, DOI 10.1097/CHI.0b013e31817eecae; Lester P., 2008, EVIDENCE BASED TREAT, P170; Lester P, 2011, RISK AND RESILIENCE IN U S MILITARY FAMILIES, P149, DOI 10.1007/978-1-4419-7064-0_8; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lincoln A, 2008, J CLIN PSYCHOL, V64, P984, DOI 10.1002/jclp.20520; McCarroll JE, 2008, CHILD ABUSE REV, V17, P108, DOI 10.1002/car.986; Mrazek PJ, 1994, RED RISKS MENT DIS F; Nash WP, 2011, PSYCHOSOC STRES, P33; Nash WP, OPERATIONAL IN PRESS; National Research Council and Institute of Medicine, 2009, PREV MENT EM BEH DIS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Paavonen EJ., 2009, INT J MENT HEALTH PR, V11, P15, DOI [10.1080/14623730.2009.9721796, DOI 10.1080/14623730.2009.9721796]; Palmer C, 2008, MIL PSYCHOL, V20, P205, DOI 10.1080/08995600802118858; PATTERSON JM, 1987, J ADOLESCENCE, V10, P163, DOI 10.1016/S0140-1971(87)80086-6; Podorefsky DL, 2001, J AM ACAD CHILD PSY, V40, P879, DOI 10.1097/00004583-200108000-00008; Reger GM, 2009, TELEMED J E-HEALTH, V15, P101, DOI 10.1089/tmj.2008.0050; Rentz ED, 2007, AM J EPIDEMIOL, V165, P1199, DOI 10.1093/aje/kwm008; Riggs DS, 1998, J TRAUMA STRESS, V11, P87, DOI 10.1023/A:1024409200155; Rotheram-Borus MJ, 2004, ARCH PEDIAT ADOL MED, V158, P742, DOI 10.1001/archpedi.158.8.742; Rotheram-Borus MJ, 2001, J CONSULT CLIN PSYCH, V69, P763, DOI 10.1037//0022-006X.69.5.763; Rotherarn-Borus MJ, 2003, AIDS, V17, P1217, DOI 10.1097/01.aids.0000060337.12269.1d; Saltzman WR, 2009, FOCUS MILITARY UNPUB; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Waldrep DA, 2004, IRAQ WAR CLIN GUIDE, P83	44	71	71	0	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	JAN	2011	176	1					19	25		10.7205/MILMED-D-10-00122			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	703XS	WOS:000286015800005	21305955	Bronze			2022-02-06	
J	Yeo, RA; Gasparovic, C; Merideth, F; Ruhl, D; Doezema, D; Mayer, AR				Yeo, Ronald A.; Gasparovic, Charles; Merideth, Flannery; Ruhl, David; Doezema, David; Mayer, Andrew R.			A Longitudinal Proton Magnetic Resonance Spectroscopy Study of Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						creatine; mild traumatic brain injury; glutamate-glutamine signal; recovery; spectroscopy	HEAD-INJURY; WORKING-MEMORY; AXONAL INJURY; CREATINE; INTELLIGENCE; TBI; DYSFUNCTION; METABOLISM; ACTIVATION; MECHANISMS	Despite the prevalence and impact of mild traumatic brain injury (mTBI), common clinical assessment methods for mTBI have insufficient sensitivity and specificity. Moreover, few researchers have attempted to document underlying changes in physiology as a function of recovery from mTBI. Proton magnetic resonance spectroscopy (H-1-MRS) was used to assess neurometabolite concentrations in a supraventricular tissue slab in 30 individuals with semi-acute mTBI, and 30 sex-, age-, and education-matched controls. No significant group differences were evident on traditional measures of attention, memory, working memory, processing speed, and executive skills, though the mTBI group reported significantly more somatic, cognitive, and emotional symptoms. At a mean of 13 days post-injury, white matter concentrations of creatine (Cre) and phosphocreatine (PCre) and the combined glutamate-glutamine signal (Glx) were elevated in the mTBI group, while gray matter concentrations of Glx were reduced. Partial normalization of these three neurometabolites and N-acetyl aspartate occurred in the early days post-injury, during the semi-acute period of recovery. In addition, 17 mTBI patients (57%) returned for a follow-up evaluation (mean = 120 days post-injury). A significant group x time interaction indicated recovery in the mTBI group for gray matter Glx, and trends toward recovery in white matter Cre and Glx. An estimate of premorbid intelligence predicted the magnitude of neurometabolite normalization over the follow-up interval for the mTBI group, indicating that biological factors underlying intelligence may also be associated with more rapid recovery.	[Yeo, Ronald A.; Gasparovic, Charles; Merideth, Flannery; Ruhl, David; Mayer, Andrew R.] Mind Res Network, Albuquerque, NM 87106 USA; [Gasparovic, Charles; Mayer, Andrew R.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA; [Doezema, David] Univ New Mexico, Sch Med, Dept Emergency Med, Albuquerque, NM 87131 USA; [Yeo, Ronald A.; Gasparovic, Charles] Univ New Mexico, Sch Med, Dept Psychol, Albuquerque, NM 87131 USA		Mayer, AR (corresponding author), Mind Res Network, Pete & Nancy Domenici Hall,1101 Yale Blvd NE, Albuquerque, NM 87106 USA.	amayer@mrn.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R24-HD050836, R21-NS064464-01A1, 3 R21 NS064464-01S1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS064464] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (grants R24-HD050836, R21-NS064464-01A1, and 3 R21 NS064464-01S1 to A.M.).	Andres RH, 2008, BRAIN RES BULL, V76, P329, DOI 10.1016/j.brainresbull.2008.02.035; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bakiri Y, 2009, NEUROSCIENCE, V158, P266, DOI 10.1016/j.neuroscience.2008.01.015; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Dawson KS, 2007, BRAIN INJURY, V21, P943, DOI 10.1080/02699050701553171; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Furlow FB, 1997, P ROY SOC B-BIOL SCI, V264, P823, DOI 10.1098/rspb.1997.0115; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Govindaraju V, 2004, AM J NEURORADIOL, V25, P730; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Gussew A, 2010, NEUROIMAGE, V49, P1895, DOI 10.1016/j.neuroimage.2009.09.007; Hattingen E, 2008, NEURORADIOLOGY, V50, P759, DOI 10.1007/s00234-008-0409-3; Hinzman JM, 2010, J NEUROTRAUM, V27, P889, DOI 10.1089/neu.2009.1238; Holli Kirsi K, 2010, BMC Med Imaging, V10, P8, DOI 10.1186/1471-2342-10-8; Hyder F, 2006, J CEREBR BLOOD F MET, V26, P865, DOI 10.1038/sj.jcbfm.9600263; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2003, MAGNET RESON MED, V50, P190, DOI 10.1002/mrm.10481; Izhikevich EM, 2008, P NATL ACAD SCI USA, V105, P3593, DOI 10.1073/pnas.0712231105; Jung RE, 1999, P ROY SOC B-BIOL SCI, V266, P1375, DOI 10.1098/rspb.1999.0790; Jung RE, 2009, INTELLIGENCE, V37, P192, DOI 10.1016/j.intell.2008.10.009; Konrad C, 2011, PSYCHOL MED, V41, P1197, DOI 10.1017/S0033291710001728; Kukley M, 2007, NAT NEUROSCI, V10, P311, DOI 10.1038/nn1850; Lange RT, 2007, NEUROPSYCHOLOGY, V21, P590, DOI 10.1037/0894-4105.21.5.590; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Magistretti PJ, 1999, PHILOS T R SOC B, V354, P1155, DOI 10.1098/rstb.1999.0471; Mangia S, 2007, J CEREBR BLOOD F MET, V27, P1055, DOI 10.1038/sj.jcbfm.9600401; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2009, HUM BRAIN MAPP, V30, P4152, DOI 10.1002/hbm.20836; MAYER AR, HUM BRAIN M IN PRESS; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McKenna MC, 2007, J NEUROSCI RES, V85, P3347, DOI 10.1002/jnr.21444; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Michael N, 2003, EUR J NEUROSCI, V17, P2462, DOI 10.1046/j.1460-9568.2003.02683.x; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mullins PG, 2005, NEUROIMAGE, V26, P642, DOI 10.1016/j.neuroimage.2005.02.001; MUNOZ MS, 2008, STROKE, V39, P2467; Nave KA, 2010, NAT REV NEUROSCI, V11, P275, DOI 10.1038/nrn2797; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Plomin R, 2004, J PERS SOC PSYCHOL, V86, P112, DOI 10.1037/0022-3514.86.1.112; Prokosch MD, 2005, INTELLIGENCE, V33, P203, DOI 10.1016/j.intell.2004.07.007; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Sakellaris G, 2006, J TRAUMA, V61, P322, DOI 10.1097/01.ta.0000230269.46108.d5; Sakellaris G, 2008, ACTA PAEDIATR, V97, P31, DOI 10.1111/j.1651-2227.2007.00529.x; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; YEO RA, CURR ALZHEI IN PRESS	59	71	73	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2011	28	1					1	11		10.1089/neu.2010.1578			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	710DT	WOS:000286491800001	21054143	Green Published			2022-02-06	
J	Zohar, O; Rubovitch, V; Milman, A; Schreiber, S; Pick, CG				Zohar, Ofer; Rubovitch, Vardit; Milman, Anat; Schreiber, Shaul; Pick, Chaim G.			Behavioral consequences of minimal traumatic brain injury in mice	ACTA NEUROBIOLOGIAE EXPERIMENTALIS			English	Article						forced swimming test; Morris water maze; mTBI; passive avoidance; swim T-maze	RIGHT PARIETAL CORTEX; CLOSED-HEAD INJURY; COGNITIVE DEFICITS; MODELS; SENSITIVITY; IMPAIRMENT; PEPTIDE; IMPACT; LESION; DEATH	Victims of minor traumatic brain injury (mTBI), who show no clear morphological brain defects, frequently manifest cognitive, behavioral and emotional difficulties that can be long-lasting. In this paper we present a modified weight drop model used to deliver a closed head minimal traumatic brain injury to mice, which closely mimics real-life injuries and the symptoms observed in mTBI patients. Our choice of impact force does not produce structural damage to the brain and its surrounding tissue (as examined by MRI), any skull fracture, no edema and no evident damage to the blood-brain barrier (BBB). Moreover, our mTBI mice show no abnormal behavior on recovering from the weight drop, or any change in other brain functions such as reflexes, balance, exploration, strength, locomotor activity and swim speed. Since our mTBI model does not produce neurological, motor or sensory damage to the mice, it allows the direct evaluation of mTBI sequelae on the mice behavior and cognitive abilities. Using a variety of cognitive and behavioral tests (Morris water maze, staircase test, passive avoidance test, water T-maze, hot palate, elevated plus maze and forced swimming test) we assessed the short- and long-term sequelae induced by our model. Our results indicate that our closed head mTBI cause profound and long-lasting, irreversible learning and memory impairments, accompanied by a depressive-like behavior in mice that are evident even 90 days post injury. Our results indicate that the closed head mTBI model presented here may be useful in the development of novel therapeutic approaches, such as neuroprotective agents, for mTBI.	[Rubovitch, Vardit; Milman, Anat; Pick, Chaim G.] Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Zohar, Ofer] Johns Hopkins Univ, Blanchette Rockefeller Neurosci Inst, Rockville, MD USA; [Schreiber, Shaul] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Psychiat, IL-69978 Tel Aviv, Israel		Pick, CG (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel.	pickc@post.tau.ac.il	Schreiber, Shaul/E-5821-2010	Schreiber, Shaul/0000-0002-2189-0693; Milman, Anat/0000-0002-8551-4101			Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alcalay RN, 2004, NEUROSCI LETT, V361, P128, DOI 10.1016/j.neulet.2003.12.005; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Badowska-Szalewska E, 2009, ACTA NEUROBIOL EXP, V69, P448; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Finset A, 1999, PSYCHOSOM MED, V61, P576, DOI 10.1097/00006842-199907000-00024; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Heinrichs SC, 1996, NEUROSCIENCE, V74, P303, DOI 10.1016/0306-4522(96)00140-6; Hogg S, 1996, PHARMACOL BIOCHEM BE, V54, P21, DOI 10.1016/0091-3057(95)02126-4; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; Hogg S, 1998, BEHAV BRAIN RES, V93, P157, DOI 10.1016/S0166-4328(97)00145-9; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lehner M, 2010, ACTA NEUROBIOL EXP, V70, P56; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; Margulies S, 2000, J CLIN NEUROSCI, V7, P400, DOI 10.1054/jocn.1999.0681; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; PICK CG, 1991, BRAIN RES, V566, P295, DOI 10.1016/0006-8993(91)91712-A; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Ustun ME, 2001, INTENS CARE MED, V27, P264, DOI 10.1007/s001340000780; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WILLNER P, 1990, PHARMACOL THERAPEUT, V45, P425, DOI 10.1016/0163-7258(90)90076-E; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yamamoto T, 1988, J NEUROTRAUM, V5, P69, DOI 10.1089/neu.1988.5.69; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	44	71	72	0	8	NENCKI INST EXPERIMENTAL BIOLOGY	WARSAW	UL PASTEURA 3, 02-093 WARSAW, POLAND	0065-1400	1689-0035		ACTA NEUROBIOL EXP	Acta Neurobiol. Exp.		2011	71	1					36	45					10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	755ET	WOS:000289910500004	21499325				2022-02-06	
J	Feng, Y; Abney, TM; Okamoto, RJ; Pless, RB; Genin, GM; Bayly, PV				Feng, Y.; Abney, T. M.; Okamoto, R. J.; Pless, R. B.; Genin, G. M.; Bayly, P. V.			Relative brain displacement and deformation during constrained mild frontal head impact	JOURNAL OF THE ROYAL SOCIETY INTERFACE			English	Article						traumatic brain injury; displacement; deformation; magnetic resonance imaging; image registration	MOTION; CALVARIUM; INJURY	This study describes the measurement of fields of relative displacement between the brain and the skull in vivo by tagged magnetic resonance imaging and digital image analysis. Motion of the brain relative to the skull occurs during normal activity, but if the head undergoes high accelerations, the resulting large and rapid deformation of neuronal and axonal tissue can lead to long-term disability or death. Mathematical modelling and computer simulation of acceleration-induced traumatic brain injury promise to illuminate the mechanisms of axonal and neuronal pathology, but numerical studies require knowledge of boundary conditions at the brain-skull interface, material properties and experimental data for validation. The current study provides a dense set of displacement measurements in the human brain during mild frontal skull impact constrained to the sagittal plane. Although head motion is dominated by translation, these data show that the brain rotates relative to the skull. For these mild events, characterized by linear decelerations near 1.5g (g = 9.81 m s(-2)) and angular accelerations of 120-140 rad s(-2), relative brain-skull displacements of 2-3 mm are typical; regions of smaller displacements reflect the tethering effects of brain-skull connections. Strain fields exhibit significant areas with maximal principal strains of 5 per cent or greater. These displacement and strain fields illuminate the skull-brain boundary conditions, and can be used to validate simulations of brain biomechanics.	[Feng, Y.; Abney, T. M.; Okamoto, R. J.; Genin, G. M.; Bayly, P. V.] Dept Mech Aerosp & Struct Engn, St Louis, MO 63130 USA; [Bayly, P. V.] Dept Biomed Engn, St Louis, MO 63130 USA; [Pless, R. B.] Dept Comp Sci & Engn, St Louis, MO 63130 USA		Bayly, PV (corresponding author), Dept Mech Aerosp & Struct Engn, St Louis 1 Brookings Dr,Box 1185, St Louis, MO 63130 USA.	pvb@me.wustl.edu	Feng, Yuan/C-7417-2011; Pless, Robert B/I-4698-2013	Feng, Yuan/0000-0003-1902-3408; Okamoto, Ruth/0000-0002-3085-3878; Bayly, Philip/0000-0003-4303-0704	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS055951, HL079165]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K25HL079165] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS055951, R01NS055951] Funding Source: NIH RePORTER	We gratefully acknowledge the assistance of Richard Nagel in acquisition of tagged MR images. Funding for the study was provided by the National Institutes of Health grants NS055951 and HL079165.	AXEL L, 1989, RADIOLOGY, V172, P349, DOI 10.1148/radiology.172.2.2748813; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; GOSCH H H, 1969, Surgical Forum (Chicago), V20, P425; Hardy W N, 2001, Stapp Car Crash J, V45, P337; HODGSON VR, 1966, J NEUROSURG, V25, P549, DOI 10.3171/jns.1966.25.5.0549; Ivancevic VG, 2009, COGN NEURODYNAMICS, V3, P281, DOI 10.1007/s11571-008-9070-0; Ji SB, 2007, J BIOMECH, V40, P92, DOI 10.1016/j.jbiomech.2005.11.009; Kimpara Hideyuki, 2006, Stapp Car Crash J, V50, P509; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; OMMAYA AK, 1969, J NEUROSURG, V30, P25, DOI 10.3171/jns.1969.30.1.0025; Osman NF, 2000, IEEE T MED IMAGING, V19, P186, DOI 10.1109/42.845177; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; SHATSKY SA, 1974, P 18 STAPP CAR CRASH, P351; Shelden CH, 1944, J NEUROSURG, V1, P67, DOI 10.3171/jns.1944.1.1.0067; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; STALNAKER RL, 1977, P 21 STAPP CAR CRASH, P305; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zou H, 2007, INT J CRASHWORTHINES, V12, P341, DOI 10.1080/13588260701433024; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	23	71	73	0	16	ROYAL SOC	LONDON	6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1742-5689	1742-5662		J R SOC INTERFACE	J. R. Soc. Interface	DEC 6	2010	7	53					1677	1688		10.1098/rsif.2010.0210			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673KT	WOS:000283660900003	20504801	Green Published			2022-02-06	
J	Alvarez, TL; Vicci, VR; Alkan, Y; Kim, EH; Gohel, S; Barrett, AM; Chiaravalloti, N; Biswal, BB				Alvarez, Tara L.; Vicci, Vincent R.; Alkan, Yelda; Kim, Eun H.; Gohel, Suril; Barrett, Anna M.; Chiaravalloti, Nancy; Biswal, Bharat B.			Vision Therapy in Adults with Convergence Insufficiency: Clinical and Functional Magnetic Resonance Imaging Measures	OPTOMETRY AND VISION SCIENCE			English	Article						convergence insufficiency; vision therapy; vergence; traumatic brain injury; prediction; frontal eye fields; supplementary eye field; dorsolateral prefrontal cortex; cerebellum; brain stem	VERGENCE EYE-MOVEMENTS; DISPARITY VERGENCE; PHORIA ADAPTATION; SYMPTOM SURVEY; CHILDREN; TRIAL; DYNAMICS; FREQUENCY; PRISM; MODEL	Purpose. This research quantified clinical measurements and functional neural changes associated with vision therapy in subjects with convergence insufficiency (CI). Methods. Convergence and divergence 4 degrees step responses were compared between 13 control adult subjects with normal binocular vision and four CI adult subjects. All CI subjects participated in 18 h of vision therapy. Clinical parameters quantified throughout the therapy included: nearpoint of convergence, recovery point of convergence, positive fusional vergence at near, near dissociated phoria, and eye movements that were quantified using peak velocity. Neural correlates of the CI subjects were quantified with functional magnetic resonance imaging scans comparing random vs. predictable vergence movements using a block design before and after vision therapy. Images were quantified by measuring the spatial extent of activation and the average correlation within five regions of interests (ROI). The ROIs were the dorsolateral prefrontal cortex, a portion of the frontal lobe, part of the parietal lobe, the cerebellum, and the brain stem. All measurements were repeated 4 months to 1 year post-therapy in three of the CI subjects. Results. Convergence average peak velocities to step stimuli were significantly slower (p = 0.016) in CI subjects compared with controls; however, significant differences in average peak velocities were not observed for divergence step responses (p = 0.30). The investigation of CI subjects participating in vision therapy showed that the nearpoint of convergence, recovery point of convergence, and near dissociated phoria significantly decreased. Furthermore, the positive fusional vergence, average peak velocity from 4 degrees convergence steps, and the amount of functional activity within the frontal areas, cerebellum, and brain stem significantly increased. Several clinical and cortical parameters were significantly correlated. Conclusions. Convergence peak velocity was significantly slower in CI subjects compared with controls, which may result in asthenopic complaints reported by the CI subjects. Vision therapy was associated with and may have evoked clinical and cortical activity changes. (Optom Vis Sci 2010;87:E985-E1002)	[Alvarez, Tara L.; Alkan, Yelda; Kim, Eun H.; Gohel, Suril] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Vicci, Vincent R.] Kessler Inst Rehabil, Dept Vis Rehabil, W Orange, NJ USA; [Gohel, Suril; Biswal, Bharat B.] Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA; [Barrett, Anna M.] Kessler Fdn, Stroke Res Lab, W Orange, NJ USA; [Chiaravalloti, Nancy] Kessler Fdn, Neuropsychol & Neurosci Lab, W Orange, NJ USA		Alvarez, TL (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	tara.l.alvarez@njit.edu; bbiswal@gmail.com	Barrett, A.M./ABG-4475-2021	Barrett, A.M./0000-0002-0789-2887; Alvarez, Tara/0000-0002-8797-1613	NSFNational Science Foundation (NSF) [BES-044713]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5R01NS049176, 5R01NS055808, 5K02NS047099-6]; Department of EducationUS Department of Education; NIDRR [H133P090009]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD062647] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055808, K02NS047099, R01NS049176] Funding Source: NIH RePORTER	This research was supported in part by NSF CAREER BES-044713 (to TLA), NIH 5R01NS049176 (to BBB), and NIH 5R01NS055808 and 5K02NS047099-6 (to AMB). The contents of this article were developed under a grant from the Department of Education, NIDRR Grant H133P090009 (to NC) but do not necessarily represent policy of the Department of Education.	Alvarez TL, 2007, COMPUT BIOL MED, V37, P903, DOI 10.1016/j.compbiomed.2006.03.009; Alvarez TL, 2010, VISION RES, V50, P2163, DOI 10.1016/j.visres.2010.08.018; Alvarez TL, 2005, J VISION, V5, P640, DOI 10.1167/5.7.4; Alvarez TL, 2002, CAH PSYCHOL COGN, V21, P243; Alvarez TL, 1999, ANN BIOMED ENG, V27, P380, DOI 10.1114/1.162; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; BAHILL AT, 1982, BIOL CYBERN, V45, P1, DOI 10.1007/BF00387207; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Berns G S, 1999, J Neurosci, V19, pRC17; Binder JR, 2004, NAT NEUROSCI, V7, P295, DOI 10.1038/nn1198; Birnbaum M H, 1999, J Am Optom Assoc, V70, P225; Borsting EJ, 2003, OPTOMETRY VISION SCI, V80, P832, DOI 10.1097/00006324-200312000-00014; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Brautaset RL, 2005, OPHTHAL PHYSL OPT, V25, P215, DOI 10.1111/j.1475-1313.2005.00276.x; Brautaset RL, 2006, INVEST OPHTH VIS SCI, V47, P2876, DOI 10.1167/iovs.04-1372; Calhoun VD, 2008, HUM BRAIN MAPP, V29, P828, DOI 10.1002/hbm.20581; Chen YF, 2010, J MED BIOL ENG, V30, P1; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Ciuffreda Kenneth J, 2008, Optometry, V79, P18, DOI 10.1016/j.optm.2007.10.004; Cohen A H, 1984, J Am Optom Assoc, V55, P491; Cohen M, 1989, Brain Inj, V3, P187, DOI 10.3109/02699058909004551; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; D'Esposito M, 1999, NEUROIMAGE, V10, P6, DOI 10.1006/nimg.1999.0444; DAUM KM, 1984, AM J OPTOM PHYS OPT, V61, P16; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; Gavrilescu M, 2008, HUM BRAIN MAPP, V29, P1040, DOI 10.1002/hbm.20446; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Griffin J. R, 1988, BINOCULAR ANOMALIES; GRISHAM JD, 1988, AM J OPTOM PHYS OPT, V65, P448; Han SJ, 2010, OPHTHAL PHYSL OPT, V30, P95, DOI 10.1111/j.1475-1313.2009.00681.x; Hokoda S C, 1985, J Am Optom Assoc, V56, P560; Horng JL, 1998, IEEE T BIO-MED ENG, V45, P249, DOI 10.1109/10.661273; HUNG GK, 1986, IEEE T BIO-MED ENG, V33, P1021, DOI 10.1109/TBME.1986.325868; Kennedy DN, 1998, CEREB CORTEX, V8, P372, DOI 10.1093/cercor/8.4.372; Kim EH, 2010, INVEST OPHTH VIS SCI, V51, P4017, DOI 10.1167/iovs.09-4560; Lee YY, 2008, J VISION, V8, DOI 10.1167/8.12.5; Lee YY, 2009, VISION RES, V49, P2960, DOI 10.1016/j.visres.2009.09.013; Lewis JW, 2005, J NEUROSCI, V25, P5148, DOI 10.1523/JNEUROSCI.0419-05.2005; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; MAYS LE, 1984, J NEUROPHYSIOL, V51, P1091, DOI 10.1152/jn.1984.51.5.1091; MILDER DG, 1983, ARCH NEUROL-CHICAGO, V40, P339, DOI 10.1001/archneur.1983.04050060039005; MORLEY JW, 1992, J NEUROPHYSIOL, V67, P1475, DOI 10.1152/jn.1992.67.6.1475; Nitta T, 2008, CEREB CORTEX, V18, P1042, DOI 10.1093/cercor/bhm143; Oakes TR, 2005, NEUROIMAGE, V28, P529, DOI 10.1016/j.neuroimage.2005.05.058; Patel SS, 1999, OPTOMETRY VISION SCI, V76, P656, DOI 10.1097/00006324-199909000-00024; PICKWELL LD, 1981, OPHTHAL PHYSL OPT, V1, P13, DOI 10.1111/j.1475-1313.1981.tb00143.x; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; PREVIC FH, 1990, BEHAV BRAIN SCI, V13, P519, DOI 10.1017/S0140525X00080018; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P1169, DOI 10.1097/OPX.0b013e3181baad13; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Rouse MW, 2004, OPHTHAL PHYSL OPT, V24, P384, DOI 10.1111/j.1475-1313.2004.00202.x; Rouse MW, 1999, OPTOMETRY VISION SCI, V76, P643, DOI 10.1097/00006324-199909000-00022; Rouse MW, 1998, OPTOMETRY VISION SCI, V75, P88, DOI 10.1097/00006324-199802000-00012; Sander T, 2009, BRAIN, V132, P103, DOI 10.1093/brain/awn306; Scheiman M, 2005, BRIT J OPHTHALMOL, V89, P1318, DOI 10.1136/bjo.2005.068197; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 1996, J Am Optom Assoc, V67, P193; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1336, DOI 10.1001/archopht.126.10.1336; Scheiman M, 2008, OPHTHAL EPIDEMIOL, V15, P24, DOI 10.1080/09286580701772037; Scheiman M, 2010, OPTOMETRY VISION SCI, V87, P593, DOI 10.1097/OPX.0b013e3181e61bad; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P1096, DOI 10.1097/OPX.0b013e3181b6210f; Scheiman M, 2009, OPTOMETRY VISION SCI, V86, P420, DOI 10.1097/OPX.0b013e31819fa712; Schmid A, 2001, NEUROREPORT, V12, P1409, DOI 10.1097/00001756-200105250-00023; Sloan JA, 2005, J CLIN EPIDEMIOL, V58, P1217, DOI 10.1016/j.jclinepi.2005.07.009; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Takagi M, 2003, PROG BRAIN RES, V142, P19; Takagi M, 2001, INVEST OPHTH VIS SCI, V42, pS319; Talairach J, 1988, COPLANNAR STEREOTAXI; Teitelbaum B, 2009, OPTOMETRY VISION SCI, V86, P153, DOI 10.1097/OPX.0b013e318194e985; Ungerleider LG., 1982, ANAL VISUAL BEHAV; van Leeuwen AF, 1999, VISION RES, V39, P3095, DOI 10.1016/S0042-6989(99)00066-8; Ward B. D., 2000, SIMULTANEOUS INFEREN; Weiss PH, 2000, BRAIN, V123, P2531, DOI 10.1093/brain/123.12.2531; Yuan WH, 2000, VISION RES, V40, P3089, DOI 10.1016/S0042-6989(00)00162-0; Yuan WH, 1999, IEEE T BIO-MED ENG, V46, P1191, DOI 10.1109/10.790495	77	71	72	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	DEC	2010	87	12					985	1002		10.1097/OPX.0b013e3181fef1aa			18	Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Ophthalmology	687CQ	WOS:000284752200010	21057347	Green Accepted			2022-02-06	
J	Hoffman, JM; Bell, KR; Powell, JM; Behr, J; Dunn, EC; Dikmen, S; Bombardier, CH				Hoffman, Jeanne M.; Bell, Kathleen R.; Powell, Janet M.; Behr, James; Dunn, Erin C.; Dikmen, Sureyya; Bombardier, Charles H.			A Randomized Controlled Trial of Exercise to Improve Mood After Traumatic Brain Injury	PM&R			English	Article							DEPRESSION FOLLOWING MILD; PHYSICAL-ACTIVITY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; COGNITIVE FUNCTION; PUBLIC-HEALTH; LIFE-STYLE; FOLLOW-UP; ADULTS; SERTRALINE	Objective: To test the hypothesis that a structured aerobic exercise regimen would decrease the severity of depressive symptoms in people with traumatic brain injury (TBI) who reported at least mild depression severity at baseline. Design: Prospective, randomized, controlled trial. Setting: Community gymnasium. Participants: Subjects with a history of a prior TBI (6 months to 5 years post-injury), recruited from the community. Inclusion criteria included scoring >= 5 on the Patient Health Questionnaire-9. Subjects were excluded if they were non-English speakers, had a medical condition precluding exercise, had suicidal ideation, regularly exercised, or could not use standard aerobic exercise equipment. Intervention: Weekly supervised exercise sessions over a 10-week period consisted of education, warm-up, 30 minutes of aerobic exercise, and cool down. The exercise intensity was adjusted to reach a heart rate goal of 60% of the participant's estimated maximal heart rate. Main Outcome Measurement: Beck Depression Inventory (BDI) comparing exercise to control groups. Post hoc analyses compared groups exercising >= 90 minutes or <90 minutes per week. Results: Between-group comparisons at 10 weeks revealed no difference between groups on the BDI (P = .250). For the groups divided by minutes exercised per week, the high-activity group had significantly better depression scores than those in the low-activity group (P = .033). Conclusions: Although there was no statistically significant difference between the treated and the control group on mood after intervention, those persons with TBI who recounted higher levels of exercise per week also reported less depression and improved sleep, community participation, and overall quality of life. PM R 2010;2:911-919	[Hoffman, Jeanne M.; Bell, Kathleen R.; Powell, Janet M.; Dikmen, Sureyya; Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Dikmen, Sureyya] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Dunn, Erin C.] St Pauls Hosp, Eating Disorders Program, Vancouver, BC V6Z 1Y6, Canada; [Behr, James] Orthoped Associates, Spartanburg, SC USA		Hoffman, JM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490,1959 NE Pacific St, Seattle, WA 98195 USA.	jeanneh@uw.edu	Bombardier, Charles H./AAZ-3260-2021	Bombardier, Charles H./0000-0003-4758-6283; Bell, Kathleen/0000-0002-0928-2046			Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Bandura A, 1986, SOCIAL FDN THOUGHT A; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bell KR, 2008, AM J PHYS MED REHAB, V87, P330, DOI 10.1097/PHM.0b013e318168d092; Blumenthal JA, 2007, PSYCHOSOM MED, V69, P587, DOI 10.1097/PSY.0b013e318148c19a; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Borg G., 1998, BORGS PERCEIVED EXER; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dunn AL, 1999, JAMA-J AM MED ASSOC, V281, P327, DOI 10.1001/jama.281.4.327; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Fann JR, 2009, J HEAD TRAUMA REHAB, V24, P272, DOI 10.1097/HTR.0b013e3181a66342; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Ferris LT, 2007, MED SCI SPORT EXER, V39, P728, DOI 10.1249/mss.0b013e31802f04c7; Forsell Y, 2007, DEPRESS ANXIETY, V24, P62, DOI 10.1002/da.20231; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Franklin B.A., 2000, ACSMS GUIDELINES EXE; Freeman MP, 2009, J CLIN PSYCHIAT, V70, P4, DOI 10.4088/JCP.8157su1c.01; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; Greer TL, 2009, CURR PSYCHIAT REP, V11, P466, DOI 10.1007/s11920-009-0071-4; Hall K., 1998, TOP SPINAL CORD INJ, V4, P16, DOI DOI 10.1310/V5RU-FRFE-50E6-E2NA; Haskell WL, 2007, CIRCULATION, V116, P1081, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hu SX, 2009, BRAIN RES, V1249, P191, DOI 10.1016/j.brainres.2008.10.054; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; King AC, 1998, MED SCI SPORT EXER, V30, P1086, DOI 10.1097/00005768-199807000-00011; Kishi Y, 2001, PSYCHOSOMATICS, V42, P382, DOI 10.1176/appi.psy.42.5.382; Kleim JA, 2003, NEUROCHEM RES, V28, P1757, DOI 10.1023/A:1026025408742; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kosinski M., 1995, SF 12 SCORE SF 12 PH; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lai SM, 2006, J AM GERIATR SOC, V54, P240, DOI 10.1111/j.1532-5415.2006.00573.x; Lane AM, 2001, J SPORT MED PHYS FIT, V41, P539; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; MARTINSEN EW, 1989, COMPR PSYCHIAT, V30, P324, DOI 10.1016/0010-440X(89)90057-6; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mead GE, 2008, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD004366.pub6, 10.1002/14651858.CD004366.pub4]; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Steptoe A, 2000, PREV MED, V31, P183, DOI 10.1006/pmed.2000.0688; Strohle A, 2009, J NEURAL TRANSM, V116, P777, DOI 10.1007/s00702-008-0092-x; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Teychenne M, 2008, PREV MED, V46, P397, DOI 10.1016/j.ypmed.2008.01.009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Williamson JD, 2009, J GERONTOL A-BIOL, V64, P688, DOI 10.1093/gerona/glp014	65	71	72	0	25	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2010	2	10					911	919		10.1016/j.pmrj.2010.06.008			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V23SE	WOS:000208361700006	20970760				2022-02-06	
J	Li, W; Lopez, L; Osher, J; Howard, JD; Parrish, TB; Gottfried, JA				Li, Wen; Lopez, Leonardo; Osher, Jason; Howard, James D.; Parrish, Todd B.; Gottfried, Jay A.			Right Orbitofrontal Cortex Mediates Conscious Olfactory Perception	PSYCHOLOGICAL SCIENCE			English	Article						olfactory perception; consciousness; orbitofrontal cortex; lesion	PREFRONTAL CORTEX; POSTTRAUMATIC ANOSMIA; TEMPORAL LOBECTOMY; HUMAN PIRIFORM; DISCRIMINATION; BRAIN; IDENTIFICATION; HUMANS; SMELL; ORGANIZATION	Understanding how the human brain translates sensory impressions into conscious percepts is a key challenge of neuroscience research. Work in this area has overwhelmingly centered on the conscious experience of vision at the exclusion of the other senses-in particular, smell. We hypothesized that the orbitofrontal cortex (OFC) is a central substrate for olfactory conscious experience because of its privileged physiological role in odor processing. Combining functional magnetic resonance imaging, peripheral autonomic recordings, and olfactory psychophysics, we studied a case of complete anosmia (smell loss) in a patient with circumscribed traumatic brain injury to the right OFC. Despite a complete absence of conscious olfaction, the patient exhibited robust "blind smell," as indexed by reliable odor-evoked neural activity in the left OFC and normal autonomic responses to odor hedonics during presentation of stimuli to the left nostril. These data highlight the right OFC's critical role in subserving human olfactory consciousness.	[Li, Wen] Univ Wisconsin, Dept Psychol, Madison, WI 53706 USA; [Li, Wen] Univ Wisconsin, Waisman Inst, Madison, WI 53706 USA; [Lopez, Leonardo; Osher, Jason; Parrish, Todd B.; Gottfried, Jay A.] Northwestern Univ, Cognit Neurol & Alzheimers Dis Ctr, Evanston, IL 60208 USA; [Howard, James D.; Gottfried, Jay A.] Northwestern Univ, Dept Neurol, Evanston, IL 60208 USA; [Parrish, Todd B.] Northwestern Univ, Dept Radiol, Evanston, IL 60208 USA; [Gottfried, Jay A.] Northwestern Univ, Dept Psychol, Evanston, IL 60208 USA		Li, W (corresponding author), Univ Wisconsin, Dept Psychol, 1202 W Johnson St, Madison, WI 53706 USA.	wenli@psych.wisc.edu	Li, Wen/AAU-8505-2020	Parrish, Todd/0000-0002-1184-1572; Lopez, Leonardo/0000-0001-9769-7737	NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K08 DC007653, R01 DC010014] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC010014, K08DC007653] Funding Source: NIH RePORTER		ABRAHAM A, 1983, NEUROPSYCHOLOGIA, V21, P277, DOI 10.1016/0028-3932(83)90045-3; Allen WF, 1940, AM J PHYSIOL, V128, P0754, DOI 10.1152/ajplegacy.1940.128.4.754; Anderson AK, 2003, NAT NEUROSCI, V6, P196, DOI 10.1038/nn1001; CARMICHAEL ST, 1994, J COMP NEUROL, V346, P403, DOI 10.1002/cne.903460306; Crick F, 2003, NAT NEUROSCI, V6, P119, DOI 10.1038/nn0203-119; Dehaene S, 2006, TRENDS COGN SCI, V10, P204, DOI 10.1016/j.tics.2006.03.007; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Eftekhari M, 2006, AM J RHINOL, V20, P577, DOI 10.2500/ajr.2006.20.2906; Flykt A, 2007, BIOL PSYCHOL, V74, P328, DOI 10.1016/j.biopsycho.2006.08.004; Functional Imaging Laboratory, 2003, STAT PAR MAPP VERS 2; Fuster, 2015, PREFRONTAL CORTEX; Gottfried JA, 2006, NEURON, V49, P467, DOI 10.1016/j.neuron.2006.01.007; Gottfried JA, 2005, BRAIN RES REV, V50, P287, DOI 10.1016/j.brainresrev.2005.08.004; Gottfried JA, 2002, J NEUROSCI, V22, P10829; Gottfried JA, 2007, ANN NY ACAD SCI, V1121, P102, DOI 10.1196/annals.1401.018; Hummel T, 1997, CHEM SENSES, V22, P39, DOI 10.1093/chemse/22.1.39; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; JONESGOTMAN M, 1993, BRAIN COGNITION, V22, P182, DOI 10.1006/brcg.1993.1033; Li W, 2008, J COGNITIVE NEUROSCI, V20, P95; Li W, 2006, NEURON, V52, P1097, DOI 10.1016/j.neuron.2006.10.026; Lundqvist D., 1998, KAROLINSKA DIRECTED; Mai JK, 1997, ATLAS HUMAN BRAIN; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; Phelps EA, 2006, ANNU REV PSYCHOL, V57, P27, DOI 10.1146/annurev.psych.56.091103.070234; Plailly J, 2008, J NEUROSCI, V28, P5257, DOI 10.1523/JNEUROSCI.5607-07.2008; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; Price JL, 2007, ANN NY ACAD SCI, V1121, P54, DOI 10.1196/annals.1401.008; RAUSCH R, 1977, CORTEX, V13, P445, DOI 10.1016/S0010-9452(77)80024-5; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; SCHOENBAUM G, 1995, J NEUROPHYSIOL, V74, P751, DOI 10.1152/jn.1995.74.2.751; Shepherd GM, 2007, ANN NY ACAD SCI, V1121, P87, DOI 10.1196/annals.1401.032; Shipley MT, 1996, J NEUROBIOL, V30, P123; Sobel N, 1999, BRAIN, V122, P209, DOI 10.1093/brain/122.2.209; Tait DS, 2007, ANN NY ACAD SCI, V1121, P407, DOI 10.1196/annals.1401.010; TANABE T, 1975, J NEUROPHYSIOL, V38, P1284, DOI 10.1152/jn.1975.38.5.1284; Varney NR, 2001, J HEAD TRAUMA REHAB, V16, P253, DOI 10.1097/00001199-200106000-00004; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71; Zeki S, 1998, BRAIN, V121, P25, DOI 10.1093/brain/121.1.25; Zelano C, 2005, NAT NEUROSCI, V8, P114, DOI 10.1038/nn1368	40	71	71	1	20	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0956-7976	1467-9280		PSYCHOL SCI	Psychol. Sci.	OCT	2010	21	10					1454	1463		10.1177/0956797610382121			10	Psychology, Multidisciplinary	Social Science Citation Index (SSCI)	Psychology	696QD	WOS:000285455600017	20817780	Green Accepted			2022-02-06	
J	Lustenberger, T; Talving, P; Kobayashi, L; Inaba, K; Lam, L; Plurad, D; Demetriades, D				Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Inaba, Kenji; Lam, Lydia; Plurad, David; Demetriades, Demetrios			Time course of coagulopathy in isolated severe traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Severe traumatic brain injury; Head injury severity; Coagulopathy; Time course	SEVERE HEAD-INJURY	Background: Time aspects of coagulopathy following severe traumatic brain injury (sTBI) are ill defined throughout the literature. Thus, the aim of this study was to evaluate the time course of coagulopathy following isolated sTBI and its relationship to in-hospital outcomes. Methods: Retrospective analysis of patients sustaining isolated sTBI (head AIS >= 3, extracranial injuries AIS < 3). TBI coagulopathy was defined as thrombocytopenia and/or elevated international normalised ratio (INR) and/or prolonged activated partial thromboplastin time (aPTT). Incidence, onset and duration of sTBI-coagulopathy and its impact on morbidity and mortality were analysed. Results: Overall, 45.7% (n = 127) of the 278 patients included developed coagulopathy. Coagulopathy occurred 23.1 +/- 2.2 h [range: 0.1-108.2 h (0-4.5 days)] post-admission with a mean duration of 68.0 +/- 7.4 h [range: 2.6-531.4 h (0.1-22.1 days)]. The time interval to onset of coagulopathy decreased significantly with increasing head injury severity (p = 0.015). Early coagulation abnormalities occurring within 12 h of admission along with markers of devastating head injury including head AIS 5, penetrating injury mechanism, subdural hematoma, and a low GCS on admission proved to be independent risk factors for mortality. Conclusions: The sTBI-associated coagulopathy may ensue as late as 5 days after injury with a prolonged duration (>72 h) in 30% of patients. Early coagulopathy occurring within 12 h after injury is a marker of increased morbidity and poor outcomes. Pertinent prolonged screening of this sequela is warranted. (C) 2010 Elsevier Ltd. All rights reserved.	[Lustenberger, Thomas; Talving, Peep; Kobayashi, Leslie; Inaba, Kenji; Lam, Lydia; Plurad, David; Demetriades, Demetrios] Univ So Calif, Keck Sch Med, LAC USC Med Ctr, Div Acute Care Surg Trauma Emergency Surg & Surg, Los Angeles, CA 90033 USA		Talving, P (corresponding author), Univ So Calif, Keck Sch Med, Dept Surg,Los Angeles Cty Gen Hosp,LAC USC, Div Acute Care Surg Trauma Emergency Surg & Surg, 1200 N State St,C4E100, Los Angeles, CA 90033 USA.	peep.talving@surgery.usc.edu	Talving, Peep/G-8621-2015; INABA, KENJI/AAC-8532-2020; Talving, Peep/E-6015-2013	Talving, Peep/0000-0002-9741-2073; 			Bellomo R, 2004, CRIT CARE, V8, pR204, DOI 10.1186/cc2872; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Gando S, 1999, J TRAUMA, V46, P1070, DOI 10.1097/00005373-199906000-00018; Hadjizacharia P, 2008, J AM COLL SURGEONS, V207, P477, DOI 10.1016/j.jamcollsurg.2008.04.017; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Lever A, 2007, BMJ-BRIT MED J, V335, P879, DOI 10.1136/bmj.39346.495880.AE; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	12	71	81	0	8	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	SEP	2010	41	9					924	928		10.1016/j.injury.2010.04.019			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	634SL	WOS:000280605500009	20471013				2022-02-06	
J	Honeybul, S; Ho, KM; Lind, CRP; Gillett, GR				Honeybul, Stephen; Ho, Kwok M.; Lind, Christopher R. P.; Gillett, Grant R.			Observed versus Predicted Outcome for Decompressive Craniectomy: A Population-Based Study	JOURNAL OF NEUROTRAUMA			English	Article						decompressive craniectomy; outcome; neurotrauma	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; COMPLICATIONS; VALIDATION; MANAGEMENT; DISABILITY; SECONDARY; SURGERY; MODEL	A number of studies have shown that decompressive craniectomy can reduce intracranial pressure and may improve outcome for patients with severe head injury. This cohort study assessed the long-term outcome of neurotrauma patients who had a decompressive craniectomy for severe head injury in Western Australia between 2004 and 2008. The web-based outcome prediction model developed by the CRASH trial collaborators was applied to the cohort. Predicted outcome and observed outcome were compared. Characteristics of outcome between those who had had a unilateral and those who had had a bilateral decompressive procedure were compared. All complications were recorded. Among a total of 1,786 adult neurotrauma patients admitted during the study period, 147 patients (8.2%) had a decompressive craniectomy. A significant proportion of patients who required unilateral (37.3%) and bilateral (46.5%) craniectomy were able to return to work or study at 18 months after the injury. The patients who required bilateral craniectomy more likely to be associated with an unfavorable outcome (Glasgow Outcome Scale score >= 3) than those who had unilateral craniectomy (odds ratio 4.42; 95% confidence interval 1.16, 16.81; p = 0.029), after adjusting for the timing of surgery, mechanism of injury, and the predicted risk of unfavorable outcome. The functional outcome after either unilateral or bilateral decompressive craniectomy was significantly better than that predicted by the CRASH head injury prediction model when the predicted risk was less than 80%. This study has demonstrated that in Western Australia decompressive craniectomy is a relatively common surgical procedure for the management of neurotrauma. A significant proportion of patients had a better-than-predicted long-term functional outcome.	[Honeybul, Stephen; Lind, Christopher R. P.] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia; [Honeybul, Stephen; Lind, Christopher R. P.] Royal Perth Hosp, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Dept Intens Care Med, Nedlands, WA 6009, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Lind, Christopher R. P.] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Nedlands, WA 6009, Australia; [Gillett, Grant R.] Univ Otago, Otago Bioeth Ctr, Dunedin, New Zealand; [Gillett, Grant R.] Dunedin Publ Hosp, Dunedin, New Zealand		Honeybul, S (corresponding author), Sir Charles Gairdner Hosp, Dept Neurosurg, Hosp Ave, Perth, WA, Australia.	stephen.honeybul@health.wa.gov.au	Lind, Christopher/K-3629-2012; Ho, Kwok M./E-3546-2010	Lind, Christopher/0000-0001-9991-1725; Ho, Kwok M./0000-0002-6705-6004			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bratton S.L., 2007, J NEUROTRAUMA S1, V24; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2007, J CLIN EPIDEMIOL, V60, P746, DOI 10.1016/j.jclinepi.2006.10.017; Honeybul S, 2010, J CLIN NEUROSCI, V17, P430, DOI 10.1016/j.jocn.2009.09.007; Honeybul S, 2009, J CLIN NEUROSCI, V16, P727, DOI 10.1016/j.jocn.2008.06.015; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Plesnila N, 2007, PROG BRAIN RES, V161, P393, DOI 10.1016/S0079-6123(06)61028-5; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	30	71	73	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2010	27	7					1225	1232		10.1089/neu.2010.1316			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	631FD	WOS:000280331100007	20412014				2022-02-06	
J	Cao, C; Slobounov, S				Cao, C.; Slobounov, S.			Alteration of Cortical Functional Connectivity as a Result of Traumatic Brain Injury Revealed by Graph Theory, ICA, and sLORETA Analyses of EEG Signals	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article						Connectivity; electroencephalographic (EEG); independent component analysis (ICA); mild traumatic brain injury (MTBI); standardize low resolution brain electromagnetic (sLORETA); small-world network	ALZHEIMERS-DISEASE; LOW-FREQUENCY; DEFAULT MODE; SCALP EEG; MILD; CONCUSSION; SYNCHRONIZATION; NETWORK; ORGANIZATION; FLUCTUATIONS	In this paper, a novel approach to examine the cortical functional connectivity using multichannel electroencephalographic (EEG) signals is proposed. First we utilized independent component analysis (ICA) to transform multichannel EEG recordings into independent processes and then applied source reconstruction algorithm [i.e., standardize low resolution brain electromagnetic (sLORETA)] to identify the cortical regions of interest (ROIs). Second, we performed a graph theory analysis of the bipartite network composite of ROIs and independent processes to assess the connectivity between ROIs. We applied this proposed algorithm and compared the functional connectivity network properties under resting state condition using 29 student-athletes prior to and shortly after sport-related mild traumatic brain injury (MTBI). The major findings of interest are the following. There was 1) alterations in vertex degree at frontal and occipital regions in subjects suffering from MTBI, (p < 0.05); 2) a significant decrease in the long-distance connectivity and significant increase in the short-distance connectivity as a result of MTBI, (p < 0.05); 3) a departure from small-world network configuration in MTBI subjects. These major findings are discussed in relation to current debates regarding the brain functional connectivity within and between local and distal regions both in normal controls in pathological subjects.	[Cao, C.; Slobounov, S.] Penn State Univ, Dept Kinesiol, State Coll, PA 16801 USA		Cao, C (corresponding author), Penn State Univ, Dept Kinesiol, State Coll, PA 16801 USA.	cxc687@psu.edu; sms18@psu.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227] Funding Source: NIH RePORTER	Manuscript received November 13, 2008; revised April 09, 2009; accepted April 09, 2009. First published July 17, 2009; current version published February 24, 2010. This work of S. Slobounov was supported by the National Institutes of Health under Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury."	Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Achard S, 2006, J NEUROSCI, V26, P63, DOI 10.1523/JNEUROSCI.3874-05.2006; Achard S, 2007, PLOS COMPUT BIOL, V3, P174, DOI 10.1371/journal.pcbi.0030017; BAKAY L, 1977, J NEUROSURG, V47, P525, DOI 10.3171/jns.1977.47.4.0525; Bartolomei F, 2006, CLIN NEUROPHYSIOL, V117, P2039, DOI 10.1016/j.clinph.2006.05.018; BATUEV AS, 1979, ACTA PHYSIOL HUNG, V53, P345; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Bosma I, 2008, NEURO-ONCOLOGY, V10, P734, DOI 10.1215/15228517-2008-034; Breakspear M, 2003, NEUROIMAGE, V20, P466, DOI 10.1016/S1053-8119(03)00332-X; Chafee MV, 1998, J NEUROPHYSIOL, V79, P2919, DOI 10.1152/jn.1998.79.6.2919; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Ciaramella A., 2006, INT MATH FORUM, V1, P769; Cohen AL, 2008, NEUROIMAGE, V41, P45, DOI 10.1016/j.neuroimage.2008.01.066; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ELBERT T, 1992, BIOL PSYCHIAT, V32, P595, DOI 10.1016/0006-3223(92)90072-8; Ferri R, 2007, CLIN NEUROPHYSIOL, V118, P449, DOI 10.1016/j.clinph.2006.10.021; FOSTER JK, 1994, COGNITIVE NEUROPSYCH, V11, P133, DOI 10.1080/02643299408251971; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2005, HUM BRAIN MAPP, V26, P15, DOI 10.1002/hbm.20113; Fuchs M, 1998, IEEE T BIO-MED ENG, V45, P980, DOI 10.1109/10.704867; Funahashi S, 2006, NEUROSCIENCE, V139, P251, DOI 10.1016/j.neuroscience.2005.07.003; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Guntekin B, 2008, BRAIN RES, V1235, P109, DOI 10.1016/j.brainres.2008.06.028; Horwitz B, 2003, NEUROIMAGE, V19, P466, DOI 10.1016/S1053-8119(03)00112-5; Hyvarinen A, 1997, NEURAL COMPUT, V9, P1483, DOI 10.1162/neco.1997.9.7.1483; Iwaki S, 1998, J APPL PHYS, V83, P6441, DOI 10.1063/1.367732; Jeong J, 1998, ELECTROEN CLIN NEURO, V106, P220, DOI 10.1016/S0013-4694(97)00079-5; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1017/S0048577200980259; Klein M, 2003, ANN NEUROL, V54, P514, DOI 10.1002/ana.10712; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Koles ZJ, 1998, ELECTROEN CLIN NEURO, V106, P127, DOI 10.1016/S0013-4694(97)00115-6; Locatelli T, 1998, ELECTROEN CLIN NEURO, V106, P229, DOI 10.1016/S0013-4694(97)00129-6; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lycke C, 2008, SCAND J PSYCHOL, V49, P393, DOI 10.1111/j.1467-9450.2008.00672.x; Marchal B, 2005, PHYS LIFE REV, V2, P251, DOI 10.1016/j.plrev.2005.07.001; MARZETTI L, 2008, NEUROIMAGE, V36, P68; Marzetti L, 2008, NEUROIMAGE, V42, P87, DOI 10.1016/j.neuroimage.2008.04.250; Murias M, 2007, BIOL PSYCHIAT, V62, P270, DOI 10.1016/j.biopsych.2006.11.012; Newman MEJ, 2004, PHYS REV E, V70, DOI 10.1103/PhysRevE.70.056131; Nolte G, 2004, CLIN NEUROPHYSIOL, V115, P2292, DOI 10.1016/j.clinph.2004.04.029; Olthoff A, 2008, LARYNGOSCOPE, V118, P2091, DOI 10.1097/MLG.0b013e31817fd40f; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P5; Pascual-Marqui RD, 1999, PSYCHIAT RES-NEUROIM, V90, P169, DOI 10.1016/S0925-4927(99)00013-X; Purves D, NEUROSCIENCE; Reijneveld JC, 2007, CLIN NEUROPHYSIOL, V118, P2317, DOI 10.1016/j.clinph.2007.08.010; ROSENBAUM RS, 2008, NEUROBIOL AGING  JUL; Salvador R, 2005, CEREB CORTEX, V15, P1332, DOI 10.1093/cercor/bhi016; Salvador R, 2005, PHILOS T R SOC B, V360, P937, DOI 10.1098/rstb.2005.1645; SARVAS J, 1987, PHYS MED BIOL, V32, P11, DOI 10.1088/0031-9155/32/1/004; Sekihara K, 2005, NEUROIMAGE, V25, P1056, DOI 10.1016/j.neuroimage.2004.11.051; Silberstein RB, 2004, BRAIN TOPOGR, V16, P249; Slobounov S, 2000, MOTOR CONTROL, V4, P350, DOI 10.1123/mcj.4.3.350; Slobounov S, 2008, CLIN NEUROPHYSIOL, V119, P281, DOI 10.1016/j.clinph.2007.10.006; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 1998, EXP BRAIN RES, V123, P461, DOI 10.1007/s002210050590; Sporns O, 2004, TRENDS COGN SCI, V8, P418, DOI 10.1016/j.tics.2004.07.008; Stam CJ, 2007, CEREB CORTEX, V17, P92, DOI 10.1093/cercor/bhj127; Stam CJ, 2002, PHYSICA D, V163, P236, DOI 10.1016/S0167-2789(01)00386-4; Thatcher RW, 2007, CLIN EEG NEUROSCI, V38, P35, DOI 10.1177/155005940703800109; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; TRIMBLE MR, 1990, SEMIN NEUROL, V10, P287, DOI 10.1055/s-2008-1041280; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Wagner M, 2004, BRAIN TOPOGR, V16, P277; Yao DZ, 2001, PHYSIOL MEAS, V22, P693, DOI 10.1088/0967-3334/22/4/305; Zhou YX, 2008, ALZHEIMERS DEMENT, V4, P265, DOI 10.1016/j.jalz.2008.04.006; Zhukov L, 2000, IEEE ENG MED BIOL, V19, P87, DOI 10.1109/51.844386	68	71	75	2	23	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	1534-4320	1558-0210		IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	FEB	2010	18	1					11	19		10.1109/TNSRE.2009.2027704			9	Engineering, Biomedical; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Rehabilitation	562KP	WOS:000275049400002	20064767	Green Accepted			2022-02-06	
J	Taepavarapruk, P; Song, C				Taepavarapruk, Pornnarin; Song, Cai			Reductions of acetylcholine release and nerve growth factor expression are correlated with memory impairment induced by interleukin-1 beta administrations: effects of omega-3 fatty acid EPA treatment	JOURNAL OF NEUROCHEMISTRY			English	Article						acetylcholine; eicosapentaenoate; interleukin-1beta; memory impairment; microdialysis; nerve growth factor	TRAUMATIC BRAIN-INJURY; EICOSAPENTAENOIC ACID; FATTY-ACIDS; NEUROTROPHIC FACTOR; ALZHEIMERS-DISEASE; INFLAMMATORY RESPONSE; DOCOSAHEXAENOIC ACID; HIPPOCAMPAL ATROPHY; DOWNS-SYNDROME; ETHYL-ESTERS	Interleukin (IL)-1 beta may play an important role in Alzheimer's disease. However, the relationships between glucocorticoids and acetylcholine (ACh), and between neurotrophins and ACh in IL-1-induced memory deficits are unknown. While ethyleicosapentaenoate (E-EPA) has recently been reported to reduce inflammation and improve memory, cholinergic and neurotrophic mechanisms by which E-EPA improves memory is unclear. This study evaluated: (i) the correlation between ACh release and memory impairment; (ii) the effect of glucocorticoids on ACh release; (iii) the relationship between nerve growth factor (NGF) and inflammation; and (iv) the effects of E-EPA treatment on IL-1 beta-induced changes. Intracerebroventricular IL-1 beta administrations produced a significant reduction in hippocampal ACh release in rats fed control diet, which was partially attenuated by mifepristone (RU 486) and completely blocked by IL-1 receptor antagonist. In eight-arm radial maze, significantly less ACh release was correlated with the memory deficits after IL-1 beta administrations. mRNA expression of hippocampal NGF was lower, whereas IL-1 beta was higher when compared with controls. E-EPA treatment significantly improved the memory, which was correlated with normalizing ACh release, and expressions of NGF and IL-1 beta. This study revealed important mechanisms by which IL-1 beta impairs, while E-EPA improves memory through IL-1-glucocorticoid-ACh release and IL-1-NGF-ACh release pathways.	[Taepavarapruk, Pornnarin; Song, Cai] Univ Prince Edward Isl, Dept Biomed Sci, AVC, Charlottetown, PE C1A 4P3, Canada; [Taepavarapruk, Pornnarin] Naresuan Univ, Dept Physiol, Fac Med Sci, Phitsanulok 65000, Thailand		Song, C (corresponding author), Univ Prince Edward Isl, Dept Biomed Sci, AVC, 550 Univ Ave, Charlottetown, PE C1A 4P3, Canada.	cai.song@nrc.gc.ca			Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Amarin Neurosciences Ltd.; Atlantic Innovation Foundation	This work was supported by the Canadian Institutes for Health Research (CIHR) grant to Cai Song. We thank Amarin Neurosciences Ltd. and Atlantic Innovation Foundation for their financial supports.	Avital A, 2003, HIPPOCAMPUS, V13, P826, DOI 10.1002/hipo.10135; BECKERMANN B, 1990, ARZNEIMITTEL-FORSCH, V40-1, P700; Brunton S, 2007, CURR MED RES OPIN, V23, P1139, DOI 10.1185/030079907X188017; Calon F, 2004, NEURON, V43, P633, DOI 10.1016/j.neuron.2004.08.013; Cattaneo A, 2008, J ALZHEIMERS DIS, V15, P255; Chiu CC, 2008, PROG NEURO-PSYCHOPH, V32, P1538, DOI 10.1016/j.pnpbp.2008.05.015; Ferrari CC, 2006, NEUROBIOL DIS, V24, P183, DOI 10.1016/j.nbd.2006.06.013; Colangelo AM, 2004, MOL BRAIN RES, V124, P97, DOI 10.1016/j.molbrainres.2004.01.011; Counts SE, 2005, J NEUROPATH EXP NEUR, V64, P263, DOI 10.1093/jnen/64.4.263; Crochemore C, 2005, MOL PSYCHIATR, V10, P790, DOI 10.1038/sj.mp.4001679; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; DeToledo-Morrell L, 2007, PROG BRAIN RES, V163, P741, DOI 10.1016/S0079-6123(07)63040-4; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dunn AJ, 2000, ANN NY ACAD SCI, V917, P608, DOI 10.1111/j.1749-6632.2000.tb05426.x; Griffin WST, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-5; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; Hashimoto M, 2009, J NUTR BIOCHEM, V20, P965, DOI 10.1016/j.jnutbio.2008.08.009; Isacson O, 2002, TRENDS NEUROSCI, V25, P79, DOI 10.1016/S0166-2236(02)02037-4; Johnson VJ, 2003, NEUROTOXICOLOGY, V24, P261, DOI 10.1016/S0161-813X(02)00194-8; Kornman KS, 2006, AM J CLIN NUTR, V83, p475S; Kou W, 2008, EUR J NUTR, V47, P104, DOI 10.1007/s00394-008-0703-1; Kuhlow CJ, 2003, GLIA, V44, P76, DOI 10.1002/glia.10273; LAWSON LD, 1988, BIOCHEM BIOPH RES CO, V152, P328, DOI 10.1016/S0006-291X(88)80718-6; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Lynch AM, 2007, NEUROBIOL AGING, V28, P845, DOI 10.1016/j.neurobiolaging.2006.04.006; Masuda J, 2005, NEUROSCIENCE, V132, P537, DOI 10.1016/j.neuroscience.2005.01.010; McLay RN, 1997, NEUROSCI BIOBEHAV R, V21, P615, DOI 10.1016/S0149-7634(96)00046-2; Mitsushima D, 2003, NEUROENDOCRINOLOGY, V78, P234, DOI 10.1159/000073707; Mizuno T, 1997, NEUROSCI LETT, V222, P49, DOI 10.1016/S0304-3940(97)13340-7; Mohapel P, 2005, NEUROBIOL AGING, V26, P939, DOI 10.1016/j.neurobiolaging.2004.07.015; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Murray CA, 1998, J NEUROSCI, V18, P2974; Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912; Nichols NR, 2005, BRAIN RES REV, V48, P287, DOI 10.1016/j.brainresrev.2004.12.019; Nichols NR, 2001, BRAIN RES REV, V37, P273, DOI 10.1016/S0165-0173(01)00131-X; Otsuka M, 2000, Nihon Ronen Igakkai Zasshi, V37, P970; Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x; Phillips AG, 2004, J NEUROSCI, V24, P547, DOI 10.1523/JNEUROSCI.4653-03.2004; Pinteaux E, 2009, CYTOKINE, V45, P1, DOI 10.1016/j.cyto.2008.10.008; Godoy MCP, 2008, BRAIN, V131, P1880, DOI 10.1093/brain/awn101; Puskas Laszlo G., 2006, Nutrition and Health (Bicester), V18, P227; RADA P, 1991, BRAIN RES, V550, P287, DOI 10.1016/0006-8993(91)91330-4; Salehi A, 2006, NEURON, V51, P29, DOI 10.1016/j.neuron.2006.05.022; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Shaftel SS, 2007, J CLIN INVEST, V117, P1595, DOI 10.1172/JCI31450; Singer P, 2008, INTENS CARE MED, V34, P1580, DOI 10.1007/s00134-008-1142-4; Song C, 2004, MOL PSYCHIATR, V9, P630, DOI 10.1038/sj.mp.4001462; Song C, 2003, J LIPID RES, V44, P1984, DOI 10.1194/jlr.M300217-JLR200; SONG C, 2008, BRAIN BEHAV IMMUN, V22, pS41; Song C, 2009, J NEUROSCI, V29, P14, DOI 10.1523/JNEUROSCI.3569-08.2009; Srikumar BN, 2006, NEUROSCIENCE, V143, P679, DOI 10.1016/j.neuroscience.2006.08.041; Su KP, 2009, NEUROSIGNALS, V17, P144, DOI 10.1159/000198167; Takuma K, 2004, PROG NEUROBIOL, V72, P111, DOI 10.1016/j.pneurobio.2004.02.001; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; Wu K, 2004, MOL THER, V9, P262, DOI 10.1016/j.ymthe.2003.11.010; YAU JLW, 1992, BRAIN RES, V577, P155, DOI 10.1016/0006-8993(92)90550-S	57	71	73	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	FEB	2010	112	4					1054	1064		10.1111/j.1471-4159.2009.06524.x			11	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	546PH	WOS:000273822200019	19968753	Bronze			2022-02-06	
J	Fish, J; Wilson, BA; Manly, T				Fish, Jessica; Wilson, Barbara A.; Manly, Tom			The assessment and rehabilitation of prospective memory problems in people with neurological disorders: A review	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Brain injury; Assessment; Rehabilitaion; Everyday memory	TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTIONS; EVERYDAY MEMORY; GOAL MANAGEMENT; PAGING SYSTEM; EVENT; PERFORMANCE; INTENTIONS; TIME; ADULTS	People with neurological disorders often report difficulty with prospective memory (PM), that is, remembering to do things they had intended to do. This paper briefly reviews the literature regarding the neuropsychology of PM function, concluding that from the clinical perspective, PM is best considered in terms of its separable but interacting mnemonic and executive components. Next, the strengths and limitations in the current clinical assessment of PM, including the assessment of component processes, desktop analogues of PM tasks, and naturalistic PM tasks, are outlined. The evidence base for the rehabilitation of PM is then considered, focusing on retraining PM, using retrospective memory strategies, problem-solving training, and finally, electronic memory aids. It is proposed that further research should focus on establishing the predictive validity of PM assessment, and refining promising rehabilitation techniques.	[Fish, Jessica; Wilson, Barbara A.; Manly, Tom] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England; [Wilson, Barbara A.] Princess Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely, Wales		Fish, J (corresponding author), MRC, Cognit & Brain Sci Unit, 15 Chaucer Rd, Cambridge CB2 7EF, England.	jessica.fish@mrc-cbu.cam.ac.uk		Fish, Jessica/0000-0002-9337-1489	UK Medical Research Council (MRC)UK Research & Innovation (UKRI)Medical Research Council UK (MRC) [U.1055.01.003.00001.01]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MC_U105559837] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [MC_U105559837] Funding Source: UKRI	We gratefully acknowledge the financial support of the UK Medical Research Council (MRC U.1055.01.003.00001.01), and thank the two reviewers of this manuscript for their insightful comments.	BADDELEY A, 1994, NEUROPSYCHOLOGIA, V32, P53, DOI 10.1016/0028-3932(94)90068-X; Baddeley A.D., 1997, HUMAN MEMORY THEORY; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Brooks BM, 2004, BRAIN INJURY, V18, P391, DOI 10.1080/02699050310001619855; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 2007, PHILOS T R SOC B, V362, P887, DOI 10.1098/rstb.2007.2095; Burgess PW, 2001, NEUROPSYCHOLOGIA, V39, P545, DOI 10.1016/S0028-3932(00)00149-4; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Camp C. J., 1996, PROSPECTIVE MEMORY T; Carey CL, 2006, J CLIN EXP NEUROPSYC, V28, P536, DOI 10.1080/13803390590949494; Christoff K, 2003, BEHAV NEUROSCI, V117, P1161, DOI 10.1037/0735-7044.117.6.1161; CORWIN J, 1993, CLIN NEUROPSYCHOL, V7, P3, DOI 10.1080/13854049308401883; Crawford JR, 2003, MEMORY, V11, P261, DOI 10.1080/09658210244000027; den Ouden HEM, 2005, NEUROIMAGE, V28, P787, DOI 10.1016/j.neuroimage.2005.05.001; Einstein G.O., 1996, PROSPECTIVE MEMORY T; Einstein GO, 2005, J EXP PSYCHOL GEN, V134, P327, DOI 10.1037/0096-3445.134.3.327; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J., 1996, PROSPECTIVE MEMORY T; ELLIS J, 1988, PRACTICAL ASPECTS ME, V1; Elvevag B, 2003, BMC PSYCHIATRY, V3, DOI 10.1186/1471-244X-3-9; Fish J, 2008, J NEUROL NEUROSUR PS, V79, P930, DOI 10.1136/jnnp.2007.125203; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Freeman JE, 2003, J EXP PSYCHOL LEARN, V29, P976, DOI 10.1037/0278-7393.29.5.976; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GOSCHKE T, 1993, J EXP PSYCHOL LEARN, V19, P1211, DOI 10.1037/0278-7393.19.5.1211; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Huppert FA, 2000, APPL COGNITIVE PSYCH, V14, pS63, DOI 10.1002/acp.771; Kapur N, 2004, NEUROPSYCHOL REHABIL, V14, P41, DOI 10.1080/09602010343000138; Katai S, 2003, J NEUROL NEUROSUR PS, V74, P704, DOI 10.1136/jnnp.74.6.704; Kim HJ, 2000, BRAIN INJURY, V14, P187, DOI 10.1080/026990500120844; Kime SK, 1996, BRAIN INJURY, V10, P17; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kinsella GJ, 2007, NEUROPSYCHOL REHABIL, V17, P688, DOI 10.1080/09602010600892824; Kixmiller JS, 2002, BRAIN COGNITION, V49, P237, DOI 10.1006/brcg.2001.1476; Kliegel M, 2000, MEM COGNITION, V28, P1041, DOI 10.3758/BF03209352; Kliegel M, 2005, J NEUROL NEUROSUR PS, V76, P1501, DOI 10.1136/jnnp.2004.051268; Knight RG, 2005, BRAIN INJURY, V19, P19, DOI 10.1080/02699050410001720022; Kondel TK, 2002, BRAIN COGNITION, V48, P405, DOI 10.1006/brcg.2001.1387; Kopp UA, 2003, INT J PSYCHOL, V38, P229, DOI 10.1080/00207590344000150; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; LEVINE B, 2009, GOAL MANAGEMEN UNPUB; Levine B, 2007, J INT NEUROPSYCH SOC, V13, P143, DOI 10.1017/S1355617707070178; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Manly T, 2002, NEUROPSYCHOLOGIA, V40, P271, DOI 10.1016/S0028-3932(01)00094-X; Marsh RL, 1998, J EXP PSYCHOL LEARN, V24, P350, DOI 10.1037/0278-7393.24.2.350; Martin M, 2003, INT J PSYCHOL, V38, P195, DOI 10.1080/00207590344000123; MAYLOR EA, 1990, Q J EXP PSYCHOL-A, V42, P471, DOI 10.1080/14640749008401233; MEACHAM JA, 1977, J PSYCHOL, V97, P191, DOI 10.1080/00223980.1977.9923962; MOSCOVITCH M, 1982, AGING COGNITIVE PROC, V3; Okuda J, 1998, NEUROSCI LETT, V253, P127, DOI 10.1016/S0304-3940(98)00628-4; Prigatano G.P., 1999, PRINCIPLES NEUROPSYC; Raskin S, 2004, J INT NEUROPSYCHO S1, V10, P110, DOI DOI 10.1017/S1355617704040019; Raskin SA, 1996, J HEAD TRAUMA REHAB, V11, P32, DOI 10.1097/00001199-199606000-00007; Robertson I., 1994, TEST EVERYDAY ATTENT; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Rude SS, 1999, COGNITION EMOTION, V13, P267, DOI 10.1080/026999399379276; Schmitter-Edgecombe M, 2004, NEUROPSYCHOLOGY, V18, P353, DOI 10.1037/0894-4105.18.2.353; Sellen AJ, 1997, MEMORY, V5, P483, DOI 10.1080/741941433; Shum D, 2004, SCHIZOPHRENIA BULL, V30, P693, DOI 10.1093/oxfordjournals.schbul.a007123; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Smith RE, 2003, J EXP PSYCHOL LEARN, V29, P347, DOI 10.1037/0278-7393.29.3.347; Smith RE, 2007, J EXP PSYCHOL LEARN, V33, P734, DOI 10.1037/0278-7393.33.4.734; Sohlberg M., 2001, COGNITIVE REHABILITA; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG M M, 1992, Brain Injury, V6, P139, DOI 10.3109/02699059209029652; Szymkowiak A, 2005, PERS UBIQUIT COMPUT, V9, P1, DOI 10.1007/s00779-004-0259-x; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wechsler D., 1997, WECHSLER MEMORY SCAL; West R, 2005, NEUROPSYCHOLOGIA, V43, P418, DOI 10.1016/j.neuropsychologia.2004.06.012; Wilson B., 2005, CAMBRIDGE PROSPECTIV; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 2003, NEUROPSYCHOLOG REHAB, P1; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Woods SP, 2009, J INT NEUROPSYCH SOC, V15, P42, DOI 10.1017/S1355617708090012; Yasuda K, 2002, NEUROPSYCHOL REHABIL, V12, P155, DOI 10.1080/09602010143000239	80	71	74	0	33	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2010	20	2					161	179	PII 919148239	10.1080/09602010903126029			19	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	564ER	WOS:000275196600001	20146135	Green Published			2022-02-06	
S	Roy, MJ; Francis, J; Friedlander, J; Banks-Williams, L; Lande, RG; Taylor, P; Blair, J; McLellan, J; Law, W; Tarpley, V; Patt, I; Yu, H; Mallinger, A; Difede, J; Rizzo, A; Rothbaum, B		Barchas, JD; Difede, J		Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Blair, James; McLellan, Jennifer; Law, Wendy; Tarpley, Vanita; Patt, Ivy; Yu, Henry; Mallinger, Alan; Difede, Joann; Rizzo, Albert; Rothbaum, Barbara			Improvement in cerebral function with treatment of posttraumatic stress disorder	PSYCHIATRIC AND NEUROLOGIC ASPECTS OF WAR	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	89th Annual Conference of the Association for Research in Nervous and Mental Disease	DEC 16, 2009	Rockefeller Univ, New York, NY		Rockefeller Univ	posttraumatic stress disorder; traumatic brain injury; combat stress; functional magnetic resonance imaging; virtual reality; exposure therapy	DEPRESSION INVENTORY-II; REALITY EXPOSURE THERAPY; ADMINISTERED PTSD SCALE; TRAUMATIC BRAIN-INJURY; BECK DEPRESSION; NEURAL RESPONSES; PHYSICAL HEALTH; FEARFUL FACES; PRIMARY-CARE; IRAQ	Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) are signature illnesses of the Iraq and Afghanistan wars, but current diagnostic and therapeutic measures for these conditions are suboptimal. In our study, functional magnetic resonance imaging (fMRI) is used to try to differentiate military service members with: PTSD and mTBI, PTSD alone, mTBI alone, and neither PTSD nor mTBI. Those with PTSD are then randomized to virtual reality exposure therapy or imaginal exposure. fMRI is repeated after treatment and along with the Clinician-Administered PTSD Scale (CAPS) and Clinical Global Impression (CGI) scores to compare with baseline. Twenty subjects have completed baseline fMRI scans, including four controls and one mTBI only; of 15 treated for PTSD, eight completed posttreatment scans. Most subjects have been male (93%) and Caucasian (83%), with a mean age of 34. Significant improvements are evident on fMRI scans, and corroborated by CGI scores, but CAPS scores improvements are modest. In conclusion, CGI scores and fMRI scans indicate significant improvement in PTSD in both treatment arms, though CAPS score improvements are less robust.	[Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Law, Wendy; Tarpley, Vanita; Patt, Ivy] Uniformed Serv Univ Hlth Sci, Bethesda, MD USA; [Roy, Michael J.; Francis, Jennifer; Friedlander, Joshua; Banks-Williams, Lisa; Lande, Raymond G.; Taylor, Patricia; Law, Wendy; Tarpley, Vanita; Patt, Ivy] Walter Reed Army Med Ctr, Washington, DC 20307 USA; [Blair, James; McLellan, Jennifer; Yu, Henry; Mallinger, Alan] NIMH, NIH, Bethesda, MD 20892 USA; [Difede, Joann] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Rizzo, Albert] Univ So Calif, Inst Creat Technol, Los Angeles, CA USA; [Rothbaum, Barbara] Emory Univ, Sch Med, Atlanta, GA USA		Roy, MJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Med, Room A3062,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	mroy@usuhs.mil	Blair, Robert James/ABH-7982-2020	Yu, Henry/0000-0003-3789-5250; Lande, R Gregory/0000-0002-0072-3538			Berg A., 2008, TREATMENT POSTTRAUMA; Blair RJR, 1999, BRAIN, V122, P883, DOI 10.1093/brain/122.5.883; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bradley KA, 2007, ALCOHOL CLIN EXP RES, V31, P1208, DOI 10.1111/j.1530-0277.2007.00403.x; Chisolm Theresa H, 2005, Trends Amplif, V9, P111, DOI 10.1177/108471380500900303; Cole JC, 2003, PSYCHOL REP, V93, P1115, DOI 10.2466/PR0.93.7.1115-1129; Contreras S, 2004, HISPANIC J BEHAV SCI, V26, P446, DOI 10.1177/0739986304269164; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DEROGATIS LR, 2004, USE PSYCHOL TESTING, V3, P59; Difede J, 2007, J CLIN PSYCHIAT, V68, P1639, DOI 10.4088/JCP.v68n1102; Dozois D.J.A., 2004, COMPREHENSIVE HDB PS, P50; Dutton GR, 2004, GEN HOSP PSYCHIAT, V26, P437, DOI 10.1016/j.genhosppsych.2004.06.002; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; Guy W., 1976, CLIN GLOBAL IMPRESSI; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; KING M, 1986, PSYCHOL MED, V16, P213, DOI 10.1017/S0033291700002658; Longwell BT, 2005, BEHAV THER, V36, P265, DOI 10.1016/S0005-7894(05)80075-9; Nakic M, 2006, NEUROIMAGE, V31, P1752, DOI 10.1016/j.neuroimage.2006.02.022; PINE DS, 2010, NEUROIMAGE IN PRESS; Rizzo AA, 2008, STUD HEALTH TECHNOL, V132, P420; Rothbaum BO, 2001, J CLIN PSYCHIAT, V62, P617, DOI 10.4088/JCP.v62n0808; Roy MJ, 1998, PSYCHOSOM MED, V60, P663, DOI 10.1097/00006842-199811000-00001; Schwab KA, 2006, NEUROLOGY, V66, pA235; Shin LM, 2005, ARCH GEN PSYCHIAT, V62, P273, DOI 10.1001/archpsyc.62.3.273; Shin LM, 2001, BIOL PSYCHIAT, V50, P932, DOI 10.1016/S0006-3223(01)01215-X; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Stein MB, 1997, AM J PSYCHIAT, V154, P1120; Thomas KM, 2001, ARCH GEN PSYCHIAT, V58, P1057, DOI 10.1001/archpsyc.58.11.1057; Ullman SE, 1996, J TRAUMA STRESS, V9, P703, DOI 10.1007/BF02104098; van Tubergen A, 2003, ANN RHEUM DIS, V62, P140, DOI 10.1136/ard.62.2.140; Wagner AW, 2000, J TRAUMA STRESS, V13, P41, DOI 10.1023/A:1007716813407; Walker EA, 2003, ARCH GEN PSYCHIAT, V60, P369, DOI 10.1001/archpsyc.60.4.369; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Zarahn E, 2000, COGNITIVE BRAIN RES, V9, P1, DOI 10.1016/S0926-6410(99)00033-6; Zarahn E, 2000, NEUROIMAGE, V11, P783, DOI 10.1006/nimg.2000.0560	38	71	71	1	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, ENGLAND	0077-8923		978-1-57331-804-4	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2010	1208						142	149		10.1111/j.1749-6632.2010.05689.x			8	Neurosciences; Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	BSK28	WOS:000284742000018	20955336				2022-02-06	
J	D'Ambrosio, R; Hakimian, S; Stewart, T; Verley, DR; Fender, JS; Eastman, CL; Sheerin, AH; Gupta, P; Diaz-Arrastia, R; Ojemann, J; Miller, JW				D'Ambrosio, Raimondo; Hakimian, Shahin; Stewart, Tessandra; Verley, Derek R.; Fender, Jason S.; Eastman, Clifford L.; Sheerin, Aaron H.; Gupta, Puneet; Diaz-Arrastia, Ramon; Ojemann, Jeffrey; Miller, John W.			Functional definition of seizure provides new insight into post-traumatic epileptogenesis	BRAIN			English	Article						traumatic brain injury; epileptogenesis; biomarkers; drug screening; prophylaxis	FLUID PERCUSSION INJURY; HIPPOCAMPAL SCLEROSIS; EPILEPTIC SEIZURES; ANIMAL-MODELS; THETA RHYTHM; OSCILLATIONS; PATHWAYS; RATS	Experimental animals' seizures are often defined arbitrarily based on duration, which may lead to misjudgement of the syndrome and failure to develop a cure. We employed a functional definition of seizures based on the clinical practice of observing epileptiform electrocorticography and simultaneous ictal behaviour, and examined post-traumatic epilepsy induced in rats by rostral parasagittal fluid percussion injury and epilepsy patients evaluated with invasive monitoring. We showed previously that rostral parasagittal fluid percussion injury induces different types of chronic recurrent spontaneous partial seizures that worsen in frequency and duration over the months post injury. However, a remarkable feature of rostral parasagittal fluid percussion injury is the occurrence, in the early months post injury, of brief (< 2 s) focal, recurrent and spontaneous epileptiform electrocorticography events (EEEs) that are never observed in sham-injured animals and have electrographic appearance similar to the onset of obvious chronic recurrent spontaneous partial seizures. Simultaneous epidural-electrocorticography and scalp-electroencephalography recordings in the rat demonstrated that these short EEEs are undetectable by scalp electrocorticography. Behavioural analysis performed blinded to the electrocorticography revealed that (i) brief EEEs lasting 0.8-2 s occur simultaneously with behavioural arrest; and (ii) while behavioural arrest is part of the rat's behavioural repertoire, the probability of behavioural arrest is greatly elevated during EEEs. Moreover, spectral analysis showed that EEEs lasting 0.8-2 s occurring during periods of active behaviour with dominant theta activity are immediately followed by loss of such theta activity. We thus conclude that EEEs lasting 0.8-2 s are ictal in the rat. We demonstrate that the assessment of the time course of fluid percussion injury-induced epileptogenesis is dramatically biased by the definition of seizure employed, with common duration-based arbitrary definitions resulting in artificially prolonged latencies for epileptogenesis. Finally, we present four human examples of electrocorticography capturing short (< 2 s), stereotyped, neocortically generated EEEs that occurred in the same ictal sites as obvious complex partial seizures, were electrographically similar to rat EEEs and were not noted during scalp electroencephalography. When occurring in the motor cortex, these short EEEs were accompanied by ictal behaviour detectable with simultaneous surface electromyography. These data demonstrate that short (< 2 s) focal recurrent spontaneous EEEs are seizures in both rats and humans, that they are undetectable by scalp electroencephalography, and that they are typically associated with subtle and easily missed behavioural correlates. These findings define the earliest identifiable markers of progressive post-traumatic epilepsy in the rat, with implications for mechanistic and prophylactic studies, and should prompt a re-evaluation of the concept of post-traumatic silent period in both animals and humans.	[D'Ambrosio, Raimondo; Stewart, Tessandra; Verley, Derek R.; Fender, Jason S.; Eastman, Clifford L.; Sheerin, Aaron H.; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Hakimian, Shahin; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Hakimian, Shahin; Ojemann, Jeffrey; Miller, John W.] Univ Washington, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Ojemann, Jeffrey] Univ Washington, Sch Med, Ctr Human Dev & Disabil, Seattle, WA 98104 USA; [D'Ambrosio, Raimondo; Stewart, Tessandra] Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98104 USA; [Gupta, Puneet; Diaz-Arrastia, Ramon] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA		D'Ambrosio, R (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA.	raid@u.washington.edu	Verley, Derek/J-4550-2015	Verley, Derek/0000-0002-2670-6568; Ojemann, Jeffrey/0000-0001-7580-8934; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Hakimian, Shahin/0000-0002-1310-2773	CURE Epilepsy foundation [5154001.01]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS053928, T32NS07144]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053928, T32NS007144] Funding Source: NIH RePORTER	CURE Epilepsy foundation [ 5154001.01 to R. D.]; the National Institutes of Health [NS053928 to R. D. and T32NS07144].	Binnie CD., 2003, EEG PAEDIAT NEUROPHY, V2; Blum DE, 1996, NEUROLOGY, V47, P260, DOI 10.1212/WNL.47.1.260; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Coenen AML, 2003, BEHAV GENET, V33, P635, DOI 10.1023/A:1026179013847; Cukiert A, 2001, EPILEPSIA, V42, P889, DOI 10.1046/j.1528-1157.2001.00201.x; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; D'Ambrosio R, 2007, EPILEPSIA, V48, P294; Dichter MA, 2009, EPILEPSIA, V50, P41, DOI 10.1111/j.1528-1167.2008.02009.x; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Holmes GL, 2002, NEUROLOGY, V59, pS3, DOI 10.1212/WNL.59.9_suppl_5.S3; JUULJENSEN P, 1986, INTRACTABLE EPILEPSY, P5; Kay LM, 2005, P NATL ACAD SCI USA, V102, P3863, DOI 10.1073/pnas.0407920102; Magill PJ, 2005, NEUROSCIENCE, V132, P659, DOI 10.1016/j.neuroscience.2005.01.006; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; Mattson RH, 1996, NEUROLOGY, V47, P68, DOI 10.1212/WNL.47.1.68; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Semah F, 1998, NEUROLOGY, V51, P1256, DOI 10.1212/WNL.51.5.1256; Shaw FZ, 2004, J NEUROPHYSIOL, V91, P63, DOI 10.1152/jn.00487.2003; Sloviter RS, 2008, EPILEPSIA, V49, P85, DOI 10.1111/j.1528-1167.2008.01931.x; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula TP, 2003, CURR OPIN NEUROL, V16, P189, DOI 10.1097/00019052-200304000-00012; Sutula TP, 2001, NEUROLOGY, V57, P169, DOI 10.1212/WNL.57.2.169; Tatum WO, 2001, J CLIN NEUROPHYSIOL, V18, P14, DOI 10.1097/00004691-200101000-00004; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	27	71	71	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2009	132		10				2805	2821		10.1093/brain/awp217			17	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	505IG	WOS:000270685600027	19755519	hybrid, Green Published, Green Submitted			2022-02-06	
J	Figaji, AA; Zwane, E; Fieggen, AG; Slesjo, P; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Fieggen, A. Graham; Slesjo, Peter; Peter, Jonathan C.			Transcranial Doppler pulsatility index is not a reliable indicator of intracranial pressure in children with severe traumatic brain injury	SURGICAL NEUROLOGY			English	Article						Transcranial Doppler; Intracranial pressure; Cerebral perfusion pressure; Children; Traumatic brain injury; pulsatility index	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; VELOCITY; ULTRASONOGRAPHY; ULTRASOUND; SONOGRAPHY; AUTOREGULATION; HEMODYNAMICS; METABOLISM; SCORE	Background: The TCD-derived PI has been associated with ICP in adult studies but has not been well investigated in children. We examined the relationship between PI and ICP and CPP in children with severe TBI. Methods: Data were prospectively collected from consecutive TCD studies in children with severe TBI undergoing ICP monitoring. Ipsilateral ICP and CPP values were examined with Spearman correlation coefficient (mean values and raw observations), with a GEE, and as binary values (1 and 20 mm Hg, respectively). Results: Thirty-four children underwent 275 TCD studies. There was a weak relationship between mean values of ICP and PI (P = .04, r = 0.36), but not when raw observations (P = .54) or GEE (P = .23) were used. Pulsatility index was 0.76 when ICP was lower than 20 mm Hg and 0.86 when ICP was 20 mm Hg or higher. When PI was 1 or higher, ICP was lower than 20 mm Hg in 62.5% (25 of 40 studies), and when ICP was 20 mm Hg or higher, PI was lower than 1 in 75% (46 of 61 studies). The sensitivity and specificity of a PI threshold of 1 for examining the ICP threshold of 20 mm Hg were 25% and 88%, respectively. The relationship between CPP and PI was stronger (P = .001, r -0.41), but there were too few observations below 50 mm Hg to examine PI at this threshold. Conclusion: The absolute value of the PI is not a reliable noninvasive indicator of ICP in children with severe TBI. Further study is required to examine the relationship between PI and a CPP threshold of 50 mm Hg. (C) 2009 Elsevier Inc. All rights reserved.	[Figaji, Anthony A.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Neurosurg, ZA-7700 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Child & Adolescent Hlth, Infect Dis Epidemiol Unit Biostat, ZA-7700 Cape Town, South Africa; [Slesjo, Peter] Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Pediat Crit Care, ZA-7700 Cape Town, South Africa; [Slesjo, Peter] Lund Univ, Dept Neurosurg, Univ Lund Hosp, Lund, Sweden		Figaji, AA (corresponding author), Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, Div Neurosurg, ZA-7700 Cape Town, South Africa.	anthony.figaji@uct.ac.za	Fieggen, Anthony Graham/AAT-6510-2021	Fieggen, Anthony Graham/0000-0001-6541-8377; Siesjo, Peter/0000-0002-5848-690X; Figaji, Anthony/0000-0002-3357-6490	Swedish-South African Links Programme [GUN 2072790]	This study was supported by a Swedish-South African Links Programme grant GUN 2072790, which supports a collaborative study investigating TBI in children between the University of Cape Town, Cape Town, South Africa, and Lund University, Lund, Sweden.	AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS31; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Bellner J, 2004, SURG NEUROL, V62, P45, DOI 10.1016/j.surneu.2003.12.007; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; BRUCE DA, 1979, CHILD BRAIN, V5, P174; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHIRON C, 1992, J NUCL MED, V33, P696; GOSLING RG, 1974, P ROY SOC MED, V67, P447, DOI 10.1177/00359157740676P113; HOMBURG AM, 1993, ACTA NEUROL SCAND, V87, P488; LAUMER R, 1993, NEUROSURGERY, V33, P1, DOI 10.1227/00006123-199307000-00001; Levis S, 1998, ACT NEUR S, V71, P174; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Meyer PG, 2005, CHILD NERV SYST, V21, P133, DOI 10.1007/s00381-004-1016-1; Minassian AT, 1998, J NEUROSURG, V88, P996, DOI 10.3171/jns.1998.88.6.0996; Moreno J A, 2000, Neurosurg Focus, V8, pe8; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NADVI SS, 1994, BRIT J NEUROSURG, V8, P573, DOI 10.3109/02688699409002950; Ng SCP, 2000, ACT NEUR S, V76, P479; POPLE IK, 1991, EUR J PEDIATR SURG, V1, P27, DOI 10.1055/s-2008-1042534; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; SANKER P, 1991, CHILD NERV SYST, V7, P391, DOI 10.1007/BF00304204; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Splavski B, 2006, BRIT J NEUROSURG, V20, P386, DOI 10.1080/02688690601048104; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; STEINMEIER R, 1993, NEUROSURGERY, V33, P10; STEINMEIER R, 1993, NEUROSURGERY, V33, P18; Trabold F, 2004, INTENS CARE MED, V30, P108, DOI 10.1007/s00134-003-2057-8; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Voulgaris SG, 2005, MED SCI MONITOR, V11, pCR49; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	33	71	72	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	OCT	2009	72	4					389	394		10.1016/j.surneu.2009.02.012			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	498YW	WOS:000270183900014	19608224				2022-02-06	
J	Doig, E; Fleming, J; Cornwell, PL; Kuipers, P				Doig, Emmah; Fleming, Jennifer; Cornwell, Petrea L.; Kuipers, Pim			Qualitative Exploration of a Client-Centered, Goal-Directed Approach to Community-Based Occupational Therapy for Adults With Traumatic Brain Injury	AMERICAN JOURNAL OF OCCUPATIONAL THERAPY			English	Article						brain injuries; community health services; goals; patient participation; rehabilitation	SELF-IDENTIFIED GOALS; REHABILITATION PROCESS; AWARENESS; PEOPLE; STROKE; ACHIEVEMENT; DEFICITS; COMA	OBJECTIVES. We explored the clinical application of goal-directed therapy in community-based rehabilitation from the perspective of clients with traumatic brain injury (TBI), their significant others, and their treating occupational therapists. METHOD. Twelve people with TBI and their significant others completed an outpatient, goal-directed, 12-week occupational therapy program. Semistructured interviews with 12 participants, 10 significant others, and 3 occupational therapists involved in delivering the therapy programs explored their experiences of goal-directed therapy. RESULTS. Participants, their significant others, and therapists described goal-directed therapy positively, expressing satisfaction with progress made. CONCLUSION. Goals provide structure, which facilitates participation in rehabilitation despite the presence of barriers, including reduced motivation and impaired self-awareness. A therapist-facilitated, structured, goal-setting process in which the client, therapist, and significant others work in partnership can enhance the process of goal setting and goal-directed rehabilitation in a community rehabilitation context.	[Doig, Emmah] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4062, Australia		Doig, E (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4062, Australia.	emmah.doig@optusnet.com.au	Fleming, Jennifer M/B-4436-2011; Doig, Emmah/AAG-6674-2021; Cornwell, Petrea/AAE-5547-2019	Doig, Emmah/0000-0002-7020-053X; Kuipers, Pim/0000-0003-0340-2286			Barnes M. D., 2000, TXB REHABILITATION M; Bodiam C., 1999, BRIT J OCCUP THER, V62, P123, DOI [10.1177/030802269906200310, DOI 10.1177/030802269906200310]; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; Doig E., 2008, BRIT J OCCUP THER, V71, P360, DOI [10.1177/030802260807100902, DOI 10.1177/030802260807100902]; EAMES J, 1999, BRIT J OCCUPATIONAL, V62, P257; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; Fleming JM, 1996, BRAIN INJURY, V10, P1; Gagne DE, 2003, AM J OCCUP THER, V57, P215, DOI 10.5014/ajot.57.2.215; GAUGGEL S, 2004, HDB MOTIVATIONAL COU, P421; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Jenkinson N, 2007, BRAIN INJURY, V21, P1283, DOI 10.1080/02699050701739531; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; Kielhofner G, 1998, AM J OCCUP THER, V52, P345, DOI 10.5014/ajot.52.5.345; KIRESUK TJ, 1968, COMMUNITY MENT HLT J, V4, P443, DOI 10.1007/BF01530764; Kuipers P., 2004, BRAIN IMPAIR, V5, P30, DOI DOI 10.1375/BRIM.5.1.30.35404; Lannin Natasha, 2003, Occup Ther Health Care, V17, P43, DOI 10.1080/J003v17n01_04; Law M, 1991, CANADIAN OCCUPATIONA; Lawler J, 1999, J ADV NURS, V30, P401, DOI 10.1046/j.1365-2648.1999.01086.x; LEACH E, DISABILITY IN PRESS; Levack WMM, 2006, BRAIN INJURY, V20, P1439, DOI 10.1080/02699050601118422; MacLeod GM, 1996, SPINAL CORD, V34, P525, DOI 10.1038/sc.1996.95; MALEC JF, 1999, NEUROPSYCHOL REHABIL, V314, P253; Mason J., 2002, QUALITATIVE RES; McAndrew E., 1999, PHYS OCCUP THER GERI, V17, P55; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; Paterson B, 2002, QUAL HEALTH RES, V12, P399, DOI 10.1177/104973202129119973; Patton MQ., 2015, QUALITATIVE RES EVAL, V4; Pedretti L. W., 1996, OCCUPATIONAL THERAPY, P3; Phipps S, 2007, AM J OCCUP THER, V61, P328, DOI 10.5014/ajot.61.3.328; Playford ED, 2000, CLIN REHABIL, V14, P491, DOI 10.1191/0269215500cr343oa; POLLOCK N, 1993, AM J OCCUP THER, V47, P298, DOI 10.5014/ajot.47.4.298; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reed KL., 1980, CONCEPTS OCCUPATIONA; Ritchie J., 2003, QUALITATIVE RES PRAC; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; SCHUT HA, 1994, DISABIL REHABIL, V16, P223, DOI 10.3109/09638289409166616; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Siegert R, 2004, DISABIL REHABIL, V26, P1, DOI 10.1080/09638280410001644932; Spencer L., 2003, QUALITATIVE RES PRAC, P199; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55; Sumison T, 2004, BRIT J OCCUPATIONAL, V67, P2; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Von Koch L, 1998, DISABIL REHABIL, V20, P367, DOI 10.3109/09638289809166095; WEBB PM, 1994, REHABIL PSYCHOL, V39, P179, DOI 10.1037/h0080321; Wilson BA, 2002, J HEAD TRAUMA REHAB, V17, P542, DOI 10.1097/00001199-200212000-00006; Wressle E, 2002, J REHABIL MED, V34, P5, DOI 10.1080/165019702317242640; Wressle E, 1999, DISABIL REHABIL, V21, P80, DOI 10.1080/096382899298016	51	71	71	3	19	AMER OCCUPATIONAL THERAPY ASSOC, INC	BETHESDA	4720 MONTGOMERY LANE, BETHESDA, MD 20814-3425 USA	0272-9490	1943-7676		AM J OCCUP THER	Am. J. Occup. Ther.	SEP-OCT	2009	63	5			SI		559	568		10.5014/ajot.63.5.559			10	Rehabilitation	Social Science Citation Index (SSCI)	Rehabilitation	493SG	WOS:000269757700006	19785255	Green Published			2022-02-06	
J	Shehata, N; Wiley, JP; Richea, S; Benson, BW; Duits, L; Meeuwisse, WH				Shehata, N.; Wiley, J. P.; Richea, S.; Benson, B. W.; Duits, L.; Meeuwisse, W. H.			Sport concussion assessment tool: baseline values for varsity collision sport athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							EPIDEMIOLOGY; SYMPTOMS; INJURIES	Objective: To determine baseline symptom and neurocognitive norms for non-concussed and previously concussed varsity athletes using the sport concussion assessment tool (SCAT). Study Design: Descriptive cohort study. Setting: University of Calgary. Subjects: 260 male and female university football, ice hockey and wrestling athletes over three seasons (2005-7). Methods: A baseline SCAT was completed during preseason medical evaluation. Subjects were grouped as follows: all participants, men, women, never concussed (NC) and previously concussed (PC). Main Results: The mean age of participants was 20.5 years (range 17-32). In total, 41.2% of all athletes had a total post-concussion symptom scale (PCSS) score of 0. The mean baseline PCSS scores were as follows: all participants 4.29; men 3.52; women 6.39; NC 3.75 and PC 5.25. The five most frequently reported symptoms for all athletes were fatigue/low energy (37% of subjects), drowsiness (23%), neck pain (20%), difficulty concentrating (18%) and difficulty remembering (18%). The median immediate recall score was 5/5 for all groups. Women scored a median of 5/5 on delayed recall, whereas all remaining groups scored a median of 4/5. Months in reverse order were successfully completed by 91.6% of subjects. All participants, women and PC scored a median of 6 on reverse digits, whereas men and NC scored a median of 5. Conclusions: The mean SCAT baseline PCSS score was approximately 5, although just under half of the athletes scored 0. Female athletes scored better on tests of neurocognitive function. PC athletes scored better than NC athletes on all neurocognitive tests except delayed five-word recall.	[Wiley, J. P.] Univ Calgary, Sport Med Ctr, Calgary, AB T2N 1N4, Canada; [Duits, L.] Univ Amsterdam, Amsterdam, Netherlands		Wiley, JP (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	wiley@ucalgary.ca		Duits, Lucas/0000-0002-5995-121X			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT, 1996, CLIN ELECTROENCEPHAL, V27, P183; Bruce JM, 2004, NEUROLOGY, V63, P1516; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; GRINDEL S, CLIN J SPORT MED, V11, P134; Guskiewicz KM, 2004, AM J MED SPORTS, V6, P13; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moeller James L, 2004, Curr Sports Med Rep, V3, P304; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; *U CALG, DIN AC CRIT	13	71	71	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	SEP	2009	43	10					730	734		10.1136/bjsm.2009.059832			5	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	503FY	WOS:000270520100003	19460765				2022-02-06	
J	Ding, Y; Yan, Q; Ruan, JW; Zhang, YQ; Li, WJ; Zhang, YJ; Li, Y; Dong, HX; Zeng, YS				Ding, Ying; Yan, Qing; Ruan, Jing-Wen; Zhang, Yan-Qing; Li, Wen-Jie; Zhang, Yu-Jiao; Li, Yan; Dong, Hongxin; Zeng, Yuan-Shan			Electro-acupuncture promotes survival, differentiation of the bone marrow mesenchymal stem cells as well as functional recovery in the spinal cord-transected rats	BMC NEUROSCIENCE			English	Article							TRAUMATIC BRAIN-INJURY; NEURONS IN-VITRO; STROMAL CELLS; ADULT-RAT; AXONAL REGENERATION; NEUROTROPHIC FACTOR; SCHWANN-CELLS; NERVOUS-SYSTEM; DELAYED TRANSPLANTATION; ELECTRIC-FIELDS	Background: Bone marrow mesenchymal stem cells (MSCs) are one of the potential tools for treatment of the spinal cord injury; however, the survival and differentiation of MSCs in an injured spinal cord still need to be improved. In the present study, we investigated whether Governor Vessel electro-acupuncture (EA) could efficiently promote bone marrow mesenchymal stem cells (MSCs) survival and differentiation, axonal regeneration and finally, functional recovery in the transected spinal cord. Results: The spinal cords of adult Sprague-Dawley (SD) rats were completely transected at T10, five experimental groups were performed: 1. sham operated control (Sham-control); 2. operated control (Op-control); 3. electro-acupuncture treatment (EA); 4. MSCs transplantation (MSCs); and 5. MSCs transplantation combined with electro-acupuncture (MSCs+EA). After 2-8 weeks of MSCs transplantation plus EA treatment, we found that the neurotrophin-3 (NT-3), cAMP level, the differentiation of MSCs, the 5-HT positive and CGRP positive nerve fibers in the lesion site and nearby tissue of injured spinal cord were significantly increased in the MSCs+EA group as compared to the group of the MSCs transplantation or the EA treated alone. Furthermore, behavioral test and spinal cord evoked potentials detection demonstrated a significantly functional recovery in the MSCs+EA group. Conclusion: These results suggest that EA treatment may promote grafted MSCs survival and differentiation; MSCs transplantation combined with EA treatment could promote axonal regeneration and partial locomotor functional recovery in the transected spinal cord in rats and indicate a promising avenue of treatment of spinal cord injury.	[Ding, Ying; Yan, Qing; Zhang, Yan-Qing; Li, Wen-Jie; Zhang, Yu-Jiao; Li, Yan; Zeng, Yuan-Shan] Dept Histol & Embryol, Div Neurosci, Guangzhou, Guangdong, Peoples R China; [Zeng, Yuan-Shan] Ctr Stem Cell Biol & Tissue Engn, Guangzhou, Guangdong, Peoples R China; [Zeng, Yuan-Shan] Sun Yat Sen Univ, Zhongshan Sch Med, Inst Spinal Cord Injury, Guangzhou 510275, Guangdong, Peoples R China; [Ruan, Jing-Wen] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Acupuncture, Guangzhou 510275, Guangdong, Peoples R China; [Dong, Hongxin] Northwestern Univ, Feinberg Sch Med, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA		Zeng, YS (corresponding author), Dept Histol & Embryol, Div Neurosci, 74 Zhongshan 2nd Rd, Guangzhou, Guangdong, Peoples R China.	dingying@mail.sysu.edu.cn; yanqing312@yahoo.com.cn; ruanjw@163.com; xiaomaozhang2002@yahoo.com.cn; wenjie1124@sohu.com; gzjj520@yahoo.com; liyan@mail.sysu.edu.cn; h-dong@northwestern.edu; zengysh@mail.sysu.edu.cn			Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30472132]; Administrative Bureau of Chinese Traditional Medicine of Guangdong [1050167, 2007109]	We thank Keely Murphy at Northwestern University for editing this manuscript. This research was supported by a grant from the Chinese National Natural Science Foundation (No. 30472132) and a Research Grant of the Administrative Bureau of Chinese Traditional Medicine of Guangdong Province (No. 1050167; 2007109) to Y. S. Zeng.	Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; Cao L, 2004, BRAIN, V127, P535, DOI 10.1093/brain/awh072; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen YY, 2008, ACUPUNCTURE ELECTRO, V33, P19, DOI 10.3727/036012908803861212; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; Crain BJ, 2005, J NEUROL SCI, V233, P121, DOI 10.1016/j.jns.2005.03.017; Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070; Dolbeare D, 2003, J NEUROTRAUM, V20, P1251, DOI 10.1089/089771503770802916; Dong ZQ, 2005, NEUROSCI LETT, V376, P143, DOI 10.1016/j.neulet.2004.11.044; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Fouad K, 2005, J NEUROSCI, V25, P1169, DOI 10.1523/JNEUROSCI.3562-04.2005; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; Guo JS, 2007, SPINAL CORD, V45, P15, DOI 10.1038/sj.sc.3101943; Han HS, 2005, MO CL BI CC, V4, P25; Hansen MR, 2001, J NEUROSCI, V21, P2256, DOI 10.1523/JNEUROSCI.21-07-02256.2001; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Hu Y, 2001, J NEUROL NEUROSUR PS, V71, P732, DOI 10.1136/jnnp.71.6.732; Iannotti C, 2003, EXP NEUROL, V183, P379, DOI 10.1016/S0014-4886(03)00188-2; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jean I, 2003, BRAIN RES, V972, P110, DOI 10.1016/S0006-8993(03)02510-1; Johnson JR, 2000, J NEUROCHEM, V74, P1409, DOI 10.1046/j.1471-4159.2000.0741409.x; Kamada T, 2005, J NEUROPATH EXP NEUR, V64, P37, DOI 10.1093/jnen/64.1.37; Kawaguchi S, 2004, PROG BRAIN RES, V143, P155, DOI 10.1016/S0079-6123(03)43015-X; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Li Xiao-bin, 2006, Jiepou Xuebao, V37, P622; [李晓滨 Li Xiaobin], 2004, [解剖学报, Acta Anatomica Sinica], V35, P582; Liu Y, 1999, J NEUROSCI, V19, P4370; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; Munoz-Elias G, 2004, J NEUROSCI, V24, P4585, DOI 10.1523/JNEUROSCI.5060-03.2004; PAINO CL, 1991, EXP NEUROL, V114, P254, DOI 10.1016/0014-4886(91)90043-C; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; PATEL N, 1982, J NEUROSCI, V2, P483; PATEL NB, 1984, J NEUROSCI, V4, P2939; Patist CM, 2004, BIOMATERIALS, V25, P1569, DOI 10.1016/S0142-9612(03)00503-9; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Saini HS, 2004, J NEUROCHEM, V89, P951, DOI 10.1111/j.1471-4159.2004.02365.x; Shumsky JS, 2003, EXP NEUROL, V184, P114, DOI 10.1016/S0014-4886(03)00398-4; Song S, 2004, EXP NEUROL, V185, P191, DOI 10.1016/j.expneurol.2003.09.003; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Steward O, 2006, EXP NEUROL, V198, P483, DOI 10.1016/j.expneurol.2005.12.034; Suon S, 2006, BRAIN RES, V1106, P46, DOI 10.1016/j.brainres.2006.05.109; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Tsai EC, 2004, J NEUROTRAUM, V21, P789, DOI 10.1089/0897715041269687; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wakabayashi Y, 2001, SPINE, V26, P1215, DOI 10.1097/00007632-200106010-00009; Wang TH, 2007, NEUROCHEM RES, V32, P1415, DOI 10.1007/s11064-007-9326-9; Wong AMK, 2003, AM J PHYS MED REHAB, V82, P21, DOI 10.1097/00002060-200301000-00004; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Xie Jie, 2006, J Tradit Chin Med, V26, P148; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; Yang Cheng, 2005, Zhongguo Zhen Jiu, V25, P569; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zeng YS, 2005, DEV NEUROSCI-BASEL, V27, P20, DOI 10.1159/000084529; Zhang W, 2006, NEUROSCI LETT, V408, P98, DOI 10.1016/j.neulet.2006.08.079; Zhang XB, 2007, J NEUROTRAUM, V24, P1863, DOI 10.1089/neu.2007.0334	74	71	83	3	23	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	APR 20	2009	10								35	10.1186/1471-2202-10-35			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	470OL	WOS:000267984900001	19374777	gold, Green Published			2022-02-06	
J	Dawson, DR; Gaya, A; Hunt, A; Levine, B; Lemsky, C; Polatajko, HJ				Dawson, Deirdre R.; Gaya, Arvinder; Hunt, Anne; Levine, Brian; Lemsky, Carolyn; Polatajko, Helene J.			Using the Cognitive Orientation to Occupational Performance (CO-OP) with adults with executive dysfunction following traumatic brain injury	CANADIAN JOURNAL OF OCCUPATIONAL THERAPY-REVUE CANADIENNE D ERGOTHERAPIE			English	Article						Executive dysfunction; Rehabilitation; Brain injury; Cognition; CO-OP; Problem solving	SELF-IDENTIFIED GOALS; QUALITY-OF-LIFE; REHABILITATION; ACHIEVEMENT; AWARENESS	Background. Meta-cognitive strategies have a positive effect on the rehabilitation of executive dysfunction. However, achieving generalization to daily life remains a challenge. We believe that providing rehabilitation in the person's own physical environment and using self-identified tasks will enhance the benefits of meta-cognitive training and promote generalization. Purpose. This pilot study tested the applicability of the Cognitive Orientation to Occupational Performance (CO-OP) approach for use with adults with executive dysfunction arising from traumatic brain injury (TB!). Methods. A single-case design was used with 3 adults, 5 to 20 years post-TBI and their self-identified significant others. Assessments included neuropsychological tests and the Canadian Occupational Performance Measure. The intervention entailed guiding participants to use a meta-cognitive problem-solving strategy to perform self-identified daily tasks that they needed and wanted to do and with which they were having difficulties. The intervention occurred over 20 one-hour sessions in participants' environments. Findings. Performance improved to criterion (2-point positive change) on 7 of 9 trained goals and on 4 of 7 untrained goals (self-report). Improvement was maintained at a 3-month follow-up assessment. Implications. The CO-OP approach has the potential to improve performance in daily functioning for adults with executive dysfunction following TBI.	[Dawson, Deirdre R.; Hunt, Anne] Baycrest, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; [Dawson, Deirdre R.; Polatajko, Helene J.] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON M5G 1V7, Canada; [Dawson, Deirdre R.; Polatajko, Helene J.] Univ Toronto, Grad Dept Rehabil Sci, Toronto, ON M5G 1V7, Canada; [Gaya, Arvinder] COTA Hlth, Toronto, ON M6A 3B4, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Baycrest, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; [Lemsky, Carolyn] Community Head Injury Resource Serv CHIRS, Toronto, ON M2N 7G1, Canada; [Dawson, Deirdre R.] Toronto Rehabil Inst, Toronto, ON, Canada		Dawson, DR (corresponding author), Baycrest, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	ddawson@klaru-baycrest.on.ca	Dawson, Deirdre R/I-8882-2014; Levine, Brian/O-2725-2019; Levine, Brian/G-4328-2010	Dawson, Deirdre R/0000-0001-7517-6121; Levine, Brian/0000-0003-4343-811X; Levine, Brian/0000-0003-4343-811X	Faculty of Medicine, University of TorontoUniversity of Toronto; Ontario Neurotrauma Foundation [2005-ABI-POP-363]	This research was supported by funding from the Dean's Fund, Faculty of Medicine, University of Toronto (to D. Dawson) and by funding from the Ontario Neurotrauma Foundation(2005-ABI-POP-363 to D. Dawson). Parts of these results were presented in poster format at the Annual Meeting of the International Neuropsychological Society in February 2007 and in pacer format at the Annual Meeting of the Canadian Association of Occupational Therapists in July 2007 and at the Annual Meeting of the American Congress of Rehabilitation Medicine in October 2007. We are appreciative of the assistance of the following people on this project: Adrienne Lo, Candace Ikeda-Douglas, Michelle Ryan, and Venus Sayed. Finally, we are especially thankful for the time and energy given to this project by our research participants and their significant others.	Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; *ADJ GEN OFF, 1944, MAN DIR SCOR; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P376, DOI 10.1017/S1355617705050423; Brandt J, 1991, CLIN NEUROPSYCHOL, V5, P125, DOI [10.1080/13854049108403297, DOI 10.1080/13854049108403297]; Burgess P. W., 2002, PRINCIPLES FRONTAL L, P557, DOI 10.1093/acprof:oso/9780195134971.003.0033; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; CICERONE KD, 1992, NEUROREHABILITATION, V2, P12, DOI DOI 10.3233/NRE-1992-2304; Dawson D. R., 2005, J HEAD TRAUMA REHAB, V20, P436; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Feuerstein R., 1980, INSTRUMENTAL ENRICHM; Fleming Jennifer M, 2006, Can J Occup Ther, V73, P44; Geusgens CAV, 2007, J REHABIL MED, V39, P425, DOI 10.2340/16501977-0092; Giles G. M., 1990, BRIT J OCCUPATIONAL, V53, P314; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Heaton R. K., 1991, SUPPLEMENT WESCHLER; Heaton RK, 1991, COMPREHENSIVE NORMS; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Landa-Gonzalez BELKIS, 2001, Occup Ther Int, V8, P49, DOI 10.1002/oti.131; Law M., 1994, CANADIAN OCCUPATIONA, V2; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Luria A. R, 1982, LANGUAGE COGNITION; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Mandich, 2004, ENABLING OCCUPATION; Meichenbaum, 1977, COGNITIVE BEHAV MODI; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rees L, 2007, BRAIN INJURY, V21, P161, DOI 10.1080/02699050701201813; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Smith A., 1978, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TOGLIA JP, 1991, AM J OCCUP THER, V45, P505, DOI 10.5014/ajot.45.6.505; TOGLIA JP, 2005, COGNITION OCCUPATION; Trombly CA, 1998, AM J OCCUP THER, V52, P810, DOI 10.5014/ajot.52.10.810; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Turner GR, 2004, SCI PRACT NEUROPSYCH, P224; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Vygotsky LS., 1978, MIND SOC DEV HIGHER; Wechsler D, 1985, WECHSLER ADULT INTEL; Wressle E., 1999, SCAND J OCCUP THER, V6, P84, DOI [DOI 10.1080/110381299443771, 10.1080/110381299443771]; Young DA, 2002, NEUROPSYCHOL REHABIL, V12, P257, DOI 10.1080/0960201044000066; Zasler N, 2000, NEUROPSYCHOLOGICAL M, P23	48	71	72	0	22	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0008-4174	1911-9828		CAN J OCCUP THER	Can. J. Occup. Ther.	APR	2009	76	2					115	127		10.1177/000841740907600209			13	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	V20TK	WOS:000208162100009	19456090				2022-02-06	
J	O'Phelan, K; McArthur, DL; Chang, CWJ; Green, D; Hovda, DA				O'Phelan, Kristine; McArthur, David L.; Chang, Cherylee W. J.; Green, Deborah; Hovda, David A.			The impact of substance abuse on mortality in patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; methamphetamine; alcohol; outcome	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL-BLOOD-FLOW; METHAMPHETAMINE USERS; ALCOHOL-ABUSE; HEAD-INJURY; METABOLISM; MARIJUANA; ABNORMALITIES; HYPERACTIVITY; PERFUSION	Background. Drug and alcohol use are common in neurotrauma patients. Despite growing methamphetamine use there are few studies of the impact of methamphetamine use on outcome after traumatic brain injury (TBI). Methods: We conducted a retrospective review of 5-years of data from a trauma database. Inclusion criteria included severe TBI and diagnosis codes indicating head injury. The entire database was analyzed and then a subset of patients with complete toxicology data were examined separately. Primary outcome was mortality. Results. Four hundred eighty-three patients were included. Toxicology re-suits were available for 52.6% of patients. Alcohol, amphetamines, and cannabis were the most commonly detected substances. Overall mortality was 50.9%. When the group with complete tox screen data were analyzed, a toxicology screen that was positive for alcohol or amphetamine was associated with decreased mortality with an odds ratio of 0.23 (CI: 0.10-0.56, p = 0.001) and 0.25 (CI: 0.08-0.79, p = 0.02), respectively. When the subset of patients for whom toxicology data were available was analyzed the amphetamine-positive group was more likely to use cannabis and less likely to use alcohol. Conclusions. We unexpectedly found alcohol and methamphetamine use to be associated with decreased mortality. Neurotoxic and possible neuroprotective mechanisms of these substances are discussed as well as possible interactions between cannabis and methamphetamine. The potential influence of psycho-social factors are also considered. Prospective studies are needed to further investigate the effects of drug and alcohol use on outcome after severe TBI.	[O'Phelan, Kristine; Chang, Cherylee W. J.; Green, Deborah] Queens Med Ctr, Inst Neurosci, Honolulu, HI 96813 USA; [O'Phelan, Kristine; Chang, Cherylee W. J.; Green, Deborah] Univ Hawaii, John A Burns Sch Med, Dept Med & Surg, Honolulu, HI 96822 USA; [McArthur, David L.; Hovda, David A.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA		O'Phelan, K (corresponding author), Queens Med Ctr, Inst Neurosci, 1301 Punchbowl St, Honolulu, HI 96813 USA.	kophelan@queens.org	Chang, Cherylee/Y-8450-2019; Chang, Cherylee/ABG-2080-2020; McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Green-LaRoche, MD, Deborah/0000-0001-8158-0788			Alexander S, 2004, J NEUROTRAUM, V21, P575, DOI 10.1089/089771504774129900; Biegon A, 2004, CURR PHARM DESIGN, V10, P2177, DOI 10.2174/1381612043384196; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Chang L, 2002, PSYCHIAT RES-NEUROIM, V114, P65, DOI 10.1016/S0925-4927(02)00004-5; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; ERNST M, 1994, PSYCHOPHARMACOL BULL, V30, P219; Gonzalez R, 2004, DRUG ALCOHOL DEPEN, V76, P181, DOI 10.1016/j.drugalcdep.2004.04.014; Guilarte TR, 2003, NEUROSCIENCE, V122, P499, DOI 10.1016/S0306-4522(03)00476-7; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Mathew RJ, 2002, PSYCHIAT RES-NEUROIM, V116, P173, DOI 10.1016/S0925-4927(02)00069-0; MATOCHIK JA, 1993, NEUROPSYCHOPHARMACOL, V8, P377, DOI 10.1038/npp.1993.38; O'Leary DS, 2002, NEUROPSYCHOPHARMACOL, V26, P802, DOI 10.1016/S0893-133X(01)00425-0; R-Development Core Team, 2007, SER R LANG ENV STAT; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Taylor AN, 2002, J NEUROTRAUM, V19, P1597, DOI 10.1089/089771502762300256; Thompson PM, 2004, J NEUROSCI, V24, P6028, DOI 10.1523/JNEUROSCI.0713-04.2004; Tien HC, 2007, J TRAUMA, V62, P142, DOI 10.1097/01.ta.0000251558.38388.47; Tominaga GT, 2004, ARCH SURG-CHICAGO, V139, P844, DOI 10.1001/archsurg.139.8.844; Volkow ND, 2004, J NUCL MED, V45, p13N; Volkow ND, 1996, PSYCHIAT RES-NEUROIM, V67, P29, DOI 10.1016/0925-4927(96)02817-X; Voytek B, 2005, SYNAPSE, V57, P113, DOI 10.1002/syn.20155; Wang Y, 2001, STROKE, V32, P775, DOI 10.1161/01.STR.32.3.775; WILCOX RR, 2007, INTRO ROBUST ESTIMAT; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WOLKIN A, 1987, PSYCHOPHARMACOLOGY, V92, P241; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	31	71	71	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2008	65	3					674	677		10.1097/TA.0b013e31817db0a5			4	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	350BC	WOS:000259326400034	18784583				2022-02-06	
J	Rapport, LJ; Bryer, RC; Hanks, RA				Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.			Driving and community integration after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						automobile driving; brain injuries; rehabilitation	SELF-REPORT; OUTCOMES; PREDICTORS; NEUROREHABILITATION; PARTICIPATION; CLIENTS; PEOPLE; ADULTS; DAMAGE	Objective: To examine resumption of driving after traumatic brain injury (TBI) and its relation to community integration. Design: Cross-sectional cohort study; Survey and cognitive data. Settings: Inpatient rehabilitation hospital of the Traumatic Brain Injury Model Systems and community. Participants: Persons (N=261) ranging from 3 months to 15 years postinjury. Interventions: Not applicable. Main Outcome Measures: Barriers to Driving Questionnaire, Driver Survey, community Integration Measure, and Craig Hospital Assessment and Reporting Technique. Results: Forty-four percent of survivors had resumed driving; of nondrivers. 48% reported a strong desire to resume driving. Nondriver survivors who Sought to resume driving generally rated themselves as currently fit to drive, viewed themselves as having physical and cognitive profiles like those of survivor drivers, and reported their greatest barriers to driving as social and resource related. However, cognitive functioning was similar to nondriver survivors who did not seek to resume driving and significantly worse than Survivors who were Currently driving. Nondrivers showed poorer community integration than did drivers, even after accounting for injury severity. social support. negative affectivity, and use of alternative transportation. Use of alternative transportation was common among nondrivers. but it was unrelated to community integration Outcomes. Cognitive functioning moderated risk of adverse incident: among survivors with low cognitive functioning, and high self-estimates of driving ability, which is indicative Of unawareness of deficit. adverse incidents showed positive relation to amount of driving and inverse relation to cognitive functioning. Conclusions: Driving status has unique and independent association with post-TBI community integration. Additional research is needed to evaluate transportation barriers that undermine full engagement in community living after TBI and to determine which barriers to driving, reflect valid risk to Survivors and the public.	[Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.] Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; [Rapport, Lisa J.; Bryer, Renee Coleinan; Hanks, Robin A.] Wayne State Univ, Dept Phys Med & Rehabil, Sch Med, Detroit, MI 48202 USA		Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 5057 Woodward Ave,7th Fl, Detroit, MI 48202 USA.	rapport@wayne.edu		Rapport, Lisa/0000-0001-8014-9523	National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	Anderson CJ, 2002, ARCH PHYS MED REHAB, V83, P791, DOI 10.1053/apmr.2002.32742; Arthur W, 2001, HUM FACTORS, V43, P1, DOI 10.1518/001872001775992507; Barkley RA, 2002, J INT NEUROPSYCH SOC, V8, P655, DOI 10.1017/S1355617702801345; Brouwer WH, 1997, NEUROPSYCHOL REHABIL, V7, P177, DOI 10.1080/713755536; Brown M, 2004, J HEAD TRAUMA REHAB, V19, P459, DOI 10.1097/00001199-200411000-00004; Coleman Bryer R, 2005, DRIVER REHABILITATIO, P165; Coleman RD, 2002, ARCH PHYS MED REHAB, V83, P1415, DOI 10.1053/apmr.2002.35111; Cutrona EC., 1987, ADV PERSONAL RELATIO, V1, P37, DOI DOI 10.1037/0882-7974.1.1.47; Cardoso EDS, 2007, J HEAD TRAUMA REHAB, V22, P85, DOI 10.1097/01.HTR.0000265096.44683.6b; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; GLASGOW N, 2000, SOCIAL INTEGRATION 2, P00108; Glass TA, 1999, BRIT MED J, V319, P478, DOI 10.1136/bmj.319.7208.478; Groeger JA, 1996, BRIT J PSYCHOL, V87, P61, DOI 10.1111/j.2044-8295.1996.tb02577.x; GROEGER JA, 1989, ACCIDENT ANAL PREV, V21, P155, DOI 10.1016/0001-4575(89)90083-3; Haselkorn JK, 1998, ARCH PHYS MED REHAB, V79, P738, DOI 10.1016/S0003-9993(98)90349-5; Hopewell CA, 2002, J HEAD TRAUMA REHAB, V17, P48, DOI 10.1097/00001199-200202000-00007; Jewkes R, 1996, SOC SCI MED, V43, P555, DOI 10.1016/0277-9536(95)00439-4; Johnson J E, 1999, J Gerontol Nurs, V25, P12; Johnston Mark, 2002, J Spinal Cord Med, V25, P11; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Johnstone B, 2003, NEUROREHABILITATION, V18, P197; KATZ RT, 1990, ARCH PHYS MED REHAB, V71, P133; Kiyono Y, 2001, ARCH PHYS MED REHAB, V82, P1389, DOI 10.1053/apmr.2001.26089; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; LEGHSMITH J, 1986, J ROY SOC MED, V79, P200, DOI 10.1177/014107688607900404; Leon-Carrion J, 2005, BRAIN INJURY, V19, P213, DOI 10.1080/02699050400017205; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Liddle J., 2003, BRIT J OCCUPATIONAL, V66, P125, DOI DOI 10.1177/030802260306600307; Lister R, 1999, BRIT J OCCUPATIONAL, V62, P514; Mackenzie C, 2003, APHASIOLOGY, V17, P107, DOI 10.1080/729255215; MARCOTTE T, 2000, J INT NEUROPSYCHOL S, V0006, P00233; Marottoli RA, 2000, J GERONTOL B-PSYCHOL, V55, pS334, DOI 10.1093/geronb/55.6.S334; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McKenna FP, 2006, HEALTH PSYCHOL, V25, P163, DOI 10.1037/0278-6133.25.2.163; MCKENNA FP, 1991, ACCIDENT ANAL PREV, V23, P45, DOI 10.1016/0001-4575(91)90034-3; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Rapport L, 2006, J HEAD TRAUMA REHAB, V21, P34, DOI 10.1097/00001199-200601000-00004; RAPPORT LJ, 1993, ARCH PHYS MED REHAB, V74, P621, DOI 10.1016/0003-9993(93)90160-C; Schultheis MT, 2002, J HEAD TRAUMA REHAB, V17, P38, DOI 10.1097/00001199-200202000-00006; SVENSON O, 1981, ACTA PSYCHOL, V47, P143, DOI 10.1016/0001-6918(81)90005-6; VANZOMEREN AH, 1987, ARCH PHYS MED REHAB, V68, P697; Walker N, 2003, AM J PHYS MED REHAB, V82, P936, DOI 10.1097/01.PHM.0000098041.42394.9A; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Whiteneck GG, 2004, J HEAD TRAUMA REHAB, V19, P191, DOI 10.1097/00001199-200405000-00001; [No title captured]; [No title captured]	48	71	74	2	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					922	930		10.1016/j.apmr.2008.01.009			9	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	341ST	WOS:000258735900019	18452742				2022-02-06	
J	Wood, RL; Williams, C				Wood, Rodger Ll.; Williams, Claire			Inability to empathize following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						empathy; emotion; TBI; affective disorder; neuropsychological tests; cognitive flexibility	ECOLOGICAL VALIDITY; EXECUTIVE TESTS; RECOGNITION; IMPAIRMENT; INVENTORY; EMOTION; ABILITY; LESIONS	This study examines: (a) the impact of traumatic brain injury (TBI) on emotional empathy, (b) the relationship between emotional empathy and neuropsychological ability, and (c) the influence of low emotional empathy on measures of affect. Eighty-nine patients completed the Balanced Emotional Empathy Scale (BEES), a number of neuropsychological tests, some of which were ecologically valid tests of executive ability, plus two measures of affect, the Beck Anxiety Inventory (BAI) and Beck Depression Inventory (BDI). The TBI cohort showed a high frequency (60.7%) of low emotional empathy scores compared to the control group (31%). There was no relationship between injury severity and the ability to empathize, or between emotional empathy and neuropsychological performance. There was no evidence to suggest that low scores on affective measures influenced emotional empathy scores. A high proportion of TBI patients lack the ability to empathize, but the deficit does not appear related to any specific cognitive impairment and cannot be predicted by measures of affect.	[Wood, Rodger Ll.; Williams, Claire] Swansea Univ, Sch Human Sci, Dept Psychol, Brain Injury Res Grp, Swansea, W Glam, Wales		Wood, RL (corresponding author), Univ Wales Swansea, Sch Human Sci, Dept Psychol, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Williams, Claire/0000-0002-0791-744X			Baron-Cohen S., 1995, MIND BLINDNESS ESSAY; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BISHARA SN, 1992, BRAIN INJURY, V3, P373; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess P.W., 1997, HAYLING BRIXTON TEST; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; CICERONE KD, 1983, NEUROPSYCHOLOGIA, V21, P513, DOI 10.1016/0028-3932(83)90007-6; Danziger N, 2006, BRAIN, V129, P2494, DOI 10.1093/brain/awl155; DAVIS JM, 1980, AM J NEURORADIOL, V1, P17; ENDBERG AW, 2004, BRAIN INJURY, V18, P533; Eslinger PJ, 2002, CURR OPIN NEUROL, V15, P91, DOI 10.1097/00019052-200202000-00014; GRATTAN LM, 1994, NEUROPSY NEUROPSY BE, V7, P251; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Mehrabian A, 1997, AGGRESSIVE BEHAV, V23, P433, DOI 10.1002/(SICI)1098-2337(1997)23:6<433::AID-AB3>3.0.CO;2-H; Mehrabian A, 2000, GENET SOC GEN PSYCH, V126, P133; Mehrabian A., 2000, MANUAL BALANCED EMOT; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; ODDY M, 2003, HDB NEUROLOGICAL REH; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Shamay-Tsoory SG, 2004, J CLIN EXP NEUROPSYC, V26, P1113, DOI 10.1080/13803390490515531; Shamay-Tsoory SG, 2003, J COGNITIVE NEUROSCI, V15, P324, DOI 10.1162/089892903321593063; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; STAMBROOK M, 1993, ARCH CLIN NEUROPSYCH, V8, P95; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V57, P198, DOI 10.1136/jnnp.57.2.198; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2001, BRAIN DAM B, P3; WOOD RL, 2006, BRAIN INJURY, V20, P1; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P90, DOI 10.1017/S1355617707070129; Wood RL, 2007, J INT NEUROPSYCH SOC, V13, P471, DOI 10.1017/S1355617707070518	36	71	71	0	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2008	14	2					289	296		10.1017/S1355617708080326			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	338VJ	WOS:000258537200011	18282326	Bronze			2022-02-06	
J	Yan, W; Wang, HD; Hu, ZG; Wang, QF; Yin, HX				Yan, Wei; Wang, Han-Dong; Hu, Zhi-Gang; Wang, Qing-Feng; Yin, Hong-Xia			Activation of Nrf2-ARE pathway in brain after traumatic brain injury	NEUROSCIENCE LETTERS			English	Article						nuclear factor E2-related factor 2; antioxidant response element; heme oxygenase-1; quinone oxidoreductase-1; traumatic brain injury	HEME OXYGENASE-1 HO-1; OXIDATIVE STRESS; CEREBRAL-ISCHEMIA; IN-VIVO; EXPRESSION; INDUCTION; PROTECTS; NEURONS; RAT; REDUCTASE	Secondary brain injury plays a pivotal role in the outcome of patients suffering from traumatic brain injury (TBI). The mechanisms underlying secondary brain injury are complex and interrelated. Previous studies focused on one of these mechanisms have been proved to be ineffective in clinical practice. Therefore, a target, which can interrupt multi-mechanisms underlying TBI, is desirable. Nrf2-ARE pathway has been proved to be the key regulator in reducing oxidative stress, inflammatory damage and accumulation of toxic metabolites, which are all involved in TBI. However, whether Nrf2-ARE pathway is activated after TBI has not been studied. In the present study, the nuclear Nrf2 protein level was detected by Western blot, and the mRNA levels of heme oxygenase-1 (HO-1) and NAD(P)H: quinone oxidoreductase-1 (NQO1), two Nrf2-regulated gene products, were determined using reverse-transcriptase polymerase chain reaction (RT-PCR) 24 It after TBI. Furthermore, we also localized the expression of Nrf2 and HO-I using immunohistochemical study. After TBI, the nuclear Nrf2 protein level was significantly increased, and the mRNA levels of both HO-1 and NQO1 were also up regulated. Moreover, both Nrf2 and HO-1 were localized in the same types of cells. According to these results, it could be postulated that Nrf2-ARE pathway was activated in brain after TBI. (c) 2007 Elsevier Ireland Ltd. All rights reserved.	[Yan, Wei; Wang, Han-Dong; Hu, Zhi-Gang; Wang, Qing-Feng; Yin, Hong-Xia] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Jiangsu 210002, Peoples R China		Wang, HD (corresponding author), Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, 305 E Zhongshan Rd, Jiangsu 210002, Peoples R China.	hdwang-nj@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835			Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Calabrese V, 2005, J NEUROSCI RES, V79, P509, DOI 10.1002/jnr.20386; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Ku BM, 2006, NEUROSCI LETT, V405, P168, DOI 10.1016/j.neulet.2006.06.052; Laxton AW, 2001, NEUROREPORT, V12, P1045, DOI 10.1097/00001756-200104170-00036; Le W, 1999, J NEUROSCI RES, V56, P652; Moreira TJTP, 2007, J CEREBR BLOOD F MET, V27, P1710, DOI 10.1038/sj.jcbfm.9600479; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; Orihara Yoshiyuki, 2003, Leg Med (Tokyo), V5 Suppl 1, pS278; Park HK, 1999, CRIT REV NEUROSURG, V9, P44, DOI 10.1007/s003290050108; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Stringer JL, 2004, J COMP NEUROL, V471, P289, DOI 10.1002/cne.20048; Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018; van Muiswinkel FL, 2004, NEUROBIOL AGING, V25, P1253, DOI 10.1016/j.neurobiolaging.2003.12.010; van Muiswinkel FL, 2005, CNS NEUROL DISORD-DR, V4, P267, DOI 10.2174/1568007054038238; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yi JH, 2005, BRAIN RES, V1033, P13, DOI 10.1016/j.brainres.2004.10.055; Zhao J, 2006, NEUROSCI LETT, V393, P108, DOI 10.1016/j.neulet.2005.09.065; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	28	71	74	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 31	2008	431	2					150	154		10.1016/j.neulet.2007.11.060			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	266MK	WOS:000253439800011	18162315				2022-02-06	
J	Yang, CC; Tu, YK; Hua, MS; Huang, SJ				Yang, Chi-Cheng; Tu, Yong-Kwang; Hua, Mau-Sun; Huang, Sheng-Jean			The association between the postconcussion symptoms and clinical outcomes for patients with mild traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						mild traumatic brain injury; postconcussion symptoms; outcomes; Glasgow Outcome Scale-Extended	SEVERE HEAD-INJURY; COMA-SCALE SCORE; DISABILITY; MANAGEMENT; SEQUELAE; GUIDELINES; ADULTS; CLASSIFICATION; CONSEQUENCES; DEPRESSION	Background. Postconcussion symptoms (PCS) (such as dizziness, headache, irritability, fatigue, and impaired memory) are common in patients who sustain a mild traumatic brain injury (mTBI). However, few studies have systematically investigated the association between PCS and clinical outcomes in mTBI patients. Therefore, the present study attempted to examine PCS during the disease course and to determine whether PCS adversely affect outcome. Methods. This was a prospective, cohort and controlled study of 115 mTBI patients. The PCS checklist was used to identify PCS and the Glasgow Outcome Scale and the Glasgow Outcome Scale-Extended were used to investigate clinical outcomes. All patients were evaluated four times: at 1 week, 2 weeks, 4 weeks, and 8 weeks after the injury. Results. Physical symptoms such as dizziness and headache were prominent in the early after injury stage (1 and 2 weeks). On the other hand, the psychosocial symptoms, such as depression and irritability, were significant at the late after injury stage (4 and 8 weeks). Dizziness adversely affected clinical outcome at both the early and late stages of the disease, whereas the impact of intracranial lesions and depression on outcome was greatest early and late, respectively. Conclusions. The results show that PCS during the disease course and the relationship between PCS and clinical outcome can be systematically evaluated. In fact, different postconcussion symptom domains should be monitored while the disease is progressing.	Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Psychol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Traumatol, Taipei, Taiwan		Huang, SJ (corresponding author), Natl Taiwan Univ Hosp, Dept Surg, Div Neurosurg, 7 Chung San S Rd, Taipei, Taiwan.	sjhuang@med.mc.ntu.edu.tw		Tu, Yong-kwang/0000-0003-2113-1176			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blostein P, 2003, J TRAUMA, V55, P450, DOI 10.1097/01.TA.0000038545.24879.4D; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chi H. T., 2005, CLASSIFICATION MED R; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Department of Health, 2005, HLTH NAT HLTH INS AN; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fabbri A, 2004, EUR J EMERG MED, V11, P65, DOI 10.1097/00063110-200404000-00002; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; HSIANG JN, 2005, LONG TERM EFFECTS ME, V15, P153; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kraus J, 1996, NEUROTRAUMA, P13; LEE LH, 1992, CHIN MED J TAPIEI, V50, P219; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Muller K, 2003, J TRAUMA, V55, P1029, DOI 10.1097/01.TA.0000100371.49160.2A; National Institute of Health Consensus Development Panel on Rehabilitation of Persons with Traumatic Brain Injury, 1998, JAMA-J AM MED ASSOC, V282, P974; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tellier A, 1999, BRAIN INJURY, V13, P463; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Uchino Y, 2001, ACTA NEUROCHIR, V143, P1031, DOI 10.1007/s007010170008; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Von Wild K, 2001, BRAIN INJURY, V15, P273; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Warriner EM, 2003, J CLIN EXP NEUROPSYC, V25, P904, DOI 10.1076/jcen.25.7.904.16494; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; World Health Organization, 1992, ICD 10 CLASSIFICATIO	52	71	72	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2007	62	3					657	663		10.1097/01.ta.0000203577.68764.b8			7	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	145PP	WOS:000244877300022	17414343				2022-02-06	
J	Widestrand, A; Faijerson, J; Wilhelmsson, U; Smith, PLP; Li, LZ; Sihlbom, C; Eriksson, PS; Pekny, M				Widestrand, Asa; Faijerson, Jonas; Wilhelmsson, Ulrika; Smith, Peter L. P.; Li, Lizhen; Sihlbom, Carina; Eriksson, Peter S.; Pekny, Milos			Increased neurogenesis and astrogenesis from neural progenitor cells grafted in the hippocampus of GFAP(-/-) Vim(-/-) mice	STEM CELLS			English	Article						glial fibrillary acidic protein; vimentin; intermediate filaments; astrocytes; reactive gliosis	FIBRILLARY ACIDIC PROTEIN; STEM-CELLS; INTERMEDIATE-FILAMENTS; DENTATE GYRUS; ADULT-RAT; REACTIVE ASTROCYTES; TRANSGENIC MICE; GLIAL SCAR; CNS; VIMENTIN	After neurotrauma, ischemia, or neurodegenerative disease, astrocytes upregulate their expression of the intermediate filament proteins glial fibrillary acidic protein ( GFAP), vimentin ( Vim), and nestin. This response, reactive gliosis, is attenuated in GFAP(-/-) Vim(-/-) mice, resulting in the promotion of synaptic regeneration after neurotrauma and improved integration of retinal grafts. Here we assessed whether GFAP(-/-) Vim(-/-) astrocytes affect the differentiation of neural progenitor cells. In coculture with GFAP(-/-) Vim(-/-) astrocytes, neural progenitor cells increased neurogenesis by 65% and astrogenesis by 124%. At 35 days after transplantation of neural progenitor cells into the hippocampus, adult GFAP(-/-) Vim(-/-) mice had more transplant-derived neurons and astrocytes than wild-type controls, as well as increased branching of neurite-like processes on transplanted cells. Wnt3 immunoreactivity was readily detected in hippocampal astrocytes in wild-type but not in GFAP(-/-) Vim(-/-) mice. These findings suggest that GFAP(-/-) Vim(-/-) astrocytes allow more neural progenitor cell-derived neurons and astrocytes to survive weeks after transplantation. Thus, reactive gliosis may adversely affect the integration of transplanted neural progenitor cells in the brain.	Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, SE-41390 Gothenburg, Sweden		Pekny, M (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Ctr Brain Repair & Rehabil,Dept Clin Neurosci & R, Medicinaregatan 9A, SE-41390 Gothenburg, Sweden.	milos.pekny@medkem.gu.se		Smith, Peter/0000-0001-7258-1711; Wilhelmsson, Ulrika/0000-0003-3227-2687			Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Cai J, 2007, DEVELOPMENT, V134, P1887, DOI 10.1242/dev.02847; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cho KS, 2005, J CELL SCI, V118, P863, DOI 10.1242/jcs.01658; COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3; Dziewczapolski G, 2003, EXP NEUROL, V183, P653, DOI 10.1016/S0014-4886(03)00212-7; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GAGE FH, 1995, P NATL ACAD SCI USA, V92, P11879, DOI 10.1073/pnas.92.25.11879; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.ne.18.030195.001111; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; Hinterkeuser S, 2000, EUR J NEUROSCI, V12, P2087, DOI 10.1046/j.1460-9568.2000.00104.x; Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088; Larsson A, 2004, NEUROCHEM RES, V29, P2069, DOI 10.1007/s11064-004-6880-2; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu B, 2002, BRAIN RES, V943, P292, DOI 10.1016/S0006-8993(02)02906-2; Lundberg C, 1996, NEUROREPORT, V7, P847, DOI 10.1097/00001756-199603220-00002; Menet V, 2003, P NATL ACAD SCI USA, V100, P8999, DOI 10.1073/pnas.1533187100; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Pekny M, 1999, J CELL BIOL, V145, P503, DOI 10.1083/jcb.145.3.503; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Pekny M, 2004, J PATHOL, V204, P428, DOI 10.1002/path.1645; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Takahashi M, 1998, MOL CELL NEUROSCI, V12, P340, DOI 10.1006/mcne.1998.0721; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wilhelmsson U, 2004, J NEUROSCI, V24, P5016, DOI 10.1523/JNEUROSCI.0820-04.2004; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	41	71	72	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1066-5099	1549-4918		STEM CELLS	Stem Cells		2007	25	10					2619	2627		10.1634/stemcells.2007-0122			9	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Oncology; Cell Biology; Hematology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology	217DZ	WOS:000249929900025	17628017	Bronze			2022-02-06	
J	Silver, JM; Koumaras, B; Chen, M; Mirski, D; Potkin, SG; Reyes, P; Warden, D; Harvey, PD; Arciniegas, D; Katz, DI; Gunay, I				Silver, J. M.; Koumaras, B.; Chen, M.; Mirski, D.; Potkin, S. G.; Reyes, P.; Warden, D.; Harvey, P. D.; Arciniegas, D.; Katz, D. I.; Gunay, I.			Effects of rivastigmine on cognitive function in patients with traumatic brain injury	NEUROLOGY			English	Article							ALZHEIMERS-DISEASE; SENILE DEMENTIA; HEAD-INJURY; ACETYLCHOLINE; INVENTORY; DEPRESSION; VALIDATION; DEFICITS	Objective: To compare the efficacy and safety of rivastigmine (3 to 6 mg/day) vs placebo over 12 weeks in patients with traumatic brain injury and persistent cognitive impairment. Methods: This prospective, randomized, double-blind, placebo-controlled study was conducted in 157 patients at least 12 months after injury. The primary efficacy measures were the Cambridge Neuropsychological Test Automated Battery (CANTAB) Rapid Visual Information Processing (RVIP) A' subtest and the Hopkins Verbal Learning Test (HVLT). The primary efficacy outcome was the proportion of patients who demonstrated 1.0 SD or greater improvement from baseline at week 12 on CANTAB RVIP A' or HVLT. Results: The percentage of responders at week 12 on either the CANTAB RVIP A' or HVLT was 48.7% for rivastigmine and 49.3% for placebo (p = 0.940). Furthermore, for the overall study population, there were no significant differences for any of the secondary efficacy variables. In a subgroup of patients with moderate to severe memory impairment (n = 81), defined as 25% impairment or greater on HVLT at baseline, rivastigmine was significantly better than placebo for a number of measures, including the proportion of HVLT responders and CANTAB RVIP mean latency. Conclusions: Rivastigmine was safe and well tolerated in patients with traumatic brain injury with cognitive deficits. Rivastigmine shows promising results in the subgroup of patients with traumatic brain injury with moderate to severe memory deficits.	Novartis Pharmacuet, E Hanover, NJ 07936 USA; NYU, Sch Med, New York, NY 10021 USA; Univ Calif Irvine, Med Ctr, Orange, CA USA; Creighton Univ, Sch Med, Omaha, NE USA; Walter Reed Army Med Ctr, Washington, DC 20307 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Healths Braintree Rehabil Hosp, Braintree, MA USA		Gunay, I (corresponding author), Novartis Pharmacuet, 1 Hlth Pl, E Hanover, NJ 07936 USA.	ibrahim.gunay@novartis.com	Noble, James/AAA-4218-2020; Potkin, Steven G/A-2021-2013; Arciniegas, David/A-3792-2009	Noble, James/0000-0003-0648-6702; Katz, Douglas/0000-0002-7502-8505; Potkin, Steven/0000-0003-1028-1013			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Corey-Bloom J, 1998, INT J GERIATR PSYCHO, V1, P55; Dixon CE, 1997, J NEUROTRAUM, V14, P161, DOI 10.1089/neu.1997.14.161; ESLINGER PJ, 1985, JAMA-J AM MED ASSOC, V253, P670, DOI 10.1001/jama.253.5.670; Giacobini E, 2002, J NEURAL TRANSM, V109, P1053, DOI 10.1007/s007020200089; GUY W, 1976, PUBLICATION ADM USDA; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; PERRY EK, 1978, BRIT MED J, V2, P1457, DOI 10.1136/bmj.2.6150.1457; PERRY EK, 1978, NEUROPATH APPL NEURO, V4, P273, DOI 10.1111/j.1365-2990.1978.tb00545.x; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Sarter M, 1997, BRAIN RES REV, V23, P28, DOI 10.1016/S0165-0173(96)00009-4; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Steer RA, 1999, J CLIN PSYCHOL, V55, P117, DOI 10.1002/(SICI)1097-4679(199901)55:1<117::AID-JCLP12>3.0.CO;2-A; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	25	71	76	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP 12	2006	67	5					748	755		10.1212/01.wnl.0000234062.98062.e9			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	083EC	WOS:000240437700005	16966534				2022-02-06	
J	Chappell, MH; Ulug, AM; Zhang, L; Heitger, MH; Jordan, BD; Zimmerman, RD; Watts, R				Chappell, Michael H.; Ulug, Aziz M.; Zhang, Lijuan; Heitger, Marcus H.; Jordan, Barry D.; Zimmerman, Robert D.; Watts, Richard			Distribution of microstructural damage in the brains of professional boxers: A diffusion MRI study	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article						boxers; diffusion tensor imaging (DTI); apparent diffusion coefficient (ADC); fractional anisotropy (FA); traumatic brain injury (TBI); voxel-based analysis (VBA)	AXONAL INJURY; HEAD-INJURY; ACTIVATION; TENSOR; CONCUSSION	Purpose: To investigate and localize cerebral abnormalities in professional boxers with no history of moderate or severe head trauma. Materials and Methods: Diffusion tensor imaging (DTI) was used to determine the apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in the brains of 81 professional male boxers and 12 male control subjects. Voxel-based analysis (VBA) of both the diffusion and anisotropy values was performed using statistical parametric mapping (SPM). From this objective analysis, regions of microstructural abnormalities in the brains of the boxers were located. Results: Increases in the ADC, and decreases in FA were identified in deep white matter (WM), while decreases in ADC were identified in cortical gray matter (GM). Regions of positive correlation between ADC and age were also found in both the boxer and control groups, although the regions and strength of the correlation were not the same in each group. Conclusion: Using VBA, we localized previously unreported abnormalities in the brains of professional boxers. These abnormalities are assumed to reflect cumulative (chronic) brain injury resulting from nonsevere head trauma.	Univ Canterbury, Dept Phys & Astron, Christchurch 8020, New Zealand; Cornell Univ, Dept Radiol, Weill Med Coll, New York, NY USA; Christchurch Sch Med & Hlth Sci, Dept Med, Christchurch, New Zealand; Burke Rehabil Hosp, New York, NY USA		Chappell, MH (corresponding author), Univ Canterbury, Dept Phys & Astron, Ilam Rd,Private Bag 4800, Christchurch 8020, New Zealand.	mhc15@student.canterbury.ac.nz	Ulug, Aziz M/F-6592-2011	Ulug, Aziz M/0000-0002-2315-0322			Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P227, DOI 10.1016/S0887-6177(00)00081-0; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chun T, 2000, AM J NEURORADIOL, V21, P1078; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; Pointinger H, 2002, BRAIN INJURY, V16, P799, DOI 10.1080/02699050210131911; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Soto-Ares G, 2001, CHILD NERV SYST, V17, P263, DOI 10.1007/s003810000411; Witzel T, 2001, NEUROIMAGE, V13, pS286; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	26	71	75	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	SEP	2006	24	3					537	542		10.1002/jmri.20656			6	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Radiology, Nuclear Medicine & Medical Imaging	081EU	WOS:000240300800008	16878306	Bronze, Green Published			2022-02-06	
J	Carpentier, A; Galanaud, D; Puybasset, L; Muller, JC; Lescot, T; Boch, AL; Riedl, V; Cornu, P; Coriat, P; Dormont, D; Van Effenterre, R				Carpentier, Alexandre; Galanaud, Damien; Puybasset, Louis; Muller, Jean-Charles; Lescot, Thomas; Boch, Anne-Laure; Riedl, Vincent; Cornu, Philippe; Coriat, Pierre; Dormont, Didier; Van Effenterre, Remy			Early morphologic and spectroscopic magnetic resonance in severe traumatic brain injuries can detect "invisible brain stem damage" and predict "vegetative states"	JOURNAL OF NEUROTRAUMA			English	Article						brain stem; diffuse axonal injury; Glasgow Outcome Scale; neurological outcome; spectroscopy; traumatic brain injury; vegetative states	PROTON MR SPECTROSCOPY; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; COMA; RECOVERY; SCALE	A precise evaluation of the brain damage in the first days of severe traumatic brain injured (TBI) patients is still uncertain despite numerous available cerebral evaluation methods and imaging. In 5-10% of severe TBI patients, clinicians remain concerned with prolonged coma and long-term marked cognitive impairment unexplained by normal morphological T2 star, flair, and diffusion magnetic resonance imaging (MRI). For this reason, we prospectively assessed the potential value of magnetic resonance spectroscopy (MRS) of the brain stem to evaluate the functionality of the consciousness areas. Forty consecutive patients with severe TBI were included. Single voxel proton MRS or the brain stem and morphological MRI of the whole brain were performed at day 17.5 +/- 6.4. Disability Rating Scale and Glasgow Outcome Scale (GOS) were evaluated at 18 months post-trauma. MRS appeared to be a reliable tool in the exploration of brainstem metabolism in TBI. Three different spectra were observed (normal, cholinergic reaction, or neuronal damage) allowing an evaluation of functional damage. MRS disturbances were not correlated with anatomical MRI lesions suggesting that the two techniques are strongly complementarity. In two GOS 2 vegetative patients with normal morphological MRI, MRS detected severe functional damage of the brainstem (NAA/Cr < 1.50) that was described as "invisible brain stem damage." MRI and MRS taken separately could not distinguish patients GOS 3 (n = 7) from GOS 1-2 (n = 11) and GOS 4-5 (n = 20). However, a principal component analysis of combined MRI and MRS data enabled a clear-cut separation between GOS 1-2, GOS 3, and GOS 4-5 patients with no overlap between groups. This study showed that combined MRI and MRS provide a reliable evaluation of patients presenting in deep coma, specially when there are insufficient MRI lesions of the consciousness pathways to explain their status. In the first few days post-trauma metabolic (brainstem spectroscopy) and morphological (T2 star and Flair) MRI studies can predict the long-term neurological outcome, especially the persistent vegetative states and minimally conscious state.	Univ Paris 06, Hop La Pitie Salpetriere, Dept Neurosurg, Paris, France; Univ Paris 06, Hop La Pitie Salpetriere, Dept Neuroradiol, Paris, France; Univ Paris 06, Hop La Pitie Salpetriere, Dept Anesthesiol, Paris, France		Carpentier, A (corresponding author), Univ Paris 06, Hop La Pitie Salpetriere, Dept Nedurochirurg, Batiment Babinski,47-83 Blvd Hop, F-75013 Paris, France.	alexandre.carpentier@lrb.aphp.fr	dormont, didier/B-2175-2012; Dormont, Didier/F-5492-2012				Alessandri B, 2000, NEUROL RES, V22, P705; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Galanaud D, 2003, J NEUROSURG, V98, P269, DOI 10.3171/jns.2003.98.2.0269; Galanaud D, 2001, MAGN RESON MATER PHY, V13, P127, DOI 10.1016/S1352-8661(01)00135-1; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Holshouser BA, 2000, J MAGN RESON IMAGING, V11, P9, DOI 10.1002/(SICI)1522-2586(200001)11:1<9::AID-JMRI2>3.3.CO;2-Y; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Macmillan CSA, 2002, ACTA NEUROCHIR, V144, P853, DOI 10.1007/s00701-002-0966-x; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; RANGO M, 1995, MAGNET RESON MED, V33, P595, DOI 10.1002/mrm.1910330503; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ricci B, 1997, NEURORADIOLOGY, V39, P313, DOI 10.1007/s002340050415; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Wedekind C, 1999, J TRAUMA, V47, P44, DOI 10.1097/00005373-199907000-00010	32	71	77	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2006	23	5					674	685		10.1089/neu.2006.23.674			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	042LJ	WOS:000237529200006	16689669				2022-02-06	
J	Bor-Seng-Shu, E; Hirsch, R; Teixeira, MJ; De Andrade, AF; Marino, R				Bor-Seng-Shu, E; Hirsch, R; Teixeira, MJ; De Andrade, AF; Marino, R			Cerebral hemodynamic changes gauged by transcranial Doppler ultrasonooraphy in patients with posttraumatic brain swelling treated by surgical decompression	JOURNAL OF NEUROSURGERY			English	Article						brain swelling; head injury; intracranial hypertension; decompressive craniectomy; transcranial Doppler ultrasonography; cerebral hemodynamics	VENOUS OXYGEN-SATURATION; PERFUSION-PRESSURE; INTRACRANIAL-PRESSURE; HEAD-INJURY; BLOOD-FLOW; CEREBROVASCULAR AUTOREGULATION; VASOMOTOR REACTIVITY; HYPEREMIA PRIOR; CRANIECTOMY; MANAGEMENT	Object. The use of decompressive craniectomy has experienced a revival in the previous decade, although its actual benefit on patients' neurological outcome remains the Subject of debate. A better understanding of the intracranial pressure dynamics, as well as of the metabolic and hemodynamic brain processes, may be useful in assessing the effect of this surgery oil the pathophysiology of the swollen brain. The aim of this study was to use transcranial Doppler (TCD) ultrasonography to examine the hemodynamic changes in the brain after decompressive craniectomy in patients with head ill injury, in addition to examining the relationship between such hemodynamic changes and the patient's neurological outcome. Methods. Nineteen patients presenting with traumatic brain swelling and cerebral herniation syndrome who had undergone decompressive craniectomy with dural expansion were Studied prospectively. The TCD ultrasonography measurements were performed bilaterally in both the middle cerebral artery (MCA) and in the distal portion of the cervical internal carotid artery (ICA) immediately prior to and after Surgical decompression. After surgery, the wean blood flow velocity (BFV) rose to 175 +/- 209% of preoperative Values in the MCA of the operated side, while rising to 132 +/- 183% in the contralateral side; the difference between the mean BFV increase in in the MCA of both the decompressed and the opposite side reached statistical significance (p < 0.05). The mean BFV of the extracranial ICA increased to 91 +/- 119% in the surgical side and 45 +/- 60% in the opposite side. Conversely, the MCA pulsatility index (PI) values decreased, oil average, to 33 +/- 36% of the preoperative value in the operated side and to 30 +/- 34% on the opposite side; the MCA PI value reductions were significantly greater in the decompressed side when compared with the contralateral side (p < 0.05). The PI of the extracranial ICA reduced, on average, to 37 +/- 23% of the initial values in the operated side and to 24 +/- 34%, contralaterally. No correlation was verified between the neurological outcome and cerebral hemodynamic changes seen on TCD ultrasonography. Conclusions. Decompressive craniectomy results in a significant elevation of cerebral BFV ill most patients with traumatic brain swelling and transtentorial herniation syndrome. The increase in cerebral BFV may also occur in the side opposite the decompressed hemisphere; the cerebral BFV increase is significantly greater in the operated hemisphere than contralaterally. Concomitantly, PI values decrease significantly postoperatively, mainly in the decompressed cerebral hemisphere, indicating reduction in cerebrovascular resistance.	Univ Sao Paulo, Sch Med, Div Neurosurg, Hosp Clin, Sao Paulo, Brazil		Bor-Seng-Shu, E (corresponding author), Rua Loefgreen 1272, BR-04040001 Sao Paulo, Brazil.	edsonshu@hotmail.com	BOR-SENG-SHU, EDSON/H-7784-2013; BOR-SENG-SHU, EDSON/AAC-9762-2019; Teixeira, Manoel J/E-3110-2012	BOR-SENG-SHU, EDSON/0000-0002-6713-8974; BOR-SENG-SHU, EDSON/0000-0002-6713-8974; 			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Babikian VL, 2000, J NEUROIMAGING, V10, P101, DOI 10.1111/jon2000102101; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cruz J, 2002, NEUROSURGERY, V50, P774, DOI 10.1097/00006123-200204000-00017; Cruz J, 2002, ARQ NEURO-PSIQUIAT, V60, P670, DOI 10.1590/S0004-282X2002000400031; Csokay A, 2002, SURG NEUROL, V57, P126, DOI 10.1016/S0090-3019(01)00686-3; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Da Silva J A, 1976, Arq Neuropsiquiatr, V34, P232; de Andrade AF, 2001, WORLD J SURG, V25, P1186; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Doerfler A, 2002, J NEUROSURG, V96, P933, DOI 10.3171/jns.2002.96.5.0933; Engelhorn T, 2003, NEUROSCI LETT, V344, P127, DOI 10.1016/S0304-3940(03)00441-5; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; HASSLER W, 1988, J NEUROSURG, V68, P745; Iida K, 2003, J NEUROSURG, V98, P793, DOI 10.3171/jns.2003.98.4.0793; JENNETT B, 1975, LANCET, V1, P480; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KIRKHAM FJ, 1986, ULTRASOUND MED BIOL, V12, P15, DOI 10.1016/0301-5629(86)90139-0; Kunze E, 1998, ACT NEUR S, V71, P16; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2003, J NEUROTRAUM, V20, P69, DOI 10.1089/08977150360517191; Lee E, 1997, OPT EXPRESS, V1, P221, DOI 10.1364/OE.1.000221; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martin N A, 1994, Neurosurg Clin N Am, V5, P607; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Meier U, 2003, ACTA NEUROCHIR SUPPL, V86, P367; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; MUTTAQIN Z, 1993, ACTA NEUROCHIR, V123, P76, DOI 10.1007/BF01476289; Newell D W, 1994, Neurosurg Clin N Am, V5, P619; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RINALDI A, 1990, ACT NEUR S, V51, P394; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Schmidt B, 2003, STROKE, V34, P84, DOI 10.1161/01.STR.0000047849.01376.AE; Schneider GH, 2002, ACT NEUR S, V81, P77; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, BRIT J NEUROSURG, V16, P429, DOI 10.1080/0268869021000030221; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; Wagner S, 2001, J NEUROSURG, V94, P693, DOI 10.3171/jns.2001.94.5.0693; Whitfield PC, 2001, NEUROSURGERY, V49, P225, DOI 10.1097/00006123-200107000-00042; Wirtz C R, 1997, Neurosurg Focus, V2, pE3; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yoo DS, 1999, J NEUROSURG, V91, P953, DOI 10.3171/jns.1999.91.6.0953	55	71	75	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2006	104	1					93	100		10.3171/jns.2006.104.1.93			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	001OX	WOS:000234547300015	16509152				2022-02-06	
J	Bennett, PC; Ong, B; Ponsford, J				Bennett, PC; Ong, B; Ponsford, J			Measuring executive dysfunction in an acute rehabilitation setting: Using the Dysexecutive Questionnaire (DEX)	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						dysexecutive questionnaire (DEX); executive dysfunction (ED); behavioral assessment of the dysexecutive syndrome (BADS); clinical neuropsychology	CARD SORTING TEST; FRONTAL-LOBE DAMAGE; HEAD-INJURY; BEHAVIORAL-ASSESSMENT; PERFORMANCE; VALIDITY; DEFICITS; ABILITY; SAMPLE	It is recognized that existing neuropsychological measures of executive dysfunction lack adequate sensitivity and selectivity. While attempts have been made to develop improved measures, these have not yet been of great value to those who need to accurately identify executive deficits in a clinical setting. Several behavioral rating scales have been developed for this reason, including the 20-item Dysexecutive Questionnaire (DEX), which forms part of the Behavioral Assessment of the Dysexecutive Syndrome (BADS) test battery. To investigate the ability of the DEX to identify executive dysfunction in an acute rehabilitation setting, the BADS was administered to 64 persons who had sustained traumatic brain injury. It was found to be almost as sensitive to executive dysfunction, as measured by the total score obtained on the BADS battery, as an extended 65-item version of the scale, when completed by either the occupational therapist or clinical neuropsychologist working with each patient. Family members and the patient themselves provided, as expected, less accurate information. Our results indicate that the DEX can be used with some confidence as a screening instrument to identify executive dysfunction in an acute rehabilitation setting, provided it is completed by professional personnel, trained to be sensitive to the cognitive and behavioral concomitants of this disorder.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Dept Psychol, Caulfield, Vic 3145, Australia; La Trobe Univ, Sch Psychol Sci, Bundoora, Vic, Australia		Bennett, PC (corresponding author), Monash Univ, Sch Psychol Psychiat & Psychol Med, Dept Psychol, POB 197, Caulfield, Vic 3145, Australia.	p.bennett@med.monash.edu.au	Bennett, Pauleen/C-2138-2016	Bennett, Pauleen/0000-0001-5864-4464			ALDERMAN N, 1993, J CLIN EXP NEUROPSYC, V15, P69; ANDERSON SW, 1991, J CLIN EXP NEUROPSYC, V13, P909, DOI 10.1080/01688639108405107; Axelrod BN, 1996, J CLIN EXP NEUROPSYC, V18, P338, DOI 10.1080/01688639608408991; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Banich M.T., 1997, NEUROPSYCHOLOGY NEUR; Benson D.F., 1986, FRONTAL LOBES; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; Bryan J, 2000, J CLIN EXP NEUROPSYC, V22, P40, DOI 10.1076/1380-3395(200002)22:1;1-8;FT040; Burgess P, 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 2000, NEUROPSYCHOLOGIA, V38, P848, DOI 10.1016/S0028-3932(99)00134-7; Chan RCK, 2001, BRIT J PSYCHOL, V92, P551, DOI 10.1348/000712601162338; Channon S, 1999, NEUROPSYCHOLOGIA, V37, P757, DOI 10.1016/S0028-3932(98)00138-9; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P209, DOI 10.1080/713755574; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Evans JJ, 1997, PSYCHOL MED, V27, P635, DOI 10.1017/S0033291797004790; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; Greve KW, 1997, BRIT J CLIN PSYCHOL, V36, P283, DOI 10.1111/j.2044-8260.1997.tb01414.x; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Levin HS, 1989, NEUROPSYCHOLOGY, V3, P243, DOI 10.1037//0894-4105.3.4.243; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Nelson H.E., 1982, NATL ADULT READING T; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, 1995, TRAUMATIC BRAIN INJU; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; RICCIO CA, 1994, DEV NEUROPSYCHOL, V10, P215, DOI 10.1080/87565649409540580; ROSENTHAL M, 1992, NEUROREHABILITATION, V2, P1; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, P125; VANDENBROEK MD, 1993, BRIT J CLIN PSYCHOL, V32, P333; Wilson BA, 1998, NEUROPSYCHOL REHABIL, V8, P213, DOI 10.1080/713755570; WILSON J T L, 1992, Brain Injury, V6, P391, DOI 10.3109/02699059209008135	40	71	73	1	20	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2005	11	4					376	385		10.1017/S1355617705050423			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	948UY	WOS:000230742400004	16209417				2022-02-06	
J	Chiaravalloti, ND; Hillary, FG; Ricker, JH; Christodoulou, C; Kalnin, AJ; Liu, WC; Steffener, J; Deluca, J				Chiaravalloti, ND; Hillary, FG; Ricker, JH; Christodoulou, C; Kalnin, AJ; Liu, WC; Steffener, J; Deluca, J			Cerebral activation patterns during working memory performance in multiple sclerosis using fMRI	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; ADAPTIVE FUNCTIONAL-CHANGES; RIGHT-HEMISPHERE INVOLVEMENT; CORTICAL ACTIVATION; GLUCOSE-METABOLISM; COGNITIVE FUNCTION; OPTIC NEURITIS; AXONAL INJURY; CORTEX	Working memory deficits are common in Multiple Sclerosis (MS) and have been identified behaviorally in numerous studies. Despite recent advance in functional magnetic resonance imaging (fMRI), few published studies have examined cerebral activations associated with working memory dysfunction in MS. The present study examines brain activation patterns during performance of a working memory task in individuals with clinically definite MS, compared to healthy controls (HC). fMRI was performed using a 1.5 Tesla GE scanner during a modified Paced Auditory Serial Addition Test (mPA-SAT). Participants were 6 individuals with MS with working memory impairment as evidenced on neuropsychological testing, 5 individuals with MS without working memory impairment, and 5 HC Groups were demographically equivalent. Data were analyzed using Statistical Parametric Mapping (SPM99) software, with a stringent significance level (alpha <.005, voxel extent >= 8). Both MS groups and the HC group were able to perform the task, with comparable performance in terms of numbers of correct responses. Activation patterns within the HC and MS not-impaired groups were noted in similar brain regions, consistent with published observations in healthy samples. That is, activations were lateralized to the left hemisphere, involving predominantly frontal regions. In contrast, the MS impaired group showed greater right frontal and right parietal lobe activation, when compared with the HC group. Thus, it appears that working memory dysfunction in MS is associated with altered patterns of cerebral activation that are related to the presence of cognitive impairment, and not solely a function of MS.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Newark, NJ 07103 USA		Deluca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.	jdeluca@kmrrec.org	Hillary, Frank/AAN-8622-2021	Ricker, Joseph/0000-0003-3415-991X			[Anonymous], 1993, NEUROPSYCHOLOGY, V7, P364, DOI [DOI 10.1037/0894-4105.7.3.364, 10.1037/0894-4105.7.3.364]; Ashburner J, 2001, NEUROIMAGE, V14, P1238, DOI 10.1006/nimg.2001.0961; Baddeley A.D., 1986, WORKING MEMORY; Bakshi R, 1998, J NEUROIMAGING, V8, P228, DOI 10.1111/jon199884228; Belger A, 1998, HUM BRAIN MAPP, V6, P14, DOI 10.1002/(SICI)1097-0193(1998)6:1<14::AID-HBM2>3.0.CO;2-O; Blinkenberg M, 1999, NEUROLOGY, V53, P149, DOI 10.1212/WNL.53.1.149; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Cabeza R, 1997, J NEUROSCI, V17, P391; Chang L, 2001, NEUROLOGY, V57, P1001, DOI 10.1212/WNL.57.6.1001; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cobble N., 1992, J NEUROL REHABIL, V6, P141; Crosson B, 1999, NEUROPSYCHOLOGY, V13, P171, DOI 10.1037/0894-4105.13.2.171; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; Deshpande SA, 1996, J CLIN EXP NEUROPSYC, V18, P836, DOI 10.1080/01688639608408306; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; Diamond BJ, 1997, J CLIN EXP NEUROPSYC, V19, P34, DOI 10.1080/01688639708403834; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; DUARA R, 1992, J CEREBR BLOOD F MET, V12, P927, DOI 10.1038/jcbfm.1992.129; Evangelou N, 2000, BRAIN, V123, P1845, DOI 10.1093/brain/123.9.1845; Filippi M, 2002, NEUROIMAGE, V15, P559, DOI 10.1006/nimg.2001.1011; Filippi M, 2002, NEUROIMAGE, V15, P537, DOI 10.1006/nimg.2001.1023; Filippi M, 1999, NEUROLOGY, V53, pS18; Foong J, 1999, J NEUROPSYCH CLIN N, V11, P45, DOI 10.1176/jnp.11.1.45; GOLDBERG E, 1981, BRAIN LANG, V14, P144, DOI 10.1016/0093-934X(81)90072-9; GOLDBERG E, 1994, J NEUROPSYCH CLIN N, V6, P371; GORDON PA, 1994, J REHABIL, V60, P34; GRIGSBY J, 1994, J NEUROL, V241, P125; GRIGSBY J, 1994, ARCH CLIN NEUROPSYCH, V9, P134; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GROSSMAN M, 1994, NEUROPSY NEUROPSY BE, V7, P194; JOHNSON MK, 1992, J COGNITIVE NEUROSCI, V4, P268, DOI 10.1162/jocn.1992.4.3.268; Jonides J, 1998, J NEUROSCI, V18, P5026; Kollias SS, 1996, INT J NEURORADIOL, V2, P450; Lee M, 2000, ANN NEUROL, V47, P606, DOI 10.1002/1531-8249(200005)47:5<606::AID-ANA8>3.0.CO;2-L; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LITVAN I, 1988, ARCH NEUROL-CHICAGO, V45, P281, DOI 10.1001/archneur.1988.00520270059021; LYCKE J, 1993, EUR NEUROL, V33, P163, DOI 10.1159/000116926; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MINOSHIMA S, 1993, INT CONGR SER, V1030, P409; Pan J W, 2001, Appl Neuropsychol, V8, P155, DOI 10.1207/S15324826AN0803_4; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; Paulesu E, 1996, NEUROIMAGE, V4, P87, DOI 10.1006/nimg.1996.0032; Pelletier J, 2001, ARCH NEUROL-CHICAGO, V58, P105, DOI 10.1001/archneur.58.1.105; Pfefferbaum A, 2001, NEUROIMAGE, V14, P7, DOI 10.1006/nimg.2001.0785; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1989, NEUROLOGY, V39, P161, DOI 10.1212/WNL.39.2.161; Reddy H, 2000, BRAIN, V123, P2314, DOI 10.1093/brain/123.11.2314; Reddy H, 2000, NEUROLOGY, V54, P236, DOI 10.1212/WNL.54.1.236; Reuter-Lorenz PA, 2000, J COGNITIVE NEUROSCI, V12, P174, DOI 10.1162/089892900561814; Rocca MA, 2002, NEUROLOGY, V58, P866, DOI 10.1212/WNL.58.6.866; Rocca MA, 2002, ANN NEUROL, V51, P330, DOI 10.1002/ana.10120; Roelcke U, 1997, NEUROLOGY, V48, P1566, DOI 10.1212/WNL.48.6.1566; Rombouts SARB, 1998, NEUROLOGY, V50, P1896, DOI 10.1212/WNL.50.6.1896; Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719; Rovaris M, 1999, NEUROLOGY, V53, pS40; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Seger CA, 2000, NEUROPSYCHOLOGY, V14, P361, DOI 10.1037//0894-4105.14.3.361; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; Staffen W, 2002, BRAIN, V125, P1275, DOI 10.1093/brain/awf125; STEIN DG, 2000, INT HDB NEUROPSYCHOL, P9; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; van Waesberghe JHTM, 1999, NEUROLOGY, V53, pS46; Wechsler D, 1981, WESCHELER ADULT INTE; Wechsler D., 1997, WECHSLER MEMORY SCAL; Werring DJ, 2000, J NEUROL NEUROSUR PS, V68, P441, DOI 10.1136/jnnp.68.4.441; [No title captured]	73	71	73	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN	2005	27	1					33	54		10.1080/138033990513609			22	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	908NM	WOS:000227793700003	15814441				2022-02-06	
J	Gill, M; Windemuth, R; Steele, R; Green, SM				Gill, M; Windemuth, R; Steele, R; Green, SM			A comparison of the Glasgow coma scale score to simplified alternative scores for the prediction of traumatic brain injury outcomes	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Research Forum of the American-College-of-Emergency-Physicians	OCT 12-13, 2003	Boston, MA	Amer Coll Emergency Phys			RULE; CRITERIA; TRIAGE; SPINE	Study objective: The 15-point Glasgow Coma Scale (GCS) is extensively used in the initial evaluation of traumatic brain injury in emergency department (ED) settings. We hypothesized that the GCS might be unnecessarily complex and that a simpler scoring system might demonstrate similar accuracy in the prediction of traumatic brain injury outcomes. Methods: We analyzed a prospectively maintained trauma registry of patients evaluated at our Level 1 trauma center from 1990 to 2002. We calculated the test performance of ED GCS scores relative to 4 clinically relevant traumatic brain injury outcomes (emergency intubation, neurosurgical intervention, brain injury, and mortality) using areas under their receiver operating characteristic (ROC) curves. We performed similar analyses for each of the 3 GCS components and for 2 simplified 3-point scores (simplified verbal score: oriented=2, confused conversation=1, inappropriate words or less=0; simplified motor score: obeys commands=2, localizes pain=1, withdrawal to pain or less=0). We then compared the test performance of each of these 5 to the total GCS score using a priori thresholds for clinically important differences. Results: Each of the 3 GCS components alone and the 2 simplified 3-point scores demonstrated ROC areas within 9% of that of the GCS score for the 4 outcomes, with a median difference of 3.0% (interquartile range 1.6% to 4.5%). These differences were all below our a priori definitions of clinical importance. Conclusion: The 3 individual GCS components alone and two 3-point simplified scores demonstrated test performance similar to the total GCS score for the prediction of 4 clinically relevant traumatic brain injury outcomes. Despite the widespread use of the GCS for the initial evaluation of traumatic brain injury, this score may be unnecessarily complex for this indication.	Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, Loma Linda, CA 92354 USA		Gill, M (corresponding author), Loma Linda Univ, Med Ctr, Sch Med, Dept Emergency Med, 11234 Anderson St,POB 2000,Room A-108, Loma Linda, CA 92354 USA.	mgill@ahs.llumc.edu					American College of Surgeons Committee on Trauma, 1997, ADV TRAUM LIF SUPP M; Andersson RE, 1999, WORLD J SURG, V23, P133, DOI 10.1007/PL00013174; [Anonymous], 1999, RES OPT CAR INJ PAT; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; CAMPBELL JE, 1999, BASIC TRAUMA LIFE SU; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Crossman J, 1998, INJURY, V29, P435, DOI 10.1016/S0020-1383(98)00079-5; CUMMINS RO, 2002, TXB ADV CARDIAC LIFE; Fischer J, 2001, Crit Care Nurs Q, V23, P52; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Hamani C, 2003, ARQ NEURO-PSIQUIAT, V61, P376, DOI 10.1590/S0004-282X2003000300010; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Holmen CD, 2002, J TRAUMA, V53, P345, DOI 10.1097/00005373-200208000-00026; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Norwood SH, 2002, J TRAUMA, V53, P503, DOI 10.1097/00005373-200209000-00018; Punglia RS, 2003, NEW ENGL J MED, V349, P335, DOI 10.1056/NEJMoa021659; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Rutledge R, 1996, J TRAUMA, V41, P514, DOI 10.1097/00005373-199609000-00022; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Stiell IG, 2003, NEW ENGL J MED, V349, P2510, DOI 10.1056/NEJMoa031375; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; TEASDALE G, 1974, LANCET, V2, P81; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P479, DOI DOI 10.1089/NEU.2000.17.479; Tinkoff GH, 2002, J TRAUMA, V52, P1153, DOI 10.1097/00005373-200206000-00022; World Health Organization, 1977, INT CLASS DIS	34	71	72	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JAN	2005	45	1					37	42		10.1016/j.annemergmed.2004.07.429			6	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	886SY	WOS:000226250100009	15635308				2022-02-06	
J	Kelestimur, F; Tanriverdi, F; Atmaca, H; Unluhizarci, K; Selcuklu, A; Casanueva, F				Kelestimur, F; Tanriverdi, F; Atmaca, H; Unluhizarci, K; Selcuklu, A; Casanueva, F			Boxing as a sport activity associated with isolated GH deficiency	JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION			English	Article						boxer; GH deficiency; traumatic brain injury; GHRH+GHRP-6 test; pituitary	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC HYPOPITUITARISM; NEUROENDOCRINE DYSFUNCTION; PROFESSIONAL BOXERS; GROWTH-HORMONE; HEAD TRAUMA; ADULTS; DIAGNOSIS	Traumatic brain injury (TBI) has long been known as a cause of hypopituitarism, and it is characterized by a high prevalence of neuroendocrine abnormalities. Boxing, one of the most common combative sports, may also result in TBI. As far as we know, pituitary functions including GH status have not been investigated in boxers. Therefore, in this preliminary study, we have assessed the pituitary functions in boxers. Eleven actively competing or retired male boxers with a mean age of 38.0 +/- 3.6 yr and 7 age-, sex- and BMI-matched healthy non-boxing controls were included in the study. Biochemical and basal hormonal parameters including IGF-1 levels were measured. To assess GH secretory status in boxers and healthy controls, GHRH (1 mug/kg) +GHRP-6 (1 mug/kg) test was performed. After GHRH+GHRP-6 test, mean peak GH level in boxers and in controls were 10.9 +/- 1.7 and 41.4 +/- 6.7 mug/l, respectively (p<0.05). Peak GH levels in 5 (45%) boxers were found to be lower than 10 mug/l and considered as severe GH deficient. In the control group, mean IGF-I levels (367 +/- 18.8 ng/ml) were significantly higher than that obtained in boxers (237 +/- 23.3 ng/dl) (p<0.01). All the other pituitary hormones were normal including ADH as no signs and symptoms of diabetes insipidus. There was a significant negative correlation between peak GH levels and boxing duration, and between peak GH levels and number of bouts. In conclusion, we think that boxing is a cause of TBI, and GH deficiency is very common among boxers. Further studies including large number of boxers, both professional and amateur, are needed to clarify pituitary dysfunction in boxers. (C) 2004, Editrice Kurtis.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; Karaelmas Univ, Sch Med, Dept Endocrinol, Zonguldak, Turkey; Univ Santiago de Compostela, Dept Med, Sch Med, Santiago De Compostela, Spain; Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain		Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur2001@yahoo.co.uk	kelestimur, f/ABE-9873-2021				Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; ALTMAN R, 1961, ANN INTERN MED, V55, P149, DOI 10.7326/0003-4819-55-1-149; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BATES AS, 1995, CLIN ENDOCRINOL, V42, P425, DOI 10.1111/j.1365-2265.1995.tb02652.x; Benvenga S, 2004, AM J MED, V116, P767, DOI 10.1016/j.amjmed.2003.12.038; DANIEL PM, 1961, MOD TRENDS ENDOCRINO, V2, P55; Hillier SL, 1997, BRAIN INJURY, V11, P649; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Molitch ME, 2002, J CLIN ENDOCR METAB, V87, P473, DOI 10.1210/jc.87.2.473; Ohhashi G, 2002, BRIT J SPORT MED, V36, P346, DOI 10.1136/bjsm.36.5.346; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Powell JW, 2001, J ATHL TRAINING, V36, P307; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	20	71	73	1	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1720-8386			J ENDOCRINOL INVEST	J. Endocrinol. Invest.	DEC	2004	27	11					RC28	RC32		10.1007/BF03345299			5	Endocrinology & Metabolism	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism	898LR	WOS:000227078800001	15754728				2022-02-06	
J	Pellman, E; Viano, DC; Casson, IR; Tucker, AM; Waeckerle, JF; Powell, JW; Feuer, H				Pellman, E; Viano, DC; Casson, IR; Tucker, AM; Waeckerle, JF; Powell, JW; Feuer, H			Concussion in professional football: Repeat injuries - Part 4	NEUROSURGERY			English	Article						concussion; epidemiology; injury surveillance; repeat or multiple concussions; second-impact syndrome; traumatic brain injury	2ND IMPACT; COLLEGIATE; PLAYERS	OBJECTIVE: A 6-year study was conducted to determine the signs, symptoms, and management of repeat concussion in National Football League players. METHODS: From 1996 to 2001, concussions were reported by 30 National Football League teams using a standardized reporting form filled out by team physicians with input from athletic trainers. Signs and symptoms were grouped by general symptoms, somatic complaints, cranial nerve effects, cognition problems, memory problems, and unconsciousness. Medical actions taken and management were recorded. RESULTS: Data were captured for 887 concussions in practices and games involving 650 players. A total of 160 players experienced repeat injury, with 51 having three or more concussions during the study period. The median time between injuries was 374.5 days, with only six concussions occurring within 2 weeks of the initial injury. Repeat concussions were more prevalent in the secondary (16.9%), the kick unit on special teams (16.3%), and wide receivers (12.5%). The ball return carrier on special teams (odds ratio [OR] = 2.08, P = not significant) and quarterbacks (OR = 1.92, P < 0.1) had elevated odds for repeat injury, followed by the tight end (OR = 1.24, P = not significant) and linebackers (OR = 1.22, P = not significant). There were similar signs and symptoms with single and repeat concussion, except for a higher prevalence of somatic complaints in players on their repeat concussions compared with their first concussion (27.5% versus 18.8%, P< 0.05). More than 90% of players were managed by rest, and 57.5% of those with second injuries returned to play within a day. Players with three or more concussions had signs, symptoms, and treatment similar to those with only a single injury. CONCLUSION: The most vulnerable players for repeat concussion in professional football are the ball return carrier on special teams and quarterbacks. Single and repeat concussions are managed conservatively with rest, and most players return quickly to play.	ProHLTH Care Associates LLP, Lake Success, NY USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; Probiomech LLC, Bloomfield Hills, MI 48304 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10467 USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA; Acute Care & Emergency Specialists MD PC, Leawood, KS USA; Michigan State Univ, Dept Kinesiol, Lansing, MI USA; Michigan State Univ, Dept Phys Med & Rehabil, Lansing, MI USA; Indianapolis Neurosurg Grp, Indianapolis, IN USA		Viano, DC (corresponding author), Probiomech LLC, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net		Kaye, Andrew Henry/0000-0001-5049-8861			BAILES J, 2003, NEUROL REV      0627; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P172; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KWARTZ J, 1990, INJURY, V21, P351, DOI 10.1016/0020-1383(90)90116-C; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MORRISON RG, 1986, JAMA-J AM MED ASSOC, V255, P2475, DOI 10.1001/jama.255.18.2475; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POLIN R, 1996, NEUROLOGY TRAUMA, P166; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROSS RJ, 1983, JAMA-J AM MED ASSOC, V249, P211, DOI 10.1001/jama.249.2.211; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P77; THORNDIKE A, 1952, NEW ENGL J MED, V247, P554, DOI 10.1056/NEJM195210092471504; UNTERHARNSCHEID.FJ, 1975, HDB CLIN NEUROLOGY, V23, P527; Warden Deborah L., 2003, Neurology, V60, pA362	45	71	71	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2004	55	4					860	873		10.1227/01.NEU.0000137657.00146.7D			14	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	860AI	WOS:000224309100029	15458594				2022-02-06	
J	Karimi-Abdolrezaee, S; Eftekharpour, E; Fehlings, MG				Karimi-Abdolrezaee, S; Eftekharpour, E; Fehlings, MG			Temporal and spatial patterns of Kv1.1 and Kv1.2 protein and gene expression in spinal cord white matter after acute and chronic spinal cord injury in rats: implications for axonal pathophysiology after neurotrauma	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Caspr; NF200; rat; real-time PCR; western blotting	GATED POTASSIUM CHANNELS; K+ CHANNELS; IN-VITRO; COMPRESSIVE INJURY; EVOKED-POTENTIALS; GLIA INTERACTIONS; CONDUCTION-BLOCK; LOCALIZATION; APOPTOSIS; MYELIN	After spinal cord injury (SCI), surviving white matter axons display axonal dysfunction associated with demyelination and altered K+ channel activity To clarify the molecular basis of posttraumatic axonal pathophysiology after SCI, we investigated the changes in expression and distribution of the axonal K+ channel subunits Kv1.1 and Kv1.2 in spinal cord white matter after in vivo SCI in the rat. Using Western blot analysis, we found an increased expression of Kv1.1 and Kv1.2 at 2 and 6 weeks after SCI. By real-time PCR we observed an increase in Kv1.1 and Kv1.2 mRNA levels 1 day after SCI, which persisted until 6 weeks. Confocal immunohistochemistry showed a markedly dispersed labelling of Kv1.1 and Kv1.2 along the injured axons, in contrast to the tight localization of these channels to the juxtaparanodes of noninjured axons. This redistribution of Kv1.1 and Kv1.2 occurred as early as 1 h postinjury along some injured axons, and persisted at 6 weeks postinjury. In parallel with the redistribution of Kv1.1 and 1.2, contactin-associated protein (Caspr), which is normally confined to a paranodal location, also displayed a more diffuse distribution along the injured spinal cord axons. Our results suggest that the increased expression of Kv1.1 and Kv1.2 proteins is transcriptionally regulated. In contrast, the redistribution of the axonal K+ channel subunits occurs very early postinjury and probably reflects a disruption of the juxtaparanodal axonal region due to physical trauma, as shown by altered localization of Caspr.	Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Krembil Neurosci Ctr, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON M5T 2S8, Canada		Fehlings, MG (corresponding author), Univ Hlth Network, Toronto Western Hosp, Room 4W-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael@uhnres.utoronto.ca		Fehlings, Michael/0000-0002-5722-6364; Eftekharpour, Eftekhar/0000-0002-2849-3754; Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663			Agrawal SK, 1996, J NEUROSCI, V16, P545; Arroyo EJ, 2002, J NEUROSCI, V22, P1726, DOI 10.1523/JNEUROSCI.22-05-01726.2002; BALENTINE JD, 1978, LAB INVEST, V39, P254; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; BLIGHT AR, 1983, NEUROSCIENCE, V10, P1471, DOI 10.1016/0306-4522(83)90128-8; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge R P, 1997, Adv Neurol, V72, P305; BUNGE RP, 1993, ADV NEUROL, V59, P75; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; Edwards L, 2002, J COMP NEUROL, V443, P154, DOI 10.1002/cne.10115; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Eng H, 1999, J NEUROSCI, V19, P1; FEHLINGS MG, 1992, BRAIN RES, V579, P32, DOI 10.1016/0006-8993(92)90738-U; FEHLINGS MG, 1995, BRAIN RES, V677, P291, DOI 10.1016/0006-8993(95)00141-C; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/S0006-8993(96)00667-1; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; FEHLINGS MG, 1989, ELECTROEN CLIN NEURO, V74, P241, DOI 10.1016/0168-5597(89)90055-5; GRIFFITHS IR, 1983, J NEUROL SCI, V58, P335, DOI 10.1016/0022-510X(83)90093-X; Hayes KC, 1997, J NEUROTRAUM, V14, P235, DOI 10.1089/neu.1997.14.235; KARIMIABDOLREZA.S, 2002, J NEUROTRAUM, V19, P566; Kirkpatrick LL, 2001, J NEUROSCI, V21, P2288, DOI 10.1523/JNEUROSCI.21-07-02288.2001; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Liu XZ, 1997, J NEUROSCI, V17, P5395; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Peles E, 1997, EMBO J, V16, P978, DOI 10.1093/emboj/16.5.978; Poliak S, 2001, J NEUROSCI, V21, P7568, DOI 10.1523/JNEUROSCI.21-19-07568.2001; Rasband M, 1998, J NEUROSCI, V18, P36; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Schmidt K, 1999, BRAIN RES, V843, P145, DOI 10.1016/S0006-8993(99)01938-1; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shi RY, 1997, EXP NEUROL, V148, P495, DOI 10.1006/exnr.1997.6706; Shuman SL, 1997, J NEUROSCI RES, V50, P798, DOI 10.1002/(SICI)1097-4547(19971201)50:5<798::AID-JNR16>3.0.CO;2-Y; Sobko A, 1998, J NEUROSCI, V18, P10398; VEH RW, 1995, EUR J NEUROSCI, V7, P2189, DOI 10.1111/j.1460-9568.1995.tb00641.x; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Wrathall JR, 1998, J NEUROSCI, V18, P8780	49	71	71	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	FEB	2004	19	3					577	589		10.1111/j.0953-816X.2004.03164.x			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	775WU	WOS:000189084300009	14984408				2022-02-06	
J	Carmichael, ST				Carmichael, ST			Gene expression changes after focal stroke, traumatic brain and spinal cord injuries	CURRENT OPINION IN NEUROLOGY			English	Article						aging; angiogenesis; axonal sprouting; inflammation; neural repair; stem cell	MESSENGER-RNA EXPRESSION; DNA MICROARRAY ANALYSIS; CEREBRAL-ISCHEMIA; SERIAL ANALYSIS; CELL-DEATH; KAPPA-B; ANGIOGENESIS; GROWTH; RECEPTOR; NEUROGENESIS	Purpose of review Large-scale gene expression profiling has recently been performed on stroke and spinal cord injuries. These studies provide insights into coordinated patterns of gene expression within the injury and the interrelationships of neurodegenerative and neural repair processes after injury. Recent findings The molecular signals for post-stroke angiogenesis begin within hours of initial cerebral ischemia, with sequential increases in message for initially destabilizing combinations of vascular growth factors and growth factor receptors, followed by growth factor combinations that promote endothelial cell division and stabilization. The overlap in molecular signaling between post-stroke angiogenesis, neurogenesis and axonal sprouting suggests a continuum of vascular and neural reorganization in the tissue adjacent to stroke. Inflammation after injury extends through early and late changes in the cytokine message. SOCS-3, a negative regulator of cytokine signaling, is increased after injury and may be neuroprotective. Components of an adult neuronal growth program have been identified in the peripheral nervous system during axonal regeneration, with overlap to axonal sprouting after stroke. The gene expression profile of the aged brain suggests an altered central nervous system environment that may exacerbate initial injury and impair neural reorganization after stroke and spinal cord injury. Summary When rigorously tested and independently validated, data from large-scale gene expression analyses provide new insights into the aggregate genetic control of stroke and spinal cord injury, and the interrelationship of important cellular events within the damaged region. These data also highlight novel genes in these processes, and suggest new directions in the investigation of tissue reorganization and repair after central nervous system injury.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA		Carmichael, ST (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	scarmichael@mednet.ucla.edu		Carmichael, S Thomas/0000-0002-1169-9203			Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Adams RH, 2000, TRENDS CARDIOVAS MED, V10, P183, DOI 10.1016/S1050-1738(00)00046-3; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Bates S, 2001, MOL BRAIN RES, V93, P70, DOI 10.1016/S0169-328X(01)00186-3; Berti R, 2002, J CEREBR BLOOD F MET, V22, P1068, DOI 10.1097/00004647-200209000-00004; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Blalock EM, 2003, J NEUROSCI, V23, P3807; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Bulsara KR, 2002, SPINE, V27, P1946, DOI 10.1097/00007632-200209010-00030; BULSARA KR, 2002, SOC NEUROSCI; Cafferty WBJ, 2001, J NEUROSCI, V21, P7161, DOI 10.1523/JNEUROSCI.21-18-07161.2001; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmichael ST, 2001, NEUROBIOL DIS, V8, P910, DOI 10.1006/nbdi.2001.0425; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Chong ZZ, 2002, J HEMATOTH STEM CELL, V11, P863, DOI 10.1089/152581602321080529; Chuaqui RF, 2002, NAT GENET, V32, P509, DOI 10.1038/ng1034; Chung RS, 2003, J NEUROSCI, V23, P3336; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510, DOI 10.1523/JNEUROSCI.23-02-00510.2003; Felmeden DC, 2003, EUR HEART J, V24, P586, DOI 10.1016/S0195-668X(02)00635-8; Gu CH, 2003, DEV CELL, V5, P45, DOI 10.1016/S1534-5807(03)00169-2; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hindges R, 2002, NEURON, V35, P475, DOI 10.1016/S0896-6273(02)00799-7; Hoffman JR, 1999, BRAIN RES BULL, V48, P421, DOI 10.1016/S0361-9230(99)00022-2; Iadecola C, 2001, CURR OPIN NEUROL, V14, P89, DOI 10.1097/00019052-200102000-00014; Katsman D, 2003, J CEREBR BLOOD F MET, V23, P997, DOI 10.1097/01.WCB.0000084252.20114.BE; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Keyvani K, 2002, J CEREBR BLOOD F MET, V22, P153, DOI 10.1097/00004647-200202000-00003; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KRUPINSKI J, 1994, STROKE, V25, P1794, DOI 10.1161/01.STR.25.9.1794; Larsen L, 2002, APMIS, V110, P833, DOI 10.1034/j.1600-0463.2002.1101201.x; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lin TN, 2003, STROKE, V34, P177, DOI 10.1161/01.STR.0000047100.84604.BA; Lin TN, 2002, STROKE, V33, P2985, DOI 10.1161/01.STR.0000037675.97888.9D; Lin TN, 2001, J CEREBR BLOOD F MET, V21, P690, DOI 10.1097/00004647-200106000-00007; Lin TN, 2000, J CEREBR BLOOD F MET, V20, P387, DOI 10.1097/00004647-200002000-00021; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06; McGee AW, 2003, TRENDS NEUROSCI, V26, P193, DOI 10.1016/S0166-2236(03)00062-6; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Patino WD, 2002, CIRC RES, V91, P565, DOI 10.1161/01.RES.0000036018.76903.18; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Rao VLR, 2002, J NEUROCHEM, V83, P1072, DOI 10.1046/j.1471-4159.2002.01208.x; Renner O, 2003, MOL BRAIN RES, V113, P44, DOI 10.1016/S0169-328X(03)00085-8; Schmidt-Kastner R, 2002, MOL BRAIN RES, V108, P81, DOI 10.1016/S0169-328X(02)00516-8; Schmidt-Kastner R, 2000, MOL BRAIN RES, V79, P88, DOI 10.1016/S0169-328X(00)00104-2; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shusta EV, 2002, J CEREBR BLOOD F MET, V22, P245, DOI 10.1097/00004647-200203000-00001; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Studer L, 2000, J NEUROSCI, V20, P7377; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Suri C, 1998, SCIENCE, V282, P468, DOI 10.1126/science.282.5388.468; TODA H, 2002, SOC NEUROSCI, P16; Trendelenburg G, 2002, J NEUROSCI, V22, P5879; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Willson CA, 2003, CELL TRANSPLANT, V12, P279, DOI 10.3727/000000003108746830; Wright LS, 2003, J NEUROCHEM, V86, P179, DOI 10.1046/j.1471-4159.2003.01826.x; Yang YH, 2002, NAT REV GENET, V3, P579, DOI 10.1038/nrg863; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369; Zhang ZG, 2002, J CEREBR BLOOD F MET, V22, P379, DOI 10.1097/00004647-200204000-00002	75	71	75	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2003	16	6					699	704		10.1097/00019052-200312000-00009			6	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	805MU	WOS:000220371200009	14624079				2022-02-06	
J	Seel, RT; Kreutzer, JS				Seel, RT; Kreutzer, JS			Depression assessment after traumatic brain injury: An empirically based classification method	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; depression; outcome assessment (health care); rehabilitation	MINOR HEAD-INJURIES; PSYCHOMETRIC PROPERTIES; INVENTORY; DISORDERS; CONCORDANCE; OUTPATIENTS; PERSONALITY; VALIDATION; DISABILITY; RELATIVES	Objectives: To describe the patterns of depression in patients with traumatic brain injury (TBI), to evaluate the psychometric properties of the Neurobehavioral Functioning Inventory (NFI) Depression Scale, and to classify empirically NFI Depression Scale scores. Design: Depressive symptoms were characterized by using the NFI Depression Scale. the Beck Depression Inventory (BDI), and the Minnesota Multiphasic Personality Inventory-2 (MMPI-2) Depression Scale. Setting: An outpatient clinic within a Traumatic Brain Injury Model Systems center. Participants: A demographically diverse sample of 172 outpatients with TBI. evaluated between 1996 and 2000. Interventions: Not applicable. Main Outcome Measures: The NFI, BDI, and MMPI-2 Depression Scale. The Cronbach alpha, analysis of variance, Pearson correlations. and canonical discriminant function analysis were used to examine the psychometric properties of the NFI Depression Scale. Results: Patients with TBI most frequently reported problems with frustration (81%), restlessness (73%), rumination (69%), boredom (66%). and sadness (66%) with the NFI Depression Scale. The percentages of patients classified as depressed with the BDI and the NFI Depression Scale were 37% and 30%, respectively. The Cronbach alpha for the NFI Depression Scale was 93, indicating a high degree of internal consistency. As hypothesized. NFI Depression Scale scores correlated highly with BDI (r=.765) and MMPI-2 Depression Scale T scores (r=.752). The NFI Depression Scale did not correlate significantly with the MMPI-2 Hypomania Scale, thus showing discriminant validity. Normal and clinically depressed BDI scores were most likely to be accurately predicted by the NFI Depression Scale. with 81% and 87% of grouped cases, respectively, correctly classified. Normal and depressed MMPI-2 Depression Scale scores were accurately predicted by the NFI Depression Scale. with 75% and 83% of grouped cases correctly classified, respectively. Patients' NFI Depression Scale scores were mapped to the corresponding BDI categories, and 3 NFI score classifications emerged: minimally depressed (13-28), borderline depressed (29-42), and clinically depressed (43-65). Conclusions: Our study provided further evidence that screening for depression should be a standard component of TBI assessment protocols. Between 30% and 38% of patients with TBI were classified as depressed with the NFI Depression Scale and the BDI, respectively. Our findings also provided empirical evidence that the NFI Depression Scale is a useful tool for classifying postinjury depression.	McGuire Vetr Adm Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; Virginia Commonwealth Univ Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA USA		Seel, RT (corresponding author), VAMC, Def & Vet Brain Injury Ctr, Dept Phys Med & Rehabil, ATT, 117, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.						Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anastasi A., 1988, PSYCHOL TESTING; Arbisi PA, 1999, NEUROREHABILITATION, V13, P117; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Beck A. T., 1993, BECK DEPRESSION INVE; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BETZ NE, 1987, J COUNS PSYCHOL, V34, P393, DOI 10.1037/0022-0167.34.4.393; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROWN C, 1995, PSYCHOL ASSESSMENT, V7, P59; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dawes R. V., 1987, J COUNS PSYCHOL, V34, P481; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; GARSKE GG, 1992, REHABIL COUNS BULL, V36, P44; GRAHAM JR, 1993, MMPI 2 ASSESSING PER; Green R.L., 1991, MMPI 2 MMPI INTERPRE; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kaemmer, 1989, MINNESOTA MULTIPHASI; Keppel G., 1991, DESIGN ANAL RES HDB; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KREUTZER J, 1999, NEUROBEHAVIORAL FUNC; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN BE, 1988, J NEUROL NEUROSUR PS, V51, P1401, DOI 10.1136/jnnp.51.11.1401; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Lykouras L, 1998, PSYCHOPATHOLOGY, V31, P213, DOI 10.1159/000029042; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NG KC, 1995, ACTA PSYCHIAT SCAND, V92, P75, DOI 10.1111/j.1600-0447.1995.tb09546.x; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PATRICK J, 1988, J CLIN PSYCHOL, V44, P186, DOI 10.1002/1097-4679(198803)44:2<186::AID-JCLP2270440215>3.0.CO;2-0; PORTER JH, 1986, STAT APPL BEHAV SCI; REYNOLDS WM, 1981, J CONSULT CLIN PSYCH, V49, P306, DOI 10.1037/0022-006X.49.2.306; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; STEER RA, 1989, J PERS ASSESS, V53, P693, DOI 10.1207/s15327752jpa5304_6; Tabachnick B. G., 1989, USING MULTIVARIATE S; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7	52	71	74	0	21	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2003	84	11					1621	1628		10.1053/S0003-9993(03)00270-3			8	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	741PR	WOS:000186466900008	14639561				2022-02-06	
J	Chiang, MF; Chang, JG; Hu, CJ				Chiang, MF; Chang, JG; Hu, CJ			Association between apolipoprotein E genotype and outcome of traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						apolipoprotein E; genotype; PCR; traumatic brain injury	AMYLOID PROTEIN DEPOSITION; CLOSED-HEAD INJURY; E EPSILON-4 ALLELE; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; APOE GENOTYPE; BETA-PROTEIN; RISK; GENE; POLYMORPHISM	Background. The prognosis of traumatic brain injury is quite variable and not fully explained by the known factors. This study is to examine if the polymorphism of apolipoprotein E (apoE) influences the outcome of traumatic brain injury. Methods. Over a period of twelve months, we prospectively studied 100 patients who sustained traumatic brain injuries and were admitted to our neurosurgical unit. Findings. Nineteen patients were apoE4(+) and 81 patients were apoE4(-). There was no significant difference between apoE4(+) and apoE4(-) groups in the cause of injury (p=0.288), type of brain injury (p=0.983) and choice of treatment (p=0.88). The proportion of patients with a lower GCS (<13), indicating a poor prognosis, was higher in the apoE4(+) group (73.7%) than that in apoE4(-) group (61.7%), although the difference was not significant (p=0.654). Six patients (7.4%) in the apoE4(-) group and 5(26.3%) in the apoE4(+) group had been drinking alcohol at the time of injury (p=0.018). The mean duration of hospital stay for apoE4(+) patients was significantly longer than for apoE4(-) patients (p<0.001). Six months after injury, 10 of 19 patients (52.6%) with apoE4 had an unfavorable outcome (dead, vegetative state, or severe disability) compared with 20 of the 81 (24.1%) patients without apoE4 (p=0.017). The apoE4(+) patients had a significantly longer hospital stay and unfavorable outcomes a er brain injury. Interpretation. This study discloses a significant genetic association between the apoE genotypes and outcomes of traumatic brain injury. Patients with apoE4 allele are more likely to have an unfavorable clinical outcome after brain injury.	Mackay Mem Hosp, Dept Neurosurg, Mackay Jr Coll Nursing, Taipei 104, Taiwan; China Med Coll, Dept Mol Med, Taichung, Taiwan; Taipei Municipal Jen Ai Hosp, Dept Neurol, Taipei, Taiwan		Chiang, MF (corresponding author), Mackay Mem Hosp, Dept Neurosurg, Mackay Jr Coll Nursing, 92 Sec 2,Chung Shan N Rd, Taipei 104, Taiwan.		Chang, Jan-Gowth/C-9544-2009				ALBERTS MJ, 1995, LANCET, V346, P575, DOI 10.1016/S0140-6736(95)91411-0; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Graham DI, 1999, CELL MOL NEUROBIOL, V19, P19, DOI 10.1023/A:1006937205905; Graham DI, 1999, ACT NEUR S, V73, P89; HIXSON JE, 1990, J LIPID RES, V31, P545; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horsburgh K, 1997, BRAIN RES, V763, P103, DOI 10.1016/S0006-8993(97)00411-3; Hu CJ, 1998, J NEUROL SCI, V157, P158, DOI 10.1016/S0022-510X(98)00052-5; Johansson K, 1997, LANCET, V349, P1143, DOI 10.1016/S0140-6736(97)24016-X; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Katzman R, 1998, NEUROCHEM RES, V23, P369, DOI 10.1023/A:1022461601609; Katzman R, 1996, NEUROLOGY, V46, P889; Kerr M E, 1998, AACN Clin Issues, V9, P524, DOI 10.1097/00044067-199811000-00007; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Roses AD, 1997, ANN NY ACAD SCI, V826, P200, DOI 10.1111/j.1749-6632.1997.tb48471.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	31	71	75	0	0	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2003	145	8					649	654		10.1007/s00701-003-0069-3			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	719WL	WOS:000185228000010	14520543				2022-02-06	
J	Cantu, RC				Cantu, RC			Recurrent athletic head injury: risks and when to retire	CLINICS IN SPORTS MEDICINE			English	Article							2ND IMPACT SYNDROME; COLLEGE FOOTBALL; CONCUSSION; PERFORMANCE; SPORTS	This article focuses on the issues related to recurrent athletic head injuries; specifically, when cumulative exponential injury or the second impact syndrome may be anticipated. Case histories and research studies are used to illustrate the salient points. A signs-and-symptoms checklist for use in concussion evaluation and management is included. Finally, the topic of when to retire after repeated athletic head injuries is discussed and illustrated with a case study.	Emerson Hosp, Neurosurg Serv, Concord, MA 01742 USA; Emerson Hosp, Serv Sports Med, Concord, MA 01742 USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA		Cantu, RC (corresponding author), Emerson Hosp, Neurosurg Serv, 133 Ormac, Concord, MA 01742 USA.	rcantu@emersonhosp.org					ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Badie H, 1992, J NEUROTRAUM, V9, P56; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; ERLANGER D, 2002, UNPUB JAMA; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GIZA C, 2002, NEUROLOGIC ATHLETIC, P80; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1977, PERCEPT MOTOR SKILL, V4, P367; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider RC., 1973, HEAD NECK INJURIES F	24	71	71	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JUL	2003	22	3					593	+		10.1016/S0278-5919(02)00095-9			12	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	692LT	WOS:000183663100013	12852688				2022-02-06	
J	Shinoda, S; Skradski, SL; Araki, T; Schindler, CK; Meller, R; Lan, JQ; Taki, W; Simon, RP; Henshall, DC				Shinoda, S; Skradski, SL; Araki, T; Schindler, CK; Meller, R; Lan, JQ; Taki, W; Simon, RP; Henshall, DC			Formation of a tumour necrosis factor receptor 1 molecular scaffolding complex and activation of apoptosis signal-regulating kinase 1 during seizure-induced neuronal death	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						14-3-3; epilepsy; Fas; MAP kinase; neurodegeneration; rat; TNF	KAINATE-INDUCED SEIZURES; TRAUMATIC BRAIN INJURY; EVOKED LIMBIC SEIZURES; SPINAL-CORD INJURY; ADULT-RAT BRAIN; CELL-DEATH; CEREBRAL-ISCHEMIA; TNF-ALPHA; PROTEIN PHOSPHATASE-5; DNA FRAGMENTATION	The consequences of activation of tumour necrosis factor receptor 1 (TNFR1) during neuronal injury remain controversial. The apoptosis signal-regulating kinase 1 (ASK1), a mitogen-activated protein kinase kinase kinase, can mediate cell death downstream of TNFR1. Presently, we examined the formation of the TNFR1 signalling cascade and response of ASK1 during seizure-induced neuronal death. Brief (40 min) seizures were induced in rats by intra-amygdala microinjection of kainic acid, which elicited unilateral hippocampal CA3 neuronal death. Seizures caused a rapid decline in the expression of the silencer of:death domains protein within injured CA3. Coimmunoprecipitation analysis revealed a commensurate assembly of a TNFR1 scaffold complex containing TNFR-associated death domain protein, receptor interacting protein and TNFR-activating factor 2. In addition, recruitment of TNFR-activating factor 2 was likely promoted by Bc110-mediated sequestering of cellular inhibitor of apoptosis protein 2. Apoptosis signal-regulating kinase 1 was sequestered in a complex that contained the molecular chaperone 14-3-3beta and protein phosphatase 5. Seizures triggered its dissociation, and the phosphorylation of the ASK1 substrates, mitogen-activated protein kinase kinase 3/6 and 4. Subsequently, protein phosphatase 5 translocated into the nuclei of degenerating CA3 neurons, while ASK1 colocalized with the adaptor proteins Daxx and TNFR-activating factor2 at the outer membrane of injured CA3 neurons. Neutralizing antibodies to TNFalpha reduced the numbers of DNA damaged cells within the injured hippocampus. These data suggest ASK1 may be involved in the mechanism of seizure-induced neuronal death downstream of a TNFR1 death-signalling complex.	Robert S Dow Neurobiol Labs, Legacy Res, Portland, OR USA; Mie Univ, Sch Med, Dept Neurosurg, Tsu, Mie 514, Japan		Henshall, DC (corresponding author), Robert S Dow Neurobiol Labs, Legacy Res, Portland, OR USA.		Henshall, David/C-3364-2012	Henshall, David/0000-0001-6237-9632	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41935, NS39016] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039016, R01NS041935] Funding Source: NIH RePORTER		Akbar MT, 2001, MOL BRAIN RES, V93, P148, DOI 10.1016/S0169-328X(01)00199-1; Albensi BC, 2000, SYNAPSE, V35, P151; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bahl R, 2001, MOL BRAIN RES, V90, P101, DOI 10.1016/S0169-328X(01)00089-4; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bengzon J, 2002, PROG BRAIN RES, V135, P111; Benn SC, 2002, NEURON, V36, P45, DOI 10.1016/S0896-6273(02)00941-8; Borthwick EB, 2001, FEBS LETT, V491, P279, DOI 10.1016/S0014-5793(01)02177-9; Brisman JL, 2002, BRAIN RES, V933, P50, DOI 10.1016/S0006-8993(02)02304-1; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Charette SJ, 2001, J BIOL CHEM, V276, P36071, DOI 10.1074/jbc.C100340200; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; Dean DA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-6; deBock F, 1996, NEUROREPORT, V7, P1125, DOI 10.1097/00001756-199604260-00004; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 2002, ACTA NEUROPATHOL, V103, P391, DOI 10.1007/s00401-001-0481-9; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Henshall DC, 2002, J NEUROSCI, V22, P8458; Henshall DC, 2000, BRAIN RES, V858, P290, DOI 10.1016/S0006-8993(99)02452-X; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Henshall DC, 2001, NEUROBIOL DIS, V8, P568, DOI 10.1006/nbdi.2001.0415; Henshall DC, 2001, J NEUROCHEM, V77, P886, DOI 10.1046/j.1471-4159.2001.00291.x; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; Hofmann TG, 2001, INT J CANCER, V93, P185, DOI 10.1002/ijc.1316; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jeon SH, 2000, EXP MOL MED, V32, P227, DOI 10.1038/emm.2000.37; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Kanamoto T, 2000, MOL CELL BIOL, V20, P196, DOI 10.1128/MCB.20.1.196-204.2000; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim GM, 2001, J NEUROSCI, V21, P6617, DOI 10.1523/JNEUROSCI.21-17-06617.2001; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Meistrell ME, 1997, SHOCK, V8, P341; Mielke K, 1999, NEUROSCIENCE, V91, P471, DOI 10.1016/S0306-4522(98)00667-8; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nakahara S, 1999, J NEUROPATH EXP NEUR, V58, P442, DOI 10.1097/00005072-199905000-00003; Nawashiro H, 1997, BRAIN RES, V778, P265, DOI 10.1016/S0006-8993(97)00981-5; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Paxinos P., 1997, RAT BRAIN STEREOTAXI; Qiu JH, 2002, J NEUROSCI, V22, P3504; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Tan ZQ, 2001, NEUROREPORT, V12, P1979, DOI 10.1097/00001756-200107030-00040; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041; Yang LB, 2002, J NEUROSCI, V22, P3025, DOI 10.1523/JNEUROSCI.22-08-03025.2002; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yoneda T, 2000, J BIOL CHEM, V275, P11114, DOI 10.1074/jbc.275.15.11114; Yui D, 2001, ONCOGENE, V20, P4317, DOI 10.1038/sj.onc.1204576; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhang QG, 2002, NEUROSCI LETT, V329, P232, DOI 10.1016/S0304-3940(02)00650-X	67	71	74	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	MAY	2003	17	10					2065	2076		10.1046/j.1460-9568.2003.02655.x			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	689FT	WOS:000183481500009	12786973				2022-02-06	
J	Fee, D; Crumbaugh, A; Jacques, T; Herdrich, B; Sewell, D; Auerbach, D; Piaskowski, S; Hart, MN; Sandor, M; Fabry, Z				Fee, D; Crumbaugh, A; Jacques, T; Herdrich, B; Sewell, D; Auerbach, D; Piaskowski, S; Hart, MN; Sandor, M; Fabry, Z			Activated/effector CD4(+) cells exacerbate acute damage in the central nervous system following traumatic injury	JOURNAL OF NEUROIMMUNOLOGY			English	Article						CD4(+) T cells; traumatic injury; aseptic cerebral injury	INFLAMMATORY-BOWEL-DISEASE; AUTOIMMUNE T-CELLS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MICROVESSEL ENDOTHELIAL-CELLS; EXPERIMENTAL BRAIN INJURY; NECROSIS-FACTOR-ALPHA; SPINAL-CORD INJURY; IN-VITRO; MULTIPLE-SCLEROSIS; IMMUNE-RESPONSES	CD4(+) helper T cells (Th) have been demonstrated to participate in the chronic phase of traumatic injury repair in the central nervous system (CNS). Here, we show that CD4(+) T cells can also contribute to the severity of the acute phase of CNS traumatic injury. We compared the area of tissue damage and the level of cellular apoptosis in aseptic cerebral injury (ACI) sites of C57BL/6 wild type and RAG1(-/-) immunodeficient mice. We demonstrate that ACI is attenuated in RAG1(-/-) mice compared to C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(low)CD44(high) activated/effector T cells 24 h prior to ACI into RAG1(-/-) mice resulted in a significantly enhanced acute ACI that was comparable to ACI in the C57BL/6 animals. Adoptive transfer of CD4(+)CD62L(high)CD44(low) naive/non-activated T cells did not increase ACI in the brains of RAG1(-/-) mice. T cell inhibitory agents, cyclosporin A (CsA) and FK506, significantly decreased ACI-induced acute damage in C57BL/6 mice. These results suggest a previously undescribed role for activated/effector CD4(+) T cells in exacerbating ACI-induced acute damage in the CNS and raise a novel possibility for acute treatment of sterile traumatic brain injury. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA		Fabry, Z (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, 1300 Univ Ave,6130 MSC, Madison, WI 53706 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS037570] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037570] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Asensio VC, 1997, J VIROL, V71, P7832, DOI 10.1128/JVI.71.10.7832-7840.1997; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; Bregenholt S, 1998, EUR J IMMUNOL, V28, P379, DOI 10.1002/(SICI)1521-4141(199801)28:01<379::AID-IMMU379>3.0.CO;2-X; Cancilla P A, 1980, Adv Exp Med Biol, V131, P257; CANCILLA PA, 1972, LAB INVEST, V26, P376; CANCILLA PA, 1979, LAB INVEST, V40, P74; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; Chang LK, 2002, J CELL BIOL, V157, P771, DOI 10.1083/jcb.200112130; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Ellison JA, 1999, ANN NY ACAD SCI, V890, P204, DOI 10.1111/j.1749-6632.1999.tb07996.x; FABRY Z, 1993, J IMMUNOL, V151, P38; FABRY Z, 1990, J IMMUNOL, V145, P1099; FABRY Z, 1992, J NEUROIMMUNOL, V36, P1, DOI 10.1016/0165-5728(92)90026-H; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fukuzuka K, 2000, AM J PHYSIOL-REG I, V278, pR1005, DOI 10.1152/ajpregu.2000.278.4.R1005; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; HAWKINS CP, 1990, BRAIN, V113, P365, DOI 10.1093/brain/113.2.365; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Hofstetter HH, 2003, J NEUROIMMUNOL, V134, P25, DOI 10.1016/S0165-5728(02)00358-2; Hornquist CE, 1997, J IMMUNOL, V158, P1068; Huber SA, 2000, CARDIOVASC RES, V45, P579, DOI 10.1016/S0008-6363(99)00267-9; Ikegami M, 2002, J NEUROIMMUNOL, V127, P134, DOI 10.1016/S0165-5728(02)00100-5; Knopf PM, 1998, J IMMUNOL, V161, P692; Lane TE, 2000, J VIROL, V74, P1415, DOI 10.1128/JVI.74.3.1415-1424.2000; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; Markovic-Plese S, 2001, Curr Neurol Neurosci Rep, V1, P257, DOI 10.1007/s11910-001-0028-4; Matyszak MK, 1998, PROG NEUROBIOL, V56, P19, DOI 10.1016/S0301-0082(98)00014-8; MCLAURIN J, 1995, INT J DEV NEUROSCI, V13, P369, DOI 10.1016/0736-5748(95)00012-6; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 2000, J NEUROIMMUNOL, V106, P189, DOI 10.1016/S0165-5728(00)00240-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207, DOI 10.1096/fasebj.13.10.1207; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrissey SP, 1996, BRAIN, V119, P239, DOI 10.1093/brain/119.1.239; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Ohminami H, 1999, BLOOD, V93, P925, DOI 10.1182/blood.V93.3.925.403k32_925_935; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; Qing Z, 2000, J NEUROIMMUNOL, V105, P169, DOI 10.1016/S0165-5728(99)00265-9; Qing Z, 2001, J NEUROPATH EXP NEUR, V60, P798, DOI 10.1093/jnen/60.8.798; Raghupathi R, 1998, J NEUROTRAUM, V15, P555, DOI 10.1089/neu.1998.15.555; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reiss Y, 1999, INT IMMUNOL, V11, P1527, DOI 10.1093/intimm/11.9.1527; Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756-3282(01)00682-2; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Silver N, 1999, J NEUROL, V246, P728, DOI 10.1007/s004150050442; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werring DJ, 2000, BRAIN, V123, P1667, DOI 10.1093/brain/123.8.1667	57	71	73	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR	2003	136	1-2					54	66		10.1016/S0165-5728(03)00008-0			13	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	660PC	WOS:000181840700007	12620643				2022-02-06	
J	Vickers, JC; Craig, JE; Stankovich, J; McCormack, GH; West, AK; Dickinson, JL; McCartney, PJ; Coote, MA; Healey, DL; Mackey, DA				Vickers, JC; Craig, JE; Stankovich, J; McCormack, GH; West, AK; Dickinson, JL; McCartney, PJ; Coote, MA; Healey, DL; Mackey, DA			The apolipoprotein epsilon 4 gene is associated with elevated risk of normal tension glaucoma	MOLECULAR VISION			English	Article							RETINAL GANGLION-CELLS; TRAUMATIC BRAIN INJURY; ALZHEIMERS-DISEASE; OPTIC-NERVE; MACULAR DEGENERATION; NEURONAL DEGENERATION; MULTIPLE-SCLEROSIS; FAMILY HISTORY; ALLELE; PATHOLOGY	PURPOSE: Inheritance of a particular apolipoprotein E gene polymorphism, the epsilon4 allele, has been associated with elevated risk for Alzheimer's disease and a poor outcome following head injury. The neuronal injury associated with Alzheimer's disease and brain injury may have a number of similarities with the nerve cell changes associated with glaucoma. Thus, we have investigated the association of inheritance of apolipoprotein E allelic isoforms (epsilon2, epsilon3, and epsilon4) with relative risk for different forms of glaucoma. METHODS: Apolipoprotein E genotype was examined in a Tasmanian population sample comprised of glaucoma sufferers with elevated or normal intraocular pressure and compared to a control sample of elderly Tasmanians without glaucoma. RESULTS: Approximately twice as many normal tension (38.0%) and high tension (34.2%) glaucoma cases possessed an epsilon4 allele compared to control cases (18.9%). The odds of epsilon4 carriers having normal tension glaucoma were significantly greater than for epsilon3 homozygotes (odds ratio 2.45, 95% confidence interval {1.02-5.91}) even after adjusting for age and gender (odd ratio 2.87 {1.02-8.05}). The increased odds of high tension glaucoma among epsilon4 allele carriers were not significant (adjusted odds ratio 1.53 {0.64-3.68}). CONCLUSIONS: The data indicate that, in the Tasmanian population, inheritance of the epsilon4 allele is associated with elevated risk for glaucomatous changes that are not related to increased intraocular pressure.	Univ Tasmania, Sch Med, Hobart, Tas 7001, Australia; Flinders Med Ctr, Dept Ophthalmol, Bedford Pk, SA, Australia; Menzies Res Inst, Hobart, Tas, Australia; Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia		Vickers, JC (corresponding author), Univ Tasmania, Sch Med, GPO Box 252-29, Hobart, Tas 7001, Australia.		Vickers, James C/J-7464-2014; Mackey, David A/H-5340-2014; Dickinson, Joanne/J-7728-2014; West, Adrian/AAR-8857-2021	Vickers, James C/0000-0001-5671-4879; Mackey, David A/0000-0001-7914-4709; Craig, Jamie/0000-0001-9955-9696; Dickinson, Joanne/0000-0003-4621-1703; Stankovich, Jim/0000-0001-9344-7749			Agresti A., 1990, CATEGORICAL DATA ANA; Amaratunga A, 1996, J BIOL CHEM, V271, P5628, DOI 10.1074/jbc.271.10.5628; Aung T, 2002, HUM GENET, V110, P52, DOI 10.1007/s00439-001-0645-7; Bayer AU, 2002, AM J OPHTHALMOL, V133, P135, DOI 10.1016/S0002-9394(01)01196-5; Chapman J, 1999, ARCH NEUROL-CHICAGO, V56, P1484, DOI 10.1001/archneur.56.12.1484; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Craig JE, 2001, OPHTHALMOLOGY, V108, P1607, DOI 10.1016/S0161-6420(01)00654-6; CURCIO CA, 1993, ANN NEUROL, V33, P248, DOI 10.1002/ana.410330305; DAVIES DC, 1995, BRIT J OPHTHALMOL, V79, P596, DOI 10.1136/bjo.79.6.596; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Evangelou N, 1999, J NEUROL NEUROSUR PS, V67, P203, DOI 10.1136/jnnp.67.2.203; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HINTON DR, 1986, NEW ENGL J MED, V315, P485, DOI 10.1056/NEJM198608213150804; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901; Kuhrt H, 1997, J BRAIN RES, V38, P223; LEUBA G, 1995, NEUROPATH APPL NEURO, V21, P410, DOI 10.1111/j.1365-2990.1995.tb01078.x; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; McNaught AI, 2000, ARCH OPHTHALMOL-CHIC, V118, P900; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; QUIGLEY HA, 1995, AUST NZ J OPHTHALMOL, V23, P85, DOI 10.1111/j.1442-9071.1995.tb00135.x; REBECK GW, 1993, NEURON, V11, P575; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Sack J, 1996, OPHTHALMIC GENET, V17, P209, DOI 10.3109/13816819609057895; SADUN AA, 1990, OPHTHALMOLOGY, V97, P9; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; Schmidt S, 2000, MOL VIS, V6, P287; Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TRICK GL, 1989, ANN NEUROL, V26, P226, DOI 10.1002/ana.410260208; TSAI CS, 1991, ARCH OPHTHALMOL-CHIC, V109, P199, DOI 10.1001/archopht.1991.01080020045040; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; VICKERS JC, 1995, BRAIN RES, V680, P23, DOI 10.1016/0006-8993(95)00211-8; Vickers JC, 1997, AUST NZ J OPHTHALMOL, V25, P105, DOI 10.1111/j.1442-9071.1997.tb01290.x; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C	40	71	73	0	5	MOLECULAR VISION	ATLANTA	C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E, ATLANTA, GA 30322 USA	1090-0535			MOL VIS	Mol. Vis.	OCT 14	2002	8	40					389	393					5	Biochemistry & Molecular Biology; Ophthalmology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Ophthalmology	604EC	WOS:000178602300001	12379839				2022-02-06	
J	Walhovd, KB; Fjell, AM				Walhovd, KB; Fjell, AM			One-year test-retest reliability of auditory ERPs in young and old adults	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						ERP; P3; reliability; life-span; aging; waveform-measures	EVENT-RELATED POTENTIALS; CLOSED-HEAD INJURY; REACTION-TIME; BRAIN POTENTIALS; ELDERLY SUBJECTS; P300; VARIABILITY; UTILITY; PERFORMANCE; COMPONENTS	The reliability of ERP measures was investigated in a sample covering the adult life span (n = 59, age 21-92). This sample was divided into a young and an old group. ERPs to an auditory two-stimuli oddball task were recorded in the sample at two occasions separated by 12-14 months (T1 and T2). The recordings of T1 were split in half, to assess within session reliability. Correlations were calculated for N1, P2 and P3 peak latency and amplitude, for average amplitude during 50 ms epochs within the defined P3-window 250-550, and for average amplitude in successive 15 ms epochs from I to 705 ms. The results show that amplitude measures were more reliable than the latency measures at all electrodes. Time window/epoch amplitude measures yielded reliabilities in the same range as peak amplitude. Reliabilities peaked around the conventionally studied N1, P2 and P3, and this is seen as a validation of the components. In general, the old group exhibited weaker P3 peak latency reliabilities than the young group. However, many of these differences did not reach statistical significance. Implications of the findings are discussed. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Oslo, Inst Psychol, N-0317 Oslo, Norway; Ulleval Univ Hosp, Dept Neuropsychol, N-0407 Oslo, Norway		Walhovd, KB (corresponding author), Univ Oslo, Inst Psychol, POB 1094, N-0317 Oslo, Norway.						Anderer P, 1996, ELECTROEN CLIN NEURO, V99, P458, DOI 10.1016/S0013-4694(96)96518-9; Anstey KJ, 1999, AGING NEUROPSYCHOL C, V6, P84, DOI 10.1076/anec.6.2.84.786; Clark-Carter D., 1997, DOING QUANTITATIVE P; Fabiani M., 1987, ADV PSYCHOPHYSIOLOGY, V2, P1; Fjell AM, 2001, BRAIN TOPOGR, V14, P25, DOI 10.1023/A:1012563605837; GEISLER MW, 1992, PSYCHOPHYSIOLOGY, V29, P86, DOI 10.1111/j.1469-8986.1992.tb02019.x; GOODIN DS, 1978, ELECTROEN CLIN NEURO, V44, P447, DOI 10.1016/0013-4694(78)90029-9; GOODIN DS, 1978, BRAIN, V101, P635, DOI 10.1093/brain/101.4.635; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; IRAGUI VJ, 1993, PSYCHOPHYSIOLOGY, V30, P10, DOI 10.1111/j.1469-8986.1993.tb03200.x; Kinoshita S, 1996, PHYSIOL BEHAV, V60, P1087, DOI 10.1016/0031-9384(96)00130-8; Kok A, 2001, PSYCHOPHYSIOLOGY, V38, P557, DOI 10.1017/S0048577201990559; Maeda H, 1995, PSYCHIAT CLIN NEUROS, V49, P281, DOI 10.1111/j.1440-1819.1995.tb01902.x; PAPALIA DE, 1996, ADULT DEV AGING; PFEFFERBAUM A, 1984, ELECTROEN CLIN NEURO, V59, P85, DOI 10.1016/0168-5597(84)90026-1; Polich J, 1996, PSYCHOPHYSIOLOGY, V33, P334, DOI 10.1111/j.1469-8986.1996.tb01058.x; POLICH J, 1990, ELECTROEN CLIN NEURO, V77, P179, DOI 10.1016/0168-5597(90)90036-D; Polich J, 2000, INT J PSYCHOPHYSIOL, V38, P3, DOI 10.1016/S0167-8760(00)00127-6; Polich J, 1986, ELECTROEN CLIN NEURO, V65, P665; Pratt H, 2000, CLIN NEUROPHYSIOL, V111, P1425, DOI 10.1016/S1388-2457(00)00344-8; Sandman CA, 2000, CLIN NEUROPHYSIOL, V111, P1427, DOI 10.1016/S1388-2457(00)00320-5; SEGALOWITZ SJ, 1993, PSYCHOPHYSIOLOGY, V30, P451, DOI 10.1111/j.1469-8986.1993.tb02068.x; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Shammi P, 1998, AGING NEUROPSYCHOL C, V5, P1, DOI 10.1076/anec.5.1.1.23; Solbakk AK, 2000, J CLIN EXP NEUROPSYC, V22, P743, DOI 10.1076/jcen.22.6.743.953; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; VESCO KK, 1993, ELECTROEN CLIN NEURO, V88, P302, DOI 10.1016/0168-5597(93)90054-S; Walhovd KB, 2001, NEUROREPORT, V12, P3149, DOI 10.1097/00001756-200110080-00033; Wechsler D., 2011, WECHSLER ABBREVIATED; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924	31	71	73	0	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760			INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2002	46	1					29	40	PII S0167-8760(02)00039-9	10.1016/S0167-8760(02)00039-9			12	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology; Physiology	601WP	WOS:000178472000003	12374644				2022-02-06	
J	Rousselet, E; Callebert, J; Parain, K; Joubert, C; Hunot, S; Hartmann, A; Jacque, C; Perez-Diaz, F; Cohen-Salmon, C; Launay, JM; Hirsch, EC				Rousselet, E; Callebert, J; Parain, K; Joubert, C; Hunot, S; Hartmann, A; Jacque, C; Perez-Diaz, F; Cohen-Salmon, C; Launay, JM; Hirsch, EC			Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP	EXPERIMENTAL NEUROLOGY			English	Article						Parkinson's disease; MPTP; TNF-alpha; inflammation; behavior; neuroprotection	TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; VENTRICULAR CEREBROSPINAL-FLUID; GROWTH-FACTOR-ALPHA; CLOSED-HEAD INJURY; BRAIN INJURY; IN-VITRO; DOPAMINERGIC-NEURONS; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MPTP; PROLONGED ACTIVATION	The loss of dopaminergic neurons in Parkinson's disease is associated with a glial reaction and the overproduction of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha). TNF-alpha acts via two different receptors, TNFR1 and TNFR2, and is believed to have both a neuroprotective and a deleterious role for neurons. In order to analyze the putative role of TNF-a in parkinsonism, we compared the effect of the parkinsonian drug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice lacking TNFR1, TNFR2, or both receptors and in wild-type littermates. We show that MPTP does not affect spontaneous activity or anxiety in any of the groups and that it reduces motor activity on a rotarod in double knock out mice but not in mice lacking only one receptor. Postmortem analysis revealed no differences in the number of nigral dopaminergic neurons whatever the group. In contrast, striatal dopamine level was slightly decreased in double knock-out mice and more reduced by MPTP in this group than in the other groups of mice. In addition, dopamine turnover was significantly more increased in double knock out mice after MPTP injection. These data suggest that TNF-a does not participate in the death of dopaminergic neurons in parkinsonism but that it slightly alters dopamine metabolism or the survival of dopaminergic terminals by a mechanism involving both receptors. (C) 2002 Elsevier Science (USA).	Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Hop La Pitie Salpetriere, CNRS, UMR 7593, F-75013 Paris, France; Hop La Pitie Salpetriere, INSERM, U495, F-75013 Paris, France; Hop La Pitie Salpetriere, IFR Neurosci, F-75013 Paris, France; Hop Lariboisiere, Serv Biochim, CR C Bernard, IFR6,AP HP, F-75010 Paris, France		Rousselet, E (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France.		Hirsch, Etienne/AAC-7655-2019; callebert, jacques/L-4569-2017; Hunot, Stephane/ABE-4204-2021	Hirsch, Etienne/0000-0003-4823-276X; Hunot, Stephane/0000-0002-8266-5211			Akaneya Y, 1995, BRAIN RES, V704, P175, DOI 10.1016/0006-8993(95)01110-2; Aloe L, 1997, NEUROSCI LETT, V238, P65, DOI 10.1016/S0304-3940(97)00850-1; Appel E, 1997, NEUROREPORT, V8, P3309, DOI 10.1097/00001756-199710200-00023; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; BOLIN LM, 2001, SOC NEUR ABSTR; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bruce-Keller AJ, 1999, J NEUROIMMUNOL, V93, P53, DOI 10.1016/S0165-5728(98)00190-8; CAMBI F, 1989, J NEUROCHEM, V53, P1656, DOI 10.1111/j.1471-4159.1989.tb08567.x; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Cho I, 1999, NAT TOXINS, V7, P187, DOI 10.1002/1522-7189(200009/10)7:5<187::AID-NT58>3.0.CO;2-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Damier P, 1999, BRAIN, V122, P1421, DOI 10.1093/brain/122.8.1421; Declercq W, 1998, J IMMUNOL, V161, P390; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Elliott JL, 2001, MOL BRAIN RES, V95, P172, DOI 10.1016/S0169-328X(01)00242-X; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FORNO LS, 1992, PROG BRAIN RES, V94, P429; GAMACHE P, 1993, J CHROMATOGR-BIOMED, V614, P213, DOI 10.1016/0378-4347(93)80311-Q; Grell M, 1998, EUR J IMMUNOL, V28, P257, DOI 10.1002/(SICI)1521-4141(199801)28:01<257::AID-IMMU257>3.0.CO;2-G; Guo GJ, 2001, AM J PHYSIOL-RENAL, V280, pF777, DOI 10.1152/ajprenal.2001.280.5.F777; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; Hamre K, 1999, BRAIN RES, V828, P91, DOI 10.1016/S0006-8993(99)01273-1; Hirsch E C, 1999, Adv Neurol, V80, P9; HOFMAN FM, 1989, J EXP MED, V170, P607, DOI 10.1084/jem.170.2.607; HOSKINS JA, 1989, NEUROPHARMACOLOGY, V28, P1389, DOI 10.1016/0028-3908(89)90015-4; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jarskog LF, 1997, INT J DEV NEUROSCI, V15, P711, DOI 10.1016/S0736-5748(97)00029-4; Kalb A, 1996, J BIOL CHEM, V271, P28097, DOI 10.1074/jbc.271.45.28097; Krajcsi P, 1998, SEMIN CELL DEV BIOL, V9, P351, DOI 10.1006/scdb.1998.0244; Kurkowska-Jastrzebska I, 1999, ACTA NEUROBIOL EXP, V59, P1; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Lucas R, 1998, EUR J IMMUNOL, V28, P3577, DOI 10.1002/(SICI)1521-4141(199811)28:11<3577::AID-IMMU3577>3.0.CO;2-#; MACKAY F, 1994, J IMMUNOL, V153, P5274; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCGEER PL, 1993, GLIA, V7, P84, DOI 10.1002/glia.440070114; McGuire SO, 2001, EXP NEUROL, V169, P219, DOI 10.1006/exnr.2001.7688; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mogi M, 1996, NEUROSCI LETT, V211, P13, DOI 10.1016/0304-3940(96)12706-3; Mogi M, 1998, NEUROSCI LETT, V250, P25, DOI 10.1016/S0304-3940(98)00427-3; MOGI M, 1994, NEUROSCI LETT, V180, P147, DOI 10.1016/0304-3940(94)90508-8; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Mogi M, 1999, NEUROSCI LETT, V268, P101, DOI 10.1016/S0304-3940(99)00388-2; MOGI M, 1995, NEUROSCI LETT, V193, P129, DOI 10.1016/0304-3940(95)11686-Q; MOGI M, 1995, J NEURAL TRANSM-PARK, V9, P87, DOI 10.1007/BF02252965; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nuovo GJ, 1996, MOL MED, V2, P358, DOI 10.1007/BF03401633; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; Rozas G, 1997, BRAIN RES, V749, P188, DOI 10.1016/S0006-8993(96)01162-6; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; Shinpo K, 1999, BRAIN RES, V819, P170, DOI 10.1016/S0006-8993(98)01354-7; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SRIRAM K, 2001, SOC NEUR ABSTR; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TCHELINGERIAN JL, 1995, J NEUROCHEM, V65, P2377; Tomimoto H, 1996, ACTA NEUROPATHOL, V92, P281, DOI 10.1007/s004010050519; VONCOELLN R, 1995, DEV BRAIN RES, V89, P150, DOI 10.1016/0165-3806(95)00123-U; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; Wilde GJC, 2000, EUR J NEUROSCI, V12, P3863, DOI 10.1046/j.1460-9568.2000.00273.x; WILT SG, 1995, ANN NEUROL, V37, P381, DOI 10.1002/ana.410370315; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; Yamada Y, 1998, AM J PATHOL, V152, P1577	82	71	76	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2002	177	1					183	192		10.1006/exnr.2002.7960			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	598EY	WOS:000178263600017	12429221				2022-02-06	
J	Paniak, C; Reynolds, S; Phillips, K; Toller-Lobe, G; Melnyk, A; Nagy, J				Paniak, C; Reynolds, S; Phillips, K; Toller-Lobe, G; Melnyk, A; Nagy, J			Patient complaints within 1 month of mild traumatic brain injury: A controlled study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						mild traumatic brain injury	POST-CONCUSSION SYMPTOMS; MINOR HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RANDOMIZED-TRIAL; LONG	Symptom complaints of 118 patients with mild traumatic brain injury (MTBI), within I month postinjury, were compared with those of 118 control participants without a MTBI. The MTBI and control subjects were group-matched on age, gender, socioeconomic status (SES), and education status. Differences in symptom endorsements and severity ratings were found between the groups, with 16 of the 43 queried symptoms endorsed significantly more often (Bonferroni-corrected P < .00116) by MTBI patients than by controls. A total of 23 of the 43 symptoms were endorsed at a significantly higher severity by MTBI patients. The MTBI sample showed significantly higher within-group variability, with severity ranging from minimal to high. Perhaps because of this high variability, a logistic regression used to discriminate MTBI patients from controls was only moderately successful. This indicates that subjective complaints probably cannot be used, even soon after injury, to decisively distinguish individual MTBI patients from uninjured persons. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Science Ltd.	Glenrose Rehabil Hosp, Dept Psychol, Edmonton, AB T5G 0B7, Canada; Univ Alberta, Edmonton, AB, Canada		Paniak, C (corresponding author), Glenrose Rehabil Hosp, Dept Psychol, 10230-111 Ave, Edmonton, AB T5G 0B7, Canada.	cpaniak@cha.ab.ca					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BLISHEN BR, 1987, CAN REV SOC ANTHROP, V24, P465; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Gasquoine PG, 1997, NEUROPSYCHOL REV, V7, P77, DOI 10.1023/B:NERV.0000005945.58251.c0; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUAS JF, 1989, MILD HEAD INJURY, P8; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Paniak C, 2000, BRAIN INJURY, V14, P219; PANIAK C, 1992, DISS ABSTR INT, V52, P6093; PANIAK CE, 1992, ARCH CLIN NEUROPSYCH, V7, P529, DOI 10.1016/0887-6177(92)90143-B; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; YOUNG RP, 1995, STUD AM POLIT DEV, V9, P1, DOI 10.1017/S0898588X00001164	37	71	71	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2002	17	4					319	334	PII S0887-6177(01)00115-9	10.1016/S0887-6177(01)00115-9			16	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	556DW	WOS:000175834900002	14589717	Bronze			2022-02-06	
J	Liu, WF; Wang, GP; Yakovlev, AG				Liu, WF; Wang, GP; Yakovlev, AG			Identification and functional analysis of the rat caspase-3 gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; EMBRYONIC CORTICAL-NEURONS; CEREBELLAR GRANULE CELLS; TRAUMATIC BRAIN INJURY; CEREBRAL-ISCHEMIA; INDUCED APOPTOSIS; ACTIVATION; EXPRESSION; INHIBITION; TRANSCRIPTION	Caspase-3 is the major effector in apoptosis triggered by various stimuli. Previous studies demonstrated a significant increase in transcriptional activity of the caspase-3 gene during neuronal apoptosis. Recent findings suggest that differential expression of the caspase-3 gene may underlie the regulation of apoptotic susceptibility during brain development and after acute injury to the mature brain. We identified and cloned the rat caspase-3 gene promoter, determined its structure, and examined its regulation during a course of apoptosis in PC 12 cells. Results demonstrate that this promoter lacks a TATA-box and contains a cluster of Sp1 elements and multiple transcription start sites. The first identified transcription start site is located 87-bp upstream from the first splicing site. A role of Sp1 elements in the regulation of caspase-3 promoter activity is demonstrated by the inhibition of Sp1 binding using mithramycin A. Results of deletion analysis show that an Ets-1-like element located between nucleotides -1646 and -1632 relative to the most extended transcription start site is necessary to achieve sustained transcriptional activity. Homology analysis revealed that the 5'-flanking region of the human caspase-3 gene exhibits significant similarity to a regulatory region of the rat gene.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA		Yakovlev, AG (corresponding author), Georgetown Univ, Dept Neurosci, Res Bldg,WP14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	yakovlev@giccs.georgetown.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS38941] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038941] Funding Source: NIH RePORTER		Allen JW, 1999, FASEB J, V13, P1875, DOI 10.1096/fasebj.13.13.1875; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Chatterjee S, 2001, ANN NEUROL, V49, P345, DOI 10.1002/ana.71; Chen J, 1998, J NEUROSCI, V18, P4914; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; de Nigris F, 2001, CANCER RES, V61, P2267; Earle E, 2000, HUM MOL GENET, V9, P187, DOI 10.1093/hmg/9.2.187; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; Esch F, 1998, J NEUROSCI, V18, P4083; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Gottron FJ, 1997, MOL CELL NEUROSCI, V9, P159, DOI 10.1006/mcne.1997.0618; Harrison DC, 2000, MOL BRAIN RES, V75, P143, DOI 10.1016/S0169-328X(99)00305-8; Haviv R, 1997, J NEUROSCI RES, V50, P69, DOI 10.1002/(SICI)1097-4547(19971001)50:1<69::AID-JNR8>3.0.CO;2-J; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; JOHNSON EM, 1993, ANNU REV NEUROSCI, V16, P31, DOI 10.1146/annurev.ne.16.030193.000335; Kermer P, 1998, J NEUROSCI, V18, P4656; Kobayashi D, 2000, INT J HYPERTHER, V16, P471, DOI 10.1080/02656730050199322; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Maroulakou IG, 2000, ONCOGENE, V19, P6432, DOI 10.1038/sj.onc.1204039; Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205; Moran J, 1999, J NEUROCHEM, V73, P568, DOI 10.1046/j.1471-4159.1999.0730568.x; Namura S, 1998, J NEUROSCI, V18, P3659; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; OWENS GP, 1992, CANCER METAST REV, V11, P149, DOI 10.1007/BF00048061; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; RATAN RR, 1994, J NEUROCHEM, V62, P376; RATAN RR, 1994, J NEUROSCI, V14, P4385; Sanij E, 2001, BIOCHEM BIOPH RES CO, V287, P1003, DOI 10.1006/bbrc.2001.5680; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Teruyama K, 2001, J CELL PHYSIOL, V188, P243, DOI 10.1002/jcp.1112; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; YAKOVLEV AG, 1995, J BIOL CHEM, V270, P6421, DOI 10.1074/jbc.270.12.6421; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamada T, 2001, BLOOD, V97, P2300, DOI 10.1182/blood.V97.8.2300	45	71	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					8273	8278		10.1074/jbc.M110768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	WOS:000174268000084	11773055	hybrid			2022-02-06	
J	Bazarian, JJ; Atabaki, S				Bazarian, JJ; Atabaki, S			Predicting postconcussion syndrome after minor traumatic brain injury	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting	MAY, 2000	SAN FRANCISCO, CA	SAEM		traumatic brain injury; brain concussion; postconcussion syndrome; logistic regression; recursive partitioning; decision rule	HEAD-INJURY; SYMPTOMS; SEQUELAE; RULES	Background: Up to 50% of patients with minor traumatic brain injury (mTBI) develop postconcussion syndrome (PCS). A decision rule to stratify risk for PCS is needed. Objective: To identify mTBI patients at low and high risk of PCS by comparing the predictive values of variables generated by logistic regression (LR) and recursive partitioning (RP). Methods: This was a prospective, observational study of 69 mTBI patients aged > 16 years presenting to the emergency department of a university teaching hospital. Minor TBI was defined as loss of consciousness < 10 minutes or amnesia, Glasgow Coma Scale score (GCS) of 15, no skull fracture on physical examination, nonfocal neurologic exam, and no brain injury on computed tomography if one was done. Clinical/demographic data and the results of a brief neurobehavioral test battery were collected for all patients. The presence of PCS was determined by a validated telephone questionnaire at one month after initial presentation. All variables were subjected to both LR and RP. Results: Fifty-eight percent had PCS at one month after initial presentation. Low risk: PCS occurred in 9% of men scoring > 24 on the Hopkins Verbal Learning A (HVLA) (by LR) and in 9% of those injured in sports scoring > 22 on HVLA (RP). High risk: PCS occurred in 89% of women scoring <9 on the Digit Span test (LR) and in 92% of those injured via falls or motor vehicle collision scoring < 11.5 on HVLB2 (RP). Conclusions: Despite the high incidence of PCS, we were able to identify a low-risk subgroup with an average PCS risk of < 10% and a high-risk subgroup with a PCS risk of similar to 90%. Combining results from LR and RP expanded the number of patients able to be classified as high/low risk. Prospective validation is necessary.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; George Washington Univ, Sch Med, Washington, DC USA; Childrens Natl Med Ctr, Dept Emergency Med, Washington, DC 20010 USA		Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 655,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu					*AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; Breiman L., 1984, CLASSIFICATION REGRE; COOK EF, 1984, J CHRON DIS, V37, P721, DOI 10.1016/0021-9681(84)90041-9; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; Hadzikadic M, 1996, ARTIF INTELL MED, V8, P493, DOI 10.1016/S0933-3657(96)00356-9; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; MCCONNOCHIE KM, 1993, MED DECIS MAKING, V13, P30, DOI 10.1177/0272989X9301300105; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAUBERTAS RF, 1994, MED DECIS MAKING, V14, P169, DOI 10.1177/0272989X9401400209; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Tsien CL, 1998, ST HEAL T, V52, P493; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; Zafonte RD, 1997, ARCH PHYS MED REHAB, V78, P1103, DOI 10.1016/S0003-9993(97)90135-0	28	71	71	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	AUG	2001	8	8					788	795		10.1111/j.1553-2712.2001.tb00208.x			8	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Emergency Medicine	459VR	WOS:000170272600003	11483453				2022-02-06	
J	Bain, AC; Raghupathi, R; Meaney, DF				Bain, AC; Raghupathi, R; Meaney, DF			Dynamic stretch correlates to both morphological abnormalities and electrophysiological impairment in a model of traumatic axonal injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomechanics; injury tolerance; stretch injury; head injury	VISUAL EVOKED-POTENTIALS; RAT OPTIC-NERVE; HEAD-INJURY; NEUROFILAMENT SUBUNITS; BRAIN; HUMANS; DAMAGE; RESPONSES; CRUSH; APP	In this investigation, the relationships between stretch and both morphological and electrophysiological signs of axonal injury were examined in the guinea pig optic nerve stretch model. Additionally, the relationship between axonal morphology and electrophysiological impairment was assessed. Axonal injury was produced in vivo by elongating the guinea pig optic nerve between 0 and 8 mm (N-total = 70). Morphological damage was detected using neurofilament immunohistochemistry (SMI 32). Electrophysiological impairment was determined using changes in visual evoked potentials (VEPs) measured prior to injury, every 5 min for 40 min following injury, and at sacrifice (72 h). All nerves subjected to ocular displacements greater than 6 mm demonstrated axonal swellings and retraction bulbs, while nerves subjected to displacements below 4 mm did not show any signs of morphological injury. Planned comparisons of latency shifts of the N-35 peak in the VEPs showed that ocular displacements greater than 5 mm produced electrophysiological impairment that was significantly different from sham animals. Logit analysis demonstrated that less stretch was required to elicit electrophysiological changes (5.5 mm) than morphological signs of damage (6.8 mm). Moreover, Student t tests indicated that the mean latency shift measured in animals exhibiting morphological injury was significantly greater than that calculated from animals lacking morphological injury (p < 0.01). These data show that distinct mechanical thresholds exist for both morphological and electrophysiological damage to the white matter. In a larger context, the distinct injury thresholds presented in the report will aid in the biomechanical assessment of animate models of head injury, as well as assist in extending these findings to predict the conditions that cause white matter injury in humans.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA		Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 3320 Smith Walk, Philadelphia, PA 19104 USA.			Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35712, P50-NS09903] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR312712] Funding Source: Medline		Adams J H, 1981, Acta Neuropathol Suppl, V7, P26; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Altman D.G., 1990, PRACTICAL STAT MED R; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CONNELL FA, 1985, AM J EPIDEMIOL, V121, P744; CREEL DJ, 1972, EXP NEUROL, V36, P411, DOI 10.1016/0014-4886(72)90002-7; CREEL DJ, 1973, EXP NEUROL, V40, P351, DOI 10.1016/0014-4886(73)90079-4; DUCATI A, 1988, ELECTROEN CLIN NEURO, V71, P89, DOI 10.1016/0168-5597(88)90010-X; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Einstein AJ, 1997, ARCH PATHOL LAB MED, V121, P110; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1989, HISTOCHEMISTRY, V92, P355, DOI 10.1007/BF00500553; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HARDING GFA, 1984, OPHTHAL PHYSL OPT, V4, P293; Heshner D., 1981, APPL DISCRETE CHOICE; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; KAWARABAYASHI T, 1993, NEUROSCI LETT, V153, P73, DOI 10.1016/0304-3940(93)90080-5; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; MAHAPATRA AK, 1989, SURG NEUROL, V31, P339, DOI 10.1016/0090-3019(89)90064-5; MASLIAH E, 1993, AM J PATHOL, V142, P871; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1999, J NEUROTRAUM, V16, P1225, DOI 10.1089/neu.1999.16.1225; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRICE DL, 1990, PROG BRAIN RES, V86, P297; ROSENE DL, 1978, J HISTOCHEM CYTOCHEM, V26, P28, DOI 10.1177/26.1.413864; ROSENFELD J, 1987, J NEUROPATH EXP NEUR, V46, P269, DOI 10.1097/00005072-198705000-00004; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; SABEL BA, 1993, NEUROPSYCHOBIOLOGY, V28, P62, DOI 10.1159/000119001; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOKOL S, 1976, Survey of Ophthalmology, V21, P18, DOI 10.1016/0039-6257(76)90046-1; Steinberg D., 1991, LOGIT SUPPLEMENTARY; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; SUGIOKA M, 1995, EXP NEUROL, V132, P262, DOI 10.1016/0014-4886(95)90031-4; SUZUKI M, 1991, J VET MED SCI, V53, P301, DOI 10.1292/jvms.53.301; SUZUKI M, 1991, J VET MED SCI, V53, P911, DOI 10.1292/jvms.53.911; TOMEI G, 1990, ACTA NEUROPATHOL, V80, P506, DOI 10.1007/BF00294611; TROJANOWSKI JQ, 1983, BRAIN RES, V267, P365, DOI 10.1016/0006-8993(83)90891-0; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; WALSH C, 1986, J NEUROSCI, V6, P1635; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	50	71	74	1	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2001	18	5					499	511		10.1089/089771501300227305			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	435CN	WOS:000168860000003	11393253				2022-02-06	
J	Rancan, M; Otto, VI; Hans, VHJ; Gerlach, I; Jork, R; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Rancan, M; Otto, VI; Hans, VHJ; Gerlach, I; Jork, R; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Upregulation of ICAM-1 and MCP-1 but not of MIP-2 and sensorimotor deficit in response to traumatic axonal injury in rats	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						traumatic brain injury; axonal injury; impact acceleration model; inflammation; sensorimotor deficit	CONTROLLED CORTICAL IMPACT; ADHESION MOLECULE-1 ICAM-1; MESSENGER-RNA EXPRESSION; CENTRAL-NERVOUS-SYSTEM; DIFFUSE BRAIN INJURY; CLOSED-HEAD INJURY; ENDOTHELIAL-CELLS; NEUTROPHIL ACCUMULATION; CEREBROSPINAL-FLUID; COGNITIVE DEFICITS	The pathophysiology of traumatic axonal injury (TAI) is only partially understood. In this study, we investigated the inflammatory response as well as the extent of neurological deficit in a rat model of traumatic brain injury (TBI). Forty-two adult rats were subjected to moderate impact-acceleration brain injury and their brains were analyzed immunohistochemically for ICAM-1 expression and neutrophil infiltration from 1 hr up to 14 days after trauma. In addition, the chemotactic factors MIP-2 and MCP-1 were measured in brain homogenates by ELISA. For evaluating the neurological deficit, three sensorimotor tests were applied for the first time in this model. In the first 24 hr after trauma, the number of ICAM-1 positive vessels increased up to 4-fold in cortical and subcortical regions compared with sham operated controls (P < 0.05). Maximal ICAM-1 expression (up to 8-fold increase) was detected after 4 days (P < 0.001 vs, 24 hr), returning to control levels in all brain regions by 7 days after trauma. MCP-1 was elevated between 4 hr and 16 hr post-injury as compared with controls. In contrast, neither neutrophil infiltration nor elevation of MIP-2, both events relevant in focal brain injury, could be detected. In all neurological tests, a significant deficit was observed in traumatized rats as compared with sham operated animals from Day 1 post-injury (grasping reflex of the hindpaws: P < 0.001, vibrissae-evoked forelimb placing: P = 0.002, lateral stepping: P = 0.037). In conclusion, after moderate impact acceleration brain injury ICAM-1 upregulation has been demonstrated in the absence of neutrophil infiltration and is paralleled by a selective induction of chemokines, pointing out that individual and distinct inflammatory events occur after diffuse vs, focal TBI. (C) 2001 Wiley-Liss, Inc.	Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Hosp Bonn, Inst Neuropathol, Bonn, Germany; Bayer AG, CNS Res, Pharma Res Ctr, Wuppertal, Germany		Morganti-Kossmann, MC (corresponding author), Univ Zurich Hosp, Dept Surg, Div Res, Ramistr 100, CH-8091 Zurich, Switzerland.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Eijkenboom M, 2000, NEUROPHARMACOLOGY, V39, P817, DOI 10.1016/S0028-3908(00)00002-2; Etienne S, 1998, J IMMUNOL, V161, P5755; Flecknell PA, 1999, LAB ANIM, V33, P169, DOI 10.1258/002367799780578381; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GERLACH I, 1998, J NEUROTRAUM, V15, P870; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Gray C, 1998, BRAIN INJURY, V12, P429, DOI 10.1080/026990598122548; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184, DOI 10.1097/00004647-199902000-00010; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hayes JH, 1999, LAB ANIM-UK, V33, P16, DOI 10.1258/002367799780578534; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Kraus J, 1996, NEUROTRAUMA, P13; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 2000, CURR OPIN CRIT CARE, V6, P98; OLSSON M, 1995, J NEUROSCI, V15, P3863; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Pleines UE, 1998, J NEUROTRAUM, V15, P399, DOI 10.1089/neu.1998.15.399; Povlishock JT, 1999, ACT NEUR S, V73, P15; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; RIECKMANN P, 1995, J NEUROIMMUNOL, V60, P9, DOI 10.1016/0165-5728(95)00047-6; Sano H, 1998, BIOCHEM BIOPH RES CO, V250, P694, DOI 10.1006/bbrc.1998.9385; Schmal H, 1998, J IMMUNOL, V161, P3685; Schmanke T, 1997, J NEUROTRAUM, V14, P459, DOI 10.1089/neu.1997.14.459; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shrikant P, 1996, J IMMUNOL, V157, P1819; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Soares HD, 1995, J NEUROSCI, V15, P8223; SOBEL RA, 1990, AM J PATHOL, V136, P1309; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; STOCKER R, 1995, INTEGRATED APPROACH, P196; vanderStaay FJ, 1996, BRAIN RES, V735, P271; Whalen MJ, 1997, ACT NEUR S, V70, P260	57	71	79	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAR 1	2001	63	5					438	446		10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.3.CO;2-G			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	405LV	WOS:000167161900009	11223919				2022-02-06	
J	Combes, P; Fauvage, B; Oleyer, C				Combes, P; Fauvage, B; Oleyer, C			Nosocomial pneumonia in mechanically ventilated patients, a prospective randomised evaluation of the Stericath closed suctioning system	INTENSIVE CARE MEDICINE			English	Article						nosocomial pneumopathy; mechanical ventilation; Cox model; closed suctioning device; ICU	INTENSIVE-CARE UNIT; CRITICALLY ILL PATIENTS; RISK-FACTORS; HEAD-INJURY; BRONCHOALVEOLAR LAVAGE; CONTROLLED TRIAL; MORTALITY; ADULTS; BRONCHOSCOPY; COLONIZATION	Objective: To compare the ventilator-associated pneumonia (VAP) incidence rates in mechanically ventilated patients according to the type of endotracheal suctioning (closed versus open). Setting: The Neurosurgery Intensive Care Unit of the Grenoble University Hospital, France. Design: A prospective randomised study performed after a 6-month period of nursing personnel training. Patients: One hundred four consecutive patients needing mechanical ventilation for more than 48 h were randomised into two groups. To be eligible, patients had to have no active infection or respiratory affection in their passes. In the Stericath group (S + n = 54), patients were not; disconnected from the ventilator during suctioning. The others were routinely managed (S-, n = 50). In both groups patterns of frequency and duration of suctioning were performed according to a standardised protocol. Measurements: The non-adjusted incidence rate of VAP was lower for S + than for S- (7.32 versus15.89 per 1000 patient-days, p = 0.07). Multivariate analysis performed using the Cox model showed an adjusted risk of VAP 3.5 times higher in S- (95 % Cl: 11.00-12.33). The risk being 4.3 higher in patients receiving gastric acid secretion inhibitors (1.08-16.82). In non-censored cases (n = 76) length of ICU stay increased by an average of 16.8 days when VAP was present (p = 0.0008). No adverse effect due to Stericath use was noted and volume of tracheal aspirate was similar between groups (p = 0.178). Conclusion: The use of Stericath reduced the incidence rate of VAP without demonstrating any adverse effect.	CHU Grenoble, F-38043 Grenoble 9, France; Ctr Hosp Roanne, Dept Informat Med & Sante Publ, F-42300 Roanne, France		Fauvage, B (corresponding author), CHU Grenoble, BP 217, F-38043 Grenoble 9, France.						BROWN SE, 1983, CHEST, V83, P621, DOI 10.1378/chest.83.4.621; Brucia J, 1996, HEART LUNG, V25, P295, DOI 10.1016/S0147-9563(96)80065-3; BUENOCAVANILLAS A, 1994, CRIT CARE MED, V22, P55, DOI 10.1097/00003246-199401000-00013; CARLON GC, 1987, CRIT CARE MED, V15, P522, DOI 10.1097/00003246-198705000-00015; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CLARK AP, 1990, HEART LUNG, V19, P552; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/BF01709556; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; CROCE MA, 1994, J TRAUMA, V37, P721, DOI 10.1097/00005373-199411000-00005; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; DEPPE SA, 1990, CRIT CARE MED, V18, P1389, DOI 10.1097/00003246-199012000-00016; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; JENNETT B, 1975, LANCET, V1, P480; JOHNSON KL, 1994, CRIT CARE MED, V22, P658, DOI 10.1097/00003246-199404000-00023; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; Kirton OC, 1997, CHEST, V112, P1055, DOI 10.1378/chest.112.4.1055; KOLLEF MH, 1995, ANN INTERN MED, V123, P168, DOI 10.7326/0003-4819-123-3-199508010-00002; LEGALL JR, 1984, CRIT CARE MED, V12, P975; MAYHALL CG, 1988, INFECT CONT HOSP EP, V9, P125; MONTRAVERS P, 1993, CHEST, V104, P1541, DOI 10.1378/chest.104.5.1541; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; PAPAZIAN L, 1993, CHEST, V104, P1548, DOI 10.1378/chest.104.5.1548; PEERLESS JR, 1995, CHEST, V108, P962, DOI 10.1378/chest.108.4.962; RELLO J, 1991, CHEST, V100, P439, DOI 10.1378/chest.100.2.439; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; RUDY EB, 1991, HEART LUNG, V20, P667; Sanchez-Nieto JM, 1998, AM J RESP CRIT CARE, V157, P371, DOI 10.1164/ajrccm.157.2.97-02039; TEASDALE G, 1974, LANCET, V2, P81; Timsit JF, 1996, AM J RESP CRIT CARE, V154, P116, DOI 10.1164/ajrccm.154.1.8680666; TORRES A, 1990, AM REV RESPIR DIS, V142, P521; Verwaest C, 1997, CRIT CARE MED, V25, P63, DOI 10.1097/00003246-199701000-00014; WEINSTEIN R, 1991, AM J MED S3B, V91, P180; Wunderink RG, 1998, AM J RESP CRIT CARE, V157, P349; WUNDERINK RG, 1992, CHEST, V102, P580	40	71	82	0	11	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	JUL	2000	26	7					878	882		10.1007/s001340051276			5	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	342AR	WOS:000088623500008	10990101				2022-02-06	
J	Ghirnikar, RS; Lee, YL; Eng, LF				Ghirnikar, RS; Lee, YL; Eng, LF			Chemokine antagonist infusion attenuates cellular infiltration following spinal cord contusion injury in rat	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						spinal cord injury; chemokine receptors; antagonist; vMIPII, apoptosis	CHEMOATTRACTANT PROTEIN-1 MCP-1; TRAUMATIC BRAIN INJURY; MESSENGER-RNA; RECEPTOR ANTAGONIST; APOPTOSIS; RECRUITMENT; INHIBITION; DEATH; MICE; DEGENERATION	Spinal cord injury is accompanied by an initial inflammatory reaction followed by secondary injury that is caused, in part, by apoptosis. Recruitment of leukocytes from the blood compartment to the site of inflammation in the injured spinal cord has been attributed to locally generated chemotactic agents (cytokines and chemokines). In addition to upregulation in the message levels of a number of chemokines, we have found up-regulation in the message levels of several chemokine receptors following spinal cord contusion injury. To reduce the inflammatory response after spinal cord injury, we have blocked the interaction of chemokine receptors with their ligands using the vMIPII chemokine antagonist. Using a rat model of spinal cord contusion injury, we show that continuous infusion of the antagonist for up to 7 days;results in a decrease in infiltrating hematogenous cells at the site of injury. Histological evaluation ofthe tissue showed fewer activated macrophages at the site of injury. Concomitantly, reduced neuronal loss and gliosis were observed in the antagonist infused spinal cord. In addition, increased expression of Bcl-2 gene, an endogenous inhibitor of apoptosis, was seen in the antagonist infused spinal cord at 7 days post injury. Morphologically, staining with the bisbenzamide dye Hoechst 33342 showed significantly more apoptotic bodies in the vehicle compared to antagonist infused spinal cord. Our data suggest that chemokine antagonist infusion post-injury results in limiting the inflammatory response following spinal cord contusion injury, thereby attenuating neuronal loss, possibly due to decreased apoptosis. These findings support the contention that disrupting chemokine interactions with their receptors may be an effective approach in reducing the secondary damage after spinal cord injury. Published 2000 Wiley-Liss, Inc.(dagger).	VAPA Hlth Care Syst, Dept Pathol, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Stanford, CA USA		Eng, LF (corresponding author), VAPA Hlth Care Syst, Dept Pathol, 3801 Miranda Ave, Palo Alto, CA 94304 USA.	lfeng@leland.stanford.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA 94304] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-11632] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R33CA094304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS011632] Funding Source: NIH RePORTER		Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; ANDERSON DK, 1992, J NEUROTRAUM, V9, P143, DOI 10.1089/neu.1992.9.143; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BENBARUCH A, 1995, J BIOL CHEM, V270, P11703, DOI 10.1074/jbc.270.20.11703; BROADWELL RD, 1994, MICROSC RES TECHNIQ, V27, P471, DOI 10.1002/jemt.1070270603; BROADWELL RD, 1992, PROG BRAIN RES, V91, P95; Chen AQ, 1996, EXP NEUROL, V138, P261, DOI 10.1006/exnr.1996.0065; Chen SH, 1998, J EXP MED, V188, P193, DOI 10.1084/jem.188.1.193; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CROWE MJ, 1997, IN PRESS NAT MED, P240; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Elsner J, 1997, EUR J IMMUNOL, V27, P2892, DOI 10.1002/eji.1830271122; Eng LF, 1987, PROG BRAIN RES <D>, V71, P439; Eng LF, 1999, J NEUROCHEM, V73, pS194; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Ghirnikar RS, 1998, NEUROSCI LETT, V247, P21, DOI 10.1016/S0304-3940(98)00268-7; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong JH, 1997, J EXP MED, V186, P131, DOI 10.1084/jem.186.1.131; HORUK R, 1994, TRENDS PHARMACOL SCI, V15, P159, DOI 10.1016/0165-6147(94)90077-9; Howard OMZ, 1996, TRENDS BIOTECHNOL, V14, P46, DOI 10.1016/0167-7799(96)80920-6; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee YL, 1997, J NEUROCHEM, V69, pS144; LEE YL, 1999, IN PRESS NEUROCHEM I; Lou J, 1998, SPINAL CORD, V36, P683, DOI 10.1038/sj.sc.3100632; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; McTigue DM, 1998, J NEUROSCI, V18, P5354, DOI 10.1523/JNEUROSCI.18-14-05354.1998; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MURPHY GM, 1993, J NEUROSCI RES, V35, P643, DOI 10.1002/jnr.490350607; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; SHIH K, 1997, 7 INT S NEUR REG P74; Soares HD, 1995, J NEUROSCI, V15, P8223; Sozzani S, 1996, Prog Drug Res, V47, P53; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Takahashi K, 1999, J COMP NEUROL, V404, P159, DOI 10.1002/(SICI)1096-9861(19990208)404:2<159::AID-CNE2>3.0.CO;2-E; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459; Zagorski J, 1997, J IMMUNOL, V159, P1059; ZHANG YJ, 1994, J BIOL CHEM, V269, P15918	45	71	80	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN 1	2000	59	1					63	73		10.1002/(SICI)1097-4547(20000101)59:1<63::AID-JNR8>3.3.CO;2-N			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	270ZY	WOS:000084568000008	10658186				2022-02-06	
J	Bank, U; Reinhold, D; Schneemilch, C; Kunz, D; Synowitz, HJ; Ansorge, S				Bank, U; Reinhold, D; Schneemilch, C; Kunz, D; Synowitz, HJ; Ansorge, S			Selective proteolytic cleavage of IL-2 receptor and IL-6 receptor ligand binding chains by neutrophil-derived serine proteases at foci of inflammation	JOURNAL OF INTERFERON AND CYTOKINE RESEARCH			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN INTERLEUKIN-2 RECEPTOR; TRAUMATIC BRAIN INJURY; CATHEPSIN-G; LEUKOCYTE ELASTASE; MOLECULAR-CLONING; TNF RECEPTOR; CELLS; EXPRESSION; GROWTH	Traumatic brain injuries induce a strong, locally restricted inflammatory response. Here we demonstrate that activated neutrophils infiltrate the site of tissue destruction and release large amounts of enzymatically active elastase, cathepsin G, and proteinase 3, High intracerebral protease concentrations were found to be accompanied by a reduced inhibitory potential at foci of inflammation. In 39 neurotrauma patients, a temporal correlation between the protease release from neutrophils and the solubilization of interleukin-2 (IL-2) receptor and IL-6 receptor ectodomains at sites of tissue destruction was observed, suggesting that neutrophil-derived proteases may play a crucial role in the cytokine receptor shedding at foci of inflammation. Under in vitro conditions, the cleavage of membrane-bound IL-2R alpha was found to be predominantly catalyzed by elastase and, to a lesser extent, by proteinase 3, Cathepsin G was found to be incapable of solubilizing this receptor. In contrast, the cleavage of the IL-6R 80 kDa chain was catalyzed by cathepsin G but not by elastase or proteinase 3, The receptor fragments released by the action of these enzymes were found to retain their ligand-binding capacity. These results strongly suggest a pathophysiologic role of neutrophil-derived serine proteases, particularly in regulation of the expression of functional IL-2 and IL-6 receptors at foci of inflammation.	Otto Von Guericke Univ, Inst Expt Internal Med, Ctr Internal Med, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Clin Anesthesiol & Intens Care Therapy, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Inst Clin Chem, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Clin Neurosurg, D-39120 Magdeburg, Germany		Bank, U (corresponding author), Otto Von Guericke Univ, Inst Expt Internal Med, Ctr Internal Med, Leipziger Str 44, D-39120 Magdeburg, Germany.						Anderson RM, 1998, AM J FOREN MED PATH, V19, P1, DOI 10.1097/00000433-199803000-00001; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BANGALORE N, 1994, BIOL CHEM H-S, V375, P659, DOI 10.1515/bchm3.1994.375.10.659; BANK U, 1995, INFLAMMATION, V19, P83, DOI 10.1007/BF01534383; BAUGH RJ, 1976, BIOCHEMISTRY-US, V15, P836, DOI 10.1021/bi00649a017; BLOW AMJ, 1977, BIOCHEM J, V161, P13, DOI 10.1042/bj1610013; BORISH L, 1989, CELL IMMUNOL, V121, P280, DOI 10.1016/0008-8749(89)90026-9; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; DESROCHERS PE, 1992, J BIOL CHEM, V267, P5005; DORING G, 1995, J IMMUNOL, V154, P4842; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; HANISCH UK, 1996, BRAIN RES REV, V21, P246; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; LLOYD AR, 1992, IMMUNOL TODAY, V13, P169, DOI 10.1016/0167-5699(92)90121-M; MCCLAIN C, 1991, J CLIN LAB MED, V118, P226; MIEDEL MC, 1989, J BIOL CHEM, V264, P21097; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLBERG J, 1995, J IMMUNOL, V155, P5198; NAKAJIMA K, 1979, J BIOL CHEM, V254, P4027; NEEPER MP, 1987, J IMMUNOL, V138, P3532; NORTIER J, 1991, LIFE SCI, V49, P1879, DOI 10.1016/0024-3205(91)90288-M; OLSSON I, 1974, BLOOD, V44, P235, DOI 10.1182/blood.V44.2.235.235; Ozbek S, 1998, J BIOL CHEM, V273, P21374, DOI 10.1074/jbc.273.33.21374; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Reinhold D, 1997, IMMUNOLOGY, V91, P354, DOI 10.1046/j.1365-2567.1997.d01-2258.x; REMOLDODONNELL E, 1995, BLOOD, V86, P2395, DOI 10.1182/blood.V86.6.2395.bloodjournal8662395; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; ROSEN GM, 1995, FASEB J, V9, P200, DOI 10.1096/fasebj.9.2.7540156; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; TADA M, 1994, J NEUROSURG, V80, P1063, DOI 10.3171/jns.1994.80.6.1063; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Vollmer P, 1996, INFECT IMMUN, V64, P3646, DOI 10.1128/IAI.64.9.3646-3651.1996; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546	43	71	74	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	1079-9907			J INTERF CYTOK RES	J. Interferon Cytokine Res.	NOV	1999	19	11					1277	1287		10.1089/107999099312957			11	Biochemistry & Molecular Biology; Cell Biology; Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Immunology	255RN	WOS:000083684100008	10574621				2022-02-06	
J	Zarkovic, N; Zarkovic, K; Schaur, RJ; Stolc, S; Schlag, G; Redl, H; Waeg, G; Borovic, S; Loncaric, I; Juric, G; Hlavka, V				Zarkovic, N; Zarkovic, K; Schaur, RJ; Stolc, S; Schlag, G; Redl, H; Waeg, G; Borovic, S; Loncaric, I; Juric, G; Hlavka, V			4-Hydroxynonenal as a second messenger of free radicals and growth modifying factor	LIFE SCIENCES			English	Article; Proceedings Paper	International Symposium on Drug Action on Reactive Oxygen Species	SEP 29-30, 1997	CASTLE SMOLENICE, SLOVAKIA	Slovak Acad Sci, Inst Exptl Pharmacol, Centaur Pharmaceut Inc, Slovak Pharmacol Soc, Slovak Soc Biochem & Molec Biol, Free Radical Sect		oxidative stress; lipid peroxidation; 4-hydroxynonenal; brain; c-fos; immunohistochemistry; cell growth; free radicals; reactive oxygen species	CELL	Immunohistochemical analysis of the distribution of the lipid peroxidation product 4-hydroxynonenal (HNE) in the brain of baboons exposed to experimental hemorrhagic traumatic shock or sepsis showed that systemic oxidative stress and the thereby generated HNE affect the blood:brain barrier and the regulation of cerebral blood now determing secondary brain damage. Similarly, HNE was determined during ischemia in the brain blood vessels of rats exposed to ischemia/reperfusion injury of the brain. After reperfusion, HNE disappeared from the blood vessels but remained in neurones and in glial cells. Since HNE modulates cell proliferation and differentiation (including proto-oncogene expression), it is postulated that HNE might have prominent local and systemic effects that are not only harmful but beneficial too, determing the outcome of various pathophysiologcial conditions based on oxidative stress.	Rudjer Boskovic Inst, Zagreb, Croatia; KBC Rebro, Inst Neuropathol, Fac Med, Zagreb, Croatia; Inst Biochem, Graz, Austria; Slovak Acad Sci, Inst Expt Pharmacol, Bratislava 84216, Slovakia; Ludwig Boltzmann Inst Traumatol, Vienna, Austria		Zarkovic, N (corresponding author), Rudjer Boskovic Inst, Pob 1016, Zagreb, Croatia.		Zarkovic, Neven/AAG-5836-2019	Zarkovic, Neven/0000-0001-5032-0369			ESTERBAU.H, 1967, MONATSH CHEM, V98, P1884, DOI 10.1007/BF01167149; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; HORAKOVA L, 1990, PHYSIOL BOHEMOSLOV, V39, P513; Kreuzer T, 1997, CANCER BIOTHER RADIO, V12, P131, DOI 10.1089/cbr.1997.12.131; Schlag G, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P3; Waeg G, 1996, FREE RADICAL RES, V25, P149, DOI 10.3109/10715769609149920; Zarkovic K, 1997, SHOCK, SEPSIS AND ORGAN FAILURE, P146; ZARKOVIC N, 1993, CELL BIOCHEM FUNCT, V11, P279, DOI 10.1002/cbf.290110409; ZARKOVIC N, 1994, FREE RADICAL BIO MED, V16, P877, DOI 10.1016/0891-5849(94)90208-9	9	71	72	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0024-3205			LIFE SCI	Life Sci.	OCT 1	1999	65	18-19					1901	1904		10.1016/S0024-3205(99)00444-0			4	Medicine, Research & Experimental; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Research & Experimental Medicine; Pharmacology & Pharmacy	245GX	WOS:000083099100008	10576434				2022-02-06	
J	Max, JE; Roberts, MA; Koele, SL; Lindgren, SD; Robin, DA; Arndt, S; Smith, WL; Sato, Y				Max, JE; Roberts, MA; Koele, SL; Lindgren, SD; Robin, DA; Arndt, S; Smith, WL; Sato, Y			Cognitive outcome in children and adolescents following severe traumatic brain injury: Influence of psychosocial, psychiatric, and injury-related variables	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; orthopedic injury; children; IQ; memory	PEDIATRIC HEAD-INJURY; BEHAVIOR PROBLEMS; FAMILY; SEQUELAE; COHORT; PERFORMANCE; CHILDHOOD; DISORDERS; VALIDITY; RECOVERY	Previous studies of childhood traumatic brain injury (TBI) have emphasized injury-related variables rather than psychiatric or psychosocial factors as correlates of cognitive outcomes. We addressed this concern by recruiting a consecutive series (N = 24) of children age 5 through 14 years who suffered a severe TBI, a matched group who sustained a mild TBI, and a second matched group who sustained an orthopedic injury. Standardized intellectual, memory, psychiatric, family functioning, family psychiatric history, neurological, and neuroimaging assessments were conducted at an average of 2 years following injury. Severe TBI, when compared to mild TBI and orthopedic injury, was associated with significant decrements in intellectual and memory function. A principal components analysis of independent variables that showed significant (p < .05) bivariate correlations with the outcome measures yielded a nc neuropsychiatric factor encompassing severity of TBI indices and postinjury psychiatric disorders and a psychosocial disadvantage factor. Both factors were independently and significantly related to intellectual and memory function outcome. Postinjury psychiatric disorders added significantly to severity indices and family functioning and family psychiatric history added significantly to socioeconomic status in explaining several specific cognitive outcomes. These results may help to define subgroups of children who will require more intensive services following their injuries.	Univ Iowa, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Speech Pathol & Audiol, Iowa City, IA 52242 USA		Max, JE (corresponding author), Univ Iowa Hosp & Clin, Dept Psychiat, 1876 JPP, Iowa City, IA 52242 USA.		Robin, Donald/F-2109-2010; Arndt, Stephan/A-6976-2013	Arndt, Stephan/0000-0003-0783-8204; Sato, Yutaka/0000-0002-5245-232X	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R37MH031593, P50MH043271, R01MH040856, P30MH043271, R01MH031593] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MHCRC43271, MH40856, MH31593] Funding Source: Medline		Achenbach, 1991, MANUAL TEACHERS REPO; Adams W., 1990, WIDE RANGE ASSESSMEN; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; Hollingshead AB., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KAUFMAN AS, 1991, J PSYCHOEDUC ASSESS, V9, P4, DOI 10.1177/073428299100900101; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Max JE, 1998, J AM ACAD CHILD PSY, V37, P297, DOI 10.1097/00004583-199803000-00015; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MAX JE, 1997, J AM ACAD CHILD ADOL, V36, P96; MAX JE, 1998, J AM ACAD CHILD ADOL; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; ORVASCHEL H, 1982, J AM ACAD CHILD PSY, V21, P392, DOI 10.1016/S0002-7138(09)60944-4; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Shaffer D, 1975, Ciba Found Symp, P191; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wechsler D., 1974, WECHSLER INTELLIGENC; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	43	71	71	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	1999	5	1					58	68		10.1017/S1355617799511089			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	162BR	WOS:000078325800008	9989025				2022-02-06	
S	Merchant, RE; Bullock, MR; Carmack, CA; Shah, AK; Wilner, KD; Ko, G; Williams, SA		Trembly, B; Slikker, W		Merchant, RE; Bullock, MR; Carmack, CA; Shah, AK; Wilner, KD; Ko, G; Williams, SA			A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			REGIONAL CEREBRAL EDEMA; ANTAGONIST; CP101,606; RAT; NEUROPROTECTANT; CP-98,113; POTENT; DAMAGE	CP-101,606 is a postsynaptic antagonist of the glutamate-mediated NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor. When administered intravenously (i.v.) at the time of injury, CP-101,606 Is neuroprotective in animal models of traumatic brain injury (TBI) and ischemia, Minimal adverse effects have been observed in normal human volunteers given i.v. doses of up to 3 mg/kg/hr for 72 hours. The objective of the present clinical trial was to assess the safety, pharmacokinetics, and tolerability of CP-101,606 infused for various times in patients who had suffered either an acute moderate or mild TBI (Glasgow Coma Score 9-14) or hemorrhagic stroke, Patients began receiving treatment within 12 hours of brain injury, ii total of 53 subjects (45 with TBI and 8 with stroke) were randomized in a double-blind fashion to receive CP-101,606 or placebo (4 drug:1 placebo). Drug/placebo was administered by i.v. infusion (0.75 mg/kg/hr) for 2 hours and then stopped (n = 25) or continued for 22 hours (n = 4) or 70 hours (n = 24) at a rate of 0.37 mg/kg/hr, Mean plasma drug concentrations were well above the predicted therapeutic concentration of 200 ng/ml within two hours of initiating treatment and were sustained as long as drug was infused. All the patients tolerated their drug/placebo treatment, and there were no clinically significant cardiovascular or hematological abnormalities in either group. A Neurobehavioral Rating Scale, used to detect personality changes and behavioral disturbances, indicated that all subjects showed an improvement from their postinjury, predosing baseline but did not significantly differ from each other with respect to type of head injury and/or treatment with drug or placebo. Modified Kurtzke Scoring also showed a similar pattern of improvement irrespective of type of head injury or drug/placebo treatment. This study suggests that CP-101,606, infused for up to 72 hours has no psychotropic effects and is well-tolerated in patients who have sustained a mild or moderate TBI or hemorrhagic stroke.	Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Richmond, VA 23298 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA		Merchant, RE (corresponding author), Virginia Commonwealth Univ, Div Neurosurg, MCV Stn, Med Coll Virginia, Box 980631, Richmond, VA 23298 USA.						Brimecombe JC, 1998, J PHARMACOL EXP THER, V286, P627; CHENARD BL, 1995, J MED CHEM, V38, P3138, DOI 10.1021/jm00016a017; Di X, 1997, STROKE, V28, P2244, DOI 10.1161/01.STR.28.11.2244; KURTZKE JF, 1955, NEUROLOGY, V5, P580, DOI 10.1212/WNL.5.8.580; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Menniti F, 1997, EUR J PHARMACOL, V331, P117, DOI 10.1016/S0014-2999(97)10092-9; MENNITI FS, 1998, UNPUB EUR J PHARM; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409	11	71	71	0	1	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						42	50		10.1111/j.1749-6632.1999.tb07979.x			9	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700004	10668412				2022-02-06	
J	Prince, DA; Jacobs, K				Prince, DA; Jacobs, K			Inhibitory function in two models of chronic epileptogenesis	EPILEPSY RESEARCH			English	Article; Proceedings Paper	4th Workshop on the Neurobiology of Epilepsy	JUN 26-28, 1997	ADARE, IRELAND	Amer Epilepsy Soc, Hoechst Marion Roussel, Japan Fdn Neurosci & Mental Health, Novartis Pharmaceutical Corp, Parke-Davis/Div Warner-Lambert Co		epilepsy; neocortex; microgyria; post-traumatic; rat; inhibition	NEURONAL MIGRATION DISORDERS; HIPPOCAMPUS IN-VITRO; SYNAPTIC TRANSMISSION; NEOCORTICAL EPILEPTOGENESIS; EPILEPTIFORM ACTIVITY; DEPENDENT DEPRESSION; TEMPORAL NEOCORTEX; PYRAMIDAL NEURONS; RAT HIPPOCAMPUS; CEREBRAL-CORTEX	Although drug-induced disinhibition is a potent method for producing acute epileptogenesis, data with respect to possible disorders of GABAergic inhibitory function in models of chronic epilepsy are incomplete and inconsistent. We examined rat models of cortical post-traumatic epilepsy, and epileptogenic cortical microgyri. Results suggest enhanced rather than decreased inhibitory function in cortical networks in these preparations. In brain slices from epileptogenic chronically isolated cortex, the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) and miniature (m)IPSCs in layer V pyramidal neurons is increased compared to control. In the epileptogenic zone adjacent to the microgyrus, both spontaneous and stimulus-induced IPSCs are larger in amplitude than control, and the frequency of sIPSCs is more dependent upon glutamatergic excitation of interneurons than in control layer V neurons of homotopic cortex. Immunocytochemical studies show that there is enhanced immunoreactivity for several proteins in GABAergic interneurons of chronic cortical isolations, and suggest that there may be sprouting of GABAergic axons in the area of injury. This conclusion is supported by anatomic data showing an approximate doubling of the number of presumed inhibitory synapses on somata of layer V pyramidal neurons. These anatomic findings are consistent with the increased frequency of mIPSCs on these neurons. Inhibition is robust in both of these chronic models of epileptogenesis. Increased inhibitory electrogenesis might be pictured as part of the epileptogenic process, e.g. a mechanism for synchronizing the discharge of pyramidal neurons, or as a compensatory mechanism that might prevent the development of abnormal activities in some cases, or limit the intensity of epileptogenesis in others. (C) 1998 Elsevier Science B.V. All rights reserved.	Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA		Prince, DA (corresponding author), Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Jacobs, Kimberle/AAW-7526-2020		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012151, P50NS012151] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07288, NS09806, NS12151] Funding Source: Medline		ARAM JA, 1991, J NEUROPHYSIOL, V65, P1034, DOI 10.1152/jn.1991.65.5.1034; ASHWOOD TJ, 1986, BRAIN RES, V367, P390, DOI 10.1016/0006-8993(86)91625-2; BABB TL, 1989, J NEUROSCI, V9, P2562; BARKOVICH AJ, 1992, AM J NEURORADIOL, V13, P95; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; Carmignoto G, 1997, J PHYSIOL-LONDON, V498, P153, DOI 10.1113/jphysiol.1997.sp021848; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V62, P1149, DOI 10.1152/jn.1989.62.5.1149; CHAGNACAMITAI Y, 1989, J NEUROPHYSIOL, V61, P747, DOI 10.1152/jn.1989.61.4.747; DAVENPORT CJ, 1990, EXP NEUROL, V109, P180, DOI 10.1016/0014-4886(90)90072-Z; DEFELIPE J, 1994, BRAIN RES, V657, P150, DOI 10.1016/0006-8993(94)90962-8; DEISZ RA, 1989, J PHYSIOL-LONDON, V412, P513, DOI 10.1113/jphysiol.1989.sp017629; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; DOMANN R, 1991, EXP BRAIN RES, V83, P683; DVORAK K, 1977, ACTA NEUROPATHOL, V38, P203; ENGEL J, 1995, ADV NEUROL, V67, P157; ESCLAPEZ M, 1997, P NATL ACAD SCI USA, V94, P1; FRANCK JE, 1985, BRAIN RES, V329, P309, DOI 10.1016/0006-8993(85)90540-2; FRANCK JE, 1988, J NEUROSCI, V8, P1991; GONZALES C, 1992, NEUROSCI LETT, V135, P53, DOI 10.1016/0304-3940(92)90134-S; HALPERN LM, 1972, EXPT MODELS EPILEPSY, P197; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762, DOI 10.1152/jn.1994.71.5.1762; HUMPHREYS P, 1991, J NEUROPATH EXP NEUR, V50, P145, DOI 10.1097/00005072-199103000-00006; Jacobs K. M., 1996, Society for Neuroscience Abstracts, V22, P2102; Jacobs K. M., 1997, Society for Neuroscience Abstracts, V23, P811; Jacobs Kimberle M., 1996, Epilepsia, V37, P77; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; KREINDLER A, 1960, ARCH ITAL BIOL, V98, P10; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; Marco P, 1997, EXP BRAIN RES, V114, P1, DOI 10.1007/PL00005608; Marco P, 1996, BRAIN, V119, P1327, DOI 10.1093/brain/119.4.1327; MATHERN GW, 1995, J NEUROSCI, V15, P3990; MATSUMOTO H, 1964, EXP NEUROL, V9, P286, DOI 10.1016/0014-4886(64)90025-1; MCCARREN M, 1985, J NEUROPHYSIOL, V53, P557, DOI 10.1152/jn.1985.53.2.557; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MICHELSON HB, 1991, SCIENCE, V253, P1420, DOI 10.1126/science.1654594; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; NIEOULLON A, 1981, BRAIN RES, V224, P129, DOI 10.1016/0006-8993(81)91122-7; OBENAUS A, 1993, J NEUROSCI, V13, P4470; PALMINI A, 1991, CAN J NEUROL SCI, V18, P580, DOI 10.1017/S0317167100032753; PALMINI A, 1994, EPILEPSIA, V35, pS57, DOI 10.1111/j.1528-1157.1994.tb05989.x; PALMINI A, 1991, ANN NEUROL, V30, P741, DOI 10.1002/ana.410300602; PERREAULT P, 1992, J NEUROSCI, V12, P104; PRINCE DA, 1978, ANNU REV NEUROSCI, V1, P395, DOI 10.1146/annurev.ne.01.030178.002143; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276, DOI 10.1152/jn.1993.69.4.1276; Prince DA, 1997, CAN J PHYSIOL PHARM, V75, P500, DOI 10.1139/cjpp-75-5-500; PRINCE DA, 1998, ADV NEUROLOGY; PRINCE DA, 1992, NEUROTRANSMITTERS EP, P31; Prince David A., 1996, V72, P1; Purpura D P, 1968, Prog Brain Res, V22, P107; RIBAK CE, 1982, J NEUROSCI, V2, P1725; RIBAK CE, 1982, CAN J PHYSIOL PHARM, V60, P864, DOI 10.1139/y82-122; ROMIJN HJ, 1988, EXP NEUROL, V100, P332, DOI 10.1016/0014-4886(88)90112-4; Rosen G. D., 1996, Society for Neuroscience Abstracts, V22, P485; RUTECKI PA, 1987, J NEUROPHYSIOL, V57, P1911, DOI 10.1152/jn.1987.57.6.1911; Salin P, 1995, J NEUROSCI, V15, P8234; SEIL FJ, 1994, DEV BRAIN RES, V77, P123, DOI 10.1016/0165-3806(94)90219-4; SLOPER JJ, 1980, BRAIN RES, V198, P204, DOI 10.1016/0006-8993(80)90356-X; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SLOVITER RS, 1987, SCIENCE, V235, P73, DOI 10.1126/science.2879352; TECOMA ES, 1989, NEUROLOGY, V39, P676, DOI 10.1212/WNL.39.5.676; THOMPSON SM, 1989, J NEUROPHYSIOL, V61, P501, DOI 10.1152/jn.1989.61.3.501; WESTENBROEK RE, 1988, J COMP NEUROL, V274, P334, DOI 10.1002/cne.902740304; WHITTINGTON MA, 1994, J PHYSIOL-LONDON, V481, P593, DOI 10.1113/jphysiol.1994.sp020466	63	71	72	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211			EPILEPSY RES	Epilepsy Res.	SEP	1998	32	1-2			SI		83	92		10.1016/S0920-1211(98)00042-4			10	Clinical Neurology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	121UX	WOS:000076034000009	9761311				2022-02-06	
J	Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghahremani, F; Ghajar, J				Hartl, R; Medary, MB; Ruge, M; Arfors, KE; Ghahremani, F; Ghajar, J			Hypertonic/hyperoncotic saline attenuates microcirculatory disturbances after traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	14th Bodensee Symposium on Microcirculation: Small Volume Resuscitation in Head Injury	JUN 14-16, 1996	BODENSEE, GERMANY			leukocytes; head injury; hypertonic saline; small-volume resuscitation	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; ISCHEMIC CELL-DAMAGE; INTRACRANIAL-PRESSURE; HEMORRHAGIC-SHOCK; HYPERTONIC SALINE; FLUID RESUSCITATION; WATER-CONTENT; REPERFUSION; ABNORMALITIES	Background: Traumatic brain injury (TBI) induces an acute inflammatory response characterized by early recruitment of inflammatory cells (white blood cells). Rapid resuscitation of TBI with hypertonic saline/dextran (HS/DEX) yields promising results in clinical and experimental studies. The purpose of this paper was to test the hypothesis that HS/DEX exerts its effects in part through a modulation of the acute inflammatory response to TBI. Methods: Rabbits equipped with chronic cranial windows underwent fluid-percussion injury and were followed up for 6 hours. Intravital fluorescence videomicroscopy technique was used to visualize white blood cell trafficking and to measure pia vessel diameters and venular shear rates. Three groups were studied: sham (group I, n = 5), trauma (group II, n = 7), and trauma and 4 mL/kg 7.2% NaCl/10% dextran 60 IV over 5 minutes at 10 minutes after TBI (group III, n = 7). Results: TBI in groups TI and III led to significant increases of intracranial pressure. Arteriolar diameters after trauma increased by 17 +/- 8% at 6 hours in group LT. Infusion of HS/DEX completely prevented this secondary diameter increase. At 6 hours, the increase of ''sticking'' white blood cells in group III was reduced by approximately 90% compared with group II. Conclusion: Whether the anti-inflammatory effect of HS/DEX plays a role in reducing delayed brain damage (> 6 hours after TBI) or other systemic complications of TBI arises as an important question and should be investigated further.	CORNELL UNIV,COLL MED,NEW YORK,NY; ALLEGHENY GEN HOSP,PITTSBURGH,PA 15212		Hartl, R (corresponding author), AITKEN NEUROSCI INST,523 E 72ND ST,NEW YORK,NY 10021, USA.		Ghahremani, Fatemeh/M-1719-2018	Ghahremani, Fatemeh/0000-0002-7244-6066			BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; BATTISTELLA F, 1992, CIRC SHOCK, V37, P16; BAUER M, 1993, CIRC SHOCK, V40, P187; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; CIOFFI WG, 1993, ARCH SURG-CHICAGO, V128, P1260; DELZOPPO GJ, 1994, CEREBROVAS BRAIN MET, V6, P47; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662, DOI 10.1002/jlb.55.5.662; HALL ED, 1993, RES P ARNMD, V71, P81; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; HARTL R, 1995, SHOCK, V3, P274; HEINEL LA, 1994, BRAIN RES BULL, V34, P137, DOI 10.1016/0361-9230(94)90010-8; HORNER HC, 1992, SOC NEUR ABSTR, V8, P173; KESKIL S, 1994, ACTA NEUROCHIR, V131, P211, DOI 10.1007/BF01808615; KREIMEIER U, 1993, CURR OPIN ANESTHESIO, V6, P400; KUBES P, 1992, CELL MOL MECH INFLAM, P125; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; LINDSBERG PJ, 1991, ANN NEUROL, V30, P117, DOI 10.1002/ana.410300202; LIPOWSKY HH, 1978, MICROVASC RES, V15, P93, DOI 10.1016/0026-2862(78)90009-2; MAZZONI MC, 1988, AM J PHYSIOL, V255, pH629, DOI 10.1152/ajpheart.1988.255.3.H629; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MORI E, 1992, STROKE, V23, P712, DOI 10.1161/01.STR.23.5.712; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; NOLTE D, 1992, AM J PHYSIOL, V263, pH1411, DOI 10.1152/ajpheart.1992.263.5.H1411; NUYTINCK HKS, 1988, ARCH SURG-CHICAGO, V123, P1519; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; PROUGH D S, 1991, Anesthesia and Analgesia, V73, P738; ROSENGREN S, 1994, AM J PHYSIOL-CELL PH, V267, pC1623, DOI 10.1152/ajpcell.1994.267.6.C1623; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SCHURER L, 1992, EUR SURG RES, V24, P1, DOI 10.1159/000129183; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; SIESJO BK, 1993, ANN EMERG MED, V22, P959, DOI 10.1016/S0196-0644(05)82736-2; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VOLLMAR B, 1994, AM J PHYSIOL, V266, pH1927; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WELBOURN CRB, 1991, BRIT J SURG, V78, P651, DOI 10.1002/bjs.1800780607; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; WISNER DH, 1992, J TRAUMA, V32, P351, DOI 10.1097/00005373-199203000-00013; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011	48	71	73	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	1997	42	5		S			S41	S47		10.1097/00005373-199705001-00008			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	XE879	WOS:A1997XE87900009	9191695				2022-02-06	
J	Moseley, AM				Moseley, AM			The effect of casting combined with stretching on passive ankle dorsiflexion in adults with traumatic head injuries	PHYSICAL THERAPY			English	Article						ankle; contracture; head injuries; physical therapy; rehabilitation	IMMOBILIZED MUSCLE; CONNECTIVE-TISSUE; SOLEUS MUSCLE; CONTRACTURE; STIFFNESS; LENGTH; RABBIT	Background and Purpose. Ankle plantar-flexion contractures are a common problem following traumatic head injury. Although serial. casting is used to correct and prevent ankle plantar-flexion contractures, treatment efficacy has not been evaluated using an experimental design, The aim of this research was to establish the effect of a regimen of casting combined with stretching on passive ankle dorsiflexion motion. Subjects. Nine people who had sustained traumatic closed head injuries and had limited dorsiflexion motion participated in the study. Methods. A crossover design was used in the study. Subjects were assigned to both experimental and control groups. Torque-controlled measurements of passive ankle dorsiflexion motion were obtained for all subjects before and after 1 week of casting combined with stretching, as well as before and after a 1-week control period. The order of the experimental and control conditions was randomized. Results. Passive ankle dorsiflexion increased by a mean of 13.5 degrees (SD = 9.3) during the experimental condition, as compared with a mean decrease of 1.9 degrees (SD = 10.2) during the control condition. The difference between the experimental and control conditions was statistically significant. Conclusion and Discussion. These findings suggest that casting combined with stretching is an effective method Of correcting ankle plantar-flexion contractures in patients with traumatic head injuries.			Moseley, AM (corresponding author), LIVERPOOL HLTH SERV, BRAIN INJURY REHABIL UNIT, ELIZABETH ST, LIVERPOOL, NSW 2170, AUSTRALIA.						Ada L, 1980, Aust J Physiother, V26, P57, DOI 10.1016/S0004-9514(14)60801-1; AKESON WH, 1974, CONNECT TISSUE RES, V2, P315, DOI 10.3109/03008207409152261; BOOTH BJ, 1983, PHYS THER, V63, P1960, DOI 10.1093/ptj/63.12.1960; CARR JH, 1985, PHYS THER, V65, P175, DOI 10.1093/ptj/65.2.175; Carr JH, 1987, MOTOR RELEARNING PRO; CHESWORTH BM, 1995, PHYS THER, V75, P253, DOI 10.1093/ptj/75.4.253; CONINE TA, 1990, ARCH PHYS MED REHAB, V71, P310; Cook TD., 1979, QUASIEXPERIMENTATION; GRIEVE DW, 1978, BIOMECHANICS, P00405; HERBERT RD, 1993, J ORTHOPAED RES, V11, P358, DOI 10.1002/jor.1100110307; HERBERT RD, 1995, 15 C INT SOC BIOM, P380; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; IMIE PC, 1986, PHYS THER, V66, P748; JONES A, 1990, Physiotherapy Canada, V42, P15; KENT H, 1990, Physiotherapy Canada, V42, P189; Moore S, 1993, Aust J Physiother, V39, P271, DOI 10.1016/S0004-9514(14)60487-6; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Moseley A, 1993, Aust J Physiother, V39, P259, DOI 10.1016/S0004-9514(14)60486-4; Moseley Anne M., 1993, Physiotherapy Theory and Practice, V9, P215, DOI 10.3109/09593989309036493; Narici MV, 1996, J PHYSIOL-LONDON, V496, P287, DOI 10.1113/jphysiol.1996.sp021685; SIEGLER S, 1984, J BIOMECH, V17, P647, DOI 10.1016/0021-9290(84)90118-0; SULLIVAN T, 1988, Physiotherapy Canada, V40, P346; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; TARDIEU C, 1989, PHYS THER, V69, P656, DOI 10.1093/ptj/69.8.656; WILLIAMS PE, 1988, ANN RHEUM DIS, V47, P1014, DOI 10.1136/ard.47.12.1014; WILLIAMS PE, 1978, J ANAT, V127, P459; WILLIAMS PE, 1984, J ANAT, V138, P343; YARKONY GM, 1987, CLIN ORTHOP RELAT R, P93; ZACHAZEWSKI JE, 1982, PHYS THER, V62, P453, DOI 10.1093/ptj/62.4.453	29	71	71	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	MAR	1997	77	3					240	247		10.1093/ptj/77.3.240			8	Orthopedics; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Rehabilitation	WL837	WOS:A1997WL83700002	9062567				2022-02-06	
J	Farooque, M; Hillered, L; Holtz, A; Olsson, Y				Farooque, M; Hillered, L; Holtz, A; Olsson, Y			Changes of extracellular levels of amino acids after graded compression trauma to the spinal cord: An experimental study in the rat using microdialysis	JOURNAL OF NEUROTRAUMA			English	Article						excitatory amino acids; glutamate; lactate; microdialysis; rat; spinal cord; trauma	CENTRAL-NERVOUS-SYSTEM; CONCUSSIVE BRAIN INJURY; LIPID-PEROXIDATION; GLUTAMATE; EDEMA; BLOOD; RECOVERY; INFUSION; ALBUMIN; PROTEIN	We evaluated in rats, the time course of changes in extracellular levels of amino acids, lactate and pyruvate, which ensued spinal cord compression of mild, moderate, and severe degrees. The neurochemical findings measured by HPLC were compared with known outcome measures of this model. A laminectomy of vertebrae Th-7 and Th-8 was made and a microdialysis probe was inserted in one dorsal horn. Fluid samples were collected at intervals of 10 min. Dialysate lactate and lactate/pyruvate ratios increased in proportion to the severity of injury, suggesting a progressive derangement of energy metabolism. Mild trauma, with no neurologic deficits, did not induce any remarkable change of amino acids, but taurine values were temporarily slightly elevated. Moderate trauma, leading to transient paraparesis, resulted in a transient rise of glutamate and taurine. Severe trauma resulting in paraplegia of the hind limbs induced profound changes of extracellular amino acids. Glutamate and aspartate rose 5-6 times above basal level. There were marked elevations of taurine, glycine, arginine, alanine, asparagine, histidine, serine, threonine, and tyrosine after this degree of trauma. Glutamate, aspartate, and taurine returned to the basal level within 50 min, whereas most of the other amino acids remained elevated throughout the experiment. Thus, we found profound disturbances of extracellular amino acids and energy metabolites. The elevations of glutamate and aspartate correlated with previously recorded data on neurological outcome. The composition of the early extracellular edema showed marked temporal changes related to the severity of impact. Future studies regarding treatment of traumatic edema should focus on its chemical composition as well as its volume since such edema is not uniform in composition.	UNIV UPPSALA HOSP, DEPT NEUROSURG, S-75185 UPPSALA, SWEDEN; UNIV UPPSALA HOSP, DEPT CLIN CHEM, S-75185 UPPSALA, SWEDEN		Farooque, M (corresponding author), UNIV UPPSALA HOSP, NEUROPATHOL LAB, S-75185 UPPSALA, SWEDEN.						ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Baethmann A, 1980, Adv Neurol, V28, P171; BEGGS JL, 1975, EXP NEUROL, V49, P86, DOI 10.1016/0014-4886(75)90196-X; BUISSON A, 1992, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1992, P417; DELGADO JMR, 1972, ARCH INT PHARMACOD T, V198, P9; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FAROOQUE M, 1992, ACTA NEUROPATHOL, V84, P613; FAROOQUE M, 1994, ACTA NEUROL SCAND, V89, P36; FAROOQUE M, 1995, J NEUROTRAUM, V12, P41, DOI 10.1089/neu.1995.12.41; GRAHAM LT, 1967, J NEUROCHEM, V14, P465, DOI 10.1111/j.1471-4159.1967.tb09545.x; GREENAMYRE JT, 1984, J NEUROSCI, V4, P2133; GRIFFITHS IR, 1974, J NEUROL SCI, V22, P291, DOI 10.1016/0022-510X(74)90002-1; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HALL ED, 1993, RES P ARNMD, V71, P81; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HALLSTROM A, 1989, J PHARMACOL METHOD, V22, P113; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HILLERED L, 1992, CLIN NEUROPHARMACOL, V15, P695; HOLTZ A, 1990, NEUROSURGERY, V26, P952, DOI 10.1227/00006123-199006000-00005; HOSSMANN KA, 1994, BRAIN PATHOL, V4, P23; IIZUKA H, 1987, J NEUROSURG, V66, P595, DOI 10.3171/jns.1987.66.4.0595; JANSEN KLR, 1990, NEUROSCI LETT, V108, P53, DOI 10.1016/0304-3940(90)90705-E; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kempski O, 1990, Adv Neurol, V52, P219; Li GL, 1996, ACTA NEUROPATHOL, V91, P155, DOI 10.1007/s004010050407; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; LI GL, 1995, RESTOR NEUROL NEUROS, V8, P189, DOI 10.3233/RNN-1995-8404; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NYSTROM B, 1988, ACTA NEUROL SCAND, V78, P460, DOI 10.1111/j.1600-0404.1988.tb03688.x; Olney J W, 1986, Adv Exp Med Biol, V203, P631; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; REHNCRONA S, 1989, J CEREBR BLOOD F MET, V9, P65, DOI 10.1038/jcbfm.1989.9; SANDLER AN, 1967, J NEUROSURG, V5, P638; SCHOUSBOE A, 1992, CAN J PHYSIOL PHARM, V70, pS356, DOI 10.1139/y92-283; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; SWANSON RA, 1994, J CEREBR BLOOD F MET, V14, P1; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; TOSSMAN U, 1986, ACTA PHYSIOL SCAND, V127, P533, DOI 10.1111/j.1748-1716.1986.tb07938.x; UNGERSTEDT U, 1974, B SCHWEIZ AKAD MED, V30, P44; WAGNER FC, 1981, J NEUROSURG, V54, P802, DOI 10.3171/jns.1981.54.6.0802; WELLS MR, 1978, EXP NEUROL, V61, P214, DOI 10.1016/0014-4886(78)90192-9; WESTERGREN I, 1992, BRAIN RES, V573, P324, DOI 10.1016/0006-8993(92)90781-4; WESTERGREN I, 1994, J NEUROCHEM, V62, P159; WESTERGREN I, 1993, ACTA NEUROPATHOL, V85, P285; ZHANG Y, 1993, SURG NEUROL, V39, P297, DOI 10.1016/0090-3019(93)90009-P; [No title captured]; [No title captured]	55	71	71	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1996	13	9					537	548		10.1089/neu.1996.13.537			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	VP266	WOS:A1996VP26600006	8913970				2022-02-06	
J	OMMAYA, AK				OMMAYA, AK			HEAD-INJURY MECHANISMS AND THE CONCEPT OF PREVENTIVE MANAGEMENT - A REVIEW AND CRITICAL SYNTHESIS	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	Head Injury 1994 - International Symposium on Head Injury Research	OCT 12-14, 1994	WASHINGTON, D.C.	Natl Highway Traff Safety Adm, Head Injury Res Program, George Washington Univ		TRAUMATIC BRAIN INJURY; BIOMECHANICS; CENTRIPETAL THEORY; TADD SYNDROME; VENOSPASM; HEAD INJURY MECHANISMS; PREVENTION	DIFFUSE AXONAL INJURY; NEUROFILAMENT SUBUNITS; CEREBRAL CONCUSSION; BRAIN; DETERIORATE; SECONDARY; HEMATOMA; SPORTS; IMPACT; MILD	Recent advances in head injury research have produced a plethora of useful data coupled with a paucity of conceptual integration across the four ways in which this research is pursued, These research orientations are the epidemiological, biomechanical, basic neuroscientific, and clinicopathologic/therapeutic (including rehabilitation). This overview of the history and current state of the art assumes that biomechanics is the basic science of causation in head injury research and when fully integrated with its counterparts, physiology and pathology, it can serve to overcome our conceptual handicaps, A paradigm integrating biomechanics into the sequence of preventive, protective, acute therapeutic, and rehabilitative interventions will. be described as the concept of preventive management, From this we derive the hypothesized claim that the exact biomechanics and the physiopathologic response at the time of injury (at the macroscopic and microscopic levels) determine the sequence of so-called secondary effects that are conceived as the inexorable delayed manifestations of the primary events and concomitant boundary conditions, Knowledge of these events will enable accurate predictions of the natural history and outcome of head injuries from observations carried out in the early acute phase, Examples to test this claim will be given with particular reference to the two types of traumatic brain injury (TBI) phenomenologically associated with disturbances of consciousness, the onset of which can be either immediate or delayed, The current economics and availability of computational power provide a significant opportunity for the development of selected experimental, physical, and simulated models of head injury on the basis of which the complex neurovascular and nonneural cellular and fluid elements of the nervous system may be accurately modeled. This approach will significantly improve the efficiency and quality of the essential biological and clinical observations and model experiments required to validate the theoretical methods and their predictions.	GEORGE WASHINGTON UNIV, MED CTR, WASHINGTON, DC 20052 USA		OMMAYA, AK (corresponding author), CYBORGAN INC, 8006 GLENBROOK RD, BETHESDA, MD 20814 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1982, RECENT ADV NEUROPATH, P165; ADAMS JH, 1990, HDB CLIN NEUROLOGY, V13, pCH3; ADVANI SH, 1982, HUMAN BODY DYNAMICS, P3; BLUMBERGS PC, 1967, J NEUROL NEUROSUR PS, V52, P839; BOOCK JR, 1990, P IRCOBI LYON; BRUCE DA, 1983, J NEUROSURG, V54, P285; Cairns H, 1941, BRIT MED J, V1941, P465, DOI 10.1136/bmj.2.4213.465; CHOI SC, 1994, NEUROSURGERY, V81, P169; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DENNYBROWN D, 1941, BRAIN, P64; ENGIN AE, 1970, J BIOMECH, V3, P283, DOI 10.1016/0021-9290(70)90030-8; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FISHMAN RA, 1993, NEUROLOGY, V43, P609, DOI 10.1212/WNL.43.3_Part_1.609; GADD CW, 1966, 10TH P STAPP CAR CRA; Gennarelli T. A., 1972, 16 STAPP CAR CRASH C, P296; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; GENNARELLI TA, 1971, 15TH P STAPP CAR CRA; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GOLDSMITH W, 1984, BIOMECHANICS IMPACT; GOLDSMITH W, 1966, HEAD INJURY C P; GOLDSMITH W, 1989, AAAM M NEED ANGULAR; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1993, HEAD INJURY; GRONWALL D, 1974, LANCET, V2, P605; Gurdjian ES, 1966, CLIN NEUROSURG, V12, P112; Gurdjian ES, 1975, IMPACT HEAD INJURY; HAYASHI T, 1969, J FAC ENG U TOKYO B, V30, P117; HAYASHI T, 1969, J FACULTY ENG U TO B, V30, P59; Holbourn AHS, 1943, LANCET, V2, P438; HUMAYUN MS, 1987, P SOC NEUROSCI, V2, P137; JANE J, 1982, SEMINARS NEUROLOGIC; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1972, LANCET, V1, P734; Kellie George, 1824, Trans Med Chir Soc Edinb, V1, P84; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEE Y-C, 1970, Mathematical Biosciences, V6, P473, DOI 10.1016/0025-5564(70)90080-5; Levin H.S., 1989, MILD HEAD INJURY; Levin HS., 1982, NEUROBEHAVIORAL CONS; LINDENBERG R, 1960, ARCH PATHOL, V69, P440; LINDGREN SO, 1966, ACTA CHIR SCAND S, V360; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; LOWENHIELM P, 1974, Z RECHTSMED, V74, P55, DOI 10.1007/BF01869185; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MAMELAK AN, 1994, P CNS CHICAGO, P75; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MEANEY DF, 1994, UNPUB ULTIMATE FAILU; Meaney DF, 1991, THESIS U PENNSYLVANI; MEANEY DF, 1994, UNPUB PROPOSED ADSH; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Ommaya A, 1967, 11 P STAPP CAR CRASH, P47; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1987, PUBLIC HEALTH REP, V102, P587; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OMMAYA AK, 1982, DTNH2282C07247 NAT T; OMMAYA AK, UNPUB HIST HEAD INJU; OMMAYA AK, 1985, IRCOBI P GOTEBERG, P32; Ommaya AK, 1968, J BIOMECH; OMMAYA AK, 1966, 10TH P STAPP CAR CRA; OMMAYA AK, 1983, DOTHS806434 PUBL; Ommaya AK, 1995, PRINCIPLES NUCLEAR M; OMMAYA AK, 1973, PB226828; OMMAYA AK, 1989, SPORTS NEUROLOGY, pCH8; OMMAYA AK, 1969, ACCIDENT PATHOLOGY; OMMAYA AK, 1994, ASTM STP, V1229; OMMAYA AK, 1982, NEUROLOGICAL SURGERY, V4, P1877; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pettus E., 1994, Society for Neuroscience Abstracts, V20, P421; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; REILLY PL, 1975, LANCET, V2, P375; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTS GW, 1994, LANCET, V342, P863; RUSSELL RW, 1969, HDB CLIN NEUROLOGY, V3, P293; Sano K, 1967, Neurol Med Chir (Tokyo), V9, P21, DOI 10.2176/nmc.9.21; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNIEDER RC, 1973, HEAD NECK INJURIES F; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SYMONDS C, 1962, LANCET, V1, P1; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; VIANO D, 1989, 881708 STAPP CAR CRA; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; 1985, INJURY AM CONTINUING; 1988, INJURY CONTROL REV S; [No title captured]	100	71	76	1	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	1995	12	4					527	546		10.1089/neu.1995.12.527			20	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Neurosciences & Neurology	RY920	WOS:A1995RY92000004	8683604				2022-02-06	
J	HICKS, RR; SMITH, DH; GENNARELLI, TA; MCINTOSH, T				HICKS, RR; SMITH, DH; GENNARELLI, TA; MCINTOSH, T			KYNURENATE IS NEUROPROTECTIVE FOLLOWING EXPERIMENTAL BRAIN INJURY IN THE RAT	BRAIN RESEARCH			English	Article						KYNURENATE; HEAD INJURY PATHOLOGY; EXCITOTOXICITY; NEUROPROTECTION; NMDA ANTAGONIST; HIPPOCAMPUS	D-ASPARTATE RECEPTORS; GLUTAMATE NEUROTOXICITY; NMDA RECEPTOR; NEURONAL DAMAGE; ISCHEMIA; ACID; MECHANISMS; ANTAGONIST; GLYCINE; VULNERABILITY	Pharmacologic inhibition of excitatory amino acid neurotransmission improves physiologic, metabolic, and neurobehavioral outcome following experimental brain trauma. However, no studies to date have demonstrated pharmacologically-induced attenuation of histopathological changes associated with experimental brain injury models. The present study examined the effects of kynurenate, an NMDA and non-NMDA receptor antagonist, on neuronal survival in the hippocampus after lateral fluid-percussion brain injury in the rat. Animals (n = 10/treatment) randomly received an intravenous injection of either kynurenate (300 mg/kg) or buffer (equal volume) 15 min following fluid-percussion brain injury of moderate severity. Two weeks after injury, animals were sacrificed and neuronal cell loss in the hippocampus was examined with Nissl staining. Selective loss of neurons in the CA3 region of the hippocampus, which has previously been characterized in this model of brain injury, was found to be significantly attenuated following kynurenate treatment (P < 0.05). These data suggest that pharmacologic compounds which are known to have beneficial effects on neurobehavioral and physiological outcome following brain injury may also significantly attenuate post-traumatic neuronal cell loss. Our results also support other recent data chat pharmacological intervention with an excitatory amino acid receptor antagonist may be of therapeutic value in the treatment of brain injury.	UNIV PENN,DEPT NEUROSURG,PHILADELPHIA,PA 19104		HICKS, RR (corresponding author), UNIV KENTUCKY,DIV PHYS THERAPY,ANNEX 1,LEXINGTON,KY 40536, USA.		smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R55NS026818, R01NS026818] Funding Source: NIH RePORTER		AUER RN, 1986, STROKE, V17, P699, DOI 10.1161/01.STR.17.4.699; BAKKER MHM, 1991, NEUROSCIENCE, V42, P387; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; BERTOLINO M, 1989, NEUROPHARMACOLOGY, V28, P453, DOI 10.1016/0028-3908(89)90078-6; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BUCHAN A, 1990, J NEUROSCI, V10, P311; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; FADEN AI, 1989, SCIENCE, V244, P780; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; HAYES RL, 1991, J NEUROTRAUM, V9, P173; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HEUTTNER JE, 1989, SCIENCE, V243, P1611; HICKS RR, 1992, J NEUROTRAUM, V9, P388; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JOHNSON KM, 1987, PSYCHOPHARMACOLOGY 3, P1581; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KEMP JA, 1993, TRENDS PHARMACOL SCI, V14, P20, DOI 10.1016/0165-6147(93)90108-V; KEMP JA, 1988, P NATL ACAD SCI USA, V85, P6547, DOI 10.1073/pnas.85.17.6547; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1992, EXCITATORY AMINO ACI, P247; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS RGM, 1988, TRENDS NEUROSCI, V11, P125, DOI 10.1016/0166-2236(88)90136-1; MOSSINGER JL, 1991, EXP NEUROL, V113, P10; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1986, NEUROSCI LETT, V65, P65, DOI 10.1016/0304-3940(86)90121-7; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SEISJO BK, 1988, ANN NY ACAD SCI, V522, P638; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SIMON RP, 1986, NEUROPATH APPL NEURO, V12, P567, DOI 10.1111/j.1365-2990.1986.tb00160.x; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, PSYCHOL REV, V99, P5821; TREVES A, 1992, HIPPOCAMPUS, V2, P189, DOI 10.1002/hipo.450020209; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; WRTHALL JR, 1992, EUR J PHARMACOL, V218, P273	52	71	72	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 29	1994	655	1-2					91	96		10.1016/0006-8993(94)91601-2			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	PD247	WOS:A1994PD24700013	7812795				2022-02-06	
J	TANNO, H; NOCKELS, RP; PITTS, LH; NOBLE, LJ				TANNO, H; NOCKELS, RP; PITTS, LH; NOBLE, LJ			BREAKDOWN OF THE BLOOD-BRAIN-BARRIER AFTER FLUID PERCUSSION BRAIN INJURY IN THE RAT .2. EFFECT OF HYPOXIA ON PERMEABILITY TO PLASMA-PROTEINS	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-ISCHEMIA; HEAD-INJURY; METABOLISM; EDEMA	Clinical studies have demonstrated that hypoxia after severe brain injury is common and significantly worsens neurologic outcome. We have, therefore, developed a rat model of posttraumatic hypoxic injury in order to identify the pathophysiologic responses after head injury that are worsened by this secondary insult. We examined the effect of hypoxia after brain injury on permeability of the blood-brain barrier to plasma proteins. Animals were divided into two experimental groups: group I (impact alone) and group IH (impact plus hypoxia). Rats were subjected to a lateral fluid percussive brain injury (4.8-5.2 atm). Animals in group IH were exposed to hypoxic conditions (10% O2) for 45 min immediately after injury. In each group, vascular permeability to endogenous immunoglobulins (IgG) and to horseradish peroxidase (HRP) was examined at the light microscopic level. IgG was immunolocalized in brain sections at 1-24 h after injury. In other studies, HRP was given i.v. either before impact or 10 min before killing. Permeability to this protein was assessed at 1-72 h after injury. The distribution of extravasated proteins was similar between the experimental groups at 1 h postinjury. Pronounced abnormal permeability to IgG and HRP (given before impact) occurred in discrete regions throughout both the ipsilateral and contralateral hemispheres. By 6 h after injury, a differential response of the blood-brain barrier was noted between groups I and IH. Widespread leakage of proteins was observed in the injured hemisphere in group IH. This finding was in sharp contrast to group I, in which extravasated proteins remained more localized in the injured hemisphere. The time course for reestablishment of the blood-brain barrier to HRP (given before killing) was determined. The impact site remained permeable to HRP up to at least 72 h postinjury within groups I and IH. In group I, the blood-brain barrier was reestablished in the parasagittal cortex and deep cortical layer by 6 h postinjury. In contrast, the blood-brain barrier in group IH was not restored in similar brain regions until 24 h postinjury. These studies demonstrate that (1) hypoxia after brain injury exacerbates the regional breakdown of the blood-brain barrier to circulating proteins, (2) this influence of hypoxia on permeability is not apparent immediately after injury but rather is expressed at 6 h after injury, and (3) hypoxia after traumatic brain injury delays recovery of the blood-brain barrier. These findings suggest that secondary posttraumatic hypoxia contributes to the vascular pathogenesis of brain injury.	SAN FRANCISCO GEN HOSP, DEPT NEUROSURG, 4M-39, 1001 POTRERO AVE, SAN FRANCISCO, CA 94110 USA; UNIV CALIF SAN FRANCISCO, DEPT NEUROSURG, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CNS INJURY & EDEMA RES CTR, SAN FRANCISCO, CA 94143 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS014543, P01NS014543] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS14543] Funding Source: Medline		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; DOBBIN J, 1989, J CEREBR BLOOD F MET, V9, P71, DOI 10.1038/jcbfm.1989.10; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; ITO U, 1975, ACTA NEUROPATHOL, V34, P1; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATSURADA K, 1973, SURGERY, V73, P191; KUROIWA T, 1985, ACTA NEUROPATHOL, V68, P122, DOI 10.1007/BF00688633; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LUTZ HA, 1982, HEAD INJURY BASIC CL, P221; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; SINHA RP, 1973, JAMA-J AM MED ASSOC, V224, P1258, DOI 10.1001/jama.224.9.1258; TODD NV, 1986, ACTA NEUROL SCAND, V74, P269; TORNHEIM PA, 1984, J NEUROSURG, V60, P473, DOI 10.3171/jns.1984.60.3.0473; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37	19	71	71	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	WIN	1992	9	4					335	347		10.1089/neu.1992.9.335			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	KH753	WOS:A1992KH75300003	1291693				2022-02-06	
J	ROCKSWOLD, GL; LEONARD, PR; NAGIB, MG				ROCKSWOLD, GL; LEONARD, PR; NAGIB, MG			ANALYSIS OF MANAGEMENT IN 33 CLOSED HEAD-INJURY PATIENTS WHO TALKED AND DETERIORATED	NEUROSURGERY			English	Article									UNIV MINNESOTA,DEPT NEUROSURG,MINNEAPOLIS,MN 55455		ROCKSWOLD, GL (corresponding author), HENNEPIN CTY MED CTR,DIV NEUROSURG,701 PK AVE S,MINNEAPOLIS,MN 55415, USA.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; DIAG FG, 1979, J NEUROSURG, V50, P217; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1975, LANCET, V1, P480; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; REILLY PL, 1975, LANCET, V2, P375; RICHARDS T, 1974, SURGERY, V75, P253; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SEELIG JM, 1981, J NEUROSURG, V55, P516, DOI 10.3171/jns.1981.55.4.0516	11	71	71	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JUL	1987	21	1					51	55		10.1227/00006123-198707000-00010			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	J1313	WOS:A1987J131300009	3614604				2022-02-06	
J	FILLEY, CM; CRANBERG, LD; ALEXANDER, MP; HART, EJ				FILLEY, CM; CRANBERG, LD; ALEXANDER, MP; HART, EJ			NEUROBEHAVIORAL OUTCOME AFTER CLOSED HEAD-INJURY IN CHILDHOOD AND ADOLESCENCE	ARCHIVES OF NEUROLOGY			English	Article									KENNEDY MEM HOSP, DEPT NEUROL, BOSTON, MA USA; VET ADM MED CTR JAMAICA PLAIN, DEPT NEUROL, BOSTON, MA 02130 USA; VET ADM MED CTR, BEDFORD, MA USA		FILLEY, CM (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT NEUROL, 4200 E 9TH AVE, DENVER, CO 80262 USA.						ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CRAFT AW, 1972, BMJ-BRIT MED J, V4, P200, DOI 10.1136/bmj.4.5834.200; Damasio A., 1979, CLIN NEUROPSYCHOLOGY, P360; Flach J, 1972, Scand J Rehabil Med, V4, P9; FULD PA, 1977, DEV MED CHILD NEUROL, V19, P495; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, MANAGEMENT HEAD INJU, P80; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1982, NEUROBEHAVIORAL CONS, P49; LISHMAN WA, 1978, ORGANIC PSYCHIATRY, P191; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; MITCHELL DE, 1973, LANCET, V2, P215; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163	31	71	71	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-9942	1538-3687		ARCH NEUROL-CHICAGO	Arch. Neurol.	FEB	1987	44	2					194	198		10.1001/archneur.1987.00520140058018			5	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	F8054	WOS:A1987F805400016	3813936				2022-02-06	
J	CROMPTON, MR				CROMPTON, MR			BRAINSTEM LESIONS DUE TO CLOSED HEAD INJURY	LANCET			English	Article																	Courville CB, 1945, TRAUMA; CROMPTON MR, 1966, LANCET, V2, P938; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FREIDE RL, 1961, ARCH NEUROLOGY, V4, P449; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; GRASHENKOV NI, 1965, 3 INT C NEUR SURG, P78; GURDJIAN ES, 1968, J NEUROSURG, V29, P70, DOI 10.3171/jns.1968.29.1.0070; GURDJIAN ES, 1958, MECHANISMS DIAGNOSIS; JEFFERSON G, 1960, SELECTED PATERS, V11, P526; ROSSI GF, 1965, EXCERPTA MED INT  93, P117; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; VONGIERKE HE, 1966, HEAD INJURY C P, P383; WRIGHT RL, 1966, J NEUROSURG, V25, P402, DOI 10.3171/jns.1966.25.4.0402; [No title captured]	14	71	71	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet		1971	1	7701					669	&					0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	I9695	WOS:A1971I969500003	4101614				2022-02-06	
J	RINDER, L; OLSSON, Y				RINDER, L; OLSSON, Y			STUDIES ON VASCULAR PERMEABILITY CHANGES IN EXPERIMENTAL BRAIN CONCUSSION .1. DISTRIBUTION OF CIRCULATING FLUORESCENT INDICATORS IN BRAIN AND CERVICAL CORD AFTER SUDDEN MECHANICAL LOADING OF BRAIN	ACTA NEUROPATHOLOGICA			English	Article																		0	71	71	0	0	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.		1968	11	3					183	&					0	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	B9000	WOS:A1968B900000001	5709759				2022-02-06	
J	GURDJIAN, ES; WEBSTER, JE; LISSNER, HR				GURDJIAN, ES; WEBSTER, JE; LISSNER, HR			OBSERVATIONS ON THE MECHANISM OF BRAIN CONCUSSION, CONTUSION, AND LACERATION	SURGERY GYNECOLOGY & OBSTETRICS			English	Article																	Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DURET H, 1920, TRAUMATISMES CRANIO; Goggio AF, 1941, J NEUROL PSYCHIATRY, V4, P11, DOI 10.1136/jnnp.4.1.11; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; Gurdjian ES, 1944, SURGERY, V16, P381; GURDJIAN ES, 1946, FED P, V5, P1; HADDAD BF, UNPUBLISHED; LeCount ER, 1920, J AMER MED ASSOC, V74, P501, DOI 10.1001/jama.1920.02620080003002; LITTRE A, 1705, HIST ACADEMIE ROYALE, P54; Petit J-L, 1774, TRAITE MALADIES CHIR; POLIS A, 1894, REV CHIR PARIS, V14, P274; POLIS A, 1894, REV CHIR, V14, P645; PUDENZ R, 1943, DEC M ASS RES NERV M; WALKER EA, 1944, J NEUROSURG, V1, P103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WYCIS HT, 1947, CALIFORNIA NEUROL, V8, P292	16	71	71	0	3	FRANKLIN H MARTIN FOUNDATION	CHICAGO	55 E ERIE ST, CHICAGO, IL 60611	0039-6087			SURG GYNECOL OBSTET	Surg. Gynecol. Obstet.		1955	101	6					680	690					11	Obstetrics & Gynecology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Obstetrics & Gynecology; Surgery	WF745	WOS:A1955WF74500004	13274275				2022-02-06	
J	Yan, RJ; Sun, S; Yang, J; Long, W; Wang, JY; Mu, XY; Li, QF; Hao, WT; Zhang, SF; Liu, HL; Gao, YL; Ouyang, LF; Chen, JC; Liu, SJ; Zhang, XD; Ming, D				Yan, Ruijuan; Sun, Si; Yang, Jiang; Long, Wei; Wang, Junying; Mu, Xiaoyu; Li, Qifeng; Hao, Wenting; Zhang, Shaofang; Liu, Haile; Gao, Yalong; Ouyang, Lufei; Chen, Junchi; Liu, Shuangjie; Zhang, Xiao-Dong; Ming, Dong			Nanozyme-Based Bandage with Single-Atom Catalysis for Brain Trauma	ACS NANO			English	Article						nanozyme; single-atom catalysis; brain trauma; wound repair; noninvasive therapy	CERIA NANOPARTICLES; LOW-TEMPERATURE; NEUROPROTECTION; ANTIOXIDANTS; DISEASE; PROTECT	Neurotrauma is one of the most serious traumatic injuries, which can induce an excess amount of reactive oxygen and nitrogen species (RONS) around the wound, triggering a series of biochemical responses and neuroinflammation. Traditional antioxidant-based bandages can effectively decrease infection via preventing oxidative stress, but its effectiveness is limited to a short period of time due to the rapid loss of electron-donating ability. Herein, we developed a nanozyme-based bandage using single-atom Pt/CeO2 with a persistent catalytic activity for noninvasive treatment of neurotrauma. Single-atom Pt induced the lattice expansion and preferred distribution on (111) facets of CeO2, enormously increasing the endogenous catalytic activity. Pt/CeO2 showed a 2-10 times higher scavenging activity against RONS as well as 3-10 times higher multienzyme activities compared to CeO2 clusters. The single-atom Pt/CeO2 retained the long-lasting catalytic activity for up to a month without obvious decay due to enhanced electron donation through the Mars-van Krevelen reaction. In vivo studies disclosed that the nanozyme-based bandage at the single-atom level can significantly improve the wound healing of neurotrauma and reduce neuroinflammation.	[Yan, Ruijuan; Sun, Si; Wang, Junying; Mu, Xiaoyu; Zhang, Shaofang; Liu, Haile; Ouyang, Lufei; Chen, Junchi; Zhang, Xiao-Dong] Tianjin Univ, Sch Sci, Dept Phys, Tianjin 300350, Peoples R China; [Yan, Ruijuan; Sun, Si; Wang, Junying; Mu, Xiaoyu; Zhang, Shaofang; Liu, Haile; Ouyang, Lufei; Chen, Junchi; Zhang, Xiao-Dong] Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China; [Long, Wei] Chinese Acad Med Sci & Peking Union Med Coll, Inst Radiat Med, 238 Baidi Rd, Tianjin 300192, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China; [Li, Qifeng; Gao, Yalong] Tianjin Med Univ, Gen Hosp, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin 300052, Peoples R China; [Yang, Jiang] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Hao, Wenting; Liu, Shuangjie; Ming, Dong] Tianjin Univ, Acad Med Engn & Translat Med, Tianjin Int Joint Res Ctr Neural Engn, Tianjin 300072, Peoples R China		Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Dept Phys, Tianjin 300350, Peoples R China.; Zhang, XD (corresponding author), Tianjin Univ, Sch Sci, Tianjin Key Lab Low Dimens Mat Phys & Preparing T, Tianjin 300350, Peoples R China.; Ming, D (corresponding author), Tianjin Univ, Acad Med Engn & Translat Med, Tianjin Int Joint Res Ctr Neural Engn, Tianjin 300072, Peoples R China.	xiaodongzhang@tju.edu.cn; richardming@tju.edu.cn	Zhang, Xiaodong/F-4665-2015; Nanozymes, Nanozymes/D-8197-2019	Zhang, Xiaodong/0000-0002-7212-0138; 	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [91859101, 81971744, U1932107, 81471786]; National Natural Science Foundation of Tianjin [19JCZDJC34000]; Innovation Foundation of Tianjin University	This work was financially supported by the National Natural Science Foundation of China (Grant Nos. 91859101, 81971744, U1932107, and 81471786) and National Natural Science Foundation of Tianjin (No. 19JCZDJC34000), the Innovation Foundation of Tianjin University.	Bao QQ, 2018, ACS NANO, V12, P6794, DOI 10.1021/acsnano.8b01994; Bhabak KP, 2010, ACCOUNTS CHEM RES, V43, P1408, DOI 10.1021/ar100059g; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bruix A, 2012, J AM CHEM SOC, V134, P8968, DOI 10.1021/ja302070k; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Das R, 2019, ACS NANO, V13, P229, DOI 10.1021/acsnano.8b05370; Ding H, 2019, NANO LETT, V19, P203, DOI 10.1021/acs.nanolett.8b03709; Dvorak F, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10801; Fan KL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03903-8; Fan KL, 2012, NAT NANOTECHNOL, V7, P459, DOI [10.1038/nnano.2012.90, 10.1038/NNANO.2012.90]; Feng YX, 2018, J PHYS CHEM C, V122, P22460, DOI 10.1021/acs.jpcc.8b05815; Gao L, 2015, ACS NANO, V9, P10979, DOI 10.1021/acsnano.5b04261; Gao LZ, 2007, NAT NANOTECHNOL, V2, P577, DOI 10.1038/nnano.2007.260; Ghosh S., 2018, ANGEW CHEM INT EDIT, V130, P4600, DOI [DOI 10.1002/ANGE.201800681, 10.1002/anie.201800681]; Gupta A, 2018, ACS NANO, V12, P89, DOI 10.1021/acsnano.7b07496; Heckman KL, 2013, ACS NANO, V7, P10582, DOI 10.1021/nn403743b; Huang YY, 2019, CHEM REV, V119, P4357, DOI 10.1021/acs.chemrev.8b00672; Huo MF, 2019, ACS NANO, V13, P2643, DOI 10.1021/acsnano.9b00457; Jiao L., 2019, ANGEW CHEM INT EDIT, DOI [10.1002/ange.201905645, DOI 10.1002/ANGE.201905645]; Jones J, 2016, SCIENCE, V353, P150, DOI 10.1126/science.aaf8800; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kim CK, 2012, ANGEW CHEM INT EDIT, V51, P11039, DOI 10.1002/anie.201203780; Kopelent R, 2015, ANGEW CHEM INT EDIT, V54, P8728, DOI 10.1002/anie.201503022; Kwon HJ, 2016, ACS NANO, V10, P2860, DOI 10.1021/acsnano.5b08045; Li YY, 2015, ANGEW CHEM INT EDIT, V54, P1832, DOI 10.1002/anie.201410398; Lin H, 2018, CHEM SOC REV, V47, P1938, DOI 10.1039/c7cs00471k; Liu BW, 2017, NANO RES, V10, P1125, DOI 10.1007/s12274-017-1426-5; Liu F, 2019, ADV MATER, V31, DOI 10.1002/adma.201902885; Manea F, 2004, ANGEW CHEM INT EDIT, V43, P6165, DOI 10.1002/anie.200460649; Mu XY, 2019, ACS NANO, V13, P1870, DOI 10.1021/acsnano.8b08045; Neri S, 2017, J AM CHEM SOC, V139, P1794, DOI 10.1021/jacs.6b12932; Nie L, 2017, SCIENCE, V358, P1419, DOI 10.1126/science.aao2109; Qiao BT, 2011, NAT CHEM, V3, P634, DOI [10.1038/nchem.1095, 10.1038/NCHEM.1095]; Reading-Ikkanda L, 2015, NATURE, V527, pS218, DOI 10.1038/527S217a; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Singh N, 2017, ANGEW CHEM INT EDIT, V56, P14267, DOI 10.1002/anie.201708573; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Song YC, 2016, 2016 3RD INTERNATIONAL CONFERENCE ON ADVANCED EDUCATION AND TECHNOLOGY AND MANAGEMENT SCIENCE (AETMS 2016), P464; Song YK, 2018, ADV MATH PHYS, V2018, DOI 10.1155/2018/2028657; Sood A, 2014, ADV WOUND CARE, V3, P511, DOI 10.1089/wound.2012.0401; Sun HJ, 2018, ANGEW CHEM INT EDIT, V57, P9224, DOI 10.1002/anie.201712469; Tamura M, 2015, ANGEW CHEM INT EDIT, V54, P864, DOI 10.1002/anie.201409601; Tang Y, 2017, J PHYS CHEM C, V121, P11281, DOI 10.1021/acs.jpcc.7b00313; Vernekar AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6301; Wang AQ, 2018, NAT REV CHEM, V2, P65, DOI 10.1038/s41570-018-0010-1; Wang CL, 2017, ACS CATAL, V7, P887, DOI 10.1021/acscatal.6b02685; Wang Y, 2019, CHEM REV, V119, P1806, DOI 10.1021/acs.chemrev.8b00501; Wang ZZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05798-x; Wei H, 2013, CHEM SOC REV, V42, P6060, DOI 10.1039/c3cs35486e; Wu JJX, 2019, CHEM SOC REV, V48, P1004, DOI 10.1039/c8cs00457a; Xu BL, 2019, ANGEW CHEM INT EDIT, V58, P4911, DOI 10.1002/anie.201813994; Xu YQ, 2019, ANGEW CHEM INT EDIT, V58, P5572, DOI 10.1002/anie.201813771; Yang BW, 2019, CHEM REV, V119, P4881, DOI 10.1021/acs.chemrev.8b00626; Yao J, 2018, CHEM SCI, V9, P2927, DOI 10.1039/c7sc05476a; Yu TY, 2010, ADV MATER, V22, P5188, DOI 10.1002/adma.201002763; Zhang Y, 2018, ACS NANO, V12, P651, DOI 10.1021/acsnano.7b07746; Zhang ZJ, 2017, J AM CHEM SOC, V139, P5412, DOI 10.1021/jacs.7b00601	59	70	72	54	356	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1936-0851	1936-086X		ACS NANO	ACS Nano	OCT	2019	13	10					11552	11560		10.1021/acsnano.9b05075			9	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science	JH5IF	WOS:000492801600065	31553878				2022-02-06	
J	Liu, W; Chen, YH; Meng, J; Wu, MF; Bi, FF; Chang, CC; Li, H; Zhang, LJ				Liu, Wei; Chen, Yuhua; Meng, Jiao; Wu, Minfei; Bi, Fangfang; Chang, Cuicui; Li, Hua; Zhang, Liangjun			Ablation of caspase-1 protects against TBI-induced pyroptosis in vitro and in vivo	JOURNAL OF NEUROINFLAMMATION			English	Article						TBI; Inflammation; Neuroinflammation; Pyroptosis; Caspase-1; Neuron damage	TRAUMATIC BRAIN-INJURY; INFLAMMASOME ACTIVATION; NLRP3 INFLAMMASOME; CELL-DEATH; INHIBITION; ISCHEMIA; PORE; NEUROPROTECTION; APOPTOSIS; STROKE	Background: Traumatic brain injury (TBI) is a critical public health and socioeconomic problem throughout the world. Inflammation-induced secondary injury is one of the vital pathogenic parameters of TBI. Molecular signaling cascades of pyroptosis, a specific type of cellular necrosis, are key drivers of TBI-induced inflammation. Methods: In this study, mice with genetically ablated caspase-1 (caspase-1(-/-)) were subjected to controlled cortical impact injury in vivo, and primary neuron deficient in caspase-1 through siRNA knockdown and pharmacologic inhibition was stimulated by mechanical scratch, equiaxial stretch, and LPS/ATP in vitro. We evaluated the effects of caspase-1 deficiency on neurological deficits, inflammatory factors, histopathology, cell apoptosis, and pyroptosis. Results: During the acute post-injury period (0-48 h) in vivo, motor deficits, anti-inflammatory cytokines (TGF-beta and IL-10), pro-inflammatory cytokines (IFN-gamma, IL-1 beta, and IL-18), and blood lactate dehydrogenase (LDH), as well as pyroptosis-related proteins (caspase-1, caspase-1 fragments, caspase-11 and GSDMD), were increased. Caspase-1 was activated in the cortex of TBI mice. Inflammatory activation was more profound in injured wild-type mice than in caspase-1(-/-) mice. In vitro, mechanical scratch, equiaxial stretch, and LPS/ATP-induced neuron pyroptosis, apoptosis, LDH release, and increased expression of inflammatory factors. The effects of mechanical and inflammatory stress were reduced through inhibition of caspase-1 activity through siRNA knockdown and pharmacologic inhibition. Conclusion: Collectively, these data demonstrate that pyroptosis is involved in neuroinflammation and neuronal injury after TBI, and ablation of caspase-1 inhibits TBI-induced pyroptosis. Our findings suggest that caspase-1 may be a potential target for TBI therapy.	[Liu, Wei; Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui] Peihua Univ, Dept Med Sci, Res Ctr, Xian 710125, Shaanxi, Peoples R China; [Liu, Wei; Chen, Yuhua; Meng, Jiao; Bi, Fangfang; Chang, Cuicui; Li, Hua; Zhang, Liangjun] Shaanxi Fourth People Hosp, Res Ctr, Dept Med Sci, Xian 710043, Shaanxi, Peoples R China; [Wu, Minfei] Jilin Univ, Hosp 2, Dept Orthoped, Changchun 8974617, Jilin, Peoples R China		Liu, W; Chen, YH (corresponding author), Peihua Univ, Dept Med Sci, Res Ctr, Xian 710125, Shaanxi, Peoples R China.	vincelau@sina.com; chenyuhua.358@163.com			Shaanxi Fourth People Hospital [2017SY-006]	This work was supported by the Development Funding of Shaanxi Fourth People Hospital (2017SY-006).	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Albalawi F, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00227; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Barrington J, 2017, BRAIN PATHOL, V27, P205, DOI 10.1111/bpa.12476; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Chen QX, 2014, INNATE IMMUN-LONDON, V20, P290, DOI 10.1177/1753425913490575; Corrigan F, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0738-9; Dang BQ, 2017, NEURAL PLAST, V2017, DOI 10.1155/2017/1582182; de Zoete MR, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016287; Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590; DiPeso L, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.70; Dobrachinski F, 2017, J NEUROTRAUM, V34, P1318, DOI 10.1089/neu.2016.4563; Esterov D, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7080100; Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x; Gardner AJ, 2017, PHYS MED REH CLIN N, V28, P413, DOI 10.1016/j.pmr.2016.12.014; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hiebert JB, 2015, AM J MED SCI, V350, P132, DOI 10.1097/MAJ.0000000000000506; Irrera N, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00459; Janowitz T, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000330; Julien J, 2017, ANN PHYS REHABIL MED, V60, P347, DOI 10.1016/j.rehab.2017.03.009; Kaushal V, 2015, CELL DEATH DIFFER, V22, P1676, DOI 10.1038/cdd.2015.16; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Li R, 2017, BRAIN RES BULL, V130, P236, DOI 10.1016/j.brainresbull.2017.01.016; Lin QR, 2016, TOXICOL APPL PHARM, V292, P56, DOI 10.1016/j.taap.2015.12.027; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Liu ZJ, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12414; Mezzaroma E, 2011, P NATL ACAD SCI USA, V108, P19725, DOI 10.1073/pnas.1108586108; Mortezaee K, 2017, J CELL PHYSL; Okondo MC, 2017, NAT CHEM BIOL, V13, P46, DOI [10.1038/NCHEMBIO.2229, 10.1038/nchembio.2229]; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Rao W, 2015, BBA-MOL BASIS DIS, V1852, P2402, DOI 10.1016/j.bbadis.2015.08.014; Ray AM, 2000, BRAIN RES, V867, P62, DOI 10.1016/S0006-8993(00)02230-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Ross J, 2007, NEUROPHARMACOLOGY, V53, P638, DOI 10.1016/j.neuropharm.2007.07.015; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Russo MV, 2016, SCIENCE, V353, P783, DOI 10.1126/science.aaf6260; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089; Shradhanjali A, 2017, BIOCHEM BIOPH RES CO, V488, P590, DOI 10.1016/j.bbrc.2017.05.092; Sun M, 2017, BRAIN BEHAV IMMUN; Sun Q, 2016, J LEUKOCYTE BIOL, V100, P961, DOI 10.1189/jlb.3MR0516-224R; Thelin EP, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00351; Van Horn JD, 2017, TRENDS NEUROSCI, V40, P39, DOI 10.1016/j.tins.2016.10.007; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wellington M, 2014, EUKARYOT CELL, V13, P329, DOI 10.1128/EC.00336-13; Wu DD, 2016, SHOCK, V46, P329, DOI 10.1097/SHK.0000000000000595; Wu HY, 2016, CELL PHYSIOL BIOCHEM, V40, P1692, DOI 10.1159/000453218; Xu X, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0934-2; Yang DH, 2015, IMMUNITY, V43, P923, DOI 10.1016/j.immuni.2015.10.009; Ye YQ, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5841814; Yu HS, 2016, J TISSUE ENG, V7, DOI [10.1177/2041731416676337, 10.1177/2041731415618342]; Yuan JY, 2016, CELL, V167, P1693, DOI 10.1016/j.cell.2016.11.047; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	58	70	76	5	22	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 19	2018	15								48	10.1186/s12974-018-1083-y			16	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	FX3LI	WOS:000425973100001	29458437	Green Published, gold			2022-02-06	
J	Lindquist, LK; Love, HC; Elbogen, EB				Lindquist, Lisa K.; Love, Holly C.; Elbogen, Eric B.			Traumatic Brain Injury in Iraq and Afghanistan Veterans: New Results From a National Random Sample Study	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DEPLOYED MILITARY PERSONNEL; PSYCHIATRIC-DISORDERS; SUICIDE RISK; DEPRESSION; ASSOCIATION; PREVALENCE; DIAGNOSES; SYMPTOMS; SOLDIERS	This study randomly sampled post -9/11 military veterans and reports on causes, predictors, and frequency of traumatic brain injury (TBI) (N=1,388). A total of 17.3% met criteria for TBI during military service, with about one-half reporting multiple head injuries, which were related to higher rates of posttraumatic stress disorder, depression, back pain, and suicidal ideation. The most common mechanisms of TBI included blasts (33.1%), objects hitting head (31.7%), and fall (13.5%). TBI was associated with enlisted rank, male gender, high combat exposure, and sustaining TBI prior to military service. Clinical and research efforts in veterans should consider TBI mechanism, effects of cumulative TBI, and screening for premilitary TBI.	[Lindquist, Lisa K.; Love, Holly C.] Univ North Carolina Chapel Hill, Dept Psychiat, Chapel Hill, NC USA; [Elbogen, Eric B.] Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; [Elbogen, Eric B.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA		Elbogen, EB (corresponding author), Durham Vet Affairs Med Ctr, Durham, NC 27705 USA.; Elbogen, EB (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27708 USA.	eric.elbogen@duke.edu			Mid-Atlantic Mental Illness Research, Education and Clinical Center; Office of Research and Development Clinical Science, Department of Veterans AffairsUS Department of Veterans Affairs; Department of DefenseUnited States Department of Defense [W81XWH1110796]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH080988] Funding Source: NIH RePORTER	Supported by the Mid-Atlantic Mental Illness Research, Education and Clinical Center, the Office of Research and Development Clinical Science, Department of Veterans Affairs, the Department of Defense (grant W81XWH1110796), and the National Institute of Mental Health (grant R01MH080988).	Adams RS, 2012, J HEAD TRAUMA REHAB, V27, P349, DOI 10.1097/HTR.0b013e318268db94; Amick MM, 2013, J INT NEUROPSYCH SOC, V19, P792, DOI 10.1017/S1355617713000544; Armed Forces Health Surveillance Center, 2013, EXT CAUS TRAUM BRAIN; Beckham JC, 2008, MIL MED, V173, P448, DOI 10.7205/MILMED.173.5.448; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Bryan CJ, 2013, JAMA PSYCHIAT, V70, P686, DOI 10.1001/jamapsychiatry.2013.1093; Bryan CJ, 2013, J HEAD TRAUMA REHAB, V28, P13, DOI 10.1097/HTR.0b013e31826c73cc; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Center DMD, 2010, FY2009 ANN DEM PROF, V08-10; Cifu DX, 2013, J REHABIL RES DEV, V50, P1169, DOI 10.1682/JRRD.2013.01.0006; Dillman D.A., 2009, INTERNET MAIL MIXED, V3rd ed.; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; Formisano R, 2005, BRAIN INJURY, V19, P159, DOI 10.1080/02699050400017163; Gray GC, 2000, AM J EPIDEMIOL, V151, P63, DOI 10.1093/oxfordjournals.aje.a010123; Hellmuth JC, 2012, J TRAUMA STRESS, V25, P527, DOI 10.1002/jts.21732; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; King D. W., 2003, MANUAL DEPLOYMENT RI; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; McDonald SD, 2009, J ANXIETY DISORD, V23, P247, DOI 10.1016/j.janxdis.2008.07.007; Pogoda T, 2014, J HEAD TRAUMA REHABI; Regasa LE, 2016, J HEAD TRAUMA REHAB, V31, pE28, DOI 10.1097/HTR.0000000000000155; Rona RJ, 2012, J HEAD TRAUMA REHAB, V27, P33, DOI 10.1097/HTR.0b013e318212f814; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scholten AC, 2016, J NEUROTRAUM; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Steadman HJ, 2000, LAW HUMAN BEHAV, V24, P83, DOI 10.1023/A:1005478820425; Straus MA, 2005, VIOLENCE WOMEN CLASS; Tanielian T., 2008, INVISIBLE WOUNDS WAR; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080	37	70	71	0	3	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2017	29	3					254	259		10.1176/appi.neuropsych.16050100			6	Clinical Neurology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	FE5CN	WOS:000408229700008	28121256	Green Accepted, Bronze			2022-02-06	
J	Taylor, DJ; Pruiksma, KE; Hale, WJ; Kelly, K; Maurer, D; Peterson, AL; Mintz, J; Litz, BT; Williamson, DE				Taylor, Daniel J.; Pruiksma, Kristi E.; Hale, Willie J.; Kelly, Kevin; Maurer, Douglas; Peterson, Alan L.; Mintz, Jim; Litz, Brett T.; Williamson, Douglas E.		STRONG STAR Consortium	Prevalence, Correlates, and Predictors of Insomnia in the US Army prior to Deployment	SLEEP			English	Article						anxiety; Army; depression; insomnia; military; PTSD	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCE; PSYCHIATRIC-DISORDERS; LIFE EVENTS; DEPRESSION; MILITARY; SEVERITY; SYMPTOMS; EPIDEMIOLOGY	Study Objectives: To determine the prevalence, correlates, and predictors of insomnia in US Army personnel prior to deployment. Methods: Cross-sectional cohort design assessing insomnia and other psychosocial variables in active duty service members (n = 4,101), at Fort Hood, Texas, prior to military deployment. Insomnia was defined as an Insomnia Severity Index >= 15. Results: The prevalence of insomnia was 19.9%. Enlisted personnel were five times more likely to report insomnia than officers (odds ratio [OR] = 5.17). Insomnia was higher among American Indian/Alaskan Natives than other groups (ORs = 1.86-2.85). Those in the Insomnia Group were older, had longer military careers, and reported more marriages, children, and military deployments (ds = 0.13-0.34) than the No Insomnia group. The Insomnia Group reported more severe mental health symptoms, more recent stressful life events, greater childhood abuse, and lower levels of trait resilience, social support, and unit cohesion (Cohen ds = 0.27-1.29). After controlling for covariates, the Insomnia Group was more likely to have a history of head injuries and clinically significant posttraumatic stress disorder (PTSD), anxiety, depression, alcohol use problems, back pain, extremity pain, headaches, and fatigue (ORs = 1.40-3.30). A simultaneous logistic regression found that greater PTSD, depression, fatigue, stressful life events, headaches, anxiety, alcohol use problems, extremity pain, history of head injury, childhood physical neglect, back pain, number of times married, and lower leader support/unit cohesion and tangible social support were statistically significant predictors of insomnia status. Conclusions: Insomnia occurs in about one of five service members prior to a military deployment and is associated with a wide array of psychosocial stressors and mental and physical health problems.	[Taylor, Daniel J.] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA; [Pruiksma, Kristi E.; Hale, Willie J.; Peterson, Alan L.; Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Kelly, Kevin; Maurer, Douglas] Carl R Darnall Army Med Ctr, Ft Hood, TX USA; [Peterson, Alan L.] South Texas Vet Healthcare Syst, San Antonio, TX USA; [Peterson, Alan L.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA; [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MS USA; [Litz, Brett T.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Williamson, Douglas E.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA; [Williamson, Douglas E.] Durham VA Med Ctr, Durham, NC USA		Taylor, DJ (corresponding author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.	Daniel.Taylor@unt.edu		Taylor, Daniel/0000-0003-3433-2516; Williamson, Douglas/0000-0002-5310-1716; Litz, Brett/0000-0002-0479-8887	US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program [W81XWH-08-2-0110, W81XWH-08-02-109, W81XWH-10-1-0828]	The work was performed at the United States Army installation at Fort Hood in Killeen, TX. The views expressed in this article are solely those of the authors and do not reflect an endorsement by or the official policy of the US Army, the US Air Force, the Department of Defense, the Department of Veterans Affairs, or the US Government. Funding for this work was made possible by the US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program awards W81XWH-08-2-0110 (Dr. Williamson), W81XWH-08-02-109 (Dr. Peterson), and W81XWH-10-1-0828 (Dr. Taylor). There was no other financial support for this research nor are there any conflicts of interest for any of the authors. No off-label or investigational drugs were used in this study. Portions of these findings have previously been presented: Taylor DJ, Pruiksma KE, Kelly K, Maurer D, Litz B, Peterson A, Mintz J, Williamson DE. Insomnia in the military: prevalence and comorbidities. Sleep 2015;38(Abstract Suppl):A614.	Affleck G, 1996, PAIN, V68, P363, DOI 10.1016/S0304-3959(96)03226-5; American Psychiatric Association, 2012, DIAGN STAT MAN MENT, V5th; Babson KA, 2010, J ANXIETY DISORD, V24, P1, DOI 10.1016/j.janxdis.2009.08.002; Bader K, 2007, J SLEEP RES, V16, P285, DOI 10.1111/j.1365-2869.2007.00608.x; Baglioni C, 2011, J AFFECT DISORDERS, V135, P10, DOI 10.1016/j.jad.2011.01.011; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bernstein D., 1998, MANUAL CHILDHOOD TRA; Bernstein DP, 2003, CHILD ABUSE NEGLECT, V27, P169, DOI 10.1016/S0145-2134(02)00541-0; Brailey K, 2007, J TRAUMA STRESS, V20, P495, DOI 10.1002/jts.20234; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Brown G.K., 1996, BDI 2 BECK DEPRESSIO; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Budhiraja R, 2011, SLEEP, V34, P859, DOI 10.5665/SLEEP.1114; Buysse DJ, 2008, SLEEP, V31, P473, DOI 10.1093/sleep/31.4.473; Chambers E, 1998, CHILD ABUSE NEGLECT, V22, P753, DOI 10.1016/S0145-2134(98)00059-3; Chang PP, 1997, AM J EPIDEMIOL, V146, P105; Cohen S, 1983, APPL SOC PSYCHOL, V58, P304; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; DOHRENWEND BS, 1978, J HEALTH SOC BEHAV, V19, P205, DOI 10.2307/2136536; DRYMAN A, 1991, ACTA PSYCHIAT SCAND, V84, P1, DOI 10.1111/j.1600-0447.1991.tb01410.x; Edinger JD, 2004, SLEEP, V27, P1567, DOI 10.1093/sleep/27.8.1567; Farrell EI, 2013, THESIS; Fidell L.S., 2007, USING MULTIVARIATE S, V5, P481; FOLEY DJ, 1995, SLEEP, V18, P425, DOI 10.1093/sleep/18.6.425; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; FRIEDMAN GD, 1974, PSYCHOSOM MED, V36, P327, DOI 10.1097/00006842-197407000-00007; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2013, AM J PSYCHIAT, V170, P372, DOI 10.1176/appi.ajp.2012.12040432; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jarrett M, 2000, DIGEST DIS SCI, V45, P952, DOI 10.1023/A:1005581226265; Johnson DC, 2011, MIL MED, V176, P161, DOI 10.7205/MILMED-D-10-00258; Johnson EO, 2006, J PSYCHIATR RES, V40, P700, DOI 10.1016/j.jpsychires.2006.07.008; Katz DA, 1998, ARCH INTERN MED, V158, P1099, DOI 10.1001/archinte.158.10.1099; Kripke Daniel F, 2001, Clin J Womens Health, V1, P244, DOI 10.1053/cjwh.2001.30491; Kroenke K, 2002, PSYCHOSOM MED, V64, P258, DOI 10.1097/00006842-200203000-00008; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; KUPPERMANN M, 1995, J GEN INTERN MED, V10, P25, DOI 10.1007/BF02599573; Lavie P, 2001, NEW ENGL J MED, V345, P1825, DOI 10.1056/NEJMra012893; Lehavot K, 2012, AM J PREV MED, V42, P473, DOI 10.1016/j.amepre.2012.01.006; Lichstein KL, 2003, BEHAV RES THER, V41, P427, DOI 10.1016/S0005-7967(02)00023-2; Lichstein KL, 2004, EPIDEMIOLOGY OF SLEEP AGE, GENDER, AND ETHNICITY, P1; LUNDBERG U, 1994, SCAND J PSYCHOL, V35, P315, DOI 10.1111/j.1467-9450.1994.tb00956.x; McCracken Lance M, 2002, Pain Res Manag, V7, P75; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; Moldofsky H, 2001, SLEEP MED REV, V5, P387, DOI 10.1053/smrv.2001.0179; Morin CM, 2011, SLEEP, V34, P601, DOI 10.1093/sleep/34.5.601; Morin CM, 2006, SLEEP MED, V7, P123, DOI 10.1016/j.sleep.2005.08.008; Morin CM, 2003, PSYCHOSOM MED, V65, P259, DOI 10.1097/01.PSY.0000030391.09558.A3; Morin CM, 1993, INSOMNIA PSYCHOL ASS; Morrow CE, 2013, MIL PSYCHOL, V25, P568, DOI 10.1037/mil0000021; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Nakata A, 2004, SOC SCI MED, V59, P1719, DOI 10.1016/j.socscimed.2004.02.002; National Institutes of Health, 2001, NIH POL REP RAC ETHN; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; Oliver LW, 1999, MIL PSYCHOL, V11, P57, DOI 10.1207/s15327876mp1101_4; Pallesen S, 2001, SLEEP, V24, P771; Perlis ML, 1997, J AFFECT DISORDERS, V42, P209, DOI 10.1016/S0165-0327(96)01411-5; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Phillips B, 2007, J CLIN SLEEP MED, V3, P489; Plumb TR, 2014, PSYCHOL SERV, V11, P209, DOI 10.1037/a0034958; Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81; ROSS RJ, 1989, AM J PSYCHIAT, V146, P697; ROTH T, 1988, INT CLIN PSYCHOPHARM, V3, P111; Ruiter ME, 2010, BEHAV SLEEP MED, V8, P246, DOI 10.1080/15402002.2010.509251; Sabanayagam C, 2011, J ENV PUBLIC HLTH, V2011; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz S, 1999, J PSYCHOSOM RES, V47, P313, DOI 10.1016/S0022-3999(99)00029-X; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Spielberger CD., 1988, STATE TRAIT ANGER EX; Spoormaker VI, 2008, SLEEP MED REV, V12, P169, DOI 10.1016/j.smrv.2007.08.008; Taylor DJ, 2008, SLEEP, V31, P447, DOI 10.1093/sleep/31.4.447; Taylor DJ, 2007, SLEEP, V30, P213, DOI 10.1093/sleep/30.2.213; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Taylor DJ, 2005, SLEEP, V28, P1457, DOI 10.1093/sleep/28.11.1457; Troxel WM, 2015, SLEEP MIL PROM HLTH; Vaitkus MA., 1994, UNIT MANNING SYSTEM; Walsh JK, 2004, J CLIN PSYCHIAT, V65, P13; WATERS WF, 1993, SLEEP, V16, P128, DOI 10.1093/sleep/16.2.128; Weathers F., 1993, INT SOC TRAUM STRESS; Weissman MM, 1997, GEN HOSP PSYCHIAT, V19, P245, DOI 10.1016/S0163-8343(97)00056-X; Zhang B, 2006, SLEEP, V29, P85, DOI 10.1093/sleep/29.1.85	82	70	72	2	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	OCT 1	2016	39	10					1795	1806		10.5665/sleep.6156			12	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology	DX4ET	WOS:000384334700004	27450687	Bronze, Green Published			2022-02-06	
J	Matsumura, Y; Yamashita, T; Sasaki, A; Nakata, E; Kohno, K; Masuda, T; Tozaki-Saitoh, H; Imai, T; Kuraishi, Y; Tsuda, M; Inoue, K				Matsumura, Yuta; Yamashita, Tomohiro; Sasaki, Atsushi; Nakata, Eriko; Kohno, Keita; Masuda, Takahiro; Tozaki-Saitoh, Hidetoshi; Imai, Toshiyasu; Kuraishi, Yasushi; Tsuda, Makoto; Inoue, Kazuhide			A novel P2X4 receptor-selective antagonist produces anti-allodynic effect in a mouse model of herpetic pain	SCIENTIFIC REPORTS			English	Article							PROTEIN-KINASE ACTIVATION; PERIPHERAL-NERVE INJURY; NEUROPATHIC PAIN; SPINAL MICROGLIA; NEUROTROPHIC FACTOR; PURINERGIC RECEPTORS; P2X(4) RECEPTORS; POSTHERPETIC NEURALGIA; TRANSCRIPTION FACTOR; UP-REGULATION	Accumulating evidence indicates that purinergic P2X4 receptors (P2X4R: cation channels activated by extracellular ATP) expressed in spinal microglia are crucial for pathological chronic pain caused by nerve damage, suggesting a potential target for drug discovery. We identified NP-1815-PX (5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1,2-b][1,4]diazepine-2,4(3H,5H)-dione) as a novel antagonist selective for P2X4R with high potency and selectivity compared with other P2XR subtypes. In in vivo assay for acute and chronic pain, intrathecal administration of NP-1815-PX produced an anti-allodynic effect in mice with traumatic nerve damage without affecting acute nociceptive pain and motor function (although its oral administration did not produce the effect). Furthermore, in a mouse model of herpetic pain, P2X4R upregulation in the spinal cord exclusively occurred in microglia, and intrathecal NP-1815-PX suppressed induction of mechanical allodynia. This model also showed K+/Cl- cotransporter 2 (KCC2) downregulation, which is implicated in dorsal horn neuron hyperexcitability; this downregulation was restored by intrathecal treatment with NP-1815-PX or by interfering with brain-derived neurotrophic factor (BDNF) signaling, a P2X4R-activated microglial factor implicated in KCC2 downregulation. Taken together, the newly developed P2X4R antagonist NP-1815-PX produces anti-allodynic effects in chronic pain models without altering acute pain sensitivity, suggesting that microglial P2X4R could be an attractive target for treating chronic pain.	[Matsumura, Yuta; Kohno, Keita; Masuda, Takahiro; Tozaki-Saitoh, Hidetoshi; Tsuda, Makoto] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Life Innovat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Matsumura, Yuta; Yamashita, Tomohiro; Tsuda, Makoto; Inoue, Kazuhide] Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan; [Sasaki, Atsushi; Kuraishi, Yasushi] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan; [Nakata, Eriko; Imai, Toshiyasu] Nippon Chemiphar Co Ltd, Discovery Res Labs, Misato, Saitama 3410005, Japan; [Masuda, Takahiro] Univ Freiburg, Inst Neuropathol, Neurozentrum, Breisacherstr 64, D-79106 Freiburg, Germany		Tsuda, M (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Life Innovat, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.; Tsuda, M (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol & Syst Pharmacol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	tsuda@phar.kyushu-u.ac.jp	Masuda, Takahiro/AAY-6719-2021; Tsuda, Makoto/AAE-7256-2020	Masuda, Takahiro/0000-0003-3687-452X; , hidetoshi/0000-0003-0423-2143	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15H02522, 25117013]; Japan Science and Technology Agency (JST) through Core Research for Evolutional Science and Technology (CREST) program; Adaptable and Seamless Technology Transfer Program (A-STEP) through Target-driven R&D from Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED); AMEDJapan Agency for Medical Research and Development (AMED); Toray Science FoundationToray Industries, Inc.; Takeda Science FoundationTakeda Science Foundation (TSF); Nakatomi Foundation	This work was supported by JSPS KAKENHI Grant Numbers 15H02522 (MT), 25117013 (KI, HTS), the Japan Science and Technology Agency (JST) through the Core Research for Evolutional Science and Technology (CREST) program (K.I.), the Adaptable and Seamless Technology Transfer Program (A-STEP) through Target-driven R&D (T.I., K.I.) from Japan Agency for Medical Research and Development (AMED), the Research Project on Elucidation of Chronic Pain from AMED (M.T.), Platform for Drug Discovery, Informatics, and Structural Life Science from AMED (K.I.), the Toray Science Foundation (M.T.), Takeda Science Foundation (M.T.), and The Nakatomi Foundation (M.T.).	Alexander K, 1999, J PHARMACOL EXP THER, V291, P1135; Ase AR, 2015, MOL PHARMACOL, V87, P606, DOI 10.1124/mol.114.096222; Balazs B, 2013, CELL PHYSIOL BIOCHEM, V32, P11, DOI 10.1159/000350119; Beggs S, 2012, NAT NEUROSCI, V15, P1068, DOI 10.1038/nn.3155; Binder DK, 1999, J NEUROSCI, V19, P1424; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Donnelly-Roberts D, 2008, J PHARMACOL EXP THER, V324, P409, DOI 10.1124/jpet.106.105890; Dworkin RH, 1996, PAIN, V67, P241, DOI 10.1016/0304-3959(96)03122-3; Gagnon M, 2013, NAT MED, V19, P1524, DOI 10.1038/nm.3356; GNANN JW, 1994, ANN NEUROL, V35, pS69, DOI 10.1002/ana.410350720; Goldmann T, 2013, NAT NEUROSCI, V16, P1618, DOI 10.1038/nn.3531; Hernandez-Olmos V, 2012, J MED CHEM, V55, P9576, DOI 10.1021/jm300845v; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; Horvath G, 2014, NEUROBIOL DIS, V70, P162, DOI 10.1016/j.nbd.2014.06.011; HYLDEN JLK, 1980, EUR J PHARMACOL, V67, P313, DOI 10.1016/0014-2999(80)90515-4; Inoue K, 2006, PHARMACOL THERAPEUT, V109, P210, DOI 10.1016/j.pharmthera.2005.07.001; Jacobson KA, 2016, NEUROPHARMACOLOGY, V104, P31, DOI 10.1016/j.neuropharm.2015.12.001; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khakh BS, 2012, NEURON, V76, P51, DOI 10.1016/j.neuron.2012.09.024; Khakh BS, 1999, J NEUROSCI, V19, P7289, DOI 10.1523/JNEUROSCI.19-17-07289.1999; Kobayashi K, 2008, J NEUROSCI, V28, P2892, DOI 10.1523/JNEUROSCI.5589-07.2008; Kobayashi K, 2011, NEUROSCI LETT, V504, P57, DOI 10.1016/j.neulet.2011.08.058; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kuraishi Y, 2004, LIFE SCI, V74, P2619, DOI 10.1016/j.lfs.2004.01.005; LANCASTER T, 1995, BRIT J GEN PRACT, V45, P39; LOESER JD, 1986, PAIN, V25, P149, DOI 10.1016/0304-3959(86)90089-8; Masuda T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4771; Masuda T, 2012, CELL REP, V1, P334, DOI 10.1016/j.celrep.2012.02.014; Nagata K, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-20; NAKAJIMA K, 1992, J NEUROCHEM, V58, P1401, DOI 10.1111/j.1471-4159.1992.tb11356.x; Ochi-ishi R, 2014, MOL PAIN, V10, DOI 10.1186/1744-8069-10-53; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Peng JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12029; Sasaki A, 2008, J PHARMACOL SCI, V108, P266, DOI 10.1254/jphs.08154FP; Sorge RE, 2015, NAT NEUROSCI, V18, P1081, DOI 10.1038/nn.4053; Takasaki I, 2000, JPN J PHARMACOL, V83, P319, DOI 10.1254/jjp.83.319; Takasaki I, 2000, PAIN, V86, P95, DOI 10.1016/S0304-3959(00)00240-2; Takasaki I, 2012, PAIN, V153, P585, DOI 10.1016/j.pain.2011.11.022; Toyomitsu E, 2012, PURINERG SIGNAL, V8, P301, DOI 10.1007/s11302-011-9288-x; Tozaki-Saitoh H, 2008, J NEUROSCI, V28, P4949, DOI 10.1523/JNEUROSCI.0323-08.2008; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; Tsuda M, 2007, J NEUROCHEM, V102, P1658, DOI 10.1111/j.1471-4159.2007.04796.x; Tsuda M, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-28; Tsuda M, 2009, P NATL ACAD SCI USA, V106, P8032, DOI 10.1073/pnas.0810420106; Ulmann L, 2008, J NEUROSCI, V28, P11263, DOI 10.1523/JNEUROSCI.2308-08.2008; Unezaki S, 2012, MOL PAIN, V8, DOI 10.1186/1744-8069-8-59; Yajima Y, 2005, J NEUROCHEM, V93, P584, DOI 10.1111/j.1471-4159.2005.03045.x; Zhao J, 2006, MOL CELL NEUROSCI, V31, P539, DOI 10.1016/j.mcn.2005.11.008	53	70	74	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 31	2016	6								32461	10.1038/srep32461			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	DU5IN	WOS:000382245500001	27576299	Green Published, gold			2022-02-06	
J	Clausen, M; Pendergast, DR; Willer, B; Leddy, J				Clausen, Mary; Pendergast, David R.; Willer, Barry; Leddy, John			Cerebral Blood Flow During Treadmill Exercise Is a Marker of Physiological Postconcussion Syndrome in Female Athletes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						carbon dioxide sensitivity; cerebral blood flow; exercise; postconcussion syndrome; ventilation	HEART-RATE-VARIABILITY; SPORTS-RELATED CONCUSSION; DYNAMIC EXERCISE; CARBON-DIOXIDE; VENTILATORY RESPONSE; BRAIN-INJURY; VELOCITY; AUTOREGULATION; HUMANS; CO2	Objective: Some patients with postconcussion syndrome (PCS) have reduced exercise capacity that may reflect altered central cardiorespiratory control. The purpose of this study was to evaluate control of cerebral blood flow (CBF) during exercise in females with PCS. Setting: University Concussion Clinic. Participants: Nine female Division 1 collegiate team athletes with PCS (23 +/- 6 years) and a reference group of 13 healthy female recreational aerobic athletes (21 +/- 3 years). Design: A prospective experimental study. All PCS athletes were compared with the reference group at the beginning of the study. Six of the PCS athletes were subsequently measured before and after a subsymptom threshold aerobic exercise treatment program. Main Measures: Exercise treadmill test during which blood pressure (BP), minute ventilation ((V)over dotE), end-tidal CO2 (PETCO2), and CBF velocity (CBFV, by transcranial Doppler) were measured. Results: Participants with PCS had significantly lower. (V)over dot (by 18%) and greater PETCO2 (5%) and CBFV (14%) versus the reference group at similar workloads in association with appearance of symptoms and premature exercise cessation. Subthreshold exercise normalized. VE, PETCO2, CBFV and exercise tolerance. Before treatment, PCS had low CO2 sensitivity that blunted their exercise ventilation. CO2 sensitivity and ventilation improved after exercise treatment. Conclusion: Some PCS patients have exercise intolerance due to abnormal CBF regulation that may be the result of concussion-induced altered sensitivity to CO2. Return of normal CBF control and exercise tolerance may be physiological markers of recovery from concussion.	[Clausen, Mary; Pendergast, David R.] SUNY Buffalo, Ctr Res & Educ Special Environm, Dept Physiol, Buffalo, NY USA; [Leddy, John] SUNY Buffalo, Univ Sports Med, Orthopaed, 160 Farber Hall, Buffalo, NY 14214 USA; [Willer, Barry] SUNY Buffalo, Dept Psychiat, Buffalo, NY 14214 USA		Leddy, J (corresponding author), SUNY Buffalo, Univ Sports Med, Orthopaed, 160 Farber Hall, Buffalo, NY 14214 USA.	leddy@buffalo.edu					[Anonymous], 2006, ACSMS GUID EX TEST P; Brys M, 2003, AM J PHYSIOL-HEART C, V285, pH1048, DOI 10.1152/ajpheart.00062.2003; Carter JB, 2003, MED SCI SPORT EXER, V35, P1333, DOI 10.1249/01.MSS.0000079046.01763.8F; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Doering TJ, 1998, AM J PHYS MED REHAB, V77, P490, DOI 10.1097/00002060-199811000-00006; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Fisher JP, 2008, J APPL PHYSIOL, V105, P266, DOI 10.1152/japplphysiol.00118.2008; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giller CA, 2000, J APPL PHYSIOL, V88, P2205, DOI 10.1152/jappl.2000.88.6.2205; GOFF LG, 1957, J APPL PHYSIOL, V10, P203, DOI 10.1152/jappl.1957.10.2.203; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heckmann JG, 2003, CEREBROVASC DIS, V16, P423, DOI 10.1159/000072567; HELLSTROM G, 1993, NEUROSURG REV, V16, P151, DOI 10.1007/BF00258249; Hellstrom G, 1996, J APPL PHYSIOL, V81, P413, DOI 10.1152/jappl.1996.81.1.413; Hetzel A, 1999, STROKE, V30, P398, DOI 10.1161/01.STR.30.2.398; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Ide K, 1998, ACTA PHYSIOL SCAND, V162, P13; Ide K, 1999, J APPL PHYSIOL, V87, P1604, DOI 10.1152/jappl.1999.87.5.1604; Imray CHE, 2005, J APPL PHYSIOL, V99, P699, DOI 10.1152/japplphysiol.00973.2004; Imray CHE, 2003, CLIN SCI, V104, P203, DOI 10.1042/CS20020102; JORGENSEN LG, 1992, J APPL PHYSIOL, V73, P1825, DOI 10.1152/jappl.1992.73.5.1825; JORGENSEN LG, 1992, J APPL PHYSIOL, V72, P1123, DOI 10.1152/jappl.1992.72.3.1123; Katayama K, 1999, J APPL PHYSIOL, V86, P1805, DOI 10.1152/jappl.1999.86.6.1805; KELLEY MA, 1984, RESP PHYSIOL, V55, P393, DOI 10.1016/0034-5687(84)90060-4; KEREM D, 1980, UNDERSEA BIOMED RES, V7, P17; King ML, 1997, BRAIN INJURY, V11, P445; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; LALLY DA, 1974, RESP PHYSIOL, V20, P117, DOI 10.1016/0034-5687(74)90101-7; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2013, CURR SPORT MED REP, V12, P370, DOI 10.1249/JSR.0000000000000008; Leddy JJ, 2013, J HEAD TRAUMA REHAB, V28, P241, DOI 10.1097/HTR.0b013e31826da964; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levy M.N., 2006, BERNE LEVY PRINCIPLE; LINKIS P, 1995, J APPL PHYSIOL, V78, P12, DOI 10.1152/jappl.1995.78.1.12; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McConnell AK, 1996, MED SCI SPORT EXER, V28, P685, DOI 10.1097/00005768-199606000-00007; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; Miyamoto T, 2012, EUR J APPL PHYSIOL, V112, P237, DOI 10.1007/s00421-011-1968-2; MIYAMURA M, 1990, EUR J APPL PHYSIOL O, V60, P353, DOI 10.1007/BF00713498; MIYAMURA M, 1988, Tohoku Journal of Experimental Medicine, V156, P125; MORAINE JJ, 1993, EUR J APPL PHYSIOL O, V67, P35, DOI 10.1007/BF00377701; Mutch WAC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102181; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; Nybo L, 2001, J PHYSIOL-LONDON, V534, P279, DOI 10.1111/j.1469-7793.2001.t01-1-00279.x; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1526, DOI 10.1152/ajpheart.00979.2004; Ogoh S, 2005, AM J PHYSIOL-HEART C, V288, pH1461, DOI 10.1152/ajpheart.00948.2004; Ogoh S, 2009, EXERC SPORT SCI REV, V37, P123, DOI 10.1097/JES.0b013e3181aa64d7; Ogoh S, 2009, J APPL PHYSIOL, V106, P880, DOI 10.1152/japplphysiol.91292.2008; Pendergast DR, 2006, UNDERSEA HYPERBAR M, V33, P447; Polak P, 2015, J HEAD TRAUMA REHAB, V30, pE32, DOI 10.1097/HTR.0000000000000037; Pott F, 1997, ACTA PHYSIOL SCAND, V160, P251, DOI 10.1046/j.1365-201X.1997.00144.x; Pott F, 1997, ACTA PHYSIOL SCAND, V160, P43, DOI 10.1046/j.1365-201X.1997.00126.x; Querido JS, 2007, SPORTS MED, V37, P765, DOI 10.2165/00007256-200737090-00002; Querido JS, 2009, EUR J APPL PHYSIOL, V105, P403, DOI 10.1007/s00421-008-0917-1; READ DJC, 1967, J APPL PHYSIOL, V23, P53, DOI 10.1152/jappl.1967.23.1.53; Serrador JM, 2000, STROKE, V31, P1672, DOI 10.1161/01.STR.31.7.1672; Sviri GE, 2009, J NEUROSURG, V111, P695, DOI 10.3171/2008.10.17686; Tarasow Eugeniusz, 2007, Med Sci Monit, V13 Suppl 1, P65; Ter Minassian A, 2002, CRIT CARE MED, V30, P1616, DOI 10.1097/00003246-200207000-00036; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744, DOI 10.1152/jappl.1989.67.2.744; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Whaley M., 2005, ACSMS GUID EX TEST P; WHO, 1992, INT STAT CLASS DIS R; Yosefy C, 2004, EMERG MED J, V21, P557, DOI 10.1136/emj.2003.005819	72	70	71	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2016	31	3					215	224		10.1097/HTR.0000000000000145			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	DR3FK	WOS:000379787800013	26098254				2022-02-06	
J	Ponsford, J; Lee, NK; Wong, D; Mckay, A; Haines, K; Alway, Y; Downing, M; Furtado, C; O'Donnell, ML				Ponsford, J.; Lee, N. K.; Wong, D.; McKay, A.; Haines, K.; Alway, Y.; Downing, M.; Furtado, C.; O'Donnell, M. L.			Efficacy of motivational interviewing and cognitive behavioral therapy for anxiety and depression symptoms following traumatic brain injury	PSYCHOLOGICAL MEDICINE			English	Article						Anxiety; cognitive behavioral therapy; depression; motivational interviewing; traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC-DISORDERS; STRESS-DISORDER; INDIVIDUALS; CBT; REHABILITATION; PSYCHOTHERAPY; ENGAGEMENT; FREQUENCY; PROGRAM	Background Anxiety and depression are common following traumatic brain injury (TBI), often co-occurring. This study evaluated the efficacy of a 9-week cognitive behavioral therapy (CBT) program in reducing anxiety and depression and whether a three-session motivational interviewing (MI) preparatory intervention increased treatment response. Method A randomized parallel three-group design was employed. Following diagnosis of anxiety and/or depression using the Structured Clinical Interview for DSM-IV, 75 participants with mild-severe TBI (mean age 42.2 years, mean post-traumatic amnesia 22 days) were randomly assigned to an Adapted CBT group: (1) MI + CBT (n = 26), or (2) non-directive counseling (NDC) + CBT (n = 26); or a (3) waitlist control (WC, n = 23) group. Groups did not differ in baseline demographics, injury severity, anxiety or depression. MI and CBT interventions were guided by manuals adapted for individuals with TBI. Three CBT booster sessions were provided at week 21 to intervention groups. Results Using intention-to-treat analyses, random-effects regressions controlling for baseline scores revealed that Adapted CBT groups (MI + CBT and NDC + CBT) showed significantly greater reduction in anxiety on the Hospital Anxiety and Depression Scale [95% confidence interval (CI) -2.07 to -0.06] and depression on the Depression Anxiety and Stress Scale (95% CI -5.61 to -0.12) (primary outcomes), and greater gains in psychosocial functioning on Sydney Psychosocial Reintegration Scale (95% CI 0.04-3.69) (secondary outcome) over 30 weeks post-baseline relative to WC. The group receiving MI + CBT did not show greater gains than the group receiving NDC + CBT. Conclusions Findings suggest that modified CBT with booster sessions over extended periods may alleviate anxiety and depression following TBI.	[Ponsford, J.; Wong, D.; McKay, A.; Haines, K.; Alway, Y.; Downing, M.; Furtado, C.] Monash Univ, Sch Psychol Sci, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia; [Lee, N. K.] Flinders Univ S Australia, Natl Ctr Educ & Training Addict, Adelaide, SA, Australia; [Lee, N. K.] Curtin Univ, Natl Drug Res Inst, Perth, WA, Australia; [O'Donnell, M. L.] Univ Melbourne, Phoenix Australia, Melbourne, Vic 3010, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol Sci, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Downing, Marina/AAX-2380-2020; McKay, Adam/M-6003-2017	Downing, Marina/0000-0002-3126-6632; O'Donnell, Meaghan/0000-0003-4349-0022; McKay, Adam/0000-0002-0479-7681; Wong, Dana/0000-0001-9619-1929	NHMRCNational Health and Medical Research Council of Australia [606432]	This study was funded by NHMRC grant No 606432. The authors thank Ming-Yun Hsieh for work in developing and piloting the manualized intervention.	Arkowitz H., 2008, MOTIVATIONAL INTERVI; Ashman T, 2014, J HEAD TRAUMA REHAB, V29, P467, DOI 10.1097/HTR.0000000000000098; Baker A, 2005, ADDICTION, V100, P367, DOI 10.1111/j.1360-0443.2005.01002.x; Beck AT., 1979, COGNITIVE THERAPY DE; Beck J.S., 1995, COGNITIVE THERAPY BA; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carroll KM, 2006, DRUG ALCOHOL DEPEN, V81, P301, DOI 10.1016/j.drugalcdep.2005.08.002; Coughlin A, 2007, MEMORY INFORM PROCES; Cuijpers P, 2008, J CONSULT CLIN PSYCH, V76, P909, DOI 10.1037/a0013075; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Dugas MJ, 2005, COGNITIVE BEHAV TREA; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; First M, 2007, STRUCTURED CLIN INTE; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HODGSON J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P563, DOI 10.1080/09602011.2012.676284; Hsieh MY, 2012, BRAIN INJURY, V26, P126, DOI 10.3109/02699052.2011.635365; Hsieh MY, 2012, DISABIL REHABIL, V34, P408, DOI 10.3109/09638288.2011.607219; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Medley AR, 2010, NEUROPSYCHOL REHABIL, V20, P481, DOI 10.1080/09602010903529610; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; O'Donnell ML, 2012, J TRAUMA STRESS, V25, P125, DOI 10.1002/jts.21677; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P1, DOI [10.1017/S135561771000111621083962, DOI 10.1017/S1355617710001116]; Schulz KF, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c332; Soo C, 2007, COCHRANE DB SYST REV, V3; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Waldron B, 2013, NEUROPSYCHOL REHABIL, V23, P64, DOI 10.1080/09602011.2012.724196; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Watkins CL, 2007, STROKE, V38, P1004, DOI 10.1161/01.STR.0000258114.28006.d7; Westra H. A., 2003, MOTIVATIONAL INTERVI; Westra HA, 2007, J CONSULT CLIN PSYCH, V75, P363, DOI 10.1037/0022-006X.75.3.363; Westra HA, 2006, COGNITIVE THER RES, V30, P481, DOI 10.1007/s10608-006-9016-y; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662	49	70	70	1	41	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	APR	2016	46	5					1079	1090		10.1017/S0033291715002640			12	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	DF8PQ	WOS:000371620700016	26708017				2022-02-06	
J	Wickwire, EM; Williams, SG; Roth, T; Capaldi, VF; Jaffe, M; Moline, M; Motamedi, GK; Morgan, GW; Mysliwiec, V; Germain, A; Pazdan, RM; Ferziger, R; Balkin, TJ; MacDonald, ME; Macek, TA; Yochelson, MR; Scharf, SM; Lettieri, CJ				Wickwire, Emerson M.; Williams, Scott G.; Roth, Thomas; Capaldi, Vincent F.; Jaffe, Michael; Moline, Margaret; Motamedi, Gholam K.; Morgan, Gregory W.; Mysliwiec, Vincent; Germain, Anne; Pazdan, Renee M.; Ferziger, Reuven; Balkin, Thomas J.; MacDonald, Margaret E.; Macek, Thomas A.; Yochelson, Michael R.; Scharf, Steven M.; Lettieri, Christopher J.			Sleep, Sleep Disorders, and Mild Traumatic Brain Injury. What We Know and What We Need to Know: Findings from a National Working Group	NEUROTHERAPEUTICS			English	Article						Sleep; Sleep disorders; Traumatic brain injury; Concussion; Insomnia; Sleep apnea	COGNITIVE-BEHAVIORAL THERAPY; EXCESSIVE DAYTIME SLEEPINESS; WAKE DISTURBANCES; CEREBRAL-ISCHEMIA; CLINICAL-SIGNIFICANCE; BLAST EXPOSURE; QUALITY INDEX; HEAD-INJURY; REM-SLEEP; INSOMNIA	Disturbed sleep is one of the most common complaints following traumatic brain injury (TBI) and worsens morbidity and long-term sequelae. Further, sleep and TBI share neurophysiologic underpinnings with direct relevance to recovery from TBI. As such, disturbed sleep and clinical sleep disorders represent modifiable treatment targets to improve outcomes in TBI. This paper presents key findings from a national working group on sleep and TBI, with a specific focus on the testing and development of sleep-related therapeutic interventions for mild TBI (mTBI). First, mTBI and sleep physiology are briefly reviewed. Next, essential empirical and clinical questions and knowledge gaps are addressed. Finally, actionable recommendations are offered to guide active and efficient collaboration between academic, industry, and governmental stakeholders.	[Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA; [Wickwire, Emerson M.; Scharf, Steven M.] Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care, Baltimore, MD 21201 USA; [Williams, Scott G.] Walter Reed Natl Mil Med Ctr, Dept Med, Bethesda, MD USA; [Williams, Scott G.; Mysliwiec, Vincent; Lettieri, Christopher J.] Uniformed Serv Univ Hlth Sci, Dept Med, Room A3060, Bethesda, MD 20814 USA; [Roth, Thomas] Henry Ford Hosp, Sleep Disorders & Res Ctr, Detroit, MI 48202 USA; [Capaldi, Vincent F.; Balkin, Thomas J.] Ctr Mil Psychiat & Neurosci Res, Walter Reed Army Inst Res, Dept Behav Biol, Silver Spring, MD USA; [Jaffe, Michael] Univ Florida, Dept Neurol, Gainesville, FL USA; [Jaffe, Michael] Univ Florida Trauma, Concuss & Sports Program, Gainesville, FL USA; [Jaffe, Michael] UF Hlth Sleep Disorders Ctr, Gainesville, FL USA; [Moline, Margaret] Eisai Inc, Woodcliff Lake, NJ USA; [Motamedi, Gholam K.] Georgetown Univ Hosp, Dept Neurol, Washington, DC 20007 USA; [Morgan, Gregory W.] Natl Intrepid Ctr Excellence, Sleep Disorders Ctr, Bethesda, MD USA; [Mysliwiec, Vincent] San Antonio Mil Med Ctr, Dept Sleep Med, San Antonio, TX USA; [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Pazdan, Renee M.] US PHS, Ft Carson, CO USA; [Ferziger, Reuven] Merck & Co Inc, Kenilworth, NJ USA; [MacDonald, Margaret E.] Evans Army Community Hosp, Def & Vet Brain Injury Ctr, Gen Dynam Hlth Solut, Ft Carson, CO USA; [Macek, Thomas A.] Takeda Dev Ctr Amer, CNS, Dept Clin Sci, Deerfield, IL USA; [Yochelson, Michael R.] Medstar Natl Rehabil Network, Washington, DC USA; [Yochelson, Michael R.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA; [Yochelson, Michael R.] Georgetown Univ, Sch Med, Dept Rehabil Med, Washington, DC USA		Wickwire, EM (corresponding author), Univ Maryland, Sch Med, Dept Psychiat, Baltimore, MD 21201 USA.; Wickwire, EM (corresponding author), Univ Maryland, Sch Med, Dept Med, Sleep Disorders Ctr,Div Pulm & Crit Care, Baltimore, MD 21201 USA.	ewickwire@medicine.umaryland.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146			Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; [Anonymous], 2005, J Clin Sleep Med, V1, P412; Assefa SZ, 2015, AIMS NEUROSCI, V2, P155, DOI 10.3934/Neuroscience.2015.3.155; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Banks S, 2007, J CLIN SLEEP MED, V3, P519; Barr T, 2015, ANNU REV NURS RES-SE, V33, P249, DOI 10.1891/0739-6686.33.249; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Berry RB, 2012, AASM MANUAL SCORING, P47; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Bruce ED, 2015, MOL CELL NEUROSCI, V66, P103, DOI 10.1016/j.mcn.2015.03.017; Buysse DJ, 2006, SLEEP, V29, P1155, DOI 10.1093/sleep/29.9.1155; Buysse DJ, 2010, SLEEP MED, V11, P56, DOI 10.1016/j.sleep.2009.02.010; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cam E, 2013, EXP NEUROL, V247, P673, DOI 10.1016/j.expneurol.2013.03.003; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Centers for Disease Control and Prevention, WHAT AR SIGNS SYMPT; Cheng OM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125877; Chiu HY, 2015, EUR NEUROPSYCHOPHARM, V25, P2271, DOI 10.1016/j.euroneuro.2015.09.011; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Chong CD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0485-0; Cirelli C, 2012, GERONTOLOGY, V58, P441, DOI 10.1159/000336149; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Collen JF, 2012, J CLIN SLEEP MED, V8, P667, DOI 10.5664/jcsm.2260; Colorado Division of Workers' Compensation, 2012, TRAUM BRAIN INJ MED, P1; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cote KA, 2015, AIMS NEUROSCI, V2, P203, DOI 10.3934/Neuroscience.2015.4.203; Currie S, 2016, POSTGRAD MED J, V92, P41, DOI 10.1136/postgradmedj-2014-133211; Dash MB, 2009, J NEUROSCI, V29, P580, DOI 10.1523/JNEUROSCI.5486-08.2009; De La Rue-Evans L, 2013, REHABIL NURS, V38, P2, DOI 10.1002/rnj.66; Dean PJ, 2015, BRAIN INJ; Delouche A, 2016, EUR J RADIOL, V85, P25, DOI 10.1016/j.ejrad.2015.11.004; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dirnagl U, 2009, LANCET NEUROL, V8, P398, DOI 10.1016/S1474-4422(09)70054-7; Farrell-Carnahan L, 2013, MIL MED, V178, P951, DOI 10.7205/MILMED-D-13-00037; Faul M, 2010, TRAUMATIC BRAIN INJU; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198, DOI 10.1152/ajpregu.1991.261.1.R198; Gagner C, 2015, J NEUROTRAUM, V32, P1539, DOI 10.1089/neu.2014.3753; Gao B, 2010, SLEEP, V33, P879, DOI 10.1093/sleep/33.7.879; Gerberding JLBS, 2003, REP C MILD TRAUM BRA; Gerdes L, 2013, BRAIN BEHAV, V3, P193, DOI 10.1002/brb3.116; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Hasler BP, 2013, BIOL PSYCHOL, V94, P255, DOI 10.1016/j.biopsycho.2013.06.007; Hodor A, 2014, ANN CLIN TRANSL NEUR, V1, P765, DOI 10.1002/acn3.115; Hsu JC, 2003, BRAIN RES, V984, P170, DOI 10.1016/S0006-8993(03)03128-7; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Jaffee MS, 2015, BRAIN INJURY, V29, P221, DOI 10.3109/02699052.2014.983978; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Khoury S, 2013, J NEUROTRAUM, V30, P633, DOI 10.1089/neu.2012.2519; Kong JM, 2002, J NEUROSCI, V22, P5581; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laakso ML, 2004, SLEEP MED, V5, P541, DOI 10.1016/j.sleep.2004.05.002; Lam JC, 2011, BEHAV SLEEP MED, V9, P184, DOI 10.1080/15402002.2011.583906; Lavigne G, 2015, PAIN, V156, pS75, DOI 10.1097/j.pain.0000000000000111; Lee SW, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00843; Leo P, 2016, TRANSLATIONAL RES TR; Lequerica A, 2015, ARCH PHYS MED REHAB, V96, P1802, DOI 10.1016/j.apmr.2015.05.011; Lequerica A, 2014, NEUROREHABILITATION, V35, P485, DOI 10.3233/NRE-141141; Lettieri CJ, 2015, CHEST; Lu W, 2014, NEUROREHABILITATION, V35, P245, DOI 10.3233/NRE-141117; Lucke-Wold BP, 2015, NEUROSCI BIOBEHAV R, V55, P68, DOI 10.1016/j.neubiorev.2015.04.010; Lusardi TA, 2012, EXP NEUROL, V234, P161, DOI 10.1016/j.expneurol.2011.12.026; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Martinez-Vargas M, 2012, NEUROSCI LETT, V529, P118, DOI 10.1016/j.neulet.2012.09.037; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Menn SJ, 2014, J CLIN SLEEP MED, V10, P1181, DOI 10.5664/jcsm.4196; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Moldovan M, 2010, EXP NEUROL, V222, P135, DOI 10.1016/j.expneurol.2009.12.023; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morries LD, 2015, NEUROPSYCH DIS TREAT, V11, P2159, DOI 10.2147/NDT.S65809; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Newell J, 2012, PSYCHIAT RES, V200, P795, DOI 10.1016/j.psychres.2012.07.045; Nofzinger EA, 2005, SLEEP MED REV, V9, P157, DOI 10.1016/j.smrv.2004.07.003; Okun ML, 2011, PSYCHOSOM MED, V73, P142, DOI 10.1097/PSY.0b013e3182020d08; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2015, LANCET NEUROL, V14, P746, DOI 10.1016/S1474-4422(15)00068-X; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pace M, 2015, SLEEP, V38, P1707, DOI 10.5665/sleep.5148; Paparrigopoulos T, 2006, BRAIN INJURY, V20, P873, DOI 10.1080/02699050600832114; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Pisarenco I, 2014, INT J PSYCHOPHYSIOL; Plante DT, 2016, CLIN NEUROPHYSIOL, V127, P1436, DOI 10.1016/j.clinph.2015.10.040; Polinder S, 2015, POPUL HEALTH METR, V13, DOI 10.1186/s12963-015-0037-1; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Poryazova R, 2015, J SLEEP RES, V24, P54, DOI 10.1111/jsr.12208; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Rye DB, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004685; Sanchez-Ortuno MM, 2012, J SLEEP RES, V21, P527, DOI 10.1111/j.1365-2869.2012.01010.x; Saper CB, 2010, NEURON, V68, P1023, DOI 10.1016/j.neuron.2010.11.032; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Seifman MA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00237; Shearer WT, 2001, J ALLERGY CLIN IMMUN, V107, P165, DOI 10.1067/mai.2001.112270; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; Shiffman S, 2008, ANNU REV CLIN PSYCHO, V4, P1, DOI 10.1146/annurev.clinpsy.3.022806.091415; Sinclair KL, 2014, BEHAV SLEEP MED, V12, P13, DOI 10.1080/15402002.2012.726203; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stocker RPJ, 2014, NEUROIMAGE, V99, P207, DOI 10.1016/j.neuroimage.2014.05.067; Suh S, 2012, SLEEP MED, V13, P469, DOI 10.1016/j.sleep.2011.10.034; Tan G, 2009, PAIN MED, V10, P1237, DOI 10.1111/j.1526-4637.2009.00712.x; TEASDALE G, 1974, LANCET, V2, P81; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tham SW, 2015, J NEUROTRAUM, V32, P847, DOI 10.1089/neu.2014.3559; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Vgontzas AN, 2004, J CLIN ENDOCR METAB, V89, P2119, DOI 10.1210/jc.2003-031562; Weil ZM, 2009, EXP NEUROL, V218, P129, DOI 10.1016/j.expneurol.2009.04.018; Wickwire EM, 2016, SLEEP MED REV, V30, P72, DOI 10.1016/j.smrv.2015.11.004; Wickwire EM, 2013, CHEST, V144, P680, DOI 10.1378/chest.12-2681; Wickwire EM, 2010, SLEEP MED, V11, P772, DOI 10.1016/j.sleep.2010.03.012; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	136	70	70	0	23	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	APR	2016	13	2					403	417		10.1007/s13311-016-0429-3			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Pharmacology & Pharmacy	DI6WY	WOS:000373642100013	27002812	Green Published, Bronze			2022-02-06	
J	Scholz, R; Caramoy, A; Bhuckory, MB; Rashid, K; Chen, M; Xu, HP; Grimm, C; Langmann, T				Scholz, Rebecca; Caramoy, Albert; Bhuckory, Mohajeet B.; Rashid, Khalid; Chen, Mei; Xu, Heping; Grimm, Christian; Langmann, Thomas			Targeting translocator protein (18 kDa) (TSPO) dampens pro-inflammatory microglia reactivity in the retina and protects from degeneration	JOURNAL OF NEUROINFLAMMATION			English	Article						Translocator protein (18 kDa) (TSPO); Microglia; Photoreceptors; Retinal degeneration; Light damage; Age-related macular degeneration	TRAUMATIC BRAIN-INJURY; MACULAR DEGENERATION; MOUSE MODEL; THERAPEUTIC TARGET; AGING RETINA; LIGHT DAMAGE; CELL-DEATH; IN-VIVO; PROGESTERONE; DISEASE	Background: Reactive microglia are commonly seen in retinal degenerative diseases, and neurotoxic microglia responses can contribute to photoreceptor cell death. We and others have previously shown that translocator protein (18 kDa) (TSPO) is highly induced in retinal degenerations and that the selective TSPO ligand XBD173 (AC-5216, emapunil) exerts strong anti-inflammatory effects on microglia in vitro and ex vivo. Here, we investigated whether targeting TSPO with XBD173 has immuno-modulatory and neuroprotective functions in two mouse models of acute retinal degeneration using bright white light exposure. Methods: BALB/cJ and Cx3cr1(GFP/+) mice received intraperitoneal injections of 10 mg/kg XBD173 or vehicle for five consecutive days, starting 1 day prior to exposure to either 15,000 lux white light for 1 h or 50,000 lux focal light for 10 min, respectively. The effects of XBD173 treatment on microglia and Muller cell reactivity were analyzed by immuno-stainings of retinal sections and flat mounts, fluorescence-activated cell sorting (FACS) analysis, and mRNA expression of microglia markers using quantitative real-time PCR (qRT-PCR). Optical coherence tomography (OCT), terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) stainings, and morphometric analyses were used to quantify the extent of retinal degeneration and photoreceptor apoptosis. Results: Four days after the mice were challenged with bright white light, a large number of amoeboid-shaped alerted microglia appeared in the degenerating outer retina, which was nearly completely prevented by treatment with XBD173. This treatment also down-regulated the expression of TSPO protein in microglia but did not change the TSPO levels in the retinal pigment epithelium (RPE). RT-PCR analysis showed that the microglia/macrophage markers Cd68 and activated microglia/macrophage whey acidic protein (Amwap) as well as the pro-inflammatory genes Ccl2 and Il6 were reduced after XBD173 treatment. Light-induced degeneration of the outer retina was nearly fully blocked by XBD173 treatment. We further confirmed these findings in an independent mouse model of focal light damage. Retinas of animals receiving XBD173 therapy displayed significantly more ramified non-reactive microglia and more viable arrestin-positive cone photoreceptors than vehicle controls. Conclusions: Targeting TSPO with XBD173 effectively counter-regulates microgliosis and ameliorates light-induced retinal damage, highlighting a new pharmacological concept for the treatment of retinal degenerations.	[Scholz, Rebecca; Caramoy, Albert; Rashid, Khalid; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, D-50931 Cologne, Germany; [Bhuckory, Mohajeet B.; Chen, Mei; Xu, Heping] Queens Univ Belfast, Ctr Med Expt, Sch Med Dent & Biomed Sci, Belfast BT12 6BA, Antrim, North Ireland; [Grimm, Christian] Univ Zurich, Dept Ophthalmol, Lab Retinal Cell Biol, CH-8057 Zurich, Switzerland		Langmann, T (corresponding author), Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, D-50931 Cologne, Germany.	thomas.langmann@uk-koeln.de	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X; Grimm, Christian/0000-0001-9318-4352; Rashid, Khalid/0000-0002-5070-8010	DFGGerman Research Foundation (DFG)European Commission [LA1203/6-2, LA1203/9-1, LA1203/10-1, FOR2240]; Velux FoundationVelux Fonden; Hans und Marlies Stock-Foundation; Pro Retina Foundation; Bayer Graduate Program in Pharmacology; Fight for Sight [1425/1426]; Fight for Sight [1425/26] Funding Source: researchfish	This work was supported by the DFG (LA1203/6-2, LA1203/9-1, LA1203/10-1, and FOR2240), the Velux Foundation, the Hans und Marlies Stock-Foundation, the Pro Retina Foundation, the Bayer Graduate Program in Pharmacology, and Fight for Sight (1425/1426). We thank the members of the Brachvogel Laboratory, Institute of Biochemistry, University of Cologne, for their help with the FACS analyses.	Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Aslanidis A, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0296-6; Balasubramaniam B, 2009, EXP EYE RES, V89, P757, DOI 10.1016/j.exer.2009.06.019; Barron AM, 2013, J NEUROSCI, V33, P8891, DOI 10.1523/JNEUROSCI.1350-13.2013; Cascio C, 2000, J STEROID BIOCHEM, V75, P177, DOI 10.1016/S0960-0760(00)00163-1; Chauveau F, 2008, EUR J NUCL MED MOL I, V35, P2304, DOI 10.1007/s00259-008-0908-9; Chen M, 2015, J LEUKOC BIOL; Chen M, 2012, GLIA, V60, P833, DOI 10.1002/glia.22315; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042; Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x; Daugherty DJ, 2013, EMBO MOL MED, V5, P891, DOI 10.1002/emmm.201202124; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Girard C, 2012, J NEUROENDOCRINOL, V24, P71, DOI 10.1111/j.1365-2826.2011.02215.x; Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497; Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6; Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9; Gut P, 2015, TRENDS ENDOCRIN MET, V26, P349, DOI 10.1016/j.tem.2015.04.001; HUME DA, 1983, J CELL BIOL, V97, P253, DOI 10.1083/jcb.97.1.253; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Karlstetter M, 2014, ADV EXP MED BIOL, V801, P207, DOI 10.1007/978-1-4614-3209-8_27; Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3; Karlstetter M, 2010, J IMMUNOL, V185, P3379, DOI 10.4049/jimmunol.0903300; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kuhlmann AC, 2000, J NEUROCHEM, V74, P1694, DOI 10.1046/j.1471-4159.2000.0741694.x; Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114; Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524; Maeda J, 2007, BRAIN RES, V1157, P100, DOI 10.1016/j.brainres.2007.04.054; Marc RE, 2008, MOL VIS, V14, P782; Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Nothdurfter C, 2012, J NEUROENDOCRINOL, V24, P82, DOI 10.1111/j.1365-2826.2011.02166.x; Nothdurfter C, 2012, EUR ARCH PSY CLIN N, V262, pS107, DOI 10.1007/s00406-012-0352-5; Papadopoulos V, 2007, MOL CELL ENDOCRINOL, V265, P59, DOI 10.1016/j.mce.2006.12.004; Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003; Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87; Rogue RS, 1999, BRAIN RES, V836, P110, DOI 10.1016/S0006-8993(99)01625-X; Rupprecht R, 2010, NAT REV DRUG DISCOV, V9, P971, DOI 10.1038/nrd3295; Rupprecht R, 2009, SCIENCE, V325, P490, DOI 10.1126/science.1175055; Sanchez-Vallejo V, 2015, PHARMACOL RES, V99, P276, DOI 10.1016/j.phrs.2015.06.019; Schubert T, 2015, CELL MOL LIFE SCI, V72, P3953, DOI 10.1007/s00018-015-1913-3; Selvaraj V, 2015, TRENDS ENDOCRIN MET, V26, P341, DOI 10.1016/j.tem.2015.02.007; Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350; Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015; Veiga S, 2005, NEUROREPORT, V16, P1599, DOI 10.1097/01.wnr.0000179081.39659.7d; Venneti S, 2013, GLIA, V61, P10, DOI 10.1002/glia.22357; Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014; Wei XH, 2013, J NEUROSCI, V33, P1540, DOI 10.1523/JNEUROSCI.0324-12.2013; Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149; Zhang C, 2004, INVEST OPHTH VIS SCI, V45, P2753, DOI 10.1167/iovs.03-1344; Zhao L, 2015, EMBO MOL MED, V7, P1179, DOI 10.15252/emmm.201505298	59	70	72	0	12	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	NOV 2	2015	12								201	10.1186/s12974-015-0422-5			12	Immunology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology	CV5BX	WOS:000364282300002	26527153	Green Accepted, Green Published, gold			2022-02-06	
J	Brommeland, T; Rydning, PN; Pripp, AH; Helseth, E				Brommeland, Tor; Rydning, Pal Nicolay; Pripp, Are Hugo; Helseth, Eirik			Cranioplasty complications and risk factors associated with bone flap resorption	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Craniectomy; Cranioplasty; Bone flap resorption; Post-operative complications	DECOMPRESSIVE CRANIECTOMY; AUTOLOGOUS BONE; MULTICENTER; IMPROVEMENT; EXPERIENCE; INFECTION; OUTCOMES; SURGERY	Background: Decompressive craniectomy (DC) may be performed in patients with acutely raised intracranial pressure due to traumatic brain injury or stroke. It is later followed by a cranioplasty procedure (CP) in the surviving patients. This procedure is associated with a high frequency of post-operative complications. Identifying risk factors for these adverse events is important in order to improve the clinical outcome. This study examines possible predictive parameters for post-operative complications in CP. Methods: Retrospective, single institution review of all patients undergoing a DC for acutely raised intracranial pressure over a 10 year period at Oslo University Hospital Ullev, Norway. Subsequent CP using autologous bone flaps or synthetic implants were registered along with all post-operative complications. Predictors of post-operative complications were identified using uni -and multivariable regression analyses. Results: A DC was carried out in 125 patients, of whom 33 died, 4 were lost to follow-up, and 1 (an infant) later underwent cranial remodeling. A CP was performed in the remaining 87 patients. Post-operative complications were recorded in 31 (36 %) patients of whom 22 lost their primary implant. Surgical site infection (SSI) and bone flap resorption (BFR) were the two most common complications, affecting 8 (9.2 %) and 14 (19.7 %) patients, respectively. Only BFR was associated with some of the recorded variables. Using multivariable logistic regression analysis, young age (OR = 0.94, 95 % CI 0.88-1.00, p = 0.04), bone flap fragmentation (OR = 14.3, 95 % CI 2.26-89, p = 0.005), long storage time (OR = 1.03, 95 % CI 1.00-1.04, p = 0.02) and Glasgow Outcome Scale at the time of cranioplasty (OR = 2.55, 95 % CI 1.04-6.23, p = 0.04) were found to be significant risk factors for bone flap resorption. Conclusions: Cranioplasty after decompressive craniectomy carries a high rate of complications. In this study, SSI and BFR were the two most common complications of which predictive clinical parameters could be identified for BFR only. The results indicate that synthetic implants may be considered in pediatric patients and in cases with fragmented bone flaps or delayed time to cranioplasty. Although the rate of complications was high, 73 % had a successful reinsertion of the autologous graft at a low cost. We feel this result justifies the continued use of cryopreserved bone flaps.	[Brommeland, Tor; Rydning, Pal Nicolay; Helseth, Eirik] Univ Oslo, Ulleval Hosp, Dept Neurosurg, Oslo, Norway; [Pripp, Are Hugo] Oslo Univ Hosp, Oslo Ctr Biostat & Epidemiol, Res Support Serv, Oslo, Norway; [Helseth, Eirik] Univ Oslo, Fac Med, Oslo, Norway		Brommeland, T (corresponding author), Univ Oslo, Ulleval Hosp, Dept Neurosurg, POB 4950, Oslo, Norway.	torbro@ous-hf.no	Brommeland, Tor/AAW-4941-2021; Brommeland, Tor/AAJ-8483-2020; Helseth, Eirik/AAH-2466-2020				Bobinski L, 2013, CLIN NEUROL NEUROSUR, V115, P1788, DOI 10.1016/j.clineuro.2013.04.013; Bowers CA, 2013, J NEUROSURG-PEDIATR, V11, P526, DOI 10.3171/2013.1.PEDS12483; Broughton E, 2014, BRIT J NEUROSURG, V28, P34, DOI 10.3109/02688697.2013.815319; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coulter IC, 2014, ACTA NEUROCHIR, V156, P1361, DOI 10.1007/s00701-014-2081-1; Di Stefano C, 2012, BRIT J NEUROSURG, V26, P827, DOI 10.3109/02688697.2012.692838; Dunisch P, 2013, J NEUROSURG, V118, P1141, DOI 10.3171/2013.1.JNS12860; Finkemeier CG, 2002, J BONE JOINT SURG AM, V84A, P454, DOI 10.2106/00004623-200203000-00020; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Gosain AK, 2011, PLAST RECONSTR SURG, V128, P85, DOI 10.1097/PRS.0b013e31821740cc; Harris DA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13560; Honeybul S, 2013, BRIT J NEUROSURG, V27, P636, DOI 10.3109/02688697.2013.817532; Im SH, 2012, J KOREAN NEUROSURG S, V52, P396, DOI 10.3340/jkns.2012.52.4.396; Jelcic N, 2013, ACTA NEUROCHIR, V155, P1597, DOI 10.1007/s00701-012-1519-6; Klinger DR, 2014, WORLD NEUROSURG, V82, pE525, DOI 10.1016/j.wneu.2013.08.005; Lee L, 2013, BRIT J NEUROSURG, V27, P629, DOI 10.3109/02688697.2013.815313; Martin KD, 2014, ACTA NEUROCHIR, V156, P813, DOI 10.1007/s00701-014-2021-0; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; Movassaghi K, 2006, PLAST RECONSTR SURG, V117, P202, DOI 10.1097/01.prs.0000187152.48402.17; Piedra MP, 2012, J NEUROSURG-PEDIATR, V10, P268, DOI 10.3171/2012.6.PEDS1268; Reddy S, 2014, PLAST RECONSTR SURG, V133, P864, DOI 10.1097/PRS.0000000000000013; Schoekler B, 2014, CLIN NEUROL NEUROSUR, V120, P64, DOI 10.1016/j.clineuro.2014.02.014; Schuss P, 2013, J NEUROTRAUM, V30, P91, DOI 10.1089/neu.2012.2542; Shah AM, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.2.FOCUS13561; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stefini Roberto, 2013, Surg Neurol Int, V4, P12, DOI 10.4103/2152-7806.106290; Sundseth J, 2014, ACTA NEUROCHIR, V156, P805, DOI 10.1007/s00701-013-1992-6; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Wachter D, 2013, CLIN NEUROL NEUROSUR, V115, P1293, DOI 10.1016/j.clineuro.2012.12.002; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	31	70	73	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	OCT 6	2015	23								75	10.1186/s13049-015-0155-6			7	Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	Emergency Medicine	CS7SB	WOS:000362284500001	26437934	gold, Green Published			2022-02-06	
J	Harrison, JL; Rowe, RK; Ellis, TW; Yee, NS; O'Hara, BF; Adelson, PD; Lifshitz, J				Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; O'Hara, Bruce F.; Adelson, P. David; Lifshitz, Jonathan			Resolvins AT-D1 and E1 differentially impact functional outcome, post-traumatic sleep, and microglial activation following diffuse brain injury in the mouse	BRAIN BEHAVIOR AND IMMUNITY			English	Article						TBI; Inflammation; Resolvins; Protectins; Sleep; Mouse; Behavior; Aspirin-triggered resolvin	RAT MODEL; MICE; CYTOKINES; WAKE; WAKEFULNESS; PATHOPHYSIOLOGY; NEUROPROTECTION; INFLAMMATION; EXPRESSION; MEDIATORS	Traumatic brain injury (TBI) is induced by mechanical forces which initiate a cascade of secondary injury processes, including inflammation. Therapies which resolve the inflammatory response may promote neural repair without exacerbating the primary injury. Specific derivatives of omega-3 fatty acids loosely grouped as specialized pro-resolving lipid mediators (SPMs) and termed resolvins promote the active resolution of inflammation. In the current study, we investigate the effect of two resolvin molecules, RvE1 and AT-RvD1, on post-traumatic sleep and functional outcome following diffuse TBI through modulation of the inflammatory response. Adult, male C57BL/6 mice were injured using a midline fluid percussion injury (mFPI) model (6-10 min righting reflex time for brain-injured mice). Experimental groups included mFPI administered RvE1 (100 ng daily), AT-RvD1 (100 ng daily), or vehicle (sterile saline) and counterbalanced with uninjured sham mice. Resolvins or saline were administered daily for seven consecutive days beginning 3 days prior to TBI to evaluate proof-of-principle to improve outcome. Immediately following diffuse TBI, post-traumatic sleep was recorded for 24 h post-injury. For days 1-7 post-injury, motor outcome was assessed by rotarod. Cognitive function was measured at 6 days post-injury using novel object recognition (NOR). At 7 days post-injury, microglial activation was quantified using immunohistochemistry for Iba-1. In the diffuse brain-injured mouse, AT-RvD1 treatment, but not RvE1, mitigated motor and cognitive deficits. RvEl treatment significantly increased post-traumatic sleep in brain-injured mice compared to all other groups. RvEl treated mice displayed a higher proportion of ramified microglia and lower proportion of activated rod microglia in the cortex compared to saline or AT-RvD1 treated brain-injured mice. Thus, RvEl treatment modulated post-traumatic sleep and the inflammatory response to TB!, albeit independently of improvement in motor and cognitive outcome as seen in AT-RvD1-treated mice. This suggests AT-RvD1 may impart functional benefit through mechanisms other than resolution of inflammation alone. (C) 2015 Elsevier Inc. All rights reserved.	[Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; Adelson, P. David; Lifshitz, Jonathan] Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA; [Harrison, Jordan L.; Rowe, Rachel K.; Ellis, Timothy W.; Yee, Nicole S.; Adelson, P. David; Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Harrison, Jordan L.; Adelson, P. David; Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA; [Rowe, Rachel K.; Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Ellis, Timothy W.] Midwestern Univ, Coll Osteopath Med, Glendale, AZ USA; [O'Hara, Bruce F.] Univ Kentucky, Dept Biol, Coll Arts & Sci, Lexington, KY USA; [O'Hara, Bruce F.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA		Lifshitz, J (corresponding author), Phoenix Childrens Hosp, Barrow Neurol Inst, Phoenix, AZ 85016 USA.	jlifshitz@email.arizona.edu	Adelson, David/W-2083-2019	Rowe, Rachel/0000-0002-9034-3159	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS072611, RO1 NS-065052]; PCH Mission Support Funds; Kentucky Spinal Cord & Head Injury Research Trust [10-5A]; Diane and Bruce Halle Foundation; Science Foundation Arizona Bisgrove Scholarship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS065052, R21NS072611] Funding Source: NIH RePORTER	Research reported in this manuscript was supported, in part, by National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award numbers R21 NS072611 and RO1 NS-065052, PCH Mission Support Funds, and Kentucky Spinal Cord & Head Injury Research Trust award 10-5A. The generosity of the Diane and Bruce Halle Foundation supported JLH during the conduct of these studies. RKR was supported by a Science Foundation Arizona Bisgrove Scholarship during the conduct of these studies.	Albensi BC, 2003, BRAIN INJURY, V17, P653, DOI 10.1080/0269905031000107142; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Arciniegas DB, 2000, CURRENT TREATMENT OP, V2, P169; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bazan NG, 2012, EXP NEUROL, V236, P122, DOI 10.1016/j.expneurol.2012.04.007; Belayev L, 2011, TRANSL STROKE RES, V2, P33, DOI 10.1007/s12975-010-0046-0; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Donohue KD, 2008, BIOMED ENG ONLINE, V7, DOI 10.1186/1475-925X-7-14; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Ennaceur A, 1997, BEHAV BRAIN RES, V88, P181, DOI 10.1016/S0166-4328(97)02297-3; Faul M, 2010, TRAUMATIC BRAIN INJU; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Han XD, 2011, J NEUROTRAUM, V28, P995, DOI 10.1089/neu.2010.1563; Harrison JL, 2014, EXP BRAIN RES, V232, P2709, DOI 10.1007/s00221-014-3948-3; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Hazra A, 2014, J NEUROSCI RES, V92, P1434, DOI 10.1002/jnr.23430; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hsu JC, 2003, CELLS TISSUES ORGANS, V173, P242, DOI 10.1159/000070380; Ingiosi AM, 2013, CURR OPIN NEUROBIOL, V23, P806, DOI 10.1016/j.conb.2013.02.003; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Klein CP, 2014, NEUROPHARMACOLOGY, V86, P57, DOI 10.1016/j.neuropharm.2014.05.043; Krueger JM, 2007, SLEEP MED CLIN, V2, P161, DOI 10.1016/j.jsmc.2007.03.003; KRUEGER JM, 1995, ADV NEUROIMMUNOL, V5, P171, DOI 10.1016/0960-5428(95)00007-O; Krueger JM, 2001, ANN NY ACAD SCI, V933, P211; Lifshitz J, 2008, ANIMAL MODELS ACUTE; Lifshitz J, 2012, BRAIN STRUCT FUNCT, V217, P49, DOI 10.1007/s00429-011-0323-z; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Mang GM, 2014, SLEEP, V37, P1383, DOI 10.5665/sleep.3936; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McShane BB, 2010, J NEUROSCI METH, V193, P321, DOI 10.1016/j.jneumeth.2010.08.024; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Mukherjee S, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00028; Recchiuti A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00298; Rowe RK, 2014, SLEEP, V37, P743, DOI 10.5665/sleep.3582; Rowe RK, 2014, BRAIN INJURY, V28, P504, DOI 10.3109/02699052.2014.888768; Rowe RK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082507; Russell KL, 2014, PROSTAG LEUKOTR ESS, V90, P5, DOI 10.1016/j.plefa.2013.11.003; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Tallarida RJ, 2012, J PHARMACOL EXP THER, V342, P2, DOI 10.1124/jpet.112.193474; Taylor SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097096; Tham SW, 2013, J PAIN, V14, P1242, DOI 10.1016/j.jpain.2013.05.007; Thomas KS, 2011, BRAIN BEHAV IMMUN, V25, P53, DOI 10.1016/j.bbi.2010.07.245; Wang L, 2014, CHINESE MED J-PEKING, V127, P803, DOI 10.3760/cma.j.issn.0366-6999.20131044; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willie JT, 2012, J NEUROTRAUM, V29, P1908, DOI 10.1089/neu.2012.2404; Wirenfeldt M, 2009, NEUROBIOL DIS, V34, P432, DOI 10.1016/j.nbd.2009.02.015; Wisor JP, 2011, BRAIN BEHAV IMMUN, V25, P767, DOI 10.1016/j.bbi.2011.02.002; Wu A, 2013, NEUROSCIENCE, V248, P655, DOI 10.1016/j.neuroscience.2013.06.041; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	70	70	0	16	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JUL	2015	47				SI		131	140		10.1016/j.bbi.2015.01.001			10	Immunology; Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Immunology; Neurosciences & Neurology; Psychiatry	CL8NM	WOS:000357231400015	25585137	Green Accepted			2022-02-06	
J	Hellyer, PJ; Scott, G; Shanahan, M; Sharp, DJ; Leech, R				Hellyer, Peter J.; Scott, Gregory; Shanahan, Murray; Sharp, David J.; Leech, Robert			Cognitive Flexibility through Metastable Neural Dynamics Is Disrupted by Damage to the Structural Connectome	JOURNAL OF NEUROSCIENCE			English	Article						cognitive flexibility; computational modeling; connectome; metastability; traumatic brain injury	RICH-CLUB ORGANIZATION; DIFFUSE AXONAL INJURY; RESPONSE-INHIBITION; SALIENCE NETWORK; BRAIN; CONNECTIVITY; CRITICALITY; MODEL; SYNCHRONIZATION; DIAGNOSIS	Current theory proposes that healthy neural dynamics operate in a metastable regime, where brain regions interact to simultaneously maximize integration and segregation. Metastability may confer important behavioral properties, such as cognitive flexibility. It is increasingly recognized that neural dynamics are constrained by the underlying structural connections between brain regions. An important challenge is, therefore, to relate structural connectivity, neural dynamics, and behavior. Traumatic brain injury (TBI) is a pre-eminent structural disconnection disorder whereby traumatic axonal injury damages large-scale connectivity, producing characteristic cognitive impairments, including slowed information processing speed and reduced cognitive flexibility, that may be a result of disrupted metastable dynamics. Therefore, TBI provides an experimental and theoretical model to examine how metastable dynamics relate to structural connectivity and cognition. Here, we use complementary empirical and computational approaches to investigate how metastability arises from the healthy structural connectome and relates to cognitive performance. We found reduced metastability in large-scale neural dynamics after TBI, measured with resting-state functional MRI. This reduction in metastability was associated with damage to the connectome, measured using diffusion MRI. Furthermore, decreased metastability was associated with reduced cognitive flexibility and information processing. A computational model, defined by empirically derived connectivity data, demonstrates how behaviorally relevant changes in neural dynamics result from structural disconnection. Our findings suggest how metastable dynamics are important for normal brain function and contingent on the structure of the human connectome.	[Hellyer, Peter J.; Scott, Gregory; Sharp, David J.; Leech, Robert] Univ London Imperial Coll Sci Technol & Med, Fac Med, Div Brain Sci, Computat Cognit & Clin Neuroimaging Lab, London W12 0NN, England; [Hellyer, Peter J.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Ctr Neuroimaging Sci, London SE5 8AF, England; [Shanahan, Murray] Univ London Imperial Coll Sci Technol & Med, Dept Comp, London SW7 2RH, England		Leech, R (corresponding author), Hammersmith Hosp, Computat Cognit & Clin Neuroimaging Lab, 3rd Floor,Burlington Danes,Du Cane Rd, London W12 0NN, England.	r.leech@imperial.ac.uk	Leech, Robert/AAE-8254-2019; Sharp, David J/A-2119-2013; Hellyer, Peter J/F-7112-2013	Leech, Robert/0000-0002-5801-6318; Hellyer, Peter J/0000-0002-5139-3401; Scott, Gregory/0000-0001-8063-5871	Medical Research Council Doctoral Training AwardUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [1110783] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-011-048] Funding Source: researchfish	P.J.H. was supported by a Medical Research Council Doctoral Training Award. G.S. was supported by a clinical research fellowship awarded in the Wellcome Trust-GlaxoSmithKline Translational Medicine Training Programme. We thank Frantisek Vasa for useful conversations on comparing simulated and empirical networks. We also thank the participants who were involved in this research.	Acebron JA, 2005, REV MOD PHYS, V77, P137, DOI 10.1103/RevModPhys.77.137; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Baddeley A.D., 1986, WORKING MEMORY; Baddeley AD, 1994, DOORS PEOPLE TEST VI; Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Beggs JM, 2003, J NEUROSCI, V23, P11167; Beggs JM, 2008, PHILOS T R SOC A, V366, P329, DOI 10.1098/rsta.2007.2092; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bhowmik D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062234; Bird CM, 2004, BRAIN, V127, P914, DOI 10.1093/brain/awh108; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Cabral J, 2012, NEUROIMAGE, V62, P1342, DOI 10.1016/j.neuroimage.2012.06.007; Cabral J, 2011, NEUROIMAGE, V57, P130, DOI 10.1016/j.neuroimage.2011.04.010; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Chang C, 2010, NEUROIMAGE, V50, P81, DOI 10.1016/j.neuroimage.2009.12.011; Chialvo DR, 2010, NAT PHYS, V6, P744, DOI 10.1038/NPHYS1803; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Deco G, 2009, PROG NEUROBIOL, V88, P1, DOI 10.1016/j.pneurobio.2009.01.006; Deco G, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000092; Erika-Florence M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5073; Fagerholm ED, 2015, J NEUROSCI, V35, P4626, DOI 10.1523/JNEUROSCI.3694-14.2015; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; FREEMAN LC, 1978, SOCIOL METHOD RES, V6, P411, DOI 10.1177/004912417800600401; Friston Karl J, 2002, World Psychiatry, V1, P66; Friston KJ, 2000, NEUROIMAGE, V12, P466, DOI 10.1006/nimg.2000.0630; Friston KJ, 1997, NEUROIMAGE, V5, P164, DOI 10.1006/nimg.1997.0259; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gigandet X, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004006; Glerean E, 2012, BRAIN CONNECT, V2, P91, DOI 10.1089/brain.2011.0068; Gong GL, 2009, CEREB CORTEX, V19, P524, DOI 10.1093/cercor/bhn102; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Greve DN, 2009, NEUROIMAGE, V48, P63, DOI 10.1016/j.neuroimage.2009.06.060; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Haldeman C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058101; Hellyer PJ, 2014, J NEUROSCI, V34, P451, DOI 10.1523/JNEUROSCI.1853-13.2014; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Honey CJ, 2009, P NATL ACAD SCI USA, V106, P2035, DOI 10.1073/pnas.0811168106; Humphries MD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002051; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones Derek K, 2010, Top Magn Reson Imaging, V21, P87, DOI 10.1097/RMR.0b013e31821e56ac; Jones DK., 2010, IMAGING MED, V2, P341, DOI 10.2217/iim.10.21; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kitzbichler MG, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000314; Kuramoto Y., 2003, CHEM OSCILLATIONS WA; LOGAN GD, 1984, J EXP PSYCHOL HUMAN, V10, P276, DOI 10.1037/0096-1523.10.2.276; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Messe A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003530; Niazy RK, 2011, PROG BRAIN RES, V193, P259, DOI 10.1016/B978-0-444-53839-0.00017-X; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; RABBITT PMA, 1966, J EXP PSYCHOL, V71, P264, DOI 10.1037/h0022853; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Scott G, 2014, J NEUROSCI, V34, P16611, DOI 10.1523/JNEUROSCI.3474-14.2014; Senden M, 2014, NEUROIMAGE, V96, P174, DOI 10.1016/j.neuroimage.2014.03.066; Shanahan M, 2010, CHAOS, V20, DOI 10.1063/1.3305451; Sharp DJ, 2010, P NATL ACAD SCI USA, V107, P6106, DOI 10.1073/pnas.1000175107; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Sharp DJ, 2010, ANN NEUROL, V68, P753, DOI 10.1002/ana.21866; Shew WL, 2013, NEUROSCIENTIST, V19, P88, DOI 10.1177/1073858412445487; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sporns O, 2006, BIOSYSTEMS, V85, P55, DOI 10.1016/j.biosystems.2006.02.008; Spreng RN, 2010, J COGNITIVE NEUROSCI, V22, P1112, DOI 10.1162/jocn.2009.21282; Squarcina L, 2012, NEUROIMAGE, V63, P779, DOI 10.1016/j.neuroimage.2012.07.016; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Tagliazucchi E, 2014, NEURON, V82, P695, DOI 10.1016/j.neuron.2014.03.020; Tognoli E, 2014, NEURON, V81, P35, DOI 10.1016/j.neuron.2013.12.022; Uhhaas PJ, 2006, NEURON, V52, P155, DOI 10.1016/j.neuron.2006.09.020; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; Werner G, 2007, BIOSYSTEMS, V90, P496, DOI 10.1016/j.biosystems.2006.12.001; Wildie M, 2012, CHAOS, V22, DOI 10.1063/1.4766592; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060	82	70	71	0	19	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUN 17	2015	35	24					9050	9063		10.1523/JNEUROSCI.4648-14.2015			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CN2KU	WOS:000358250700010	26085630	Green Published, Bronze			2022-02-06	
J	Scholten, AC; Haagsma, JA; Andriessen, TMJC; Vos, PE; Steyerberg, EW; van Beeck, EF; Polinder, S				Scholten, A. C.; Haagsma, J. A.; Andriessen, T. M. J. C.; Vos, P. E.; Steyerberg, E. W.; van Beeck, E. F.; Polinder, S.			Health-related quality of life after mild, moderate and severe traumatic brain injury: Patterns and predictors of suboptimal functioning during the first year after injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Follow-up studies; Glasgow outcome scale-extended; Health-related quality of life; SF-36	SEVERE HEAD-INJURY; GLASGOW OUTCOME SCALE; MULTIPLE TRAUMA; QOLIBRI; SATISFACTION; DISABILITY; RECOVERY; S100B; SF-36	Background: The Glasgow Outcome Scale Extended (GOSE) is the established functional outcome scale to assess disability following traumatic brain injury (TBI), however does not capture the patient's subjective perspective. Health-related quality of life (HRQL) does capture the individual's perception of disability after TBI, and has therefore been recognized as an important outcome in TBI. In contrast to GOSE, HRQL enables comparison of health outcome across various disease states and with healthy individuals. We aimed to assess functional outcome, HRQL, recovery, and predictors of 6 and 12-month outcome in a comprehensive sample of patients with mild, moderate or severe TBI, and to examine the relationship between functional impairment (GOSE) and HRQL. Methods: A prospective cohort study was conducted among a sample of 2066 adult TBI patients who attended the emergency department (ED). GOSE was determined through questionnaires or structured interviews. Questionnaires 6 and 12 months after ED treatment included socio-demographic information and HRQL measured with Short-Form Health Survey (SF-36; reflecting physical, mental and social functioning) and Perceived Quality of Life Scale (PQoL; measuring degree of satisfaction with functioning). Results: 996 TBI survivors with mild, moderate or severe TBI completed the 6-month questionnaire. Functional outcome and HRQL after moderate or severe TBI was significantly lower than after mild TBI. Patients with moderate TBI showed greatest improvement. After one year, the mild TBI group reached outcomes comparable to population norms. TBI of all severities highly affected SF-36 domains physical and social functioning, and physical and emotional role functioning. GOSE scores were highly related to all SF-36 domains and PQoL scores. Female gender, older age, co-morbidity and high ISS were strongest independent predictors of decreased HRQL at 6 and 12 months after TBI. Conclusions: HRQL and recovery patterns differ for mild, moderate and severe TBI. This study indicates that GOSE, although clinically relevant, fails to capture the subjective perspective of TBI patients, which endorses the use of HRQL as valuable addition to established instruments in assessing disability following TBI. Influence of TBI severity on recovery, together with female gender, older age, co-morbidity and high ISS should be considered in long-term follow-up and intervention programs. (C) 2014 Elsevier Ltd. All rights reserved.	[Scholten, A. C.; Haagsma, J. A.; Steyerberg, E. W.; van Beeck, E. F.; Polinder, S.] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; [Andriessen, T. M. J. C.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Vos, P. E.] Slingeland Hosp, Dept Neurol, NL-7000 AD Doetinchem, Netherlands		Scholten, AC (corresponding author), Erasmus MC, Dept Publ Hlth, POB 2040, NL-3000 CA Rotterdam, Netherlands.	a.scholten@erasmusmc.nl					Aaronson NK, 1998, J CLIN EPIDEMIOL, V51, P1055, DOI 10.1016/S0895-4356(98)00097-3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Arango-Lasprilla JC, 2012, BRAIN INJURY, V26, P825, DOI 10.3109/02699052.2012.655364; Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Beseoglu K, 2013, BRIT J NEUROSURG, V27, P202, DOI 10.3109/02688697.2012.717984; Brain Injury Association of America, 2012, AB BRAIN INJ; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; Diaz AP, 2012, J NEUROTRAUM, V29, P1029, DOI 10.1089/neu.2011.2089; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Forslund M.V., 2013, ACTA NEUROL SCAND; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Guyatt G. H., 1996, QUALITY LIFE PHARMAC, P41; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hu XB, 2012, BRAIN INJURY, V26, P183, DOI 10.3109/02699052.2011.648707; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobsson LJ, 2010, BRAIN INJURY, V24, P1075, DOI 10.3109/02699052.2010.494590; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lippert-Gruner M, 2007, BRAIN INJURY, V21, P451, DOI 10.1080/02699050701343961; Machamer J, 2013, J NEUROTRAUM, V30, P1845, DOI 10.1089/neu.2013.2920; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; McLean AM, 2014, DISABIL REHABIL, V36, P1409, DOI 10.3109/09638288.2013.834986; Neugebauer E, 2002, RESTOR NEUROL NEUROS, V20, P161; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; PATRICK DL, 1988, J GEN INTERN MED, V3, P218, DOI 10.1007/BF02596335; Patrick DL, 2000, J CLIN EPIDEMIOL, V53, P779, DOI 10.1016/S0895-4356(00)00205-5; Polinder S, 2013, LANCET, V381, P116; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Riemsma R P, 2001, Health Technol Assess, V5, P1; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Seattle Quality of Life Group, 2008, INF SHEET PERC QUAL; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; Soberg HL, 2013, J REHABIL MED, V45, P785, DOI 10.2340/16501977-1158; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; TEASDALE G, 1974, LANCET, V2, P81; Vittinghoff E, 2012, REGRESSION METHODS B; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Ware J.E., 1993, SF 36 HLTH SURVEY MA; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Weir J, 2012, J NEUROTRAUM, V29, P53, DOI 10.1089/neu.2011.2137; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	57	70	71	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	APR	2015	46	4					616	624		10.1016/j.injury.2014.10.064			9	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CD7MZ	WOS:000351275900017	25476014				2022-02-06	
J	Imbach, LL; Valko, PO; Li, TZ; Maric, A; Symeonidou, ER; Stover, JF; Bassetti, CL; Mica, L; Werth, E; Baumann, CR				Imbach, Lukas L.; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Symeonidou, Evangelia-Regkina; Stover, John F.; Bassetti, Claudio L.; Mica, Ladislav; Werth, Esther; Baumann, Christian R.			Increased sleep need and daytime sleepiness 6 months after traumatic brain injury: a prospective controlled clinical trial	BRAIN			English	Article						traumatic brain injury; sleep; post-traumatic pleiosomnia; post-traumatic daytime sleepiness	NEURON-SPECIFIC ENOLASE; PERIODIC LEG MOVEMENTS; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; LESIONS; DISTURBANCES; ALERTNESS; PATTERNS; ADULTS; BLOOD	Post-traumatic sleep-wake disturbances are common after acute traumatic brain injury. Increased sleep need per 24 h and excessive daytime sleepiness are among the most prevalent post-traumatic sleep disorders and impair quality of life of trauma patients. Nevertheless, the relation between traumatic brain injury and sleep outcome, but also the link between post-traumatic sleep problems and clinical measures in the acute phase after traumatic brain injury has so far not been addressed in a controlled and prospective approach. We therefore performed a prospective controlled clinical study to examine (i) sleep-wake outcome after traumatic brain injury; and (ii) to screen for clinical and laboratory predictors of poor sleep-wake outcome after acute traumatic brain injury. Forty-two of 60 included patients with first-ever traumatic brain injury were available for follow-up examinations. Six months after trauma, the average sleep need per 24 h as assessed by actigraphy was markedly increased in patients as compared to controls (8.3 +/- 1.1 h versus 7.1 +/- 0.8 h, P < 0.0001). Objective daytime sleepiness was found in 57% of trauma patients and 19% of healthy subjects, and the average sleep latency in patients was reduced to 8.7 +/- 4.6 min (12.1 +/- 4.7 min in controls, P = 0.0009). Patients, but not controls, markedly underestimated both excessive sleep need and excessive daytime sleepiness when assessed only by subjective means, emphasizing the unreliability of self-assessment of increased sleep propensity in traumatic brain injury patients. At polysomnography, slow wave sleep after traumatic brain injury was more consolidated. The most important risk factor for developing increased sleep need after traumatic brain injury was the presence of an intracranial haemorrhage. In conclusion, we provide controlled and objective evidence for a direct relation between sleep-wake disturbances and traumatic brain injury, and for clinically significant underestimation of post-traumatic sleep-wake disturbances by trauma patients.	[Imbach, Lukas L.; Valko, Philipp O.; Li, Tongzhou; Maric, Angelina; Symeonidou, Evangelia-Regkina; Werth, Esther; Baumann, Christian R.] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; [Stover, John F.; Mica, Ladislav] Univ Zurich Hosp, Dept Traumatol, CH-8091 Zurich, Switzerland; [Bassetti, Claudio L.] Inselspital Bern, Dept Neurol, CH-3010 Bern, Switzerland		Baumann, CR (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklin Str 26, CH-8091 Zurich, Switzerland.	christian.baumann@usz.ch	Werth, E/AAN-7955-2021	Baumann, Christian/0000-0003-3417-1978; Maric, Angelina/0000-0002-1416-6728; Bassetti, Claudio/0000-0002-4535-0245; Werth, Esther/0000-0002-5099-3122; Imbach, Lukas/0000-0002-6135-8642	Swiss National Science Foundation (SNF)Swiss National Science Foundation (SNSF) [32003B-125504]; Clinical Research Priority Program 'Sleep and Health' of the University of Zurich	This study was supported by the Swiss National Science Foundation (SNF, grant no. 32003B-125504), and by the Clinical Research Priority Program 'Sleep and Health' of the University of Zurich.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cetas JS, 2009, NEUROSCIENCE, V163, P719, DOI 10.1016/j.neuroscience.2009.06.031; Chapotot F, 1998, J CLIN ENDOCR METAB, V83, P4263, DOI 10.1210/jc.83.12.4263; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Cippa MAT, 2013, J SLEEP RES, V22, P589, DOI 10.1111/jsr.12053; CROMPTON MR, 1971, LANCET, V1, P669; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Dijk DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030037; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Hautzinger M., 1993, ALLGEMEINE DEPRESSIO; King MA, 2005, SLEEP MED, V6, P507, DOI 10.1016/j.sleep.2004.12.010; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mathias JL, 2012, SLEEP MED, V13, P898, DOI 10.1016/j.sleep.2012.04.006; Mignot E, 2006, BRAIN, V129, P1609, DOI 10.1093/brain/awl079; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford JL, 2013, NEUROREHAB NEURAL RE, V27, P613, DOI 10.1177/1545968313481283; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; Valko PO, ANN NEUROL; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC	29	70	74	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	MAR 1	2015	138		3				726	735		10.1093/brain/awu391			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CE0QY	WOS:000351510700027	25595147	Green Published, Bronze, Green Accepted			2022-02-06	
J	Meagher, AD; Beadles, CA; Doorey, J; Charles, AG				Meagher, Ashley D.; Beadles, Christopher A.; Doorey, Jennifer; Charles, Anthony G.			Racial and ethnic disparities in discharge to rehabilitation following traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						trauma; traumatic brain injury; disparities; level of rehabilitation	INSTITUTE-OF-MEDICINE; UNEQUAL TREATMENT; HEALTH-CARE; UNITED-STATES; HEAD-INJURY; OUTCOMES	OBJECT Disparities in access to inpatient rehabilitation services after traumatic brain injury (TBI) have been identified, but less well described is the likelihood of discharge to a higher level of rehabilitation for Hispanic or black patients compared with non-Hispanic white patients. The authors investigate racial disparities in discharge destination (inpatient rehabilitation vs skilled nursing facility vs home health vs home) following TBI by using a nationwide database and methods to address racial differences in prehospital characteristics. METHODS Analysis of discharge destination for adults with moderate to severe TBI was performed using National Trauma Data Bank data for the years 2007-2010. The authors performed propensity score weighting followed by ordered logistic regression in their analytical sample and in a subgroup analysis of older adults with Medicare. Likelihood of discharge to a higher level of rehabilitation based on race/ethnicity accounting for prehospital and in-hospital variables was determined. RESULTS The authors identified 299,205 TBI incidents: 232,392 non-Hispanic white, 29,611 Hispanic, and 37,202 black. Propensity weighting resulted in covariate balance among racial groups. Hispanic (adjusted OR 0.71, 95% Cl 0.68-0.75) and black (adjusted OR 0.94, 95% Cl 0.91-0.97) populations were less likely to be discharged to a higher level of rehabilitation than were non-Hispanic whites. The subgroup analysis indicated that Hispanic (adjusted OR 0.79, 95% Cl 0.71-0.86) and black (OR 0.87, 95% Cl 0.81-0.94) populations were still less likely to receive a higher level of rehabilitation, despite uniform insurance coverage (Medicare). CONCLUSIONS Adult Hispanic and black patients with TBI are significantly less likely to receive intensive rehabilitation than their non-Hispanic white counterparts; notably, this difference persists in the. Medicare population (age >= 65 years), indicating that uniform insurance coverage alone does not account for the disparity. Given that insurance coverage and a wide range of prehospital characteristics do not eliminate racial disparities in discharge destination, it is crucial that additional unmeasured patient, physician, and institutional factors be explored to eliminate them.	[Meagher, Ashley D.; Doorey, Jennifer; Charles, Anthony G.] Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA; [Meagher, Ashley D.; Beadles, Christopher A.; Charles, Anthony G.] Univ N Carolina, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA; [Beadles, Christopher A.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, Chapel Hill, NC 27599 USA; [Doorey, Jennifer; Charles, Anthony G.] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA; [Beadles, Christopher A.] Ctr Hlth Serv Res Primary Care, Dept Vet Affairs, Med Ctr, Durham, NC USA		Charles, AG (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, UNC Sch Med, 4008 Burnett Womack Bldg,CB 7228, Chapel Hill, NC 27599 USA.	anthchar@med.unc.edu		Beadles, Christopher/0000-0001-6410-1722; Meagher, Ashley/0000-0003-2429-2274	National Research Service Award Post-Doctoral Traineeship from the Agency for Health Care Research and Quality - Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill [5T32-HS000032]; NIH CTSA at UNCUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [2KR391203]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [T32HS000032] Funding Source: NIH RePORTER	DISCLOSURE This research was partially supported by a National Research Service Award Post-Doctoral Traineeship from the Agency for Health Care Research and Quality sponsored by the Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Grant No. 5T32-HS000032 (salary support for Drs. Meagher and Beadles), and NIH CTSA at UNC Grant No. 2KR391203 (data acquisition).	Alban RF, 2010, AM SURGEON, V76, P1108; Betancourt JR, 2003, PUBLIC HEALTH REP, V118, P287, DOI 10.1093/phr/118.4.287; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Drewery MP, BLACK POPULATION 201; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Ennis SR, HISPANIC POPULATION; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Greenwood RJ, 2004, BRIT J NEUROSURG, V18, P462, DOI 10.1080/02688690400012327; Haider AH, 2013, J TRAUMA ACUTE CARE, V74, P1195, DOI 10.1097/TA.0b013e31828c331d; Lefebvre H, 2005, BRAIN INJURY, V19, P585, DOI 10.1080/02699050400025026; Nelson A, 2002, J NATL MED ASSOC, V94, P666; Nelson AR, 2003, ANN THORAC SURG, V76, pS1377, DOI 10.1016/S0003-4975(03)01205-0; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Shafi S, 2007, J TRAUMA, V63, P1263, DOI 10.1097/TA.0b013e31815b8f00; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; WHITLOCK JA, 1995, ARCH PHYS MED REHAB, V76, P1103, DOI 10.1016/S0003-9993(95)80117-0	21	70	70	2	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2015	122	3					595	601		10.3171/2014.10.JNS14187			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	CC3RJ	WOS:000350266600015	25415069	Bronze			2022-02-06	
J	Westover, MB; Shafi, MM; Bianchi, MT; Moura, LMVR; O'Rourke, D; Rosenthal, ES; Chu, CJ; Donovan, S; Hoch, DB; Kilbride, RD; Cole, AJ; Cash, SS				Westover, M. Brandon; Shafi, Mouhsin M.; Bianchi, Matt T.; Moura, Lidia M. V. R.; O'Rourke, Deirdre; Rosenthal, Eric S.; Chu, Catherine J.; Donovan, Samantha; Hoch, Daniel B.; Kilbride, Ronan D.; Cole, Andrew J.; Cash, Sydney S.			The probability of seizures during EEG monitoring in critically ill adults	CLINICAL NEUROPHYSIOLOGY			English	Article						Continuous electroencephalography; ICU EEG monitoring; Nonconvulsive seizures	NONCONVULSIVE STATUS EPILEPTICUS; TRAUMATIC BRAIN-INJURY; INTENSIVE-CARE-UNIT; INTRACEREBRAL HEMORRHAGE; ELECTROGRAPHIC SEIZURES; DISCHARGES; FREQUENCY; IMPACT	Objective: To characterize the risk for seizures over time in relation to EEG findings in hospitalized adults undergoing continuous EEG monitoring (cEEG). Methods: Retrospective analysis of cEEG data and medical records from 625 consecutive adult inpatients monitored at a tertiary medical center. Using survival analysis methods, we estimated the time-dependent probability that a seizure will occur within the next 72-h, if no seizure has occurred yet, as a function of EEG abnormalities detected so far. Results: Seizures occurred in 27% (168/625). The first seizure occurred early (< 30 min of monitoring) in 58% (98/168). In 527 patients without early seizures, 159 (30%) had early epileptiform abnormalities, versus 368 (70%) without. Seizures were eventually detected in 25% of patients with early epileptiform discharges, versus 8% without early discharges. The 72-h risk of seizures declined below 5% if no epileptiform abnormalities were present in the first two hours, whereas 16 h of monitoring were required when epileptiform discharges were present. 20% (74/388) of patients without early epileptiform abnormalities later developed them; 23% (17/74) of these ultimately had seizures. Only 4% (12/294) experienced a seizure without preceding epileptiform abnormalities. Conclusions: Seizure risk in acute neurological illness decays rapidly, at a rate dependent on abnormalities detected early during monitoring. This study demonstrates that substantial risk stratification is possible based on early EEG abnormalities. Significance: These findings have implications for patient-specific determination of the required duration of cEEG monitoring in hospitalized patients. (C) 2014 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	[Westover, M. Brandon; Shafi, Mouhsin M.; Bianchi, Matt T.; Moura, Lidia M. V. R.; O'Rourke, Deirdre; Rosenthal, Eric S.; Chu, Catherine J.; Donovan, Samantha; Hoch, Daniel B.; Kilbride, Ronan D.; Cole, Andrew J.; Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Epilepsy Serv, Boston, MA 02114 USA; [Shafi, Mouhsin M.] Beth Israel Deaconess Med Ctr, Epilepsy Serv, Dept Neurol, Boston, MA 02214 USA		Westover, MB (corresponding author), Massachusetts Gen Hosp, Wang 7 Neurol,55 Fruit St, Boston, MA 02114 USA.	mwestover@mgh.harvard.edu; mshafi@bidmc.harvard.edu; mtbianchi@mgh.harvard.edu; lmoura@mgh.harvard.edu; daorourke@mgh.harvard.edu; erosenthal@mgh.harvard.edu; cchu3@mgh.harvard.edu; dbhoch@mgh.harvard.edu; rkilbride@mgh.harvard.edu; acole1@mgh.harvard.edu; scash@mgh.harvard.edu	Rosenthal, Eric Scott/A-2085-2017	Rosenthal, Eric Scott/0000-0003-3900-356X; Hoch, Daniel/0000-0002-4294-024X; Moura, Lidia/0000-0002-1191-1315	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS092923, K12 NS066225] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K12NS066225] Funding Source: NIH RePORTER		Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BAKER CJ, 1995, NEUROSURGERY, V37, P863, DOI 10.1227/00006123-199511000-00003; Butzkueven H, 2000, NEUROLOGY, V55, P1315, DOI 10.1212/WNL.55.9.1315; Carrera E, 2008, ARCH NEUROL-CHICAGO, V65, P1612, DOI 10.1001/archneur.65.12.1612; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2001, NEUROLOGY, V57, P1036, DOI 10.1212/WNL.57.6.1036; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Collett D., 2003, MODELLING SURVIVAL D, V2nd; DeLorenzo RJ, 1998, EPILEPSIA, V39, P833, DOI 10.1111/j.1528-1157.1998.tb01177.x; FOY PM, 1981, ACTA NEUROCHIR, V55, P253, DOI 10.1007/BF01808441; HASAN D, 1993, ANN NEUROL, V33, P286; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; Jordan K, 1992, NEUROLOGY, V42, P180; Jordan KG, 1999, J CLIN NEUROPHYSIOL, V16, P14, DOI 10.1097/00004691-199901000-00002; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Kaplan PW, 1999, J CLIN NEUROPHYSIOL, V16, P341, DOI 10.1097/00004691-199907000-00006; Kleinbaum DG, 2012, STAT BIOL HEALTH, P1, DOI 10.1007/978-1-4419-6646-9; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; KVAM DA, 1983, NEUROSURGERY, V12, P14, DOI 10.1227/00006123-198301000-00003; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; MATTHEW E, 1980, CAN J NEUROL SCI, V7, P285, DOI 10.1017/S0317167100022757; Mayer SA, 2002, ARCH NEUROL-CHICAGO, V59, P205, DOI 10.1001/archneur.59.2.205; Murthy JMK, 2003, NEUROL INDIA, V51, P453; PRIVITERA M, 1994, EPILEPSY RES, V18, P155, DOI 10.1016/0920-1211(94)90008-6; Rausand M., 2003, SYSTEM RELIABILITY T; Shafi MM, 2012, NEUROLOGY, V79, P1796, DOI 10.1212/WNL.0b013e3182703fbc; SUNDARAM MBM, 1986, CAN J NEUROL SCI, V13, P229, DOI 10.1017/S0317167100036325; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Wright WL, 2006, SEMIN NEUROL, V26, P396, DOI 10.1055/s-2006-948320; Young GB, 1998, ARCH NEUROL-CHICAGO, V55, P117, DOI 10.1001/archneur.55.1.117	40	70	72	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	MAR	2015	126	3					463	471		10.1016/j.clinph.2014.05.037			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CB4RX	WOS:000349616700008	25082090	Green Published, Green Accepted			2022-02-06	
J	Gibson, TB; Herring, SA; Kutcher, JS; Broglio, SP				Gibson, Teresa B.; Herring, Stanley A.; Kutcher, Jeffrey S.; Broglio, Steven P.			Analyzing the Effect of State Legislation on Health Care Utilization for Children With Concussion	JAMA PEDIATRICS			English	Article							COLLEGIATE FOOTBALL PLAYERS; TRAUMATIC BRAIN-INJURY; NCAA CONCUSSION; SPORT; EPIDEMIOLOGY; RECOVERY	IMPORTANCE In 2009, Washington State enacted legislation outlining the medical care of children and adolescents with concussion (ie, the Lystedt Law), with all other states and Washington, DC passing legislation by January 2014. OBJECTIVE To evaluate the effect of concussion laws on health care utilization rates from January 1, 2006, through June 30, 2012, in states with and without legislation. DESIGN, SETTING, AND PARTICIPANTS For commercially insured children aged 12 to 18 years from all 50 states and DC from January 1, 2006, through June 30, 2009, we examined the following: (1) prelegislation trends in concussion-related health care utilization from January 1, 2006, through June 30, 2009, (2) postlegislation trends in states without concussion legislation, and (3) the effect of state concussion laws on trends in states with concussion legislation in effect by means of negative binomial multivariable estimation with state and time fixed effects. EXPOSURES Concussion diagnosis. MAIN OUTCOMES AND MEASURES Emergency department and related health care utilization rates for concussion. RESULTS Between academic school years 2008-2009 and 2011-2012, states with legislation experienced a 92% increase in concussion-related health care utilization, while states without legislation had a 75% overall increase in concussion-related health care utilization during the same period. In the multivariable fixed-effects models, controlling for differences across states, rates of treated concussion in states without legislation were 7% higher in the 2009-2010 school year, 20% higher in the 2010-2011 school year, and 34% higher in the 2011-2012 school year compared with the prelegislation trends (2005-2009) (all P < .01). During the same period, states with concussion laws demonstrated a 10% higher concussion-related health care utilization rate compared with states without laws (P < .01). CONCLUSIONS AND RELEVANCE Increased health care utilization rates among children with concussion in the United States are both directly and indirectly related to concussion legislation. A portion of the increased rates (60%) in states without legislation is attributable to an ongoing upward trend demonstrated before enactment of the first state law in 2009. The remaining 40% increase in these states is thought to have resulted from elevated awareness brought about by heightened local and national media attention. Concussion legislation has had a seemingly positive effect on health care utilization, but the overall increase can also be attributed to increased injury awareness.	[Gibson, Teresa B.] Harvard Univ, Sch Med, Ann Arbor, MI USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed & Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Michigan NeuroSport, Ann Arbor, MI USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Michigan NeuroSport, Michigan Injury Ctr, Ann Arbor, MI 48109 USA		Broglio, SP (corresponding author), Univ Michigan, Sch Kinesiol, Michigan NeuroSport, Michigan Injury Ctr, 401 Washtenaw Ave, Ann Arbor, MI 48109 USA.	broglio@umich.edu	Meijer, Anna/K-5118-2016		Truven Health from the National Institute of Child Health and Human Development	This investigation was supported in part by Truven Health from the National Institute of Child Health and Human Development (Dr Gibson).	Bloodgood B, 2013, J ADOLESCENT HEALTH, V53, P34, DOI 10.1016/j.jadohealth.2013.01.022; Bompadre V, 2014, J ATHL TRAINING, V49, P486, DOI 10.4085/1062-6050-49.3.30; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hilbe, 2011, NEGATIVE BINOMIAL RE; Institute of Medicine, 2013, SPORTS REL CONC YOUT; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Truven Health Analytics, MARKETSCAN COMM CLAI	17	70	70	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	FEB	2015	169	2					163	168		10.1001/jamapediatrics.2014.2320			6	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CA8DV	WOS:000349147700014	25531065	Bronze			2022-02-06	
J	Kochanek, PM; Jackson, TC; Ferguson, NM; Carlson, SW; Simon, DW; Brockman, EC; Ji, J; Bayir, H; Poloyac, SM; Wagner, AK; Kline, AE; Empey, PE; Clark, RSB; Jackson, EK; Dixon, CE				Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Carlson, Shaun W.; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Poloyac, Samuel M.; Wagner, Amy K.; Kline, Anthony E.; Empey, Philip E.; Clark, Robert S. B.; Jackson, Edwin K.; Dixon, C. Edward			Emerging Therapies in Traumatic Brain Injury	SEMINARS IN NEUROLOGY			English	Article						head injury; concussion; neurocritical care; treatment; drugs; excitotoxicity; inflammation; oxidative stress; regeneration; rehabilitation; secondary injury	CONTROLLED CORTICAL IMPACT; MARROW STROMAL CELLS; CEREBRAL-BLOOD-FLOW; MITOCHONDRIAL PERMEABILITY TRANSITION; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CHRONIC METHYLPHENIDATE TREATMENT; RANDOMIZED CLINICAL-TRIAL; RAT HIPPOCAMPAL-NEURONS; WATER MAZE PERFORMANCE; DIFFUSE AXONAL INJURY	Despite decades of basic and clinical research, treatments to improve outcomes after traumatic brain injury (TBI) are limited. However, based on the recent recognition of the prevalence of mild TBI, and its potential link to neurodegenerative disease, many new and exciting secondary injury mechanisms have been identified and several new therapies are being evaluated targeting both classic and novel paradigms. This includes a robust increase in both preclinical and clinical investigations. Using a mechanism-based approach the authors define the targets and emerging therapies for TBI. They address putative new therapies for TBI across both the spectrum of injury severity and the continuum of care, from the field to rehabilitation. They discuss TBI therapy using 11 categories, namely, (1) excitotoxicity and neuronal death, (2) brain edema, (3) mitochondria and oxidative stress, (4) axonal injury, (5) inflammation, (6) ischemia and cerebral blood flow dysregulation, (7) cognitive enhancement, (8) augmentation of endogenous neuroprotection, (9) cellular therapies, (10) combination therapy, and (11) TBI resuscitation. The current golden age of TBI research represents a special opportunity for the development of breakthroughs in the field.	[Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Carlson, Shaun W.; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Poloyac, Samuel M.; Wagner, Amy K.; Kline, Anthony E.; Empey, Philip E.; Clark, Robert S. B.; Jackson, Edwin K.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Jackson, Travis C.; Ferguson, Nikki Miller; Simon, Dennis W.; Brockman, Erik C.; Ji, Jing; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Carlson, Shaun W.; Dixon, C. Edward] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wagner, Amy K.; Kline, Anthony E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Ferguson, Nikki Miller; Simon, Dennis W.; Brockman, Erik C.; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Bayir, Huelya] Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Ferguson, Nikki Miller/AAA-4548-2020; Empey, Philip/L-9604-2019; Kochanek, Patrick M/D-2371-2015	Empey, Philip/0000-0001-7474-2339; Kochanek, Patrick M/0000-0002-2627-913X; Jackson, Edwin/0000-0002-8101-6009; Carlson, Shaun/0000-0002-1413-5075	U.S. ArmyUnited States Department of Defense [W81XWH-10-1-0623, W81XWH-14-2-0018]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS088145, NS087978, T32HD040686]; NCATS as part of the Multidisciplinary Clinical Research Scholars Program [KL2-TR000146]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS088145, R01NS087978] Funding Source: NIH RePORTER	Supported by U.S. Army grants W81XWH-10-1-0623 (PMK) and W81XWH-14-2-0018 (PMK), NIH grants NS088145 (TJ), NS087978 (PMK, EKJ), and T32HD040686 (NF, EB, SC); and KL2-TR000146 from the NCATS as part of the Multidisciplinary Clinical Research Scholars Program (PE).	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Aguzzi A, 2013, SCIENCE, V339, P156, DOI 10.1126/science.1227901; ALLEN RM, 1983, CLIN NEUROPHARMACOL, V6, pS64; Armstead WM, 2010, BRAIN RES, V1330, P142, DOI 10.1016/j.brainres.2010.03.024; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baki SGA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012490; Bales James W, 2010, Open Drug Discov J, V2, P119; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Baroncelli L, 2010, CELL DEATH DIFFER, V17, P1092, DOI 10.1038/cdd.2009.193; Bashir S, 2012, RESTOR NEUROL NEUROS, V30, P277, DOI 10.3233/RNN-2012-110207; Baumgartner HK, 2009, J BIOL CHEM, V284, P20796, DOI 10.1074/jbc.M109.025353; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Benge JF, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00195; Bigford GE, 2009, J NEUROTRAUM, V26, P703, DOI 10.1089/neu.2008.0783; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Boison D, 2008, PROG NEUROBIOL, V84, P249, DOI 10.1016/j.pneurobio.2007.12.002; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brands J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077252; BRANNAN T, 1993, J NEURAL TRANSM-PARK, V6, P81, DOI 10.1007/BF02261001; Bregy A, 2012, EXP NEUROL, V233, P821, DOI 10.1016/j.expneurol.2011.12.008; Brockman EC, 2013, J CEREBR BLOOD F MET, V33, P1457, DOI 10.1038/jcbfm.2013.104; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Carlson SW, 2014, J NEUROPATH EXP NEUR, V73, P734, DOI 10.1097/NEN.0000000000000092; Chamoun R, 2010, J NEUROSURG, V113, P564, DOI 10.3171/2009.12.JNS09689; Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545; Chesnut R M, 1995, New Horiz, V3, P366; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Chip S, 2011, NEUROBIOL DIS, V43, P388, DOI 10.1016/j.nbd.2011.04.010; Cho J, 2007, CORONARY ARTERY DIS, V18, P215, DOI 10.1097/01.mca.0000236285.71683.b6; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; CHOI DW, 1987, J NEUROSCI, V7, P369; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Conti AC, 1998, J NEUROSCI, V18, P5663; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Davies DJ, 2012, BIOORG MED CHEM LETT, V22, P2620, DOI 10.1016/j.bmcl.2012.01.108; Dela Pena I, 2014, J NEUROSURG SCI, V58, P145; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Dezfulian C, 2009, CIRCULATION, V120, P897, DOI 10.1161/CIRCULATIONAHA.109.853267; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dixon CE, 2015, BRAIN NEURO IN PRESS; Eakin K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090617; Elkind MSV, 2008, INT J STROKE, V3, P210, DOI 10.1111/j.1747-4949.2008.00200.x; Empey PE, 2012, J NEUROTRAUM, V29, P229; FAN L, 1995, MOL BRAIN RES, V30, P125; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1991, J NEUROL REHABIL, V5, P113; Ferrario CR, 2013, J NEUROPHYSIOL, V110, P131, DOI 10.1152/jn.01011.2012; Fordsmann JC, 2013, J NEUROSCI, V33, P2562, DOI 10.1523/JNEUROSCI.2308-12.2013; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; Giannopoulos S, 2012, J CEREBR BLOOD F MET, V32, P1973, DOI 10.1038/jcbfm.2012.122; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; Giunti D, 2014, IMMUNOLOGY, V141, P328, DOI 10.1111/imm.12177; Gonda DD, 2013, PEDIATR CRIT CARE ME, V14, P610, DOI 10.1097/PCC.0b013e318291772b; GRELAK RP, 1970, SCIENCE, V169, P203, DOI 10.1126/science.169.3941.203; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; Hall CN, 2014, NATURE, V508, P55, DOI 10.1038/nature13165; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Harun R, 2013, UNDERSTANDING TRAUMA, P255; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Helmy A, 2014, J CEREBR BLOOD F MET, V34, P845, DOI 10.1038/jcbfm.2014.23; Hoane MR, 2004, J NEUROTRAUM, V21, P163, DOI 10.1089/089771504322778622; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; HOVDA DA, 1989, BEHAV NEUROSCI, V103, P574, DOI 10.1037/0735-7044.103.3.574; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Jackson TC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.187; Jansen JO, 2013, CRIT CARE, V17, DOI 10.1186/cc12499; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Jones DP, 2006, ANTIOXID REDOX SIGN, V8, P1865, DOI 10.1089/ars.2006.8.1865; Jungner M, 2010, ANESTHESIOLOGY, V112, P1194, DOI 10.1097/ALN.0b013e3181d94d6e; Kabadi SV, 2014, J CEREBR BLOOD F MET, V34, P502, DOI 10.1038/jcbfm.2013.228; Kagan VE, 2009, ADV DRUG DELIVER REV, V61, P1375, DOI 10.1016/j.addr.2009.06.008; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Karpova A, 2013, CELL, V152, P1119, DOI 10.1016/j.cell.2013.02.002; Kaufman AM, 2012, J NEUROSCI, V32, P3992, DOI 10.1523/JNEUROSCI.4129-11.2012; Khuman J, 2012, J NEUROTRAUM, V29, P408, DOI 10.1089/neu.2010.1745; Kim M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099950; Kleindienst A, 2005, J NEUROTRAUM, V22, P645, DOI 10.1089/neu.2005.22.645; KLINE AE, 1994, PHARMACOL BIOCHEM BE, V48, P773, DOI 10.1016/0091-3057(94)90345-X; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kochanek P. M., 2012, ADENOSINE KEY LINK M, P307; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kumar A, 2002, J NEUROSCI RES, V67, P781, DOI 10.1002/jnr.10181; Lafrenaye AD, 2012, J CEREBR BLOOD F MET, V32, P1919, DOI 10.1038/jcbfm.2012.95; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Lee CY, 2009, BRIT J PHARMACOL, V158, P1753, DOI 10.1111/j.1476-5381.2009.00463.x; Li YL, 2008, NEUROSCI LETT, V447, P120, DOI 10.1016/j.neulet.2008.08.037; Liu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.69; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9; Macias CA, 2004, SHOCK, V22, P151, DOI 10.1097/01.shk.0000131489.83194.1a; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Maruta J, 2013, BEHAV RES METHODS, V45, P289, DOI 10.3758/s13428-012-0248-3; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Mendez DR, 2004, J TRAUMA, V56, P1235, DOI 10.1097/01.TA.0000130759.62286.0E; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003; Miyauchi T, 2014, J NEUROTRAUM, V31, P773, DOI 10.1089/neu.2013.3181; MUIZELAAR JP, 1995, J NEUROSURG, V83, P942; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Pacella JJ, 2012, MICROCIRCULATION, V19, P580, DOI 10.1111/j.1549-8719.2012.00190.x; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Patel SP, 2014, EXP NEUROL, V257, P95, DOI 10.1016/j.expneurol.2014.04.026; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Poloyac SM, 2006, J CEREBR BLOOD F MET, V26, P1551, DOI 10.1038/sj.jcbfm.9600309; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Rammes G, 2008, CURR NEUROPHARMACOL, V6, P55, DOI 10.2174/157015908783769671; RANDALL RD, 1992, J NEUROSCI, V12, P1882; Rao VLR, 2001, BRAIN RES, V911, P96; Rassaf T, 2014, CIRC RES, V114, P1601, DOI 10.1161/CIRCRESAHA.114.303822; Reeves TM, 2007, BRAIN RES, V1154, P225, DOI 10.1016/j.brainres.2007.04.002; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; Salonia R, 2010, J NEUROTRAUM, V27, P1819, DOI 10.1089/neu.2010.1402; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Schwarzschild MA, 2014, JAMA NEUROL, V71, P141, DOI 10.1001/jamaneurol.2013.5528; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Shaik JSB, 2013, AM J PHYSIOL-HEART C, V305, pH1605, DOI 10.1152/ajpheart.00471.2013; Shear DA, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00073; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sies H., 1985, OXIDATIVE STRESS, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; Sikoglu EM, 2014, BEHAV BRAIN RES, V259, P354, DOI 10.1016/j.bbr.2013.11.008; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Singleton RH, 2010, J NEUROTRAUM, V27, P1091, DOI 10.1089/neu.2010.1291; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969; Smith RAJ, 2010, ANN NY ACAD SCI, V1201, P96, DOI 10.1111/j.1749-6632.2010.05627.x; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stein DM, J TRAUMA, P373; Su E, 2012, NEUROCRIT CARE, V17, P401, DOI 10.1007/s12028-012-9767-0; Su X, 2011, MEDIAT INFLAMM, V2011, P807; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Szaflarski JP, 2007, NEUROCRIT CARE, V7, P140, DOI 10.1007/s12028-007-0042-8; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tang HL, 2013, HORM BEHAV, V64, P527, DOI 10.1016/j.yhbeh.2013.06.009; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; Tas PWL, 2003, NEUROSCI LETT, V338, P229, DOI 10.1016/S0304-3940(02)01420-9; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Terpolilli NA, 2013, J CEREBR BLOOD F MET, V33, P311, DOI 10.1038/jcbfm.2012.176; Thiels E, 2000, J NEUROSCI, V20, P7631; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tu WH, 2010, CELL, V140, P222, DOI 10.1016/j.cell.2009.12.055; Tyurina YY, 2014, NAT CHEM, V6, P542, DOI [10.1038/nchem.1924, 10.1038/NCHEM.1924]; Valle EJ, 2014, J TRAUMA ACUTE CARE, V76, P1373, DOI 10.1097/TA.0000000000000242; Van Houten B, 2006, DNA REPAIR, V5, P145, DOI 10.1016/j.dnarep.2005.03.002; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; Wagner AK, 2007, J NEUROSURG, V106, P538, DOI 10.3171/jns.2007.106.4.538; Wagner AK, 2014, J CEREBR BLOOD F MET, V34, P1328, DOI 10.1038/jcbfm.2014.87; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Wagner AK, 2009, J NEUROCHEM, V108, P986, DOI 10.1111/j.1471-4159.2008.05840.x; Wakita M, 2014, J PHARMACOL EXP THER, V348, P246, DOI 10.1124/jpet.113.208751; Wang F, 2014, NEUROTOXICOLOGY, V41, P54, DOI 10.1016/j.neuro.2014.01.002; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang T, 2014, J NEUROTRAUM, V31, P370, DOI 10.1089/neu.2013.2917; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44; Zafonte RD, 2012, JAMA-J AM MED ASSOC, V308, P1993, DOI 10.1001/jama.2012.13256; Zhang DD, 2014, NEUROCHEM INT, V75, P11, DOI 10.1016/j.neuint.2014.05.003; Zhang Yan-Bo, 2008, Neurosci Bull, V24, P143, DOI 10.1007/s12264-008-1108-0; Zhou ZL, 2012, BRAIN RES, V1481, P79, DOI 10.1016/j.brainres.2012.08.051; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484; Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013; Zou HC, 2013, NEUROREHAB NEURAL RE, V27, P878, DOI 10.1177/1545968313491007; Zweckberger K, 2014, NEUROSCIENCE, V272, P199, DOI 10.1016/j.neuroscience.2014.04.040	232	70	71	0	37	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	0271-8235	1098-9021		SEMIN NEUROL	Semin. Neurol.	FEB	2015	35	1					83	100		10.1055/s-0035-1544237			18	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CC4AP	WOS:000350293300011	25714870	Green Accepted, Bronze			2022-02-06	
J	Putukian, M; Echemendia, R; Dettwiler-Danspeckgruber, A; Duliba, T; Bruce, J; Furtado, JL; Murugavel, M				Putukian, Margot; Echemendia, Ruben; Dettwiler-Danspeckgruber, Annegret; Duliba, Tawny; Bruce, Jared; Furtado, John L.; Murugavel, Murali			Prospective Clinical Assessment Using Sideline Concussion Assessment Tool-2 Testing in the Evaluation of Sport-Related Concussion in College Athletes	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; SCAT-2; SCAT-3; sideline assessment; college athlete; sport-related concussion	NEUROPSYCHOLOGICAL TEST PROTOCOL; TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; FOOTBALL PLAYERS; SOCCER PLAYERS; MANAGEMENT; SYMPTOMS	Objective: To evaluate the utility of the Sideline Concussion Assessment Tool (SCAT)-2 in collegiate athletes with sport-related concussion. Design: Prospective cross-sectional study with baseline testing and serial repeat testing after concussion in contact sport athletes and non-concussed control athletes. Setting: Division I University. Participants: Male and female club rugby and varsity athletes. Interventions: Baseline measures of concussion symptoms, cognitive function, and balance were obtained using the SCAT-2. Serial postinjury testing was conducted as clinically indicated. Main Outcome Measures: The SCAT-2 total and subset scores were calculated and evaluated at baseline and after injury. Results: The total SCAT-2 score and the composite scores of symptoms, symptom severity, and balance were significantly different in concussed groups after injury when compared with baseline. When comparing performance in concussed versus control athletes, all subcomponents of the SCAT-2 were significantly different. No differences in baseline SCAT-2 scores were seen based on self-reported history of concussion. At baseline, anxiety and depression screening scores were associated with higher symptom scores. When compared with baseline, a 3.5-point drop in SCAT-2 score had 96% sensitivity and 81% specificity in detecting concussion. When examined to exclude baseline scores, a cutoff value of 74.5 was associated with 83% sensitivity and 91% specificity in predicting concussion versus control status. Conclusions: The SCAT-2 total composite score and each sub-component are useful in the assessment of concussion. As SCAT-3 is similar to SCAT-2, it is expected that it too will be a useful tool.	[Putukian, Margot; Furtado, John L.] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Princeton, NJ USA; [Echemendia, Ruben; Bruce, Jared] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Echemendia, Ruben] Univ Orthoped Comprehens Concuss Care Clin, State Coll, PA USA; [Dettwiler-Danspeckgruber, Annegret; Duliba, Tawny; Murugavel, Murali] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA		Putukian, M (corresponding author), Princeton Univ, Univ Hlth Serv, Washington Rd, Princeton, NJ 08544 USA.	putukian@princeton.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462	American Medical Society for Sports Medicine Foundation; New Jersey Commission on Brain Injury Research; Princeton UniversityPrinceton University; National Hockey League; Major League Soccer; Archives of Clinical Neuropsychology	Supported by the American Medical Society for Sports Medicine Foundation and the New Jersey Commission on Brain Injury Research.; All authors participated in the design, implementation, and/or review of the manuscript. M. Putukian reports nonfinancial support from National Football League Head Neck and Spine Committee, US Lacrosse Sports Science Safety Committee, and National Collegiate Athletics Association during the conduct of the study. R. Echemendia reports personal fees from Princeton University and personal fees and nonfinancial support from National Hockey League and Major League Soccer during the conduct of the study. J. Bruce reports personal fees from Princeton University, National Hockey League, and Archives of Clinical Neuropsychology during the conduct of the study. The remaining authors report no conflicts of interest.	Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P69; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2003, J ATHL TRAINING, V38, P104; Putukian M, 2011, CLIN SPORT MED, V30, P49, DOI 10.1016/j.csm.2010.09.005; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Runkle D., NCAA REQUIRED CONCUS; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	42	70	70	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2015	25	1					36	42		10.1097/JSM.0000000000000102			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Orthopedics; Physiology; Sport Sciences	AX7BX	WOS:000347072800011	24915173				2022-02-06	
J	Johnson, B; Neuberger, T; Gay, M; Hallett, M; Slobounov, S				Johnson, Brian; Neuberger, Thomas; Gay, Michael; Hallett, Mark; Slobounov, Semyon			Effects of Subconcussive Head Trauma on the Default Mode Network of the Brain	JOURNAL OF NEUROTRAUMA			English	Article						default mode network; concussion; subconcussive head trauma; resting-state	RECURRENT CONCUSSION; IMPACT; MILD; ENCEPHALOPATHY; CONNECTIVITY; INJURY; ACTIVATION; PLAYERS; CORTEX; SCHOOL	Although they are less severe than a full blown concussive episodes, subconcussive impacts happen much more frequently and current research has suggested this form of head trauma may have an accumulative effect and lead to neurological impairment later in life. To investigate the acute effects that subconcussive head trauma may have on the default mode network of the brain resting-state, functional magnetic resonance was performed. Twenty-four current collegiate rugby players were recruited and all subjects underwent initial scanning 24 h prior to a scheduled full contact game to provide a baseline. Follow-up scanning of the rugby players occurred within 24 h following that game to assess acute effects from subconcussive head trauma. Differences between pre-game and post-game scans showed both increased connectivity from the left supramarginal gyrus to bilateral orbitofrontal cortex and decreased connectivity from the retrosplenial cortex and dorsal posterior cingulate cortex. To assess whether or not a history of previous concussion may lead to a differential response following subconcussive impacts, subjects were further divided into two subgroups based upon history of previous concussion. Individuals with a prior history of concussion exhibited only decreased functional connectivity following exposure to subconcussive head trauma, while those with no history showed increased connectivity. Even acute exposure to subconcussive head trauma demonstrates the ability to alter functional connectivity and there is possible evidence of a differential response in the brain for those with and without a history of concussion.	[Johnson, Brian; Gay, Michael; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Neuberger, Thomas] Penn State Univ, Dept Bioengn, University Pk, PA 16802 USA; [Neuberger, Thomas] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA; [Hallett, Mark; Slobounov, Semyon] NINDS, NIH, Bethesda, MD 20892 USA; [Slobounov, Semyon] Penn State Milton S Hershey Med Ctr, Dept Neurosurg, Hershey, PA USA		Johnson, B (corresponding author), Penn State Univ, Dept Kinesiol, Ctr Sport Concuss Res, 19 Recreat Bldg, University Pk, PA 16802 USA.	bdj5039@psu.edu	Neuberger, Thomas/ABE-3055-2021		American Society of Radiological Technologists Education and Research Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS002667] Funding Source: NIH RePORTER	This research was partly supported by The American Society of Radiological Technologists Education and Research Foundation.	Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Broglio SP, 2012, EXERC SPORT SCI REV, V40, P138, DOI 10.1097/JES.0b013e3182524273; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Gabbett TJ, 2011, J SCI MED SPORT, V14, P210, DOI 10.1016/j.jsams.2011.01.002; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giza CC, 2001, J ATHL TRAINING, V36, P228; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horovitz SG, 2008, HUM BRAIN MAPP, V29, P671, DOI 10.1002/hbm.20428; Jacobs AH, 2012, J CEREBR BLOOD F MET, V32, P1393, DOI 10.1038/jcbfm.2012.53; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI [10.4085/1062-6050-44.4.434, 10.1016/j.jocn.2009.02.002]; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; Noble RL, 1942, Q J EXP PHYSIOL CMS, V31, P187, DOI 10.1113/expphysiol.1942.sp000856; Parker TM, 2008, MED ENG PHYS, V30, P959, DOI 10.1016/j.medengphy.2007.12.006; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Ralchle ME, 2007, NEUROIMAGE, V37, P1083, DOI 10.1016/j.neuroimage.2007.02.041; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rushworth MFS, 2001, J COGNITIVE NEUROSCI, V13, P698, DOI 10.1162/089892901750363244; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Seghier ML, 2013, NEUROSCIENTIST, V19, P43, DOI 10.1177/1073858412440596; Seitz JA, 2000, NEW IDEAS PSYCHOL, V18, P23, DOI 10.1016/S0732-118X(99)00035-5; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Wolf RC, 2011, J PSYCHIATR NEUROSCI, V36, P402, DOI 10.1503/jpn.100150; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	45	70	70	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2014	31	23					1907	1913		10.1089/neu.2014.3415			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	AT6US	WOS:000345075500002	25010992	Green Published			2022-02-06	
J	Ding, K; Wang, HD; Xu, JG; Lu, XY; Zhang, L; Zhu, L				Ding, Ke; Wang, Handong; Xu, Jianguo; Lu, Xinyu; Zhang, Li; Zhu, Lin			Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway	NEUROCHEMISTRY INTERNATIONAL			English	Article						Traumatic brain injury; Melatonin; Microglia activation; Inflammation; Mammalian target of rapamycin	CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; MAMMALIAN TARGET; FUNCTIONAL RECOVERY; OXIDATIVE STRESS; UP-REGULATION; KAPPA-B; RAPAMYCIN; CELLS; MODEL	This study was designed to detect the modulation manner of melatonin on microglial activation and explore herein possible involvement of mammalian target of rapamycin (mTOR) pathway following traumatic brain injury (TBI). ICR mice were divided into four groups: sham group, TBI group, TBI + sal group and TBI + Melatonin group. A weight-drop model was employed to cause TBI. Neurological severity score (NSS) tests were performed to measure behavioral outcomes. Nissl staining was conducted to observe the neuronal degeneration and wet-to-dry weight ratio indicated brain water content. Immunofluorescence was designed to investigate microglial activation. Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate proinflammatory cytokine levels (interleukin-beta (IL-1 beta), tumor necrosis factor-alpha (TNF-alpha)). Western blotting was engaged to analyze the protein content of mammalian target of rapamycin (mTOR), p70 ribosomal S6 kinase (p70S6K) and S6 ribosomal protein (S6RP). Melatonin administration was associated with markedly restrained microglial activation, decreased release of proinflammatory cytokines and increased the number of surviving neurons at the site of pen-contusion. Meanwhile, melatonin administration resulted in dephosphorylated mTOR pathway. In conclusion, this study presents a new insight into the mechanisms responsible for the anti-neuroinflammation of melatonin, with possible involvement of mTOR pathway. (C) 2014 Elsevier Ltd. All rights reserved.	[Ding, Ke; Wang, Handong; Xu, Jianguo; Lu, Xinyu; Zhang, Li; Zhu, Lin] Nanjing Univ, Jinling Hosp, Sch Med, Dept Neurosurg, Nanjing 210008, Jiangsu, Peoples R China		Wang, HD (corresponding author), Jinling Hosp, Dept Neurosurg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.	njhdwang@hotmail.com			Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81271377, 81371357]; Research Project of Jinling Hospital [2014040]	This work was supported by Grants from the Natural Science Fund of China (Nos. 81271377 and 81371357) and the Research Project of Jinling Hospital (No. 2014040).	Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cekic M, 2012, RESTOR NEUROL NEUROS, V30, P115, DOI 10.3233/RNN-2011-0628; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P374, DOI 10.4161/oxim.3.6.14787; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Dan HC, 2008, J IMMUNOL, V180, P7582, DOI 10.4049/jimmunol.180.11.7582; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dello Russo C, 2009, BIOCHEM PHARMACOL, V78, P1242, DOI 10.1016/j.bcp.2009.06.097; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hara A, 2000, STROKE, V31, P236, DOI 10.1161/01.STR.31.1.231-e; Kauppinen TM, 2008, J NEUROSCI, V28, P5827, DOI 10.1523/JNEUROSCI.1236-08.2008; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kirino T, 2000, NEUROPATHOLOGY, V20, pS95; Krueger F, 2011, J NEUROSCI, V31, P598, DOI 10.1523/JNEUROSCI.1399-10.2011; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee DF, 2007, CELL CYCLE, V6, P3011, DOI 10.4161/cc.6.24.5085; Lee MY, 2007, J PINEAL RES, V42, P297, DOI 10.1111/j.1600-079X.2007.00420.x; Lee SH, 2006, J PINEAL RES, V40, P79, DOI 10.1111/j.1600-079X.2005.00283.x; Lieberthal W, 2009, J AM SOC NEPHROL, V20, P2493, DOI 10.1681/ASN.2008111186; Ling ZD, 2006, EXP NEUROL, V199, P499, DOI 10.1016/j.expneurol.2006.01.010; Ma HY, 2012, NEUROCHEM RES, V37, P69, DOI 10.1007/s11064-011-0584-1; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Min KJ, 2003, BIOCHEM BIOPH RES CO, V312, P969, DOI 10.1016/j.bbrc.2003.11.010; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Ng SY, 2012, J NEUROTRAUM, V29, P1410, DOI 10.1089/neu.2011.2188; Park J, 2012, J CEREBR BLOOD F MET, V32, P330, DOI 10.1038/jcbfm.2011.131; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Pyo H, 1998, NEUROREPORT, V9, P871, DOI 10.1097/00001756-199803300-00020; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Ricker JL, 2004, CLIN CANCER RES, V10, P8665, DOI 10.1158/1078-0432.CCR-04-1393; Rostami E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027389; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Tarantino G, 2013, ANN MED, V45, P348, DOI 10.3109/07853890.2013.770333; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Wang JW, 2013, BIOCHEM BIOPH RES CO, V430, P1016, DOI 10.1016/j.bbrc.2012.12.046; Wang Z, 2013, PHARMACOL RES, V76, P84, DOI 10.1016/j.phrs.2013.07.008; Welp A, 2010, J IMMUNOL METHODS, V358, P1, DOI 10.1016/j.jim.2010.03.018; Wong Michael, 2013, Biomed J, V36, P40, DOI 10.4103/2319-4170.110365; Wu UI, 2011, J PINEAL RES, V50, P159, DOI 10.1111/j.1600-079X.2010.00825.x; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhuang Z, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-47; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	68	70	70	0	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	OCT	2014	76						23	31		10.1016/j.neuint.2014.06.015			9	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	AQ0MO	WOS:000342477600003	24995391				2022-02-06	
J	Naziroglu, M; Senol, N; Ghazizadeh, V; Yuruker, V				Naziroglu, Mustafa; Senol, Nilgun; Ghazizadeh, Vahid; Yuruker, Vehbi			Neuroprotection Induced by N-acetylcysteine and Selenium Against Traumatic Brain Injury-Induced Apoptosis and Calcium Entry in Hippocampus of Rat	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Apoptosis; Hippocampus; N-acetylcysteine; Oxidative stress; Traumatic brain injury; TRPV1 channels	DORSAL-ROOT GANGLION; OXIDATIVE STRESS; CELL-DEATH; MOLECULAR PATHWAYS; TRPM2 CHANNELS; SPINAL-CORD; IN-VITRO; MITOCHONDRIA; INFLUX; ANTIOXIDANT	Neurodegeneration associated with acute central nervous system injuries and diseases such as spinal cord injury and traumatic brain injury (TBI) are reported to be mediated by the regulation of apoptosis and oxidative stress through Ca2+ influx. The thiol redox system antioxidants, such as N-acetylcysteine (NAC) and selenium (Se), display neuroprotective activities mediated at least in part by their antioxidant and anti-inflammatory properties. However, there are no reports on hippocampal apoptosis, cytosolic reactive oxygen species (ROS), or Ca2+ values in rats with an induced TBI. Therefore, we tested the effects of Se and NAC administration on apoptosis, oxidative stress, and Ca2+ influx through TRPV1 channel activations in the hippocampus of TBI-induced rats. The 32 rats were divided into four groups: control, TBI, TBI + NAC, and TBI + Se groups. Intraperitoneal administrations of NAC and Se were performed at 1, 24, 48, and 72 h after TBI induction. After 3 days, the hippocampal neurons were freshly isolated from the rats. In cytosolic-free Ca2+ analyses, the neurons were stimulated with the TRPV1 channel agonist capsaicin, a pungent compound found in hot chili peppers. Cytosolic-free Ca2+, apoptosis, cytosolic ROS levels, and caspase-3 and -9 activities were higher in the TBI group than control. The values in the hippocampus were decreased by Se and NAC administrations. In conclusion, we observed that NAC and Se have protective effects on oxidative stress, apoptosis, and Ca2+ entry via TRPV1 channel activation in the hippocampus of this TBI model, but the effect of NAC appears to be much greater than that of Se. They are both interesting candidates for studying the amelioration of TBIs. Possible molecular pathways of TBI on oxidative stress, apoptosis and Ca2+ entry through TRPV1 cation channels in hippocampus and DRG neurons. It is likely that TRPV1-mediated Ca2+ entry in the hippocampus of epileptic rats involves accumulation of ROS and opening of mitochondrial membrane pores that consequently leads to mitochondrial dysfunction, substantial swelling of the mitochondria with rupture of the outer membrane and release of apoptosis-inducing factors such as caspase-3 and -9.	[Naziroglu, Mustafa; Ghazizadeh, Vahid] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey; [Senol, Nilgun; Yuruker, Vehbi] Suleyman Demirel Univ, Fac Med, Dept Neurosurg, TR-32260 Isparta, Turkey		Naziroglu, M (corresponding author), Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.	mustafanaziroglu@sdu.edu.tr			Free Oxygen Radical Society, Isparta, Turkey	Dr. Vahid Ghazizadeh was partially supported for the project by Free Oxygen Radical Society, Isparta, Turkey. MN formulated the present hypothesis and was responsible for writing the report. NS, VG, and VY were responsible for the analyses. The authors wish to thank the Research Assistant, Ahmi Oz (Department of Biophysics, Medical Faculty, Suleyman Demirel University, Isparta, Turkey) for preparation of graphical abstract.	Al-Samsam RH, 2000, J NEUROTRAUM, V17, P31, DOI 10.1089/neu.2000.17.31; Arakawa M, 2007, CEREBELLUM, V6, P308, DOI 10.1080/14734220601142878; Celik O, 2012, PHYSIOL BEHAV, V107, P458, DOI 10.1016/j.physbeh.2012.09.013; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Daiber A, 2013, CELL MEMBR FREE RADI, V5, P221; Elphick LM, 2008, TOXICOL APPL PHARM, V232, P258, DOI 10.1016/j.taap.2008.07.008; Englezou PC, 2012, EXP BRAIN RES, V221, P357, DOI 10.1007/s00221-012-3179-4; Espino J, 2011, J PINEAL RES, V51, P195, DOI 10.1111/j.1600-079X.2011.00876.x; Gonzalez A, 2007, BRAIN RES, V1178, P28, DOI 10.1016/j.brainres.2007.08.040; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hallak M, 2008, APOPTOSIS, V13, P147, DOI 10.1007/s10495-007-0156-7; Hoffer ME, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054163, 10.1371/journal.pone.0060061]; Junn E, 2001, J NEUROCHEM, V78, P374, DOI 10.1046/j.1471-4159.2001.00425.x; Karalija A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041086; Kim TS, 2002, BIOCHEM BIOPH RES CO, V294, P1130, DOI 10.1016/S0006-291X(02)00612-5; Limbrick DD, 2003, CELL CALCIUM, V33, P69, DOI 10.1016/S0143-4160(02)00054-4; Liu Y, 2009, CELL ADHES MIGR, V3, P94, DOI 10.4161/cam.3.1.7516; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Naziroglu M, 2013, NEUROSCIENCE, V242, P151, DOI 10.1016/j.neuroscience.2013.03.032; Naziroglu M, 2013, NUTR NEUROS IN PRESS; Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x; Naziroglu M, 2013, MUSCLE NERVE, V48, P945, DOI 10.1002/mus.23844; Naziroglu M, 2013, CELL MOL NEUROBIOL, V33, P589, DOI 10.1007/s10571-013-9936-5; Naziroglu M, 2012, NEUROCHEM RES, V37, P2065, DOI 10.1007/s11064-012-0850-x; Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4; Naziroglu M, 2009, NEUROCHEM RES, V34, P2181, DOI 10.1007/s11064-009-0015-8; Naziroglu M, 2008, J MEMBRANE BIOL, V225, P39, DOI 10.1007/s00232-008-9132-6; Oksay T, 2013, ANDROLOGIA, V45, P171, DOI 10.1111/j.1439-0272.2012.01329.x; Ozgul C, 2012, PHYSIOL BEHAV, V106, P122, DOI 10.1016/j.physbeh.2012.01.014; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Puppa LD, 2007, ANN NY ACAD SCI, V1096, P179, DOI 10.1196/annals.1397.084; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; ROTHE G, 1988, NATURWISSENSCHAFTEN, V75, P354, DOI 10.1007/BF00368326; Senol N, 2014, NEUROCHEM RES, V39, P685, DOI 10.1007/s11064-014-1255-9; Shang DJ, 2011, ONCOL REP, V25, P267, DOI 10.3892/or_00001070; Sierra A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00006; Uguz AC, 2012, J PINEAL RES, V53, P91, DOI 10.1111/j.1600-079X.2012.00974.x; Uguz AC, 2012, NEUROCHEM RES, V37, P1631, DOI 10.1007/s11064-012-0758-5; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Yeo JE, 2008, CELL PHYSIOL BIOCHEM, V21, P225, DOI 10.1159/000113764; Yeo JE, 2007, BBA-MOL BASIS DIS, V1772, P1199, DOI 10.1016/j.bbadis.2007.09.004; Zhang YF, 2010, ANTI-CANCER DRUG, V21, P494, DOI 10.1097/CAD.0b013e328336e927; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635	45	70	72	2	25	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	AUG	2014	34	6					895	903		10.1007/s10571-014-0069-2			9	Cell Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Neurosciences & Neurology	AL8IT	WOS:000339382500012	24842665				2022-02-06	
J	Shany-Ur, T; Lin, N; Rosen, HJ; Sollberger, M; Miller, BL; Rankin, KP				Shany-Ur, Tal; Lin, Nancy; Rosen, Howard J.; Sollberger, Marc; Miller, Bruce L.; Rankin, Katherine P.			Self-awareness in neurodegenerative disease relies on neural structures mediating reward-driven attention	BRAIN			English	Article						ageing; awareness; neurodegenerative diseases; attention; voxel based morphometry	VARIANT FRONTOTEMPORAL DEMENTIA; TRAUMATIC BRAIN-INJURY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; BEHAVIORAL VARIANT; PREFRONTAL CORTEX; ORBITOFRONTAL CORTEX; ANOSOGNOSIA; DEFICITS; MEMORY	Patients with neurodegenerative diseases often overestimate their functional capacities. Using structural MRI, Shany-Ur et al. examine the neuroanatomical correlates of impaired self-awareness. Overestimation of functioning correlates with degeneration of dorsal frontal regions involved in attention, as well as orbitofrontal and subcortical regions that may assign reward value to self-related knowledge.Accurate self-awareness is essential for adapting one's tasks and goals to one's actual abilities. Patients with neurodegenerative diseases, particularly those with right frontal involvement, often present with poor self-awareness of their functional limitations that may exacerbate their already jeopardized decision-making and behaviour. We studied the structural neuroanatomical basis for impaired self-awareness among patients with neurodegenerative disease and healthy older adults. One hundred and twenty-four participants (78 patients with neurodegenerative diseases including Alzheimer's disease, behavioural variant frontotemporal dementia, right-temporal frontotemporal dementia, semantic variant and non-fluent variant primary progressive aphasia, and 46 healthy controls) described themselves on the Patient Competency Rating Scale, rating observable functioning across four domains (daily living activities, cognitive, emotional control, interpersonal). All participants underwent structural magnetic resonance imaging. Informants also described subjects' functioning on the same scale. Self-awareness was measured by comparing self and informant ratings. Group differences in discrepancy scores were analysed using general linear models, controlling for age, sex and disease severity. Compared with controls, patients with behavioural variant frontotemporal dementia overestimated their functioning in all domains, patients with Alzheimer's disease overestimated cognitive and emotional functioning, patients with right-temporal frontotemporal dementia overestimated interpersonal functioning, and patients with non-fluent aphasia overestimated emotional and interpersonal functioning. Patients with semantic variant aphasia did not overestimate functioning on any domain. To examine the neuroanatomic correlates of impaired self-awareness, discrepancy scores were correlated with brain volume using voxel-based morphometry. To identify the unique neural correlates of overlooking versus exaggerating deficits, overestimation and underestimation scores were analysed separately, controlling for age, sex, total intracranial volume and extent of actual functional decline. Atrophy related to overestimating one's functioning included bilateral, right greater than left frontal and subcortical regions, including dorsal superior and middle frontal gyri, lateral and medial orbitofrontal gyri, right anterior insula, putamen, thalamus, and caudate, and midbrain and pons. Thus, our patients' tendency to under-represent their functional decline was related to degeneration of domain-general dorsal frontal regions involved in attention, as well as orbitofrontal and subcortical regions likely involved in assigning a reward value to self-related processing and maintaining accurate self-knowledge. The anatomic correlates of underestimation (right rostral anterior cingulate cortex, uncorrected significance level) were distinct from overestimation and had a substantially smaller effect size. This suggests that underestimation or 'tarnishing' may be influenced by non-structural neurobiological and sociocultural factors, and should not be considered to be on a continuum with overestimation or 'polishing' of functional capacity, which appears to be more directly mediated by neural circuit dysfunction.	[Shany-Ur, Tal; Lin, Nancy; Rosen, Howard J.; Sollberger, Marc; Miller, Bruce L.; Rankin, Katherine P.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94158 USA; [Shany-Ur, Tal] Natl Inst Rehabil Brain Injured, Tel Aviv, Israel; [Sollberger, Marc] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland		Rankin, KP (corresponding author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, 675 Nelson Rising Lane,Suite 190, San Francisco, CA 94158 USA.	krankin@memory.ucsf.edu	Sollberger, Marc/AAD-7796-2022	Shany-Ur, Tal/0000-0003-0319-5969	National Institute on Aging (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5-R01 AG029577, 5-P01 AG019724, P50 AG02350]; State of California Alzheimer's Disease Research Center of California (ARCC) [03-75271]; NIH/UCSF-CTSI [UL1 RR024131]; Larry L. Hillblom Foundation [R01 AG030688]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000004] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG017586, R01AG029577, R01AG030688, R01AG032306, P50AG023501, P01AG019724] Funding Source: NIH RePORTER	This research was supported in part by the National Institute on Aging (NIA) grants 5-R01 AG029577, 5-P01 AG019724 and P50 AG02350; the State of California Alzheimer's Disease Research Center of California (ARCC) grant 03-75271; NIH/UCSF-CTSI grant UL1 RR024131 and the Larry L. Hillblom Foundation 2007/2I grant R01 AG030688.	Aalten P, 2005, AGING MENT HEALTH, V9, P414, DOI 10.1080/13607860500143075; Abdulkadir A, 2011, NEUROIMAGE, V58, P785, DOI 10.1016/j.neuroimage.2011.06.029; ADAIR JC, 1995, NEUROLOGY, V45, P241, DOI 10.1212/WNL.45.2.241; Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007; Babinski J, 1914, REV NEUROL, V27; Banks S, 2008, BRAIN COGNITION, V67, P58, DOI 10.1016/j.bandc.2007.11.004; Bates E, 2003, NAT NEUROSCI, V6, P448, DOI 10.1038/nn1050; BELYI BI, 1987, INT J NEUROSCI, V32, P799, DOI 10.3109/00207458709043334; Berti A, 2005, SCIENCE, V309, P488, DOI 10.1126/science.1110625; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Craig AD, 2009, NAT REV NEUROSCI, V10, P59, DOI 10.1038/nrn2555; Delgado MR, 2007, ANN NY ACAD SCI, V1104, P70, DOI 10.1196/annals.1390.002; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Eslinger PJ, 2005, J NEUROL NEUROSUR PS, V76, P1630, DOI 10.1136/jnnp.2004.053157; Flashman LA, 2001, J NEUROPSYCH CLIN N, V13, P255, DOI 10.1176/appi.neuropsych.13.2.255; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Fossati P, 2003, AM J PSYCHIAT, V160, P1938, DOI 10.1176/appi.ajp.160.11.1938; Gilleen J, 2011, SCHIZOPHRENIA BULL, V37, P61, DOI 10.1093/schbul/sbq100; Gorno-Tempini ML, 2011, NEUROLOGY, V76, P1006, DOI 10.1212/WNL.0b013e31821103e6; Hayasaka S, 2004, NEUROIMAGE, V23, P54, DOI 10.1016/j.neuroimage.2004.04.035; Hornberger M, 2014, HUM BRAIN MAPP, V35, P616, DOI 10.1002/hbm.22200; Jenkins AC, 2011, SOC NEUROSCI-UK, V6, P211, DOI 10.1080/17470919.2010.507948; Johnson SC, 2002, BRAIN, V125, P1808, DOI 10.1093/brain/awf181; Josephs KA, 2009, NEUROLOGY, V73, P1443, DOI 10.1212/WNL.0b013e3181bf9945; Kanwisher N, 2006, PHILOS T R SOC B, V361, P2109, DOI 10.1098/rstb.2006.1934; Kloppel S, 2008, BRAIN, V131, P681, DOI 10.1093/brain/awm319; Krebs RM, 2012, CEREB CORTEX, V22, P607, DOI 10.1093/cercor/bhr134; Leung KK, 2009, PSYCHOL MED, V39, P1097, DOI 10.1017/S0033291708004546; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mendez MF, 2011, CONSCIOUS COGN, V20, P1690, DOI 10.1016/j.concog.2011.09.005; Mendez ME, 2005, J NEUROPSYCH CLIN N, V17, P413, DOI 10.1176/appi.neuropsych.17.3.413; Miller BL, 2001, NEUROLOGY, V57, P817, DOI 10.1212/WNL.57.5.817; Mograbi DC, 2009, CONSCIOUS COGN, V18, P989, DOI 10.1016/j.concog.2009.07.005; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; O'Doherty JP, 2004, CURR OPIN NEUROBIOL, V14, P769, DOI 10.1016/j.conb.2004.10.016; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; Phan KL, 2004, NEUROIMAGE, V21, P768, DOI 10.1016/j.neuroimage.2003.09.072; Possin KL, 2012, J INT NEUROPSYCH SOC, V18, P834, DOI 10.1017/S1355617712000604; Possin KL, 2009, J INT NEUROPSYCH SOC, V15, P354, DOI 10.1017/S135561770909050X; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2009, CURR OPIN NEUROL, V22, P606, DOI 10.1097/WCO.0b013e328332a1e7; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Rankin KP, 2009, NEUROIMAGE, V47, P2005, DOI 10.1016/j.neuroimage.2009.05.077; Rankin KP, 2005, J NEUROL NEUROSUR PS, V76, P632, DOI 10.1136/jnnp.2004.042879; REED BR, 1993, J CLIN EXP NEUROPSYC, V15, P231, DOI 10.1080/01688639308402560; Renoult L, 2012, TRENDS COGN SCI, V16, P550, DOI 10.1016/j.tics.2012.09.003; Ries ML, 2007, J INT NEUROPSYCH SOC, V13, P450, DOI 10.1017/S1355617707070488; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Rosen HJ, 2011, NEUROCASE, V17, P231, DOI 10.1080/13554794.2010.522588; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; Rothkirch M, 2012, NEUROIMAGE, V62, P1717, DOI 10.1016/j.neuroimage.2012.06.016; Ruby P, 2007, J COGNITIVE NEUROSCI, V19, P671, DOI 10.1162/jocn.2007.19.4.671; Salmon E, 2006, HUM BRAIN MAPP, V27, P588, DOI 10.1002/hbm.20203; Sara SJ, 2012, NEURON, V76, P130, DOI 10.1016/j.neuron.2012.09.011; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2007, NEUROSCI BIOBEHAV R, V31, P585, DOI 10.1016/j.neubiorev.2006.12.003; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schmitz TW, 2004, NEUROIMAGE, V22, P941, DOI 10.1016/j.neuroimage.2004.02.018; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharot T, 2009, J NEUROSCI, V29, P3760, DOI 10.1523/JNEUROSCI.4972-08.2009; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Shibata K, 2008, NEUROSCI LETT, V435, P7, DOI 10.1016/j.neulet.2008.01.065; Sitek EJ, 2011, J INT NEUROPSYCH SOC, V17, P788, DOI 10.1017/S1355617711000725; Sollberger M, 2014, BRAIN BEHAV, V4, P201, DOI 10.1002/brb3.211; Sperduti M, 2013, FRONT BEHAV NEUROSCI, V7, DOI 10.3389/fnbeh.2013.00041; Sturm VE, 2013, P NATL ACAD SCI USA, V110, P9944, DOI 10.1073/pnas.1301119110; Sturm VE, 2013, SOC COGN AFFECT NEUR, V8, P468, DOI 10.1093/scan/nss023; Whitwell JL, 2009, BRAIN, V132, P2932, DOI 10.1093/brain/awp232; Williamson C, 2010, J NEUROL NEUROSUR PS, V81, P140, DOI 10.1136/jnnp.2008.166041; Zamboni G, 2011, INT J GERIATR PSYCH, V26, P783, DOI 10.1002/gps.2620; Zamboni G, 2010, DEMENT GERIATR COGN, V29, P88, DOI 10.1159/000255141	76	70	70	1	34	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	AUG	2014	137		8				2368	2381		10.1093/brain/awu161			14	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AM7MI	WOS:000340051100026	24951639	Green Published, Bronze			2022-02-06	
J	Villemagne, VL; Okamura, N				Villemagne, Victor L.; Okamura, Nobuyuki			In vivo tau imaging: Obstacles and progress	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Chronic traumatic encephalopathy; Tau; Tauopathies; Molecular neuroimaging; Neurodegeneration; Radiotracer design	POSITRON-EMISSION-TOMOGRAPHY; PAIRED HELICAL FILAMENTS; BETA-AMYLOID PLAQUES; CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; MOUSE MODEL; A-BETA; COGNITIVE DECLINE; SENILE DEMENTIA	The military conflicts of the last decade have highlighted the growing problem of traumatic brain injury in combatants returning from the battlefield. The considerable evidence pointing at the accumulation of tau aggregates and its recognition as a risk factor in neurodegenerative conditions such as Alzheimer's disease have led to a major effort to develop selective tau ligands that would allow research into the physiopathologic underpinnings of traumatic brain injury and chronic traumatic encephalopathy in military personnel and the civilian population. These tracers will allow new insights into tau pathology in the human brain, facilitating research into causes, diagnosis, and treatment of traumatic encephalopathy and major neurodegenerative dementias, such as Alzheimer's disease and some variants of frontotemporal lobar degeneration, in which tau plays a role. The field of selective tau imaging has to overcome several obstacles, some of them associated with the idiosyncrasies of tau aggregation and others related to radiotracer design. A worldwide effort has focused on the development of imaging agents that will allow selective tau imaging in vivo. Recent progress in the development of these tracers is enabling the noninvasive assessment of the extent of tau pathology in the brain, eventually allowing the quantification of changes in tau pathology over time and its relation to cognitive performance, brain volumetrics, and other biomarkers, as well as assessment of efficacy and patient recruitment for antitau therapeutic trials. (C) 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Villemagne, Victor L.] Austin Hlth, Dept Nucl Med, Melbourne, Vic, Australia; [Villemagne, Victor L.] Austin Hlth, Ctr PET, Melbourne, Vic, Australia; [Villemagne, Victor L.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Okamura, Nobuyuki] Tohoku Univ, Sch Med, Dept Pharmacol, Sendai, Miyagi 980, Japan		Villemagne, VL (corresponding author), Austin Hlth, Dept Nucl Med, Melbourne, Vic, Australia.	victorlv@unimelb.edu.au	Villemagne, Victor/AAC-5406-2019; Okamura, Nobuyuki/C-3541-2017	Okamura, Nobuyuki/0000-0002-5991-7812	Alzheimer Drug Discovery Foundation Research Grant [20101208 AFTD]; National Health and Medical Research Council of Australia Project GrantNational Health and Medical Research Council of Australia [1044361]; National Health and Medical Research Council of Australia Research FellowshipNational Health and Medical Research Council of Australia [1046471]; Ministry of Education, Culture, Sports, Science, and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [20019006]	This study was supported in part by Alzheimer Drug Discovery Foundation Research Grant (20101208 AFTD), National Health and Medical Research Council of Australia Project Grant 1044361, National Health and Medical Research Council of Australia Research Fellowship 1046471, and the Grant-in-Aid for Scientific Research on Priority Areas "Integrative Brain Research" from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (20019006). The funding sources had no input into the design of this study, the analysis of data, or writing of the manuscript.	Agdeppa ED, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0004.2001; Agdeppa ED, 2001, J NUCL MED, V42, p65P; Arima K, 2006, NEUROPATHOLOGY, V26, P475, DOI 10.1111/j.1440-1789.2006.00669.x; ARRIAGADA PV, 1992, NEUROLOGY, V42, P631, DOI 10.1212/WNL.42.3.631; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Barrio J. R., 1999, Journal of Labelled Compounds and Radiopharmaceuticals, V42, pS194; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bolander A, 2012, J MED CHEM, V55, P9170, DOI 10.1021/jm300653b; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; Braak H, 1998, J NEURAL TRANSM-SUPP, P127; BRAAK H, 1995, NEUROBIOL AGING, V16, P271, DOI 10.1016/0197-4580(95)00021-6; Bresjanac M, 2003, J NEUROSCI, V23, P8029; Brunden KR, 2010, J NEUROSCI, V30, P13861, DOI 10.1523/JNEUROSCI.3059-10.2010; Buee L, 2000, BRAIN RES REV, V33, P95, DOI 10.1016/S0165-0173(00)00019-9; Bugiani O, 2007, NEUROL SCI, V28, P241, DOI 10.1007/s10072-007-0829-6; Cairns NJ, 2009, ARCH NEUROL-CHICAGO, V66, P1557, DOI 10.1001/archneurol.2009.279; Carpenter GM, 2011, P NAT C UND RES 2011; Chen F, 2004, CURR DRUG TARGETS, V5, P503, DOI 10.2174/1389450043345236; Chien DT, 2014, J ALZHEIMERS DIS, V38, P171, DOI 10.3233/JAD-130098; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Delacourte A, 2005, FOLIA NEUROPATHOL, V43, P244; Delacourte A, 2002, EXP GERONTOL, V37, P1291, DOI 10.1016/S0531-5565(02)00141-9; Delacourte A, 1999, NEUROLOGY, V52, P1158, DOI 10.1212/WNL.52.6.1158; Delacourte Andre, 2000, Current Opinion in Neurology, V13, P371, DOI 10.1097/00019052-200008000-00002; DELAERE P, 1990, NEUROSCI LETT, V116, P87, DOI 10.1016/0304-3940(90)90391-L; DELAERE P, 1989, ACTA NEUROPATHOL, V77, P645, DOI 10.1007/BF00687893; Dickson DW, 1997, NEUROBIOL AGING, V18, pS21, DOI 10.1016/S0197-4580(97)00065-1; DISCHINO DD, 1983, J NUCL MED, V24, P1030; DUYCKAERTS C, 1990, J NEUROL SCI, V97, P295, DOI 10.1016/0022-510X(90)90226-D; DUYCKAERTS C, 1987, ACTA NEUROPATHOL, V73, P167, DOI 10.1007/BF00693783; Fodero-Tavoletti MT, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt240; Fodero-Tavoletti MT, 2011, BRAIN, V134, P1089, DOI 10.1093/brain/awr038; Giacobini E, 2007, J ALZHEIMERS DIS, V12, P37; GOEDERT M, 1989, EMBO J, V8, P393, DOI 10.1002/j.1460-2075.1989.tb03390.x; Goedert M, 2005, BBA-MOL BASIS DIS, V1739, P240, DOI 10.1016/j.bbadis.2004.08.007; Gotz J, 2010, BBA-MOL BASIS DIS, V1802, P860, DOI 10.1016/j.bbadis.2009.09.008; Gozes I, 2009, CURR ALZHEIMER RES, V6, P455, DOI 10.2174/156720509789207895; Hampel H, 2009, J CLIN PSYCHIAT, V70, P922, DOI 10.4088/JCP.08m04606; HANIHARA T, 1995, NEUROPATH APPL NEURO, V21, P319, DOI 10.1111/j.1365-2990.1995.tb01066.x; Harada R, 2013, EUR J NUCL MED MOL I, V40, P125, DOI 10.1007/s00259-012-2261-2; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Honson NS, 2007, NEUROBIOL DIS, V28, P251, DOI 10.1016/j.nbd.2007.07.018; Honson NS, 2007, BIOCHEM BIOPH RES CO, V363, P229, DOI 10.1016/j.bbrc.2007.08.166; Jack CR, 2008, BRAIN, V131, P665, DOI 10.1093/brain/awm336; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; JELLINGER K, 1990, KEY TOP BRAIN RES, P61; Jensen JR, 2011, J ALZHEIMERS DIS, V26, P147, DOI 10.3233/JAD-2011-0003; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kemp S.J., 2010, PCT Int. Appl. WO, Patent No. [2010034982 Al 20100401, 2010034982]; Kepe V, 2013, J ALZHEIMERS DIS, V36, P145, DOI 10.3233/JAD-130032; Kepe V, 2010, BRAIN PATHOL, V20, P419, DOI 10.1111/j.1750-3639.2009.00306.x; Klunk WE, 2005, J NEUROSCI, V25, P10598, DOI 10.1523/JNEUROSCI.2990-05.2005; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Klunk WE, 2007, J NEUROSCI, V27, P6174, DOI 10.1523/JNEUROSCI.0730-07.2007; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kolb H., 2013, ALZHEIMERS DEMENTIA, V9, pP844; Komori T, 1999, BRAIN PATHOL, V9, P663; Kudo Y, 2006, U.S. Patent, Patent No. [7,118,730, 7118730]; Kudo Y, 2010, U.S. Patent Application, Patent No. [2010/0021385, 20100021385]; Laruelle Marc, 2003, Mol Imaging Biol, V5, P363, DOI 10.1016/j.mibio.2003.09.009; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; LeVine H, 2010, NEUROBIOL AGING, V31, P542, DOI 10.1016/j.neurobiolaging.2008.05.026; Li XY, 2011, EMBO J, V30, P4825, DOI 10.1038/emboj.2011.376; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; Mandelkow E, 2007, BRAIN PATHOL, V17, P83, DOI 10.1111/j.1750-3639.2007.00053.x; Martin L, 2011, NEUROCHEM INT, V58, P458, DOI 10.1016/j.neuint.2010.12.023; Maruyama M, 2013, NEURON, V79, P1094, DOI 10.1016/j.neuron.2013.07.037; Masters CL, 2005, DEMENTIA, P393; Masters CL, 2005, NEURODEGENER DIS, P433; Masters CL, 2006, J NEUROCHEM, V97, P1700, DOI 10.1111/j.1471-4159.2006.03989.x; Matsumura K, 2013, BIOORGAN MED CHEM, V21, P3356, DOI 10.1016/j.bmc.2013.02.054; Matsuoka Y, 2008, J PHARMACOL EXP THER, V325, P146, DOI 10.1124/jpet.107.130526; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; Mintun M., 2013, ALZHEIMERS DEMENT, V9, pP842; Mohorko N, 2008, ZDR VESTN, V77, pII35; MUKAETOVALADINSKA EB, 1993, AM J PATHOL, V143, P565; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Neary D, 1998, NEUROLOGY, V51, P1546, DOI 10.1212/WNL.51.6.1546; Nelson LD, 2011, ARCH NEUROL-CHICAGO, V68, P768, DOI 10.1001/archneurol.2011.104; Noda A, 2008, SYNAPSE, V62, P472, DOI 10.1002/syn.20508; Okamura N, 2005, J NEUROSCI, V25, P10857, DOI 10.1523/JNEUROSCI.1738-05.2005; Okamura N, 2014, BRAIN, V137, P1762, DOI 10.1093/brain/awu064; Okamura N, 2013, J NUCL MED, V54, P1420, DOI 10.2967/jnumed.112.117341; Ono M, 2011, ACS CHEM NEUROSCI, V2, P269, DOI 10.1021/cn200002t; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pike VW, 2009, TRENDS PHARMACOL SCI, V30, P431, DOI 10.1016/j.tips.2009.05.005; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Price JL, 2009, NEUROBIOL AGING, V30, P1026, DOI 10.1016/j.neurobiolaging.2009.04.002; Ratnavalli E, 2002, NEUROLOGY, V58, P1615, DOI 10.1212/WNL.58.11.1615; Roberson ED, 2007, SCIENCE, V316, P750, DOI 10.1126/science.1141736; Rojo LE, 2010, J ALZHEIMERS DIS, V19, P573, DOI 10.3233/JAD-2010-1262; Rosen RF, 2011, NEUROBIOL AGING, V32, P223, DOI 10.1016/j.neurobiolaging.2009.02.011; Rowe CC, 2007, NEUROLOGY, V68, P1718, DOI 10.1212/01.wnl.0000261919.22630.ea; Schafer KN, 2012, NEUROIMAGE, V60, P1724, DOI 10.1016/j.neuroimage.2012.01.066; Selenica ML, 2007, BRIT J PHARMACOL, V152, P959, DOI 10.1038/sj.bjp.0707471; Sergeant N, 2008, EXPERT REV PROTEOMIC, V5, P207, DOI 10.1586/14789450.5.2.207; Serrano-Pozo A, 2011, AM J PATHOL, V179, P1373, DOI 10.1016/j.ajpath.2011.05.047; Shao X, 2012, ACS MED CHEM LETT, V3, P936, DOI 10.1021/ml300216t; Shin J, 2008, NEUROIMAGE, V43, P236, DOI 10.1016/j.neuroimage.2008.07.022; Shoghi-Jadid K, 2002, AM J GERIAT PSYCHIAT, V10, P24, DOI 10.1176/appi.ajgp.10.1.24; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Small GW, 2006, NEW ENGL J MED, V355, P2652, DOI 10.1056/NEJMoa054625; Small GW, 2002, J MOL NEUROSCI, V19, P323; Smid LM, 2013, J ALZHEIMERS DIS, V36, P261, DOI 10.3233/JAD-122434; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Szardenings A. K., 2011, U.S. Patent, Patent No. [20,110,182,812 A1, 20110182812]; Taghavi A, 2011, J ALZHEIMERS DIS, V27, P835, DOI 10.3233/JAD-2011-111238; Tago T, 2014, J LABELLED COMPD RAD, V57, P18, DOI 10.1002/jlcr.3133; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; Thompson PW, 2009, J NEUROCHEM, V109, P623, DOI 10.1111/j.1471-4159.2009.05996.x; Tolboom N, 2009, J NUCL MED, V50, P191, DOI 10.2967/jnumed.108.056499; Tomiyama T, 2008, ANN NEUROL, V63, P377, DOI 10.1002/ana.21321; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Veitch DP, 2013, CURR ALZHEIMER RES, V10, P907, DOI 10.2174/15672050113109990142; Villemagne VL, 2008, NEUROPSYCHOLOGIA, V46, P1688, DOI 10.1016/j.neuropsychologia.2008.02.008; Villemagne VL, 2008, MOL NEUROBIOL, V38, P1, DOI 10.1007/s12035-008-8019-y; Villemagne VL, 2014, EUR J NUCL MED MOL I, V41, P816, DOI 10.1007/s00259-013-2681-7; Villemagne VL, 2013, LANCET NEUROL, V12, P357, DOI 10.1016/S1474-4422(13)70044-9; Villemagne VL, 2012, FUTUR NEUROL, V7, P409, DOI 10.2217/FNL.12.34; Villemagne VL, 2011, ANN NEUROL, V69, P181, DOI 10.1002/ana.22248; Villemagne VL, 2013, ALZHEIMERS DEMENT, V9, pP94; von Bergen M, 2001, J BIOL CHEM, V276, P48165, DOI 10.1074/jbc.M105196200; Watanabe H, 2012, BIOORG MED CHEM LETT, V22, P5700, DOI 10.1016/j.bmcl.2012.06.086; Wischik C, 2009, J NUTR HEALTH AGING, V13, P367, DOI 10.1007/s12603-009-0046-5; Wischik CM, 1996, P NATL ACAD SCI USA, V93, P11213, DOI 10.1073/pnas.93.20.11213; Xia CF, 2013, ALZHEIMERS DEMENT, V9, P666, DOI 10.1016/j.jalz.2012.11.008; Xu SH, 2010, ALZHEIMERS DEMENT, V6, P110, DOI 10.1016/j.jalz.2009.06.002; Zhang B, 2005, P NATL ACAD SCI USA, V102, P227, DOI 10.1073/pnas.0406361102; Zhang W, 2012, J ALZHEIMERS DIS, V31, P601, DOI 10.3233/JAD-2012-120712	132	70	72	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	JUN	2014	10	3		1			S254	S264		10.1016/j.jalz.2014.04.013			11	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CP8GM	WOS:000360130700019	24924676	hybrid			2022-02-06	
J	Schonfeld, D; Bressan, S; Da Dalt, L; Henien, MN; Winnett, JA; Nigrovic, LE				Schonfeld, Deborah; Bressan, Silvia; Da Dalt, Liviana; Henien, Mira N.; Winnett, Jill A.; Nigrovic, Lise E.			Pediatric Emergency Care Applied Research Network head injury clinical prediction rules are reliable in practice	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							COMPUTED-TOMOGRAPHY; RADIATION-EXPOSURE; SKELETAL SURVEYS; CHILDREN; MANAGEMENT; CHILDHOOD; SCANS; RISK	Objective The Pediatric Emergency Care Applied Research Network (PECARN) traumatic brain injury (TBI) age-based clinical prediction rules identify children at very low risk of a significant head injury who can safely avoid CT. Our goal was to independently validate these prediction rules. Design Cross-sectional study. Setting Two paediatric emergency departments located in USA and in Italy. Patients All children presenting within 24 h of a head injury with a Glasgow Coma Score of >= 14. Intervention Assessment of PECARN TBI clinical predictors. Main outcome measure Clinically important TBI defined as head injury resulting in death, intubation for >24 h, neurosurgery or two or more nights of hospitalisation for the management of head trauma. Results During the study period, we included 2439 children (91% of eligible patients), of which 959 (39%) were <2 years of age and 1439 (59%) were male. Of the study patients, 373 (15%) had a CT performed, 69 (3%) had traumatic findings on their CT and 19 (0.8%) had a clinically important TBI. None of the children with a clinically important TBI were classified as very low risk by the PECARN TBI prediction rules (overall sensitivity 100%; 95% CI 83.2% to 100%, specificity 55%, 95% CI 52.5% to 56.6%, and negative predictive value 100%, 95% CI 99.6% to 100%). Conclusions In our external validation, the age-based PECARN TBI prediction rules accurately identified children at very low risk for a clinically significant TBI and can be used to assist CT decision making for children with minor blunt head trauma.	[Schonfeld, Deborah; Henien, Mira N.; Winnett, Jill A.; Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Schonfeld, Deborah] Hosp Sick Children, Div Emergency Med, Toronto, ON M5G 1X8, Canada; [Bressan, Silvia; Da Dalt, Liviana] Univ Padua, Dept Womans & Childs Hlth, Padua, Italy		Nigrovic, LE (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	Lise.nigrovic@childrens.harvard.edu	Li, Jun/A-5088-2009; Tan, Weihong/A-5412-2008	Tan, Weihong/0000-0002-8066-1524; Nigrovic, Lise/0000-0002-6369-3997	Hood Childhood Research Grant, Boston Children's Hospital House-officers Grant	Hood Childhood Research Grant, Boston Children's Hospital House-officers Grant.	[Anonymous], 2012, PASW STAT 21; Boutis K, 2013, PEDIATRICS, V132, P305, DOI 10.1542/peds.2013-0378; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Colvin JD, 2013, ARCH DIS CHILD, V98, P934, DOI 10.1136/archdischild-2012-303588; Forsyth R, 2013, ARCH DIS CHILD; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Hamilton M, 2010, PEDIATRICS, V126, pE33, DOI 10.1542/peds.2009-0692; Karpas A, 2013, PEDIATR EMERG CARE, V29, P30, DOI 10.1097/PEC.0b013e31827b5090; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Laskey AL, 2013, J PEDIATR-US, V162, P86, DOI 10.1016/j.jpeds.2012.06.038; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2013, ANN EMERG MED, V62, P327, DOI 10.1016/j.annemergmed.2013.02.027; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Nigrovic LE, 2011, PEDIATRICS, V127, P1067, DOI 10.1542/peds.2010-3373; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pickering A, 2011, ARCH DIS CHILD, V96, P414, DOI 10.1136/adc.2010.202820; Schonfeld D, 2013, ANN EMERG MED, V62, P597, DOI 10.1016/j.annemergmed.2013.06.020; Stiell IG, 1999, ANN EMERG MED, V33, P437, DOI 10.1016/S0196-0644(99)70309-4; Wood JN, 2009, PEDIATRICS, V123, pE247, DOI 10.1542/peds.2008-2467	22	70	71	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888	1468-2044		ARCH DIS CHILD	Arch. Dis. Child.	MAY	2014	99	5					427	431		10.1136/archdischild-2013-305004			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	AF0IH	WOS:000334397000007	24431418				2022-02-06	
J	Wang, C; Klechikov, AG; Gharibyan, AL; Warmlander, SKTS; Jarvet, J; Zhao, LN; Jia, XE; Shankar, SK; Olofsson, A; Brannstrom, T; Mu, YG; Graslund, A; Morozova-Roche, LA				Wang, Chao; Klechikov, Alexey G.; Gharibyan, Anna L.; Warmlander, Sebastian K. T. S.; Jarvet, Juri; Zhao, Lina; Jia, Xueen; Shankar, S. K.; Olofsson, Anders; Brannstrom, Thomas; Mu, Yuguang; Graslund, Astrid; Morozova-Roche, Ludmilla A.			The role of pro-inflammatory S100A9 in Alzheimer's disease amyloid-neuroinflammatory cascade	ACTA NEUROPATHOLOGICA			English	Article						A beta; Alzheimer's disease; Amyloid; Cytotoxicity; Neuroinflammation; S100A9; Traumatic brain injury	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRAUMATIC BRAIN-INJURY; MICROGLIAL ACTIVATION; BETA-PEPTIDE; PROTEINS; EXPRESSION; MRP14; CYTOTOXICITY; AGGREGATION; NEUROPATHOLOGY	Pro-inflammatory S100A9 protein is increasingly recognized as an important contributor to inflammation-related neurodegeneration. Here, we provide insights into S100A9 specific mechanisms of action in Alzheimer's disease (AD). Due to its inherent amyloidogenicity S100A9 contributes to amyloid plaque formation together with A beta. In traumatic brain injury (TBI) S100A9 itself rapidly forms amyloid plaques, which were reactive with oligomer-specific antibodies, but not with A beta and amyloid fibrillar antibodies. They may serve as precursor-plaques for AD, implicating TBI as an AD risk factor. S100A9 was observed in some hippocampal and cortical neurons in TBI, AD and non-demented aging. In vitro S100A9 forms neurotoxic linear and annular amyloids resembling A beta protofilaments. S100A9 amyloid cytotoxicity and native S100A9 pro-inflammatory signaling can be mitigated by its co-aggregation with A beta, which results in a variety of micron-scale amyloid complexes. NMR and molecular docking demonstrated transient interactions between native S100A9 and A beta. Thus, abundantly present in AD brain pro-inflammatory S100A9, possessing also intrinsic amyloidogenic properties and ability to modulate A beta aggregation, can serve as a link between the AD amyloid and neuroinflammatory cascades and as a prospective therapeutic target.	[Wang, Chao; Klechikov, Alexey G.; Gharibyan, Anna L.; Jia, Xueen; Olofsson, Anders; Morozova-Roche, Ludmilla A.] Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden; [Warmlander, Sebastian K. T. S.; Jarvet, Juri; Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; [Jarvet, Juri] NICPB, EE-12618 Tallinn, Estonia; [Zhao, Lina; Mu, Yuguang] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore; [Shankar, S. K.] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol, Bangalore 560029, Karnataka, India; [Brannstrom, Thomas] Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden		Morozova-Roche, LA (corresponding author), Umea Univ, Dept Med Biochem & Biophys, S-90187 Umea, Sweden.	ludmilla.morozova-roche@medchem.umu.se	Gharibyan, Anna L./B-3401-2010; Morozova-Roche, Ludmilla/AAV-9983-2021; Morozova-Roche, Ludmilla A./AAU-9044-2021; Zhao, Li Na/AAF-1190-2021; Jarvet, Juri/A-7330-2008; Klechikov, Alexey/D-5110-2018	Gharibyan, Anna L./0000-0001-9070-6215; Morozova-Roche, Ludmilla/0000-0001-5886-2023; Zhao, Li Na/0000-0001-6552-0929; Jarvet, Juri/0000-0002-7863-1887; 	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission; Insamlingsstiftelsen; Kempe foundation. A. G; Swedish Institute for his fellowship; Magnus Berg-vall Foundation	We are deeply grateful to Rakez Kayed for a gift of A11 and fibrillar antibodies. We thank Thomas Hockenstrom for usage of an Aperio scanscope and Maria Johansson, Kristoffer Brannstrom and Ulla-Stina Spetz for invaluable technical help. L. A. M- R., T. B. and A. G. acknowledge support from the Swedish Medical Research Council, and L. A. M- R. from the Insamlingsstiftelsen and the Kempe foundation. A. G. K. thanks the Swedish Institute for his fellowship. S. W. received funding from the Magnus Berg-vall Foundation. Y. Mu thanks the support of the IDA Cloud Computing Call, NTU Tier 1 grant RG 23/11, Nanyang Analytics NTU HPC Cluster and the A* STAR Computational Resource Centre (http://www.acrc.astar.edu.sg) for the use of its high performance computing facilities.	Andrusier N, 2007, PROTEINS, V69, P139, DOI 10.1002/prot.21495; Bhaskar K, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-14; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Botelho HM, 2012, J BIOL CHEM, V287, P42233, DOI 10.1074/jbc.M112.396416; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Carvalho SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076629; Cole GM, 2010, CNS NEUROL DISORD-DR, V9, P140, DOI 10.2174/187152710791011991; Cooper JR, 2009, CURR OPIN CELL BIOL, V21, P68, DOI 10.1016/j.ceb.2009.01.005; Danielsson J, 2006, MAGN RESON CHEM, V44, pS114, DOI 10.1002/mrc.1814; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Eremenko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058218; Fezoui Y, 2000, AMYLOID, V7, P166, DOI 10.3109/13506120009146831; Fritz G, 2010, FEBS J, V277, P4578, DOI 10.1111/j.1742-4658.2010.07887.x; Gandy S, 2013, NEURON, V78, P575, DOI 10.1016/j.neuron.2013.05.007; Glass G, 2009, J HISTOCHEM CYTOCHEM, V57, P899, DOI 10.1369/jhc.2009.953612; Ha TY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008840; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Itou H, 2002, J MOL BIOL, V316, P265, DOI 10.1006/jmbi.2001.5340; Jan A, 2012, METHODS MOL BIOL, V849, P227, DOI 10.1007/978-1-61779-551-0_16; Jia XE, 2011, J MOL BIOL, V414, P699, DOI 10.1016/j.jmb.2011.09.044; Kayed R, 2007, MOL NEURODEGENER, V2, DOI 10.1186/1750-1326-2-18; Krebs MRH, 2004, PROTEIN SCI, V13, P1933, DOI 10.1110/ps.04707004; Kummer MP, 2012, J NEUROSCI, V32, P17824, DOI 10.1523/JNEUROSCI.1504-12.2012; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; Park KM, 2008, J BIOL CHEM, V283, P33069, DOI 10.1074/jbc.M802209200; Pellarin R, 2010, J AM CHEM SOC, V132, P14960, DOI 10.1021/ja106044u; Pirici D, 2009, J HISTOCHEM CYTOCHEM, V57, P567, DOI 10.1369/jhc.2009.953240; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Rogers J, 2001, NEUROCHEM INT, V39, P333, DOI 10.1016/S0197-0186(01)00040-7; Ryu MJ, 2012, J BIOL CHEM, V287, P22948, DOI 10.1074/jbc.M112.357772; Schlachetzki JCM, 2009, CURR ALZHEIMER RES, V6, P554, DOI 10.2174/156720509790147179; Schluesener HJ, 1998, ACTA NEUROPATHOL, V96, P575, DOI 10.1007/s004010050938; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shepherd CE, 2006, NEUROBIOL AGING, V27, P1554, DOI 10.1016/j.neurobiolaging.2005.09.033; Swindell WR, 2013, SCI REP-UK, V3, DOI 10.1038/srep01215; Vivekanandan S, 2011, BIOCHEM BIOPH RES CO, V411, P312, DOI [10.1016/j.bbrc.2011.06.133, 10.13018/BMR17764]; Vogl T, 2006, BBA-MOL CELL RES, V1763, P1298, DOI 10.1016/j.bbamcr.2006.08.028; Vogl T, 2012, INT J MOL SCI, V13, P2893, DOI 10.3390/ijms13032893; Wahlstrom A, 2008, FEBS J, V275, P5117, DOI 10.1111/j.1742-4658.2008.06643.x; Wang DD, 2008, PROG NEUROBIOL, V86, P342, DOI 10.1016/j.pneurobio.2008.09.015; Warmlander S, 2013, CHEMBIOCHEM, V14, P1692, DOI 10.1002/cbic.201300262; Yanamandra K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005562; Yoshiyama Y, 2007, NEURON, V53, P337, DOI 10.1016/j.neuron.2007.01.010; Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032953; Zhao LN, 2013, RSC ADV, V3, P24081, DOI 10.1039/c3ra43665a	48	70	73	4	17	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	APR	2014	127	4					507	522		10.1007/s00401-013-1208-4			16	Clinical Neurology; Neurosciences; Pathology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pathology	AD0XJ	WOS:000332957400004	24240735	hybrid, Green Published			2022-02-06	
J	Acosta, SA; Tajiri, N; Shinozuka, K; Ishikawa, H; Sanberg, PR; Sanchez-Ramos, J; Song, SJ; Kaneko, Y; Borlongan, CV				Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Sanchez-Ramos, Juan; Song, Shijie; Kaneko, Yuji; Borlongan, Cesar V.			Combination Therapy of Human Umbilical Cord Blood Cells and Granulocyte Colony Stimulating Factor Reduces Histopathological and Motor Impairments in an Experimental Model of Chronic Traumatic Brain Injury	PLOS ONE			English	Article							MARROW STROMAL CELLS; CEREBRAL-ARTERY OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; MESENCHYMAL STEM-CELLS; FACTOR G-CSF; FUNCTIONAL RECOVERY; NEUROTROPHIC FACTORS; COLLAGEN SCAFFOLDS; MILD HYPOTHERMIA; PROGENITOR CELLS	Traumatic brain injury (TBI) is associated with neuro-inflammation, debilitating sensory-motor deficits, and learning and memory impairments. Cell-based therapies are currently being investigated in treating neurotrauma due to their ability to secrete neurotrophic factors and anti-inflammatory cytokines that can regulate the hostile milieu associated with chronic neuroinflammation found in TBI. In tandem, the stimulation and mobilization of endogenous stem/progenitor cells from the bone marrow through granulocyte colony stimulating factor (G-CSF) poses as an attractive therapeutic intervention for chronic TBI. Here, we tested the potential of a combined therapy of human umbilical cord blood cells (hUCB) and G-CSF at the acute stage of TBI to counteract the progressive secondary effects of chronic TBI using the controlled cortical impact model. Four different groups of adult Sprague Dawley rats were treated with saline alone, G-CSF+saline, hUCB+saline or hUCB+G-CSF, 7-days post CCI moderate TBI. Eight weeks after TBI, brains were harvested to analyze hippocampal cell loss, neuroinflammatory response, and neurogenesis by using immunohistochemical techniques. Results revealed that the rats exposed to TBI treated with saline exhibited widespread neuroinflammation, impaired endogenous neurogenesis in DG and SVZ, and severe hippocampal cell loss. hUCB monotherapy suppressed neuroinflammation, nearly normalized the neurogenesis, and reduced hippocampal cell loss compared to saline alone. G-CSF monotherapy produced partial and short-lived benefits characterized by low levels of neuroinflammation in striatum, DG, SVZ, and corpus callosum and fornix, a modest neurogenesis, and a moderate reduction of hippocampal cells loss. On the other hand, combined therapy of hUCB+G-CSF displayed synergistic effects that robustly dampened neuroinflammation, while enhancing endogenous neurogenesis and reducing hippocampal cell loss. Vigorous and long-lasting recovery of motor function accompanied the combined therapy, which was either moderately or short-lived in the monotherapy conditions. These results suggest that combined treatment rather than monotherapy appears optimal for abrogating histophalogical and motor impairments in chronic TBI.	[Acosta, Sandra A.; Tajiri, Naoki; Shinozuka, Kazutaka; Ishikawa, Hiroto; Sanberg, Paul R.; Kaneko, Yuji; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA; [Sanberg, Paul R.] Univ S Florida, Off Res & Innovat, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] James Haley Vet Affairs Med Ctr, Tampa, FL USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Neurol, Tampa, FL 33620 USA; [Sanchez-Ramos, Juan; Song, Shijie] Univ S Florida, Dept Mol Pharmacol & Physiol, Tampa, FL USA		Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain Repair, Tampa, FL 33620 USA.	cborlong@health.usf.edu	Sanchez-Ramos, Juan/O-7870-2014; Borlongan, Cesar/I-5696-2012; Sanchez-Ramos, Juan/A-1188-2009	Borlongan, Cesar/0000-0002-2966-9782; Sanchez-Ramos, Juan/0000-0002-3391-7857; Shinozuka, Kazutaka/0000-0002-6435-4460; Ishikawa, Hiroto/0000-0003-0760-7203	Department of DefenseUnited States Department of Defense [W81XWH-11-1-0634]; University of South Florida Signature Interdisciplinary Program in Neuroscience funds; University of South Florida; Veterans Administration Reintegration Funds; University of South Florida Neuroscience Collaborative Program; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01NS071956-01A1]; James and Esther King Biomedical Research Foundation [1KG01-33966]; SanBio Inc.; KMPHC; NeuralStem Inc.; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071956] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001407] Funding Source: NIH RePORTER	Financial support for this study was provided by the Department of Defense W81XWH-11-1-0634, the University of South Florida Signature Interdisciplinary Program in Neuroscience funds, the University of South Florida and Veterans Administration Reintegration Funds, and the University of South Florida Neuroscience Collaborative Program. CVB and PRS serve as consultant and founder, respectively, of Saneron CCEL Therapeutics, Inc. CVB is funded by the National Institutes of Health 1R01NS071956-01A1, James and Esther King Biomedical Research Foundation 1KG01-33966, SanBio Inc., KMPHC and NeuralStem Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bakhtiary Mehrdad, 2010, Iranian Biomedical Journal, V14, P142; Bath PMW, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005207.pub4; Bigler ED, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00395; Borlongan CV, 2011, LEUKEMIA, V25, P1674, DOI 10.1038/leu.2011.167; Borlongan CV, 2004, STROKE, V35, P2385, DOI 10.1161/01.STR.0000141680.49960.d7; BORLONGAN CV, 1995, J NEUROSCI, V15, P5372; Campbell K, 2013, BRAIN RES, V1502, P47, DOI 10.1016/j.brainres.2013.01.038; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cox CS, 2011, NEUROSURGERY, V68, P588, DOI 10.1227/NEU.0b013e318207734c; Cui LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064684; Dasari VR, 2008, NEUROBIOL DIS, V32, P486, DOI 10.1016/j.nbd.2008.09.005; England TJ, 2012, STROKE, V43, P405, DOI 10.1161/STROKEAHA.111.636449; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fabrizio KS, 2010, NURS CLIN N AM, V45, P569, DOI 10.1016/j.cnur.2010.06.003; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Faul M, 2010, TRAUMATIC BRAIN INJU; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Glover LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033646; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Guo XH, 2012, INT J NEUROSCI, V122, P723, DOI 10.3109/00207454.2012.716109; Hartung T, 1998, Curr Opin Hematol, V5, P221, DOI 10.1097/00062752-199805000-00013; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Huang XT, 2013, J NEUROTRAUM, V30, P2080, DOI 10.1089/neu.2013.2996; Imamura K, 2005, ACTA NEUROPATHOL, V109, P141, DOI 10.1007/s00401-004-0919-y; Imamura K, 2003, ACTA NEUROPATHOL, V106, P518, DOI 10.1007/s00401-003-0766-2; Iskander A, 2013, STEM CELL TRANSL MED, V2, P703, DOI 10.5966/sctm.2013-0066; Joo YD, 2011, CYTOKINE, V54, P36, DOI 10.1016/j.cyto.2010.12.020; Jung KH, 2006, BRAIN RES, V1073, P190, DOI 10.1016/j.brainres.2005.12.037; Khatibi NH, 2011, ACTA NEUROCHIR SUPPL, V111, P265, DOI 10.1007/978-3-7091-0693-8_44; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Lewis Frank D, 2013, J Spec Oper Med, V13, P56; Liu CY, 2008, NEUROSURGERY, V63, pN12, DOI 10.1227/01.NEU.0000339457.01711.3B; Lopes FRP, 2013, NEUROSCIENCE, V230, P184, DOI 10.1016/j.neuroscience.2012.10.025; Loving CL, 2013, BIOLOGICALS, V41, P368, DOI 10.1016/j.biologicals.2013.07.001; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lyman GH, 2013, ANN ONCOL, V24, P2475, DOI 10.1093/annonc/mdt226; Maegele M, 2008, MINIM INVASIV THER, V17, P119, DOI 10.1080/13645700801970087; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2013, J NEUROSURG, V118, P381, DOI 10.3171/2012.11.JNS12753; Massengale M, 2005, J EXP MED, V201, P1579, DOI 10.1084/jem.20050030; Maurer MH, 2008, CURR MED CHEM, V15, P1407, DOI 10.2174/092986708784567671; Minnerup Jens, 2009, Exp Transl Stroke Med, V1, P2, DOI 10.1186/2040-7378-1-2; Morita Y, 2007, NEUROSCI RES, V58, P356, DOI 10.1016/j.neures.2007.04.006; Ng K, 2008, ARCH PHYS MED REHAB, V89, pS35, DOI 10.1016/j.apmr.2008.07.006; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Paxinos G., 2005, RAT BRAIN STEREOTAXI, V400; Popa-Wagner A, 2010, STROKE, V41, P1027, DOI 10.1161/STROKEAHA.109.575621; Prakash A, 2013, PHARMACOL BIOCHEM BE, V110, P46, DOI 10.1016/j.pbb.2013.05.015; Sakowitz OW, 2006, ACTA NEUROCHIR SUPPL, V96, P139; Sanberg PR, 2012, PROG BRAIN RES, V201, P99, DOI 10.1016/B978-0-444-59544-7.00006-8; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sasaki A, 2008, BRAIN RES, V1214, P159, DOI 10.1016/j.brainres.2008.02.084; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shahaduzzaman M, 2013, AGE, V35, P2071, DOI 10.1007/s11357-012-9496-5; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Stachura DL, 2013, BLOOD; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Tajiri N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043779; Takahashi K, 2008, BRAIN RES, V1234, P172, DOI 10.1016/j.brainres.2008.07.086; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Tsuji T, 1999, GROWTH FACTORS, V16, P225, DOI 10.3109/08977199909002132; Tu Y, 2012, J NEUROTRAUM, V29, P2393, DOI 10.1089/neu.2012.2374; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Willing AE, 2003, CELL TRANSPLANT, V12, P449, DOI 10.3727/000000003108746885; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yang M, 2010, CELL TRANSPLANT, V19, P1073, DOI 10.3727/096368910X503415; Yang YN, 2013, PEDIATR NEONATOL, V54, P380, DOI 10.1016/j.pedneo.2013.04.011; Yasuda Y, 2007, BRAIN RES, V1138, P196, DOI 10.1016/j.brainres.2006.12.054; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067; Zhang C, 2006, NEUROSCIENCE, V141, P687, DOI 10.1016/j.neuroscience.2006.04.054; Zhao Li R, 2013, Recent Pat CNS Drug Discov, V8, P2; Zhao LR, 2007, EXP NEUROL, V204, P569, DOI 10.1016/j.expneurol.2006.12.001	83	70	70	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2014	9	3							e90953	10.1371/journal.pone.0090953			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	AC9HN	WOS:000332845300037	24621603	Green Published, gold, Green Submitted			2022-02-06	
J	Pugh, MJV; Finley, EP; Copeland, LA; Wang, CP; Noel, PH; Amuan, ME; Parsons, HM; Wells, M; Elizondo, B; Pugh, JA				Pugh, Mary Jo V.; Finley, Erin P.; Copeland, Laurel A.; Wang, Chen-Pin; Noel, Polly H.; Amuan, Megan E.; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.			Complex Comorbidity Clusters in OEF/OIF Veterans The Polytrauma Clinical Triad and Beyond	MEDICAL CARE			English	Article						Afghan Campaign 2001 (Operation Enduring Freedom); comorbidity; Iraq War 2003 (Operation Iraqi Freedom); veterans	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH DISORDERS; OPERATION-IRAQI-FREEDOM; ENDURING FREEDOM; US VETERANS; WAR; AFGHANISTAN; PAIN; CARE	Background:A growing body of research on US Veterans from Afghanistan and Iraq [Operations Enduring and Iraqi Freedom, and Operation New Dawn (OEF/OIF)] has described the polytrauma clinical triad (PCT): traumatic brain injury (TBI), posttraumatic stress disorder (PTSD), and pain. Extant research has not explored comorbidity clusters in this population more broadly, particularly co-occurring chronic diseases.Objectives:The aim of the study was to identify comorbidity clusters among diagnoses of deployment-specific (TBI, PTSD, pain) and chronic (eg, hypertension, diabetes) conditions, and to examine the association of these clusters with health care utilization and adverse outcomes.Research Design:This was a retrospective cohort study.Subjects:The cohort comprised OEF/OIF Veterans who received care in the Veterans Health Administration in fiscal years (FY) 2008-2010.Measures:We identified comorbidity using validated ICD-9-CM code-based algorithms and FY08-09 data, followed by which we applied latent class analysis to identify the most statistically distinct and clinically meaningful patterns of comorbidity. We examined the association of these clusters with process measures/outcomes using logistic regression to correlate medication use, acute health care utilization, and adverse outcomes in FY10.Results:In this cohort (N=191,797), we found 6 comorbidity clusters. Cluster 1: PCT+Chronic Disease (5%); Cluster 2: PCT (9%); Cluster 3: Mental Health+Substance Abuse (24%); Cluster 4: Sleep, Amputation, Chronic Disease (4%); Cluster 5: Pain, Moderate PTSD (6%); and Cluster 6: Relatively Healthy (53%). Subsequent health care utilization patterns and adverse events were consistent with disease patterns.Conclusions:These comorbidity clusters extend beyond the PCT and may be used as a foundation to examine coordination/quality of care and outcomes for OEF/OIF Veterans with different patterns of comorbidity.	[Pugh, Mary Jo V.; Finley, Erin P.; Wang, Chen-Pin; Noel, Polly H.; Wells, Margaret; Elizondo, Barbara; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.; Wang, Chen-Pin; Parsons, Helen M.; Wells, Margaret; Elizondo, Barbara] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Pugh, Mary Jo V.; Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Bryan, TX USA; [Finley, Erin P.; Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA; [Copeland, Laurel A.] Cent Texas Vet Hlth Care Syst, Ctr Appl Hlth Res, Temple, TX USA; [Copeland, Laurel A.] Scott & White Healthcare Syst, Temple, TX USA; [Amuan, Megan E.] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA; [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Hosp Med, San Antonio, TX 78229 USA		Pugh, MJV (corresponding author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	Maryjo.pughm@uthscsa.edu	Pugh, Mary Jo/K-5336-2019; Copeland, Laurel A/C-3763-2017; Pugh, Jacqueline/I-6199-2013	Pugh, Mary Jo/0000-0003-4196-7763; Copeland, Laurel A/0000-0002-9478-0209; Finley, Erin/0000-0003-4497-7721; Pugh, Jacqueline/0000-0003-4933-141X; Noel, Polly/0000-0002-1519-7489	Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; Veterans AffairsUS Department of Veterans Affairs [I01HX000329] Funding Source: NIH RePORTER	Funded by the Department of Veterans Affairs, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237).	Agency for Healthcare Research and Quality, MULT CHRON COND; Bandeen-Roche K, 1997, J AM STAT ASSOC, V92, P1375, DOI 10.2307/2965407; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carter AC, 2011, J DUAL DIAGN, V7, P285, DOI 10.1080/15504263.2011.620453; Clark ME, 2007, J REHABIL RES DEV, V44, P179, DOI 10.1682/JRRD.2006.05.0057; Cohen BE, 2009, JAMA-J AM MED ASSOC, V302, P489, DOI 10.1001/jama.2009.1084; Defense Science Board Task Force, 2007, DEPL MEMB NAT GUARD; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Gailey R, 2010, J REHABIL RES DEV, V47, P317, DOI 10.1682/JRRD.2009.04.0039; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hoge CW, 2005, AM J PSYCHIAT, V162, P585, DOI 10.1176/appi.ajp.162.3.585; Jakupcak M, 2010, ADDICT BEHAV, V35, P840, DOI 10.1016/j.addbeh.2010.03.023; Lemaire CM, 2011, J AFFECT DISORDERS, V130, P231, DOI 10.1016/j.jad.2010.10.021; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Morgan RO, 2005, HEALTH SERV RES, V40, P1573, DOI 10.1111/j.1475-6773.2005.00448.x; Nazarian D, 2012, J TRAUMA STRESS, V25, P220, DOI 10.1002/jts.21690; Petrakis IL, 2011, AM J ADDICTION, V20, P185, DOI 10.1111/j.1521-0391.2011.00126.x; Pietrzak RH, 2011, J PSYCHIATR RES, V45, P1579, DOI 10.1016/j.jpsychires.2011.07.010; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seal KH, 2012, JAMA-J AM MED ASSOC, V307, P940, DOI 10.1001/jama.2012.234; Shepperd S, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000086; Sullenberger L, 2008, MIL MED, V173, P193, DOI 10.7205/MILMED.173.2.193; Taylor BC, 2012, MED CARE, V50, P342, DOI 10.1097/MLR.0b013e318245a558; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; White JM, 2011, ANN SURG, V253, P1184, DOI [10.1097/SLA.0b013e31820752e3, 10.2165/11537150-000000000-00000]; Zouris JM, 2008, MIL MED, V173, P247, DOI 10.7205/MILMED.173.3.247	34	70	70	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079	1537-1948		MED CARE	Med. Care	FEB	2014	52	2					172	181		10.1097/MLR.0000000000000059			10	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services; Public, Environmental & Occupational Health	AA4SS	WOS:000331087100014	24374417				2022-02-06	
J	Dettwiler, A; Murugavel, M; Putukian, M; Cubon, V; Furtado, J; Osherson, D				Dettwiler, Annegret; Murugavel, Murali; Putukian, Margot; Cubon, Valerie; Furtado, John; Osherson, Daniel			Persistent Differences in Patterns of Brain Activation after Sports-Related Concussion: A Longitudinal Functional Magnetic Resonance Imaging Study	JOURNAL OF NEUROTRAUMA			English	Article						concussion; DLPFC; fMRI; n-back task; working memory	COMPENSATORY CORTICAL ACTIVATION; WORKING-MEMORY; MULTIPLE-SCLEROSIS; PREFRONTAL CORTEX; INJURY; FMRI; REORGANIZATION; PERFORMANCE; RECOVERY; ABNORMALITIES	Avoiding recurrent injury in sports-related concussion (SRC) requires understanding the neural mechanisms involved during the time of recovery after injury. The decision for return-to-play is one of the most difficult responsibilities facing the physician, and so far this decision has been based primarily on neurological examination, symptom checklists, and neuropsychological (NP) testing. Functional magnetic resonance imaging (fMRI) may be an additional, more objective tool to assess the severity and recovery of function after concussion. The purpose of this study was to define neural correlates of SRC during the 2 months after injury in varsity contact sport athletes who suffered a SRC. All athletes were scanned as they performed an n-back task, for n=1, 2, 3. Subjects were scanned within 72 hours (session one), at 2 weeks (session two), and 2 months (session three) post-injury. Compared with age and sex matched normal controls, concussed subjects demonstrated persistent, significantly increased activation for the 2 minus 1 n-back contrast in bilateral dorsolateral prefrontal cortex (DLPFC) in all three sessions and in the inferior parietal lobe in session one and two (0.01 corrected). Measures of task performance revealed no significant differences between concussed versus control groups at any of the three time points with respect to any of the three n-back tasks. These findings suggest that functional brain activation differences persist at 2 months after injury in concussed athletes, despite the fact that their performance on a standard working memory task is comparable to normal controls and normalization of clinical and NP test results. These results might indicate a delay between neural and behaviorally assessed recovery after SRC.	[Dettwiler, Annegret; Murugavel, Murali] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08540 USA; [Furtado, John] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08540 USA; [Cubon, Valerie] Kent State Univ, Dept Chem, Warren, OH USA; [Osherson, Daniel] Princeton Univ, Dept Psychol, Princeton, NJ 08540 USA		Dettwiler, A (corresponding author), Princeton Univ, Princeton Neurosci Inst, Green Hall, Princeton, NJ 08540 USA.	adettwil@princeton.edu			New Jersey Commission for Brain Injury Research [10-3217-BIR-E-0]; AMSSM Foundation [005548]; Goldstein Family Fund; Peter & Cynthia Kellogg Foundation	We would like to acknowledge the athletic trainers of University Health Services for their assistance with subject recruitment and NP testing. This work was funded by the New Jersey Commission for Brain Injury Research grant No. 10-3217-BIR-E-0, AMSSM Foundation grant No. 005548, the Goldstein Family Fund, and the Peter & Cynthia Kellogg Foundation.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Audoin B, 2003, HUM BRAIN MAPP, V20, P51, DOI 10.1002/hbm.10128; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; Brainard DH, 1997, SPATIAL VISION, V10, P433, DOI 10.1163/156856897X00357; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chiaravalloti ND, 2005, J CLIN EXP NEUROPSYC, V27, P33, DOI 10.1080/138033990513609; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hillary FG, 2010, BRAIN IMAGING BEHAV, V4, P141, DOI 10.1007/s11682-010-9094-z; Hockey A, 2004, INTELLIGENCE, V32, P591, DOI 10.1016/j.intell.2004.07.009; Hoptman MJ, 2010, SCHIZOPHR RES, V117, P13, DOI 10.1016/j.schres.2009.09.030; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jaeggi SM, 2003, NEUROIMAGE, V19, P210, DOI 10.1016/S1053-8119(03)00098-3; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Jezzard P., 2003, FUNCTIONAL MRI INTRO; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; KARNI A, 1995, NATURE, V377, P155; Kiviniemi V, 2000, MAGN RESON MED, V44, P373, DOI 10.1002/1522-2594(200009)44:3<373::AID-MRM5>3.0.CO;2-P; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Landau SM, 2004, NEUROIMAGE, V22, P211, DOI 10.1016/j.neuroimage.2004.01.003; Langlois J, 2005, TRAUMATIC BRAIN INJU; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell M. R., 2007, IMMEDIATE POSTCONCUS; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Mainero C, 2006, J NEUROL SCI, V245, P93, DOI 10.1016/j.jns.2005.08.024; Maruishi M, 2007, J NEUROL NEUROSUR PS, V78, P168, DOI 10.1136/jnnp.2006.097345; Matthews PM, 2004, J NEUROL NEUROSUR PS, V75, P6; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Niehorster, 2007, WHATS NEW PSYCHTOOLB; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Pantano P, 2006, J NEUROIMAGING, V16, P104, DOI 10.1111/j.1552-6569.2006.00029.x; Partington JE, 1949, PSYCHOL SERV CTR B, V1, P9; Pauling L, 1936, P NATL ACAD SCI USA, V22, P210, DOI 10.1073/pnas.22.4.210; Pelli DG, 1997, SPATIAL VISION, V10, P437, DOI 10.1163/156856897X00366; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith A., 1982, SYMBOL DIGIT MODALIT; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Vagnozzi R, 2013, J HEAD TRAUMA REHAB, V28, P284, DOI 10.1097/HTR.0b013e3182795045; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Williams M, 1991, COGNITIVE BEHAV RATI; Zang YF, 2007, BRAIN DEV-JPN, V29, P83, DOI 10.1016/j.braindev.2006.07.002; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	69	70	72	1	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2014	31	2					180	188		10.1089/neu.2013.2983			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	291ZE	WOS:000329870600004	23914845	Green Published			2022-02-06	
J	Kontos, AP; Elbin, RJ; Fazio-Sumrock, VC; Burkhart, S; Swindell, H; Maroon, J; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Fazio-Sumrock, Vanessa C.; Burkhart, Scott; Swindell, Hasani; Maroon, Joseph; Collins, Michael W.			Incidence of Sports-Related Concussion among Youth Football Players Aged 8-12 Years	JOURNAL OF PEDIATRICS			English	Article							STATES HIGH-SCHOOL; COLLEGIATE; EPIDEMIOLOGY; INJURY	Objective To determine the risk of concussion among youth football players (ages 8-12 years). Study design Participants included 468 male youth football players in western Pennsylvania during the 2011 youth football season. Incidence rates (IRs) and incidence density ratios (IDRs) of concussion were calculated for games and practices and for age groups. Results There was a total of 11 338 (8415 practice and 2923 game) athletic exposures (AEs) in the study period, during which 20 medically diagnosed concussions occurred. A majority of concussions were the result of head-to-head (45%) contact. The combined concussion IR for practices and games was 1.76 per 1000 AEs (95% CI 0.99-2.54). The concussion IR was 0.24 per 1000 AEs (95% CI 0.04-0.79) in practices and 6.16 per 1000 AEs (95% CI 3.76-9.54) in games. The IDR for concussions in games to practices was 25.91 (95% CI 6.01-111.70). The IDR of concussions for youth aged 11-12 years compared with youth aged 8-10 years was 2.72 (95% CI 0.66-4.78). Conclusions The overall IR for concussion in youth football players aged 8-12 years was comparable with that reported previously for high school and collegiate samples. However, participation in games was associated with an increase in risk of concussion compared with practices, which was higher than rates previously reported for high school and collegiate athletes. Younger players were slightly less likely to incur a concussion than were older players.	[Kontos, Anthony P.; Elbin, R. J.; Fazio-Sumrock, Vanessa C.; Burkhart, Scott; Collins, Michael W.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthopaed Surg,Concuss Program, Pittsburgh, PA USA; [Swindell, Hasani] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Maroon, Joseph] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA		Kontos, AP (corresponding author), UPMC, Ctr Sports Med, 3200 S Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310	National Football League Charities Medical Research grant	Funded by National Football League Charities Medical Research grant. The authors declare no conflicts of interest.	Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Centers for Disease Control and Prevention (CDC), HEADS CONC YOUTH SPO; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Pop Warner National Office, RUL CHANG REG PRACT; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; USA Football's Tackle Advisory Committee, US FOOTB HEADS TRACK	15	70	70	0	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	SEP	2013	163	3					717	720		10.1016/j.jpeds.2013.04.011			4	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	212LQ	WOS:000323985300024	23751761				2022-02-06	
J	Lewis, LD; Ching, SN; Weiner, VS; Peterfreund, RA; Eskandar, EN; Cash, SS; Brown, EN; Purdon, PL				Lewis, Laura D.; Ching, ShiNung; Weiner, Veronica S.; Peterfreund, Robert A.; Eskandar, Emad N.; Cash, Sydney S.; Brown, Emery N.; Purdon, Patrick L.			Local cortical dynamics of burst suppression in the anaesthetized brain	BRAIN			English	Article						intracranial electroencephalogram; human; neurophysiology; general anaesthesia	REFRACTORY STATUS EPILEPTICUS; GENERAL-ANESTHESIA; ELECTROENCEPHALOGRAM; PROPOFOL; ISOFLURANE; SLEEP; MODEL; EEG	Burst suppression is an electroencephalogram pattern that consists of a quasi-periodic alternation between isoelectric 'suppressions' lasting seconds or minutes, and high-voltage 'bursts'. It is characteristic of a profoundly inactivated brain, occurring in conditions including hypothermia, deep general anaesthesia, infant encephalopathy and coma. It is also used in neurology as an electrophysiological endpoint in pharmacologically induced coma for brain protection after traumatic injury and during status epilepticus. Classically, burst suppression has been regarded as a 'global' state with synchronous activity throughout cortex. This assumption has influenced the clinical use of burst suppression as a way to broadly reduce neural activity. However, the extent of spatial homogeneity has not been fully explored due to the challenges in recording from multiple cortical sites simultaneously. The neurophysiological dynamics of large-scale cortical circuits during burst suppression are therefore not well understood. To address this question, we recorded intracranial electrocorticograms from patients who entered burst suppression while receiving propofol general anaesthesia. The electrodes were broadly distributed across cortex, enabling us to examine both the dynamics of burst suppression within local cortical regions and larger-scale network interactions. We found that in contrast to previous characterizations, bursts could be substantially asynchronous across the cortex. Furthermore, the state of burst suppression itself could occur in a limited cortical region while other areas exhibited ongoing continuous activity. In addition, we found a complex temporal structure within bursts, which recapitulated the spectral dynamics of the state preceding burst suppression, and evolved throughout the course of a single burst. Our observations imply that local cortical dynamics are not homogeneous, even during significant brain inactivation. Instead, cortical and, implicitly, subcortical circuits express seemingly different sensitivities to high doses of anaesthetics that suggest a hierarchy governing how the brain enters burst suppression, and emphasize the role of local dynamics in what has previously been regarded as a global state. These findings suggest a conceptual shift in how neurologists could assess the brain function of patients undergoing burst suppression. First, analysing spatial variation in burst suppression could provide insight into the circuit dysfunction underlying a given pathology, and could improve monitoring of medically-induced coma. Second, analysing the temporal dynamics within a burst could help assess the underlying brain state. This approach could be explored as a prognostic tool for recovery from coma, and for guiding treatment of status epilepticus. Overall, these results suggest new research directions and methods that could improve patient monitoring in clinical practice.	[Lewis, Laura D.; Ching, ShiNung; Weiner, Veronica S.; Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; [Ching, ShiNung] Washington Univ, Dept Elect & Syst Engn, St Louis, MO 63130 USA; [Peterfreund, Robert A.; Brown, Emery N.; Purdon, Patrick L.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Peterfreund, Robert A.; Brown, Emery N.; Purdon, Patrick L.] Harvard Univ, Dept Anaesthesia, Sch Med, Boston, MA 02115 USA; [Eskandar, Emad N.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Eskandar, Emad N.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; [Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Cash, Sydney S.] Harvard Univ, Dept Neurol, Sch Med, Boston, MA 02115 USA; [Brown, Emery N.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Brown, Emery N.] MIT, Inst Med Engn & Sci, Cambridge, MA 02139 USA		Purdon, PL (corresponding author), CNY 149-4,149 13th St, Charlestown, MA 02129 USA.	patrickp@nmr.mgh.harvard.edu		Lewis, Laura/0000-0002-4003-0277	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Burroughs-Wellcome FundBurroughs Wellcome Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1OD003646]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R01GM104948, DP2-OD006454]; Direct For Mathematical & Physical ScienNational Science Foundation (NSF)NSF - Directorate for Mathematical & Physical Sciences (MPS) [1042134] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM104948] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DP1OD003646, DP2OD006454] Funding Source: NIH RePORTER	This work was supported by a doctoral fellowship from the Canadian Institutes of Health Research to L. D. L., a Career Award at the Scientific Interface from the Burroughs-Wellcome Fund to S. C., and by the National Institutes of Health [Director's Pioneer Award DP1OD003646 to E.N.B., NIH Transformative 1R01GM104948 to E.N.B., NIH New Innovator Award DP2-OD006454 to P.L.P.].	Akrawi WP, 1996, J NEUROSURG ANESTH, V8, P40, DOI 10.1097/00008506-199601000-00010; Amzica F, 2009, EPILEPSIA, V50, P38, DOI 10.1111/j.1528-1167.2009.02345.x; Bokil H, 2010, J NEUROSCI METH, V192, P146, DOI 10.1016/j.jneumeth.2010.06.020; Brown EN, 2010, NEW ENGL J MED, V363, P2638, DOI 10.1056/NEJMra0808281; Cash SS, 2009, SCIENCE, V324, P1084, DOI 10.1126/science.1169626; Chemali JJ, 2011, IEEE ENG MED BIO, P1431, DOI 10.1109/IEMBS.2011.6090354; Ching SN, 2012, P NATL ACAD SCI USA, V109, P3095, DOI 10.1073/pnas.1121461109; Cimenser A, 2011, P NATL ACAD SCI USA, V108, P8832, DOI 10.1073/pnas.1017041108; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; CLARK DL, 1973, ANESTHESIOLOGY, V38, P564, DOI 10.1097/00000542-197306000-00011; Dykstra AR, 2012, NEUROIMAGE, V59, P3563, DOI 10.1016/j.neuroimage.2011.11.046; Ferron JF, 2009, J NEUROSCI, V29, P9850, DOI 10.1523/JNEUROSCI.5176-08.2009; HALL R, 1990, CAN J ANAESTH, V37, P762, DOI 10.1007/BF03006535; Kroeger D, 2007, J NEUROSCI, V27, P10597, DOI 10.1523/JNEUROSCI.3440-07.2007; Lewis LD, 2012, P NATL ACAD SCI USA, V109, pE3377, DOI 10.1073/pnas.1210907109; Lofhede J, 2008, J NEURAL ENG, V5, P402, DOI 10.1088/1741-2560/5/4/005; MICHENFELDER JD, 1991, ANESTHESIOLOGY, V75, P130, DOI 10.1097/00000542-199107000-00021; Murphy M, 2011, SLEEP, V34, P283, DOI 10.1093/sleep/34.3.283; Nir Y, 2011, NEURON, V70, P153, DOI 10.1016/j.neuron.2011.02.043; Ohtahara S, 2003, J CLIN NEUROPHYSIOL, V20, P398, DOI 10.1097/00004691-200311000-00003; Purdon PL, 2013, P NATL ACAD SCI USA, V110, pE1142, DOI 10.1073/pnas.1221180110; Rossetti AO, 2004, EPILEPSIA, V45, P757, DOI 10.1111/j.0013-9580.2004.01904.x; Stecker MM, 2001, ANN THORAC SURG, V71, P22, DOI 10.1016/S0003-4975(00)02021-X; STERIADE M, 1994, ELECTROEN CLIN NEURO, V90, P1, DOI 10.1016/0013-4694(94)90108-2; Supp GG, 2011, CURR BIOL, V21, P1988, DOI 10.1016/j.cub.2011.10.017; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006	26	70	70	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	SEP	2013	136		9				2727	2737		10.1093/brain/awt174			11	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	212EM	WOS:000323965100013	23887187	Green Published, hybrid			2022-02-06	
J	Pu, HJ; Guo, YL; Zhang, WT; Huang, LT; Wang, GH; Liou, AK; Zhang, J; Zhang, PY; Leak, RK; Wang, Y; Chen, J; Gao, YQ				Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Liou, Anthony K.; Zhang, Jia; Zhang, Pengyue; Leak, Rehana K.; Wang, Yun; Chen, Jun; Gao, Yanqin			Omega-3 polyunsaturated fatty acid supplementation improves neurologic recovery and attenuates white matter injury after experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						behavior (rodent); brain trauma; inflammation; neurodegeneration; white matter/oligodendrocytes	SPINAL-CORD-INJURY; DOCOSAHEXAENOIC ACID; PARKINSONS-DISEASE; MODEL; RAT; OMEGA-3-FATTY-ACIDS; EXCITOTOXICITY; MECHANISMS; GLUTAMATE; VULNERABILITY	Dietary supplementation with omega-3 (omega-3) fatty acids is a safe, economical mean of preventive medicine that has shown protection against several neurologic disorders. The present study tested the hypothesis that this method is protective against controlled cortical impact (CCI). Indeed, mice fed with omega-3 polyunsaturated fatty acid (PUFA)-enriched diet for 2 months exhibited attenuated short and long-term behavioral deficits due to CCI. Although omega-3 PUFAs did not decrease cortical lesion volume, these fatty acids did protect against hippocampal neuronal loss after CCI and reduced pro-inflammatory response. Interestingly, omega-3 PUFAs prevented the loss of myelin basic protein (MPB), preserved the integrity of the myelin sheath, and maintained the nerve fiber conductivity in the CCI model. omega-3 PUFAs also directly protected oligodendrocyte cultures from excitotoxicity and blunted the microglial activation-induced death of oligodendrocytes in microglia/oligodendrocyte cocultures. In sum, omega-3 PUFAs elicit multifaceted protection against behavioral dysfunction, hippocampal neuronal loss, inflammation, and loss of myelination and impulse conductivity. The present report is the first demonstration that omega-3 PUFAs protect against white matter injury in vivo and in vitro. The protective impact of omega-3 PUFAs supports the clinical use of this dietary supplement as a prophylaxis against traumatic brain injury and other nervous system disorders.	[Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Pu, Hongjian; Guo, Yanling; Zhang, Wenting; Huang, Lanting; Wang, Guohua; Zhang, Jia; Zhang, Pengyue; Wang, Yun; Chen, Jun; Gao, Yanqin] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Liou, Anthony K.; Chen, Jun; Gao, Yanqin] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA USA; [Liou, Anthony K.; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA		Gao, YQ (corresponding author), Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.	chenj2@upmc.edu; yqgao@shmu.edu.cn	Pu, Hongjian/AAW-3322-2020; Gao, Yanqin/I-6790-2016; Leak, Rehana K/I-2607-2019	Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana K/0000-0003-2817-7417	Chinese Ministry of Science and TechnologyMinistry of Science and Technology, China; National Institutes of Health/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36736, NS43802, NS45048, NS056118]; Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [30870794, 81020108021, 81171149, 81150110494, 81000497]; VA Research Career Scientist Award; VA Merit Review grantUS Department of Veterans Affairs; UPMC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056118, R01NS036736, R01NS045048, R01NS043802] Funding Source: NIH RePORTER	This research is supported in part by the Special Research Funds from Chinese Ministry of Science and Technology to State Key laboratories (to YG and JC), National Institutes of Health/NINDS grants NS36736, NS43802, NS45048 and NS056118 (to JC), and Chinese Natural Science Foundation grants No 30870794, No 81020108021, No 81171149, No 81150110494, and No 81000497 (to YG). JC is a recipient of the VA Research Career Scientist Award, VA Merit Review grant, and the RK Mellon Endowed Chair from UPMC.	Allen NJ, 2009, NATURE, V457, P675, DOI 10.1038/457675a; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Bousquet M, 2011, AGEING RES REV, V10, P453, DOI 10.1016/j.arr.2011.03.001; Chen Y, 2007, NAT PROTOC, V2, P1044, DOI 10.1038/nprot.2007.149; Cole GM, 2010, NUTR REV, V68, pS102, DOI 10.1111/j.1753-4887.2010.00345.x; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Deng W, 2010, NAT REV NEUROSCI, V11, P339, DOI 10.1038/nrn2822; Domercq M, 2011, J BIOL CHEM, V286, P11825, DOI 10.1074/jbc.M110.153049; Eady Tiffany N, 2012, Exp Transl Stroke Med, V4, P19, DOI 10.1186/2040-7378-4-19; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; Ge YL, 2002, J NEUROCHEM, V82, P1360, DOI 10.1046/j.1471-4159.2002.01077.x; Hall JCE, 2012, J NEUROCHEM, V121, P738, DOI 10.1111/j.1471-4159.2012.07726.x; Hasadsri L, 2013, J NEUROTRAUM, V30, P897, DOI 10.1089/neu.2012.2672; Liu YQ, 2002, PEDIATR RES, V51, P25, DOI 10.1203/00006450-200201000-00007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lotocki G, 2011, THER HYPOTHERMIA TEM, V1, DOI 10.1089/ther.2010.0011; Lotocki G, 2011, NEUROSCI LETT, V499, P143, DOI 10.1016/j.neulet.2011.05.056; Luchtman DW, 2012, BEHAV BRAIN RES, V226, P386, DOI 10.1016/j.bbr.2011.09.033; Mamere AE, 2009, AM J NEURORADIOL, V30, P947, DOI 10.3174/ajnr.A1477; Martin A, 2011, MOL IMAGING BIOL, V13, P10, DOI 10.1007/s11307-010-0324-y; Matute C, 2001, TRENDS NEUROSCI, V24, P224, DOI 10.1016/S0166-2236(00)01746-X; Matute C, 2011, J ANAT, V219, P53, DOI 10.1111/j.1469-7580.2010.01339.x; Nguemeni C, 2010, PHARMACOL RES, V61, P226, DOI 10.1016/j.phrs.2009.12.007; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Okabe N, 2011, J STROKE CEREBROVASC, V20, P188, DOI 10.1016/j.jstrokecerebrovasdis.2009.11.016; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Park E, 2004, J NEUROTRAUM, V21, P754, DOI 10.1089/0897715041269641; Pignier C, 2007, BASIC RES CARDIOL, V102, P553, DOI 10.1007/s00395-007-0676-x; Potts MB, 2009, CEREBELLUM, V8, P211, DOI 10.1007/s12311-009-0114-8; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rosival V, 1990, Vnitr Lek, V36, P783; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Shen HX, 2010, NEUROBIOL DIS, V37, P711, DOI 10.1016/j.nbd.2009.12.010; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	40	70	71	1	29	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2013	33	9					1474	1484		10.1038/jcbfm.2013.108			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	214IQ	WOS:000324126400020	23801244	Green Published, Bronze			2022-02-06	
J	Mannix, R; O'Brien, MJ; Meehan, WP				Mannix, Rebekah; O'Brien, Michael J.; Meehan, William P., III			The Epidemiology of Outpatient Visits for Minor Head Injury: 2005 to 2009	NEUROSURGERY			English	Article						Concussion; Epidemiology; Traumatic brain injury	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; 3RD INTERNATIONAL-CONFERENCE; UNITED-STATES; EMERGENCY-DEPARTMENTS; HIGH-SCHOOL; COMPUTED-TOMOGRAPHY; CONSENSUS STATEMENT; FOOTBALL PLAYERS; MANAGEMENT	BACKGROUND: The Centers for Disease Control and Prevention have called for studies detailing the prevalence and burden of mild traumatic brain injury (mTBI) in the outpatient clinical setting. OBJECTIVE: The aim of this study was to describe the prevalence of outpatient visits for minor head injury and compare the number of outpatient visits for minor head injury with the number of emergency department (ED) visits. METHODS: This was a cross-sectional study of outpatient visits for minor head injuries from the National Ambulatory Medical Care Survey (NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS). We examined outpatient visits for minor head injury between 2005 and 2009 and compared them with visits in the ED for the same diagnoses using simple survey-weighted descriptive statistics. RESULTS: In the 5-year study period, there were 4 146 777 outpatient visits for minor head injury and 6 077 147 ED visits for minor head injury. In the outpatient setting, 14% of office-based visits and 21% of hospital-based visits referred patients for advanced imaging, whereas 63% of minor head injury patients in the ED underwent imaging. A return visit was arranged for 54% of minor head injury patients in office-based practices and 29% of patients in hospital-based clinics, while 67% of minor head injury patients were given instructions to follow-up after an ED visit. CONCLUSION: More than 800 000 outpatient visits for minor head injury occur each year. The diagnostics and management associated with these visits differ from those seen in the ED setting.	[Mannix, Rebekah; Meehan, William P., III] Childrens Hosp, Div Emergency Med, Boston, MA 02115 USA; [Mannix, Rebekah; Meehan, William P., III] Childrens Hosp, Brain Injury Ctr, Boston, MA 02115 USA; [O'Brien, Michael J.; Meehan, William P., III] Childrens Hosp, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA; [O'Brien, Michael J.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA		Mannix, R (corresponding author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.	Rebekah.Mannix@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020				Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P133, DOI 10.1016/j.csm.2010.08.004; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Oman JA, 2006, PEDIATRICS, V117, pE238, DOI 10.1542/peds.2005-1063; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Schootman M, 2003, BRAIN INJURY, V17, P983, DOI 10.1080/0269905031000110427; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Sue Binder, 2003, MILD TRAUMATIC BRAIN; Tommasone BA, 2006, J ATHL TRAINING, V41, P470; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	40	70	71	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2013	73	1					129	134		10.1227/01.neu.0000429846.14579.41			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	299FJ	WOS:000330380900038	23615100				2022-02-06	
J	Kochanek, PM; Dixon, CE; Shellington, DK; Shin, SS; Bayir, H; Jackson, EK; Kagan, VE; Yan, HQ; Swauger, PV; Parks, SA; Ritzel, DV; Bauman, R; Clark, RSB; Garman, RH; Bandak, F; Ling, G; Jenkins, LW				Kochanek, Patrick M.; Dixon, C. Edward; Shellington, David K.; Shin, Samuel S.; Bayir, Huelya; Jackson, Edwin K.; Kagan, Valerian E.; Yan, Hong Q.; Swauger, Peter V.; Parks, Steven A.; Ritzel, David V.; Bauman, Richard; Clark, Robert S. B.; Garman, Robert H.; Bandak, Faris; Ling, Geoffrey; Jenkins, Larry W.			Screening of Biochemical and Molecular Mechanisms of Secondary Injury and Repair in the Brain after Experimental Blast-Induced Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						adenosine; antioxidant; ascorbate; ATP; axonal injury; chemokine; combat casualty care; cyclic AMP; cytokine; gene array; glutathione; improvised explosive device; lipid peroxidation; multiplex; post-traumatic stress disorder; purine	POSTTRAUMATIC-STRESS-DISORDER; HUMAN CEREBROSPINAL-FLUID; OXIDATIVE STRESS; GENE-EXPRESSION; CELLS; MODEL; INTERLEUKIN-6; ACTIVATION; MIP-1-ALPHA; CHEMOKINE	Explosive blast-induced traumatic brain injury (TBI) is the signature insult in modern combat casualty care and has been linked to post-traumatic stress disorder, memory loss, and chronic traumatic encephalopathy. In this article we report on blast-induced mild TBI (mTBI) characterized by fiber-tract degeneration and axonal injury revealed by cupric silver staining in adult male rats after head-only exposure to 35 psi in a helium-driven shock tube with head restraint. We now explore pathways of secondary injury and repair using biochemical/molecular strategies. Injury produced similar to 25% mortality from apnea. Shams received identical anesthesia exposure. Rats were sacrificed at 2 or 24 h, and brain was sampled in the hippocampus and prefrontal cortex. Hippocampal samples were used to assess gene array (RatRef-12 Expression BeadChip; Illumina, Inc., San Diego, CA) and oxidative stress (OS; ascorbate, glutathione, low-molecular-weight thiols [LMWT], protein thiols, and 4-hydroxynonenal [HNE]). Cortical samples were used to assess neuroinflammation (cytokines, chemokines, and growth factors; Luminex Corporation, Austin, TX) and purines (adenosine triphosphate [ATP], adenosine diphosphate, adenosine, inosine, 2'-AMP [adenosine monophosphate], and 5'-AMP). Gene array revealed marked increases in astrocyte and neuroinflammatory markers at 24 h (glial fibrillary acidic protein, vimentin, and complement component 1) with expression patterns bioinformatically consistent with those noted in Alzheimer's disease and long-term potentiation. Ascorbate, LMWT, and protein thiols were reduced at 2 and 24 h; by 24 h, HNE was increased. At 2 h, multiple cytokines and chemokines (interleukin [IL]-1 alpha, IL-6, IL-10, and macrophage inflammatory protein 1 alpha [MIP-1 alpha]) were increased; by 24 h, only MIP-1 alpha remained elevated. ATP was not depleted, and adenosine correlated with 2'-cyclic AMP (cAMP), and not 5'-cAMP. Our data reveal (1) gene-array alterations similar to disorders of memory processing and a marked astrocyte response, (2) OS, (3) neuroinflammation with a sustained chemokine response, and (4) adenosine production despite lack of energy failure-possibly resulting from metabolism of 2'-3'-cAMP. A robust biochemical/molecular response occurs after blast-induced mTBI, with the body protected from blast and the head constrained to limit motion.	[Kochanek, Patrick M.; Dixon, C. Edward; Shin, Samuel S.; Bayir, Huelya; Yan, Hong Q.; Clark, Robert S. B.; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Kochanek, Patrick M.; Bayir, Huelya; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Dixon, C. Edward; Shin, Samuel S.; Yan, Hong Q.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Med Pharmacol, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Bayir, Huelya; Kagan, Valerian E.] Univ Pittsburgh, Sch Med, Pittsburgh Ctr Free Radical & Antioxidant Hlth, Pittsburgh, PA 15260 USA; [Shellington, David K.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Swauger, Peter V.; Parks, Steven A.] ORA Inc, Fredericksburg, VA USA; [Bauman, Richard] Walter Reed Army Inst Res, Silver Spring, MD USA; [Ritzel, David V.] Dyn FX Consulting Ltd, Amherstburg, ON, Canada; [Bandak, Faris; Ling, Geoffrey] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Neurol, Bethesda, MD 20814 USA; [Bandak, Faris] Integrated Serv Grp Inc, Potomac, MD USA		Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Kagan, Valerian E./0000-0002-7245-1885; Jackson, Edwin/0000-0002-8101-6009; Shellington, David/0000-0001-6708-6978	DARPA PREVENT [N660001-10C2124]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM113746] Funding Source: NIH RePORTER	This work was supported by DARPA PREVENT (N660001-10C2124). The authors thank Keri Janesko-Feldman and Jeremy Henchir for their technical support. The authors thank Marci Provins and Fran Mistrick for their help with manuscript preparation. Microarray data were generated by the Genomics Core Laboratory, University of Pittsburgh, and statistical analyses were performed by the GPCL-Bioinformatics Analysis Core (GPCL-BAC), University of Pittsburgh. The authors thank Dr. James Lyons-Weiler for his valuable assistance. The views, opinions, and/or findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies either expressed or implied of DARPA or the DoD. This work has been approved for public release, distribution unlimited.	Andre R, 2005, NEUROREPORT, V16, P153, DOI 10.1097/00001756-200502080-00017; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI [10.1089/neu.2008.0898, 10.1089/neu.2009-0898]; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Belikova NA, 2011, J NEUROSCI METH, V201, P185, DOI 10.1016/j.jneumeth.2011.08.001; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2010, Front Neurol, V1, P151, DOI 10.3389/fneur.2010.00151; Clahsen T, 2008, J LEUKOCYTE BIOL, V84, P1521, DOI 10.1189/jlb.0308178; Cohen I, 2010, P NATL ACAD SCI USA, V107, P2574, DOI 10.1073/pnas.0915018107; de Lanerolle NC, 2011, J NEUROPATH EXP NEUR, V70, P1046, DOI 10.1097/NEN.0b013e318235bef2; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607; Elder GA, 2012, J NEUROTRAUM, V29, P2564, DOI 10.1089/neu.2012.2510; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gao WM, 2007, J NEUROTRAUM, V24, P43, DOI 10.1089/neu.2006.0061; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hulse RE, 2004, J NEUROSCI METH, V136, P87, DOI 10.1016/j.jneumeth.2003.12.023; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Jordan BR, 2004, BIOESSAYS, V26, P1236, DOI 10.1002/bies.20128; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kochanek AR, 2006, DEV NEUROSCI-BASEL, V28, P410, DOI 10.1159/000094167; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Kwon Sook-Kyung C, 2011, Front Neurol, V2, P12, DOI 10.3389/fneur.2011.00012; Lemke R, 1999, GLIA, V27, P75, DOI 10.1002/(SICI)1098-1136(199907)27:1<75::AID-GLIA8>3.0.CO;2-J; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Long Y, 2003, J NEUROSCI RES, V71, P710, DOI 10.1002/jnr.10524; Lu J, 2012, J NEUROTRAUM, V29, P1434, DOI 10.1089/neu.2010.1591; Mac Donald C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055823; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Morey R.A., 2012, HUM BRAIN MAPP, DOI [10.1002/hbm.22117, DOI 10.1002/HBM.22117.[]; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Patel Satish, 2004, Appl Bioinformatics, V3, P49; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Scheibel RS, 2012, J INT NEUROPSYCH SOC, V18, P89, DOI 10.1017/S1355617711001433; Svetlov Stanislav I, 2012, Front Neurol, V3, P15, DOI 10.3389/fneur.2012.00015; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Thornton P, 2010, BLOOD, V115, P3632, DOI 10.1182/blood-2009-11-252643; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Waxham MN, 1996, J CEREBR BLOOD F MET, V16, P1, DOI 10.1097/00004647-199601000-00001; Yaguchi M, 2008, J NEUROSCI RES, V86, P1972, DOI 10.1002/jnr.21658; Yoshiya K, 2003, J NEUROTRAUM, V20, P1147, DOI 10.1089/089771503770802844; Zalewska T, 1996, ACTA NEUROBIOL EXP, V56, P41; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	63	70	71	1	34	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2013	30	11					920	937		10.1089/neu.2013.2862			18	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	166WD	WOS:000320589300003	23496248	Green Published			2022-02-06	
J	Sareen, J; Erickson, J; Medved, MI; Asmundson, GJG; Enns, MW; Stein, M; Leslie, W; Doupe, M; Logsetty, S				Sareen, Jitender; Erickson, Julie; Medved, Maria I.; Asmundson, Gordon J. G.; Enns, Murray W.; Stein, Murray; Leslie, William; Doupe, Malcolm; Logsetty, Sarvesh			RISK FACTORS FOR POST-INJURY MENTAL HEALTH PROBLEMS	DEPRESSION AND ANXIETY			English	Article						injury; burns; risk factor; posttraumatic stress; adjustment; anxiety; biopsychosocial; mental health	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MAJOR BURN INJURY; BODY-IMAGE DISSATISFACTION; MOTOR-VEHICLE ACCIDENTS; SPINAL-CORD-INJURY; PSYCHIATRIC MORBIDITY; HEART-RATE; FOLLOW-UP; FUNCTIONAL OUTCOMES	Serious nonfatal physical injuries and burns are common occurrences that can have substantial implications for personal, social, and occupational functioning. Such injuries are frequently associated with significant mental health issues, and compromised quality of life and well-being. The purpose of this review is to summarize the current literature on physical, psychological, and social risk factors for mental health issues post-injury and to contextualize findings using Engel's biopsychosocial framework. We distinguish between pre-injury, injury-related, and post-injury risk factors for mental health problems. Female sex, history of mental health problems or trauma, type of injury, and level of pain are among the strong risk factors for mental health problems post-injury. We highlight inconsistent findings in the literature, identify directions for future research, and explore the implications of the risk factors identified for treatment and prevention.	[Sareen, Jitender; Enns, Murray W.] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; [Sareen, Jitender; Erickson, Julie; Medved, Maria I.] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada; [Sareen, Jitender; Doupe, Malcolm] Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; [Asmundson, Gordon J. G.] Univ Regina, Dept Psychol, Regina, SK S4S 0A2, Canada; [Stein, Murray] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Leslie, William; Logsetty, Sarvesh] Univ Manitoba, Dept Surg, Winnipeg, MB R3T 2N2, Canada		Sareen, J (corresponding author), PZ430-771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada.	sareen@cc.umanitoba.ca		Enns, Murray/0000-0002-8375-0151; Leslie, William/0000-0002-1056-1691; Sareen, Jitender/0000-0001-8573-6495	Manitoba Medical Services Foundation; Health Sciences Foundation; Manitoba Health Research Council Chair; Manitoba Health Research Council Chair award	Contract grant sponsors: Manitoba Medical Services Foundation, Health Sciences Foundation, Manitoba Health Research Council Chair.; Preparation of this article was supported by grants from Manitoba Medical Services Foundation, Health Sciences Foundation, and Manitoba Health Research Council Chair award.	Asmundson GJG, 2002, CAN J PSYCHIAT, V47, P930, DOI 10.1177/070674370204701004; Association A. P., 1994, DIAGN STAT MAN MENT; Birmes P, 2003, AM J PSYCHIAT, V160, P1337, DOI 10.1176/appi.ajp.160.7.1337; Blanchard EB, 2002, J TRAUMA STRESS, V15, P199, DOI 10.1023/A:1015299126858; Blaszczynski A, 1998, COMPR PSYCHIAT, V39, P111, DOI 10.1016/S0010-440X(98)90069-4; Breslau Naomi, 2002, J Gend Specif Med, V5, P34; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 2008, J CLIN PSYCHIAT, V69, P923, DOI 10.4088/JCP.v69n0606; Cairns DM, 1996, ARCH PHYS MED REHAB, V77, P329, DOI 10.1016/S0003-9993(96)90079-9; Cameron CM, 2008, BRAIN INJURY, V22, P437, DOI 10.1080/02699050802060621; Chilcoat HD, 1998, ARCH GEN PSYCHIAT, V55, P913, DOI 10.1001/archpsyc.55.10.913; Cloitre M, 2009, J TRAUMA STRESS, V22, P399, DOI 10.1002/jts.20444; Collimore KC, 2010, DEPRESS ANXIETY, V27, P1017, DOI [10.1002/da.20728, 10.1002/da.20771, 10.1002/da.20759]; Duckworth MP, 2005, CLIN J PAIN, V21, P251, DOI 10.1097/00002508-200505000-00008; Dyster-Aas J, 2008, J TRAUMA, V64, P1349, DOI 10.1097/TA.0b013e318047e005; Edwards RR, 2007, ARCH PHYS MED REHAB, V88, pS36, DOI 10.1016/j.apmr.2007.05.031; ENGEL GL, 1981, J MED PHILOS, V6, P101, DOI 10.1093/jmp/6.2.101; Esselman PC, 2007, ARCH PHYS MED REHAB, V88, pS50, DOI 10.1016/j.apmr.2007.09.009; Fauerbach JA, 2001, J BURN CARE REHABIL, V22, P26, DOI 10.1097/00004630-200101000-00007; Fauerbach JA, 2000, PSYCHOSOM MED, V62, P576, DOI 10.1097/00006842-200007000-00017; Fauerbach JA, 2000, J NERV MENT DIS, V188, P510, DOI 10.1097/00005053-200008000-00006; Fauerbach JA, 2007, PSYCHOSOM MED, V69, P473, DOI 10.1097/psy.0b013e31806bf393; Friedman MJ, 2004, J NERV MENT DIS, V192, P42, DOI 10.1097/01.nmd.0000105999.57129.ee; Gill JM, 2009, PERSPECT PSYCHIATR C, V45, P262, DOI 10.1111/j.1744-6163.2009.00229.x; Han PP, 2011, J TRAUMA, V70, P923, DOI 10.1097/TA.0b013e31820cf03e; Hart T, 2012, ARCH PHYS MED REHAB, V93, P1343, DOI 10.1016/j.apmr.2012.03.036; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Holbrook TL, 2010, NEW ENGL J MED, V362, P110, DOI 10.1056/NEJMoa0903326; Information CIfH, 2006, NAT TRAUM REG REP MA; Kendler KS, 1997, BRIT J PSYCHIAT, V170, P541, DOI 10.1192/bjp.170.6.541; Kessler RC, 2005, NEW ENGL J MED, V352, P2515, DOI 10.1056/NEJMsa043266; Klein MB, 2007, J BURN CARE RES, V28, P84, DOI 10.1097/BCR.0b013E31802C888E; Klose M, 2004, Arch Womens Ment Health, V7, P133, DOI 10.1007/s00737-004-0047-7; Koenen KC, 2003, J CONSULT CLIN PSYCH, V71, P980, DOI 10.1037/0022-006X.71.6.980; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; Mayou RA, 2002, BEHAV RES THER, V40, P665, DOI 10.1016/S0005-7967(01)00069-9; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McKibben JBA, 2008, J BURN CARE RES, V29, P22, DOI 10.1097/BCR.0b013e31815f59c4; McLaughlin KA, 2012, BRIT J PSYCHIAT, V200, P290, DOI 10.1192/bjp.bp.111.101253; McNally RJ, 2003, BIOL PSYCHIAT, V53, P779, DOI 10.1016/S0006-3223(02)01663-3; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; Norton PJ, 2004, PAIN, V111, P218, DOI 10.1016/j.pain.2004.06.018; O'Donnell ML, 2008, CLIN PSYCHOL REV, V28, P387, DOI 10.1016/j.cpr.2007.07.008; O'Donnell ML, 2007, PSYCHOSOM MED, V69, P256, DOI 10.1097/PSY.0b013e3180417d04; O'Donnell ML, 2010, J TRAUMA, V69, P627, DOI 10.1097/TA.0b013e3181bc0923; O'Donnell ML, 2008, J CONSULT CLIN PSYCH, V76, P923, DOI 10.1037/a0012918; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Oakley PA, 2004, INJURY, V35, P379, DOI 10.1016/S0020-1383(03)00096-2; Ozer E. J., 2008, PSYCHOL TRAUMA-US, DOI [10.1037/1942-9681.S.1.3, DOI 10.1037/1942-9681.S.1.3]; Pagura J, 2010, J PSYCHIATR RES, V44, P1190, DOI 10.1016/j.jpsychires.2010.04.016; Park SY, 2008, BURNS, V34, P24, DOI 10.1016/j.burns.2007.03.012; Pole Nnamdi, 2005, Cultur Divers Ethnic Minor Psychol, V11, P144, DOI 10.1037/1099-9809.11.2.144; Richter JC, 2006, PSYCHOSOMATICS, V47, P223, DOI 10.1176/appi.psy.47.3.223; Roberts NP, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007944.pub2; Shalev AY, 2012, ARCH GEN PSYCHIAT, V69, P166, DOI 10.1001/archgenpsychiatry.2011.127; Smith MT, 2008, PAIN, V138, P497, DOI 10.1016/j.pain.2008.01.028; Stein MB, 2000, BEHAV RES THER, V38, P619, DOI 10.1016/S0005-7967(99)00098-4; Stein MB, 2002, JAMA-J AM MED ASSOC, V288, P1513, DOI 10.1001/jama.288.12.1513; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Street AE, 2005, J TRAUMA STRESS, V18, P245, DOI 10.1002/jts.20026; Suliman S, 2009, COMPR PSYCHIAT, V50, P121, DOI 10.1016/j.comppsych.2008.06.006; Sutherland AG, 2003, CYTOKINE, V24, P219, DOI 10.1016/j.cyto.2003.09.004; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; ter Smitten MH, 2011, BURNS, V37, P753, DOI 10.1016/j.burns.2010.12.018; Thombs BD, 2007, GEN HOSP PSYCHIAT, V29, P14, DOI 10.1016/j.genhosppsych.2006.09.002; Thombs BD, 2006, GEN HOSP PSYCHIAT, V28, P494, DOI 10.1016/j.genhosppsych.2006.08.010; Van Loey NEE, 2008, BURNS, V34, P1082, DOI 10.1016/j.burns.2008.01.012; Van Loey NEE, 2003, AM J CLIN DERMATOL, V4, P245, DOI 10.2165/00128071-200304040-00004; Wiechman SA, 2004, BRIT MED J, V329, P391, DOI 10.1136/bmj.329.7462.391; Wiechman SA, 2001, J BURN CARE REHABIL, V22, P417, DOI 10.1097/00004630-200111000-00012; Wisely JA, 2010, BURNS, V36, P183, DOI 10.1016/j.burns.2009.08.008; Young E, 2010, MOL PSYCHIATR, V15, P23, DOI 10.1038/mp.2009.94; Zatzick D, 2004, ARCH GEN PSYCHIAT, V61, P498, DOI 10.1001/archpsyc.61.5.498; Zatzick DF, 2005, BIOL PSYCHIAT, V57, P91, DOI 10.1016/j.biopsych.2004.10.005; Zatzick D, 2008, ANN SURG, V248, P429, DOI 10.1097/SLA.0b013e318185a6b8; Zatzick DF, 2008, ARCH PEDIAT ADOL MED, V162, P642, DOI 10.1001/archpedi.162.7.642	79	70	74	1	25	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269			DEPRESS ANXIETY	Depress. Anxiety	APR	2013	30	4					321	327		10.1002/da.22077			7	Psychology, Clinical; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Psychiatry	126GJ	WOS:000317600800006	23408506				2022-02-06	
J	King, D; Brughelli, M; Hume, P; Gissane, C				King, Doug; Brughelli, Matt; Hume, Patria; Gissane, Conor			Concussions in amateur rugby union identified with the use of a rapid visual screening tool	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Vision; Eye movements; Sports-related concussion; King-Devick test	INJURIES; EPIDEMIOLOGY; RELIABILITY; SPORTS; LEAGUE; HEAD	Aim: To use the King-Devick (KD) test and Sports Concussion Assessment Tool 2 (SCAT2) in amateur rugby union players to identify witnessed and unrecognised episodes of concussion that occurred from match participation. Methods: A prospective observational cohort study was conducted on a premier club level amateur rugby union team during the 2012 competition in New Zealand. Every player completed a pre-competition questionnaire on concussion history, a baseline PCSS and two trials of the KD before they participated in any match activities. Results: For players reporting a concussion in the previous three years there was an average of 4.0 +/- 2.8 concussions per player. There were 22 concussive incidents recorded over the duration of the competition (46 per 1000 match hours). Five concussive incidents were witnessed (11 per 1000 match hours) and 17 unrecognised concussive incidents were identified with the KD (37 per 1000 match hours). Witnessed concussions recorded, on average, a longer KD on the day of injury (5.5 +/- 2.4 s) than unrecognised concussions (4.4 +/- 0.9 s) when compared with their baseline KD. Discussion: The KD was able to identify players that had not shown, or reported, any signs or symptoms of a concussion but who had meaningful head injury. The current rate of concussion reported was a ten-fold increase in previously reported concussion injury rates. This makes the KD suitable for rapid assessment in a limited time frame on the sideline such as a five-minute window to assess and review suspected concussed players in rugby union. (c) 2013 Elsevier B.V. All rights reserved.	[King, Doug; Brughelli, Matt; Hume, Patria] Auckland Univ Technol, Fac Hlth & Environm Sci, Sch Sport & Recreat, Sports Performance Res Inst New Zealand, Auckland, New Zealand; [Gissane, Conor] St Marys Univ Coll, Sch Sport Hlth & Appl Sci, Twickenham, Middx, England		King, D (corresponding author), Hutt Valley Dist Hlth Board, Emergency Dept, Private Bag 31-907, Lower Hutt, New Zealand.	dking@aut.ac.nz	Gissane, Conor/I-3661-2019; Hume, Patria Anne/P-1084-2017; Hume, Patria/AAN-5514-2021	Gissane, Conor/0000-0003-4677-3853; Hume, Patria Anne/0000-0003-1847-8128; Hume, Patria/0000-0003-1847-8128			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Borg G., 1998, BORGS PERCEIVED EXER; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; Eckner JT, 2010, CURR SPORT MED REP, V9, P8, DOI 10.1249/JSR.0b013e3181caa778; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Galetta KM, 2011, J NEUROL SCI, V309, P34, DOI 10.1016/j.jns.2011.07.039; Giza CC, 2001, J ATHL TRAINING, V36, P228; Heitger M., 2008, C P IEEE ENG MED BIO; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; King DA, 2009, J SCI MED SPORT, V12, P12, DOI 10.1016/j.jsams.2007.12.001; King D, 2012, J NEUROL SCI, V320, P16, DOI 10.1016/j.jns.2012.05.049; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; Moriarity JM, 2012, BRIT J SPORT MED, V46, P1011, DOI 10.1136/bjsports-2011-090893; Mujika I, 2009, J SPORT SCI, V27, P1581, DOI 10.1080/02640410903350281; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Spencer M, 2006, J SCI MED SPORT, V9, P181, DOI 10.1016/j.jsams.2005.05.001; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019	27	70	70	1	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2013	326	1-2					59	63		10.1016/j.jns.2013.01.012			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	128WA	WOS:000317799200010	23374885				2022-02-06	
J	Lingsma, H; Andriessen, TMJC; Haitsema, I; Horn, J; van der Naalt, J; Franschman, G; Maas, AIR; Vos, PE; Steyerberg, EW				Lingsma, Hester; Andriessen, Teuntje M. J. C.; Haitsema, Iain; Horn, Janneke; van der Naalt, Joukje; Franschman, Gaby; Maas, Andrew I. R.; Vos, Pieter E.; Steyerberg, Ewout W.			Prognosis in moderate and severe traumatic brain injury: External validation of the IMPACT models and the role of extracranial injuries	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; trauma; prognosis; prognostic model; validation	HEAD-INJURY; PREDICTION	BACKGROUND: Several prognostic models to predict outcome in traumatic brain injury (TBI) have been developed, but few are externally validated. We aimed to validate the International Mission on Prognosis and Analysis of Clinical Trials in TBI (IMPACT) prognostic models in a recent unselected patient cohort and to assess the additional prognostic value of extracranial injury. METHODS: The Prospective Observational COhort Neurotrauma (POCON) registry contains 508 patients with moderate or severe TBI, who were admitted in 2008 and 2009 to five trauma centers in the Netherlands. We predicted the probability of mortality and unfavorable outcome at 6 months after injury with the IMPACT prognostic models. We studied discrimination (area under the curve [AUC]) and calibration. We added the extracranial component of the Injury Severity Score (ISS) to the models and calculated the increase in AUC. RESULTS: The IMPACT models had an adequate discrimination in the POCON registry, with AUCs in the external validation between 0.85 and 0.90 for mortality and between 0.82 and 0.87 for unfavorable outcome. Observed outcomes agreed well with predicted outcomes. Adding extracranial injury slightly improved predictions in the overall population (unfavorable outcome: AUC increase of 0.002, p = 0.02; mortality: AUC increase of 0.000, p = 0.37) but more clearly in patients with moderate TBI (unfavorable outcome: AUC increase of 0.008, p < 0.01, mortality: AUC increase of 0.012, p = 0.02) and patients with minor computed tomographic result abnormalities (unfavorable outcome: AUC increase of 0.013, p < 0.01; mortality: AUC increase of 0.001, p = 0.08). CONCLUSION: The IMPACT models performed well in a recent series of TBI patients. We found some additional impact of extracranial injury on outcome, specifically in patients with less severe TBI or minor computed tomographic result abnormalities. (J Trauma Acute Care Surg. 2013;74: 639-646. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Lingsma, Hester; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Haitsema, Iain] Erasmus MC, Ctr Med Decis Making, Dept Neurosurg, Rotterdam, Netherlands; [Andriessen, Teuntje M. J. C.; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6525 ED Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9713 AV Groningen, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, Amsterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium		Lingsma, H (corresponding author), Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, POB 2040, NL-3000 CA Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Steyerberg, Ewout W/C-1509-2018; Maas, Andrew IR/C-5584-2013	Steyerberg, Ewout W/0000-0002-7787-0122; Maas, Andrew IR/0000-0003-1612-1264; van der Naalt, Joukje/0000-0001-9873-2418	Dutch Brain Foundation [HSN-07-01]	The POCON study is funded by the Dutch Brain Foundation (Hersenstichting, HSN-07-01). We thank Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, and Vivian de Ruijter for their help with the data collection. We thank Amon Heijne for his help with the development and maintenance of the POCON database and Carel Gosling (Trauma Unit AMC) for providing us with emergency department admission data.	Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Roozenbeek B, 2012, J NEUROTRAUM, P133; Roozenbeek B, 2012, CRIT CARE MED, V40, P1609, DOI 10.1097/CCM.0b013e31824519ce; Roozenbeek Bob, 2012, Clin Investig (Lond), V2, P153; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg, 2019, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; van Leeuwen N, 2012, NEUROSURGERY, V70, P811, DOI 10.1227/NEU.0b013e318235d640; Vergouwe Y, 2005, J CLIN EPIDEMIOL, V58, P475, DOI 10.1016/j.jclinepi.2004.06.017; Vergouwe Y, 2010, AM J EPIDEMIOL, V172, P971, DOI 10.1093/aje/kwq223	23	70	71	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2013	74	2					639	646		10.1097/TA.0b013e31827d602e			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	108UH	WOS:000316321200059	23354263	Green Published			2022-02-06	
J	Lindemer, ER; Salat, DH; Leritz, EC; McGlinchey, RE; Milberg, WP				Lindemer, Emily R.; Salat, David H.; Leritz, Elizabeth C.; McGlinchey, Regina E.; Milberg, William P.			Reduced cortical thickness with increased lifetime burden of PTSD in OEF/OIF Veterans and the impact of comorbid TBI	NEUROIMAGE-CLINICAL			English	Article						Posttraumatic stress disorder; Mild traumatic brain injury; Cortical thickness; Whole-brain analysis; Neuroimaging; Comorbidity	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; GRAY-MATTER VOLUME; DEFAULT-MODE; GEOMETRICALLY ACCURATE; COGNITIVE PERFORMANCE; NETWORK CONNECTIVITY; HIPPOCAMPAL VOLUME; CORTEX	Posttraumatic stress disorder (PTSD) and mild traumatic brain injury (mTBI) in military personnel is increasing dramatically following the OEF/OIF conflicts and is associated with alterations to brain structure. The present study examined the relationship between PTSD and cortical thickness, and its possible modification by mTBI, in a 104-subject OEF/OIF veteran cohort ranging in age from 20 to 62 years. For each participant, two T1-weighted scans were averaged to create high-resolution images for calculation of regional cortical thickness. PTSD symptoms were assessed using the Clinician Administered PTSD Scale (CAPS) and scores were derived based on the previous month's symptoms ("current") and a Cumulative Lifetime Burden of PTSD (CLB-P) reflecting the integral of CAPS scores across the lifetime. Mild TBI was diagnosed using the Boston Assessment of TBI-Lifetime (BAT-L). Results demonstrated a clear negative relationship between current PTSD severity and thickness in both postcentral gyri and middle temporal gyri. This relationship was stronger and more extensive when considering lifetime burden (CLB-P), demonstrating the importance of looking at trauma in the context of an individual's lifetime, rather than only at their current symptoms. Finally, interactions with current PTSD only and comorbid current PTSD and mTBI were found in several regions, implying an additive effect of lifetime PTSD and mTBI on cortical thickness. (C) 2013 The Authors. Published by Elsevier Inc.	[Lindemer, Emily R.; Salat, David H.; Leritz, Elizabeth C.; McGlinchey, Regina E.; Milberg, William P.] VA Boston Healthcare Syst, Translat Res Ctr TBI & Stress Disorders TRACTS, Boston, MA 02130 USA; [Salat, David H.; Leritz, Elizabeth C.] AA Martinos Ctr Biomed Imaging, Boston, MA USA; [McGlinchey, Regina E.; Milberg, William P.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Leritz, Elizabeth C.] Brigham & Womens Hosp, Div Aging, Boston, MA 02115 USA		Milberg, WP (corresponding author), VA Boston Healthcare Syst, TRACTS GRECC 182,150 S Huntington Ave, Boston, MA 02130 USA.	William_milberg@hms.harvard.edu	McGlinchey, Regina E/R-1971-2016		Translational Research Center for TBI and Stress Disorders (TRACTS); VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; VA Merit Review AwardUS Department of Veterans Affairs	This research was support by the Translational Research Center for TBI and Stress Disorders (TRACTS), a VA Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C) and VA Merit Review Award to Regina McGlinchey.	Ahmed F, 2012, NEUROPSYCHOBIOLOGY, V66, P174, DOI 10.1159/000339558; Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Atkinson M.P., 2009, MANAGE SCI, V55, P13; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1007/BF02105408; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Brands AMA, 2006, DIABETES, V55, P1800, DOI 10.2337/db05-1226; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Breslau N, 2002, CAN J PSYCHIAT, V47, P923, DOI 10.1177/070674370204701003; Breslau N, 2010, BEHAV RES THER, V48, P1063, DOI 10.1016/j.brat.2010.07.001; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Chao LL, 2012, NEUROREPORT, V23, P412, DOI 10.1097/WNR.0b013e328352025e; Cougle JR, 2009, BEHAV RES THER, V47, P1012, DOI 10.1016/j.brat.2009.07.014; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; De Bellis MD, 2006, BIOL PSYCHIAT, V60, P697, DOI 10.1016/j.biopsych.2006.04.035; Dickerson BC, 2008, NEUROIMAGE, V39, P10, DOI 10.1016/j.neuroimage.2007.08.042; Fennema-Notestine C, 2002, BIOL PSYCHIAT, V52, P1089, DOI 10.1016/S0006-3223(02)01413-0; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fortier C.B., 2012, J HEAD TRAUMA; Fortier CB, 2011, ALCOHOL CLIN EXP RES, V35, P2193, DOI 10.1111/j.1530-0277.2011.01576.x; Geuze E, 2008, NEUROIMAGE, V41, P675, DOI 10.1016/j.neuroimage.2008.03.007; Geuze E, 2007, PROG BRAIN RES, V167, P293, DOI 10.1016/S0079-6123(07)67026-5; Glover DA, 2006, PSYCHIATRY, V69, P191, DOI 10.1521/psyc.2006.69.3.191; Green B., 1996, MEASUREMENT STRESS T, P366; Gschwind M, 2012, CEREB CORTEX, V22, P1564, DOI 10.1093/cercor/bhr226; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hayes JP, 2011, J PSYCHIATR RES, V45, P660, DOI 10.1016/j.jpsychires.2010.10.007; HERMAN JL, 1989, AM J PSYCHIAT, V146, P490; Herringa R, 2012, PSYCHIAT RES-NEUROIM, V203, P139, DOI 10.1016/j.pscychresns.2012.02.005; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hooper LM, 2011, J LOSS TRAUMA, V16, P258, DOI 10.1080/15325024.2011.572035; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Johnson B, 2012, J NEUROTRAUM, V29, P2297, DOI 10.1089/neu.2011.2294; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kashdan TB, 2010, BEHAV THER, V41, P350, DOI 10.1016/j.beth.2009.09.003; Kerr KM, 2007, HIPPOCAMPUS, V17, P697, DOI 10.1002/hipo.20315; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroes MCW, 2011, J PSYCHIATR NEUROSCI, V36, P256, DOI 10.1503/jpn.100077; Lanius RA, 2010, ACTA PSYCHIAT SCAND, V121, P33, DOI 10.1111/j.1600-0447.2009.01391.x; Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039025; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; MALLOY PF, 1983, J CONSULT CLIN PSYCH, V51, P488, DOI 10.1037/0022-006X.51.4.488; MASON JW, 1986, J NERV MENT DIS, V174, P145, DOI 10.1097/00005053-198603000-00003; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McEwen BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/j.1749-6632.1999.tb08103.x; Morra L., 2011, INT NEUR SOC ANN M F; Nardo D, 2010, J PSYCHIATR RES, V44, P477, DOI 10.1016/j.jpsychires.2009.10.014; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Rubin DC, 2008, PSYCHOL REV, V115, P985, DOI 10.1037/a0013397; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shi CJ, 1999, J COMP NEUROL, V406, P299, DOI 10.1002/(SICI)1096-9861(19990412)406:3<299::AID-CNE2>3.0.CO;2-9; SKINNER HA, 1982, J STUD ALCOHOL, V43, P1157, DOI 10.15288/jsa.1982.43.1157; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Tate DF, 2012, BRAIN IMAGING BEHAV, V6, P103, DOI 10.1007/s11682-012-9185-0; Tavanti M, 2012, NEUROL SCI, V33, P59, DOI 10.1007/s10072-011-0659-4; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2009, J INT NEUROPSYCH SOC, V15, P826, DOI 10.1017/S1355617709990683; Whalley MG, 2013, BRAIN COGNITION, V81, P151, DOI 10.1016/j.bandc.2012.10.002; Woodward SH, 2006, BIOL PSYCHIAT, V59, P582, DOI 10.1016/j.biopsych.2005.07.033; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Yamasue H, 2003, P NATL ACAD SCI USA, V100, P9039, DOI 10.1073/pnas.1530467100; Yehuda R, 2007, J PSYCHIATR RES, V41, P435, DOI 10.1016/j.jpsychires.2005.12.002; Zhang J, 2011, PSYCHIAT RES-NEUROIM, V192, P84, DOI 10.1016/j.pscychresns.2010.09.001; Zhou YX, 2012, RADIOLOGY, V265, P882, DOI 10.1148/radiol.12120748	82	70	70	2	9	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2013	2						601	611		10.1016/j.nicl.2013.04.009			11	Neuroimaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V37LH	WOS:000209276800066	24179811	gold, Green Published			2022-02-06	
J	Ponsford, J				Ponsford, Jennie			Factors contributing to outcome following traumatic brain injury	NEUROREHABILITATION			English	Article						Traumatic brain injury; outcome; prediction	POSTTRAUMATIC AMNESIA DURATION; QUALITY-OF-LIFE; HEAD-INJURY; PSYCHOSOCIAL ADJUSTMENT; ALZHEIMERS-DISEASE; GENDER-DIFFERENCES; PSYCHIATRIC-DISORDERS; COGNITIVE RECOVERY; COPING STRATEGIES; PROGNOSTIC VALUE	BACKGROUND: Traumatic brain injury results in some distinctive patterns of cognitive, behavioural and physical impairment which impact significantly on independent living skills and participation in work or study, social and leisure activities and interpersonal relationships. There is, however, still considerable variability in outcome across individuals in each of the reported domains. This has led to a significant body of research examining factors associated with outcome. A range of injury-related, personal and social factors have been shown to influence survival, as well as cognitive, functional and employment outcome. METHODS: This paper reviews the factors associated with each of these aspects of outcome specifically injury-related factors, including neuroimaging findings, GCS and PTA, other injuries, and cognitive and behavioural impairments; demographic factors, including age, gender, genetic status, education, pre-injury IQ and employment status; and social factors including family and other social support, cultural factors, pre-injury psychiatric history and coping style. CONCLUSION: The paper identifies contributions and complex interrelationships of all of these factors to outcome following TBI. It concludes with a brief discussion of the implications of these factors for the rehabilitation process.	Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia		Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	Jennie.ponsford@monash.edu					Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; Alway Y, 2012, NEUROPSYCHOL REHABIL, V22, P374, DOI 10.1080/09602011.2011.648757; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Colantonio A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-102; CORKIN S, 1989, J NEUROSCI, V9, P3876; Corrigan JA, 2008, ARCH PHYS MED REHAB, V89, P912, DOI 10.1016/j.apmr.2007.12.027; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Czosnyka M, 2008, ACTA NEUROCHIR SUPPL, V102, P25, DOI 10.1007/978-3-211-85578-2_5; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; de Guise E, 2006, J HEAD TRAUMA REHAB, V21, P527, DOI 10.1097/00001199-200611000-00007; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Doctor JN, 2005, J INT NEUROPSYCH SOC, V11, P747, DOI 10.1017/S1355617705050836; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Eastvold AD, 2013, J HEAD TRAUMA REHAB, V28, P48, DOI 10.1097/HTR.0b013e31823c9317; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Folkman S., 1984, STRESS; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Kendall E, 2009, SOC SCI MED, V69, P947, DOI 10.1016/j.socscimed.2009.06.021; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kim YJ, 2011, J CLIN NURS, V20, P1518, DOI 10.1111/j.1365-2702.2010.03618.x; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Lannsjo M., 2012, EUROPEAN J NEUROLOGY, DOI [10.1111/j.1468-1331.2012.03813x, DOI 10.1111/J.1468-1331.2012.03813X]; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moore DW, 2010, NEUROPSYCHOL REHABIL, V20, P340, DOI 10.1080/09602010903250928; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Park JE, 2009, J KOREAN NEUROSURG S, V45, P90, DOI 10.3340/jkns.2009.45.2.90; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P1; Ponsford J., 2012, TRAUMATIC BRAIN INJU, V2nd Edition; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Ponsford J, 2010, BRAIN IMPAIR, V11, P253, DOI 10.1375/brim.11.3.253; Ponsford JL, 2008, INJURY, V39, P67, DOI 10.1016/j.injury.2007.08.028; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Poon WS, 2005, ACT NEUR S, V93, P207; Rapoport MJ, 2000, BRAIN INJURY, V14, P749; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Saltapidas H, 2008, BRAIN IMPAIR, V9, P1, DOI 10.1375/brim.9.1.1; Saltapidas H, 2007, J HEAD TRAUMA REHAB, V22, P132, DOI 10.1097/01.HTR.0000265101.75177.8d; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Schonberger M, 2009, J NEUROTRAUM, V26, P2157, DOI 10.1089/neu.2009.0939; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Senathi-Raja D, 2010, J HEAD TRAUMA REHAB, V25, P330, DOI 10.1097/HTR.0b013e3181ccc893; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Senathi-Raja D, 2009, J REHABIL MED, V41, P666, DOI 10.2340/16501977-0396; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Slewa-Younan S, 2008, BRAIN INJURY, V22, P183, DOI 10.1080/02699050801888808; Son AHPWV, 2007, CLIN REHABIL, V21, P1024, DOI 10.1177/0269215507077603; Soo CA., 2005, BRAIN IMPAIR, V6, P75, DOI [DOI 10.1375/BRIM.2005.6.2.75, 10.1375/brim.2005.6.2.75]; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Stein DM, 2011, NEUROCRIT CARE, V14, P200, DOI 10.1007/s12028-010-9496-1; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Tasaki O, 2009, J TRAUMA, V66, P304, DOI 10.1097/TA.0b013e31815d9d3f; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Wolters G, 2010, NEUROPSYCHOL REHABIL, V20, P587, DOI 10.1080/09602011003683836; Wolters Gregorio G., J HEAD TRAU IN PRESS; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Wood RL, 2013, J HEAD TRAUMA REHAB, V28, P98, DOI 10.1097/HTR.0b013e3182426029; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	128	70	71	0	53	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2013	32	4					803	815		10.3233/NRE-130904			13	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	184QF	WOS:000321907100011	23867406				2022-02-06	
J	Tweedie, D; Rachmany, L; Rubovitch, V; Lehrmann, E; Zhang, YQ; Becker, KG; Perez, E; Miller, J; Hoffer, BJ; Greig, NH; Pick, CG				Tweedie, David; Rachmany, Lital; Rubovitch, Vardit; Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.; Perez, Evelyn; Miller, Jonathan; Hoffer, Barry J.; Greig, Nigel H.; Pick, Chaim G.			Exendin-4, a glucagon-like peptide-1 receptor agonist prevents mTBI-induced changes in hippocampus gene expression and memory deficits in mice	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury (mTBI); Glucagon-like peptide-1; Exendin-4; Gene expression; Novel object recognition; Alzheimer's disease	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; NECROSIS-FACTOR-ALPHA; CELL-CYCLE; ALZHEIMERS-DISEASE; AMYLOID-BETA; MOUSE MODEL; A-BETA; COGNITIVE DEFICITS; BINDING-SITES	Traumatic brain injury (TBI) is a global problem reaching near epidemic numbers that manifests clinically with cognitive problems that decades later may result in dementias like Alzheimer's disease (AD). Presently, little can be done to prevent ensuing neurological dysfunctions by pharmacological means. Recently, it has become apparent that several CNS diseases share common terminal features of neuronal cell death. The effects of exendin-4 (Ex-4), a neuroprotective agent delivered via a subcutaneous micro-osmotic pump, were examined in the setting of mild TBI (mTBI). Utilizing a model of mTBI, where cognitive disturbances occur over time, animals were subjected to four treatments: sham; Ex-4; mTBI and Ex-4/mTBI. mTBI mice displayed deficits in novel object recognition, while Ex-4/mTBI mice performed similar to sham. Hippocampal gene expression, assessed by gene array methods, showed significant differences with little overlap in co-regulated genes between groups. Importantly, changes in gene expression induced by mTBI, including genes associated with AD were largely prevented by Ex-4. These data suggest a strong beneficial action of Ex-4 in managing secondary events induced by a traumatic brain injury. (c) 2012 Elsevier Inc. All rights reserved.	[Tweedie, David] NIA, Translat Gerontol Branch, Intramural Res Program, Drug Design & Dev Sect,Lab Neurosci,NIH, Baltimore, MD 21224 USA; [Rachmany, Lital; Rubovitch, Vardit; Pick, Chaim G.] Tel Aviv Univ, Sackler Sch Med, Dept Anat & Anthropol, IL-69978 Tel Aviv, Israel; [Lehrmann, Elin; Zhang, Yongqing; Becker, Kevin G.] NIA, Gene Express & Genom Unit, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Perez, Evelyn] NIA, Lab Expt Gerontol, Intramural Res Program, NIH, Baltimore, MD 21224 USA; [Miller, Jonathan; Hoffer, Barry J.] Case Western Reserve Univ, Sch Med, Dept Neurosurg, Cleveland, OH 44106 USA		Tweedie, D (corresponding author), NIA, Translat Gerontol Branch, Intramural Res Program, Drug Design & Dev Sect,Lab Neurosci,NIH, BRC Room 05C220,251 Bayview Blvd, Baltimore, MD 21224 USA.	tweedieda@grc.nia.nih.gov; litalrac@post.tau.ac.il; rubovitc@post.tau.ac.il; elehrman@mail.nih.gov; zhangyon@grc.nia.nih.gov; BeckerK@grc.nia.nih.gov; perezev@grc.nia.nih.gov; Jonathan.Miller@UHhospitals.org; bjh82@case.edu; greign@grc.nia.nih.gov; pickc@post.tau.ac.il		Becker, Kevin/0000-0002-6794-6656; Lehrmann, Elin/0000-0002-9869-9475; Miller, Jonathan/0000-0001-5441-1751	Sackler School of Medicine, Tel-Aviv University; Intramural Research Program of the National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Intramural Research Program of the National Institute on Drug Abuse, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [ZIAAG000333, ZIAAG000311, ZICAG000616] Funding Source: NIH RePORTER	This research was supported in part by the Sackler School of Medicine, Tel-Aviv University, and the Intramural Research Programs of both the National Institute on Aging and National Institute on Drug Abuse, National Institutes of Health.	Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974; Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054; Bak AM, 2011, EXPERT OPIN THER TAR, V15, P1153, DOI 10.1517/14728222.2011.600691; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Belsham DD, 2009, FASEB J, V23, P4256, DOI 10.1096/fj.09-133454; Bennin DA, 2002, J BIOL CHEM, V277, P27449, DOI 10.1074/jbc.M111693200; Bertilsson G, 2008, J NEUROSCI RES, V86, P326, DOI 10.1002/jnr.21483; Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Chung LTK, 2009, BIOCHEM BIOPH RES CO, V390, P613, DOI 10.1016/j.bbrc.2009.10.015; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Currais A, 2009, AGING-US, V1, P363, DOI 10.18632/aging.100045; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; Darsalia V, 2012, CLIN SCI, V122, P473, DOI 10.1042/CS20110374; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Drucker DJ, 2008, LANCET, V372, P1240, DOI 10.1016/S0140-6736(08)61206-4; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.278.16.1349; Faul M, 2010, TRAUMATIC BRAIN INJU; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fernando RN, 2011, P NATL ACAD SCI USA, V108, P5837, DOI 10.1073/pnas.1014993108; Gibson CJ, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-38; GOKE R, 1995, NEUROENDOCRINOLOGY, V62, P130, DOI 10.1159/000126997; GOKE R, 1995, EUR J NEUROSCI, V7, P2294, DOI 10.1111/j.1460-9568.1995.tb00650.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Griffioen KJ, 2011, CARDIOVASC RES, V89, P72, DOI 10.1093/cvr/cvq271; Guzowski JF, 1999, NAT NEUROSCI, V2, P1120, DOI 10.1038/16046; Hamilton A, 2011, J NEUROSCI RES, V89, P481, DOI 10.1002/jnr.22565; Hayes MR, 2008, ENDOCRINOLOGY, V149, P4059, DOI 10.1210/en.2007-1743; Holscher C, 2010, VITAM HORM, V84, P331, DOI [10.1016/S0083-6729(10)84005-1, 10.1016/B978-0-12-381517-0.00013-8]; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holst JJ, 2011, CURR MED RES OPIN, V27, P547, DOI 10.1185/03007995.2010.549466; Isacson R, 2011, EUR J PHARMACOL, V650, P249, DOI 10.1016/j.ejphar.2010.10.008; Israelsson C, 2009, J NEUROTRAUM, V26, P1307, DOI [10.1089/neu.2008.0676, 10.1089/neu.2008-0676]; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Jordan-Sciutto Kelly L., 1999, J Alzheimers Dis, V1, P409; Kastin AJ, 2003, INT J OBESITY, V27, P313, DOI 10.1038/sj.ijo.0802206; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Lahiri DK, 2004, NEUROBIOL AGING, V25, P651, DOI 10.1016/j.neurobiolaging.2003.12.024; Li H, 2010, NEUROSCI LETT, V486, P38, DOI 10.1016/j.neulet.2010.09.040; Li YZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032008; Li YZ, 2010, J NEUROCHEM, V113, P1621, DOI 10.1111/j.1471-4159.2010.06731.x; Li YZ, 2010, J ALZHEIMERS DIS, V19, P1205, DOI 10.3233/JAD-2010-1314; Li YZ, 2009, P NATL ACAD SCI USA, V106, P1285, DOI 10.1073/pnas.0806720106; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Liu XX, 2005, NAT NEUROSCI, V8, P1179, DOI 10.1038/nn1522; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin B, 2009, DIABETES, V58, P318, DOI 10.2337/db08-0799; Martinez-Gac L, 2004, MOL CELL BIOL, V24, P2181, DOI 10.1128/MCB.24.5.2181-2189.2004; McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Messier C, 1997, NEUROBIOL LEARN MEM, V67, P172, DOI 10.1006/nlme.1996.3755; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morita N, 1996, J NEUROSCI, V16, P5961; OShea D, 1996, NEUROREPORT, V7, P830, DOI 10.1097/00001756-199602290-00035; Pan WH, 2003, EXP BRAIN RES, V149, P195, DOI 10.1007/s00221-002-1355-7; Perry T, 2003, TRENDS PHARMACOL SCI, V24, P377, DOI 10.1016/S0165-6147(03)00160-3; Perry T, 2003, J NEUROSCI RES, V72, P603, DOI 10.1002/jnr.10611; Perry T, 2007, EXP NEUROL, V203, P293, DOI 10.1016/j.expneurol.2006.09.028; Rachmany L., 2012, AGE DORDR; Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF; Russo I, 2011, CELL CYCLE, V10, P2568, DOI 10.4161/cc.10.15.15946; Russo I, 2011, J NEUROCHEM, V116, P947, DOI 10.1111/j.1471-4159.2010.07168.x; Sadaka F, 2012, BRAIN INJURY, V26, P899, DOI 10.3109/02699052.2012.661120; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Salcedo I, 2012, BRIT J PHARMACOL, V166, P1586, DOI 10.1111/j.1476-5381.2012.01971.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Sultana R, 2007, NEUROCHEM RES, V32, P655, DOI 10.1007/s11064-006-9123-x; Tashlykov V, 2009, J MOL NEUROSCI, V37, P16, DOI 10.1007/s12031-008-9094-2; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Tweedie D, 2007, J NEUROSCI RES, V85, P805, DOI 10.1002/jnr.21160; Uryu K, 2003, EXP NEUROL, V184, P214, DOI 10.1016/S0014-4886(03)00245-0; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Zhong N, 2009, CURR ALZHEIMER RES, V6, P415, DOI 10.2174/156720509789207921; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	84	70	71	0	24	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2013	239						170	182		10.1016/j.expneurol.2012.10.001			13	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	073TH	WOS:000313765000021	23059457	Green Accepted			2022-02-06	
J	Wright, RM; Post, A; Hoshizaki, B; Ramesh, KT				Wright, Rika M.; Post, Andrew; Hoshizaki, Blaine; Ramesh, Kaliat T.			A Multiscale Computational Approach to Estimating Axonal Damage under Inertial Loading of the Head	JOURNAL OF NEUROTRAUMA			English	Article						axonal strain; DAI; FE model; traumatic brain injury	IN-VITRO; BRAIN RESPONSES; INJURY; MODELS; FOOTBALL; CRITERIA; IMPACTS; TRAUMA	A computational modeling framework is developed to estimate the location and degree of diffuse axonal injury (DAI) under inertial loading of the head. DAI is one of the most common pathological features of traumatic brain injury and is characterized by damage to the neural axons in the white matter regions of the brain. We incorporate the microstructure of the white matter (i.e., the fiber orientations and fiber dispersion) through the use of diffusion tensor imaging (DTI), and model the white matter with an anisotropic, hyper-viscoelastic constitutive model. The extent of DAI is estimated using an axonal strain injury criterion. A novel injury analysis method is developed to quantify the degree of axonal damage in the fiber tracts of the brain and identify the tracts that are at the greatest risk for functional failure. Our modeling framework is applied to analyze DAI in a real-life ice hockey incident that resulted in concussive injury. To simulate the impact, two-dimensional finite element (FE) models of the head were constructed from detailed MRI and DTI data and validated using available human head experimental data. Acceleration loading curves from accident reconstruction data were then applied to the FE models. The rotational (rather than translational) accelerations were shown to dominate the injury response, which is consistent with previous studies. Through this accident reconstruction, we demonstrate a conceptual framework to estimate the degree of axonal injury in the fiber tracts of the human brain, enabling the future development of relationships between computational simulation and neurocognitive impairment.	[Wright, Rika M.; Ramesh, Kaliat T.] Johns Hopkins Univ, Dept Mech Engn, Baltimore, MD 21218 USA; [Post, Andrew; Hoshizaki, Blaine] Univ Ottawa, Dept Human Kinet, Neurotrauma Impact Sci Lab, Ottawa, ON, Canada		Wright, RM (corresponding author), Johns Hopkins Univ, Dept Mech Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	rika@jhu.edu	Ramesh, KT/D-5451-2009	Ramesh, KT/0000-0003-2659-4698; Post, Andrew/0000-0002-5960-5552	National Science FoundationNational Science Foundation (NSF); Center for Advanced Metallic and Ceramic Systems	We gratefully acknowledge Dr. Susumu Mori at the Johns Hopkins University School of Medicine for providing the medical imaging data used in this study, and Dr. Reuben Kraft at the Army Research Laboratory (ARL) for providing access to ARL's High Performance Computing Systems. This work was supported by a National Science Foundation Graduate Research Fellowship and by the Center for Advanced Metallic and Ceramic Systems. Dr. Wright developed the modeling framework, conducted the computational analysis, and prepared the manuscript, with assistance and advice on formulation from her doctoral advisor, Dr. Ramesh. Mr. Post provided the accelerometer data and provided clarification on the accident reconstruction procedure, and Dr. Hoshizaki provided insight on applications.	Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Bammer R, 2003, EUR J RADIOL, V45, P223, DOI 10.1016/S0720-048X(02)00311-X; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chatelin S, 2011, J MECH BEHAV BIOMED, V4, P1905, DOI 10.1016/j.jmbbm.2011.06.007; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Cloots RJH, 2012, J MECH BEHAV BIOMED, V5, P41, DOI 10.1016/j.jmbbm.2011.09.012; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Colgan NC, 2010, PROG BIOPHYS MOL BIO, V103, P304, DOI 10.1016/j.pbiomolbio.2010.09.008; Deck C, 2008, INT J CRASHWORTHINES, V13, P667, DOI 10.1080/13588260802411523; El Sayed T, 2008, COMPUT METHOD APPL M, V197, P4692, DOI 10.1016/j.cma.2008.06.006; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Feist F., 2009, 21 INT C ENH SAF VEH, P1; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gasser TC, 2006, J R SOC INTERFACE, V3, P15, DOI 10.1098/rsif.2005.0073; Goldberg II, 2006, NEURON, V50, P329, DOI 10.1016/j.neuron.2006.03.015; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Itoh S., 2002, 12 INT DET S SAN DIE; Karnath HO, 2001, NATURE, V411, P950, DOI 10.1038/35082075; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Kraft RH, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002619; Kyriacou SK, 2002, BIOMECH MODEL MECHAN, V1, P151, DOI 10.1007/s10237-002-0013-0; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Merodio J, 2005, INT J NONLIN MECH, V40, P213, DOI 10.1016/j.ijnontinmec.2004.05.003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Post A., 2011, COMPUT METHODS BIOME; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raul JS, 2008, INT J LEGAL MED, V122, P359, DOI 10.1007/s00414-008-0248-0; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Tamura A., 2006, J BIOMECH SCI ENG, V1, P304; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; van Dommelen J.A., 2012, BIOMECH MODEL MECHAN; van Dommelen J.A.W., 2008, J BIOMECH ENG, V130, P663; Velardi F, 2006, BIOMECH MODEL MECHAN, V5, P53, DOI 10.1007/s10237-005-0007-9; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Voo L, 1996, MED BIOL ENG COMPUT, V34, P375, DOI 10.1007/BF02520009; Walsh ES, 2011, SPORTS ENG, V13, P135, DOI 10.1007/s12283-011-0060-9; Ward CC., 1977, INTRACRANIAL PRESSUR; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; Wittek A, 2003, JSME INT J C-MECH SY, V46, P1388, DOI 10.1299/jsmec.46.1388; Wright RM, 2012, BIOMECH MODEL MECHAN, V11, P245, DOI 10.1007/s10237-011-0307-1; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zhang J, 2011, J BIOMECH, V44, P1909, DOI 10.1016/j.jbiomech.2011.04.034; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhang YJ, 2010, NEUROIMAGE, V52, P1289, DOI 10.1016/j.neuroimage.2010.05.049	60	70	72	1	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					102	118		10.1089/neu.2012.2418			17	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000006	22992118				2022-02-06	
J	Reis, PA; Estato, V; da Silva, TI; d'Avila, JC; Siqueira, LD; Assis, EF; Bozza, PT; Bozza, FA; Tibirica, EV; Zimmerman, GA; Castro-Faria-Neto, HC				Reis, Patricia A.; Estato, Vanessa; da Silva, Tathiany I.; d'Avila, Joana C.; Siqueira, Luciana D.; Assis, Edson F.; Bozza, Patricia T.; Bozza, Fernando A.; Tibirica, Eduardo V.; Zimmerman, Guy A.; Castro-Faria-Neto, Hugo C.			Statins Decrease Neuroinflammation and Prevent Cognitive Impairment after Cerebral Malaria	PLOS PATHOGENS			English	Article							SEVERE FALCIPARUM-MALARIA; TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1; IN-VIVO; CEREBROSPINAL-FLUID; MALAWIAN CHILDREN; SEPSIS; ATORVASTATIN; PATHOGENESIS; DYSFUNCTION	Cerebral malaria (CM) is the most severe manifestation of Plasmodium falciparum infection in children and non-immune adults. Previous work has documented a persistent cognitive impairment in children who survive an episode of CM that is mimicked in animal models of the disease. Potential therapeutic interventions for this complication have not been investigated, and are urgently needed. HMG-CoA reductase inhibitors (statins) are widely prescribed for cardiovascular diseases. In addition to their effects on the inhibition of cholesterol synthesis, statins have pleiotropic immunomodulatory activities. Here we tested if statins would prevent cognitive impairment in a murine model of cerebral malaria. Six days after infection with Plasmodium berghei ANKA (PbA) mice displayed clear signs of CM and were treated with chloroquine, or chloroquine and lovastatin. Intravital examination of pial vessels of infected animals demonstrated a decrease in functional capillary density and an increase in rolling and adhesion of leukocytes to inflamed endothelium that were reversed by treatment with lovastatin. In addition, oedema, ICAM-1, and CD11b mRNA levels were reduced in lovastatin-treated PbA-infected mice brains. Moreover, HMOX-1 mRNA levels are enhanced in lovastatin-treated healthy and infected brains. Oxidative stress and key inflammatory chemokines and cytokines were reduced to non-infected control levels in animals treated with lovastatin. Fifteen days post-infection cognitive dysfunction was detected by a battery of cognition tests in animals rescued from CM by chloroquine treatment. In contrast, it was absent in animals treated with lovastatin and chloroquine. The outcome was similar in experimental bacterial sepsis, suggesting that statins have neuroprotective effects in severe infectious syndromes in addition to CM. Statin treatment prevents neuroinflammation and blood brain barrier dysfunction in experimental CM and related conditions that are associated with cognitive sequelae, and may be a valuable adjuvant therapeutic agent for prevention of cognitive impairment in patients surviving an episode of CM.	[Reis, Patricia A.; da Silva, Tathiany I.; d'Avila, Joana C.; Siqueira, Luciana D.; Assis, Edson F.; Bozza, Patricia T.; Castro-Faria-Neto, Hugo C.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil; [Estato, Vanessa; Tibirica, Eduardo V.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Invest Cardiovasc, Rio De Janeiro, RJ, Brazil; [Bozza, Fernando A.] Fundacao Oswaldo Cruz, Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, RJ, Brazil; [Zimmerman, Guy A.] Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT USA		Reis, PA (corresponding author), Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Imunofarmacol, Rio De Janeiro, RJ, Brazil.	reispa@gmail.com; reispa@gmail.com	Estato, Vanessa/AAJ-9060-2020; Bozza, Patricia T./AAM-4537-2021; d'Avila, Joana/L-8970-2013; Bozza, Fernando A/A-2618-2013; Bozza, Patricia T./AAE-2933-2021	Bozza, Patricia T./0000-0001-8349-9529; d'Avila, Joana/0000-0002-2045-0813; Bozza, Fernando A/0000-0003-4878-0256; 	CNPq (National Counsel of Technological and Scientific Development)Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ); Faperj (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro)Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ); Pronex (Programa de Apoio a Nucleos de Excelencia); NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO3 NS04512]; NIHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 HL044525]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL044525] Funding Source: NIH RePORTER	Financial support was provided by CNPq (National Counsel of Technological and Scientific Development), Faperj (Fundacao Carlos Chagas de Amparo a Pesquisa do Estado do Rio de Janeiro), Pronex (Programa de Apoio a Nucleos de Excelencia), NIH/NINDS RO3 NS04512 and NIHS R37 HL044525. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali F, 2009, J BIOL CHEM, V284, P18882, DOI 10.1074/jbc.M109.009886; Araujo CV, 2012, MICROVASC RES, V84, P218, DOI 10.1016/j.mvr.2012.05.006; Armah H, 2005, ANN TROP MED PARASIT, V99, P629, DOI 10.1179/136485905X51508; Barichello T, 2006, CRIT CARE MED, V34, P886, DOI 10.1097/01.CCM.0000201880.50116.12; Barichello T, 2007, CRIT CARE MED, V35, P2186, DOI 10.1097/01.CCM.0000281452.60683.96; Bienvenu AL, 2008, ANTIMICROB AGENTS CH, V52, P4203, DOI 10.1128/AAC.00513-08; Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027; Brown H, 1999, NEUROPATH APPL NEURO, V25, P331; Brown H, 2001, AM J TROP MED HYG, V64, P207, DOI 10.4269/ajtmh.2001.64.207; Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41; Carter JA, 2006, DEV MED CHILD NEUROL, V48, P51, DOI 10.1017/S0012162206000107; Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893; Carvalho LJM, 2010, TRENDS PARASITOL, V26, P271, DOI 10.1016/j.pt.2010.03.001; Carvalho-Tavares J, 2000, CIRC RES, V87, P1141, DOI 10.1161/01.RES.87.12.1141; Cordoliani YS, 1998, AM J NEURORADIOL, V19, P871; Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401; de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715; Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284; Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016; DRAPER HH, 1990, METHOD ENZYMOL, V186, P421; Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2; Faille D, 2009, THROMB HAEMOSTASIS, V102, P1093, DOI 10.1160/TH09-05-0337; Golenser J, 2006, INT J PARASITOL, V36, P583, DOI 10.1016/j.ijpara.2006.02.009; Greenwood J, 2006, NAT REV IMMUNOL, V6, P358, DOI 10.1038/nri1839; Greenwood J, 2003, FASEB J, V17, P905, DOI 10.1096/fj.02-1014fje; Hsu M, 2006, BIOCHEM BIOPH RES CO, V343, P738, DOI 10.1016/j.bbrc.2006.03.036; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667; Hunt NH, 2010, TRENDS PARASITOL, V26, P272, DOI 10.1016/j.pt.2010.03.006; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709; John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198; Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785; Kouroumichakis I, 2011, EUR J INTERN MED, V22, P125, DOI 10.1016/j.ejim.2010.12.004; Lackner P, 2006, NEUROPATH APPL NEURO, V32, P177, DOI 10.1111/j.1365-2990.2006.00706.x; Langhorne J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-23; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; LOOAREESUWAN S, 1995, CLIN INFECT DIS, V21, P300, DOI 10.1093/clinids/21.2.300; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; McGown CC, 2010, BRIT J ANAESTH, V104, P183, DOI 10.1093/bja/aep361; MILLAN JM, 1993, AM J NEURORADIOL, V14, P493; Morandi A, 2011, CHEST, V140, P580, DOI 10.1378/chest.10-3065; Nath N, 2004, J IMMUNOL, V172, P1273, DOI 10.4049/jimmunol.172.2.1273; Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4; Nie CQ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000369; Niessner A, 2006, ATHEROSCLEROSIS, V189, P408, DOI 10.1016/j.atherosclerosis.2005.12.022; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Papadopoulos G, 2002, EUR J ANAESTH, V19, P152, DOI 10.1017/S0265021502250267; Patankar TF, 2002, RADIOLOGY, V224, P811, DOI 10.1148/radiol.2243010588; Paul R, 2007, EXP NEUROL, V203, P158, DOI 10.1016/j.expneurol.2006.08.003; Penet MF, 2007, J BIOL CHEM, V282, P14505, DOI 10.1074/jbc.M608035200; Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005; Pino P, 2005, THROMB HAEMOSTASIS, V94, P336, DOI 10.1160/TH05-05-0354; PUHL H, 1994, METHOD ENZYMOL, V233, P425; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Rosenthal PJ, 2008, NEW ENGL J MED, V358, P1829, DOI 10.1056/NEJMct0709050; Rozen S, 2000, Methods Mol Biol, V132, P365; Sabino B, 2008, J CARDIOVASC PHARM, V51, P402, DOI 10.1097/FJC.0b013e3181673bc5; Sacanella E, 2011, CRIT CARE, V15, DOI 10.1186/cc10121; Semmler A, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-38; Souraud JB, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-13; Stocker R, 2006, CIRCULATION, V114, P2178, DOI 10.1161/CIRCULATIONAHA.105.598698; Taoufiq Z, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-52; Tapia-Perez JH, 2008, J NEUROTRAUM, V25, P1011, DOI 10.1089/neu.2008.0554; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Terblanche M, 2007, LANCET INFECT DIS, V7, P358, DOI 10.1016/S1473-3099(07)70111-1; van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; WILLIMANN K, 1995, J EXP MED, V182, P643, DOI 10.1084/jem.182.3.643; Wurtz N, 2010, J ANTIMICROB CHEMOTH, V65, P1387, DOI 10.1093/jac/dkq173; Yadava A, 1996, P NATL ACAD SCI USA, V93, P4595, DOI 10.1073/pnas.93.10.4595; Yoshimoto T, 1998, J IMMUNOL, V160, P5500; Zimmerman GA, 2010, EXPERT REV ANTI-INFE, V8, P1209, DOI 10.1586/ERI.10.117	78	70	72	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7366	1553-7374		PLOS PATHOG	PLoS Pathog.	DEC	2012	8	12							e1003099	10.1371/journal.ppat.1003099			13	Microbiology; Parasitology; Virology	Science Citation Index Expanded (SCI-EXPANDED)	Microbiology; Parasitology; Virology	062GJ	WOS:000312907100046	23300448	Green Published, Green Submitted, gold			2022-02-06	
J	Villapol, S; Yaszemski, AK; Logan, TT; Sanchez-Lemus, E; Saavedra, JM; Symes, AJ				Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Sanchez-Lemus, Enrique; Saavedra, Juan M.; Symes, Aviva J.			Candesartan, an Angiotensin II AT(1)-Receptor Blocker and PPAR-gamma Agonist, Reduces Lesion Volume and Improves Motor and Memory Function After Traumatic Brain Injury in Mice	NEUROPSYCHOPHARMACOLOGY			English	Article						traumatic brain injury; candesartan; TGF beta; inflammation; neuroprotection; PPAR gamma	ACTIVATED-RECEPTOR-GAMMA; CEREBRAL-BLOOD-FLOW; TRANSFORMING GROWTH FACTOR-BETA(1); INNATE IMMUNE-RESPONSE; TYPE-1 RECEPTOR; MICROGLIAL ACTIVATION; VASCULAR INFLAMMATION; HYPERTENSIVE-RATS; OXIDATIVE STRESS; EPITHELIAL-CELLS	Traumatic brain injury (TBI) results in complex pathological reactions, the initial lesion worsened by secondary inflammation and edema. Angiotensin II (Ang II) is produced in the brain and Ang II receptor type 1 (AT(1)R) overstimulation produces vasoconstriction and inflammation. Ang II receptor blockers (ARBs) are neuroprotective in models of stroke but little is known of their effect when administered in TBI models. We therefore performed controlled cortical impact (CCI) injury on mice to investigate whether the ARB candesartan would mitigate any effects of TBI. We administered candesartan or vehicle to mice 5 h before CCI injury. Candesartan treatment reduced the lesion volume after CCI injury by approximately 50%, decreased the number of dying neurons, lessened the number of activated microglial cells, protected cerebral blood flow (CBF), and reduced the expression of the cytokine TGF beta 1 while increasing expression of TGF beta 3. Candesartan-treated mice also showed better motor skills on the rotarod 3 days after injury, and improved performance in the Morris water maze 4 weeks after injury. These results indicate that candesartan is neuroprotective, reducing neuronal injury, decreasing lesion volume and microglial activation, protecting CBF and improving functional behavior in a mouse model of TBI. Co-treatment with a peroxisome proliferator-activated receptor-gamma (PPAR gamma) antagonist significantly reduced some of the beneficial effects of candesartan after CCI, suggesting that PPAR gamma activation may contribute to part or to all of the neuroprotective effect of candesartan. Overall, our data suggest that ARBs with dual AT(1)R-blocking and PPAR gamma activation properties may have therapeutic value in treating TBI. Neuropsychopharmacology (2012) 37, 2817-2829; doi: 10.1038/npp.2012.152; published online 15 August 2012	[Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Villapol, Sonia; Yaszemski, Alexandra K.; Logan, Trevor T.; Symes, Aviva J.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Sanchez-Lemus, Enrique; Saavedra, Juan M.] NIMH, Pharmacol Sect, Div Intramural Res Programs, Dept Hlth & Human Serv,NIH, Bethesda, MD 20892 USA		Symes, AJ (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pharmacol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	aviva.symes@usuhs.edu	Villapol, Sonia/D-1949-2014; Saavedra, Juan/AAO-7149-2020; Symes, Aviva J/S-7471-2016	Saavedra, Juan/0000-0002-7238-9647; Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense; CNRM postdoctoral fellowship; Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ZIAMH002762] Funding Source: NIH RePORTER	This study was supported by a pilot award from the Center for Neuroscience and Regenerative Medicine (CNRM) grant (AJS). SV is supported by a CNRM postdoctoral fellowship. JMS and ESL are supported by the Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health. We thank Laura Tucker, Oz Malkesman, and Amanda Fu from the CNRM pre-clinical core facility for expert advice, Dr Tim ONeil for his assistance with blood pressure measurements. We are grateful to members of the Symes and Saavedra laboratories for their helpful comments and suggestions. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences or the US Department of Defense.	An JB, 2010, HYPERTENS RES, V33, P831, DOI 10.1038/hr.2010.79; Ando H, 2004, ANN NY ACAD SCI, V1018, P345, DOI 10.1196/annals.1296.043; Ando H, 2004, STROKE, V35, P1726, DOI 10.1161/01.STR.0000129788.26346.18; Ariza M, 2006, J NEUROPSYCH CLIN N, V18, P39, DOI 10.1176/appi.neuropsych.18.1.39; Awad AS, 2011, J STROKE CEREBROVASC, V20, P541, DOI 10.1016/j.jstrokecerebrovasdis.2010.03.008; Baranov D, 2003, ANESTHESIOLOGY, V99, P1118, DOI 10.1097/00000542-200311000-00018; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Benicky J, 2011, NEUROPSYCHOPHARMACOL, V36, P857, DOI 10.1038/npp.2010.225; Benigni A, 2010, EMBO MOL MED, V2, P247, DOI 10.1002/emmm.201000080; Benson SC, 2004, HYPERTENSION, V43, P993, DOI 10.1161/01.HYP.0000123072.34629.57; Bernardo A, 2006, CURR PHARM DESIGN, V12, P93, DOI 10.2174/138161206780574579; BURSON JM, 1994, AM J PHYSIOL, V267, pE260, DOI 10.1152/ajpendo.1994.267.2.E260; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Davies NM, 2011, J ALZHEIMERS DIS, V26, P699, DOI 10.3233/JAD-2011-110347; Davisson RL, 2000, J CLIN INVEST, V106, P103, DOI 10.1172/JCI10022; dos Santos CC, 2005, CRIT CARE, V9, P280, DOI 10.1186/cc3022; Engelhorn T, 2004, J CEREBR BLOOD F MET, V24, P467, DOI 10.1097/00004647-200404000-00012; Erbe DV, 2006, VASC PHARMACOL, V45, P154, DOI 10.1016/j.vph.2006.05.002; Fogari R, 2004, DRUG AGING, V21, P377, DOI 10.2165/00002512-200421060-00003; Gillespie W, 2011, INDIAN J BIOCHEM BIO, V48, P73; Guan WH, 2011, TRANSL STROKE RES, V2, P179, DOI 10.1007/s12975-010-0061-1; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hansson L, 1999, BLOOD PRESSURE, V8, P177; Harasawa S, 2010, J PHARM PHARMACOL, V62, P1740, DOI 10.1111/j.2042-7158.2010.01164.x; Igase M, 2012, INT J HYPERTENS, V2012, DOI 10.1155/2012/320648; Ito T, 2001, J RENIN-ANGIO-ALDO S, V2, P174, DOI 10.3317/jraas.2001.024; Ito T, 2002, STROKE, V33, P2297, DOI 10.1161/01.STR.0000027274.03779.F3; Ji YY, 2009, LAB INVEST, V89, P887, DOI 10.1038/labinvest.2009.45; Jiao B, 2011, BIOSCI TRENDS, V5, P173, DOI 10.5582/bst.2011.v5.4.173; Johren O, 1996, AM J PHYSIOL-ENDOC M, V271, pE104, DOI 10.1152/ajpendo.1996.271.1.E104; Jung KH, 2007, J PHARMACOL EXP THER, V322, P1051, DOI 10.1124/jpet.107.120097; Kasahara Y, 2010, BRAIN RES, V1340, P70, DOI 10.1016/j.brainres.2010.03.101; Lanz TV, 2010, J CLIN INVEST, V120, P2782, DOI 10.1172/JCI41709; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Li JM, 2008, STROKE, V39, P2029, DOI 10.1161/STROKEAHA.107.503458; Liu H, 2008, J HYPERTENS, V26, P1435, DOI 10.1097/HJH.0b013e3283013b6e; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maeda A, 2009, INT IMMUNOPHARMACOL, V9, P1183, DOI 10.1016/j.intimp.2009.06.006; Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Meredith PA, 2004, J RENIN-ANGIO-ALDO S, V5, P59, DOI 10.3317/jraas.2004.011; Nishimura Y, 2000, BRAIN RES, V871, P29, DOI 10.1016/S0006-8993(00)02377-5; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Occleston NL, 2008, J BIOMAT SCI-POLYM E, V19, P1047, DOI 10.1163/156856208784909345; Omura-Matsuoka E, 2009, HYPERTENS RES, V32, P548, DOI 10.1038/hr.2009.69; Ozacmak VH, 2007, NEUROCHEM RES, V32, P1314, DOI 10.1007/s11064-007-9305-1; Pang T, 2012, J HYPERTENS, V30, P87, DOI 10.1097/HJH.0b013e32834dde5f; Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005; Poon IO, 2008, PHARMACOTHERAPY, V28, P366, DOI 10.1592/phco.28.3.366; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; Robbins ME, 2010, CURR DRUG TARGETS, V11, P1413; Rodriguez-Pallares J, 2008, NEUROBIOL DIS, V31, P58, DOI 10.1016/j.nbd.2008.03.003; Rosenkranz S, 2004, CARDIOVASC RES, V63, P423, DOI 10.1016/j.cardiores.2004.04.030; Rotman N, 2010, PHYSIOLOGY, V25, P176, DOI 10.1152/physiol.00018.2010; SAAVEDRA JM, 1992, ENDOCR REV, V13, P329, DOI 10.1210/er.13.2.329; Saavedra JM, 2011, PSYCHONEUROENDOCRINO, V36, P1, DOI 10.1016/j.psyneuen.2010.10.001; Savoia C, 2007, CLIN SCI, V112, P375, DOI 10.1042/CS20060247; Sookplung P, 2011, NEUROCRIT CARE, V15, P46, DOI 10.1007/s12028-010-9448-9; Stenman E, 2004, STROKE, V35, P970, DOI 10.1161/01.STR.0000121642.53822.58; Sugawara A, 2011, CURR MOL PHARM; Sugawara T, 2005, NEUROREPORT, V16, P325, DOI 10.1097/00001756-200503150-00004; Sun YO, 1998, J MOL CELL CARDIOL, V30, P1559, DOI 10.1006/jmcc.1998.0721; Susarla BTS, 2011, J NEUROCHEM, V119, P868, DOI 10.1111/j.1471-4159.2011.07470.x; Tham DM, 2002, PHYSIOL GENOMICS, V11, P21, DOI 10.1152/physiolgenomics.00062.2002; Thone-Reineke C, 2006, J HYPERTENS, V24, pS115; Timaru-Kast R, 2012, CRIT CARE MED, V40, P935, DOI 10.1097/CCM.0b013e31822f08b9; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; Van Mieghem W, 2010, ACTA CLIN BELG, V65, P107, DOI 10.1179/acb.2010.022; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; Vivien D, 2006, CYTOKINE GROWTH F R, V17, P121, DOI 10.1016/j.cytogfr.2005.09.011; Wang Y, 2007, EXP NEUROL, V203, P168, DOI 10.1016/j.expneurol.2006.08.006; Xiao J, 2009, CLIN IMMUNOL, V132, P266, DOI 10.1016/j.clim.2009.04.004; Yamakawa H, 2003, J CEREBR BLOOD F MET, V23, P371, DOI 10.1097/01.WCB.0000047369.05600.03; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Yu CM, 2001, J AM COLL CARDIOL, V38, P1207, DOI 10.1016/S0735-1097(01)01518-2; Zanchetti A, 2006, BLOOD PRESSURE, V15, P71, DOI 10.1080/08037050600771583; Zhao SM, 2008, CHINESE J PHYSIOL, V51, P357; Zhou J, 2006, STROKE, V37, P1271, DOI 10.1161/01.STR.0000217404.64352.d7; Zhou J, 2005, J CEREBR BLOOD F MET, V25, P878, DOI 10.1038/sj.jcbfm.9600082; Zorad S, 2006, EUR J PHARMACOL, V552, P112, DOI 10.1016/j.ejphar.2006.08.062; Zuhayra M, 2011, NEUROPATH APPL NEURO, V37, P738, DOI 10.1111/j.1365-2990.2011.01169.x	82	70	72	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	DEC	2012	37	13					2817	2829		10.1038/npp.2012.152			13	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	037GT	WOS:000311090900009	22892395	Green Published, Bronze			2022-02-06	
J	Berry, C; Ley, EJ; Bukur, M; Malinoski, D; Margulies, DR; Mirocha, J; Salim, A				Berry, Cherisse; Ley, Eric J.; Bukur, Marko; Malinoski, Darren; Margulies, Daniel R.; Mirocha, James; Salim, Ali			Redefining hypotension in traumatic brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Hypotension; Traumatic brain injury; Mortality	SERUM ETHANOL LEVELS; CEREBRAL-BLOOD-FLOW; ACUTE HEAD-INJURY; PRESSURE; MODERATE; MORTALITY; OUTCOMES; GENDER	Background: Systemic hypotension is a well documented predictor of increased mortality following traumatic brain injury (TBI). Hypotension is traditionally defined as systolic blood pressure (SBP) < 90 mm Hg. Recent evidence defines hypotension by a higher SBP in injured (non-TBI) trauma patients. We hypothesize that hypotension threshold requires a higher SBP in isolated moderate to severe TBI. Patients and methods: A retrospective database review of all adults (>= 15 years) with isolated moderate to severe TBI (head abbreviated injury score (AIS) >= 3, all other AIS <= 3), admitted from five Level I and eight Level II trauma centres (Los Angeles County), between 1998 and 2005. Several fit statistic analyses were performed for each admission SBP from 60 to 180 mm Hg to identify the model that most accurately defined hypotension for three age groups: 15-49 years, 50-69 years, and >= 70 years. The main outcome variable was mortality, and the optimal definition of hypotension for each group was determined from the best fit model. Adjusted odds ratios (AOR) were then calculated to determine increased odds in mortality for the defined optimal SBP within each age group. Results: A total of 15,733 patients were analysed. The optimal threshold of hypotension according to the best fit model was SBP of 110 mm Hg for patients 15-49 years (AOR 1.98, CI 1.65-2.39, p < 0.0001), 100 mm Hg for patients 50-69 years (AOR 2.20, CI 1.46-3.31, p = 0.0002), and 110 mm Hg for patients >= 70 years (AOR 1.92, CI 1.35-2.74, p = 0.0003). Conclusions: Patients with isolated moderate to severe TBI should be considered hypotensive for SBP < 110 mm Hg. Further research should confirm this new definition of hypotension by correlation with indices of perfusion. (C) 2011 Elsevier Ltd. All rights reserved.	[Berry, Cherisse; Ley, Eric J.; Bukur, Marko; Malinoski, Darren; Margulies, Daniel R.; Mirocha, James; Salim, Ali] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215N, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	Berry, Cherisse/AAO-5701-2020	Bukur, Marko/0000-0002-1850-7147			Alban RF, 2010, AM SURGEON, V76, P1108; Berry C, 2011, AM J SURG, V201, P429, DOI 10.1016/j.amjsurg.2010.10.008; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Berry C, 2009, J TRAUMA, V67, P950, DOI 10.1097/TA.0b013e3181ba3354; Berry C, 2010, AM SURGEON, V76, P1067; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BOUMA GJ, 1993, ACTA NEUROCHIR, P34; Brain Trauma Foundation Guidelines, MAN PROGN SEV TRAUM; Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis JW, 2003, J TRAUMA, V55, P860, DOI 10.1097/01.TA.0000092686.91877.DE; Eastridge BJ, 2007, J TRAUMA, V63, P291, DOI 10.1097/TA.0b013e31809ed924; Edelman DA, 2007, SHOCK, V27, P134, DOI 10.1097/01.shk.0000239772.18151.18; Edwards M, 2010, AM SURGEON, V76, P1035; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; GENTLEMAN D, 1992, INT SURG, V77, P297; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JEFFREYS RV, 1981, LANCET, V2, P459; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Ottochian M, 2009, AM J SURG, V197, P155, DOI 10.1016/j.amjsurg.2008.09.008; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Salim A, 2009, J TRAUMA, V67, P697, DOI 10.1097/TA.0b013e3181b5dcf2; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; WO CCJ, 1993, CRIT CARE MED, V21, P218, DOI 10.1097/00003246-199302000-00012	31	70	71	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1833	1837		10.1016/j.injury.2011.08.014			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300010	21939970				2022-02-06	
J	Hart, T; Hoffman, JM; Pretz, C; Kennedy, R; Clark, AN; Brenner, LA				Hart, Tessa; Hoffman, Jeanne M.; Pretz, Christopher; Kennedy, Richard; Clark, Allison N.; Brenner, Lisa A.			A Longitudinal Study of Major and Minor Depression Following Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Depression; Mental health; Rehabilitation	PATIENT HEALTH QUESTIONNAIRE-9; SOCIAL SUPPORT; SERVICE UTILIZATION; SYSTEMATIC BIAS; DISORDERS; OUTCOMES; ADULTS; REHABILITATION; PREVALENCE; MORBIDITY	Objective: To examine patterns of change and factors associated with change in depression, both major (major depressive disorder [MDD]) and minor, between 1 and 2 years after traumatic brain injury (TBI). Design: Observational prospective longitudinal study. Setting: Inpatient rehabilitation centers, with 1- and 2-year follow-up) conducted primarily by telephone. Participants: Persons with TBI (N = 1089) enrolled in the Traumatic Brain Injury Model Systems database, followed at 1 and 2 years postinjury. Interventions: Not applicable. Main Outcome Measure: Patient Health Questionnaire-9. Results: Among participants not depressed at I year, close to three fourths remained so at 2-year follow-up. However, 26% developed MDD or minor depression between the first and second years postinjury. Over half of participants with MDD at year 1 also reported MDD the following year, with another 22% reporting minor depression; thus three fourths of those with MDD at year I experienced clinically significant symptoms at year 2. Almost one third of those with minor depression at year I traversed to MDD at year 2. Polytomous logistic regression confirmed that worse depression at year 1 was associated with higher odds of depression a year later. For those without depression at year 1, symptom worsening over time was related to year 2 problematic substance use and lower FIM motor and cognitive scores. For those with depression at year 1, worsening was associated with lower cognitive FIM, poor social support, and preinjury mental health issues including subslance abuse. Conclusion: Major and minor depression exist on a continuum along which individuals with TBI may traverse over time. Predictors of change differ according to symptom onset. Results highlight importance of long-term monitoring for depression, treating minor as well as major depression, and developing interventions for comorbid depression and substance abuse.	Moss Rehabil Res Inst, Elkins Pk, PA 19027 USA; [Pretz, Christopher; Brenner, Lisa A.] Craig Hosp, Englewood, CO USA; [Hoffman, Jeanne M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Kennedy, Richard] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA; [Clark, Allison N.] TIRR Mem Hermann, Houston, TX USA; [Clark, Allison N.] Baylor Coll Med, Houston, TX 77030 USA; [Brenner, Lisa A.] VISN 19 Mental Illness Res Educ & Clin Ctr, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado, Sch Med, Aurora, CO USA		Hart, T (corresponding author), Moss Rehabil Res Inst, 50 Township Line Rd, Elkins Pk, PA 19027 USA.	thart@einstein.edu	Brenner, Lisa A./AAG-2442-2019; Kennedy, Richard/K-1525-2018	Kennedy, Richard/0000-0003-4638-126X	National Institute on Disability and Rehabilitation Research [H133A070040, H133A070032, H133A070022, H133A070043, H133A070039, H133A 110016]	Supported by the National Institute on Disability and Rehabilitation Research (grant nos. H133A070040, H133A070032, H133A070022, H133A070043. H133A070039, and H133A 110016).	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Brenner LA, 2011, J HEAD TRAUMA REHAB, V26, P257, DOI 10.1097/HTR.0b013e31821fdb6e; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; COHEN S, 1985, PSYCHOL BULL, V98, P310, DOI 10.1037//0033-2909.98.2.310; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Cuijpers P, 2004, J AFFECT DISORDERS, V79, P71, DOI 10.1016/S0165-0327(02)00348-8; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Gould KR, 2011, J HEAD TRAUMA REHAB, V26, P79, DOI 10.1097/HTR.0b013e3182036799; Granger CV, 1987, UNIFORM DATA SET MED; Graves DE, 1999, ARCH PHYS MED REHAB, V80, P1464, DOI 10.1016/S0003-9993(99)90259-9; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Howland RH, 2008, PSYCHOTHER PSYCHOSOM, V77, P384, DOI 10.1159/000151519; JOHNSON J, 1992, JAMA-J AM MED ASSOC, V267, P1478, DOI 10.1001/jama.267.11.1478; Jorge R, 2002, NEUROREHABILITATION, V17, P311; Judd LL, 1997, J AFFECT DISORDERS, V45, P5, DOI 10.1016/S0165-0327(97)00055-4; JUDD LL, 1997, J AFFECT DISORDERS, V45, P17; Kennedy RE, 2005, J HEAD TRAUMA REHAB, V20, P512, DOI 10.1097/00001199-200511000-00004; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kessler RC, 1997, J AFFECT DISORDERS, V45, P19, DOI 10.1016/S0165-0327(97)00056-6; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCDANIEL JS, 2000, PSYCHIAT CARE MED PA, P149; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Rapaport MH, 2002, AM J PSYCHIAT, V159, P637, DOI 10.1176/appi.ajp.159.4.637; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; SKODOL AE, 1994, ARCH GEN PSYCHIAT, V51, P542; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; U.S. Department of Health and Human Services, 1998, NAT HOUS SURV DRUG A; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Wagner HR, 2000, PSYCHOL MED, V30, P1377, DOI 10.1017/S0033291799002998; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002	49	70	71	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2012	93	8					1343	1349		10.1016/j.apmr.2012.03.036			7	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	983XJ	WOS:000307151700008	22840833				2022-02-06	
J	Crisco, JJ; Wilcox, BJ; Machan, JT; McAllister, TW; Duhaime, AC; Duma, SM; Rowson, S; Beckwith, JG; Chu, JJ; Greenwald, RM				Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.; McAllister, Thomas W.; Duhaime, Ann-Christine; Duma, Stefan M.; Rowson, Steven; Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.			Magnitude of Head Impact Exposures in Individual Collegiate Football Players	JOURNAL OF APPLIED BIOMECHANICS			English	Article						football; biomechanics; impacts; magnitude; acceleration	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; UNITED-STATES; EPIDEMIOLOGY; ACCELERATION; CONCUSSION; SPORTS; LOCATION	The purpose of this study was to quantify the severity of head impacts sustained by individual collegiate football players and to investigate differences between impacts sustained during practice and game sessions, as well as by player position and impact location. Head impacts (N = 184,358) were analyzed for 254 collegiate players at three collegiate institutions. In practice, the 50th and 95th percentile values for individual players were 20.0 g and 49.5 g for peak linear acceleration, 1187 rad/s(2) and 3147 rad/s(2) for peak rotational acceleration, and 13.4 and 29.9 for HITsp, respectively. Only the 95th percentile HITsp increased significantly in games compared with practices (8.4%, p = .0002). Player position and impact location were the largest factors associated with differences in head impacts. Running backs consistently sustained the greatest impact magnitudes. Peak linear accelerations were greatest for impacts to the top of the helmet, whereas rotational accelerations were greatest for impacts to the front and back. The findings of this study provide essential data for future investigations that aim to establish the correlations between head impact exposure, acute brain injury, and long-term cognitive deficits.	[Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA; [Crisco, Joseph J.; Wilcox, Bethany J.; Machan, Jason T.] Rhode Isl Hosp, Providence, RI USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Duma, Stefan M.; Rowson, Steven] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [McAllister, Thomas W.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH USA		Crisco, JJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02912 USA.		Machan, Jason T/D-3897-2013; Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012	Machan, Jason T/0000-0003-2048-4914; Rowson, Steven/0000-0002-3227-0596; Crisco, Joseph/0000-0002-8786-0905	National Center for Medical Rehabilitation Research at the National Institute of Child Health [R01HD048638]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RO1NS055020]; NOCSAE [04-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD040743, R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This work was supported in part by award R01HD048638 from the National Center for Medical Rehabilitation Research at the National Institute of Child Health and 1RO1NS055020 from the National Institute of Neurological Disorders and Stroke, and NOCSAE 04-07. HIT System technology was developed in part under NIH R44HD40743 and research and development support from Riddell, Inc. (Chicago, IL). We appreciate and acknowledge the researchers and institutions from which the data were collected: Mike Goforth and Dave Dieter, Virginia Tech Sports Medicine; Jeff Frechette and Scott Roy, Dartmouth College Sports Medicine; Mary Hynes, Dartmouth Medical School; and Russell Fiore, David J. Murray, and Kevin R. Francis, Brown University. We acknowledge Lindley Brainard from Simbex for coordination of all data collection.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick R, 2009, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Gerbeding J.L., 2003, COSTS INTIMATE PARTN, P1; Greenwald R.M., 2008, J NEUROSURG, V62, P798, DOI [10.1227/01.neu.0000318162.67472.ad, DOI 10.1227/01.NEU.0000318162.67472.AD]; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Meehan 3rd W.P., 2010, AM J SPORTS MED; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik J.P., 2007, J NEUROSURG, V61, P1235, DOI [10.1227/01.neu.0000306101.83882.c8, DOI 10.1227/01.NEU.0000306101.83882.C8]; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D.W., 1971, SCANDINAVIAN J MED S, V3, P44; Pellman E.J., 2003, J NEUROSURG, V53, P812; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Schnebel B., 2007, J NEUROSURG, V60, P495; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	31	70	70	0	17	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1065-8483			J APPL BIOMECH	J. Appl. Biomech.	MAY	2012	28	2					174	183		10.1123/jab.28.2.174			10	Engineering, Biomedical; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Sport Sciences	970WS	WOS:000306163600008	21911854	Green Accepted			2022-02-06	
J	Jinguji, TM; Bompadre, V; Harmon, KG; Satchell, EK; Gilbert, K; Wild, J; Eary, JF				Jinguji, Thomas M.; Bompadre, Viviana; Harmon, Kimberly G.; Satchell, Emma K.; Gilbert, Kaiulani; Wild, Jennifer; Eary, Janet F.			Sport Concussion Assessment Tool-2: Baseline Values for High School Athletes	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; POSTURAL STABILITY; INTERNATIONAL-CONFERENCE; STANDARDIZED ASSESSMENT; STATEMENT; SYMPTOMS; DEFICITS	Background Concussion head injuries are common in high school athletes. The Sport Concussion Assessment Tool - 2 (SCAT2) has been recommended and widely adopted as a standardised method of evaluating an injured athlete with a suspected concussion. Sideline return to play decisions can hinge on the results of a SCAT2 score. However, most athletes will not have had baseline testing performed for comparison if injury occurs. Therefore, establishing of age-, sex- and sport-matched normative data for the high school athlete population is critical. Purpose To determine baseline scores in all SCAT2 domains among high school athletes with no prior history of a concussion and to examine subgroup differences for girls and boys, age and sport to establish normative ranges. Materials and methods The SCAT2 was administered to 214 high school athletes (155 males and 59 females) who participated in football, women's soccer, men's basketball, gymnastics, baseball, softball and track with no prior history of concussion. There were 111 athletes in the 13-15-year-old cohort and 103 in the 16-19-yearold group with a mean age of 15.7 years of age. In all SCAT2 domains the mean and SD of the results were determined. The domains were analysed using age, sex and sport as covariates. Component parts of the cognitive (concentration) domain (digit sequencing and months of year in reverse order) were also analysed by age, sex and sport. The percentage of high school athletes able to perform each digit-sequencing test was calculated as was the percentage of participants who could recite the months of the year in reverse order. Results The average SCAT2 score for these high school athletes was 89 of a possible 100 with a SD of 6 units. Athletes reported two or three symptoms at baseline with older students reporting more symptoms than younger ones. The average balance score was 25.82 (of 30), and all athletes were able to complete the double-leg stance. Females scored significantly higher on the balance, immediate memory and concentration scores. Concentration scores in non-concussed high school athletes were low. Only 67% of high school athletes could recite the months of the year backward and only 41% could correctly sequence 5 digits backward. Only 55% of high school football players could correctly recite the months of the year backward and 32% could sequence 5 digits. Conclusions Non-concussed high school athletes scored near the total possible in most domains of the SCAT2 with the exception of concentration testing and balance testing. All athletes were able to complete the double-leg stance at baseline; however, there was significant variability of tandem and single-leg stance. Baseline testing is important when considering balance tests. Concentration testing in high school athletes is unreliable because of high baseline error and is likely to result in a high rate of false positives and false negatives. Return to play decisions should not rely on concentration testing without a baseline test for comparison.	[Jinguji, Thomas M.; Bompadre, Viviana; Satchell, Emma K.; Gilbert, Kaiulani; Eary, Janet F.] Seattle Childrens Hosp, Dept Orthopaed & Sports Med, Seattle, WA 98105 USA; [Harmon, Kimberly G.; Eary, Janet F.] Univ Washington, Dept Sports Med, Seattle, WA 98195 USA; [Wild, Jennifer] Univ Washington, Dept Pediat, Seattle, WA 98195 USA		Jinguji, TM (corresponding author), Seattle Childrens Hosp, Dept Orthopaed & Sports Med, 4800 Sand Point Way NE, Seattle, WA 98105 USA.	thomas.jinguji@seattlechildrens.org			Seattle Children's Hospital	Academic Enrichment Fund - Seattle Children's Hospital.	Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Patel AV, 2007, J ATHL TRAINING, V42, P66; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schneider KJ, 2010, BRIT J SPORT MED, V44, P1112, DOI 10.1136/bjsm.2009.071266; Shehata N, 2009, BRIT J SPORT MED, V43, P730, DOI 10.1136/bjsm.2009.059832	25	70	71	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2012	46	5					365	370		10.1136/bjsports-2011-090526			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	919QH	WOS:000302342800015	22228554				2022-02-06	
J	Kerr, ZY; Marshall, SW; Guskiewicz, KM				Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Reliability of Concussion History in Former Professional Football Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						CONCUSSION; HEAD INJURY; TRAUMATIC BRAIN INJURY	LIFE COGNITIVE IMPAIRMENT; RECURRENT CONCUSSION; SPORTS CONCUSSION; AGREEMENT; ASSOCIATION; RISK	KERR, Z. Y., S. W. MARSHALL, and K. M. GUSKIEWICZ. Reliability of Concussion History in Former Professional Football Players. Med. Sci. Sports Exerc., Vol. 44, No. 3, pp. 377-382, 2012. Purpose: The reliability of athletes to recall and self-report a concussion history has never been quantified. This study examined the reliability of the self-report concussion history measure and explored determinants of recall in the number of self-reported concussions in a group of retired professional football players. Methods: In 2001, a short questionnaire was administered to a cohort of former professional football players to ascertain the number of self-reported concussions they sustained during their professional playing careers. In 2010, the same instrument was readministered to a subset (n = 899) of the original cohort to assess reliability. Results: Overall reliability was moderate (weighted Cohen kappa = 0.48). The majority (62.1%) reported the same number of concussions in both administrations (2001 and 2010); 31.4% reported more concussions in the second administration. Compared with the "same number reported" group, the "greater number reported" group had more deficits in the second administration in their Short Form 36 physical health (composite score combining physical functioning, role physical, bodily pain, general health) and mental health (e. g., composite score combining vitality, social functioning, role emotional) scales. Conclusions: The self-reported concussion history had moderate reliability in former professional football players, on the basis of two administrations of the same instrument, 9 yr apart. However, changes in health status may be differentially associated with recall of concussions.	[Kerr, Zachary Y.; Marshall, Stephen W.] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew A Gfeller Sport Related Traumat Brain Inj, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Ctr Study Retired Athletes, Chapel Hill, NC 27599 USA		Marshall, SW (corresponding author), Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, 2101 McGavran Greenberg Hall,CB 7435, Chapel Hill, NC 27599 USA.	smarshall@unc.edu		Kerr, Zachary/0000-0003-1423-1259; Guskiewicz, Kevin/0000-0002-8682-2130; Marshall, Stephen/0000-0002-2664-9233	NFL Players Association; Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research; Center for the Study of Retired Athletes	The authors also thank the support of the NFL Players Association. The Matthew A. Gfeller Sport-Related Traumatic Brain Injury Research and the Center for the Study of Retired Athletes are funded by private donations and various grant funding agencies interested in understanding the late-life consequences and benefits of playing sports.	Bandura A., 1986, SOCIAL FDN THOUGHT A, P544; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Gerbner G., 1986, PERSPECTIVES MEDIA E, V1986, P17; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MCCOMBS ME, 1972, PUBLIC OPIN QUART, V36, P176, DOI 10.1086/267990; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; Valadka AB, 2005, NEUROSURGERY, V57, P725; Ware JE, 1998, J CLIN EPIDEMIOL, V51, P1167, DOI 10.1016/S0895-4356(98)00108-5	15	70	70	1	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	MAR	2012	44	3					377	382		10.1249/MSS.0b013e31823240f2			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Sport Sciences	897HR	WOS:000300639500002	21857370				2022-02-06	
J	Chen, YH; Kang, JH; Lin, HC				Chen, Yi-Hua; Kang, Jiunn-Horng; Lin, Herng-Ching			Patients With Traumatic Brain Injury Population-Based Study Suggests Increased Risk of Stroke	STROKE			English	Article						Traumatic brain injury; stroke; epidemiology	ISCHEMIC-STROKE; REHABILITATION; EPIDEMIOLOGY; ADULTS	Background and Purpose-Previous studies have identified an array of morbidities following traumatic brain injury (TBI), including certain neurological disorders. However, no direct evidence has been reported on the link between TBI and stroke. This population-based study was designed to estimate the risk of stroke during a period of 5 years following a TBI, compared with individuals who did not suffer TBI during the same period. Methods-Data were obtained from the Longitudinal Health Insurance Database 2000 (LHID 2000). A total of 23 199 patients receiving ambulatory or hospitalization care with a diagnosis of TBI were included, together with 69 597 non-TBI patients as our comparison group, matched by sex, age, and year of index use of health care. Each individual was followed for 5 years to identify subsequent occurrence of stroke. Cox proportional hazard regressions were performed for analysis. Results-During the 3-month follow-up period, 675 strokes (2.91%) occurred in TBI patients and in 207 patients (0.30%) in the non-TBI comparison cohort. A diagnosis of TBI was independently associated with a 10.21 (95% CI, 8.71-11.96), 4.61 (95% CI, 4.16-5.11), and 2.32 (95% CI, 2.17-2.47) times greater risk of stroke during 3-month, 1-year, and 5-year follow-up, respectively, after adjusting for sociodemographic characteristics and selected comorbidities. The risk of intracerebral hemorrhage was more noticeable among patients with TBI compared with those without a TBI. Conclusions-This is the first report showing an increased risk of stroke among individuals who have sustained a TBI. We suggest a need for more intensive medical monitoring and health education following TBI, especially during the first few months and years. (Stroke. 2011; 42: 2733-2739.)	[Lin, Herng-Ching] Taipei Med Univ, Sch Hlth Care Adm, Taipei 110, Taiwan; [Chen, Yi-Hua] Taipei Med Univ, Sch Publ Hlth, Taipei 110, Taiwan; Taipei Med Univ, Coll Med, Sch Med, Dept Phys Med & Rehabil, Taipei 110, Taiwan; Taipei Med Univ Hosp, Neurosci Res Ctr, Taipei, Taiwan		Lin, HC (corresponding author), Taipei Med Univ, Sch Hlth Care Adm, 250 Wu Hsing St, Taipei 110, Taiwan.	henry11111@tmu.edu.tw					Alaranta H, 2000, Wien Med Wochenschr, V150, P444; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1053/apmr.2000.0810176; Borsheim E, 2007, ARCH PHYS MED REHAB, V88, P234, DOI 10.1016/j.apmr.2006.11.003; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chen YC, 2011, SCIENTOMETRICS, V86, P365, DOI 10.1007/s11192-010-0289-2; Chiu WT, 1997, NEUROL RES, V19, P261, DOI 10.1080/01616412.1997.11740811; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Gill SS, 2005, BMJ-BRIT MED J, V330, P445, DOI 10.1136/bmj.38330.470486.8F; Glenn MB, 2010, J HEAD TRAUMA REHAB, V25, P68, DOI 10.1097/HTR.0b013e3181be1eab; Graham D. I., 2000, HEAD INJURY; GURURAJ G, 2004, NEUROTRAUMA REGISTRY; Herrmann N, 2004, AM J PSYCHIAT, V161, P1113, DOI 10.1176/appi.ajp.161.6.1113; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Kang JH, 2011, STROKE, V42, P336, DOI 10.1161/STROKEAHA.110.595538; Kim YS, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-2; KRAUS J, 2004, NEUROEPIDEMIOLOGY PR; LABI M L C, 1990, Brain Injury, V4, P365, DOI 10.3109/02699059009026189; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P196, DOI 10.1097/00001199-200505000-00003; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LeonCarrion J, 2006, STUD NEUROPSYCH DEV, P1; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Reed SD, 2001, STROKE, V32, P1832, DOI 10.1161/01.STR.32.8.1832; Romero Jose Rafael, 2008, Ther Adv Cardiovasc Dis, V2, P287, DOI 10.1177/1753944708093847; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Sims NR, 2010, BBA-MOL BASIS DIS, V1802, P80, DOI 10.1016/j.bbadis.2009.09.003; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tan Teng-Yeow, 2002, Chang Gung Med J, V25, P458; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; TORNER J, 1999, TRAUMATIC BRAIN INJU; VITAL M, 2002, NIH PUBLICATION; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983; Yasseen B, 2008, BRAIN INJURY, V22, P752, DOI 10.1080/02699050802320132	38	70	70	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2011	42	10					2733	2739		10.1161/STROKEAHA.111.620112			7	Clinical Neurology; Peripheral Vascular Disease	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Cardiovascular System & Cardiology	824QM	WOS:000295217100021	21799162	Bronze			2022-02-06	
J	Cottenceau, V; Masson, F; Mahamid, E; Petit, L; Shik, V; Sztark, F; Zaaroor, M; Soustiel, JF				Cottenceau, Vincent; Masson, Francoise; Mahamid, Eugenia; Petit, Laurent; Shik, Venyamin; Sztark, Francois; Zaaroor, Menashe; Soustiel, Jean Francois			Comparison of Effects of Equiosmolar Doses of Mannitol and Hypertonic Saline on Cerebral Blood Flow and Metabolism in Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CBF; cerebral metabolism; HTS; ICP; MTL; TBI	INCREASED INTRACRANIAL-PRESSURE; SEVERE HEAD-INJURY; 20-PERCENT MANNITOL; PERFUSION-PRESSURE; PRACTICAL SCALE; HYPERTENSION; ISCHEMIA; TOMOGRAPHY; HEMORRHAGE; MORTALITY	The potential superiority of hypertonic saline (HTS) over mannitol (MTL) for control of intracranial pressure (ICP) following traumatic brain injury (TBI) is still debated. Forty-seven severe TBI patients with increased ICP were prospectively recruited in two university hospitals and randomly treated with equiosmolar infusions of either MTL 20% (4mL/kg; n = 25 patients) or HTS 7.5% (2 mL/kg; n = 22 patients). Serum sodium, hematocrit, ICP, arterial blood pressure, cerebral perfusion pressure (CPP), shear rate, global indices of cerebral blood flow (CBF) and metabolism were measured before, and 30 and 120 min following each infusion during the course of illness. Outcome was assessed at 6 months. Both HTS and MTL effectively and equally reduced ICP levels with subsequent elevation of CPP and CBF, although this effect was significantly stronger and of longer duration after HTS and correlated with improved rheological blood properties induced by HTS. Further, effect of HTS on ICP appeared to be more robust in patients with diffuse brain injury. In contrast, oxygen and glucose metabolic rates were left equally unaffected by both solutions. Accordingly, there was no significant difference in neurological outcome between the two groups. In conclusion, MTL was as effective as HTS in decreasing ICP in TBI patients although both solutions failed to improved cerebral metabolism. HTS showed an additional and stronger effect on cerebral perfusion of potential benefit in the presence of cerebral ischemia. Treatment selection should therefore be individually based on sodium level and cerebral hemodynamics.	[Mahamid, Eugenia; Shik, Venyamin; Zaaroor, Menashe; Soustiel, Jean Francois] Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Neurosurg, IL-31096 Haifa, Israel; [Cottenceau, Vincent; Masson, Francoise; Petit, Laurent; Sztark, Francois] CHU Bordeaux, Hop Pellegrin, Serv Anesthesie Reanimat 1, Bordeaux, France		Soustiel, JF (corresponding author), Technion Israel Inst Technol, Rambam Med Ctr, Fac Med, Dept Neurosurg, POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il		LAURENT, PETIT/0000-0003-1530-5678			Al-Rawi PG, 2010, STROKE, V41, P122, DOI 10.1161/STROKEAHA.109.560698; BARRY KG, 1961, NEW ENGL J MED, V264, P1085, DOI 10.1056/NEJM196105252642105; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Becker D.P., 1972, INTRACRANIAL PRESSUR; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; BROWN FD, 1979, J NEUROSURG, V50, P423, DOI 10.3171/jns.1979.50.4.0423; Chieregato A, 2004, J NEUROTRAUM, V21, P655, DOI 10.1089/0897715041269669; Chieregato A, 2007, INTENS CARE MED, V33, P856, DOI 10.1007/s00134-007-0604-4; Chieregato A, 2009, NEUROSURGERY, V64, P705, DOI 10.1227/01.NEU.0000341872.17024.44; Francony G, 2008, CRIT CARE MED, V36, P795, DOI 10.1097/CCM.0B013E3181643B41; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Harutjunyan L, 2005, CRIT CARE, V9, pR530, DOI 10.1186/cc3767; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; JENNETT B, 1975, LANCET, V1, P480; Kamel H, 2011, CRIT CARE MED, V39, P554, DOI 10.1097/CCM.0b013e318206b9be; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; Qureshi AI, 1999, NEUROSURGERY, V44, P1055, DOI 10.1097/00006123-199905000-00064; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; ROBERTSON CS, 1995, J NEUROTRAUM, V12, P891, DOI 10.1089/neu.1995.12.891; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Sakellaridis N, 2011, J NEUROSURG, V114, P545, DOI 10.3171/2010.5.JNS091685; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2007, NEUROL RES, V29, P654, DOI 10.1179/016164107X240017; Soustiel JF, 2010, NEUROSURGERY, V67, P65, DOI 10.1227/01.NEU.0000370604.30037.F5; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Soustiel JF, 2003, STROKE, V34, P1876, DOI 10.1161/01.STR.0000080942.32331.39; Soustiel JF, 2002, J ULTRAS MED, V21, P1405, DOI 10.7863/jum.2002.21.12.1405; TEASDALE G, 1974, LANCET, V2, P81; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; Zhao L, 2009, RESUSCITATION, V80, P253, DOI 10.1016/j.resuscitation.2008.10.014	41	70	73	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2003	2012		10.1089/neu.2011.1929			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500001	21787184				2022-02-06	
J	Stein, DM; Hu, PF; Brenner, M; Sheth, KN; Liu, KH; Xiong, W; Aarabi, B; Scalea, TM				Stein, Deborah M.; Hu, Peter F.; Brenner, Megan; Sheth, Kevin N.; Liu, Keng-Hao; Xiong, Wei; Aarabi, Bizhan; Scalea, Thomas M.			Brief Episodes of Intracranial Hypertension and Cerebral Hypoperfusion Are Associated With Poor Functional Outcome After Severe Traumatic Brain Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	24th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 25-29, 2011	Naples, FL	Eastern Assoc Surg Trauma		Traumatic brain injury; Secondary insults; Intracranial hypertension; Cerebral hypoperfusion	SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; PERFUSION-PRESSURE; FIBEROPTIC BRONCHOSCOPY; AGGRESSIVE TREATMENT; INTENSIVE-CARE; MORTALITY; ICP; MANAGEMENT; CHILDREN	Background: Management strategies after severe traumatic brain injury (TBI) target prevention and treatment of intracranial hypertension (ICH) and cerebral hypoperfusion (CH). We have previously established that continuous automated recordings of vital signs (VS) are more highly correlated with outcome than manual end-hour recordings. One potential benefit of automated vital sign data capture is the ability to detect brief episodes of ICH and CH. The purpose of this study was to establish whether a relationship exists between brief episodes of ICH and CH and outcome after severe TBI. Materials: Patients at the R Adams Cowley Shock Trauma Center were prospectively enrolled over a 2-year period. Inclusion criteria were as follows: age > 14 years, admission within the first 6 hours after injury, Glasgow Coma Scale score < 9 on admission, and placement of a clinically indicated ICP monitor. From high-resolution automated VS data recording system, we calculated the 5-minute means of intracranial pressure (ICP), cerebral perfusion pressure (CPP), and Brain Trauma Index (BTI = CPP/ICP). Patients were stratified by mortality and 6-month Extended Glasgow Outcome Score (GOSE). Results: Sixty subjects were enrolled with a mean admission Glasgow Coma Scale score of 6.4 +/- 3.1, a mean Head Abbreviated Injury Severity Scale score of 4.2 +/- 0.7, and a mean Marshall CT score of 2.5 +/- 0.9. Significant differences in the mean number of brief episodes of CPP < 50 and BTI < 2 in patients with a GOSE 1-4 versus GOSE 5-8 (9.4 vs. 4.7, p = 0.02 and 9.3 vs. 4.9, p = 0.03) were found. There were significantly more mean brief episodes per day of ICP > 30 (0.52 vs. 0.29, p = 0.02), CPP < 50 (0.65 vs. 0.28, p < 0.001), CPP < 60 (1.09 vs. 0.7, p = 0.03), BTI < 2 (0.66 vs. 0.31, p = 0.002), and BTI < 3 (1.1 vs. 0.64, p = 0.01) in those patients with GOSE 1-4. Number of brief episodes of CPP < 50, CPP < 60, BTI < 2, and BTI < 3 all demonstrated high predictive power for unfavorable functional outcome (area under the curve = 0.65-0.75, p < 0.05). Conclusions: This study demonstrates that the number of brief 5-minute episodes of ICH and CH is predictive of poor outcome after severe TBI. This finding has important implications for management paradigms which are currently targeted to treatment rather than prevention of ICH and CH. This study demonstrates that these brief episodes may play a significant role in outcome after severe TBI.	[Stein, Deborah M.; Brenner, Megan; Sheth, Kevin N.; Aarabi, Bizhan; Scalea, Thomas M.] Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Baltimore, MD 21201 USA; [Stein, Deborah M.; Hu, Peter F.; Brenner, Megan; Sheth, Kevin N.; Liu, Keng-Hao; Xiong, Wei; Scalea, Thomas M.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res Organized Res Ctr, Baltimore, MD 21201 USA		Stein, DM (corresponding author), Univ Maryland, Med Ctr, Div Crit Care, Program Trauma R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	dstein@umm.edu		Stein, Deborah/0000-0003-3683-3963			Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Barton CW, 2005, ACAD EMERG MED, V12, P1, DOI 10.1197/j.aem.2004.08.043; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Caruselli G, 1992, J Neurosurg Sci, V36, P219; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; Clifton GL, 2002, CRIT CARE MED, V30, P739, DOI 10.1097/00003246-200204000-00003; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Harviel JD, 2000, J TRAUMA, V48, P882; Helbok R, 2009, NEUROCRIT CARE, V11, P133, DOI 10.1007/s12028-009-9262-4; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kahraman S, 2011, J TRAUMA, V70, P547, DOI 10.1097/TA.0b013e31820c768a; Kahraman S, 2010, J NEUROSURG ANESTH, V22, P296, DOI 10.1097/ANA.0b013e3181e25fc3; Kahraman S, 2010, J TRAUMA, V69, P110, DOI 10.1097/TA.0b013e3181c99853; Kerwin AJ, 2000, J TRAUMA, V48, P878, DOI 10.1097/00005373-200005000-00011; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marmarou A, 2005, ACT NEUR S, V95, P277; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Marshall GT, 2010, J TRAUMA, V69, P275, DOI 10.1097/TA.0b013e3181de74c7; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; Mauritz W, 2007, WIEN KLIN WOCHENSCHR, V119, P46, DOI 10.1007/s00508-006-0763-2; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; NORDBY HK, 1985, ACTA NEUROCHIR, V74, P21, DOI 10.1007/BF01413271; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Scalea TM, 2007, J TRAUMA, V62, P647, DOI 10.1097/TA.0b013e31802ee542; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Skoglund K, 2009, NEUROCRIT CARE, V11, P135, DOI 10.1007/s12028-009-9255-3; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Young Jeffrey S, 2003, Neurosurg Focus, V15, pE2; Zanier ER, 2007, CRIT CARE, V11, DOI 10.1186/cc5155; [No title captured]	53	70	71	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					364	373		10.1097/TA.0b013e31822820da			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	806XH	WOS:000293850200032	21825940				2022-02-06	
J	Sullivan, PG; Sebastian, AH; Hall, ED				Sullivan, Patrick G.; Sebastian, Andrea H.; Hall, Edward D.			Therapeutic Window Analysis of the Neuroprotective Effects of Cyclosporine A after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cortical contusion; cyclosporine; cyclosporine A; mitochondrial permeability transition; neuroprotection	NERVOUS-SYSTEM TOXICITY; ALPHA-II-SPECTRIN; MITOCHONDRIAL PERMEABILITY TRANSITION; CONTROLLED CORTICAL IMPACT; CEREBROSPINAL-FLUID; CELL-DEATH; NEUROLOGIC COMPLICATIONS; BREAKDOWN PRODUCTS; OXIDATIVE DAMAGE; FREE-RADICALS	Mitochondrial dysfunction plays a pivotal role in secondary cell death mechanisms following traumatic brain injury (TBI). Several reports have demonstrated that inhibition of the mitochondrial permeability transition pore with the immunosuppressant drug cyclosporine A (CsA) is efficacious. Accordingly, CsA is being moved forward into late-stage clinical trials for the treatment of moderate and severe TBI. However, several unknowns exist concerning the optimal therapeutic window for administering CsA at the proposed dosages to be used in human studies. The present study utilized a moderate (1.75 mm) unilateral controlled cortical impact model of TBI to determine the most efficacious therapeutic window for initiating CsA therapy. Rats were administered an IP dose of CsA (20 mg/kg) or vehicle at 1, 3, 4, 5, 6, and 8 h post-injury. Immediately following the initial IP dose, osmotic mini-pumps were implanted at these time points to deliver 10 mg/kg/d of CsA or vehicle. Seventy-two hours following the initiation of treatment the pumps were removed to stop CsA administration. Quantitative analysis of cortical tissue sparing 7 days post-injury revealed that CsA treatment initiated at any of the post-injury initiation times out to 8 h resulted in significantly less cortical damage compared to animals receiving vehicle treatment. However, earlier treatment begun in the first 3 h was significantly more protective than that begun at 4 and 8 h. Treatment initiated at 1 h post-injury (similar to 68% decrease) was not significantly different than that seen at 3 h (similar to 46% decrease), but resulted in significantly greater cortical tissue sparing compared to CsA treatment initiated at least 4 h post-injury (28% decrease). Together these results illustrate the importance of initiating therapeutic interventions such as CsA as soon as possible following TBI, preferably within 4 h post-injury, to achieve the best possible neuroprotective effect. However, the drug appears to retain some protective efficacy even when initiated as late as 8 h post-injury.	[Sullivan, Patrick G.; Sebastian, Andrea H.; Hall, Edward D.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Sullivan, Patrick G.; Hall, Edward D.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA		Sullivan, PG (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, 475 BBSRB, Lexington, KY 40536 USA.	patsullivan@uky.edu	Hall, Edward D/F-8930-2013		National Institutes of Health, U.S. Public Health ServiceUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [R01 NS48191, R01 NS062993, P30 NS051220]; Kentucky Spinal Cord and Head Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS062993, R01NS048191] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health, U.S. Public Health Service grants R01 NS48191 and R01 NS062993 (to P.G.S.), and P30 NS051220 (to E.D.H.), and funding from the Kentucky Spinal Cord and Head Injury Research Trust.	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BERDEN JHM, 1985, LANCET, V1, P219; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; CHOI DW, 1987, J NEUROSCI, V7, P357; Cook AM, 2009, EXPERT OPIN DRUG SAF, V8, P411, DOI 10.1517/14740330903066742; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hatton J, 2008, J NEUROSURG, V109, P699, DOI 10.3171/JNS/2008/109/10/0699; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jordan J, 2003, J PHYSIOL BIOCHEM, V59, P129, DOI 10.1007/BF03179878; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Maragos WF, 2004, J NEUROCHEM, V91, P257, DOI 10.1111/j.1471-4159.2004.02736.x; Mazzeo AT, 2009, J NEUROTRAUM, V26, P2195, DOI 10.1089/neu.2009.1012; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Pandya JD, 2009, EXP NEUROL, V218, P381, DOI 10.1016/j.expneurol.2009.05.023; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; REYNOLDS IJ, 1995, J NEUROSCI, V15, P3318, DOI 10.1523/jneurosci.15-05-03318.1995; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Starkov AA, 2003, J NEUROCHEM, V86, P1101, DOI 10.1046/j.1471-4159.2003.01908.x; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Vink R, 2001, CLIN EXP PHARMACOL P, V28, P919, DOI 10.1046/j.1440-1681.2001.03548.x; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	68	70	71	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					311	318		10.1089/neu.2010.1646			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700014	21142667	Green Published			2022-02-06	
J	Wang, YG; Neumann, M; Hansen, K; Hong, SM; Kim, S; Noble-Haeusslein, LJ; Liu, JL				Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Noble-Haeusslein, Linda J.; Liu, Jialing			Fluoxetine Increases Hippocampal Neurogenesis and Induces Epigenetic Factors But Does Not Improve Functional Recovery after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; histone acetylation; memory; methyl-CpG binding domain 1; selective serotonin reuptake inhibitor	HISTONE H3 ACETYLATION; SYNAPTIC PLASTICITY; COGNITIVE DEFICITS; GENE-EXPRESSION; MOTOR RECOVERY; ANIMAL-MODEL; TERM-MEMORY; ADULT; 5-HT1A; IMPAIRMENT	The selective serotonin reuptake inhibitor fluoxetine induces hippocampal neurogenesis, stimulates maturation and synaptic plasticity of adult hippocampal neurons, and reduces motor/sensory and memory impairments in several CNS disorders. In the setting of traumatic brain injury (TBI), its effects on neuroplasticity and function have yet to be thoroughly investigated. Here we examined the efficacy of fluoxetine after a moderate to severe TBI, produced by a controlled cortical impact. Three days after TBI or sham surgery, mice were treated with fluoxetine (10 mg/kg/d) or vehicle for 4 weeks. To evaluate the effects of fluoxetine on neuroplasticity, hippocampal neurogenesis and epigenetic modification were studied. Stereologic analysis of the dentate gyrus revealed a significant increase in doublecortin-positive cells in brain-injured animals treated with fluoxetine relative to controls, a finding consistent with enhanced hippocampal neurogenesis. Epigenetic modifications, including an increase in histone 3 acetylation and induction of methyl-CpG-binding protein, a transcription factor involved in DNA methylation, were likewise seen by immunohistochemistry and quantitative Western immunoblots, respectively, in brain-injured animals treated with fluoxetine. To determine if fluoxetine improves neurological outcomes after TBI, gait function and spatial learning and memory were assessed by the CatWalk-assisted gait test and Barnes maze test, respectively. No differences in these parameters were seen between fluoxetine- and vehicle-treated animals. Thus while fluoxetine enhanced neuroplasticity in the hippocampus after TBI, its chronic administration did not restore locomotor function or ameliorate memory deficits.	[Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Noble-Haeusslein, Linda J.; Liu, Jialing] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94121 USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Dept Phys Therapy Rehabil Sci, San Francisco, CA 94121 USA; [Wang, Yonggang; Neumann, Melanie; Hansen, Katharina; Hong, Shuwhey M.; Kim, Sharon; Liu, Jialing] San Francisco VA Med Ctr, San Francisco, CA USA; [Wang, Yonggang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol Surg, Beijing, Peoples R China; [Neumann, Melanie] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany		Liu, JL (corresponding author), Univ Calif San Francisco, Dept Neurol Surg 112C, 4150 Clement St, San Francisco, CA 94121 USA.	jialing.liu@ucsf.edu	Liu, Jialing/A-8627-2012	Liu, Jialing/0000-0003-4420-4382	VA Merit awardUS Department of Veterans Affairs; Department of Defense collaborative in Neuroscience Center of ExcellenceUnited States Department of Defense; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050159] Funding Source: NIH RePORTER	This work was supported by a VA Merit award (to J.L.), and a Department of Defense collaborative in Neuroscience Center of Excellence (to J.L.).	Beauquis J, 2009, ANN NY ACAD SCI, V1153, P203, DOI 10.1111/j.1749-6632.2008.03983.x; Berends HI, 2009, CLIN NEUROPHARMACOL, V32, P1, DOI 10.1097/wnf.0b013e3181633482; Bilgen M, 2005, NEUROREHAB NEURAL RE, V19, P219, DOI 10.1177/1545968305278635; Boast C, 1999, NEUROBIOL LEARN MEM, V71, P259, DOI 10.1006/nlme.1998.3886; BOYESON MG, 1994, AM J PHYS MED REHAB, V73, P76, DOI 10.1097/00002060-199404000-00002; Carli M, 1997, BRAIN RES, V774, P167, DOI 10.1016/S0006-8993(97)81700-3; CARLI M, 1992, BRAIN RES, V595, P50, DOI 10.1016/0006-8993(92)91451-J; CARLI M, 1992, BRIT J PHARMACOL, V105, P720, DOI 10.1111/j.1476-5381.1992.tb09045.x; Cassel S, 2006, MOL PHARMACOL, V70, P487, DOI 10.1124/mol.106.022301; CHEN Y, 1995, BRAIN RES BULL, V38, P153, DOI 10.1016/0361-9230(95)00082-P; Cheng JP, 2008, BEHAV BRAIN RES, V194, P79, DOI 10.1016/j.bbr.2008.06.025; Crosio C, 2003, J CELL SCI, V116, P4905, DOI 10.1242/jcs.00804; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; David DJ, 2009, NEURON, V62, P479, DOI 10.1016/j.neuron.2009.04.017; Dulawa SC, 2004, NEUROPSYCHOPHARMACOL, V29, P1321, DOI 10.1038/sj.npp.1300433; Encinas JM, 2006, P NATL ACAD SCI USA, V103, P8233, DOI 10.1073/pnas.0601992103; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Guan ZH, 2002, CELL, V111, P483, DOI 10.1016/S0092-8674(02)01074-7; Holick KA, 2008, NEUROPSYCHOPHARMACOL, V33, P406, DOI 10.1038/sj.npp.1301399; Jin Y, 2009, BRAIN RES, V1281, P108, DOI 10.1016/j.brainres.2009.04.053; Jones NC, 2008, EXP NEUROL, V209, P254, DOI 10.1016/j.expneurol.2007.09.026; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kennard LE, 2005, BRIT J PHARMACOL, V144, P821, DOI 10.1038/sj.bjp.0706068; Kong EKC, 2002, NEUROCHEM RES, V27, P113, DOI 10.1023/A:1014862808126; Levenson JM, 2006, CELL MOL LIFE SCI, V63, P1009, DOI 10.1007/s00018-006-6026-6; Li WL, 2009, J NEUROSCI RES, V87, P112, DOI 10.1002/jnr.21829; Liang KC, 1998, CHINESE J PHYSIOL, V41, P33; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Maya-Vetencourt JF, 2008, SCIENCE, V320, P385, DOI 10.1126/science.1150516; Meneses A, 2002, CELL MOL NEUROBIOL, V22, P675, DOI 10.1023/A:1021800822997; Meneses A, 2007, BEHAV BRAIN RES, V184, P81, DOI 10.1016/j.bbr.2007.06.026; Miller CA, 2010, NAT NEUROSCI, V13, P664, DOI 10.1038/nn.2560; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Mostert JP, 2008, CNS NEUROSCI THER, V14, P153, DOI 10.1111/j.1527-3458.2008.00040.x; Mowla A, 2007, J CLIN PSYCHOPHARM, V27, P67, DOI 10.1097/jcp.0b013e31802e0002; Nahon E, 2005, FEBS LETT, V579, P5105, DOI 10.1016/j.febslet.2005.08.020; Narushima K, 2007, BRIT J PSYCHIAT, V190, P260, DOI 10.1192/bjp.bp.106.025064; Neumann M, 2009, J NEUROSCI METH, V176, P34, DOI 10.1016/j.jneumeth.2008.08.026; Ouardouz M, 2005, NEUROPHARMACOLOGY, V48, P566, DOI 10.1016/j.neuropharm.2004.12.007; Pariente J, 2001, ANN NEUROL, V50, P718, DOI 10.1002/ana.1257; Patterson DE, 1997, BRAIN INJURY, V11, P287, DOI 10.1080/026990597123593; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Richardson-Jones JW, 2010, NEURON, V65, P40, DOI 10.1016/j.neuron.2009.12.003; Rola R, 2006, EXP NEUROL, V202, P189, DOI 10.1016/j.expneurol.2006.05.034; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Shapira M, 2007, MOL CELL NEUROSCI, V34, P571, DOI 10.1016/j.mcn.2006.12.006; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Singh RP, 2009, CELL TRANSPLANT, V18, P1197, DOI 10.3727/096368909X12483162197204; Svenningsson P, 2005, AAPS J, V7, DOI 10.1208/aapsj070235; Wang JW, 2008, J NEUROSCI, V28, P1374, DOI 10.1523/JNEUROSCI.3632-07.2008; Wilson MA, 2002, FUEL, V81, P5, DOI 10.1016/S0016-2361(00)00192-7; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085; ZHANG XH, 1993, NEUROREPORT, V4, P1235, DOI 10.1097/00001756-199309000-00006	57	70	71	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					259	268		10.1089/neu.2010.1648			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700009	21175261	Green Published			2022-02-06	
J	Haseler, CM; Carmont, MR; England, M				Haseler, Christine M.; Carmont, Michael R.; England, Michael			The epidemiology of injuries in English youth community rugby union	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TACKLE INJURIES; FOOTBALL; SCHOOL; PLAYERS	Introduction Recent studies report the incidence and epidemiology of injury in professional rugby union; however, there is limited research in amateur and youth rugby. Injuries in youth rugby may have consequences for sports participation and physical development. The authors performed a prospective cohort study of injuries during youth community rugby. Methods An injury surveillance programme was established for the 2008-2009 season (9 months, 1636 player-hours) of an English community rugby club. The study included 210 players, all males, in Under 9 to Under 17 (U9-U17) age groups. These were categorised into mini, junior, pubertal and school participation age groupings. Injuries were defined according to the International Rugby Board consensus statements. Results There were 39 injuries reported (overall injury rate 24/1000 player-hours). Injury rates ranged from 0 to 49.3/1000 player-hours. More injuries occurred in junior (34.2/1000 player-hours) than in minis (11.9/1000 player-hours) (p<0.025). Higher numbers of moderate (20.6/1000 player-hours, p<0.005) and severe (9.5/1000 player-hours, p<0.05) injuries occurred in the U16-U17 age groups compared with younger age groups (U9-U10) where only minor injuries were reported. Most injuries occurred in the tackle (59%). The knee (4.9/1000 player-hours), shoulder (4.9/1000 player-hours) and head (4.3/1000 player-hours) were the most commonly affected areas. Concussion (1.8/1000 player-hours) affected half of the head injuries. Conclusions Injuries in youth rugby occur infrequently and are lower than in adult series. The risk of injury and severity of injury increases with age. This study highlights the need for further research into injury risk factors around puberty and the need for first aid provision.	[Haseler, Christine M.] Univ Bath, Ctr Hlth & Exercise Sci, Bath BA2 7AY, Avon, England; [Carmont, Michael R.] Princess Royal Hosp, Telford TF6 6TF, Shrops, England; [England, Michael] Rugby Football Union, Twickenham, England		Haseler, CM (corresponding author), Springbank, Springbank Surg, Cheltenham GL51 0LG, Glos, England.	christinehas@doctors.org.uk					Abernethy L, 2003, BRIT J SPORT MED, V37, P354, DOI 10.1136/bjsm.37.4.354; Adams DG, 2001, SPORTS MED SPECIFIC, P95, DOI DOI 10.1136/BJSM.2006.033282; Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; Agran PF, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.3.e45; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Best JP, 2005, BRIT J SPORT MED, V39, P812, DOI 10.1136/bjsm.2004.016402; Boreham C., 2001, SPORTS MED SPECIFIC, P65, DOI DOI 10.1136/BJSM.2008.050864; Bottini E, 2000, BRIT J SPORT MED, V34, P94, DOI 10.1136/bjsm.34.2.94; BROOKS JH, 2006, AM J SPORT MED, V38, pS351, DOI DOI 10.1177/0363546508316768; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; DALLEY DR, 1982, NZ J SPORTS MED, V10, P5; Damore DT, 2003, PEDIATR EMERG CARE, V19, P65, DOI 10.1097/00006565-200304000-00001; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; DURIE RM, 2000, NZ J SPORTS MED, V28, P84; Emery CA, 2010, BRIT J SPORT MED, V44, P64, DOI 10.1136/bjsm.2009.068353; Emery CA, 2003, CLIN J SPORT MED, V13, P256, DOI 10.1097/00042752-200307000-00011; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Lee AJ, 1996, BRIT J SPORT MED, V30, P213, DOI 10.1136/bjsm.30.3.213; McIntosh AS, 2010, BRIT J SPORT MED, V44, P188, DOI 10.1136/bjsm.2007.041400; McIntosh Andrew S, 2005, Med Sport Sci, V49, P120, DOI 10.1159/000085394; Price RJ, 2004, BRIT J SPORT MED, V38, P466, DOI 10.1136/bjsm.2003.005165; Pringle RG, 1998, BRIT J SPORT MED, V32, P49, DOI 10.1136/bjsm.32.1.49; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; ROUX CE, 1987, S AFR MED J, V71, P307; SCARAMELLA TJ, 1978, PSYCHOSOM MED, V40, P262, DOI 10.1097/00006842-197805000-00007; Schmidt-Olsen S, 1985, Br J Sports Med, V19, P161; Sparks J P, 1985, Br J Sports Med, V19, P71; Sparks J P, 1981, Br J Sports Med, V15, P30; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	34	70	72	0	30	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2010	44	15					1093	1099		10.1136/bjsm.2010.074021			7	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	696CW	WOS:000285420500005	20961921				2022-02-06	
J	Gioia, GA; Kenworthy, L; Isquith, PK				Gioia, Gerard A.; Kenworthy, Lauren; Isquith, Peter K.			Executive Function in the Real World: BRIEF Lessons From Mark Ylvisaker	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assessment; executive function; traumatic brain injury; TBI; Ylvisaker	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; NEUROPSYCHOLOGICAL ASSESSMENT; ECOLOGICAL VALIDITY; EARLY-CHILDHOOD; YOUNG-CHILDREN; TBI; PERFORMANCE; ADOLESCENTS; IMPAIRMENT	It is well established that brain injuries adversely affect the executive functions and their development. Mark Ylvisaker had a substantial impact on how we assess and treat children and adolescents with disrupted executive functions secondary to traumatic brain injury. He articulated core principles for effective assessment and intervention that emphasized the importance of real-world meaning and application. He taught us that assessment that captures a child's everyday functioning in the context of real-world demands is often more informative than traditional neuropsychological measures alone and that interventions that improve functioning in the real-world environment are most useful. His pragmatic model influenced our own efforts to measure executive function and to develop intervention systems for children with executive function deficits. This article reviews the development of the Behavior Rating Inventory for Executive Function as an approach to ecological assessment of children and adolescents with traumatic brain injury. As we take what we learned from Mark Ylvisaker, it becomes increasingly apparent that our assessment and intervention methods, especially as related to the executive functions, demand an everyday, real-world context.	[Gioia, Gerard A.; Kenworthy, Lauren] Childrens Natl Med Ctr, Div Pediat Neuropsychol, Rockville, MD 20850 USA; [Gioia, Gerard A.; Kenworthy, Lauren] George Washington Univ, Sch Med, Washington, DC USA; [Isquith, Peter K.] Dartmouth Med Sch, Lebanon, NH USA		Gioia, GA (corresponding author), Childrens Natl Med Ctr, Div Pediat Neuropsychol, 15245 Shady Grove Rd,Ste 350, Rockville, MD 20850 USA.	ggioia@cnmc.org	Isquith, Peter/AAY-4851-2020; Kenworthy, Lauren/AAI-7572-2020		Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352]; National Center for Research Resources, a component of the National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359]; Gudelsky Family Foundation; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HDO40677-07]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR020359] Funding Source: NIH RePORTER	This publication was made possible in part by Centers for Disease Control and Prevention award U17/CCU323352 and grant M01RR020359 from the National Center for Research Resources, a component of the National Institutes of Health (NIH), and the Gudelsky Family Foundation. Other grant support included NIH P30/HDO40677-07.	Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Antshel KM, 2005, PSYCHIAT RES-NEUROIM, V138, P235, DOI 10.1016/j.pscychresns.2005.02.003; Antshel KM, 2003, NEUROPSYCHOLOGY, V17, P458, DOI 10.1037/0894-4105.17.3.458; Barkley RA, 2010, ARCH CLIN NEUROPSYCH, V25, P157, DOI 10.1093/arclin/acq014; Beebe DW, 2004, J INT NEUROPSYCH SOC, V10, P962, DOI 10.1017/S135561770410708X; Bernstein J.H., 2007, EXECUTIVE FUNCTION E, V1st ed., P39; Braga LW, 2005, BRAIN INJURY, V19, P819, DOI 10.1080/02699050500110165; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Dise-Lewis JE, 2009, J HEAD TRAUMA REHAB, V24, P166, DOI 10.1097/HTR.0b013e3181a7ecb0; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Feeney T, 2006, BRAIN INJURY, V20, P629, DOI 10.1080/02699050600744194; Gioia G.A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2005, PSYCHOL ASSESS RESOU; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Turkstra Lyn S., 2005, Seminars in Speech and Language, V26, P215, DOI 10.1055/s-2005-922101; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; Wade SL, 2010, J HEAD TRAUMA REHAB, V25, P409, DOI 10.1097/HTR.0b013e3181fb900d; Wade SL, 2005, REHABIL PSYCHOL, V50, P337, DOI 10.1037/0090-5550.50.4.337; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Ylvisaker M., 1998, COLLABORATIVE BRAIN; Ylvisaker M. E., 1998, TRAUMATIC BRAIN INJU; Ylvisaker M, 2007, BRAIN INJURY, V21, P769, DOI 10.1080/02699050701482470	43	70	71	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2010	25	6					433	439		10.1097/HTR.0b013e3181fbc272			7	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	679HA	WOS:000284151300005	21076244				2022-02-06	
J	Mazur, M; Miller, RH; Robinson, S				Mazur, Marcus; Miller, Robert H.; Robinson, Shenandoah			Postnatal erythropoietin treatment mitigates neural cell loss after systemic prenatal hypoxic-ischemic injury Laboratory investigation	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						cerebral palsy; epilepsy; oligodendrocyte; erythropoietin receptor; gamma-aminobutyric acid; preterm brain injury	TRAUMATIC BRAIN-INJURY; LOW-BIRTH-WEIGHT; DOSE RECOMBINANT ERYTHROPOIETIN; CEREBRAL-ISCHEMIA; PERIVENTRICULAR LEUKOMALACIA; MEDIATED NEUROPROTECTION; EXPRESSION PATTERNS; CEREBROSPINAL-FLUID; WHITE-MATTER; SPINAL-CORD	Object. Brain injury from preterm birth predisposes children to cerebral palsy, epilepsy, cognitive delay, and behavioral abnormalities. The CNS injury often begins before the early birth, which hinders diagnosis and concurrent treatment. Safe, effective postnatal interventions are urgently needed to minimize these chronic neurological deficits. Erythropoietin (EPO) is a pleiotropic neuroprotective cytokine, but the biological basis of its efficacy in the damaged developing brain remains unclear. Coordinated expression of EPO ligand and receptor expression occurs during CNS development to promote neural cell survival. The authors propose that prenatal third trimester global hypoxia-ischemia disrupts the developmentally regulated expression of neural cell EPO signaling, and predisposes neural cells to death. Furthermore, the authors suggest that neonatal exogenous recombinant human EPO (rhEPO) administration can restore the mismatch of EPO ligand and receptor levels, and enhance neural cell survival. Methods. Transient systemic hypoxia-ischemia (TSHI) on embryonic Day 18 in rats mimics human early-third-trimester placental insufficiency. This model was used to test the authors' hypothesis using a novel clinically relevant paradigm of prenatal injury on embryonic Day 18, neonatal systemic rhEPO administration initiated 4 days after injury on postnatal Day 1, and histological, biochemical, and functional analyses in neonatal, juvenile, and adult rats. Results. The results showed that prenatal TSHI upregulates brain EPO receptors, but not EPO ligand. Sustained EPO receptor upregulation was pronounced on oligodendroglial lineage cells and neurons, neural cell populations particularly prone to loss from CNS injury due to preterm birth. Postnatal rhEPO administration after prenatal TSHI minimized histological damage and rescued oligodendrocytes and gamma-aminobutyric acidergic interneurons. Myelin basic protein expression in adult rats after insult was reduced compared with sham controls, but could be restored to near normal levels by neonatal rhEPO treatment. Erythropoietin-treated TSHI rats performed significantly better than their saline-treated peers as adults in motor skills tests, and showed significant seizure threshold restoration using a pentylenetetrazole increasing-dose paradigm. Conclusions. These data demonstrate that neonatal rhEPO administration in a novel clinically relevant paradigm initiated 4 days after a global prenatal hypoxic-ischemic insult in rats rescues neural cells, and induces lasting histological and functional improvement in adult rats. (DOI: 10.3171/2010.5.PEDS1032)	[Mazur, Marcus; Robinson, Shenandoah] Rainbow Babies & Childrens Hosp, Dept Neurosurg, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, Cleveland, OH 44106 USA; [Miller, Robert H.] Rainbow Babies & Childrens Hosp, Dept Neurosci, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, Cleveland, OH 44106 USA		Robinson, S (corresponding author), Rainbow Babies & Childrens Hosp, Dept Neurosurg, Neurol Inst,Ctr Translat Neurosci, Univ Hosp Case Med Ctr,Case Western Reserve Sch M, B501,11100 Euclid Ave, Cleveland, OH 44106 USA.	shenandoah.robinson@UHhospitals.org			National Institute of Neurological Disorders and Stroke, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08 NS46486, R01 NS060765]; Rainbow Babies and Children's Hospital Board of Trustees; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030800, K08NS046486, R01NS060765] Funding Source: NIH RePORTER	This work was supported by grants to Dr. Robinson from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, No. K08 NS46486 and R01 NS060765, and from the Rainbow Babies and Children's Hospital Board of Trustees.	Anderson J, 2009, J NEUROTRAUM, V26, P1557, DOI 10.1089/neu.2008-0765; Arrieta O, 2005, EPILEPSIA, V46, P1599, DOI 10.1111/j.1528-1167.2005.00267.x; Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Back SA, 2002, J NEUROPATH EXP NEUR, V61, P197, DOI 10.1093/jnen/61.2.197; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Chang YS, 2005, PEDIATR RES, V58, P106, DOI 10.1203/01.PDR.0000163616.89767.69; Chavez JC, 2006, J NEUROSCI, V26, P9471, DOI 10.1523/JNEUROSCI.2838-06.2006; Chen G, 2007, NEUROSCI LETT, V425, P177, DOI 10.1016/j.neulet.2007.08.022; Chen ZY, 2007, J BIOL CHEM, V282, P25875, DOI 10.1074/jbc.M701988200; Daw MI, 2007, NAT NEUROSCI, V10, P453, DOI 10.1038/nn1866; Demers EJ, 2005, PEDIATR RES, V58, P297, DOI 10.1203/01.PDR.0000169971.64558.5A; Digicaylioglu M, 2004, P NATL ACAD SCI USA, V101, P9855, DOI 10.1073/pnas.0403172101; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fauchere JC, 2008, PEDIATRICS, V122, P375, DOI 10.1542/peds.2007-2591; Golan H, 2006, DEVELOPMENTAL SCI, V9, P338, DOI 10.1111/j.1467-7687.2006.00498.x; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Hack M, 2005, JAMA-J AM MED ASSOC, V294, P318, DOI 10.1001/jama.294.3.318; Iai M, 1999, NEUROPEDIATRICS, V30, P14, DOI 10.1055/s-2007-973450; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Li Y, 2007, J CEREBR BLOOD F MET, V27, P1043, DOI 10.1038/sj.jcbfm.9600417; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; Liu C, 1997, J BIOL CHEM, V272, P32395, DOI 10.1074/jbc.272.51.32395; McPherson RJ, 2008, INT J DEV NEUROSCI, V26, P103, DOI 10.1016/j.ijdevneu.2007.08.012; McPherson RJ, 2007, NEONATOLOGY, V91, P36, DOI 10.1159/000096969; Metz GA, 2002, J NEUROSCI METH, V115, P169, DOI 10.1016/S0165-0270(02)00012-2; Minino Arialdi M, 2007, Natl Vital Stat Rep, V55, P1; Mizuno K, 2008, NEONATOLOGY, V94, P255, DOI 10.1159/000151644; Nakajima W, 2000, J NEUROSCI, V20, P7994; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Petrou S, 2005, BJOG-INT J OBSTET GY, V112, P10, DOI 10.1111/j.1471-0528.2005.00577.x; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Robinson S, 2005, EPILEPSY BEHAV, V7, P345, DOI 10.1016/j.yebeh.2005.06.005; Robinson S, 2005, NEUROBIOL DIS, V18, P568, DOI 10.1016/j.nbd.2004.10.024; Robinson S, 2006, J NEUROSURG, V104, P396, DOI 10.3171/ped.2006.104.6.396; Ronen GM, 2007, NEUROLOGY, V69, P1816, DOI 10.1212/01.wnl.0000279335.85797.2c; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Siren AL, 2001, ACTA NEUROPATHOL, V101, P271, DOI 10.1007/s004010000297; Sizonenko SV, 2005, PEDIATR RES, V57, P865, DOI 10.1203/01.PDR.0000157673.36848.67; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Spandou E, 2005, BRAIN RES, V1045, P22, DOI 10.1016/j.brainres.2005.03.013; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Taoufik E, 2008, P NATL ACAD SCI USA, V105, P6185, DOI 10.1073/pnas.0801447105; Trollmann R, 2008, AM J PHYSIOL-REG I, V295, pR1973, DOI 10.1152/ajpregu.00053.2008; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Uzum G, 2006, LIFE SCI, V78, P2571, DOI 10.1016/j.lfs.2005.10.027; Vitellaro-Zuccarello L, 2007, NEUROSCIENCE, V144, P865, DOI 10.1016/j.neuroscience.2006.10.023; Volpe JJ, 2005, PEDIATRICS, V116, P221, DOI 10.1542/peds.2005-0191; Volpe JJ, 2009, LANCET NEUROL, V8, P110, DOI 10.1016/S1474-4422(08)70294-1; Wen TC, 2004, NEUROSCI LETT, V355, P165, DOI 10.1016/j.neulet.2003.10.078; Wilson-Costello D, 2005, PEDIATRICS, V115, P997, DOI 10.1542/peds.2004-0221; Xenocostas A, 2005, EUR J CLIN PHARMACOL, V61, P189, DOI 10.1007/s00228-005-0896-7; Yu XB, 2002, DEVELOPMENT, V129, P505	62	70	76	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	SEP	2010	6	3					206	221		10.3171/2010.5.PEDS1032			16	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	641FT	WOS:000281110900003	20809703	Green Accepted			2022-02-06	
J	Grady, MF				Grady, Matthew F.			Concussion in the Adolescent Athlete	CURRENT PROBLEMS IN PEDIATRIC AND ADOLESCENT HEALTH CARE			English	Article							TRAUMATIC BRAIN-INJURY; NATIONAL-FOOTBALL-LEAGUE; SPORTS-RELATED CONCUSSION; FLUID PERCUSSION INJURY; TEST-RETEST RELIABILITY; ICE HOCKEY INJURIES; CEREBRAL-BLOOD-FLOW; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; SEX-DIFFERENCES	Concussion in the adolescent athlete is a common sports and recreation injury. Traditional management of concussion in this age group has focused on sport return-to-play decisions. However, new research on mild traumatic brain injury has dramatically changed the management of concussion. During the acute healing phase, physical and cognitive rest are crucial for healing. In the school-aged athlete, new concepts, such as complete brain rest, have made school management decisions as important as sport return-to-play decisions. Despite tremendous improvements in the understanding of concussion, most of the research has been done in young adults. The lack of prospective studies in early adolescent student athletes limits definitive management recommendations. This article reviews the current understanding of the epidemiology, pathophysiology, and clinical presentation of concussion and discusses the unique factors involved in clinical management of concussion in the adolescent student-athlete. Curr Probl Pediatr Adolesc Health Care 2010;40:154-169	Childrens Hosp Philadelphia, Sports Med & Performance Ctr, King Of Prussia, PA USA		Grady, MF (corresponding author), Childrens Hosp Philadelphia, Sports Med & Performance Ctr, King Of Prussia, PA USA.						Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; [Anonymous], 2007, MMWR-MORBID MORTAL W, V56, P733; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Bergschneider M, 2003, J NEUROSURG, V86, P241; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 2009, CURR SPORT MED REP, V8, P6, DOI 10.1249/JSR.0b013e31819677db; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P624, DOI 10.1080/13803390490918589; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Donat CK, 2010, INT J DEV NEUROSCI, V28, P31, DOI 10.1016/j.ijdevneu.2009.10.001; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gladwell M, 2009, NEW YORKER, V85, P50; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, CLIN J SPORT MED, V17, P31; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P1; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Kraus J F, 2000, Neurosurg Focus, V8, pe5; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langham J, 2003, COCHRANE DB SYST REV, V4; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lee LL, 2004, EXP NEUROL, V190, P70, DOI 10.1016/j.expneurol.2004.07.003; Lee Michael A, 2009, Conn Med, V73, P171; Lovell M, 2008, NEUROL CLIN, V26, P45, DOI 10.1016/j.ncl.2007.12.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McCrory PR, 2001, NEUROLOGY, V57, P2283, DOI 10.1212/WNL.57.12.2283; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; McKeag DB, 2009, CLIN J SPORT MED, V19, P343, DOI 10.1097/JSM.0b013e3181b2c114; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140, DOI 10.1097/JSM.0b013e31803212ae; Mintun MA, 2001, P NATL ACAD SCI USA, V98, P6859, DOI 10.1073/pnas.111164398; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pickering A, 2008, ANN EMERG MED, V51, P471, DOI 10.1016/j.annemergmed.2008.01.271; Preece MHW, 2007, BRAIN INJURY, V21, P951, DOI 10.1080/02699050701481647; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Tang-Schomer MD, 2009, FASEB J; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Thurman, 1999, TRAUMATIC BRAIN INJU; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; Udomphorn Y, 2008, PEDIATR NEUROL, V38, P225, DOI 10.1016/j.pediatrneurol.2007.09.012; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Viccellio P, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e20; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zornow M H, 1996, New Horiz, V4, P107	124	70	70	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1538-5442	1538-3199		CURR PROB PEDIATR AD	Curr. Probl. Pediatr. Adolesc. Health Care	AUG	2010	40	7					154	169		10.1016/j.cppeds.2010.06.002			16	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	V26OH	WOS:000208554400002	20705248				2022-02-06	
J	Schnuriger, B; Inaba, K; Abdelsayed, GA; Lustenberger, T; Eberle, BM; Barmparas, G; Talving, P; Demetriades, D				Schnuriger, Beat; Inaba, Kenji; Abdelsayed, George A.; Lustenberger, Thomas; Eberle, Barbara M.; Barmparas, Galinos; Talving, Peep; Demetriades, Demetrios			The Impact of Platelets on the Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma; Platelet; Traumatic brain injury; Intracranial; Hemorrhage; Progression; Blunt	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; COAGULOPATHY; CRITERIA; MODERATE	Background: The purpose of this study was to analyze the association of the initial platelet count with mortality and progression of intracranial hemorrhage (ICH) in blunt traumatic brain injured (TBI) patients. Methods: All blunt trauma patients with severe TBI admitted from January 2006 to December 2007 were retrospectively identified. Patients with a chest, abdomen, or extremity AIS score >3 were excluded to minimize the impact of concomitant injuries on the outcomes of the patients. All brain computed tomography scans were reviewed to analyze ICH progression. Discrete platelet cutoff values were entered into a multiple regression model to detect critical thresholds associated with ICH progression and mortality. Results: Of 626 TBI patients, 310 (49.5%) had a minimum of two brain computed tomography scans and were able to have ICH progression evaluated. Patients with platelets <175,000/mm(3) had a significantly increased risk for ICH progression (OR [95% CI]: 2.09 [1.07-4.37]; adjusted p = 0.043). ICH progression was associated with increased need for craniotomy (OR [95% CI]: 3.27 [1.28-8.33]; adjusted p = 0.013) and mortality (OR [95% CI]: 3.41 [1.11-10.53]; adjusted p = 0.033). A platelet count <100,000/m(3) was an independent predictor for mortality (OR [95% CI]: 9.5 [1.3-71.4]; adjusted p = 0.029). Conclusion: A platelet count <100,000/mm(3) is associated with a ninefold adjusted risk of death, and a platelet count <175,000/mm(3) is a significant predictor of ICH progression. The impact of early correction of the admission platelet count warrants further validation.	[Schnuriger, Beat; Inaba, Kenji; Abdelsayed, George A.; Lustenberger, Thomas; Eberle, Barbara M.; Barmparas, Galinos; Talving, Peep; Demetriades, Demetrios] Univ So Calif, Los Angeles Cty Med Ctr, Div Trauma & Surg Crit Care, Los Angeles, CA 90033 USA		Schnuriger, B (corresponding author), 1200 N State St,Inpatient Tower C,5th Floor,Room, Los Angeles, CA 90033 USA.	kinaba@surgery.usc.edu	Talving, Peep/G-8621-2015; Talving, Peep/E-6015-2013; INABA, KENJI/AAC-8532-2020; Barmparas, Galinos/L-6530-2019	Talving, Peep/0000-0002-9741-2073; 			Akca S, 2002, CRIT CARE MED, V30, P753, DOI 10.1097/00003246-200204000-00005; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Brohi K, 2007, ANN SURG, V245, P812, DOI 10.1097/01.sla.0000256862.79374.31; Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Carrick MM, 2005, J TRAUMA, V58, P725, DOI 10.1097/01.TA.0000159249.68363.78; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; Gando S, 2006, CRIT CARE MED, V34, P625, DOI 10.1097/01.CCM.0000202209.42491.38; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Ivascu FA, 2005, J TRAUMA, V59, P1131, DOI 10.1097/01.ta.0000189067.16368.83; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levi M, 1999, NEW ENGL J MED, V341, P586, DOI 10.1056/NEJM199908193410807; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Pondaag W, 1979, Acta Neurochir Suppl (Wien), V28, P98; REILLY PL, 1975, LANCET, V2, P375; Selladurai BM, 1997, BRIT J NEUROSURG, V11, P398; Servadei F, 2000, NEUROSURGERY, V46, P70, DOI 10.1093/neurosurgery/46.1.70; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327, DOI 10.1055/s-0037-1616068; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034	25	70	76	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2010	68	4					881	885		10.1097/TA.0b013e3181d3cc58			5	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	583GY	WOS:000276663100025	20386283				2022-02-06	
J	Poca, MA; Benejam, B; Sahuquillo, J; Riveiro, M; Frascheri, L; Merino, MA; Delgado, P; Alvarez-Sabin, J				Antonia Poca, Maria; Benejam, Bessy; Sahuquillo, Juan; Riveiro, Marilyn; Frascheri, Laura; Angels Merino, Maria; Delgado, Pilar; Alvarez-Sabin, Jose			Monitoring intracranial pressure in patients with malignant middle cerebral artery infarction: is it useful? Clinical article	JOURNAL OF NEUROSURGERY			English	Article						intracranial pressure monitoring; middle cerebral artery; infarction; midline shift; pupillary abnormality; intracranial hypertension	SEVERE HEAD-INJURY; ACUTE HEMISPHERIC STROKE; MODERATE HYPOTHERMIA; DECOMPRESSIVE CRANIECTOMY; MILD HYPOTHERMIA; THERAPEUTIC HYPOTHERMIA; ISCHEMIC-STROKE; HEMICRANIECTOMY; BRAIN; SURGERY	Object. Intracranial pressure (ICP) monitoring is increasingly used in the treatment of patients with malignant middle cerebral artery (MCA) infarction. However, neurological deterioration may exist independent from intracranial hypertension. This study aimed to present the findings of continuous ICP monitoring in a cohort of patients with malignant MCA infarction and to correlate these findings with clinical and radiological features. Methods. The authors studied a prospective cohort of 25 patients with malignant MCA infarction consecutively admitted to the neurotrauma intensive care unit of the Vall d'Hebron University Hospital between March 2002 and September 2006. The patients were treated using a combined protocol of initial moderate hypothermia and hemicraniectomy. The latter was performed when patients showed a midline shift (MLS) >= 5 mm or ICP > 20 mm Hg. Six patients had an MLS >= 5 mm on the first CT scan and underwent surgery without prior ICP monitoring. This study focuses on the subgroup of 19 patients who underwent intraparenchymatous ICP monitoring before surgery. Results. Intracranial pressure readings were evaluated and correlated with pupillary abnormalities, MLS, and ischemic tissue volume. In 12 of the 19 patients, ICP values were always <= 20 mm Hg, despite a mean (+/- SD) MLS of 6.7 +/- 2 mm and a mean ischemic tissue volume of 241.3 +/- 83 cm(3). In 2 patients with anisocoria, ICP values were also normal. Conclusions. In patients with a malignant MCA infarction, pupillary abnormalities and severe brainstem compression may be present despite normal ICP values. Therefore, continuous ICP monitoring cannot substitute for close clinical and radiological follow-up in the management of these patients. (DOI: 10.3171/2009.7.JNS081677)	[Antonia Poca, Maria; Sahuquillo, Juan] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurosurg, E-08035 Barcelona, Spain; [Antonia Poca, Maria; Benejam, Bessy; Sahuquillo, Juan; Angels Merino, Maria] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurotraumatol Neurosurg Res Unit, E-08035 Barcelona, Spain; [Riveiro, Marilyn] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurotraumatol Intens Care Unit, E-08035 Barcelona, Spain; [Frascheri, Laura] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Inst Diagnost Imaging, E-08035 Barcelona, Spain; [Delgado, Pilar; Alvarez-Sabin, Jose] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Neurovasc Unit, E-08035 Barcelona, Spain; [Delgado, Pilar; Alvarez-Sabin, Jose] Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurol, E-08035 Barcelona, Spain		Poca, MA (corresponding author), Autonomous Univ Barcelona, Vall Hebron Univ Hosp, Inst Recerca Vall Hebron, Dept Neurosurg, Passeig Vall Hebron 119-129, E-08035 Barcelona, Spain.	pocama@neurotrauma.net	Sahuquillo, Juan/B-3577-2008; Poca, Maria A./B-8475-2008; Riveiro, Marilyn/S-5242-2016	Sahuquillo, Juan/0000-0003-0713-5875; Poca, Maria A./0000-0002-3831-0536; Riveiro, Marilyn/0000-0002-1645-3720; Alvarez-Sabin, Jose/0000-0002-8054-9209; Delgado Martinez, Maria Pilar/0000-0002-1628-4488	Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS)Instituto de Salud Carlos III [05/1092, 07/0681]; European CommissionEuropean CommissionEuropean Commission Joint Research Centre [QLK1-CT-2002-02583]	This work was supported in part by Fondo de Investigaciones Sanitarias de la Seguridad Social (FIS) grants received by Dr. J. Sahuquillo (No. 05/1092) and Dr. M. A. Poca ( No. 07/0681), and by the Fifth European Framework of the European Commission (SMILE project QLK1-CT-2002-02583). Dr. Sahuquillo is a consultant for Vasopharm Gmbh. The authors report no other conflicts of interest concerning the materials or methods used in this study or the findings specified in this paper.	BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Benejam B, 2008, NEUROLOGIA, V23, P40; Bennett JA, 2002, HEART LUNG, V31, P262, DOI 10.1067/mhl.2002.124554; Berrouschot J, 1998, INTENS CARE MED, V24, P620, DOI 10.1007/s001340050625; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P597; Brandt T, 1996, BAILLIERE CLIN NEUR, V5, P515; Carhuapoma JR, 2002, J NEUROSURG ANESTH, V14, P299, DOI 10.1097/00008506-200210000-00005; Cho DY, 2003, SURG NEUROL, V60, P227, DOI 10.1016/S0090-3019(03)00266-0; Delgado-Lopez P, 2004, NEUROCIRUGIA, V15, P43; Desco M, 1999, INT CONGR SER, V1191, P218; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; Els T, 2006, CEREBROVASC DIS, V21, P79, DOI 10.1159/000090007; FORSTING M, 1995, STROKE, V26, P259, DOI 10.1161/01.STR.26.2.259; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; Georgiadis D, 2002, STROKE, V33, P1584, DOI 10.1161/01.STR.0000016970.51004.D9; Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012; Keller E, 2000, CRIT CARE MED, V28, P511, DOI 10.1097/00003246-200002000-00037; Kraus JJ, 2002, NEUROL RES, V24, pS47; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Schneweis S, 2001, STROKE, V32, P1863, DOI 10.1161/01.STR.32.8.1863; Schwab S, 1996, NEUROLOGY, V47, P393, DOI 10.1212/WNL.47.2.393; Schwab S, 2005, Cerebrovasc Dis, V20 Suppl 2, P169, DOI 10.1159/000089371; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Schwab S, 1998, ACT NEUR S, V71, P131; Schwab S, 2001, STROKE, V32, P2033, DOI 10.1161/hs0901.095394; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Steiner T, 2001, NEUROLOGY, V57, pS61, DOI 10.1212/WNL.57.suppl_2.S61; Stolz E, 1999, STROKE, V30, P70, DOI 10.1161/01.STR.30.1.70; Su J, 2003, INT J DEV NEUROSCI, V21, P353, DOI 10.1016/S0736-5748(03)00070-4; The Brain TraumaFoundation, 2000, J NEUROTRAUM, V17, P583, DOI [10.1089/neu.2000.17.583, DOI 10.1089/NEU.2000.17.583]; Vahedi K, 2007, LANCET NEUROL, V6, P215, DOI 10.1016/S1474-4422(07)70036-4; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Yanamoto H, 2001, STROKE, V32, P232, DOI 10.1161/01.STR.32.1.232	38	70	79	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2010	112	3					648	657		10.3171/2009.7.JNS081677			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	562IQ	WOS:000275043900028	19663552				2022-02-06	
J	Garden, N; Sullivan, KA				Garden, Natalie; Sullivan, Karen A.			An Examination of the Base Rates of Post-Concussion Symptoms: The Influence of Demographics and Depression	APPLIED NEUROPSYCHOLOGY			English	Article						base rates; depression; mild traumatic brain injury; neuropsychology; post-concussion syndrome	TRAUMATIC-BRAIN-INJURY; MILD HEAD-INJURY; POSTCONCUSSION-LIKE SYMPTOMS; CHRONIC PAIN; STRESS; ADULTS	Post-concussion syndrome (PCS) is a controversial constellation of cognitive, emotional, and physical symptoms that some patients experience following a mild traumatic brain injury or concussion. PCS-like symptoms are commonly found in individuals with depression, pain, and stress, as well as healthy individuals. This study investigated the base rate of PCS symptoms in a healthy sample of 96 participants and examined the relationship between these symptoms, depression, and sample demographics. PCS symptoms were assessed using the British-Columbia Post-Concussion Symptom Inventory. Depression was measured using the Beck Depression Inventory II. Results demonstrated that: The base rate of PCS was very high; there was a strong positive relationship between depression and PCS; and demographic characteristics were not related to PCS in this sample. These findings are broadly consistent with literature suggesting a significant role for non-neurological factors in the expression of PCS symptomatology. This study adds to the growing body of literature that calls for caution in the clinical interpretation of results from PCS symptom inventories.	[Sullivan, Karen A.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Garden, Natalie] Queensland Univ Technol, Sch Psychol & Counseling, Clin Neuropsychol Res Grp, Brisbane, Qld 4001, Australia		Sullivan, KA (corresponding author), Queensland Univ Technol, Sch Psychol & Counseling, Clin Neuropsychol Res Grp, O Block B Wing Room 523,Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.	karen.sullivan@qut.edu.au			School of Psychology and Counseling, Queensland University of Technology	The Human Research Ethics Committee of Queensland University of Technology (approval no. 0700000965) approved all research documented in this report. The authors wish to acknowledge the generous assistance of Dr. Patricia Obst, statistics consultant, School of Psychology and Counseling, Queensland University of Technology, and Dr. Rael T. Lange who contributed to early discussions about this manuscript. Funding for this project was provided by the School of Psychology and Counseling, Queensland University of Technology.	Anderson T, 2006, PRACTICAL NEUROLOGY, V6, P342, DOI DOI 10.1136/JNNP.2006.106583; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Draguns JG, 2003, BEHAV RES THER, V41, P755, DOI 10.1016/S0005-7967(02)00190-0; GFELLER J, 1996, ASSESSMENT, V3, P393; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Iverson G.L, 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; Rush BK, 2006, REHABIL PSYCHOL, V51, P257, DOI 10.1037/0090-5550.51.3.257; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Santa Maria MP, 2001, ARCH CLIN NEUROPSYCH, V16, P133; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stonnington CM, 2001, BRAIN INJURY, V15, P561, DOI 10.1080/02699050110034316; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Sullivan K. A., J HEAD TRAU IN PRESS; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang Y, 2006, ARCH CLIN NEUROPSYCH, V21, P339, DOI 10.1016/j.acn.2006.03.006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	36	70	70	0	7	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCHOL	Appl. Neuropsychol.		2010	17	1					1	7	PII 919154553	10.1080/09084280903297495			7	Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	554JY	WOS:000274432500001	20146116				2022-02-06	
J	Jacobsson, LJ; Westerberg, M; Lexell, J				Jacobsson, L. J.; Westerberg, M.; Lexell, J.			Health-related quality-of-life and life satisfaction 6-15 years after traumatic brain injuries in northern Sweden	BRAIN INJURY			English	Article						Long-term outcome; outcome assessment; traumatic brain injury; quality of life; questionnaires	COMMUNITY INTEGRATION; COPING STRATEGIES; SOCIAL SUPPORT; YOUNG-ADULTS; HEAD-INJURY; SCALE SWLS; SF-36; MODERATE; INDIVIDUALS; EMPLOYMENT	Objective: To describe health-related quality-of-life (HRQoL) and life satisfaction many years after a traumatic brain injury (TBI) and assess possible associations with variables related to the time of injury and follow-up and the individuals' self-appraisal of the impact of the TBI. Method: Sixty-seven individuals (18-65 years), on average 10 years post-injury, were interviewed. Data on HRQoL, using the SF-36 questionnaire, were compared with a Swedish age-and sex-matched reference sample, and life satisfaction, using the Satisfaction With Life Scale (SWLS), were compared with a nationwide Swedish sample of students. The participant's self-appraisal of the TBI was assessed with two supplementary questions. Data were analysed with hierarchical multiple regression analyses. Results: HRQoL as well as life satisfaction were lower compared with the reference samples. From the regression analyses, the individuals' own appraisal of the impact of the TBI and whether they were vocationally productive or not were strongly associated with their current physical health and life satisfaction. Conclusion: These results confirm the importance of TBI as a cause of long-term disability and the impact of the injury on the individuals' self-perceived values of health, quality-of-life and life satisfaction.	[Jacobsson, L. J.] Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden; [Jacobsson, L. J.; Lexell, J.] Lulea Univ Technol, Dept Hlth Sci, S-95187 Lulea, Sweden; [Westerberg, M.] Lulea Univ Technol, Dept Business Adm & Social Sci, S-95187 Lulea, Sweden; [Lexell, J.] Skane Univ Hosp, Dept Rehabil Med, Lund, Sweden; [Lexell, J.] Lund Univ, Dept Clin Sci, Div Rehabil Med, Lund, Sweden		Jacobsson, LJ (corresponding author), Kalix Hosp, Dept Gen Med, Med Rehabil Sect, SE-95282 Kalix, Sweden.	lars_j@glocalnet.net	Westerberg, Mats/C-3300-2012	Westerberg, Mats/0000-0001-5464-9292; Jacobsson, Lars/0000-0002-1127-1178; Lexell, Jan/0000-0001-5294-3332	Norrbacka-Eugenia Foundation; Cancer and Traffic Injury Fund; Norrbotten County Council; Swedish Association of Brain Injured and their Families; Skane county council's research and development foundation	This study was supported by grants from the Norrbacka-Eugenia Foundation, the Cancer and Traffic Injury Fund, Norrbotten County Council, the Swedish Association of Brain Injured and their Families and Skane county council's research and development foundation.	Anaby D, 2010, SOC INDIC RES, V96, P267, DOI 10.1007/s11205-009-9476-z; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Antonovsky A., 1987, UNRAVELING MYSTERY H; Arrindell WA, 1999, PERS INDIV DIFFER, V26, P815, DOI 10.1016/S0191-8869(98)00180-9; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown SA, 2004, APPL NEUROPSYCHOL, V11, P54, DOI 10.1207/s15324826an1101_7; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Charles ST, 2009, PSYCHOL AGING, V24, P645, DOI 10.1037/a0016673; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gouveia VV, 2009, SOC INDIC RES, V90, P267, DOI 10.1007/s11205-008-9257-0; Hann M, 2008, QUAL LIFE RES, V17, P413, DOI 10.1007/s11136-008-9310-0; Hultell D, 2008, PERS INDIV DIFFER, V44, P1070, DOI 10.1016/j.paid.2007.10.030; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Mazaux JM, 2002, ACT NEUR S, V79, P49; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Pavot W., 1993, PSYCHOL ASSESSMENT, V52, P164, DOI DOI 10.1037/1040-3590.5.2.164; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Powell T, 2007, BRAIN INJURY, V21, P31, DOI 10.1080/02699050601106245; Riemsma R P, 2001, Health Technol Assess, V5, P1; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schopp LH, 2006, BRAIN INJURY, V20, P1155, DOI 10.1080/02699050600983735; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Slocum-Gori SL, 2009, SOC INDIC RES, V92, P489, DOI 10.1007/s11205-008-9303-y; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Sullivan M, 2002, SVENSK MANUAL TOLKNI; Taft C, 2004, QUAL LIFE RES, V13, P251, DOI 10.1023/B:QURE.0000015290.76254.a5; Taft C, 2001, QUAL LIFE RES, V10, P395, DOI 10.1023/A:1012552211996; TEASDALE G, 1974, LANCET, V2, P81; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; Tomberg T, 2007, BRAIN INJURY, V21, P479, DOI 10.1080/02699050701311737; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Tsaousides T, 2008, REHABIL PSYCHOL, V53, P456, DOI 10.1037/a0012579; von Steinbuechel N, 2005, CURR OPIN NEUROL, V18, P681, DOI 10.1097/01.wco.0000194140.56429.75; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	53	70	70	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	9					1075	1086		10.3109/02699052.2010.494590			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	636RH	WOS:000280756700004	20597636				2022-02-06	
J	MacGregor, AJ; Shaffer, RA; Dougherty, AL; Galarneau, MR; Raman, R; Baker, DG; Lindsay, SR; Golomb, BA; Corson, KS				MacGregor, Andrew J.; Shaffer, Richard A.; Dougherty, Amber L.; Galarneau, Michael R.; Raman, Rema; Baker, Dewleen G.; Lindsay, Suzanne R.; Golomb, Beatrice A.; Corson, Karen S.			Prevalence and Psychological Correlates of Traumatic Brain Injury in Operation Iraqi Freedom	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						military; posttraumatic stress disorder; PTSD; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; HEAD-INJURY; SEVERITY SCORE; AMNESIA; PTSD; DEPRESSION; SYMPTOMS; CHILDREN; HISTORY	Objective: To describe the prevalence and psychological correlates of traumatic brain injury (TBI) among injured male combatants in the Iraq conflict. Participants: A total of 781 men injured during military combat between September 2004 and February 2005. Main Outcome Measures: Mental health diagnosis (ICD-9 290-319), particularly posttraumatic stress disorder and mood/anxiety disorders, assigned through November 2006. Results: 15.8% met criteria for TBI (13.4% mild, 2.4% moderate-severe TBI), 35.0% other head injury, and 49.2% non-head injury. Multivariate logistic regression suggested lower rates of posttraumatic stress disorder and mood/anxiety disorders among those with mild and moderate-severe TBI. Conclusions: These findings could reflect a problem with differential diagnosis or, conversely, a low rate of self-presentation for symptoms. Further research is needed to elucidate the psychological consequences, clinical implications, and overall impact of TBI among military combat veterans.	[MacGregor, Andrew J.; Shaffer, Richard A.; Galarneau, Michael R.; Corson, Karen S.] USN, Hlth Res Ctr, San Diego, CA 92106 USA; [Dougherty, Amber L.] Sci Applications Int Corp, San Diego, CA USA; [Raman, Rema; Baker, Dewleen G.; Golomb, Beatrice A.] Univ Calif San Diego, San Diego, CA 92103 USA; [Baker, Dewleen G.] VA San Diego Healthcare Syst, San Diego, CA USA; [Lindsay, Suzanne R.] San Diego State Univ, San Diego, CA 92182 USA		Dougherty, AL (corresponding author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil	Baker, Dewleen/O-4957-2019	Baker, Dewleen/0000-0002-1736-9838; MacGregor, Andrew/0000-0003-1020-7390	US Navy Bureau of Medicine and Surgery, Washington, DC	This work was supported by the US Navy Bureau of Medicine and Surgery, Washington, DC, under Work Unit No. 60819. The views and opinions expressed herein are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the US Government. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (Protocol NHRC.2007.0004).	Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BONTKE CF, 1996, J HEAD TRAUMA REHAB, V11, P95, DOI DOI 10.1097/00001199-199602000-00011; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Chemtob CM, 1998, J NERV MENT DIS, V186, P701, DOI 10.1097/00005053-199811000-00007; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; DOBSON JE, 1989, BRIT J ORAL MAX SURG, V27, P441, DOI 10.1016/S0266-4356(89)80001-4; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli T WE, ABBREVIATED INJURY S; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; Gunderson EKE, 2005, MIL MED, V170, P172; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KIM E, 2007, J NEUROPSYCHIATRY CL, V159, P1315; Klein E, 2003, CAN J PSYCHIAT, V48, P28, DOI 10.1177/070674370304800106; LINN S, 1993, INT J EPIDEMIOL, V22, P905, DOI 10.1093/ije/22.5.905; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mather FJ, 2003, BRAIN INJURY, V17, P1077, DOI 10.1080/0269905031000114045; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ommaya AK, 1996, J TRAUMA, V40, P211, DOI 10.1097/00005373-199602000-00007; Price K. P., 1994, DEF LAW J, V43, P113; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Shalev AY, 2001, J CLIN PSYCHIAT, V62, P4; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; *US DEP DEF, 1984, 1340 DOD US MIL ENTR; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P441, DOI 10.1023/A:1007781107513; Wade AL, 2007, J TRAUMA, V63, P836, DOI 10.1097/01.ta.0000251453.54663.66; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; [No title captured]	53	70	71	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2010	25	1					1	8		10.1097/HTR.0b013e3181c2993d			8	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	550XC	WOS:000274165800001	20051901				2022-02-06	
J	Maxwell, WL; MacKinnon, MA; Stewart, JE; Graham, DI				Maxwell, William L.; MacKinnon, Mary-Anne; Stewart, Janice E.; Graham, David I.			Stereology of cerebral cortex after traumatic brain injury matched to the Glasgow Outcome Score	BRAIN			English	Article						cortical neurons; head injury; stereology	WHITE-MATTER; DIFFUSION-TENSOR; HEAD-INJURY; LONGITUDINAL CHANGES; PROGRESSIVE ATROPHY; CORTICAL THICKNESS; CORPUS-CALLOSUM; THALAMIC NUCLEI; AXONAL INJURY; MODERATE	Magnetic resonance imaging provides evidence for loss of both white and grey matter, in terms of tissue volume, from the cerebral hemispheres after traumatic brain injury. However, quantitative histopathological data are lacking. From the archive of the Department of Neuropathology at Glasgow, the cerebral cortex of 48 patients was investigated using stereology. Patients had survived 3 months after traumatic brain injury and were classified using the Glasgow Outcome Scale as follows: moderately disabled (n = 13), severely disabled (n = 12) and vegetative state (n = 12); and controls. Some patients from the archive were diagnosed with diffuse axonal injury post-mortem. Comparisons of changes in cortical neuron population across Glasgow Outcome Scale groups between diffuse axonal injury and non-diffuse axonal injury patients were undertaken using effect size analyses. The hypotheses tested were that (i) thinning of the cerebral cortex occurred after traumatic brain injury; (ii) changes in thickness of cortical layers in Brodmann areas 11, 10, 24a and 4 differed; and (iii) different changes occurred for neuronal number, their size and nearest neighbour index across Glasgow Outcome Scale groups. There was a greater loss of large pyramidal and large non-pyramidal neurons with a more severe score on the Glasgow Outcome Scale from all four cortical regions, with the greatest loss of neurons from the prefrontal cortex of patients with diffuse axonal injury. There were differences in the changes of number of medium and small pyramidal and non-pyramidal neurons between different cortical regions, and between patients with and without diffuse axonal injury. Generally, a decrease in the somatic diameter of pyramidal and non-pyramidal neurons was associated with a more severe clinical outcome. However, in the motor cortex a more severe Glasgow Outcome Scale was associated with an increased diameter of medium pyramidal neurons and small non-pyramidal cells. Pyramidal and non-pyramidal neurons did not follow a Poisson distribution within the neuropil of control patients. Pyramidal neurons were usually scattered while medium and small non-pyramidal neurons were clustered. An increased spacing between remaining neurons usually occurred across Glasgow Outcome Scale groups. It is concluded that loss of neurons resulted in reduced executive and integrative capability in patients after traumatic head injury.	[Maxwell, William L.] Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; [MacKinnon, Mary-Anne; Stewart, Janice E.; Graham, David I.] Univ Glasgow, Acad Unit Neuropathol, So Gen Hosp, Inst Neurol Sci, Glasgow G53 4TF, Lanark, Scotland		Maxwell, WL (corresponding author), Inst Biomed & Life Sci, Thomson Bldg,Gilmorehill, Glasgow G12 8QQ, Lanark, Scotland.	wmaxwell@bio.gla.ac.uk					*ABS, 2008, SURV DIS AG CAR DEF; ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BENES FM, 1986, ARCH GEN PSYCHIAT, V43, P31; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blinkov SM., 1968, HUMAN BRAIN FIGURES; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Buxhoeveden DP, 2002, BRAIN, V125, P935, DOI 10.1093/brain/awf110; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; COE R, 2002, EFFECT SIZE CALCULAT; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Cossa FM, 1999, ITAL J NEUROL SCI, V20, P145, DOI 10.1007/s100720050024; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Diggle P., 1983, STAT ANAL SPATIAL PO; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; Evans SA, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-8; FARAONE SV, 2008, UNDERSTANDING EFFECT; Fujiwara E, 2008, NEUROPSYCHOLOGIA, V46, P461, DOI 10.1016/j.neuropsychologia.2007.08.027; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Harrison PJ, 1995, NEUROSCI LETT, V200, P151, DOI 10.1016/0304-3940(95)12102-A; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Hofman PAM, 2002, J NEUROPSYCH CLIN N, V14, P176, DOI 10.1176/appi.neuropsych.14.2.176; Howard C.V., 1998, UNBIASED STEREOLOGY, V1; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 2001, NEUROLOGY, V56, P486, DOI 10.1212/WNL.56.4.486; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lewis DA, 2004, AM J PSYCHIAT, V161, P1366, DOI 10.1176/appi.ajp.161.8.1366; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Maegele M, 2007, EUR SURG RES, V39, P372, DOI 10.1159/000107097; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; Mouton P. R., 2002, PRINCIPLES PRACTICES; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; ONG WY, 1991, J ANAT, V175, P79; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Preul C, 2006, J MAGN RESON IMAGING, V24, P513, DOI 10.1002/jmri.20665; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; REILLY PL, 1975, LANCET, V2, P375; Rivara CB, 2003, ANAT REC PART A, V270A, P137, DOI 10.1002/ar.a.10015; Rodriguez-Paez AC, 2005, ACTA NEUROPATHOL, V109, P603, DOI 10.1007/s00401-005-1010-z; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Sasaki S, 2001, J ANAT, V199, P699, DOI 10.1046/j.1469-7580.2001.19960699.x; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SCHLAUG G, 1995, J COMP NEUROL, V351, P441, DOI 10.1002/cne.903510310; Schmahmann JD, 2007, BRAIN, V130, P630, DOI 10.1093/brain/awl359; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmitz C, 2002, CEREB CORTEX, V12, P954, DOI 10.1093/cercor/12.9.954; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tasker RC, 2006, DEV NEUROSCI-BASEL, V28, P302, DOI 10.1159/000094156; Thomson AM, 2003, CEREB CORTEX, V13, P5, DOI 10.1093/cercor/13.1.5; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; WILLIAMS RW, 1988, J COMP NEUROL, V278, P344, DOI 10.1002/cne.902780305; Woods TM, 2000, J NEUROSCI, V20, P3884, DOI 10.1523/JNEUROSCI.20-10-03884.2000; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698	85	70	77	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JAN	2010	133		1				139	160		10.1093/brain/awp264			22	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	542KT	WOS:000273492800013	19897544	Bronze			2022-02-06	
J	Bell, JD; Park, E; Ai, J; Baker, AJ				Bell, J. D.; Park, E.; Ai, J.; Baker, A. J.			PICK1-mediated GluR2 endocytosis contributes to cellular injury after neuronal trauma	CELL DEATH AND DIFFERENTIATION			English	Article						AMPA; PICK1; trauma; GluR2; stretch; PKC alpha	PROTEIN-KINASE-C; GLUTAMATE-RECEPTOR SUBUNIT-2; AMPA RECEPTORS; BRAIN-INJURY; SYNAPTIC-TRANSMISSION; HIPPOCAMPAL-NEURONS; CORTICAL-NEURONS; CELLS; PHOSPHORYLATION; POTENTIATION	Constitutive and activity-dependent regulation of the AMPA receptor GluR2 content is recognized as an important mediator of both neuronal plasticity and vulnerability to excitotoxic neuron death. In the latter case, inclusion of GluR2 protects against glutamate excitotoxicity in CNS disease by lowering receptor single-channel conductance and preventing deleterious calcium influx. We investigated the hypothesis that aberrations in GluR2 trafficking after in vitro and in vivo cerebral trauma contribute to excitotoxicity and associated calcium-dependent cell death processes. First, in an in vitro model of traumatic brain injury (TBI), we observed PICK1 and N-methyl-D-aspartic acid (NMDA) receptor-dependent phosphorylation and internalization of GluR2. The contributing cell signaling mechanisms involved enhanced binding between PKC alpha (the kinase that phosphorylates GluR2) and PICK1 (its PDZ-binding partner), and a novel protein interaction between PKC alpha and the NMDA receptor scaffolding protein PSD-95. Functionally, these phenomena enhanced single cell AMPAR mEPSCs and protracted calcium extrusion. In vivo TBI similarly promoted GluR2 phosphorylation and internalization, with enhanced expression of calcium-permeable AMPARs in the injured hippocampus. Peptide-mediated perturbation of the PKC alpha/PICK1 protein interaction after trauma preserved surface GluR2 expression, attenuated AMPAR-mediated toxicity, and occluded the sensitivity of neuronal physiology to calcium-permeable AMPAR antagonists. These findings suggest that experimental TBI promotes the expression of injurious GluR2-lacking AMPARs, thereby enhancing cellular vulnerability to secondary excitotoxicity. Cell Death and Differentiation (2009) 16, 1665-1680; doi: 10.1038/cdd.2009.106; published online 31 July 2009	[Baker, A. J.] St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; [Baker, A. J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Park, E.; Baker, A. J.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Park, E.; Baker, A. J.] St Michaels Hosp, Cara Phelan Ctr Trauma Res, Toronto, ON M5B 1W8, Canada; [Bell, J. D.; Baker, A. J.] Univ Toronto, Inst Med Sci, Fac Med, Toronto, ON M5S 1A1, Canada; [Ai, J.] St Michaels Hosp, Div Neurosurg, Toronto, ON M5B 1W8, Canada		Baker, AJ (corresponding author), St Michaels Hosp, Dept Crit Care, 30 Bond St,7th Floor Bond Wing,Rm 088, Toronto, ON M5B 1W8, Canada.	bakera@smh.toronto.on.ca			Ontario Neurotrauma Foundation; Heart and Stroke Foundation of OntarioHeart & Stroke Foundation of Ontario	We thank Elaine Liu for technical assistance with intravenous drug injections and Kevin Park for help with mathematical integration of calcium curves. We also thank Matthew Common for technical assistance. This work was supported by funding to AJB and JDB from the Ontario Neurotrauma Foundation and the Heart and Stroke Foundation of Ontario.	Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Borges K, 1998, PROG BRAIN RES, V116, P153, DOI 10.1016/S0079-6123(08)60436-7; Chung HJ, 2000, J NEUROSCI, V20, P7258; Chung HJ, 2003, SCIENCE, V300, P1751, DOI 10.1126/science.1082915; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Isaac JTR, 2007, NEURON, V54, P859, DOI 10.1016/j.neuron.2007.06.001; Knapp LT, 2002, J NEUROSCI RES, V70, P1, DOI 10.1002/jnr.10371; Knapp LT, 2002, J NEUROSCI, V22, P674, DOI 10.1523/JNEUROSCI.22-03-00674.2002; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kwak S, 2006, CURR OPIN NEUROBIOL, V16, P281, DOI 10.1016/j.conb.2006.05.004; Lau A, 2006, J NEUROSCI, V26, P11540, DOI 10.1523/JNEUROSCI.3507-06.2006; Leitges M, 2004, NEURON, V44, P585, DOI 10.1016/j.neuron.2004.10.024; Lim IA, 2002, J BIOL CHEM, V277, P21697, DOI 10.1074/jbc.M112339200; Liu BS, 2006, J NEUROSCI, V26, P5309, DOI 10.1523/JNEUROSCI.0567-06.2006; Lu YM, 1996, J NEUROSCI, V16, P5457; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Noh KM, 2005, P NATL ACAD SCI USA, V102, P12230, DOI 10.1073/pnas.0505408102; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rakhade SN, 2008, J NEUROSCI, V28, P7979, DOI 10.1523/JNEUROSCI.1734-08.2008; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Saglietti L, 2007, NEURON, V54, P461, DOI 10.1016/j.neuron.2007.04.012; Santos AE, 2006, CELL DEATH DIFFER, V13, P652, DOI 10.1038/sj.cdd.4401785; Seidenman KJ, 2003, J NEUROSCI, V23, P9220; Serulle Y, 2007, NEURON, V56, P670, DOI 10.1016/j.neuron.2007.09.016; Soriano FX, 2006, J NEUROSCI, V26, P4509, DOI 10.1523/JNEUROSCI.0455-06.2006; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; Terashima A, 2004, J NEUROSCI, V24, P5381, DOI 10.1523/JNEUROSCI.4378-03.2004; Terashima A, 2008, NEURON, V57, P872, DOI 10.1016/j.neuron.2008.01.028; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	37	70	71	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047	1476-5403		CELL DEATH DIFFER	Cell Death Differ.	DEC	2009	16	12					1665	1680		10.1038/cdd.2009.106			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	519QY	WOS:000271783600011	19644508	Bronze			2022-02-06	
J	Wygant, DB; Ben-Porath, YS; Arbisi, PA; Berry, DTR; Freeman, DB; Heilbronner, RL				Wygant, Dustin B.; Ben-Porath, Yossef S.; Arbisi, Paul A.; Berry, David T. R.; Freeman, David B.; Heilbronner, Robert L.			Examination of the MMPI-2 Restructured Form (MMPI-2-RF) Validity Scales in Civil Forensic Settings: Findings from Simulation and Known Group Samples	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						MMPI-2-RF; MMPI-2 Restructured Form; Malingering; Forensic evaluation; Medico-legal	FAKE-BAD SCALE; MALINGERED NEUROCOGNITIVE DYSFUNCTION; PERSONAL-INJURY LITIGANTS; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; DEPRESSION; TOMM; PERFORMANCE; VALIDATION; INDICATORS	The current study examined the effectiveness of the MMPI-2 Restructured Form (MMPI-2-RF; Ben-Porath and Tellegen, 2008) over-reporting indicators in civil forensic settings. The MMPI-2-RF includes three revised MMPI-2 over-reporting validity scales and a new scale to detect over-reported somatic complaints. Participants dissimulated medical and neuropsychological complaints in two simulation samples, and a known-groups sample used symptom validity tests as a response bias criterion. Results indicated large effect sizes for the MMPI-2-RF validity scales, including a Cohen's d of .90 for Fs in a head injury simulation sample, 2.31 for FBS-r, 2.01 for F-r, and 1.97 for Fs in a medical simulation sample, and 1.45 for FBS-r and 1.30 for F-r in identifying poor effort on SVTs. Classification results indicated good sensitivity and specificity for the scales across the samples. This study indicates that the MMPI-2-RF over-reporting validity scales are effective at detecting symptom over-reporting in civil forensic settings.	[Wygant, Dustin B.] Eastern Kentucky Univ, Dept Psychol, Richmond, KY 40475 USA; [Ben-Porath, Yossef S.] Kent State Univ, Dept Psychol, Kent, OH 44242 USA; [Arbisi, Paul A.] Univ Minnesota, Dept Psychol, Minneapolis VA Med Ctr, Minneapolis, MN 55455 USA; [Berry, David T. R.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA; [Freeman, David B.] Cal Psych FMT, Los Angeles, CA USA; [Heilbronner, Robert L.] Chicago Neuropsychol Grp, Chicago, IL USA		Wygant, DB (corresponding author), Eastern Kentucky Univ, Dept Psychol, 127 Cammack Bldg,521 Lancaster Ave, Richmond, KY 40475 USA.	dustin.wygant@eku.edu					Allen L. M., 1997, COMPUTERIZED ASSESSM; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Arbisi P. A., 2006, PSYCHOL SERV, V3, P249, DOI DOI 10.1037/1541-1559.3.4.249; Arbisi PA, 1995, PSYCHOL ASSESSMENT, V7, P424, DOI 10.1037/1040-3590.7.4.424; Archer RP, 2006, FORENSIC USES OF CLINICAL ASSESSMENT INSTRUMENTS, P1; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Astner K., 2004, WORD MEMORY TEST MAN; Ben-Porath, 2008, MINNESOTA MULTIPHASI; Ben-Porath Y.S., 2008, MMPI 2 SYMPTOM VALID; Bianchini Kevin J, 2005, Spine J, V5, P404, DOI 10.1016/j.spinee.2004.11.016; Crawford EF, 2006, J PERS ASSESS, V86, P217, DOI 10.1207/s15327752jpa8602_11; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Dunn TM, 2003, ARCH CLIN NEUROPSYCH, V18, P121, DOI 10.1016/S0887-6177(01)00188-3; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Green, 2003, WORD MEMORY TEST; Greiffenstein MF, 2002, J CLIN PSYCHOL, V58, P1591, DOI 10.1002/jclp.10077; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P491, DOI 10.1080/13854040590967144; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; Larrabee GJ, 2003, ARCH CLIN NEUROPSYCH, V18, P673, DOI 10.1016/S0887-6177(02)00157-9; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; ROGERS R, 1997, CLIN ASSESSMENT MALI, P427; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Sellbom M, 2005, ASSESSMENT, V12, P79, DOI 10.1177/1073191104273515; SELLBOM M, 2008, 2008 SOC PERS ASS AN; Sellbom M, 2008, PSYCHOL ASSESSMENT, V20, P370, DOI 10.1037/a0012952; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; Slick D.J., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tellegen, 2008, MINNESOTA MULTIPHASI; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Wygant D. B., 2007, THESIS KENT STATE U; Wygant D.B., 2004, 39 ANN S REC DEV MMP; WYGANT DB, 2007, 27 ANN M NAT AC NEUR; Wygant DB, 2007, ARCH CLIN NEUROPSYCH, V22, P489, DOI 10.1016/j.acn.2007.01.027; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009	40	70	72	1	12	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	NOV	2009	24	7					671	680		10.1093/arclin/acp073			10	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	514GU	WOS:000271383200004	19797242	Bronze			2022-02-06	
J	Cusimano, MD				Cusimano, Michael D.			Canadian Minor Hockey Participants' Knowledge about Concussion	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							SCHOOL FOOTBALL PLAYERS; ICE HOCKEY; SPORTS; GUIDELINES; MANAGEMENT; COLLEGIATE; INJURY; RISK	Background and Objectives: In Canada and the USA, ice hockey is a cause of traumatic brain injury. Post-concussive symptoms are the most important feature of the diagnosis of concussion in sports and it is recommended that athletes not return to play while still symptomatic. Lack of knowledge of concussions could therefore be one of the main detriments to concussion prevention in hockey. The purpose of this research is to describe what minor league hockey players, coaches, parents and trainers know about concussion and its management. Methods: A questionnaire to assess concussion knowledge and return to play guidelines was developed and administered to players at different competitive levels (n = 267), coaches, trainers and parents (total adults n = 142) from the Greater Toronto Area. Results: Although a majority of adults and players could identify mechanisms responsible for concussion, about one-quarter of adults and about a quarter to a half of children could not recall any symptoms or recalled only one symptom of a concussion. A significant number of players and some adults did not know what it concussion was or how it occurred. Almost half of the players and a fifth of the adults incorrectly stated that concussion was treated with medication or physical therapy. Nearly one quarter of all players did not know if an athlete experiencing symptoms of concussion should continue playing. Conclusions: This study demonstrated that a significant number of people held misconceptions about concussion in hockey which could lead to serious health consequences and creates a need for better preventive and educational strategies.	St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, Toronto, ON M5B 1W8, Canada		Cusimano, MD (corresponding author), St Michaels Hosp, Injury Prevent Res Off, Div Neurosurg, 30 Bond St, Toronto, ON M5B 1W8, Canada.		Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650			Akers R.L., 1998, SOCIAL LEARNING SOCI; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; COLLINS MW, 2002, NEUROSURGERY, V51, P1; FICK DS, 1995, POSTGRAD MED, V97, P53, DOI 10.1080/00325481.1995.11945958; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; GOODWINGERBERIC.S, 1983, AM J PUBLIC HEALTH, V73, P1370; GRANT K, 2003, GLOBE MAIL; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; JOHNSTON KM, 2001, BRIT J SPORT MED, V35, P367; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; NASH JE, 1981, YOUTH SOC, V13, P229, DOI 10.1177/0044118X8101300202; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Roos R, 1996, PHYSICIAN SPORTSMED, V24, P67, DOI 10.3810/psm.1996.10.1327; Sturmi JE, 1998, SPORTS MED, V25, P351, DOI 10.2165/00007256-199825060-00001; Wennberg RA, 2003, CAN J NEUROL SCI, V30, P206, DOI 10.1017/S0317167100002596; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; 1997, MMWR WKLY REP, V46, P224	26	70	70	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0317-1671	2057-0155		CAN J NEUROL SCI	Can. J. Neurol. Sci.	MAY	2009	36	3					315	320		10.1017/S0317167100007046			6	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	448HL	WOS:000266253600013	19534331	Bronze			2022-02-06	
J	Willmott, C; Ponsford, J				Willmott, C.; Ponsford, J.			Efficacy of methylphenidate in the rehabilitation of attention following traumatic brain injury: a randomised, crossover, double blind, placebo controlled inpatient trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; DEFICITS; PERFORMANCE	Objectives: Most previous studies evaluating the use of methylphenidate following traumatic brain injury (TBI) have been conducted many years post-injury. This study evaluated the efficacy of methylphenidate in facilitating cognitive function in the inpatient rehabilitation phase. Methods: 40 participants with moderate-severe TBI (mean 68 days post-injury) were recruited into a randomised, crossover, double blind, placebo controlled trial. Methylphenidate was administered at a dose of 0.3 mg/kg twice daily and lactose in identical capsules served as placebo. Methylphenidate and placebo administration was randomised in a crossover design across six sessions over a 2 week period. Primary efficacy outcomes were neuropsychological tests of attention. Results: No participants were withdrawn because of side effects or adverse events. Methylphenidate significantly increased speed of information processing on the Symbol Digit Modalities Test (95% CI 0.30 to 2.95, Cohen's d = 0.39, p = 0.02), Ruff 2 and 7 Test-Automatic Condition (95% CI 1.38 to 6.12, Cohen's d = 0.51, p = 0.003), Simple Selective Attention Task (95% CI -58.35 to -17.43, Cohen's d = 0.59, p = 0.001) and Dissimilar Compatible (95% CI -70.13 to -15.38, Cohen's d = 0.51, p = 0.003) and Similar Compatible (95% CI -74.82 to -19.06, Cohen's d = 0.55, p = 0.002) conditions of the Four Choice Reaction Time Task. Those with more severe injuries and slower baseline information processing speed demonstrated a greater drug response. Conclusions: Methylphenidate enhances information processing speed in the inpatient rehabilitation phase following TBI. This trial is registered with the Australian New Zealand Clinical Trials Registry (12607000503426).	[Willmott, C.; Ponsford, J.] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia; [Willmott, C.; Ponsford, J.] Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia		Willmott, C (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia.	catherine.willmott@med.monash.edu.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035	Victorian Neurotrauma Initiative; Wenkart Foundation	This study was supported by the Victorian Neurotrauma Initiative and the Wenkart Foundation, neither of which had any involvement in study design, analysis and interpretation of data, writing of the report or the decision to submit the article for publication. Drugs were purchased for the trial on a commercial basis, and the company that manufactures Ritalin made no contribution to the study.	Al-Adawi S., 2005, Journal of Applied Research, V5, P61; ARNSTEN AF, 2005, BEHAV BRAIN FUNCT, V1, DOI DOI 10.1186/744-9081-1-2; DANIEL A, 1983, POWER PRIVILEDGE PRE; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Gualtieri CT, 2002, BRAIN INJURY MENTAL; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; Kim YH, 2006, CLIN REHABIL, V20, P24, DOI 10.1191/0269215506cr927oa; Knight R. T, 2002, PRINCIPLES FRONTAL L, P51, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0004; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Leonard BE, 2004, HUM PSYCHOPHARM CLIN, V19, P151, DOI 10.1002/hup.579; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Ponsford JL, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; RUFF R, 1995, RUFF 2 7 SELECTIVE A; SHUM DHK, 1990, J CLIN EXP NEUROPSYC, V12, P247, DOI 10.1080/01688639008400971; Smith A., 1991, SYMBOL DIGIT MODALIT; Speech Thomas J., 1993, Brain Injury, V7, P333, DOI 10.3109/02699059309034959; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WechslerD, 2001, WECHSLER TEST ADULT; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; WILLMOTT C, NEUROPSYCHO IN PRESS; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	30	70	70	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2009	80	5					552	557		10.1136/jnnp.2008.159632			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	433ZN	WOS:000265244900020	19060022				2022-02-06	
J	Salim, A; Hadjizacharia, P; Dubose, J; Brown, C; Inaba, K; Chan, LS; Margulies, D				Salim, Ali; Hadjizacharia, Pantelis; Dubose, Joseph; Brown, Carlos; Inaba, Kenji; Chan, Linda S.; Margulies, Daniel			Persistent Hyperglycemia in Severe Traumatic Brain Injury: An Independent Predictor of Outcome	AMERICAN SURGEON			English	Article							ADMISSION HYPERGLYCEMIA; MORTALITY; IMPACT	In patients with severe traumatic brain injury (TBI), admission hyperglycemia is associated with poor outcome. The effect of persistent hyperglycemia (PH) on outcome in severe TBI, however, remains unknown. We performed a retrospective review of all blunt trauma patients with severe TBI (head Abbreviated Injury Score >= 3) admitted to the intensive care unit at a Level I trauma center from January 1998 through December 2005. Admission and daily intensive care unit blood glucose levels up to the end of the first week were measured. PH was defined as an average daily blood glucose >= 1.50 mg/dL on all days for the first week of the hospital stay. TBI patients with and without PH were compared with respect to baseline demographics, injury characteristics, and outcomes. Independent risk factors for mortality were identified using logistic regression analysis. One hundred and five (12.6%) out of 834 severe TBI patients had PH. Patients with PH were older, more severely injured, and had worse head injury compared with patients without PH. After adjusting for significant risk factors, PH was identified as an independent risk factor for mortality (odds ratio (OR): 4.91 [95% confidence interval (CI), 2.88-8.56, P < 0.0001]). PH is associated with significantly higher mortality rates in severe TBI patients.	[Salim, Ali; Margulies, Daniel] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA; [Hadjizacharia, Pantelis; Dubose, Joseph; Inaba, Kenji; Chan, Linda S.] Univ So Calif, Med Ctr, Div Trauma & Crit Care Los Angeles Cty, Los Angeles, CA 90033 USA; [Brown, Carlos] Brackenridge Hosp, Austin, TX USA		Salim, A (corresponding author), Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, 8700 Beverly Blvd,Suite 8215 North, Los Angeles, CA 90048 USA.	ali.salim@cshs.org	INABA, KENJI/AAC-8532-2020				Biffl W, 2007, J TRAUMA, V62, P1375; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Gale SC, 2007, AM SURGEON, V73, P454; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MERGUERIAN PA, 1981, CRIT CARE MED, V9, P838, DOI 10.1097/00003246-198112000-00007; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vogelzang M, 2006, J TRAUMA, V60, P873, DOI 10.1097/01.ta.0000195715.63978.80; Whitcomb BW, 2005, CRIT CARE MED, V33, P2772, DOI 10.1097/01.CCM.0000189741.44071.25; Yendamuri S, 2003, J TRAUMA, V55, P33, DOI 10.1097/01.TA.0000074434.39928.72; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	18	70	80	0	2	SOUTHEASTERN SURGICAL CONGRESS	CUMMING	115 SAMARITAN DR, #200, CUMMING, GA 30040-2354 USA	0003-1348	1555-9823		AM SURGEON	Am. Surg.	JAN	2009	75	1					25	29					5	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	392WD	WOS:000262332000005	19213392				2022-02-06	
J	Sayer, NA; Cifu, DX; McNamee, S; Chiros, CE; Sigford, BJ; Scoff, S; Lew, HL				Sayer, Nina A.; Cifu, David X.; McNamee, Shane; Chiros, Christine E.; Sigford, Barbara J.; Scoff, Steve; Lew, Henry L.			Rehabilitation Needs of Combat-Injured Service Members Admitted to the VA Polytrauma Rehabilitation Centers: The Role of PM&R in the Care of Wounded Warriors	PM&R			English	Article							TRAUMATIC BRAIN-INJURY; PHYSICAL MEDICINE; KRUSEN,FRANK; HISTORY; BLAST; DIARY	Objective: To describe the rehabilitation course of combat-injured service members who sustained polytraumatic injuries during the current wars in and around Iraq and Afghanistan. Design: Retrospective descriptive analysis. Setting: Department of Veterans Administration Polytrauma Rehabilitation Centers (PRCs). Participants: One hundred eighty-eight consecutive, acutely combat-injured service members suffering polytraumatic injuries requiring inpatient rehabilitation and being treated at PRCs between October 2001 and January 2006. Interventions: Not applicable. Main Outcome Measures: Medications prescribed, devices used, injuries and impairment information, and consultative services. Results: Ninety-three percent of the patients had sustained a traumatic brain injury (TBI) and more than half of these were incurred secondary to blast explosions. Over half of the patients had infections or surgeries prior to PRC admission that required continued medical attention during their stay. Pain and mental health issues were present in 100% and 39%, respectively, of all patients admitted and added complexity to the brain injury rehabilitation process. Common treatment needs included cognitive-behavioral interventions, pain care, assistive devices, mental health interventions for both patients and their families, and specialty consultations, in particular to ophthalmology, otolaryngology, and neurology. Conclusions: Combat-injured polytrauma patients have complex rehabilitation needs that require a high level of specialized training and skill. Physical medicine and rehabilitation specialists treating war injured service members need a high level of expertise in assessment and treatment of co-occurring pain, TBI, and stress disorders. Physiatrists are playing an important role in providing and coordinating the rehabilitation care for individuals with significant polytraumatic war injuries from the Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) conflicts.	[Lew, Henry L.] VA Boston Healthcare Syst, VA Med Ctr, Phys Med & Rehabil, Boston, MA 02130 USA; [Sayer, Nina A.; Chiros, Christine E.] VA Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Cifu, David X.; McNamee, Shane] VA Med Ctr, Richmond, VA USA; [Scoff, Steve] VA Med Ctr, Tampa, FL USA		Lew, HL (corresponding author), VA Boston Healthcare Syst, VA Med Ctr, Phys Med & Rehabil, 150 S Huntington Ave, Boston, MA 02130 USA.	henry.lew@va.gov	Sayer, Nina/E-3249-2016	Cifu, David/0000-0003-1600-9387	VA Health Service Research & Development (HSRD) [RRP 06-150]	This research was supported by VA Health Service Research & Development (HSR&D) grant RRP 06-150.	American Academy of Physical Medicine & Rehabilitation, WHAT IS PHYS; Baruch Committee on Physical Medicine, 1944, NCEA ANN REP, p[1, 17]; Department of Veterans Affairs, 2005, VHA HDB, V1172.1; Farahmand JM, 2001, COMPREHENSIVE REHABI, P241; Folz TJ, 1997, ARCH PHYS MED REHAB, V78, P446, DOI 10.1016/S0003-9993(97)90241-0; Gaylord Kathryn M, 2006, Crit Care Nurs Clin North Am, V18, P349, DOI 10.1016/j.ccell.2006.05.010; Gelfman R, 1997, ARCH PHYS MED REHAB, V78, P556, DOI 10.1016/S0003-9993(97)90178-7; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Grieger T. A., 2006, PRIM PSYCHIAT, V13, P45; HUMAYUN F, 2006, CAPABILITIES COMMUN, V14, P8; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; MALKMUS D, 1980, REHABILITATION HEAD; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Opitz JL, 1997, ARCH PHYS MED REHAB, V78, P442, DOI 10.1016/S0003-9993(97)90240-9; Peters DJ, 1997, ARCH PHYS MED REHAB, V78, P562, DOI 10.1016/S0003-9993(97)90179-9; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025	22	70	71	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JAN	2009	1	1					23	28		10.1016/j.pmrj.2008.10.003			6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Rehabilitation; Sport Sciences	V24LD	WOS:000208411000005	19627869				2022-02-06	
J	Vajtr, D; Benada, O; Kukacka, J; Prusa, R; Houstava, L; Toupalik, P; Kizek, R				Vajtr, D.; Benada, O.; Kukacka, J.; Prusa, R.; Houstava, L.; Toupalik, P.; Kizek, R.			Correlation of Ultrastructural Changes of Endothelial Cells and Astrocytes Occurring during Blood Brain Barrier Damage after Traumatic Brain Injury with Biochemical Markers of Blood Brain Barrier Leakage and Inflammatory Response	PHYSIOLOGICAL RESEARCH			English	Article						Blood brain barrier; Expansive contusion; Metalloproteinases; S-100B protein; Interleukin-6	NEURON-SPECIFIC-ENOLASE; S-100B PROTEIN; RELEASE	Focal cerebral contusion can be dynamic and expansive. It has been proved that subsequent expansive contusion is caused by brain parenchyma damage, especially BBB damage. We investigated a group of patients with traumatic brain injury. The patients (n=18) were divided into group I (n=7) of patients submitted to neurosurgery due to expansive contusion, and group II (n=11) of patients without surgery. Serum concentrations of NSE and S-100B protein were measured by electrochemiluminescence immunoassay, interleukin-6 (IL-6) was measured by chemiluminescent sequential immunometric assay and matrix metalloproteinases (MMP-9, MMP-2) were measured by immunoassays. Cortical biopsy specimens of brain were investigated by electron microscopy in patients with trauma brain injury submitted to neurosurgery. Biochemical investigation from first day up to third day after traumatic brain injury proved increased values of IL-6 (302.2 +/- 119.9 vs. 59.6 +/- 11.9 ng/l, p<0.02) and S-100B protein (3.064 +/- 1.064 vs. 0.649 +/- 0.182 mu g/l, p<0.05) in patients with expansive lesion compared to patients without expansive contusion. Significantly higher levels of MMP-9 (150.4 +/- 28.46 vs. 74.11 +/- 13.16 ng/l, p<0.05) and of MMP- 2 (814.5 +/- 126.3 vs. 523.1 +/- 25.28 ng/l, p<0.05) were found during first 3 days after admission in group I compared to group II. MMP- 9 has also elevated in group II from lower values after admission (74.11 +/- 13.16 ng/l) up to high levels on the 10th day of hospitalization (225.1 +/- 49.35 ng/l). Ultrastructural investigation of endothelial cells and surrounded tissue revealed perivascular hemorrhage, increased pinocytic activity of endothelial cells, and cytotoxic edema of astroglial cells. Multivesical bodies were disclosed inside the endothelial cells. Higher levels of serum protein S-100B and IL-6 correlated with ultrastructural changes of endothelial cells, and with inflammatory response following TBI, respectively.	[Vajtr, D.; Kukacka, J.; Prusa, R.] Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic; [Vajtr, D.; Kukacka, J.; Prusa, R.] Univ Hosp Motol, Prague, Czech Republic; [Benada, O.] Acad Sci Czech Republ, Inst Microbiol, Prague, Czech Republic; [Vajtr, D.] Charles Univ Prague, Fac Med 1, Dept Forens Med & Toxicol, Prague 15006 5, Czech Republic; [Houstava, L.] Charles Univ Prague, Fac Med 3, Dept Neurosurg, Prague 15006 5, Czech Republic; [Toupalik, P.] Charles Univ Prague, Fac Med 2, Dept Forens Med, Prague 15006 5, Czech Republic; [Kizek, R.] Mendel Univ Brno, Dept Chem & Biochem, Brno, Czech Republic		Vajtr, D (corresponding author), Charles Univ Prague, Fac Med 2, Dept Clin Biochem & Pathobiochem, V Uvalu 84, Prague 15006 5, Czech Republic.	vajtr.david.1LFUK@seznam.cz	Benada, Oldrich/H-2437-2014; Kizek, Rene/D-7748-2012; Kukacka, Jiri/C-4770-2013	Benada, Oldrich/0000-0002-4592-6216; Kizek, Rene/0000-0002-0467-6169	IGA CR [NR/8793-3/2006]; Institutional Scientific Project [AV0Z50200510]	We thank M. Elleder for expert assistance. Our work was supported by IGA CR, reg. no. NR/8793-3/2006 and Institutional Scientific Project AV0Z50200510.	Adelson PD, 1998, ACT NEUR S, V71, P104; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Castejon O. J., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P263; Castejon OJ, 1998, J SUBMICR CYTOL PATH, V30, P145; Conti AC, 1998, J NEUROSCI, V18, P5663; Cucullo L, 2003, MOL CELL PROTEOMICS, V2, P234, DOI 10.1074/mcp.M200077-MCP200; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Kukacka J, 2006, NEUROENDOCRINOL LETT, V27, P116; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Sawaughi S, 2005, NEUROL SURG TOKYO, V33, P1073; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2002, BRAIN INJURY, V16, P807, DOI 10.1080/02699050210128933	21	70	74	0	10	ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY	PRAGUE 4	VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC	0862-8408	1802-9973		PHYSIOL RES	Physiol. Res.		2009	58	2					263	268		10.33549/physiolres.931253			6	Physiology	Science Citation Index Expanded (SCI-EXPANDED)	Physiology	442PM	WOS:000265853100013	18380546	gold			2022-02-06	
J	Dejda, A; Jolivel, V; Bourgault, S; Seaborn, T; Fournier, A; Vaudry, H; Vaudry, D				Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Fournier, Alain; Vaudry, Hubert; Vaudry, David			Inhibitory Effect of PACAP on Caspase Activity in Neuronal Apoptosis: A Better Understanding Towards Therapeutic Applications in Neurodegenerative Diseases	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article; Proceedings Paper	8th International Symposium on VIP, PACAP and Related Peptides	SEP 03-08, 2007	Manchester, VT			Apoptosis; Caspase; PACAP; Neuroprotection	CYCLASE-ACTIVATING POLYPEPTIDE; CEREBELLAR GRANULE NEURONS; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; PROGRAMMED CELL-DEATH; VASOACTIVE INTESTINAL POLYPEPTIDE; TRANSIENT CEREBRAL-ISCHEMIA; OXYGEN-GLUCOSE DEPRIVATION; DIPEPTIDYL-PEPTIDASE-IV; SPINAL-CORD-INJURY	Programmed cell death, which is part of the normal development of the central nervous system, is also implicated in various neurodegenerative disorders. Cysteine-dependent aspartate-specific proteases (caspases) play a pivotal role in the cascade of events leading to apoptosis. Many factors that inhibit cell death have now been identified, but the underlying mechanisms are not fully understood. Pituitary adenylate cylase-activating polypeptide (PACAP) has been shown to exert neurotrophic activities during development and to prevent neuronal apoptosis induced by various insults such as ischemia. Most of the neuroprotective effects of PACAP are mediated through the PAC1 receptor. This receptor activates a transduction cascade of second messengers to stimulate Bcl-2 expression, which inhibits cytochrome c release and blocks the activation of caspases. The inhibitory effect of PACAP on the apoptotic cascade suggests that selective, stable, and potent PACAP derivatives could potentially be of therapeutic value for the treatment of post-traumatic and/or chronic neurodegenerative processes.	[Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Vaudry, Hubert; Vaudry, David] INSERM, Lab Cellular & Mol Neuroendocrinol, U413, Mont St Aignan, France; [Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Vaudry, Hubert; Vaudry, David] Univ Rouen, European Inst Peptide Res, IFRMP 23, F-76821 Mont St Aignan, France; [Dejda, Agnieszka; Jolivel, Valerie; Bourgault, Steve; Seaborn, Tommy; Fournier, Alain; Vaudry, Hubert; Vaudry, David] Int Associated Lab Samuel Champlain, Mont St Aignan, France; [Dejda, Agnieszka] Polish Acad Sci, Inst Med Biol, Lodz, Poland; [Jolivel, Valerie] QUIDD, F-76801 St Etienne, France; [Bourgault, Steve; Fournier, Alain] Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ H7V 1B7, Canada		Vaudry, D (corresponding author), INSERM, Lab Cellular & Mol Neuroendocrinol, U413, Mont St Aignan, France.	hubert.vaudry@univ-rouen.fr; david.vaudry@univ-rouen.fr	VAUDRY, David/M-1454-2018; Jolivel, Valerie/A-6810-2017; Jolivel, Valerie/ABB-1136-2021; Seaborn, Tommy/J-1638-2012	VAUDRY, David/0000-0003-3567-7452; Jolivel, Valerie/0000-0002-4114-4559; Jolivel, Valerie/0000-0002-4114-4559; 			Acehan D, 2002, MOL CELL, V9, P423, DOI 10.1016/S1097-2765(02)00442-2; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ahmad M, 1997, CANCER RES, V57, P615; Allais A, 2007, EUR J NEUROSCI, V25, P2604, DOI 10.1111/j.1460-9568.2007.05535.x; Allen JW, 2001, J NEUROSCI RES, V65, P45, DOI 10.1002/jnr.1126; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; AUBERT N, 2005, REGULATORY PEPTIDES, V130, P156; Aubert N, 2006, J NEUROCHEM, V99, P1237, DOI 10.1111/j.1471-4159.2006.04148.x; BANKS WA, 1993, J PHARMACOL EXP THER, V267, P690; BASILLE M, 1993, NEUROSCIENCE, V57, P329, DOI 10.1016/0306-4522(93)90066-O; BASILLE M, 1994, DEV BRAIN RES, V82, P81, DOI 10.1016/0165-3806(94)90150-3; Beebe X, 2008, BIOORG MED CHEM LETT, V18, P2162, DOI 10.1016/j.bmcl.2008.01.052; Bhave SV, 2004, J NEUROCHEM, V88, P359, DOI 10.1046/j.1471-4159.2003.02167.x; Birk S, 2007, REGUL PEPTIDES, V140, P185, DOI 10.1016/j.regpep.2006.12.010; BOURGAULT S, 2008, PEPTIDES IN PRESS, DOI DOI 10.1016/J.PEPTIDES.2008.01.022; Braun JS, 2007, EXP NEUROL, V206, P183, DOI 10.1016/j.expneurol.2007.03.032; Cameron DB, 2007, NEUROSCIENCE, V146, P697, DOI 10.1016/j.neuroscience.2007.02.025; Cao GD, 2002, J CEREBR BLOOD F MET, V22, P534, DOI 10.1097/00004647-200205000-00005; Cavallaro S, 1996, MOL PHARMACOL, V50, P60; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chang JY, 1996, NEUROSCI LETT, V206, P181, DOI 10.1016/S0304-3940(96)12468-X; Chauvier D, 2005, APOPTOSIS, V10, P1243, DOI 10.1007/s10495-005-1681-x; Chen J, 1998, J NEUROSCI, V18, P4914; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; Chen Y, 2006, REGUL PEPTIDES, V137, P4, DOI 10.1016/j.regpep.2006.06.016; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; David C, 2005, J MOL NEUROSCI, V27, P91, DOI 10.1385/JMN:27:01:91; Davoli MA, 2002, NEUROSCIENCE, V115, P125, DOI 10.1016/S0306-4522(02)00376-7; Dejda A, 2005, PHARMACOL REP, V57, P307; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Doberer D, 2007, EUR J CLIN INVEST, V37, P665, DOI 10.1111/j.1365-2362.2007.01832.x; Dohi K, 2002, REGUL PEPTIDES, V109, P83, DOI 10.1016/S0167-0115(02)00190-8; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; Engidawork E, 2001, BIOCHEM BIOPH RES CO, V281, P84, DOI 10.1006/bbrc.2001.4306; Falluel-Morel A, 2004, J NEUROCHEM, V91, P1231, DOI 10.1111/j.1471-4159.2004.02810.x; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Gao Z, 2007, J BIOL CHEM, V282, P30718, DOI 10.1074/jbc.M705258200; Gonzalez BJ, 1997, NEUROSCIENCE, V78, P419, DOI 10.1016/S0306-4522(96)00617-3; Graf D, 2007, ARCH BIOCHEM BIOPHYS, V462, P162, DOI 10.1016/j.abb.2007.03.029; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han P, 2005, NEUROSCIENCE, V134, P745, DOI 10.1016/j.neuroscience.2005.05.007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hermel E, 2004, CELL DEATH DIFFER, V11, P424, DOI 10.1038/sj.cdd.4401358; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hitomi J, 2004, NEUROSCI LETT, V357, P127, DOI 10.1016/j.neulet.2003.12.080; Inoue H, 2003, EMBO J, V22, P6665, DOI 10.1093/emboj/cdg634; Journot L, 1998, ANN NY ACAD SCI, V865, P100, DOI 10.1111/j.1749-6632.1998.tb11168.x; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Kang SJ, 2002, CELL DEATH DIFFER, V9, P1115, DOI 10.1038/sj.cdd.4401087; Katahira M., 2003, Regulatory Peptides, V115, P49; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Klevenyi P, 1999, NEUROREPORT, V10, P635, DOI 10.1097/00001756-199902250-00035; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knoblach SM, 2005, J NEUROSCI RES, V80, P369, DOI 10.1002/jnr.20465; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Le DA, 2002, P NATL ACAD SCI USA, V99, P15188, DOI 10.1073/pnas.232473399; LERNER EA, 1991, J BIOL CHEM, V266, P11234; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li M, 2007, PEPTIDES, V28, P1891, DOI 10.1016/j.peptides.2007.05.002; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu HT, 2005, J BIOL CHEM, V280, P11578, DOI 10.1074/jbc.M414385200; Liu XH, 1999, J CEREBR BLOOD F MET, V19, P1099, DOI 10.1097/00004647-199910000-00006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; Malagelada C, 2005, NEUROBIOL DIS, V20, P27, DOI 10.1016/j.nbd.2005.01.028; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; MASUO Y, 1994, NEUROSCI LETT, V170, P43, DOI 10.1016/0304-3940(94)90234-8; Matsui T, 2006, J NEUROPATH EXP NEUR, V65, P508, DOI 10.1097/01.jnen.0000229238.05748.12; Mei YA, 2004, EUR J NEUROSCI, V19, P1446, DOI 10.1111/j.1460-9568.2004.03227.x; Mentlein R, 1999, REGUL PEPTIDES, V85, P9, DOI 10.1016/S0167-0115(99)00089-0; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Namura S, 1998, J NEUROSCI, V18, P3659; NANDHA KA, 1991, J ENDOCRINOL, V129, P69, DOI 10.1677/joe.0.1290069; Ni BH, 1998, J CEREBR BLOOD F MET, V18, P248, DOI 10.1097/00004647-199803000-00003; Niewiadomski P, 2002, POL J PHARMACOL, V54, P717; Obeng EA, 2005, J BIOL CHEM, V280, P29578, DOI 10.1074/jbc.M502685200; Ohtaki H, 2005, REGUL PEPTIDES, V130, P149; Ohtaki H, 2006, P NATL ACAD SCI USA, V103, P7488, DOI 10.1073/pnas.0600375103; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Onoue S, 2002, PEPTIDES, V23, P1471, DOI 10.1016/S0196-9781(02)00085-2; Onoue S, 2002, FEBS LETT, V522, P65, DOI 10.1016/S0014-5793(02)02886-7; Onyuksel H, 2006, PEPTIDES, V27, P2271, DOI 10.1016/j.peptides.2006.03.003; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Racz B, 2006, REGUL PEPTIDES, V137, P20, DOI 10.1016/j.regpep.2006.02.009; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Renatus M, 2001, P NATL ACAD SCI USA, V98, P14250, DOI 10.1073/pnas.231465798; Renolleau S, 2007, J NEUROCHEM, V100, P1062, DOI 10.1111/j.1471-4159.2006.04269.x; ROBBERECHT P, 1992, EUR J BIOCHEM, V207, P239, DOI 10.1111/j.1432-1033.1992.tb17043.x; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Rohn TT, 2001, NEUROBIOL DIS, V8, P1006, DOI 10.1006/nbdi.2001.0449; Sakamaki K, 2002, CELL DEATH DIFFER, V9, P1196, DOI 10.1038/sj.cdd.4401090; Samantaray S, 2007, NEUROSCIENCE, V146, P741, DOI 10.1016/j.neuroscience.2007.01.056; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; SAWANGJAROEN K, 1992, PEPTIDES, V13, P1029, DOI 10.1016/0196-9781(92)90068-E; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Sherwood NM, 2000, ENDOCR REV, V21, P619, DOI 10.1210/er.21.6.619; Shi GX, 2006, MOL CELL BIOL, V26, P9136, DOI 10.1128/MCB.00332-06; Shibata M, 2003, NEUROSCIENCE, V118, P491, DOI 10.1016/S0306-4522(02)00910-7; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stumm R, 2007, J NEUROCHEM, V103, P1666, DOI 10.1111/j.1471-4159.2007.04895.x; Sun CH, 2007, P NATL ACAD SCI USA, V104, P7875, DOI 10.1073/pnas.0611397104; SUZUKI H, 1995, LIFE SCI, V57, P1451, DOI 10.1016/0024-3205(95)02108-U; Tamas A, 2006, ANN NY ACAD SCI, V1070, P570, DOI 10.1196/annals.1317.083; Tamas A, 2006, J NEUROTRAUM, V23, P686, DOI 10.1089/neu.2006.23.686; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tokuda E, 2007, BRAIN RES, V1148, P234, DOI 10.1016/j.brainres.2007.02.087; Troy CM, 2000, J NEUROSCI, V20, P1386; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Vaudry D, 2004, REGUL PEPTIDES, V123, P43, DOI 10.1016/j.regpep.2004.05.025; Vaudry D, 1999, P NATL ACAD SCI USA, V96, P9415, DOI 10.1073/pnas.96.16.9415; Vaudry D, 2003, SCIENCE, V300, P1532, DOI 10.1126/science.1085260; Vaudry D, 2003, J NEUROSCI RES, V72, P303, DOI 10.1002/jnr.10530; Vaudry D, 2002, EUR J NEUROSCI, V15, P1451, DOI 10.1046/j.1460-9568.2002.01981.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Villalba M, 1997, J NEUROSCI, V17, P83, DOI 10.1523/JNEUROSCI.17-01-00083.1997; Wang G, 2005, FEBS LETT, V579, P4005, DOI 10.1016/j.febslet.2005.06.013; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang Y, 2006, EMBO J, V25, P5896, DOI 10.1038/sj.emboj.7601445; Zhou P, 1999, P NATL ACAD SCI USA, V96, P11265, DOI 10.1073/pnas.96.20.11265; Zhu L, 2003, J BIOL CHEM, V278, P22418, DOI 10.1074/jbc.M212355200	150	70	70	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	NOV	2008	36	1-3					26	37		10.1007/s12031-008-9087-1			12	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Neurosciences & Neurology	376JP	WOS:000261180200005	18506634				2022-02-06	
J	Bivona, U; Ciurli, P; Barba, C; Onder, G; Azicnuda, E; Silvestro, D; Mangano, R; Rigon, J; Formisano, R				Bivona, Umberto; Ciurli, Paola; Barba, Carmen; Onder, Graziano; Azicnuda, Eva; Silvestro, Daniela; Mangano, Renata; Rigon, Jessica; Formisano, Rita			Executive function and metacognitive self-awareness after Severe Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						executive functions; metacognitive self-awareness; set shifting ability; perseverative responses; TBI rehabilitation	CLOSED-HEAD-INJURY; COMPETENCE RATING-SCALE; MULTIDIMENSIONAL APPROACH; BEHAVIORAL LIMITATIONS; PRACTICAL SCALE; REHABILITATION; DEFICITS; DYSFUNCTION; ADULTS; QUESTIONNAIRE	The objective of this Study is to identify the clinical, neuropsychological, neuropsychiatric, and functional variables that correlate with metacognitive self-awareness (SA) in severe traumatic brain injury (TBI) outpatients and to assess the influence of the same variables oil the sensory-motor, cognitive, and behavioral-affective indicators of SA. This cross-sectional observational study evaluated 37 outpatients from May 2006 to June 2007 in a neurorehabilitation hospital on the basis of the following inclusion criteria: (1) age >= 15 years; (2) diagnosis of severe TBI (Glasgow Coma Scale, GCS <= 8); (3) posttraumatic amnesia (PTA) resolution; (4) capacity to undergo formal psychometric evaluation despite cognitive and sensory-motor deficits; (5) absence of aphasia; (6) availability of informed consent. A neuropsychological battery was used to evaluate attention, memory, and executive functions. SA was assessed by the awareness questionnaire (AQ), administered to both patients and relatives. Decreased metacognitive self-awareness is significantly correlated with increased problems in some components of executive system, even when the AQ subscales were considered separately. The significant correlation found between some components of executive system and metacognitive self-awareness confirmed the importance of addressing this issue to treat SA contextually in the rehabilitation of executive functions.	[Bivona, Umberto; Ciurli, Paola; Azicnuda, Eva; Silvestro, Daniela; Mangano, Renata; Rigon, Jessica; Formisano, Rita] Fdn Santa Lucia, Unita Post Coma, I-00179 Rome, Italy; [Barba, Carmen] Childrens Hosp A Meyer, Pediat Neurol Unit, Florence, Italy; [Onder, Graziano] Catholic Univ, Dept Geriatr, Rome, Italy		Bivona, U (corresponding author), Fdn Santa Lucia, Unita Post Coma, Via Ardeatina 306, I-00179 Rome, Italy.	u.bivona@hsantalucia.it	barba, carmen/K-4942-2016; Barba, Carmen/AAB-7162-2022; Azicnuda, Eva/K-9010-2016; MANGANO, Giuseppa Renata/M-5292-2014	barba, carmen/0000-0001-5445-5842; MANGANO, Giuseppa Renata/0000-0001-6552-4014			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; APOLLONIO I, 2005, J NEUROL SCI, V26, P108; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; BOAKE C, 1995, BRAIN INJURY, V9, P273, DOI 10.3109/02699059509008198; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Borgaro SR, 2002, J HEAD TRAUMA REHAB, V17, P526, DOI 10.1097/00001199-200212000-00004; Burgess P, 1996, BEHAV ASSESSMENT DYS; CICERONE KD, 1991, J HEAD TRAUMA REHAB, V6, P30, DOI DOI 10.1097/00001199-199112000-00007; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; CROSSON C, 1989, J HEAD TRAUMA REHAB, V4, P46; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Flashman, 1998, Semin Clin Neuropsychiatry, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Hagen C., 1972, LEVELS COGNITIVE FUN; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.2307/2336190; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KRIKORIAN R, 1994, J CLIN EXP NEUROPSYC, V16, P840, DOI 10.1080/01688639408402697; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIGHT LL, 1992, HDB AGING COGNITION; Malec JF, 2000, REHABIL PSYCHOL, V45, P227, DOI 10.1037/0090-5550.45.3.227; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Mukhopadhyay P, 2008, PROG BRAIN RES, V168, P95, DOI 10.1016/S0079-6123(07)68008-X; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; NOVELLI G, 1986, Archivio di Psicologia Neurologia e Psichiatria, V47, P477; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; Orsini A., 2003, B PSICOL APPL, V239, P73; Ownsworth T, 2007, NEUROPSYCHOL REHABIL, V17, P129, DOI 10.1080/09602010600615506; Phillips LH, 1999, DEV NEUROPSYCHOL, V15, P249, DOI 10.1080/87565649909540748; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; Prigatano G.P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Randolph C., 1993, NEUROPSYCHOLOGY, V7, P82, DOI [10.1037/0894-4105.7.1.82, DOI 10.1037/0894-4105.7.1.82]; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schwartz S, 2003, BRAIN LANG, V87, P400, DOI 10.1016/S0093-934X(03)00141-X; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2000, NEUROREHABILITATION, V15, P57; TRUDEL TM, 1998, REHABIL PSYCHOL, V43, P276; Unterrainer JM, 2006, J PHYSIOL-PARIS, V99, P308, DOI 10.1016/j.jphysparis.2006.03.014; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zimmerman P., 1992, TEST BATTERIE AUFMER	59	70	71	0	14	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					862	868		10.1017/S1355617708081125			7	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400016	18764981	Bronze			2022-02-06	
J	McCabe, A; Bliss, L; Barra, G; Bennett, M				McCabe, Allyssa; Bliss, Lynn; Barra, Gabriela; Bennett, MariBeth			Comparison of personal versus fictional narratives of children with language impairment	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						children; language disorders; assessment; narrative	TRAUMATIC BRAIN INJURY; STORY STRUCTURE; POOR READERS; DISCOURSE; PERFORMANCE; GENERATION; ABILITIES; LITERACY; COHESION; EVENT	Purpose: Personal narratives are common in children's conversations, recommended as the appropriate genre for early writing by educators, and part of many high-stakes tests, possibly because they tend to be better formed than fictional narratives. However, current practice in the field of speech-language pathology employs fictional narratives in assessment, intervention, and study of children with impaired language development. This article explored performance on personal versus fictional narratives by children with language. impairment (LI), hypothesizing that performance on the former would be better and a minimal relationship between performances in the 2 genres. Method: Twenty-seven children age 7;0-9;9 (years;months) with LI orally produced personal and fictional narratives (responses to a wordless picture book). Narratives were analyzed by raters blind to experimental hypotheses using high-point analysis and an analysis derived from scoring of a high-stakes composition for 4th grade. Results: High-point ratings of personal significantly exceeded those of fictional narratives. Disproportionate fictional stories did not meet minimal narrative criteria. However, more personal narratives than would be expected by chance did. The analyses were significantly correlated. Quality of a child's performance of personal was minimally related to that of fictional narratives. Conclusions: Clinicians may want to consider functional aspects of personal narratives.	[McCabe, Allyssa; Barra, Gabriela; Bennett, MariBeth] Univ Massachusetts, Lowell, MA USA; [Bliss, Lynn] Univ Houston, Houston, TX USA		McCabe, A (corresponding author), Univ Massachusetts Lowell, Dept Psychol, 870 Broadway St,Suite 1, Lowell, MA 01854 USA.	allyssa-mccabe@uml.edu					ALLEN MS, 1994, APPL PSYCHOLINGUIST, V15, P149, DOI 10.1017/S0142716400005300; ALTMAN D, 1990, PRACTICAL STAT MEDIC; Bamberg M, 2002, J CHILD LANG, V29, P449, DOI 10.1017/S0305000902215342; BAMBERG M, 1994, RELATING EVENTS NARR, P189; BAMBERG M, IN PRESS FESTSCHRIFT; Berman R., 1994, RELATING EVENTS NARR; BERMAN RA, 1995, J NARRAT LIFE HIST, V5, P285, DOI 10.1075/jnlh.5.4.01nar; Bernays A., 1995, WHAT WRITING EXERCIS; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Boland AM, 2003, J COGN DEV, V4, P39, DOI 10.1207/S15327647JCD4,1-02; Bourg T., 1997, DEV SPANS EVENT COMP, P385; BROWN L, 1977, TEST NONVERBAL INTEL; Calkins L., 1994, ART TEACHING WRITING; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Catts HW, 2003, J LEARN DISABIL-US, V36, P151, DOI 10.1177/002221940303600208; CHAPMAN R, 1992, CHILDTALK PROCESS LA; Duke N.K., 2009, WHAT RES HAS SAY REA, V189, P107, DOI https://doi.org/10.1177/0022057409189001-208; Dunn LM., 1981, PEABODY PICTURE VOCA; Fey M., 1986, LANGUAGE INTERVENTIO; FINESTACK LH, 2006, SHARING BOOKS STORIE, P319; Fivush R, 2006, CHILD DEV, V77, P1568, DOI 10.1111/j.1467-8624.2006.00960.x; FORDHAM AE, 1989, CHILDRENS LIT COUNCI, V2, P20; GARCIAMARQUEZ G, 1982, SOLITUDE LATIN AM; GARDINER M, 2000, EXPRESSIVE ONE WORD; GHEZZI PM, 1987, PSYCHOL REC, V37, P109, DOI 10.1007/BF03395877; Gillam RB, 2002, TOP LANG DISORD, V22, P30, DOI 10.1097/00011363-200205000-00005; GRAYBEAL CM, 1981, APPL PSYCHOLINGUIST, V2, P269, DOI 10.1017/S014271640000655X; GRIFFITH PL, 1986, J PSYCHOLINGUIST RES, V15, P539, DOI 10.1007/BF01067635; Hadley PA, 1998, LANG SPEECH HEAR SER, V29, P132, DOI 10.1044/0161-1461.2903.132; HANSEN CL, 1978, LEARN DISABILITY Q, V1, P62, DOI 10.2307/1510938; Hay E, 2005, AM J SPEECH-LANG PAT, V14, P324, DOI 10.1044/1058-0360(2005/031); Hayward D., 2000, CHILD LANG TEACH THE, V16, P255, DOI DOI 10.1191/026565900680410215; Hedberg N., 1993, ANAL STORYTELLING SK; HEWITT LE, 1995, TOP LANG DISORD, V15, P1, DOI 10.1097/00011363-199508000-00003; Hoffman P. R, 1990, LANG SPEECH HEAR SER, V21, P102; Hughes DL., 1997, GUIDE NARRATIVE LANG; Janes H, 2001, J ADOLESC ADULT LIT, V44, P458; JOHN VP, 1968, DISADVANTAGED CHILD, V2, P259; Johnston J. R., 1982, LANG SPEECH HEAR SER, V13, P144, DOI [10.1044/0161-1461.1303.144, DOI 10.1044/0161-1461.1303.144]; JOHNSTON JR, 2006, TALKING CHILD LANGUA; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Justice LM, 2006, AM J SPEECH-LANG PAT, V15, P177, DOI 10.1044/1058-0360(2006/017); Kaderavek JN, 2000, J SPEECH LANG HEAR R, V43, P34, DOI 10.1044/jslhr.4301.34; Kamhi A., 1988, LANG SPEECH HEAR SER, V19, P304; King S., 2000, WRITING MEMOIR CRAFT; KLECANAKER JS, 1997, CONT ISSUES COMMUNIC, V24, P17, DOI DOI 10.1044/CICSD_24_S_17; Labov W., 1972, LANGUAGE INNER CITY; Lahey M., 1988, LANGUAGE DISORDERS L; LANDIS JR, 1977, BIOMETRICS, V33, P174; Losh M, 2003, J AUTISM DEV DISORD, V33, P239, DOI 10.1023/A:1024446215446; *MASS DEP ED, 2006, MASS COMPR ASS SYST; Mayer M., 1967, BOY FROG DOG; MAYER M, 1969, FROG WHERE ARE YOU; McCabe A., 2005, IMAG COGN PERS, V24, P331, DOI [10.2190/CJQ8-8C9G-05LG-0C2M, DOI 10.2190/CJQ8-8C9G-05LG-0C2M]; McCabe A., 1994, AM J SPEECH-LANG PAT, V3, P45, DOI [10. 1044/10580360.0301.45., DOI 10.1044/1058-0360.0301.45, 10.1044/1058-0360.0301.45]; McCabe A, 2003, PATTERNS NARRATIVE D; McCardle P., 2001, LEARN DISABIL RES PR, V16, P230, DOI [10.1111/0938-8982.00023, DOI 10.1111/0938-8982.00023]; MCCONAUGHY SH, 1985, READ RES QUART, V20, P219, DOI 10.2307/747757; MENIGPETERSON CL, 1975, CHILD DEV, V46, P1015; MERRITT DD, 1987, J SPEECH HEAR RES, V30, P539, DOI 10.1044/jshr.3004.539; MERRITT DD, 1989, J SPEECH HEAR DISORD, V54, P438, DOI 10.1044/jshd.5403.438; Miller L, 2001, DYNAMIC ASSESSMENT I; Miranda AE, 1998, APPL PSYCHOLINGUIST, V19, P647, DOI 10.1017/S0142716400010407; OWENS RE, 2004, LANGUAGE DISORDERS; Paul R., 2006, LANGUAGE DISORDERS I; Pearson, 2004, TEST NARRATIVE LANGU; Perry T., 1998, REAL EBONICS DEBATE; Peterson C, 1999, J CHILD LANG, V26, P49, DOI 10.1017/S0305000998003651; Peterson C., 1983, DEV NARRATIVE STRUCT; PREECE A, 1987, J CHILD LANG, V14, P273; RIPICH DN, 1988, J LEARN DISABIL, V21, P165, DOI 10.1177/002221948802100309; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; Scarborough H. S., 2001, HDB RES EARLY LITERA, P97; Semel E., 1995, CLIN EVALUATION LANG, VThird; Shapiro L., 1991, DEVELOPING NARRATIVE, P89; Shiro M, 2003, J CHILD LANG, V30, P165, DOI 10.1017/S0305000902005500; Snow C.E., 1998, PREVENTING READING D; Snyder LE, 2002, TOP LANG DISORD, V22, P1, DOI 10.1097/00011363-200205000-00003; Stein N. L., 1979, NEW DIRECTIONS DISCO, P53; Strong C. J., 1998, STRONG NARRATIVE ASS; Swanson LA, 2005, AM J SPEECH-LANG PAT, V14, P131, DOI 10.1044/1058-0360(2005/014); Tabors PO, 2001, BEGINNING LITERACY L, P313; WEAVER PA, 1982, DISCOURSE PROCESS, V5, P225, DOI 10.1080/01638538209544544; WESTBY CE, 1999, LANGUAGE READING DIS, P154; Wolf D.P., 2004, FIRST LANG, V24, DOI [10.1177/0142723704042369, DOI 10.1177/0142723704042369]; [No title captured]; [No title captured]	87	70	71	0	13	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	MAY	2008	17	2					194	206		10.1044/1058-0360(2008/019)			13	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	295OZ	WOS:000255485100009	18448606				2022-02-06	
J	Nylen, K; Ost, M; Csajbok, LZ; Nilsson, I; Hall, C; Blennow, K; Nellgard, B; Rosengren, L				Nylen, K.; Oest, M.; Csajbok, L. Z.; Nilsson, I.; Hall, C.; Blennow, K.; Nellgard, B.; Rosengren, L.			Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						S100B; S100A1B; S100BB; traumatic brain injury; outcome; biochemical brain damage markers	MARKER; PROTEIN	Objectives. S100B is an established marker of brain damage. Used in the context as a biochemical marker, S100B denotes a measurement of all S100 proteins, including at least one S100B monomer, i.e. the sum of the two dimers S100A1B and S100BB. Almost all published studies are based on this "sum concentration". However, the brain specificity of S100B has been questioned and increased serum levels have also been reported after trauma without head injury. Since the S100B monomer dominates in the brain, we hypothesised that the S100BB dimer should be better related to outcome after severe traumatic brain injury than S100A1B or the "sum concentration". Methods. Daily serum samples were collected from 59 patients with severe traumatic brain injury. Three different ELISA methods were used for measurements of S100B, S100A1B and S100BB respectively. Outcome was assessed after one year and categorised according to the Glasgow Outcome Scale. Results. Serum levels of S100B, S100A1B and S100BB followed the same temporal course, with early maximum and rapidly decreasing values over the first days after the trauma. Maximum serum concentrations of each of the parameters were increased in the patient group with an unfavourable outcome compared with those with a favourable outcome (p = 0.01, 0.006 and 0.004, respectively). Conclusion. Both S100A1B and S100BB were related to outcome after severe traumatic brain injury. Even though this study is small, it seems unlikely that separate analyses of the dimers are of any advantage compared with measuring S100B alone.	[Nylen, K.; Rosengren, L.] Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden; [Oest, M.; Csajbok, L. Z.; Nellgard, B.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Anaesthesia, Neurointens Care Unit, S-41345 Gothenburg, Sweden; [Nilsson, I.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Neuroradiol, Gothenburg, Sweden; [Blennow, K.] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Clin Neurosci, Unit Expt Neurosci, Gothenburg, Sweden; [Hall, C.] Fujirebio Diagnost AB, Gothenburg, Sweden		Nylen, K (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, Dept Neurol, S-41345 Gothenburg, Sweden.	karin.nylen@neuro.gu.se	Ost, Martin/AAY-5827-2020	Rosengren, Lars/0000-0003-0505-8896			Anderson RE, 2003, J CARDIOTHOR VASC AN, V17, P598, DOI 10.1016/S1053-0770(03)00203-9; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; ISOBE T, 1983, BIOCHEM INT, V6, P419; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; Kanner AA, 2003, CANCER, V97, P2806, DOI 10.1002/cncr.11409; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Rothoerl RD, 2000, ACT NEUR S, V76, P97; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Unden J, 2004, BRIT J NEUROSURG, V18, P277, DOI 10.1080/02688690410001732742; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026	20	70	73	0	3	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	MAR	2008	150	3					221	227		10.1007/s00701-007-1489-2			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	274AP	WOS:000253974500003	18193148				2022-02-06	
J	Bornhofen, C; McDonald, S				Bornhofen, Cristina; McDonald, Skye			Treating deficits in emotion perception following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							FACIAL EXPRESSION; HEAD TRAUMA; SOCIAL-PERCEPTION; RECOGNITION; ADULTS; REHABILITATION; COMMUNICATION; IMPAIRMENTS; REMEDIATION; RECOVERY	The present research aimed to investigate whether social perception deficits commonly experienced in the adult traumatic brain injury (TBI) population can be successfully remediated through cognitive rehabilitation. Twelve outC, patient volunteers (11 male, 1 female; age range 20-57 years) with severe, chronic TBI (mean length of post-traumatic amnesia 121 days, range 58-210 days; mean months post-injury 93.58, range 17-207 months) participated in a randomised controlled trial. Participants were randomly allocated to treatment and waitlist control groups following assessment on a range of emotion perception and psychosocial measures. Treatment comprised 25 hours, across 8 weeks, of a programme specifically designed to address emotion perception which incorporated a variety of remediation techniques shown to be effective with the TBI population. Results indicated that participants significantly improved both in judging basic emotional stimuli when presented in a naturalistic format (i.e., video vignettes) and in making social inferences on the basis of speaker demeanour. This is the first known treatment study dealing with emotion perception deficits in individuals with TBI.	[Bornhofen, Cristina; McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia		Bornhofen, C (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	cristinab@iinet.net.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			Bauminger N, 2002, J AUTISM DEV DISORD, V32, P283, DOI 10.1023/A:1016378718278; Benton A.L., 1983, CONTRIBUTIONS NEUROP; BIRD K, 2001, PSY PROGRAM CONTRAST; BRAUNLINGMCMORROW D, 1986, J REHABIL, V52, P39; BROTHERTON FA, 1988, ARCH PHYS MED REHAB, V69, P827; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; CICERONE KD, 1987, ARCH PHYS MED REHAB, V68, P111; Cornelissen K, 2003, J COGNITIVE NEUROSCI, V15, P444, DOI 10.1162/089892903321593153; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Duchaine BC, 2003, PERCEPTION, V32, P827, DOI 10.1068/p5067; EKMAN P, 1994, PSYCHOL BULL, V115, P268, DOI 10.1037/0033-2909.115.2.268; EKMAN P, 1976, FUNDAMENTALS NONVERB; EKMAN P, 1975, UMASKING FACE; Ekman Paul, 2003, EMOTIONS REVEALED RE; Frommann N, 2003, PSYCHIAT RES, V117, P281, DOI 10.1016/S0165-1781(03)00039-8; GAJAR A, 1984, J APPL BEHAV ANAL, V17, P353, DOI 10.1901/jaba.1984.17-353; GILES GM, 1988, BRAIN INJURY, V2, P101; Grattan LM, 2002, NEUROPSYCHOLOGICAL INTERVENTIONS, P266; Green REA, 2004, NEUROPSYCHOLOGIA, V42, P133, DOI 10.1016/j.neuropsychologia.2003.07.005; Grote I, 2003, J DEV PHYS DISABIL, V15, P281, DOI 10.1023/A:1026317815160; Hefter RL, 2005, NEUROLOGY, V65, P1620, DOI 10.1212/01.wnl.0000184498.16959.c0; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Hughes C, 1996, AM J MENT RETARD, V100, P565; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; JOHNSON DA, 1987, BRIT J CLIN PSYCHOL, V26, P289, DOI 10.1111/j.2044-8260.1987.tb01362.x; Keane J, 2002, NEUROPSYCHOLOGIA, V40, P655, DOI 10.1016/S0028-3932(01)00156-7; Kern RS, 2005, AM J PSYCHIAT, V162, P513, DOI 10.1176/appi.ajp.162.3.513; Kern RS, 2003, PSYCHOL MED, V33, P433, DOI 10.1017/S0033291702007298; Kuipers P, 2004, BRAIN INJURY, V18, P161, DOI 10.1080/0269905031000149524; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; Ley P., 1972, QUANTITATIVE ASPECTS; LONGONI F, 2000, Z NEUROPSYCHOL, V11, P250, DOI DOI 10.1024//1016-264X.11.4.250; MCALPINE C, 1992, BEHAV MODIF, V16, P559, DOI 10.1177/01454455920164007; McCandliss BD, 2002, COGN AFFECT BEHAV NE, V2, P89, DOI 10.3758/CABN.2.2.89; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; MCDONALD S, IN PRESS DISABILITY; McDonald S., 2003, BRAIN IMPAIR, V4, P36, DOI [10.1375/brim.4.1.36.27032, DOI 10.1375/BRIM.4.1.36.27032, DOI 10.1375/brim.4.1.36.27032]; McKenzie K., 2000, BRIT J LEARN DISABIL, V28, P143; Mehrabian A., 1972, NONVERBAL COMMUNICAT; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; MEICHENBAUM D, 1974, PSYCHOTHER-THEOR RES, V11, P103, DOI 10.1037/h0086326; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; MORRISON RL, 1981, BEHAV THER, V12, P69, DOI 10.1016/S0005-7894(81)80107-4; Mueser K.T., 1998, HDB SOCIAL FUNCTIONI, P79; O'Reilly MF, 2000, J VOCAT REHABIL, V14, P187; Penn DL, 2000, SCHIZOPHR RES, V46, P217, DOI 10.1016/S0920-9964(00)00005-0; PETERS RD, 1981, AM J MENT DEF, V85, P377; PETERSON L, 1988, MANUAL SOCIAL SKILLS; Pizzamiglio L, 1998, ARCH NEUROL-CHICAGO, V55, P561, DOI 10.1001/archneur.55.4.561; Pleger B, 2003, NEUROSCI LETT, V335, P192, DOI 10.1016/S0304-3940(02)01153-9; Polirstok SR, 2003, TOP LANG DISORD, V23, P146, DOI 10.1097/00011363-200304000-00007; Prigatano G. F., 2005, REHABILITATION TRAUM, P118; PRIGATANO GP, 1982, PERCEPT MOTOR SKILL, V54, P859, DOI 10.2466/pms.1982.54.3.859; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Roudier M, 1998, J NEUROL SCI, V154, P151, DOI 10.1016/S0022-510X(97)00222-0; SCHLOSS PJ, 1985, APPL RES MENT RETARD, V6, P269, DOI 10.1016/0270-3092(85)90001-3; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Spence S. H., 1995, SOCIAL SKILLS TRAINI; Squires EJ, 1997, NEUROPSYCHOLOGIA, V35, P1103, DOI 10.1016/S0028-3932(97)00039-0; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE R, 2002, SYDNEY PSYCHOSOCIAL; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor I, 1997, J APPL BEHAV ANAL, V30, P43, DOI 10.1901/jaba.1997.30-43; Temple E, 2003, P NATL ACAD SCI USA, V100, P2860, DOI 10.1073/pnas.0030098100; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TROWER P, 1980, J CONSULT CLIN PSYCH, V48, P327, DOI 10.1037/0022-006X.48.3.327; van der Gaag M, 2002, SCHIZOPHRENIA BULL, V28, P167, DOI 10.1093/oxfordjournals.schbul.a006919; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; Wechsler D., 1997, WECHSLER MEMORY SCAL; WechslerD, 2001, WECHSLER TEST ADULT; WILSON BA, 1994, NEUROPSYCHOL REHABIL, V4, P307, DOI 10.1080/09602019408401463; Winter J, 1999, INT J GERIATR PSYCH, V14, P987; Yates PJ, 2003, NEUROPSYCHOL REHABIL, V13, P291, DOI 10.1080/09602010244000408; Ylvisaker M, 2000, APHASIOLOGY, V14, P407, DOI 10.1080/026870300401432; YLVISAKER M, 1998, COLLABRATIVE BRAIN I	80	70	72	1	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	2008	18	1					22	44		10.1080/09602010601061213			23	Neurosciences; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychology	249HD	WOS:000252218000002	17852760				2022-02-06	
J	Conklin, HM; Salorio, CF; Slomine, BS				Conklin, Heather M.; Salorio, Cynthia F.; Slomine, Beth S.			Working memory performance following paediatric traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; executive function; frontal-subcortical pathways; neurodevelopment; childhood	BEHAVIOR RATING INVENTORY; HUMAN FRONTAL-CORTEX; EXECUTIVE FUNCTION; ACADEMIC-PERFORMANCE; CHILDREN; ADOLESCENTS; RECOVERY; OUTCOMES; SKILLS; COMPREHENSION	Primary objective: The present study investigated working memory ability in children who sustained moderate-to-severe traumatic brain injuries in relation to pre-injury, injury-related and developmental factors. It was hypothesized that there would be a correlation between performance- and rater-based working memory measures; factors predictive of working memory impairment would include earlier age at injury, more severe injury, longer time since injury and poorer overall cognitive functioning; and working memory performance would be significantly impaired when compared to normative populations. Methods and procedures: Working memory was assessed in 62 children using a traditional performance measure (digit span backward) and parent report (Behaviour Rating Inventory of Executive Function (BRIEF)). Main outcomes and results: Contrary to prediction, there was no statistical association between performance- and rater-based measures of working memory. Regression analyses revealed injury severity, time-since-injury, overall cognitive ability and attention span were predictive of working memory performance. As a group, working memory was impaired relative to normative samples on both measures. Conclusions: Performance- and rater-based working memory measures, while not significantly correlated, are both sensitive to acquired cognitive dysfunction following paediatric traumatic brain injury. Demographic and clinical factors may be used to predict cognitive outcomes, educate caregivers and design clinical interventions.	[Conklin, Heather M.] St Jude Childrens Res Hosp, Div Behav Med, Memphis, TN 38105 USA; [Salorio, Cynthia F.; Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Salorio, Cynthia F.] Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; [Slomine, Beth S.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA		Conklin, HM (corresponding author), St Jude Childrens Res Hosp, Div Behav Med, 332 N Lauderdale St, Memphis, TN 38105 USA.	heather.conklin@stjude.org	Conklin, Heather M/N-2696-2018				Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Ayr LK, 2005, J INT NEUROPSYCH SOC, V11, P249, DOI 10.1017/S1355617705050307; Baddeley A.D., 1986, WORKING MEMORY; Catroppa C, 2008, J CHILD NEUROL, V23, P486, DOI 10.1177/0883073807309773; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Cohen M.J., 1997, CHILDRENS MEMORY SCA; Conklin HM, 2007, DEV NEUROPSYCHOL, V31, P103, DOI 10.1207/s15326942dn3101_6; deJonge P, 1996, PERS INDIV DIFFER, V21, P1007, DOI 10.1016/S0191-8869(96)00161-4; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Giedd JN, 2004, ANN NY ACAD SCI, V1021, P77, DOI 10.1196/annals.1308.009; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; GOLDMANRAKIC PS, 1987, CHILD DEV, V58, P601, DOI 10.2307/1130201; GoldmanRakic PS, 1995, ANN NY ACAD SCI, V769, P71, DOI 10.1111/j.1749-6632.1995.tb38132.x; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hanten G, 2003, BRAIN INJURY, V17, P871, DOI 10.1080/02699050210147220; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Moran C, 2005, BRAIN INJURY, V19, P743, DOI 10.1080/02699050500110199; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Petrides M, 1995, ANN NY ACAD SCI, V769, P85, DOI 10.1111/j.1749-6632.1995.tb38133.x; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; RUDEL RG, 1974, NEUROPSYCHOLOGIA, V12, P109, DOI 10.1016/0028-3932(74)90032-3; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; Sowell ER, 2001, J NEUROSCI, V21, P8819, DOI 10.1523/JNEUROSCI.21-22-08819.2001; *SPSS INC, 2004, STAT PACK SOC SCI 13; Swanson HL, 1999, DEV PSYCHOL, V35, P986, DOI 10.1037/0012-1649.35.4.986; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; TEASDALE G, 1974, LANCET, V2, P81; Thomsen I V, 1989, Brain Inj, V3, P157, DOI 10.3109/02699058909004547; Verger K, 2000, BRAIN INJURY, V14, P495; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Warschausky S, 1996, ARCH CLIN NEUROPSYCH, V11, P147, DOI 10.1016/0887-6177(95)00004-6; Wechsler D, 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091; Yakovlev PI, 1967, REGIONAL DEV BRAIN E, P3; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	73	70	70	0	23	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	11					847	857		10.1080/02699050802403565			11	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	371RT	WOS:000260849700004	18850343				2022-02-06	
J	McCrea, M; Pliskin, N; Barth, J; Cox, D; Fink, J; French, L; Hammeke, T; Hess, D; Hopewell, A; Orme, D; Powell, M; Ruff, R; Schrock, B; Terryberryspohr, L; Vanderploeg, R; Yoash-Gantz, R				McCrea, Michael; Pliskin, Neil; Barth, Jeffrey; Cox, David; Fink, Joseph; French, Louis; Hammeke, Thomas; Hess, David; Hopewell, Alan; Orme, Daniel; Powell, Matthew; Ruff, Ron; Schrock, Barbara; Terryberryspohr, Lori; Vanderploeg, Rodney; Yoash-Gantz, Ruth			Official position of the military TBI task force on the role of neuropsychology and rehabilitation psychology in the evaluation, management, and research of military veterans with traumatic brain injury	CLINICAL NEUROPSYCHOLOGIST			English	Article							MENTAL-HEALTH PROBLEMS; FOOTBALL PLAYERS; CONCUSSION; IRAQ; AFGHANISTAN; NEUROTRAUMA; RECOVERY	This Position Statement is a summary of the literature and learning regarding current issues raised by the occurrence, treatment, and study of traumatic brain injury in military service members and veterans. The Report has been approved by the American Academy of Clinical Neuropsychology (AACN), Divisions 40 (Neuropsychology) and 22 (Rehabilitation Psychology) of the American psychological Association (APA), and the National Academy of Neuropsychology (NAN), with the goal of providing information of relevance on an important public policy matter within their respective areas of expertise. The Report is not intended to establish guidelines or standards for the professional practice of psychology, nor has it been adopted as official policy by the American Psychological Association or any other division or subunit of APA.	[McCrea, Michael; Pliskin, Neil; Barth, Jeffrey; Cox, David; Fink, Joseph; French, Louis; Hammeke, Thomas; Hess, David; Hopewell, Alan; Orme, Daniel; Powell, Matthew; Ruff, Ron; Schrock, Barbara; Terryberryspohr, Lori; Vanderploeg, Rodney; Yoash-Gantz, Ruth] Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA		McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.	Michael.mccrea@phci.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT; Barr WB, 2001, J ATHL TRAINING, V36, P297; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; *DVBIC, 2006, DEF VET BRAIN INJ CT; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Jennett B, 1981, MANAGEMENT HEAD INJU; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEADHAM CS, 1993, MIL MED, V158, P508; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M.A., 2007, MILD TRAUMATIC BRAIN; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; *NAT INJ PREV CONT, 2003, REP C MILD TRAUM BAR; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Randolph C, 2005, J ATHL TRAINING, V40, P139; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2005, J NEUROTRAUM, V22, P1178; World Health Organization, 2004, ICD 10 INT STAT CLAS; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; ZOROYA G, 2006, US TODAY        0808	34	70	71	0	6	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN	2008	22	1					10	26		10.1080/13854040701760981			17	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	258TF	WOS:000252891700002	18247218				2022-02-06	
J	Bondanelli, M; Ambrosio, MR; Cavazzini, L; Bertocchi, A; Zatelli, MC; Carli, A; Valle, D; Basaglia, N; Uberti, ECD				Bondanelli, Marta; Ambrosio, Maria Rosaria; Cavazzini, Lorenza; Bertocchi, Amedeo; Zatelli, Maria Chiara; Carli, Anna; Valle, Domenico; Basaglia, Nino; Uberti, Ettore C. Degli			Anterior pituitary function may predict functional and cognitive outcome in patients with traumatic brain injury undergoing rehabilitation	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone; hypopituitarism; rehabilitation; TBI	DISABILITY RATING-SCALE; SEVERE HEAD TRAUMA; GROWTH-HORMONE; ADRENAL INSUFFICIENCY; HYPOPITUITARISM; COMA; IMPACT; ADULTS; REPLACEMENT; DIAGNOSIS	Traumatic brain injury (TBI) is the leading cause of death and disability in young adults. Growth hormone-insulin-like growth factor I (GH-IGF-I) system has an important role in the recovery of the central nervous system. The aim of the study was to evaluate the relationship between pituitary function (in particular, the GH-IGF-I axis) and outcome from TBI. We studied 72 patients (56 males; mean age 37.2 +/- 1.8 years) receiving rehabilitation after TBI. According to the Glasgow Coma Scale (GCS), 10 patients had moderate and 52 severe TBI. Ten patients had growth hormone GH deficiency (GHD), 10 LH-FSH, three TSH, and three ACTH deficiency. Overall pituitary dysfunction occurred in 22 (30.5%) patients, with anterior hypopituitarism in 19 (26.4%), isolated diabetes insipidus in one, and isolated hyperprolactinemia in two. GH response to GHRH+ARG ( arginine) positively correlated with Functional Independence Measure (FIMD; r = 0.267, p < 0.02) and Level of Cognitive Functioning Scale (LCFSD; r = 0.287, p < 0.01) at discharge, and negatively with Disability Rating Score at discharge (DRSD; r = -0.324, p < 0.005). Unfavorable outcome measures (FIMD, LCFSD, and DRSD) occurred in patients with hypopituitarism as compared with normal pituitary function p < 0.05). Multiple regression analysis identified both GCS (p < 0.005) and GH peak (p < 0.05) as strong independent predictors of outcome. In conclusion, recovery after TBI may be negatively influenced by concomitant pituitary dysfunction. The GH peak value is an independent predictor of outcome, indicating that recovery during an intensive rehabilitation program after TBI may be positively influenced by normal GH secretion.	Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, I-44100 Ferrara, Italy; Arcispedale St Anna, Dept Rehabil Med, Ferrara, Italy; Eli Lilly & Co, Florence, Italy		Bondanelli, M (corresponding author), Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, Via Savonarola 9, I-44100 Ferrara, Italy.		Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	ambrosio, maria rosaria/0000-0002-7911-9770; Zatelli, Maria Chiara/0000-0001-8408-7796; Bondanelli, Marta/0000-0001-8071-6559; degli Uberti, Ettore/0000-0002-9441-7223			Aberg ND, 2006, THESCIENTIFICWORLDJO, V6, P53, DOI 10.1100/tsw.2006.22; Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Bondanelli M, 2006, J CLIN ENDOCR METAB, V91, P3928, DOI 10.1210/jc.2006-1040; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Falleti MG, 2006, PSYCHONEUROENDOCRINO, V31, P681, DOI 10.1016/j.psyneuen.2006.01.005; HAGEN C, 1982, COGNITIVE REHABILITA, P131; High WM, 2006, ARCH PHYS MED REHAB, V87, P334, DOI 10.1016/j.apmr.2005.11.028; James R, 2005, ARCH PHYS MED REHAB, V86, pS82, DOI 10.1016/j.apmr.2005.07.314; Keith R A, 1987, Adv Clin Rehabil, V1, P6; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Schmidt IL, 2003, J CLIN ENDOCR METAB, V88, P4193, DOI 10.1210/jc.2002-021897; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Simpson H, 2002, GROWTH HORM IGF RES, V12, P1, DOI 10.1054/ghir.2001.0263; Sonntag WE, 2006, AM J PHYSIOL-ENDOC M, V291, pE604, DOI 10.1152/ajpendo.00012.2006; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Suliman AM, 2002, CLIN ENDOCRINOL, V56, P533, DOI 10.1046/j.1365-2265.2002.01509.x; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Toschlog EA, 2003, AM SURGEON, V69, P491; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Van der Heljde D, 2005, ANN RHEUM DIS, V64, P109; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Young TP, 2007, BRAIN INJURY, V21, P645, DOI 10.1080/02699050701210426	42	70	73	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2007	24	11					1687	1697		10.1089/neu.2007.0343			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	234MZ	WOS:000251169500002	18001199				2022-02-06	
J	Fitzpatrick, W; Lowry, N				Fitzpatrick, W.; Lowry, N.			PLEDS: Clinical correlates	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							LATERALIZED EPILEPTIFORM DISCHARGES; CRITICALLY-ILL; METABOLIC ABNORMALITIES; NONCONVULSIVE SEIZURES; STRUCTURAL LESIONS; EEG PATTERNS; CHILDREN; ASSOCIATION; EVOLUTION; ETIOLOGY	Objective: We reviewed our experience in 96 consecutive patients exhibiting periodic lateralized epileptiform discharges (PLEDs) on EEG. Methods: EEG reports from January 1, 1999 to September 30, 2006 were screened for the term 'PLEDs' and its variants. A retrospective chart review, including examination of neuroimaging and other investigations, was conducted on each patient identified. Results: Acute stroke, tumor and central nervous system infection were the most common etiologies, accounting for 26%, 12% and 12% of cases respectively. Acute hemorrhage and traumatic brain injury combined accounted for another 12%. Previously unreported etiologies included posterior reversible encephalopathy syndrome (PRES), familial hemiplegic migraine and cerebral amyloiclosis. There were 9 cases of chronic PLEDs attributable to underlying cortical dysplasia or severe remote cerebral injury, all with an accompanying partial seizure disorder. A prominent role for alcohol withdrawal was noted, and in 6 cases was the sole etiological factor. Fever was present as a potential contributing factor in 40% of cases, and significant metabolic abnormalities in 35%. Seizure activity occurred in 85% of patients overall., but in 100% of patients with PLEDs Plus and BiPLEDs Plus. The overall mortality rate was 27%. Mortality among patients with BiPLEDs however was almost twice that, at 52%. Conclusions: This case series demonstrates the wide variety of potential PLED etiologies. It also emphasizes that despite advances in neurocritical care, the morbidity and mortality associated with PLEDs has changed little since their recognition four decades ago.	Univ Saskatchewan, Dept Med, Div Neurol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Pediat Neurol, Saskatoon, SK, Canada		Fitzpatrick, W (corresponding author), 106 Brookdale Crescent, Saskatoon, SK S7V 1K5, Canada.						Assal F, 2001, SEIZURE-EUR J EPILEP, V10, P260, DOI 10.1053/seiz.2000.0506; Baykan B, 2000, SEIZURE-EUR J EPILEP, V9, P402, DOI 10.1053/seiz.2000.0435; Beaumanoir A, 1996, ELECTROEN CLIN NEURO, V99, P287; CHATRIAN GE, 1964, ELECTROEN CLIN NEURO, V17, P177, DOI 10.1016/0013-4694(64)90149-X; Chen KS, 2003, PEDIATR NEUROL, V28, P100, DOI 10.1016/S0887-8994(02)00493-9; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; CHU NS, 1980, ARCH NEUROL-CHICAGO, V37, P551, DOI 10.1001/archneur.1980.00500580047006; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; DAUBEN RD, 1977, CLIN ELECTROENCEPHAL, V8, P116, DOI 10.1177/155005947700800302; DELAPAZ D, 1981, ARCH NEUROL-CHICAGO, V38, P713, DOI 10.1001/archneur.1981.00510110073012; DRURY I, 1985, NEUROLOGY, V35, P911, DOI 10.1212/WNL.35.6.911; Ebersole J, 2003, CURRENT PRACTICE CLI, P506; Garcia-Morales I, 2002, J CLIN NEUROPHYSIOL, V19, P172, DOI 10.1097/00004691-200203000-00009; GARG BP, 1995, PEDIATR NEUROL, V12, P225, DOI 10.1016/0887-8994(95)00020-G; Gross DW, 1999, CLIN NEUROPHYSIOL, V110, P1516, DOI 10.1016/S1388-2457(99)00119-4; Gurer G, 2004, CLIN EEG NEUROSCI, V35, P88, DOI 10.1177/155005940403500207; HAMANO K, 1994, PEDIATR NEUROL, V11, P28, DOI 10.1016/0887-8994(94)90086-8; HANDFORTH A, 1994, EPILEPSIA, V35, P876, DOI 10.1111/j.1528-1157.1994.tb02526.x; Jette N, 2006, ARCH NEUROL-CHICAGO, V63, P1750, DOI 10.1001/archneur.63.12.1750; KUROIWA Y, 1980, ARCH NEUROL-CHICAGO, V37, P15, DOI 10.1001/archneur.1980.00500500045005; Lawn ND, 2000, CLIN NEUROPHYSIOL, V111, P2125, DOI 10.1016/S1388-2457(00)00466-1; LESSER RP, 1985, EPILEPSIA, V26, P622, DOI 10.1111/j.1528-1157.1985.tb05702.x; MARKAND ON, 1971, NEUROLOGY, V21, P975, DOI 10.1212/WNL.21.10.975; Neufeld MY, 1997, ELECTROEN CLIN NEURO, V102, P295, DOI 10.1016/S0013-4694(96)95726-0; PEBENITO R, 1979, ANN NEUROL, V6, P47, DOI 10.1002/ana.410060111; PohlmannEden B, 1996, J CLIN NEUROPHYSIOL, V13, P519, DOI 10.1097/00004691-199611000-00007; RAROQUE HG, 1993, EPILEPSIA, V34, P279, DOI 10.1111/j.1528-1157.1993.tb02411.x; REIHER J, 1991, ELECTROEN CLIN NEURO, V78, P12, DOI 10.1016/0013-4694(91)90013-T; SCHRAEDER PL, 1980, EPILEPSIA, V21, P647, DOI 10.1111/j.1528-1157.1980.tb04318.x; SCHWARTZ MS, 1973, BRAIN, V96, P613, DOI 10.1093/brain/96.3.613; SINGH BM, 1980, ANN NEUROL, V8, P155, DOI 10.1002/ana.410080205; SNODGRASS SM, 1989, J CLIN NEUROPHYSIOL, V6, P159, DOI 10.1097/00004691-198904000-00003; Striano S, 1986, Acta Neurol (Napoli), V8, P1; TERZANO MG, 1986, EPILEPSIA, V27, P446, DOI 10.1111/j.1528-1157.1986.tb03566.x; WALSH JM, 1987, EPILEPSIA, V28, P533, DOI 10.1111/j.1528-1157.1987.tb03684.x; WESTMORELAND BF, 1986, ARCH NEUROL-CHICAGO, V43, P494, DOI 10.1001/archneur.1986.00520050066024; Young G, 1988, AM J EEG TECHNOL, V28, P1; Young GB, 1996, NEUROLOGY, V47, P83	38	70	74	0	4	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	NOV	2007	34	4					443	450		10.1017/S0317167100007332			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	233YO	WOS:000251126400009	18062453	Bronze			2022-02-06	
J	Scalea, TM; Bochicchio, GV; Habashi, N; McCunn, M; Shih, D; McQuillan, K; Aarabi, B				Scalea, Thomas M.; Bochicchio, Grant V.; Habashi, Nader; McCunn, Maureen; Shih, Diane; McQuillan, Karen; Aarabi, Bizhan			Increased intra-abdominal, intrathoracic, and intracranial pressure after severe brain injury: Mulitple compartment syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	64th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-24, 2005	Atlanta, GA	Amer Assoc Surg Trauma		critical care; decompressive craniectomy; injury; morbidity; traumatic brain injury; trauma outcomes	CEREBRAL PERFUSION-PRESSURE; DECOMPRESSIVE CRANIECTOMY; ORGAN DYSFUNCTION; HYPERTENSION; MANAGEMENT	Objectives. Fluid therapy and/or acute lung injury may increase intra-abdominal pressure (IAP) and intrathoracic pressure, thereby increasing intracranial pressure (ICP) after traumatic brain injury (TBI). Further fluid administration to support cerebral perfusion or increasing ventilatory support to treat acute lung injury further increases ICP. This can create a cycle that ultimately produces multiple compartment syndrome (MCS). Both decompressive craniectomy (DC) and decompressive laparotomy (DL) decrease ICP. DL can also decrease IAP and ICP. We evaluated the serial application of DC and DL to treat MCS. Methods. Data were analyzed for 102 consecutive patients with severe TBI who underwent DC alone to decrease ICP or in combination with DL to treat MCS. Results: All 102 patients sustained blunt injury. Seventy percent were men with a mean age of 29.5 years, an Injury Severity Score of 34.4, and admission Glasgow Coma Scale score of 7.1. Fifty-one patients had diffuse brain injury and 51 had mass lesions. Seventy-eight patients (76%) underwent DC alone. Twenty-four (22%) had both therapies for MCS. Fifteen patients had DC before DL and nine had DL before DC. Mean time between DC and DL was 3.4 +/- 6 days. The mean IAP before DL was 28 +/- 5 turn Hg. Twenty-four-hour cumulative mean intrathoracic pressure decreased significantly after DL in the MCS group (p = 0.01). Mean ICP decreased significantly after both DC and DL (p < 0.05). Conclusion. Increased ICP may be from primary TBI or MCS. Patients with MCS have a higher Injury Severity Score, ICP, and fluid requirements, but no increase in mortality. Both DC and DL reduce ICP and can be used in sequence. MCS should be considered in multiply injured patients with increased ICP that does not respond to therapy.	Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, Baltimore, MD 21201 USA		Scalea, TM (corresponding author), Univ Maryland, Sch Med, R Adams Cowley Shock Trauma Ctr, Program Trauma, 22 S Greene St, Baltimore, MD 21201 USA.	tscalea@umm.edu					ABRAMSON D, 1993, J TRAUMA, V35, P584, DOI 10.1097/00005373-199310000-00014; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; BULLOCK R, 2000, MANAGEMENT PROGNOSIS; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; Jaeger M, 2003, J NEUROL NEUROSUR PS, V74, P513, DOI 10.1136/jnnp.74.4.513; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Lacroix J, 2005, CRIT CARE MED, V33, P697, DOI 10.1097/01.CCM.0000155778.87402.56; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McKeating EG, 1997, BRIT J ANAESTH, V78, P520, DOI 10.1093/bja/78.5.520; MEERT KL, 1995, CRIT CARE MED, V23, P822, DOI 10.1097/00003246-199505000-00008; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V203, P1778; van Kaam AH, 2004, AM J RESP CRIT CARE, V169, P1046, DOI 10.1164/rccm.200312-1779OC; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; WILSON NW, 1991, AM J DIS CHILD, V145, P326, DOI 10.1001/archpedi.1991.02160030096029; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	23	70	74	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2007	62	3					647	656		10.1097/TA.0b013e31802ee542			10	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	145PP	WOS:000244877300020	17414342				2022-02-06	
J	Horn, EM; Feiz-Erfan, I; Lekovic, GP; Dickman, CA; Sonntag, VKH; Theodore, N				Horn, Eric M.; Feiz-Erfan, Iman; Lekovic, Gregory P.; Dickman, Curtis A.; Sonntag, Volker K. H.; Theodore, Nicholas			Survivors of occipitoatlantal dislocation injuries: imaging and clinical correlates	JOURNAL OF NEUROSURGERY-SPINE			English	Article						occipitoatlantal dislocation; spinal cord injury; atlantoaxial distraction; occipitoatlantal joint; craniocervical junction	TRAUMATIC ATLANTOOCCIPITAL DISLOCATION; ATLANTO-OCCIPITAL DISLOCATION; CERVICAL-SPINE; CRUCIATE PARALYSIS; FRACTURE-DISLOCATION; CHILDREN; DIAGNOSIS; JUNCTION; PSEUDOMENINGOCELE; DISSOCIATION	Object. Although rare, traumatic occipitoatlantal dislocation (OAD) injuries are associated with a high mortality rate. The authors evaluated the imaging and clinical factors that determined treatment and were predictive of outcomes, respectively, in survivors of this injury. Methods. The medical records and imaging studies obtained in 33 patients with OAD were reviewed retrospectively. Clinical factors that predicted outcomes, especially neurological injury at presentation and imaging findings, were evaluated. The most sensitive method for the diagnosis of OAD was the measurement of basion axial-basion dens interval on computed tomography (CT) scanning. Five patients with severe traumatic brain injuries (TBIs) were not treated and subsequently died. Of the 28 patients in whom treatment was performed, 23 underwent fusion and five were fitted with an external orthosis. Abnormal findings of the occipitoatlantal ligaments on magnetic resonance (MR) imaging, associated with no or questionable abnormalities on CT scanning, provided the rationale for nonoperative treatment. Of the 28 patients treated for their injuries, perioperative death occur-red in five, three of whom had presented with severe neurological injuries. The mortality rate was highest in patients with a TBI at presentation. The mortality rate was lower in patients presenting with a spinal cord injury, but in this group there was a higher rate of persistent neurological deficits. Conclusions. The spines in patients with CT-documented OAD are most likely unstable and need surgical fixation. In patients for whom CT findings are normal and MR imaging findings suggest marginal abnormalities, nonoperative treatment should be considered. The best predictors of outcome were severe brain or upper cervical injuries at initial presentation.	St Josephs Hosp, Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, Phoenix, AZ 85013 USA		Theodore, N (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	neuropub@chw.edu		Theodore, Nicholas/0000-0001-5355-2683			ALKER GJ, 1978, ORTHOP CLIN N AM, V9, P1003; Apostolides PJ, 1996, SPINE, V21, P1630, DOI 10.1097/00007632-199607150-00004; Bani Alan, 2003, Spine (Phila Pa 1976), V28, pE95; Bellabarba C, 2006, J NEUROSURG-SPINE, V4, P429, DOI 10.3171/spi.2006.4.6.429; Blackwood NJ, 1908, ANN SURG, V47, P654, DOI 10.1097/00000658-190805000-00003; BOHLMAN HH, 1979, J BONE JOINT SURG AM, V61, P1119, DOI 10.2106/00004623-197961080-00001; BOOLS JC, 1986, AM J NEURORADIOL, V7, P901; BULAS DI, 1993, RADIOLOGY, V188, P155, DOI 10.1148/radiology.188.1.8511290; BUNDSCHUH CV, 1992, SPINE, V17, P245, DOI 10.1097/00007632-199202000-00024; Chaljub G, 2001, NEURORADIOLOGY, V43, P41, DOI 10.1007/s002340000483; Deliganis AV, 2000, RADIOGRAPHICS, V20, pS237, DOI 10.1148/radiographics.20.suppl_1.g00oc23s237; DEOLIVEIRA E, 1985, SURG NEUROL, V24, P293, DOI 10.1016/0090-3019(85)90042-4; DICKMAN CA, 1993, J SPINAL DISORD, V6, P300, DOI 10.1097/00002517-199306040-00004; DICKMAN CA, 1990, J NEUROSURG, V73, P850, DOI 10.3171/jns.1990.73.6.0850; DONAHUE DJ, 1994, PEDIATR NEUROSURG, V21, P105, DOI 10.1159/000120822; Dziurzynski K, 2005, SPINE, V30, P1427, DOI 10.1097/01.brs.0000166524.88394.b3; FARTHING J W, 1948, N C Med J, V9, P34; Feiz-Erfan I, 2005, J NEUROSURG-SPINE, V2, P381, DOI 10.3171/spi.2005.2.3.0381; FRUIN AH, 1977, J NEUROSURG, V46, P663, DOI 10.3171/jns.1977.46.5.0663; FUJIMURA Y, 1995, PARAPLEGIA, V33, P195, DOI 10.1038/sc.1995.44; Gonzalez LF, 2005, J NEUROSURG-SPINE, V3, P318, DOI 10.3171/spi.2005.3.4.0318; Gonzalez LF, 2004, J NEUROSURG-SPINE, V1, P273, DOI 10.3171/spi.2004.1.3.0273; Govender S, 2003, J BONE JOINT SURG BR, V85B, P875, DOI 10.1302/0301-620X.85B6.14092; Grabb BC, 1999, PEDIATR RADIOL, V29, P275, DOI 10.1007/s002470050588; Guigui P, 1995, Eur Spine J, V4, P242, DOI 10.1007/BF00303419; Hadley MN, 2002, NEUROSURGERY, V50, pS105; HARRIS JH, 1994, AM J ROENTGENOL, V162, P887, DOI 10.2214/ajr.162.4.8141013; Horn EM, 2004, J NEUROSURG-SPINE, V1, P39, DOI 10.3171/spi.2004.1.1.0039; Hosalkar HS, 2005, J BONE JOINT SURG AM, V87A, P2480, DOI 10.2106/JBJS.D.01897; Houle P, 2001, PEDIATR NEUROSURG, V34, P193, DOI 10.1159/000056019; Kenter K, 2001, J PEDIATR ORTHOPED, V21, P585, DOI 10.1097/00004694-200109000-00006; Labbe JL, 2001, J PEDIATR ORTHOP B, V10, P319, DOI 10.1097/00009957-200110000-00010; Labler L, 2004, EUR SPINE J, V13, P172, DOI 10.1007/s00586-003-0653-5; LADOUCEUR D, 1991, SPINE, V16, P1383, DOI 10.1097/00007632-199112000-00010; Naso WB, 1997, NEUROSURGERY, V40, P1288, DOI 10.1097/00006123-199706000-00033; PAGE CP, 1973, J NEUROSURG, V39, P394, DOI 10.3171/jns.1973.39.3.0394; PAPADOPOULOS SM, 1991, NEUROSURGERY, V28, P574, DOI 10.1227/00006123-199104000-00015; PAPPAS CTE, 1991, J NEUROSURG, V75, P935, DOI 10.3171/jns.1991.75.6.0935; Park JB, 2001, EUR SPINE J, V10, P524, DOI 10.1007/s005860100334; Przybylski GJ, 1996, SPINE, V21, P1761, DOI 10.1097/00007632-199608010-00009; Rahimi Scott Y, 2003, Neurosurg Focus, V15, pECP1; Reed CM, 2005, SPINE, V30, pE128, DOI 10.1097/01.brs.0000154654.37815.01; Rhoton  Jr AL, 1998, SURG CRANIOVERTEBRAL, P13; Saeheng S, 2001, SURG NEUROL, V55, P35, DOI 10.1016/S0090-3019(00)00350-5; Seibert PS, 2005, ACTA NEUROCHIR, V147, P435, DOI 10.1007/s00701-004-0461-7; Steinmetz Michael P, 2003, Neurosurg Focus, V14, pecp1; Sun PP, 2000, J NEUROSURG, V93, P28, DOI 10.3171/spi.2000.93.1.0028; TRAYNELIS VC, 1986, J NEUROSURG, V65, P863, DOI 10.3171/jns.1986.65.6.0863; van de Pol GJ, 2005, SPINE, V30, pE424, DOI 10.1097/01.brs.0000170595.83169.94; WERNE SVEN, 1957, ACTA ORTHOPAED SCAND SUPPL, V23, P1; WILLIAMS MJ, 1995, J CLIN ANESTH, V7, P156, DOI 10.1016/0952-8180(94)00031-X; WOODRING JH, 1981, AM J ROENTGENOL, V137, P21, DOI 10.2214/ajr.137.1.21	52	70	73	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	FEB	2007	6	2					113	120		10.3171/spi.2007.6.2.113			8	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	132ZQ	WOS:000243981800004	17330577				2022-02-06	
J	Piolino, P; Desgranges, B; Manning, L; North, P; Jokic, C; Eustache, F				Piolino, Pascale; Desgranges, Beatrice; Manning, Liliane; North, Pierre; Jokic, Corinne; Eustache, Francis			Autobiographical memory, the sense of recollection and executive functions after severe traumatic brain injury	CORTEX			English	Article						autobiographical memory; autonoetic consciousness; remembering; self-perspective; executive functions	FOCAL RETROGRADE-AMNESIA; CLOSED-HEAD INJURY; EPISODIC MEMORY; REMOTE MEMORY; AUTONOETIC CONSCIOUSNESS; CONTEXT MEMORY; TEMPORAL-LOBE; OLD MEMORIES; MILD; AGE	Residual disorders of autobiographical memory long after trauma resulting from head injury are rarely assessed, even though they may affect social adjustment and the resumption of daily life. We conducted a thorough study of autobiographical memory in severe traumatic brain injury (TBI) patients, examined at least one year post-trauma. Twenty-five patients were submitted to a novel and controlled autobiographical procedure specially designed to measure episodic memories (i.e., unique, specific in time and space, and detailed) from their entire life span with two kinds of self-remembering experience. The ability to mentally travel back through time and re-experience the source of acquisition, i.e. autonoetic consciousness, was assessed via the "Remember/Know" paradigm and a checking procedure of sense of remembering. Self-perspective in visual imagery, which is also critically involved in episodic recollection, was assessed by the "Field/Observer perspective" paradigm. In addition, the patients underwent a battery of standardized neuropsychological, tests to assess episodic and semantic memory, orientation and executive functions. The results showed that the patients, compared with healthy controls, were significantly impaired in recalling episodic autobiographical memories. This impairment was not related to the life period tested or the patients' ages nor the intellectual impairment. Deficits involved disturbances in sense of remembering, visual imagery self-perspective and recollection of spatiotemporal details. Stepwise-regression analyses carried out in the TBI patients revealed a significant relationship between an abnormal sense of remembering and executive dysfunction covering both anterograde and retrograde components. The novel assessment used in this study provides the first detailed evidence of a more fine-grained deficit of autobiographical memory in TBI patients. Indeed, the results suggest that these patients, long after trauma, present autonoetic consciousness and self-perspective disorders, which include sense of identity (the self) as a continuous entity across time, probably related to frontal dysfunction.	Univ Caen, EPHE, Neuropsychol Lab, CHU Cote Nacre,INSERM E0218, F-14033 Caen, France; Univ Paris 05, Ecole Prat Hautes Etud, CNRS, UMR 8581, Paris, France; Univ Strasbourg, CNRS, Lab Behav & Cognit Neurosci, UMR 7521, Strasbourg, France; Hosp Mulhouse, Dept Funct Rehabil, Mulhouse, France		Eustache, F (corresponding author), Univ Caen, EPHE, Neuropsychol Lab, CHU Cote Nacre,INSERM E0218, EO218, F-14033 Caen, France.	neuropsycho@chu-caen.fr	Desgranges, Beatrice/L-7739-2015; Eustache, Francis/J-9465-2015; Piolino, pascale/F-8075-2014; DESGRANGES, BEATRICE/AAK-4756-2021	Eustache, Francis/0000-0003-4460-8686; Piolino, pascale/0000-0002-7787-924X; DESGRANGES, BEATRICE/0000-0002-3657-9996; Manning, Liliann/0000-0001-5027-8551			Baddeley A, 2001, PHILOS T R SOC B, V356, P1345, DOI 10.1098/rstb.2001.0957; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; BREWER W, 1996, THEORETICAL PERSPECT; Calabrese P, 1996, J NEUROL NEUROSUR PS, V61, P304, DOI 10.1136/jnnp.61.3.304; CARDEBAT D, 1990, ACTA NEUROL BELG, V90, P207; Carlesimo GA, 1998, CORTEX, V34, P1, DOI 10.1016/S0010-9452(08)70734-2; Clarys D, 2002, ACTA PSYCHOL, V109, P315, DOI 10.1016/S0001-6918(01)00064-6; Cohen J., 2013, STAT POWER ANAL BEHA; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Conway MA, 1999, MEMORY, V7, P679, DOI 10.1080/096582199387805; Conway MA, 2003, CORTEX, V39, P667, DOI 10.1016/S0010-9452(08)70859-1; Conway MA, 2001, PHILOS T R SOC B, V356, P1375, DOI 10.1098/rstb.2001.0940; CONWAY MA, 2000, HDB NEUROPSYCHOLOGY, V2; CONWAY MA, 1996, REMEMBERING OUR PAST; CROVITZ HF, 1986, AUTOBIOGRAPHICAL MEM; DELLASALA S, 1993, NEUROPSYCHOLOGIA, V31, P823; DELOCHE G, 1997, TEST DENOMIATION ORA; DERENZI E, 1995, CORTEX, V31, P531, DOI 10.1016/S0010-9452(13)80064-0; DIKMEN S, 1987, NEUROBEHAVIORAL RECO; Fink GR, 1996, J NEUROSCI, V16, P4275; FITZGERLD JM, 1996, REMEMBERGING PAST ST; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GARDINER JM, 1988, MEM COGNITION, V16, P309, DOI 10.3758/BF03197041; Gardiner JM, 2001, PHILOS T R SOC B, V356, P1351, DOI 10.1098/rstb.2001.0955; GOLDSTEIN FC, 1995, HDB MEMORY DISORDERS; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; GROBER E, 1987, DEV NEUROPSYCHOL, V3, P13, DOI 10.1080/87565648709540361; HOLLAND CA, 1990, Q J EXP PSYCHOL-A, V42, P441, DOI 10.1080/14640749008401232; HOWELL DC, 1998, METHODES STAT SCI HU; HUNKIN NM, 1995, NEUROPSYCHOLOGIA, V33, P509, DOI 10.1016/0028-3932(94)00136-D; Kapur N, 1999, PSYCHOL BULL, V125, P800, DOI 10.1037/0033-2909.125.6.800; KENAN JP, 2003, SELF NEUROSCIENCE PS; KNOWLTON BJ, 1995, J EXP PSYCHOL LEARN, V21, P699, DOI 10.1037/0278-7393.21.3.699; Knowlton BJ, 1998, ACTA PSYCHOL, V98, P253, DOI 10.1016/S0001-6918(97)00045-0; Kopelman MD, 2000, COGNITIVE NEUROPSYCH, V17, P585, DOI 10.1080/026432900750002172; Kopelman MD, 2003, HIPPOCAMPUS, V13, P879, DOI 10.1002/hipo.10140; KOPELMAN MD, 1991, BRAIN, V114, P117; Kopelman MD, 2002, BRAIN, V125, P2152, DOI 10.1093/brain/awf229; Kopelman MD, 1997, NEUROPSYCHOLOGIA, V35, P1533, DOI 10.1016/S0028-3932(97)00076-6; KOPELMAN MD, 1989, NEUROPSYCHOLOGIA, V27, P437, DOI 10.1016/0028-3932(89)90050-X; Kopelman MD, 2001, PHILOS T R SOC B, V356, P1409, DOI 10.1098/rstb.2001.0942; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; Kopelman MD, 1999, NEUROPSYCHOLOGIA, V37, P939, DOI 10.1016/S0028-3932(98)00143-2; KOPELMAN MD, 2000, HDB NEUROPSYCHOLOGY; Kroll NEA, 1997, BRAIN, V120, P1377, DOI 10.1093/brain/120.8.1377; LEVIN HS, 1985, J NEUROL NEUROSUR PS, V48, P556, DOI 10.1136/jnnp.48.6.556; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Maguire EA, 2001, PHILOS T R SOC B, V356, P1441, DOI 10.1098/rstb.2001.0944; Mangels JA, 1996, NEUROPSYCHOLOGY, V10, P32, DOI 10.1037/0894-4105.10.1.32; MANTYLA T, 1993, MEM COGNITION, V21, P379, DOI 10.3758/BF03208271; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCARTHY RA, 1992, NEUROPSYCHOLOGIA, V30, P633, DOI 10.1016/0028-3932(92)90068-W; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M, 1999, MEMORY CONSCIOUSNESS; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NIGRO G, 1983, COGNITIVE PSYCHOL, V15, P467, DOI 10.1016/0010-0285(83)90016-6; PETRIDES M, 2000, HDB NEUROPSYCHOLOGY, V2; Piolino P, 2005, COGN NEUROPSYCHOL, V22, P1005, DOI 10.1080/02643290442000428; Piolino P, 2004, NEUROIMAGE, V22, P1371, DOI 10.1016/j.neuroimage.2004.02.025; Piolino P, 2003, BRAIN, V126, P2203, DOI 10.1093/brain/awg222; Piolino P, 2003, COGN NEUROPSYCHOL, V20, P619, DOI 10.1080/02643290242000899; Piolino P, 2002, MEMORY, V10, P239, DOI 10.1080/09658210143000353; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Ribot, 1881, MALADIES MEMOIRE; Robinson J A, 1993, Memory, V1, P169; Ross SM, 2000, CORTEX, V36, P521, DOI 10.1016/S0010-9452(08)70536-7; Rubin DC, 1998, MEM COGNITION, V26, P3, DOI 10.3758/BF03211366; Schacter Daniel L., 1996, SEARCHING MEMORY BRA; SHIMAMURA AP, 1991, PSYCHOBIOLOGY, V19, P1; SHIMAMURA AP, 1986, BEHAV NEUROSCI, V100, P165, DOI 10.1037/0735-7044.100.2.165; Sirigu A, 1996, CORTEX, V32, P83, DOI 10.1016/S0010-9452(96)80018-9; SQUIRE LR, 1975, J EXP PSYCHOL-HUM L, V104, P50; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; TEASDALE G, 1974, LANCET, V2, P81; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; WECHSLER D, 1985, ECHELLE INTELLIGENCE; West RL, 1996, PSYCHOL BULL, V120, P272, DOI 10.1037/0033-2909.120.2.272; Wheeler M A, 1995, J Int Neuropsychol Soc, V1, P525; Wheeler MA, 1997, PSYCHOL BULL, V121, P331, DOI 10.1037/0033-2909.121.3.331; Wheeler MA, 2003, CORTEX, V39, P827, DOI 10.1016/S0010-9452(08)70866-9; WILSON B, 1992, J NEUROL NEUROSUR PS, V55, P177, DOI 10.1136/jnnp.55.3.177	88	70	70	0	17	ELSEVIER MASSON, CORP OFF	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex	FEB	2007	43	2					176	195		10.1016/S0010-9452(08)70474-X			20	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	155JZ	WOS:000245575000003	17405665				2022-02-06	
J	Gemma, C; Bickford, PC				Gemma, Carmelina; Bickford, Paula C.			Interleukin-1 beta and caspase-1: Players in the regulation of age-related cognitive dysfunction	REVIEWS IN THE NEUROSCIENCES			English	Article						interleukin-1 beta; caspase-1; inflammation; apoptosis; microglia; aging; learning; memory	LONG-TERM POTENTIATION; TUMOR-NECROSIS-FACTOR; NEURONAL SIGNAL-TRANSDUCTION; TRANSGENIC MOUSE MODEL; TRAUMATIC BRAIN INJURY; RAT DENTATE GYRUS; GENE-EXPRESSION; RECEPTOR ANTAGONIST; FISCHER-344 RATS; AGING BRAIN	Scientific research on the unprecedented and growing number of older adults in the United States and other industrialized countries has focused much attention on the health consequences of aging. Over the last few decades, inflammation in the brain and its implication in the progression of aging and age-related cognitive dysfunction has been an area of increasing importance to neuroscientists and is now considered as one of the most interesting and promising topics for aging research. One of the critical aspects of inflammatory processes is that the activation of one upstream inflammatory molecule initiates a cascade of self-sustaining inflammatory events which leads to the activation of a number of different downstream functions. Recently, a great deal of attention has been given to the interplay between inflammatory and apoptotic processes and the regulation of these processes by the caspases. The caspase family of proteases can be divided into proapoptotic and pro-inflammatory members. The present review summarizes recent observations of the interactions between the inflammatory cytokine interleukin-1 (IL-1) beta and the inflammatory/apoptotic caspase-1 and their involvement in age-related impairments in cognition. A comprehensive understanding of these mechanisms could potentially lead to the development of preventive or protective therapies that reduce or inhibit the cognitive decline associated with aging and age-related neurodegenerative disease.	Univ S Florida, Ctr Excellence Aging & Brain Repair, Coll Med, Dept Neurosurg, Tampa, FL 33612 USA; Univ S Florida, Dept Mol Pharmacol & Physiol, Coll Med, Tampa, FL 33612 USA; James A Haley Vet Adm Med Ctr, Tampa, FL USA		Bickford, PC (corresponding author), Univ S Florida, Ctr Excellence Aging & Brain Repair, Coll Med, Dept Neurosurg, 12901 Bruce B Downs Blvd,MDC-78, Tampa, FL 33612 USA.	pbickfor@health.usf.edu	Bickford, Paula C/J-5970-2012	Bickford, Paula C/0000-0001-9657-7725; Gemma, Carmelina/0000-0002-4480-0056			Ali A, 1999, J HEMATOTH STEM CELL, V8, P343, DOI 10.1089/152581699320108; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Anisman H, 1999, ADV EXP MED BIOL, V461, P199; Balschun D, 2003, ANN NY ACAD SCI, V992, P1, DOI 10.1111/j.1749-6632.2003.tb03132.x; Barrientos RM, 2002, BEHAV BRAIN RES, V134, P291, DOI 10.1016/S0166-4328(02)00043-8; Batchelor PE, 1999, J NEUROSCI, V19, P1708; BENVENISTE EN, 1992, AM J PHYSIOL, V263, P16; Burns K, 2003, CURR OPIN IMMUNOL, V15, P26, DOI 10.1016/S0952-7915(02)00017-1; Cartford MC, 2002, J NEUROSCI, V22, P5813; Cavallaro S, 2002, P NATL ACAD SCI USA, V99, P16279, DOI 10.1073/pnas.242597199; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Coleman GJ, 1999, BRAIN RES, V832, P188, DOI 10.1016/S0006-8993(99)01498-5; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; COLTON CA, 1987, FEBS LETT, V223, P284, DOI 10.1016/0014-5793(87)80305-8; Conde JR, 2006, J NEUROPATH EXP NEUR, V65, P199, DOI 10.1097/01.jnen.0000202887.22082.63; CRESTANI F, 1991, BRAIN RES, V542, P330, DOI 10.1016/0006-8993(91)91587-Q; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Dash PK, 2000, NEUROREPORT, V11, P2811, DOI 10.1097/00001756-200008210-00040; David JP, 1997, NEUROSCI LETT, V235, P53, DOI 10.1016/S0304-3940(97)00708-8; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Eriksson C, 1999, NEUROSCIENCE, V93, P915, DOI 10.1016/S0306-4522(99)00178-5; FARRAR WL, 1987, J IMMUNOL, V139, P459; Festoff BW, 2006, J NEUROCHEM, V97, P1314, DOI 10.1111/j.1471-4159.2006.03799.x; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Friedlander RM, 2000, ARCH NEUROL-CHICAGO, V57, P1273, DOI 10.1001/archneur.57.9.1273; Gahtan E, 1999, NEUROSCI BIOBEHAV R, V23, P615, DOI 10.1016/S0149-7634(98)00058-X; Gemma C, 2005, EUR J NEUROSCI, V22, P1751, DOI 10.1111/j.1460-9568.2005.04334.x; Gemma C, 2002, J NEUROSCI, V22, P6114; Granholm AC, 1997, EXP BRAIN RES, V116, P29, DOI 10.1007/PL00005741; Hirsch E, 1996, P NATL ACAD SCI USA, V93, P11008, DOI 10.1073/pnas.93.20.11008; Hwang DY, 2002, FASEB J, V16, DOI 10.1096/fj.01-0732com; Joseph JA, 1999, J NEUROSCI, V19, P8114; Joseph JA, 1998, J NEUROSCI, V18, P8047; Joshi VD, 2003, FEBS LETT, V555, P180, DOI 10.1016/S0014-5793(03)01271-7; Joshi VD, 2002, INFECT IMMUN, V70, P6896, DOI 10.1128/IAI.70.12.6896-6903.2002; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Kotloski R, 2002, PROG BRAIN RES, V135, P95; Krueger JM, 1998, ANN NY ACAD SCI, V856, P148, DOI 10.1111/j.1749-6632.1998.tb08323.x; Lynch MA, 2002, VITAM HORM, V64, P185, DOI 10.1016/S0083-6729(02)64006-3; Lynch MA, 1998, REV NEUROSCIENCE, V9, P169; MAIER SF, 1995, BRAIN RES, V695, P279, DOI 10.1016/0006-8993(95)00930-O; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; McGahon BM, 1999, NEUROSCIENCE, V94, P305, DOI 10.1016/S0306-4522(99)00219-5; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Mesches MH, 2004, NEUROBIOL AGING, V25, P315, DOI 10.1016/S0197-4580(03)00116-7; MILLER DK, 1993, ANN NY ACAD SCI, V696, P133; Morrison JH, 1997, SCIENCE, V278, P412, DOI 10.1126/science.278.5337.412; Murray CA, 1997, NEUROBIOL AGING, V18, P343, DOI 10.1016/S0197-4580(97)80317-X; OPP MR, 1994, AM J PHYSIOL, V266, pR688, DOI 10.1152/ajpregu.1994.266.3.R688; PETERSON PK, 1994, CLIN INFECT DIS, V19, P1158, DOI 10.1093/clinids/19.6.1158; PLATASALAMAN CR, 1988, BRAIN RES, V448, P106, DOI 10.1016/0006-8993(88)91106-7; Pugh CR, 2001, NEUROSCI BIOBEHAV R, V25, P29, DOI 10.1016/S0149-7634(00)00048-8; Pugh CR, 1999, BEHAV BRAIN RES, V106, P109, DOI 10.1016/S0166-4328(99)00098-4; Pugh CR, 1998, BRAIN BEHAV IMMUN, V12, P212, DOI 10.1006/brbi.1998.0524; Randle JCR, 2001, EXPERT OPIN INV DRUG, V10, P1207, DOI 10.1517/13543784.10.7.1207; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Sakao Y, 1999, INT IMMUNOL, V11, P471, DOI 10.1093/intimm/11.3.471; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; SMITH A, 1988, PSYCHOPHARMACOLOGY, V96, P414, DOI 10.1007/BF00216072; SPADARO F, 1990, BRAIN BEHAV IMMUN, V4, P308, DOI 10.1016/0889-1591(90)90034-N; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sue W, 2006, AM J CLIN NUTR, V83, p470S; Sugaya K, 2001, Nihon Yakurigaku Zasshi, V118, P251; Taglialatela G, 1996, NEUROREPORT, V7, P977, DOI 10.1097/00001756-199604100-00004; Taishi P, 1997, J NEUROIMMUNOL, V75, P69, DOI 10.1016/S0165-5728(97)00002-7; TAKAO T, 1990, ENDOCRINOLOGY, V127, P3070, DOI 10.1210/endo-127-6-3070; Terao A, 2002, J NEUROIMMUNOL, V132, P99, DOI 10.1016/S0165-5728(02)00317-X; Tikka TM, 2001, J IMMUNOL, V166, P7527, DOI 10.4049/jimmunol.166.12.7527; Troy CM, 2002, J NEUROSCI RES, V69, P145, DOI 10.1002/jnr.10294; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Vereker E, 2000, J BIOL CHEM, V275, P26252, DOI 10.1074/jbc.M002226200; Warner HR, 1999, ANN NY ACAD SCI, V887, P1; Weindruch R, 2002, ARCH NEUROL-CHICAGO, V59, P1712, DOI 10.1001/archneur.59.11.1712; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wilson CJ, 2002, J AM GERIATR SOC, V50, P2041, DOI 10.1046/j.1532-5415.2002.50619.x; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Ye SM, 1999, J NEUROIMMUNOL, V93, P139, DOI 10.1016/S0165-5728(98)00217-3; Yirmiya R, 2002, NEUROBIOL LEARN MEM, V78, P379, DOI 10.1006/nlme.2002.4072; YIRMIYA R, 1995, BRAIN BEHAV IMMUN, V9, P220, DOI 10.1006/brbi.1995.1021; Zhang YJ, 1998, J BIOL CHEM, V273, P1144, DOI 10.1074/jbc.273.2.1144; Zhang YP, 2002, MECH AGEING DEV, V123, P245, DOI 10.1016/S0047-6374(01)00349-9; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	89	70	72	0	2	FREUND & PETTMAN PUBLISHERS	EAST YORKSHIRE	ENHOLMES HALL, PATRINGTON, EAST YORKSHIRE HU12 OPR, ENGLAND	0334-1763			REV NEUROSCIENCE	Rev. Neurosci.		2007	18	2					137	148					12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	177AL	WOS:000247125900003	17593876				2022-02-06	
J	Ichord, RN; Naim, M; Pollock, AN; Nance, ML; Margulies, SS; Christian, CW				Ichord, Rebecca N.; Naim, Maryam; Pollock, Avrum N.; Nance, Michael L.; Margulies, Susan S.; Christian, Cindy W.			Hypoxic-ischemic injury complicates inflicted and accidental traumatic brain injury in young children: The role of diffusion-weighted imaging	JOURNAL OF NEUROTRAUMA			English	Article						infants; inflicted trauma; MRI; traumatic brain injury	HEAD-INJURY; APNEA; NEUROPATHOLOGY; ASSOCIATION; MECHANISMS; PATTERNS; INFANTS	We evaluated the relationship between clinical features and hypoxic-ischemic injury (HII) shown by diffusion-weighted MRI (DWI) in young children with head trauma, comparing inflicted trauma (IT) to accidental trauma (AT). This single-center consecutive cohort study included children age birth to 36 months admitted for head injury July 2001 to December 2004 with brain magnetic resonance imaging (MRI) obtained :5 1 week, identified from prospectively maintained registries of children with trauma. Clinical and radiological data during the hospital stay were extracted from medical records. MRIs were analyzed by study examiners blinded to clinical status and scored by type, severity and location of lesions attributable to traumatic, hypoxic-ischemic, or mixed injury patterns. 30 IT patients and 22 AT patients met inclusion criteria. IT cases were younger than AT, 3.0 versus 8.5 months. Mean time to MRI in IT (2.1 days) was similar to AT (1.9 days). HII was more common in IT (11 of 30) than AT (2/22, p = 0.03). Children with HII more commonly had seizures, needed intubation at presentation, and needed neurosurgical intervention compared to those without HII. Most patients with HII (10/14) required in-patient rehabilitation compared to those without HII (4/38). Our study is the first to characterize HII using diffusion-weighted MRI in young children, comparing IT and AT. The higher rate of HII on DWI-MRI in IT than in AT is likely multifactorial, involving respiratory insufficiency, seizures, and intracranial mass-occupying lesions requiring neurosurgical intervention. HII predicted need for in-patient rehabilitation in a large majority of children.	Childrens Hosp Philadelphia, Dept Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Crit Care Anesthesiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neuroradiol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA		Ichord, RN (corresponding author), Childrens Hosp Philadelphia, Dept Neurol, Wood 6th Fl,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	ichord@email.chop.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 39679] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Arbogast KB, 2005, PEDIATRICS, V116, P180, DOI 10.1542/peds.2004-2671; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; KAUFMANN CR, 1990, JAMA-J AM MED ASSOC, V263, P69, DOI 10.1001/jama.263.1.69; KELLAWAY P, 1990, NEONATAL SEIZURES, P1; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Miller SP, 2002, NEUROLOGY, V58, P542, DOI 10.1212/WNL.58.4.542; Phillips MD, 1999, NEUROIMAG CLIN N AM, V9, P41; Shannon P, 2001, LANCET, V358, P686, DOI 10.1016/S0140-6736(01)05849-4; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011	28	70	72	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					106	118		10.1089/neu.2006.0087			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100010	17263674				2022-02-06	
J	Morris, KP; Forsyth, RJ; Parslow, RC; Tasker, RC; Hawley, CA				Morris, Kevin P.; Forsyth, Robert J.; Parslow, Roger C.; Tasker, Robert C.; Hawley, Carol A.			Intracranial pressure complicating severe traumatic brain injury in children: monitoring and management	INTENSIVE CARE MEDICINE			English	Article						traumatic brain injury; children; intensive care; intracranial pressure; treatment; monitoring	SEVERE HEAD-INJURY; CARE	Objective: To identify factors associated with the use of intracranial pressure (ICP) monitoring and to establish which ICP-targetted therapies are being used in children with severe traumatic brain injury (TBI) in the United Kingdom. To evaluate current practice against recently published guidelines. Design and setting: Prospective data collection of clinical and demographic information from paediatric and adult intensive care units in the UK and Ireland admitting children (< 16 years) with TBI between February 2001 and August 2003. Results: Detailed clinical information was obtained for 501 children, with information on the use of ICP monitoring available in 445. ICP monitoring was used in only 59% (75/127) of children presenting with an emergency room Glasgow Coma Scale of 8 or below. Large between centre variation was seen in the use of ICP monitoring, independent of severity of injury. There were 86 children who received ICP-targetted therapies without ICP monitoring. Wide between centre variation was found in the use of ICP-targetted therapies and in general aspects of management, such as fluid restriction, the use of muscle relaxants and prophylactic anticonvulsants. Intraventricular catheters are rarely placed (6% of cases); therefore cerebrospinal fluid drainage is seldom used as a first-line therapy for raised ICP. Jugular venous bulb oximetry (4%), brain microdialysis (< 1%) and brain tissue oxygen monitoring (< 1%) are rarely used in current practice. Contrary to published guidelines, moderate to severe hyperventilation is being used without monitoring for cerebral ischaemia. Conclusions: There is an urgent need for greater standardisation of practice across UK centres admitting children with severe TBI.	Diana Princess Wales Hosp, Birmingham BN 6NH, W Midlands, England; Royal Victoria Infirm, Sch Clin Med Sci, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 41P, Tyne & Wear, England; Univ Leeds, Ctr Biostat & Epidemiol, Leeds Inst Genet Hlth & Therapeut, Paediat Epidemiol Grp, Leeds LS2 9JT, W Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin, Cambridge CB2 2QQ, England; Univ Warwick, Sch Med, Div Hlth Community, Coventry CV4 7AL, W Midlands, England		Morris, KP (corresponding author), Diana Princess Wales Hosp, Steelhouse Lane, Birmingham BN 6NH, W Midlands, England.	kevin.morris@bch.nhs.uk	Hawley, Carol/AAG-3830-2019; Forsyth, Rob J/I-9226-2012; Parslow, Roger/AAV-1477-2020; Tasker, Robert C/R-5837-2019; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180; Tasker, Robert/0000-0003-3647-8113; Parslow, Roger/0000-0002-3945-5294			Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; MENDELOW AD, 1983, J NEUROSURG, V58, P45, DOI 10.3171/jns.1983.58.1.0045; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Raabe A, 1998, NEUROSURGERY, V43, P306, DOI 10.1097/00006123-199808000-00073; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Tilford JM, 2001, CRIT CARE MED, V29, P1056, DOI 10.1097/00003246-200105000-00037	11	70	70	0	3	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	OCT	2006	32	10					1606	1612		10.1007/s00134-006-0285-4			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	089WF	WOS:000240911500022	16874495				2022-02-06	
J	Collie, A; McCrory, P; Makdissi, M				Collie, A.; McCrory, P.; Makdissi, M.			Does history of concussion affect current cognitive status?	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL SOCCER PLAYERS; SPORT-RELATED CONCUSSION; AGREEMENT STATEMENT; BRAIN-INJURY; IMPAIRMENT; FOOTBALL; SCIENCE	The association between self reported history of concussion and current neurocognitive status is controversial. Some football studies suggest that athletes with a history of concussion display cognitive impairment relative to athletes with no history of concussion, but other studies have not been able to reproduce such findings. This study shows that there is no relation between the number of previous self reported episodes of concussion and current cognitive state, directly contradicting the findings of previous research.	Univ Melbourne, Melbourne, Vic, Australia; CogState Ltd, London, England		Collie, A (corresponding author), Level 7,21 Victoria St, Melbourne, Vic 3000, Australia.	acollie@cogstate.com	McCrory, Paul/Q-8688-2019	makdissi, michael/0000-0003-0334-7133; Collie, Alex/0000-0003-2617-9339			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Falleti MG, 2003, J SLEEP RES, V12, P265, DOI 10.1111/j.1365-2869.2003.00363.x; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan BD, 1996, AM J SPORT MED, V24, P704, DOI 10.1177/036354659602400526; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Moriarity J, 2004, NEUROLOGY, V62, P1497, DOI 10.1212/WNL.62.9.1497	22	70	71	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JUN	2006	40	6					550	551		10.1136/bjsm.2005.019802			2	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	045LG	WOS:000237743000015	16720889	Green Published			2022-02-06	
J	Ouellet, MC; Morin, CA				Ouellet, MC; Morin, CA			Fatigue following traumatic brain injury: Frequency, characteristics, and associated factors	REHABILITATION PSYCHOLOGY			English	Article						fatigue; traumatic brain inury	MINOR HEAD-INJURY; COGNITIVE-BEHAVIOR-THERAPY; MULTIPLE-SCLEROSIS; VALIDATION; COMPLAINTS; DISORDERS; INVENTORY; SYMPTOMS; INSOMNIA; IMPACT	Objectives: To document the frequency, characteristics, and factors associated with fatigue following traumatic brain injury (TBI). Design: Survey methodology and multivariate statistical design. Setting: Rehabilitation center and community. Participants: 452 participants aged 16 years and over with minor to severe TBI who answered a questionnaire measuring diverse aspects of fatigue as well as different dimensions of psychological distress, pain, and sleep quality. Measures: Proportion of participants reporting being significantly fatigued. Validated measures of fatigue, sleep quality, and psychological distress. Results of a logistic regression analysis. Results: Significant fatigue was reported by 68.5% of participants. Mental fatigue was the most prominent type of fatigue, followed by physical fatigue. Fatigue was present even several years following the accident and had many perceived impacts on day-to-day function. Factors associated with fatigue were a shorter time since injury; being on long-term disability leave; and higher levels of sleep problems, cognitive disturbances, and anxiety. Conclusion: Fatigue is a prevalent problem after TBI that requires more clinical and scientific attention because it probably has important repercussions on the quality of rehabilitation.	Univ Laval, Ecole Psychol, Quebec City, PQ GK1 7P4, Canada		Ouellet, MC (corresponding author), Univ Laval, Ecole Psychol, Pavilon Felix Antoine Savard, Quebec City, PQ GK1 7P4, Canada.	marie-christine.ouellet.1@ulaval.ca	Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895			Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Blais FC, 1997, ENCEPHALE, V23, P447; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BUTLER S, 1991, J NEUROL NEUROSUR PS, V54, P153, DOI 10.1136/jnnp.54.2.153; Chaudhuri A, 2004, LANCET, V363, P978, DOI 10.1016/S0140-6736(04)15794-2; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P10; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; Gervais M, 1999, ETUDE EXPLORATOIRE B; Gibson AS, 2003, SPORTS MED, V33, P167; Holzner B, 2003, CANCER-AM CANCER SOC, V97, P1564, DOI 10.1002/cncr.11253; Holzner B, 2002, ANN ONCOL, V13, P965, DOI 10.1093/annonc/mdf122; ILFELD FW, 1976, PSYCHOL REP, V39, P1215, DOI 10.2466/pr0.1976.39.3f.1215; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; KISCHKA U, 1991, EUR NEUROL, V31, P136, DOI 10.1159/000116663; KLONOFF DC, 1992, CLIN INFECT DIS, V15, P812, DOI 10.1093/clind/15.5.812; KRAUS F, 1993, HEAD INJURY, P1; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lichstein KL, 1997, BEHAV RES THER, V35, P733, DOI 10.1016/S0005-7967(97)00029-6; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Morin CM, 1993, INSOMNIA PSYCHOL ASS; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; OUELLET MC, IN PRESS J HEAD TRAU; Preville M, 1992, DETRESSE PSYCHOL DET; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; Strober LB, 2005, ARCH CLIN NEUROPSYCH, V20, P631, DOI 10.1016/j.acn.2005.04.002; Tabachnick B. G., 2013, USING MULTIVARIATE S, V6th; van der Werf SP, 1998, J NEUROL SCI, V160, P164, DOI 10.1016/S0022-510X(98)00251-2; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	38	70	70	0	10	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2006	51	2					140	149		10.1037/0090-5550.51.2.140			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	047PO	WOS:000237891400005					2022-02-06	
J	Stalnacke, BM; Ohlsson, A; Tegner, Y; Sojka, P				Stalnacke, BM; Ohlsson, A; Tegner, Y; Sojka, P			Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROTEIN FAMILY; S100B PROTEIN; INJURY; CONCUSSIONS; EXERCISE; HISTORY; LEAD	Background: It is a matter of debate whether or not ordinary heading of the ball in soccer causes injury to brain tissue. Objective: To analyse concentrations of the biochemical markers of brain tissue damage S-100B and neurone specific enolase (NSE) in serum of female elite soccer players in association with a competitive game. Methods: Venous blood samples were obtained from 44 female soccer players before and after a competitive game for analysis. The number of headers and trauma events (falls, collisions, etc) was assessed from videotape recordings for each player. Results: Concentrations of both brain damage markers were increased after the game (S-100B, 0.18 (0.11) v 0.11 (0.05) mg/l (p = 0.000); NSE, 10.14 (1.74) v 9.05 (1.59) mg/l (p = 0.001)). There was a significant correlation between changes in S-100B concentrations and both the number of headers (r = 0.430, p = 0.004) and the number of other trauma events (r = 0.517, p < 0.001). Conclusion: The concentrations of both S-100B and NSE were increased by game associated activities and events. The increases in S-100B concentration were significantly related to the number of headers and other trauma events, which indicates that both these factors may have contributed to these increases.	Umea Univ, Dept Community Med & Rehabil Med, S-90185 Umea, Sweden; Umea Univ, Dept Surg & Perioperat Sci Sports Med, S-90185 Umea, Sweden; Lulea Tech Univ, Dept Hlth Sci, Baden, Sweden		Stalnacke, BM (corresponding author), Umea Univ, Dept Community Med & Rehabil Med, S-90185 Umea, Sweden.	brittmarie.stalhacke@rehabmed.umu.se		Tegner, Yelverton/0000-0003-3628-0705			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Covassin T, 2003, J ATHL TRAINING, V38, P238; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Ekstrand J, 1990, Br J Sports Med, V24, P117; FANO G, 1995, PROG NEUROBIOL, V46, P71, DOI 10.1016/0301-0082(94)00062-M; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Mandelbaum BR, 1999, SCI SPORT, V14, P254, DOI 10.1016/S0765-1597(00)88245-3; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mussack T, 2003, EUR J MED RES, V8, P457; *NAT COLL ATHL ASS, 2000, INJ SURV SYST AC YEA; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Powell JW, 2000, AM J SPORT MED, V28, P385, DOI 10.1177/03635465000280031801; Scaccianoce S, 2004, BRAIN RES, V1004, P208, DOI 10.1016/j.brainres.2004.01.028; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	33	70	71	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR	2006	40	4					313	316		10.1136/bjsm.2005.021584			4	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	024VI	WOS:000236224000007	16556784	Green Published			2022-02-06	
J	Gowda, NK; Agrawal, D; Bal, C; Chandrashekar, N; Tripati, M; Bandopadhyaya, GP; Malhotra, A; Mahapatra, AK				Gowda, NK; Agrawal, D; Bal, C; Chandrashekar, N; Tripati, M; Bandopadhyaya, GP; Malhotra, A; Mahapatra, AK			Technetium Tc-99m ethyl cysteinate dimer brain single-photon emission CT in mild traumatic brain injury: A prospective study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							CLOSED-HEAD-INJURY; CEREBRAL BLOOD-FLOW; COMPUTED-TOMOGRAPHY; HMPAO SPECT; PERFUSION; MRI	PURPOSE: To explore the role of single-photon emission CT (SPECT) in initial diagnostic evaluation of patients with mild traumatic brain injury (MTBI) and to identify subgroups in which it may serve as a useful diagnostic tool. MATERIALS AND METHODS: Patients with MTBI seen during a 14-month period were prospectively included in this study. All patients had a CT of head within 12 hours of injury and SPECT by using technetium Tc99m ethyl cysteinate dimer (Tc99m-ECD) within 72 hours of injury. Both SPECT and CT findings were compared with clinical features such as posttraumatic amnesia (PTA), postconcussion syndrome (PCS), and loss of consciousness (LOC). RESULTS: Ninety-two patients with MTBI underwent SPECT in the study period. There were 28 children and 64 adults, with male-to-female ratio of 4.5 to 1. CT findings were abnormal in 31 (34%) and SPECT in 58 (63%). The most common abnormality was hypoperfusion in the frontal lobe(s) in adults and the temporal lobe in children. A significantly higher number of perfusion abnormalities were seen in patients with PTA (P = .03), LOC (P = .02), and PCS (P = .01) than in patients without these symptoms. Compared to CT, SPECT had a much higher sensitivity for detecting an organic basis in these subgroup, of patients (P < .05). CONCLUSION: Tc99m-ECD SPECT can be used as a complementary technique to CT in initial evaluation of patients with MTBI. It is particularly useful in patients having PCS, LOC, or PTA with normal CT scan.	All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India; All India Inst Med Sci, Dept Neurosurg, New Delhi, India; All India Inst Med Sci, Ctr Neurosci, New Delhi, India		Gowda, NK (corresponding author), All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India.			Agrawal, Deepak/0000-0002-5499-0746			Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; AHMADI A, 1989, J NEUROPSYCHIATRY S, V1, P45; [Anonymous], 1999, WORLD HLTH REP 1999; BAVETTA S, 1994, NUCL MED COMMUN, V15, P961, DOI 10.1097/00006231-199412000-00007; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Catafau AM, 2001, J NUCL MED, V42, P259; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GRAY BG, 1992, J NUCL MED, V33, P52; Gururaj G, 2002, NEUROL RES, V24, P24, DOI 10.1179/016164102101199503; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; INGEBRIGSTEN T, 1998, ASPECTS MANAGEMENT M; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Jennett B, 1991, J NEUROTRAUM, V8, P81; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Korinthenberg R, 2004, BRAIN DEV-JPN, V26, P113, DOI 10.1016/S0387-7604(03)00110-4; LINDVALL HF, 1974, ACTA NEUROL SCAND  S, V56, P1; Lorberboym M, 2002, AM J EMERG MED, V20, P310, DOI 10.1053/ajem.2002.34201; MAHAPATRA AK, 1999, TXB HEAD INJURY; Masdeu J C, 1994, J Neuroimaging, V4, P177; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWBERG AB, 2003, SEMIN NUCL MED, V33, P36; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; ROPER SN, 1991, J NUCL MED, V32, P1684; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TIKOFSKY RS, 1994, J NUCL MED, V35, P947; *WHO, 2003, ICD10 CLASS MENT BEH, P67; *WHO, 1999, INJ LEAD CAUS GLOB B; WILSON JTL, 1997, SPECT IMAGING BRAIN, P69	34	70	71	0	5	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	FEB	2006	27	2					447	451					5	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	014GJ	WOS:000235467100054	16484427				2022-02-06	
J	Hill, AJ; Theodoros, DG; Russell, TG; Cahill, LM; Ward, EC; Clark, KM				Hill, AJ; Theodoros, DG; Russell, TG; Cahill, LM; Ward, EC; Clark, KM			An Internet-based telerehabilitation system for the assessment of motor speech disorders: A pilot study	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article						telepractice; rehabilitation; assessment; speech disorders	CLOSED-HEAD-INJURY; RELIABILITY; TELEHEALTH; HYPERNASALITY; AGREEMENT; RATINGS	Purpose: This pilot study explored the feasibility and effectiveness of an Internet-based telerehabilitation application for the assessment of motor speech disorders in adults with acquired neurological impairment. Method: Using a counterbalanced, repeated measures research design, 2 speech-language pathologists assessed 19 speakers with dysarthria on a battery of perceptual assessments. The assessments included a 19-item version of the Frenchay Dysarthria Assessment (FDA; P. Enderby, 1983), the Assessment of Intelligibility of Dysarthric Speech (K. M. Yorkston & D. R. Beukelman, 1981), perceptual analysis of a speech sample, and an overall rating of severity of the dysarthria. One assessment was conducted in the traditional face-to-face manner, whereas the other assessment was conducted using an online, custom-built telerehabilitation application. This application enabled real-time videoconferencing at 128 kb/s and the transfer of store-and-forward audio and video data between the speaker and speech-language pathologist sites. The assessment methods were compared using the J.M.Bland and D.G.Altman (1986, 1999) limits-of-agreement method and percentage level of agreement between the 2 methods. Results: Measurements of severity of dysarthria, percentage intelligibility in sentences, and most perceptual ratings made in the telerehabilitation environment were found to fall within the clinically acceptable criteria. However, several ratings on the FDA were not comparable between the environments, and explanations for these results were explored. Conclusions: The online assessment of motor speech disorders using an Internet-based telerehabilitation system is feasible. This study suggests that with additional refinement of the technology and assessment protocols, reliable assessment of motor speech disorders over the Internet is possible. Future research methods are outlined.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia; Princess Alexandra Hosp, Brisbane, Qld 4102, Australia		Hill, AJ (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Speech Pathol, Brisbane, Qld 4072, Australia.	a.hill@shrs.uq.edu.au	Russell, Trevor/AAS-2590-2020; Theodoros, Deborah/F-1362-2010; Cahill, Louise/C-7919-2012; Ward, Elizabeth/F-9652-2010; Hill, Anne/F-4106-2010; Russell, Trevor/F-6888-2010	Russell, Trevor/0000-0002-9732-6167; Ward, Elizabeth/0000-0002-2680-8978; Hill, Anne/0000-0003-3907-8369; Russell, Trevor/0000-0002-9732-6167; Cahill, Louise/0000-0003-3662-896X			*AUSTR BUR STAT, 2004, MEAS KNOWL BAS EC SO; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Brown J.R., 1975, MOTOR SPEECH DISORDE; CHENERY HJ, 1998, DYSARTHRIA PHYSL APP, P36; Duffy, 2005, MOTOR SPEECH DISORDE; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Enderby P, 1983, FRENCHAY DYSARTHRIA; Farrell A, 2005, J SPEECH LANG HEAR R, V48, P5, DOI 10.1044/1092-4388(2005/002); HAYES JM, 2003, MICROSOFT NETMEETING; Hill A, 2002, J TELEMED TELECARE, V8, P187, DOI 10.1258/135763302320272158; KARNELL MP, 1995, CLEFT PALATE-CRAN J, V32, P145, DOI 10.1597/1545-1569(1995)032<0145:NDOHAT>2.3.CO;2; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KREIMAN J, 1993, J SPEECH HEAR RES, V36, P21, DOI 10.1044/jshr.3601.21; LLOYD R, 2004, AUSTR ONLINE AUSTR A; Loh PK, 2004, INTERN MED J, V34, P239, DOI 10.1111/j.1444-0903.2004.00531.x; Ludlow C. L., 1983, DYSARTHRIAS PHYSL AC, P163; Mashima PA, 2003, AM J SPEECH-LANG PAT, V12, P432, DOI 10.1044/1058-0360(2003/089); McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Rosen MJ, 2004, TELEMED J E-HEALTH, V10, P115, DOI 10.1089/1530562041641318; Russell TG, 2003, MANUAL THER, V8, P242, DOI 10.1016/S1356-689X(03)00016-X; Russell TG, 2002, J TELEMED TELECARE, V8, P50, DOI 10.1258/13576330260440853; SHEARD C, 1991, J SPEECH HEAR RES, V34, P285, DOI 10.1044/jshr.3402.285; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; Torsney K, 2003, NEUROREHABILITATION, V18, P183; Wertz R. T., 1987, CLIN APHASIOLOGY, V17, P117; WERTZ RT, 1992, APHASIOLOGY, V6, P195, DOI 10.1080/02687039208248591; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA; [No title captured]	33	70	71	1	24	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	FEB	2006	15	1					45	56		10.1044/1058-0360(2006/006)			12	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Social Science Citation Index (SSCI)	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	027PZ	WOS:000236428800006	16533092				2022-02-06	
J	Siren, AL; Radyushkin, K; Boretius, S; Kammer, D; Riechers, CC; Natt, O; Sargin, D; Watanabe, T; Sperling, S; Michaelis, T; Price, J; Meyer, B; Frahm, J; Ehrenreich, H				Siren, AL; Radyushkin, K; Boretius, S; Kammer, D; Riechers, CC; Natt, O; Sargin, D; Watanabe, T; Sperling, S; Michaelis, T; Price, J; Meyer, B; Frahm, J; Ehrenreich, H			Global brain atrophy after unilateral parietal lesion and its prevention by erythropoietin	BRAIN			English	Article						EPO; MRI; neuroprotection; neurodegeneration; neurotrauma; schizophrenia	DENTATE GYRUS; CEREBRAL-ISCHEMIA; HEAD-INJURY; ADULT; NEUROGENESIS; ONSET; NEUROPROTECTION; SCHIZOPHRENIA; EXPRESSION; DISORDER	In humans, neurotrauma is suspected to cause brain atrophy and accelerate slowly progressive neurodegenerative disorders, such as Alzheimer's disease or schizophrenia. However, a direct link between brain injury and subsequent delayed global neurodegeneration has remained elusive. Here we show that juvenile (4-week-old) mice that are given a discrete unilateral lesion of the parietal cortex, develop to adulthood without obvious clinical symptoms. However, when monitored 3 and 9 months after lesioning, using high-resolution three-dimensional MRI and behavioural testing, the same mice display global neurodegenerative changes. Surprisingly, erythropoietin, a haematopoietic growth factor with potent neuroprotective activity, prevents behavioural abnormalities, cognitive dysfunction and brain atrophy when given for 2 weeks after acute brain injury. This demonstrates that a localized brain lesion is a primary cause of delayed global neurodegeneration that can be efficiently counteracted by neuroprotection.	Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Max Planck Inst Biophys Chem, Biomed NMR Forsch GmbH, D-37077 Gottingen, Germany; Univ Wurzburg, Sect Expt Neurosurg, Dept Neurosurg, Wurzburg, Germany; Kings Coll London, Inst Psychiat, London WC2R 2LS, England		Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Price, Jack/G-9510-2011; Meyer, Bernhard/Q-9413-2016; Meyer, Bernhard/AAH-3329-2019; Boretius, Susann/ABF-4993-2021; Siren, Anna-Leena/AAE-1374-2019	Meyer, Bernhard/0000-0001-6486-7955; Boretius, Susann/0000-0003-2792-7423; Siren, Anna-Leena/0000-0002-2217-0081; Ehrenreich, Hannelore/0000-0001-8371-5711; Watanabe, Takashi/0000-0002-4096-7908; Price, Jack/0000-0003-2235-9180			AbdelMalik P, 2003, ARCH GEN PSYCHIAT, V60, P231, DOI 10.1001/archpsyc.60.3.231; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benedict RHB, 2004, J NEUROIMAGING, V14, p36S, DOI 10.1111/j.1552-6569.2004.tb00277.x; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; Braff DL, 2001, PSYCHOPHARMACOLOGY, V156, P234, DOI 10.1007/s002130100810; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; DELATOUR B, IN VIVO MRI HISTOLOG; Diem R, 2005, BRAIN, V128, P375, DOI 10.1093/brain/awh365; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Ehrenreich H, 2005, P NATL ACAD SCI USA, V102, P862, DOI 10.1073/pnas.0406008102; Ehrenreich H, 2004, SCIENCE, V305, P184, DOI 10.1126/science.1100891; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Ekdahl CT, 2001, EUR J NEUROSCI, V14, P937, DOI 10.1046/j.0953-816x.2001.01713.x; Knerlich F, 1999, MOL BRAIN RES, V68, P73, DOI 10.1016/S0169-328X(99)00064-9; KOLB B, 1985, BEHAV BRAIN RES, V17, P25, DOI 10.1016/0166-4328(85)90005-1; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McAllister, 1998, Semin Clin Neuropsychiatry, V3, P211; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Natt O, 2002, J NEUROSCI METH, V120, P203, DOI 10.1016/S0165-0270(02)00211-X; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.3.CO;2-1; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; Resnick SM, 2003, J NEUROSCI, V23, P3295; Rusinek H, 2003, RADIOLOGY, V229, P691, DOI 10.1148/radiol.2293021299; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schott JM, 2005, NEUROLOGY, V65, P119, DOI 10.1212/01.wnl.0000167542.89697.0f; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Siren AL, 2000, NEUROCHEM RES, V25, P957, DOI 10.1023/A:1007552408463; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Sirigu A, 2004, NAT NEUROSCI, V7, P80, DOI 10.1038/nn1160; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Thompson PM, 2001, P NATL ACAD SCI USA, V98, P11650, DOI 10.1073/pnas.201243998; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu XB, 2002, DEVELOPMENT, V129, P505	48	70	77	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2006	129		2				480	489		10.1093/brain/awh703			10	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	007JR	WOS:000234965500019	16339796	Bronze			2022-02-06	
J	Fang, SH; Wei, EQ; Zhou, Y; Wang, ML; Zhang, WP; Yu, GL; Chu, LS; Chen, Z				Fang, S. H.; Wei, E. Q.; Zhou, Y.; Wang, M. L.; Zhang, W. P.; Yu, G. L.; Chu, L. S.; Chen, Z.			Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats	NEUROSCIENCE			English	Article						cysteinyl leukotriene receptor; cerebral ischemia; neuronal damage; astrogliosis; pranlukast; cysteinyl leukotriene receptor antagonist	FIBRILLARY ACIDIC PROTEIN; ARTERY OCCLUSION; ARACHIDONIC-ACID; CELL-DEATH; GLIAL SCAR; INJURY; EDEMA; ANTAGONIST; PROLIFERATION; REPERFUSION	Cysteinyl leukotrienes are potent pro-inflammatory mediators. Cysteinyl leukotriene receptor 1 is one of the two cysteinyl leukotriene receptors cloned. We recently reported that cysteinyl leukotriene receptor 1 antagonists protected against cerebral ischemic injury, and an inducible expression of cysteinyl leukotriene receptor 1 was found in neuron- and glial-appearing cells after traumatic injury in human brain. To determine the role of cysteinyl leukotriene receptor 1 in ischemic brain injury, we investigated the temporal and spatial profile of cysteinyl leukotriene receptor 1 expression in rat brain from 3 h to 14 days after 30 min of middle cerebral artery occlusion, and observed the effect of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, on the ischemic injury. We found that cysteinyl leukotriene receptor 1 mRNA expression was up-regulated in the ischemic core both 3-12 h and 7-14 days, and in the boundary zone 7-14 days after reperfusion. In the ischemic core, cysteinyl leukotriene receptor 1 was primarily localized in neurons 24 h, and in macrophage/microglia 14 days after reperfusion; while in the boundary zone it was localized in proliferated astrocytes 14 days after reperfusion. Pranlukast attenuated neurological deficits, reduced infarct volume and ameliorated neuron loss in the ischemic core 24 h after reperfusion; it reduced infarct volume, ameliorated neuron loss and inhibited astrocyte proliferation in the boundary zone 14 days after reperfusion. Thus, we conclude that cysteinyl leukotriene receptor 1 mediates acute neuronal damage and subacute/chronic astrogliosis after focal cerebral ischemia. (c) 2006 Published by Elsevier Ltd on behalf of IBRO.	Zhejiang Univ, Sch Med, Dept Pharmacol, Hangzhou 310031, Peoples R China		Wei, EQ (corresponding author), Zhejiang Univ, Sch Med, Dept Pharmacol, 353 Yanan Rd, Hangzhou 310031, Peoples R China.	weieq2001@yahoo.com					BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; Ballerini P, 2005, INT J IMMUNOPATH PH, V18, P255, DOI 10.1177/039463200501800208; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; BAUD L, 1987, J IMMUNOL, V138, P1190; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BLACK KL, 1986, ANN NEUROL, V19, P592, DOI 10.1002/ana.410190613; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; Ciccarelli R, 2004, EUR J NEUROSCI, V20, P1514, DOI 10.1111/j.1460-9568.2004.03613.x; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Dirnagl U, 2003, TRENDS NEUROSCI, V26, P248, DOI 10.1016/S0166-2236(03)00071-7; Fagan SC, 2004, STROKE, V35, P2220, DOI 10.1161/01.STR.0000138023.60272.9e; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; HENDERSON WR, 1994, ANN INTERN MED, V121, P684, DOI 10.7326/0003-4819-121-9-199411010-00010; LEIKAUF GD, 1990, AM J PHYSIOL, V259, pL255, DOI 10.1152/ajplung.1990.259.4.L255; LI Y, 1995, J NEUROL SCI, V128, P134, DOI 10.1016/0022-510X(94)00228-G; Lipton P, 1999, PHYSIOL REV, V79, P1431, DOI 10.1152/physrev.1999.79.4.1431; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lynch KR, 1999, NATURE, V399, P789; MATSUO M, 1995, BRAIN RES, V685, P201, DOI 10.1016/0006-8993(95)00490-H; Mazzetti L, 2003, BRIT J PHARMACOL, V138, P707, DOI 10.1038/sj.bjp.0705087; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; OHTSUKI T, 1995, AM J PHYSIOL-HEART C, V268, pH1249, DOI 10.1152/ajpheart.1995.268.3.H1249; PAPADOPOULOS SM, 1989, NEUROSURGERY, V25, P369, DOI 10.1227/00006123-198909000-00008; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Schroeter M, 2002, J NEUROSCI METH, V117, P43, DOI 10.1016/S0165-0270(02)00072-9; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Shishido Y, 2001, PHARMACOL BIOCHEM BE, V69, P469, DOI 10.1016/S0091-3057(01)00572-X; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; SIMMET T, 1990, BRAIN RES, V515, P79, DOI 10.1016/0006-8993(90)90579-Z; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Yano T, 2003, ANESTHESIOLOGY, V98, P465, DOI 10.1097/00000542-200302000-00028; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; Yu GL, 2005, BRAIN RES, V1053, P116, DOI 10.1016/j.brainres.2005.06.046; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; ZENG LH, 2001, ACTA PHARMACOL SINIC, V36, P148; Zhang RL, 2003, EXP NEUROL, V184, P746, DOI 10.1016/S0014-4886(03)00296-6; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088; Zhang WP, 2002, ACTA PHARMACOL SIN, V23, P871	43	70	89	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	140	3					969	979		10.1016/j.neuroscience.2006.02.051			11	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	052KG	WOS:000238232000020	16650938				2022-02-06	
J	Jagodic, HK; Jagodic, K; Podbregar, M				Jagodic, Helena Korosec; Jagodic, Klemen; Podbregar, Matej			Long-term outcome and quality of life of patients treated in surgical intensive care: a comparison between sepsis and trauma	CRITICAL CARE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; HEALTH-STATUS; SEPTIC SHOCK; SURVIVORS; RECOMMENDATIONS; POPULATION; EQ-5D	Introduction Our aim was to determine long-term survival and quality of life of patients admitted to a surgical intensive care unit (ICU) because of sepsis or trauma. Methods This was an observational study conducted in an 11-bed, closed surgical ICU at a 860-bed teaching general hospital over a 1-year period ( January 2003 to December 2003). Patients were divided into two groups according to admission diagnoses: group 1 included patients with sepsis; and group 2 included patients with trauma (polytrauma, multiple trauma, head injury, or spinal injury). Quality of life was assessed after 2 years following ICU admission using the EuroQol 5D questionnaire. Results A total of 164 patients ( 98 trauma patients and 66 patients with sepsis) were included in the study. Trauma patients were younger than patients with sepsis ( 53 +/- 21 years versus 64 +/- 13 years; P <= 0.001). There was no significant difference between groups in Acute Physiology and Chronic Health Evaluation II score or length of stay in the surgical SICU. Trauma patients stayed longer on the general ward ( 35 +/- 44 days versus 17 +/- 24 days; P < 001). Surgical ICU survival, in-hospital survival, and post-hospital and cumulative 2-year survival were lower in the sepsis group than in the trauma group ( surgical ICU survival: 60% versus 74%; in-hospital survival: 42% versus 62%; post-hospital survival: 78% versus 92%; cumulative 2-year survival: 33% versus 57%; P < 0.05). There was no significant difference in quality of life in all five dimensions of the EuroQol 5D between groups: 60% of patients had signs of depression, almost 60% had problems in usual activities and 56% had pain. Conclusion Patients with sepsis treated in a surgical ICU have higher short-term and long-term mortality than do trauma patients. However, quality of life is reduced to the same level in both groups.	Gen Hosp Celje, Dept Anesthesiol & Intens Therapy, Celje 3000, Slovenia; Gen Hosp Celje, Dept Urol, Celje 3000, Slovenia; Univ Med Ctr Ljubljana, Clin Dept Intens Internal Med, Ljubljana 1000, Slovenia		Jagodic, HK (corresponding author), Gen Hosp Celje, Dept Anesthesiol & Intens Therapy, Oblakova Ulica, Celje 3000, Slovenia.	helena.korosec-jagodic@guest.arnes.si					Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; Badia X, 2001, INTENS CARE MED, V27, P1901, DOI 10.1007/s00134-001-1137-x; Badia X, 1998, QUAL LIFE RES, V7, P311, DOI 10.1023/A:1024933913698; Balk RA, 2000, CRIT CARE CLIN, V16, P179, DOI 10.1016/S0749-0704(05)70106-8; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Chang SY, 2005, CRIT CARE CLIN, V21, P43, DOI 10.1016/j.ccc.2004.07.003; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; Davidson TA, 1999, AM J RESP CRIT CARE, V160, P1838, DOI 10.1164/ajrccm.160.6.9903058; Davidson TA, 1999, JAMA-J AM MED ASSOC, V281, P354, DOI 10.1001/jama.281.4.354; Ferdinande P, 1997, INTENS CARE MED, V23, P226, DOI 10.1007/s001340050321; Fisher M, 1998, Ann Acad Med Singap, V27, P376; Grady KL, 2001, CRIT CARE MED, V29, P1844, DOI 10.1097/00003246-200109000-00036; Granja C, 2004, CRIT CARE, V8, pR91, DOI 10.1186/cc2818; Granja C, 2002, INTENS CARE MED, V28, P898, DOI 10.1007/s00134-002-1345-z; Haraldsen Pernille, 2003, Eur J Surg Suppl, P23; Herridge Margaret S, 2002, Curr Opin Crit Care, V8, P331, DOI 10.1097/00075198-200208000-00010; Kind P, 1998, BMJ-BRIT MED J, V316, P736, DOI 10.1136/bmj.316.7133.736; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Marshall JC, 2005, CRIT CARE MED, V33, P1708, DOI 10.1097/01.CCM.0000174478.70338.03; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Needham DM, 2005, INTENS CARE MED, V31, P1153, DOI 10.1007/s00134-005-2656-7; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Sznajder M, 2001, INTENS CARE MED, V27, P146, DOI 10.1007/s001340000760; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vincent JL, 2006, AM J RESP CRIT CARE, V173, P256, DOI 10.1164/rccm.200510-1604OE; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wright JC, 2003, ANAESTHESIA, V58, P637, DOI 10.1046/j.1365-2044.2003.03205.x	28	70	73	1	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2006	10	5							R134	10.1186/cc5047			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	185NS	WOS:000247718300010		gold, Green Published			2022-02-06	
J	Busch, RM; McBride, A; Curtiss, G; Vanderploeg, RD				Busch, RM; McBride, A; Curtiss, G; Vanderploeg, RD			The components of executive functioning in traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	111th Annual Convention of the American-Psychological-Association	AUG 07-10, 2003	Toronto, CANADA	Amer Psychol Assoc			FRONTAL-LOBE; RHESUS-MONKEY; PREFRONTAL CORTEX; INTERDIGITATION; PROJECTIONS; ATTENTION; BEHAVIOR; DAMAGE	Theorists have proposed models of executive functioning, and functional neuroimaging and factor analytic studies have attempted to examine the components of executive functioning. These studies have arrived at different conclusions and many empirical studies are wrought with methodological confounds. The purpose of this exploratory study was to investigate the subcomponents of executive abilities while addressing some of the limitations common in previous studies. Neuropsychological test data were obtained from a sample of individuals with a history of TBI seen at one-year follow-up (n = 104). Principal components factor analysis was conducted and yielded three factors that accounted for 52.7% of the variance. The first factor included higher-order executive functions with two components: self-generative behavior and cognitive flexibility/set shifting. The second factor appeared to represent mental control, particularly of ongoing working memory. The third factor consisted of memory errors, representing failure to inhibit reporting of inaccurate information. Although the results are not entirely consistent with any of the current theoretical models of executive function, they appear to be most consistent with the 1986 model of Stuss and Benson.	James A Haley Vet Hosp, Psychol Serv, Tampa, FL 33612 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv, 116B,13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				AMASIO AR, 1983, NEUROPSYCHOLOGY HUMA, P85; ANDERSON SW, 1993, ACTA PSYCHOL, V82, P193, DOI 10.1016/0001-6918(93)90012-G; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Baddeley A., 2002, PRINCIPLES FRONTAL L, P246, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0016; Baddeley A.D., 1986, WORKING MEMORY; Benson D.F., 1986, FRONTAL LOBES; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Ferland MB, 1998, J CLIN EXP NEUROPSYC, V20, P473, DOI 10.1076/jcen.20.4.473.1475; Golden CJ, 1978, STROOP COLOR WORD TE; Goldman-Rakic P. S., 2002, PRINCIPLES FRONTAL L, P85, DOI DOI 10.1093/ACPR0F:0S0/9780195134971.003.0005; GOLDMANRAKIC PS, 1982, SCIENCE, V216, P755, DOI 10.1126/science.6177037; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; Gorsuch R.L., 1983, FACTOR ANAL; Hamsher K., 1989, MULTILINGUAL APHASIA; Heaton PDRK., 1993, WISCONSIN CARD SORTI; HEATON RK, 1993, WCST COMPUTER VERSIO; Kane MJ, 2002, PSYCHON B REV, V9, P637, DOI 10.3758/BF03196323; Knight RT., 2002, PRINCIPLES FRONTAL L, P261, DOI [10.1093/acprof:oso/9780195134971.003.0017, DOI 10.1093/ACPROF:OSO/9780195134971.003.0017]; Lezak M.D., 1987, NEUROPSYCHOL REHABIL, P41; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; Lezak MD., 1995, NEUROPSYCHOLOGICAL A, V3rd; MALEC JF, 1991, PSYCHOL ASSESSMENT J, V3, P82; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moscovitch M., 2002, PRINCIPLES FRONTAL L, P188, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0012; NORMAN DA, 1980, COGNITIVE SCI, V4, P1, DOI 10.1207/s15516709cog0401_1; Reitan RM, 1985, HALSTEADREITAN NEURO; Russell E.W., 1993, HALSTEAD RUSSELL NEU; Sarazin M, 2003, J NEUROL, V250, P827, DOI 10.1007/s00415-003-1087-z; SELEMON LD, 1985, J NEUROSCI, V5, P776; SELEMON LD, 1988, J NEUROSCI, V8, P4049; Shah, 1999, MODELS WORKING MEMOR, DOI DOI 10.1017/CBO9781139174909.005; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; *SPSS INC, 2002, SPSS STAT PROGR SOC; Strauss ME, 2000, NEUROPSYCHOLOGY, V14, P201, DOI 10.1037//0894-4105.14.2.201; Stuss D., 2002, PR FRONTAL LOBE FUNC, P392, DOI DOI 10.1093/ACPROF:OSO/9780195134971.003.0025; STUSS DT, 1992, J CONSULT CLIN PSYCH, V60, P349, DOI 10.1037/0022-006X.60.3.349; Stuss DT, 2001, PSYCHOL ASSESSMENT, V13, P230, DOI 10.1037//1040-3590.13.2.230; Vanderploeg R. D, 2000, CLIN GUIDE NEUROPSYC CLIN GUIDE NEUROPSYC, V2nd; Wechsler, 1997, WECHSLER ADULT INTEL; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1	44	70	73	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	NOV	2005	27	8					1022	1032		10.1080/13803390490919263			11	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Psychology; Neurosciences & Neurology	977CJ	WOS:000232779700006	16207623				2022-02-06	
J	Wood, RL; Liossi, C; Wood, L				Wood, RL; Liossi, C; Wood, L			The impact of head injury neurobehavioural sequelae on personal relationships: Preliminary findings	BRAIN INJURY			English	Article						brain injury; personal relationships; neurobehavioural sequelae	TRAUMATIC BRAIN INJURY; ADJUSTMENT; CAREGIVERS; PATIENT	Background: Existing evidence suggests that neurobehavioural disability is a frequent legacy of serious head trauma and has a major impact on the psychological well-being of relatives and friends of people with brain injuries. Objective: To explore which neurobehavioural legacies of serious head trauma have the greatest impact on personal relationships and increase the risk of relationship breakdown. Method: Forty-eight partners of people who had suffered serious head trauma were asked to complete a 12-item measure to rate how different neurobehavioural characteristics had adversely affected their relationship with the brain injured person. Twenty-three couples who had divorced or separated from their injured partner in the years following injury comprised the 'separated' group, 25 still in the relationship at the time data were collected comprised the 'together' group. Results: Even though many neurobehavioural characteristics of brain injury were reported by partners of both the separated and the together group as placing a strain on the relationship only mood swings accounted for a significant between groups difference [t(40.13) = 3.33, p = 0.002]. The magnitude of the difference in the means was large (eta(2) = 0.19). Conclusions: Unpredictable patterns of behaviour, as perceived by partners of brain injured individuals, impose the greatest burden on personal relationships and may contribute to relationship breakdown.	Univ Coll Swansea, Dept Psychol, Swansea SA2 8PP, W Glam, Wales; HMP Leyhill, Gloucester, England		Wood, RL (corresponding author), Univ Coll Swansea, Dept Psychol, Singleton Pk, Swansea SA2 8PP, W Glam, Wales.	r.l.wood@swansea.ac.uk		Liossi, Christina/0000-0003-0627-6377			Amato PR, 1997, J MARRIAGE FAM, V59, P612, DOI 10.2307/353949; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P508; HOLM S, 1979, SCAND J STAT, V6, P65; Hoofien D, 2001, BRAIN INJURY, V15, P189; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LAZARUS RS, 1981, MODELS CLIN PSYCHOPA, P177, DOI DOI 10.1007/978-94-015-7129-6; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; NOVACK TA, 1987, ARCH PHYS MED REHAB, V68, P729; Panting A, 1972, REHABILITATION, V38, P33; RODRIGUE JR, 1994, PSYCHO-ONCOLOGY, V3, P205, DOI 10.1002/pon.2960030307; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VELLEMAN PF, 1993, AM STAT, V47, P65, DOI 10.2307/2684788; VITALIANO PP, 1991, PSYCHOL AGING, V6, P392, DOI 10.1037/0882-7974.6.3.392; Wolcott I, 1999, 20 AUSTR I FAM STUD; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183	23	70	71	0	3	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2005	19	10					845	851		10.1080/02699050500058778			7	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	945EI	WOS:000230484800010	16175844				2022-02-06	
J	Kraus, J; Schaffer, K; Ayers, K; Stenehjem, T; Shen, HK				Kraus, J; Schaffer, K; Ayers, K; Stenehjem, T; Shen, HK			Physical complaints, medical service use, and social and employment changes following mild traumatic brain injury - A 6-month longitudinal study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cohort study; epidemiology; mild traumatic brain injury; outcomes; risk estimates	MINOR HEAD-INJURY; ALCOHOL-USE; ACOUSTIC HYPERESTHESIA; SEQUELAE; EMERGENCY; SYMPTOMS; RISK; VALIDATION; DISCHARGE; PATTERNS	Using a prospective, dual-cohort study design in which selected preinjury factors were controlled, we present outcomes of 235 patients in a case cohort and 235 patients in a comparison cohort following emergency-department-diagnosed mild traumatic brain injury (MTBI). Symptoms, medical services use, and social and employment concerns were evaluated 6 months after the injury. After adjusting for preinjury characteristics, headaches, dizziness, vision difficulties, memory or learning problems, and alcohol intolerance were found to occur significantly more often in the MTBI cohort than in the comparison cohort. Problems sleeping, use of prescribed medications, and changes in employment were less likely in the MTBI cohort. Although MTBI is not life threatening, our findings suggest that 6 months after injury persons still have related health problems that require routine medical management.	Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Biostat, Los Angeles, CA 90024 USA; Sharp Mem Hosp & Rehabil Ctr, Trauma Serv, San Diego, CA USA; Sharp Mem Hosp & Rehabil Ctr, Rehabil Ctr, San Diego, CA USA		Kraus, J (corresponding author), Univ Calif Los Angeles, So Calif Injury Prevent Res Ctr, Dept Epidemiol, 10911 Weyburn Ave,Suite 200, Los Angeles, CA 90024 USA.	jfkraus@ucla.edu		SCHAFFER, KATHRYN/0000-0002-3550-1679			ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; BOHNEN N, 1991, BRIT J PSYCHIAT, V159, P860, DOI 10.1192/bjp.159.6.860; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; CHERPITEL CJ, 1995, J STUD ALCOHOL, V56, P83, DOI 10.15288/jsa.1995.56.83; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EVANS RW, 1992, NEUROL CLIN, V10, P815, DOI 10.1016/S0733-8619(18)30182-8; Feinstein A, 2000, CAN J PUBLIC HEALTH, V91, P325, DOI 10.1007/BF03404799; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Hanlon RE, 1999, BRAIN INJURY, V13, P873; Hungerford DW, 2003, ACAD EMERG MED, V10, P79, DOI 10.1197/aemj.10.1.79; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Longabaugh R, 2001, J STUD ALCOHOL, V62, P806, DOI 10.15288/jsa.2001.62.806; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROSENTHAL M, 1993, ANN EMERG MED, V22, P1048, DOI 10.1016/S0196-0644(05)82749-0; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; *SAS I INC, 1999, SAS STAT; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; Tellier A, 1999, BRAIN INJURY, V13, P463; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; *WHO COLL CTR TASK, 2004, J REHABIL MED S, V43, P126; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; 1997, INT CLASSIFICATION D	57	70	71	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					239	256		10.1097/00001199-200505000-00007			18	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500007	15908824				2022-02-06	
J	Mathias, JL; Mansfield, KM				Mathias, JL; Mansfield, KM			Prospective and declarative memory problems following moderate and severe traumatic brain injury	BRAIN INJURY			English	Article						traumatic brain injury; prospective memory; declarative memory; memory	CLOSED-HEAD INJURY; ATTENTION; DEFICITS; TIME; PERFORMANCE; PATTERNS; FAILURE; DAMAGE; EVENT; MILD	Primary objective: To examine prospective and declarative memory problems following moderate and severe traumatic brain injury (TBI) and the relationship between prospective memory ( PM) and declarative memory and PM and other cognitive functions. Research design: The performance of persons who suffered a TBI (n=25) was compared with that of a demographically matched control group (n=25). Methods and procedures: Measures of time- and event-based PM, visual and verbal declarative memory, attention and executive functioning were administered to both groups. Main outcome and results: The group with a TBI performed more poorly on event- and time-based PM, verbal declarative memory, certain aspects of attention and executive functioning. The correlations between the measures of PM, declarative memory and the other cognitive tests were all non-significant. Conclusions: Problems with declarative memory, attention, and executive functioning do not adequately account for poorer PM performance following a TBI, suggesting that PM should also be assessed following TBI.	Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia		Mathias, JL (corresponding author), Univ Adelaide, Dept Psychol, Adelaide, SA 5005, Australia.	jane.mathias@psychology.adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			Baddeley A.D., 1995, HDB MEMORY DISORDERS, P3; Bate AJ, 2001, J CLIN EXP NEUROPSYC, V23, P386, DOI 10.1076/jcen.23.3.386.1190; Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Beck A., 1996, BECK DEPRESSION INVE, V78, P490; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Blumbergs PC, 1997, HEAD INJURY PATHOPHY, P39; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; CURRY LM, 1991, PHILADELPHIA HEAD IN; d'Ydewalle G, 1999, EUR J COGN PSYCHOL, V11, P219, DOI 10.1080/713752309; Delis DC, 1987, CALIFORNIA VERBAL LE; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; EINSTEIN GO, 1995, J EXP PSYCHOL LEARN, V21, P996, DOI 10.1037/0278-7393.21.4.996; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Fortin S, 2002, BRAIN COGNITION, V48, P361, DOI 10.1006/brcg.2001.1378; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hillier SL, 1997, BRAIN INJURY, V11, P649; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; Kvavilashvili L., 1996, PROSPECTIVE MEMORY T, V6, P183; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MATHIAS JL, IN PRESS APPL NEUROP; McDaniel MA., 1996, PROSPECTIVE MEMORY T, P1; Nelson H.E., 1991, NATL ADULT READING T, V2nd ed.; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; OReilly R.C., 1996, PROSPECTIVE MEMORY T, P267; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; Schmidt M., 1996, REY AUDITORY VERBAL; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; SINNOTT JD, 1989, EVERYDAY COGNITION IN ADULTHOOD AND LATE LIFE, P352; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Vakil E, 2001, J CLIN EXP NEUROPSYC, V23, P207, DOI 10.1076/jcen.23.2.207.1209; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Wechsler D., 1997, WECHSLER MEMORY SCAL; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1991, RIVERMEAD BEHAV MEMO; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7; Zeller R.A., 1979, RELIABILITY VALIDITY, V17, P1; [No title captured]	53	70	72	1	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	2005	19	4					271	282		10.1080/02699050400005028			12	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	917MN	WOS:000228466400005	15832873				2022-02-06	
J	Zhong, CL; Zhao, XR; Sarva, J; Kozikowski, A; Neale, JH; Lyeth, BG				Zhong, CL; Zhao, XR; Sarva, J; Kozikowski, A; Neale, JH; Lyeth, BG			NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats	JOURNAL OF NEUROTRAUMA			English	Article						N-acetylaspartylglutamate (NAAG); fluid percussion; glutamate; hippocampus; metabotropic glutamate receptor; traumatic brain injury	TRAUMATIC BRAIN-INJURY; METABOTROPIC GLUTAMATE-RECEPTOR; EXCITATORY AMINO-ACIDS; N-ACETYLASPARTYLGLUTAMATE; GROUP-II; CARBOXYPEPTIDASE-II; NEUROPROTECTIVE ACTIVITY; ARBITRARY PARTICLES; BEHAVIORAL DEFICITS; FLUORO-JADE	Traumatic brain injury (TBI) produces a rapid and excessive elevation in extracellular glutamate associated with excitotoxicity and secondary brain pathology. The peptide neurotransmitter N-acetylaspartylglutamate (NAAG) suppresses glutamate transmission through selective activation of presynaptic Group II metabotropic glutamate receptor subtype 3 (mGluR3). Thus, inhibition of NAAG peptidase activity and the prolong presence of synaptic NAAG were hypothesized to have significant potential for cellular protection following TBI. In the present study, a novel NAAG peptidase inhibitor, ZJ-43, was used in four different doses (0, 50, 100, or 150 mg/kg). Each dose was repeatedly administered i.p. (n = 5/group) by multiple injections at three times (0 time, 8 h, 16 h) after moderate lateral fluid percussion TBI in the rat. An additional group was co-administered ZJ-43 (150 mg/kg) and the Group II mGluR antagonist, LY341495 (1 mg/kg), which was predicted to abolish any protective effects of ZJ-43. Rats were euthanized at 24 h after TBI, and brains were processed with a selective marker for degenerating neurons (Fluoro-Jade B) and a marker for astrocytes (GFAP). Ipsilateral neuronal degeneration and bilateral astrocyte loss in the CA2/3 regions of the hippocampus were quantified using stereological techniques. Compared with vehicle, ZJ-43 significantly reduced the number of the ipsilateral degenerating neurons (p < 0.01) with the greatest neuroprotection at the 50 mg/kg dose. Moreover, LY341495 successfully abolished the protective effects of ZJ-43. 50 mg/kg of ZJ-43 also significantly reduced the ipsilateral astrocyte loss (p < 0.05). We conclude that the NAAG peptidase inhibitor ZJ-43 is a potential novel strategy to reduce both neuronal and astrocyte damage associated with the glutamate excitotoxicity after TBI.	Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, Davis, CA 95616 USA; Shanghai Med Univ 2, Renji Hosp, Dept Neurosurg, Shanghai, Peoples R China; Univ Illinois, Dept Med Chem & Pharmacognosy, Chicago, IL USA; Georgetown Univ, Dept Biol, Washington, DC USA		Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, Ctr Neurosci, 1515 Newton Ct,1 Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042672, R01NS029995, R01NS045136] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 45136, NS 42672, NS 29995] Funding Source: Medline		Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Bischofberger J, 1996, J NEUROPHYSIOL, V76, P2089, DOI 10.1152/jn.1996.76.3.2089; Bruno V, 1998, NEUROSCIENCE, V85, P751, DOI 10.1016/S0306-4522(97)00531-9; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bzdega T, 2004, J NEUROCHEM, V89, P627, DOI 10.1111/j.1471-4159.2004.02361.x; DANBOLT NC, 1994, PROG NEUROBIOL, V44, P377, DOI 10.1016/0301-0082(94)90033-7; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Ghadge GD, 2003, P NATL ACAD SCI USA, V100, P9554, DOI 10.1073/pnas.1530168100; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GUNDERSEN HJG, 1986, J MICROSC-OXFORD, V143, P3, DOI 10.1111/j.1365-2818.1986.tb02764.x; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; Hansson E, 1997, ACT NEUR S, V70, P148; Jackson PF, 1996, J MED CHEM, V39, P619, DOI 10.1021/jm950801q; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; Kingston AE, 1998, NEUROPHARMACOLOGY, V37, P1, DOI 10.1016/S0028-3908(97)00191-3; Kozikowski AP, 2004, J MED CHEM, V47, P1729, DOI 10.1021/jm0306226; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Neale JH, 2000, J NEUROCHEM, V75, P443, DOI 10.1046/j.1471-4159.2000.0750443.x; Olszewski RT, 2004, J NEUROCHEM, V89, P876, DOI 10.1111/j.1471-4159.2004.02358.x; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riba-Bosch A, 2004, NEUROSCIENCE, V125, P803, DOI 10.1016/j.neuroscience.2004.02.017; Rong SB, 2002, J MED CHEM, V45, P4140, DOI 10.1021/jm010561g; Sanabria ERG, 2004, J NEUROPHYSIOL, V91, P182, DOI 10.1152/jn.00465.2003; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schweitzer C, 2000, NEUROPHARMACOLOGY, V39, P1700, DOI 10.1016/S0028-3908(99)00265-8; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Takahashi M, 1997, J EXP BIOL, V200, P401; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wroblewska B, 1997, J NEUROCHEM, V69, P174; Wroblewska B, 1998, GLIA, V24, P172, DOI 10.1002/(SICI)1098-1136(199810)24:2<172::AID-GLIA2>3.0.CO;2-6; WROBLEWSKA B, 1993, J NEUROCHEM, V61, P943, DOI 10.1111/j.1471-4159.1993.tb03606.x; Xi ZX, 2002, J PHARMACOL EXP THER, V300, P162, DOI 10.1124/jpet.300.1.162; Yamamoto T, 2004, EUR J NEUROSCI, V20, P483, DOI 10.1111/j.1460-9568.2004.03504.x; Yamamoto T, 2001, BRAIN RES, V909, P138, DOI 10.1016/S0006-8993(01)02650-6; Yamamoto T, 2001, NEUROSCIENCE, V102, P473, DOI 10.1016/S0306-4522(00)00502-9; Zhang W, 2002, J NEUROL SCI, V194, P21, DOI 10.1016/S0022-510X(01)00670-0; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283; Zhao ZX, 2001, SOLID STATE SCI, V3, P339, DOI 10.1016/S1293-2558(00)01087-6; Zucchini S, 2002, NEUROREPORT, V13, P2071, DOI 10.1097/00001756-200211150-00016; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	46	70	72	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					266	276		10.1089/neu.2005.22.266			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400006	15716632				2022-02-06	
J	Longhi, L; Watson, DJ; Saatman, KE; Thompson, HJ; Zhang, C; Fujimoto, S; Royo, N; Castelbuono, D; Raghupathi, R; Trojanowski, JQ; Lee, VMY; Wolfe, JH; Stocchetti, N; McIntosh, TK				Longhi, L; Watson, DJ; Saatman, KE; Thompson, HJ; Zhang, C; Fujimoto, S; Royo, N; Castelbuono, D; Raghupathi, R; Trojanowski, JQ; Lee, VMY; Wolfe, JH; Stocchetti, N; McIntosh, TK			Ex vivo gene therapy using targeted engraftment of NGF-expressing human NT2N neurons attenuates cognitive deficits following traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; gene therapy; nerve growth factor; neurotrophins	NERVE GROWTH-FACTOR; CONTROLLED CORTICAL IMPACT; NF-KAPPA-B; VESICULAR ACETYLCHOLINE TRANSPORTER; CELL-LINE; CHOLINERGIC INNERVATION; NEURAL TRANSPLANTATION; FUNCTIONAL RECOVERY; TRANSGENIC MOUSE; MESSENGER-RNA	Infusion of nerve growth factor (NGF) has been shown to be neuroprotective following traumatic brain injury (TBI). In this study, we tested the hypothesis that NGF-expressing human NT2N neurons transplanted into the basal forebrain of brain-injured mice can attenuate long-term cognitive dysfunction associated with TBI. Undifferentiated NT2 cells were transduced in vitro with a lentiviral vector to release NGF, differentiated into NT2N neurons by exposure to retinoic acid and transplanted into the medial septum of mice 24 h following controlled cortical impact (CCI) brain injury or sham injury. Adult mice (n = 78) were randomly assigned to one of four groups: (1) sham-injured and vehicle (serum-free medium)-treated, (2) brain-injured and vehicle-treated, (3) brain-injured engrafted with untransduced NT2N neurons, and (4) brain-injured engrafted with transduced NGF-NT2N neurons. All groups were immunosuppressed daily with cyclosporin A (CsA) for 4 weeks. At 1 month post-transplantation, animals engrafted with NGF-expressing NT2N neurons showed significantly improved learning ability (evaluated with the Morris water maze) compared to brain-injured mice receiving either vehicle (p < 0.05) or untransduced NT2N neurons (p < 0.01). No effect of NGF-secreting NT2N cells on motor function deficits at 1-4 weeks post-transplantation was observed. These data suggest that NGF gene therapy using transduced NT2N neurons (as a source of delivery) may selectively improve cognitive function following TBI.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Neurol & Neurosci Res, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; IRCCS, Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Milan, Italy; Drexel Univ, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA		McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021; Raghupathi, Ramesh/AAX-5538-2021	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; 	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK42707] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, NS11024, NS38690, R01-NS40978] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK042707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, F32NS011024, P50NS008803] Funding Source: NIH RePORTER		Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Bartus RT, 2000, EXP NEUROL, V163, P495, DOI 10.1006/exnr.2000.7397; Blesch A, 1998, PROG BRAIN RES, V117, P473; Blomer U, 1998, P NATL ACAD SCI USA, V95, P2603, DOI 10.1073/pnas.95.5.2603; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conte V., 2003, EUR J TRAUMA, V7, P335; Conti AC, 1998, J NEUROSCI, V18, P5663; COOK DG, 1994, METHOD CELL BIOL, V43, P289; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1997, J NEUROTRAUM, V14, P159; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; GAGE FH, 1989, NEURON, V2, P1177, DOI 10.1016/0896-6273(89)90184-0; Galpern WR, 1996, NEUROREPORT, V7, P2639, DOI 10.1097/00001756-199611040-00046; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hamanoue M, 1999, MOL CELL NEUROSCI, V14, P28, DOI 10.1006/mcne.1999.0770; Hartley RS, 1999, J COMP NEUROL, V415, P404, DOI 10.1002/(SICI)1096-9861(19991220)415:3<404::AID-CNE6>3.0.CO;2-R; HIGGINS GA, 1989, NEURON, V3, P247, DOI 10.1016/0896-6273(89)90038-X; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Kawaja MD, 1998, EUR J NEUROSCI, V10, P2207, DOI 10.1046/j.1460-9568.1998.00228.x; Kimpinski K, 1999, NEUROSCIENCE, V93, P253, DOI 10.1016/S0306-4522(99)00156-6; KITT CA, 1994, J COMP NEUROL, V341, P117, DOI 10.1002/cne.903410110; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Maggirwar SB, 1998, J NEUROSCI, V18, P10356; MartinezSerrano A, 1996, P NATL ACAD SCI USA, V93, P6355, DOI 10.1073/pnas.93.13.6355; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Modo M, 2000, J NEUROSCI METH, V104, P99, DOI 10.1016/S0165-0270(00)00329-0; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Murdoch I, 2002, J NEUROTRAUM, V19, P279, DOI 10.1089/08977150252807018; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; NEFTI F, 1986, J NEUROSCI, V6, P2155; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NOBES CD, 1995, EUR J NEUROSCI, V7, P344, DOI 10.1111/j.1460-9568.1995.tb01069.x; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Paxinos GFK., 2001, MOUSE BRAIN STEREOTA, V2nd ed.; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pike BR, 1997, EXP NEUROL, V147, P55, DOI 10.1006/exnr.1997.6582; Pike BR, 1997, PHARMACOL BIOCHEM BE, V57, P785, DOI 10.1016/S0091-3057(96)00453-4; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romero MI, 2000, J NEUROSCI, V20, P4435, DOI 10.1523/JNEUROSCI.20-12-04435.2000; ROYO NC, 2002, J NEUROTRAUM, V19, P1362; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Saragovi HU, 2000, TRENDS PHARMACOL SCI, V21, P93, DOI 10.1016/S0165-6147(99)01444-3; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schmidt RH, 1999, J NEUROTRAUM, V16, P1139, DOI 10.1089/neu.1999.16.1139; Shao LF, 1999, J NEUROTRAUM, V16, P555, DOI 10.1089/neu.1999.16.555; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Tuszynski MH, 2000, CELL TRANSPLANT, V9, P629, DOI 10.1177/096368970000900508; TUSZYNSKI MH, 1995, P NATL ACAD SCI USA, V92, P4621, DOI 10.1073/pnas.92.10.4621; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Watson Deborah J, 2003, Methods Mol Med, V76, P383; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	79	70	71	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2004	21	12					1723	1736		10.1089/neu.2004.21.1723			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	877FY	WOS:000225554400004	15684764				2022-02-06	
J	Cato, MA; Delis, DC; Abildskov, TJ; Bigler, E				Cato, MA; Delis, DC; Abildskov, TJ; Bigler, E			Assessing the elusive cognitive deficits associated with ventromedial prefrontal damage: A case of a modern-day Phineas Gage	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						ventromedial prefrontal cortex; executive functions; traumatic brain injury	FRONTAL-LOBE; DECISION-MAKING; WORKING-MEMORY; CORTEX; PATIENT; NETWORKS; EMOTION; BRAIN	Cognitive deficits following ventromedial prefrontal damage (VM-PFD) have been elusive, with most studies reporting primarily emotional and behavioral changes. The present case illustrates the utility of a process approach to assessing cognitive deficits following VM-PFD. At age 26, C.D. acquired bilateral VM-PFD, more so in the left frontal region, following a penetrating head injury. Despite exemplary premorbid academic and military performances, his subsequent history suggests dramatic occupational and social changes, reminiscent of Phineas Gage. In fact, lesion analysis revealed similar structural damage to that estimated of Gage. C.D.'s scores on the vast majority of neuropsychological measures were average to superior (e.g., Verbal IQ = 119). However, on several new process measures, particularly those that quantify error rates on multilevel executive function and memory tasks, C.D. exhibited marked impairments. From his pattern of deficits, C.D. appeared to sacrifice accuracy for speed and to adopt liberal response strategies, implicating problems with cognitive inflexibility, impulsivity, and disinhibition. The current findings suggest that VM-PFD may be associated with a wider spectrum of cognitive deficits than previously characterized.	VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL USA; Univ Florida, Malcom Randall VA RR&D Brain Rehabil Res Ctr, Gainesville, FL USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA		Cato, MA (corresponding author), VA San Diego Healthcare Syst, 116B MIRECC,3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	acato@ucsd.edu					Angrilli A, 1999, NEUROREPORT, V10, P1741, DOI 10.1097/00001756-199906030-00021; Barch DM, 1997, NEUROPSYCHOLOGIA, V35, P1373, DOI 10.1016/S0028-3932(97)00072-9; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; Bechara A, 1998, J NEUROSCI, V18, P428; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Chao LL, 1998, J COGNITIVE NEUROSCI, V10, P167, DOI 10.1162/089892998562636; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [DOI 10.1097/00001199-198909000-00008, 10.1097/00001199-198909000-00008]; Damasio A., 1994, DESCARTES ERROR EMOT; Damasio A. R., 1995, SOME FUNCTIONS HUMAN; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Damasio H., 1989, LESION ANAL NEUROPSY; Delis DC., 2001, DELIS KAPLAN EXECUTI; DELIS DC, 2000, CALIFORNIA VERGAL LE; DELIS DC, 2000, NEUROPSYCHOLOGICAL T; Dimitrov M, 1999, NEUROCASE, V5, P345, DOI 10.1093/neucas/5.4.345; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FLEISCHMAN JOHN, 2002, PHINEAS GAGE GRUESOM; Fuster JM, 2000, BRAIN RES BULL, V52, P331, DOI 10.1016/S0361-9230(99)00258-0; Goldman-Rakic P. S., 2002, PRINCIPLES FRONTAL L, P85, DOI DOI 10.1093/ACPR0F:0S0/9780195134971.003.0005; GOLDSTEIN K, 1941, PSYCHOL MONOGR, V53, P151; Goldstein K, 1944, J PSYCHOL, V17, P187, DOI 10.1080/00223980.1944.9917192; Harlow JM, 1848, BOSTON MED SURGICAL, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Hebb DO, 1940, ARCH NEURO PSYCHIATR, V44, P421, DOI 10.1001/archneurpsyc.1940.02280080181011; HEBB DO, 1945, ARCH NEURO PSYCHIATR, V54, P10, DOI 10.1001/archneurpsyc.1945.02300070020002; Kaplan E., 1988, CLIN NEUROPSYCHOLOGY; Luria A R, 1969, Hyg Ment, V58, P1; LURIA AR, 1977, AM PSYCHOL, V32, P959, DOI 10.1037/0003-066X.32.11.959; Macmillan M, 2000, ODD KIND FAME STORIE; Milberg WP, 1996, NEUROPSYCHOLOGICAL A, P58; NAUTA WJH, 1971, J PSYCHIAT RES, V8, P167, DOI 10.1016/0022-3956(71)90017-3; Ongur D, 2000, CEREB CORTEX, V10, P206, DOI 10.1093/cercor/10.3.206; RASBAND W, 1996, IMAGE VERSION 1 60; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; Robb RA, 2001, IEEE T MED IMAGING, V20, P854, DOI 10.1109/42.952724; ROLLS ET, 1994, J NEUROL NEUROSUR PS, V57, P1518, DOI 10.1136/jnnp.57.12.1518; RUFF RM, 1987, DEV NEUROPSYCHOL, V3, P37, DOI 10.1080/87565648709540362; Teuber H L, 1968, Neurology, V18, P287; Teuber HL, 1954, J PSYCHOL, V38, P177, DOI 10.1080/00223980.1954.9712928; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Tranel D., 2002, PRINCIPLES FRONTAL L, P338, DOI DOI 10.1093/ACPROF:OSO/9780195134971.001.0001; Wechsler D., 2011, WECHSLER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; WHITE RF, 1997, CRIT ISS NE, P171; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; [No title captured]	46	70	70	2	40	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH ST, NEW YORK, NY 10011-4211 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2004	10	3					453	465		10.1017/S1355617704103123			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Psychology	817MB	WOS:000221180500014	15147602				2022-02-06	
J	Zhao, ZM; Li, HJ; Liu, HY; Lu, SH; Yang, RC; Zhang, QJ; Han, ZC				Zhao, ZM; Li, HJ; Liu, HY; Lu, SH; Yang, RC; Zhang, QJ; Han, ZC			Intraspinal transplantation of CD34+human umbilical cord blood cells after spinal cord hemisection injury improves functional recovery in adult rats	CELL TRANSPLANTATION			English	Article						spinal cord injury; bone marrow stromal cells; human umbilical cord blood cells; transplantation; stem cell plasticity; rats	MARROW STROMAL CELLS; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; REPLACEMENT THERAPIES; PROMOTE RECOVERY; IN-VITRO; DIFFERENTIATE; STROKE; ENGRAFTMENT	The present study was designed to compare the functional outcome of the intraspinal transplantation of CD34+ human umbilical cord blood (CB) cells with that of human bone marrow stromal (BMS) cells in adult rats with spinal cord injury. Sixty adult Wistar rats were subjected to left spinal cord hemisection. and then divided into three groups randomly. The control group received an injection of PBS without cells, while the two other groups of rats received a transplantation of 5 x 10(5) CD34+ CB or BMS cells, respectively. Functional outcome was measured using the modified Tarlov score at days 1, 7, 14, 21, and 28 after transplantation. A statistically significant improvement in functional outcome and survival rate in the experimental groups of rats was observed compared with the control group. Rats that received CD34+ CB cells achieved a better improvement in functional score than those that received BMS cells at days 7 and 14 after transplantation. Histological evaluation revealed that bromodeoxyuridine (BrdU)-labeled CD34+ CB and BMS cells survived and migrated into the injured area. Some of these cells expressed galial fibriliary acidic protein (GFAP) or neuronal nuclear antigen (NeuN). Our data demonstrate for the first time that intraspinal transplantation of human CD34+ CB cells provides benefit in function recovery after spinal cord hemisection in rats and suggest that CD34+ CB cells may be an excellent choice of cells as routine starting material of allogenic and autologous transplantations for the treatment of spinal cord injury.	Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Natl Res Ctr Stem Cell Engn & Technol, Tianjin 300020, Peoples R China; Peking Union Med Coll, Tianjin, Peoples R China; Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang, Peoples R China		Han, ZC (corresponding author), Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Natl Res Ctr Stem Cell Engn & Technol, Tianjin 300020, Peoples R China.	tihzch@public.tpt.tj.cn	Han, Zhong Chao/D-7157-2016	Han, Zhong Chao/0000-0002-2687-7682			Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Broxmeyer H E, 1996, Cancer Treat Res, V84, P139; Buzanska L, 2002, J CELL SCI, V115, P2131; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DENG W, 2001, BIOCHEM BIOPH RES CO, V282, P1418; Diener PS, 1998, J NEUROSCI, V18, P779; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Gage FH, 1998, NATURE, V392, P18; Galvin KA, 2002, MED J AUSTRALIA, V177, P316, DOI 10.5694/j.1326-5377.2002.tb04791.x; Gluckman E, 2001, Rev Clin Exp Hematol, V5, P87, DOI 10.1046/j.1468-0734.2001.00034.x; Ha Y, 2001, NEUROREPORT, V12, P3523, DOI 10.1097/00001756-200111160-00030; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Tariq M, 1998, J NEUROTRAUM, V15, P239, DOI 10.1089/neu.1998.15.239; Wickelgren I, 2002, SCIENCE, V297, P178, DOI 10.1126/science.297.5579.178; Willing AE, 2003, J NEUROSCI RES, V73, P296, DOI 10.1002/jnr.10659; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zhao Zong-mao, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P484	33	70	88	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2004	13	2					113	122		10.3727/000000004773301780			10	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology; Research & Experimental Medicine; Transplantation	813MD	WOS:000220910300003	15129757				2022-02-06	
J	MacKay, CI; Han, PP; Albuquerque, FC; McDougall, CG				MacKay, CI; Han, PP; Albuquerque, FC; McDougall, CG			Recurrence of a vertebral artery dissecting pseudoaneurysm after successful stent-supported coil embolization: Case report	NEUROSURGERY			English	Article						coil embolization; dissection; pseudoaneurysm; stent; subarachnoid hemorrhage; vertebral artery	TECHNICAL CASE-REPORT; SUBARACHNOID HEMORRHAGE; ENDOVASCULAR TREATMENT; FOLLOW-UP; ANEURYSMS; OCCLUSION; FUSIFORM	OBJECTIVE AND IMPORTANCE: Dissecting aneurysms of the intracranial vertebral artery are increasingly recognized as a cause of subarachnoid hemorrhage. We present a case involving technical success of the stent-supported coil embolization but with recurrence of the dissecting pseudoaneurysm of the intracranial vertebral artery. The implications for the endovascular management of ruptured dissecting pseudoaneurysms of the intracranial vertebral artery are discussed. CLINICAL PRESENTATION: A 36-year-old man with a remote history of head injury had recovered functionally to the point of independent living. He experienced the spontaneous onset of severe head and neck pain, which progressed rapidly to obtundation. A computed tomographic scan of the head revealed subarachnoid hemorrhage centered in the posterior fossa. The patient underwent cerebral angiography, which revealed dilation of the distal left vertebral artery consistent with a dissecting pseudoaneurysm. INTERVENTION: Transfemoral access was achieved under general anesthesia, and two overlapping stents (3 mm in diameter and 14 mm long) were placed to cover the entire dissected segment. Follow-up angiography of the left vertebral artery showed the placement of the stents across the neck of the aneurysm; coil placement was satisfactory, with no residual aneurysm filling. Approximately 6 weeks after the patient's initial presentation, he developed the sudden onset of severe neck pain. A computed tomographic scan showed no subarachnoid hemorrhage, but computed tomographic angiography revealed that the previously treated left vertebral artery aneurysm had recurred. Angiography confirmed a recurrent pseudoaneurysm around the previously placed Guglielmi detachable coils. A test balloon occlusion was performed for 30 minutes. The patient's neurological examination was stable throughout the test occlusion period. Guglielmi detachable coil embolization of the left vertebral artery was then performed, sacrificing the artery at the level of the dissection. After the procedure was completed, no new neurological deficits occurred. On the second day after the procedure, the patient was discharged from the hospital. He was alert, oriented, and able to walk. CONCLUSION: We appreciate the value of preserving a parent vessel when a dissecting pseudoaneurysm of the intracranial vertebral artery ruptures in patients with inadequate collateral blood flow, in patients with disease involving the contralateral vertebral artery, or in patients with both. However, our case represents a cautionary note that patients treated in this fashion require close clinical follow-up. We suggest that parent vessel occlusion be considered the first option for treatment in patients who will tolerate sacrifice of the parent vessel along its diseased segment. In the future, covered stent technology may resolve this dilemma for many of these patients.	St Josephs Hosp, Barrow Neurol Inst, Div Neurol Surg, Phoenix, AZ USA		McDougall, CG (corresponding author), Barrow Neurol Inst, Neurosci Publicat, Div Neurol Surg, 350 W Thomas Rd, Phoenix, AZ 85013 USA.						AOKI N, 1990, STROKE, V21, P1628, DOI 10.1161/01.STR.21.11.1628; COSSU M, 1993, NEUROSURGERY, V32, P344, DOI 10.1227/00006123-199303000-00002; ENDO S, 1993, NEUROSURGERY, V33, P732, DOI 10.1227/00006123-199310000-00026; Kurata A, 2001, AM J NEURORADIOL, V22, P11; Lanzino G, 1999, J NEUROSURG, V91, P538, DOI 10.3171/jns.1999.91.4.0538; Lawton MT, 1996, NEUROSURGERY, V38, P83, DOI 10.1097/00006123-199601000-00020; Lylyk P, 1998, NEUROSURGERY, V43, P385, DOI 10.1097/00006123-199808000-00132; Lylyk P, 2001, J NEUROSURG, V94, P427, DOI 10.3171/jns.2001.94.3.0427; Malek AM, 2000, J TRAUMA, V48, P143, DOI 10.1097/00005373-200001000-00027; Mizutani T, 1999, NEUROSURGERY, V45, P253, DOI 10.1097/00006123-199908000-00010; MIZUTANI T, 1995, NEUROSURGERY, V36, P905, DOI 10.1227/00006123-199505000-00003; Mizutani T, 2001, J NEUROSURG, V94, P712, DOI 10.3171/jns.2001.94.5.0712; Nakagawa K, 2000, J NEUROSURG, V93, P19, DOI 10.3171/jns.2000.93.1.0019; Phatouros CC, 2000, NEUROSURGERY, V47, P107, DOI 10.1097/00006123-200007000-00023; Redekop G, 1999, NEUROSURGERY, V45, P1258, DOI 10.1097/00006123-199911000-00056; TSUKAHARA T, 1995, NEUROSURGERY, V36, P914, DOI 10.1227/00006123-199505000-00004; Yamaura I, 1999, J NEUROSURG, V90, P853, DOI 10.3171/jns.1999.90.5.0853; Yasui T, 1999, J NEUROSURG, V91, P139, DOI 10.3171/jns.1999.91.1.0139	18	70	77	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2003	53	3					754	759		10.1227/01.NEU.0000080065.49651.48			6	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	718AL	WOS:000185122900047	12943592				2022-02-06	
J	Sherer, M; Nick, TG; Sander, AM; Hart, T; Hanks, R; Rosenthal, M; High, WM; Yablon, SA				Sherer, M; Nick, TG; Sander, AM; Hart, T; Hanks, R; Rosenthal, M; High, WM; Yablon, SA			Race and productivity outcome after traumatic brain injury - Influence of confounding factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment; outcome; productivity; race; traumatic brain injury	DISABILITY RATING-SCALE; HEAD-INJURY; HEALTH BELIEFS; RECOVERY; REHABILITATION; COMMUNITY; VIOLENCE; CARE	Objective: Investigate the impact of race on productivity outcome after traumatic brain injury (TBI) and evaluate the influence of confounding factors on this relationship. Design: Inception cohort of 1083 adults with TBI for whom 1-year productivity follow-up data were available. Results: Univariable logistic regression indicated that race was a significant predictor of productivity outcome after TBI. African Americans were 2.76 times more likely to be nonproductive than whites and other racial minorities were 1.92 times more likely to be nonproductive than whites. Multivariable logistic regression analyses revealed that the effect of race on employability was influenced by confounds with preinjury productivity, education level, and cause of injury. After adjustment for other predictors, African Americans were 2.00 times more likely to be nonproductive than whites and other racial minorities were 2.08 times more likely to be nonproductive than whites. The multivariable logistic regression model with all predictors except race accounted for 39% of the variability in productivity outcome (R-2-Nagelkerke = 0.39), whereas the full logistic regression model including race accounted for 41% of the variability in productivity outcome (R-2-Nagelkerke = 0.41); a difference of only 2%. Conclusion: Any effect of race on productivity is significantly influenced by confounding with preinjury productivity, education level, and cause of injury.	Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS 39216 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Brain Injury Res Ctr, Inst Rehabil & Res, Houston, TX USA; Thomas Jefferson Univ, Moss Rehabil Res Inst, Jefferson Med Coll, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Rehabil Med, Jefferson Med Coll, Philadelphia, PA 19107 USA; Rehabil Inst Michigan, Detroit, MI USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; UMDNJ, New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA		Sherer, M (corresponding author), Methodist Rehabil Ctr, Neuropsychol Dept, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.						ALZOLA C, 2001, INTRO S PLUS HMISC D; Be lin T. R., 2000, HLTH SERV OUTCOMES R, V1, P7; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Chamberlain K, 1998, PSYCHOL HEALTH, V13, P1105, DOI 10.1080/08870449808407453; Christensen AJ, 1999, HEALTH PSYCHOL, V18, P169, DOI 10.1037/0278-6133.18.2.169; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Greenland S, 1995, AM J EPIDEMIOL, V142, P1255, DOI 10.1093/oxfordjournals.aje.a117592; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall K. M., 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199308020-00008; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HAMILTON BB, 1987, REHABILITATION OUTCO, P135; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES; KRAUS JF, 1986, AM J PUBLIC HEALTH, V76, P1345, DOI 10.2105/AJPH.76.11.1345; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; NORMAN P, 2001, UNDERSTANDING CHANGI; Pourat N, 2000, J AGING HEALTH, V12, P112, DOI 10.1177/089826430001200106; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774	29	70	70	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2003	18	5					408	424		10.1097/00001199-200309000-00003			17	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	725BF	WOS:000185522200003	12973271				2022-02-06	
J	Fan, P; Yamauchi, T; Noble, LJ; Ferriero, DM				Fan, P; Yamauchi, T; Noble, LJ; Ferriero, DM			Age-dependent differences in glutathione peroxidase activity after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						cortical impactor; glutathione peroxidase; immature; posttraumatic brain edema	ZINC-SUPEROXIDE-DISMUTASE; PERINATAL HYPOXIA-ISCHEMIA; HEAD-INJURY; TRANSGENIC MICE; ANTIOXIDANT ENZYMES; OXIDATIVE STRESS; REGIONAL VULNERABILITY; LIPID-PEROXIDATION; MOUSE-BRAIN; RAT-BRAIN	Children younger than 4 years old have worse outcome after traumatic brain injury (TBI) compared to older children and adults. This increased susceptibility may in part be due to differences in the response to oxidative stress. We hypothesized that the immature brain does not have an adequate compensatory response to injury from oxidative stress. To begin to address this hypothesis, we first compared the general dimensions and water content in postnatal day 21 (P21) and adult murine brain in the naive state as well as after injury (edema). We examined glutathione peroxidase (GPx) activity in cortical and subcortical regions in P21 and adult murine brain following a controlled cortical impact. Brain dimensions including areas of the mantle and hemispheres were similar in each of these groups. The thickness of the cortical mantle was significantly greater in the immature brain as compared to the mature brain (p = 0.01, respectively). Brain edema was assessed through changes in water content, and the response to oxidative challenge was identified by changes in GPx activity. The P21 brain was similar in vulnerability to posttraumatic brain edema when compared to adult. GPx activity in the adult brain was increased within 24 h post-injury in the cortex, thalamus and hippocampus (ANOVA, p < 0.05), whereas there was no compensatory increase in GPx activity in P21 brain, although baseline levels had reached adult levels developmentally. These findings support our hypothesis and illuminate the important role of oxidative stress after TBI in the immature brain that warrants further study.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Chang Gung Childrens Hosp, Dept Pediat, Taipei, Taiwan		Ferriero, DM (corresponding author), Univ Calif San Francisco, Dept Neurol, Rm C215,521 Parnassus Ave, San Francisco, CA 94143 USA.			FAN, PI-CHUAN/0000-0002-6974-971X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 41256] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS041256] Funding Source: NIH RePORTER		Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ASPBERG A, 1992, DEV BRAIN RES, V66, P55, DOI 10.1016/0165-3806(92)90139-N; Barzo P, 1997, ACT NEUR S, V70, P119; Bauer R, 1999, EXP TOXICOL PATHOL, V51, P143, DOI 10.1016/S0940-2993(99)80088-8; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BRIZZEE K. R., 1959, GROWTH, V23, P337; BUARD A, 1992, NEUROSCI LETT, V141, P72, DOI 10.1016/0304-3940(92)90337-7; CEBALLOSPICOT I, 1992, MUTAT RES, V275, P281, DOI 10.1016/0921-8734(92)90032-K; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Conti AC, 1998, J NEUROSCI, V18, P5663; Crack PJ, 2001, J NEUROCHEM, V78, P1389, DOI 10.1046/j.1471-4159.2001.00535.x; DAVISON AN, 1968, CONT NEUROLOGY SERIE, V4, P253; DEHAAN JB, 1994, PEDIATR RES, V35, P188, DOI 10.1203/00006450-199402000-00013; Ditelberg JS, 1996, PEDIATR RES, V39, P204, DOI 10.1203/00006450-199602000-00003; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dringen R, 2000, PROG NEUROBIOL, V62, P649, DOI 10.1016/S0301-0082(99)00060-X; Durkin MS, 1998, NEUROSURGERY, V42, P300, DOI 10.1097/00006123-199802000-00052; EAYRS JT, 1959, J ANAT, V93, P385; Ferriero DM, 2001, DEV NEUROSCI-BASEL, V23, P198, DOI 10.1159/000046143; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; Franklin K.B., 1997, MOUSE BRAIN STEREOTA; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Fullerton HJ, 1998, ANN NEUROL, V44, P357, DOI 10.1002/ana.410440311; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; HADDARA M, 1956, J ANAT, V90, P494; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kempski O, 2001, SEMIN NEPHROL, V21, P303, DOI 10.1053/snep.2001.21665; LAZO O, 1991, J NEUROCHEM, V56, P1343, DOI 10.1111/j.1471-4159.1991.tb11431.x; LEUBA G, 1978, J HIRNFORSCH, V19, P301; Levin HS., 1982, NEUROBEHAVIORAL CONS; MELLER K, 1968, Z ZELLFORSCH MIK ANA, V92, P217, DOI 10.1007/BF00335649; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Northington FJ, 2001, J NEUROSCI, V21, P1931, DOI 10.1523/JNEUROSCI.21-06-01931.2001; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Ustun ME, 2001, J NEUROSURG ANESTH, V13, P227; Ustun ME, 2001, J TRAUMA, V51, P503; VEXLER ZS, 2000, SEMIN NEONATOL, V6, P99; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	44	70	70	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2003	20	5					437	445		10.1089/089771503765355513			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	682MY	WOS:000183096900004	12803976				2022-02-06	
J	Suehiro, E; Ueda, Y; Wei, EP; Kontos, HA; Povlishocki, JT				Suehiro, E; Ueda, Y; Wei, EP; Kontos, HA; Povlishocki, JT			Posttraumatic hypothermia followed by slow rewarming protects the cerebral microcirculation	JOURNAL OF NEUROTRAUMA			English	Article						hypothermia with rewarming; pial vaculature; rats; traumatic brain injury; vasoreactivity	SEVERE HEAD-INJURY; CONCUSSIVE BRAIN INJURY; MILD HYPOTHERMIA; POSTISCHEMIC HYPOTHERMIA; CARDIOPULMONARY BYPASS; MODERATE HYPOTHERMIA; PIAL ARTERIOLES; RELAXING FACTOR; CO2 REACTIVITY; CYCLOSPORINE-A	In the clinical and laboratory setting, multiple reports have suggested the efficacy of hypothermia in blunting the damaging consequences of traumatic brain injury (TBI). With the use of posttraumatic hypothermia, it has been recognized that the time of initiation and duration of hypothermia are important variables in determining the degree of neuroprotection provided. Further, it has been recently recognized that the rate of posttraumatic rewarming is an important variable, with rapid rewarming exacerbating neuronal/axonal damage in contrast to slow rewarming which appears to provide enhanced neuroprotection. Although these findings have been confirmed in the brain parenchyma, no information exists for the cerebral microcirculation on the potential benefits of posttraumatic hypothermia followed by either slow or rapid rewarming. In the current communication we assess these issues in the pial circulation using a well-characterized model of TBI. Rats were prepared for the placement of cranial widows for direct assessment of the pial microcirculation prior to and after the induction of impact acceleration injury followed by moderate hypothermia with either subsequent slow or rapid rewarming strategies. The cranial windows allowed for the measurement of pial vessel diameter to assess ACh-dependent and CO2 reactivity in the chosen paradigms. ACh was applied topically to assess ACh-dependent dilation, while CO2 reactivity was assessed by changing the concentration of the inspired gas. Through this approach, it was found that posttraumatic hypothermia followed by slow rewarming maintained normal arteriolar vascular responses in terms of ACh-dependent dilation and CO2 reactivity. In contrast, arterioles subjected to TBI followed by normothermia or hypothermia and rapid rewarming showed impaired vasoreactivity in terms of their ACh-dependent and CO2 responses. This study provides additional evidence of the benefits of posttraumatic hypothermia followed by slow rewarming, demonstrating for the first time that the previously described neuroprotective effects extend to the cerebral microcirculation.	Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi, Japan; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA		Povlishocki, JT (corresponding author), Virginia Commonwealth Univ, Dept Anat, Med Coll Virginia Campus,POB 980709, Richmond, VA 23298 USA.	jpovlish@hsc.vcu.edu	Suehiro, Eiichi/I-5852-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Brian JE, 1998, ANESTHESIOLOGY, V88, P1365, DOI 10.1097/00000542-199805000-00029; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; ELLISON MD, 1989, STROKE, V20, P911, DOI 10.1161/01.STR.20.7.911; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; Enomoto S, 1996, ANESTHESIOLOGY, V84, P1392, DOI 10.1097/00000542-199606000-00016; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FURCHGOTT RF, 1983, CIRC RES, V53, P557, DOI 10.1161/01.RES.53.5.557; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Golding EM, 2000, J CEREBR BLOOD F MET, V20, P820, DOI 10.1097/00004647-200005000-00008; Irikura K, 1998, J CEREBR BLOOD F MET, V18, P1294, DOI 10.1097/00004647-199812000-00003; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kishi K, 2000, ANESTH ANALG, V91, P140, DOI 10.1097/00000539-200007000-00026; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259, DOI 10.1152/ajpheart.1988.255.5.H1259; Kontos HA, 1996, AM J PHYSIOL-HEART C, V271, pH1498, DOI 10.1152/ajpheart.1996.271.4.H1498; Kontos HA, 1998, AM J PHYSIOL-HEART C, V274, pH974; LeDucq N, 1998, BIOCHEM J, V336, P501, DOI 10.1042/bj3360501; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; Nakamura T, 1999, J NEUROSURG, V91, P114, DOI 10.3171/jns.1999.91.1.0114; Nakamura T, 1998, ACT NEUR S, V71, P85; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NELSON CW, 1992, AM J PHYSIOL, V271, pH1356; Rehman A, 1997, BRIT J PHARMACOL, V122, P1702, DOI 10.1038/sj.bjp.0701556; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; UEDA Y, 2002, J NEUROTRAUM, V19, P1357; Wagerle LC, 1998, J THORAC CARDIOV SUR, V115, P1047, DOI 10.1016/S0022-5223(98)70404-0; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Wei EP, 1999, STROKE, V30, P851, DOI 10.1161/01.STR.30.4.851; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262, DOI 10.1152/ajpheart.1996.271.3.H1262; WEI EP, 2002, J NEUROTRAUM, V19, P1358	46	70	74	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2003	20	4					381	390		10.1089/089771503765172336			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	673YY	WOS:000182609900007	12866817				2022-02-06	
J	Hart, T; Hawkey, K; Whyte, J				Hart, T; Hawkey, K; Whyte, J			Use of a portable voice organizer to remember therapy goals in traumatic brain injury rehabilitation: A within-subjects trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						assistive technology; cognitive remediation; traumatic brain injury	MEMORY-IMPAIRED PATIENTS; EVERYDAY MEMORY; AID; ACQUISITION; RETENTION; DEFICITS	Objective: To test the efficacy of a portable voice organizer in helping people with traumatic brain injury (TBI) to recall therapy goals and plans discussed with their clinical case managers. Design: Prospective within-subjects trial, in which individualized therapy goals were randomly assigned to intervention or no intervention. Setting: Comprehensive postacute TBI rehabilitation program. Participants: Ten people with moderate to severe Till enrolled from 3 months to 18 years after injury. Outcome measure: Memory for therapy goals. Clinicians generated statements describing six current therapy goals, half of which were randomly assigned to be recorded on a voice organizer during the next case management session. Participants selected three times per day to listen to the recorded goals, prompted by an alarm. One-week recall was tested using both free- and cued-recall formats. Results: Recorded goals were recalled better than unrecorded goals and appeared to be associated with better awareness or follow-through with therapy objectives. Conclusion: Portable electronic devices have the potential to assist with treatment areas beyond tasks involving prospective memory.	Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Dept Rehabil Med, Philadelphia, PA 19141 USA; MossRehab, Drucker Brain Injury Ctr, Moss Rehabil Res Inst, Philadelphia, PA USA		Hart, T (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Moss Rehabil Res Inst, Dept Rehabil Med, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474			Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Donaghy S, 1998, BRAIN INJURY, V12, P1061, DOI 10.1080/026990598121963; GILES GM, 1989, AM J OCCUP THER, V43, P409, DOI 10.5014/ajot.43.6.409; GLISKY EL, 1986, NEUROPSYCHOLOGIA, V24, P313, DOI 10.1016/0028-3932(86)90017-5; GLISKY EL, 1986, J CLIN EXP NEUROPSYC, V8, P292, DOI 10.1080/01688638608401320; GLISKY EL, 1995, NEUROPSYCHOL REHABIL, V5, P299, DOI 10.1080/09602019508401474; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Kim HJ, 1999, BRAIN INJURY, V13, P147, DOI 10.1080/026990599121818; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KIRSCH NL, 1987, J HEAD TRAUMA REHAB, V2, P77; KIRSCH NL, 1992, J HEAD TRAUMA REHAB, V7, P13, DOI DOI 10.1097/00001199-199209000-00004; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI DOI 10.1097/00001199-198709000-00009; Prigatano G. P., 1993, NEUROPSYCHOL REHABIL, V3, P53; Sohlberg M.M., 1989, INTRO COGNITIVE REHA; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Wade TK, 2001, BRAIN INJURY, V15, P305, DOI 10.1080/026990501750111256; WEHMAN PH, 1991, ARCH PHYS MED REHAB, V72, P101; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 2001, J NEUROL NEUROSUR PS, V70, P477, DOI 10.1136/jnnp.70.4.477; Wilson BA, 2000, NEUROPSYCHOL REV, V10, P233, DOI 10.1023/A:1026464827874; Wright P, 2001, BRAIN INJURY, V15, P787, DOI 10.1080/02699050110045161; Wright P, 2000, ERGONOMICS, V43, P702, DOI 10.1080/001401300404689	23	70	71	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2002	17	6					556	570		10.1097/00001199-200212000-00007			15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	617NN	WOS:000179367900007	12802246				2022-02-06	
J	de Turco, EBR; Belayev, L; Liu, YT; Busto, R; Parkins, N; Bazan, NG; Ginsberg, MD				de Turco, EBR; Belayev, L; Liu, YT; Busto, R; Parkins, N; Bazan, NG; Ginsberg, MD			Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin	JOURNAL OF NEUROCHEMISTRY			English	Article						arachidonic acid; brain ischemia; docosahexaenoic acid; human albumin; middle cerebral artery occlusion; neuroprotection	IMPROVES NEUROLOGICAL DEFICIT; REDUCES INFARCT VOLUME; TRAUMATIC BRAIN INJURY; D-ASPARTATE ANTAGONIST; DOCOSAHEXAENOIC ACID; ARTERY OCCLUSION; ARACHIDONIC-ACID; CELLULAR UPTAKE; RAT-BRAIN; ELECTROCONVULSIVE SHOCK	Human albumin therapy is highly neuroprotective in focal cerebral ischemia. Because albumin is the main carrier of free fatty acids (FFA) in plasma, we investigated the content and composition of plasma FFA in jugular vein (JV), femoral artery (FA) and femoral vein (FV) of rats given intravenous human albumin (1.25 g/kg) or saline vehicle (5 mL/kg) 1 h after a 2 h middle cerebral artery occlusion (MCAo) or sham surgery. Arachidonic acid was the only FFA significantly increased by MCAo in all plasma samples prior to albumin administration, remaining at the same level regardless of subsequent treatments. Albumin treatment induced in both MCAo- and sham-groups a 1.7-fold increase in total plasma FFA (mainly 16:0, 18:1, 18:2n-6) during 90-min reperfusion. MCAo selectively stimulated the albumin-mediated mobilization of n-3 polyunsaturated fatty acids (PUFA), with an early increase in 22:5n-3 and 22:6n-3 in the FA prior to detectable changes in the JV. In the MCAo-albumin group, the lower level of FFA in JV as compared with FA and FV suggests an albumin-mediated systemic mobilization and supply of FFA to the brain, which may favor the replenishment of PUFA lost from cellular membranes during ischemia and/or to serve as an alternative source of energy, thus contributing to albumin neuroprotection.	Univ Miami, Sch Med, Dept Neurol, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Louisiana State Univ, Hlth Sci Ctr, Sch Med, Neurosci Ctr Excellence, New Orleans, LA USA		Ginsberg, MD (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, POB 016960, Miami, FL 33101 USA.		Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS005820, P50NS005820] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820] Funding Source: Medline		Bazan N G, 1980, Adv Neurol, V28, P197; Bazan NG, 1996, PHARMACOLOGY OF CEREBRAL ISCHEMIA 1996, P173; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bazan NG, 1996, RETINAL DEGENERATION AND REGENERATION, P89; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1992, AM OIL CHEM SOC, P107; BAZAN NG, 1990, NUTR BRAIN, P1; BAZXAN NG, 2001, NEUROPROTECTION BASI, P196; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; Belayev L, 1997, J CEREBR BLOOD F MET, V17, P1266, DOI 10.1097/00004647-199712000-00002; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1999, J NEUROTRAUM, V16, P445, DOI 10.1089/neu.1999.16.445; Belayev L, 1999, BRAIN RES, V845, P107, DOI 10.1016/S0006-8993(99)01952-6; Belayev L, 2001, STROKE, V32, P553, DOI 10.1161/01.STR.32.2.553; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; Bogaert YE, 2000, EXP NEUROL, V161, P115, DOI 10.1006/exnr.1999.7250; BOGAERT YE, 1994, FREE RADICAL BIO MED, V16, P811, DOI 10.1016/0891-5849(94)90197-X; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; deTurco EBR, 1997, J BIOL CHEM, V272, P10491; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ginsberg MD, 1999, ACTA NEUROCHIR SUPPL, V73, P45; Ginsberg MD, 2001, J NEUROSURG, V94, P499, DOI 10.3171/jns.2001.94.3.0499; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; KATSURA K, 1993, J NEUROCHEM, V61, P1677, DOI 10.1111/j.1471-4159.1993.tb09803.x; Kim HY, 2000, J BIOL CHEM, V275, P35215, DOI 10.1074/jbc.M004446200; Lauritzen I, 2000, EMBO J, V19, P1784, DOI 10.1093/emboj/19.8.1784; Liu YT, 2000, BRAIN RES, V862, P111, DOI 10.1016/S0006-8993(00)02078-3; MARCHESELLI VL, 1990, J NUTR BIOCHEM, V1, P382, DOI 10.1016/0955-2863(90)90009-A; MARTIN RE, 1994, J NUTR BIOCHEM, V5, P151, DOI 10.1016/0955-2863(94)90087-6; MOORE SA, 1990, J NEUROCHEM, V55, P391, DOI 10.1111/j.1471-4159.1990.tb04150.x; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MOORE SA, 1993, ADV EXP MED BIOL, V331, P229; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; NAKANO S, 1990, J NEUROCHEM, V54, P1911, DOI 10.1111/j.1471-4159.1990.tb04890.x; Narita K, 2000, NEUROL RES, V22, P393, DOI 10.1080/01616412.2000.11740689; POTTER BJ, 1989, ANNU REV NUTR, V9, P253, DOI 10.1146/annurev.nu.09.070189.001345; Rapoport SI, 2001, J LIPID RES, V42, P678; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; REDDY TS, 1984, EUR J BIOCHEM, V145, P21, DOI 10.1111/j.1432-1033.1984.tb08517.x; REDDY TS, 1985, J NEUROSCI RES, V13, P381, DOI 10.1002/jnr.490130305; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; ROSENTHAL MD, 1987, PROG LIPID RES, V26, P87, DOI 10.1016/0163-7827(87)90009-9; SALEM N, 1995, MOL MEMBR BIOL, V12, P131, DOI 10.3109/09687689509038508; SCOTT BL, 1989, P NATL ACAD SCI USA, V86, P2903, DOI 10.1073/pnas.86.8.2903; SPECTOR AA, 1975, J LIPID RES, V16, P165; TRIGATTI BL, 1995, BIOCHEM J, V308, P155, DOI 10.1042/bj3080155; YOSHIDA S, 1986, J NEUROCHEM, V47, P744; ZHANG JP, 1995, J NEUROCHEM, V64, P1688	54	70	70	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	2002	83	3					515	524		10.1046/j.1471-4159.2002.01121.x			10	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	605KJ	WOS:000178676800004	12390513	Bronze			2022-02-06	
J	Teng, AL; Pinzur, MS; Lomasney, L; Mahoney, L; Havey, R				Teng, AL; Pinzur, MS; Lomasney, L; Mahoney, L; Havey, R			Functional outcome following anatomic restoration of tarsal-metatarsal fracture dislocation	FOOT & ANKLE INTERNATIONAL			English	Article							MIDFOOT	Anatomic restoration of displaced fracture-dislocation of the tarsometatarsal junction of the foot is essential, as even "minor" disruptions of this joint complex leads to poor clinical results. In order to determine a "key" element associated with good or poor functional outcomes, 11 patients with excellent radiographic results following surgical treatment of unilateral closed Lisfranc fracture dislocation of the tarsometatarsal joint of the foot were evaluated at an average of 41.2 (range, 14 to 53) months following their injury and surgery. Their average age was 40.6 (range, 21 to 58) years. AOFAS midfoot scores averaged 71.0 (range, 30 to 95). Radiographic analysis at follow-up revealed anatomic reduction in 10 of 11. Eight of 11 had evidence of arthritis of the tarsometatarsal joints. Clinical alignment was normal in all subjects, with nine of 11 clinically exhibiting decreased relative range of motion. Gait analysis was performed with the F-Scan (Tekscan, Boston, MA) in-shoe pressure-monitoring system. Vertical ground reaction force was recorded under the hallux, first metatarsal head, lateral metatarsals, and heel. Stance phase duration, rate of loading, rate of unloading, peak loading, and total loading were recorded at each of the named regions. There was no statistical difference in the parameters measured between the injured and normal control feet.	Loyola Univ, Ctr Med, Dept Orthopaed Surg & Rehabil, Maywood, IL 60153 USA; Loyola Univ, Ctr Med, Dept Radiol, Maywood, IL 60153 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA		Pinzur, MS (corresponding author), Loyola Univ, Ctr Med, Dept Orthopaed Surg & Rehabil, 2160 S 1st Ave, Maywood, IL 60153 USA.						Ahroni JH, 1998, FOOT ANKLE INT, V19, P668, DOI 10.1177/107110079801901004; AITKEN AP, 1963, J BONE JOINT SURG AM, V45, P246, DOI 10.2106/00004623-196345020-00003; ARNTZ CT, 1988, J BONE JOINT SURG AM, V70A, P173, DOI 10.2106/00004623-198870020-00003; BRUNET JA, 1987, J BONE JOINT SURG BR, V69, P437, DOI 10.1302/0301-620X.69B3.3108261; Coester LM, 2001, J BONE JOINT SURG AM, V83A, P219, DOI 10.2106/00004623-200102000-00009; Corbett M L, 1993, Foot Ankle, V14, P520; GOOSSENS, 1982, CLIN ORTHOP, V176, P154; GRANBERRY WM, 1962, SURG GYNECOL OBSTET, V114, P467; KELLGREN JH, 1952, BRIT MED J, V1, P181, DOI 10.1136/bmj.1.4751.181; KITAOKA HB, 1994, FOOT ANKLE INT, V15, P349, DOI 10.1177/107110079401500701; Kuo RS, 2000, J BONE JOINT SURG AM, V82A, P1609, DOI 10.2106/00004623-200011000-00015; Lakin RC, 2001, J BONE JOINT SURG AM, V83A, P520, DOI 10.2106/00004623-200104000-00006; MYERSON MS, 1986, FOOT ANKLE, V6, P225, DOI 10.1177/107110078600600504; Pinzur MS, 1997, FOOT ANKLE INT, V18, P635, DOI 10.1177/107110079701801006	14	70	76	0	3	AMER ORTHOPAEDIC FOOT & ANKLE SOC, INC	SEATTLE	2517 EASTLAKE AVE EAST, STE 200, SEATTLE, WA 98102 USA	1071-1007			FOOT ANKLE INT	Foot Ankle Int.	OCT	2002	23	10					922	926		10.1177/107110070202301006			5	Orthopedics	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics	603PH	WOS:000178568000006	12398144				2022-02-06	
J	Prasad, MR; Ewing-Cobbs, L; Swank, PR; Kramer, L				Prasad, MR; Ewing-Cobbs, L; Swank, PR; Kramer, L			Predictors of outcome following traumatic brain injury in young children	PEDIATRIC NEUROSURGERY			English	Article						outcome; Glasgow coma scale; Glasgow outcome scale; child abuse; brain injury; children; infants; neuroimaging	SEVERE HEAD-INJURY; GLASGOW COMA SCALE; AGE; RECOVERY; INFANTS; ABUSE; PRESCHOOLERS; MECHANISMS; CHILDHOOD; PROGNOSIS	The relationship between clinical and neuroimaging variables and multiple outcome measures was examined in a longitudinal, prospective study of 60 children less than 6 years of age who sustained either inflicted or noninflicted traumatic brain injury. Hierarchical multiple regression indicated that the modified Glasgow Coma Scale score, the duration of impaired consciousness and the number of intracranial lesions visualized on CT/MRI accounted for a significant amount of the variance in the Glasgow Outcome Scale (GOS), cognitive and motor scores at baseline, 3- and 12-month evaluations. Inflicted brain injury adversely affected both GOS and cognitive outcomes. Pupillary abnormalities were associated with poorer motor outcome. Neither age at injury nor the Injury Severity Score accounted for significant variability in outcomes. Copyright (C) 2002 S. Karger AG, Basel.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA		Prasad, MR (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7000 Fannin,Suite 2431, Houston, TX 77030 USA.	Mary.R.Prasad@uth.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029462] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS29462] Funding Source: Medline		Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; APPELBAUM AS, 1977, J ABNORM CHILD PSYCH, V5, P417, DOI 10.1007/BF00915089; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRUCE DA, 1978, J NEUROSURG, V48, P679, DOI 10.3171/jns.1978.48.5.0679; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; COSTEFF H, 1990, J NEUROSURG, V73, P684, DOI 10.3171/jns.1990.73.5.0684; Crouchman M, 2001, ARCH DIS CHILD, V84, P120, DOI 10.1136/adc.84.2.120; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; HAHN YS, 1983, CHILD BRAIN, V10, P229; HAHN YS, 1988, CHILD NERV SYST, V4, P34; HOFFMANPLOTKIN D, 1984, CHILD DEV, V55, P794, DOI 10.2307/1130130; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LUERSSEN TG, 2001, PEDIAT NEUROSURGERY, P601; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; McCarthy, 1972, MCCARTHY SCALES CHIL; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; Ong LC, 1996, PEDIATR NEUROSURG, V24, P285, DOI 10.1159/000121057; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; REILLY PL, 1988, CHILD NERV SYST, V4, P30; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; Thorndike R. L., 1986, STANFORD BINET INTEL; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617	45	70	73	1	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1016-2291	1423-0305		PEDIATR NEUROSURG	Pediatr. Neurosurg.	FEB	2002	36	2					64	74		10.1159/000048355			11	Clinical Neurology; Pediatrics; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pediatrics; Surgery	531QN	WOS:000174427100002	11893887				2022-02-06	
J	Hoofien, D; Vakil, E; Gilboa, A; Donovick, PJ; Barak, OHR				Hoofien, D; Vakil, E; Gilboa, A; Donovick, PJ; Barak, OHR			Comparison of the predictive power of socioeconomic variables, severity of injury and age on long-term outcome of traumatic brain injury: sample-specific variables versus factors as predictors	BRAIN INJURY			English	Article							COMMUNITY INTEGRATION; HEAD-INJURY; REHABILITATION; RECOVERY; ABILITY	The primary objective of this study was to measure the predictive power of pre-injury socio-economic status (SES), severity of injury and age variables on the very long-term outcomes of traumatic brain injury (TBI). By applying a within-subjects retroactive Follow-up design and a factor analysis, the study also compared the relative power of sample-specific predictors to that of more commonly used variables and conceptually based factors. Seventy-six participants with severe TBI were evaluated at an average of 14 years post-injury with in extensive neuropsychological battery. The results show that pre-injury SES variables predict long-term cognitive, psychiatric, vocational, and social/familial functioning. Measures of severity of injury Predict daily functioning, while age at injury fails to predict any of these variables. Sample-specific predictors were more powerful than more commonly used predictors. Implications regarding long-term clinically based and conceptually based prediction, and those regarding comparisons of predictors across samples are further discussed.	Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel; Bar Ilan Univ, Ramat Gan, Israel; SUNY Binghamton, Binghamton, NY USA		Hoofien, D (corresponding author), Hebrew Univ Jerusalem, Dept Psychol, IL-91905 Jerusalem, Israel.	mshoofi@mscc.huji.ac.il					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BROSCH I, 2000, MEGAMOT, V40, P198; Chamberlain M. A., 1995, TRAUMATIC BRAIN INJU, P3; Derogatis L.R., 1977, SCL 90 MANUAL SCORIN; Diringer MN, 1997, ARCH NEUROL-CHICAGO, V54, P606, DOI 10.1001/archneur.1997.00550170078017; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming J, 1999, BRAIN INJURY, V13, P417; GAL R, 1986, PORTRAIT ISRAELI SOL, P81; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Haslam E., 1992, PHENOLIC COMPOUNDS F, P8; Hoofien D, 2001, BRAIN INJURY, V15, P189; HOOFIEN D, 1994, FINAL REPORT COMPREH; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JENNETT B, 1975, LANCET, V1, P480; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Melamed S, 1999, SCAND J REHABIL MED, V31, P23; MELAMED S, 1985, SCAND J REHABIL MED, P129; Millis S R, 1994, Int J Neurosci, V79, P165; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Roe A., 1956, PSYCHOL OCCUPATIONS, P76; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; Sherer M, 1999, BRAIN INJURY, V13, P973; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; SOLOMON Z, 1988, BEHAV MED, V14, P171, DOI 10.1080/08964289.1988.9935142; SOLOMON Z, 1992, BRIT J CLIN PSYCHOL, V31, P21, DOI 10.1111/j.2044-8260.1992.tb00965.x; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; TEASDALE G, 1974, LANCET, V2, P81; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; Wechsler, 1997, WECHSLER ADULT INTEL; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	39	70	70	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2002	16	1					9	27		10.1080/02699050110088227			19	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	515BM	WOS:000173475600002	11796096				2022-02-06	
J	Luis, CA; Mittenberg, W				Luis, CA; Mittenberg, W			Mood and anxiety disorders following pediatric traumatic brain injury: A prospective study	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; PSYCHIATRIC-DISORDERS; CHILDREN; ADOLESCENTS; SEQUELAE; INTERVIEWS	Studies utilizing standardized instruments for assessing mood and/or anxiety disorders following pediatric traumatic brain injury have seldom been reported in the literature. Previous reports have largely focused on cognitive impairment, behavioral dysfunction, or adaptive functioning, and have typically relied on parental informants. In this study, children hospitalized for mild (N = 42) and moderate/severe (N = 19) brain injury were assessed 6-months postinjury using the Anxiety disorders Module A and the Mood disorders Module C of the Diagnostic Interview Schedule for Children - IV Revision (DISC-IV). The data collected for the brain injury groups were compared to an orthopedic control group (N = 35). The relationship between a new onset mood and/or anxiety disorder (NOD) and injury severity indices was examined. Sequential logistical regression was also utilized to examine the impact of a brain injury, demographic variables, preinjury psychiatric disturbance, development disorders, litigation status and postinjury environmental stress on emotional outcome. Results indicated a relationship between brain injury and NOD. Multivariate analysis demonstrated that postinjury level of stress and severity of brain injury were the most robust predictors of NOD, accounting for 23% of the variance in the model. These results support the premise that the development of a mood and/or anxiety disorder following pediatric head injury is mediated by multiple determinants. The findings suggest that early psychosocial assessment and interventions aimed at increasing a child's coping may attenuate the emotional consequences of pediatric brain injury.	Nova SE Univ, Ctr Psychol Studies, Ft Lauderdale, FL 33314 USA		Luis, CA (corresponding author), 13251 SW 16th Ct, Davie, FL 33325 USA.						ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Achenbach TM, 1991, MANUAL CHILD BEHAV C; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BARRY C, 1997, 25 ANN M INT NEUR SO; Binder LM, 1997, AM J PSYCHIAT, V154, P135; BLACK P, 1981, BRAIN DYSFUNCTION CH, P171; BLOOM D, 1999, J INT NEUROPSYCH SOC, V5, P127; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CODDINGTON RD, 1972, J PSYCHOSOM RES, V16, P7, DOI 10.1016/0022-3999(72)90018-9; DiGallo A, 1997, BRIT J PSYCHIAT, V170, P358, DOI 10.1192/bjp.170.4.358; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; FALLON T, 1994, J CHILD PSYCHOL PSYC, V35, P1391, DOI 10.1111/j.1469-7610.1994.tb01282.x; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; HODGES K, 1993, J CHILD PSYCHOL PSYC, V34, P49, DOI 10.1111/j.1469-7610.1993.tb00967.x; Kaplan H., 1994, SYNOPSIS PSYCHIAT; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1979, CHILD BRAIN, V5, P281; Lund R., 1985, Journal of Vertebrate Paleontology, V5, P1; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P94, DOI 10.1097/00004583-199701000-00022; Max JE, 1997, J NERV MENT DIS, V185, P394, DOI 10.1097/00005053-199706000-00006; MCGUIRE TL, 1986, J HEAD TRAUMA REHAB, V1, P106; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W., 1997, CLIN NEUROPSYCHOL, V11, P305; PATRICK PD, 1998, BRAIN INJURY SOURCE, V2, P26; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Woodward H, 1999, J HEAD TRAUMA REHAB, V14, P351, DOI 10.1097/00001199-199908000-00004; ZAHNER GEP, 1991, J AM ACAD CHILD PSY, V30, P659, DOI 10.1097/00004583-199107000-00020	40	70	72	0	10	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2002	24	3					270	279		10.1076/jcen.24.3.270.982			10	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	549MR	WOS:000175448400002	11992209				2022-02-06	
J	Cushman, JG; Agarwal, N; Fabian, TC; Garcia, V; Nagy, KK; Pasquale, MD; Salotto, AG				Cushman, JG; Agarwal, N; Fabian, TC; Garcia, V; Nagy, KK; Pasquale, MD; Salotto, AG			Practice management guidelines for the management of mild traumatic brain injury: The EAST Practice Management Guidelines Work Group	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article							MINOR HEAD-INJURY; INTRACRANIAL INJURY; COMPUTED-TOMOGRAPHY; SKULL RADIOGRAPHY; CT SCANS; RISK; CLASSIFICATION; SEQUELAE; RECOVERY; TALK		Lehigh Valley Hosp, Div Trauma Surg Crit Care, Dept Surg, Allentown, PA 18105 USA; Wyntrebrooke SA, York, PA USA; Univ Tennessee, Memphis, TN USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Cook Cty Hosp, Chicago, IL 60612 USA; Rush Univ, Chicago, IL 60612 USA		Pasquale, MD (corresponding author), Lehigh Valley Hosp, Div Trauma Surg Crit Care, Dept Surg, POB 689,Cedar Crest & I-78, Allentown, PA 18105 USA.						ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; Bailes JE, 1999, SPORTS-RELATED CONCUSSION, P115; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BASSETT SS, 1990, J PEDIATR PSYCHOL, V15, P225, DOI 10.1093/jpepsy/15.2.225; BEERS SR, 1992, NEUROPSYCHOL REV, V3, P281, DOI 10.1007/BF01108414; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Camins M B, 1996, Bull Am Coll Surg, V81, P16; Camins MB, 1996, B AM COLL SURG, V81, P47; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HAALAND KY, 1994, J CLIN EXP NEUROPSYC, V16, P448, DOI 10.1080/01688639408402655; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; HIGH WM, 1990, J CLIN EXP NEUROPSYC, V12, P703, DOI 10.1080/01688639008401013; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1978, Practitioner, V221, P77; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Kelly JP, 1997, NEUROLOGY, V48, P581; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; Klein M, 1996, J NERV MENT DIS, V184, P459, DOI 10.1097/00005053-199608000-00002; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin HS, 1996, NEUROTRAUMA, P749; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MURSHID WR, 1994, ACTA NEUROCHIR, V129, P11, DOI 10.1007/BF01400866; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARKER RS, 1994, SEMIN NEUROL, V14, P67, DOI 10.1055/s-2008-1041061; REILLY PL, 1975, LANCET, V2, P375; REIMER W, 1995, BRAIN INJURY, V9, P55, DOI 10.3109/02699059509004572; Rhodes M, 1993, J TRAUMA, V35, P979; RHODES M, 1996, NEUROTRAUMA, P991; Riesgo P, 1997, SURG NEUROL, V48, P226, DOI 10.1016/S0090-3019(97)00194-8; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; ROS S P, 1989, Pediatric Emergency Care, V5, P216, DOI 10.1097/00006565-198912000-00003; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SERVADEI F, 1988, J NEUROL NEUROSUR PS, V51, P526, DOI 10.1136/jnnp.51.4.526; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STEIN SC, 1996, NEUROTRAUMA, P755; SZYMANSKI HV, 1992, INT J PSYCHIAT MED, V22, P357, DOI 10.2190/XARA-B1EF-J2HC-VAE0; TAHERI PA, 1993, ARCH SURG-CHICAGO, V128, P289; Veltman R H, 1993, J Neurosci Nurs, V25, P367; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; Wilberger J E Jr, 1997, Bull Am Coll Surg, V82, P29; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WISNER DH, 1993, ADV TRAUMA CRIT CARE, V8, P183	73	70	72	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2001	51	5					1016	1026		10.1097/00005373-200111000-00034			11	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Surgery	495QJ	WOS:000172351600041	11706358				2022-02-06	
J	Arand, M; Melzner, H; Kinzl, L; Bruckner, UB; Gebhard, F				Arand, M; Melzner, H; Kinzl, L; Bruckner, UB; Gebhard, F			Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans	LANGENBECKS ARCHIVES OF SURGERY			English	Article						traumatic brain injury; inflammatory response; interleukin-6; interleukin-12; malone dialdehyde	ACUTE-PHASE RESPONSE; HEAD-INJURY; CEREBROSPINAL-FLUID; ADHESION MOLECULES; INTERLEUKIN-6; PLASMA; EPIDEMIOLOGY; HYPOTHERMIA; CYTOKINES; SEVERITY	The inflammatory response following isolated traumatic brain injury (TBI) is characterised by the release of pro- and anti-inflammatory mediators. In order to determine the important mediators regarding survival and outcome of patients with severe traumatic isolated head injuries, we performed this prospective preclinical and clinical study starting upon arrival at the site of the accident. After approval by the local ethics board committee, 94 multiple-injury patients were. enrolled. Of these, 72 patients suffered from major injuries; the other 22 patients had a severe isolated brain injury and were allotted to subsets of survival or nonsurvival. Of the pro- and antiinflammatory mediators (cytokines, arachidonic acid metabolites and soluble adhesion molecules), interleukin-6 (IL-6), IL-12 and malone dialdehyde (MDA) appeared to be of specific importance; maximum IL-6 plasma levels were eightfold higher in cases of nonsurvival than in those of survival. Patients that did not survive TBI were the only ones to express an IL-12 increase, whereas survivors and patients with other major trauma did not show any increase within the first 24 h. An early distinct decrease of MDA showed in patients who did not survive TBI, in contrast to survivor patients who exposed almost constant levels during the first 24 h.	Univ Ulm, Dept Trauma Surg Hand & Reconstruct Surg, D-89075 Ulm, Germany		Gebhard, F (corresponding author), Univ Ulm, Dept Trauma Surg Hand & Reconstruct Surg, Steinhovelstr 9, D-89075 Ulm, Germany.						BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bell MJ, 1997, ACT NEUR S, V70, P96; Bitsch A, 1998, STROKE, V29, P2129, DOI 10.1161/01.STR.29.10.2129; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hans VHJ, 1999, NEUROREPORT, V10, P409; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; KOCHANEK P, 1997, TRAUMATIC BRAIN INJU, V6, P2; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; KOSSMANN T, 1996, SHOCK SEPSIS ORGAN F, P263; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MORGANTIKOSSMAN.MC, 1997, IMMUNE RESPONSES NER, P159; MOVAT HZ, 1987, J LAB CLIN MED, V110, P668; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; Povlishock JT, 1999, ACT NEUR S, V73, P15; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Stahel PF, 1998, NEUROSCI LETT, V249, P123, DOI 10.1016/S0304-3940(98)00410-8; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; WESTCOTT JY, 1987, PROSTAGLANDINS, V34, P877, DOI 10.1016/0090-6980(87)90068-2; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767	31	70	81	0	3	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	1435-2443			LANGENBECK ARCH SURG	Langenbecks Arch. Surg.	JUL	2001	386	4					241	248		10.1007/s004230100204			8	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	461AA	WOS:000170341700001	11466564				2022-02-06	
J	Becker, KJ				Becker, KJ			Targeting the central nervous system inflammatory response in ischemic stroke	CURRENT OPINION IN NEUROLOGY			English	Article							FOCAL CEREBRAL-ISCHEMIA; C-REACTIVE PROTEIN; TRAUMATIC BRAIN INJURY; NF-KAPPA-B; MATRIX METALLOPROTEINASES; TRANSGENIC MICE; PROINFLAMMATORY CYTOKINES; CARDIOVASCULAR-DISEASE; MODERATE HYPOTHERMIA; IL-6 EXPRESSION	In experimental models of stroke, inflammation appears to contribute to cerebral ischemic injury. Clinical trials that are aimed at limiting the postischemic inflammatory response, however, have thus far had disappointing results. These clinical failures probably reflect the fact that there has been insufficient preclinical data and inadequate trial design, rather than provide evidence against a role for inflammation in ischemic brain injury. Curr Opin Neurol 14:349-353. (C) 2001 Lippincott Williams & Wilkins.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Seattle, WA 98104 USA		Becker, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Box 359775,325 9th Ave, Seattle, WA 98104 USA.		Becker, Kyra/L-1420-2019	Becker, Kyra/0000-0002-8310-4846	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [KO2 NS02160-01 NST] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K02NS002160] Funding Source: NIH RePORTER		Ahmed SH, 2000, STROKE, V31, P193, DOI 10.1161/01.STR.31.1.193; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Albertsson P, 2000, IN VIVO, V14, P269; Ali C, 2000, J CEREBR BLOOD F MET, V20, P956, DOI 10.1097/00004647-200006000-00008; Allan SM, 2000, J CEREBR BLOOD F MET, V20, P1409, DOI 10.1097/00004647-200010000-00002; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Becker K, 2001, STROKE, V32, P206, DOI 10.1161/01.STR.32.1.206; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Berman NEJ, 1999, NEUROBIOL DIS, V6, P486, DOI 10.1006/nbdi.1999.0261; Block F, 2000, NEUROREPORT, V11, P963, DOI 10.1097/00001756-200004070-00013; Bond M, 1998, FEBS LETT, V435, P29, DOI 10.1016/S0014-5793(98)01034-5; Bordet R, 2000, J CEREBR BLOOD F MET, V20, P1190, DOI 10.1097/00004647-200008000-00004; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Calapai G, 2000, EUR J PHARMACOL, V401, P349, DOI 10.1016/S0014-2999(00)00466-0; Carlson NG, 1999, J IMMUNOL, V163, P3963; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; Clark WM, 1999, NEUROL RES, V21, P287, DOI 10.1080/01616412.1999.11740933; Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; DiSanto E, 1996, BRAIN RES, V740, P239, DOI 10.1016/S0006-8993(96)00865-7; Ducrocq S, 2000, J NEUROCHEM, V74, P2504, DOI 10.1046/j.1471-4159.2000.0742504.x; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; Fassbender K, 1999, STROKE, V30, P1647, DOI 10.1161/01.STR.30.8.1647; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; Ford ES, 2000, ARTERIOSCL THROM VAS, V20, P1052, DOI 10.1161/01.ATV.20.4.1052; Forster C, 1999, ACTA NEUROPATHOL, V97, P215, DOI 10.1007/s004010050977; Fujimura M, 1999, BRAIN RES, V842, P92, DOI 10.1016/S0006-8993(99)01843-0; Furuya K, 2000, STROKE, V31, P277; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Harkness KA, 2000, BRAIN, V123, P698, DOI 10.1093/brain/123.4.698; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hill JK, 1999, BRAIN RES, V820, P45, DOI 10.1016/S0006-8993(98)01140-8; Ikonomidis I, 1999, CIRCULATION, V100, P793, DOI 10.1161/01.CIR.100.8.793; Johansson A, 2000, J INTERN MED, V247, P179, DOI 10.1046/j.1365-2796.2000.00600.x; Kano T, 2000, BRAIN RES, V854, P245, DOI 10.1016/S0006-8993(99)02276-3; Kawai N, 2000, STROKE, V31, P1982, DOI 10.1161/01.STR.31.8.1982; Kim MH, 2000, J IMMUNOL, V164, P5883, DOI 10.4049/jimmunol.164.11.5883; Lapchak PA, 2000, STROKE, V31, P3034, DOI 10.1161/01.STR.31.12.3034; Legos JJ, 2000, NEUROSCI LETT, V282, P189, DOI 10.1016/S0304-3940(00)00907-1; Letterio JJ, 2000, CYTOKINE GROWTH F R, V11, P81, DOI 10.1016/S1359-6101(99)00031-3; Loddick SA, 1998, J CEREBR BLOOD F MET, V18, P176, DOI 10.1097/00004647-199802000-00008; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Moalem G, 2000, J AUTOIMMUN, V15, P331, DOI 10.1006/jaut.2000.0441; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moncayo J, 2000, NEUROLOGY, V54, P2089, DOI 10.1212/WNL.54.11.2089; Nomura F, 2000, J IMMUNOL, V164, P3476, DOI 10.4049/jimmunol.164.7.3476; Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Relton JK, 2001, STROKE, V32, P199, DOI 10.1161/01.STR.32.1.199; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Savitz SI, 2000, J CEREBR BLOOD F MET, V20, P1197, DOI 10.1097/00004647-200008000-00005; SHERMAN DG, 1997, NEUROLOGY, V48, pA270; Shimakura A, 2000, BRAIN RES, V858, P55, DOI 10.1016/S0006-8993(99)02431-2; Toyoda T, 2000, J NEUROSURG, V92, P435, DOI 10.3171/jns.2000.92.3.0435; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vila N, 2000, J INTERF CYTOK RES, V20, P325, DOI 10.1089/107999000312478; Vila N, 2000, STROKE, V31, P2325, DOI 10.1161/01.STR.31.10.2325; Vos CMP, 2000, J NEUROIMMUNOL, V109, P221, DOI 10.1016/S0165-5728(00)00308-8; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Wyss-Coray T, 2000, AM J PATHOL, V156, P139, DOI 10.1016/S0002-9440(10)64713-X	67	70	74	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2001	14	3					349	353		10.1097/00019052-200106000-00014			5	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	439NM	WOS:000169123400014	11371759				2022-02-06	
J	Kline, AE; Yu, J; Horvath, E; Marion, DW; Dixon, CE				Kline, AE; Yu, J; Horvath, E; Marion, DW; Dixon, CE			The selective 5-HT1a receptor agonist repinotan HCL attenuates histopathology and spatial learning deficits following traumatic brain injury in rats	NEUROSCIENCE			English	Article						trauma; neuroprotection; recovery; learning; controlled cortical impact injury	CONTROLLED CORTICAL IMPACT; ACUTE SUBDURAL-HEMATOMA; TRANSIENT FOREBRAIN ISCHEMIA; GLOBAL CEREBRAL-ISCHEMIA; EXCITATORY AMINO-ACIDS; REDUCED EVOKED RELEASE; CENTRAL-NERVOUS-SYSTEM; POSTTRAUMATIC HYPOTHERMIA; MODERATE HYPOTHERMIA; NEUROTROPHIC FACTOR	The selective 5-HT1A receptor agonist Repinotan HCl (BAY x3702) has been reported to attenuate cortical damage and improve functional performance in experimental models of cerebral ischemia and acute subdural hematoma. Using a clinically relevant contusion model of traumatic brain injury, we tested the hypothesis that a 4-h continuous infusion of Repinotan HCl (10 mug/kg/h i.v.) commencing 5 min post-injury would ameliorate functional outcome and attenuate histopathology. Forty isoflurane-anesthetized male adult rats were randomly assigned to receive either a controlled cortical impact (2.7 mm tissue deformation, 4 m/s) or sham injury (Injury/Vehicle = 10, Injury/MK-801 = 10, Injury/Repinotan HCl = 10, Sham/Vehicle = 10), then tested for vestibulomotor function on post-operative days 1-5 and for spatial learning on days 14-18. Neither Repinotan HCI nor the non-competitive N-methyl-D-aspartate receptor antagonist MK-801, which served as a positive control. improved vestibulomotor function on beam balance and beam walk tasks relative to the Injury/Vehicle group, but both did significantly attenuate spatial learning and memory deficits on a water maze task. Repinotan HCI also reduced hippocampal CAI and CA,,, neuronal loss, as welt as cortical tissue damage, compared to the Injury/Vehicle group at 4 weeks post-trauma. No significant difference in histological outcome was revealed between the Repinotan HCl- and MK-801-treated groups. These findings extend the therapeutic efficacy of Repinotan HCI to a contusion model of experimental brain injury and demonstrate for the first time that 5-HT1A receptor agonists confer neuroprotection and attenuate spatial learning deficits following controlled cortical impact injury. This treatment strategy may be beneficial in a clinical context where memory impairments are common following human traumatic brain injury. (C) 2001 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Bayer AG, CNR Res, D-42096 Wuppertal, Germany; Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurosurg, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA		Dixon, CE (corresponding author), 3430 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Marion, Donald/AAR-5749-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS040125, P01NS030318, R01NS033150, P20NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS30318, NS40125] Funding Source: Medline		Ahlemeyer B, 2000, BRAIN RES, V858, P121, DOI 10.1016/S0006-8993(99)02438-5; Ahlemeyer B, 1999, EUR J PHARMACOL, V370, P211, DOI 10.1016/S0014-2999(99)00136-3; Alessandri B, 1999, BRAIN RES, V845, P232, DOI 10.1016/S0006-8993(99)01948-4; Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; ANDRADE R, 1992, DRUG DEVELOP RES, V26, P275, DOI 10.1002/ddr.430260307; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Busto R, 1997, J NEUROTRAUM, V14, P35, DOI 10.1089/neu.1997.14.35; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Cryan JF, 1999, J PSYCHOPHARMACOL, V13, P278, DOI 10.1177/026988119901300310; De Vry J, 1998, J PHARMACOL EXP THER, V284, P1082; De Vry J, 1998, EUR J PHARMACOL, V357, P1, DOI 10.1016/S0014-2999(98)00503-2; De Vry Jean, 1997, Drugs of the Future, V22, P341; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Galter D, 2000, MOL CELL NEUROSCI, V15, P446, DOI 10.1006/mcne.2000.0841; GERLACH I, 1998, J NEUROTRAUM, V15, P870; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; HAYES RL, 1994, SEMIN NEUROL, V14, P25, DOI 10.1055/s-2008-1041055; HJORTH S, 1985, J NEURAL TRANSM, V61, P131, DOI 10.1007/BF01253058; Horvath E., 1997, Society for Neuroscience Abstracts, V23, P1923; HORVATH E, 1997, J NEUROTRAUMA ABSTR, V14, P170; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kiprianova I, 1999, EXP NEUROL, V159, P511, DOI 10.1006/exnr.1999.7109; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2001, HEAD TRAUMA, P65; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Matsushita Y, 2000, J NEUROTRAUM, V17, P143, DOI 10.1089/neu.2000.17.143; Matsuyama S, 1996, BRAIN RES, V728, P175, DOI 10.1016/0006-8993(96)00395-2; Mauler F, 2001, BRAIN RES, V888, P150, DOI 10.1016/S0006-8993(00)03074-2; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; Melena J, 2000, EUR J PHARMACOL, V406, P319, DOI 10.1016/S0014-2999(00)00688-9; MILLAN MJ, 1993, J PHARMACOL EXP THER, V264, P1364; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.3.CO;2-9; Phillips LL, 1997, J NEUROSCI RES, V49, P197; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAITERI M, 1991, J PHARMACOL EXP THER, V257, P1184; RINK A, 1995, AM J PATHOL, V147, P1575; Schaper C, 2000, BRAIN RES, V883, P41, DOI 10.1016/S0006-8993(00)02876-6; Semkova I, 1998, EUR J PHARMACOL, V359, P251, DOI 10.1016/S0014-2999(98)00634-7; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Stover JF, 1999, J NEUROTRAUM, V16, P135, DOI 10.1089/neu.1999.16.135; Suchanek B, 1998, EUR J PHARMACOL, V355, P95, DOI 10.1016/S0014-2999(98)00469-5; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Torup L, 2000, EUR J PHARMACOL, V395, P137, DOI 10.1016/S0014-2999(00)00175-8; Tsuchida E, 1997, J NEUROTRAUM, V14, P409, DOI 10.1089/neu.1997.14.409; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yan HQ, 2000, BRAIN RES, V887, P134, DOI 10.1016/S0006-8993(00)03002-X; Yan Q, 1997, J COMP NEUROL, V378, P135; Yan Q, 1997, NEUROSCIENCE, V78, P431, DOI 10.1016/S0306-4522(96)00613-6; Yang K, 1996, J NEUROSCI RES, V44, P157, DOI 10.1002/(SICI)1097-4547(19960415)44:2<157::AID-JNR8>3.0.CO;2-C	87	70	77	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2001	106	3					547	555		10.1016/S0306-4522(01)00300-1			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	483NH	WOS:000171640800006	11591455				2022-02-06	
J	Mahone, EM; Koth, CW; Cutting, L; Singer, HS; Denckla, MB				Mahone, EM; Koth, CW; Cutting, L; Singer, HS; Denckla, MB			Executive function in fluency and recall measures among children with Tourette syndrome or ADHD	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article; Proceedings Paper	27th Annual Meeting of the International-Neuropsychological-Society	FEB, 1999	BOSTON, MASSACHUSETTS	Int Neuropsychol Soc		Tourette syndrome; executive function; attention deficit/hyperactivity disorder; verbal fluency; verbal learning	DEFICIT HYPERACTIVITY DISORDER; FRONTAL-SUBCORTICAL CIRCUITS; CONTINUOUS PERFORMANCE-TEST; CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; VERBAL FLUENCY; BASAL GANGLIA; WORKING-MEMORY; DESIGN FLUENCY; HEALTHY-ADULTS	This study assessed two relevant aspects of executive dysfunction in children with either Tourette syndrome (TS) or ADHD. Process variables derived from existing neuropsychological measures were used to clarify the executive function construct. Clustering of responses on measures of verbal fluency, figural fluency, and verbal learning was examined to assess strategic response organization. Rule breaks, intrusions, and repetition errors were recorded to assess inhibition errors. No significant differences were found among the three groups (TS, ADHD, and controls) on tasks of response organization (clustering). In our sample, both the ADHD and the TS groups were largely free from executive function impairment. and their performance on thr fluency and list learning tasks was in the average range. There was a significant group difference on one of the disinhibition variables, with both TS and ADHD groups showing significantly more intrusions on verbal list learning trials than controls. When more traditional total score variables were analyzed among the three groups, there were no significant differences; however, analysis of effect size revealed medium-to-large effect sizes for Letter Word Fluency total score differences (ADHD vs. controls), and for Semantic Word Fluency total score differences (ADHD vs. TS), with the ADHD group having weaker performance in both comparisons. Results provide some support for the use and analysis of process variables-particularly those related to inhibition and intrusion errors, in addition to the total score variables when assessing executive function deficits in children with ADHD and TS. While group differences may be found, children with uncomplicated TS should not routinely be considered to have significant executive function impairments, and when deficits are found, they may be attributable to other comorbid disorders.	Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD 21205 USA; Kennedy Krieger Inst, Dept Dev Cognit Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA		Mahone, EM (corresponding author), Kennedy Krieger Inst, Dept Neuropsychol, 707 N Broadway,5th Floor TWR, Baltimore, MD 21205 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD024061] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD-24061] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-25806] Funding Source: Medline		Achenbach TM, 1991, MANUAL CHILD BEHAV C; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; ALYWARD EH, 1996, J CHILD NEUROL, V11, P112; Barkley R.A., 1997, ADHD NATURE SELF CON; BAUMGARDNER TL, 1996, NEUROLOGY, V47, P1; BAXTER LR, 1993, HDB TOURETTES SYNDRO, P298; BEEBE DW, 2000, J INT NEUROPSYCH SOC, V6, P107; Castellanos FX, 1996, ARCH GEN PSYCHIAT, V53, P607; CASTRO AM, 1994, PLANT BREEDING, V112, P151, DOI 10.1111/j.1439-0523.1994.tb00663.x; Cohen J., 2013, STAT POWER ANAL BEHA; Cornoldi C, 1999, DEV NEUROPSYCHOL, V15, P53; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; De Beni R, 1998, Q J EXP PSYCHOL-A, V51, P305, DOI 10.1080/713755761; Demakis GJ, 1997, PSYCHOL REP, V81, P443; Denckla M B, 1994, FRAMES REFERENCE ASS, P117; Denckla MB, 1996, DEV NEUROPSYCHOL, V12, P5, DOI 10.1080/87565649609540637; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; DUPAUL GJ, 1998, ADHD RATING SCALE, V0004; DUPAUL GR, 1991, J CLIN CHILD PSYCHOL, V20, P2425; Elfgren CI, 1998, NEUROPSYCHOLOGIA, V36, P505, DOI 10.1016/S0028-3932(97)00146-2; ELIS D, 1994, CALIFORNIA VERBAL LE; FAHN S, 1993, ARCH NEUROL-CHICAGO, V50, P1013; Filipek PA, 1997, NEUROLOGY, V48, P589, DOI 10.1212/WNL.48.3.589; GERSHBERG FB, 1995, NEUROPSYCHOLOGIA, V33, P1305, DOI 10.1016/0028-3932(95)00103-A; HALL TM, 1991, NUCL MED STATE ART N, P243; Harris E L, 1995, J Int Neuropsychol Soc, V1, P511; Heilman K. M., 1994, NIH C ATT MEM EX FUN; Heishman SJ, 1999, PSYCHOL ADDICT BEHAV, V13, P227; Hill D, 1999, ARCH CLIN NEUROPSYCH, V14, P692, DOI 10.1016/S0887-6177(99)80139-5; HYND GW, 1990, ARCH NEUROL-CHICAGO, V47, P919, DOI 10.1001/archneur.1990.00530080107018; HYND GW, 1993, J CHILD NEUROL, V8, P339, DOI 10.1177/088307389300800409; Kane H, 1994, World Watch, V7, P33; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levy F, 1997, J PAEDIATR CHILD H, V33, P384; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mahone EM, 1999, ARCH CLIN NEUROPSYCH, V14, P12, DOI 10.1093/arclin/14.1.12; Mataix-Cols D, 1999, J NEUROPSYCH CLIN N, V11, P395, DOI 10.1176/jnp.11.3.395; MEGA MS, 1994, J NEUROPSYCH CLIN N, V6, P358; OZONOFF S, 1994, J CHILD PSYCHOL PSYC, V35, P1015, DOI 10.1111/j.1469-7610.1994.tb01807.x; Parkin AJ, 1996, BRAIN COGNITION, V32, P14, DOI 10.1006/brcg.1996.0055; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; PETERSON B, 1993, NEUROLOGY, V43, P941, DOI 10.1212/WNL.43.5.941; Pineda D, 1999, J LEARN DISABIL, V32, P159, DOI 10.1177/002221949903200206; READER MJ, 1994, DEV NEUROPSYCHOL, V10, P493, DOI 10.1080/87565649409540598; RIDDLE MA, 1992, ADV NEUROL, V58, P208; Robert PH, 1998, J INT NEUROPSYCH SOC, V4, P539, DOI 10.1017/S1355617798466025; RUFF RM, 1994, ARCH CLIN NEUROPSYCH, V9, P41, DOI 10.1016/0887-6177(94)90013-2; Schuerholz LJ, 1997, J CHILD NEUROL, V12, P438, DOI 10.1177/088307389701200705; Schuerholz LJ, 1996, NEUROLOGY, V46, P958, DOI 10.1212/WNL.46.4.958; SCHUERHOLZ LJ, 1998, J CLIN NEUROLOGY, V13, P27; Shucard DW, 1997, NEUROPSYCHOLOGY, V11, P147, DOI 10.1037/0894-4105.11.1.147; SINGER HS, 1993, NEUROLOGY, V43, P950, DOI 10.1212/WNL.43.5.950; SINGER HS, 1994, BRAIN DEV-JPN, V16, P353, DOI 10.1016/0387-7604(94)90122-8; SINGER HS, 1995, J CHILD NEUROL, V10, pS58, DOI 10.1177/08830738950100S112; Spencer T, 1998, J CHILD PSYCHOL PSYC, V39, P1037, DOI 10.1017/S0021963098002984; SUTHERLAND RJ, 1982, GILLES TOURETTE SYND, P311; Troyer AK, 1998, J INT NEUROPSYCH SOC, V4, P137, DOI 10.1017/S1355617798001374; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Turner MA, 1999, J CHILD PSYCHOL PSYC, V40, P189, DOI 10.1111/1469-7610.00432; Vaidya CJ, 1998, P NATL ACAD SCI USA, V95, P14494, DOI 10.1073/pnas.95.24.14494; Varney NR, 1996, ARCH CLIN NEUROPSYCH, V11, P345, DOI 10.1016/0887-6177(95)00015-1; VIC P, 1988, DEV NEUROPSYCHOL, V4, P63; WECHSLER D, 1992, WECHSLER INDIVIDUAL; WOZNIAK JR, 1998, J INT NEUROPSYCH SOC, V4, P42; Yeates KO, 1994, NEUROPSYCHOLOGY, V8, P65, DOI 10.1037/0894-4105.8.1.65; Zimmerman IL, 1997, PERCEPT MOTOR SKILL, V85, P531; [No title captured]; [No title captured]	68	70	73	0	7	CAMBRIDGE UNIV PRESS	PORT CHESTER	110 MIDLAND AVE, PORT CHESTER, NY 10573-4930 USA	1355-6177			J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2001	7	1					102	111		10.1017/S1355617701711101			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	427UX	WOS:000168424800010	11253836				2022-02-06	
J	Brookshire, BL; Chapman, SB; Song, J; Levin, HS				Brookshire, BL; Chapman, SB; Song, J; Levin, HS			Cognitive and linguistic correlates of children's discourse after closed bead injury: A three-year follow-up	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed head injury; children; discourse	TRAUMATIC BRAIN INJURY; HEAD-INJURY; NARRATIVE DISCOURSE; ADOLESCENTS; CHILDHOOD; COMPREHENSION; IMPAIRMENTS; PERFORMANCE; ADULTHOOD; RECALL	The discourse of 91 children who had sustained severe (n = 68) or mild (n = 23) closed head injury (CHI) was examined at least three years postinjury. The groups' retellings of a narrative story were analyzed according to two domains, information and language. In comparison to the mild CHI group, the severe group produced stories characterized by reduced content and information, impaired organization, fewer words, and less complex sentences. The relationships between discourse production and the groups' performance on measures of language, executive function, memory, and processing speed were examined. Correlations were found between discourse production and general verbal ability including verbal fluency. Correlations were also found for discourse performance and executive function measures associated with problem solving and working memory. Site and extent of lesion were not useful in predicting discourse production. These findings indicate that children who sustain a severe closed head injury during early to middle childhood are at risk for persisting deficits in discourse processing and other cognitive abilities.	Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Univ Texas, Callier Ctr Commun Disorders, Dallas, TX 75230 USA		Levin, HS (corresponding author), Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 1333 Moursund Ave,Rm A205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; BADDELEY A, 1988, BRAIN COGNITION, V7, P212, DOI 10.1016/0278-2626(88)90031-0; Baddeley A.D., 1987, WORKING MEMORY; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Brownell, 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; CHAPMAN SB, 1995, J HEAD TRAUMA REHAB, V10, P36, DOI 10.1097/00001199-199510000-00006; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COELHO CA, 1995, BRAIN INJURY, V9, P471, DOI 10.3109/02699059509008206; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DENCKLA M B, 1974, Cortex, V10, P186; DENNIS M, 1991, DEV NEUROPSYCHOL, V7, P327, DOI 10.1080/87565649109540497; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DREWE E A, 1975, Cortex, V11, P8; Dunn LM., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1998, J CLIN EXPT NEUROPSY, V20, P1; GAIDOLFI E, 1980, ITAL J NEUROL SCI, V1, P65; GRAFMAN J, 1995, TRAUMATIC HEAD INJUR, P235; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; HISCOCK M, 1987, BRAIN COGNITION, V6, P24, DOI 10.1016/0278-2626(87)90044-3; Hunt K. W., 1965, 3 NAT COUNC TEACH EN; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JENNETT B, 1975, LANCET, V1, P480; JOHNSON DA, 1989, CHILDRENS HEAD INJUR, P96; JORDAN FM, 1994, BRAIN INJURY, V8, P501, DOI 10.3109/02699059409151002; JORDAN FM, 1988, BRAIN INJURY, V2, P175; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Klonoff H, 1995, TRAUMATIC HEAD INJUR, P219; Kufera J. A., 1997, AM J SPEECH-LANG PAT, V6, P66, DOI 10.1044/1058-0360.0602.66; Labov W., 1972, LANGUAGE INNER CITY; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin H. S., 1994, NEUROPSYCHOLOGY, V87, P171, DOI DOI 10.1037/0894-4105.8.2.171; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MANDLER JM, 1977, COGNITIVE PSYCHOL, V9, P111, DOI 10.1016/0010-0285(77)90006-8; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; ROTH FP, 1986, J SPEECH HEAR DISORD, V51, P8, DOI 10.1044/jshd.5101.08; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Ulatowska H. K., 1994, DISCOURSE ANAL APPL, P29; Van Dijk TA., 1983, STRATEGIES DISCOURSE; van Dijk Teun, 1980, MACROSTRUCTURES; VANDIJK TA, 1985, HDB DISCOURSE ANAL; Wechsler D., 1974, WECHSLER INTELLIGENC; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yorkston KM, 1997, ARCH PHYS MED REHAB, V78, P1096, DOI 10.1016/S0003-9993(97)90134-9; [No title captured]; [No title captured]; [No title captured]	63	70	72	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	NOV	2000	6	7					741	751		10.1017/S1355617700677019			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	370QG	WOS:000165133300001	11105464				2022-02-06	
J	Bredesen, DE				Bredesen, DE			Apoptosis: Overview and signal transduction pathways	JOURNAL OF NEUROTRAUMA			English	Article						programmed cell death; caspase; physiological cell death; neurodegeneration; neurotrauma	PROGRAMMED CELL-DEATH; KEEPING NEURONS ALIVE; CYTOCHROME-C; BRAIN INJURY; SYMPATHETIC NEURONS; PROTOONCOGENE BCL-2; MOLECULAR CONTROL; GENE-EXPRESSION; CASPASE FAMILY; NEURAL CELLS	Apoptosis is a form of cell death that is driven by an intrinsic cellular suicide program, The roles of apoptosis and other forms of programmed cell death in neural development, maintenance, and disease states are increasingly being recognized and defined, Therapies directed at the apoptotic program have seen at least some degree of success in animal models of neurodegenerative disease, vascular disease, and traumatic CNS injury, This article describes the signal transduction pathways that mediate apoptosis, Broadly speaking, intrinsic and extrinsic pathways for apoptosis activation may be distinguished, as can be cross-talk between these two, These pathways converge on a system of proteases referred to as "capases" (cysteinyl aspartic proteinases), and modulators exist that multimerize, activate, amplify, or inhibit caspases, Activated caspases are the executioners of the apoptotic program, and carry out this function by cleaving specific cellular substrates, Modulation of this process holds promise as a therapeutic approach in neurotrauma.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA		Bredesen, DE (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033376, R01NS035155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012282] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12282] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35155, NS33376] Funding Source: Medline		Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056; Bredesen DE, 1996, NEUROSCIENTIST, V2, P211, DOI 10.1177/107385849600200409; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1996, NEUROSCIENTIST, V2, P181, DOI 10.1177/107385849600200313; BREDESEN DE, 1999, NEURAL NOTES, V70, P31; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; Conti AC, 1998, J NEUROSCI, V18, P5663; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Ellerby LM, 1999, J NEUROCHEM, V72, P185, DOI 10.1046/j.1471-4159.1999.0720185.x; Ellerby LM, 1999, J BIOL CHEM, V274, P8730, DOI 10.1074/jbc.274.13.8730; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Frasch SC, 2000, J BIOL CHEM, V275, P23065, DOI 10.1074/jbc.M003116200; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HERSHBERGER PA, 1992, J VIROL, V66, P5525, DOI 10.1128/JVI.66.9.5525-5533.1992; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOCKSHIN RA, 1964, J INSECT PHYSIOL, V10, P643, DOI 10.1016/0022-1910(64)90034-4; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; MARTIN DP, 1992, J NEUROBIOL, V23, P1205, DOI 10.1002/neu.480230911; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MIYASHITA T, 1995, CELL, V80, P293; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; MYERS KM, 1995, J NEUROCHEM, V65, P2432; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PILAR G, 1976, J CELL BIOL, V68, P339, DOI 10.1083/jcb.68.2.339; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; Reed JC, 1999, P NATL ACAD SCI USA, V96, P7614, DOI 10.1073/pnas.96.14.7614; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; SCHWARTZ LM, 1991, BIOESSAYS, V13, P389, DOI 10.1002/bies.950130805; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zhong L. T., 1992, Society for Neuroscience Abstracts, V18, P44; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZHONG LT, 1993, MOL BRAIN RES, V19, P353, DOI 10.1016/0169-328X(93)90139-G; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	74	70	76	1	8	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2000	17	10					801	810		10.1089/neu.2000.17.801			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	364LR	WOS:000089894300002	11063049				2022-02-06	
J	Gaviria, M; Privat, A; d'Arbigny, P; Kamenka, JM; Haton, H; Ohanna, F				Gaviria, M; Privat, A; d'Arbigny, P; Kamenka, JM; Haton, H; Ohanna, F			Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats	BRAIN RESEARCH			English	Article						critical time window; Gacyclidine; N-Methyl-D-aspartate; contusive spinal cord injury; secondary injury; neurochemical cascade	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; GLUTAMATE NEUROTOXICITY; EXTRACELLULAR LEVELS; HYDROXYL RADICALS; IN-VITRO; MECHANISMS; MICRODIALYSIS; RECEPTORS; SECONDARY	The aim of this study was to analyze the optimal time-window for neuroprotection by a novel NMDA antagonist, Gacyclidine, after experimental spinal cord injury, in terms of its functional, histopathological and electrophysiological effects. This molecule has already demonstrated its capacity for reducing the extent of an ischemic lesion and is currently experimented in a clinical trial of spinal cord injury. In this study, the spinal cord of rats was damaged by a contusive method and the animals were treated by saline or 1 mg/kg of Gacyclidine i.v., 10, 30, 60 and 120 min after injury. The time-course of the motor score was evaluated on days 1, 7 and 18 after injury, and somatosensory evoked potentials were determined on day 20. The animals were then killed and the cross-sectional area of the spinal cord (at the epicenter of the injury, above and below the injury), was measured. Walking recovery was better (P<0.0125) in the group treated 10 min after injury than in the untreated injured animals after 18 days of injury. Motor performances were related to the preservation of a larger undamaged area of spinal cord at the level of the injury (P<0.0125). Somatosensory evoked potential amplitudes were also higher in this group. These results confirm that Gacyclidine attenuates spinal cord damage after an experimental spinal cord lesion. Recovery was better within the group treated 10 min after injury compared with the other groups, which certainly confirms that the acute time-course of glutamate release requires rapid pharmacological intervention to achieve good results. (C) 2000 Elsevier Science B.V. All rights reserved.	Ctr PROPARA, Lab Neurophysiol Clin, F-34195 Montpellier, France; Ctr PROPARA, Lab Chirurg Fonct Expt, F-34195 Montpellier, France; USTL, INSERM, U336, F-34095 Montpellier, France; Beaufour Ipsen, Res & Dev, F-75781 Paris, France; ENSCM, CNRS, UPR 1086, F-34296 Montpellier, France; Fac Med Montpellier, Lab Physiopathol Malad Neuromusculaires, F-34000 Montpellier, France		Gaviria, M (corresponding author), Ctr PROPARA, Lab Neurophysiol Clin, Parc Euromed, F-34195 Montpellier, France.	mgaviria@club-internet.fr; manuelgaviri@hotmail.com	Gaviria, Manuel/AAH-4403-2019	Gaviria, Manuel/0000-0001-6106-6538			Allen AR., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; BAKER AJ, 1993, J NEUROSURG, V79, P369, DOI 10.3171/jns.1993.79.3.0369; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BIRCH PJ, 1988, EUR J PHARMACOL, V151, P313, DOI 10.1016/0014-2999(88)90814-X; BLACK P, 1988, NEUROSURGERY, V22, P51, DOI 10.1227/00006123-198801000-00008; BRESNAHAN JC, 1976, J NEUROL SCI, V28, P521, DOI 10.1016/0022-510X(76)90122-2; CAMERON T, 1990, EXP NEUROL, V109, P214, DOI 10.1016/0014-4886(90)90076-5; Cauquil-Caubere I, 1999, J NEUROSCI RES, V56, P160, DOI 10.1002/(SICI)1097-4547(19990415)56:2<160::AID-JNR5>3.0.CO;2-C; Cauquil-Caubere I, 1998, EUR J MED CHEM, V33, P867, DOI 10.1016/S0223-5234(99)80011-7; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Drian MJ, 1999, J NEUROSCI RES, V57, P927, DOI 10.1002/(SICI)1097-4547(19990915)57:6<927::AID-JNR18>3.0.CO;2-C; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; GALE K, 1985, EXP NEUROL, V88, P123, DOI 10.1016/0014-4886(85)90118-9; Gaviria M, 2000, J NEUROTRAUM, V17, P19, DOI 10.1089/neu.2000.17.19; GOMEZPINILLA F, 1989, EXP NEUROL, V104, P118, DOI 10.1016/S0014-4886(89)80004-4; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; Hebel R., 1986, ANATOMY EMBRYOLOGY L; Juurlink BHJ, 1997, NEUROSCI BIOBEHAV R, V21, P151, DOI 10.1016/S0149-7634(96)00005-X; KAMENKA JM, 1982, J MED CHEM, V25, P431, DOI 10.1021/jm00346a019; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; Kuhn PL, 1998, J NEUROTRAUM, V15, P125, DOI 10.1089/neu.1998.15.125; Lancelot E, 1998, BRAIN RES, V809, P294, DOI 10.1016/S0006-8993(98)00942-1; LIU DX, 1993, BRAIN RES, V609, P293, DOI 10.1016/0006-8993(93)90885-Q; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; Lu YM, 1996, J NEUROSCI, V16, P5457; MAIER CM, 1995, J NEUROCHEM, V65, P652; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Michaelis EK, 1998, PROG NEUROBIOL, V54, P369, DOI 10.1016/S0301-0082(97)00055-5; MOLANDER C, 1984, J COMP NEUROL, V230, P133, DOI 10.1002/cne.902300112; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANJABI MM, 1988, SPINE, V13, P1365, DOI 10.1097/00007632-198812000-00007; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; PRIVAT A, 1990, ACTUAL CHIM THER, V17, P187; RAINES A, 1988, Journal of Neurotrauma, V5, P151, DOI 10.1089/neu.1988.5.151; Ribotta MGY, 1998, CURR OPIN NEUROL, V11, P647, DOI 10.1097/00019052-199812000-00007; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; RONDOUIN G, 1988, NEUROSCI LETT, V91, P199, DOI 10.1016/0304-3940(88)90768-9; Rosenberg LJ, 1999, J NEUROSCI, V19, P464, DOI 10.1523/JNEUROSCI.19-01-00464.1999; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; SIESJO BK, 1985, BRIT J ANAESTH, V57, P47, DOI 10.1093/bja/57.1.47; SYKOVA E, 1992, PROG BRAIN RES, V94, P47; TARLOV IM, 1954, AMA ARCH NEUROL PSY, V71, P588, DOI 10.1001/archneurpsyc.1954.02320410050004; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7	58	70	74	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 25	2000	874	2					200	209		10.1016/S0006-8993(00)02581-6			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	350NK	WOS:000089107800013	10960605				2022-02-06	
J	Nakagawa, Y; Reed, L; Nakamura, M; McIntosh, TK; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Lee, VMY; Trojanowski, JQ				Nakagawa, Y; Reed, L; Nakamura, M; McIntosh, TK; Smith, DH; Saatman, KE; Raghupathi, R; Clemens, J; Saido, TC; Lee, VMY; Trojanowski, JQ			Brain trauma in aged transgenic mice induces regression of established A beta deposits	EXPERIMENTAL NEUROLOGY			English	Article						Alzheimer's disease; amyloid plaques; brain injury; head trauma; PDAPP mice	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; HEAD-INJURY; SENILE PLAQUES; CELL-DEATH; MEMORY DEFICITS; NERVOUS-SYSTEM; NEURON DEATH; MOUSE MODEL	Traumatic brain injury (TBI) increases susceptibility to Alzheimer's disease (AD), but it is not known if TBI affects the progression of AD. To address this question, we studied the neuropathological consequences of TBI in transgenic (TG) mice with a mutant human A beta precursor protein (APP) mini-gene driven by a platelet-derived (PD) growth factor promoter resulting in overexpression of mutant APP (V717F), elevated brain A beta levels, and AD-like amyloidosis. Since brain A beta deposits first appear in 6-month-old TG (PDAPP) mice and accumulate with age, 2-year-old PDAPP and wild-type (WT) mice were subjected to controlled cortical impact (CCI) TBI or sham treatment. At 1, 9, and 16 weeks after TBI, neuron loss, gliosis, and atrophy were most prominent near the CCI site in PDAPP and WT mice. However, there also was a remarkable regression in the A beta amyloid plaque burden in the hippocampus ipsilateral to TBI compared to the contralateral hippocampus of the PDAPP mice by 16 weeks postinjury. Thus, these data suggest that previously accumulated A beta plaques resulting from progressive amyloidosis in the AD brain also may be reversible. (C) 2000 Academic Press.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anatom Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Fukuoka, Japan; Eli Lilly Inc, Indianapolis, IN USA		Nakagawa, Y (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Anatom Pathol,Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA.		Sado, Takaomi/AAN-2759-2021; smith, douglas/A-1321-2007; Raghupathi, Ramesh/AAX-5538-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG09215, AG11542] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM34690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542, P01AG009215] Funding Source: NIH RePORTER		ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; Arnold SE, 1998, ARCH GEN PSYCHIAT, V55, P225, DOI 10.1001/archpsyc.55.3.225; BUXBAUM JD, 1993, BIOCHEM BIOPH RES CO, V197, P639, DOI 10.1006/bbrc.1993.2527; Chen KS, 1998, PROG BRAIN RES, V117, P327; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Cummings BJ, 1996, NEUROBIOL AGING, V17, P921, DOI 10.1016/S0197-4580(96)00170-4; CURZ L, 1997, P NATL ACAD SCI USA, V94, P7612; Dickson DW, 1999, AM J PATHOL, V154, P1627, DOI 10.1016/S0002-9440(10)65416-8; Dickson DW, 1997, J NEUROPATH EXP NEUR, V56, P321, DOI 10.1097/00005072-199704000-00001; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Frautschy SA, 1998, AM J PATHOL, V152, P307; FUNG KM, 1995, AM J PATHOL, V146, P1376; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; GOEDERT M, 1997, MOL GENETIC BASIS NE, P613; Guillery RW, 1997, J COMP NEUROL, V386, P2, DOI 10.1002/(SICI)1096-9861(19970915)386:1<2::AID-CNE2>3.0.CO;2-6; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HSIAO KK, 1997, MOL MECH DEMENTIA, P39; HYMAN BT, 1993, J NEUROPATH EXP NEUR, V52, P594, DOI 10.1097/00005072-199311000-00006; Irizarry MC, 1997, J NEUROPATH EXP NEUR, V56, P965, DOI 10.1097/00005072-199709000-00002; Irizarry MC, 1997, J NEUROSCI, V17, P7053; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Iwatsubo T, 1996, AM J PATHOL, V149, P1823; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; LEE VMY, 1984, J NEUROCHEM, V42, P25, DOI 10.1111/j.1471-4159.1984.tb09692.x; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Loring JF, 1996, NEUROBIOL AGING, V17, P173, DOI 10.1016/0197-4580(95)02076-4; Masliah E, 1996, J NEUROSCI, V16, P5795; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MORRISONBOGORAD M, 1997, MOL GENETIC BASIS NE, P581; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Namura S, 1998, J NEUROSCI, V18, P3659; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; PEARSON BE, 1993, P NATL ACAD SCI USA, V90, P10578, DOI 10.1073/pnas.90.22.10578; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; REAUME AG, 1996, J BIOL CHEM, V271, P2338; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROCKENSTEIN E, 1995, J BIOL CHEM, V47, P28257; Saido TC, 1996, NEUROSCI LETT, V215, P173, DOI 10.1016/S0304-3940(96)12970-0; Saido TC, 1998, NEUROBIOL AGING, V19, pS69, DOI 10.1016/S0197-4580(98)00033-5; SAIDO TC, 1995, NEURON, V14, P1; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schmidt ML, 1998, ACTA NEUROPATHOL, V95, P117, DOI 10.1007/s004010050774; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1997, MOL GENETIC BASIS NE, P601; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shin RW, 1997, J NEUROSCI, V17, P8187; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Stalder M, 1999, AM J PATHOL, V154, P1673, DOI 10.1016/S0002-9440(10)65423-5; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Su Y, 1998, J NEUROSCI RES, V53, P177, DOI 10.1002/(SICI)1097-4547(19980715)53:2<177::AID-JNR6>3.0.CO;2-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281	76	70	70	0	4	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2000	163	1					244	252		10.1006/exnr.2000.7375			9	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	313NV	WOS:000087006500027	10785464				2022-02-06	
J	Kelly, DF; Kozlowski, DA; Haddad, E; Echiverri, A; Hovda, DA; Lee, SM				Kelly, DF; Kozlowski, DA; Haddad, E; Echiverri, A; Hovda, DA; Lee, SM			Ethanol reduces metabolic uncoupling following experimental head injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; ethanol; excitotoxicity; glucose metabolism; NMDA receptor; traumatic brain injury	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; CORTICAL IMPACT MODEL; EXTRACELLULAR LEVELS; ALCOHOL INGESTION; CONTUSION TRAUMA; RAT; INTOXICATION; ACETATE; EXCITOTOXICITY	Previous investigations have shown that ethanol is neuroprotective following experimental traumatic brain injury (TBI). This study sought to determine if the neuroprotective effects of ethanol in a controlled cortical impact (CCI) injury model are related to its effects on cerebral glucose metabolism and blood flow. Adult rats were given ethanol (1.0 g/kg) or saline by intraperitoneal injection followed 40 min later by injury. Regional cerebral blood flow (CBF) and cerebral metabolic rates of glucose (CMRglc) were determined immediately, and at 3, 6, 12, 24, and 72 h postinjury using quantitative autoradiography. Immediately after injury, CMRglc in the contusion core and penumbra was reduced in the ethanol group compared to the saline group: (core CMRglc: 52.2 +/- 16.0 versus 94.2 +/- 14.1 mu mol/100 g/min, respectively, p < 0.001; penumbral CMRglc: 58.2 +/- 12.8 versus 82.8 +/- 19.7 mu mol/100 g/min, respectively; p < 0.05) However, at 24 and 72 h postinjury, penumbral CMRglc in the ethanol group was increased compared to the saline group (p < 0.05 and p < 0.001, respectively). Regarding CBF, contusion core values in the ethanol group were elevated compared to the saline group immediately postinjury, (70.4 +/- 17.1 versus 31.5 +/- 27.8 mL/100 g/min, respectively (p < .05), and at 6, 12, and 24 h postinjury (p < 0.05). Penumbral CBF was also higher at 6 and 72 h in the ethanol group compared to the saline group (p < 0.05). These results indicate that low-dose ethanol is associated with a marked attenuation of immediate postinjury hyperglycolysis and with more normal glucose metabolism in the injury penumbra over the ensuing 3 days. Simultaneously, the reduction in CBF typically seen within the contusion core and penumbra after CCI is less severe when ethanol is present. The net effect of these changes is a decreased degree of uncoupling between glucose metabolism and CBF that otherwise occurs in the absence of ethanol. These changes may likely explain the neuroprotective effect of ethanol.	Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA		Kelly, DF (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Room 18-218A NPI,Box 957039, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37363, NS 27544, NS 30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037363, P50NS030308, R01NS027544] Funding Source: NIH RePORTER		ABEL EL, 1979, PHYSIOL PSYCHOL, V7, P391; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALTURA BM, 1982, FED PROC, V41, P2447; BARBOUR RL, 1993, ALCOHOL CLIN EXP RES, V17, P1319, DOI 10.1111/j.1530-0277.1993.tb05248.x; BENGMARK S, 1980, THROMB HAEMOSTASIS, V43, P203; BLOOM F, 1982, BRIT J PHARMACOL, V75, P251, DOI 10.1111/j.1476-5381.1982.tb08780.x; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; BRUNO R, 1983, FORENSIC SCI INT, V21, P215, DOI 10.1016/0379-0738(83)90125-1; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; BUTCHER T, 1951, KLIN WOCHENSCHR, V20, P615; CARMICHAEL FJ, 1991, J PHARMACOL EXP THER, V259, P403; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; DEWIT H, 1990, ALCOHOL CLIN EXP RES, V14, P482; DEYKIN D, 1982, NEW ENGL J MED, V306, P852, DOI 10.1056/NEJM198204083061406; DIXON CE, 1991, J NEUROSCI METH, V39, P253; ECKARDT MJ, 1988, BRAIN RES, V444, P53, DOI 10.1016/0006-8993(88)90912-2; ELMER O, 1984, HAEMOSTASIS, V14, P223; FERRARO TN, 1990, ALCOHOL, V7, P129, DOI 10.1016/0741-8329(90)90073-L; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GERSHMAN H, 1991, Journal of Emergency Medicine, V9, P307, DOI 10.1016/0736-4679(91)90371-L; GRANT KA, 1990, EUR J PHARMACOL, V176, P289, DOI 10.1016/0014-2999(90)90022-X; GULYA K, 1991, BRAIN RES, V547, P129; HALT PS, 1992, ARCH NEUROL-CHICAGO, V49, P1178, DOI 10.1001/archneur.1992.00530350096025; HANNAK D, 1985, BIOL CHEM H-S, V366, P749, DOI 10.1515/bchm3.1985.366.2.749; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; Ikonomidou C, 1996, METAB BRAIN DIS, V11, P125, DOI 10.1007/BF02069500; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KELLY DF, 1995, CRIT CARE MED, V23, pA245; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LITTLE HJ, 1986, LIFE SCI, V39, P2059, DOI 10.1016/0024-3205(86)90356-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LOVINGER DM, 1993, ALCOHOL CLIN EXP RES, V17, P19, DOI 10.1111/j.1530-0277.1993.tb00720.x; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; Maeda T, 1998, J NEUROTRAUM, V15, P655, DOI 10.1089/neu.1998.15.655; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; MATHEW RJ, 1991, AM J PSYCHIAT, V148, P292; MATHEW RJ, 1986, STROKE, V17, P1156, DOI 10.1161/01.STR.17.6.1156; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MONTPIED P, 1991, MOL PHARMACOL, V39, P157; NEWLIN DB, 1982, INT J NEUROSCI, V17, P145, DOI 10.3109/00207458208985916; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OTT JF, 1985, ALCOHOL CLIN EXP RES, V9, P59, DOI 10.1111/j.1530-0277.1985.tb05051.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59, DOI 10.1152/ajpheart.1978.234.1.H59; SANO M, 1993, J STUD ALCOHOL, V54, P369, DOI 10.15288/jsa.1993.54.369; SCHWARTZ JA, 1993, ALCOHOL CLIN EXP RES, V17, P1119, DOI 10.1111/j.1530-0277.1993.tb05217.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKADERA T, 1990, BRAIN RES, V537, P109, DOI 10.1016/0006-8993(90)90346-D; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; VOLKOW ND, 1990, PSYCHIAT RES-NEUROIM, V35, P39, DOI 10.1016/S0165-1781(06)80006-5; WALLER PF, 1986, JAMA-J AM MED ASSOC, V256, P1461, DOI 10.1001/jama.256.11.1461; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WENDT PE, 1994, J CEREBR BLOOD F MET, V14, P963, DOI 10.1038/jcbfm.1994.129; WHITE G, 1990, BRAIN RES, V507, P332, DOI 10.1016/0006-8993(90)90292-J; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983	72	70	70	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2000	17	4					261	272		10.1089/neu.2000.17.261			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	302LA	WOS:000086365500001	10776911				2022-02-06	
J	Cusick, CP; Gerhart, KA; Mellick, DC				Cusick, CP; Gerhart, KA; Mellick, DC			Participant-proxy reliability in traumatic brain injury outcome research	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; outcomes research; proxy ratings reliability and validity; surveys	QUALITY-OF-LIFE; SIGNIFICANT OTHERS; HEAD-INJURY; FUNCTIONAL STATUS; PATIENT HEALTH; COMMUNITY; SATISFACTION; INDIVIDUALS; RECOVERY; HANDICAP	Objective: To assess reliability between persons with Traumatic Brain Injury (TBT) and their self-selected proxies. Design: Intraclass Correlation Coefficients were used to assess participant-proxy reliability on the Craig Handicap Assessment and Reporting Technique (CHART), the Community Integration Questionnaire (CIQ), and the Functional Independence Measure (FIM). Setting: Participants had been discharged to the community from inpatient rehabilitation between six months and approximately five years prior to the study's beginning. Participants: 204 persons with moderate to severe TBI and their self-selected proxies. Results: Eighty-seven percent of the items on the three instruments exhibited moderate to high intraclass correlation (ICC), with strongest participant-proxy agreement for questions assessing con crete, observable information. Participant-proxy agreement was poorest when assessing cognitive and money management capacity as well as out-of-home activities. Conclusions: For many types of items, participant-proxy reliability is sufficient to merit the use of proxies in TBI outcome research when the participants are allowed to select their own proxy.	Craig Hosp, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80110 USA		Cusick, CP (corresponding author), Craig Hosp, Rocky Mt Reg Brain Injury Syst, 3425 S Clarkson St, Englewood, CO 80110 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B30041] Funding Source: Medline		BLAND JM, 1990, COMPUT BIOL MED, V20, P337, DOI 10.1016/0010-4825(90)90013-F; Brooks CA, 1997, ARCH PHYS MED REHAB, V78, pS26, DOI 10.1016/S0003-9993(97)90152-0; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; BURTON LA, 1993, J REHABILITATION OCT, P34; CLARRIDGE BR, 1989, MED CARE, V27, P352, DOI 10.1097/00005650-198904000-00003; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dijkers M., 1991, J AM PARAPLEGIA SOC, V14, P85; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; GRANGER CV, 1997, ASSESSING MED REHABI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Kurtz JE, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199806000-00002; Long K, 1998, J AM GERIATR SOC, V46, P1103, DOI 10.1111/j.1532-5415.1998.tb06648.x; MAGAZINER J, 1988, J CLIN EPIDEMIOL, V41, P1065, DOI 10.1016/0895-4356(88)90076-5; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; ROTHMAN ML, 1991, MED CARE, V29, P115, DOI 10.1097/00005650-199102000-00004; SCHMIDT MF, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199508000-00003; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Sneeuw KCA, 1997, MED CARE, V35, P490, DOI 10.1097/00005650-199705000-00006; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WEINBERGER M, 1992, J AM GERIATR SOC, V40, P585, DOI 10.1111/j.1532-5415.1992.tb02107.x; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1993, J HEAD TRAUMA REHABI, V0003, P00075, DOI DOI 10.1097/00001199-199308020-00009; WILSON BA, 1997, J REHABILITATION OUT, V1, P60; World Health Organization, 1980, INT CLASS IMP DIS HA; 1996, GUIDE UNIFORM DATA S	32	70	70	0	0	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	FEB	2000	15	1					739	749		10.1097/00001199-200002000-00012			11	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	287MX	WOS:000085510800013	10745189				2022-02-06	
J	Hibbard, MR; Gordon, WA; Flanagan, S; Haddad, L; Labinsky, E				Hibbard, MR; Gordon, WA; Flanagan, S; Haddad, L; Labinsky, E			Sexual dysfunction after traumatic brain injury	NEUROREHABILITATION			English	Article						traumatic brain injury; sexual dysfunction	INDIVIDUALS; MEN	Objective: The frequency of self reported sexual difficulties was examined in a group of 322 individuals with traumatic brain injury (TBI) (N = 193 men; 129 women) and contrasted with reports of sexual difficulties in 264 individuals without disability (152 men; 112 women) residing in the community. Physiological, physical, and body images problems impacting sexual functioning were examined individually and then summed into a sexual dysfunction score. Mood, quality of life, health status and presence of an endocrine disorder were examined as predictors of sexual difficulties post TBI. Study design: In this retrospective study, data about sexual difficulties were analyzed separately for men and women with TBI and without disability. ANOVAs with post hoc analysis for continuous variables, chi-square analyses for categorical variables, and ANCOVAs for predictors of sexual difficulties were utilized. Results: When contrasted to individuals without disability, individuals with TBI reported more frequent: (1) physiological difficulties influencing their energy for sex; sex drive, ability to initiate sexual activities and achieve orgasm; (2) physical difficulties influencing body positioning, body movement and sensation, and (3) body image difficulties influencing feelings of attractive and comfort with having a partner view one's body;during sexual activity. Additional gender specific TBI findings were observed. In comparison to gender matched groups without disability, men with TBI reported less frequent involvement in sexual activity and relationships, and more frequent difficulties in sustaining an erection; women with TBI reported more frequent difficulties in sexual arousal, pain with sex, masturbation and:vaginal lubrication. While groups differed in core demographic variables, age was the only demographic variable that was related to reports of sexual difficulties in individuals with TBI and men without disability. Age at onset and severity of injury were negatively related to reports of sexual difficulties in individuals with TBI. In men with TBI and without disability, the most sensitive predictor of sexual dysfunction was;level of depression. For women without disability, an endocrine disorder was the most sensitive predictor of sexual dysfunction. For women with TBI, an endocrine disorder and level depression combined were the most sensitive predictors of sexual difficulties. Conclusion: Individuals Post TBI report frequent physiological, physical and:body images difficulties which negatively impact sexual activity and interest. For men post TBI, predictors of sexual difficulties included age at interview, age at injury, and having milder injuries, however, depression was the most sensitive predictor of sexual dysfunctions. For women post TBI, predictors of their sexual difficulties included age at injury and having milder injuries, however, depression and Bn endocrine disorder combined were the most sensitive predictors of sexual dysfunction. implications of this study include the need for broad-based assessment of sexual dysfunction, and the implementation of treatment studies to enhance sexual functioning post TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA		Hibbard, MR (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, 1425 Madison Ave,Room L4-21, New York, NY 10029 USA.	mary.hibbard@mssm.edu	; Carneiro D'Albuquerque, Luiz Augusto/A-8812-2013	Fernandez Agis, Inmaculada/0000-0002-3160-5569; Flanagan, Steven/0000-0001-9005-5897; Haddad, Lisa/0000-0002-7631-6760; Carneiro D'Albuquerque, Luiz Augusto/0000-0001-7607-7168			Aloni A, 1999, BRAIN INJURY, V13, P89, DOI 10.1080/026990599121755; *AM PSYCH ASS, 1994, DIAGN STAT MAN, P494; Andrews F. M., 1976, SOCIAL INDICATORS WE; BARRECA T, 1980, J CLIN ENDOCR METAB, V51, P1279, DOI 10.1210/jcem-51-6-1279; Bartlik B, 1999, PSYCHIAT ANN, V29, P27, DOI 10.3928/0048-5713-19990101-08; BASSON R, 1995, OBSTET GYNECOL, V4, pS54; Beck AT, 1987, BECK DEPRESSION INVE; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Cernak I, 1999, BRAIN INJURY, V13, P1005; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; CHIOLERO RL, 1988, ACTA ENDOCRINOL-COP, V117, P80, DOI 10.1530/acta.0.1170080; Cole TM, 1990, KRUSENS HDB PHYSICAL, P988; DAVIS DL, 1990, J HEAD TRAUMA REHAB, V5, P31, DOI DOI 10.1097/00001199-199005020-00006; Dunn KM, 1999, J EPIDEMIOL COMMUN H, V53, P144, DOI 10.1136/jech.53.3.144; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; Garden F. H., 1990, J HEAD TRAUMA REHAB, V5, P52, DOI DOI 10.1097/00001199-199005020-00009; Giuliano F, 1999, ANN NEUROL, V46, P15, DOI 10.1002/1531-8249(199907)46:1<15::AID-ANA5>3.0.CO;2-U; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hirschfeld RMA, 1999, J CLIN PSYCHIAT, V60, P32; HORN LJ, 1988, J HEAD TRAUMA REHAB, V3, P87; KOSTELJANETZ M, 1981, ACTA NEUROL SCAND, V63, P163; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer J S, 1989, Brain Inj, V3, P177, DOI 10.3109/02699058909004550; LABI MLC, 1996, MED REHAB TRAUMATIC; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; Maytom MC, 1999, SPINAL CORD, V37, P110, DOI 10.1038/sj.sc.3100803; McCarthy BW, 1998, J SEX EDUC THER, V23, P302; MCCLELLAND RJ, 1988, BRIT J PSYCHIAT, V153, P141, DOI 10.1192/bjp.153.2.141; MEYER J, 1971, J NEUROVISCERAL RE S, V10, P519; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; Porter S, 1989, PHY MED REHAB, P3143; Ravart M., 1996, CANADIAN J HUMAN SEX, V5, P279; Sandel ME, 1996, BRAIN INJURY, V10, P719, DOI 10.1080/026990596123981; SIPSKI M, 1991, SEX DISABIL, P45; SIPSKI ML, 1992, PHYS REHABIL CLIN N, V3, P811; SIPSKI ML, 1995, TOPICS SPINAL CORD I, V4, P1; Sliwinski M, 1998, J HEAD TRAUMA REHAB, V13, P40, DOI 10.1097/00001199-199808000-00004; SOULAIRAC A, 1978, PSYCHONEUROENDOCRINO, V3, P17, DOI 10.1016/0306-4530(78)90038-0; *SPSS INC, 1998, SPSS WIND VERS 9 0 C; STEWARD DG, 1997, PHYS MED REHABIL CLI, V8, P827; Striar S, 1999, PSYCHIAT ANN, V29, P60, DOI 10.3928/0048-5713-19990101-13; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Ware J.E., 1993, SF 36 HLTH SURVEY MA; ZEISS AM, 1999, HDB COUNSELING PSYCH, P294	45	70	71	1	6	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2000	15	2					109	120					12	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	406RN	WOS:000167229100004	11455088				2022-02-06	
J	Leclercq, M; Couillet, J; Azouvi, P; Marlier, N; Martin, Y; Strypstein, E; Rousseaux, M				Leclercq, M; Couillet, J; Azouvi, P; Marlier, N; Martin, Y; Strypstein, E; Rousseaux, M			Dual task performance after severe diffuse traumatic brain injury or vascular prefrontal damage	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; ANTERIOR COMMUNICATING ARTERY; RANDOM NUMBER GENERATION; WORKING-MEMORY; DYSEXECUTIVE SYNDROME; COGNITIVE DEFICITS; DIVIDED ATTENTION; FRONTAL-CORTEX; ANEURYSMS; DISORDERS	The ability to perform two tasks simultaneously is a key function of the central executive of working memory (Baddeley, 1986). This study addressed dual-task performance after diffuse very severe traumatic brain injury (TBI) (mean coma duration = 21 days, mean post-traumatic amnesia = 70 days) or prefrontal damage due to a ruptured aneurysm of the anterior communicating artery (AACA). Mean time since injury was 8 and 16 months in the TBI and the AACA group respectively. A simple visual reaction time and random number generation were used as single and dual tasks. Randomization was self-paced, to control for individual differences in speed. Both patient groups had greater reaction time decrements than controls under the dual-task condition, suggesting a divided attention deficit. In addition, patients with AACA performed significantly poorer in random generation. These results suggest that patients with AACA and with severe TBI suffer from an impairment of the central executive system.	Ctr Neurol William Lennox, Ottignies Louvain Neuve, Belgium; Univ Paris 05, Hop Raymond Poincare, Serv Reeduc Neurol, F-75270 Paris 06, France; Ctr Reeduc Espoir, Lille Hellemmes, France; Hop Swynghedauw, Serv Reeduc Neurol, Lille, France		Azouvi, P (corresponding author), Raymond Poincare Hosp, Dept Neurol Rehabilitat, F-92380 Garches, France.						ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ALEXANDER MP, 1984, NEUROLOGY, V34, P752, DOI 10.1212/WNL.34.6.752; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A.D., 1986, WORKING MEMORY; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; Brugger P, 1996, NEUROPSYCHOLOGIA, V34, P97, DOI 10.1016/0028-3932(95)00066-6; CHATFIELD C, 1984, ANAL TIME SERIES; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Godefroy O, 1996, BRAIN COGNITION, V30, P155, DOI 10.1006/brcg.1996.0010; Godefroy O, 1996, BRAIN, V119, P191, DOI 10.1093/brain/119.1.191; Godefroy O, 1999, CORTEX, V35, P1, DOI 10.1016/S0010-9452(08)70782-2; GOLDENBERG G, 1992, J NEUROL NEUROSUR PS, V55, P362, DOI 10.1136/jnnp.55.5.362; GOLDSTEIN LH, 1993, J NEUROL NEUROSUR PS, V56, P274, DOI 10.1136/jnnp.56.3.274; HORNE RL, 1982, ARCH GEN PSYCHIAT, V39, P680; Jahanshahi M, 1998, BRAIN, V121, P1533, DOI 10.1093/brain/121.8.1533; Kendall MG, 1973, TIME SERIES; LAIACONA M, 1989, CORTEX, V25, P261, DOI 10.1016/S0010-9452(89)80042-5; LECLERCQ M, 1990, NORMALISATION 3 EPRE; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; NORMAN DA, 1980, 99 CHIP U CAL; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; REZAI K, 1993, ARCH NEUROL-CHICAGO, V50, P636, DOI 10.1001/archneur.1993.00540060066020; Robertson C, 1996, NEUROPSYCHOLOGIA, V34, P1069, DOI 10.1016/0028-3932(96)00031-0; ROSENBERG S, 1990, PSYCHOL MED, V20, P953, DOI 10.1017/S0033291700036643; Rousseaux M, 1996, REV NEUROL-FRANCE, V152, P678; Rousseaux M, 1996, REV NEUROL, V152, P517; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; SPATT J, 1993, BRAIN COGNITION, V23, P231, DOI 10.1006/brcg.1993.1057; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; STENHOUSE LM, 1991, J NEUROL NEUROSUR PS, V54, P909, DOI 10.1136/jnnp.54.10.909; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; Weiskrantz L., 1998, PREFRONTAL CORTEX EX, P9, DOI 10.1093/acprof:oso/9780198524410.003.0002; [No title captured]; [No title captured], DOI DOI 10.1016/S0079-7421(08)60452-1; [No title captured]	47	70	71	0	7	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	3					339	350		10.1076/1380-3395(200006)22:3;1-V;FT339			12	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	327UB	WOS:000087811000004	10855042				2022-02-06	
J	Ownsworth, TL; McFarland, K				Ownsworth, TL; McFarland, K			Memory remediation in long-term acquired brain injury: two approaches in diary training	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; REAL-LIFE	This study investigated the remediation and assessment of everyday memory impairment in a sample of long-term acquired brain injury (ABI) subjects. The Rivermead Behavioural Memory Test (RBMT) and subtests of the Wechsler Memory Scale-Revised (WMS-R) were selected to measure global memory performance. A memory questionnaire and a daily memory checklist were developed from a review of existing self-report questionnaires. The interrelationships among self-report measures and standardized psychometric tests of memory were examined and the findings suggest that self-report measures may be used to obtain relatively accurate information about everyday memory performance. A baseline across groups' design evaluated the relative effectiveness of two different approaches in training subjects to use a diary to compensate for memory problems. There was a Diary Only (DO) approach, which emphasized compensation based upon task specific learning, and a Diary and Self-instructional Training (DSIT) approach, which taught compensation using higher cognitive skills of self-awarenes and self-regulation. The results obtained show that, during the treatment phase, the DSIT group more consistently made diary entries, reported less memory problems, and made more positive ratings associated with treatment efficacy. The implications arising from the current study are that: (1) the choice of memory assessment procedures need to be guided by the patients' real daily living needs; and (2) an approach based upon self-instructional training has greater ecological validity than an approach that focuses on task specific learning. In general, successful assessment and rehabilitation of memory deficits requires a well-established theoretical basis and sound ecological validity.	Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia		Ownsworth, TL (corresponding author), Univ Queensland, Sch Psychol, Brisbane, Qld 4072, Australia.	tamarao@psy.uq.edu.au		Ownsworth, Tamara/0000-0003-1835-7094			BAUER RM, 1993, CLIN NEUROPSYCHOLOGY, P523; BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENYISHAY Y, 1993, ARCH PHYS MED REHAB, V74, P204; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Cockburn J, 1996, J CLIN EXP NEUROPSYC, V18, P304, DOI 10.1080/01688639608408284; Davis~ AM, 1995, CLIN REHABIL, V9, P238, DOI DOI 10.1177/026921559500900310; GODFREY HP, 1995, FAMILY SUPPORT PROGR; GODFREY HPD, 1987, BRIT J CLIN PSYCHOL, V26, P83, DOI 10.1111/j.2044-8260.1987.tb00735.x; GOLDSTEIN G, 1990, INT HDB BEHAV MODIFI, P139; GORDON WA, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P175; GORDON WA, 1992, NEUROPSYCHOLOGY, V6, P361; Herrmann D.J., 1978, PRACTICAL ASPECTS ME, V2, P35; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Hersen M., 1990, INT HDB BEHAV MODIFI, P175, DOI DOI 10.1007/978-1-4613-0523-1_9; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; KOLB B, 1992, ADV EXP MED BIOL, V325, P169; LAWSON MJ, 1989, J CLIN EXP NEUROPSYC, V11, P842, DOI 10.1080/01688638908400939; McNair D.M., 1981, PROFILE MOOD STATES; MEICHENBAUM D, 1973, BEHAV THER, V4, P515, DOI 10.1016/S0005-7894(73)80003-6; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; REID DB, 1993, J CLIN PSYCHOL, V49, P245, DOI 10.1002/1097-4679(199303)49:2<245::AID-JCLP2270490219>3.0.CO;2-1; SOHLBERG M M, 1992, Brain Injury, V6, P129, DOI 10.3109/02699059209029651; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; Squire LR., 1987, MEMORY BRAIN; Squires EJ, 1996, NEUROPSYCHOL REHABIL, V6, P55, DOI 10.1080/713755494; SUNDERLAND A, 1990, NEUROPSYCHOLOGY EVER, P169; Tate RL, 1997, BRAIN INJURY, V11, P907, DOI 10.1080/026990597122972; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEBSTER JS, 1983, CLIN NEUROPSYCHOL, V5, P69; WECHSLER O, 1987, WECHSLER MEMORY SCAL; WILSON B, 1987, REHABILITATION MEMOR; WILSON B, 1989, J CLIN EXPT NEUROPSY, V11, P885; Wilson B.A., 1985, RIVERMEAD BEHAV MEMO; ZENCIUS AH, 1994, PRACTICAL GUIDE HEAD; [No title captured]; [No title captured]; [No title captured]	40	70	70	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	1999	13	8					605	626		10.1080/026990599121340			22	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200005	10901689				2022-02-06	
J	Belayev, L; Alonso, OF; Huh, PW; Zhao, WZ; Busto, R; Ginsberg, MD				Belayev, L; Alonso, OF; Huh, PW; Zhao, WZ; Busto, R; Ginsberg, MD			Posttreatment with high-dose albumin reduces histopathological damage and improves neurological deficit following fluid percussion brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						albumin; histopathology; neuroprotection; traumatic brain injury	CEREBRAL-ARTERY OCCLUSION; COLLOID ONCOTIC PRESSURE; HUMAN EXTRACELLULAR FLUIDS; SERUM-ALBUMIN; MODERATE HYPOTHERMIA; BARRIER DISRUPTION; HYPOCHLOROUS ACID; CRYOGENIC INJURY; DRUG-THERAPY; HEAD-INJURY	We have recently shown that high-dose human serum albumin (HSA) therapy confers marked histological protection in experimental middle cerebral artery occlusion. Thus, the purpose of this study was to determine whether treatment with high-dose HSA would protect in a rat model of traumatic brain injury (TBI). Twenty-four hours prior to TBI, the fluid percussion interface was positioned parasagittally over the right cerebral cortex. On the following day, fasted rats were anesthetized with 3% halothane, 70% nitrous oxide, and 30% oxygen and received right parieto-occipital parasagittal fluid-percussion injury (1.5-2.0 atm). Cranial and rectal temperatures were monitored throughout the experiment and held at normothermic levels (36.5-37.5 degrees C) by a warming lamp above the animal's head. The agent (25% human serum albumin, HSA) or vehicle (sodium chloride 0.9%) was administered i.v. (1% of body weight) 15 min after trauma. Behavioral function was evaluated in all rats before and after TBI (at 2 h, 24 h, 48 h, 72 h, and 7 days). Neurological function was graded on a scale of 0-12 (normal score 0; maximal score = 12). Seven days after TBI, brains were perfusion-fixed, coronal sections at various levels were digitized, and contusion areas in the superficial, middle and deep layers of cortex and in the underlying fimbria were measured. HSA significantly improved the neurological score compared to saline at 24 h, 72 h, and 7 days after TBI (6.0 +/- 0.6 [albumin] versus 8.4 +/- 0.5 [saline]; 3.6 +/- 0.7 versus 6.8 +/- 1.0; and 2.6 +/- 0.6 versus 5.7 +/- 0.8, respectively; p < 0.05). HSA therapy also significantly reduced total contusion area (0.89 +/- 0.2 versus 1.82 +/- 0.3 mm(2); p = 0.02). Our findings document that high-concentration albumin therapy instituted 15 min after trauma significantly improves the neurological score and reduces histological damage. We believe that this pharmacological agent may have promising potential for the clinical treatment of brain injury.	Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol, Neurotrauma Res Ctr, Miami, FL 33101 USA		Belayev, L (corresponding author), Univ Miami, Sch Med, Dept Neurol D4 5, Cerebral Vasc Dis Res Ctr, POB 016960, Miami, FL 33101 USA.	lbelayev@stroke.med.miami.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 05820, NS 30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291, P50NS005820, P01NS005820] Funding Source: NIH RePORTER		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Belayev L, 1998, STROKE, V29, P2587, DOI 10.1161/01.STR.29.12.2587; Belayev L, 1997, J NEUROSURG, V87, P595, DOI 10.3171/jns.1997.87.4.0595; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; Curry S, 1998, NAT STRUCT BIOL, V5, P827, DOI 10.1038/1869; DERYCK M, 1989, STROKE, V20, P1383, DOI 10.1161/01.STR.20.10.1383; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Drummond JC, 1998, ANESTHESIOLOGY, V88, P993, DOI 10.1097/00000542-199804000-00020; EMERSON TE, 1989, CRIT CARE MED, V17, P690, DOI 10.1097/00003246-198907000-00020; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Ginsberg MD, 1995, NEUROSCIENTIST, V1, P95; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HALLIWELL B, 1990, ARCH BIOCHEM BIOPHYS, V280, P1, DOI 10.1016/0003-9861(90)90510-6; HALLIWELL B, 1988, BIOCHEM PHARMACOL, V37, P569, DOI 10.1016/0006-2952(88)90126-8; HU ML, 1993, J LAB CLIN MED, V121, P257; Huh PW, 1998, BRAIN RES, V804, P105, DOI 10.1016/S0006-8993(98)00674-X; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KAIEDA R, 1989, ANESTHESIOLOGY, V71, P554, DOI 10.1097/00000542-198910000-00013; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; KOCHWESER J, 1976, NEW ENGL J MED, V294, P311, DOI 10.1056/NEJM197602052940605; KOCHWESER J, 1976, NEW ENGL J MED, V294, P526, DOI 10.1056/NEJM197603042941005; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MATSUI T, 1993, NEUROSURGERY, V32, P79, DOI 10.1227/00006123-199301000-00012; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; Remmers M, 1999, BRAIN RES, V827, P237, DOI 10.1016/S0006-8993(99)01304-9; SMITH C, 1992, FOOD CHEM TOXICOL, V30, P483, DOI 10.1016/0278-6915(92)90099-7; Teasdale GM, 1998, NEUROSURGERY, V43, P723, DOI 10.1097/00006123-199810000-00001; TOMITA H, 1994, ACTA NEUROCHIR, P547; TRIGATTI BL, 1995, BIOCHEM J, V308, P155, DOI 10.1042/bj3080155; TULLIS JL, 1977, JAMA-J AM MED ASSOC, V237, P355; TULLIS JL, 1977, JAMA-J AM MED ASSOC, V237, P460, DOI 10.1001/jama.237.5.460; WASIL M, 1987, BIOCHEM J, V243, P219, DOI 10.1042/bj2430219; WAYNER DDM, 1985, FEBS LETT, V187, P33, DOI 10.1016/0014-5793(85)81208-4; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v; ZHUANG J, 1995, CRIT CARE MED, V23, P140, DOI 10.1097/00003246-199501000-00023; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005	42	70	72	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1999	16	6					445	453		10.1089/neu.1999.16.445			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	206LD	WOS:000080879800002	10391362				2022-02-06	
J	Cormio, M; Valadka, AB; Robertson, CS				Cormio, M; Valadka, AB; Robertson, CS			Elevated jugular venous oxygen saturation after severe head injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral blood flow; cerebral metabolic rate of oxygen; cerebral perfusion pressure; dysoxia; head injury; ischemia; jugular venous oxygen saturation	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; INTRACRANIAL HYPERTENSION; PERFUSION-PRESSURE; METABOLISM; CONSUMPTION; HYPEREMIA; BULB; COMA	Object. The aim of this study was to investigate the incidence of elevated (greater than or equal to 75%) jugular venous oxygen saturation (SjvO(2),) and its relationship to-cerebral hemodynamic and metabolic parameters and to outcome after severe head injury. Methods. Data from 450 severely head injured patients admitted to the Neurosurgical Intensive Care Unit of Ben Taub General Hospital were analyzed retrospectively. The SjvO(2), was measured in blood obtained from indwelling jugular bulb catheters. Patients were classified into the following categories: high (Group I), normal (Group II), or low SjvO(2), (Group III) if their mean SjvO(2), over the duration of monitoring was 75% or higher, 74 to 56%, or 55% or lower, respectively. A high SjvO(2), occurred in 19.1% of patients. There was no consistent relationship between SjvO(2), and simultaneous cerebral blood flow (CBF) or cerebral perfusion pressure measurements. Compared with Groups II and III, the patients in Group I had a significantly higher CBF and lower cerebral metabolic rate of oxygen (CMRO2. In Group I, the outcomes were death or persistent vegetative state in 48.8% of patients and severe disability in 25.6%. These outcomes were significantly worse than for patients in Group II. Within Group I, the patients with a poor neurological outcome were older and more likely to have suffered a focal head injury; they demonstrated a lower CMRO2, and a greater rate of cerebral lactate production than the patients who attained a favorable outcome. Conclusions. Posttraumatic elevation of SjvO(2) is common but cannot be automatically equated with hyperemia. Instead, elevated SjvO(2), is a heterogeneous condition that is associated with poor outcome after head injury and may carry important implications for the management of comatose patients.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; New Hosp San Gerardo, Dept Anesthesia & Crit Care, Milan, Italy		Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bmc.tmc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS027616] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS27616] Funding Source: Medline		Andrews PJD, 1996, J NEUROSURG ANESTH, V8, P220, DOI 10.1097/00008506-199607000-00006; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; COHEN PJ, 1967, J APPL PHYSIOL, V23, P183, DOI 10.1152/jappl.1967.23.2.183; Cold GE, 1992, INTENSIVE CARE WORLD, V9, P172; CONNETT RJ, 1990, J APPL PHYSIOL, V68, P833, DOI 10.1152/jappl.1990.68.3.833; Cruz J, 1996, CRIT CARE MED, V24, P953, DOI 10.1097/00003246-199606000-00013; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; JING ZA, 1992, J TRAUMA, V33, P83, DOI 10.1097/00005373-199207000-00016; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1996, J NEUROSURG, V85, P762, DOI 10.3171/jns.1996.85.5.0762; Marion D W, 1995, New Horiz, V3, P439; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Matta BF, 1997, ANESTHESIOLOGY, V86, P806, DOI 10.1097/00000542-199704000-00010; MATTHEWS DSF, 1995, J NEUROL NEUROSUR PS, V59, P359, DOI 10.1136/jnnp.59.4.359; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; ROBIN ED, 1977, ARCH INTERN MED, V137, P905, DOI 10.1001/archinte.137.7.905; ROQUEFEUIL B, 1907, NEUROCHIRURGIA, V23, P401; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; STOCCHETTI N, 1994, NEUROSURGERY, V34, P38; TEASDALE G, 1974, LANCET, V2, P81; YUKOTA H, 1994, NEUROCHEMICAL MONITO, P98	30	70	78	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	1999	90	1					9	15		10.3171/jns.1999.90.1.0009			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	168TH	WOS:000078708400002	10413150				2022-02-06	
J	Sullivan, TP; Jarvik, JG; Cohen, WA				Sullivan, TP; Jarvik, JG; Cohen, WA			Follow-up of conservatively managed epidural hematomas: Implications for timing of repeat CT	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	35th Annual Meeting of the American-Society-of-Neuroradiology	MAY, 1997	TORONTO, CANADA	Amer Soc Neuroradiol			EXTRADURAL HEMATOMAS; NONOPERATIVE MANAGEMENT; NONSURGICAL TREATMENT; HEAD-INJURY; TRAUMA	BACKGROUND AND PURPOSE: Small asymptomatic epidural hematomas (EDHs) are frequently managed nonoperatively with good neurologic outcome. Our goals were to determine the frequency and timing of enlargement of acute traumatic EDHs that are not immediately surgically evacuated as well as to identify factors associated with rehemorrhage. METHODS: Of 252 consecutive patients with acute traumatic EDH who were treated over a 5-year period, 160 were managed nonoperatively. Their CT scans, imaging reports, and medical records were reviewed retrospectively. Parameters analyzed as possible predictors of rehemorrhage during nonoperative management were size of the EDH, presence of an associated fracture, contralateral brain injury, midline shift, coagulopathy, and neurologic and physiological injury as measured by the Revised Trauma Score. We compared discharge disposition as a proxy for neurologic condition at discharge. RESULTS: The EDH enlarged in 37 (23%) of the 160 patients during conservative management. Mean enlargement was 7 mm, and the mean time to enlargement was 8 hours after injury and 5.3 hours after CT diagnosis. EDH enlargement occurred within 36 hours after injury in all cases, Of the parameters analyzed, only a high Revised Trauma Score correlated significantly with EDH rehemorrhage, suggesting that intubation and chemical paralysis may prevent rehemorrhage through the restriction of head movement and the control of blood pressure. The subgroup of patients with rehemorrhage experienced no difference in neurologic outcome despite a higher rate of clinical deterioration, CONCLUSION: EDH enlargement occurs frequently, but early. Repeat imaging with CT is most appropriate within 36 hours after injury.	Univ Washington, Med Ctr, Dept Radiol, Seattle, WA 98195 USA		Jarvik, JG (corresponding author), Univ Washington, Med Ctr, Dept Radiol, 1959 NE Pacific St,357115, Seattle, WA 98195 USA.		Jarvik, Jeffrey/AAL-4292-2021				BENDER MB, 1974, ARCH NEUROL-CHICAGO, V31, P73, DOI 10.1001/archneur.1974.00490380021001; BULLOCK R, 1985, NEUROSURGERY, V16, P602, DOI 10.1227/00006123-198505000-00003; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; COOPER PR, 1986, NEUROSURGERY, V18, P700; DIROCCO A, 1991, NEURORADIOLOGY, V33, P253, DOI 10.1007/BF00588229; DOMENICUCCI M, 1995, NEUROSURG REV, V18, P109, DOI 10.1007/BF00417668; FORD LE, 1963, J NEUROSURG, V20, P760, DOI 10.3171/jns.1963.20.9.0760; GEAN AD, 1994, IMAGING HEAD TRAUMA, P107; HAMILTON M, 1992, AM J NEURORADIOL, V13, P853; KAWAKAMI Y, 1990, PEDIATR NEUROL, V6, P112, DOI 10.1016/0887-8994(90)90044-2; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; Lofgren J, 1986, Acta Neurochir Suppl (Wien), V36, P151; MARSHALL LF, 1985, NEUROSURGERY, V16, P606; MAURER JJ, 1965, J NEUROSURG, V23, P63, DOI 10.3171/jns.1965.23.1.0063; MCLAURIN RL, 1964, J NEUROSURG, V21, P364, DOI 10.3171/jns.1964.21.5.0364; PANG D, 1983, J NEUROSURG, V59, P958, DOI 10.3171/jns.1983.59.6.0958; POZZATI E, 1986, NEUROSURGERY, V18, P696, DOI 10.1227/00006123-198606000-00003; SAGHER O, 1992, AJNR AM J NEURORADIO, V13, P853; SAKAI H, 1988, J NEUROSURG, V68, P566, DOI 10.3171/jns.1988.68.4.0566; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; ZIMMERMAN RA, 1978, AM J ROENTGENOL, V131, P27, DOI 10.2214/ajr.131.1.27	23	70	74	0	1	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	1999	20	1					107	113					7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	163CQ	WOS:000078385300018	9974064				2022-02-06	
J	Salame, P; Danion, JM; Peretti, S; Cuervo, C				Salame, P; Danion, JM; Peretti, S; Cuervo, C			The state of functioning of working memory in schizophrenia	SCHIZOPHRENIA RESEARCH			English	Article; Proceedings Paper	2nd European Neuroscience Meeting	SEP 24-28, 1996	STRASBOURG, FRANCE			schizophrenia; working memory; phonological loop; visuo-spatial; central executive; slowness	SHORT-TERM-MEMORY; CLOSED-HEAD INJURY; PARKINSONS-DISEASE; PHONOLOGICAL LOOP; PERFORMANCE; DYSFUNCTION; HALLUCINATIONS; HETEROGENEITY; GENERATION; IMPAIRMENT	The functioning of working memory in schizophrenic patients according to Baddeley's model was examined in two complementary experiments. Experiment 1 comprised 27 patients and their controls, matched in age and level of education. Of this pool, 20 pairs participated also in Experiment 2. Digit span, reading rate, and immediate serial recall assessed the functioning of the phonological loop. Corsi and pattern span tasks assessed the capacity of visuospatial memory. The central executive's ability to monitor two concurrent tasks was evaluated in a dual task paradigm, and its capacity to control action in a random generation task. A preliminary jet of analyses showed that the patients' performances were reduced in all tasks explored, except in digit span. This initial pattern changed consistently after controlling for reading rate. While slow and fast reading patients were comparable in demographic and clinical criteria, slow reading patients showed impaired performance in all tasks, whereas fast reading patients exhibited reduced performance in visuo-spatial tasks and in the random generation task only. The state of functioning of working memory in schizophrenia appears, therefore, to vary consistently among the components of the model and is markedly impaired in slow reading patients. The implication of slowness are discussed. (C) 1998 Elsevier Science B.V.	Hop Civil, Dept Psychiat, INSERM, U405, F-67091 Strasbourg, France		Salame, P (corresponding author), Hop Civil, Dept Psychiat, INSERM, U405, F-67091 Strasbourg, France.	salame@alsace.u-strasbg.fr		DANION, Jean-Marie/0000-0002-1980-1006			American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th ed., P273; ANDREASEN NC, 1987, PSYCHIAT PSYCHOBIOL, V6, P1; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1996, Q J EXP PSYCHOL-A, V49, P5, DOI 10.1080/713755608; Baddeley A.D., 1986, WORKING MEMORY; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BADDELEY AD, 1966, Q J EXP PSYCHOL, V18, P119, DOI 10.1080/14640746608400019; BADDELEY AD, 1975, J VERB LEARN VERB BE, V14, P575, DOI 10.1016/S0022-5371(75)80045-4; BADDELEY AD, 1993, CURR BIOL, V3, P563, DOI 10.1016/0960-9822(93)90059-W; BADDELEY AD, 1994, MEMORY SYSTEMS, V11, P351; Beats BC, 1996, PSYCHOL MED, V26, P591, DOI 10.1017/S0033291700035662; Bentall R., 1993, J MENT HLTH, V2, P223, DOI DOI 10.3109/09638239309003768; Brebion G, 1997, PSYCHOL MED, V27, P383, DOI 10.1017/S0033291796004448; CARDNO AG, 1995, SCHIZOPHR RES, V17, P153, DOI 10.1016/0920-9964(95)95686-4; CLARE L, 1993, NEUROPSYCHOLOGIA, V31, P1225, DOI 10.1016/0028-3932(93)90070-G; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; COLLE HA, 1976, J VERB LEARN VERB BE, V15, P17, DOI 10.1016/S0022-5371(76)90003-7; CONRAD R, 1964, BRIT J PSYCHOL, V55, P75, DOI 10.1111/j.2044-8295.1964.tb00899.x; CROW TJ, 1995, SCHIZOPHR RES, V17, P135, DOI 10.1016/0920-9964(95)00059-U; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DAVID AS, 1993, BRIT J CLIN PSYCHOL, V32, P431, DOI 10.1111/j.2044-8260.1993.tb01077.x; EVANS FJ, 1978, B PSYCHONOMIC SOC, V12, P35; FLEMING K, 1995, PSYCHIAT RES, V56, P155, DOI 10.1016/0165-1781(95)02589-3; Fournet N, 1996, J NEUROL NEUROSUR PS, V60, P313, DOI 10.1136/jnnp.60.3.313; Gathercole S.E., 1993, WORKING MEMORY LANGU; GOLDBERG TE, 1995, SCHIZOPHR RES, V17, P147, DOI 10.1016/0920-9964(95)00060-Y; GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348; Greene JDW, 1995, NEUROPSYCHOLOGIA, V33, P1647, DOI 10.1016/0028-3932(95)00046-1; Haddock G, 1996, PERS INDIV DIFFER, V20, P753, DOI 10.1016/0191-8869(96)00006-2; JOYCE EM, 1991, NEUROPSYCHOLOGIA, V29, P709, DOI 10.1016/0028-3932(91)90067-I; KOLB B, 1983, J NERV MENT DIS, V171, P435, DOI 10.1097/00005053-198307000-00008; Kryter K.D, 1970, EFFECTS NOISE MAN; KUJALA P, 1994, BRAIN, V117, P1115, DOI 10.1093/brain/117.5.1115; LEVY BA, 1971, J VERB LEARN VERB BE, V10, P123, DOI 10.1016/S0022-5371(71)80003-8; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MCKENNA PJ, 1990, PSYCHOL MED, V20, P967, DOI 10.1017/S0033291700036667; MILNER B, 1971, BRIT MED BULL, V27, P272, DOI 10.1093/oxfordjournals.bmb.a070866; MORRIS RG, 1986, COGNITIVE NEUROPSYCH, V3, P77, DOI 10.1080/02643298608252670; NELSON HE, 1990, PSYCHOL MED, V20, P357, DOI 10.1017/S0033291700017670; PARK S, 1992, ARCH GEN PSYCHIAT, V49, P975; Rizzo L, 1996, NEUROPSYCHOLOGY, V10, P376, DOI 10.1037/0894-4105.10.3.376; SALAME P, 1989, Q J EXP PSYCHOL-A, V41, P107, DOI 10.1080/14640748908402355; SALAME P, 1982, J VERB LEARN VERB BE, V21, P150, DOI 10.1016/S0022-5371(82)90521-7; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; SALWAY AFS, 1995, BRIT J PSYCHOL, V86, P253, DOI 10.1111/j.2044-8295.1995.tb02560.x; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; TAMLYN D, 1992, PSYCHOL MED, V22, P101, DOI 10.1017/S0033291700032773; TSUANG MT, 1995, SCHIZOPHR RES, V17, P161, DOI 10.1016/0920-9964(95)00057-S; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VERDOUX H, 1995, SCHIZOPHR RES, V14, P133, DOI 10.1016/0920-9964(94)00018-4; Wilson, 1997, VISUAL PATTERNS TEST; [No title captured]	55	70	70	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	FEB 27	1998	30	1					11	29		10.1016/S0920-9964(97)00107-2			19	Psychiatry	Conference Proceedings Citation Index - Science (CPCI-S); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	YZ142	WOS:000072224500002	9542785				2022-02-06	
J	Mukhin, AG; Ivanova, SA; Knoblach, SM; Faden, AI				Mukhin, AG; Ivanova, SA; Knoblach, SM; Faden, AI			New in vitro model of traumatic neuronal injury evaluation of secondary injury and glutamate receptor-mediated neurotoxicity	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; cell culture; glutamate antagonists; in vitro model; neuronal death	SPINAL-CORD INJURY; BRAIN INJURY; IN-VITRO; DEATH; NMDA; DEPRIVATION; CULTURE; ANTAGONISTS; BLOCKADE; GLUCOSE	The multiplicity and complexity of secondary injury processes following brain trauma in vivo make it difficult to elucidate the roles of specific injury mechanisms, As with other areas of CNS injury, such as ischemia, this has led to the development of in vitro models, Here we describe a new trauma model, in which standardized trauma is delivered to neuronal/glial cultures using a special mechanical device that produces concentric circular cuts in the cell layer. Changes in the number of circles (from 1 to 6) allows variation of injury severity, Comparison studies of cell death induced by such trauma in glial and neuronal/glial cultures demonstrated that glial cells are relatively resistant to this injury, and that the cell death after trauma to neuronal/glial cultures reflects primarily neuronal death, Consistent with other in vivo and in vitro studies, glutamate receptor antagonists MK 801 and MCPG were neuroprotective, Thus, this model appears useful for studying glutamatergic mechanisms involved in secondary injury, and may prove useful for evaluating certain pharmacological strategies for CNS trauma.	GEORGETOWN UNIV,MED CTR,GEORGETOWN INST COGNIT & COMPUTAT SCI,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT NEUROL,WASHINGTON,DC 20007						PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR 306634-06] Funding Source: Medline		AMADOR E, 1963, CLIN CHEM, V9, P391; BIRRELL GJ, 1993, BRAIN RES, V607, P337, DOI 10.1016/0006-8993(93)91527-Y; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; CHENG B, 1995, J NEUROSCI, V15, P7095; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Flavin MP, 1996, EXP NEUROL, V139, P34, DOI 10.1006/exnr.1996.0078; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; KEILHOFF G, 1993, NEUROREPORT, V5, P129, DOI 10.1097/00001756-199311180-00008; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; KOH JY, 1995, SCIENCE, V268, P573, DOI 10.1126/science.7725105; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; LUCAS JH, 1985, CNS TRAUMA, V2, P321; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, RECENT ADV EXCITATOR, P653; Mukhin A, 1996, J NEUROSCI, V16, P6012; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Panter S. S., 1992, PRINCIPLES PRACTICE, P32; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; Regan R. F., 1994, Society for Neuroscience Abstracts, V20, P192; REGAN RF, 1994, BRAIN RES, V633, P236, DOI 10.1016/0006-8993(94)91544-X; SHARPIRA Y, 1990, J NEUROTRAUM, V7, P131; SUN FY, 1995, BRAIN RES, V693, P163, DOI 10.1016/0006-8993(95)00731-5; WRATHALL JR, 1992, BRAIN RES, V586, P140, DOI 10.1016/0006-8993(92)91384-Q; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	32	70	73	1	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1997	14	9					651	663		10.1089/neu.1997.14.651			13	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	XZ489	WOS:A1997XZ48900006	9337127				2022-02-06	
J	Goss, JR; Taffe, KM; Kochanek, PM; DeKosky, ST				Goss, JR; Taffe, KM; Kochanek, PM; DeKosky, ST			The antioxidant enzymes glutathione peroxidase and catalase increase following traumatic brain injury in the rat	EXPERIMENTAL NEUROLOGY			English	Article							NERVE GROWTH-FACTOR; DELAYED NEURONAL DEATH; ISCHEMIA-REPERFUSION; SYSTEM TRAUMA; HEAD-INJURY; TOXICITY	The inflammatory response following mechanical brain injury is characterized by an increase in the cytokine interleukin-1 beta (IL-1 beta) followed by a large elevation in the neurotrophin, nerve growth factor (NGF). The substantial upregulation in NGF observed in our previous studies suggests that it may have functions in addition to that of a target-derived neuronal support mechanism. We hypothesize that NGF is a mediator of oxidative homeostasis, by inducing the production of oxygen-free radical scavengers in brain tissue following injury. We tested this hypothesis by measuring the activity of the antioxidant enzymes, glutathione peroxidase (GSH-Px), and catalase in cortical brain tissue following experimentally induced cortical contusion. We observed a twofold increase in GSH-Px and a threefold increase in catalase activities in a time course which reflected the temporal increase in NGF observed following the same cortical contusion model. These findings support the hypothesis and illuminate an important reparative role for NGF following trauma. (C) 1997 Academic Press.	UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT NEUROBIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT ANESTHESIOL, PITTSBURGH, PA 15260 USA; UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT NEUROL, PITTSBURGH, PA 15260 USA; SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA USA		Goss, JR (corresponding author), UNIV PITTSBURGH, SCH MED, WESTERN PSYCHIAT INST & CLIN, DEPT PSYCHIAT, PITTSBURGH, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758			AEBI H, 1984, METHOD ENZYMOL, V105, P121; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DEMPLE B, 1991, CELL, V67, P837, DOI 10.1016/0092-8674(91)90355-3; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FLOYD RA, 1991, ARCH GERONTOL GERIAT, V12, P155, DOI 10.1016/0167-4943(91)90025-L; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; GUIDOT DM, 1994, INFLAMMATION, V18, P537, DOI 10.1007/BF01560700; Hall E D, 1991, J Neurotrauma, V8 Suppl 1, pS31; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; JACKSON GR, 1994, BRAIN RES, V634, P69, DOI 10.1016/0006-8993(94)90259-3; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MATTSON MP, 1993, EXP NEUROL, V124, P89, DOI 10.1006/exnr.1993.1178; MATTSON MP, 1993, STROKE, V24, pI136; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NISTICO G, 1991, NEUROSCI LETT, V130, P117, DOI 10.1016/0304-3940(91)90241-K; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; PASINETTI GM, 1991, ADV EXP MED BIOL, V296, P249; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SINET PM, 1980, J NEUROCHEM, V34, P1421, DOI 10.1111/j.1471-4159.1980.tb11222.x; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; TSAN MF, 1991, J APPL PHYSIOL, V71, P688, DOI 10.1152/jappl.1991.71.2.688; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YAMAMOTO S, 1992, NEUROSCI LETT, V141, P161, DOI 10.1016/0304-3940(92)90885-B	32	70	72	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	1997	146	1					291	294		10.1006/exnr.1997.6515			4	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	XJ922	WOS:A1997XJ92200033	9225764				2022-02-06	
J	Gasquoine, PG				Gasquoine, PG			Postconcussion symptoms	NEUROPSYCHOLOGY REVIEW			English	Article						concussion; head injury; self-reported symptoms; emotional distress; motivation	MILD HEAD-INJURY; POST-CONCUSSIONAL SYMPTOMS; TRAUMATIC BRAIN INJURY; NEUROPSYCHOLOGICAL DEFICITS; COMPENSATION NEUROSIS; DISORDER; SEQUELAE; AMNESIA; DAMAGE; LONG	Research pertaining to the self-report of symptoms after traumatic brain injury was reviewed. Cognitive, emotional, and motivational factors have more relevance than demographic (except for female sex) and personality factors. Specific neuropsychological deficits in attention and memory have been found in the early stages after head injury of even mild severity. This is unlikely to be the only factor affecting symptom persistence. Exaggeration of cognitive dysfunction occurs in some cases, but appears unrelated to symptom overreport. Increased emotional distress typically accompanies symptom persistence. The psychological reaction of preoccupation with symptoms and emotional distress is not unique to concussion, but also occurs after severe head injury and back injury and relates more to the personal interpretation of the effect of the trauma than to objective indicators of brain injury severity.			Gasquoine, PG (corresponding author), S TEXAS NEUROPSYCHOL,3857 S STAPLES,CORPUS CHRISTI,TX 78411, USA.						Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BENNETTLEVY JM, 1984, ACTA NEUROL SCAND, V70, P285; Benton A. L, 1989, MILD HEAD INJURY, P3; BIGLER ED, 1995, ARCH CLIN NEUROPSYCH, V10, P159, DOI 10.1016/0887-6177(94)E0003-8; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BOHNEN N, 1992, NEUROSURGERY, V30, P692, DOI 10.1097/00006123-199205000-00007; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BRACKSTONE MJ, 1995, INT J REHABILITATION, V1, P37; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; COUCH JR, 1995, J NEUROL REHABIL, V9, P83; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; FEE CRA, 1988, ARCH EMERG MED, V5, P12; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine P., 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187, https://doi.org/10.1037/0894-4105.6.3.187]; GASS CS, 1991, PSYCHOL ASSESSMENT J, V3, P27; GENNARELLI TA, 1988, J HEAD TRAUMA REHABI, V1, P23; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein G., 1995, INT J REHABILITATION, V1, DOI [10.1007/BF02214959, DOI 10.1007/BF02214959]; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; GORMAN WF, 1993, LEGAL NEUROLOGY MALI; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Gronwall D, 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1975, LANCET, V2, P945; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; Hathaway S.R., 1983, MINNESOTA MULTIPHASI; HATHAWAY SR, 1989, MINNESOTA MULTIPHASI, V2; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Jennett B, 1989, MILD HEAD INJURY, P23; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P74, DOI [DOI 10.1097/00001199-199309000-00009, 10.1097/00001199-199309000-00009]; Keller L S., 1991, ASSESSMENT CHRONIC P; KELLY R, 1975, Forensic Science, V6, P17, DOI 10.1016/0300-9432(75)90219-8; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1988, NEUROTRAUMA MED REPO, V2, P1; Lidvall HF, 1974, ACTA NEUROLOGICA S56, V50, P7; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LONG CJ, 1986, SOUTHERN MED J, V79, P728, DOI 10.1097/00007611-198606000-00020; LONG CJ, 1991, J HEAD INJURY, V2, P18; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1983, J NEUROL NEUROSUR PS, V46, P1084, DOI 10.1136/jnnp.46.12.1084; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1972, LANCET, V2, P580; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nemeth AJ, 1996, ARCH CLIN NEUROPSYCH, V11, P677, DOI 10.1016/S0887-6177(96)80004-7; POPE KS, 1993, MMPI MMPI 2 MMPI A C; PRIGATANO GP, 1990, CLIN NEUROPSYCHOL, V4, P163, DOI DOI 10.1080/13854049008401509; Rimel R. W., 1981, NEUROSURGERY, V9, P35; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; RUFF RM, 1993, J HEAD TRAUMA REHAB, V8, P60, DOI DOI 10.1097/00001199-199309000-00008; Rutherford W. H., 1989, MILD HEAD INJURY, P217; Stuss DT, 1989, CLIN NEUROPSYCHOL, V3, P145, DOI [DOI 10.1080/13854048908403287, 10.1080/ 13854048908403287]; SWEENEY JE, 1992, CLIN NEUROPSYCHOL, V6, P443, DOI 10.1080/13854049208401870; TEASDALE G, 1974, LANCET, V2, P81; TRUEBLOOD W, 1993, J CLIN EXP NEUROPSYC, V15, P578, DOI 10.1080/01688639308402580; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WADDELL G, 1984, SPINE, V9, P209, DOI 10.1097/00007632-198403000-00013; WEIGHILL VE, 1983, J PSYCHOSOM RES, V27, P97, DOI 10.1016/0022-3999(83)90085-5; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfson, 1993, HALSTEAD REITAN NEUR; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13, DOI 10.1097/00001199-199309000-00004	78	70	70	0	11	PLENUM PUBL CORP	NEW YORK	CONSULTANTS BUREAU, 233 SPRING ST, NEW YORK, NY 10013	1040-7308			NEUROPSYCHOL REV	Neuropsychol. Rev.	JUN	1997	7	2					77	85		10.1023/B:NERV.0000005945.58251.c0			9	Psychology, Clinical; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	XN256	WOS:A1997XN25600002	9253770				2022-02-06	
J	Kilaru, S; Garb, J; Emhoff, T; Fiallo, V; Simon, B; Swiencicki, T; Lee, KF				Kilaru, S; Garb, J; Emhoff, T; Fiallo, V; Simon, B; Swiencicki, T; Lee, KF			Long-term functional status and mortality of elderly patients with severe closed head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	26th Annual Meeting of the Western-Trauma-Association	FEB 26-MAR 01, 1996	GRAND TARGHEE, WY	W Trauma Assoc		elderly; closed head injury; mortality; functional outcome	BRAIN INJURY; TRAUMA; MANAGEMENT; SURVIVAL	Objective: To evaluate long-term clinical outcome of elderly patients with severe closed head injuries, Design: Retrospective study, Patients and methods: All patients older than 65 years of age admitted to a regional trauma center with a diagnosis of closed head injury and an admission Glasgow Coma Scale (GCS) score of 8 or less, Using chi(2) analysis, Student's t test, and multiple logistic regression, we correlated age, sex, mechanism of injury, pupillary reactivity, alcohol and drug use, admission GCS score, Injury Severity Score, Revised Trauma Score, heart rate, and blood pressure to the main outcome measures, i.e. long-term functional outcome and mortality, Results: Among 40 elderly patients who met the criteria, 27% were still alive at the end of 38 +/- 3 month follow-up, Eighty-five percent of patients who were discharged from the hospital were still alive long-term, but did not show significant neurologic improvement, In a univariate analysis, GCS and pupillary reactivity were predictive for long-term functional outcome and mortality, In a multivariate analysis, GCS and heart rate were predictive, All patients with an admission GCS score of 3 died in-hospital, All patients with an admission GCS score of 3 to 7 were either deceased or lived in persistent vegetative or dependent functional states. Conclusions: Elderly patients with severe closed head injuries have high in-hospital mortality, Those who survived the hospital stay had high long-term survival, but did not show significant functional improvement, Prediction of long-term functional status is vital to the trauma care of elderly patients with severe closed head injuries.	BAYSTATE MED CTR,DEPT SURG,TRAUMA GEN SURG SERV,SPRINGFIELD,MA 01199								BULLOCK R, 1995, GUIDLINES MANAGEMENT; CENTURA TA, 1994, SURG CLIN N AM, V74, P163; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; DEMARIA EJ, 1987, ANN SURG, V206, P738, DOI 10.1097/00000658-198712000-00009; GIBSON RM, 1989, LANCET, V2, P369; GRANGER CV, 1994, GUIDE USE UNIFORM DA; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; JAMJOOM A, 1992, BRIT J NEUROSURG, V6, P27, DOI 10.3109/02688699209002898; JENNETT B, 1975, LANCET, V1, P480; LAWTON MP, 1982, J GERONTOL, V37, P91, DOI 10.1093/geronj/37.1.91; LAWTON MP, 1990, MILBANK Q, V68, P1, DOI 10.2307/3350075; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; *NATL SAF COUNC, 1992, ACC FACTS; ORESKOVICH MR, 1984, J TRAUMA, V24, P565, DOI 10.1097/00005373-198407000-00003; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Ross A M, 1992, J Neurosci Nurs, V24, P88; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1591; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37	21	70	70	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1996	41	6					957	963		10.1097/00005373-199612000-00003			7	Critical Care Medicine; Surgery	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Surgery	VY407	WOS:A1996VY40700003	8970546				2022-02-06	
J	McIntosh, TK; Smith, DH; Voddi, M; Perri, BR; Stutzmann, JM				McIntosh, TK; Smith, DH; Voddi, M; Perri, BR; Stutzmann, JM			Riluzole, a novel neuroprotective agent, attenuates both neurologic motor and cognitive dysfunction following experimental brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; cognition; edema; excitotoxicity; glutamate; neuroprotection; rat	CONTROLLED CORTICAL IMPACT; AMINO-ACID NEUROTRANSMISSION; GLUTAMATE RELEASE INHIBITOR; REGIONAL CEREBRAL EDEMA; FLUID-PERCUSSION MODEL; SODIUM-CHANNEL BLOCKER; D-ASPARTATE RECEPTORS; MODERATE HYPOTHERMIA; 2-AMINO-6-TRIFLUOROMETHOXY BENZOTHIAZOLE; NEUROCHEMICAL SEQUELAE	Several potential mechanisms are involved in mediating the pathophysiology of traumatic brain injury (TBI), including inflammatory processes and excitotoxicity. In the present study, we evaluated the ability of the use-dependent sodium channel inhibitor Riluzole to attenuate cognitive and neurologic motor deficits and reduce regional cerebral edema and histologic cell damage following lateral fluid-percussion (FP) brain injury in rats (n = 109). In study 1, 58 anesthetized male Sprague-Dawley rats (350-400 g) were subjected to FP brain injury of moderate severity (2.3-2.5 atm). Fifteen minutes following brain injury, animals randomly received an i.v. bolus of either Riluzole (4 mg/kg, n = 11), Riluzole (8 mg/kg, n = 11), or glycol vehicle (n = 20), followed by 6 h and 24 h s.c. injections (identical dose). Surgically prepared but uninjured animals received vehicle (n = 16) and served as controls. Animals were evaluated for cognitive deficits at 48 h postinjury and killed for assessment of regional brain edema. Administration of vehicle or Riluzole (4 mg/kg x 3) had no significant effect on memory or edema, whereas Riluzole (8 mg/kg x 3) significantly attenuated posttraumatic cognitive dysfunction (p < 0.05). In study 2, a second group of animals (n = 25) was injured, treated with Riluzole (8 mg/kg x 3 doses, n = 13) or vehicle (n = 12), and evaluated for neurologic motor function over 2 weeks. Animals treated with Riluzole demonstrated significantly improved motor scores beginning 1 week postinjury (p < 0.05). In study 3, brain-injured animals were treated with Riluzole (8 mg/kg x 3 doses, n = 10) or vehicle (n = 10), and posttraumatic Iesion volume was assessed at 48 h postinjury using 2,3,5-triphenyltetrazolium chloride (TTC) staining. Treatment with Riluzole had no significant effect on posttraumatic lesion volume. The present study demonstrates that use-dependent sodium channel inhibitors, such as Riluzole, can attenuate both cognitive and neuromotor dysfunction associated with brain trauma.	RHONE POULENC RORER,CTR RECH VITRY ALFORTVILLE,DEPT NEUROL DIS,VITRY SUR SEINE,FRANCE		McIntosh, TK (corresponding author), UNIV PENN,DIV NEUROSURG,105 HAYDEN HALL,3320 SMITH WALK,PHILADELPHIA,PA 19104, USA.		smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818, P50NS008803, P01NS008803] Funding Source: NIH RePORTER		ALAOUI F, 1995, EUR J PHARMACOL, V276, P55, DOI 10.1016/0014-2999(95)00006-7; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; BENAZZOUZ A, 1995, EUR J PHARMACOL, V284, P299, DOI 10.1016/0014-2999(95)00362-O; BENOIT E, 1991, PFLUG ARCH EUR J PHY, V419, P603, DOI 10.1007/BF00370302; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; BOIREAU A, 1994, NEUROREPORT, V5, P2157, DOI 10.1097/00001756-199410270-00042; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CLINESCHMIDT BV, 1982, DRUG DEVELOP RES, V2, P123, DOI 10.1002/ddr.430020203; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEBONO MW, 1993, EUR J PHARMACOL, V235, P283, DOI 10.1016/0014-2999(93)90147-A; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DOBLE A, 1989, NEUROCHEM INT, V15, P1, DOI 10.1016/0197-0186(89)90069-7; DOBLE A, 1992, NEUROSCI LETT, V140, P251, DOI 10.1016/0304-3940(92)90114-M; DOBLE A, 1996, IN PRESS NEUROLOGY; ESTEVEZ AG, 1995, EUR J PHARMACOL, V280, P47, DOI 10.1016/0014-2999(95)00186-O; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; FADEN AI, 1989, SCIENCE, V244, P789; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYWARD NJ, 1993, EUR J PHARMACOL, V236, P247, DOI 10.1016/0014-2999(93)90595-9; HEBERT T, 1994, MOL PHARMACOL, V45, P1055; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HYLTON C, 1995, J NEUROTRAUM, V12, P124; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KRAUS JF, 1995, 1 WORLD C BRAIN INJ, P5; LEACH MJ, 1993, STROKE, V24, P1063, DOI 10.1161/01.STR.24.7.1063; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LOWENSTEIN DH, 1990, BRAIN RES, V531, P173, DOI 10.1016/0006-8993(90)90771-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LUSTIG HS, 1992, NEUROSCI LETT, V143, P229, DOI 10.1016/0304-3940(92)90271-8; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MALGOURIS C, 1989, J NEUROSCI, V9, P3720; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MELDRUM BS, 1992, BRAIN RES, V593, P1, DOI 10.1016/0006-8993(92)91254-C; Miyazaki S, 1989, INTRACRANIAL PRESSUR, P651; MIZOULE J, 1985, NEUROPHARMACOLOGY, V24, P767, DOI 10.1016/0028-3908(85)90011-5; MONAGHAN DT, 1986, P NATL ACAD SCI USA, V83, P7532, DOI 10.1073/pnas.83.19.7532; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; Perri Brain, 1995, Journal of Neurotrauma, V12, P481; PRATT J, 1992, NEUROSCI LETT, V140, P225, DOI 10.1016/0304-3940(92)90108-J; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHOHAMI E, 1995, BRAIN RES, V674, P44; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383, DOI 10.1523/JNEUROSCI.13-12-05383.1993; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SMITH SE, 1989, NEUROREPORT, V32, P1339; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STUTZMANN JM, 1991, EUR J PHARMACOL, V193, P223, DOI 10.1016/0014-2999(91)90040-W; STUTZMANN JM, 1995, NEURODEGENERATIVE DI, P205; STUTZMANN JM, 1996, IN PRESS NEUROREPORT; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TORREGROSA G, 1994, J VASC RES, V31, P221, DOI 10.1159/000159047; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; VODDI MD, 1995, J NEUROTRAUM, V12, P146; ZHANG RL, 1993, STROKE, V24, P1235, DOI 10.1161/01.STR.24.8.1235; ZOLAMORGAN S, 1986, BEHAV NEUROSCI, V100, P155, DOI 10.1037/0735-7044.100.2.155	86	70	70	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1996	13	12					767	780		10.1089/neu.1996.13.767			14	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	WC105	WOS:A1996WC10500004	9002062				2022-02-06	
J	Breese, CR; DCosta, A; Rollins, YD; Adams, C; Booze, RM; Sonntag, WE; Leonard, S				Breese, CR; DCosta, A; Rollins, YD; Adams, C; Booze, RM; Sonntag, WE; Leonard, S			Expression of insulin-like growth factor-1 (IGF-1) and IGF-binding protein 2 (IGF-BP2) in the hippocampus following cytotoxic lesion of the dentate gyrus	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						colchicine; brain injury; astroglia; neurotrophic factor; microglia	FIBRILLARY ACIDIC PROTEIN; HYPOXIC-ISCHEMIC INJURY; CENTRAL NERVOUS-SYSTEM; I GENE-EXPRESSION; RAT-BRAIN; MESSENGER-RNA; GRANULE CELLS; GLIAL-CELLS; ADULT-RAT; SPREADING DEPRESSION	Receptor binding and gene expression of several members of the IGF gene family were examined in the rat brain following lesion of the hippocampal dentate gyrus granular cells by intradentate colchicine injection. Dentate granular cell loss was accompanied by extensive reactive gliosis in the lesioned hippocampus and damaged overlying cortex, as verified by the increase in GFAP mRNA and BS-P lectin binding. At 4 days post-lesion, I-125-IGF-2 binding was dramatically increased within the lesioned dentate gyrus and damaged overlying cortex, and corresponded temporally and anatomically with increased IGF-BP2 gene expression following the lesion. Increased IGF-BP3 gene expression was only observed in the overlying cortex at 10 days post-lesion, and corresponded with an increase in I-125-IGF-1 binding at the injured surface of the cortex. Type-2 IGF receptor mRNA expression was reduced to background levels in the lesioned dentate gyrus, suggesting that IGF-BP2 was a major component of the observed increase in I-125-IGF-2 binding. In situ hybridization also revealed a prominent increase in IGF-L mRNA expression by 4 days post-lesion, which was localized within the lesioned dentate gyrus and damaged cortical areas, and was shown to be expressed by microglia. While no IGF-S mRNA expression was observed within the CNS, either prior to, or following the lesion, IGF-2 mRNA expression was observed in the choroid plexus, meningeal membranes, and in blood vessel endothelium, providing a potential source for the transport of IGF-2 into the CNS. In the injured CNS, increased IGF-BP2 expression may act to maintain or transport IGF-1 or IGF-2, as well as modulate the local autocrine and paracrine actions of the IGFs. Increased microglial IGF-1 expression following colchicine treatment con elates with the timing of a number of post-traumatic post-traumatic events within the CNS, suggesting that IGF-1 may have a role as a neuroprotectant for surviving neurons and signal for local neuronal sprouting, as well as a role in reactive astrogliosis. (C) 1996 Wiley-Liss, Inc.	UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL & PSYCHIAT, DENVER, CO 80262 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PHYSIOL & PHARMACOL, WINSTON SALEM, NC 27157 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT NEUROBIOL & ANAT, WINSTON SALEM, NC 27157 USA; UNIV KENTUCKY, ALBERT B CHANDLER MED CTR, DEPT PHARMACOL, LEXINGTON, KY 40536 USA					Booze, Rosemarie/0000-0003-3908-8313; sonntag, William/0000-0003-1850-2407	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [T32AA007464, F31AA005315, R01AA008536] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA05315, AA07464-17, AA08536] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01 AG011370] Funding Source: Medline		AIZENMAN Y, 1987, BRAIN RES, V406, P32, DOI 10.1016/0006-8993(87)90766-9; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANG LC, 1993, DEV BRAIN RES, V74, P83, DOI 10.1016/0165-3806(93)90086-P; AULETTA M, 1992, J NEUROSCI RES, V31, P14, DOI 10.1002/jnr.490310103; BAKHIT C, 1991, BRAIN RES, V560, P76, DOI 10.1016/0006-8993(91)91217-O; BALLARD FJ, 1991, J ENDOCRINOL, V128, P197, DOI 10.1677/joe.0.1280197; BALLARIN M, 1991, EXP NEUROL, V114, P35, DOI 10.1016/0014-4886(91)90082-N; BALLOTTI R, 1987, EMBO J, V6, P3633, DOI 10.1002/j.1460-2075.1987.tb02695.x; BEILHARZ EJ, 1993, MOL BRAIN RES, V18, P209, DOI 10.1016/0169-328X(93)90191-Q; BENVENISTE EN, 1992, CHEM IMMUNOL, V52, P106; BONDY C, 1992, NEUROSCIENCE, V46, P909, DOI 10.1016/0306-4522(92)90193-6; BONDY CA, 1991, J NEUROSCI, V11, P3442; BONTHIUS DJ, 1993, BRAIN RES, V618, P83, DOI 10.1016/0006-8993(93)90432-M; BOVOLENTA P, 1992, PROG BRAIN RES, V94, P367; BRADSHAW SL, 1993, ENDOCRINOLOGY, V133, P1767, DOI 10.1210/en.133.4.1767; BREESE CR, 1991, ADV EXP MED BIOL, V293, P449; BREESE CR, 1994, NEUROSCIENCE, V63, P579, DOI 10.1016/0306-4522(94)90551-7; BREESE CR, 1991, NEUR ABTS, V26, P9; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; DEMELLOW JSM, 1988, BIOCHEM BIOPH RES CO, V156, P199, DOI 10.1016/S0006-291X(88)80824-6; DRUST EG, 1985, BRAIN RES BULL, V14, P9, DOI 10.1016/0361-9230(85)90172-8; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; ENBERG G, 1985, ACTA PHYSIOL SCAND, V125, P305, DOI 10.1111/j.1748-1716.1985.tb07720.x; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GARCIAESTRADA J, 1992, BRAIN RES, V592, P343, DOI 10.1016/0006-8993(92)91695-B; GINN SR, 1991, BRAIN RES, V554, P257, DOI 10.1016/0006-8993(91)90198-5; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GIULIAN D, 1985, J CELL BIOL, V101, P2411, DOI 10.1083/jcb.101.6.2411; GIULIAN D, 1986, J CELL BIOL, V102, P803, DOI 10.1083/jcb.102.3.803; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GOLDSCHMIDT RB, 1980, P NATL ACAD SCI-BIOL, V77, P3047, DOI 10.1073/pnas.77.5.3047; GOMEZPINILLA F, 1992, NEUROSCIENCE, V49, P771, DOI 10.1016/0306-4522(92)90355-6; GUAN J, 1993, J CEREBR BLOOD F MET, V13, P609, DOI 10.1038/jcbfm.1993.79; GUTHRIE KM, 1995, J COMP NEUROL, V352, P147, DOI 10.1002/cne.903520111; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KANJE M, 1989, BRAIN RES, V486, P396, DOI 10.1016/0006-8993(89)90531-3; KIESS W, 1989, ENDOCRINOLOGY, V124, P1727, DOI 10.1210/endo-124-4-1727; KLEMPT M, 1993, MOL BRAIN RES, V17, P347, DOI 10.1016/0169-328X(93)90021-G; KOMOLY S, 1992, P NATL ACAD SCI USA, V89, P1894, DOI 10.1073/pnas.89.5.1894; KRAIG RP, 1991, J NEUROSCI, V11, P2187; LAPCHAK PA, 1993, NEUROREPORT, V4, P191, DOI 10.1097/00001756-199302000-00019; LAUTERIO TJ, 1992, ADV EXP MED BIOL, V321, P31; LEE WH, 1993, NEUROSCIENCE, V53, P251, DOI 10.1016/0306-4522(93)90303-W; LEE WH, 1992, MOL CELL NEUROSCI, V3, P36, DOI 10.1016/1044-7431(92)90006-N; LEONARD S, 1993, MOL BRAIN RES, V18, P275, DOI 10.1016/0169-328X(93)90090-C; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LIU X, 1994, MOL CELL NEUROSCI, V5, P418, DOI 10.1006/mcne.1994.1052; LOGAN A, 1992, J NEUROSCI, V12, P3828; MASTERS BA, 1991, REGUL PEPTIDES, V33, P117, DOI 10.1016/0167-0115(91)90207-W; MAXWELL WL, 1990, PHILOS T R SOC B, V328, P479, DOI 10.1098/rstb.1990.0121; MCMORRIS FA, 1986, P NATL ACAD SCI USA, V83, P822, DOI 10.1073/pnas.83.3.822; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; MUNDY WR, 1990, NEUROTOXICOLOGY, V11, P539; Nachemson AK, 1990, GROWTH FACTORS, V3, P309, DOI 10.3109/08977199009003673; OH Y, 1993, ENDOCRINOLOGY, V132, P1337, DOI 10.1210/en.132.3.1337; Paxinos G, 1986, RAT BRAIN STEREOTAXI; RECIOPINTO E, 1986, J NEUROSCI, V6, P1211; ROBAIN O, 1989, J COMP NEUROL, V285, P274, DOI 10.1002/cne.902850209; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SHEMER J, 1987, J BIOL CHEM, V262, P7693; SONNTAG WE, 1980, ENDOCRINOLOGY, V107, P1875, DOI 10.1210/endo-107-6-1875; STEWARD O, 1993, EXP NEUROL, V124, P167, DOI 10.1006/exnr.1993.1187; STREIT WJ, 1987, J NEUROCYTOL, V16, P249, DOI 10.1007/BF01795308; STYLIANOPOULOU F, 1988, P NATL ACAD SCI USA, V85, P141, DOI 10.1073/pnas.85.1.141; TANDON P, 1994, NEUROTOXICOLOGY, V15, P513; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131	66	70	70	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0021-9967			J COMP NEUROL	J. Comp. Neurol.	JUN 3	1996	369	3					388	404					17	Neurosciences; Zoology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Zoology	UM590	WOS:A1996UM59000005	8743420				2022-02-06	
J	Hamm, RJ; Temple, MD; Pike, BR; ODell, DM; Buck, DL; Lyeth, BG				Hamm, RJ; Temple, MD; Pike, BR; ODell, DM; Buck, DL; Lyeth, BG			Working memory deficits following traumatic brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						spatial working memory; traumatic brain injury, Morris water maze; rats	CLOSED HEAD-INJURY; CELL-DEATH; WATER-MAZE; IMPAIRMENT; HIPPOCAMPAL; DISRUPTION	This study was designed to examine working memory following fluid-percussion traumatic brain injury (TBI) using the Morris water maze (MWM). Rats were injured (n = 9) at a moderate level of central fluid percussion injury (2.1 atm) or were prepared for injury but did not receive a fluid pulse (sham injury) (n = 10). On days 11-15 postinjury, working memory was assessed using the MWM, Each animal received 8 pairs of trials per day, For each pair of trials, animals were randomly assigned to one of four possible starting points and one of four possible escape platform positions, On the first trial of each pair, rats were placed in the maze facing the wall and were given 120 sec to locate the hidden escape platform, After remaining on the goal platform for 10 sec, they were placed back into the maze for the second trial of the pair, The platform position and the start position remained unchanged on this trial, After the second trial, the animal was given a 4 min intertrial rest. Between pairs of trials, both the start position and the goal location were changed, Analyses of the latency to reach the goal platform indicated that sham-injured animals performed significantly better on the second trial than on the first trial of each pair, However, injured animals did not significantly differ between first and second trial goal latencies on any day, These results indicate that injured animals have a profound and enduring deficit in spatial working memory function on days 11-15 after TBI.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23284		Hamm, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,POB 842018,RICHMOND,VA 23284, USA.			Lyeth, Bruce/0000-0003-4811-1474	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-12587] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, P01NS012587] Funding Source: NIH RePORTER		BOISSARD CG, 1992, NEUROSCIENCE, V48, P807, DOI 10.1016/0306-4522(92)90268-7; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879, DOI 10.1016/S0733-8619(18)30185-3; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FRICK KM, 1995, NEUROBIOL AGING, V16, P149, DOI 10.1016/0197-4580(94)00155-3; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Morris RGM., 1983, NEUROBIOLOGY HIPPOCA, P405; OKeefe J., 1978, HIPPOCAMPUS COGNITIV; RAPP PR, 1987, BEHAV NEUROSCI, V101, P3, DOI 10.1037/0735-7044.101.1.3; ROFF RL, 1993, BEHAV BRAIN RES, V57, P47; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; WILKINS RH, 1985, NEUROSURGERY; [No title captured]	22	70	72	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	1996	13	6					317	323		10.1089/neu.1996.13.317			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	UZ052	WOS:A1996UZ05200004	8835799				2022-02-06	
J	DIETRICH, WD; ALONSO, O; BUSTO, R; GINSBERG, MD				DIETRICH, WD; ALONSO, O; BUSTO, R; GINSBERG, MD			WIDESPREAD METABOLIC DEPRESSION AND REDUCED SOMATOSENSORY CIRCUIT ACTIVATION FOLLOWING TRAUMATIC BRAIN INJURY IN RATS	JOURNAL OF NEUROTRAUMA			English	Article								The effects of fluid percussion brain injury on the basal metabolic state and responsiveness of a somatosensory circuit to physiologic activation were investigated with [C-14]2-deoxyglucose autoradiography. Under controlled physiologic conditions and normothermic brain temperature (37 degrees C), rats were injured with a moderate fluid percussion pulse ranging from 1.7 to 2.1 atm. At 4 or 24 h after traumatic brain injury (TBI), unilateral vibrissae stimulation was carried out, resulting in the metabolic activation of the whisker-barrel circuit. In sham-operated control animals, whisker stimulation resulted in the metabolic activation of the ipsilateral trigeminal medullary complex (177% of control), contralateral ventrobasal thalamus (143% control), and primary somatosensory cortex (153% control). At 4 h after injury, local cerebral metabolic rates of glucose (ICMRglu) were significantly depressed throughout the traumatized hemisphere. Although depressed ICMRglu was most pronounced in cortical regions adjacent to the evolving contusion (53% of control), significant decreases were also seen in more remote areas, including the frontal cortex (75% of control), hippocampus (79% control), and lateral thalamus (68% of control). At 24 h following TBI, ICMRglu remained significantly reduced at the impact site, within the ipsilateral somatosensory cortex and lateral thalamus. Stimulus-evoked increases in ICMRglu were depressed within all three relay stations of the vibrissae-barrel-field circuit at 4 and 24 h after TBI. These results demonstrate both focal and diffuse metabolic depression after moderate TBI. Although the most severe and longer lasting metabolic consequences occurred in cortical and thalamic regions destined to exhibit histopathologic damage, milder abnormalities, most prominent in the early posttraumatic period, were also seen in noninjured areas. The inability to activate the somatosensory circuit metabolically indicates that circuit dysfunction is an acute consequence of TBI. Widespread circuit or synaptic dysfunction would be expected to participate in the functional and behavioral consequences of TBI.			DIETRICH, WD (corresponding author), UNIV MIAMI, SCH MED, DEPT NEUROL D4-5, NEUROTRAUMA CLIN RES CTR, POB 016960, MIAMI, FL 33101 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027127, P50NS030291] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-27127, NS-30291] Funding Source: Medline		BECKER DP, 1987, PHYSL BASIS MODERN S, P763; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; DEWITT DS, 1989, J CEREB BLOOD FLO S1, V9, pS93; DIETRICH WD, 1986, J CEREBR BLOOD F MET, V6, P405, DOI 10.1038/jcbfm.1986.73; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GINSBERG MD, 1989, J CEREBR BLOOD F MET, V9, P329, DOI 10.1038/jcbfm.1989.51; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRONWALL D, 1974, LANCET, V2, P605; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEVIN HS, 1985, CENTRAL NERVOUS SYST, P281; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIAZAKI S, 1989, INTRACRANIAL PRESSUR, V7, P651; MITCHELL DE, 1973, LANCET, V2, P215; NAPPER C H, 1989, Society for Neuroscience Abstracts, V15, P134; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKIN AJ, 1984, CORTEX, V20, P479, DOI 10.1016/S0010-9452(84)80053-2; Paxinos G., 1982, RAT BRAIN STEREOTAXI, V1st ed.; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1990, ADV NEUROTRAUMA RES, V2, P1; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; UEKI M, 1988, J CEREBR BLOOD F MET, V8, P486, DOI 10.1038/jcbfm.1988.89; VANDERLOOS H, 1976, NEUROSCI LETT, V2, P1, DOI 10.1016/0304-3940(76)90036-7; WARD AA, 1966, HEAD INJURY C P; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOSHINO A, J CEREB BLOOD FLOW M, V12, P996	52	70	70	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	1994	11	6					629	640		10.1089/neu.1994.11.629			12	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	QD215	WOS:A1994QD21500001	7723063				2022-02-06	
J	CORRIGAN, JD; BOGNER, JA				CORRIGAN, JD; BOGNER, JA			FACTOR STRUCTURE OF THE AGITATED BEHAVIOR SCALE	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY	The Agitated Behavior Scale (ABS; Corrigan, 1989) is a 14-item scale developed to monitor agitation during the acute phase of recovery from acquired brain injury. While previous studies have supported the reliability, internal consistency, and concurrent validity of the ABS, the current study was designed to investigate its underlying factor structure, as well as to determine systematic effects of time-of-day on the occurrence of agitation. Subjects were 212 patients with traumatic or other recently acquired brain injury who exhibited agitation during their treatment on a specialized brain-injury unit of an acute rehabilitation hospital. Confirmatory factor analysis revealed that agitation is best represented by one general construct with three underlying factors: Aggression, Disinhibition, and Lability. Analysis of agitation by nursing shift in which ratings were made confirmed that overall level was lowest during the night shift; however, the relationship between time-of-day and underlying factors deviated from this pattern. Results are discussed in terms of the necessity for objective measurement, definition of the construct of agitation, and time-of-day issues in sampling agitated behavior.			CORRIGAN, JD (corresponding author), OHIO STATE UNIV,DEPT PHYS MED & REHABIL,DIV REHABIL PSYCHOL,480 W 9TH AVE,COLUMBUS,OH 43210, USA.		Corrigan, John D./E-2921-2011				BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN J D, 1992, Brain Injury, V6, P155, DOI 10.3109/02699059209029653; CORRIGAN JD, 1989, J CLIN EXP NEUROPSYC, V11, P261, DOI 10.1080/01688638908400888; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; Herbel K, 1990, Rehabil Nurs, V15, P66; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Kelly G., 2020, PSYCHOL PERSONAL CON; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; MALKMUS D, 1980, REHABILITATION HEAD; MYSIW WJ, 1988, J PHYSICAL MED REHAB, V67, P29; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20	12	70	70	0	8	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JUN	1994	16	3					386	392		10.1080/01688639408402649			7	Psychology, Clinical; Clinical Neurology; Psychology	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Psychology; Neurosciences & Neurology	NR764	WOS:A1994NR76400007	7929706				2022-02-06	
J	HAMM, RJ; WHITEGBADEBO, DM; LYETH, BG; JENKINS, LW; HAYES, RL				HAMM, RJ; WHITEGBADEBO, DM; LYETH, BG; JENKINS, LW; HAYES, RL			THE EFFECT OF AGE ON MOTOR AND COGNITIVE DEFICITS AFTER TRAUMATIC BRAIN INJURY IN RATS	NEUROSURGERY			English	Article						AGE; BRAIN INJURY; CONCUSSION; FLUID PERCUSSION MODEL; HEAD INJURY	SEVERE HEAD-INJURY; PROGNOSIS; CONCUSSION; RECEPTORS; GLUTAMATE; DISEASE; ADULT; COMA	AGE IS ONE of the most important predictors of outcome after human traumatic brain injury. This study used fluid percussion brain injury to investigate the effects of aging on outcome after brain injury in rats. Three-month-old (n = 8) and 20-month-old (n = 11) rats were injured at a low level (1.7-1.8 atm) of fluid percussion brain injury or received a sham injury (n = 6 for both age groups). Body weight and motor function (beam balance and beam walking) were assessed before injury and for the first 5 days after injury. Cognitive outcome was assessed with the Morris water maze on Days 11 to 15 after injury. Injury did not produce significant weight loss in either age group. At the low level of brain injury used in this study, the 3-month-old rats did not demonstrate any significant motor deficits on the beam-balance or beam-walking tasks. However, the 20-month-old rats displayed significant beam-balance deficits on each of the 5 postinjury test days and significant beam-walking deficits for the first 3 postinjury days. Although Morris water maze performance was impaired in both age groups, the magnitude of impairment was greater in the aged animals. These data demonstrate that traumatic brain injury in the aged animal is marked by increased motor and cognitive deficits, in the absence of pronounced compromise of the animal's general health. Because the rat model of fluid percussion brain injury reproduces the age-related increase in chronic morbidity observed in cases of human brain injury, the fluid percussion model should be useful for studying mechanisms responsible for the age-related increase in vulnerability to brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298		HAMM, RJ (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PSYCHOL,VCU BOX 2018,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019950, R01NS021458, P01NS012587, P50NS012587] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS21458, NS19950, NS12587] Funding Source: Medline		ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BRICOLO A, 1977, J NEUROSURG, V47, P680, DOI 10.3171/jns.1977.47.5.0680; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CHIO SC, 1983, J NEUROSURG, V59, P294; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; COTMAN CW, 1989, DRUG DEVELOP RES, V17, P331, DOI 10.1002/ddr.430170408; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GREENAMYRE JT, 1986, ARCH NEUROL-CHICAGO, V43, P1058, DOI 10.1001/archneur.1986.00520100062016; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HAMM RJ, 1991, J NEUROSURG, V85, P915; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; KENNARD MA, 1940, AM J PHYSIOL, V115, P138; KENNARD MA, 1942, ARCH NEUROL PSYCHIAT, V48, P228; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAKIYAMA Y, IN PRESS ACTA NEUROP; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; OVERGAARD J, 1973, LANCET, V2, P631; PAZZAGLIA P, 1975, J NEUROL NEUROSUR PS, V38, P149, DOI 10.1136/jnnp.38.2.149; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SCHWARCZ R, 1984, LIFE SCI, V35, P19, DOI 10.1016/0024-3205(84)90148-6; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILSON JA, 1988, BRAIN INJURY, V1, P183; [No title captured]	41	70	71	0	2	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	DEC	1992	31	6					1072	1078		10.1227/00006123-199212000-00013			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	KD087	WOS:A1992KD08700013	1335138				2022-02-06	
J	THOMSEN, IV				THOMSEN, IV			LATE PSYCHOSOCIAL OUTCOME IN SEVERE TRAUMATIC BRAIN INJURY - PRELIMINARY-RESULTS OF A 3RD FOLLOW-UP-STUDY AFTER 20 YEARS	SCANDINAVIAN JOURNAL OF REHABILITATION MEDICINE			English	Article						SEVERE HEAD INJURY; LATE PSYCHOSOCIAL OUTCOME; BEHAVIORAL DEFICITS; FAMILY RELATIONSHIPS		More than 20 years after severe head injury the preliminary results of the present study indicate that the very late psychosocial outcome differed much in the individual subjects. The most decisive negative factors were severely disturbed behaviour and lack of insight. Improvement many years after injury was, however, possible. During the years the relationship between parent(s) and severely head injured sons often became strained. After the first posttraumatic year or two the patient with severe behavioural deficits must be helped to adopt some other type of living.			THOMSEN, IV (corresponding author), UNIV COPENHAGEN HOSP,RIGSHOSP,DEPT NEUROL,DK-2100 COPENHAGEN,DENMARK.							0	70	71	0	1	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0036-5505			SCAND J REHABIL MED	Scand. J. Rehabil. Med.		1992				26			142	152					11	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	KG064	WOS:A1992KG06400014	1488637				2022-02-06	
J	WEHMAN, PH; KREUTZER, JS; WEST, MD; SHERRON, PD; ZASLER, ND; GROAH, CH; STONNINGTON, HH; BURNS, CT; SALE, PR				WEHMAN, PH; KREUTZER, JS; WEST, MD; SHERRON, PD; ZASLER, ND; GROAH, CH; STONNINGTON, HH; BURNS, CT; SALE, PR			RETURN TO WORK FOR PERSONS WITH TRAUMATIC BRAIN INJURY - A SUPPORTED EMPLOYMENT APPROACH	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article											WEHMAN, PH (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT REHABIL MED,RICHMOND,VA 23298, USA.						Ben-Yishay Y., 1987, J HEAD TRAUMA REHAB, V2, P35, DOI [10.1097/00001199-198703000-00007, DOI 10.1097/00001199-198703000-00007]; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Burke W H, 1988, Brain Inj, V2, P313, DOI 10.3109/02699058809150902; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; Dahlstrom W. G., 1972, MMPI HDB, V1; EAMES P, 1988, J HEAD TRAUMA REHAB, V3, P1; FRASER RT, 1988, REHABILITATION ED, V2, P179; GRANGER CV, 1982, KRUSENS HDB PHYSICAL, P253; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kreutzer J S, 1988, Brain Inj, V2, P205, DOI 10.3109/02699058809150945; KREUTZER JS, 1989, REHABIL PSYCHOL, V34, P117; KREUTZER JS, 1988, VOCATIONAL REHABILIT, P291; KREUTZER JS, 1987, REHABILITATION RES T; MANK D, 1986, PATHWAYS EMPLOYMENT, P139; MCMORDLE W, 1989, BRAIN INJURY, V4, P57; MOON MS, 1988, VOCATIONAL REHABILIT, P17; PECK G, 1984, ANN M INT NEUROPSYCH; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1988, J HEAD TRAUMA REHAB, V3, P23; REITAN RM, 1979, HALSTEAD REITAN NEUR; Wechsler, 1997, WECHSLER ADULT INTEL; Wehman P, 1989, Brain Inj, V3, P397, DOI 10.3109/02699058909004563; WEHMAN P, 1989, ARCH PHYS MED REHAB, V70, P109; WEHMAN P, 1988, REHABIL COUNS BULL, V31, P298; Wehman P., 1988, J HEAD TRAUMA REHAB, V3, P82, DOI DOI 10.1097/00001199-198812000-00012; Wehman P., 1989, J HEAD TRAUMA REHAB, V4, P66, DOI [10.1097/00001199-198909000-00010, DOI 10.1097/00001199-198909000-00010]; Wehman P, 1985, J ASSOC PERS SEVERE, V10, P3; WEHMAN P, 1990, VOCATIONAL REHABILIT; WIEDERHOLT FL, 1986, GRAY ORAL READING TE; ZASLER ND, 1990, VOCATIONAL REHABILIT, P71; ZUNG BJ, 1975, J STUD ALCOHOL, V36, P127, DOI 10.15288/jsa.1975.36.127; ZUNG BJ, 1979, J STUD ALCOHOL, V40, P845, DOI 10.15288/jsa.1979.40.845; 1984, WIDE RANGE ACHIEVEME; 1985, STATISTICAL ANAL SYS	35	70	70	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1990	71	13					1047	1052					6	Rehabilitation; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation; Sport Sciences	EN093	WOS:A1990EN09300002	2256804				2022-02-06	
J	EVANS, RW; GUALTIERI, CT; PATTERSON, D				EVANS, RW; GUALTIERI, CT; PATTERSON, D			TREATMENT OF CHRONIC CLOSED HEAD-INJURY WITH PSYCHOSTIMULANT DRUGS - A CONTROLLED CASE-STUDY AND AN APPROPRIATE EVALUATION PROCEDURE	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article									UNIV N CAROLINA,SCH MED,DEPT PSYCHIAT,CHAPEL HILL,NC 27514		EVANS, RW (corresponding author), UNIV N CAROLINA,SCH MED,BIOL SCI RES CTR,220-H,CHAPEL HILL,NC 27514, USA.				NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD 07201] Funding Source: Medline		EVANS RW, 1986, CLIN NEUROPHARMACOL, V9, P264, DOI 10.1097/00002826-198606000-00005; EVANS RW, 1986, 14TH ANN M INT NEUR; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GOYETTE CH, 1978, J ABNORM CHILD PSYCH, V6, P221, DOI 10.1007/BF00919127; GUALTIERI CT, 1982, J AM ACAD CHILD PSY, V21, P19, DOI 10.1097/00004583-198201000-00005; GUALTIERI CT, 1984, PSYCHOPHARMACOLOGY, V83, P44, DOI 10.1007/BF00427420; HAAS JF, 1985, ARCH PHYS MED REHAB, V66, P472; JACKSON RD, 1985, ARCH PHYS MED REHAB, V66, P180; Levin HS., 1982, NEUROBEHAVIORAL CONS; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; RAPOPORT JL, 1980, ARCH GEN PSYCHIAT, V37, P933; STERN JM, 1978, SCAND J REHABIL MED, V10, P7; WEINGARTNER H, 1982, PSYCHIAT RES, V6, P21, DOI 10.1016/0165-1781(82)90034-8; WEINSTEIN GS, 1981, J CLIN PSYCHIAT, V42, P120; WENDER PH, 1985, AM J PSYCHIAT, V142, P547; WERRY JS, 1978, PEDIATRIC PSYCHOPHAR	17	70	70	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0022-3018			J NERV MENT DIS	J. Nerv. Ment. Dis.	FEB	1987	175	2					106	110		10.1097/00005053-198702000-00007			5	Clinical Neurology; Psychiatry	Social Science Citation Index (SSCI); Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry	G0548	WOS:A1987G054800007	3543216				2022-02-06	
J	HADLEY, MN; GRAHM, TW; HARRINGTON, T; SCHILLER, WR; MCDERMOTT, MK; POSILLICO, DB				HADLEY, MN; GRAHM, TW; HARRINGTON, T; SCHILLER, WR; MCDERMOTT, MK; POSILLICO, DB			NUTRITIONAL SUPPORT AND NEUROTRAUMA - A CRITICAL-REVIEW OF EARLY NUTRITION IN 45 ACUTE HEAD-INJURY PATIENTS	NEUROSURGERY			English	Article									ST JOSEPHS HOSP & MED CTR, TRAUMA SERV, PHOENIX, AZ 85013 USA		HADLEY, MN (corresponding author), ST JOSEPHS HOSP & MED CTR, BARROW NEUROL INST, DIV NEUROL SURG, PHOENIX, AZ 85013 USA.						ASKANAZI J, 1980, ANN SURG, V191, P40, DOI 10.1097/00000658-198001000-00008; BLACKETT RL, 1978, BRIT J SURG, V65, P393, DOI 10.1002/bjs.1800650607; BORDER JR, 1976, SURG CLIN N AM, V56, P1147; BOZZETTI F, 1982, SURGERY, V91, P383; CERRA FB, 1980, ANN SURG, V192, P570, DOI 10.1097/00000658-198010000-00015; CLIFTON GL, 1984, J NEUROSURG, V60, P687, DOI 10.3171/jns.1984.60.4.0687; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; DEUTSCHMAN CS, 1986, J NEUROSURG, V64, P89, DOI 10.3171/jns.1986.64.1.0089; DOMINIONI L, 1985, JPEN-PARENTER ENTER, V9, P269, DOI 10.1177/0148607185009003269; FELL D, 1984, CRIT CARE MED, V12, P649, DOI 10.1097/00003246-198408000-00009; GADISSEUX P, 1984, J NEUROSURG, V60, P219, DOI 10.3171/jns.1984.60.2.0219; Garden O J, 1983, Clin Nutr, V2, P51, DOI 10.1016/0261-5614(83)90031-6; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Harris J, 1919, CARNEGIE I WASHINGTO, V279; KEOHANE PP, 1983, LANCET, V2, P1388; LONG CL, 1979, JPEN-PARENTER ENTER, V3, P69, DOI 10.1177/014860717900300269; MULLEN JL, 1980, ANN SURG, V192, P604, DOI 10.1097/00000658-198019250-00004; OMAHONY JB, 1984, J TRAUMA, V24, P869, DOI 10.1097/00005373-198410000-00001; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; ROBERTSON CS, 1984, NEUROSURGERY, V15, P307, DOI 10.1227/00006123-198409000-00003; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; SCHILLER WR, 1979, SURG GYNECOL OBSTET, V149, P561; SITGESSERRA A, 1985, JPEN-PARENTER ENTER, V9, P322, DOI 10.1177/0148607185009003322; SOROFF HS, 1961, SURG GYNECOL OBSTET, V112, P159	24	70	73	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	1986	19	3					367	373		10.1227/00006123-198609000-00006			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	D9560	WOS:A1986D956000006	3093915				2022-02-06	
J	Williams, D; Denny-Brown, D				Williams, D; Denny-Brown, D			Cerebral electrical changes in experimental concussion	BRAIN			English	Article																	Adrian ED, 1934, BRAIN, V57, P355, DOI 10.1093/brain/57.4.355; Berger H, 1930, J PSYCHOL NEUROL, V40, P160; COURTNEY JW, 1899, BOSTON M S J, V140, P373; COURTNEY JW, 1899, BOSTON MED SURG J, V140, P397; COURTNEY JW, 1899, BOSTON M S J, V140, P345; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DENNYBROWN D, 1941, BRAIN, V64; Derbyshire AJ, 1936, AM J PHYSIOL, V116, P577, DOI 10.1152/ajplegacy.1936.116.3.577; Dixon KC, 1940, LANCET, V2, P360; Lennox WG, 1938, J NEUROL PSYCHIATRY, V1, P211, DOI 10.1136/jnnp.1.3.211; LOOMIS ALFRED L., 1935, SCIENCE, V81, P597, DOI 10.1126/science.81.2111.597; MARTIN JP, 1939, P ROY SOC MED, V32, P141; TROTTER W, 1923, SYSTEM SURG, V3, P464; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P107, DOI 10.1136/jnnp.4.2.107; Williams D, 1941, J NEUROL PSYCHIATRY, V4, P131, DOI 10.1136/jnnp.4.2.131; WILLIAMS DE, UNPUB	16	70	70	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain		1941	64						223	238		10.1093/brain/64.4.223			16	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V20IW	WOS:000201375000010					2022-02-06	
J	Stern, RA; Adler, CH; Chen, KW; Navitsky, M; Luo, J; Dodick, DW; Alosco, ML; Tripodis, Y; Goradia, DD; Martin, B; Mastroeni, D; Fritts, NG; Jarnagin, J; Devous, MD; Mintun, MA; Pontecorvo, MJ; Shenton, ME; Reiman, EM				Stern, Robert A.; Adler, Charles H.; Chen, Kewei; Navitsky, Michael; Luo, Ji; Dodick, David W.; Alosco, Michael L.; Tripodis, Yorghos; Goradia, Dhruman D.; Martin, Brett; Mastroeni, Diego; Fritts, Nathan G.; Jarnagin, Johnny; Devous, Michael D., Sr.; Mintun, Mark A.; Pontecorvo, Michael J.; Shenton, Martha E.; Reiman, Eric M.			Tau Positron-Emission Tomography in Former National Football League Players	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMER-DISEASE; BETA	BACKGROUND Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease that has been associated with a history of repetitive head impacts. The neuropathological diagnosis is based on a specific pattern of tau deposition with minimal amyloid-beta deposition that differs from other disorders, including Alzheimer's disease. The feasibility of detecting tau and amyloid deposition in the brains of living persons at risk for CTE has not been well studied. METHODS We used flortaucipir positron-emission tomography (PET) and florbetapir PET to measure deposition of tau and amyloid-beta, respectively, in the brains of former National Football League (NFL) players with cognitive and neuropsychiatric symptoms and in asymptomatic men with no history of traumatic brain injury. Automated image-analysis algorithms were used to compare the regional tau standardized uptake value ratio (SUVR, the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference) between the two groups and to explore the associations of SUVR with symptom severity and with years of football play in the former-player group. RESULTS A total of 26 former players and 31 controls were included in the analysis. The mean flortaucipir SUVR was higher among former players than among controls in three regions of the brain: bilateral superior frontal (1.09 vs. 0.98; adjusted mean difference, 0.13; 95% confidence interval [CI], 0.06 to 0.20; P<0.001), bilateral medial temporal (1.23 vs. 1.12; adjusted mean difference, 0.13; 95% CI, 0.05 to 0.21; P<0.001), and left parietal (1.12 vs. 1.01; adjusted mean difference, 0.12; 95% CI, 0.05 to 0.20; P = 0.002). In exploratory analyses, the correlation coefficients in these three regions between the SUVRs and years of play were 0.58 (95% CI, 0.25 to 0.79), 0.45 (95% CI, 0.07 to 0.71), and 0.50 (95% CI, 0.14 to 0.74), respectively. There was no association between tau deposition and scores on cognitive and neuropsychiatric tests. Only one former player had levels of amyloid-beta deposition similar to those in persons with Alzheimer's disease. CONCLUSIONS A group of living former NFL players with cognitive and neuropsychiatric symptoms had higher tau levels measured by PET than controls in brain regions that are affected by CTE and did not have elevated amyloid-beta levels. Further studies are needed to determine whether elevated CTE-associated tau can be detected in individual persons.	[Stern, Robert A.; Alosco, Michael L.; Fritts, Nathan G.; Jarnagin, Johnny] Boston Univ, Sch Med, Boston, MA 02118 USA; [Tripodis, Yorghos; Martin, Brett] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Shenton, Martha E.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Shenton, Martha E.] Harvard Med Sch, Boston, MA 02115 USA; [Shenton, Martha E.] Vet Affairs Boston Healthcare Syst, Boston, MA USA; [Adler, Charles H.; Dodick, David W.] Mayo Clin Arizona, Scottsdale, AZ USA; [Chen, Kewei; Luo, Ji; Goradia, Dhruman D.; Reiman, Eric M.] Banner Alzheimers Inst, Phoenix, AZ USA; [Mastroeni, Diego] Arizona State Univ, Tempe, AZ USA; [Navitsky, Michael; Devous, Michael D., Sr.; Mintun, Mark A.; Pontecorvo, Michael J.] Avid Radio Pharmaceut, Philadelphia, PA USA		Stern, RA (corresponding author), Boston Univ, Sch Med, Alzheimers Dis Ctr, 72 E Concord St,B-7800, Boston, MA 02118 USA.	bobstern@bu.edu	Shenton, Martha/V-8780-2019; Adler, Charles/ABD-5276-2021; , Bob/ABA-8507-2020	Tripodis, Yorghos/0000-0003-2190-7608	Avid Radiopharmaceuticals; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS093334, K23NS102399] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, U19AG024904, P30AG019610] Funding Source: NIH RePORTER	Funded by Avid Radiopharmaceuticals and others.	Alosco ML, 2018, ALZHEIMERS DEMENT, V14, P1159, DOI 10.1016/j.jalz.2018.05.004; Alosco ML, 2018, ANN NEUROL, V83, P886, DOI 10.1002/ana.25245; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Alosco ML, 2016, ALZHEIMERS DEMENT, V7, P33; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Congdon EE, 2018, NAT REV NEUROL, V14, P399, DOI 10.1038/s41582-018-0013-z; Dickstein DL, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.175; Falcon B, 2019, NATURE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Laforce R, 2018, ALZHEIMERS DEMENT, V14, P1522, DOI 10.1016/j.jalz.2018.06.2855; Lee CM, 2018, J ALZHEIMERS DIS, V62, P1691, DOI 10.3233/JAD-170840; Lyoo CH, 2018, J MOV DISORD, V11, P1, DOI 10.14802/jmd.17071; Marquie M, 2017, ANN NEUROL, V81, P117, DOI 10.1002/ana.24844; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Ossenkoppele R, 2018, JAMA-J AM MED ASSOC, V320, P1151, DOI 10.1001/jama.2018.12917; Phillips JS, 2018, HUM BRAIN MAPP, V39, P691, DOI 10.1002/hbm.23874; Pontecorvo MJ, 2017, BRAIN, V140, P748, DOI 10.1093/brain/aww334; Schonhaut DR, 2017, ANN NEUROL, V82, P622, DOI 10.1002/ana.25060; Smith R, 2018, JAMA NEUROL; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Villemagne VL, 2018, NAT REV NEUROL, V14, P225, DOI 10.1038/nrneurol.2018.9; 2012, LANCET NEUROL, V11, P669, DOI DOI 10.1016/S1474-4422(12)70142-4; 2017, ACTA NEUROPATHOL, V133, P337, DOI DOI 10.1007/S00401-017-1680-3	28	69	71	2	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	2019	380	18					1716	1725		10.1056/NEJMoa1900757			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	HX9ZK	WOS:000467767800007	30969506	Green Accepted, Bronze			2022-02-06	
J	Zhang, J; Liu, XJ; Xu, WJ; Luo, WH; Li, M; Chu, FB; Xu, L; Cao, AY; Guan, JS; Tang, SM; Duan, XJ				Zhang, Jing; Liu, Xiaojun; Xu, Wenjing; Luo, Wenhan; Li, Ming; Chu, Fangbing; Xu, Lu; Cao, Anyuan; Guan, Jisong; Tang, Shiming; Duan, Xiaojie			Stretchable Transparent Electrode Arrays for Simultaneous Electrical and Optical Interrogation of Neural Circuits in Vivo	NANO LETTERS			English	Article						Stretchable electronics; transparent electrode; neural electrode array; brain activity mapping; optogenetics; calcium imaging; traumatic brain injury; nanobio interface; carbon nanotube	WALLED CARBON NANOTUBES; LARGE-AREA; BRAIN; OPTOGENETICS; GRAPHENE; NEURONS; ACCELERATION; BIOMECHANICS; DEFORMATION; STIMULATION	Recent developments of transparent electrode arrays provide a unique capability for simultaneous optical and electrical interrogation of neural circuits in the brain. However, none of these electrode arrays possess the stretchability highly desired for interfacing with mechanically active neural systems, such as the brain under injury, the spinal cord, and the peripheral nervous system (PNS). Here, we report a stretchable transparent electrode array from carbon nanotube (CNT) web-like thin films that retains excellent electrochemical performance and broad-band optical transparency under stretching and is highly durable under cyclic stretching deformation. We show that the CNT electrodes record well-defined neuronal response signals with negligible light-induced artifacts from cortical surfaces under optogenetic stimulation. Simultaneous two-photon calcium imaging through the transparent CNT electrodes from cortical surfaces of GCaMP-expressing mice with epilepsy shows individual activated neurons in brain regions from which the concurrent electrical recording is taken, thus providing complementary cellular information in addition to the high-temporal-resolution electrical recording. Notably, the studies on rats show that the CNT electrodes remain operational during and after brain contusion that involves the rapid deformation of both the electrode array and brain tissue. This enables real-time, continuous electrophysiological monitoring of cortical activity under traumatic brain injury. These results highlight the potential application of the stretchable transparent CNT electrode arrays in combining electrical and optical modalities to study neural circuits, especially under mechanically active conditions, which could potentially provide important new insights into the local circuit dynamics of the spinal cord and PNS as well as the mechanism underlying traumatic injuries of the nervous system.	[Zhang, Jing; Liu, Xiaojun; Chu, Fangbing; Duan, Xiaojie] Peking Univ, Coll Engn, Dept Biomed Engn, Beijing 100871, Peoples R China; [Zhang, Jing; Luo, Wenhan; Li, Ming; Tang, Shiming] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China; [Zhang, Jing; Luo, Wenhan; Li, Ming; Tang, Shiming; Duan, Xiaojie] Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China; [Zhang, Jing; Liu, Xiaojun; Chu, Fangbing; Duan, Xiaojie] Peking Univ, Ctr Nanochem, Beijing Sci & Engn Ctr Nanocarbons, Beijing 100871, Peoples R China; [Xu, Wenjing; Xu, Lu; Cao, Anyuan] Peking Univ, Dept Mat Sci & Engn, Coll Engn, Beijing 100871, Peoples R China; [Li, Ming; Tang, Shiming] Peking Univ, Sch Life Sci, Beijing 100871, Peoples R China; [Luo, Wenhan; Guan, Jisong] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Guan, Jisong] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China		Duan, XJ (corresponding author), Peking Univ, Coll Engn, Dept Biomed Engn, Beijing 100871, Peoples R China.; Duan, XJ (corresponding author), Peking Univ, Acad Adv Interdisciplinary Studies, Beijing 100871, Peoples R China.; Duan, XJ (corresponding author), Peking Univ, Ctr Nanochem, Beijing Sci & Engn Ctr Nanocarbons, Beijing 100871, Peoples R China.	xjduan@pku.edu.cn		Luo, Wenhan/0000-0001-5202-8855; Li, Ming/0000-0001-5173-1602; Guan, Ji-Song/0000-0001-5219-0289	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [21422301, 91648207, 21373013]; National Basic Research Program of ChinaNational Basic Research Program of China [2016YFA0200103, 2014CB932500]; China's 1000 Young Talent Award program; Microelectronics Research Center at Peking University	We thank the Microelectronics Research Center at Peking University for the microfabrication facility and support, the Animal Resources Center at Peking University for animal housing and care, and the Core Facilities at the School of Life Sciences, Peking University, for assistance with two-photon imaging. This work was supported by grants from the National Natural Science Foundation of China (grant nos. 21422301, 91648207, and 21373013), the National Basic Research Program of China (grant nos. 2016YFA0200103 and 2014CB932500), and China's 1000 Young Talent Award program.	Anikeeva P, 2012, NAT NEUROSCI, V15, P163, DOI 10.1038/nn.2992; [Anonymous], 2007, J NEUROSCI, V27, P14231; Bachilo SM, 2002, SCIENCE, V298, P2361, DOI 10.1126/science.1078727; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Berciaud S, 2007, NANO LETT, V7, P1203, DOI 10.1021/nl062933k; Canales A, 2015, NAT BIOTECHNOL, V33, P277, DOI 10.1038/nbt.3093; Cardin JA, 2010, NAT PROTOC, V5, P247, DOI 10.1038/nprot.2009.228; Carlson GC, 2008, NAT PROTOC, V3, P249, DOI 10.1038/nprot.2007.539; Carriero G, 2010, J NEUROPHYSIOL, V103, P2728, DOI 10.1152/jn.00862.2009; Carvalho-de-Souza JL, 2015, NEURON, V86, P207, DOI 10.1016/j.neuron.2015.02.033; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen Q, 2012, NEURON, V76, P297, DOI 10.1016/j.neuron.2012.07.011; Chen T, 2014, ACS NANO, V8, P1039, DOI 10.1021/nn405939w; Cheng A, 2011, NAT METHODS, V8, P139, DOI 10.1038/NMETH.1552; Deisseroth K, 2011, NAT METHODS, V8, P26, DOI 10.1038/NMETH.F.324; Dresselhaus MS, 2001, CARBON NANOTUBES SYN; Ghezzi D, 2013, NAT PHOTONICS, V7, P400, DOI [10.1038/NPHOTON.2013.34, 10.1038/nphoton.2013.34]; Goncalves JT, 2013, NAT NEUROSCI, V16, P903, DOI 10.1038/nn.3415; Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607; Harrison DE, 1999, J MANIP PHYSIOL THER, V22, P227, DOI 10.1016/S0161-4754(99)70049-7; Honda K, 2004, J PHOTOCH PHOTOBIO A, V166, P63, DOI 10.1016/j.jphotochem.2004.04.027; Jiang YW, 2016, NAT MATER, V15, P1023, DOI [10.1038/nmat4673, 10.1038/NMAT4673]; Kim KS, 2009, NATURE, V457, P706, DOI 10.1038/nature07719; Kim K, 2015, NANOSCALE, V7, P14577, DOI 10.1039/c5nr04341g; Kim KH, 2011, ADV MATER, V23, P2865, DOI 10.1002/adma.201100310; Kim TI, 2013, SCIENCE, V340, P211, DOI 10.1126/science.1232437; Kuzum D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6259; Lacour SP, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.63; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Laxpati Nealen G, 2014, Front Neuroeng, V7, P40, DOI 10.3389/fneng.2014.00040; Ledochowitsch P, 2015, J NEUROSCI METH, V256, P220, DOI 10.1016/j.jneumeth.2015.07.028; Lee J, 2015, NAT METHODS, V12, P1157, DOI 10.1038/nmeth.3620; Li Z, 2010, J MATER CHEM, V20, P7236, DOI 10.1039/c0jm01361g; Lipomi DJ, 2011, NAT NANOTECHNOL, V6, P788, DOI [10.1038/nnano.2011.184, 10.1038/NNANO.2011.184]; Liu KH, 2012, NAT NANOTECHNOL, V7, P325, DOI [10.1038/nnano.2012.52, 10.1038/NNANO.2012.52]; Mayevsky A., 2003, J NEUROTRAUM, V20, P1315; Minev IR, 2015, SCIENCE, V347, P159, DOI 10.1126/science.1260318; Montgomery KL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7577; Nikolenko V, 2007, NAT METHODS, V4, P943, DOI 10.1038/NMETH1105; Packer AM, 2013, NAT NEUROSCI, V16, P805, DOI 10.1038/nn.3427; Park DW, 2016, NAT PROTOC, V11, P2201, DOI 10.1038/nprot.2016.127; Park DW, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6258; Park S, 2017, NAT NEUROSCI, V20, P612, DOI 10.1038/nn.4510; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Scanziani M, 2009, NATURE, V461, P930, DOI 10.1038/nature08540; Topp KS, 2006, PHYS THER, V86, P92, DOI 10.1093/ptj/86.1.92; Wang GF, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.019; Wu H, 2013, NAT NANOTECHNOL, V8, P421, DOI [10.1038/nnano.2013.84, 10.1038/NNANO.2013.84]; Yang L, 2017, NANO LETT, V17, P71, DOI 10.1021/acs.nanolett.6b03356; Zang JF, 2013, NAT MATER, V12, P321, DOI [10.1038/nmat3542, 10.1038/NMAT3542]; Zhang JY, 2009, J NEURAL ENG, V6, DOI 10.1088/1741-2560/6/5/055007; Zhao SY, 2016, NANO LETT, V16, P7731, DOI 10.1021/acs.nanolett.6b03829	52	69	73	23	161	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	1530-6984	1530-6992		NANO LETT	Nano Lett.	MAY	2018	18	5					2903	2911		10.1021/acs.nanolett.8b00087			9	Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied; Physics, Condensed Matter	Science Citation Index Expanded (SCI-EXPANDED)	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	GF6QT	WOS:000432093200023	29608857				2022-02-06	
J	Wang, MH; Ding, FF; Deng, SY; Guo, XQ; Wang, W; Iliff, JJ; Nedergaard, M				Wang, Minghuan; Ding, Fengfei; Deng, SaiYue; Guo, Xuequn; Wang, Wei; Iliff, Jeffrey J.; Nedergaard, Maiken			Focal Solute Trapping and Global Glymphatic Pathway Impairment in a Murine Model of Multiple Microinfarcts	JOURNAL OF NEUROSCIENCE			English	Article						glymphatic; microinfarct; vascular dementia	CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; CONTRAST-ENHANCED MRI; VASCULAR DEMENTIA; CORTICAL MICROINFARCTS; INTERSTITIAL FLUID; CLEARANCE; DISEASE; LESIONS; SYSTEM	Microinfarcts occur commonly in the aging brain as a consequence of diffuse embolic events and are associated with the development of vascular dementia and Alzheimer's disease. However, the manner in which disperse microscopic lesions reduce global cognitive function and increase the risk for Alzheimer's disease is unclear. The glymphatic system, which is a brain-wide perivascular network that supports the recirculation of CSF through the brain parenchyma, facilitates the clearance of interstitial solutes including amyloid beta and tau. We investigated whether glymphatic pathway function is impaired in a murine model of multiple microinfarcts induced by intraarterial injection of cholesterol crystals. The analysis showed that multiple microinfarcts markedly impaired global influx of CSF along the glymphatic pathway. Although suppression of global glymphatic function was transient, resolving within 2 weeks of injury, CSF tracers also accumulated within tissue associated with microinfarcts. The effect of diffuse microinfarcts on global glymphatic pathway function was exacerbated in the mice aged 12 months compared with the 2-to 3-month-old mice. These findings indicate that glymphatic function is focally disrupted around microinfarcts and that the aging brain is more vulnerable to this disruption than the young brain. These observations suggest that microlesions may trap proteins and other interstitial solutes within the brain parenchyma, increasing the risk of amyloid plaque formation.	[Wang, Minghuan; Ding, Fengfei; Iliff, Jeffrey J.; Nedergaard, Maiken] Univ Rochester, Div Glial Dis & Therapeut, Dept Neurosurg, Med Ctr,Ctr Translat Neuromed, Rochester, NY 14642 USA; [Wang, Minghuan; Ding, Fengfei; Deng, SaiYue; Guo, Xuequn; Wang, Wei] Huazhong Univ Sci & Technol, Tongii Hosp, Dept Neurol, Tongii Med Coll, Wuhan 430030, Peoples R China; [Iliff, Jeffrey J.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA; [Nedergaard, Maiken] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Basic & Translat Neurosci, DK-2200 Copenhagen, Denmark		Nedergaard, M (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Ctr Basic & Translat Neurosci, DK-2200 Copenhagen, Denmark.; Iliff, JJ (corresponding author), Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, 3181 SW Sam Jackson Pk Rd Mail Code L458, Portland, OR 97239 USA.; Nedergaard, M (corresponding author), Univ Rochester, Ctr Translat Neuromed, Med Ctr, Box 645,575 Elmwood Ave, Rochester, NY 14642 USA.	iliffj@ohsu.edu; Nedergaard@URMC.Rochester.edu		Nedergaard, Maiken/0000-0001-6502-6031	National Institute of Neurological DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Stroke-National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); American Heart AssociationAmerican Heart Association; Leducq FoundationLeducq Foundation; European UnionEuropean Commission [666881]; Lundbeck FoundationLundbeckfonden [R155-2016-552] Funding Source: researchfish; Novo Nordisk FondenNovo Nordisk Foundation [NNF13OC0004258] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS100366, R01NS089709, R01NS078304, R01NS075177, R01NS078167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048769] Funding Source: NIH RePORTER	This work was supported by the National Institute of Neurological Disorders and Stroke-National Institutes of Health, the American Heart Association, the Leducq Foundation, and the European Union's Horizon 2020 Research and Innovation Programme (Grant 666881, SVDs@ target). We thank Yonghong Liao for expert technical support.	Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; de Leeuw FE, 2001, J NEUROL NEUROSUR PS, V70, P9, DOI 10.1136/jnnp.70.1.9; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; Esiri MM, 1997, J NEUROL NEUROSUR PS, V63, P749, DOI 10.1136/jnnp.63.6.749; Gaberel T, 2014, STROKE, V45, P3092, DOI 10.1161/STROKEAHA.114.006617; Haglund M, 2006, INT J GERIATR PSYCH, V21, P681, DOI 10.1002/gps.1550; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Kovari E, 2013, NEUROPATH APPL NEURO, V39, P498, DOI 10.1111/nan.12003; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Simon MJ, 2016, BBA-MOL BASIS DIS, V1862, P442, DOI 10.1016/j.bbadis.2015.10.014; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Sonnen JA, 2011, ARCH NEUROL-CHICAGO, V68, P1049, DOI 10.1001/archneurol.2011.157; Vinters HV, 2000, J NEUROPATH EXP NEUR, V59, P931, DOI 10.1093/jnen/59.11.931; Wang MH, 2012, J NEUROSCI, V32, P17948, DOI 10.1523/JNEUROSCI.1860-12.2012; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224	20	69	73	1	19	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 11	2017	37	11					2870	2877		10.1523/JNEUROSCI.2112-16.2017			8	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	EQ1CX	WOS:000397808000008	28188218	Green Published, Bronze			2022-02-06	
J	Novak, Z; Aglipay, M; Barrowman, N; Yeates, K; Beauchamp, MH; Gravel, J; Freedman, SB; Gagnon, I; Gioia, G; Boutis, K; Burns, E; Ledoux, AA; Osmond, MH; Zemek, RL				Novak, Zuzana; Aglipay, Mary; Barrowman, Nick; Yeates, Keith O.; Beauchamp, Miriam H.; Gravel, Jocelyn; Freedman, Stephen B.; Gagnon, Isabelle; Gioia, Gerard; Boutis, Kathy; Burns, Emma; Ledoux, Andree-Anne; Osmond, Martin H.; Zemek, Roger L.		Pediat Emergency Res Canada	Association of Persistent Postconcussion Symptoms With Pediatric Quality of Life	JAMA PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; ACUTE CONCUSSION; RISK-FACTORS; 1ST YEAR; CHILDREN; MILD; ADOLESCENTS; MODERATE; INVENTORY; VALIDITY	IMPORTANCE Persistent postconcussion symptoms (PPCS) pose long-term challenges and can negatively affect patients' health-related quality of life (HRQoL). To date, no large comprehensive study has addressed the association between PPCS and HRQoL. OBJECTIVES To determine the association between HRQoL and PPCS at 4 weeks after concussion and assess the degree of impairment of HRQoL in the subsequent 12 weeks. DESIGN, SETTING, AND PARTICIPANTS In a prospective, multicenter cohort study (Predicting Persistent Postconcussive Problems in Pediatrics [5P]) from August 14, 2013, to September 30, 2014, children aged 5 to 18 years who presented to the emergency department within 48 hours after head injury and were considered to have an acute concussion were enrolled across 9 pediatric emergency departments within the Pediatric Emergency Research Canada Network. Persistent postconcussion symptoms were defined as 3 or more persistent symptoms on the validated Post-Concussion Symptom Inventory at 4 weeks. Linear mixed effects random coefficients models evaluated the association between PPCS and HRQoL, adjusting for potential confounders including age, sex, prior concussions, migraine, anxiety, learning disability, depression, and sleep disorder. MAIN OUTCOMES AND MEASURES The primary outcomewas HRQoL assessed with the validated Pediatric Quality of Life Inventory version 4.0 (PedsQL-4.0) at 4, 8, and 12 weeks after head injury. RESULTS Of 2006 children enrolled (median age, 11.8 years [interquartile range, 8.9-14.6 years]; 1241 boys and 765 girls), 1667 (83.1%) completed the PedsQL-4.0 at all 3 time points. Of these 1667 children, the 510 with PPCS (30.6%) had lower total PedsQL-4.0 scores (mean, 70.0) than did those without PPCS (mean, 80.3; mean difference, -10.3; 95% CI, -9.4 to -11.2). Patients with PPCS also had significantly lower physical, emotional, social, and school PedsQL-4.0 subscores at 4, 8, and 12 weeks. Patients with PPCS had lower HRQoL than published healthy norms at 4 weeks (mean difference, 13.89; 95% CI, 11.55-16.23), 8 weeks (mean difference, 11.63; 95% CI, 9.34-13.93), and 12 weeks (mean difference, 9.38; 95% CI, 7.01-11.75; P<.001). Patients who recovered from concussion also had lower HRQoL than norms at 4 weeks (mean difference, 3.56; 95% CI, 1.28-5.85) and 8 weeks (mean difference, 2.75; 95% CI, 0.48-5.02; P<.05). School functioning PedsQL-4.0 subscores were significantly lower for all children regardless of PPCS status at all time points. CONCLUSIONS AND RELEVANCE Children with PPCS have lower HRQoL compared with those who have recovered from concussion, yet deficits in HRQoL are pervasive across all domains and may persist for months even in children whose symptoms have resolved. Future interventional research should target the effect of concussion on HRQoL.	[Aglipay, Mary; Barrowman, Nick; Ledoux, Andree-Anne; Osmond, Martin H.; Zemek, Roger L.] Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada; [Novak, Zuzana] Univ Ottawa, Fac Med, Ottawa, ON, Canada; [Yeates, Keith O.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, Keith O.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Beauchamp, Miriam H.; Gravel, Jocelyn] Univ Montreal, Ste Justine Res Ctr, Montreal, PQ, Canada; [Beauchamp, Miriam H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Gravel, Jocelyn] Hosp Ste Justine, Dept Pediat, Montreal, PQ, Canada; [Freedman, Stephen B.] Alberta Childrens Prov Gen Hosp, Dept Pediat, Calgary, AB, Canada; [Gagnon, Isabelle] McGill Univ, Ctr Hlth, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Gioia, Gerard] George Washington Univ, Sch Med, Childrens Natl Hlth Syst, Dept Neuropsychol, Rockville, MD USA; [Boutis, Kathy] Hosp Sick Children, Dept Pediat, Toronto, ON, Canada; [Burns, Emma] Izaak Walton Killam Hlth Ctr, Dept Pediat, Halifax, NS, Canada; [Osmond, Martin H.; Zemek, Roger L.] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada		Zemek, RL (corresponding author), Childrens Hosp Eastern Ontario, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	rzernek@crieo.on.ca	Zemek, Roger/H-1039-2018; Barrowman, Nick/AAL-3166-2020; Yeates, Keith/AAJ-4223-2020; Freedman, Stephen/H-9102-2012	Barrowman, Nick/0000-0002-4704-9595; Osmond, Martin/0000-0001-8275-8381; Gagnon, Isabelle/0000-0003-2043-1644; Freedman, Stephen/0000-0003-2319-6192; Burns, Emma/0000-0001-8042-7124; Gravel, Jocelyn/0000-0001-5901-4990; Yeates, Keith/0000-0001-7680-2892	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [TM1 127047, MRP 119829]; Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team [126197]	This study was supported by operating grant TM1 127047 from the Canadian Institutes of Health Research and grant 126197 from the Canadian Institutes of Health Research-Ontario Neurotrauma Foundation Mild Traumatic Brain Injury Team. Preliminary work was funded by planning grant MRP 119829 from the Canadian Institutes of Health Research.	Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Arbogast KB, 2016, JAMA PEDIATR, V170, DOI 10.1001/jamapediatrics.2016.0294; Carroll L J, 2011, CONCUSSION CRISIS AN; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Desai AD, 2014, JAMA PEDIATR, V168, P1114, DOI 10.1001/jamapediatrics.2014.1600; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Gioia GA, 2009, TOP LANG DISORD, V29, P266, DOI 10.1097/TLD.0b013e3181b5322b; GRONWALL D, 1975, LANCET, V2, P995; Grubenhoff JA, 2014, PEDIATRICS, V134, P54, DOI 10.1542/peds.2013-2988; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Naughton MJ, 2014, J PEDIAT, V164; Pieper P, 2014, BRAIN INJURY, V28, P105, DOI 10.3109/02699052.2013.847208; Ransom DM, 2015, PEDIATRICS, V135, P1043, DOI 10.1542/peds.2014-3434; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivara FP, 2012, ARCH PEDIAT ADOL MED, V166, P666, DOI 10.1001/archpediatrics.2011.1602; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Rodgers C, 2015, J PEDIATR ONCOL NURS, V32, P329, DOI 10.1177/1043454214563413; Sady MD, 2014, ARCH CLIN NEUROPSYCH, V29, P348, DOI 10.1093/arclin/acu014; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Scorza KA, 2012, AM FAM PHYSICIAN, V85, P123; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 2015, J HEAD TRAUMA REHAB, V30, P302, DOI 10.1097/HTR.0000000000000106; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Upton P, 2008, QUAL LIFE RES, V17, P895, DOI 10.1007/s11136-008-9350-5; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; World Health Organization, 1992, INT STAT CLASS DIS; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550corr1; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203; Zemek R, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003550; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216; Zonfrillo MR, 2014, J NEUROTRAUM, V31, P722, DOI 10.1089/neu.2013.3088	37	69	69	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	DEC 1	2016	170	12							e162900	10.1001/jamapediatrics.2016.2900			8	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Pediatrics	EF3WZ	WOS:000390256900002	27775762	Bronze			2022-02-06	
J	Greco, T; Glenn, TC; Hovda, DA; Prins, ML				Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.			Ketogenic diet decreases oxidative stress and improves mitochondrial respiratory complex activity	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Traumatic brain injury; juvenile; ketogenic diet; oxidative stress; mitochondria	TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE SYNTHASE; OXYGEN SPECIES PRODUCTION; CORTICAL IMPACT INJURY; D-BETA-HYDROXYBUTYRATE; KETONE-BODIES; ADULT RATS; FREE-RADICALS; MOUSE MODEL; METABOLISM	Cerebral metabolism of ketones after traumatic brain injury (TBI) improves neuropathology and behavior in an age-dependent manner. Neuroprotection is attributed to improved cellular energetics, although other properties contribute to the beneficial effects. Oxidative stress is responsible for mitochondrial dysfunction after TBI. Ketones decrease oxidative stress, increase antioxidants and scavenge free radicals. It is hypothesized that ketogenic diet (KD) will decrease post-TBI oxidative stress and improve mitochondria. Postnatal day 35 (PND35) male rats were given sham or controlled cortical impact (CCI) injury and placed on standard (STD) or KD. Ipsilateral cortex homogenates and mitochondria were assayed for markers of oxidative stress, antioxidant expression and mitochondrial function. Oxidative stress was significantly increased at 6 and 24h post-injury and attenuated by KD while inducing protein expression of antioxidants, NAD(P)H dehydrogenase quinone 1 (NQO1) and superoxide dismutase (SOD1/2). Complex I activity was inhibited in STD and KD groups at 6h and normalized by 24h. KD significantly improved Complex II-III activity that was reduced in STD at 6h. Activity remained reduced at 24h in STD and unchanged in KD animals. These results strongly suggest that ketones improve post-TBI cerebral metabolism by providing alternative substrates and through antioxidant properties, preventing oxidative stress-mediated mitochondrial dysfunction.	[Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.] Dept Neurosurg, Los Angeles, CA USA; [Greco, Tiffany; Glenn, Thomas C.; Hovda, David A.; Prins, Mayumi L.] UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Hovda, David A.; Prins, Mayumi L.] Interdept Program Neurosci, Los Angeles, CA USA; [Hovda, David A.] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA USA		Greco, T (corresponding author), UCLA Dept Neurosurg, 300 Stein Plaza,Suite 562,POB 957039, Los Angeles, CA 90024 USA.	tgreco@mednet.ucla.edu	Greco, Tiffany/ABA-3519-2021	Glenn, Thomas/0000-0003-4273-3408	NFL Charities; UCLA Brain Injury Research Center; Marilyn and Austin Anderson Fellowship [NS058489-01, NS27544]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: NFL Charities, UCLA Brain Injury Research Center, Marilyn and Austin Anderson Fellowship (grant nos NS058489-01, NS27544).	Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Balietti M, 2010, MICRON, V41, P143, DOI 10.1016/j.micron.2009.08.010; Brookes PS, 2004, MITOCHONDRION, V3, P187, DOI 10.1016/j.mito.2003.10.001; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; GUELDRY S, 1994, J NEUROCHEM, V62, P223; GUIDOUX R, 1991, ARCH BIOCHEM BIOPHYS, V287, P397, DOI 10.1016/0003-9861(91)90495-5; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Malinska D, 2010, BBA-BIOENERGETICS, V1797, P1163, DOI 10.1016/j.bbabio.2010.03.001; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; Nehlig A, 2004, PROSTAG LEUKOTR ESS, V70, P265, DOI 10.1016/j.plefa.2003.07.006; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Park EY, 2002, MOL CELL BIOCHEM, V240, P47, DOI 10.1023/A:1020600509965; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Prins M, 2008, EPILEPSIA, V49, P111, DOI 10.1111/j.1528-1167.2008.01852.x; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI 10.1089/neu.2008-0769; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Radi R, 2002, BIOL CHEM, V383, P401, DOI 10.1515/BC.2002.044; Rho JM, 1999, EPILEPSY RES, V37, P233, DOI 10.1016/S0920-1211(99)00068-6; Sadek HA, 2004, BIOCHEMISTRY-US, V43, P8494, DOI 10.1021/bi049803f; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Veech RL, 2001, IUBMB LIFE, V51, P241; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Xie G, 2014, FREE RADICAL RES, V11, P1; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	43	69	70	0	21	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2016	36	9					1603	1613		10.1177/0271678X15610584			11	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	DV5UU	WOS:000382996800011	26661201	Bronze, Green Published			2022-02-06	
J	Liu, SJ; Zheng, P; Wright, DK; Dezsi, G; Braine, E; Nguyen, T; Corcoran, NM; Johnston, LA; Hovens, CM; Mayo, JN; Hudson, M; Shultz, SR; Jones, NC; O'Brien, TJ				Liu, Shi-jie; Zheng, Ping; Wright, David K.; Dezsi, Gabi; Braine, Emma; Thanh Nguyen; Corcoran, Niall M.; Johnston, Leigh A.; Hovens, Christopher M.; Mayo, Jamie N.; Hudson, Matthew; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.			Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau	BRAIN			English	Article						epilepsy; animal model; MRI; traumatic brain injury; PR55	TRAUMATIC BRAIN-INJURY; TEMPORAL-LOBE EPILEPSY; STATUS EPILEPTICUS; SEIZURES; HIPPOCAMPUS; PATHOLOGY; NEURODEGENERATION; PHOSPHORYLATION; HOLOENZYME; EXPRESSION	Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.Hyperphosphorylation of tau may contribute to epileptogenesis. Liu et al. reveal a reduction in the activity of protein phosphatase 2A (PP2A), with concomitant hyperphosphorylation of tau, in animal models of kindling, post-status epilepticus and post-traumatic epilepsy. Sodium selenate, a PP2A activator, prevents epileptogenesis in all three models.There are no treatments in clinical practice known to mitigate the neurobiological processes that convert a healthy brain into an epileptic one, a phenomenon known as epileptogenesis. Downregulation of protein phosphatase 2A, a protein that causes the hyperphosphorylation of tau, is implicated in neurodegenerative diseases commonly associated with epilepsy, such as Alzheimer's disease and traumatic brain injury. Here we used the protein phosphatase 2A activator sodium selenate to investigate the role of protein phosphatase 2A in three different rat models of epileptogenesis: amygdala kindling, post-kainic acid status epilepticus, and post-traumatic epilepsy. Protein phosphatase 2A activity was decreased, and tau phosphorylation increased, in epileptogenic brain regions in all three models. Continuous sodium selenate treatment mitigated epileptogenesis and prevented the biochemical abnormalities, effects which persisted after drug withdrawal. Our studies indicate that limbic epileptogenesis is associated with downregulation of protein phosphatase 2A and the hyperphosphorylation of tau, and that targeting this mechanism with sodium selenate is a potential anti-epileptogenic therapy.	[Liu, Shi-jie; Zheng, Ping; Dezsi, Gabi; Braine, Emma; Mayo, Jamie N.; Hudson, Matthew; Shultz, Sandy R.; Jones, Nigel C.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3052, Australia; [Wright, David K.; Johnston, Leigh A.] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia; [Wright, David K.] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia; [Thanh Nguyen; Corcoran, Niall M.; Hovens, Christopher M.; O'Brien, Terence J.] Univ Melbourne, Royal Melbourne Hosp, Dept Neurol, Melbourne Brain Ctr, Parkville, Vic, Australia; [Johnston, Leigh A.] Univ Melbourne, Dept Elect & Elect Engn, Parkville, Vic, Australia		Shultz, SR; Jones, NC (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Melbourne Brain Ctr, Dept Med, Parkville, Vic 3052, Australia.; O'Brien, TJ (corresponding author), Univ Melbourne, Royal Melbourne Hosp, Level 4,Clin Sci Bldg, Parkville, Vic 3050, Australia.	sshultz@unimelb.edu.au; ncjones@unimelb.edu.au; obrientj@unimelb.edu.au	O'Brien, Terence/L-8102-2013; O'Brien, Terence/AAU-5525-2021; Johnston, Leigh A/D-7102-2014; Hudson, Matthew/AAH-9168-2020	Johnston, Leigh A/0000-0002-5032-4674; Jones, Nigel/0000-0002-1080-8439; Hovens, Christopher/0000-0002-0610-1289; Wright, David/0000-0002-7535-8651; O'Brien, Terence/0000-0002-7198-8621; Hudson, Matthew/0000-0001-5016-735X	Australian National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia [1006077, 1062653]; Victorian Neurotrauma Initiative Grant from Victorian Government Transport Accident Commission (VNI) [DNP13]; Royal Melbourne Hospital Neuroscience Foundation	This study was funded by grants from the Australian National Health and Medical Research Council (NHMRC Project Grants #1006077 and #1062653), a Victorian Neurotrauma Initiative Grant from the Victorian Government Transport Accident Commission (VNI Project Grant #DNP13) and the Royal Melbourne Hospital Neuroscience Foundation.	Abramoff M.D., 2004, BIOPHOTONICS INT, V11, P36, DOI [DOI 10.1117/1.3589100, DOI 10.1201/9781420005615.AX4]; Amatniek JC, 2006, EPILEPSIA, V47, P867, DOI 10.1111/j.1528-1167.2006.00554.x; Arias C, 2002, EXP NEUROL, V177, P284, DOI 10.1006/exnr.2002.7988; Aroniadou-Anderjaska V, 2008, EPILEPSY RES, V78, P102, DOI 10.1016/j.eplepsyres.2007.11.011; Ashford JW, 2011, J ALZHEIMERS DIS, V26, P331, DOI 10.3233/JAD-2011-0021; Begum N, 1996, J BIOL CHEM, V271, P31166, DOI 10.1074/jbc.271.49.31166; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bolognin S, 2012, ACTA NEUROPATHOL, V123, P133, DOI 10.1007/s00401-011-0908-x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; Briellmann RS, 2002, NEUROLOGY, V58, P265, DOI 10.1212/WNL.58.2.265; Casillas-Espinosa PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130012; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2010, J CLIN NEUROSCI, V17, P1025, DOI 10.1016/j.jocn.2010.04.020; Desikan RS, 2011, ANN NEUROL, V70, P657, DOI 10.1002/ana.22509; Dudek FE, 2011, NEUROSCI LETT, V497, P240, DOI 10.1016/j.neulet.2011.03.071; Fisher RS, 2005, EPILEPSIA, V46, P470, DOI 10.1111/j.0013-9580.2005.66104.x; Franko E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071354; Galanopoulou AS, 2012, EPILEPSIA, V53, P571, DOI 10.1111/j.1528-1167.2011.03391.x; Gunbey HP, 2011, NEURORADIOL J, V24, P316; Hanger DP, 1998, J NEUROCHEM, V71, P2465; HIGUCHI N, 1992, MAGNET RESON MED, V27, P107, DOI 10.1002/mrm.1910270111; Iqbal K, 2009, ACTA NEUROPATHOL, V118, P53, DOI 10.1007/s00401-009-0486-3; Ittner LM, 2011, NAT REV NEUROSCI, V12, P67, DOI 10.1038/nrn2967; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Janssens V, 2008, TRENDS BIOCHEM SCI, V33, P113, DOI 10.1016/j.tibs.2007.12.004; Jones NC, 2012, NEUROBIOL DIS, V45, P897, DOI 10.1016/j.nbd.2011.12.005; Jupp B, 2006, EPILEPSIA, V47, P41, DOI 10.1111/j.1528-1167.2006.00368.x; Jupp B, 2012, EPILEPSIA, V53, P1233, DOI 10.1111/j.1528-1167.2012.03525.x; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Loscher W, 2010, PHARMACOL REV, V62, P668, DOI 10.1124/pr.110.003046; Machnes ZM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076299; Mendez M F, 1994, J Geriatr Psychiatry Neurol, V7, P230; Morales I, 2013, J ALZHEIMERS DIS, V37, P849, DOI 10.3233/JAD-131843; Morimoto K, 2004, PROG NEUROBIOL, V73, P1, DOI 10.1016/j.pneurobio.2004.03.009; Palop JJ, 2009, ARCH NEUROL-CHICAGO, V66, P435, DOI 10.1001/archneurol.2009.15; Pitkanen A, 2011, LANCET NEUROL, V10, P173, DOI 10.1016/S1474-4422(10)70310-0; Powell KL, 2008, EPILEPSIA, V49, P1686, DOI 10.1111/j.1528-1167.2008.01593.x; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Qian W, 2010, J ALZHEIMERS DIS, V19, P1221, DOI [10.3233/JAD-2009-1317, 10.3233/JAD-2010-1317]; Ramirez-Munguia N, 2003, NEUROCHEM RES, V28, P1517, DOI 10.1023/A:1025670308663; Sen A, 2007, EPILEPSIA, V48, P1447, DOI 10.1111/j.1528-1167.2007.01107.x; Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006; Shultz SR, 2015, BRAIN, V138, P1297, DOI 10.1093/brain/awv053; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Simonato M, 2014, LANCET NEUROL, V13, P949, DOI 10.1016/S1474-4422(14)70076-6; Sontag JM, 2008, J NEUROSCI, V28, P11477, DOI 10.1523/JNEUROSCI.2816-08.2008; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Tringham E, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003120; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Vespa P, 2016, ANN NEUROL, V79, P579, DOI 10.1002/ana.24606; Xu YH, 2008, MOL CELL, V31, P873, DOI 10.1016/j.molcel.2008.08.006; Zilka N, 2009, J NEUROIMMUNOL, V209, P16, DOI 10.1016/j.jneuroim.2009.01.013	55	69	70	2	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2016	139		7				1919	1938		10.1093/brain/aww116			20	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DR2VW	WOS:000379763000015	27289302	Bronze			2022-02-06	
J	Tilahun, D; Hanlon, C; Fekadu, A; Tekola, B; Baheretibeb, Y; Hoekstra, RA				Tilahun, Dejene; Hanlon, Charlotte; Fekadu, Abebaw; Tekola, Bethlehem; Baheretibeb, Yonas; Hoekstra, Rosa A.			Stigma, explanatory models and unmet needs of caregivers of children with developmental disorders in a low-income African country: a cross-sectional facility-based survey	BMC HEALTH SERVICES RESEARCH			English	Article						Stigma; Developmental disorder; Autism Spectrum Disorder; Intellectual disability; Developing countries; Africa	FAMILY-MEMBERS; DISABILITIES; PARENTS; AUTISM; SCHIZOPHRENIA; INDIVIDUALS; CHALLENGES; ILLNESS; IMPACT	Background: Understanding the perspectives of caregivers of children with developmental disorders living in low-income countries is important to inform intervention programmes. The purpose of this study was to examine the stigma experiences, explanatory models, unmet needs, preferred interventions and coping mechanisms of caregivers of children with developmental disorders in Ethiopia. Methods: Participants comprised caregivers (n = 102) of children with developmental disorders attending two child mental health clinics in Addis Ababa. The majority (66.7 %; n = 68) had a diagnosis of intellectual disability (ID); 34 children (33.3 %) had autism spectrum disorder (ASD) as their primary diagnosis. All caregivers were administered a structured questionnaire via a face-to-face interview, which included an adaptation of the Family Interview Schedule, closed questions about socio-demographic characteristics, explanatory models of illness, type of interventions used or desired and coping strategies, and an open ended question regarding the family's unmet needs. Results: Most caregivers reported experience of stigma: 43.1 % worried about being treated differently, 45.1 % felt ashamed about their child's condition and 26.7 % made an effort to keep their child's condition secret. Stigma did not depend on the type of developmental disorder, the child's age or gender, or on the age or level of education of the caregiver (all p > 0.05). Reported stigma was significantly higher in caregivers who had sought traditional help (p < 0.01), provided supernatural explanations for their child's condition (p = .02) and in caregivers of Orthodox Christian faith (p = .03). Caregivers gave a mixture of biomedical explanations (e.g. head injury (30.4 %) or birth complications (25.5 %)) and supernatural explanations (e.g. spirit possession (40.2 %) or sinful act (27.5 %)) for their child's condition. The biggest reported unmet need was educational provision for their child (74.5 %), followed by treatment by a health professional (47.1 %), financial support (30.4 %) and expert help to support their child's development (27.5 %). Most caregivers reported that talking to health professionals (86.3 %) and family (85.3 %) helped them to cope. Many caregivers also used support from friends (76.5 %) and prayer (57.8 %) as coping mechanisms. Conclusions: This study highlights the stigma experienced by families caring for a child with a developmental disorder. Designing interventions appropriate for low-income settings that improve awareness about developmental disorders, decrease stigma, improve access to appropriate education and strengthen caregivers' support are needed.	[Tilahun, Dejene; Hanlon, Charlotte; Fekadu, Abebaw; Baheretibeb, Yonas] Univ Addis Ababa, Coll Hlth Sci, Sch Med, Dept Psychiat, Addis Ababa, Ethiopia; [Hanlon, Charlotte] Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, Ctr Global Mental Hlth, London WC2R 2LS, England; [Fekadu, Abebaw] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Psychol Med, Ctr Affect Disorders, London WC2R 2LS, England; [Tekola, Bethlehem; Hoekstra, Rosa A.] Open Univ, Dept Life Hlth & Chem Sci, Milton Keynes MK7 6AA, Bucks, England; [Tilahun, Dejene] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Hlth Educ & Behav Sci, Jimma, Ethiopia		Hanlon, C (corresponding author), Univ Addis Ababa, Coll Hlth Sci, Sch Med, Dept Psychiat, Addis Ababa, Ethiopia.; Hanlon, C (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Hlth Serv & Populat Res Dept, Ctr Global Mental Hlth, London WC2R 2LS, England.	charlotte.hanlon@kcl.ac.uk		Gebru, Bethlehem/0000-0001-7641-1517; Fekadu, Abebaw/0000-0003-2219-0952; Hoekstra, Rosa/0000-0002-1333-9762	Autism Speaks [7770]	The study was funded by Autism Speaks (grant #7770 to Rosa Hoekstra). The funding body had no role in the design of the study, collection, analysis, or interpretation of data or in writing the manuscript.	Abera M, 2015, CHILD ADOL PSYCH MEN, V9, DOI 10.1186/s13034-015-0072-5; Altiere MJ, 2009, J INTELLECT DEV DIS, V34, P142, DOI 10.1080/13668250902845202; Ambikile Joel Semel, 2012, Child Adolesc Psychiatry Ment Health, V6, P16, DOI 10.1186/1753-2000-6-16; Bakare Muideen Owolabi, 2009, Ann Gen Psychiatry, V8, P6, DOI 10.1186/1744-859X-8-6; Brown HK, 2012, J APPL RES INTELLECT, V25, P497, DOI 10.1111/j.1468-3148.2012.00692.x; DePape AM, 2015, QUAL HEALTH RES, V25, P569, DOI 10.1177/1049732314552455; Divan G, 2012, AUTISM RES, V5, P190, DOI 10.1002/aur.1225; Douma JCH, 2006, J INTELL DISABIL RES, V50, P570, DOI 10.1111/j.1365-2788.2006.00825.x; Durban J. M., 2012, ASIAN J SOCIAL SCI H, V1, P177; Elsabbagh M, 2012, AUTISM RES, V5, P160, DOI 10.1002/aur.239; Goin-Kochel, 2005, J DEV DISABILITIES, V12, P41, DOI DOI 10.1177/1088357611423542; Gomes PTM, 2015, J PEDIAT-BRAZIL, V91, P111, DOI 10.1016/j.jped.2014.08.009; Gona JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132729; GRAY DE, 1993, SOCIOL HEALTH ILL, V15, P102, DOI 10.1111/1467-9566.ep11343802; Gray DE, 2002, SOCIOL HEALTH ILL, V24, P734, DOI 10.1111/1467-9566.00316; Green S, 2005, SOCIOL INQ, V75, P197, DOI 10.1111/j.1475-682X.2005.00119.x; Gureje O, 2005, BRIT J PSYCHIAT, V186, P436, DOI 10.1192/bjp.186.5.436; Gureje O, 2015, LANCET PSYCHIAT, V2, P168, DOI 10.1016/S2215-0366(15)00013-9; Heiman T, 2002, J DEV PHYS DISABIL, V14, P159, DOI 10.1023/A:1015219514621; Hoekstra RA, 2014, 13 INT M AUT RES ATL; Jegatheesan B, 2010, FOCUS AUTISM DEV DIS, V25, P98, DOI 10.1177/1088357610361344; Lauritsen JM., 2003, EPIDATA VERSION 3 1; Maulik PK, 2011, RES DEV DISABIL, V32, P419, DOI 10.1016/j.ridd.2010.12.018; Patel V, 2013, ARCH DIS CHILD, V98, P323, DOI 10.1136/archdischild-2012-302079; Ravindran N, 2013, FOCUS AUTISM DEV DIS, V28, P44, DOI 10.1177/1088357612458970; Sartorius N, 1996, SOC PSYCH PSYCH EPID, V31, P55, DOI 10.1007/BF00801901; Shibre T, 2001, SOC PSYCH PSYCH EPID, V36, P299, DOI 10.1007/s001270170048; Shibre T, 2003, SOC PSYCH PSYCH EPID, V38, P27, DOI 10.1007/s00127-003-0594-7; Shyu YIL, 2010, J AUTISM DEV DISORD, V40, P1323, DOI 10.1007/s10803-010-0991-1; Tekola B, 2014, 13 INT M AUT RES ATL; Wang PS, 2011, J AUTISM DEV DISORD, V41, P783, DOI 10.1007/s10803-010-1099-3; World Health Organization, 2008, SCAL CAR MENT NEUR S	32	69	70	0	30	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1472-6963		BMC HEALTH SERV RES	BMC Health Serv. Res.	APR 27	2016	16								152	10.1186/s12913-016-1383-9			12	Health Care Sciences & Services	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Health Care Sciences & Services	DK6KI	WOS:000375032000001	27117326	Green Published, gold			2022-02-06	
J	Kulbe, JR; Geddes, JW				Kulbe, Jacqueline R.; Geddes, James W.			Current status of fluid biomarkers in mild traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						Mild traumatic brain injury; Biomarkers; Serum; Cerebral spinal fluid; Biofluid; Novel; Discovery; Unbiased	NEURON-SPECIFIC-ENOLASE; MYELIN BASIC-PROTEIN; ALPHA-II-SPECTRIN; FIBRILLARY ACIDIC PROTEIN; MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; CONTROLLED CORTICAL IMPACT; POST-CONCUSSION SYMPTOMS; C-TERMINAL HYDROLASE-L1; SERUM S-100B PROTEIN	Mild traumatic brain injury (mTBI) affects millions of people annually and is difficult to diagnose. Mild injury is insensitive to conventional imaging techniques and diagnoses are often made using subjective criteria such as self-reported symptoms. Many people who sustain a mTBI develop persistent post-concussive symptoms. Athletes and military personnel are at great risk for repeat injury which can result in second impact syndrome or chronic traumatic encephalopathy. An objective and quantifiable measure, such as a serum biomarker, is needed to aid in mTBI diagnosis, prognosis, return to play/duty assessments, and would further elucidate mTBI pathophysiology. The majority of TBI biomarker research focuses on severe TBI with few studies specific to mild injury. Most studies use a hypothesis-driven approach, screening biofluids for markers known to be associated with TBI pathophysiology. This approach has yielded limited success in identifying markers that can be used clinically, additional candidate biomarkers are needed. Innovative and unbiased methods such as proteomics, microRNA arrays, urinary screens, autoantibody identification and phage display would complement more traditional approaches to aid in the discovery of novel mTBI biomarkers. (C) 2015 Elsevier Inc. All rights reserved.	Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Coll Med, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Coll Med, Lexington, KY 40536 USA		Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, B483 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	jgeddes@uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 NS084088, RO1 NS062993]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, R01NS062993, R21NS084088, P01NS058484] Funding Source: NIH RePORTER	The author's research was supported by NIH grants R21 NS084088 and RO1 NS062993.	Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ahmed FA, 2013, ELECTROPHORESIS, V34, P2229, DOI 10.1002/elps.201300077; Alsaif M, 2012, PROTEOM CLIN APPL, V6, P297, DOI 10.1002/prca.201100061; Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Anderson KJ, 2008, J NEUROTRAUM, V25, P1079, DOI 10.1089/neu.2007.0488; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Astrand R, 2011, CLIN CHIM ACTA, V412, P2190, DOI 10.1016/j.cca.2011.08.009; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; Baker JG, 2014, INT J CLIN PRACT, V68, P1286, DOI 10.1111/ijcp.12517; Balakathiresan N, 2012, J NEUROTRAUM, V29, P1379, DOI 10.1089/neu.2011.2146; BARBARESE E, 1988, J NEUROCHEM, V51, P1737, DOI 10.1111/j.1471-4159.1988.tb01153.x; Bay Esther, 2005, J Neurosci Nurs, V37, P4; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Berger RP, 2006, J HEAD TRAUMA REHAB, V21, P315, DOI 10.1097/00001199-200607000-00004; Berger RP, 2006, PEDIATRICS, V117, P325, DOI 10.1542/peds.2005-0711; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Boggs JM, 2006, CELL MOL LIFE SCI, V63, P1945, DOI 10.1007/s00018-006-6094-7; BOHNEN N, 1992, INT J NEUROSCI, V64, P97, DOI 10.3109/00207459209000536; Bolton AN, 2014, J NEUROPATH EXP NEUR, V73, P933, DOI 10.1097/NEN.0000000000000115; Bradbury A.R., 2010, CURR PROTOC NEUROSCI; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cadosch D, 2010, ANZ J SURG, V80, P542, DOI 10.1111/j.1445-2197.2010.05268.x; Cai XY, 2011, ATHEROSCLEROSIS, V217, P536, DOI 10.1016/j.atherosclerosis.2011.05.023; Campbell LK, 2003, MODERN PATHOL, V16, P963, DOI 10.1097/01.MP.0000087088.88280.B0; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Caner H, 2004, ACTA NEUROCHIR, V146, P611, DOI 10.1007/s00701-003-0209-9; Canu N, 1998, J NEUROSCI, V18, P7061; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chen FJ, 2010, P NATL ACAD SCI USA, V107, P1636, DOI 10.1073/pnas.0911516107; Chen JX, 2014, OTOLARYNG HEAD NECK, V151, P554, DOI 10.1177/0194599814542588; Conti A, 2004, J NEUROTRAUM, V21, P854, DOI 10.1089/0897715041526212; Corcoran TB, 2011, ANTIOXID REDOX SIGN, V15, P2663, DOI 10.1089/ars.2011.4125; Cortes DF, 2012, ELECTROPHORESIS, V33, P3712, DOI 10.1002/elps.201200341; Crawford F, 2012, J NEUROTRAUM, V29, P246, DOI 10.1089/neu.2011.1789; Dash PK, 2010, NEUROTHERAPEUTICS, V7, P100, DOI 10.1016/j.nurt.2009.10.019; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; De Guire V, 2013, CLIN BIOCHEM, V46, P846, DOI 10.1016/j.clinbiochem.2013.03.015; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Diamandis EP, 2004, J NATL CANCER I, V96, P353, DOI 10.1093/jnci/djh056; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; DORAN JF, 1983, J NEUROCHEM, V40, P1542, DOI 10.1111/j.1471-4159.1983.tb08124.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Gatson JW, 2014, J NEUROSURG, V121, P1232, DOI 10.3171/2014.7.JNS132474; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gogas H, 2009, ANN ONCOL, V20, pvi8, DOI DOI 10.1093/ANN0NC/MDP251; Good DM, 2007, J PROTEOME RES, V6, P4549, DOI 10.1021/pr070529w; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Guingab-Cagmat JD, 2012, ELECTROPHORESIS, V33, P3786, DOI 10.1002/elps.201200326; Guzel A, 2010, AM J EMERG MED, V28, P399, DOI 10.1016/j.ajem.2008.12.025; Gyorgy A, 2011, J NEUROTRAUM, V28, P1121, DOI 10.1089/neu.2010.1561; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; HAIMOTO H, 1987, LAB INVEST, V57, P489; HALL ED, 1993, RES P ARNMD, V71, P81; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Hallen M, 2010, J TRAUMA, V69, P284, DOI 10.1097/TA.0b013e3181ca060b; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hylin MJ, 2013, J NEUROTRAUM, V30, P702, DOI 10.1089/neu.2012.2630; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; JACKSON P, 1981, J NEUROL SCI, V49, P429, DOI 10.1016/0022-510X(81)90032-0; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI [10.1067/mem.2002.125782, 10.1016/j.jen.2008.12.010]; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kavalci C, 2007, AM J EMERG MED, V25, P391, DOI 10.1016/j.ajem.2006.10.008; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kobeissy FH, 2008, PROTEOM CLIN APPL, V2, P1467, DOI 10.1002/prca.200800011; Kobeissy FH, 2006, MOL CELL PROTEOMICS, V5, P1887, DOI 10.1074/mcp.M600157-MCP200; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Koh SXT, 2014, SPORTS MED, V44, P369, DOI 10.1007/s40279-013-0119-9; Kontogeorgis D, 2013, EMERG MED J, V30, P597, DOI 10.1136/emermed-2013-202853.3; Kou ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080296; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lakshmanan R, 2010, NEUROCRIT CARE, V12, P324, DOI 10.1007/s12028-010-9342-5; Lamers KJB, 2003, BRAIN RES BULL, V61, P261, DOI 10.1016/S0361-9230(03)00089-3; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lash GE, 2006, J IMMUNOL METHODS, V309, P205, DOI 10.1016/j.jim.2005.12.007; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; Lundblad R., 2003, INTERNET J GENOMICS, V1; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MAIR J, 1992, CRIT REV CL LAB SCI, V29, P31, DOI 10.3109/10408369209105245; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Martins TB, 2002, AM J CLIN PATHOL, V118, P346; Mazzini GS, 2005, LIFE SCI, V77, P882, DOI 10.1016/j.lfs.2004.12.035; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Michetti F, 2012, J NEUROCHEM, V120, P644, DOI 10.1111/j.1471-4159.2011.07612.x; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2014, MED RES REV, V34, P503, DOI 10.1002/med.21295; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Morris M, 2011, NEURON, V70, P410, DOI 10.1016/j.neuron.2011.04.009; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; O'Neal WK, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-9; Ojo JO, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00213; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Ottens AK, 2006, MASS SPECTROM REV, V25, P380, DOI 10.1002/mas.20073; Ottens AK, 2007, PROG BRAIN RES, V161, P401, DOI 10.1016/S0079-6123(06)61029-7; Ottens AK, 2014, J NEUROTRAUM, V31, P782, DOI 10.1089/neu.2013.3116; Ottens AK, 2010, J NEUROTRAUM, V27, P1837, DOI 10.1089/neu.2010.1374; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Berger RP, 2006, PEDIATR CRIT CARE ME, V7, P557, DOI 10.1097/01.PCC.0000244426.37793.23; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Pelinka LE, 2004, SHOCK, V22, P88, DOI 10.1097/01.shk.0000130157.34382.3f; Pelinka LE, 2004, SHOCK, V21, P72, DOI 10.1097/01.shk.0000101672.49265.14; Pelsers MMAL, 2004, CLIN CHEM, V50, P1568, DOI 10.1373/clinchem.2003.030361; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pickering A, 2008, EMERG MED J, V25, P88, DOI 10.1136/emj.2007.046631; Pike BR, 2001, J NEUROCHEM, V78, P1297, DOI 10.1046/j.1471-4159.2001.00510.x; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Pogoda TK, 2014, J REHABIL RES DEV, V51, P363, DOI 10.1682/JRRD.2013.05.0115; Puvenna V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096296; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; RAND Corporation, 2008, INV WOUNDS MENT HLTH; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Ringger NC, 2004, J NEUROTRAUM, V21, P1443, DOI 10.1089/neu.2004.21.1443; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Rodriguez-Rodriguez A, 2012, CLIN CHIM ACTA, V414, P228, DOI 10.1016/j.cca.2012.09.025; Romeo MJ, 2005, EXPERT REV PROTEOMIC, V2, P57, DOI 10.1586/14789450.2.1.57; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Rostami Elham, 2012, Front Neurol, V3, P115, DOI 10.3389/fneur.2012.00115; Rubenstein R, 2015, J NEUROTRAUM, V32, P342, DOI 10.1089/neu.2014.3548; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Sakai K, 2003, J CLIN NEUROSCI, V10, P677, DOI 10.1016/S0967-5868(03)00073-0; Sandler SJI, 2010, CHILD NERV SYST, V26, P205, DOI 10.1007/s00381-009-1009-1; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schroeter ML, 2013, CURR DRUG TARGETS, V14, P1237; SCHWAB C, 1994, HIPPOCAMPUS, V4, P210, DOI 10.1002/hipo.450040212; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Seifman MA, 2008, J CEREBR BLOOD F MET, V28, P684, DOI 10.1038/sj.jcbfm.9600603; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Siman R., 2014, J NEUROTRAU IN PRESS; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Sojka P, 2006, BRAIN INJURY, V20, P613, DOI 10.1080/02699050600676982; Somers V, 2008, J IMMUNOL, V180, P3957, DOI 10.4049/jimmunol.180.6.3957; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2007, J REHABIL MED, V39, P405, DOI 10.2340/16501977-0057; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Stein SC, 2001, J TRAUMA, V50, P759, DOI 10.1097/00005373-200104000-00032; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Svetlov SI, 2009, J NEUROTRAUM, V26, P913, DOI 10.1089/neu.2008.0609; Takami Y, 2007, ARTERIOSCL THROM VAS, V27, P2184, DOI 10.1161/ATVBAHA.107.142505; Tandler N, 2012, AMINO ACIDS, V43, P2203, DOI 10.1007/s00726-012-1409-5; THOMPSON RJ, 1983, BRAIN RES, V278, P224, DOI 10.1016/0006-8993(83)90241-X; Tolan NV, 2013, CLIN CHIM ACTA, V424, P216, DOI 10.1016/j.cca.2013.06.009; Topolovec-Vranic J, 2011, J TRAUMA, V71, pS478, DOI 10.1097/TA.0b013e318232fa70; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; Tsai YD, 2013, BRAIN INJURY, V27, P361, DOI 10.3109/02699052.2012.750738; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; VINORES SA, 1984, J HISTOCHEM CYTOCHEM, V32, P1295, DOI 10.1177/32.12.6389693; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2004, INT REV NEUROBIOL, V61, P215; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wang KKW, 1996, ARCH BIOCHEM BIOPHYS, V331, P208, DOI 10.1006/abbi.1996.0300; Wang M, 2011, RHEUMATOL INT, V31, P1009, DOI 10.1007/s00296-010-1403-8; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; Weiss ES, 2009, ANN THORAC SURG, V88, P543, DOI 10.1016/j.athoracsur.2009.04.016; Weng XJ, 2012, CLIN BIOCHEM, V45, P303, DOI 10.1016/j.clinbiochem.2011.12.018; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woertgen C, 2001, J NEUROTRAUM, V18, P569, DOI 10.1089/089771501300227378; Wolf H, 2013, J NEUROSURG, V118, P1298, DOI 10.3171/2013.1.JNS121181; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Yang SH, 2013, J SURG RES, V184, P981, DOI 10.1016/j.jss.2013.03.075; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang ZF, 2014, EURASIP J AUDIO SPEE, DOI 10.1186/1687-4722-2014-15; Zhang ZJ, 2011, J CLIN LAB ANAL, V25, P402, DOI 10.1002/jcla.20491; Zurbig P, 2012, ELECTROPHORESIS, V33, P3617, DOI 10.1002/elps.201200360	225	69	69	2	47	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		334	352		10.1016/j.expneurol.2015.05.004			19	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB2ED	WOS:000368320200005	25981889	Green Accepted			2022-02-06	
J	Wu, Q; Xia, SX; Li, QQ; Gao, Y; Shen, X; Ma, L; Zhang, MY; Wang, T; Li, YS; Wang, ZF; Luo, CL; Tao, LY				Wu, Qiong; Xia, Shui-Xiu; Li, Qian-Qian; Gao, Yuan; Shen, Xi; Ma, Lu; Zhang, Ming-Yang; Wang, Tao; Li, Yong-Sheng; Wang, Zu-Feng; Luo, Cheng-Liang; Tao, Lu-Yang			Mitochondrial division inhibitor 1 (Mdivi-1) offers neuroprotection through diminishing cell death and improving functional outcome in a mouse model of traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Mitochondrial fusion; Dynamin-related protein 1; Apoptosis	CONTROLLED CORTICAL IMPACT; DYNAMIN-RELATED PROTEIN-1; INTRACEREBRAL HEMORRHAGE; PLASMALEMMA PERMEABILITY; APOPTOTIC PATHWAY; BARRIER DAMAGE; CYTOCHROME-C; MICE; FISSION; AUTOPHAGY	Mitochondria dysfunction, an enormous potential crisis, has attracted increasing attention. Disturbed regulation of mitochondrial dynamics, the balance of mitochondrial fusion and fission, has been implicated in neurodegenerative diseases, such as Parkinson's disease and cerebral ischemia/reperfusion. However the role of mitochondrial dynamics in traumatic brain injury (TBI) has not been illuminated. The aim of the present study was to investigate the role of Mdivi-1, a small molecule inhibitor of a key mitochondrial fission protein dynamin-related protein 1 (Drp1), in TBI-induced cell death and functional outcome deficits. Protein expression of Drp1 was first investigated. Outcome parameters consist of motor test, Morris water maze, brain edema and lesion volume. Cell death was detected by propidium iodide (PI) labeling, and mitochondrial morphology was assessed using transmission electron microscopy. In addition, the expression of apoptosis-related proteins cytochrome c (cyt-c) and caspase-3 was investigated. Our findings showed that up-regulation of Drp1 expression started at 1 h post-TBI and peaked at 24 h, but inhibition of Drp1 by Mdivi-1 significantly alleviated TBI-induced behavioral deficits and brain edema, reduced morphological change of mitochondria, and decreased TBI-induced cell death together with lesion volume. Moreover, treatment with Mdivi-1 remarkably inhibited TBI-induced the release of cyt-c from mitochondria to cytoplasm, and activation of caspase-3 at 24 h after TBI. Taken together, these data imply that inhibition of Drp1 may help attenuate TBI-induced functional outcome and cell death through maintaining normal mitochondrial morphology and inhibiting activation of apoptosis. (C) 2015 Elsevier B.V. All rights reserved.	[Wu, Qiong; Xia, Shui-Xiu; Gao, Yuan; Shen, Xi; Ma, Lu; Zhang, Ming-Yang; Wang, Tao; Wang, Zu-Feng; Luo, Cheng-Liang; Tao, Lu-Yang] Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China; [Li, Qian-Qian] Wannan Med Coll, Dept Forens Med, Wuhu 241002, Peoples R China; [Li, Yong-Sheng] Suzhou Publ Secur Bur, Wuzhong Branch, Suzhou 215128, Peoples R China		Wang, ZF (corresponding author), Soochow Univ, Coll Med, Dept Forens Med, Suzhou 215123, Peoples R China.	zufengwang@suda.edu.cn; clluo@suda.edu.cn	Mingyang, Zhang/J-7412-2019	Mingyang, Zhang/0000-0001-7084-6237; Shen, Xi/0000-0001-7568-7335	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81400999, 81172911, 81373251, 81530062]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2014M551660]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by the National Natural Science Foundation of China (Nos. 81400999, 81172911, 81373251, and 81530062), China Postdoctoral Science Foundation (No. 2014M551660), and a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Al Nimer F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132177; Babbitt SE, 2015, TRENDS BIOCHEM SCI, V40, P446, DOI 10.1016/j.tibs.2015.05.006; Bao HJ, 2012, NEUROCHEM RES, V37, P2856, DOI 10.1007/s11064-012-0880-4; Boland K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.250; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cui T, 2015, CELL BIOCHEM BIOPHYS, V71, P595, DOI 10.1007/s12013-014-0239-3; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Estaquier J, 2007, CELL DEATH DIFFER, V14, P1086, DOI 10.1038/sj.cdd.4402107; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gajavelli S, 2015, J BIOENERG BIOMEMBR, V47, P133, DOI 10.1007/s10863-014-9589-1; Jin YC, 2015, WORLD NEUROSURG, V84, P420, DOI 10.1016/j.wneu.2015.03.039; Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030; Lackner LL, 2009, BBA-MOL BASIS DIS, V1792, P1138, DOI 10.1016/j.bbadis.2008.11.011; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Luo CL, 2013, J NEUROTRAUM, V30, P597, DOI 10.1089/neu.2012.2425; Luo CL, 2010, J NEUROSCI RES, V88, P2847, DOI 10.1002/jnr.22453; Mbye LH, 2012, J CEREBR BLOOD F MET, V32, P515, DOI 10.1038/jcbfm.2011.158; Mustafa AG, 2010, J NEUROCHEM, V114, P271, DOI 10.1111/j.1471-4159.2010.06749.x; Ong SB, 2010, CIRCULATION, V121, P2012, DOI 10.1161/CIRCULATIONAHA.109.906610; Purnell PR, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-86; Qi X, 2013, J CELL SCI, V126, P789, DOI 10.1242/jcs.114439; Santopietro John, 2015, N C Med J, V76, P96; Sharp Willard W, 2015, Crit Care Med, V43, pe38, DOI 10.1097/CCM.0000000000000817; Wall DM, 2014, CELL MICROBIOL, V16, P1746, DOI 10.1111/cmi.12368; Wang DB, 2013, J NEUROSCI, V33, P1357, DOI 10.1523/JNEUROSCI.3365-12.2013; Wang T, 2015, J MOL NEUROSCI, V55, P240, DOI 10.1007/s12031-014-0313-8; Wang T, 2013, BEHAV BRAIN RES, V247, P132, DOI 10.1016/j.bbr.2013.03.023; Wang X, 2011, J NEUROSCI, V31, P14496, DOI 10.1523/JNEUROSCI.3059-11.2011; Wang YQ, 2012, NEUROCHEM RES, V37, P1849, DOI 10.1007/s11064-012-0791-4; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Watson William D, 2013, Front Neuroenergetics, V5, P12, DOI 10.3389/fnene.2013.00012; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Xu XW, 2008, CELL MOL NEUROBIOL, V28, P875, DOI 10.1007/s10571-008-9265-2; Yuan H, 2007, CELL DEATH DIFFER, V14, P462, DOI 10.1038/sj.cdd.4402046; Zhang MY, 2013, J MOL NEUROSCI, V51, P57, DOI 10.1007/s12031-012-9948-5; Zhang N, 2013, NEUROSCI LETT, V535, P104, DOI 10.1016/j.neulet.2012.12.049; Zhu XX, 2012, STROKE, V43, P524, DOI 10.1161/STROKEAHA.111.635672; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	39	69	70	2	19	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 1	2016	1630						134	143		10.1016/j.brainres.2015.11.016			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CZ4YU	WOS:000367109900014	26596858				2022-02-06	
J	Xu, LY; Nguyen, JV; Lehar, M; Menon, A; Rha, E; Arena, J; Ryu, J; Marsh-Armstrong, N; Marmarou, CR; Koliatsos, VE				Xu, Leyan; Nguyen, Judy V.; Lehar, Mohamed; Menon, Adarsh; Rha, Elizabeth; Arena, John; Ryu, Jiwon; Marsh-Armstrong, Nicholas; Marmarou, Christina R.; Koliatsos, Vassilis E.			Repetitive mild traumatic brain injury with impact acceleration in the mouse: Multifocal axonopathy, neuroinflammation, and neurodegeneration in the visual system	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic axonal injury; Diffuse axonal injury; Concussion; CTE; Retinal ganglion cell; Optic nerve; Tau	FLUORO-JADE-C; FOOTBALL-LEAGUE PLAYER; DIFFUSE AXONAL INJURY; SPINAL-CORD-INJURY; OPTIC-NERVE; HEAD-INJURY; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; DEGENERATING NEURONS; APOLIPOPROTEIN-E	Repetitive mild traumatic brain injury (mTBI) is implicated in chronic neurological illness. The development of animal models of repetitive mTBI in mice is essential for exploring mechanisms of these chronic diseases, including genetic vulnerability by using transgenic backgrounds. In this study, the rat model of impact acceleration (IA) was redesigned for the mouse cranium and used in two clinically relevant repetitive mTBI paradigms. We first determined, by using increments of weight dropped from 1 m that the 40 g weight was most representative of mTBI and was not associated with fractures, brain contusions, anoxic-ischemic injury, mortality, or significant neurological impairments. Quantitative evaluation of traumatic axonal injury (TAI) in the optic nerve/tract, cerebellum and corpus callosum confirmed that weight increase produced a graded injury. We next evaluated two novel repetitive mTBI paradigms (1 time per day or 3 times per day at days 0, 1, 3, and 7) and compared the resulting TAI, neuronal cell death, and neuroinflammation to single hit mTBI at sub-acute (7 days) and chronic time points (10 weeks) post-injury. Both single and repetitive mTBI caused TAI in the optic nerve/tract, cerebellum, corticospinal tract, lateral lemniscus and corpus callosum. Reactive microglia with phagocytic phenotypes were present at injury sites. Severity of axonal injury corresponded to impact load and frequency in the optic nerve/tract and cerebellum. Both single and repeat injury protocols were associated with retinal ganglion cell loss and optic nerve degeneration; these outcomes correlated with impact load and number/frequency. No phosphorylated tau immunoreactivity was detected in the brains of animals subjected to repetitive mTBI. Our findings establish a new model of repetitive mTBI model featured by TAI in discrete CNS tracts, especially the visual system and cerebellum. Injury in retina and optic nerve provides a sensitive measure of severity of mTBI, thus enabling further studies on mechanisms and experimental therapeutics. Our model can also be useful in exploring mechanisms of chronic neurological disease caused by repetitive mTBI in wild-type and transgenic mice. (C) 2014 Elsevier Inc. All rights reserved.	[Xu, Leyan; Menon, Adarsh; Rha, Elizabeth; Arena, John; Ryu, Jiwon; Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA; [Nguyen, Judy V.; Marsh-Armstrong, Nicholas] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; [Lehar, Mohamed] Johns Hopkins Univ, Sch Med, Dept Otolaryngol HNS, Baltimore, MD 21205 USA; [Marsh-Armstrong, Nicholas] Johns Hopkins Univ, Sch Med, Hugo W Moser Res Inst Kennedy Krieger, Baltimore, MD 21205 USA; [Marmarou, Christina R.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Koliatsos, Vassilis E.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA		Xu, LY (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, 720 Rutland Ave,Ross Res Bldg 558, Baltimore, MD 21205 USA.	lxu9@jhmi.edu; judy.v.nguyen@gmail.com; mlehar@jhmi.edu; amen692@gmail.com; lizrha@gmail.com; jarena2@jhu.edu; jryu4@jhmi.edu; Marsh-Armstrong@Kennedykrieger.Org; crmarmar@vcu.edu; koliat@jhmi.edu		Ryu, Jiwon/0000-0003-0251-7858; Arena, John/0000-0002-4322-4472	Maryland Technology Development Corporation funds; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY019960] Funding Source: NIH RePORTER	This work was supported by Maryland Technology Development Corporation funds to VEK.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Banati RB, 2002, GLIA, V40, P206, DOI 10.1002/glia.10144; Barth J.T., 2011, SPORTS CONCUSSION CO; Beaumont A, 1999, NEUROL RES, V21, P742, DOI 10.1080/01616412.1999.11741008; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bharti K, 2014, INVEST OPHTH VIS SCI, V55, P1191, DOI 10.1167/iovs.13-13481; Bian GL, 2007, BRAIN RES, V1150, P55, DOI 10.1016/j.brainres.2007.02.078; Bowen Anne Phelan, 2003, J Emerg Nurs, V29, P287, DOI 10.1067/men.2003.90; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Bu GJ, 2009, NAT REV NEUROSCI, V10, P333, DOI 10.1038/nrn2620; Carter SF, 2012, J NUCL MED, V53, P37, DOI 10.2967/jnumed.110.087031; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chidlow G, 2009, EXP EYE RES, V88, P426, DOI 10.1016/j.exer.2008.10.015; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Dratviman-Storobinsky O, 2008, MOL VIS, V14, P2171; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Ferrari R, 2011, J MOL NEUROSCI, V45, P500, DOI 10.1007/s12031-011-9635-y; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hartman RE, 2005, J NEUROSCI, V25, P6213, DOI 10.1523/JNEUROSCI.0664-05.2005; Hellerstein L F, 1995, J Am Optom Assoc, V66, P634; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Horn KP, 2008, J NEUROSCI, V28, P9330, DOI 10.1523/JNEUROSCI.2488-08.2008; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jefferson SC, 2011, J NEUROSCI, V31, P5710, DOI 10.1523/JNEUROSCI.4459-10.2011; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4898, DOI 10.1167/iovs.07-1447; Liao B, 2012, EXP NEUROL, V237, P147, DOI 10.1016/j.expneurol.2012.06.011; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McPhail LT, 2004, EUR J NEUROSCI, V20, P1984, DOI 10.1111/j.1460-9568.2004.03662.x; Millspaugh, 1937, US NAV MED B, V35, P297; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Ojo JO, 2013, J NEUROPATH EXP NEUR, V72, P137, DOI 10.1097/NEN.0b013e3182814cdf; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pohl HBF, 2011, J NEUROSCI, V31, P1069, DOI 10.1523/JNEUROSCI.5035-10.2011; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rees PM, 2003, ARCH PHYS MED REHAB, V84, P1885, DOI 10.1016/j.apmr.2003.03.001; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sosa MAG, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-67; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Soto I, 2008, J NEUROSCI, V28, P548, DOI 10.1523/JNEUROSCI.3714-07.2008; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Summers MJ, 2006, BRAIN INJURY, V20, P51, DOI 10.1080/02699050500309742; Turgut M, 2010, J BRACHIAL PLEX PERI, V5, DOI 10.1186/1749-7221-5-10; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Vandrovcova J, 2010, CURR ALZHEIMER RES, V7, P726, DOI 10.2174/156720510793611619; Wang JQ, 2013, J NEUROPATH EXP NEUR, V72, P768, DOI 10.1097/NEN.0b013e31829d8d9d; Wang JQ, 2011, J NEUROTRAUM, V28, P1185, DOI 10.1089/neu.2011.1756; Wang YP, 2007, P NATL ACAD SCI USA, V104, P10252, DOI 10.1073/pnas.0703676104; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Xin XB, 2013, P NATL ACAD SCI USA, V110, pE3425, DOI 10.1073/pnas.1217091110; Xu H, 2014, NEUROPATH APPL NEURO, V40, P833, DOI 10.1111/nan.12160; Xu LY, 2009, J COMP NEUROL, V514, P297, DOI 10.1002/cne.22022; Yamada J, 2013, J COMP NEUROL, V521, P1184, DOI 10.1002/cne.23228	90	69	69	2	36	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2016	275		3		SI		436	449		10.1016/j.expneurol.2014.11.004			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	DB2ED	WOS:000368320200013	25450468				2022-02-06	
J	Rangarajan, P; Karthikeyan, A; Lu, J; Ling, EA; Dheen, ST				Rangarajan, P.; Karthikeyan, A.; Lu, J.; Ling, E. -A.; Dheen, S. T.			SIRTUIN 3 REGULATES Foxo3a-MEDIATED ANTIOXIDANT PATHWAY IN MICROGLIA	NEUROSCIENCE			English	Article						microglia; Sirt3; Foxo3a; ROS; antioxidant; brain injury	OXIDATIVE STRESS; BRAIN-INJURY; MITOCHONDRIA; ACTIVATION; SUPPRESSION	Microglia are the prime cellular sources of reactive oxygen species (ROS) in the central nervous system (CNS). Chronic activation of microglia has been linked to aging-associated neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) since they produce excessive amounts of ROS for a prolonged duration leading to oxidative stress. The present study was aimed at investigating the expression and role of Sirtuin 3 (Sirt3), a protein deacetylase which is implicated in regulating cellular ROS levels. It has been shown that Sirt3 reduces cellular ROS levels by deacetylating forkhead box O 3a (Foxo3a), a transcription factor which transactivates antioxidant genes, catalase (Cat) and manganese superoxide dismutase (mnSod). In the present study, Sirt3 immunoreactivity was localized in the ameboid microglial cells distributed in the corpus callosum (CC) of the early postnatal rat brain and diminished in the ramified microglial cells in the CC of the adult rat brain. A marked induction of Sirt3 expression was seen in lipopolysaccharide (LPS)-activated microglia in vivo and in vitro as well as in adult rat brains subjected to traumatic brain injury (TBI). Knock-down of Sirt3 in microglia led to an increase in the cellular and mitochondrial ROS and decrease in the expression of antioxidant, mnSod which is indicative of the function of Sirt3 in ROS regulation in microglia. Conversely, Sirt3 overexpression led to increase in the expression of antioxidants Cat and mnSod. Further, increase in the expression and nuclear translocation of Foxo3a was observed following Sirt3 overexpression, suggesting that Sirt3 regulates ROS by inducing the expression of antioxidants via activation of Foxo3a. The above results point to an antioxidant defense mechanism presented by Sirt3 through the activation of Foxo3a, in microglia. (C) 2015 IBRO. Published by Elsevier Ltd. All rights reserved.	[Rangarajan, P.; Karthikeyan, A.; Lu, J.; Ling, E. -A.; Dheen, S. T.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117597, Singapore; [Lu, J.] Def Med & Environm Res Inst, DSO Natl Labs, Singapore, Singapore		Dheen, ST (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Block MD10,4 Med Dr, Singapore 117597, Singapore.	thameem_dheen@nuhs.edu.sg	Dheen, S. Thameem/AAU-8627-2020	Dheen, S. Thameem/0000-0001-9600-6789	NUHS Seed Fund for Basic Science Research Grant, Singapore [R-181-000-166-112]; National University of Singapore, University Strategic Research [DPRT/944/09/14]; NUS Yong Loo Lin School of Medicine Aspiration Fund, Singapore [R-185-000-271-720]	This research was supported by the NUHS Seed Fund for Basic Science Research Grant, Singapore (R-181-000-166-112) and supported by the National University of Singapore, University Strategic Research (DPRT/944/09/14) and NUS Yong Loo Lin School of Medicine Aspiration Fund (R-185-000-271-720), Singapore. We also thank Dr. Li Yali for providing technical assistance.	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Bao JJ, 2010, FREE RADICAL BIO MED, V49, P1230, DOI 10.1016/j.freeradbiomed.2010.07.009; Bao JJ, 2010, J CELL BIOCHEM, V110, P238, DOI 10.1002/jcb.22531; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Blomgren K, 2006, FREE RADICAL BIO MED, V40, P388, DOI 10.1016/j.freeradbiomed.2005.08.040; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Dohi K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-41; Droge W, 2007, AGING CELL, V6, P361, DOI 10.1111/j.1474-9726.2007.00294.x; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Hristova M, 2010, GLIA, V58, P11, DOI 10.1002/glia.20896; Huo YQ, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-49; Jacobs KM, 2008, INT J BIOL SCI, V4, P291; Jing EX, 2011, P NATL ACAD SCI USA, V108, P14608, DOI 10.1073/pnas.1111308108; Keller JN, 1998, J NEUROSCI, V18, P687; Kim SH, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0014731, 10.1371/journal.pone.0026214]; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marques CP, 2008, J NEUROVIROL, V14, P229, DOI 10.1080/13550280802093927; Nakanishi H, 2009, BEHAV BRAIN RES, V201, P1, DOI 10.1016/j.bbr.2009.02.001; Pillai VB, 2010, J BIOL CHEM, V285, P3133, DOI 10.1074/jbc.M109.077271; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Shen X, 2006, DIABETES, V55, P798, DOI 10.2337/diabetes.55.03.06.db05-1039; Sidorova-Darmos E, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00333; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Tseng AHH, 2013, FREE RADICAL BIO MED, V63, P222, DOI 10.1016/j.freeradbiomed.2013.05.002; Wilkinson BL, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-30	26	69	76	1	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	DEC 17	2015	311						398	414		10.1016/j.neuroscience.2015.10.048			17	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	CY1CJ	WOS:000366144000034	26523980				2022-02-06	
J	Linam, WM; Ahmed, M; Cope, JR; Chu, C; Visvesvara, GS; da Silva, AJ; Qvarnstrom, Y; Green, J				Linam, W. Matthew; Ahmed, Mubbasheer; Cope, Jennifer R.; Chu, Craig; Visvesvara, Govinda S.; da Silva, Alexandre J.; Qvarnstrom, Yvonne; Green, Jerril			Successful Treatment of an Adolescent With Naegleria fowleri Primary Amebic Meningoencephalitis	PEDIATRICS			English	Article							SEVERE BACTERIAL-MENINGITIS; FREE-LIVING AMEBAS; IN-VITRO; BALAMUTHIA-MANDRILLARIS; AMPHOTERICIN-B; ACANTHAMOEBA SPP.; BRAIN-INJURY; MOUSE MODEL; HYPOTHERMIA; INFECTION	Naegleria fowleri is a thermophilic, free-living ameba that causes primary amebic meningoencephalitis. The infections are nearly always fatal. We present the third well-documented survivor of this infection in North America. The patient's survival most likely resulted from a variety of factors: early identification and treatment, use of a combination of antimicrobial agents (including miltefosine), and management of elevated intracranial pressure based on the principles of traumatic brain injury.	[Linam, W. Matthew] Arkansas Childrens Hosp, Pediat Infect Dis Sect, Little Rock, AR 72202 USA; [Ahmed, Mubbasheer; Chu, Craig; Green, Jerril] Arkansas Childrens Hosp, Pediat Crit Care Sect, Little Rock, AR 72202 USA; [Cope, Jennifer R.; Visvesvara, Govinda S.; da Silva, Alexandre J.; Qvarnstrom, Yvonne] Ctr Dis Control & Prevent, Atlanta, GA USA		Linam, WM (corresponding author), Arkansas Childrens Hosp, Pediat Infect Dis Sect, 1 Childrens Way,Slot 512-11, Little Rock, AR 72202 USA.	wlinam@uams.edu			Intramural CDC HHS [CC999999] Funding Source: Medline		Aichelburg AC, 2008, EMERG INFECT DIS, V14, P1743, DOI 10.3201/eid1411.070854; Centers for Disease Control and Prevention, NAEGL FOWL PRIM AM M; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Cope JR, 2013, MMWR-MORBID MORTAL W, V62, P666; Goswick SM, 2003, ANTIMICROB AGENTS CH, V47, P524, DOI 10.1128/AAC.47.2.524-528.2003; Hunte T, 2013, MMWR-MORBID MORTAL W, V62, P903; Irazuzta JE, 2000, BRAIN RES, V881, P88, DOI 10.1016/S0006-8993(00)02894-8; Kemble SK, 2012, CLIN INFECT DIS, V54, P805, DOI 10.1093/cid/cir961; Lepur D, 2011, J INFECTION, V62, P172, DOI 10.1016/j.jinf.2010.10.001; Martinez DY, 2010, CLIN INFECT DIS, V51, pE7, DOI 10.1086/653609; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Mourvillier B, 2013, JAMA-J AM MED ASSOC, V310, P2174, DOI 10.1001/jama.2013.280506; Polderman KH, 2009, CRIT CARE MED, V37, pS186, DOI 10.1097/CCM.0b013e3181aa5241; Rojas-Hernandez S, 2004, PARASITOL RES, V94, P31, DOI 10.1007/s00436-004-1177-6; Schuster FL, 2006, J EUKARYOT MICROBIOL, V53, P121, DOI 10.1111/j.1550-7408.2005.00082.x; SEIDEL JS, 1982, NEW ENGL J MED, V306, P346, DOI 10.1056/NEJM198202113060607; Soltow SM, 2007, ANTIMICROB AGENTS CH, V51, P23, DOI 10.1128/AAC.00788-06; Tiewcharoen Supathra, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P38; van de Beek D, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004405.pub2; Vargas-Zepeda J, 2005, ARCH MED RES, V36, P83, DOI 10.1016/j.arcmed.2004.11.003; Visvesvara GS, 2007, FEMS IMMUNOL MED MIC, V50, P1, DOI 10.1111/j.1574-695X.2007.00232.x; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003; Yoder JS, 2010, EPIDEMIOL INFECT, V138, P968, DOI 10.1017/S0950268809991014; Yoder JS, 2012, CLIN INFECT DIS, V55, pE79, DOI 10.1093/cid/cis626	24	69	71	0	24	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2015	135	3					E744	E748		10.1542/peds.2014-2292			5	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	CF0BD	WOS:000352206600027	25667249	Green Accepted			2022-02-06	
J	El-Etr, M; Rame, M; Boucher, C; Ghoumari, AM; Kumar, N; Liere, P; Pianos, A; Schumacher, M; Sitruk-Ware, R				El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Kumar, Narender; Liere, Philippe; Pianos, Antoine; Schumacher, Michael; Sitruk-Ware, Regine			Progesterone and Nestorone Promote Myelin Regeneration in Chronic Demyelinating Lesions of Corpus Callosum and Cerebral Cortex	GLIA			English	Article						remyelination; oligodendrocytes; progestogens; cuprizone; progesterone receptor	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; SPINAL-CORD; NEURODEGENERATIVE DISORDERS; TRANSCRIPTION FACTORS; CNS REMYELINATION; AXONAL DAMAGE; IN-VITRO	Multiple Sclerosis affects mainly women and consists in intermittent or chronic damages to the myelin sheaths, focal inflammation, and axonal degeneration. Current therapies are limited to immunomodulators and antiinflammatory drugs, but there is no efficient treatment for stimulating the endogenous capacity of myelin repair. Progesterone and synthetic progestins have been shown in animal models of demyelination to attenuate myelin loss, reduce clinical symptoms severity, modulate inflammatory responses and partially reverse the age-dependent decline in remyelination. Moreover, progesterone has been demonstrated to promote myelin formation in organotypic cultures of cerebellar slices. In the present study, we show that progesterone and the synthetic 19-nor-progesterone derivative Nestorone (R) promote the repair of severe chronic demyelinating lesions induced by feeding cuprizone to female mice for up to 12 weeks. Progesterone and Nestorone increase the density of NG2(+) oligodendrocyte progenitor cells and CA II+ mature oligodendrocytes and enhance the formation of myelin basic protein (MBP)- and proteolipid protein (PLP)-immunoreactive myelin. However, while demyelination in response to cuprizone was less marked in corpus callosum than in cerebral cortex, remyelination appeared earlier in the former. The remyelinating effect of progesterone was progesterone receptor (PR)-dependent, as it was absent in PR-knockout mice. Progesterone and Nestorone also decreased (but did not suppress) neuroinflammatory responses, specifically astrocyte and microglial cell activation. Therefore, some progestogens are promising therapeutic candidates for promoting the regeneration of myelin. GLIA 2015;63:104-117 Main Points <list id="glia22736-list-0001" list-type="bulleted"> <list-item id="glia22736-li-0001">Progesterone and the specific analog Nestorone arrest neuroinflammation and facilitate remyelination when administered to female mice as a treatment after a chronic demyelination. <list-item id="glia22736-li-0056">This effect requires intracellular progesterone receptors.	[El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Liere, Philippe; Pianos, Antoine; Schumacher, Michael] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France; [El-Etr, Martine; Rame, Marion; Boucher, Celine; Ghoumari, Abdel. M.; Liere, Philippe; Pianos, Antoine; Schumacher, Michael] Univ Paris Sud, F-94276 Le Kremlin Bicetre, France; [Kumar, Narender; Sitruk-Ware, Regine] Populat Council, New York, NY 10021 USA; [Kumar, Narender; Sitruk-Ware, Regine] Rockefeller Univ, New York, NY 10021 USA		El-Etr, M (corresponding author), INSERM, UMR 788, 80 Rue Gen Leclerc, F-94276 Le Kremlin Bicetre, France.	martine.el-etr@inserm.fr	Schumacher, Michael/G-3581-2013	Schumacher, Michael/0000-0001-6117-5371	NICHD U54 [5U54HD9990]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD029990] Funding Source: NIH RePORTER	Grant sponsor: NICHD U54; Grant number: # 5U54HD9990.	Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Bastida CM, 2002, BIOCHEM BIOPH RES CO, V293, P106, DOI 10.1016/S0006-291X(02)00191-2; BLAUSTEIN JD, 1989, BRAIN RES, V495, P75, DOI 10.1016/0006-8993(89)91219-5; Calabrese M, 2012, BRAIN, V135, P2952, DOI 10.1093/brain/aws246; Calabrese M, 2010, NAT REV NEUROL, V6, P438, DOI 10.1038/nrneurol.2010.93; De Nicola AF, 2009, FRONT NEUROENDOCRIN, V30, P173, DOI 10.1016/j.yfrne.2009.03.001; Deboy CA, 2007, BRAIN, V130, P2199, DOI 10.1093/brain/awm122; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; Franklin RJM, 2012, NAT REV NEUROL, V8, P624, DOI 10.1038/nrneurol.2012.200; Fraser IS, 2007, CONTRACEPTION, V76, P432, DOI 10.1016/j.contraception.2007.08.006; Friese MA, 2014, NAT REV NEUROL, V10, P225, DOI 10.1038/nrneurol.2014.37; Garay L, 2011, NEUROSCIENCE, V192, P588, DOI 10.1016/j.neuroscience.2011.06.065; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Geldenhuys WJ, 2013, EXPERT OPIN DRUG DIS, V8, P115, DOI 10.1517/17460441.2013.744746; Geurts JJG, 2012, LANCET NEUROL, V11, P1082, DOI 10.1016/S1474-4422(12)70230-2; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; Giatti S, 2012, J NEUROENDOCRINOL, V24, P851, DOI 10.1111/j.1365-2826.2012.02284.x; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Gofflot F, 2007, CELL, V131, P405, DOI 10.1016/j.cell.2007.09.012; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hussain R, 2013, BRAIN, V136, P132, DOI 10.1093/brain/aws284; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Ibanez C, 2004, NEUROPATH APPL NEURO, V30, P80, DOI 10.1046/j.0305-1846.2003.00515.x; Ismail PM, 2002, MOL ENDOCRINOL, V16, P2475, DOI 10.1210/me.2002-0169; JUNGTESTAS I, 1991, EXP CELL RES, V193, P12, DOI 10.1016/0014-4827(91)90532-Y; Khalaj AJ, 2013, P NATL ACAD SCI USA, V110, P19125, DOI [10.1073/pnas.311763110, 10.1073/pnas.1311763110]; Kieseier BC, 2011, NAT REV NEUROL, V7, P255, DOI 10.1038/nrneurol.2011.41; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Kumar N, 2000, STEROIDS, V65, P629, DOI 10.1016/S0039-128X(00)00119-7; Labombarda F, 2009, GLIA, V57, P884, DOI 10.1002/glia.20814; Ligon KL, 2006, GLIA, V54, P1, DOI 10.1002/glia.20273; Lindner M, 2009, NEUROSCI LETT, V453, P120, DOI 10.1016/j.neulet.2009.02.004; Liu AL, 2012, ENDOCRINOLOGY, V153, P3747, DOI 10.1210/en.2012-1138; Liu LF, 2010, ENDOCRINOLOGY, V151, P5782, DOI 10.1210/en.2010-0005; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; Mani SK, 1997, HORM BEHAV, V31, P244, DOI 10.1006/hbeh.1997.1393; Martino G, 2010, NAT REV NEUROL, V6, P247, DOI 10.1038/nrneurol.2010.35; Mason JL, 2004, AM J PATHOL, V164, P1673, DOI 10.1016/S0002-9440(10)63726-1; Matsushima GK, 2001, BRAIN PATHOL, V11, P107; Melcangi RC, 2014, PROG NEUROBIOL, V113, P1, DOI 10.1016/j.pneurobio.2013.09.005; Moore CS, 2011, J NEUROSCI RES, V89, P13, DOI 10.1002/jnr.22482; Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309; PARSONS B, 1982, J NEUROSCI, V2, P1446; Polanczyk M, 2003, AM J PATHOL, V163, P1599, DOI 10.1016/S0002-9440(10)63516-X; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Sakamoto H, 2001, J NEUROSCI, V21, P6221, DOI 10.1523/JNEUROSCI.21-16-06221.2001; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schumacher M, 2014, PROG NEUROBIOL, V113, P6, DOI 10.1016/j.pneurobio.2013.09.004; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Sitruk-Ware R, 2010, CONTRACEPTION, V82, P410, DOI 10.1016/j.contraception.2010.04.004; Skripuletz T, 2008, AM J PATHOL, V172, P1053, DOI 10.2353/ajpath.2008.070850; Skripuletz T, 2010, NEUROCHEM RES, V35, P1422, DOI 10.1007/s11064-010-0202-7; Spence RD, 2011, P NATL ACAD SCI USA, V108, P8867, DOI 10.1073/pnas.1103833108; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Taylor LC, 2010, J NEUROSCI RES, V88, P391, DOI 10.1002/jnr.22215; van der Star BJ, 2012, CNS NEUROL DISORD-DR, V11, P570, DOI 10.2174/187152712801661284; Wang C, 2009, IMMUNOLOGY, V126, P329, DOI 10.1111/j.1365-2567.2008.03051.x; WAREMBOURG M, 1989, BRAIN RES, V480, P1, DOI 10.1016/0006-8993(89)91561-8; Waters EM, 2008, J COMP NEUROL, V511, P34, DOI 10.1002/cne.21826; Wood GA, 2007, REPRODUCTION, V133, P1035, DOI 10.1530/REP-06-0302; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yates MA, 2010, J NEUROIMMUNOL, V220, P136, DOI 10.1016/j.jneuroim.2010.01.013; Youdim MBH, 2005, TRENDS PHARMACOL SCI, V26, P27, DOI 10.1016/j.tips.2004.11.007; Yu HJ, 2010, NEUROSCI LETT, V476, P42, DOI 10.1016/j.neulet.2010.03.079	70	69	69	0	27	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JAN	2015	63	1					104	117		10.1002/glia.22736			14	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AU0XC	WOS:000345344500008	25092805	Green Accepted			2022-02-06	
J	Vanderploeg, RD; Silva, MA; Soble, JR; Curtiss, G; Belanger, HG; Donnell, AJ; Scott, SG				Vanderploeg, Rodney D.; Silva, Marc A.; Soble, Jason R.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.			The Structure of Postconcussion Symptoms on the Neurobehavioral Symptom Inventory: A Comparison of Alternative Models	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						concussion; mild traumatic brain injury; postconcussion syndrome; structural equation modeling	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYMPTOMS; SERVICE MEMBERS; ASSOCIATIONS; RATES	Objective: To evaluate and compare the existing Neurobehavioral Symptom Inventory factor structure models to determine which model provides the best overall fit for postconcussion symptoms and determine which model is useful across different samples (eg, with and without mild traumatic brain injury [TBI] history). Setting: N/A. Participants: A Florida National Guard sample (N = 3098) and a national Department of Veterans Affairs sample (N = 48 175). Design: Retrospective structural equation modeling was used to compare 16 alternative factor structure models. First, these 16 possible models were examined separately in both samples. Then, to determine whether the same factor structures applied across subsamples within these samples, the models were compared for those deployed and those not deployed in the Florida National Guard sample and between those with TBI confirmed on clinical evaluation and those who were determined not to have sustained a TBI within the Department of Veterans Affairs sample. Main Measures: Neurobehavioral Symptom Inventory. Results: A 4-factor model-vestibular, somatic, cognitive, and affective-had the best overall fit, after elimination of 2 items (ie, hearing problems and appetite disturbance), and was most applicable across samples. Conclusions: These findings extend the findings of Meterko et al to other samples. Because findings were consistent across sample and subsamples, the current findings are applicable to both Department of Veteran Affairs and Department of Defense postdeployment medical evaluation settings.	[Vanderploeg, Rodney D.; Silva, Marc A.; Soble, Jason R.; Curtiss, Glenn; Belanger, Heather G.; Donnell, Alison J.] James A Haley Vet Hosp, Mental Hlth & Behav Sci Serv, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Scott, Steven G.] James A Haley Vet Hosp, HSR&D, RR&D, Ctr Excellence Maximizing Rehabil Outcomes, Tampa, FL 33612 USA; [Scott, Steven G.] James A Haley Vet Hosp, Phys Med & Rehabil Serv, Tampa, FL 33612 USA; [Vanderploeg, Rodney D.; Silva, Marc A.; Curtiss, Glenn; Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Donnell, Alison J.; Scott, Steven G.] Def & Vet Brain Injury Ctr, Tampa, FL USA		Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020; Silva, Marc A./J-1874-2019	Silva, Marc A./0000-0002-3879-6054	Department of Veterans Affairs (VA)US Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Defense and Veterans Brain Injury Center (DVBIC)US Department of Veterans Affairs; VA grant SDR HSRD [08-411-TBI]; VA HSRD [CCN 06-164]; James A. Haley Veterans' HospitalUS Department of Veterans Affairs; HSR&D/RR&D Center of Excellence; DVBICUS Department of Veterans Affairs	The research reported here was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, and Defense and Veterans Brain Injury Center (DVBIC) and by VA grant SDR HSR&D #08-411-TBI Screening Instruments and Processes to Rodney D. Vanderploeg, PhD, and VA HSR&D grant CCN 06-164 to Steven G. Scott, DO. Further support was provided by the James A. Haley Veterans' Hospital and its HSR&D/RR&D Center of Excellence and the DVBIC. The views expressed herein are those of the authors and do not necessarily reflect the views or the official policy of the Department of Army, Department of Defense, VA, or US Government. No potential conflict of interest relevant to this article was reported.	American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ANDERSON JC, 1988, PSYCHOL BULL, V103, P411, DOI 10.1037/0033-2909.103.3.411; Arbuckle JL, 2007, AMOS 16 USERS GUIDE; Belanger HG, 2012, ARCH PHYS MED REHAB, V93, P1234, DOI 10.1016/j.apmr.2012.03.003; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; BENTLER PM, 1990, PSYCHOL BULL, V107, P238, DOI 10.1037/0033-2909.88.3.588; BOZDOGAN H, 1987, PSYCHOMETRIKA, V52, P345, DOI 10.1007/BF02294361; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Brown M.W., 1993, SOCIOL METHOD RES, P136; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Burnham KP., 2002, MODEL SELECTION MULT; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Cooper DB, 2011, BRAIN INJURY, V25, P1, DOI 10.3109/02699052.2010.531692; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Donnell AJ, 2012, CLIN NEUROPSYCHOL, V26, P1092, DOI 10.1080/13854046.2012.713984; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Gizzi M, 2003, J HEAD TRAUMA REHAB, V18, P398, DOI 10.1097/00001199-200309000-00002; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; J?reskog, 1989, LISREL 7 GUIDE PROGR; Jaycox, 2008, INVISIBLE WOUNDS WAR; Kelloway E. K., 1998, USING LISREL STRUCTU; King PR, 2012, J REHABIL RES DEV, V49, P879, DOI 10.1682/JRRD.2011.03.0051; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; STEIGER JH, 1990, MULTIVAR BEHAV RES, V25, P173, DOI 10.1207/s15327906mbr2502_4; Tabachnick B.G., 2001, USING MULTIVARIATE S; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vanderploeg RD, 2014, J HEAD TRAUMA REHAB, V29, P1, DOI 10.1097/HTR.0b013e318281966e; Vanderploeg RD, 2012, ARCH PHYS MED REHAB, V93, P1887, DOI 10.1016/j.apmr.2012.05.024; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Weathers F.W., 1993, ANN CONV INT SOC TRA; Weathers FW, 1996, MEASUREMENT STRESS T, P250; World Health Organization, 1992, ICD 10 CLASSIFICATIO; [No title captured]; [No title captured]	46	69	69	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					1	11		10.1097/HTR.0000000000000009			11	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400009	24263177				2022-02-06	
J	Bayley, MT; Tate, R; Douglas, JM; Turkstra, LS; Ponsford, J; Stergiou-Kita, M; Kua, A; Bragge, P				Bayley, Mark Theodore; Tate, Robyn; Douglas, Jacinta Mary; Turkstra, Lyn S.; Ponsford, Jennie; Stergiou-Kita, Mary; Kua, Ailene; Bragge, Peter		INCOG Expert Panel	INCOG Guidelines for Cognitive Rehabilitation Following Traumatic Brain Injury: Methods and Overview	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive rehabilitation; guidelines; knowledge translation; neuropsychology; rehabilitation; therapeutic approaches for the treatment of CNS injury; traumatic brain injury		Introduction: Traumatic brain injury results in complex cognitive sequelae. However, clinicians have difficulty implementing the available evidence. An international group of researchers and clinicians (known as INCOG) convened to develop clinical practice guidelines for cognitive rehabilitation posttraumatic brain injury. Methods: The Guidelines Adaptation and Development cycle was used to derive the recommendations. Previously published cognitive rehabilitation recommendations were identified and tabulated. An expert panel met to select appropriate recommendations. Afterward, the team enhanced the recommendations by reviewing available literature. To address shortfalls of previous guidelines, the team developed decision algorithms incorporating the recommendations based on inclusion and exclusion criteria of published trials and expert opinion. The team then prioritized the recommendations for implementation and developed audit criteria to evaluate adherence to best practice. Results: The team recommends that individuals have detailed assessments of cognition after resolution of posttraumatic amnesia. Cognitive assessment and rehabilitation should be tailored to the patient's neuropsychological profile, premorbid cognitive characteristics, and goals for life activities and participation. Clinical algorithms and audit tools to evaluate current practice are provided. Conclusion: Cognitive rehabilitation should be offered to select individuals with traumatic brain injury. These guidelines provide assistance to clinicians who want to provide evidence-based care.	[Bayley, Mark Theodore] Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, Toronto, ON M5G 2C4, Canada; [Kua, Ailene] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON M5G 2C4, Canada; [Bayley, Mark Theodore] Univ Toronto, Fac Med, Toronto, ON, Canada; [Tate, Robyn] Univ Sydney, Royal Rehabil Ctr, Sydney Med Sch Northern, Ctr Rehabil Res,Kolling Inst, Sydney, NSW 2006, Australia; [Douglas, Jacinta Mary] La Trobe Univ, Dept Human Commun Sci, Melbourne, Vic, Australia; [Turkstra, Lyn S.] Univ Wisconsin Madison, Dept Commun Sci & Disorders, Madison, WI USA; [Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Melbourne, Vic 3004, Australia; [Stergiou-Kita, Mary] Toronto Rehabil Inst, Toronto, ON, Canada; [Stergiou-Kita, Mary] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Toronto, ON, Canada; [Bragge, Peter] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Bragge, Peter] Monash Univ, Melbourne, Vic 3004, Australia		Bayley, MT (corresponding author), Univ Hlth Network, Toronto Rehabil Inst, Brain & Spinal Cord Rehabil Program, 190 Elizabeth St, Toronto, ON M5G 2C4, Canada.	mark.bayley@uhn.ca	Turkstra, Lyn/ABC-5831-2021	Bragge, Peter/0000-0003-0745-5131; Douglas, Jacinta/0000-0003-0940-6624; Bayley, Mark/0000-0001-7860-9463; Turkstra, Lyn/0000-0002-6948-6921	Victorian Neurotrauma Initiative- a research program of the Transport Accident Commission; Monash UniversityMonash University; Ontario Neurotrauma Foundation; Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University	The project described in this article was funded by the Victorian Neurotrauma Initiative- a research program of the Transport Accident Commission and Monash University's Strategic Grants Scheme (Lead CI: Peter Bragge) and the Ontario Neurotrauma Foundation (Lead CI: Mark Bayley). The authors gratefully acknowledge the support of the Victorian Transport Accident Commission through its Victorian Neurotrauma Initiative, Monash University, and the Ontario Neurotrauma Foundation for their support of this project.	[Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P353; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P338; [Anonymous], 1990, CLIN PRACTICE GUIDEL; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P321; [Anonymous], 2014, J HEAD TRAUMA REHAB, V29, P307; Bayley MT, 2014, J HEAD TRAUMA REHAB, V29, P268, DOI 10.1097/HTR.0000000000000053; Bosch M, 2013, J EVAL CLIN PRACT, V19, P763, DOI 10.1111/j.1365-2753.2012.01835.x; Bragge P, 2014, J HEAD TRAUMA REHAB, V29, P277, DOI 10.1097/HTR.0000000000000066; Bragge P, 2012, J NEUROTRAUM, V29, P1539, DOI 10.1089/neu.2011.2193; Bragge P, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-92; Brouwers MC, 2010, PREV MED, V51, P421, DOI 10.1016/j.ypmed.2010.08.005; Ciliska D K, 2001, AACN Clin Issues, V12, P520, DOI 10.1097/00044067-200111000-00008; Davies BL, 2002, JOGNN-J OBST GYN NEO, V31, P558, DOI 10.1111/j.1552-6909.2002.tb00081.x; Graham Ian D, 2005, Evid Based Nurs, V8, P68, DOI 10.1136/ebn.8.3.68; Grol R, 2001, MED CARE, V39, pII46; Haskins EC, 2012, AM C REH; Ivers N, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000259.PUB3; Lindsay M, 2010, CANADIAN BEST PRACTI; *ROYAL COLL PHYS, 2002, NAT CLIN GUID STROK; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075; Scottish Intercollegiate Guidelines Network, 2002, MAN PAT STROK REH PR; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 2013, NEUROREHABILITATION, V32, P729, DOI 10.3233/NRE-130898; Teasell R, 2007, BRAIN INJURY, V21, P107, DOI 10.1080/02699050701201524; Turkstra L, 2005, J MED SPEECH-LANG PA, V13, pIX; Velikonja D, 2014, J HEAD TRAUMA REHAB, V29, P369, DOI 10.1097/HTR.0000000000000069; Woolf SH, 1999, BRIT MED J, V318, P527, DOI 10.1136/bmj.318.7182.527; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	28	69	71	0	41	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2014	29	4					290	306		10.1097/HTR.0000000000000070			17	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	AM2AK	WOS:000339650300007	24984093				2022-02-06	
J	Karvellas, CJ; Fix, OK; Battenhouse, H; Durkalski, V; Sanders, C; Lee, WM				Karvellas, Constantine J.; Fix, Oren K.; Battenhouse, Holly; Durkalski, Valerie; Sanders, Corron; Lee, William M.		US Acute Liver Failure Study Grp	Outcomes and Complications of Intracranial Pressure Monitoring in Acute Liver Failure: A Retrospective Cohort Study*	CRITICAL CARE MEDICINE			English	Article						cerebral edema; intracranial pressure monitoring; intracranial hypertension; acute liver failure; acetaminophen; fulminant hepatic failure	FULMINANT HEPATIC-FAILURE; TRAUMATIC BRAIN-INJURY; FACTOR-VII; ENCEPHALOPATHY; MANAGEMENT	Objective: To determine if intracranial pressure monitor placement in patients with acute liver failure is associated with significant clinical outcomes. Design: Retrospective multicenter cohort study. Setting: Academic liver transplant centers comprising the U.S. Acute Liver Failure Study Group. Patients: Adult critically ill patients with acute liver failure presenting with grade III/IV hepatic encephalopathy (n = 629) prospectively enrolled between March 2004 and August 2011. Intervention: Intracranial pressure monitored (n = 140) versus nonmonitored controls (n = 489). Measurements and Main Results: Intracranial pressure monitored patients were younger than controls (35 vs 43 yr, p < 0.001) and more likely to be on renal replacement therapy (52% vs 38%, p = 0.003). Of 87 intracranial pressure monitored patients with detailed information, 44 (51%) had evidence of intracranial hypertension (intracranial pressure > 25 mm Hg) and overall 21-day mortality was higher in patients with intracranial hypertension (43% vs 23%, p = 0.05). During the first 7 days, intracranial pressure monitored patients received more intracranial hypertension-directed therapies (mannitol, 56% vs 21%; hypertonic saline, 14% vs 7%; hypothermia, 24% vs 10%; p < 0.03 for each). Forty-one percent of intracranial pressure monitored patients received liver transplant (vs 18% controls; p < 0.001). Overall 21-day mortality was similar (intracranial pressure monitored 33% vs controls 38%, p = 0.24). Where data were available, hemorrhagic complications were rare in intracranial pressure monitored patients (4 of 56 [7%]; three died). When stratifying by acetaminophen status and adjusting for confounders, intracranial pressure monitor placement did not impact 21-day mortality in acetaminophen patients (p = 0.89). However, intracranial pressure monitor was associated with increased 21-day mortality in nonacetaminophen patients (odds ratio, ~ 3.04; p = 0.014). Conclusions: In intracranial pressure monitored patients with acute liver failure, intracranial hypertension is commonly observed. The use of intracranial pressure monitor in acetaminophen acute liver failure did not confer a significant 21-day mortality benefit, whereas in nonacetaminophen acute liver failure, it may be associated with worse outcomes. Hemorrhagic complications from intracranial pressure monitor placement were uncommon and cannot account for mortality trends. Although our results cannot conclusively confirm or refute the utility of intracranial pressure monitoring in patients with acute liver failure, patient selection and ancillary assessments of cerebral blood flow likely have a significant role. Prospective studies would be required to conclusively account for confounding by illness severity and transplant.	[Karvellas, Constantine J.] Univ Alberta, Div Hepatol, Edmonton, AB, Canada; [Karvellas, Constantine J.] Univ Alberta, Div Crit Care Med, Edmonton, AB, Canada; [Fix, Oren K.] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; [Battenhouse, Holly; Durkalski, Valerie] Med Univ S Carolina, Fac Med, Charleston, SC 29425 USA; [Sanders, Corron; Lee, William M.] Univ Texas SW Med Ctr Dallas, Div Digest & Liver Dis, Dallas, TX 75390 USA		Karvellas, CJ (corresponding author), Univ Alberta, Div Hepatol, Edmonton, AB, Canada.	dean.karvellas@ualberta.ca		Karvellas, Constantine/0000-0002-1555-1089	National Institutes of Health (NIH) (United States Acute Liver Failure Study Group [U.S. ALFSG] - NIH [National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK] [DK U-01 58369]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIDDK/NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); NIH (NIDDK)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01-DK58369, U-01 58369]; Medical University of South Carolina; Medical University of South Carolina [U01 DK0583691]; University of Texas Southwestern (UTSW) MCD (NIH) [U-01 58369]; UTSW Medical Center (Anadys); UTSW Medical Center (BMS); UTSW Medical Center (BI); UTSW Medical Center (Gilead); UTSW Medical Center (Merck); UTSW Medical Center (Siemens); UTSW Medical Center (Vertex)Vertex Pharmaceuticals; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK026743, U01DK058369] Funding Source: NIH RePORTER	Dr. Karvellas received support for article research from the National Institutes of Health (NIH) (United States Acute Liver Failure Study Group [U.S. ALFSG] is funded by an NIH grant [National Institute of Diabetes and Digestive and Kidney Diseases, NIDDK, DK U-01 58369]). Dr. Fix is employed by University of California San Francisco and received support for article research from NIH. His institution received grant support from NIDDK/NIH. Ms. Battenhouse received support for article research from NIH. Her institution received grant support from NIH (U01-DK58369) and is employed by NIH. Dr. Durkalski is employed by Medical University of South Carolina and received support for article research from NIH. His institution received grant support from the Medical University of South Carolina (funding provided by ALFSG grant U01 DK0583691). Dr. Sanders received support for article research from NIH grant U-01 58369 (from NIDDK). Dr. Lee consulted for Lilly, Novartis, and Pfizer (drug safety review) and received support for article research from NIH. His institution received grant support from University of Texas Southwestern (UTSW) MCD (NIH grant U-01 58369 to UTSW) and UTSW Medical Center (Anadys, BMS, BI, Gilead, Merck, Siemens, Vertex).	Agarwal B, 2012, J HEPATOL, V57, P780, DOI 10.1016/j.jhep.2012.06.020; ATTERBURY CE, 1978, AM J DIG DIS, V23, P398, DOI 10.1007/BF01072921; Bernal W, 1999, EUR J GASTROEN HEPAT, V11, P977, DOI 10.1097/00042737-199909000-00005; Bernal W, 2007, HEPATOLOGY, V46, P1844, DOI 10.1002/hep.21838; Bernal W, 2010, LANCET, V376, P190, DOI 10.1016/S0140-6736(10)60274-7; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; Caldwell SH, 2004, HEPATOLOGY, V39, P592, DOI 10.1002/hep.20123; Daas M, 1995, Liver Transpl Surg, V1, P210, DOI 10.1002/lt.500010403; DAVIES MH, 1994, LANCET, V343, P1329, DOI 10.1016/S0140-6736(94)92471-6; Fagan E, 1996, BRIT MED J, V313, P1417, DOI 10.1136/bmj.313.7070.1417; Griesdale DEG, 2010, CAN J NEUROL SCI, V37, P43, DOI 10.1017/S031716710000963X; Kamat P, 2012, PEDIATR CRIT CARE ME, V13, pE33, DOI 10.1097/PCC.0b013e31820ac08f; Kasotakis G, 2012, J AM COLL SURGEONS, V214, P950, DOI 10.1016/j.jamcollsurg.2012.03.004; KEAYS RT, 1993, J HEPATOL, V18, P205, DOI 10.1016/S0168-8278(05)80247-8; Larson AM, 2005, HEPATOLOGY, V42, P1364, DOI 10.1002/hep.20948; Le TV, 2010, NEUROSURGERY, V66, P455, DOI 10.1227/01.NEU.0000365517.52586.A2; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Lieberthal MM., 1979, HEPATIC COMA SYNDROM; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1993, LANCET, V342, P743, DOI 10.1016/0140-6736(93)91736-6; Peck M, 2010, CRIT CARE S1, V14, pP542, DOI DOI 10.1186/cc8774; Polson J, 2005, HEPATOLOGY, V41, P1179, DOI 10.1002/hep.20703; Stravitz RT, 2007, CRIT CARE MED, V35, P2498, DOI 10.1097/01.CCM.0000287592.94554.5F; Stravitz RT, 2012, J HEPATOL, V56, P129, DOI 10.1016/j.jhep.2011.04.020; Vaquero J, 2005, LIVER TRANSPLANT, V11, P1581, DOI 10.1002/lt.20625; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877	27	69	69	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAY	2014	42	5					1157	1167		10.1097/CCM.0000000000000144			11	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	AG4IU	WOS:000335383900032	24351370	Green Accepted			2022-02-06	
J	Su, Y; Fan, W; Ma, Z; Wen, X; Wang, W; Wu, Q; Huang, H				Su, Y.; Fan, W.; Ma, Z.; Wen, X.; Wang, W.; Wu, Q.; Huang, H.			TAURINE IMPROVES FUNCTIONAL AND HISTOLOGICAL OUTCOMES AND REDUCES INFLAMMATION IN TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						taurine; traumatic brain injury; cytokine; inflammation; Luminex.	COLONY-STIMULATING FACTOR; TUMOR-NECROSIS-FACTOR; IN-SITU DETECTION; BARRIER PERMEABILITY; CEREBROSPINAL-FLUID; CYTOKINE EXPRESSION; TEMPORAL PROFILE; LUNG INJURY; LEPTIN; PLASMA	We investigated the effect of taurine on inflammatory cytokine expression, on astrocyte activity and cerebral edema and functional outcomes, following traumatic brain injury (TBI) in rats. 72 rats were randomly divided into sham, TBI and Taurine groups. Rats subjected to moderate lateral fluid percussion injury were injected intravenously with taurine (200 mg/kg) or saline immediately after injury or daily for 7 days. Functional outcome was evaluated using Modified Neurological Severity Score (mNSS). Glial fibrillary acidic protein (GFAP) of the brain was measured using immunofluorescence. Concentration of 23 cytokines and chemokines in the injured cortex at 1 and 7 days after TBI was assessed by Luminex xMAP technology. The results showed that taurine significantly improved functional recovery except 1 day, reduced accumulation of GFAP and water content in the penumbral region at 7 days after TBI. Compared with the TBI group, taurine significantly suppressed growth-related oncogene (GRO/KC) and interleukin (IL)-1 beta levels while elevating the levels of regulated on activation, normal T cell expressed and secreted (RANTES) at 1 day. And taurine markedly decreased the level of 17 cytokine: eotaxin, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GMCSF), interferon-gamma (IFN-gamma), IL-1 alpha, IL-1 beta, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-17, leptin, monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-alpha (TNF-alpha), vascular endothelial growth factor (VEGF), and only increased the level of MIP-1 alpha in a week. The results suggest that taurine effectively mitigates the severity of brain damage in TBI by attenuating the increase of astrocyte activity and edema as well as pro-inflammatory cytokines. (C) 2014 IBRO. Published by Elsevier Ltd. All rights reserved.	[Su, Y.; Wen, X.] Tianjin Med Univ, Grad Sch, Tianjin 300070, Peoples R China; [Fan, W.; Wang, W.; Wu, Q.; Huang, H.] Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin 300060, Peoples R China; [Ma, Z.] Baoding 1 Hosp, Baoding 071000, Hebei, Peoples R China		Huang, H (corresponding author), Tianjin Huanhu Hosp, Tianjin Neurosurg Inst, Tianjin 300060, Peoples R China.	huanghuiling@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30973089]; Tianjin Research Program of Application Foundation and Advanced Technology [10JCYBJC12200]; Tianjin Municipal Health Bureau of Science and Technology [2012KR09]	This work was supported by the National Natural Science Foundation of China (30973089), Tianjin Research Program of Application Foundation and Advanced Technology (10JCYBJC12200) and fund project of Tianjin Municipal Health Bureau of Science and Technology (2012KR09).	Abdih H, 2000, EUR SURG RES, V32, P347, DOI 10.1159/000052216; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chang X-L, 2012, TIANJIN MED J, V40, P493; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Dalgard CL, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00006; El Idrissi A, 2008, AMINO ACIDS, V34, P321, DOI 10.1007/s00726-006-0396-9; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Gurujeyalakshmi G, 2000, J PHARMACOL EXP THER, V293, P82; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hergenroeder GW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-19; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; HUXTABLE RJ, 1989, PROG NEUROBIOL, V32, P471, DOI 10.1016/0301-0082(89)90019-1; Ivashkova Y, 2006, J TRAUMA, V61, P879, DOI 10.1097/01.ta.0000234722.98537.01; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kelley BJ, 2006, EXP NEUROL, V198, P350, DOI 10.1016/j.expneurol.2005.12.017; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lin C, 2012, PEPTIDES, V35, P166, DOI 10.1016/j.peptides.2012.03.024; Liu Y, 2002, IMMUNOL LETT, V80, P27, DOI 10.1016/S0165-2478(01)00291-7; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marcinkiewicz J, 1998, IMMUNOPHARMACOLOGY, V40, P27, DOI 10.1016/S0162-3109(98)00023-X; Messina SA, 2000, ADV EXP MED BIOL, V483, P355; Mo L-D, 2012, SHANDONG MED J, V52, P4; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nakajima Y, 2010, J NEUROTRAUM, V27, P403, DOI 10.1089/neu.2009.1044; Park E, 1998, ADV EXP MED BIOL, V442, P177; Park KW, 2005, J NEUROSCI RES, V81, P397, DOI 10.1002/jnr.20483; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Schaffer S, 2000, AMINO ACIDS, V19, P527, DOI 10.1007/s007260070004; Schuller-Levis GB, 2004, NEUROCHEM RES, V29, P117, DOI 10.1023/B:NERE.0000010440.37629.17; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sheibani N, 2004, CRIT CARE MED, V32, P2274, DOI 10.1097/01.CCM.0000145998.11686.ED; Skold MK, 2005, J NEUROTRAUM, V22, P353, DOI 10.1089/neu.2005.22.353; Sun M, 2012, AMINO ACIDS, V42, P1735, DOI 10.1007/s00726-011-0885-3; Takamiya M, 2007, J NEUROTRAUM, V24, P1833, DOI 10.1089/neu.2007.0336; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Ward JL, 2011, J TRAUMA, V70, P1471, DOI 10.1097/TA.0b013e31821c38bd; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Xiao BG, 1998, NEUROREPORT, V9, P1487, DOI 10.1097/00001756-199805110-00044; Xiong XX, 2011, STROKE, V42, P2026, DOI 10.1161/STROKEAHA.110.593772; Yang DY, 2010, NEUROL RES, V32, P1041, DOI 10.1179/016164110X12807570510013; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang F, 2010, AMINO ACIDS, V38, P237, DOI 10.1007/s00726-009-0233-z; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	55	69	74	3	19	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	APR 25	2014	266						56	65		10.1016/j.neuroscience.2014.02.006			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	AE8VO	WOS:000334281200006	24530657				2022-02-06	
J	Orlovska, S; Pedersen, MS; Benros, ME; Mortensen, PB; Agerbo, E; Nordentoft, M				Orlovska, Sonja; Pedersen, Michael Skaarup; Benros, Michael Eriksen; Mortensen, Preben Bo; Agerbo, Esben; Nordentoft, Merete			Head Injury as Risk Factor for Psychiatric Disorders: A Nationwide Register-Based Follow-Up Study of 113,906 Persons With Head Injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; SCHIZOPHRENIA-LIKE PSYCHOSIS; AUTOIMMUNE-DISEASES; SEVERE INFECTIONS; BIPOLAR DISORDER; DEPRESSION; EPILEPSY; CHILDREN; ILLNESS; ASSOCIATION	Objective: Studies investigating the relationship between head injury and subsequent psychiatric disorders often suffer from methodological weaknesses and show conflicting results. The authors investigated the incidence of severe psychiatric disorders following hospital contact for head injury. Method: The authors used linkable Danish nationwide population-based registers to investigate the incidence of schizophrenia spectrum disorders, unipolar depression, bipolar disorder, and organic mental disorders in 113,906 persons who had suffered head injuries. Data were analyzed by survival analysis and adjusted for gender, age, calendar year, presence of a psychiatric family history, epilepsy, infections, autoimmune diseases, and fractures not involving the skull or spine. Results: Head injury was associated with a higher risk of schizophrenia (incidence rate ratio [IRR]=1.65, 95% CI=1.55-1.75), depression (IRR=1.59 95% CI=1.53-1.65), bipolar disorder (IRR=1.28, 95% CI=1.10-1.48), and organic mental disorders (IRR=439, 95% CI=3.86-4.99). This effect was larger than that of fractures not involving the skull or spine for schizophrenia, depression, and organic mental disorders, which suggests that the results were not merely due to accident proneness. Head injury between ages 11 and 15 years was the strongest predictor for subsequent development of schizophrenia, depression, and bipolar disorder. The added risk of mental illness following head injury did not differ between individuals with and without a psychiatric family history. Conclusions: This is the largest study to date investigating head injury and subsequent mental illness. The authors demonstrated an increase in risk for all psychiatric outcomes after head injury. The effect did not seem to be solely due to accident proneness, and the added risk was not more pronounced in persons with a psychiatric family history.	[Orlovska, Sonja] Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, iPSYCH, DK-1168 Copenhagen, Denmark; Aarhus Univ, Natl Ctr Register Based Res, iPSYCH, DK-8000 Aarhus C, Denmark; Aarhus Univ CIRRAU, Ctr Integrated Register Based Res, iPSYCH, Aarhus, Denmark		Orlovska, S (corresponding author), Univ Copenhagen, Fac Hlth Sci, Mental Hlth Ctr Copenhagen, iPSYCH, DK-1168 Copenhagen, Denmark.	sonjaorlovska@gmail.com	Benros, Michael Eriksen/N-5868-2016; Nordentoft, Merete/AAH-3253-2019; Orlovska-Waast, Sonja/K-3057-2019; Mortensen, Preben B/D-2358-2015; Agerbo, Esben/A-2645-2012	Benros, Michael Eriksen/0000-0003-4939-9465; Mortensen, Preben B/0000-0002-5230-9865; Agerbo, Esben/0000-0002-2849-524X; Nordentoft, Merete/0000-0003-4895-7023	Stanley Medical Research Institute; Lundbeck FoundationLundbeckfonden; Lundbeck FoundationLundbeckfonden [R155-2014-1724] Funding Source: researchfish	Supported by a grant from the Stanley Medical Research Institute and an unrestricted grant from the Lundbeck Foundation.	Andersen TF, 1999, DAN MED BULL, V46, P263; Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Benros ME, 2013, JAMA PSYCHIAT, V70, P812, DOI 10.1001/jamapsychiatry.2013.1111; Benros ME, 2011, AM J PSYCHIAT, V168, P1303, DOI 10.1176/appi.ajp.2011.11030516; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen YH, 2011, PSYCHOL MED, V41, P1271, DOI 10.1017/S0033291710001819; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Coetzer R, 2008, CNS SPECTRUMS, V13, P1022, DOI 10.1017/S1092852900017065; Diamond B, 2009, NAT REV IMMUNOL, V9, P449, DOI 10.1038/nri2529; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Harrison G, 2006, SCHIZOPHR RES, V88, P119, DOI 10.1016/j.schres.2006.07.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Insel TR, 2010, NATURE, V468, P187, DOI 10.1038/nature09552; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Malaspina D, 2001, AM J PSYCHIAT, V158, P440, DOI 10.1176/appi.ajp.158.3.440; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; Max JE, 2012, INT J DEV NEUROSCI, V30, P239, DOI 10.1016/j.ijdevneu.2011.12.005; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Mortensen PB, 2003, J AFFECT DISORDERS, V76, P79, DOI 10.1016/S0165-0327(02)00073-3; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Nielsen AS, 2002, SCHIZOPHR RES, V55, P93, DOI 10.1016/S0920-9964(01)00205-5; Pedersen CB, 2011, SCAND J PUBLIC HEALT, V39, P22, DOI 10.1177/1403494810387965; Qin P, 2005, BMJ-BRIT MED J, V331, P23, DOI 10.1136/bmj.38488.462037.8F; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; Wirrell EC, 2006, EPILEPSIA, V47, P79, DOI 10.1111/j.1528-1167.2006.00666.x; Zhang Qingchen, 2003, Curr Psychiatry Rep, V5, P197, DOI 10.1007/s11920-003-0042-0; Zhang Y, 2011, DISCOV MED, V11, P395	40	69	72	0	28	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	APR	2014	171	4					463	469		10.1176/appi.ajp.2013.13020190			7	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	AD8FD	WOS:000333501000014	24322397				2022-02-06	
J	Wilcox, BJ; Beckwith, JG; Greenwald, RM; Chu, JJ; McAllister, TW; Flashman, LA; Maerlender, AC; Duhaime, AC; Crisco, JJ				Wilcox, Bethany J.; Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.; McAllister, Thomas W.; Flashman, Laura A.; Maerlender, Arthur C.; Duhaime, Ann-Christine; Crisco, Joseph J.			Head impact exposure in male and female collegiate ice hockey players	JOURNAL OF BIOMECHANICS			English	Article						Impact biomechanics; Hockey; Gender; Concussion	PHYSICIAN-OBSERVED CONCUSSION; INJURY SURVEILLANCE SYSTEM; WHITE-MATTER INTEGRITY; TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; DESCRIPTIVE EPIDEMIOLOGY; ACCELERATION; MAGNITUDE; SEVERITY; LOCATION	The purpose of this study was to quantify head impact exposure (frequency, location and magnitude of head impacts) for individual male and female collegiate ice hockey players and to investigate differences in exposure by sex, player position, session type, and team. Ninety-nine (41 male, 58 female) players were enrolled and 37,411 impacts were recorded over three seasons. Frequency of impacts varied significantly by sex (males: 287 per season, females: 170, p < 0.001) and helmet impact location (p < 0.001), but not by player position (p=0.088). Head impact frequency also varied by session type; both male and female players sustained more impacts in games than in practices (p < 0.001), however the magnitude of impacts did not differ between session types. There was no difference in 95th percentile peak linear acceleration between sexes (males: 41.6 g, females: 40.8 g), but 95th percentile peak rotational acceleration and HITsp (a composite severity measure) were greater for males than females (4424, 3409 rad/s(2), and 25.6, 22.3, respectively). Impacts to the back of the helmet resulted in the greatest 95th percentile peak linear accelerations for males (45.2 g) and females (50.4 g), while impacts to the side and back of the head were associated with the greatest 95th percentile peak rotational accelerations (males: 4719, 4256 rad/sec(2), females: 3567, 3784 rad/sec(2) respectively). It has been proposed that reducing an individual's head impact exposure is a practical approach for reducing the risk of brain injuries. Strategies to decrease an individual athlete's exposure need to be sport and gender specific, with considerations for team and session type. (C) 2013 Elsevier Ltd. All rights reserved.	[Wilcox, Bethany J.; Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02903 USA; [Wilcox, Bethany J.; Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI 02903 USA; [Beckwith, Jonathan G.; Greenwald, Richard M.; Chu, Jeffrey J.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [McAllister, Thomas W.; Flashman, Laura A.] Dartmouth Med Sch, Dept Psychiat, Lebanon, NH USA; [Maerlender, Arthur C.] Dartmouth Med Sch, Pediat Neuropsychol Serv, Lebanon, NH USA; [Duhaime, Ann-Christine] Childrens Hosp Dartmouth, Dartmouth Hitchcock Med Ctr, Hanover, NH USA		Wilcox, BJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02903 USA.	Bethany_Wilcox@brown.edu		Crisco, Joseph/0000-0002-8786-0905	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of General Medical Sciences at the National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01HD048638, R25GM0 83270, R25GM083270-S1]; National Operating Committee on Standards for Athletic Equipment; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR024484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM104937, R25GM083270] Funding Source: NIH RePORTER	Research reported in this publication was supported by the National Institute of Child Health and Human Development and the National Institute of General Medical Sciences at the National Institute of Health under Award nos. R01HD048638, R25GM0 83270 and R25GM083270-S1 and the National Operating Committee on Standards for Athletic Equipment. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We gratefully acknowledge and thank the engineering team at Simbex for all of their technical support. We would like to thank Lindley Brainard and Wendy Chamberlin at Simbex for their role in data collection and clinical coordination. We would also like to thank Russell Fiore, M.Ed., A.T.C, Emily Burmeister M.S., A.T.C, and Brian Daigneault, M.S., A.T.C at Brown University; as well as Jeff Frechette, A.T.C., and Tracey Poro, A.T.C., Dartmouth College Sports Medicine and Mary Hynes, R.N., M.P.H. Dartmouth Medical School for their support on this project.	Agel J, 2007, J ATHL TRAINING, V42, P241; Agel J, 2007, J ATHL TRAINING, V42, P249; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Chamard E, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12305; Chu, 2006, J BIOMECH, V39, DOI https://doi.org/10.1016/s0021-9290(06)83518-9; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2012, J APPL BIOMECH, V28, P174, DOI 10.1123/jab.28.2.174; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Flik K, 2005, AM J SPORT MED, V33, P183, DOI 10.1177/0363546504267349; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gwin J.T., 2009, J ASTM INT, V6; Hutchison M, 2011, THESIS U TORONTO TOR; Koerte IK, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12303; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; McKnight Cynthia M., 1992, Journal of Athletic Training, V27, P342; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2012, ANN BIOMED ENG, V40, P141, DOI 10.1007/s10439-011-0405-3; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Odelgard B., 1989, SAFETY ICE HOCKEY, P164; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Wilcox B.J., 2013, J ATHLETIC IN PRESS	32	69	69	2	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JAN 3	2014	47	1					109	114		10.1016/j.jbiomech.2013.10.004			6	Biophysics; Engineering, Biomedical	Science Citation Index Expanded (SCI-EXPANDED)	Biophysics; Engineering	AA3QU	WOS:000331008200016	24210478	Green Accepted, Green Published			2022-02-06	
J	Villapol, S; Byrnes, KR; Symes, AJ				Villapol, Sonia; Byrnes, Kimberly R.; Symes, Aviva J.			Temporal dynamics of cerebral blood flow, cortical damage, apoptosis, astrocyte vasculature interaction and astrogliosis in the pericontusional region after traumatic brain injury	FRONTIERS IN NEUROLOGY			English	Article						astrogliosis; cell death; cerebral blood flow; vasculature; glial scar		Traumatic brain injury (TBI) results in a loss of brain tissue at the moment of impact in the cerebral cortex. Subsequent secondary injury involves the release of molecular signals with dramatic consequences for the integrity of damaged tissue, leading to the evolution of a pericontusional-damaged area minutes to days after in the initial injury. The mechanisms behind the progression of tissue loss remain under investigation. In this study, we analyzed the spatial temporal profile of blood flow, apoptotic, and astrocytic vascular events in the cortical regions around the impact site at time points ranging from 5 h to 2 months after TBI. We performed a mild moderate controlled cortical impact injury in young adult mice and analyzed the glial and vascular response to injury. We observed a dramatic decrease in perilesional cerebral blood flow (CBF) immediately following the cortical impact that lasted until days later. CBF finally returned to baseline levels by 30 days post-injury (dpi). The initial impact also resulted in an immediate loss of tissue and cavity formation that gradually increased in size until 3 dpi. An increase in dying cells localized in the pericontusional region and a robust astrogliosis were also observed at 3 dpi. A strong vasculature interaction with astrocytes was established at 7 dpi. Glial scar formation began at 7 dpi and seemed to be compact by 60 dpi. Altogether, these results suggest that TBI results in a progression from acute neurodegeneration that precedes astrocytic activation, reformation of the neurovascular unit to glial scar formation. Understanding the multiple processes occurring after TBI is critical to the ability to develop neuroprotective therapeutics to ameliorate the short and long-term consequences of brain injury.	[Villapol, Sonia; Byrnes, Kimberly R.; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Road, Bethesda, MD 20814 USA; [Villapol, Sonia; Symes, Aviva J.] Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; [Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA		Villapol, S (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Road, Bethesda, MD 20814 USA.	svilapol@gmail.com; aviva.symes@usuhs.edu	Villapol, Sonia/D-1949-2014; Symes, Aviva J/S-7471-2016	Symes, Aviva J/0000-0003-2557-9939; Villapol, Sonia/0000-0002-6174-4113; Byrnes, Kimberly/0000-0002-7501-7734	Center for Neuroscience and Regenerative Medicine (CNRM)United States Department of Defense; CNRM post-doctoral fellowship	The authors thank M. Balarezo for her excellent technical assistance. This work was supported by grants from the Center for Neuroscience and Regenerative Medicine (CNRM). Sonia Villapol is supported by a CNRM post-doctoral fellowship. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as reflecting the views of the Uniformed Services University of the Health Sciences, the US Department of Defense or the Government of the United States.	Alessandri B, 2012, J NEUROTRAUM, V29, P2181, DOI 10.1089/neu.2011.2067; Armstead WM, 2004, EXP TOXICOL PATHOL, V56, P75, DOI 10.1016/j.etp.2004.04.003; Badaut J, 2014, TRANSL STROKE RES, V5, P394, DOI 10.1007/s12975-013-0304-z; Barreto GE, 2011, NEUROSCI RES, V71, P107, DOI 10.1016/j.neures.2011.06.004; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bragin DE, 2011, J NEUROTRAUM, V28, P775, DOI 10.1089/neu.2010.1692; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Eliasson C, 1999, J BIOL CHEM, V274, P23996, DOI 10.1074/jbc.274.34.23996; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Haydon PG, 2006, PHYSIOL REV, V86, P1009, DOI 10.1152/physrev.00049.2005; Hernandez MR, 2002, GLIA, V38, P45, DOI 10.1002/glia.10051; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Iadecola C, 2007, NAT NEUROSCI, V10, P1369, DOI 10.1038/nn2003; Jakovcevic D, 2007, CURR TOP DEV BIOL, V79, P75, DOI 10.1016/S0070-2153(06)79004-4; Karki P, 2014, MOL CELL ENDOCRINOL, V389, P58, DOI 10.1016/j.mce.2014.01.010; Katsel P, 2011, NEUROPSYCHOPHARMACOL, V36, P1171, DOI 10.1038/npp.2010.252; Leffler CW, 2006, AM J PHYSIOL-HEART C, V291, pH2897, DOI 10.1152/ajpheart.00722.2006; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; Li AL, 2008, CHIN J TRAUMATOL, V11, P84, DOI 10.1016/S1008-1275(08)60018-8; Longhi L, 2003, Minerva Anestesiol, V69, P227; Martin-Lopez E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074039; Massucci FA, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-103; Mitra S, 2013, TOXICOLOGY, V310, P39, DOI 10.1016/j.tox.2013.05.011; Muellner A, 2003, J NEUROTRAUM, V20, P745, DOI 10.1089/089771503767869971; Nawashiro H, 1998, NEUROREPORT, V9, P1691, DOI 10.1097/00001756-199806010-00004; Nordal RA, 2005, INT J RADIAT ONCOL, V62, P279, DOI 10.1016/j.ijrobp.2005.01.039; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8; Ragaisis V., 2002, MEDICINA, V38, P354; Ragaisis Vytautas, 2002, Medicina (Kaunas), V38, P243; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Simard M, 2003, J NEUROSCI, V23, P9254; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sochocka M, 2013, CNS NEUROL DISORD-DR, V12, P870, DOI 10.2174/18715273113129990072; Stichel CC, 1999, EUR J NEUROSCI, V11, P632, DOI 10.1046/j.1460-9568.1999.00466.x; Stichel CC, 1999, RESTOR NEUROL NEUROS, V15, P1; Susarla BTS, 2014, ASN NEURO, V6, DOI 10.1042/AN20130034; Thompson HJ, 2006, EUR J NEUROSCI, V24, P3063, DOI 10.1111/j.1460-9568.2006.05197.x; Villapol S, 2008, NEUROSCIENTIST, V14, P339, DOI 10.1177/1073858408316003; Villapol S, 2011, PEDIATR RES, V69, P51, DOI 10.1203/PDR.0b013e3181fcb40b; Villapol S, 2009, AM J PATHOL, V175, P2111, DOI 10.2353/ajpath.2009.090257; Walton M, 1999, BRAIN RES REV, V29, P137, DOI 10.1016/S0165-0173(98)00053-8; Wang JY, 2006, CURR PHARM DESIGN, V12, P3521, DOI 10.2174/138161206778343109; WESTERGREN H, 1991, ACTA NEUROCHIR, V113, P91, DOI 10.1007/BF01402121; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zou J, 2010, NEUROCHEM INT, V56, P577, DOI 10.1016/j.neuint.2009.12.021	51	69	69	0	4	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.		2014	5								82	10.3389/fneur.2014.00082			9	Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	V42QW	WOS:000209629300081	24926283	gold, Green Published			2022-02-06	
J	Dams-O'Connor, K; Spielman, L; Singh, A; Gordon, WA; Lingsma, HF; Maas, AIR; Manley, GT; Mukherjee, P; Okonkwo, DO; Puccio, AM; Schnyer, DM; Valadka, AB; Yue, JK; Yuh, EL; Cooper, SR; Cheong, M; Hricik, AJ; Knight, EE; Menon, DK; Morabito, DJ; Pacheco, JL; Sinha, TK; Vassar, MJ				Dams-O'Connor, Kristen; Spielman, Lisa; Singh, Ayushi; Gordon, Wayne A.; Lingsma, Hester F.; Maas, Andrew I. R.; Manley, Geoffrey T.; Mukherjee, Pratik; Okonkwo, David O.; Puccio, Ava M.; Schnyer, David M.; Valadka, Alex B.; Yue, John K.; Yuh, Esther L.; Cooper, Shelly R.; Cheong, Maxwell; Hricik, Allison J.; Knight, Emily E.; Menon, David K.; Morabito, Diane J.; Pacheco, Jennifer L.; Sinha, Tuhin K.; Vassar, Mary J.		TRACK-TBI Investigators Including	The Impact of Previous Traumatic Brain Injury on Health and Functioning: A TRACK-TBI Study	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; cognitive function; recovery; traumatic brain injury	IDENTIFICATION METHOD; HEAD-INJURY; RELIABILITY; CONCUSSION; SCALE; SATISFACTION; PREDICTORS; VALIDITY; HISTORY	The idea that multiple traumatic brain injury (TBI) can have a cumulative detrimental effect on functioning is widely accepted. Most research supporting this idea comes from athlete samples, and it is not known whether remote history of previous TBI affects functioning after subsequent TBI in community-based samples. This study investigates whether a previous history of TBI with loss of consciousness (LOC) is associated with worse health and functioning in a sample of individuals who require emergency department care for current TBI. Twenty-three percent of the 586 individuals with current TBI in the Transforming Research and Clinical Knowledge in Traumatic Brain Injury study reported having sustained a previous TBI with LOC. Individuals with previous TBI were more likely to be unemployed ((2)=17.86; p=0.000), report a variety of chronic medical and psychiatric conditions (4.75(2)24.16; p<0.05), and report substance use (16.35(2)27.57; p<0.01) before the acute injury, compared to those with no previous TBI history. Those with a previous TBI had less-severe acute injuries, but experienced worse outcomes at 6-month follow-up. Results of a series of regression analyses controlling for demographics and acute injury severity indicated that individuals with previous TBI reported more mood symptoms, more postconcussive symptoms, lower life satisfaction, and had slower processing speed and poorer verbal learning, compared to those with no previous TBI history. These findings suggest that history of TBI with LOC may have important implications for health and psychological functioning after TBI in community-based samples.	[Dams-O'Connor, Kristen; Spielman, Lisa; Singh, Ayushi; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Manley, Geoffrey T.; Yue, John K.; Cooper, Shelly R.; Morabito, Diane J.; Sinha, Tuhin K.; Vassar, Mary J.; TRACK-TBI Investigators Including] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Mukherjee, Pratik; Yuh, Esther L.; Cheong, Maxwell] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Okonkwo, David O.; Puccio, Ava M.; Hricik, Allison J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Schnyer, David M.; Knight, Emily E.; Pacheco, Jennifer L.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anesthesia, Cambridge CB2 2QQ, England		Dams-O'Connor, K (corresponding author), Icahn Sch Med Mt Sinai, Dept Rehabil Med, 1 Gustave Levy Pl,Box 1240B, New York, NY 10029 USA.	kristen.dams-o'connor@mountsinai.org	Schnyer, David/ABD-6372-2021; Yue, John K/P-1348-2015; Pacheco, Jenni/AAX-5423-2021	Schnyer, David/0000-0002-7472-2853; Yue, John K/0000-0001-9694-7722; Mukherjee, Pratik/0000-0001-7473-7409; Cooper, Shelly/0000-0003-0026-6688	National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1RC2NS069409]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD074651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This work was aupported by the National Institutes of Health/National Institute of Neurological Disorders and Stroke (grant no.: 1RC2NS069409). This study is registered with ClinicalTrials.gov (identifier no.: NCT01565551). The authors gratefully acknowledge the contributions of Edwin Kulubya and Kerri Lawless to the implementation of the project and Tausif Billah for technical assistance with the manuscript.	American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; Delis D.C., 2000, CALIFORNIA VERBAL LE; Derogatis L., 2004, USE PSYCHOL TESTING, V3, P28; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Faul M, 2010, TRAUMATIC BRAIN INJU; Finkelstein E., 2006, INCIDENCE EC BURDEN; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Keane T.M., 1991, PCL M DSM 4; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; STALLINGS G, 1995, J CLIN EXP NEUROPSYC, V17, P706, DOI 10.1080/01688639508405160; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D., 2008, WECHSLER ADULT INTEL; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wrona RM, 2010, DISABIL REHABIL, V32, P650, DOI 10.3109/09638280903186327; Yue JK, 2013, J NEUROTRAUM, DOI DOI 10.1089/NEU.2013.2970; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	36	69	69	0	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 15	2013	30	24					2014	2020		10.1089/neu.2013.3049			7	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	271QK	WOS:000328406500002	23924069	Green Published			2022-02-06	
J	Selassie, AW; Wilson, DA; Pickelsimer, EE; Voronca, DC; Williams, NR; Edwards, JC				Selassie, Anbesaw W.; Wilson, Dulaney A.; Pickelsimer, E. Elisabeth; Voronca, Delia C.; Williams, Nolan R.; Edwards, Jonathan C.			Incidence of sport-related traumatic brain injury and risk factors of severity: a population-based epidemiologic study	ANNALS OF EPIDEMIOLOGY			English	Article						Sport-related TBI; Severity; Concussion; Mechanism of injury; Repetitive TBI	HIGH-SCHOOL; UNITED-STATES; CONCUSSION INCIDENCE; FOOTBALL; COLLEGIATE; HEAD; HOSPITALIZATION; TRENDS; IMPACT; US	Purpose: Few studies of sport-related traumatic brain injury (TBI) are population-based or rely on directly observed data on cause, demographic characteristics, and severity. This study addresses the epidemiology of sport-related TBI in a large population. Methods: Data on all South Carolina hospital and emergency department encounters for TBI, 1998-2011, were analyzed. Annual incidence rate of sport-related TBI was calculated, and rates were compared across demographic groups. Sport-related TBI severity was modeled as a function of demographic and TBI characteristics using logistic regression. Results: A total of 16,642 individuals with sport-related TBI yielded an average annual incidence rate of 31.5/100,000 population with a steady increase from 19.7 in 1998 to 45.6 in 2011. The most common mechanisms of sport-related TBI were kicked in football (38.1%), followed by fall injuries in sports (20.3%). Incidence rate was greatest in adolescents ages 12-18 (120.6/100,000/persons). Severe sport-related TBI was strongly associated with off-road vehicular sport (odds ratio [OR], 4.73; 95% confidence interval [95% Cl], 2.92-7.67); repeated head trauma (OR, 4.36; 95% CI, 3.69-5.15); equestrian sport (OR, 2.73; 95% CI, 1.64-4.51); and falls during sport activities (OR, 2.72; 95% Cl, 1.67-4.46). Conclusions: The high incidence of sport-related TBI in youth, potential for repetitive mild TBI, and its long-term consequences on learning warrants coordinated surveillance-activities and population-based outcome studies. (C) 2013 Elsevier Inc. All rights reserved.	[Selassie, Anbesaw W.; Wilson, Dulaney A.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Dept Publ Hlth Sci, Div Epidemiol, Charleston, SC 29425 USA; [Voronca, Delia C.] Med Univ S Carolina, Dept Publ Hlth Sci, Div Biostatistist, Charleston, SC 29425 USA; [Williams, Nolan R.; Edwards, Jonathan C.] Med Univ S Carolina, Dept Neurosci, Div Neurol, Charleston, SC 29425 USA		Selassie, AW (corresponding author), 135 Cannon St,Suite 302M, Charleston, SC 29425 USA.	selassie@musc.edu		Williams, Nolan/0000-0003-4368-3203; Wilson, Dulaney/0000-0003-4726-7848	National Center for Injury Prevention and Control, Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU421926]; South Carolina Department Disabilities and Special Needs, Head and Spinal Cord Division; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R25DA020537] Funding Source: NIH RePORTER	This study was partially supported by a grant from the National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, grant number U17/CCU421926 (PI: Anbesaw Selassie, DrPH). The study is also supported by the South Carolina Department Disabilities and Special Needs, Head and Spinal Cord Division. The contents do not necessarily represent the opinion of the funding agencies, and should not be assumed as endorsement by the Federal and State Government.	ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; American Medical Association, 2009, INT CLASS DIS; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowman SM, 2009, INJURY PREV, V15, P3, DOI 10.1136/ip.2008.019372; Butler JA, 2000, CENTRAL NERVOUS SYST; Center for Injury Research and Policy The Johns Hopkins University School of Public Health, 1997, ICDMAP 90 SOFTW; Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS), 2012, BRIDG RAC POP EST US; Centers for Disease Control and Prevention (CDC) NCHS, 2010, DROWN DEATHS SC MULT; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; DARLINGTON GA, 1998, ENCY BIOSTATISTICS, P788; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; Dempsey RL, 2005, INJURY PREV, V11, P91, DOI 10.1136/ip.2004.006205; Denning GM, 2013, ACCIDENT ANAL PREV, V52, P64, DOI 10.1016/j.aap.2012.12.015; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M, 2010, TRAUMATIC BRAIN INJU; Fleming PRI, 2001, CLIN EXP OPHTHALMOL, V29, P208, DOI 10.1046/j.1442-9071.2001.00430.x; Gelman A, 2013, BRIT J MATH STAT PSY, V66, P8, DOI 10.1111/j.2044-8317.2011.02037.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hosmer DW, 2000, MULTINOMINAL LOGISTI; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Kozlowski KF, 2007, NEUROREHABILITATION, V22, P191; Kushner DS, 2001, AM FAM PHYSICIAN, V64, P1007; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lustenberger T, 2010, J TRAUMA, V69, P924, DOI 10.1097/TA.0b013e3181b9a05a; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; Marshall SW, 2001, J ATHL TRAINING, V36, P334; Mattei TA, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11176; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Micheli LJ, 2000, CLIN SPORT MED, V19, P821, DOI 10.1016/S0278-5919(05)70239-8; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; O'Day J, 2001, CLIN EXP OPHTHALMOL, V29, P207, DOI 10.1046/j.1442-9071.2001.00415.x; Pate RR, 2000, ARCH PEDIAT ADOL MED, V154, P904, DOI 10.1001/archpedi.154.9.904; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; SAS Institute, 2011, STAT AN SOFTW VERS 9; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Selassie A, 2004, S CAROLINA TRAUMATIC; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Shoko T, 2010, J AM COLL SURGEONS, V211, P338, DOI 10.1016/j.jamcollsurg.2010.04.010; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; South Carolina Athletic Administrators Association, 2012, POP SPORTS POLL; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	64	69	73	1	39	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1047-2797	1873-2585		ANN EPIDEMIOL	Ann. Epidemiol.	DEC	2013	23	12					750	756		10.1016/j.annepidem.2013.07.022			7	Public, Environmental & Occupational Health	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Public, Environmental & Occupational Health	265CA	WOS:000327926100002	24060276	Green Accepted			2022-02-06	
J	Schatz, P; Ferris, CS				Schatz, Philip; Ferris, Charles S.			One-Month Test-Retest Reliability of the ImPACT Test Battery	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						ImPACT; Concussion; Neuropsychological testing; Mild head injury; Baseline screening	HIGH-SCHOOL; CLINICAL UTILITY; CONCUSSION	In order to better understand the test-retest reliability of the ImPACT test battery, 25 undergraduate students completed two ImPACT tests across a time frame of 4 weeks between assessments. Participants had not previously completed ImPACT and had no history of concussion. Pearson's correlation coefficients (r) and intraclass correlation coefficients (ICCs) were as follows: Verbal Memory = .66/.79 (r/ICC), Visual Memory = .43/.60, Visual Motor Speed = .78/.88, Reaction Time = .63/.77, and Total Symptoms = .75/.81. Dependent sample t-tests revealed significant improvement on only Visual Motor Speed composite scores. Reliable Change Indices showed a significant number of participants fell outside 80% and 95% confidence intervals for only Visual Motor Speed scores (but no other indices), whereas all scores were within 80% and 95% confidence intervals using regression-based measures. Results suggest that repeated exposure to the ImPACT test may result in significant improvements in the physical mechanics of how college students interact with the test (e. g., performance on Visual Motor Speed), but repeated exposure across 1 month does not result in practice effects in memory performance or reaction time.	[Schatz, Philip; Ferris, Charles S.] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA		Schatz, P (corresponding author), St Josephs Univ, Dept Psychol, 5600 City Ave,Post Hall 222, Philadelphia, PA 19131 USA.	pschatz@sju.edu					BARR WB, 2002, CNS SPECTRUMS, V7, P304; Barr William B, 2002, CNS Spectr, V7, P300; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Chicchetti D. V., 1994, PSYCHOL ASSESSMENT, V6, P294, DOI DOI 10.1037//1040-3590.6.4.284; Crawford JR, 2006, NEUROPSYCHOLOGY, V20, P259, DOI 10.1037/0894-4105.20.3.259; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; FLEISHMAN J, 1987, EDUC PSYCHOL MEAS, V47, P925, DOI 10.1177/0013164487474008; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2001, LUPUS, V10, P266, DOI 10.1191/096120301680416959; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2007, IMPACT VERSION 6 0 C; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; RODGERS JL, 1988, AM STAT, V42, P59, DOI 10.2307/2685263; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2012, J CLIN EXP NEUROPSYC, V34, P428, DOI 10.1080/13803395.2012.667789; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Wilk CM, 2002, AM J PSYCHIAT, V159, P838, DOI 10.1176/appi.ajp.159.5.838	27	69	70	0	13	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2013	28	5					499	504		10.1093/arclin/act034			6	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	186CN	WOS:000322019600012	23702678	Bronze			2022-02-06	
J	Register-Mihalik, JK; Guskiewicz, KM; Mihalik, JP; Schmidt, JD; Kerr, ZY; McCrea, MA				Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Schmidt, Julianne D.; Kerr, Zachary Y.; McCrea, Michael A.			Reliable Change, Sensitivity, and Specificity of a Multidimensional Concussion Assessment Battery: Implications for Caution in Clinical Practice	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						balance; cognition; mild traumatic brain injury; sensitivity; serial assessment; specificity	SPORTS-RELATED CONCUSSION; TEST-RETEST RELIABILITY; MILD HEAD-INJURY; NEUROPSYCHOLOGICAL ASSESSMENT; POSTURAL STABILITY; IMPACT; MANAGEMENT; STATEMENT; RECOVERY; DEFICITS	Objective: To provide reliable change confidence intervals for common clinical concussion measures using a healthy sample of collegiate athletes and to apply these reliable change parameters to a sample of concussed collegiate athletes. Methods: Two independent samples were included in the study and evaluated on common clinical measures of concussion. The healthy sample included male, collegiate football student-athletes (n = 38) assessed at 2 time points. The concussed sample included college-aged student-athletes (n = 132) evaluated before and after a concussion. Outcome measures included symptom severity scores, Automated Neuropsychological Assessment Metrics throughput scores, and Sensory Organization Test composite scores. Results: Application of the reliable change parameters suggests that a small percentage of concussed participants were impaired on each measure. We identified a low sensitivity of the entire battery (all measures combined) of 50% but high specificity of 96%. Conclusions: Clinicians should be trained in understanding clinical concussion measures and should be aware of evidence suggesting the multifaceted battery is more sensitive than any single measure. Clinicians should be cautioned that sensitivity to balance and neurocognitive impairments was low for each individual measure. Applying the confidence intervals to our injured sample suggests that these measures do not adequately identify postconcussion impairments when used in isolation.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, Raleigh, NC 27610 USA; [Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mihalik, Jason P.; Schmidt, Julianne D.; Kerr, Zachary Y.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Kerr, Zachary Y.] Univ N Carolina, Dept Epidemiol, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael A.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA		Register-Mihalik, JK (corresponding author), WakeMed Hlth & Hosp, Emergency Serv Inst, Clin Res Unit, 3024 New Bern Ave,Ste G01, Raleigh, NC 27610 USA.	jmihalik@wakemed.org		Register-Mihalik, Johna/0000-0002-4229-4743; Guskiewicz, Kevin/0000-0002-8682-2130; Mihalik, Jason/0000-0001-6085-8322; Kerr, Zachary/0000-0003-1423-1259			Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brown CN, 2007, J ATHL TRAINING, V42, P515; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Chelune G.J., 1993, NEUROPSYCHOLOGY, V7, P41, DOI [10.1037/0894-4105.7.1.41, DOI 10.1037/0894-4105.7.1.41]; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Maassen GH, 2009, J CLIN EXP NEUROPSYC, V31, P339, DOI 10.1080/13803390802169059; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Parsons TD, 2009, INT J NEUROSCI, V119, P492, DOI 10.1080/00207450802330876; Patel AV, 2007, J ATHL TRAINING, V42, P66; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Roebuck-Spencer T, 2007, ARCH CLIN NEUROPSYCH, V22, pS79, DOI 10.1016/j.acn.2006.10.011; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	31	69	69	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2013	28	4					274	283		10.1097/HTR.0b013e3182585d37			10	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	298ZO	WOS:000330363900005	22691965				2022-02-06	
J	Skop, NB; Calderon, F; Levison, SW; Gandhi, CD; Cho, CH				Skop, Nolan B.; Calderon, Frances; Levison, Steven W.; Gandhi, Chirag D.; Cho, Cheul H.			Heparin crosslinked chitosan microspheres for the delivery of neural stem cells and growth factors for central nervous system repair	ACTA BIOMATERIALIA			English	Article						Nerve tissue regeneration; Regenerative medicine; Multifunctional scaffold; Fibroblast growth factor-2; Cell transplantation	TRAUMATIC BRAIN-INJURY; INFLAMMATORY RESPONSE; IN-VIVO; CONTROLLED-RELEASE; GEL STIFFNESS; GLIAL-CELLS; GENIPIN; SURVIVAL; SCAFFOLDS; PROTEIN	An effective paradigm for transplanting large numbers of neural stem cells after central nervous system (CNS) injury has yet to be established. Biomaterial scaffolds have shown promise in cell transplantation and in regenerative medicine, but improved scaffolds are needed. In this study we designed and optimized multifunctional and biocompatible chitosan-based films and microspheres for the delivery of neural stem cells and growth factors for CNS injuries. The chitosan microspheres were fabricated by coaxial airflow techniques, with the sphere size controlled by varying the syringe needle gauge and the airflow rate. When applying a coaxial airflow at 30 standard cubic feet per hour, similar to 300 mu m diameter spheres were reproducibly generated that were physically stable yet susceptible to enzymatic degradation. Heparin was covalently crosslinked to the chitosan scaffolds using genipin, which bound fibroblast growth factor-2 (FGF-2) with high affinity while retaining its biological activity. At 1 mu g ml(-1) approximately 80% of the FGF-2 bound to the scaffold. A neural stem cell line, GFP + RG3.6 derived from embryonic rat cortex, was used to evaluate cytocompatibility, attachment and survival on the crosslinked chitosan-heparin complex surfaces. The MTT assay and microscopic analysis revealed that the scaffold containing tethered FGF-2 was superior in sustaining survival and growth of neural stem cells compared to standard culture conditions. Altogether, our results demonstrate that this multifunctional scaffold possesses good cytocompatibility and can be used as a growth factor delivery vehicle while supporting neural stem cell attachment and survival. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Skop, Nolan B.; Calderon, Frances; Levison, Steven W.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol & Neurosci, Newark, NJ 07102 USA; [Gandhi, Chirag D.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07102 USA; [Skop, Nolan B.; Cho, Cheul H.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA		Cho, CH (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	cho@njit.edu	Levison, Steven W./Q-6903-2019	Levison, Steven W./0000-0002-1264-7309	New Jersey Commission on Brain Injury Research [08.001.BIR2, CBIR12FEL025]; Wallace H. Coulter Foundation	This study was partially supported by the New Jersey Commission on Brain Injury Research grant number 08.001.BIR2 awarded to C.D.G. and S.W.L., fellowship grant number CBIR12FEL025 awarded to N.P.S. and the Wallace H. Coulter Foundation.	Ashikari-Hada S, 2004, J BIOL CHEM, V279, P12346, DOI 10.1074/jbc.M313523200; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Barbosa JN, 2010, J BIOMED MATER RES A, V93A, P20, DOI 10.1002/jbm.a.32499; Barbucci R, 2009, HYDROGELS BIOL PROPE, VXII, P200; Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019; Bottcher RT, 2005, ENDOCR REV, V26, P63, DOI 10.1210/er.2003-0040; Cervera A, 2004, J NEUROSCI RES, V77, P565, DOI 10.1002/jnr.20186; Chandy T, 2000, J MICROENCAPSUL, V17, P625; Cho CH, 2008, J BIOMED MATER RES A, V86A, P98, DOI 10.1002/jbm.a.31614; Cho Y, 2010, J EXP BIOL, V213, P1513, DOI 10.1242/jeb.035162; Crompton KE, 2007, BIOMATERIALS, V28, P441, DOI 10.1016/j.biomaterials.2006.08.044; Crompton KE, 2006, J MATER SCI-MATER M, V17, P633, DOI 10.1007/s10856-006-9226-6; Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044; Eroglu H, 2010, CHEM PHARM BULL, V58, P1161, DOI 10.1248/cpb.58.1161; FOLKMAN J, 1983, CIBA F SYMP, V100, P132; Francesko A, 2011, ADV BIOCHEM ENG BIOT, V125, P1, DOI [10.10007/10_2010_93, 10.1007/10_2010_93]; Freier T, 2005, BIOMATERIALS, V26, P5872, DOI 10.1016/j.biomaterials.2005.02.033; Guo XD, 2012, CELL TRANSPLANT, V21, P1177, DOI 10.3727/096368911X612503; Guo XL, 2003, J BIOMAT SCI-POLYM E, V14, P551, DOI 10.1163/15685620360674245; Harris R, 2010, MAR DRUGS, V8, P1750, DOI 10.3390/md8061750; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Hassan EE, 1993, J DRUG TARGET, V1, P7, DOI 10.3109/10611869308998759; Hidaka Y, 1999, J BIOMED MATER RES, V46, P418, DOI 10.1002/(SICI)1097-4636(19990905)46:3<418::AID-JBM15>3.0.CO;2-T; Hussain A, 2013, BIOTECHNOL BIOENG, V110, P637, DOI 10.1002/bit.24727; Jumaa M, 2002, EUR J PHARM BIOPHARM, V53, P115, DOI 10.1016/S0939-6411(01)00191-6; Kai D, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957-4484/23/9/095705; Khor E, 2003, BIOMATERIALS, V24, P2339, DOI 10.1016/S0142-9612(03)00026-7; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kim SE, 2003, J CONTROL RELEASE, V91, P365, DOI 10.1016/S0168-3659(03)00274-8; Kim S, 2009, BIOMATERIALS, V30, P4743, DOI 10.1016/j.biomaterials.2009.05.010; Koo HJ, 2006, J ETHNOPHARMACOL, V103, P496, DOI 10.1016/j.jep.2005.08.011; Koriyama Y, 2011, J NEUROCHEM, V119, P1232, DOI 10.1111/j.1471-4159.2011.07533.x; Kou JH, 1997, J CONTROL RELEASE, V43, P123, DOI 10.1016/S0168-3659(96)01477-0; LAMOUREUX P, 1989, NATURE, V340, P156, DOI 10.1038/340159a0; LEE KY, 1995, BIOMATERIALS, V16, P1211, DOI 10.1016/0142-9612(95)98126-Y; Leipzig ND, 2011, BIOMATERIALS, V32, P57, DOI 10.1016/j.biomaterials.2010.09.031; Li HD, 2004, DEV BIOL, V271, P225, DOI 10.1016/j.ydbio.2004.02.028; Lo CM, 2000, BIOPHYS J, V79, P144, DOI 10.1016/S0006-3495(00)76279-5; Madihally SV, 1999, BIOMATERIALS, V20, P1133, DOI 10.1016/S0142-9612(99)00011-3; Maysinger D, 1996, EXP NEUROL, V141, P47, DOI 10.1006/exnr.1996.0138; Mi FL, 2002, BIOMATERIALS, V23, P181, DOI 10.1016/S0142-9612(01)00094-1; Mo LH, 2010, BIOMATERIALS, V31, P2184, DOI 10.1016/j.biomaterials.2009.11.078; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nam KN, 2010, INT IMMUNOPHARMACOL, V10, P493, DOI 10.1016/j.intimp.2010.01.011; Nicodemus GD, 2008, TISSUE ENG PT B-REV, V14, P149, DOI 10.1089/ten.teb.2007.0332; Nomura H, 2008, TISSUE ENG PT A, V14, P649, DOI 10.1089/tea.2007.0180; Onishi H, 1999, BIOMATERIALS, V20, P175, DOI 10.1016/S0142-9612(98)00159-8; PELUSO G, 1994, BIOMATERIALS, V15, P1215, DOI 10.1016/0142-9612(94)90272-0; RIBATTI D, 1987, ACTA ANAT, V130, P257; Seo MC, 2008, J NEUROSCI RES, V86, P1087, DOI 10.1002/jnr.21552; Shen H, 2011, BIOMATERIALS, V32, P3404, DOI 10.1016/j.biomaterials.2011.01.037; Shi W, 2012, BIOMATERIALS, V33, P3119, DOI 10.1016/j.biomaterials.2012.01.009; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Sinha VR, 2004, INT J PHARMACEUT, V274, P1, DOI 10.1016/j.ijpharm.2003.12.026; Solorio L, 2010, J TISSUE ENG REGEN M, V4, P514, DOI 10.1002/term.267; SOMMER A, 1989, J CELL PHYSIOL, V138, P215, DOI 10.1002/jcp.1041380129; Stachowiak EK, 1997, ONCOGENE, V14, P2201, DOI 10.1038/sj.onc.1201057; Sun D, 2009, EXP NEUROL, V216, P56, DOI 10.1016/j.expneurol.2008.11.011; Sung HW, 1999, J BIOMAT SCI-POLYM E, V10, P63, DOI 10.1163/156856299X00289; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Thakur G, 2011, J MATER SCI-MATER M, V22, P115, DOI 10.1007/s10856-010-4185-3; Tolaimate A, 2000, POLYMER, V41, P2463, DOI 10.1016/S0032-3861(99)00400-0; Turkoglu OF, 2005, SURG NEUROL, V64, P11, DOI 10.1016/j.surneu.2005.07.041; Turkoglu OF, 2010, BRIT J NEUROSURG, V24, P578, DOI 10.3109/02688697.2010.487126; Vasavada VA, 2012, AM J OPHTHALMOL, V154, pe4; Vergano-Vera E, 2009, NEUROSCIENCE, V162, P39, DOI 10.1016/j.neuroscience.2009.03.033; Volpato FZ, 2012, ACTA BIOMATER, V8, P1551, DOI 10.1016/j.actbio.2011.12.023; Wang HB, 2000, AM J PHYSIOL-CELL PH, V279, pC1345, DOI 10.1152/ajpcell.2000.279.5.C1345; Willits RK, 2004, J BIOMAT SCI-POLYM E, V15, P1521, DOI 10.1163/1568562042459698; Wissink MJB, 2001, BIOMATERIALS, V22, P2291, DOI 10.1016/S0142-9612(00)00418-X; Wu JM, 2011, J MATER SCI-MATER M, V22, P107, DOI 10.1007/s10856-010-4176-4; Yamazaki M, 2004, EUR J PHARMACOL, V488, P35, DOI 10.1016/j.ejphar.2004.02.009; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yuan Y, 2007, CARBOHYD POLYM, V68, P561, DOI 10.1016/j.carbpol.2006.10.023; Zeng Y, 2011, MED HYPOTHESES, V77, P680, DOI 10.1016/j.mehy.2011.07.015; ZIELINSKI BA, 1994, BIOMATERIALS, V15, P1049	79	69	71	1	105	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUN	2013	9	6					6834	6843		10.1016/j.actbio.2013.02.043			10	Engineering, Biomedical; Materials Science, Biomaterials	Science Citation Index Expanded (SCI-EXPANDED)	Engineering; Materials Science	158EF	WOS:000319951500009	23467042				2022-02-06	
J	Dunisch, P; Walter, J; Sakr, Y; Kalff, R; Waschke, A; Ewald, C				Duenisch, Pedro; Walter, Jan; Sakr, Yasser; Kalff, Rolf; Waschke, Albrecht; Ewald, Christian			Risk factors of aseptic bone resorption: a study after autologous bone flap reinsertion due to decompressive craniotomy Clinical article	JOURNAL OF NEUROSURGERY			English	Article						craniotomy; cranioplasty; bone flap; aseptic bone flap necrosis; bone resorption	SKIN FLAP; CRANIOPLASTY; CRANIECTOMY; COMPLICATIONS; HEMICRANIECTOMY; RECOVERY	Object. In patients who have undergone decompressive craniectomy, autologous bone flap reinsertion becomes necessary whenever the cerebral situation has consolidated. However, aseptic necrosis of the bone flap remains a concern. The aim of this study was to report possible perioperative complications in patients undergoing autologous bone flap reinsertion and to identify the risk factors that may predispose the bone flap to necrosis. Methods. All patients admitted to the authors' neurosurgical department between September 1994 and June 2011 and who received their own cryoconserved bone flap after decompressive craniectomy were studied. The grade of the bone flap necrosis was classified into 2 types. Type II bone necrosis was characterized by aseptic resorption with circumscribed or complete lysis of tabula interna and extema requiring surgical revision. To define predisposing factors, a multivariate analysis was performed using bone necrosis as the dependent variable. Results. Among the 372 patients (mean age 48.6 years, 57.4% males) who received 414 bone flaps during the observation period, 134 (36.0%) had a diffuse traumatic brain injury, 69 (18.5%) had subarachnoid hemorrhage, 58 (15.6%) had cerebral infarction, 56 (15.1%) had extraaxial bleeding, 43 (11.6%) had intracerebral bleeding, and 12 (3.2%) had a neoplasm. Surgical relevant Type II bone flap necrosis occurred in 85 patients (22.8%) and 91 bone flaps, after a median time of 15 months (interquartile range [IQR], 10-33 months). In a multivariate analysis with Type II necrosis as the dependent variable, bone flap fragmentation with 2 (OR 3.35, 95% CI 1.59-7.01, p < 0.002) or more fragments (OR 24.00, 95% CI 10.13-56.84, p < 0.001), shunt-dependent hydrocephalus (OR 1.76, 95% CI 0.99-3.12, p = 0.04), and a younger age (OR 0.98, 95% CI 0.96-0.99, p = 0.004) was associated with a higher risk for the development of an aseptic bone flap necrosis. Conclusions. In patients undergoing bone flap reinsertion after craniotomy, aseptic bone necrosis is an underestimated problem during long-term follow-up. Especially in younger patients with an expected good neurological recovery and a fragmented bone flap, an initial allograft should be considered because of an increased risk for aseptic bone flap necrosis. (http://thejns.org/doi/abs/10.3171/2013.1.JNS12860)	[Duenisch, Pedro; Walter, Jan; Kalff, Rolf; Waschke, Albrecht; Ewald, Christian] Univ Jena, Jena Univ Hosp, Dept Neurosurg, D-07745 Jena, Germany; [Sakr, Yasser] Univ Jena, Jena Univ Hosp, Dept Anaesthesiol, D-07745 Jena, Germany		Dunisch, P (corresponding author), Hosp Friedrich Schiller Univ, Dept Neurosurg, Erlanger Allee 101, D-07747 Jena, Germany.	pedro.duenisch@med.uni-jena.de	Walter, Jan/AAE-4536-2021; Sakr, Yasser/D-9802-2013				Beauchamp KM, 2010, J TRAUMA, V69, P270, DOI 10.1097/TA.0b013e3181e491c2; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Chieregato A, 2006, INTENS CARE MED, V32, P1668, DOI 10.1007/s00134-006-0302-7; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Grant GA, 2004, J NEUROSURG, V100, P163, DOI 10.3171/ped.2004.100.2.0163; HAUPTLI J, 1980, HELV CHIR ACTA, V47, P121; Honeybul S, 2011, J NEUROTRAUM, V28, P929, DOI 10.1089/neu.2010.1612; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Joseph V, 2009, J NEUROSURG, V111, P650, DOI 10.3171/2009.3.JNS0984; Kemmling A, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-80; Meyer MJ, 2010, BRAIN INJURY, V24, P694, DOI 10.3109/02699051003692118; Nievas MNCY, 2006, NEUROL RES, V28, P139, DOI 10.1179/016164106X98008; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Schorl M, 2009, CENT EUR NEUROSURG, V70, P68, DOI 10.1055/s-0028-1093355; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; SEGAL DH, 1994, NEUROSURGERY, V34, P729, DOI 10.1227/00006123-199404000-00024; Shoakazemi A, 2009, NEUROSURGERY, V65, P505, DOI 10.1227/01.NEU.0000350870.69891.86; Stephens FL, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.2.FOCUS1026; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Waziri A, 2007, NEUROSURGERY, V61, P489, DOI 10.1227/01.NEU.0000290894.85072.37; Wen L, 2007, J CRANIOFAC SURG, V18, P526, DOI 10.1097/scs.0b013e3180534348; Yamaura A, 1977, No Shinkei Geka, V5, P345	23	69	73	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2013	118	5					1141	1147		10.3171/2013.1.JNS12860			7	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	131LT	WOS:000317995900041	23451904				2022-02-06	
J	Catroppa, C; Godfrey, C; Rosenfeld, JV; Hearps, SSJC; Anderson, VA				Catroppa, Cathy; Godfrey, Celia; Rosenfeld, Jeffrey V.; Hearps, Stephen S. J. C.; Anderson, Vicki A.			Functional Recovery Ten Years after Pediatric Traumatic Brain Injury: Outcomes and Predictors	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain injury; children; functional	CLOSED-HEAD-INJURY; SHORT-TERM; PSYCHIATRIC-DISORDERS; BEHAVIOR PROBLEMS; CHILDREN; CHILDHOOD; ADOLESCENTS; SEVERITY; PERFORMANCE; SYMPTOMS	Functional impairments (adaptive, behavioral, educational) are common after preschool traumatic brain injury (TBI). In comparison with cognitive outcome, functional outcomes have received limited attention, with little evidence to determine whether these difficulties persist in the long term. The aim of this study was to examine functional outcomes at 10 years post-injury and identify predictors of outcome. The study compared children with a diagnosis of TBI (n = 40) to a healthy age-, gender-, and socioeconomic status (SES)-matched control group (n = 19) at 10 years post-injury. Outcomes and predictors of functional skills were investigated. Poorer adaptive skills were evident for those with more severe injury. Behavioral difficulties were present regardless of injury severity. Post-injury, arithmetic skills were the most compromised in the longer term. Pre-injury status, interventions accessed, and acute intellectual function were significant predictors of outcome. These results highlight the importance of monitoring functional skills in the long term, especially for those children presenting with risk factors.	[Catroppa, Cathy; Godfrey, Celia; Anderson, Vicki A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Catroppa, Cathy; Anderson, Vicki A.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Alfred Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Rosenfeld, Jeffrey V.] Monash Univ, Dept Surg, Melbourne, Vic 3004, Australia; [Catroppa, Cathy; Godfrey, Celia; Hearps, Stephen S. J. C.; Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia		Catroppa, C (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	cathy.catroppa@mcri.edu.au	Hearps, Stephen/L-6853-2016; Rosenfeld, Jeffrey V/B-7249-2011; Catroppa, Cathy/AAX-9458-2021	Catroppa, Cathy/0000-0002-9750-0436; Hearps, Stephen/0000-0003-2984-1172	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia; Royal Children's Hospital Research Foundation; Victorian Government's Operational Infrastructure Support Program	This research was supported by the Australian National Health and Medical Research Council, the Royal Children's Hospital Research Foundation, and the Victorian Government's Operational Infrastructure Support Program.	Alves W., 1992, PHYS MED REHABIL STA, V6, P21; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Anderson V, 2009, J HEAD TRAUMA REHAB, V24, P303, DOI 10.1097/HTR.0b013e3181ada830; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; Bayley N., 1969, BAYLEY SCALES INFANT; BERGERGROSS P, 1985, PERCEPT MOTOR SKILL, V61, P254, DOI 10.2466/pms.1985.61.1.254; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2007, CHILD NEUROPSYCHOL, V13, P240, DOI 10.1080/09297040600837362; Catroppa C, 2009, NEUROPSYCHOL REHABIL, V19, P716, DOI 10.1080/09602010902732868; Cattelani R, 1998, BRAIN INJURY, V12, P283, DOI 10.1080/026990598122584; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Ciccetti D., 1984, VINELAND ADAPTIVE BE; Cohen J., 2013, STAT POWER ANAL BEHA; Daniel A., 1983, POWER PRIVILEGE PRES; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 2009, BRAIN INJURY, V23, P944, DOI 10.3109/02699050903285531; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Harrison P. L., 2003, ADAPTIVE BEHAV ASSES, V2nd; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Lachar D., 1992, PERSONALITY INVENTOR; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NEUROPSYCH CLIN N, V10, P290, DOI 10.1176/jnp.10.3.290; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Noller P., 1988, ICPS FAMILY FUNCTION; Rawlings J.O., 1998, APPL REGRESSION ANAL; Reynolds CR., 1992, BEHAV ASSESSMENT SYS; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; Slater E.J., 1989, J ADOLESCENT RES, V4, P371; Stuss DT, 2004, BRAIN COGNITION, V55, P69, DOI 10.1016/s0278-2626(03)00271-9; Tabachnick B.G., 2001, USING MULTIVARIATE S; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wade SL, 2006, J PEDIATR PSYCHOL, V31, P1072, DOI 10.1093/jpepsy/jsj077; Wechsler D., 1987, MANUAL PRESCHOOL PRI; Wechsler D, 1991, WECHSLER INTELLIGENC, VTHIRD; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Wilkinson G.S., 1993, WIDE RANGE ACHIEVEME; Woods DT, 2012, NEUROREHABILITATION, V30, P189, DOI 10.3233/NRE-2012-0744; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	63	69	69	0	29	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	16					2539	2547		10.1089/neu.2012.2403			9	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine; Neurosciences & Neurology	035CS	WOS:000310920900002	22846066				2022-02-06	
J	Budohoski, KP; Czosnyka, M; de Riva, N; Smielewski, P; Pickard, JD; Menon, DK; Kirkpatrick, PJ; Lavinio, A				Budohoski, Karol P.; Czosnyka, Marek; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Lavinio, Andrea			The Relationship Between Cerebral Blood Flow Autoregulation and Cerebrovascular Pressure Reactivity After Traumatic Brain Injury	NEUROSURGERY			English	Article						Cerebral autoregulation; Cerebrovascular reactivity; Intracranial pressure; Transcranial Doppler; Traumatic brain injury	HEAD-INJURY; INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; SUBARACHNOID HEMORRHAGE; VASOMOTOR REACTIVITY; PULSE PRESSURE; HYPERTENSION; OXYGEN; CRANIECTOMY; CIRCULATION	BACKGROUND: Cerebrovascular pressure reactivity is the principal mechanism of cerebral autoregulation. Assessment of cerebral autoregulation can be performed by using the mean flow index (Mx) based on transcranial Doppler ultrasonography. Cerebrovascular pressure reactivity can be monitored by using the pressure reactivity index (PRx), which is based on intracranial pressure monitoring. From a practical point of view, PRx can be monitored continuously, whereas Mx can only be monitored in short periods when transcranial Doppler probes can be applied. OBJECTIVE: To assess to what degree impairment in pressure reactivity (PRx) is associated with impairment in cerebral autoregulation (Mx). METHODS: A database of 345 patients with traumatic brain injury was screened for data availability including simultaneous Mx and PRx monitoring. Absolute differences, temporal changes, and association with outcome of the 2 indices were analyzed. RESULTS: A total of 486 recording sessions obtained from 201 patients were available for analysis. Overall a moderate correlation between Mx and PRx was found (r = 0.58; P < .001). The area under the receiver operator characteristic curve designed to detect the ability of PRx to predict impaired cerebral autoregulation was 0.700 (95% confidence interval: 0.607-0.880). Discrepancies between Mx and PRx were most pronounced at an intracranial pressure of 30 mm Hg and they were significantly larger for patients who died (P = .026). Both Mx and PRx were significantly lower at day 1 postadmission in patients who survived than in those who died (P < .01). CONCLUSION: There is moderate agreement between Mx and PRx. Discrepancies between Mx and PRx are particularly significant in patients with sustained intracranial hypertension. However, for clinical purposes, there is only limited interchangeability between indices.	[Budohoski, Karol P.; Czosnyka, Marek; de Riva, Nicolas; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 2QQ, England; [de Riva, Nicolas] Univ Barcelona, Dept Anaesthesiol, Hosp Clin Barcelona, Barcelona, Spain; [Pickard, John D.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 2QQ, England; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Univ Dept Anaesthesia, Cambridge CB2 2QQ, England; [Lavinio, Andrea] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Dept Anaesthesia, Cambridge, England		Budohoski, KP (corresponding author), Mazovia Brodnowski Hosp, Med Ctr Postrgrad Training, Dept Neurosurg, Ul Kondratowicza 8, PL-03242 Warsaw, Poland.		de Riva, Nicolas/AAN-3347-2020; Lavinio, Andrea/M-1778-2016	de Riva, Nicolas/0000-0003-2691-5770; Smielewski, Peter/0000-0001-5096-3938	National Institute of Health ResearchNational Institute for Health Research (NIHR); Biomedical Research Centre (Neuroscience Theme); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Clifford and Mary Corbridge Trust of Robinson College, Cambridge, UK; St. Catharine's College, University of Cambridge; Hospital Clinic de Barcelona, Barcelona, Spain; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0001237, G9439390, G0600986] Funding Source: UKRI; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	This work was supported by the National Institute of Health Research, Biomedical Research Centre (Neuroscience Theme), the Medical Research Council (grants G0600986 and G9439390), and National Institute of Health Research Senior Investigator Awards (to J. D. P. and D. K. M.); by the Clifford and Mary Corbridge Trust of Robinson College, Cambridge, UK, and the St. Catharine's College, University of Cambridge Travel and Research Fund (to K. P. B.); by the Hospital Clinic de Barcelona, Barcelona, Spain (NdR). ICM+ software (Cambridge Enterprise, Cambridge, UK http://www.neurosurg.cam.ac.uk/icmplus/) is licensed by the University of Cambridge, Cambridge Enterprise Ltd. P. S. and M. C. have a financial interest in a part of licensing fee. J. D. P. and M. C. are directors of Technicam, UK. The other authors have no personal financial or institutional interest in any of the drugs, materials, or devices described in this article.	AVEZAAT CJJ, 1980, J NEUROL NEUROSUR PS, V43, P222, DOI 10.1136/jnnp.43.3.222; Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bayliss WM, 1902, J PHYSIOL-LONDON, V28, P220; Bijlenga P, 2010, NEUROCRIT CARE, V13, P17, DOI 10.1007/s12028-010-9362-1; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; COLD GE, 1978, ACTA ANAESTH SCAND, V22, P270, DOI 10.1111/j.1399-6576.1978.tb01301.x; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 1998, ACT NEUR S, V71, P74; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Czosnyka M, 1997, NEUROSURGERY, V41, P17; Czosnyka M, 2008, ANESTH ANALG, V106, P234, DOI 10.1213/01.ane.0000295802.89962.13; Eide PK, 2007, NEUROL RES, V29, P578, DOI 10.1179/016164107X172167; HARPER AM, 1966, J NEUROL NEUROSUR PS, V29, P398, DOI 10.1136/jnnp.29.5.398; Haubrich C, 2011, J NEUROTRAUM, V28, P1133, DOI 10.1089/neu.2010.1577; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Jaeger M, 2007, STROKE, V38, P981, DOI 10.1161/01.STR.0000257964.65743.99; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371, DOI 10.1152/ajpheart.1978.234.4.H371; Lang EW, 2003, J NEUROL NEUROSUR PS, V74, P1053, DOI 10.1136/jnnp.74.8.1053; Lang EW, 2002, J NEUROL NEUROSUR PS, V72, P583, DOI 10.1136/jnnp.72.5.583; LASSEN NA, 1959, PHYSIOL REV, V39, P183, DOI 10.1152/physrev.1959.39.2.183; LASSEN NA, 1964, CIRC RES, V15, P201; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Ogoh S, 2010, J APPL PHYSIOL, V108, P538, DOI 10.1152/japplphysiol.01235.2009; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; Smielewski P, 1997, J NEUROSURG, V86, P773, DOI 10.3171/jns.1997.86.5.0773; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Sorrentino E, 2011, NEUROCRIT CARE, V14, P188, DOI 10.1007/s12028-010-9492-5; Steiner LA, 2005, ACTA NEUROCHIR SUPPL, V95, P17; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Steinmeier R, 2002, J NEUROTRAUM, V19, P1127, DOI 10.1089/08977150260337949; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Wang EC, 2006, BRIT J NEUROSURG, V20, P24, DOI 10.1080/02688690600598257; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	39	69	73	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	2012	71	3					652	660		10.1227/NEU.0b013e318260feb1			9	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	996HB	WOS:000308074400030	22653390				2022-02-06	
J	Erdal, K				Erdal, Kristi			Neuropsychological Testing for Sports-related Concussion: How Athletes Can Sandbag their Baseline Testing Without Detection	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Neuropsychological testing; Athletes; Baseline; Concussion	TEST-RETEST RELIABILITY; HEAD-INJURY; PERFORMANCE; IMPACT; SIMULATION; ABILITY	Neuropsychological baseline testing is commonplace in the assessment of concussion; however, claims of sandbagging the baseline have led neuropsychologists to ask to what extent athletes can perform intentionally poorly on baseline testing without reaching threshold on the test validity indicators. Seventy-five undergraduate athletes were re-administered the ImPACT neurocognitive battery, which they had previously taken to establish baseline functioning, but were instructed to perform more poorly than their baseline without reaching threshold on the test validity indicators. Eight participants were able to successfully fake significantly lower scores without detection by validity indicators. Concussion history was not related to performance. Successful fakers did not perform significantly worse on the Reaction Time Composite and Three Letters Total Letters Correct, questioning the utility of these measures for detecting sandbagging. Successful fakers reported using less purposeful faking strategies which naturally facilitated errors. The data suggest that sandbagging the baseline, even under conditions involving motivation, instruction, and experience with the test, is difficult to accomplish without being detected.	Colorado Coll, Dept Psychol, Colorado Springs, CO 80903 USA		Erdal, K (corresponding author), Colorado Coll, Dept Psychol, 14 E Cache La Poudre St, Colorado Springs, CO 80903 USA.	kerdal@coloradocollege.edu			Colorado College Psychology Department Sabine Funds	This work was supported by the Colorado College Psychology Department Sabine Funds.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bender SD, 2004, ARCH CLIN NEUROPSYCH, V19, P49, DOI 10.1016/S0887-6177(02)00165-8; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dearth CS, 2005, ARCH CLIN NEUROPSYCH, V20, P95, DOI 10.1016/j.acn.2004.03.004; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Hunt TN, 2007, ARCH CLIN NEUROPSYCH, V22, P615, DOI 10.1016/j.acn.2007.04.005; ImPACT, 2012, NORM BAS DAT; ImPACT Applications Inc, 2007, IMPACT 2007 6 0 CLIN; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Kaminski TW, 2009, J CLIN EXP NEUROPSYC, V31, P689, DOI 10.1080/13803390802484771; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Reicker LI, 2008, ARCH CLIN NEUROPSYCH, V23, P419, DOI 10.1016/j.acn.2008.02.003; Reilly R., 2011, TALK FOOTB ARCH PEYT; Rogers R., 2008, CLIN ASSESSMENT MALI; Schatz P, 2010, ARCH CLIN NEUROPSYCH, V25, P285, DOI 10.1093/arclin/acq022; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005	23	69	69	1	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2012	27	5					473	479		10.1093/arclin/acs050			7	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	976UN	WOS:000306611300001	22684033	Bronze			2022-02-06	
J	Karver, CL; Wade, SL; Cassedy, A; Taylor, HG; Stancin, T; Yeates, KO; Walz, NC				Karver, Christine L.; Wade, Shari L.; Cassedy, Amy; Taylor, H. Gerry; Stancin, Terry; Yeates, Keith Owen; Walz, Nicolay C.			Age at Injury and Long-Term Behavior Problems After Traumatic Brain Injury in Young Children	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; long-term behavior problems; young children	SOCIAL-BEHAVIOR; PSYCHIATRIC-DISORDERS; ANTISOCIAL-BEHAVIOR; SUSTAINED ATTENTION; CONSTRUCT-VALIDITY; EXECUTIVE FUNCTION; SELF-REGULATION; EARLY-CHILDHOOD; HEAD-INJURY; OUTCOMES	Objective: This study examined the effects of age at injury on the persistence of behavior problems and social skill deficits in young children with complicated mild to severe traumatic brain injury (TBI). Method: A concurrent cohort/prospective research design was used with repeated assessments of children with TBI (n = 82) or Orthopedic Injury (OI) (n = 114). Parents completed the Child Behavior Checklist, the Behavior Rating Inventory of Executive Functions, and the Preschool and Kindergarten Behavior Scales or the Home and Community Social and Behavior Scales shortly after injury to assess preinjury functioning, and at an extended follow-up an average of 38 months postinjury. Generalized linear modeling was used to examine the relationship of age at injury to the maintenance of behavior problems, and logistic regression was used to examine the persistence of clinically significant behavior problems. Results: At the extended follow-up, severe TBI was associated with significantly greater anxiety problems relative to the Group OI. With increasing time since injury, children who sustained a severe TBI at an earlier age had significantly higher levels of parent-reported symptoms of ADHD and anxiety than children who were older at injury. Conclusions: Findings suggest that longer-term treatment for behavior problems may be needed after severe TBI, particularly for those injured at an earlier age.	[Karver, Christine L.] Univ Cincinnati, Dept Psychol, Edwards Ctr ML 0376 1, Cincinnati, OH 45221 USA; [Karver, Christine L.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Phys Med & Rehabil, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA; [Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA; [Stancin, Terry] MetroHlth Med Ctr, Cleveland, OH USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Walz, Nicolay C.] Cincinnati Childrens Hosp Med Ctr, Dept Behav Med, Cincinnati, OH USA		Karver, CL (corresponding author), Univ Cincinnati, Dept Psychol, Edwards Ctr ML 0376 1, Cincinnati, OH 45221 USA.	karvercl@mail.uc.edu	Yeates, Keith/AAJ-4223-2020; Stancin, Terry/L-7993-2019	Yeates, Keith/0000-0001-7680-2892	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K02HD044099] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER; NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [8 UL1 TR000077-04, UL1 TR000077] Funding Source: Medline; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084, M01 RR008084] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729, K02 HD044099, K02 HD44099, R01 HD042729] Funding Source: Medline		Achenbach T.M., 2000, MANUAL ASEBA PRESCHO; Achenbach T. M., 2001, MANUAL ASEBA SCH AGE; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V, 2012, J NEUROTRAUM, V29, P143, DOI 10.1089/neu.2011.2012; Anderson V, 2010, J PEDIATR PSYCHOL, V35, P716, DOI 10.1093/jpepsy/jsp100; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Baum KT, 2010, EPILEPSY BEHAV, V17, P467, DOI 10.1016/j.yebeh.2010.01.010; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Ebesutani C, 2010, J PSYCHOPATHOL BEHAV, V32, P373, DOI 10.1007/s10862-009-9174-9; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gioia GA IP, 2000, BEHAV RATING INVENTO; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Hegewald J., 2003, P N E SAS US GROUP W; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Lund J, 2001, J PSYCHOEDUC ASSESS, V19, P112, DOI 10.1177/073428290101900201; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Mccoy H, 2008, CHILD YOUTH SERV REV, V30, P735, DOI 10.1016/j.childyouth.2007.12.003; Merrell K. W., 2002, PRESCHOOL KINDERGART; Merrell KM., 2002, HOME COMMUNITY SOCIA; Merrell KW, 1996, J EARLY INTERVENTION, V20, P132, DOI 10.1177/105381519602000205; Merrell KW, 2001, PSYCHOL SCHOOLS, V38, P313, DOI 10.1002/pits.1021; Merrell KW, 2001, J EMOT BEHAV DISORD, V9, P260, DOI 10.1177/106342660100900406; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; Schatz David Beck, 2006, J Atten Disord, V10, P141, DOI 10.1177/1087054706286698; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; van der Heijden GJMG, 2006, J CLIN EPIDEMIOL, V59, P1102, DOI 10.1016/j.jclinepi.2006.01.015; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Verger K, 2000, BRAIN INJURY, V14, P495; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Warschausky S, 1997, Pediatr Rehabil, V1, P77; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	50	69	69	1	53	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2012	57	3					256	265		10.1037/a0029522			10	Psychology, Clinical; Rehabilitation	Social Science Citation Index (SSCI)	Psychology; Rehabilitation	999AM	WOS:000308281500008	22946613	Green Accepted			2022-02-06	
J	Leitgeb, J; Mauritz, W; Brazinova, A; Janciak, I; Majdan, M; Wilbacher, I; Rusnak, M				Leitgeb, Johannes; Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin			Outcome after severe brain trauma due to acute subdural hematoma Clinical article	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; acute subdural hematoma; outcome; prognostic score	GLASGOW COMA SCALE; HEAD-INJURY; CLASSIFICATION; PREDICTION; MANAGEMENT; MORTALITY; ADMISSION; SYSTEM; IMPACT; SCORE	Object. In this paper, the authors' goal was to identify factors contributing to outcomes after severe traumatic brain injury (TBI) due to acute subdural hematoma (SDH). Methods. Between February 2002 and April 2010, 17 Austrian centers prospectively enrolled 863 patients with moderate and severe TBI into observational studies. Data regarding accident, treatment, and outcomes were collected. Data sets from patients who had severe TBI (Glasgow Coma Scale score <9) and acute SDH were selected. Six-month outcomes were classified as "favorable" if the Glasgow Outcome Scale (GOS) scores were 5 or 4, and they were classified as "unfavorable" if GOS scores were 3 or less. The Rotterdam score was used to classify CT findings, and the scores published by Hukkelhoven et al. were used to estimate the predicted rates of death and of unfavorable outcomes. Univariate (Fisher exact test, t-test, chi-square test) and multivariate (logistic regression) statistics were used to identify factors associated with hospital mortality and favorable outcome. Results. Of the 738 patients with severe TBI, 360 (49%) had acute SDH. Of these, 168 (46.7%) died in the hospital, 67(18.6%) survived with unfavorable outcome, and 116(32.2%) survived with favorable outcome. Long-term outcome was unknown in 9 survivors (2.5%). Mortality rates predicted by the Rotterdam CT score showed good correlation with observed mortality rates. According to the Hukkelhoven scores, observed/predicted ratios for mortality and unfavorable outcome were 1.09 and 1.02, respectively. Conclusions. Age, severity of TBI, and neurological status were the main factors influencing outcomes after severe TBI due to acute SDH. Nonoperative management was associated with significantly higher mortality. (http://thejns.org/doi/abs/10.3171/2012.4.JNS111448)	[Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Dept Anesthesiol & Intens Care Med, Vienna, Austria; [Mauritz, Walter; Brazinova, Alexandra; Janciak, Ivan; Majdan, Marek; Wilbacher, Ingrid; Rusnak, Martin] Int Neurotrauma Res Org, Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek; Rusnak, Martin] Trnava Univ, Dept Publ Hlth, Fac Hlth & Social Serv, Trnava, Slovakia		Leitgeb, J (corresponding author), Med Univ Vienna, Dept Traumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	johannes.leitgeb@meduniwien.ac.at	Rusnak, Martin/K-9349-2016; Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Rusnak, Martin/0000-0003-3321-1042; Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Workers' Compensation Board (AUVA) [FK 33/2003]; Austrian National Bank [8987]; Ministry of Health; AUVA [FK 11/2008, FK 11/2010]	The data used for this study were collected for a project funded by the Austrian Workers' Compensation Board (AUVA; FK 33/2003) and by the "Jubilee Fund" of the Austrian National Bank (Project 8987), and for a project funded by the Ministry of Health (Contract October 15, 2008) and the AUVA (FK 11/2008 and FK 11/2010). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Paci GM, 2009, J TRAUMA, V67, P531, DOI 10.1097/TA.0b013e3181b840e8; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	29	69	70	0	16	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2012	117	2					324	333		10.3171/2012.4.JNS111448			10	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	978ST	WOS:000306766800025	22631691				2022-02-06	
J	Garber, ST; Sivakumar, W; Schmidt, RH				Garber, Sarah T.; Sivakumar, Walavan; Schmidt, Richard H.			Neurosurgical complications of direct thrombin inhibitors catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran	JOURNAL OF NEUROSURGERY			English	Article						dabigatran; intracerebral hemorrhage; anticoagulation; thrombin; traumatic brain injury; neurosurgical complication	ATRIAL-FIBRILLATION; ANTITHROMBOTIC THERAPY; PREVENT STROKE; METAANALYSIS; WARFARIN; RISK	Dabigatran etexilate is an oral anticoagulant that acts as a direct, competitive thrombin inhibitor. Large randomized clinical trials have shown higher doses of dabigatran (150 mg taken twice daily) to be superior to warfarin in terms of stroke and systemic embolism rates in patients with nonvalvular atrial fibrillation. As a result, in 2010 the US FDA approved the use of dabigatran for the prevention of stroke and systemic embolism in patients with atrial Dabigatran is especially attractive in the outpatient setting because patients do not require routine monitoring with prothrombin times or international normalized ratios. To date, no effective reversal agent for dabigatran in the event of catastrophic hemorrhage has been identified. The authors report a case of an elderly patient, being treated with dabigatran for atrial fibrillation, who presented with a rapidly expanding intracranial hemorrhage after a ground-level fall. This case highlights an impending neurosurgical quandary of complications secondary to this new anticoagulation agent and suggests potential options for management. (http://thejns.org/doi/abs/10.3171/2012.2.JNS112132)	[Garber, Sarah T.; Sivakumar, Walavan; Schmidt, Richard H.] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84132 USA		Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, 175 N Med Dr E, Salt Lake City, UT 84132 USA.	neuropub@hsc.utah.edu					Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Eerenberg ES, 2011, CIRCULATION, V124, P1573, DOI 10.1161/CIRCULATIONAHA.111.029017; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Ganetsky M, 2011, J MED TOXICOL, V7, P281, DOI 10.1007/s13181-011-0178-y; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 2007, ANN INTERN MED, V146, P857, DOI 10.7326/0003-4819-146-12-200706190-00007; Medi C, 2010, STROKE, V41, P2705, DOI 10.1161/STROKEAHA.110.589218; Stangier J, 2008, CLIN PHARMACOKINET, V47, P47, DOI 10.2165/00003088-200847010-00005; TEASDALE G, 1974, LANCET, V2, P81; Zhou W, 2011, STROKE, V42, P3594, DOI 10.1161/STROKEAHA.111.624650	10	69	71	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1093	1096		10.3171/2012.2.JNS112132			4	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800025	22394293				2022-02-06	
J	Shively, SB; Perl, DP				Shively, Sharon B.; Perl, Daniel P.			Traumatic Brain Injury, Shell Shock, and Posttraumatic Stress Disorder in the Military-Past, Present, and Future	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic traumatic encephalopathy; improvised explosive device; military; neurodegeneration; neurofibrillary tangle; neuropathology; posttraumatic stress disorder; shell shock; tau; traumatic brain injury	REPETITIVE HEAD-INJURY; CENTRAL-NERVOUS-SYSTEM; HIGH EXPLOSIVES; ENCEPHALOPATHY; AFTERMATH	With preferential use of high explosives in modern warfare, traumatic brain injury (TBI) has become a common injury for troops. Most TBIs are classified as "mild," although military personnel with these injuries can have persistent symptoms such as headache, memory impairment, and behavioral changes. DuringWorld War I, soldiers in the trenches, undergoing unrelenting artillery bombardment, suffered from similar symptoms, designated at the time as "shell shock." Dr Frederick Mott proposed studying the brains of deceased soldiers to elucidate the neuropathology of this clinical entity. Subsequent to a British government enquiry after World War I, the term "shell shock" was banned and further investigation into a possible organic cause for these symptoms was discontinued. Nevertheless, similar clinical entities, such as combat or battle fatigue and posttraumatic stress disorder, continue to be encountered by combatants in subsequent military conflicts. To this day, there exists a paucity of neuropathology studies investigating the effects of high explosives on the human brain. By analogy, studies have recently revealed that athletes with repeated head trauma can develop a neurodegenerative disease, chronic traumatic encephalopathy, who present with similar clinical features. Given current circumstance, we propose completing the work envisioned by Dr Mott almost 100 years ago.	[Shively, Sharon B.; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA; [Shively, Sharon B.; Perl, Daniel P.] Ctr Neurosci & Regenerat Med, Neuropathol Core, Bethesda, MD USA; [Shively, Sharon B.] Henry M Jackson Fdn Advancement Mil Med, Bethesda, MD USA		Shively, SB (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Pathol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	sharon.shively.ctr@usuhs.edu			Center for Neuroscience and Regenerative MedicineUnited States Department of Defense; Uniformed Services University of the Health Sciences; United States Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC)	The authors thank the Center for Neuroscience and Regenerative Medicine for their ongoing support by, the Uniformed Services University of the Health Sciences, and the United States Army Medical Research and Materiel Command for their ongoing support. They also thank the following individuals for their invaluable discussions: Drs Ramon Diaz-Arrastia, Ann McKee, and Stanley Prusiner. Dr McKee has generously allowed one of the authors (D.P.P.) to evaluate many cases of athletes with chronic traumatic encephalopathy in her neuropathology laboratory. They also acknowledge Professor Edgar Jones's scholarship in delineating the history of World War I, shell shock, and the connection to PTSD.	CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRAMER F, 1949, ARCH NEURO PSYCHIATR, V61, P1; Defense and Veteran Brain Injury Center, DOD WORLDW NUMB TBI; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jones E, 2010, J HIST MED ALL SCI, V65, P368, DOI 10.1093/jhmas/jrq006; Jones Edgar, 2005, SHELL SHOCK PTSD MIL; Martland H, 1922, JAMA-J AM MED ASSOC, V91, P1103; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mott F. W., 1919, WAR NEUROSES SHELL S; Mott Frederick, 1926, BR MED J, P1106; Mott FW, 1916, LANCET, V1, P441; Mott FW, 1916, LANCET, V1, P331; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Roberts AH, 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Southborough Lord, 1922, REPORT WAR OFFICE CO	19	69	70	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					234	239		10.1097/HTR.0b013e318250e9dd			6	Clinical Neurology; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500013	22573042				2022-02-06	
J	Meehan, WP; d'Hemecourt, P; Collins, CL; Taylor, AM; Comstock, RD				Meehan, William P., III; d'Hemecourt, Pierre; Collins, Christy L.; Taylor, Alex M.; Comstock, R. Dawn			Computerized Neurocognitive Testing for the Management of Sport-Related Concussions	PEDIATRICS			English	Article						concussion; injuries; high school; neuropsychological testing	HIGH-SCHOOL; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE ASSESSMENT; RECOVERY; IMPACT; SENSITIVITY; PERFORMANCE; STATEMENT; INJURIES; PLAY	OBJECTIVES: To describe the prevalence of computerized neurocognitive testing for the assessment of high school athletes who sustain concussions, and to describe associations between using computerized neurocognitive tests, timing of return-to-play, and medical provider managing the athlete. METHODS: Concussions recorded in the High School Reporting Information Online injury surveillance system during the 2009-2010 academic year were included. Measures of association between use of computerized neurocognitive testing and outcomes were analyzed. A questionnaire was sent to athletic trainers (ATs) querying the use of computerized neurocognitive testing. chi(2) analyses were conducted for categorical variables. Logistic regression analyses were used to adjust for potential confounders. Statistical significance was set at P < .05. RESULTS: High School Reporting Information Online recorded 1056 concussions. Athletes who underwent computerized neurocognitive testing were less likely to be returned to play within 10 days of injury (38.5% vs 55.7%, P < .001) and more likely to be returned to play by a physician (60.9% vs 45.6%, P < .001). We had a response rate of 97.3% for the survey. Of respondents, 39.9% used computerized neurocognitive testing; 93.0% of those used ImPACT. Tests were most often interpreted by ATs (78.9%) and/or physicians (78.8%), as opposed to neuropsychologists (16.9%). CONCLUSIONS: Approximately 40% of US high schools that employ an AT use computerized neurocognitive tests when managing sport-related concussions. Tests are most often interpreted by ATs and physicians, as opposed to neuropsychologists. Computerized neurocognitive tests are significantly associated with the timing of return-to-play. Pediatrics 2012;129:38-44	[Meehan, William P., III; d'Hemecourt, Pierre; Taylor, Alex M.] Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, Boston, MA 02115 USA; [Meehan, William P., III] Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Meehan, William P., III; d'Hemecourt, Pierre; Taylor, Alex M.] Childrens Hosp Boston, Brain Injury Ctr, Boston, MA 02115 USA; [Taylor, Alex M.] Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA; [Collins, Christy L.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA		Meehan, WP (corresponding author), Childrens Hosp Boston, Sports Concuss Clin, Div Sports Med, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040128-06A1]; Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49/CE000674-01, R49/CE001172-01]; National Federation of State High School Associations; National Operating Committee on Standards for Athletic Equipment, EyeBlack, and DonJoy Orthotics; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE001172, R49CE000674] Funding Source: NIH RePORTER	This study was supported by the National Institutes of Health T32 award to Dr Meehan (T32 HD040128-06A1). In addition, the content of this report was funded in part by the Centers for Disease Control and Prevention grants R49/CE000674-01 and R49/CE001172-01. We would also like to acknowledge the generous research funding contributions of the National Federation of State High School Associations, the National Operating Committee on Standards for Athletic Equipment, EyeBlack, and DonJoy Orthotics.	[Anonymous], 2006, MED SCI SPORT EXER, V38, P395, DOI 10.1249/01.mss.0000202025.48774.31; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brooks DA, 2007, NEUROREHABILITATION, V22, P169; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; FACKELMANN K, 2003, US TODAY        1118; Ferrara Michael S., 2001, J Athl Train, V36, P145; Gilchrist J., 2007, Morbidity and Mortality Weekly Report, V56, P733; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Kirkwood MW, 2009, ACTA PAEDIATR, V98, P1409, DOI 10.1111/j.1651-2227.2009.01448.x; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2006, J ATHL TRAINING, V41, P138; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MacMullan Jackie, 2007, BOSTON GLOBE    0202; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P., 2009, J ATHL TRAINING, V44, P434, DOI [10.4085/1062-6050-44.4.434, DOI 10.4085/1062-6050-44.4.434]; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Rickerson J., 2011, CONCUSSION LAWS; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SCHWARZ A, 2007, NY TIMES        0915, pA1; Schwarz A, 2009, NY TIMES        1220; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WAXENBERG R, 2009, ATHLETIC TRAINERS FI	39	69	69	0	10	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					38	44		10.1542/peds.2011-1972			7	Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	Pediatrics	870BT	WOS:000298644800040	22129538	Green Published			2022-02-06	
J	Weir, J; Steyerberg, EW; Butcher, I; Lu, J; Lingsma, HF; McHugh, GS; Roozenbeek, B; Maas, AIR; Murray, GD				Weir, James; Steyerberg, Ewout W.; Butcher, Isabella; Lu, Juan; Lingsma, Hester F.; McHugh, Gillian S.; Roozenbeek, Bob; Maas, Andrew I. R.; Murray, Gordon D.			Does the Extended Glasgow Outcome Scale Add Value to the Conventional Glasgow Outcome Scale?	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; Glasgow Outcome Scale-Extended; Glasgow Outcome Scale; ordinal analysis; outcome; traumatic brain injury	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; REGRESSION-MODELS; CLINICAL-TRIALS; IMPACT; RELIABILITY; ADJUSTMENT; DISABILITY; VALIDITY; MODERATE	The Glasgow Outcome Scale (GOS) is firmly established as the primary outcome measure for use in Phase III trials of interventions in traumatic brain injury (TBI). However, the GOS has been criticized for its lack of sensitivity to detect small but clinically relevant changes in outcome. The Glasgow Outcome Scale-Extended (GOSE) potentially addresses this criticism, and in this study we estimate the efficiency gain associated with using the GOSE in place of the GOS in ordinal analysis of 6-month outcome. The study uses both simulation and the reanalysis of existing data from two completed TBI studies, one an observational cohort study and the other a randomized controlled trial. As expected, the results show that using an ordinal technique to analyze the GOS gives a substantial gain in efficiency relative to the conventional analysis, which collapses the GOS onto a binary scale (favorable versus unfavorable outcome). We also found that using the GOSE gave a modest but consistent increase in efficiency relative to the GOS in both studies, corresponding to a reduction in the required sample size of the order of 3-5%. We recommend that the GOSE be used in place of the GOS as the primary outcome measure in trials of TBI, with an appropriate ordinal approach being taken to the statistical analysis.	[Murray, Gordon D.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; [Steyerberg, Ewout W.; Lingsma, Hester F.; Roozenbeek, Bob] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Lu, Juan] Virginia Commonwealth Univ, Dept Neurosurg, Med Ctr, Richmond, VA USA; [Roozenbeek, Bob; Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium		Murray, GD (corresponding author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Gordon.Murray@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603	U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS-042691]; U.K. Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish; MRCUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [G0800803] Funding Source: UKRI; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER	This work was supported by the U.S. National Institutes of Health (Clinical Trial Design and Analysis in TBI Project: R01 NS-042691), and the U.K. Medical Research Council (Edinburgh Hub for Trials Methodology Research: G0800803).	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Aoki N, 1998, MED DECIS MAKING, V18, P357, DOI 10.1177/0272989X9801800401; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Ford I, 2002, STAT MED, V21, P2899, DOI 10.1002/sim.1294; GOUVIER WD, 1986, INT J CLIN NEUROPSYC, V8, P1; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; HORNE G, 1989, AUST NZ J SURG, V59, P465, DOI 10.1111/j.1445-2197.1989.tb01612.x; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1975, LANCET, V7905, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Livingston M G, 1985, Int Rehabil Med, V7, P145; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; ROBINSON LD, 1991, INT STAT REV, V59, P227, DOI 10.2307/1403444; Sandset EC, 2011, LANCET, V377, P741, DOI 10.1016/S0140-6736(11)60104-9; SMITH RM, 1979, CLIN NEUROPSYCHOL, V1, P48; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	27	69	72	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2012	29	1					53	58		10.1089/neu.2011.2137			6	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	879GI	WOS:000299317300005	22026476	Green Published, Green Submitted			2022-02-06	
J	Bembea, MM; Savage, W; Strouse, JJ; Schwartz, JM; Graham, E; Thompson, CB; Everett, A				Bembea, Melania M.; Savage, William; Strouse, John J.; Schwartz, Jamie McElrath; Graham, Ernest; Thompson, Carol B.; Everett, Allen			Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						biochemical marker; ECMO; extracorporeal membrane oxygenation; GFAP; glial fibrillary acidic protein; intracranial hemorrhage	PEDIATRIC INTENSIVE-CARE; LIFE-SUPPORT; FOLLOW-UP; CARDIOPULMONARY-RESUSCITATION; RESPIRATORY-FAILURE; TRAUMATIC BRAIN; ACUTE STROKE; INTRACEREBRAL HEMORRHAGE; INTRACRANIAL HEMORRHAGE; ISCHEMIC-INJURY	Objective: To determine whether, in children, plasma glial fibrillary acidic protein is associated with brain injury during extracorporeal membrane oxygenation and with mortality. Design: Prospective, observational study. Setting: Pediatric intensive care unit in an urban tertiary care academic center. Patients: Neonatal and pediatric patients on extracorporeal membrane oxygenation (n = 22). Interventions: Serial blood sampling for glial fibrillary acidic protein measurements. Measurements and Main Results: Prospective patients age 1 day to 18 yrs who required extracorporeal membrane oxygenation from April 2008 to August 2009 were studied. Glial fibrillary acidic protein was measured using an electrochemiluminescent immunoassay developed at Johns Hopkins. Control samples were collected from 99 healthy children (0.5-16 yrs) and 59 neonatal intensive care unit infants without neurologic injury. In controls, the median glial fibrillary acidic protein concentration was 0.055 ng/mL (interquartile range, 0-0.092 ng/mL) and the 95th percentile of glial fibrillary acidic protein was 0.436 ng/mL. In patients on extracorporeal membrane oxygenation, plasma glial fibrillary acidic protein was measured at 6, 12, and every 24 hrs after cannulation. We enrolled 22 children who underwent extracorporeal membrane oxygenation. Median age was 7 days (interquartile range, 2 days to 9 yrs), and primary extracorporeal membrane oxygenation indication was: cardiac failure, six of 22 (27.3%); respiratory failure, 12 of 22 (54.5%); extracorporeal cardiopulmonary resuscitation, three of 22 (13.6%); and sepsis, one of 22 (4.6%). Seven of 22 (32%) patients developed acute neurologic injury ( intracranial hemorrhage, brain death, or cerebral edema diagnosed by imaging). Fifteen of 22 (68%) survived to hospital discharge. In the extracorporeal membrane oxygenation group, peak glial fibrillary acidic protein levels were higher in children with brain injury than those without (median, 5.9 vs. 0.09 ng/mL, p = .04) and in nonsurvivors compared with survivors to discharge (median, 5.9 vs. 0.09 ng/mL, p = .04). The odds ratio for brain injury for glial fibrillary acidic protein >0.436 ng/mL vs. normal was 11.5 (95% confidence interval, 1.3-98.3) and the odds ratio for mortality was 13.6 (95% confidence interval, 1.7-108.5). Conclusions: High glial fibrillary acidic protein during extracorporeal membrane oxygenation is significantly associated with acute brain injury and death. Brain injury biomarkers may aid in outcome prediction and neurologic monitoring of patients on extracorporeal membrane oxygenation to improve outcomes and benchmark new therapies. (Pediatr Crit Care Med 2011; 12:572-579)	[Bembea, Melania M.; Schwartz, Jamie McElrath] Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA; [Bembea, Melania M.; Savage, William; Strouse, John J.; Schwartz, Jamie McElrath; Everett, Allen] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; [Savage, William] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21218 USA; [Graham, Ernest] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21218 USA; [Thompson, Carol B.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA		Bembea, MM (corresponding author), Johns Hopkins Univ, Dept Anesthesiol & Crit Care, Baltimore, MD 21205 USA.	mbembea1@jhmi.edu	Strouse, J/A-2690-2008	Strouse, J/0000-0003-0341-1457; Bembea, Melania/0000-0003-4984-520X	National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1 RR 025005, 1KL2RR025006-01]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH Roadmap for Medical ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Johns Hopkins Clinical Hematology Development Program [5K12HL087169, 5R01HL091759]; National Heart, Lung and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5T15HL086386]; Basic and Translational Research Program in Sickle Cell Disease [1U54HL090515]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR025006, UL1RR025005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091759, K23HL078819, U54HL090515, K12HL087169, T15HL086386] Funding Source: NIH RePORTER	The project described was supported by Grants Number UL1 RR 025005 and 1KL2RR025006-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. Information on NCRR is available at www.ncrr.nih.gov. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap. nih. gov/clinicalresearch/overview-translational.asp M.M.B.). Dr. Savage acknowledges support from the Johns Hopkins Clinical Hematology Development Program 5K12HL087169, 5R01HL091759; the National Heart, Lung and Blood Institute Proteomics and Genomics Hands-on Workshop 5T15HL086386; and Basic and Translational Research Program in Sickle Cell Disease, 1U54HL090515.	ADOLPH V, 1990, J PEDIATR SURG, V25, P43, DOI 10.1016/S0022-3468(05)80162-9; Alsoufi B, 2007, J THORAC CARDIOV SUR, V134, P952, DOI 10.1016/j.jtcvs.2007.05.054; Amigoni A, 2005, PEDIATR NEUROL, V32, P173, DOI 10.1016/j.pediatrneurol.2004.10.002; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Barrett CS, 2009, PEDIATR CRIT CARE ME, V10, P445, DOI 10.1097/PCC.0b013e318198bd85; CAMPBELL LR, 1991, J PEDIATR-US, V119, P789, DOI 10.1016/S0022-3476(05)80304-X; Cengiz P, 2005, CRIT CARE MED, V33, P2817, DOI 10.1097/01.CCM.0000189940.70617.C3; CILLEY RE, 1986, PEDIATRICS, V78, P699; Conrad SA, 2005, ASAIO J, V51, P4, DOI 10.1097/01.mat.0000151922.67540.E9; Dvorak F, 2009, CEREBROVASC DIS, V27, P37, DOI 10.1159/000172632; Field D, 1996, LANCET, V348, P75; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Fraser DD, 2010, PEDIAT CRIT CAR 0709; Gazzolo D, 2002, ACTA PAEDIATR, V91, P218, DOI 10.1080/080352502317285243; GLASS P, 1995, J PEDIATR-US, V127, P447, DOI 10.1016/S0022-3476(95)70082-X; GLASS P, 1989, PEDIATRICS, V83, P72; GRAZIANI LJ, 1994, J PEDIATR-US, V125, P969, DOI 10.1016/S0022-3476(05)82017-7; GREEN TP, 1995, CRIT CARE MED, V23, P1132, DOI 10.1097/00003246-199506000-00021; Gupta M, 2008, PEDIATR CRIT CARE ME, V9, P380, DOI 10.1097/PCC.0b013e318172d54d; Haines NM, 2009, ASAIO J, V55, P111, DOI 10.1097/MAT.0b013e318190b6f7; Hanekamp MN, 2006, CRIT CARE, V10, DOI 10.1186/cc5039; HAYASHIDA H, 2009, NEUROCRIT CARE  1222; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; HOFKOSH D, 1991, PEDIATRICS, V87, P549; Hunter Christian J, 2004, Pediatr Crit Care Med, V5, P475, DOI 10.1097/01.PCC.0000130992.73123.BC; Ibrahim AE, 2000, ANN THORAC SURG, V69, P186, DOI 10.1016/S0003-4975(99)01194-7; Jonsson H, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-24; Kaneko T, 2009, RESUSCITATION, V80, P790, DOI 10.1016/j.resuscitation.2009.04.003; KORINTHENBERG R, 1993, DEV MED CHILD NEUROL, V35, P249; Laskowitz DT, 2009, STROKE, V40, P77, DOI 10.1161/STROKEAHA.108.516377; LAZAR EL, 1994, J PEDIATR SURG, V29, P186, DOI 10.1016/0022-3468(94)90315-8; Lequier L, 2008, J THORAC CARDIOV SUR, V136, P976, DOI 10.1016/j.jtcvs.2008.02.009; Morris Marilyn C, 2004, Pediatr Crit Care Med, V5, P440, DOI 10.1097/01.PCC.0000137356.58150.2E; Niebroj-Dobosz I, 1994, Folia Neuropathol, V32, P129; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Petzold A, 2004, J IMMUNOL METHODS, V287, P169, DOI 10.1016/j.jim.2004.01.015; Prodhan P, 2009, RESUSCITATION, V80, P1124, DOI 10.1016/j.resuscitation.2009.07.004; RAJAGOPAL SK, 2009, CRIT CARE MED   0928; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; SCHUMACHER RE, 1991, PEDIATRICS, V87, P451; SHORT BL, 1994, CRIT CARE MED, V22, P1262, DOI 10.1097/00003246-199408000-00010; Taylor Anna K, 2007, Crit Care Resusc, V9, P172; TAYLOR GA, 1989, INVEST RADIOL, V24, P511, DOI 10.1097/00004424-198907000-00001; Thiagarajan RR, 2007, CIRCULATION, V116, P1693, DOI 10.1161/CIRCULATIONAHA.106.680678; Unden J, 2009, J NEUROL, V256, P72, DOI 10.1007/s00415-009-0054-8; van Heijst A, 2004, J PEDIATR-US, V144, P223, DOI 10.1016/j.jpeds.2003.11.006; Vaucher YE, 1996, J PEDIATR-US, V128, P109, DOI 10.1016/S0022-3476(96)70439-0; WIESMANN M, 2009, ACTA NEUROL SCA 1005	53	69	74	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535			PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2011	12	5					572	579		10.1097/PCC.0b013e3181fe3ec7			8	Critical Care Medicine; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Pediatrics	816KP	WOS:000294598400021	21057367	Green Accepted			2022-02-06	
J	Mihalik, JP; Guskiewicz, KM; Marshall, SW; Greenwald, RM; Blackburn, JT; Cantu, RC				Mihalik, Jason P.; Guskiewicz, Kevin M.; Marshall, Stephen W.; Greenwald, Richard M.; Blackburn, J. Troy; Cantu, Robert C.			Does Cervical Muscle Strength in Youth Ice Hockey Players Affect Head Impact Biomechanics?	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						youth athlete; biomechanics; concussion; helmets; traumatic brain injury	SEGMENT DYNAMIC STABILIZATION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; SPORTS; CONCUSSION; SEVERITY; FOOTBALL; RISK	Objective: To evaluate the effect of cervical muscle strength on head impact biomechanics. Design: Prospective cohort. Setting: Field setting. Participants: Thirty-seven volunteer ice hockey players (age = 15.0 +/- 1.0 years, height = 173.5 +/- 6.2 cm, mass = 66.6 +/- 9.0 kg, playing experience = 2.9 +/- 3.7 years). Interventions: Participants were equipped with accelerometer-instrumented helmets to collect head impact biomechanics (linear and rotational acceleration) throughout an entire playing season. Before the season, isometric cervical muscle strength was measured for the anterior neck flexors, anterolateral neck flexors, cervical rotators, posterolateral neck extensors, and upper trapezius. Data were analyzed using random intercept general mixed linear models, with each individual player as a repeating factor/cluster. Main Outcome Measures: Dependent variables included linear and rotational head accelerations. Cervical strength data were categorized into tertiles, creating groups with high, moderate, and low strength. Strength measures were averaged and normalized to body mass. Results: Significant differences in cervical muscle strength existed across our strength groups (P < 0.05). No differences were observed in linear or rotational acceleration across strength groups for the anterior neck flexors (P-Lin = 0.399; P-Rot = 0.060), anterolateral neck flexors (P-Lin = 0.987; PRot = 0.579), cervical rotators (P-Lin = 0.136; P-Rot = 0.238), posterolateral neck extensors (P-Lin = 0.883; P-Rot = 0.101), or upper trapezius (P-Lin = 0.892; P-Rot = 0.689). Conclusions: Our hypothesis that players with greater static neck strength would experience lower resultant head accelerations was not supported. This contradicts the notion that cervical muscle strength mitigates head impact acceleration. Because we evaluated cervical strength isometrically, future studies should consider dynamic (ie, isokinetic) methods in the context of head impact biomechanics.	[Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.; Blackburn, J. Troy] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Curriculum Human Movement Sci, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA; [Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Blackburn, J. Troy] Univ N Carolina, Dept Exercise & Sport Sci, Neuromuscular Res Lab, Chapel Hill, NC 27599 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Sport Med, Concord, MA USA		Mihalik, JP (corresponding author), Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Dept Exercise & Sport Sci, 313 Woollen Gymnasium,Campus Box 8605, Chapel Hill, NC 27599 USA.	jmihalik@email.unc.edu		Marshall, Stephen/0000-0002-2664-9233; Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130	Ontario Neurotrauma Foundation (Toronto, Ontario, Canada); USA Hockey Foundation (Colorado Springs, Colorado); National Operating Committee on Standards for Athletic Equipment (Overland Park, Kansas)	Supported by the Ontario Neurotrauma Foundation (Toronto, Ontario, Canada), the USA Hockey Foundation (Colorado Springs, Colorado), and the National Operating Committee on Standards for Athletic Equipment (Overland Park, Kansas).	Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hislop HJ, 1986, DANIELS WORTHINGHAMS; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kendall FP, 1993, MUSCLES TESTING FUNC, V4th; Mansell J, 2005, J ATHL TRAINING, V40, P310; Mihalik JP, 2008, P I MECH ENG P-J SPO, V222, P45, DOI 10.1243/17543371JSET4; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mihalik JP, 2010, MED SCI SPORT EXER, V42, P1431, DOI 10.1249/MSS.0b013e3181d2521a; Mihalik JP, 2010, PEDIATRICS, V125, pE1394, DOI 10.1542/peds.2009-2849; Ono K, 1996, ACCIDENT ANAL PREV, V28, P493, DOI 10.1016/0001-4575(96)00019-X; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Seng KY, 2003, AVIAT SPACE ENVIR MD, V74, P164; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA	18	69	69	1	37	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	SEP	2011	21	5					416	421		10.1097/JSM.0B013E31822C8A5C			6	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Orthopedics; Physiology; Sport Sciences	814VJ	WOS:000294485000006	21892015				2022-02-06	
J	Grujicic, M; Bell, WC; Pandurangan, B; Glomski, PS				Grujicic, M.; Bell, W. C.; Pandurangan, B.; Glomski, P. S.			Fluid/Structure Interaction Computational Investigation of Blast-Wave Mitigation Efficacy of the Advanced Combat Helmet	JOURNAL OF MATERIALS ENGINEERING AND PERFORMANCE			English	Article						advanced combat helmet; computational analysis; fluid-structure interaction; traumatic brain injury	TRAUMATIC BRAIN-INJURY; POLYUREA; IMPACT; TBI	To combat the problem of traumatic brain injury (TBI), a signature injury of the current military conflicts, there is an urgent need to design head protection systems with superior blast/ballistic impact mitigation capabilities. Toward that end, the blast impact mitigation performance of an advanced combat helmet (ACH) head protection system equipped with polyurea suspension pads and subjected to two different blast peak pressure loadings has been investigated computationally. A fairly detailed (Lagrangian) finite-element model of a helmet/skull/brain assembly is first constructed and placed into an Eulerian air domain through which a single planar blast wave propagates. A combined Eulerian/Lagrangian transient nonlinear dynamics computational fluid/solid interaction analysis is next conducted in order to assess the extent of reduction in intra-cranial shock-wave ingress (responsible for TBI). This was done by comparing temporal evolutions of intra-cranial normal and shear stresses for the cases of an unprotected head and the helmet-protected head and by correlating these quantities with the three most common types of mild traumatic brain injury (mTBI), i.e., axonal damage, contusion, and subdural hemorrhage. The results obtained show that the ACH provides some level of protection against all investigated types of mTBI and that the level of protection increases somewhat with an increase in blast peak pressure. In order to rationalize the aforementioned findings, a shockwave propagation/reflection analysis is carried out for the unprotected head and helmet-protected head cases. The analysis qualitatively corroborated the results pertaining to the blast-mitigation efficacy of an ACH, but also suggested that there are additional shockwave energy dissipation phenomena which play an important role in the mechanical response of the unprotected/protected head to blast impact.	[Grujicic, M.; Bell, W. C.; Pandurangan, B.; Glomski, P. S.] Clemson Univ, Dept Mech Engn, Clemson, SC 29634 USA		Grujicic, M (corresponding author), Clemson Univ, Dept Mech Engn, 241 Engn Innovat Bldg, Clemson, SC 29634 USA.	mica.grujicic@ces.clemson.edu			Office of Naval Research (ONR) through the Pennsylvania State UniversityOffice of Naval Research [4036-CU-ONR-1125]	The material presented in this article is based on work supported by the Office of Naval Research (ONR) research contract entitled "Elastomeric Polymer-By-Design to Protect the Warfighter Against Traumatic Brain Injury by Diverting the Blast Induced Shock Waves from the Head," Contract Number 4036-CU-ONR-1125 as funded through the Pennsylvania State University. The authors are indebted to Dr. Roshdy Barsoum of ONR for continuing support and interest in the present work and to professors J. Runt, J. Tarter, G. Settles, G. Dillon, and M. Hargether for stimulating discussions and friendship.	Amini MR, 2010, INT J IMPACT ENG, V37, P90, DOI 10.1016/j.ijimpeng.2009.04.005; Amirkhizi AV, 2006, PHILOS MAG, V86, P5847, DOI 10.1080/14786430600833198; [Anonymous], HYP; *ANSYS INC, 2007, ANSYS AUT 2D 3D VERS; Bahei-El-Din YA, 2006, INT J SOLIDS STRUCT, V43, P7644, DOI 10.1016/j.ijsolstr.2006.03.021; Bhattacharjee Y, 2008, SCIENCE, V319, P406, DOI 10.1126/science.319.5862.406; Bogoslovov RB, 2007, APPL PHYS LETT, V90, DOI 10.1063/1.2745212; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cuitino A., 1992, ENG COMPUT-GERMANY, V9, P437, DOI DOI 10.1108/EB023876>; Cullis I G, 2001, J R Army Med Corps, V147, P16; *DASS SYST, 2008, ABAQUS VERS 6 8 1 US; Grujicic M, 2010, MATER DESIGN, V31, P4050, DOI 10.1016/j.matdes.2010.05.002; Grujicic M, 2009, MATER DESIGN, V30, P4273, DOI 10.1016/j.matdes.2009.04.028; GRUJICIC M, 2009, MAT STRUCT, V6; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; KAMBOUCHEV N, 2007, COMPUT STRUCT, V23, P325; Moore DF, 2008, ANN NEUROL, V64, pS30; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tham CY, 2008, INT J IMPACT ENG, V35, P304, DOI 10.1016/j.ijimpeng.2007.03.008; *USA CORPS ENG, CONWEP BLAST SIM SOF; Wallsten S. J., 2005, 0519 SOC SCI RES NET; Walsh S. M., 2005, ARLTR3700; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; PERSPECTIVES NETWORK	27	69	71	2	38	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1059-9495	1544-1024		J MATER ENG PERFORM	J. Mater. Eng. Perform.	AUG	2011	20	6					877	893		10.1007/s11665-010-9724-z			17	Materials Science, Multidisciplinary	Science Citation Index Expanded (SCI-EXPANDED)	Materials Science	792MN	WOS:000292749800005					2022-02-06	
J	Nakase-Richardson, R; Sherer, M; Seel, RT; Hart, T; Hanks, R; Arango-Lasprilla, JC; Yablon, SA; Sander, AM; Barnett, SD; Walker, WC; Hammond, F				Nakase-Richardson, R.; Sherer, M.; Seel, R. T.; Hart, T.; Hanks, R.; Arango-Lasprilla, J. C.; Yablon, S. A.; Sander, A. M.; Barnett, S. D.; Walker, W. C.; Hammond, F.			Utility of post-traumatic amnesia in predicting 1-year productivity following traumatic brain injury: comparison of the Russell and Mississippi PTA classification intervals	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CLOSED-HEAD INJURY; GALVESTON ORIENTATION; SEVERITY; MULTICENTER; DISABILITY; MODERATE; RETURN; SCALE; REHABILITATION; RECOVERY	Background Duration of post-traumatic amnesia (PTA) correlates with global outcomes and functional disability. Russell proposed the use of PTA duration intervals as an index for classification of traumatic brain injury (TBI) severity. Alternative duration-based schemata have been recently proposed as better predictors of outcome to the commonly cited Russell intervals. Objective Validate a TBI severity classification model (Mississippi intervals) of PTA duration anchored to late productivity outcome, and compare sensitivity against the Russell intervals. Methods Prospective observational data on TBI Model System participants (n=3846) with known or imputed PTA duration during acute hospitalisation. Productivity status at 1-year postinjury was used to compare predicted outcomes using the Mississippi and Russell classification intervals. Logistic regression model-generated curves were used to compare the performance of the classification intervals by assessing the area under the curve (AUC); the highest AUC represented the best-performing model. Results All severity variables evaluated were individually associated with return to productivity at 1 year (RTP1). Age was significantly associated with RTP1; however, younger patients had a different association than older patients. After adjustment for individually significant variables, the odds of RTP1 decrease by 14% with every additional week of PTA duration (95% CI 12% to 17%; p<0.0001). The AUC for the Russell intervals was significantly smaller than the Mississippi intervals. Conclusions PTA duration is an important predictor of late productivity outcome after TBI. The Mississippi PTA interval classification model is a valid predictor of productivity at 1 year postinjury and provides a more sensitive categorisation of PTA values than the Russell intervals.	[Nakase-Richardson, R.] James A Haley Vet Hosp, MHBS Polytrauma 116B, Tampa, FL 33612 USA; [Nakase-Richardson, R.; Barnett, S. D.] James A Haley Vet Hosp, Res Ctr Excellence, Tampa, FL 33612 USA; [Nakase-Richardson, R.] TBIMS Natl Data & Stat Ctr, Denver, CO USA; [Sherer, M.] TIRR Mem Hermann, Houston, TX USA; [Sherer, M.; Sander, A. M.] Baylor Coll Med, Houston, TX 77030 USA; [Seel, R. T.] Shepherd Ctr, Atlanta, GA USA; [Hart, T.] Moss Rehabil Res Inst, Philadelphia, PA USA; [Hanks, R.] Wayne State Univ, Sch Med, Detroit, MI USA; [Arango-Lasprilla, J. C.; Walker, W. C.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA; [Yablon, S. A.] Baylor Inst Rehabil, Dallas, TX USA; [Hammond, F.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, F.] Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA		Nakase-Richardson, R (corresponding author), James A Haley Vet Hosp, MHBS Polytrauma 116B, 13000 Bruce B Downs Blvd, Tampa, FL 33612 USA.	risa.richardson@va.gov	Walker, William C/N-3162-2014		National Institute on Disability and Rehabilitation Research, Department of Education [H133A060038, H133B090023, H133A070043, H133A070040, H133A-080044, H133A070036, H133A070027, H133A070042]	The contents of this manuscript were developed under grants from the National Institute on Disability and Rehabilitation Research, Department of Education (H133A060038 (TBI Model System National Data and Statistical Center), H133B090023 (Rehabilitation Research and Training Center on Developing Stategies to Foster Community Integration and Participation for Individuals With Traumatic Brain Injury), H133A070043 (Texas TBI Model System of TIRR), H133A070040 (Moss TBI Model System), H133A-080044 (Southeastern Michigan TBI System), H133A070036 (Virginia Commonwealth TBI Model System), H133A070027 (North Texas TBI Model System), H133A070042 (Carolinas Traumatic Brain Injury Rehabilitation and Research System)).	BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Finkelstein E., 2006, INCIDENCE EC BURDEN; Gordon W, 1993, J HEAD TRAUMA REHAB, V8, P26; Gordon WA, 2006, AM J PHYS MED REHAB, V85, P343, DOI 10.1097/01.phm.0000202106.01654.61; Hamilton BB, 1987, REHABILITATION OUTCO, P137; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Richardson R, 2009, ARCH PHYS MED REHAB, V90, P17, DOI 10.1016/j.apmr.2008.06.030; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; Novack TA, 2000, J HEAD TRAUMA REHAB, V15, P957, DOI 10.1097/00001199-200006000-00008; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Sherer M, 2008, J NEUROL NEUROSUR PS, V79, P678, DOI 10.1136/jnnp.2006.111187; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Stein SC, 1996, NEUROTRAUMA; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	34	69	69	1	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2011	82	5					494	499		10.1136/jnnp.2010.222489			6	Clinical Neurology; Psychiatry; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Psychiatry; Surgery	746HL	WOS:000289234500006	21242285				2022-02-06	
J	Ling, GSF; Ecklund, JM				Ling, Geoffrey S. F.; Ecklund, James M.			Traumatic brain injury in modern war	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						clinical practice guidelines; concussion; explosive blast; return to duty; traumatic brain injury	IRAQ	Purpose of review To review the emerging literature on traumatic brain injury (TBI) caused by explosive blast. Recent findings Efforts are underway to understand how explosive blast injures brain, what is the clinical presentation and how best to manage it. A major way blast injures brain is from detonation pressure waves coupling to a victim's head leading to brain deformation. The effect of other explosion-related elements is unknown. Because scientific insights take time to develop but injuries are occurring now, the military adopts existing civilian standard of care practices developed for similar diseases, such as the Guidelines for the Management of Severe Traumatic Brain Injury developed mainly for closed head TBI. When these do not exist, the military creates them, such as the Veterans Administration and Department of Defense Clinical Practice Guidelines for Concussion/Mild TBI. Another treatment advance is the creation of the first large system-wide approach to diagnosis and clinical management of TBI, which begins at the site of injury and extends through both the military and the Veterans' Administration medical care systems. Summary Explosive blast TBI is being addressed at all levels - basic research through clinical care. New clinical practice guidelines are being used in a standardized system-wide approach.	[Ling, Geoffrey S. F.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Ecklund, James M.] Dept Neurosurg, Falls Church, VA USA		Ling, GSF (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	gling@usuhs.mil			Defense Military Research and Development Program; Defense Advanced Research Projects AgencyUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA)	The authors report no conflicts of interests and no commercial sponsorships as they pertain to this topic. They gratefully acknowledge research grant funding from the Defense Military Research and Development Program and the Defense Advanced Research Projects Agency for work being done on explosive blast TBI and spinal cord injury.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; BELLAMY RF, 1995, OFFICE SURG GEN, P1; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Geocadin R., 2004, HDB NEURO CRITICAL C, P73; JAFFEE M, 2011, BRAINWAVES; JARRELL A, 2003, COMBAT MED BASIC CLI, P351; Kay T., 1993, J HEAD TRAUMA REHAB, V8, P86, DOI [10.1097/00001199-199309000-00010, DOI 10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Knuth T., 2005, GUIDELINES FIELD MAN; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Ling Geoffrey S F, 2010, Continuum (Minneap Minn), V16, P27, DOI 10.1212/01.CON.0000391451.30299.bc; Ling GSF, 2010, ANNU REV MED, V61, P457, DOI 10.1146/annurev.med.60.071207.140903; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Ragel BT, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1028; VADOD C, 2009, J REHABIL RES DEV, V46; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; 2001, J TRAUMA 1, V51, pS3	17	69	71	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	APR	2011	24	2					124	130		10.1097/ACO.0b013e32834458da			7	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	732AS	WOS:000288154100002	21301332				2022-02-06	
J	Chibbaro, S; Di Rocco, F; Mirone, G; Fricia, M; Makiese, O; Di Emidio, P; Romano, A; Vicaut, E; Menichelli, A; Reiss, A; Mateo, J; Payen, D; Guichard, JP; George, B; Bresson, D				Chibbaro, Salvatore; Di Rocco, Fedreico; Mirone, Giuseppe; Fricia, Marco; Makiese, Orphee; Di Emidio, Paolo; Romano, Antonio; Vicaut, Eric; Menichelli, Alina; Reiss, Alisha; Mateo, Joaquim; Payen, Didier; Guichard, Jean Pierre; George, Bernard; Bresson, Damien			Decompressive Craniectomy and Early Cranioplasty for the Management of Severe Head Injury: A Prospective Multicenter Study on 147 Patients	WORLD NEUROSURGERY			English	Article						Decompressive craniectomy; Early cranioplasty; Head injury	TRAUMATIC BRAIN-INJURY; SINKING SKIN-FLAP; CEREBRAL PERFUSION-PRESSURE; INTRACRANIAL HYPERTENSION; EXPERIENCE; DAMAGE; PROTECTION; PROTOCOL; THERAPY; IMPACT	OBJECTIVE: In emergency care of patients with severe blunt head injury, uncontrollable high intracranial pressure is one of major causes of morbidity and mortality. The purpose of this study was to evaluate the efficacy of aggressive surgical treatment in managing uncontrollable elevated intracranial pressure coupled with early skull reconstruction. METHODS: This was a prospective study on a series of 147 consecutive patients, managed according to the same protocol by five different neurosurgical units, for severe head injuries (Glasgow coma scale score <= 8/15 and high intracranial pressure >25 mm Hg) during a five-year period. All patients received a wide decompressive craniectomy and duroplasty in the acute phase, and a cranioplasty was also performed within 12 weeks (median 6 weeks, range 4-12 weeks). RESULTS: The emergency decompressive surgery was performed within 28 hours (median 16 hours, range 6-28 hours) after sustaining the head injury. The median preoperative Glasgow coma scale score was 6/15 (range 3-8/15). At a mean follow-up of 26 months (range 14-74 months) 14 patients were lost to long-term follow-up, leaving only 133 patients available for the study. The outcome was favorable in 89 (67%, Glasgow outcome score 4 or 5), it was not favorable in 25 (19%, Glasgow outcome score 2 and 3), and 19 patients (14%) died. A younger age (<50 years) and earlier operation (within 9 hours from trauma) had a significant effect on positive outcomes (P < 0.0001 and P < 0.03, respectively). CONCLUSIONS: A prompt aggressive surgery, including a wide decompressive craniectomy coupled with early cranioplasty, could be an effective treatment method to improve the outcome after a severe closed head injury reducing, perhaps, many of the complications related to decompressive craniectomy.	[Chibbaro, Salvatore; Makiese, Orphee; Di Emidio, Paolo; George, Bernard; Bresson, Damien] Lariboisiere Univ Hosp, Dept Neurosurg, Paris, France; [Di Rocco, Fedreico] Necker Univ Hosp, Dept Neurosurg, Paris, France; [Mirone, Giuseppe] Naples Univ Hosp, Dept Neurosurg, Naples, Italy; [Fricia, Marco] Cannizzaro Univ Hosp, Dept Neurosurg, Catania, Italy; [Romano, Antonio] Parma Univ Hosp, Dept Neurosurg, Parma, Italy; [Vicaut, Eric] Hop Univ Lariboisiere Fernand Widal, Unite Rech Clin, Paris, France; [Menichelli, Alina] Trieste Univ Hosp, Rehabil Unit, Trieste, Italy; [Reiss, Alisha] Columbus Ohio State Univ Med Ctr, Dept Neurosurg, Columbus, OH USA; [Mateo, Joaquim; Payen, Didier] Lariboisiere Univ Hosp, Neuro ITU, Paris, France; [Guichard, Jean Pierre] Lariboisiere Univ Hosp, Dept Neuroradiol, Paris, France		Chibbaro, S (corresponding author), Lariboisiere Univ Hosp, Dept Neurosurg, Paris, France.	schibbaro@hotmail.com	Chibbaro, Salvatore/AAI-6368-2020; DI ROCCO, Federico/C-6343-2015	chibbaro, salvatore/0000-0003-1318-1245			Bostrom S, 2005, ACTA NEUROCHIR, V147, P279, DOI 10.1007/s00701-004-0480-4; Brain Trauma Foundation The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P527; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Chibbaro S, 2007, SURG NEUROL, V68, P632, DOI 10.1016/j.surneu.2006.12.046; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DeWitt D S, 1995, New Horiz, V3, P376; Dujovny M, 1997, SURG NEUROL, V47, P238, DOI 10.1016/S0090-3019(96)00013-4; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GAAB MR, 1990, ACT NEUR S, V51, P326; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; Hodozuka A, 2000, NEUROL SURG TOKYO, V28, P245; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; JENNETT B, 1975, LANCET, V1, P480; Jennett B., 1991, NIMODIPINE PHARM CLI, P225; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Kawaguchi T, 2003, NEUROL MED-CHIR, V43, P320, DOI 10.2176/nmc.43.320; Kunze E, 1998, ACT NEUR S, V71, P16; LANGFITT TW, 1966, J NEUROSURG, V24, P47, DOI 10.3171/jns.1966.24.1.0047; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LANGFITT TW, 1976, INTRACRANIAL PRESSUR, V3, P67; LUERSSEN TG, 1989, INTRACRANIAL PRESSUR, V7, P598; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Maekawa M, 1999, NEUROL SURG TOKYO, V27, P717; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1992, GREENFIELDS NEUROPAT, P69; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Munch E, 2000, NEUROSURGERY, V47, P315, DOI 10.1097/00006123-200008000-00009; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Olivecrona M, 2007, J NEUROTRAUM, V24, P927, DOI 10.1089/neu.2005.356E; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Safar P, 2001, NEW ENGL J MED, V345, P66; Sakamoto S, 2006, CLIN NEUROL NEUROSUR, V108, P583, DOI 10.1016/j.clineuro.2005.03.012; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; STULA D, 1982, J MAXILLOFAC SURG, V10, P142, DOI 10.1016/S0301-0503(82)80030-1; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; YAMAURA A, 1977, Neurologia Medico-Chirurgica, V17, P43, DOI 10.2176/nmc.17pt1.43; Yamaura A, 1977, No Shinkei Geka, V5, P345; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	47	69	78	1	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR-APR	2011	75	3-4					558	562		10.1016/j.wneu.2010.10.020			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	793KK	WOS:000292820400055	21600512				2022-02-06	
J	Skaper, SD				Skaper, Stephen D.			Ion Channels on Microglia: Therapeutic Targets for Neuroprotection	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Microglia; neuroinflammation; neurotoxicity; ATP; purinergic receptors; chloride channels; potassium channels; amyloid; Alzheimer's disease	CA2+-ACTIVATED K+ CHANNEL; ACTIVATED POTASSIUM CHANNEL; P2X(7) RECEPTOR EXPRESSION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; WHITE-MATTER CHANGES; HUMAN T-LYMPHOCYTES; INTERMEDIATE-CONDUCTANCE; ALZHEIMERS-DISEASE	Under pathological conditions microglia (resident CNS immune cells) become activated, and produce reactive oxygen and nitrogen species and pro-inflammatory cytokines: molecules that can contribute to axon demyelination and neuron death. Because some microglia functions can exacerbate CNS disorders, including stroke, traumatic brain injury, progressive neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis, and several retinal diseases, controlling their activation might ameliorate immune-mediated CNS disorders. A growing body of evidence now points to ion channels on microglia as contributing to the above neuropathologies. For example, the ATP-gated P2X(7) purinergic receptor cation channel is up-regulated around amyloid beta-peptide plaques in transgenic mouse models of Alzheimer's disease and co-localizes to microglia and astrocytes. Up-regulation of the P2X(7) receptor subtype on microglia occurs also following spinal cord injury and after ischemia in the cerebral cortex of rats, while P2X(7) receptor-like immunoreactivity is increased in activated microglial cells of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. Utilizing neuron/microglia co-cultures as an in vitro model for neuroinflammation, P2X(7) receptor activation on microglia appears necessary for microglial cell-mediated injury of neurons. A second example can be found in the chloride intracellular channel 1 (CLIC1), whose expression is related to macrophage activation, undergoes translocation from the cytosol to the plasma membrane (activation) of microglia exposed to amyloid beta-peptide, and participates in amyloid beta-peptide-induced neurotoxicity through the generation of reactive oxygen species. A final example is the small-conductance Ca2+/calmodulin-activated K+ channel KCNN4/KCa3.1/SK4/IK1, which is highly expressed in rat microglia. Lipopolysaccharide-activated microglia are capable of killing adjacent neurons in co-culture, and show markedly reduced toxicity when treated with an inhibitor of KCa3.1 channels. Moreover, blocking KCa3.1 channels mitigated the neurotoxicity of amyloid beta-peptide-stimulated microglia. Excessive microglial cell activation and production of potentially neurotoxic molecules, mediated by ion channels, may thus constitute viable targets for the discovery and development of neurodegenerative disease therapeutics. This chapter will review recent data that reflect the prevailing approaches targeting neuroinflammation as a pathophysiological process contributing to the onset or progression of neurodegenerative diseases, with a focus on microglial ion channels and their neuroprotective potential.	Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy		Skaper, SD (corresponding author), Univ Padua, Dept Pharmacol & Anesthesiol, Largo E Meneghetti 2, I-35131 Padua, Italy.	Stephen.skaper@unipd.it					Adinolfi E, 2010, FASEB J, V24, P3393, DOI 10.1096/fj.09-153601; Agresti C, 2005, GLIA, V50, P132, DOI 10.1002/glia.20160; Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Anderson CM, 2006, TRENDS NEUROSCI, V29, P257, DOI 10.1016/j.tins.2006.03.003; Bartzokis G, 2004, NEUROBIOL AGING, V25, P5, DOI 10.1016/j.neurobiolaging.2003.03.001; Bartzokis G, 2003, ARCH NEUROL-CHICAGO, V60, P393, DOI 10.1001/archneur.60.3.393; Bartzokis G, 2001, ARCH GEN PSYCHIAT, V58, P461, DOI 10.1001/archpsyc.58.5.461; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bernardino L, 2008, J NEUROCHEM, V106, P271, DOI 10.1111/j.1471-4159.2008.05387.x; BIANCA VD, 1999, J BIOL CHEM, V274, P15493; Blank T, 2004, CNS NEUROL DISORD-DR, V3, P161, DOI 10.2174/1568007043337472; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bond CT, 2005, CURR OPIN NEUROBIOL, V15, P305, DOI 10.1016/j.conb.2005.05.001; Braak H, 2000, ANN NY ACAD SCI, V924, P53; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRESNAHAN JC, 1978, J NEUROL SCI, V37, P59, DOI 10.1016/0022-510X(78)90228-9; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Chakfe Y, 2002, J NEUROSCI, V22, P3061, DOI 10.1523/JNEUROSCI.22-08-03061.2002; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; Chessell IP, 2005, PAIN, V114, P386, DOI 10.1016/j.pain.2005.01.002; Collo G, 1997, NEUROPHARMACOLOGY, V36, P1277, DOI 10.1016/S0028-3908(97)00140-8; Craft JM, 2005, EXPERT OPIN THER TAR, V9, P887, DOI 10.1517/14728222.9.5.887; Culbert AA, 2006, J BIOL CHEM, V281, P23658, DOI 10.1074/jbc.M513646200; D'Ambrosi N, 2009, J IMMUNOL, V183, P4648, DOI 10.4049/jimmunol.0901212; D'Aversa TG, 2004, J NEUROVIROL, V10, P86, DOI 10.1080/13550280490279807; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Diemel LT, 1998, NEUROCHEM RES, V23, P341, DOI 10.1023/A:1022405516630; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Domercq M, 2010, GLIA, V58, P730, DOI 10.1002/glia.20958; Duan SM, 2003, J NEUROSCI, V23, P1320, DOI 10.1523/JNEUROSCI.23-04-01320.2003; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Ducharme G, 2007, EUR J NEUROSCI, V26, P2119, DOI 10.1111/j.1460-9568.2007.05802.x; Eder C, 1997, N-S ARCH PHARMACOL, V356, P233, DOI 10.1007/PL00005046; Eikelenboom P, 2002, GLIA, V40, P232, DOI 10.1002/glia.10146; El Khoury J, 2008, TRENDS PHARMACOL SCI, V29, P626, DOI 10.1016/j.tips.2008.08.004; Farber K, 2006, GLIA, V54, P656, DOI 10.1002/glia.20412; Fan R, 2007, J NEUROSCI, V27, P3057, DOI 10.1523/JNEUROSCI.4371-06.2007; Felts PA, 1997, J NEUROSCI, V17, P7267; Ferrari D, 1997, NEUROPHARMACOLOGY, V36, P1295, DOI 10.1016/S0028-3908(97)00137-8; Ferrari D, 1996, J IMMUNOL, V156, P1531; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Fields RD, 2006, NAT REV NEUROSCI, V7, P423, DOI 10.1038/nrn1928; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; FILIPPINI A, 1990, J BIOL CHEM, V265, P334; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Franke H, 2004, J NEUROPATH EXP NEUR, V63, P686, DOI 10.1093/jnen/63.7.686; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Furber M, 2007, J MED CHEM, V50, P5882, DOI 10.1021/jm700949w; Ge YL, 2002, AM J NEURORADIOL, V23, P1334; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Giulian D, 1999, AM J HUM GENET, V65, P13, DOI 10.1086/302477; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Grgic I, 2005, ARTERIOSCL THROM VAS, V25, P704, DOI 10.1161/01.ATV.0000156399.12787.5c; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; Heneka MT, 2010, P NATL ACAD SCI USA, V107, P6058, DOI 10.1073/pnas.0909586107; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; Honore P, 2006, J PHARMACOL EXP THER, V319, P1376, DOI 10.1124/jpet.106.111559; HUITINGA I, 1990, J EXP MED, V172, P1025, DOI 10.1084/jem.172.4.1025; Humphreys BD, 1998, J LEUKOCYTE BIOL, V64, P265, DOI 10.1002/jlb.64.2.265; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Inoue K, 1998, BRIT J PHARMACOL, V123, P1304, DOI 10.1038/sj.bjp.0701732; Ishii TM, 1997, J BIOL CHEM, V272, P23195, DOI 10.1074/jbc.272.37.23195; Jager H, 2004, MOL PHARMACOL, V65, P630, DOI 10.1124/mol.65.3.630; James G, 2002, EUR J PHARMACOL, V447, P247, DOI 10.1016/S0014-2999(02)01756-9; Jensen B S, 2002, Expert Opin Ther Targets, V6, P623, DOI 10.1517/14728222.6.6.623; Joiner WJ, 1997, P NATL ACAD SCI USA, V94, P11013, DOI 10.1073/pnas.94.20.11013; Kataoka A, 2009, J NEUROCHEM, V108, P115, DOI 10.1111/j.1471-4159.2008.05744.x; Kaul M, 2001, NATURE, V410, P988, DOI 10.1038/35073667; Kaushal V, 2007, J NEUROSCI, V27, P234, DOI 10.1523/JNEUROSCI.3593-06.2007; Keane RW, 2006, J NEUROTRAUM, V23, P335, DOI 10.1089/neu.2006.23.335; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kim SU, 2005, J NEUROSCI RES, V81, P302, DOI 10.1002/jnr.20562; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kohler R, 2003, CIRCULATION, V108, P1119, DOI 10.1161/01.CIR.0000086464.04719.DD; Kohler R, 2010, EXPERT OPIN THER TAR, V14, P143, DOI 10.1517/14728220903540257; Kotter MR, 2005, NEUROBIOL DIS, V18, P166, DOI 10.1016/j.nbd.2004.09.019; Labasi JM, 2002, J IMMUNOL, V168, P6436, DOI 10.4049/jimmunol.168.12.6436; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Langford D, 2001, BRAIN PATHOL, V11, P306; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Le Feuvre R, 2002, EUR J PHARMACOL, V447, P261, DOI 10.1016/S0014-2999(02)01848-4; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; MAHAUTSMITH MP, 1989, J PHYSIOL-LONDON, V415, P69, DOI 10.1113/jphysiol.1989.sp017712; Matute C, 2006, GLIA, V53, P212, DOI 10.1002/glia.20275; Matute C, 2007, J NEUROSCI, V27, P9525, DOI 10.1523/JNEUROSCI.0579-07.2007; Mauler F, 2004, EUR J NEUROSCI, V20, P1761, DOI 10.1111/j.1460-9568.2004.03615.x; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007; McGeer PL, 2001, ARCH NEUROL-CHICAGO, V58, P1790, DOI 10.1001/archneur.58.11.1790; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; McLarnon JG, 2006, J NEUROPATH EXP NEUR, V65, P1090, DOI 10.1097/01.jnen.0000240470.97295.d3; McNeish AJ, 2006, STROKE, V37, P1277, DOI 10.1161/01.STR.0000217307.71231.43; Mesulam MM, 2000, ANN NY ACAD SCI, V924, P42; Meyer-Luehmann M, 2008, NATURE, V451, P720, DOI 10.1038/nature06616; Milton RH, 2008, J NEUROSCI, V28, P11488, DOI 10.1523/JNEUROSCI.2431-08.2008; Moller T, 2001, J BIOL CHEM, V276, P25946, DOI 10.1074/jbc.M102691200; Monif M, 2009, J NEUROSCI, V29, P3781, DOI 10.1523/JNEUROSCI.5512-08.2009; Moreland JG, 2006, J BIOL CHEM, V281, P12277, DOI 10.1074/jbc.M511030200; Narcisse L, 2005, GLIA, V49, P245, DOI 10.1002/glia.20110; Nathan C, 2005, J EXP MED, V202, P1163, DOI 10.1084/jem.20051529; Nelson DW, 2008, J MED CHEM, V51, P3030, DOI 10.1021/jm701516f; Nieber K, 1999, PROG BRAIN RES, V120, P287; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novarino G, 2004, J NEUROSCI, V24, P5322, DOI 10.1523/JNEUROSCI.1170-04.2004; O'Sullivan M, 2001, NEUROLOGY, V57, P632, DOI 10.1212/WNL.57.4.632; Parachikova A, 2007, NEUROBIOL AGING, V28, P1821, DOI 10.1016/j.neurobiolaging.2006.08.014; Paradisi S, 2008, J NEUROSCI RES, V86, P2488, DOI 10.1002/jnr.21693; Parvathenani LK, 2003, J BIOL CHEM, V278, P13309, DOI 10.1074/jbc.M209478200; Pedarzani P, 2008, CELL MOL LIFE SCI, V65, P3196, DOI 10.1007/s00018-008-8216-x; Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05-03-0222; Perregaux DG, 2000, J IMMUNOL, V165, P4615, DOI 10.4049/jimmunol.165.8.4615; Perry VH, 2002, CURR OPIN NEUROL, V15, P349, DOI 10.1097/00019052-200206000-00020; Peters A, 2000, J COMP NEUROL, V419, P364, DOI 10.1002/(SICI)1096-9861(20000410)419:3<364::AID-CNE8>3.0.CO;2-R; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Pocock JM, 2007, TRENDS NEUROSCI, V30, P527, DOI 10.1016/j.tins.2007.07.007; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Reich EP, 2005, EUR J IMMUNOL, V35, P1027, DOI 10.1002/eji.200425954; Reichert F, 2003, NEUROBIOL DIS, V12, P65, DOI 10.1016/S0969-9961(02)00008-6; Reynolds A, 2007, INT REV NEUROBIOL, V82, P297, DOI 10.1016/S0074-7742(07)82016-2; Rosin C, 2004, J NEUROCHEM, V90, P1173, DOI 10.1111/j.1471-4159.2004.02584.x; Sanz JM, 2009, J IMMUNOL, V182, P4378, DOI 10.4049/jimmunol.0803612; SCHLICHTER LC, 2002, ROLES ION CHANNELS P; Schlichter LC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-4; Sharp AJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-33; Shimohama S, 2000, BIOCHEM BIOPH RES CO, V273, P5, DOI 10.1006/bbrc.2000.2897; Sikora A, 1999, J IMMUNOL, V163, P558; Sim JA, 2004, J NEUROSCI, V24, P6307, DOI 10.1523/JNEUROSCI.1469-04.2004; Skaper SD, 2006, GLIA, V54, P234, DOI 10.1002/glia.20379; Skaper Stephen D, 2009, Cardiovasc Psychiatry Neurol, V2009, P545263, DOI 10.1155/2009/545263; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Solle M, 2001, J BIOL CHEM, V276, P125, DOI 10.1074/jbc.M006781200; Sorce S, 2009, ANTIOXID REDOX SIGN, V11, P2481, DOI [10.1089/ars.2009.2578, 10.1089/ARS.2009.2578]; Stadelmann C, 2002, BRAIN, V125, P75, DOI 10.1093/brain/awf015; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; Stocker M, 2004, NAT REV NEUROSCI, V5, P758, DOI 10.1038/nrn1516; Stokes L, 2010, FASEB J, V24, P2916, DOI 10.1096/fj.09-150862; Sultana R, 2010, J ALZHEIMERS DIS, V19, P341, DOI 10.3233/JAD-2010-1222; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Takata K, 2007, FEBS LETT, V581, P475, DOI 10.1016/j.febslet.2007.01.009; Tang Y, 1997, NEUROBIOL AGING, V18, P609, DOI 10.1016/S0197-4580(97)00155-3; Teismann P, 2004, CELL TISSUE RES, V318, P149, DOI 10.1007/s00441-004-0944-0; Tharp DL, 2006, AM J PHYSIOL-HEART C, V291, pH2493, DOI 10.1152/ajpheart.01254.2005; Tharp D. L., 2009, Cardiovascular & Hematological Agents in Medicinal Chemistry, V7, P1; Tonini R, 2000, FASEB J, V14, P1171, DOI 10.1096/fasebj.14.9.1171; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; Trapp BD, 2007, GLIA, V55, P360, DOI 10.1002/glia.20462; Valenzuela SM, 2000, J PHYSIOL-LONDON, V529, P541, DOI 10.1111/j.1469-7793.2000.00541.x; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Vasilevko V, 2007, J NEUROSCI, V27, P13376, DOI 10.1523/JNEUROSCI.2788-07.2007; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Volonte C, 2003, CNS NEUROL DISORD-DR, V2, P403, DOI 10.2174/1568007033482643; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang XH, 2004, NAT MED, V10, P821, DOI 10.1038/nm1082; WAXMAN SG, 1977, PROG NEUROBIOL, V8, P297, DOI 10.1016/0301-0082(77)90009-0; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yam PS, 1997, BRAIN RES, V760, P150, DOI 10.1016/S0006-8993(97)00290-4; Yam PS, 1998, J NEUROTRAUM, V15, P441, DOI 10.1089/neu.1998.15.441; Yiangou Y, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-12; Yu Y, 2008, BRAIN RES, V1194, P45, DOI 10.1016/j.brainres.2007.11.064	178	69	78	0	22	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	FEB	2011	10	1					44	56					13	Neurosciences; Pharmacology & Pharmacy	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Pharmacology & Pharmacy	715HE	WOS:000286872800005	21143139				2022-02-06	
J	Nelson, NW; Hoelzle, JB; McGuire, KA; Ferrier-Auerbach, AG; Charlesworth, MJ; Sponheim, SR				Nelson, Nathaniel W.; Hoelzle, James B.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.			Evaluation Context Impacts Neuropsychological Performance of OEF/OIF Veterans with Reported Combat-Related Concussion	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Forensic neuropsychology; Malingering; symptom validity testing	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TEST; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; AMERICAN-ACADEMY; TEST-SCORES; MILD TBI; SOLDIERS; SEQUELAE; IRAQ	Although soldiers of Operations Iraqi Freedom (OIF) and Enduring Freedom (OEF) encounter combat-related concussion at an unprecedented rate, relatively few studies have examined how evaluation context, insufficient effort, and concussion history impact neuropsychological performances in the years following injury. The current study explores these issues in a sample of 119 U.S. veterans (OEF/OIF forensic concussion, n = 24; non-OEF/OIF forensic concussion, n = 20; OEF/OIF research concussion, n = 38; OEF/OIF research without concussion, n = 37). The OEF/OIF forensic concussion group exhibited significantly higher rates of insufficient effort relative to the OEF/OIF research concussion group, but a comparable rate of insufficient effort relative to the non-OEF/OIF forensic concussion group. After controlling for effort, the research concussion and the research non-concussion groups demonstrated comparable neuropsychological performance. Results highlight the importance of effort assessment among OEF/OIF and other veterans with concussion history, particularly in forensic contexts.	[Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Charlesworth, Molly J.; Sponheim, Scott R.] Minneapolis VA Med Ctr, Minneapolis, MN 55417 USA; [Nelson, Nathaniel W.; McGuire, Kathryn A.; Ferrier-Auerbach, Amanda G.; Sponheim, Scott R.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Hoelzle, James B.] Marquette Univ, Dept Psychol, Milwaukee, WI 53233 USA		Nelson, NW (corresponding author), Minneapolis VA Med Ctr, 1 Vet Dr 116B, Minneapolis, MN 55417 USA.	nels5363@umn.edu	Sponheim, Scott/J-3857-2017	Sponheim, Scott/0000-0002-2782-0856	Congressionally Directed Medical Research ProgramsUnited States Department of Defense [PT074550, W81XWH-08-2-0038]; Minnesota Veterans Research Institute (MVRI)	This study was supported in part by Grants funded by the Congressionally Directed Medical Research Programs (number PT074550, contract W81XWH-08-2-0038) to SRS and the Minnesota Veterans Research Institute (MVRI) to NWN.	Armistead-Jehle P, 2010, APPL NEUROPSYCHOL, V17, P52, DOI 10.1080/09084280903526182; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boone K.B., 2007, ASSESSMENT FEIGNED C; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Brenner LA, 2010, NEUROPSYCHOLOGY, V24, P160, DOI 10.1037/a0017966; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis D.C., 2000, CALIFORNIA VERBAL LE; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; First M, 2007, STRUCTURED CLIN INTE; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gladsjo JA, 1999, ASSESSMENT, V6, P147, DOI 10.1177/107319119900600204; Golden CJ, 1978, STROOP COLOR WORD TE; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P, 2004, GREENS MED SYMPTOM V; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Grote CL, 2000, J CLIN EXP NEUROPSYC, V22, P709, DOI 10.1076/jcen.22.6.709.958; Heaton RK, 1991, COMPREHENSIVE NORMS; Heilbronner RL, 2007, CLIN NEUROPSYCHOL, V21, P209, DOI 10.1080/13825580601025932; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Rohling ML, 2010, CLIN NEUROPSYCHOL, V24, P119, DOI 10.1080/13854040903307243; Rosenfeld B, 2000, ARCH CLIN NEUROPSYCH, V15, P349, DOI 10.1016/S0887-6177(99)00025-6; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Slick DJ, 1996, J CLIN EXP NEUROPSYC, V18, P911, DOI 10.1080/01688639608408313; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh T.N., 1996, TEST MEMORY MALINGER; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; VANDERPLOEG RD, 2009, NEUROPSYCHOLOGY MALI; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird; Whitney KA, 2009, ARCH CLIN NEUROPSYCH, V24, P145, DOI 10.1093/arclin/acp020	58	69	69	0	8	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	DEC	2010	25	8					713	723		10.1093/arclin/acq075			11	Psychology, Clinical; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology	679KE	WOS:000284159500002	20923860	Bronze, Green Published			2022-02-06	
J	Hu, SL; Luo, HS; Li, JT; Xia, YZ; Li, L; Zhang, LJ; Meng, H; Cui, GY; Chen, Z; Wu, N; Lin, JK; Zhu, G; Feng, H				Hu, Sheng-Li; Luo, Hai-Shui; Li, Jiang-Tao; Xia, Yong-Zhi; Li, Lan; Zhang, Li-Jun; Meng, Hui; Cui, Gao-Yu; Chen, Zhi; Wu, Nan; Lin, Jiang-Kai; Zhu, Gang; Feng, Hua			Functional recovery in acute traumatic spinal cord injury after transplantation of human umbilical cord mesenchymal stem cells	CRITICAL CARE MEDICINE			English	Article						functional recovery; mesenchymal stem cells; spinal cord injury; transplantation; umbilical cord	IN-VITRO; STROMAL CELL; PROGENITOR CELLS; FEEDER LAYER; RODENT MODEL; DIFFERENTIATION; NEURONS; REGENERATION; EXPRESSION; THERAPY	Objective: Spinal cord injury results in loss of neurons, degeneration of axons, formation of glial scar, and severe functional impairment. Human umbilical cord mesenchymal stem cells can be induced to form neural cells in vitro. Thus, these cells have a potential therapeutic role for treating spinal cord injury. Design and Setting: Rats were randomly divided into three groups: sham operation group, control group, and human umbilical cord mesenchymal stem cell group. All groups were subjected to spinal cord injury by weight drop device except for sham group. Subjects: Thirty-six female Sprague-Dawley rats. Interventions: The control group received Dulbecco's modified essential media/nutrient mixture F-12 injections, whereas the human umbilical cord mesenchymal stem cell group undertook cells transplantation at the dorsal spinal cord 2 mm rostrally and 2 mm caudally to the injury site at 24 hrs after spinal cord injury. Measurements: Rats from each group were examined for neurologic function and contents of brain-derived neurotrophic factor, glial cell line-derived neurotrophic factor, and neurotrophin-3. Survival, migration, and differentiation of human umbilical cord mesenchymal stem cells, regeneration of axons, and formation of glial scar were also explored by using immunohistochemistry and immunofluorescence. Main Results: Recovery of hindlimb locomotor function was significantly enhanced in the human umbilical cord mesenchymal stem cells grafted animals at 5 wks after transplantation. This recovery was accompanied by increased length of neurofilament-positive fibers and increased numbers of growth cone-like structures around the lesion site. Transplanted human umbilical cord-mesenchymal stem cells survived, migrated over short distances, and produced large amounts of glial cell line-derived neurotrophic factor and neurotrophin-3 in the host spinal cord. There were fewer reactive astrocytes in both the rostral and caudal stumps of the spinal cord in the human umbilical cord-mesenchymal stem cell group than in the control group. Conclusions: Treatment with human umbilical cord mesenchymal stem cells can facilitate functional recovery after traumatic spinal cord injury and may prove to be a useful therapeutic strategy to repair the injured spinal cord. (Crit Care Med 2010; 38: 2181-2189)	[Hu, Sheng-Li; Luo, Hai-Shui; Li, Jiang-Tao; Xia, Yong-Zhi; Li, Lan; Zhang, Li-Jun; Meng, Hui; Cui, Gao-Yu; Chen, Zhi; Wu, Nan; Lin, Jiang-Kai; Zhu, Gang; Feng, Hua] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China		Hu, SL (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing, Peoples R China.	fenghua8888@yahoo.com.cn	Feng, Hua/AAX-4121-2021	Feng, Hua/0000-0003-4489-9217; Chen, Zhi/0000-0002-8404-4937	National Natural Science Foundation of China, Peking, ChinaNational Natural Science Foundation of China (NSFC) [0330220, 30572167, 30872735]; Natural Science Foundation of Chong-Qing, Chong-Qing, ChinaNatural Science Foundation of Chongqing [2008BA5002]	This work was supported, in part, by grants from the National Natural Science Foundation of China, Peking, China (0330220, 30572167, 30872735), and from the Natural Science Foundation of Chong-Qing, Chong-Qing, China (2008BA5002).	Bailey MM, 2007, TISSUE ENG, V13, P2003, DOI 10.1089/ten.2006.0150; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cao QL, 2005, J NEUROSCI, V25, P6947, DOI 10.1523/JNEUROSCI.1065-05.2005; Chang SA, 2008, STEM CELLS, V26, P1901, DOI 10.1634/stemcells.2007-0708; Civin CI, 2002, STEM CELLS, V20, P482, DOI 10.1634/stemcells.20-6-482; Conconi MT, 2006, INT J MOL MED, V18, P1089; Coutts M, 2008, EXP NEUROL, V209, P368, DOI 10.1016/j.expneurol.2007.09.002; Cummings BJ, 2005, P NATL ACAD SCI USA, V102, P14069, DOI 10.1073/pnas.0507063102; De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274; Ding DC, 2007, NEUROBIOL DIS, V27, P339, DOI 10.1016/j.nbd.2007.06.010; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; FOKSEANG J, 1995, BRAIN RES, V689, P207, DOI 10.1016/0006-8993(95)00575-B; Freed CR, 2002, P NATL ACAD SCI USA, V99, P1755, DOI 10.1073/pnas.062039699; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Fu YS, 2004, J BIOMED SCI, V11, P652, DOI 10.1159/000079678; Fu-Jiang C, 2009, CHINESE MED J-PEKING, V122, P225, DOI 10.3760/cma.j.issn.0366-6999.2009.02.021; Gao L, 2006, BLOOD CELL MOL DIS, V36, P322, DOI 10.1016/j.bcmd.2005.12.036; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Hu SL, 2009, J CELL BIOCHEM, V108, P529, DOI 10.1002/jcb.22283; Jang YK, 2006, ANN HEMATOL, V85, P212, DOI 10.1007/s00277-005-0047-3; Jomura S, 2007, STEM CELLS, V25, P98, DOI 10.1634/stemcells.2006-0055; Kadner A, 2004, EUR J CARDIO-THORAC, V25, P635, DOI 10.1016/j.ejcts.2003.12.038; Kaltz N, 2008, STEM CELLS, V26, P2419, DOI 10.1634/stemcells.2008-0304; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Karimi-Abdolrezaee S, 2006, J NEUROSCI, V26, P3377, DOI 10.1523/JNEUROSCI.4184-05.2006; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Kim JW, 2004, ANN HEMATOL, V83, P733, DOI 10.1007/s00277-004-0918-z; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Lee OK, 2004, BLOOD, V103, P1669, DOI 10.1182/blood-2003-05-1670; Lim PAC, 2007, ANN ACAD MED SINGAP, V36, P49; Lu LL, 2006, HAEMATOLOGICA, V91, P1017; Lund RD, 2007, STEM CELLS, V25, P602, DOI 10.1634/stemcells.2006-0308; Ma L, 2005, CHINESE MED J-PEKING, V118, P1987; Marcus AJ, 2008, DIFFERENTIATION, V76, P130, DOI 10.1111/j.1432-0436.2007.00194.x; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; Panepucci RA, 2004, STEM CELLS, V22, P1263, DOI 10.1634/stemcells.2004-0024; Rao MS, 2001, MECH AGEING DEV, V122, P713, DOI 10.1016/S0047-6374(01)00224-X; Romanov YA, 2003, STEM CELLS, V21, P105, DOI 10.1634/stemcells.21-1-105; Rooney GE, 2009, TISSUE ENG PT A, V15, P3049, DOI [10.1089/ten.tea.2009.0045, 10.1089/ten.TEA.2009.0045]; Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004-0166; Secco M, 2008, STEM CELLS, V26, P146, DOI 10.1634/stemcells.2007-0381; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Tuszynski MH, 2003, EXP NEUROL, V181, P47, DOI 10.1016/S0014-4886(02)00055-9; Wamil AW, 1998, P NATL ACAD SCI USA, V95, P13188, DOI 10.1073/pnas.95.22.13188; Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004-0013; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Weiss ML, 2008, STEM CELLS, V26, P2865, DOI 10.1634/stemcells.2007-1028; Willerth SM, 2008, ADV DRUG DELIVER REV, V60, P263, DOI 10.1016/j.addr.2007.08.028; Wright LS, 2006, EXP CELL RES, V312, P2107, DOI 10.1016/j.yexcr.2006.03.012; Wu KH, 2007, J CELL BIOCHEM, V100, P608, DOI 10.1002/jcb.21078; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang ZY, 2009, STEM CELLS, V27, P126, DOI 10.1634/stemcells.2008-0456	56	69	85	4	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2010	38	11					2181	2189		10.1097/CCM.0b013e3181f17c0e			9	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	667YW	WOS:000283235400014	20711072				2022-02-06	
J	Eckner, JT; Kutcher, JS; Richardson, JK				Eckner, James T.; Kutcher, Jeffrey S.; Richardson, James K.			Pilot Evaluation of a Novel Clinical Test of Reaction Time in National Collegiate Athletic Association Division I Football Players	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; mild traumatic brain injuries; neuropsychological tests; athletes; assessment; motivation	SPORTS; CONCUSSION; PERFORMANCE; IMPACT	Context: Evidence suggests that concussion prolongs reaction time (RT). We have developed a simple, reliable clinical tool for measuring reaction time that may be of value in the assessment of concussion in athletes. Objective: To compare baseline values of clinical AT (RTclin) obtained using the new clinical reaction time apparatus with computerized AT (RTcomp) obtained using a validated computerized neuropsychological test battery. Design: Cross-sectional study. Setting: Data were collected during a National Collegiate Athletic Association Division I collegiate football team's preparticipation physical examination session. Patients or Other Participants: Ninety-four Division I collegiate football players. Main Outcome Measure(s): The RTclin was measured using a 1.3-m measuring stick embedded in a weighted rubber disk that was released and caught as quickly as possible. The RTcomp was measured using the simple AT component of Cog State Sport. Results: For the 68 athletes whose CogState Sport tests passed the program's integrity check, RTclin and RTcomp were correlated (r = 0.445, P < .001). Overall, mean RTclin was shorter and less variable than mean RTcomp (203 +/- 20 milliseconds versus 268 +/- 44 milliseconds; P <.001). When RTclin and RTcomp were compared between those athletes with (n = 68) and those without (n = 26) valid CogState Sport test sessions, mean RTcli, was similar (202 +/- 19 milliseconds versus 207 +/- 23 milliseconds; P = .390), but mean RTclin was different (258 +/- 35 milliseconds versus 290 55 milliseconds; P = .009). Conclusions: The RTclin was positively correlated with RTclin and yielded more consistent reaction time values during baseline testing. Given that RTclin is easy to measure using simple, inexpensive equipment, further prospective study is warranted to determine its clinical utility in the assessment of concussion in athletes.	[Eckner, James T.; Richardson, James K.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48108 USA; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI 48108 USA		Eckner, JT (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, 325 E Eisenhower,Suite 100A, Ann Arbor, MI 48108 USA.	jeckner@med.umich.edu			Foundation for Physical Medicine and Rehabilitation (Chicago, IL)	We thank Dr David Darby, chief medical officer for CogState Ltd, for the advice and assistance he provided relating to the CogState Sport program, and Steve Nordwall, MA, ATC, and his athletic training staff for their support in organizing and conducting this project. We also thank Dr Sri Krishna Chandran for his assistance with data imputation and organization. We acknowledge the support of our sponsors: The Foundation for Physical Medicine and Rehabilitation (Chicago, IL), which gave the 2007 New Investigator Award to J.T.E., and the University of Michigan Bone & Joint Injury Prevention & Rehabilitation Center (Ann Arbor, MI) for a pilot grant awarded to J.T.E. and J.K.R.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Barth JT, 1989, MILD HEAD INJURY, P257; *CDCP, 2005, MMWR-MORBID MORTAL W, V56, P733; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; CHANDRAN S, 2008, ARCH PHYS MED REHAB, V89, pE85; Chudler E. H., NEUROSCIENCE KIDS; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A., 2006, SPORTS NEUROPSYCHOLO, P240; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Dane S, 2003, INT J NEUROSCI, V113, P923, DOI 10.1080/00207450390220367; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Eckner J. T., 2006, ARCH PHYS MED REHAB, V87, pe10; Eckner JT, 2009, PERCEPT MOTOR SKILL, V108, P717, DOI 10.2466/PMS.108.3.717-720; Fredrickson J, 2010, NEUROEPIDEMIOLOGY, V34, P65, DOI 10.1159/000264823; Goodman D, 2001, BRIT J SPORT MED, V35, P371; Grindel Scott H, 2006, Curr Sports Med Rep, V5, P9; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Lovell M., 2001, BRIT J SPORT MED, V35, P373; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory P, 2005, BRIT J SPORT MED, V39, pI58, DOI 10.1136/bjsm.2005.020776; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Straume-Naesheim TM, 2005, BRIT J SPORT MED, V39, pI64, DOI 10.1136/bjsm.2005.019620; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	29	69	72	2	18	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2010	45	4					327	332		10.4085/1062-6050-45.4.327			6	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	627FY	WOS:000280026100003	20617905	Green Published			2022-02-06	
J	Inamasu, J; Miyatake, S; Suzuki, M; Nakatsukasa, M; Tomioka, H; Honda, M; Kase, K; Kobayashi, K				Inamasu, Joji; Miyatake, Satoru; Suzuki, Masaru; Nakatsukasa, Masashi; Tomioka, Hideto; Honda, Masanori; Kase, Kenichi; Kobayashi, Kenji			Early CT signs in out-of-hospital cardiac arrest survivors: Temporal profile and prognostic significance	RESUSCITATION			English	Article						Early CT sign; Loss of boundary; Out-of-hospital cardiac arrest; Return of spontaneous circulation; Sulcal effacement	VENTRICULAR-FIBRILLATION; THERAPEUTIC HYPOTHERMIA; COMATOSE SURVIVORS; BRAIN-INJURY; CARDIOPULMONARY ARREST; COMPUTED-TOMOGRAPHY; PREDICTIVE-VALUE; WHITE-MATTER; RESUSCITATION; DEATH	Aim: Although computed tomography (CT) signs of ischaemia, including loss of boundary (LOB) between grey matter and white matter and cortical sulcal effacement, in cardiac arrest (CA) survivors are known, their temporal profile and prognostic significance remains unclear: their clarification is necessary. Methods: Brain CT scans were obtained immediately after resuscitation in 75 non-traumatic CA survivors in a prospective fashion. They were divided into two groups according to the CA-return of spontaneous circulation (ROSC) interval: <= 20 min vs. > 20 min. The incidence of the CT signs and predictability of these signs for outcome, assessed 6 months after CA, was evaluated and compared. Results: The incidence of the positive LOB sign was 24% in the <= 20-min group and 83% in the > 20-min group, and the difference was statistically significant (p < 0.001). The interval of 20 min seemed to be the time window for the LOB development. The incidence of the positive sulcal effacement sign was 0% in the <= 20 min group and 34% in the > 20-min group, and the difference was statistically significant (p = 0.004). A positive LOB sign was predictive of unfavourable outcome with an 81% sensitivity and 92% specificity. A positive sulcal effacement sign was predictive of unfavourable outcome with a 32% sensitivity and 100% specificity. Conclusion: A time window may exist for ischaemic CT signs in CA survivors. The LOB sign may develop when the CA-ROSC interval exceeds 20 min, whereas the sulcal effacement sign may develop later. However, their temporal profile and outcome predictability should be verified by multicentre studies. (c) 2010 Elsevier Ireland Ltd. All rights reserved.	[Inamasu, Joji; Miyatake, Satoru; Suzuki, Masaru; Tomioka, Hideto; Kase, Kenichi; Kobayashi, Kenji] Saiseikai Utsunomiya Hosp, Dept Emergency Med, Utsunomiya, Tochigi 3210974, Japan; [Inamasu, Joji; Nakatsukasa, Masashi] Saiseikai Utsunomiya Hosp, Dept Neurosurg, Utsunomiya, Tochigi 3210974, Japan; [Honda, Masanori] Saiseikai Utsunomiya Hosp, Dept Diagnost Radiol, Utsunomiya, Tochigi 3210974, Japan		Inamasu, J (corresponding author), Saiseikai Utsunomiya Hosp, Dept Emergency Med, 911-1 Takebayashi, Utsunomiya, Tochigi 3210974, Japan.	ginamasu@aol.com	Inamasu, Joji/R-7314-2019				Arbelaez A, 1999, AM J NEURORADIOL, V20, P999; Barrett KM, 2007, MAYO CLIN PROC, V82, P828, DOI 10.4065/82.7.828; Belliard G, 2007, RESUSCITATION, V75, P252, DOI 10.1016/j.resuscitation.2007.04.014; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bottiger BW, 2008, NEW ENGL J MED, V359, P2651, DOI 10.1056/NEJMoa070570; Choi SP, 2008, EMERG MED J, V25, P666, DOI 10.1136/emj.2007.053306; Holzer M, 2002, NEW ENGL J MED, V346, P549; Inamasu J, 2009, RESUSCITATION, V80, P977, DOI 10.1016/j.resuscitation.2009.05.010; International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations, 2005, RESUSCITATION, V67, P213; Kandiah P, 2006, SEMIN NEUROL, V26, P413, DOI 10.1055/s-2006-948322; KJOS BO, 1983, AM J ROENTGENOL, V141, P1227, DOI 10.2214/ajr.141.6.1227; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Kucinski T, 1998, AM J NEURORADIOL, V19, P839; Langhelle A, 2005, RESUSCITATION, V66, P271, DOI 10.1016/j.resuscitation.2005.06.005; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Mysiak Andrzej, 2007, Cardiol J, V14, P24; Oddo M, 2008, CRIT CARE MED, V36, P2296, DOI 10.1097/CCM.0b013e3181802599; Oksanen T, 2009, RESUSCITATION, V80, P165, DOI 10.1016/j.resuscitation.2008.08.017; Pierce LC, 2008, AM J EMERG MED, V26, P1042, DOI 10.1016/j.ajem.2007.12.014; Torbey MT, 2000, STROKE, V31, P2163, DOI 10.1161/01.STR.31.9.2163; Virkkunen I, 2008, RESUSCITATION, V77, P207, DOI 10.1016/j.resuscitation.2007.12.006; Yanagawa Y, 2005, RESUSCITATION, V64, P97, DOI 10.1016/j.resuscitation.2004.06.015	23	69	73	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	MAY	2010	81	5					534	538		10.1016/j.resuscitation.2010.01.012			5	Critical Care Medicine; Emergency Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Emergency Medicine	604MH	WOS:000278282600008	20189285				2022-02-06	
J	Ahmed, OH; Sullivan, SJ; Schneiders, AG; McCrory, P				Ahmed, Osman Hassan; Sullivan, S. John; Schneiders, Anthony G.; McCrory, Paul			iSupport: do social networking sites have a role to play in concussion awareness?	DISABILITY AND REHABILITATION			English	Article						Social networking sites; internet; brain injury; concussion; self-help groups	TRAUMATIC BRAIN-INJURY; PATIENT SUPPORT GROUPS; HEALTH INFORMATION; ONLINE; TELEREHABILITATION; INTERNET; EMPOWERMENT; TECHNOLOGY; CYBERSPACE; COMMUNITY	Purpose. The Facebook web site is an exceptionally fast-growing social networking site (SNS) containing membership groups with discussion boards on a wide variety of issues. This study uses content analysis to scrutinise postings on Facebook groups related to concussion and examine the purpose of these postings. Method. 472 Facebook groups related to concussion were screened by three researchers using a specifically developed coding scheme to examine demographic information and the purpose of the posting. In those cases where agreement was not obtained, post-analysis discussion allowed consensus to be reached. Results. From the 17 Facebook groups which met the inclusion criteria, 145 postings were included for analysis. The predominant demographic group which posted on the Facebook discussion boards were North American males. In the main part, individuals utilised the Facebook group to relate personal experiences of concussion (65%), although it was also used to seek (8%) or offer advice (2%). Supporting quotes were extracted. Conclusions. This study highlights the evolving nature of healthcare support in the twenty-first century and the rich information present relating to concussion on SNSs such as Facebook. Although the information being shared on these sites is important, the peer-to-peer interaction may be the key aspect of this health education medium.	[Ahmed, Osman Hassan; Sullivan, S. John; Schneiders, Anthony G.] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin, New Zealand; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia		Ahmed, OH (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin, New Zealand.	osman.ahmed@otago.ac.nz	McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879			[Anonymous], SOCIAL LIFE HLTH INF; Armengol CG, 1999, J HEAD TRAUMA REHAB, V14, P233, DOI 10.1097/00001199-199906000-00004; Bernstam EV, 2005, INT J MED INFORM, V74, P13, DOI 10.1016/j.ijmedinf.2004.10.001; Cain J, 2008, AM J PHARM EDUC, V72, DOI 10.5688/aj720477; *CDCP, HEADS UPTAB COACH TO; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Coulson NS, 2007, PATIENT EDUC COUNS, V68, P173, DOI 10.1016/j.pec.2007.06.002; *FAC, FAC BRAINL ORG TRAUM; *FAC, FAC WHO HAV EV ATT C; Forducey PG, 2003, NEUROREHABILITATION, V18, P103; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Giansanti D, 2008, TELEMED J E-HEALTH, V14, P76, DOI 10.1089/tmj.2007.0019; Hadert A, 2008, MUSCULOSKELET CARE, V6, P181, DOI 10.1002/msc.131; Hansen DL, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e25; HARRIS JR, 1994, J COGNITIVE REHABILI, V12, P4; *HEADW BRAIN INJ A, INT; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Idriss SZ, 2009, ARCH DERMATOL, V145, P46, DOI 10.1001/archdermatol.2008.529; *INT WORLD STATS, INT; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Krippendorff K., 2009, CONTENT ANAL READER; McMillan SJ, 2006, NEW MEDIA SOC, V8, P73, DOI 10.1177/1461444806059871; Piron L, 2004, MED INFORM INTERNET, V29, P119, DOI 10.1080/14639230410001723428; Preece J, 2004, COMPUT HUM BEHAV, V20, P201, DOI 10.1016/j.chb.2003.10.015; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Ricker JH, 2003, NEUROREHABILITATION, V18, P179; Shuyler KS, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e24; Skinner H, 2003, J MED INTERNET RES, V5, DOI 10.2196/jmir.5.4.e32; *SPORTS CONC, SPORTS CONC S AFR IN; Steinfield C, 2008, J APPL DEV PSYCHOL, V29, P434, DOI 10.1016/j.appdev.2008.07.002; Subrahmanyam K, 2008, J APPL DEV PSYCHOL, V29, P420, DOI 10.1016/j.appdev.2008.07.003; Suzuki LK, 2004, J APPL DEV PSYCHOL, V25, P685, DOI 10.1016/j.appdev.2004.09.002; van Uden-Kraan CF, 2009, PATIENT EDUC COUNS, V74, P61, DOI 10.1016/j.pec.2008.07.044; van Uden-Kraan CF, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.992; FACEBOOK STAT INTERN	36	69	69	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2010	32	22					1877	1883		10.3109/09638281003734409			7	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	671TA	WOS:000283532300010	20367328				2022-02-06	
J	Kennedy, JE; Leal, FO; Lewis, JD; Cullen, MA; Amador, RR				Kennedy, Jan E.; Leal, Felix O.; Lewis, Jeffrey D.; Cullen, Maren A.; Amador, Ricardo R.			Posttraumatic stress symptoms in OIF/OEF service members with blast-related and non-blast-related mild TBI	NEUROREHABILITATION			English	Article						Mild traumatic brain injury; blast injury; PTSD	TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; PTSD CHECKLIST; PSYCHOMETRIC PROPERTIES; US MILITARY; HEAD-INJURY; IRAQ WAR; DISORDER; AFGHANISTAN; SOLDIERS	Purpose: To examine the proportion and severity of stress-related symptoms in U. S. service members with mild traumatic brain injuries (mTBI) received during deployment to Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF). Stress-related symptoms reported by service members with mTBI from explosive munitions are compared to symptoms reported by those with mTBI received from other mechanisms (i.e. falls, motor vehicle accidents). Methods: Posttraumatic stress, as measured by scores on the Posttraumatic Stress Disorder Checklist (PCL-C), for a sample of 586 OIF/OEF service members with blast-related mTBI was compared to a sample of 138 OIF/OEF service members with non-blast mTBI selected from retrospective review of research records. Results: Re-experiencing symptoms such as flashbacks and nightmares were higher for the blast mTBI group than for the non-blast mTBI group. Symptoms on other PTSD clusters and total score did not significantly differ between groups. Equivalent proportions of the blast and non-blast groups endorsed severe PTSD symptoms, with total PCL-C scores greater than or equal to 50. Conclusions: Consistent with prior reports, high levels of posttraumatic stress symptoms occur in a substantial proportion of service members who experienced deployment-related blast and non-blast mTBI. Results suggest that the psychological rehabilitation of OIF/OEF service members with mTBI from explosive blast should include particular attention to addressing re-experiencing symptoms.	[Kennedy, Jan E.; Leal, Felix O.; Lewis, Jeffrey D.; Cullen, Maren A.; Amador, Ricardo R.] San Antonio Mil Med Ctr S, Def & Vet Brain Injury Ctr, Lackland AFB, TX 78236 USA		Kennedy, JE (corresponding author), San Antonio Mil Med Ctr S, Def & Vet Brain Injury Ctr, 59 MDOS SGO5N DVBIC,2200 Berquist Dr Suite 1, Lackland AFB, TX 78236 USA.	jan.kennedy@lackland.af.mil					American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th; Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037/0022-006X.66.3.586; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BREWIN CR, 2005, NEUROPSYCHOLOGY PTSD; Cahill S., 2007, HDB PTSD SCI PRACTIC; Centers for Disease C Prevention, 2006, MMWR-MORBID MORTAL W, V55, P201; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P1262, DOI 10.1038/jcbfm.2010.37; *DVBIC, 2008, DEF VET BRAIN INJ FA; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Lew HL, 2006, J REHABIL RES DEV, V43, pVII, DOI 10.1682/JRRD.2006.05.0054; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Nixon RDV, 2005, J ANXIETY DISORD, V19, P587, DOI 10.1016/j.janxdis.2004.05.001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Riddle JR, 2007, J CLIN EPIDEMIOL, V60, P192, DOI 10.1016/j.jclinepi.2006.04.008; Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Schell TL, 2004, J ABNORM PSYCHOL, V113, P189, DOI 10.1037/0021-843X.113.2.189; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; TANIELIAN T, 2008, RAND CORPORATION, P276; Vermetten E, 2002, DEPRESS ANXIETY, V16, P14, DOI 10.1002/da.10017; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WEATHERS FW, 1993, PTSD CHECKLIST PCL D; Wolf SJ, 2009, LANCET, V374, P405, DOI 10.1016/S0140-6736(09)60257-9; Zatzick DF, 2007, PSYCHOL MED, V37, P1469, DOI 10.1017/S0033291707000943	38	69	69	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2010	26	3					223	231		10.3233/NRE-2010-0558			9	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	603OQ	WOS:000278218300006	20448312				2022-02-06	
J	Chamoun, RB; Robertson, CS; Gopinath, SP				Chamoun, Roukoz B.; Robertson, Claudia S.; Gopinath, Shankar P.			Outcome in patients with blunt head trauma and a Glasgow Coma Scale score of 3 at presentation Clinical article	JOURNAL OF NEUROSURGERY			English	Article						blunt head injury; Glasgow Coma Scale; outcome	BRAIN-INJURY; ADMISSION; PREDICTION; VARIABLES; SURVIVAL; CHANCE; PUPIL	Object. A Glasgow Coma Scale (GCS) score of 3 on presentation in patients with severe traumatic brain injury due to blunt trauma has been recognized as a bad prognostic factor. The reported mortality rate in these patients is very high, even approaching 100% in the presence of fixed and dilated pupils in some series. Consequently, there is often a tendency to treat these patients less aggressively because of the low expectations for a good recovery. In this paper, the authors' purpose is to report their experience in the management of this patient population, analyzing the mortality rate, prognostic factors, and functional outcome of survivors. Methods. The authors performed a retrospective review of patients who presented between 1997 and 2007 with blunt head trauma and a GCS score of 3. Demographics, mechanism of injury, examination, blood alcohol level, associated injury, intracranial pressure (ICP), surgical procedures, and outcome were all recorded. Results. A total of 189 patients met the inclusion criteria and were included in this study. The overall mortality rate was 49.2%. At the 6-month follow-up, 13.2% of the entire series achieved a good functional outcome (Glasgow Outcome Scale [GOS] score of 1 or 2). The patient population was then divided into 2 groups: Group 1 (patients who survived [96]) and Group 2 (patients who died [93]). Patients in Group 1 were younger (mean 33.3 +/- 12.8 vs 40.3 +/- 16.97 years; p = 0.002) and had lower ICP on admission (mean 16.3 +/- 11.1 vs 25.7 +/- 12.7 mm Hg; p < 0.001) than those in Group 2. The difference between the 2 groups regarding sex, mechanism of injury, hypotension on admission, alcohol, surgery, and associated injuries was not statistically significant. The presence of bilateral fixed, dilated pupils was found to be associated with the highest mortality rate (79.7%). Although not statistically significant because of the sample size, pupil status was also a good predictor of the functional outcome at the 6-month follow-up; a good functional outcome (GOS Score 1 or 2) was achieved in 25.5% of patients presenting with bilateral reactive pupils, and 27.6% of patients presenting with a unilateral fixed, dilated pupil, compared with 7.5% for those presenting with bilateral fixed, nondilated pupils, and 1.4% for patients with bilateral fixed, dilated pupils. Conclusions. Overall, 50.8% of patients survived their injury and 13.2% achieved a good functional outcome afterat 6 months of follow-up (GOS Score 1 or 2). Age, ICP on admission, and pupil status were found to be significant predictive factors of outcome. In particular, pupil size and reactivity appeared to be the most important prognostic factor since the mortality rate was 23.5% in the presence of bilateral reactive pupils and 79.7% in the case of bilateral fixed, dilated pupils. The authors believe that patients having suffered traumatic brain injury and present with a GCS score of 3 should still be treated aggressively initially since a good functional outcome can be obtained in some cases. (DOI: 10.3171/2009.2.JNS08817)	[Chamoun, Roukoz B.; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA		Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 1709 Dryden,Suite 750, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study is supported by an NIH Grant No. P01-NS38660. The authors report no other conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.	ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Demetriades D, 2004, ARCH SURG-CHICAGO, V139, P1066, DOI 10.1001/archsurg.139.10.1066; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; KOTWICA Z, 1995, ACTA NEUROCHIR, V133, P56, DOI 10.1007/BF01404948; Lieberman JD, 2003, J TRAUMA, V55, P437, DOI 10.1097/01.TA.0000081882.79587.17; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; Pickett W, 2001, CAN MED ASSOC J, V165, P288; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Tien HC, 2006, J TRAUMA, V60, P274, DOI 10.1097/01.ta.0000197177.13379.f4; Valadka A, 2000, TRAUMA, P377; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237	15	69	71	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	OCT	2009	111	4					683	687		10.3171/2009.2.JNS08817			5	Clinical Neurology; Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Surgery	503PL	WOS:000270550000009	19326973	Green Accepted			2022-02-06	
J	Liu-DeRyke, X; Collingridge, DS; Orme, J; Roller, D; Zurasky, J; Rhoney, DH				Liu-DeRyke, Xi; Collingridge, Dave S.; Orme, James; Roller, Dean; Zurasky, John; Rhoney, Denise H.			Clinical Impact of Early Hyperglycemia During Acute Phase of Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Hyperglycemia; Glucose; Glucose control; Traumatic brain injury; Mortality	INTENSIVE INSULIN THERAPY; SPONTANEOUS INTRACEREBRAL HEMORRHAGE; HEAD-INJURY; STROKE-ASSOCIATION; LACTATE LEVELS; GLUCOSE; MICRODIALYSIS; GUIDELINES; MANAGEMENT; COUNCIL	While tight glucose control has been widely adopted in the critical care setting, the optimal target glucose level following acute traumatic brain injury (TBI) remains debatable. This observational study was conducted to delineate the relationship between glucose levels and clinical outcomes during acute phase (first 5 days) of TBI. We retrospectively identified 429 TBI patients admitted to the intensive care unit (ICU) from January 2005 to December 2006. Of those, 380 patients were retained for final analysis. Collected data included demographics, admission Glasgow Coma Scale (GCS), and APACHE II, glucose on admission and during the first 5 days of admission, and insulin use. Clinical outcomes included mortality, ICU, and hospital length of stay. The overall hospital mortality was 13.2% (n = 50). Demographics were similar between survivor and nonsurvivor groups; however, nonsurvivors were older and had worse disease severity on admission. Nonsurvivors also had significantly higher glucose levels at admission and during the first 24 h of admission (P < 0.001). Based on the receiver operating characteristic (ROC) curve, admission and day-1 peak glucose were better predictors for mortality compared to hospital days 2-5 glucose levels, with day-1 peak glucose being the best predictor of mortality (AUC = 0.820). A Kaplan-Meier survival analysis also showed that patients with glucose < 160 mg/dl during the first day of ICU admission had a significantly better survival rate compared to those with glucose a parts per thousand yen160 mg/dl (P < 0.001). Two glucose bands, < 60 and a parts per thousand yen160 mg/dl, were identified to be associated with increased mortality irrespective of injury severity (OR = 1.130; 95% CI 1.034-1.235; P = 0.007; OR = 1.034; 95% CI 1.021-1.047, P < 0.001; respectively). Findings from our study suggest a glucose level a parts per thousand yen160 mg/dl within the first 24 h of admission following TBI is associated with poor outcomes irrespective of severity of injury, and this presents a timeframe for which active therapeutic interventions may improve clinical outcomes. Prospective efficacy trials are needed to corroborate these findings.	[Liu-DeRyke, Xi] Orlando Reg Med Ctr Inc, Orlando, FL 32806 USA; [Collingridge, Dave S.] LDS Hosp, Stat Data Ctr, Salt Lake City, UT 84146 USA; [Rhoney, Denise H.] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48201 USA		Liu-DeRyke, X (corresponding author), Orlando Reg Med Ctr Inc, 1414 Kuhl Ave,MP 180, Orlando, FL 32806 USA.	xi.liu@orlandohealth.com; David.collingridge@imail.org; James.orme@imail.org; Dean.roller@imail.org; John.zurasky@imail.or					Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Adams HP, 2003, STROKE, V34, P1056, DOI 10.1161/01.STR.0000064841.47697.22; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Diringer MN, 2006, CRIT CARE MED, V34, P930, DOI 10.1097/01.CCM.0000202433.99341.D6; Godoy DA, 2008, NEUROCRIT CARE, V9, P217, DOI 10.1007/s12028-008-9063-1; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Lee T H, 1991, J Formos Med Assoc, V90, P465; Levetan Claresa S, 2004, Endocr Pract, V10 Suppl 2, P34; MARGULIES DR, 1994, AM SURGEON, V60, P387; Oddo M, 2008, CURR OPIN CLIN NUTR, V11, P134, DOI 10.1097/MCO.0b013e3282f37b43; Parkin MC, 2005, J CEREBR BLOOD F MET, V25, P402, DOI 10.1038/sj.jcbfm.9600051; POUNGVARIN N, 1990, Journal of the Medical Association of Thailand, V73, P206; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Strong AJ, 2005, CRIT CARE MED, V33, P2147, DOI 10.1097/01.CCM.0000179029.95415.51; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; WELSH FA, 1980, STROKE, V11, P355, DOI 10.1161/01.STR.11.4.355; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zygun DA, 2004, NEUROSURGERY, V55, P877, DOI 10.1227/01.NEU.0000137658.14906.E4; 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209	27	69	78	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2009	11	2					151	157		10.1007/s12028-009-9228-6			7	Critical Care Medicine; Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	495OG	WOS:000269902300004	19479209				2022-02-06	
J	Saljo, A; Svensson, B; Mayorga, M; Hamberger, A; Bolouri, H				Saljo, Annette; Svensson, Berndt; Mayorga, Maria; Hamberger, Anders; Bolouri, Hayde			Low-Level Blasts Raise Intracranial Pressure and Impair Cognitive Function in Rats	JOURNAL OF NEUROTRAUMA			English	Article						blast overpressure; brain edema; cognitive function; impulse noise; intracranial pressure; mild traumatic brain injury; Morris water maze	TRAUMATIC BRAIN-INJURY; CONTROLLED CORTICAL IMPACT; LASTING IMPULSE NOISE; CLOSED-HEAD INJURY; CELL-DEATH; EXPOSURE; DEFICITS; EDEMA; OVERPRESSURE; INCREASE	Brain injury after high-level blast has been established both clinically and experimentally. Less is known about the effects on the brain of exposure to low to moderate blast levels, such as those encountered by military personnel during the firing of weapons. This study investigates if exposure to occupational levels of low-level blasts affect intracranial pressure and cognitive performance. Rats were exposed to blast overpressure in a shock tube at peak levels of 10, 30, and 60 kPa. Intracranial pressure (ICP) was measured after 0.5, 3, 6, and 10 h and 1, 2, 3, 5, and 7 days. We found two features of the response: a dose-dependent rise in ICP in rats exposed to blast, and an increasing time delay in elevation with decreasing intensity of exposure. The ICP increased in a dose-dependent fashion, up to 15.7mm Hg after exposure to a 60-kPa blast from a control level of 6 mm Hg. While the initial elevation took place within 30 min after exposure to 60 kPa, it did not appear until after 2 and 6 h for 30 and 10 kPa, respectively. In all cases, the ICP returned to control levels after 7 days. The cognitive function of the blast-exposed rats was assessed with the Morris water maze. After exposure to 10 or 30 kPa and re-testing 2 days later, the latency was increased by over 100%. The results show that exposure of rats to blast levels as low as 10 kPa affects both ICP and cognitive function. Though species differences do not allow direct extrapolation to humans, these findings do pose the question as to whether the thresholds for brain injury might be lower than those of other organs used to set training standards for blast exposure.	[Saljo, Annette; Svensson, Berndt; Mayorga, Maria; Hamberger, Anders; Bolouri, Hayde] Univ Gothenburg, Inst Biomed, Dept Med Chem & Cell Biol, Sahlgren Acad, SE-40530 Gothenburg, Sweden		Saljo, A (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Chem & Cell Biol, Sahlgren Acad, Box 440, SE-40530 Gothenburg, Sweden.	annette.saljo@gu.se			Swedish Armed Forces/FMV	The authors want to express their gratitude to Svante Hojer, Samba Sensors AB, for sharing with us his knowledge on pressure sensors and pressure recording. The study was supported by grants from the Swedish Armed Forces/FMV.	Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; *BOP HHA, 2004, BLAST OV ASS SOFTW; BOWEN IG, 1965, BIOL SCALING PRIMARY; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; CERNAK I, 1997, INT REV ARMED FORCES, V70, P114; CLEMEDSON C.-J., 1957, ACTA PATHOL ET MICROBIOL SCAND, V40, P89; CLEMEDSON CJ, 1956, PHYSIOL REV, V36, P336, DOI 10.1152/physrev.1956.36.3.336; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; Elsayed NM, 2007, TOXICOL SCI, V95, P289, DOI 10.1093/toxsci/kfl138; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Fritz HG, 2005, J NEUROTRAUM, V22, P807, DOI 10.1089/neu.2005.22.807; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; Hoane MR, 2006, BRAIN RES, V1125, P185, DOI 10.1016/j.brainres.2006.10.019; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Isaksson J, 2001, ACTA NEUROPATHOL, V102, P246; Jamali S, 1998, BRAIN INJURY, V12, P525, DOI 10.1080/026990598122485; Jantzen JPAH, 2007, BEST PRACT RES-CLIN, V21, P517, DOI 10.1016/j.bpa.2007.09.001; *JAYC, 1996, J29972401158 JAYC; Jennische E, 2008, BRAIN RES, V1227, P189, DOI 10.1016/j.brainres.2008.05.083; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; Leung Lai Yee, 2008, Molecular & Cellular Biomechanics, V5, P155; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Marmarou A, 2003, ACT NEUR S, V86, P7; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MAYORGA MA, 2008, SPANISH J NEUROPSYCH, V10, P109; MAYORGA MA, 2007, 4 ANN POL BLAST M TA; *MIL, 1997, MILSTD1474D; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Mott FW, 1917, BRIT MED J, V1917, P612; NEWMAN LA, 2003, ASHA LEADER      OCT, P10; Orban JC, 2007, ANN FR ANESTH, V26, P440, DOI 10.1016/j.annfar.2007.03.001; PRUSACZYK WK, 2008, ANN BATTL HEALTHC C; RICHMOND DR, 1961, AEROSPACE MED, V32, P997; RICHMOND DR, 1991, SCAND AUDIOL, P49; Rooker S, 2003, J NEUROSCI METH, V131, P75, DOI 10.1016/S0165-0270(03)00233-4; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; Saljo A, 2002, J NEUROTRAUM, V19, P379, DOI 10.1089/089771502753594945; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmidt RH, 2000, J NEUROTRAUM, V17, P1129, DOI 10.1089/neu.2000.17.1129; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; TANIELIAN T, 2008, MG720CCF RAND; Unterberg AW, 1997, ACT NEUR S, V70, P106; Vink R, 2003, ACT NEUR S, V86, P257; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WHITE CS, 1971, AGARD C P, V88; Zitnay GA, 2008, J NEUROTRAUM, V25, P1135, DOI 10.1089/neu.2008.0599; Zohar O, 2003, NEUROSCIENCE, V118, P949, DOI 10.1016/S0306-4522(03)00048-4	58	69	69	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2009	26	8					1345	1352		10.1089/neu.2008.0856			8	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	479AF	WOS:000268629900017	19317610				2022-02-06	
J	Harting, MT; Sloan, LE; Jimenez, F; Baumgartner, J; Cox, CS				Harting, Matthew T.; Sloan, LeeAnn E.; Jimenez, Fernando; Baumgartner, James; Cox, Charles S., Jr.			Subacute Neural Stem Cell Therapy for Traumatic Brain Injury	JOURNAL OF SURGICAL RESEARCH			English	Article						traumatic brain injury; neural stem cells; cellular therapy	COGNITIVE FUNCTION; TRANSPLANTATION; SURVIVAL; RATS; DIFFERENTIATION; MIGRATION; CYTOKINES; RECOVERY; MEMORY; MOTOR	Introduction. Traumatic brain injury (TBI) frequently results in devastating and prolonged morbidity. Cellular therapy is a burgeoning field of experimental treatment that has shown promise in the management of many diseases, including TBI. Previous work suggests that certain stem and progenitor cell populations migrate to sites of inflammation and improve functional outcome in rodents after neural injury. Unfortunately, recent study has revealed potential limitations of acute and intravenous stem cell therapy. We studied subacute, direct intracerebral neural stem and progenitor cell (NSC) therapy for TBI. Materials and methods. The NSCs were characterized by flow cytometry and placed (400,000 cells in 50 mu L 1 x phosphate-buffered saline) into and around the direct injury area, using stereotactic guidance, of female Sprague Dawley rats 1 wk after undergoing a controlled cortical impact injury. Immunohistochemistry was used to identify cells located in the brain at 48 h and 2 wk after administration. Motor function was assessed using the neurological severity score, foot fault, rotarod, and beam balance. Cognitive function was assessed using the Morris water maze learning paradigm. Repeated measures analysis of variance with post-hoc analysis were used to determine significance at P < 0.05. Results. Immunohistochemistry analysis revealed that 1.4-1.9% of infused cells remained in the neural tissue at 48 h and 2 wk post placement. Nearly all cells were located along injection tracks at 48 h. At 2 wk some cell dispersion was apparent. Rotarod motor testing revealed significant increases in maximal speed among NSC-treated rats compared with saline controls at d 4 (36.4 versus 27.1 rpm, P < 0.05) and 5 (35.8 versus 28.9 rpm, P < 0.05). All other motor and cognitive evaluations were not significantly different compared to controls. Conclusions. Placement of NSCs led to the cells incorporating and remaining in the tissues 2 wk after placement. Motor function tests revealed improvements in the ability to run on a rotating rod; however, other motor and cognitive functions were not significantly improved by NSC therapy. Further examination of a dose response and optimization of placement strategy may improve long-term cell survival and maximize functional recovery. (C) 2009 Elsevier Inc. All rights reserved.	[Harting, Matthew T.; Sloan, LeeAnn E.; Jimenez, Fernando; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Baumgartner, James; Cox, Charles S., Jr.] Childrens Mem Hermann Hosp, Houston, TX USA		Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Harting, Matthew/0000-0002-8929-8311	Children's Memorial Hermann Hospital Foundation; Texas Higher Education Coordinating Board;  [T32 GM008792-06];  [MO1 RR 02558];  [R21 HD 04 2659-01Al]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024148, M01RR002558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by Grants T32 GM008792-06 (M.T.H.), MO1 RR 02558, R21 HD 04 2659-01Al, and the Children's Memorial Hermann Hospital Foundation and Texas Higher Education Coordinating Board.	Allan SM, 2000, ANN NY ACAD SCI, V917, P84; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; HARTING MT, 2008, J SURG RES, V144, P425; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; KRAUS JF, 1987, PEDIATRICS, V79, P501; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Molcanyi M, 2007, J NEUROTRAUM, V24, P625, DOI 10.1089/neu.2006.0180; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Okano H, 2002, J NEUROSCI RES, V69, P698, DOI 10.1002/jnr.10343; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Tate MC, 2002, CELL TRANSPLANT, V11, P283; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Zhang C, 2005, J NEUROTRAUM, V22, P1456, DOI 10.1089/neu.2005.22.1456	26	69	77	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	MAY 15	2009	153	2					188	194		10.1016/j.jss.2008.03.037			7	Surgery	Science Citation Index Expanded (SCI-EXPANDED)	Surgery	438VX	WOS:000265585100002	18694578	Green Accepted			2022-02-06	
J	Davis, GA; Iverson, GL; Guskiewicz, KM; Ptito, A; Johnston, KM				Davis, G. A.; Iverson, G. L.; Guskiewicz, K. M.; Ptito, A.; Johnston, K. M.			Contributions of neuroimaging, balance testing, electrophysiology and blood markers to the assessment of sport-related concussion	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	3rd International Conference on Concussion in Sport	NOV, 2008	Zurich, SWITZERLAND				TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; NEURON-SPECIFIC ENOLASE; ERROR SCORING SYSTEM; SERUM-LEVELS; BIOCHEMICAL MARKERS; POSTURAL STABILITY; NEUROCOGNITIVE PERFORMANCE; STANDARDIZED ASSESSMENT; AGREEMENT STATEMENT	Objective: To review the diagnostic tests and investigations used in the management of sports concussion, in the adult and paediatric populations, to (a) monitor the severity of symptoms and deficits, (b) track recovery and (c) advance knowledge relating to the natural history and neurobiology of the injury. Design: Qualitative literature review of the neuroimaging, balance testing, electrophysiology, blood marker and concussion literature. Intervention: PubMed and Medline databases were reviewed for investigations used in the management of adult and paediatric concussion, including structural imaging (computerised tomography, magnetic resonance imaging, diffusion tensor imaging), functional imaging (single photon emission computerised tomography, positron emission tomography, functional magnetic resonance imaging), spectroscopy (magnetic resonance spectroscopy, near infrared spectroscopy), balance testing (Balance Error Scoring System, Sensory Organization Test, gait testing, virtual reality), electrophysiological tests (electroencephalography, evoked potentials, event related potentials, magnetoencephalography, heart rate variability), genetics (apolipoprotein E4, channelopathies) and blood markers (S100, neuron-specific enolase, cleaved Tau protein, glutamate). Results: For the adult and paediatric populations, each test has been classified as being: (1) clinically useful, (2) a research tool only or (3) not useful in sports-related concussion. Conclusions: The current status of the diagnostic tests and investigations is analysed, and potential directions for future research are provided. Currently, all tests and investigations, with the exception of clinical balance testing, remain experimental. There is accumulating research, however, that shows promise for the future clinical application of functional magnetic resonance imaging in sport concussion assessment and management.	[Davis, G. A.] Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, G. A.] Austin Hosp, Melbourne, Vic, Australia; [Iverson, G. L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Iverson, G. L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada; [Guskiewicz, K. M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Ptito, A.] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Ptito, A.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada; [Johnston, K. M.] Univ Toronto, Dept Neurosurg, Toronto, ON, Canada; [Johnston, K. M.] Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada		Davis, GA (corresponding author), Cabrini Med Ctr, Suite 53 Neurosurg, Malvern, Vic 3144, Australia.	gadavis@netspace.net.au		Iverson, Grant/0000-0001-7348-9570; Guskiewicz, Kevin/0000-0002-8682-2130			Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Altrocchi PH, 1996, NEUROLOGY, V46, P278; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bergman DA, 1999, PEDIATRICS, V104, P1407; Bernard G, 2008, PEDIATR NEUROL, V38, P73, DOI 10.1016/j.pediatrneurol.2007.09.007; Biberthaler P, 2000, ACT NEUR S, V76, P177; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Biswas AK, 2000, CRIT CARE MED, V28, P3907, DOI 10.1097/00003246-200012000-00030; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; *CDCP, 2007, MORTALITY MORBIDITY, V0056; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cote C, 2005, MED SCI SPORT EXER, V37, pS469, DOI 10.1097/00005768-200505001-02448; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; DOEZEMA D, 1991, ANN EMERG MED, V20, P1281, DOI 10.1016/S0196-0644(05)81065-0; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2001, CURR OPIN NEUROL, V14, P753, DOI 10.1097/00019052-200112000-00012; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287, DOI 10.1152/ajpregu.1998.275.4.R1287; Goryunova A V, 2007, Neurosci Behav Physiol, V37, P761, DOI 10.1007/s11055-007-0079-3; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2006, BRIT J SPORT MED, V40, P6, DOI 10.1136/bjsm.2005.021683; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Herrmann M, 2001, J NEUROL NEUROSUR PS, V70, P95, DOI 10.1136/jnnp.70.1.95; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; KRAMER AF, 1988, BIOL PSYCHOL, V26, P231, DOI 10.1016/0301-0511(88)90022-1; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; KUTAS M, 1977, SCIENCE, V197, P792, DOI 10.1126/science.887923; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2007, NEUROIMAGE, V35, P166, DOI 10.1016/j.neuroimage.2006.10.040; Nioka Shoko, 2006, Dyn Med, V5, P5, DOI 10.1186/1476-5918-5-5; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Patel DR, 2005, SPORTS MED, V35, P671, DOI 10.2165/00007256-200535080-00002; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; POLICH J, 1986, ELECTROEN CLIN NEURO, V63, P251, DOI 10.1016/0013-4694(86)90093-3; Ptito A, 2007, NEUROSCIENTIST, V13, P506, DOI 10.1177/1073858407300598; Rapenne T, 2001, J NEUROSURG ANESTH, V13, P260, DOI 10.1097/00008506-200107000-00016; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Ricker JH, 2000, J HEAD TRAUMA REHAB, V15, P859, DOI 10.1097/00001199-200004000-00007; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; Susco TM, 2004, J ATHL TRAINING, V39, P241; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Thompson J, 2005, NEUROSCI LETT, V377, P158, DOI 10.1016/j.neulet.2004.11.090; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Turedi S, 2008, J EMERG MED, V34, P253, DOI 10.1016/j.jemermed.2007.05.055; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; WICKENS CD, 1983, HUM FACTORS, V25, P227, DOI 10.1177/001872088302500209; Wijnen VJM, 2006, CLIN NEUROPHYSIOL, V117, P1794, DOI 10.1016/j.clinph.2006.03.006; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilkins JC, 2004, J ATHL TRAINING, V39, P156; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; ZEMAITYTE D, 1984, PSYCHOPHYSIOLOGY, V21, P279, DOI 10.1111/j.1469-8986.1984.tb02935.x	117	69	70	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAY	2009	43			1			I36	I45		10.1136/bjsm.2009.058123			10	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	Sport Sciences	450YO	WOS:000266438100007	19433424				2022-02-06	
J	McIntosh, AS; McCrory, P; Finch, CF; Best, JP; Chalmers, DJ; Wolfe, R				McIntosh, Andrew S.; McCrory, Paul; Finch, Caroline F.; Best, John P.; Chalmers, David J.; Wolfe, Rory			Does Padded Headgear Prevent Head Injury in Rugby Union Football?	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						FOOTBALL; HEAD INJURY; CONCUSSION; HELMETS; SPORTS INJURY PREVENTION; RANDOMIZED CONTROLLED TRIAL	PROTECTIVE EQUIPMENT; PROFESSIONAL FOOTBALL; PERFORMANCE; EPIDEMIOLOGY; PLAYERS; CONCUSSION; IMPACTS; SPORT	MCINTOSH, A. S., P. MCCRORY, C. F. FINCH, J. P. BEST, D. J. CHALMERS. and R. WOLFE. Does Padded Headgear Prevent Head Injury in Rugby Union Football? Med. Sci. Sports Exerc. Vol. 41, No. 2, pp. 306-313, 2009. Background: Concussion is a serious problem in many contact sports, including rugby union football. The study's primary aim was to measure the efficacy of padded headgear in reducing the rates of head injury or Concussion. Methods: A cluster randomized controlled trial with three arms was conducted with rugby union football teams as the unit of randomization. Teams consisted of males participating in under 13-, 15- 1 8- and 20-yr age group competitions. The interventions were "standard" and "modified" padded headgear. Headgear wearing and injury were measured for each study team at each game over two seasons. Results: Eighty-two teams participated in year I and 87 in year 2. A total of 1493 participants (10,040 player hours) were in the control group. 1128 participants (8170 player hours) were assigned to the standard headgear group, and 1474 participants (10,650 player hours) were assigned to the modified headgear group. The compliance rates were low in all groups, but 46% of participants wore standard headgear. An intention-to-treat analysis showed no differences in the rates of head injury or concussion between controls and headgear arms. Incidence rate ratios for standard headgear wearers referenced to controls were 0.95 and 1.02 for game and missed game injuries. Analyses of injury rates based on observed wearing patterns also showed no significant differences. Incidence rate ratios for standard headgear wearers referenced to nonweaters were 1.11 and 1.10 for game and missed game injuries. Conclusions: Padded headgear does not reduce the rate of head injury or concussion. The low compliance rates are a limitation. Although individuals may choose to wear padded headgear, the routine or mandatory use of protective headgear cannot be recommended.	[McIntosh, Andrew S.] Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia; [Finch, Caroline F.] Univ Ballarat, Ballarat, Vic 3353, Australia; [Best, John P.] Orthosports Grp, Sydney, NSW, Australia; [Chalmers, David J.] Univ Otago, Dept Prevent & Social Med, Injury Prevent Res Unit, Dunedin, New Zealand; [Wolfe, Rory] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia		McIntosh, AS (corresponding author), Univ New S Wales, Sch Risk & Safety Sci, Sydney, NSW 2052, Australia.	a.mcintosh@unsw.edu.au	McCrory, Paul/Q-8688-2019	Wolfe, Rory/0000-0002-2126-1045; McCrory, Paul/0000-0003-4850-0568			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Braham RA, 2004, BRIT J SPORT MED, V38, DOI 10.1136/bjsm.2002.004002; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; CANTU RC, 1992, CLIN J SPORT MED, V2, P180; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch CF, 1997, SPORTS MED, V24, P157, DOI 10.2165/00007256-199724030-00002; GARRAWAY M, 1995, LANCET, V345, P1485; Garraway WM, 2000, BRIT J SPORT MED, V34, P348, DOI 10.1136/bjsm.34.5.348; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagglund M, 2005, BRIT J SPORT MED, V39, P340, DOI 10.1136/bjsm.2005.018267; Jones SJ, 2004, BRIT J SPORT MED, V38, P159, DOI 10.1136/bjsm.2002.002584; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Liu B., 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD004333.PUB2, 10.1002/14651858.CD004333.pub2]; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Marshall SW, 2002, INT J EPIDEMIOL, V31, P587, DOI 10.1093/ije/31.3.587; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2005, BRIT J SPORT MED, V39, P314, DOI 10.1136/bjsm.2005.018200; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; MURRAY DM, 1998, DESIGN ANAL GROUP RA, P99; SEWARD H, 1993, MED J AUSTRALIA, V159, P298, DOI 10.5694/j.1326-5377.1993.tb137863.x; Sparks J P, 1981, Br J Sports Med, V15, P30; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005; Thompson DC., 1999, COCHRANE DB SYST REV, V308, DOI 10.1002/14651858.CD001855; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2	30	69	69	0	43	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2009	41	2					306	313		10.1249/MSS.0b013e3181864bee			8	Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Sport Sciences	396OO	WOS:000262601200007	19127196				2022-02-06	
J	Green, P; Flaro, L; Courtney, J				Green, P.; Flaro, L.; Courtney, J.			Examining false positives on the Word Memory Test in adults with mild traumatic brain injury	BRAIN INJURY			English	Article							SYMPTOM VALIDITY TESTS; CLAIMANTS; CHILDREN; SAMPLE	Primary objective: Many adults with mild traumatic brain injury (MTBI) fail effort tests, indicating poor effort and invalid test results. However, two studies have suggested a high rate of false positives on the Word Memory Test (WMT) in adults with MTBI. This study examines the question of false positives in adults with MTBI who failed the effort subtests of the WMT. Research design: A modified and shortened version of the WMT, the Medical Symptom Validity Test (MSVT) was given to adults with MTBI, some of whom failed the WMT. It was also given to samples of schoolchildren in grades two and above, to several hundred children with developmental disabilities and to healthy adults. Outcomes and results: Failures on the MSVT were far more frequent in adults with MTBI than in second grade children or in children with developmental disabilities. Adults with MTBI who failed the WMT scored much lower on the MSVT effort subtests than children with a mean FSIQ of 63 and much lower than children with impaired memory. Conclusions: Comparison with developmentally disabled children on the MSVT suggests that the adults with MTBI who failed the WMT were not making an effort to do well on either the WMT or the MSVT. Their results were invalid. False positives on the WMT in adults with mild TBI are very rare.	[Courtney, J.] Childrens Hosp New Orleans, Dept Psychol, New Orleans, LA USA		Green, P (corresponding author), Suite 210,17010 103 Ave, Edmonton, AB T5S 1K7, Canada.	paulgreen@shaw.ca					Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bowden SC, 2006, CLIN NEUROPSYCHOL, V20, P858, DOI 10.1080/13854040500246935; BROCKHAUS R, 2008, ANN C GES NEUR TUEB; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Flaro L, 2007, BRAIN INJURY, V21, P373, DOI 10.1080/02699050701311133; Gill David, 2007, Med Leg J, V75, P64; Green P, 2001, BRAIN INJURY, V15, P1045, DOI 10.1080/02699050110088254; Green P., 2003, MANUAL WORD MEMORY T; Green P., 2004, MANUAL MED SYMPTOM V; Green P.J.E., 2008, MANUAL NONVERBAL MED; GREVE K, 2007, CLIN NEUROPSYCHOL, V22, P1; Howe L. S, 2008, CLIN NEUROPSYCHOL, V28, P1; IVERSON G, 2005, CURRENT OPINION PSYC, P18301; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Montijo J, 2008, ARCH CLIN NEUROPSYCH, V23, P633; Richman J, 2006, J OCCUP ENVIRON MED, V48, P303, DOI 10.1097/01.jom.0000183482.41957.c3; ROHLING M, CLIN NEUROP IN PRESS; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Talley J., 1993, CHILDRENS AUDTORY VE CHILDRENS AUDITORY V; Tombaugh T. N., 1997, TEST MEMORY MALINGER; [No title captured]	22	69	69	1	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	9					741	750	PII 913456043	10.1080/02699050903133962			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	475UR	WOS:000268387600005	19636999				2022-02-06	
J	Zeitzer, JM; Friedman, L; O'Hara, R				Zeitzer, Jamie M.; Friedman, Leah; O'Hara, Ruth			Insomnia in the context of traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						cognitive behavioral therapy; comorbidity; insomnia; pharmacotherapy; rehabilitation; sleep; sleep disorder; sleep disruption; traumatic brain injury; veterans	COGNITIVE-BEHAVIOR THERAPY; SLEEP DISORDERS; ACTIGRAPHIC MEASUREMENT; STIMULUS-CONTROL; HEAD-INJURY; PLACEBO; PAIN; METHYLPHENIDATE; DISTURBANCES; NEUROBIOLOGY	Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality in the United States. One of the most common comorbidities of TBI is the disruption of normal sleep. While often viewed as a nuisance symptom, sleep disruption can delay TBI recovery and negatively affect many of the psychological (e.g., anxiety, depression) and neuromuscular (e.g., pain) sequelae of TBI, decreasing quality of life. Treatment of sleep disruption in the context of TBI is complicated by issues of an altered neuronal milieu, polypharmacy, and the complex relationship between the various comorbidities often found in patients with TBI. Given the growing number of veterans returning from combat with TBI and the elevated risk of comorbid disrupted sleep, both caused by and independent of TBI, a comprehensive review of sleep disruption and its treatment is of great relevance to the Department of Veterans Affairs.	Dept Vet Affairs Palo Alto Hlth Care Syst, Psychiat Serv, Palo Alto, CA USA; Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA		Zeitzer, JM (corresponding author), VA Palo Alto Hlth Care Syst, 3801 Miranda Ave 151Y, Palo Alto, CA 94304 USA.	jzeitzer@stanford.edu	Zeitzer, Jamie M/A-1168-2007; Zeitzer, Jamie/AAO-2103-2020	Zeitzer, Jamie M/0000-0001-6174-5282; Zeitzer, Jamie/0000-0001-6174-5282	VA Mental Illness Research, Education, and Clinical Center	This material was based on work supported by the VA Mental Illness Research, Education, and Clinical Center.	ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; [Anonymous], 2005, SLEEP, V28, P1049; [Anonymous], 2005, NIH Consens State Sci Statements, V22, P1; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Broomfield NM, 2003, BEHAV COGN PSYCHOTH, V31, P313, DOI 10.1017/S1352465803003060; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; Currie SR, 2004, ADDICTION, V99, P1121, DOI 10.1111/j.1360-0443.2004.00835.x; Currie SR, 2000, J CONSULT CLIN PSYCH, V68, P407, DOI 10.1037//0022-006X.68.3.407; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Edinger JD, 2005, CLIN PSYCHOL REV, V25, P539, DOI 10.1016/J.CPR.2005.04.003; Edinger JD, 2001, JAMA-J AM MED ASSOC, V285, P1856, DOI 10.1001/jama.285.14.1856; Espana RA, 2004, SLEEP, V27, P811; ESPIE CA, 1989, BEHAV RES THER, V27, P79, DOI 10.1016/0005-7967(89)90123-X; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Fichten CS, 2001, COGNITIVE THER RES, V25, P665, DOI 10.1023/A:1012963121729; Francisco GE, 1996, AM J PHYS MED REHAB, V75, P63, DOI 10.1097/00002060-199601000-00016; FRIEDMAN L, 1991, J GERONTOL, V46, pP1, DOI 10.1093/geronj/46.1.P1; Friedman L, 2000, J GERIATR PSYCH NEUR, V13, P17, DOI 10.1177/089198870001300103; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; Hauri P. J., 1991, CASE STUDIES INSOMNI, P65, DOI [10.1007/978-1-4757-9586-8_5, DOI 10.1007/978-1-4757-9586-8_5]; Hoch CC, 2001, J GERONTOL B-PSYCHOL, V56, pP52, DOI 10.1093/geronb/56.1.P52; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kemp S, 2004, BRAIN INJURY, V18, P911, DOI 10.1080/02699050410001671892; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Krystal AD, 2008, SLEEP, V31, P79, DOI 10.1093/sleep/31.1.79; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Lew HL, 2008, J REHABIL RES DEV, V45, pXI, DOI 10.1682/JRRD.2008.05.0064; Lichstein KL, 2001, J CONSULT CLIN PSYCH, V69, P227, DOI 10.1037/0022-006X.69.2.227; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Manber R, 2005, CLIN PSYCHOL REV, V25, P535, DOI 10.1016/J.CPR.2005.04.002; Mimeault V, 1999, J CONSULT CLIN PSYCH, V67, P511, DOI 10.1037/0022-006X.67.4.511; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; MORIN CM, 1987, J CONSULT CLIN PSYCH, V55, P260, DOI 10.1037/0022-006X.55.2.260; MORIN CM, 1988, J CONSULT CLIN PSYCH, V56, P748, DOI 10.1037/0022-006X.56.5.748; Morin CM, 2004, AM J PSYCHIAT, V161, P332, DOI 10.1176/appi.ajp.161.2.332; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Mustafa Masroor, 2005, Sleep Breath, V9, P57, DOI 10.1007/s11325-005-0016-z; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Oluellet MC, 2007, ARCH PHYS MED REHAB, V88, P1581, DOI 10.1016/j.apmr.2007.09.006; Onen SH, 2001, J SLEEP RES, V10, P35, DOI 10.1046/j.1365-2869.2001.00240.x; Perlis ML, 2004, SLEEP, V27, P715, DOI 10.1093/sleep/27.4.715; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Riedel BW, 1998, BEHAV MODIF, V22, P3, DOI 10.1177/01454455980221001; Riemann D, 2007, SLEEP MED, V8, pS15, DOI 10.1016/S1389-9457(08)70004-2; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; Roth T, 2004, SLEEP MED, V5, pS23, DOI 10.1016/S1389-9457(04)90004-4; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Shan RSLP, 2004, AM J PHYS MED REHAB, V83, P421, DOI 10.1097/00002060-200406000-00003; Sharafkhaneh A, 2004, SLEEP MED, V5, P345, DOI 10.1016/j.sleep.2004.01.019; Stepanski EJ, 2003, SLEEP MED REV, V7, P215, DOI 10.1053/smrv.2001.0246; Trudel TM, 1998, REHABIL PSYCHOL, V43, P267, DOI 10.1037/0090-5550.43.4.267; Wicklow A, 2000, BEHAV RES THER, V38, P679, DOI 10.1016/S0005-7967(99)00136-9; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Zeitzer JM, 2006, TRENDS PHARMACOL SCI, V27, P368, DOI 10.1016/j.tips.2006.05.006	61	69	69	0	7	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2009	46	6					827	835		10.1682/JRRD.2008.08.0099			9	Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Rehabilitation	531BQ	WOS:000272638100014	20104406	Bronze			2022-02-06	
J	Taylor, HG; Swartwout, MD; Yeates, KO; Walz, NC; Stancin, T; Wade, SL				Taylor, H. Gerry; Swartwout, Maegan D.; Yeates, Keith Owen; Walz, Nicolay Chertkoff; Stancin, Terry; Wade, Shari L.			Traumatic brain injury in young children: Postacute effects on cognitive and school readiness skills	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						child; preschool; brain injuries; neurobehavior manifestations; outcome. moderator variables	CLOSED-HEAD-INJURY; GLASGOW COMA SCALE; EARLY-CHILDHOOD; EXECUTIVE FUNCTIONS; PRESCHOOL-CHILDREN; SEVERITY SCORE; SHORT-TERM; RECOVERY; MILD; OUTCOMES	Previous studies have documented weaknesses in cognitive ability and early academic readiness in young children with traumatic brain injury (TBI). However, few of these studies have rigorously controlled for demographic characteristics, examined the effects of TBI severity on a wide range of skills, or explored moderating influences of environmental factors on outcomes. To meet these objectives. each of three groups of children with TBI (20 with severe, 64 with moderate, and 15 with mild) were compared with a group of 117 children with orthopedic injuries (01 group). The children were hospitalized for their injuries between 3 and 6 years of age and were assessed an average of 11/2 months post injury. Analysis revealed generalized weaknesses in cognitive and school readiness skills in the severe TBI group and less pervasive effects of moderate TBI. Indices of TBI severity predicted outcomes within the TBI sample and environmental factors moderated the effects of TBI on some measures. The findings document adverse effects of TBI in early childhood on postacute cognitive and school readiness skills and indicate that these effects are related to both injury severity and the family environment.	[Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediatr Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Swartwout, Maegan D.] Univ Houston, Dept Psychol, Houston, TX USA; [Yeates, Keith Owen] Ohio State Univ, Dept Pediat, Div Psychol, Columbus, OH 43210 USA; [Yeates, Keith Owen] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA; [Walz, Nicolay Chertkoff] Cincinnati Childrens Hosp, Ctr Med, Dept Pediat, Div Behav Med & Clin Psychol, Cincinnati, OH USA; [Walz, Nicolay Chertkoff] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Dept Rehabil, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA		Taylor, HG (corresponding author), Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Pediatr Psychol, DO Walker Bldg,Suite 3150,10524 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@case.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Sady, Maegan/0000-0002-1438-4477; Yeates, Keith/0000-0001-7680-2892	NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD42729]; USPHS NIHUnited States Department of Health & Human ServicesUnited States Public Health ServiceNational Institutes of Health (NIH) - USA [M01 RR 08084]; State of Ohio Emergency Medical Services; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	Supported by grant R01 HD42729 to Dr. Wade from NICHD, in part by USPHS NIH Grant no. M01 RR 08084, and by Trauma Research grants from the State of Ohio Emergency Medical Services. The authors wish to acknowledge the contributions of Christine Abraham, Andrea Beebe, Lori Bernard, Anne Birnbaum, Beth Bishop, Tammy Matecun, Karen Oberjohn, Elizabeth Roth, and Elizabeth Shaver in data collection and coding. We also thank Nori Minich for her assistance in data analysis. The Cincinnati Children's Medical Center Trauma Registry, Rainbow Pediatric Trauma Center, Rainbow Babies & Children's Hospital, Columbus Children's Hospital Trauma Program, and MetroHealth Center Department of Pediatrics and Trauma Registry provided assistance with recruitment.	Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Anderson VA, 2000, BRAIN INJURY, V14, P679; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; BIJUR PE, 1995, TRAUMATIC HEAD INJUR, P147; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; Bracken B.A., 1998, BRACKEN BASIC CONCEP; Bronson MB, 2000, SELF-REGULATION IN EARLY CHILDHOOD, P1; Carrow-Woolfolk E, 2000, COMPREHENSIVE ASSESS; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Dennis M, 2001, J HEAD TRAUMA REHAB, V16, P456, DOI 10.1097/00001199-200110000-00005; Donders J, 2005, J INT NEUROPSYCH SOC, V11, P386, DOI 10.1017/S1355617705050435; Donders J, 2001, CHILD NEUROPSYCHOL, V7, P99, DOI 10.1076/chin.7.2.99.3126; Elliott C. D., 1990, DIFFERENTIAL ABILITY; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Espy KA, 1999, BRAIN COGNITION, V41, P178, DOI 10.1006/brcg.1999.1117; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V26, P487, DOI 10.1207/s15326942dn2601_7; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER EJ, 1995, RECEPTOR CHANNEL, V3, P21; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; GOTSCHALL CS, 1993, PEDIAT TRAUMA PREVEN, P16; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Jaccard J, 2002, J CLIN CHILD ADOLESC, V31, P130, DOI 10.1207/153744202753441747; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Kemp, 1998, NEPSY DEV NEUROPSYCH; Kirkwood M. W., CLIN NEUROP IN PRESS; Kochanska G, 2000, DEV PSYCHOL, V36, P220, DOI 10.1037//0012-1649.36.2.220; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; MCDERMOTT PA, 1995, J SCHOOL PSYCHOL, V33, P75, DOI 10.1016/0022-4405(94)00025-4; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Moos RH, 1994, LIFE STRESSORS SOCIA; Morse S, 1999, Pediatr Rehabil, V3, P139; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SCHEIBEL RS, 1997, DEV PREFRONTAL CORTE, P241; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Tabachnick B. G., 1989, USING MULTIVARIATE S; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; TEASDALE G, 1974, LANCET, V2, P81; Thompson T., 2003, J LEARNING DISABILIT, V7, P345, DOI [10.1177/1469004703074003, DOI 10.1177/1469004703074003]; Verger K, 2000, BRAIN INJURY, V14, P495; WETHERINGTON CE, 2006, EXCEPTIONALITY, V12, P155; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Woodcock R. W., 2001, WOODCOCKJOHNSON 3 TE; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; [No title captured]	82	69	69	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2008	14	5					734	745		10.1017/S1355617708081150			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	354DZ	WOS:000259620400004	18764969	Green Accepted, Bronze			2022-02-06	
J	Yune, TY; Park, HG; Lee, JY; Oh, TH				Yune, Tae Y.; Park, Hong G.; Lee, Jee Y.; Oh, Tae H.			Estrogen-Induced Bcl-2 Expression after Spinal Cord Injury Is Mediated through Phosphoinositide-3-Kinase/Akt-Dependent CREB Activation	JOURNAL OF NEUROTRAUMA			English	Article						Akt; Bcl-2; CREB; estradiol; spinal cord injury	SIGNAL-REGULATED KINASE; ELEMENT-BINDING PROTEIN; AMP RESPONSE ELEMENT; IMPROVES FUNCTIONAL RECOVERY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; DEATH-PROMOTING EVENTS; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-I; GLOBAL-ISCHEMIA	Our previous study showed that, after spinal cord injury (SCI) in rats, estrogen provides neuroprotection through expression of Bcl-2. However, molecular targets that mediate estrogen-induced expression of Bcl-2 are not fully understood. Here, we investigated whether, after SCI, the phosphatidylinositol-3 kinase (PI3K)/Akt and extracellular signal-regulated kinase (ERK) pathways are involved in estrogen-induced expression of Bcl-2. Both Akt and ERK were activated and peaked at 8 h after SCI. Treatment with estrogen significantly increased the level of phosphorylated Akt (pAkt) and ERK (pERK) after injury. Cyclic-AMP response element binding protein (CREB) transcription factor was also activated and peaked at 8 h after SCI. Treatment with estrogen significantly increased the level of phosphorylated CREB (pCREB) after injury. Administration of LY294002, an inhibitor of PI3K/Akt, decreased the level of pCREB after SCI, whereas PD98059, an inhibitor of ERK, showed no significant effect. Also, treatment with LY294002 significantly inhibited expression of Bcl-2, but PD98059 showed no significant effect. Furthermore, treatment with estrogen inhibited apoptotic cell death, whereas treatment with LY294002 or PD98059 increased apoptotic cell death after SCI. Together, these data indicate that estrogen's neuroprotection is mediated in part by induction of Bcl-2 through PI3K/Akt-dependent CREB activation.	[Yune, Tae Y.; Park, Hong G.; Lee, Jee Y.; Oh, Tae H.] Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Seoul 130701, South Korea; [Lee, Jee Y.] Korea Inst Sci & Technol, Bioanal & Biotransformat Res Ctr, Seoul, South Korea		Yune, TY (corresponding author), Kyung Hee Univ, Age Related & Brain Dis Res Ctr, Med Bldg 10th Floor,Hoegi Dong 1, Seoul 130701, South Korea.	tyune@khu.ac.kr			Korea Science and Engineering Foundation (KOSEF)Korea Science and Engineering Foundation; Korea Government (MOST)Ministry of Science and Technology (MOST) KoreaKorean Government [R01-2007-000-20617-0, M1041200011-07N1200-01110]; Seoul R BD ProgramSeoul RBD program [10524]; BK21 ProgramMinistry of Education & Human Resources Development (MOEHRD), Republic of Korea	We wish to thank Dr. George Markelonis at the University of Maryland School of Medicine for his editorial assistance. This study was supported in part by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea Government (MOST) (no. R01-2007-000-20617-0, M1041200011-07N1200-01110), Seoul R & BD Program (no. 10524), and Post BK21 Program.	Alkayed NJ, 2001, J NEUROSCI, V21, P7543, DOI 10.1523/JNEUROSCI.21-19-07543.2001; Bagetta G, 2004, NEUROSCI LETT, V368, P87, DOI 10.1016/j.neulet.2004.06.062; Cardona-Gomez GP, 2002, MOL BRAIN RES, V107, P80, DOI 10.1016/S0169-328X(02)00449-7; Chen J, 1998, NEUROSCIENCE, V87, P817, DOI 10.1016/S0306-4522(98)00198-5; Choi YC, 2004, FUND CLIN PHARMACOL, V18, P547, DOI 10.1111/j.1472-8206.2004.00284.x; Crown ED, 2006, EXP NEUROL, V199, P397, DOI 10.1016/j.expneurol.2006.01.003; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Freeland K, 2001, MOL BRAIN RES, V92, P98, DOI 10.1016/S0169-328X(01)00158-9; Furlan JC, 2005, J NEUROTRAUM, V22, P368, DOI 10.1089/neu.2005.22.368; Henderson VW, 1996, PSYCHONEUROENDOCRINO, V21, P421, DOI 10.1016/0306-4530(95)00060-7; Horsburgh K, 2002, J CEREBR BLOOD F MET, V22, P1189, DOI 10.1097/01.wcb.0000037991.07114.4e; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Jover T, 2002, J NEUROSCI, V22, P2115, DOI 10.1523/JNEUROSCI.22-06-02115.2002; Jover-Mengual T, 2007, ENDOCRINOLOGY, V148, P1131, DOI 10.1210/en.2006-1137; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Lee SJ, 2004, NEUROSCIENCE, V124, P549, DOI 10.1016/j.neuroscience.2003.11.035; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Liu XZ, 1997, J NEUROSCI, V17, P5395; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; Mannella P, 2006, J NEUROSCI, V26, P9439, DOI 10.1523/JNEUROSCI.1443-06.2006; Neary JT, 2004, NEUROCHEM RES, V29, P2037, DOI 10.1007/s11064-004-6876-y; Noshita N, 2001, J CEREBR BLOOD F MET, V21, P1442, DOI 10.1097/00004647-200112000-00009; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Ouyang YB, 1999, J CEREBR BLOOD F MET, V19, P1126, DOI 10.1097/00004647-199910000-00009; PAGANINIHILL A, 1995, PROG CARDIOVASC DIS, V38, P223, DOI 10.1016/S0033-0620(95)80014-X; Platania P, 2003, NEUROENDOCRINOLOGY, V77, P334, DOI 10.1159/000070899; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; Rajala RVS, 2001, INVEST OPHTH VIS SCI, V42, P3110; Rusa R, 1999, STROKE, V30, P1665, DOI 10.1161/01.STR.30.8.1665; Sakurai M, 2003, J THORAC CARDIOV SUR, V125, P370, DOI 10.1067/mtc.2003.112; Sakurai M, 2001, NEUROSCI LETT, V302, P17, DOI 10.1016/S0304-3940(01)01609-3; Singer CA, 1999, J NEUROSCI, V19, P2455; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Toung TJK, 1998, STROKE, V29, P1666, DOI 10.1161/01.STR.29.8.1666; Wang Q, 1999, STROKE, V30, P630, DOI 10.1161/01.STR.30.3.630; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wilson ME, 2002, MOL BRAIN RES, V102, P48, DOI 10.1016/S0169-328X(02)00181-X; Wu TW, 2005, NEUROSCIENCE, V135, P59, DOI 10.1016/j.neuroscience.2004.12.027; Xiang H, 2006, MOL CELL BIOL, V26, P8599, DOI 10.1128/MCB.01062-06; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yano S, 2001, J CEREBR BLOOD F MET, V21, P351, DOI 10.1097/00004647-200104000-00004; Yu CG, 2005, MOL BRAIN RES, V138, P244, DOI 10.1016/j.molbrainres.2005.04.013; Yu XR, 2004, J BIOL CHEM, V279, P13086, DOI 10.1074/jbc.M313283200; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116	55	69	76	1	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2008	25	9					1121	1131		10.1089/neu.2008.0544			11	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	360JX	WOS:000260054900008	18785877				2022-02-06	
J	Kristman, VL; Tator, CH; Kreiger, N; Richards, D; Mainwaring, L; Jaglal, S; Tomlinson, G; Comper, P				Kristman, Vicki L.; Tator, Charles H.; Kreiger, Nancy; Richards, Doug; Mainwaring, Lynda; Jaglal, Susan; Tomlinson, George; Comper, Paul			Does the apolipoprotein epsilon 4 allele predispose varsity athletes to concussion? A prospective cohort study	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article; Proceedings Paper	25th Annual National-Neurotrauma-Society Symposium	JUL 29-AUG 01, 2007	Kansas City, MO	Natl Neurotrauma Soc		cohort studies; collegiate athletes; concussion; genetics; risk factor	TRAUMATIC BRAIN-INJURY; E EPSILON-4 ALLELE; E-DEFICIENT MICE; E POLYMORPHISM; FOOTBALL; PROTEIN; EPIDEMIOLOGY; ASSOCIATION; E-EPSILON-4; GENOTYPE	Objective: To determine the association between the apolipoprotein epsilon 4 allele and concussion. We hypothesized that apolipoprotein epsilon 4 carriers may be more likely to sustain a concussion. Design: Prospective cohort study. Setting: University of Toronto varsity athletics. Participants: Included 318 of 822 collegiate student athletes who participated in University of Toronto varsity sports from September 2002 to April 2006. Assessment of Risk Factors: The presence of apolipoprotein EA was described dichotomously after genotyping blood samples collected from participants. Main Outcome Measurements: Concussions were identified by sport-medicine professionals present on the sidelines using on-field assessment forms. All concussion diagnoses were verified by a sports medicine physician. Survival analysis was used to determine the association between apolipoprotein epsilon 4 and first concussion. Results: The unadjusted hazard ratio for concussion in the apolipoprotein FA carriers was 1.18 (95% CI: 0.52, 2.69) compared to noncarriers. Adjustment for sex, weight, height, and team type resulted in a hazard ratio of 1.06 (95% Cl: 0.41, 2.72), indicating little effect from confounding factors. Conclusions: There is no important association between carrying the apolipoprotein epsilon 4 allele and sustaining a concussion. At this time, we do not recommend preseason genetic testing for varsity. athletes as a mechanism for targeting prevention strategies.	[Kristman, Vicki L.] Toronto Western Hosp, Univ Hlth Network, CREIDO, Toronto, ON M5T 2S8, Canada; [Kristman, Vicki L.; Kreiger, Nancy; Jaglal, Susan; Tomlinson, George] Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; [Kristman, Vicki L.; Tator, Charles H.] Univ Toronto, Univ Hlth Network, Toronto Western Res Inst, Toronto, ON, Canada; [Tator, Charles H.] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada; [Richards, Doug; Mainwaring, Lynda; Comper, Paul] Univ Toronto, Fac Phys Educ & Hlth, Toronto, ON, Canada; [Richards, Doug; Comper, Paul] Univ Toronto, Toronto Rehabil Inst, Toronto, ON, Canada; [Jaglal, Susan] Univ Toronto, Dept Phys Therapy, Toronto, ON, Canada; [Tomlinson, George] Univ Hlth Network, Toronto Gen Res Inst, Toronto, ON, Canada		Kristman, VL (corresponding author), Toronto Western Hosp, Univ Hlth Network, CREIDO, Fell Pavilion 4-132,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	vicki.kristman@uhnresearch.ca	Tomlinson, George A/L-5432-2016	Tomlinson, George A/0000-0002-9328-6399; Jaglal, Susan/0000-0002-2930-1443; Kristman, Vicki/0000-0001-5508-0552			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Blackman JA, 2005, DEV MED CHILD NEUROL, V47, P64, DOI 10.1017/S0012162205000113; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boland LL, 2006, ANN EPIDEMIOL, V16, P763, DOI 10.1016/j.annepidem.2006.04.005; Buttini M, 1999, J NEUROSCI, V19, P4867; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; COMPER PN, 2003, BRAIN INJ S1, V17, P85; de Barros EMKP, 2000, J PEDIATR ORTHOPED, V20, P786; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1999, ACT NEUR S, V73, P89; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HIXSON JE, 1990, J LIPID RES, V31, P545; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kay AD, 2003, J NEUROTRAUM, V20, P717, DOI 10.1089/089771503767869953; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2001, BRIT J SPORT MED, V35, P146, DOI 10.1136/bjsm.35.3.146; Meeuwisse WH, 2000, AM J SPORT MED, V28, P516, DOI 10.1177/03635465000280041201; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Samatovicz RA, 2000, J HEAD TRAUMA REHAB, V15, P869, DOI 10.1097/00001199-200006000-00002; *SAS I INC, 2002, SAS COMP MICR WIND E; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Schiefermeier M, 2000, STROKE, V31, P2068, DOI 10.1161/01.STR.31.9.2068; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SIEST G, 1995, CLIN CHEM, V41, P1068; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; Tardiff BE, 1997, ANN THORAC SURG, V64, P715, DOI 10.1016/S0003-4975(97)00757-1; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K	37	69	70	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2008	18	4					322	328		10.1097/JSM.0b013e31817e6f3e			7	Orthopedics; Physiology; Sport Sciences	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Orthopedics; Physiology; Sport Sciences	325DK	WOS:000257568300003	18614883				2022-02-06	
J	Tanriverdi, F; Unluhizarci, K; Kocyigit, I; Tuna, IS; Karaca, Z; Durak, AC; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Unluhizarci, Kursad; Kocyigit, Ismail; Tuna, Ibrahim S.; Karaca, Zuleyha; Durak, Ahmet C.; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			Brief communication: Pituitary volume and function in competing and retired male boxers	ANNALS OF INTERNAL MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; HYPOPITUITARISM; SPORT	Background: Pituitary consequences of chronic head trauma in boxing have not been investigated in detail. Objective: To investigate the pituitary function in retired or active amateur boxers. Design: Cross-sectional, observational study. Setting: Turkey. Participants: 61 actively competing (n = 44) or retired (n = 17) male boxers of the Turkish National Boxing Team. Measurements: Body composition variables, pituitary volume (in 38 of 61 boxers), and pituitary function. Results: 9 of 61 boxers (15%) had growth hormone (GH) deficiency and 5 of 61 boxers (8%) had adrenocorticotropic hormone deficiency. All boxers with GH deficiency except 1 were retired from boxing. Of 17 retired boxers, 8 (47%) had GH deficiency. Retired boxers with GH deficiency had significantly lower pituitary volume than retired boxers with normal GH. Limitation: Pituitary volume was measured in only 38 of 61 boxers, and the study had no comparison group. Conclusion: This study suggests that retired boxers have a high rate of pituitary dysfunction. Therefore, investigation of pituitary function in boxers, particularly retired ones, is recommended.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Inst Salud Carlos III, Santiago De Compostela, Spain		Tanriverdi, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fatihtan@erciyes.edu.tr	kelestimur, f/ABE-9873-2021; Karaca, Zuleyha/ABB-7891-2021	KOCYIGIT, ISMAIL/0000-0002-6654-4727; Tuna, Ibrahim/0000-0003-4170-6483			Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelestimur Fahrettin, 2005, Pituitary, V8, P259, DOI 10.1007/s11102-006-6051-3; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Melmed S, 2003, J CLIN INVEST, V112, P1603, DOI 10.1172/JCI200320401; Orme SM, 1996, CLIN ENDOCRINOL, V45, P135, DOI 10.1046/j.1365-2265.1996.d01-1562.x; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; Regal M, 2001, CLIN ENDOCRINOL, V55, P735, DOI 10.1046/j.1365-2265.2001.01406.x; Takano K, 1999, AM J NEURORADIOL, V20, P312; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Zazryn TR, 2003, BRIT J SPORT MED, V37, P448, DOI 10.1136/bjsm.37.5.448; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	17	69	69	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 3	2008	148	11					827	U35		10.7326/0003-4819-148-11-200806030-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	308CG	WOS:000256365300004	18519929				2022-02-06	
J	Qu, CS; Mahmood, A; Lu, DY; Goussev, A; Xiong, Y; Chopp, M				Qu, Changsheng; Mahmood, Asim; Lu, Dunyue; Goussev, Anton; Xiong, Ye; Chopp, Michael			Treatment of traumatic brain injury in mice with marrow stromal cells	BRAIN RESEARCH			English	Article						traumatic brain injury (TBI); marrow stromal cell (MSC); mice	STEM-CELLS; TRANSPLANTATION; RATS; PROMOTES; MOUSE	This study was designed to investigate the potential beneficial effects of bone marrow stromal cell (MSC) treatment of traumatic brain injury (TBI) in mice. Twelve female C57BL/6J mice (weight, 21-26 g) were injured with controlled cortical impact and divided into 2 groups (n = 6 each). The experimental group was injected with MSCs (0.3 x 10(6)) intravenously one day after TBI, whereas the control group was injected with saline. MSCs were harvested from male mice, and male to female transplantation was performed to identify male donor cells within female recipient animals. This was achieved by localizing Y chromosomes within the female mice. Neurological function was assessed using the Morris water maze and foot fault tests. All mice were sacrificed 35 days after TBI. Brain sections were stained using in situ hybridization and immunohistochemistry to identify MSCs as well as to analyze vascular density following MSC treatment. Both modalities of testing demonstrated significant improvement in neurological function in the MSC-treated group compared to the saline-treated control group (p < 0.05). Histologically, Y chromosome labeled MSCs were easily identified in the injured brain, localized primarily around the lesion boundary zone. There was also a significant increase in vascular density in the lesion boundary zone and hippocampus of MSC-treated mice compared to control mice. This is the first study to show beneficial effects of MSC treatment after TBI in mice. (C) 2008 Published by Elsevier B.V.	[Qu, Changsheng; Mahmood, Asim; Goussev, Anton; Xiong, Ye; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Qu, Changsheng; Mahmood, Asim; Goussev, Anton; Xiong, Ye; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA		Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, K-11,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu		Xiong, Ye/0000-0001-9770-6031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS42259, R01 NS042259] Funding Source: Medline		Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; BERNSTEIN DC, 1988, ANN NY ACAD SCI, V532, P207, DOI 10.1111/j.1749-6632.1988.tb36339.x; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Francois S, 2006, STEM CELLS, V24, P1020, DOI 10.1634/stemcells.2005-0260; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; HLATKY R, 2003, FOCUS, V14, P104; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Xiong Y, 2005, J NEUROCHEM, V95, P732, DOI 10.1111/j.1471-4159.2005.03412.x; Zanetta L, 2000, INT J CANCER, V85, P281, DOI 10.1002/(SICI)1097-0215(20000115)85:2<281::AID-IJC21>3.0.CO;2-3; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	22	69	75	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 7	2008	1208						234	239		10.1016/j.brainres.2008.02.042			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	316GP	WOS:000256937800026	18384759	Green Accepted			2022-02-06	
J	Oliveira, MS; Furian, AF; Royes, LF; Fighera, MR; Fiorenza, NG; Castelli, M; Machado, P; Bohrer, D; Veiga, M; Ferreira, J; Cavalheiro, EA; Mello, CF				Oliveira, Mauro Schneider; Furian, Ana Flavia; Freire Royes, Luiz Fernando; Fighera, Michele Rechia; Fiorenza, Natalia Gindri; Castelli, Marcelo; Machado, Pablo; Bohrer, Denise; Veiga, Marlei; Ferreira, Juliano; Cavalheiro, Esper Abraao; Mello, Carlos Fernando			Cyclooxygenase-2/PGE(2) pathway facilitates pentylenetetrazol-induced seizures	EPILEPSY RESEARCH			English	Article						COX-2; celecoxib; epilepsy; PGE(2); EEG; PTZ	TRAUMATIC BRAIN-INJURY; NEURONAL CYCLOOXYGENASE-2; SYNAPTIC-TRANSMISSION; MICE; RAT; HIPPOCAMPUS; INHIBITION; EXPRESSION; EXCITABILITY; PLASTICITY	Cyclooxygenases (CCXs) are rate-limiting enzymes in the metabolic pathways in which arachidonic acid is converted to prostaglandins. COX-2 is the isoform induced at injury/inflammation sites and expressed constitutively in a few tissues, such as the central nervous system, and plays a rote in neurodegenerative diseases associated with increased excitatory activity. However, the role of COX-2 and its main product, prostaglandin E-2 (PGE(2)), in the convulsive states is not fully established. In this study we showed that the selective COX-2 inhibitor, celecoxib (at the dose of 2mg/kg, but not at the doses of 0.2 or 20mg/kg, p.o.), protects against the seizures induced by pentylenetetrazol (PTZ, 60 mg/kg, i.p.). The role of PGE2 in the convulsions induced by PTZ was further investigated by administering anti-PGE(2) antibodies (4 mu g/2 mu l, i.c.v.), and assessing electroencephatographic changes induced by PTZ (PTZ, 60 mg/kg, i.p.). Anti-PGE(2) antibodies attenuated PTZ-induced seizures in rats. In addition, combining PGE(2) (100 ng/2 mu l, i.c.v.) with a subconvulsant dose of PTZ (20 mg/kg, i.p.) caused seizures, further supporting a role for this prostaglandin in the convulsions induced by PTZ. Finally, we showed that the anticonvulsant action of celecoxib (2 mg/kg, p.o.) was reversed by the intracerebroventricular administration of PGE(2) (10 ng/2 mu l, i.c.v.). These data constitute strong converging pharmacological evidence supporting a facilitatory role for the COX-2/PGE2 pathway in the seizures induced by PTZ. However, whether selective COX-2 inhibitors are safer anti-inflammatory drugs for epileptic patients than nonspecific inhibitors remains to be determined. (c) 2008 Elsevier B.V. All rights reserved.	[Oliveira, Mauro Schneider; Furian, Ana Flavia; Freire Royes, Luiz Fernando; Fighera, Michele Rechia; Fiorenza, Natalia Gindri; Castelli, Marcelo; Mello, Carlos Fernando] Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Fisiol & Farmacol, BR-97105900 Santa Maria, RS, Brazil; [Oliveira, Mauro Schneider; Furian, Ana Flavia] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Programa Posgrad Ciencias Biol Bioquim, Porto Alegre, RS, Brazil; [Freire Royes, Luiz Fernando] Univ Fed Santa Maria, Ctr Educ Fis & Desportos, Dept Metodos & Tecn Desportivas, BR-97119900 Santa Maria, RS, Brazil; [Machado, Pablo; Bohrer, Denise; Veiga, Marlei; Ferreira, Juliano] Univ Fed Santa Maria, Ctr Ciencias Nat & Exatas, Dept Quim, BR-97119900 Santa Maria, RS, Brazil; [Cavalheiro, Esper Abraao] Univ Fed Sao Paulo, Lab Neurol Expt, Sao Paulo, Brazil		Mello, CF (corresponding author), Univ Fed Santa Maria, Ctr Ciencias Saude, Dept Fisiol & Farmacol, BR-97105900 Santa Maria, RS, Brazil.	cf.mello@smail.ufsm.br	Oliveira, Mauro Schneider/G-3437-2012; Fighera, Michele R/J-9576-2014; Cavalheiro, Esper A/I-3084-2016; Machado, Pablo/M-4356-2013; Cavalheiro, Esper/N-3985-2019; Ferreira, Juliano/A-9803-2013; Cavalheiro, Esper A/F-4325-2014; royes, luiz/T-3581-2019; Mello, Carlos/C-7188-2013	Oliveira, Mauro Schneider/0000-0002-5381-1208; Cavalheiro, Esper A/0000-0002-0854-3582; Machado, Pablo/0000-0001-5616-9583; Cavalheiro, Esper/0000-0002-0854-3582; Ferreira, Juliano/0000-0002-9562-0602; Cavalheiro, Esper A/0000-0002-0854-3582; Mello, Carlos/0000-0002-1326-1045; royes, luiz/0000-0003-4045-4827; Fighera, Michele/0000-0002-3111-7530			Akarsu ES, 2006, EPILEPSY RES, V71, P181, DOI 10.1016/j.eplepsyres.2006.06.009; Andre V, 1998, EUR J NEUROSCI, V10, P2094, DOI 10.1046/j.1460-9568.1998.00223.x; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; Bezzi P, 1998, NATURE, V391, P281, DOI 10.1038/34651; CAVALHEIRO EA, 1992, EPILEPSY RES, P239; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Chen C, 2005, J NEUROPHYSIOL, V93, P929, DOI 10.1152/jn.00696.2004; Chen C, 2002, J NEUROPHYSIOL, V87, P2851, DOI 10.1152/jn.2002.87.6.2851; Ciceri P, 2002, J PHARMACOL EXP THER, V302, P846, DOI 10.1124/jpet.302.3.846; Desjardins P, 2003, NEUROCHEM INT, V42, P299, DOI 10.1016/S0197-0186(02)00101-8; DHIR A, 2006, BIOL PSYCHIAT; Ferraro TN, 1999, J NEUROSCI, V19, P6733, DOI 10.1523/JNEUROSCI.19-16-06733.1999; Kaufmann WE, 1996, P NATL ACAD SCI USA, V93, P2317, DOI 10.1073/pnas.93.6.2317; Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7; Kelley KA, 1999, AM J PATHOL, V155, P995, DOI 10.1016/S0002-9440(10)65199-1; Kim J, 2004, NAT NEUROSCI, V7, P697, DOI 10.1038/nn1262; Marklund N, 2005, RESTOR NEUROL NEUROS, V23, P31; McColl CD, 2003, NEUROPHARMACOLOGY, V44, P234, DOI 10.1016/S0028-3908(02)00369-6; Melnikova T, 2006, NEUROSCIENCE, V141, P1149, DOI 10.1016/j.neuroscience.2006.05.001; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; Okada K, 2001, BRAIN RES, V894, P332, DOI 10.1016/S0006-8993(01)02019-4; Paulson SK, 2000, DRUG METAB DISPOS, V28, P514; Sang N, 2005, J NEUROSCI, V25, P9858, DOI 10.1523/JNEUROSCI.2392-05.2005; Sang N, 2006, NEUROSCIENTIST, V12, P425, DOI 10.1177/1073858406290794; Sheerin AH, 2004, EPILEPSIA, V45, P1184, DOI 10.1111/j.0013-9580.2004.16604.x; Simmons DL, 2004, PHARMACOL REV, V56, P387, DOI 10.1124/pr.56.3.3; Slanina KA, 2005, NEUROPHARMACOLOGY, V49, P653, DOI 10.1016/j.neuropharm.2005.04.019; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tu B, 2003, EXP NEUROL, V179, P167, DOI 10.1016/S0014-4886(02)00019-5; Ueno N, 2005, BIOCHEM BIOPH RES CO, V338, P70, DOI 10.1016/j.bbrc.2005.08.152; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x; Vidensky S, 2003, NEUROMOL MED, V3, P15, DOI 10.1385/NMM:3:1:15; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	35	69	70	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	MAR	2008	79	1					14	21		10.1016/j.eplepsyres.2007.12.008			8	Clinical Neurology	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	295CZ	WOS:000255453900003	18255268				2022-02-06	
J	Li, W; Dai, S; An, J; Li, P; Chen, X; Xiong, R; Liu, P; Wang, H; Zhao, Y; Zhu, M; Liu, X; Zhu, P; Chen, JF; Zhou, Y				Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Chen, J. -F.; Zhou, Y.			Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model	NEUROSCIENCE			English	Article						adenosine receptor; caffeine; TBI; glutamate; inflammatory cytokine; neuroprotection	A(2A) ADENOSINE RECEPTORS; INDUCED EXCITOTOXICITY; REPERFUSION INJURY; GLUTAMATE RELEASE; ACTIVATION; PROTECTION; ISCHEMIA; A(1); NEUROPROTECTION; INFLAMMATION	Caffeine, the most consumed psychoactive drug and non-specific adenosine receptor antagonist, has recently been shown to exert a neuroprotective effect against brain injury in animal models of Parkinson's disease (PD) and stroke. However, the effects of caffeine on traumatic brain injury (TBI) are not known. In this study, we investigated the effects of acute and chronic caffeine treatment on brain injury in a cortical-impact model of TBI in mice. Following TBI, neurological deficits, cerebral edema, as well as inflammatory cell infiltration were all significantly attenuated in mice pretreated chronically (for 3 weeks) with caffeine in drinking water compared with the mice pretreated with saline. Furthermore, we found that chronic caffeine treatment attenuated glutamate release and inflammatory cytokine production, effects that were correlated with an upregulation of brain A, receptor mRNA. By contrast, acute treatment with caffeine (i.p. injection, 30 min before TBI) was not effective in protecting against TBI-induced brain injury. These results suggest that chronic (but not acute) caffeine treatment attenuates brain injury, possibly by A, receptor-mediated suppression of glutamate release and inhibition of excessive inflammatory cytokine production. These results highlight the potential benefit of chronic caffeine intake for preventing TBI and provide a rationale for the epidemiological investigation of the potential association between TBI and human caffeine intake. (c) 2008 IBRO. Published by Elsevier Ltd. All rights reserved.	[Chen, J. -F.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Zhou, Y.] Third Mil Med Univ, Ctr Mol Biol, Inst Surg Res, Chongqing 400042, Peoples R China; [Li, W.; Dai, S.; An, J.; Li, P.; Chen, X.; Xiong, R.; Liu, P.; Wang, H.; Zhao, Y.; Zhu, M.; Liu, X.; Zhu, P.; Zhou, Y.] Third Mil Med Univ, Daping Hosp, Chongqing 400042, Peoples R China		Chen, JF (corresponding author), Boston Univ, Sch Med, Dept Neurol, 715 Albany St, Boston, MA 02118 USA.	chenjf@bu.edu; ygzhou@cta.cq.cn	Li, ping/J-6507-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS41083] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041083] Funding Source: NIH RePORTER		ADEN U, 1994, MOL BRAIN RES, V23, P354, DOI 10.1016/0169-328X(94)90247-X; Arendash GW, 2006, NEUROSCIENCE, V142, P941, DOI 10.1016/j.neuroscience.2006.07.021; BEGLEY DJ, 1994, J CHROMATOGR B, V657, P185, DOI 10.1016/0378-4347(94)80085-5; Blum D, 2003, LANCET NEUROL, V2, P366, DOI 10.1016/S1474-4422(03)00411-3; BONA E, 1995, PEDIATR RES, V38, P312, DOI 10.1203/00006450-199509000-00007; Bruce-Keller AJ, 1999, J NEUROSCI RES, V58, P191, DOI 10.1002/(SICI)1097-4547(19991001)58:1<191::AID-JNR17>3.0.CO;2-E; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Cheng JS, 2001, J RECEPT SIGNAL TR R, V21, P1, DOI 10.1081/RRS-100107138; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Ciruela F, 2006, J NEUROSCI, V26, P2080, DOI 10.1523/JNEUROSCI.3574-05.2006; Dall'lgna OP, 2003, BRIT J PHARMACOL, V138, P1207, DOI 10.1038/sj.bjp.0705185; Day YJ, 2004, AM J PHYSIOL-GASTR L, V286, pG285, DOI 10.1152/ajpgi.00348.2003; Day YJ, 2003, J CLIN INVEST, V112, P883, DOI 10.1172/JCI200315483; de Mendonca A, 2000, BRAIN RES REV, V33, P258, DOI 10.1016/S0165-0173(00)00033-3; Deleu D, 2006, NEUROLOGY, V67, P897, DOI 10.1212/01.wnl.0000233916.57415.9d; Donadieu E, 2007, ACTA HISTOCHEM, V109, P177, DOI 10.1016/j.acthis.2007.01.004; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; ENGLER RL, 1991, CIRCULATION, V84, P951, DOI 10.1161/01.CIR.84.2.951; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fredholm BB, 2001, PHARMACOL REV, V53, P527; GOLDBERG MP, 1988, NEUROSCI LETT, V89, P323, DOI 10.1016/0304-3940(88)90547-2; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Graham TE, 2001, SPORTS MED, V31, P785, DOI 10.2165/00007256-200131110-00002; Hartley TR, 2004, AM J CARDIOL, V93, P1022, DOI 10.1016/j.amjcard.2003.12.057; Jacobson KA, 1996, TRENDS PHARMACOL SCI, V17, P108, DOI 10.1016/0165-6147(96)10002-X; Johansson B, 2001, P NATL ACAD SCI USA, V98, P9407, DOI 10.1073/pnas.161292398; Johansson B, 1997, BRAIN RES, V762, P153, DOI 10.1016/S0006-8993(97)00378-8; Jones PA, 1998, NEUROSCIENCE, V85, P229, DOI 10.1016/S0306-4522(97)00613-1; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Liu HT, 2006, GLIA, V54, P343, DOI 10.1002/glia.20400; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Mayne M, 2001, ANN NEUROL, V49, P727, DOI 10.1002/ana.1010; Ohta A, 2001, NATURE, V414, P916, DOI 10.1038/414916a; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Okusa MD, 1999, AM J PHYSIOL-RENAL, V277, pF404, DOI 10.1152/ajprenal.1999.277.3.F404; Peirce SM, 2001, AM J PHYSIOL-HEART C, V281, pH67, DOI 10.1152/ajpheart.2001.281.1.H67; Phillis JW, 1995, BRAIN RES, V705, P79, DOI 10.1016/0006-8993(95)01153-6; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Popoli P, 1995, EUR J PHARMACOL, V287, P215, DOI 10.1016/0014-2999(95)00679-6; Rachima-Maoz C, 1998, AM J HYPERTENS, V11, P1426, DOI 10.1016/S0895-7061(98)00172-1; Reinert M, 2000, Neurosurg Focus, V8, pe10; Riksen NP, 2006, J AM COLL CARDIOL, V48, P700, DOI 10.1016/j.jacc.2006.04.083; Ross SC, 1999, J HEART LUNG TRANSPL, V18, P994, DOI 10.1016/S1053-2498(99)00066-2; RUDOLPHI KA, 1992, TRENDS PHARMACOL SCI, V13, P439, DOI 10.1016/0165-6147(92)90141-R; Sachse KT, 2008, J CEREBR BLOOD F MET, V28, P395, DOI 10.1038/sj.jcbfm.9600539; SACHSE KT, 2004, ANESTHESIOLOGY, V101, pA354; Sands WA, 2005, IMMUNOL LETT, V101, P1, DOI 10.1016/j.imlet.2005.04.005; SMITH AP, 1993, J PSYCHOPHARMACOL, V7, P203, DOI 10.1177/026988119300700209; SMITH PF, 2000, REPORT EXPERT WORKIN, V20, P30; Sullivan GW, 1999, J INFECT DIS, V180, P1550, DOI 10.1086/315084; Thong FSL, 2002, CAN J APPL PHYSIOL, V27, P152, DOI 10.1139/h02-011; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Varani K, 2005, CELL MOL LIFE SCI, V62, P2350, DOI 10.1007/s00018-005-5312-z; Varani K, 2000, CIRCULATION, V102, P285; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V253, P95, DOI 10.1016/0014-2999(94)90762-5; Washington CB, 2005, J NEUROTRAUM, V22, P1256; Xu K, 2005, PHARMACOL THERAPEUT, V105, P267, DOI 10.1016/j.pharmthera.2004.10.007; Xu K, 2002, NEUROSCI LETT, V322, P13, DOI 10.1016/S0304-3940(02)00069-1; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	62	69	76	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 19	2008	151	4					1198	1207		10.1016/j.neuroscience.2007.11.020			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	264PS	WOS:000253301500025	18207647				2022-02-06	
J	Fujiwara, E; Schwartz, ML; Gao, FQ; Black, SE; Levine, B				Fujiwara, Esther; Schwartz, Michael L.; Gao, Fuqiang; Black, Sandra E.; Levine, Brian			Ventral frontal cortex functions and quantified MRI in traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						head injury; diffuse axonal injury; focal lesions; neuropsychology; orbitofrontal cortex; partial least squares analysis	CLOSED-HEAD-INJURY; HUMAN ORBITOFRONTAL CORTEX; PARTIAL LEAST-SQUARES; PREFRONTAL CORTEX; OBJECT ALTERNATION; DECISION-MAKING; TEMPORAL-LOBE; NEUROPSYCHOLOGICAL DEFICITS; OLFACTORY DISCRIMINATION; ALZHEIMERS-DISEASE	Ventral frontal cortex is commonly involved in traumatic brain injury (TBI). The smell identification test (SIT), object alternation (OA), and the Iowa gambling task (IGT) are associated with this brain region in experimental and neuropsychological research. We examined the relationship of performance on these tests to residual structural brain integrity quantified from MRI in 58 TBI patients, including 18 patients with focal cortical contusions and 40 patients with diffuse injury only. Image analysis yielded regional volumetric measures of gray matter, white matter and cerebrospinal fluid. Multivariate analyses identified distributed patterns of regional volume loss associated with test performance across all three behavioral measures. The tasks were sensitive to effects of TBI. In multivariate analyses, performance in all three tasks was related to gray matter loss including ventral frontal cortex, but the SIT was most sensitive to ventral frontal cortex damage, even in patients without focal lesions. The SIT was further related to temporal lobe and posterior cingulate/retrosplenial volumes. OA and the IGT were associated with superior medial frontal volumes. Complex tasks, such as OA and the IGT, do not consistently localize to a single cortical region. The SIT is associated with the integrity of ventral frontal regions, but it is also affected by distributed damage, although the contribution of undetected olfactory tract or bulb damage could not be ruled out. This study illustrates the scope and limitations of functional localization in human ventral frontal cortex. (C) 2007 Elsevier Ltd. All rights reserved.	[Fujiwara, Esther; Black, Sandra E.; Levine, Brian] Rotman Res Inst Baycrest, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada; [Levine, Brian] Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada; [Schwartz, Michael L.] Sunnybrook Hlth Sci Ctr, Dept Surg Neurosurg, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Med Neurol, Toronto, ON M4N 3M5, Canada; [Gao, Fuqiang; Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Cognit Neurol, Toronto, ON M4N 3M5, Canada; [Black, Sandra E.] Sunnybrook Hlth Sci Ctr, Dept Imaging Res, Toronto, ON M4N 3M5, Canada; [Schwartz, Michael L.] Univ Toronto, Dept Surg Neurosurg, Toronto, ON, Canada; [Black, Sandra E.; Levine, Brian] Univ Toronto, Dept Med Neurol, Toronto, ON, Canada		Levine, B (corresponding author), Rotman Res Inst Baycrest, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	levine@psych.moronto.ca	Black, Sandra E./C-7294-2011; Levine, Brian/G-4328-2010; Fujiwara, Esther/F-8233-2011; Levine, Brian/O-2725-2019	Levine, Brian/0000-0003-4343-811X; Fujiwara, Esther/0000-0003-4154-0145; Levine, Brian/0000-0003-4343-811X; Black, Sandra/0000-0001-7093-8289	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042385] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD042385, R01 HD042385-05, HD42385-01] Funding Source: Medline		ARNDT S, 1991, PSYCHIAT RES-NEUROIM, V40, P79; Beauchamp MS, 2005, CURR OPIN NEUROBIOL, V15, P145, DOI 10.1016/j.conb.2005.03.011; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bocti C, 2006, DEMENT GERIATR COGN, V21, P364, DOI 10.1159/000091838; Brand M, 2007, J CLIN EXP NEUROPSYC, V29, P86, DOI 10.1080/13803390500507196; Buchel C, 1998, NATURE, V394, P274, DOI 10.1038/28389; Callahan CD, 1999, J HEAD TRAUMA REHAB, V14, P581, DOI 10.1097/00001199-199912000-00006; Carone DA, 2006, NEUROIMAGE, V29, P505, DOI 10.1016/j.neuroimage.2005.07.053; Cavada C, 2000, CEREB CORTEX, V10, P220, DOI 10.1093/cercor/10.3.220; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Clark L, 2003, NEUROPSYCHOLOGIA, V41, P1474, DOI 10.1016/S0028-3932(03)00081-2; Cohen NJ., 1993, MEMORY AMNESIA HIPPO; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; Dade LA, 2004, NEUROIMAGE, V22, P1492, DOI 10.1016/j.neuroimage.2004.03.023; Dade LA, 2002, BRAIN, V125, P86, DOI 10.1093/brain/awf003; Damasio H, 2004, COGNITION, V92, P179, DOI 10.1016/j.cognition.2002.07.001; De Wit S, 2006, J NEUROSCI, V26, P5224, DOI 10.1523/JNEUROSCI.5175-05.2006; Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Doty RL, 1995, SMELL IDENTIFICATION, Vthird; Dunn BD, 2006, NEUROSCI BIOBEHAV R, V30, P239, DOI 10.1016/j.neubiorev.2005.07.001; Edgington E. S., 1980, RANDOMIZATION TESTS; Efron B., 1986, STAT SCI, V1, P54, DOI 10.1214/ss/1177013815; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Faw B, 2003, CONSCIOUS COGN, V12, P83, DOI 10.1016/S1053-8100(02)00030-2; Feinstein A, 2004, NEUROLOGY, V62, P586, DOI 10.1212/01.WNL.0000110316.12086.0C; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Freedman M, 1998, CEREB CORTEX, V8, P18, DOI 10.1093/cercor/8.1.18; GAINOTTI G, 1995, MEMORY, V3, P247, DOI 10.1080/09658219508253153; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gilboa A, 2005, HIPPOCAMPUS, V15, P535, DOI 10.1002/hipo.20090; Gold JM, 1996, NEUROPSYCHOLOGY, V10, P3; Green P, 2003, BRAIN INJURY, V17, P479, DOI 10.1080/0269905031000070242; Green P, 1996, WORD MEMORY TEST; Holbourn AHS, 1943, LANCET, V2, P438; Hornak J, 2004, J COGNITIVE NEUROSCI, V16, P463, DOI 10.1162/089892904322926791; Humphreys GW, 2001, BEHAV BRAIN SCI, V24, P453, DOI 10.1017/S0140525X01004150; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; JonesGotman M, 1997, BRAIN, V120, P1845, DOI 10.1093/brain/120.10.1845; Kovacevic N, 2005, CEREB CORTEX, V15, P639, DOI 10.1093/cercor/bhh165; Kovacevic N, 2002, NEUROIMAGE, V17, P1087, DOI 10.1006/nimg.2002.1221; Kringelbach ML, 2004, PROG NEUROBIOL, V72, P341, DOI 10.1016/j.pneurobio.2004.03.006; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1985, BRAIN, V108, P579, DOI 10.1093/brain/108.3.579; Levine B, 2005, COGN BEHAV NEUROL, V18, P45, DOI 10.1097/01.wnn.0000152227.13001.c3; LEVINE B, UNPUB QUANTIFIED MRI; LEVINE B, IN PRESS NEUROLOGY; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; McIntosh AR, 1996, NEUROIMAGE, V3, P143, DOI 10.1006/nimg.1996.0016; McIntosh AR, 2004, NEUROIMAGE, V23, pS250, DOI 10.1016/j.neuroimage.2004.07.020; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; MISHKIN M, 1969, NEUROPSYCHOLOGIA, V7, P357, DOI 10.1016/0028-3932(69)90060-8; O'Doherty J, 2001, NAT NEUROSCI, V4, P95, DOI 10.1038/82959; PANDYA DN, 1987, FRONTAL LOBES REVIST; Pol HEH, 2002, NEUROPSYCHOLOGIA, V40, P888, DOI 10.1016/S0028-3932(01)00167-1; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; PRIBRAM KH, 1956, J COMP PHYSIOL PSYCH, V49, P41, DOI 10.1037/h0046248; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Rolls ET, 2004, BRAIN COGNITION, V55, P11, DOI 10.1016/s0278-2626(03)00277-x; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Talairach J., 1988, COPLANAR STEREOTACTI; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Tranel D, 2002, CORTEX, V38, P589, DOI 10.1016/S0010-9452(08)70024-8; Turner GR, 2006, NEUROSCIENCE, V139, P327, DOI 10.1016/j.neuroscience.2005.08.067; Verger K, 2001, BRAIN INJURY, V15, P211; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Wang J, 2005, J GERONTOL A-BIOL, V60, P510, DOI 10.1093/gerona/60.4.510; WASSERMAN S, 1989, PSYCHOPHYSIOLOGY, V26, P208, DOI 10.1111/j.1469-8986.1989.tb03159.x; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P153, DOI 10.1097/00004728-199801000-00028; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Yousem DM, 1999, ACAD RADIOL, V6, P264, DOI 10.1016/S1076-6332(99)80449-8; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171; Zachary R. A., 1986, SHIPLEY I LIVING SCA; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zald DH, 2005, NEUROPSYCHOLOGY, V19, P97, DOI 10.1037/0894-4105.19.1.97; Zald DH, 2002, NEUROPSYCHOLOGY, V16, P182, DOI 10.1037//0894-4105.16.2.182; ZATORRE RJ, 1991, BRAIN, V114, P71	91	69	69	1	14	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia		2008	46	2					461	474		10.1016/j.neuropsychologia.2007.08.027			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Behavioral Sciences; Neurosciences & Neurology; Psychology	272FK	WOS:000253845100009	17976665	Green Accepted			2022-02-06	
J	Schlenk, F; Graetz, D; Nagel, A; Schmidt, M; Sarrafzadeh, AS				Schlenk, Florian; Graetz, Daniela; Nagel, Alexandra; Schmidt, Maren; Sarrafzadeh, Asita S.			Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage	CRITICAL CARE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; INTRACEREBRAL MICRODIALYSIS; SUBSTRATE DELIVERY; HEAD-INJURY; BLOOD-FLOW; HYPERGLYCEMIA; METABOLISM; ISCHEMIA; THERAPY	Introduction Hyperglycaemia following aneurysmal subarachnoid hemorrhage ( SAH) is associated with complications and impaired neurological recovery. The aim of this study was to determine the effect of insulin treatment for glucose control on cerebral metabolism in SAH patients. Methods This prospective, nonrandomized study was conducted in 31 SAH patients in an intensive care unit ( age 52 +/- 10 years, World Federation of Neurological Surgeons grade 2.9 +/- 1.6). A microdialysis catheter was inserted into the vascular territory of the aneurysm after clipping. Blood glucose levels above 140 mg/ dl were treated with intravenous insulin and the microdialysates were analyzed hourly for the first 12 hours of infusion. Results No hypoglycaemia occurred. Twenty-four patients were treated with insulin for glucose control. Higher age and World Federation of Neurological Surgeons score were risk factors for need for insulin treatment ( P < 0.05). Although blood glucose remained stable after initiation of insulin infusion, insulin induced a significant decrease in cerebral glucose at 3 hours after onset of the infusion until the end of the observation period ( P < 0.05), reflecting high glucose utilization. The lactate: pyruvate ratio and glutamate did not increase, excluding ischaemia as possible cause of the decrease in glucose. Glycerol tended toward higher values at the end of the observation period ( 9 to 12 hours), reflecting either tissue damage after SAH or the beginning of cellular distress after insulin infusion. Conclusion Higher SAH grade was among the risk factors for need for insulin. Intensive glycaemic control using insulin induced a decrease of cerebral glucose and a slight increase in glycerol, though blood glucose remained normal. Future studies might detect relevant metabolic derangements when insulin treatment starts at low cerebral glucose levels, and may allow us to design a strategy for avoidance of insulin-induced metabolic crisis in SAH patients.	[Schlenk, Florian; Graetz, Daniela; Nagel, Alexandra; Sarrafzadeh, Asita S.] Charite Campus Virchow Med Ctr, Dept Neurosurg, D-13353 Berlin, Germany; [Schmidt, Maren] Charite Campus Virchow Med Ctr, Dept Anaesthesiol & Intens Care Med, D-13353 Berlin, Germany		Sarrafzadeh, AS (corresponding author), Charite Campus Virchow Med Ctr, Dept Neurosurg, Augustenburger Pl, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de		Schmidt, Maren/0000-0002-7821-9577			Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Cranston I, 1998, J CEREBR BLOOD F MET, V18, P130, DOI 10.1097/00004647-199802000-00002; DRAKE CG, 1988, J NEUROSURG, V68, P985; Enblad P, 1996, J CEREBR BLOOD F MET, V16, P637, DOI 10.1097/00004647-199607000-00014; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Saveland H, 1996, NEUROSURGERY, V38, P12, DOI 10.1097/00006123-199601000-00004; SCHLENK F, 2008, IN PRESS INTENSIVE C; Scott JF, 1999, STROKE, V30, P793, DOI 10.1161/01.STR.30.4.793; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	21	69	70	0	0	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2008	12	1							R9	10.1186/cc6776			7	Critical Care Medicine	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	285YQ	WOS:000254812500049	18218076	gold, Green Published			2022-02-06	
J	Vannatta, K; Gerhardt, CA; Wells, RJ; Noll, RB				Vannatta, Kathryn; Gerhardt, Cynthia A.; Wells, Robert J.; Noll, Robert B.			Intensity of CNS treatment for pediatric cancer: Prediction of social outcomes in survivors	PEDIATRIC BLOOD & CANCER			English	Article						late effects; methotrexate; pediatric oncology; psychosocial; radiation therapy	ACUTE LYMPHOBLASTIC-LEUKEMIA; TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVORS; CHILDHOOD-CANCER; LEARNING-DISABILITIES; PEER RELATIONSHIPS; PSYCHOLOGICAL ADJUSTMENT; CRANIAL IRRADIATION; WHOLE-BRAIN; CHILDREN	Purpose. To evaluate the association of central nervous system (CNS) treatment intensity and the social functioning of children who have completed treatment for leukemia, lymphoma, and solid tumors outside the CNS. Furthermore, we expected that these associations would be moderated by child age at diagnosis and gender. Method. Peer, teacher, and self-report data were obtained for 82 cancer survivors (age 9-17 years) using classroom rating and nomination procedures that are widely used in research on social development. Information regarding cranial radiation therapy (CRT), intrathecal chemotherapy (ITC), and systemic methotrexate were obtained from medical records and used to create a composite index of CNS treatment intensity. Results. Higher scores on the index of CNS treatment intensity were associated with poorer peer acceptance, fewer friendships, greater social sensitivity-isolation, and diminished leadership-popularity based on peer-report. These associations were stronger for boys and children who were younger (<10 years old) at diagnosis. In contrast, CNS treatment intensity was only predictive of teacher-perceptions of aggressive-disruptive behavior and it was unrelated to social self-perceptions. Conclusion. These results suggest that children who receive CRT and ITC are at risk for problematic peer relations, particularly if they are male or younger at diagnosis. Given the stability of poor peer relationships and documented linkages between peer problems and subsequent academic and psychiatric difficulties, clinical services should address these issues. Research is needed to identify mechanisms that account for these outcomes and provide direction for prevention and treatment efforts.	Columbus Childrens Res Inst, Ctr Biobehav Hlth, Columbus, OH 43205 USA; Ohio State Univ, Columbus, OH 43210 USA; Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; Childrens Hosp Pittsburgh, Child Dev Unit, Pittsburgh, PA 15213 USA		Vannatta, K (corresponding author), Columbus Childrens Res Inst, Ctr Biobehav Hlth, Rm G361,700 Childrens Dr, Columbus, OH 43205 USA.	vannattk@pediatrics.ohio-state.edu	Vannatta, Kathryn/E-4237-2011; Gerhardt, Cynthia/E-3109-2011				Achenbach TM, 1991, MANUAL CHILD BEHAV C; Armstrong FD, 2005, J PEDIATR PSYCHOL, V30, P89, DOI 10.1093/jpepsy/jsi020; Armstrong FD, 1999, SCHOOL PSYCHOL REV, V28, P194; ASHER SR, 1979, DEV PSYCHOL, V15, P443, DOI 10.1037/0012-1649.15.4.443; Bleyer WA, 1997, EUR J CANCER, V33, P1439, DOI 10.1016/S0959-8049(97)00249-9; Brown RT, 1998, J PEDIATR PSYCHOL, V23, P333, DOI 10.1093/jpepsy/23.5.333; Bukowski W.M., 1989, PEER RELATIONS CHILD, P15; BUTLER RW, 1994, J CLIN ONCOL, V12, P2621, DOI 10.1200/JCO.1994.12.12.2621; Copeland DR, 1996, J CLIN ONCOL, V14, P2826, DOI 10.1200/JCO.1996.14.10.2826; CRICK NR, 1994, PSYCHOL BULL, V115, P74, DOI 10.1037/0033-2909.115.1.74; Deater-Deckard K, 2001, J CHILD PSYCHOL PSYC, V42, P565, DOI 10.1017/S0021963001007272; Dennis M, 2001, BRAIN LANG, V78, P1, DOI 10.1006/brln.2000.2431; Fuemmeler BF, 2002, CLIN PSYCHOL REV, V22, P547, DOI 10.1016/S0272-7358(01)00120-9; Fuss M, 2000, STRAHLENTHER ONKOL, V176, P573, DOI 10.1007/PL00002327; Guralnick MJ, 1999, MENT RETARD DEV D R, V5, P21; HAUPT R, 1994, JAMA-J AM MED ASSOC, V272, P1427, DOI 10.1001/jama.272.18.1427; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Kavale KA, 1996, J LEARN DISABIL, V29, P226, DOI 10.1177/002221949602900301; KUPST MJ, 1995, J PEDIATR PSYCHOL, V20, P601, DOI 10.1093/jpepsy/20.5.601; Lemerise EA, 2000, CHILD DEV, V71, P107, DOI 10.1111/1467-8624.00124; MASTEN AS, 1985, DEV PSYCHOL, V21, P523, DOI 10.1037/0012-1649.21.3.523; MORISON P, 1991, CHILD DEV, V62, P991, DOI 10.1111/j.1467-8624.1991.tb01585.x; Mulhern Raymond K, 2004, Pediatr Rehabil, V7, P1, DOI 10.1080/13638490310001655528; MULHERN RK, 1991, J CLIN ONCOL, V9, P1348, DOI 10.1200/JCO.1991.9.8.1348; MULHERN RK, 1989, PEDIATRICS, V83, P18; Mulhern RK, 2004, PEDIAT REHABIL, V7, P15; Nassau JH, 1997, J PEDIATR PSYCHOL, V22, P771, DOI 10.1093/jpepsy/22.6.771; Newby WL, 2000, PSYCHO-ONCOL, V9, P113; NOLL RB, 1991, J PEDIATR PSYCHOL, V16, P307, DOI 10.1093/jpepsy/16.3.307; NOLL RB, 1993, J PEDIATR PSYCHOL, V18, P351, DOI 10.1093/jpepsy/18.3.351; Noll RB, 1999, PEDIATRICS, V103, P71, DOI 10.1542/peds.103.1.71; Nowicki EA, 2003, LEARN DISABILITY Q, V26, P171, DOI 10.2307/1593650; PARKER JG, 1987, PSYCHOL BULL, V102, P357, DOI 10.1037/0033-2909.102.3.357; PARKER JG, 1995, DEV PSYCHOPATHOLOGY, V0002, P00096; Patel SK, 2005, J PEDIATR PSYCHOL, V30, P85, DOI 10.1093/jpepsy/jsi019; PERRIN EC, 1991, J PEDIATR PSYCHOL, V16, P411, DOI 10.1093/jpepsy/16.4.411; Reaman Gregory H, 2005, Clin Adv Hematol Oncol, V3, P133; Reiter-Purtill J, 2003, J PEDIATR PSYCHOL, V28, P17, DOI 10.1093/jpepsy/28.1.17; Sawyer M, 2000, J PEDIAT HEMATOL ONC, V22, P214, DOI 10.1097/00043426-200005000-00006; SILBER JH, 1992, J CLIN ONCOL, V10, P1390, DOI 10.1200/JCO.1992.10.9.1390; SPIRITO A, 1990, J PEDIATR PSYCHOL, V15, P359, DOI 10.1093/jpepsy/15.3.359; Vance YH, 2002, CHILD CARE HLTH DEV, V28, P5, DOI 10.1046/j.1365-2214.2002.00227.x; Vannatta K, 1998, J PEDIATR PSYCHOL, V23, P279, DOI 10.1093/jpepsy/23.5.279; Vannatta K, 1998, J PEDIATR PSYCHOL, V23, P169, DOI 10.1093/jpepsy/23.3.169; VARNI JW, 1993, J PEDIATR PSYCHOL, V18, P751, DOI 10.1093/jpepsy/18.6.751; Waber DP, 2004, J CLIN ONCOL, V22, P2701, DOI 10.1200/JCO.2004.10.173; Warschausky S, 2003, REHABIL PSYCHOL, V48, P250, DOI 10.1037/0090-5550.48.4.250; Wiener J, 2002, J ABNORM CHILD PSYCH, V30, P127, DOI 10.1023/A:1014701215315; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zeller M, 2003, DEV PSYCHOL, V39, P129, DOI 10.1037//0012-1649.39.1.129	50	69	69	0	9	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1545-5009			PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	OCT 15	2007	49	5					716	722		10.1002/pbc.21062			7	Oncology; Hematology; Pediatrics	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Oncology; Hematology; Pediatrics	205AO	WOS:000249085300020	17096410				2022-02-06	
J	Jorge, RE; Acion, L; Starkstein, SE; Magnotta, V				Jorge, Ricardo E.; Acion, Laura; Starkstein, Sergio E.; Magnotta, Vincent			Hippocampal volume and mood disorders after traumatic brain injury	BIOLOGICAL PSYCHIATRY			English	Article						glial loss; hippocampal; mood disorder; TBI	STRUCTURED CLINICAL INTERVIEW; HUMAN HEAD-INJURY; MAJOR DEPRESSION; GERIATRIC DEPRESSION; ACUTE PREDICTORS; TIME-COURSE; ATROPHY; MRI; MEMORY; RAT	Background: Recent evidence from clinical studies and animal models of traumatic brain injury (TBI) suggest that neuronal and glial loss might progress after the initial insult in selectively vulnerable regions of the brain such as the hippocampus. There is also evidence that hippocampal dysfunction plays a role in the pathogenesis of mood disorders. We examined the relationship between hippocampal damage and mood disorders after TBI and the effect of hippocampal atrophy on the outcome of TBI patients. Methods: The study group consisted of 37 patients with closed head injury who were evaluated at baseline and at 3,6, and 12 months after trauma. Psychiatric diagnosis was made with a structured clinical interview and DSM-IV criteria. Quantitative magnetic resonance imaging scans were obtained at 3-months follow-up. Results: Patients with moderate to severe head injury had significantly lower hippocampal volumes than patients with mild TBI. Patients who developed mood disorders had significantly lower hippocampal volumes than patients without mood disturbance. Furthermore, there was a significant interaction between mood disorders diagnosis and severity of TBI, by which patients with moderate to severe TBI who developed mood disorders had significantly smaller hippocampal volumes than patients with equivalent severe TBI who did not develop mood disturbance. Finally, reduced hippocampal volumes were associated with poor vocational outcome at 1-year follow-up. Conclusions: Our findings are consistent with a "double-hit" mechanism by which neural and glial elements already affected by trauma are further compromised by the functional changes associated with mood disorders (e.g., the neurotoxic effects of increased levels of cortisol or excitotoxic damage resulting from overactivation of glutaminergic pathways). Finally, patients with greater hippocampal damage were less likely to return to a productive life 1 year after trauma.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Univ Western Australia, Dept Psychiat, Perth, WA 6009, Australia		Jorge, RE (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, Psychiat Res 2-202 MEB, Iowa City, IA 52242 USA.	ricardo-jorge@uiowa.edu		Magnotta, Vincent/0000-0001-8639-5354; Acion, Laura/0000-0001-5213-6012	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH53592, MH52879, MH40355] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355, R01MH053592, R01MH052879] Funding Source: NIH RePORTER		ANDREASEN NC, 1994, P NATL ACAD SCI USA, V91, P93, DOI 10.1073/pnas.91.1.93; ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; Andreasen NC, 1996, J COMPUT ASSIST TOMO, V20, P98, DOI 10.1097/00004728-199601000-00018; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; ANDREASEN NC, 1977, ARCH GEN PSYCHIAT, V34, P1229; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; AXELSON DA, 1993, PSYCHIAT RES, V47, P163, DOI 10.1016/0165-1781(93)90046-J; Bell-McGinty S, 2002, AM J PSYCHIAT, V159, P1424, DOI 10.1176/appi.ajp.159.8.1424; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Bigler ED, 2003, ARCH CLIN NEUROPSYCH, V18, P595; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brown ES, 1999, NEUROPSYCHOPHARMACOL, V21, P474, DOI 10.1016/S0893-133X(99)00054-8; Campbell S, 2004, AM J PSYCHIAT, V161, P598, DOI 10.1176/appi.ajp.161.4.598; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; COHEN G, 1992, PSYCHIAT RES-NEUROIM, V45, P33, DOI 10.1016/0925-4927(92)90012-S; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; DeLorenzo RJ, 2005, PHARMACOL THERAPEUT, V105, P229, DOI 10.1016/j.pharmthera.2004.10.004; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; ENTON AL, 1994, MULTILINGUAL APHASIA; Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frodl T, 2004, ARCH GEN PSYCHIAT, V61, P177, DOI 10.1001/archpsyc.61.2.177; Frodl T, 2002, AM J PSYCHIAT, V159, P1112, DOI 10.1176/appi.ajp.159.7.1112; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gold JJ, 2005, HIPPOCAMPUS, V15, P79, DOI 10.1002/hipo.20032; Golden CJ, 1978, STROOP COLOR WORD TE; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hajek T, 2005, BIPOLAR DISORD, V7, P393, DOI 10.1111/j.1399-5618.2005.00238.x; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Heaton PDRK., 1993, WISCONSIN CARD SORTI; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Koura SS, 1998, ACT NEUR S, V71, P244; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MACKENZIE EJ, 1985, MED CARE, V23, P823, DOI 10.1097/00005650-198506000-00008; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Magnotta VA, 1999, CEREB CORTEX, V9, P151, DOI 10.1093/cercor/9.2.151; McCarthy MM, 2003, EXP NEUROL, V184, P40, DOI 10.1016/j.expneurol.2003.08.020; McEwen BS, 2000, NEUROPSYCHOPHARMACOL, V22, P108, DOI 10.1016/S0893-133X(99)00129-3; Mervaala E, 2000, PSYCHOL MED, V30, P117, DOI 10.1017/S0033291799001567; Nathoo N, 2004, J NEUROSURG, V101, P233, DOI 10.3171/jns.2004.101.2.0233; Pantel J, 2000, HIPPOCAMPUS, V10, P752, DOI 10.1002/1098-1063(2000)10:6<752::AID-HIPO1012>3.0.CO;2-Y; Phillips LL, 2001, RESTOR NEUROL NEUROS, V19, P213; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; REITAN RM, 1971, PERCEPT MOTOR SKILL, V33, P575, DOI 10.2466/pms.1971.33.2.575; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1999, J NEUROSCI, V19, P5034; Shiozaki T, 2001, J NEUROTRAUM, V18, P665, DOI 10.1089/089771501750357618; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Starr L B, 1982, Soc Work Res Abstr, V18, P28; Steffens DC, 2000, BIOL PSYCHIAT, V48, P301, DOI 10.1016/S0006-3223(00)00829-5; Stone JR, 2002, J NEUROTRAUM, V19, P601, DOI 10.1089/089771502753754073; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Vythilingam M, 2002, AM J PSYCHIAT, V159, P2072, DOI 10.1176/appi.ajp.159.12.2072; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589	92	69	69	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223			BIOL PSYCHIAT	Biol. Psychiatry	AUG 15	2007	62	4					332	338		10.1016/j.biopsych.2006.07.024			7	Neurosciences; Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry	198WL	WOS:000248658100009	17123480				2022-02-06	
J	Shimono, H; Okada, M; Kanda, E; Arakawa, I				Shimono, Hiroyuki; Okada, Masumi; Kanda, Eiji; Arakawa, Ichiro			Low temperature-induced sterility in rice: Evidence for the effects of temperature before panicle initiation	FIELD CROPS RESEARCH			English	Article						cool damage; panicle development; simulation model; spikelet sterility; rice	YOUNG MICROSPORE STAGE; SPIKELET STERILITY; WATER TEMPERATURE; COOLING TREATMENT; INJURY; PLANTS; TOLERANCE; RESPONSES; GROWTH; YIELD	Spikelet sterility of rice (Oryza sativa L.) results from low temperatures during particle development. However, this temperature alone cannot fully explain the fluctuations in sterility observed in the field, since the susceptibility of rice plants to low temperature often changes according to its physiological status during sensitive stages. In the present study, we examined whether temperatures before the particle initiation stage (PI) influence the plant's susceptibility to sterility during panicle development. To test this, we conducted a 2-year pot study and an analysis of field data using a model of cooling degree-days (CDD). In the pot study, the air temperature (T-a) and water temperature (T-w) were controlled independently for 3 weeks during the vegetative growth stage before PI. After PI, the plants were submerged in a cool water bath at a critical temperature of 19.5 degrees C to induce floral sterility. We found that low T-w during vegetative growth significantly increased the sterility. Low T-a during vegetative growth also significantly increased the sterility, but this effect was diminished by warm T-w even at low T-a. There was a close and negative correlation between sterility and T-w during vegetative growth. In the analysis of field data, we introduced CDD using temperatures below a threshold level of 20 degrees C to represent the magnitude of the exposure to low temperature from PI to the heading stage. Data of T-a was used for this analysis because data of T-w was scare. The CDD model was applied to 77 independent data sets collected at nine Agricultural Research Centers during four typical cool summers (1980, 1988, 1993, and 2003) in northern Japan. Year-to-year variations in sterility at one site were roughly accounted for by the variations in CDD, but large deviations were observed among the years. The deviations were related to T-a averaged over the 30-day period before PI. For a similar level of CDD, the lower the T-a before PI, the greater the sterility. Similar deviations were observed in the between-site relationships between sterility and CDD, and these deviations were related with the T-a before PI. These results suggest that temperatures before PI, and especially T-w change the susceptibility of a rice plant to low temperatures during panicle development. (c) 2006 Elsevier B.V. All rights reserved.	Natl Agr Res Ctr, Shimokuriyagawa, Iwate 0200198, Japan; Fukushima Agr Technol Ctr, Fukushima 9696506, Japan		Shimono, H (corresponding author), USDA ARS, Beltsville Agr Res Ctr, Crop Syst & Global Change Lab, 10300 Baltimore Ave, Beltsville, MD 20705 USA.	shimn@affrc.go.jp		Shimono, Hiroyuki/0000-0002-7328-0483			AMANO T, 1984, JPN J CROP SCI, V53, P7, DOI 10.1626/jcs.53.7; AMANO T, 1984, JPN J CROP SCI, V53; BOARD JE, 1980, AGRON J, V72, P483, DOI 10.2134/agronj1980.00021962007200030019x; COLLINSON ST, 1995, EXP AGR, V31, P151, DOI 10.1017/S0014479700025230; DINGKUHN M, 1995, AGR SYST, V48, P385, DOI 10.1016/0308-521X(94)00027-I; Farrell TC, 2006, FIELD CROP RES, V98, P178, DOI 10.1016/j.fcr.2006.01.003; GODWIN DC, 1994, AUST J EXP AGR, V34, P921, DOI 10.1071/EA9940921; Gunawardena TA, 2003, AUST J AGR RES, V54, P947, DOI 10.1071/AR03076; HAYASE H, 1969, P CROP SCI SOC JPN, V38, P706, DOI DOI 10.1626/JCS.38.706; IRRI, 2002, RIC ALM SOURC BOOK M; Ito N., 1976, Proceedings of the Crop Science Society of Japan, V45, P558; Kanda E, 2000, JPN J CROP SCI, V69, P540, DOI 10.1626/jcs.69.540; Kaneda C., 1974, SABRAO Journal, V6, P17; KONDO Y, 1952, B NATL I AGR SCI D, V3, P114; MATSUZAKI A, 1971, P CROP SCI SOC JPN, V40, P519; Nagano K., 1999, BREED RES, V1, P33; NAKAGAWA H, 1995, JPN J CROP SCI, V64, P33, DOI 10.1626/jcs.64.33; Okada M., 2000, Biotronics, V29, P43; Okada M., 2005, J AGRIC METEOROL, V60, P589; OZAWA K, 1994, SOL ENERGY, V20, P23; Sameshima Ryoji, 2004, Journal of Agricultural Meteorology, V60, P67, DOI 10.2480/agrmet.60.67; SATAKE T, 1987, JPN J CROP SCI, V56, P404; SATAKE T, 1988, JPN J CROP SCI, V57, P234, DOI 10.1626/jcs.57.234; Satake T., 1976, RES B HOKKIDO NATL A, V113, P1; SHIMAZAKI Y., 1963, Research Bulletin. Hokkaido National Agricultural Experiment Station, V80, P1; Shimono H, 2005, AGRON J, V97, P1524, DOI 10.2134/agronj2005.0043; Shimono H, 2002, FIELD CROP RES, V73, P67, DOI 10.1016/S0378-4290(01)00184-8; Shimono H, 2004, FIELD CROP RES, V89, P71, DOI 10.1016/j.fcr.2004.01.025; Shimono H, 2007, AGR ECOSYST ENVIRON, V118, P223, DOI 10.1016/j.agee.2006.05.015; Uchijima T., 1976, J AGRIC METEOROL, V31, P199, DOI [10.2480/agrmet.31.199, DOI 10.2480/AGRMET.31.199]; Wada S., 1972, Proceedings of the Crop Science Society of Japan, V41, P340; Yajima M., 1989, 1989 ANN M AGR MET S, P58; YAMAMOTO T, 1986, JPN J BREED, V36, P147; Zhang ZJ, 2001, JPN J CROP SCI, V70, P84, DOI 10.1626/jcs.70.84	34	69	85	0	31	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0378-4290	1872-6852		FIELD CROP RES	Field Crop. Res.	MAR 5	2007	101	2					221	231		10.1016/j.fcr.2006.11.010			11	Agronomy	Science Citation Index Expanded (SCI-EXPANDED)	Agriculture	135KY	WOS:000244153700010					2022-02-06	
J	Isele, NB; Lee, HS; Landshamer, S; Straube, A; Padovan, CS; Plesnila, N; Culmsee, C				Isele, Nicola B.; Lee, Hea-Sook; Landshamer, Stefan; Straube, Andreas; Padovan, Claudio S.; Plesnila, Nikolaus; Culmsee, Carsten			Bone marrow stromal cells mediate protection through stimulation of PI3-K/Akt and MAPK signaling in neurons	NEUROCHEMISTRY INTERNATIONAL			English	Article						apoptosis; neuroprotection; conditioned medium; staurosporine; amyloid-beta; growth factors	GROWTH-FACTOR PRODUCTION; TRAUMATIC BRAIN-INJURY; FACTOR-KAPPA-B; PHOSPHATIDYLINOSITOL 3-KINASE; FUNCTIONAL RECOVERY; REGULATED KINASE; PROTEIN-KINASE; SPINAL-CORD; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION	Application of adult bone marrow stromal cells (BMSC) improves functional outcome in animal models of cerebral ischemia, traumatic brain injury, and spinal cord injury. Accumulating evidence suggests that such functional recovery after BMSC treatment is mediated by enhanced trophic support of the injured neurons and improved neuronal plasticity rather than tissue replacement by bone marrow-derived stem cells. Therefore, the aim of the present study was to explore the potential of non-hematopoietic BMSC to stimulate signaling pathways in neurons that mediate trophic effects and neuroprotection. In primary embryonic rat neurons, BMSC conditioned medium (CM) attenuated staurosporine (STS) or amyloid-beta peptide-induced apoptosis in a concentration-dependent manner. The neuroprotective effect of CM required several hours of pretreatment and was abolished by heating over 90 degrees C. Immunoblot analyses revealed that CM enhanced Erk1/2 and Akt phosphorylation in neurons, and the specific MEK1 inhibitor PD98059 or the phosphomositide-3 kinase (PI3-K) inhibitor Ly294002 abolished the neuroprotective effect of CM. Further, double-conditioned medium (DCM) obtained from BMSC previously stimulated by medium from STS-challenged neurons showed a more potent anti-apoptotic effect compared to the single-conditioned medium. Overall, these findings demonstrate that BMSC trigger endogenous survival signaling pathways in neurons that mediate protection against apoptotic insults. Moreover, the interaction between stressed neurons and BMSC further amplifies the observed neuroprotective effect. (c) 2006 Elsevier Ltd. All rights reserved.	Dept Pharm, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Dept Neurol, D-81377 Munich, Germany; Univ Munich, Med Ctr, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Inst Surg Res, D-81377 Munich, Germany		Culmsee, C (corresponding author), Dept Pharm, D-81377 Munich, Germany.	carsten.culmsee@cup.uni-muenchen.de	Plesnila, Nikolaus/T-7522-2019; Culmsee, Carsten/ABC-3120-2021	Culmsee, Carsten/0000-0002-5121-5015			Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson CNG, 1999, J NEUROSCI, V19, P664; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Culmsee C, 2005, MOL PHARMACOL, V68, P1006, DOI 10.1124/mol.105.013086; Culmsee C, 2003, J NEUROSCI, V23, P8586; Culmsee C, 2002, NEUROSCIENCE, V115, P1089, DOI 10.1016/S0306-4522(02)00539-0; Culmsee C, 2001, J NEUROCHEM, V77, P220, DOI 10.1046/j.1471-4159.2001.00220.x; Culmsee C., 2005, DRUG DISCOV TODAY, V2, P463, DOI DOI 10.1016/J.DDMEC.2005.11.006; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; Gao Q, 2005, NEUROSCIENCE, V136, P123, DOI 10.1016/j.neuroscience.2005.06.091; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; Li Y, 2006, EXP NEUROL, V198, P313, DOI 10.1016/j.expneurol.2005.11.029; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Sensebe L, 1997, STEM CELLS, V15, P133, DOI 10.1002/stem.150133; TOCCI A, 2003, HEMATOL J, V2, P92; Yano S, 2005, BRAIN RES, V1065, P60, DOI 10.1016/j.brainres.2005.10.031; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zhu Y, 2004, NEUROSCIENCE, V123, P897, DOI 10.1016/j.neuroscience.2003.10.037; Zhu Y, 2002, J NEUROSCI, V22, P3898, DOI 10.1523/JNEUROSCI.22-10-03898.2002	42	69	101	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186			NEUROCHEM INT	Neurochem. Int.	JAN	2007	50	1					243	250		10.1016/j.neuint.2006.08.007			8	Biochemistry & Molecular Biology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Neurosciences & Neurology	128GA	WOS:000243645000028	17050038				2022-02-06	
J	Bailey, CM; Echemendia, RJ; Arnett, PA				Bailey, Christopher M.; Echemendia, Ruben J.; Arnett, Peter A.			The impact of motivation on neuropsychological performance in sports-related mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; closed head injury; athletics; psychological tests; psychometrics; incentive	CONCUSSION	The current project examined the impact of differential motivation on baseline versus post-mild traumatic brain injury (MTBI) neuropsychological measures in athletes. Collegiate athletes were administered a neuropsychological battery prior to and post-MTBI. High Motivation at Baseline (HMB) and Suspect Motivation at Baseline (SMB) groups were established for each measure based on whether baseline performance fell +/- one or more standard deviations from the mean of the given measure. Greater improvement was expected in the SMB group than the HMB group given hypothesized differences in baseline motivation. In repeated measures analysis of covariance (ANCOVA) that removed achievement performance, the SMB groups demonstrated greater improvement than the HMB groups for the Trail Making Test A & B (TMT-A & B), Digit Span, and Stroop-Color Word (Stroop-CW) tests. Also, the percentage of participants who improved according to reliable change indices was greater for the SMB groups on the TMT-A & B, Stroop-CW, and the Vigil. These findings are likely due to lower motivation in the SMB group for each test. However, results also suggest that some tests may be relatively unaffected by motivation. These data may have clinical implications and point to the need for better methods of identifying athletes with suspect motivation at baseline.	Penn State Univ, Dept Psychol, University Pk, PA 16802 USA; Psychol & Neurobehav Associates, State Coll, PA USA		Bailey, CM (corresponding author), Penn State Univ, Dept Psychol, 314 Moore Bldg, University Pk, PA 16802 USA.	cmb373@psu.edu	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Alves W, 1993, J HEAD TRAUMA REHABI, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Barth JT, 1989, MILD HEAD INJURY, P257; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; BINDER RL, 1991, AM J PSYCHIAT, V148, P1073; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cegalis J.A., 1994, VIGIL W CONTINUOUS P; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Echemendia R., 2006, SPORTS NEUROPSYCHOLO; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; Greiffenstein MF., 1994, PSYCHOL ASSESS, V6, P218, DOI [10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Levine AJ, 2004, CLIN NEUROPSYCHOL, V18, P373, DOI 10.1080/1385404049052420; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SCHUNK DH, 1995, J APPL SPORT PSYCHOL, V7, P112, DOI 10.1080/10413209508406961; Smith A., 1982, SYMBOL DIGIT MODALIT; SPEER DC, 1995, J CONSULT CLIN PSYCH, V63, P1044, DOI 10.1037/0022-006X.63.6.1044; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Spreen O, 1991, COMPENDIUM NEUROPSYC; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Trenerry MR, 1989, STROOP NEUROPSYCHOLO; Urbina S, 1997, PSYCHOL TESTING; Wechsler D, 1997, WECHSLER ADULT INTEL, Vthird	36	69	69	0	6	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2006	12	4					475	484		10.1017/S1355617706060619			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Psychiatry; Psychology	063DU	WOS:000238997300004	16981599				2022-02-06	
J	Liu-Snyder, P; McNally, H; Shi, R; Ben Borgens, R				Liu-Snyder, Peishan; McNally, Helen; Shi, Riyi; Ben Borgens, Richard			Acrolein-mediated mechanisms of neuronal death	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						acrolein; endogenous toxin; secondary injury; neurotrauma; lipid peroxidation	SPINAL-CORD-INJURY; AXONAL MEMBRANE DISRUPTION; CONTROLLED TRIAL; CONDUCTION LOSS; METHYLPREDNISOLONE; CHEMISTRY; NALOXONE	It is well known that traumatic injury in the central nervous system can be viewed as a primary injury and a secondary injury. Increases in oxidative stress lead to breakdown of membrane lipids (lipid peroxidation) during secondary injury. Acrolein, an alpha, beta-unsaturated aldehyde, together with other aldehydes, increases as a result of self-propagating lipid peroxidation. Historically, most research on the pathology of secondary injury has focused on reactive oxygen species (ROS) rather than lipid peroxidation products. Little is known about the toxicology and cell death mediated by these aldehydes. In this study, we investigated and characterized certain features of cell death induced by acrolein on PC12 cells as well as cells from dorsal root ganglion (DRG) and sympathetic ganglion in vitro. In the companion paper, we evaluated a possible means to interfere with this toxicity by application of a compound that can bind to and inactivate acrolein. Here we use both light and atomic force microscopy to study cell morphology after exposure to acrolein. Administration of 100 M acrolein caused a dramatic change in cell morphology as early as 4 hr. Cytoskeletal structures significantly deteriorated after exposure to 100 mu M acrolein as demonstrated by fluorescence microscopy, whereas calpain activity increased significantly at this concentration. Cell viability assays indicated significant cell death with 100 mu M acrolein by 4 hr. Caspase 3 activity and DNA fragmentation assays were performed and supported the notion that 100 mu M acrolein induced PC12 cell death by the mechanism of necrosis, not apoptosis. (c) 2006 Wiley-Liss, Inc.	Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, Sch Vet Med, W Lafayette, IN 47907 USA; Purdue Univ, Coll Engn, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA		Ben Borgens, R (corresponding author), Purdue Univ, Ctr Paralysis Res, Dept Basic Med Sci, Sch Vet Med, 408 S Univ St, W Lafayette, IN 47907 USA.	cpr@purdue.edu					BORGENS RB, 2003, ADV ANATOMY EMBRYOLO; BRACKEN MB, 1985, J NEUROSURG, V63, P704, DOI 10.3171/jns.1985.63.5.0704; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; BRONK SF, 1993, AM J PHYSIOL, V264, P744; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; Goslin, 1998, CULTURING NERVE CELL, P261; HALLED, 1993, ADV NEUROL, V59, P241; Higgins D., 1998, CULTURING NERVE CELL, P37; Luo J, 2005, NEUROCHEM RES, V30, P291, DOI 10.1007/s11064-005-2602-7; McNally HA, 2004, J NEUROCYTOL, V33, P251, DOI 10.1023/B:NEUR.0000030700.48612.0b; Nardini M, 2002, TOXICOLOGY, V170, P173, DOI 10.1016/S0300-483X(01)00540-6; Peasley MA, 2003, J NEUROL SCI, V216, P23, DOI 10.1016/S0022-510X(03)00201-6; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Satoh K, 1999, ANAL BIOCHEM, V270, P323, DOI 10.1006/abio.1999.4073; Shi R, 2002, NEUROSCIENCE, V115, P337, DOI 10.1016/S0306-4522(02)00457-8; Short DJ, 2000, SPINAL CORD, V38, P273, DOI 10.1038/sj.sc.3100986	21	69	70	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUL	2006	84	1					209	218		10.1002/jnr.20863			10	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	061UD	WOS:000238897400019	16619238				2022-02-06	
J	Love, S; Siew, LK; Dawbarn, D; Wilcock, GK; Ben-Shlomo, Y; Allen, SJ				Love, Seth; Siew, L. Khai; Dawbarn, David; Wilcock, Gordon K.; Ben-Shlomo, Yoav; Allen, Shelley J.			Premorbid effects of APOE on synaptic proteins in human temporal neocortex	NEUROBIOLOGY OF AGING			English	Article						Alzheimer's disease; apolipoprotein E; normal brain; postsynaptic density-95; synapse; synaptophysin; syntaxin 1	APOLIPOPROTEIN-E EPSILON-4; CEREBRAL AMYLOID ANGIOPATHY; TRAUMATIC BRAIN-INJURY; E ALLELE EPSILON-4; ALZHEIMERS-DISEASE; E GENOTYPE; HEAD-INJURY; INTRACEREBRAL HEMORRHAGE; NEUROFIBRILLARY TANGLES; PARKINSONS-DISEASE	APOE affects the risk of Alzheimer's disease (AD) and course of several other neurologic diseases. Experimental studies suggest that APOE influences synaptogenesis. We measured the concentration of two presynaptic proteins, synaptophysin and syntaxin 1, and also postsynaptic density-95 (PSD95), in superior temporal cortex from 42 AD and 160 normal brains, and determined the APOE genotypes. The concentration of both presynaptic proteins was approximately two-thirds lower in AD than normal brains and that of PSD95 one-third lower. No effect of APOE on synaptic proteins was found in advanced AD. However, in normal brain, epsilon 4 was associated with lower concentrations of all three synaptic proteins and epsilon 2 with significantly elevated PSD95 (p = 0.03). A combined measure of synaptic proteins showed a significant linear decrease from epsilon 2 through epsilon 3 to epsilon 4 (p = 0.01). APOE influences the concentration of synaptic proteins in normal superior temporal cortex and may thereby affect the response to injury, and the risk and outcome of a range of neurologic diseases. (c) 2005 Elsevier Inc. All rights reserved.	Univ Bristol, Dept Neuropathol, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England; Univ Bristol, Henry Wellcome Labs Integrat Neurosci & Endocrino, Bristol BS1 3NY, Avon, England; Univ Bristol, Dept Care & Elderly, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England		Love, S (corresponding author), Univ Bristol, Dept Neuropathol, Inst Clin Neurosci, Frenchay Hosp, Bristol BS16 1LE, Avon, England.	seth.love@bris.ac.uk	Love, Seth/E-6545-2012; Ben-Shlomo, Yoav/ABD-2004-2021	Allen, Shelley/0000-0001-7870-740X; Love, Seth/0000-0001-8683-3625; Ben-Shlomo, Yoav/0000-0001-6648-3007			Ahles TA, 2003, PSYCHO-ONCOL, V12, P612, DOI 10.1002/pon.742; Allen SJ, 1997, NEUROSCI LETT, V239, P33, DOI 10.1016/S0304-3940(97)00872-0; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bickeboller H, 1997, AM J HUM GENET, V60, P439; Blanche H, 2001, CR ACAD SCI III-VIE, V324, P129, DOI 10.1016/S0764-4469(00)01274-9; Bleich S, 2003, J NEURAL TRANSM, V110, P401, DOI 10.1007/s00702-002-0789-1; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CALLAHAN LM, 1995, NEUROBIOL AGING, V16, P311, DOI 10.1016/0197-4580(95)00035-D; Callahan LM, 2002, J NEUROPATH EXP NEUR, V61, P384, DOI 10.1093/jnen/61.5.384; Chalmers K, 2003, NEUROPATH APPL NEURO, V29, P231, DOI 10.1046/j.1365-2990.2003.00457.x; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corey-Bloom J, 2000, NEUROLOGY, V54, P403, DOI 10.1212/WNL.54.2.403; De Stefano N, 2004, ARCH NEUROL-CHICAGO, V61, P536, DOI 10.1001/archneur.61.4.536; DeMattos RB, 1998, J BIOL CHEM, V273, P4206, DOI 10.1074/jbc.273.7.4206; Drory VE, 2001, J NEUROL SCI, V190, P17, DOI 10.1016/S0022-510X(01)00569-X; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; FARRER LA, 1995, EXP NEUROL, V136, P162, DOI 10.1006/exnr.1995.1093; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.0.CO;2-A; GomezIsla T, 1996, ANN NEUROL, V39, P62, DOI 10.1002/ana.410390110; Harhangi BS, 2000, NEUROLOGY, V54, P1272, DOI 10.1212/WNL.54.6.1272; Hunt CA, 1996, J NEUROSCI, V16, P1380; Igbavboa U, 2002, J NEUROCHEM, V80, P255, DOI 10.1046/j.0022-3042.2001.00688.x; Kalman J, 2000, NEUROBIOL AGING, V21, P555, DOI 10.1016/S0197-4580(00)00150-0; Landen M, 1996, J NEUROL NEUROSUR PS, V61, P352, DOI 10.1136/jnnp.61.4.352; Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7; Love S, 2003, NEUROREPORT, V14, P1535, DOI 10.1097/00001756-200308060-00027; LOVE S, 2000, NEUROPATHOL APPL NEU, V26, P203; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Mahley RW, 1996, ANN NY ACAD SCI, V777, P139, DOI 10.1111/j.1749-6632.1996.tb34412.x; Masliah E, 1997, ANN NEUROL, V42, P963, DOI 10.1002/ana.410420618; MASLIAH E, 1991, ACTA NEUROPATHOL, V81, P428, DOI 10.1007/BF00293464; MATSUMOTO S, 2003, NEUROLOGY, P60; Mattila PM, 1998, ACTA NEUROPATHOL, V96, P417, DOI 10.1007/s004010050913; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McCarron MO, 2003, ACTA NEUROL SCAND, V107, P106, DOI 10.1034/j.1600-0404.2003.01365.x; McCarron MO, 1999, NEUROLOGY, V53, P2176, DOI 10.1212/WNL.53.9.2176; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Morris CM, 1995, NEUROSCI LETT, V201, P45, DOI 10.1016/0304-3940(94)12126-B; Muramatsu T, 1997, J NEURAL TRANSM, V104, P913, DOI 10.1007/BF01285559; Olichney JM, 1996, NEUROLOGY, V47, P190, DOI 10.1212/WNL.47.1.190; Pickering-Brown SM, 2000, EXP NEUROL, V163, P452, DOI 10.1006/exnr.2000.7387; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; Poirier J, 1998, J NEURAL TRANSM-SUPP, P199; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Reiman EM, 2004, P NATL ACAD SCI USA, V101, P284, DOI 10.1073/pnas.2635903100; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Sheng M, 2001, J CELL SCI, V114, P1251; Siew LK, 2004, J NEUROSCI METH, V139, P153, DOI 10.1016/j.jneumeth.2004.04.020; Sterne, 2003, ESSENTIAL MED STAT; Tang MX, 1996, ANN NY ACAD SCI, V802, P6, DOI 10.1111/j.1749-6632.1996.tb32593.x; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Veinbergs I, 1999, NEUROSCI LETT, V265, P218, DOI 10.1016/S0304-3940(99)00243-8; Warzok RW, 1998, ALZ DIS ASSOC DIS, V12, P33, DOI 10.1097/00002093-199803000-00005; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Whitehead AS, 1996, J NEUROL NEUROSUR PS, V61, P347, DOI 10.1136/jnnp.61.4.347	62	69	69	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	JUN	2006	27	6					797	803		10.1016/j.neurobiolaging.2005.04.008			7	Geriatrics & Gerontology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Geriatrics & Gerontology; Neurosciences & Neurology	045WW	WOS:000237774400002	15979210				2022-02-06	
J	Shyu, WC; Lee, YJ; Liu, DD; Lin, SZ; Li, H				Shyu, WC; Lee, YJ; Liu, DD; Lin, SZ; Li, H			Homing genes, cell therapy and stroke	FRONTIERS IN BIOSCIENCE-LANDMARK			English	Article						neuronal plasticity; stem cells; homing; SDF-1; CXCR4; stroke; review	MARROW STROMAL CELLS; COLONY-STIMULATING FACTOR; ENDOTHELIAL GROWTH-FACTOR; CHEMOKINE RECEPTOR CXCR4; NEURAL STEM-CELLS; ADULT BONE-MARROW; TRAUMATIC BRAIN INJURY; HUMAN CD34(+) CELLS; PROGENITOR CELLS; NEUROTROPHIC FACTOR	Stem cell therapies, such as bone marrow transplantation, are a promising strategy for the treatment of stroke. Bone marrow-derived stem cells (BMSCs) including both hematopoietic and mesenchymal stem cells (HSCs and MSCs) can exhibit tremendous cellular differentiation in numerous organs. BMSCs may also promote structural and functional repair in several organs such as the heart, liver, brain, and skeletal muscle via stem cell plasticity. Interestingly, ischemia is known to induce mobilization of BMSCs in both animal models and humans. The tissue injury is "sensed" by the stem cells and they migrate to the site of damage and undergo differentiation. The plasticity, differentiation, and migratory functions of BMSCs in a given tissue are dependent on the specific signals present in the local micro-environment of the damaged tissue. Therefore, the ischemic micro-environment has critical patho-biological functions that are essential for the seeding, expansion, survival, renewal, growth and differentiation of BMSCs in damaged brain remodeling. Recent studies have identified the specific molecular signals, such as SDF-1/CXCR4, required for the interaction of BMSCs and damaged host tissues. Understanding the exact molecular basis of stem cell plasticity in relation to local ischemic signals could offer new insights to permit better management of stroke and other ischemic disorders. The aim of this review is to summarize recent studies into how BMSCs reach, recognize, and function in cerebral ischemic tissues, with particular regard to phenotypical reprogramming of stem cells, or "stem cell plasticity".	Acad Sinica, Inst Mol Biol, Taipei, Taiwan; Tzu Chi Univ, Buddhist Gen Hosp, Neuro Med Sci Ctr, Hualien, Taiwan; Fu Jen Catholic Univ, Sch Med, Taipei, Taiwan		Li, H (corresponding author), Acad Sinica, Inst Mol Biol, Taipei, Taiwan.	hungli@ccvax.sinica.edu.tw	Lin, Shinn-Zong/AAX-2379-2020				Aicher A, 2003, CIRCULATION, V107, P2134, DOI 10.1161/01.CIR.0000062649.63838.C9; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Askari A, 2004, J AM COLL CARDIOL, V43, P1908, DOI 10.1016/j.jacc.2003.12.045; Askari AT, 2003, LANCET, V362, P697, DOI 10.1016/S0140-6736(03)14232-8; Bernal GM, 2004, AGING CELL, V3, P345, DOI 10.1111/j.1474-9728.2004.00132.x; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Busch HJ, 2003, J CEREBR BLOOD F MET, V23, P621, DOI 10.1097/01.WCB.0000057741.00152.E4; Buschmann IR, 2005, CIRCULATION, V111, pE297, DOI 10.1161/01.CIR.0000165120.35950.C7; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chavakis E, 2005, J EXP MED, V201, P63, DOI 10.1084/jem.20041402; Chen JL, 2003, CIRC RES, V92, P692, DOI 10.1161/01.RES.0000063425.51108.8D; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chmielnicki E, 2004, J NEUROSCI, V24, P2133, DOI 10.1523/JNEUROSCI.1554-03.2004; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; DEMETRI GD, 1991, BLOOD, V78, P2791; GAROFALO L, 1992, P NATL ACAD SCI USA, V89, P2639, DOI 10.1073/pnas.89.7.2639; Gritti A, 2002, J PHYSIOL-PARIS, V96, P81, DOI 10.1016/S0928-4257(01)00083-3; Gustafsson E, 2003, EUR J NEUROSCI, V17, P2667, DOI 10.1046/j.1460-9568.2003.02713.x; Haas S, 2005, CURR OPIN NEUROL, V18, P59, DOI 10.1097/00019052-200502000-00012; HANABUSA K, 2005, STROKE; Hattori K, 2003, LEUKEMIA LYMPHOMA, V44, P575, DOI 10.1080/1042819021000037985; Hattori K, 2001, BLOOD, V97, P3354, DOI 10.1182/blood.V97.11.3354; HEFTI F, 1986, J NEUROSCI, V6, P2155; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Hiasa K, 2004, CIRCULATION, V109, P2454, DOI 10.1161/01.CIR.0000128213.96779.61; Hill WD, 2004, J NEUROPATH EXP NEUR, V63, P84, DOI 10.1093/jnen/63.1.84; HIRSCH AT, 1991, CIRC RES, V69, P475, DOI 10.1161/01.RES.69.2.475; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Kollet O, 2003, J CLIN INVEST, V112, P160, DOI 10.1172/JCI200317902; Kollet O, 2001, BLOOD, V97, P3283, DOI 10.1182/blood.V97.10.3283; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Kuhn HG, 1997, J NEUROSCI, V17, P5820; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LACHMUND A, 1994, NEUROSCIENCE, V62, P361, DOI 10.1016/0306-4522(94)90371-9; Lataillade JJ, 2000, BLOOD, V95, P756, DOI 10.1182/blood.V95.3.756; Law Ping, 2002, Cancer Treat Res, V110, P51; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Limatola C, 2000, EUR J NEUROSCI, V12, P2497, DOI 10.1046/j.1460-9568.2000.00139.x; Lindholm D, 1997, ADV NEUROL, V73, P1; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Majka M, 2001, BLOOD, V97, P3075, DOI 10.1182/blood.V97.10.3075; Mariani M, 2003, J IMMUNOL METHODS, V273, P103, DOI 10.1016/S0022-1759(02)00503-3; Matthys P, 2001, J IMMUNOL, V167, P4686, DOI 10.4049/jimmunol.167.8.4686; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Mirshahi F, 2000, THROMB RES, V99, P587, DOI 10.1016/S0049-3848(00)00292-9; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Papayannopoulou T, 2001, BLOOD, V98, P2403, DOI 10.1182/blood.V98.8.2403; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Rodgers KE, 2000, STEM CELLS, V18, P287, DOI 10.1634/stemcells.18-4-287; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; SAWA H, 1994, MOL CELL BIOCHEM, V132, P15, DOI 10.1007/BF00925670; Schanzer A, 2004, BRAIN PATHOL, V14, P237; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Shyu WC, 2004, CIRCULATION, V110, P1847, DOI 10.1161/01.CIR.0000142616.07367.66; Stumm RK, 2002, J NEUROSCI, V22, P5865; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tham TN, 2001, EUR J NEUROSCI, V13, P845, DOI 10.1046/j.0953-816x.2000.01451.x; VANGIJN J, 1998, LANCET S3, V352, P23; Wang Y, 1997, J NEUROSCI, V17, P4341; Wechsler Lawrence R, 2004, Cleve Clin J Med, V71 Suppl 1, pS40; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231; Wong SF, 2005, PHARMACOTHERAPY, V25, P372; Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284; YAMAGISHI H, 1993, J MOL CELL CARDIOL, V25, P1369, DOI 10.1006/jmcc.1993.1149; Yamaguchi J, 2003, CIRCULATION, V107, P1322, DOI 10.1161/01.CIR.0000055313.77510.22; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	91	69	87	0	18	FRONTIERS IN BIOSCIENCE INC	IRVINE	16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA	1093-9946	1093-4715		FRONT BIOSCI-LANDMRK	Front. Biosci.	JAN 1	2006	11						899	907		10.2741/1846			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	973MX	WOS:000232528000072	16146779				2022-02-06	
J	Cantor, JB; Ashman, TA; Schwartz, ME; Gordon, WA; Hibbard, MR; Brown, M; Spielmar, L; Charatz, HJ; Cheng, ZF				Cantor, JB; Ashman, TA; Schwartz, ME; Gordon, WA; Hibbard, MR; Brown, M; Spielmar, L; Charatz, HJ; Cheng, ZF			The role of self-discrepancy theory in understanding post-traumatic brain injury affective disorders - A pilot study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article; Proceedings Paper	82nd Annual Meeting of the American-Congress-of-Rehabilitation-Medicine	SEP 28-OCT 02, 2005	Chicago, IL	Amer Congress Rehabil Med		affect; anxiety; brain injury; depression; identity; self-discrepancy; TBI	QUALITY-OF-LIFE; SPINAL-CORD-INJURY; MAJOR DEPRESSION; PSYCHIATRIC-DISORDERS; HEAD-INJURY; AXIS-I; PSYCHOSOCIAL ADJUSTMENT; COPING STRATEGIES; RESPONSE SHIFT; ANXIETY	This pilot study examined the utility of self-discrepancy theory (SDT) in explaining post-traumatic brain injury (TBI) depression and anxiety. The SDT model was expanded to include the discrepancy between the postinjury self and the preinjury self. Study participants were 21 individuals with mild to severe TBI residing in the community, who completed the Selves Interview, the Selves Adjective Checklist, the Beck Depression Inventory-II and the Beck Anxiety Inventory. Strong correlations were found between affective distress and setf-discrepancies, as measured by the checklist. Scores on the interview were not related to affective distress. The findings suggest that further research is merited to examine the utility of the SDT in addressing issues of post-TBI depression and anxiety.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Community Med, New York, NY 10029 USA; CUNY, Grad Sch, New York, NY USA; CUNY, Univ Ctr, New York, NY USA		Cantor, JB (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.	josbua.cantor@mssm.edu	Ashman, Teresa/B-1621-2013				American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Bay E, 2002, J NURS SCHOLARSHIP, V34, P221, DOI 10.1111/j.1547-5069.2002.00221.x; Beck A., 1996, BECK DEPRESSION INVE; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT, 1993, BECK ANXIETY INVENTO; Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Bond M R, 1975, Ciba Found Symp, P141; BOND MR, 1984, CLOSED HEAD INJURY P, P148; BOURDON KH, 1992, PUBLIC HEALTH REP, V107, P663; Bowen A, 1999, BRAIN INJURY, V13, P547; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1987, J HEAD TRAUMA REHAB, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Brown M, 2003, REHABIL PSYCHOL, V48, P266, DOI 10.1037/0090-5550.48.4.266; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Carver CS, 2000, SOC SCI MED, V50, P1715, DOI 10.1016/S0277-9536(99)00412-8; Childers MK, 1998, BRAIN INJURY, V12, P613; Christensen B, 1994, ADV MED PSYCHOTHERAP, V7, P23; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 1999, AM J PSYCHIAT, V156, P374; DEMBO T, 1975, REHABIL PSYCHOL, V22, P100; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Dunne EA, 2001, J HEALTH PSYCHOL, V6, P679, DOI 10.1177/135910530100600606; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; ERIKSON E, 2003, CHILDHOOD SOC; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Farrin L, 2003, J NEUROPSYCH CLIN N, V15, P98, DOI 10.1176/appi.neuropsych.15.1.98; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finset A, 2000, BRAIN INJURY, V14, P887; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; GELSO CJ, 1992, J COUNS PSYCHOL, V39, P275, DOI 10.1037/0022-0167.39.3.275; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Granger C V, 1985, Int Rehabil Med, V7, P45; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Hahn H, 1991, PSYCHOL SOCIAL IMPAC, P18; Hewson D, 1997, SOC SCI MED, V44, P1129, DOI 10.1016/S0277-9536(96)00244-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2000, NEUROREHABILITATION, V15, P109; Higgins E.Tory., 1987, SELF IDENTITY PSYCHO, P173; HIGGINS ET, 1987, PSYCHOL REV, V94, P319, DOI 10.1037/0033-295X.94.3.319; HIGGINS ET, 1986, J PERS SOC PSYCHOL, V51, P5, DOI 10.1037/0022-3514.51.1.5; HIGGINS ET, 1985, SOC COGNITION, V3, P51, DOI 10.1521/soco.1985.3.1.51; Hill C. S. E., 2000, CLIN REHABIL, V14, P279; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Hollingsworth Lisa, 2002, Issues Ment Health Nurs, V23, P135, DOI 10.1080/016128402753542776; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jean-Bay E, 2000, J Neurosci Nurs, V32, P169; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Kbler-Ross E., 1969, DEATH DYING; Kendall E, 1998, J REHABIL, V64, P16; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; KISHI Y, 1994, J NEUROPSYCH CLIN N, V6, P237; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Labbate L A, 2000, Curr Psychiatry Rep, V2, P268, DOI 10.1007/s11920-996-0021-3; Lezak M.D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI DOI 10.1097/00001199-198703000-00009; Lezak M. D., 2004, NEUROPSYCHOLOGICAL A; LIVNEH H, 1991, PSYCHOL SOCIAL IMPAC, P111; LIVNEH H, 1990, J APPL REHABIL COUNS, V34, P13; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Moldover JE, 2004, NEUROPSYCHOL REV, V14, P143, DOI 10.1023/B:NERV.0000048181.46159.61; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PEPPER GA, 1977, AM J NURS, V77, P1330; PRIGATANO GP, 1997, DEPRESSION PHYS ILLN, P341; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Robinson RG, 2002, ARCH GEN PSYCHIAT, V59, P23, DOI 10.1001/archpsyc.59.1.23; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Russo AA, 1996, ARCH CLIN NEUROPSYCH, V11, P443; Satz P, 1998, BRAIN INJURY, V12, P537, DOI 10.1080/026990598122313; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Strauman T. J., 1993, SELF EMOTIONAL DISTR, P3; STRAUMAN TJ, 1992, J ABNORM PSYCHOL, V101, P87, DOI 10.1037/0021-843X.101.1.87; STRAUMAN TJ, 1993, J PERS SOC PSYCHOL, V64, P1042, DOI 10.1037/0022-3514.64.6.1042; Strauman TJ, 1996, J PERS SOC PSYCHOL, V71, P1142, DOI 10.1037/0022-3514.71.6.1142; STRAUMAN TJ, 1989, J ABNORM PSYCHOL, V98, P14, DOI 10.1037/0021-843X.98.1.14; Strauman TJ, 2001, COGNITIVE THER RES, V25, P693, DOI 10.1023/A:1012915205800; STRAUMAN TJ, 1990, J PERS SOC PSYCHOL, V59, P869, DOI 10.1037/0022-3514.59.5.869; STRAUMAN TJ, 1991, J PERS SOC PSYCHOL, V61, P946, DOI 10.1037/0022-3514.61.6.946; STRAUMAN TJ, 2003, SELF SYSTEM THERAPY; Tangney JP, 1998, J PERS SOC PSYCHOL, V75, P256, DOI 10.1037/0022-3514.75.1.256; TATE D, 1994, AM J PHYS MED REHAB, V73, P175, DOI 10.1097/00002060-199406000-00006; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Trieschmann R, 1988, SPINAL CORD INJURIES; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wallace CA, 2000, BRAIN INJURY, V14, P549; Waters SJ, 2004, J PAIN SYMPTOM MANAG, V27, P251, DOI 10.1016/j.jpainsymman.2003.07.001; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whyte EM, 2002, BIOL PSYCHIAT, V52, P253, DOI 10.1016/S0006-3223(02)01424-5; WRIGHT B, 1960, PHYS DISABILTIY PSYC; ZOLA IK, 1993, SOC SCI MED, V36, P167, DOI 10.1016/0277-9536(93)90208-L; 1995, ROGETS, V2; [No title captured]	114	69	69	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2005	20	6					527	543		10.1097/00001199-200511000-00005			17	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Social Science &amp; Humanities (CPCI-SSH)	Neurosciences & Neurology; Rehabilitation	986YF	WOS:000233484900005	16304489				2022-02-06	
J	Van Putten, HP; Bouwhuis, MG; Muizelaar, JP; Lyeth, BG; Berman, RF				Van Putten, HP; Bouwhuis, MG; Muizelaar, JP; Lyeth, BG; Berman, RF			Diffusion-weighted imaging of edema following traumatic brain injury in rats: Effects of secondary hypoxia	JOURNAL OF NEUROTRAUMA			English	Article						cortex; cytotoxic edema; diffusion weighted-imaging; hippocampus; histology; hypoxia; lateral fluid percussion; midline shift; MRI; rats; traumatic brain injury; vasogenic edema	CONTROLLED CORTICAL IMPACT; LATERAL FLUID-PERCUSSION; CLOSED-HEAD INJURY; CEREBRAL-ISCHEMIA; TIME-COURSE; CELLULAR EDEMA; CONTUSION; MRI; ISOFLURANE; PERFUSION	Hypoxia and edema are frequent and serious complications of traumatic brain injury (TBI). Therefore, we examined the effects of hypoxia on edema formation after moderate lateral fluid percussion (LFP) injury using NMR diffusion-weighted imaging (DWI). Adult Sprague-Dawley rats were separated into four groups: sham uninjured (S), hypoxia alone (H), trauma alone (T), and trauma and hypoxia (TH). Animals in Groups T and TH received LFP brain injury, with Groups H and TH undergoing 30 min of moderately severe hypoxia (FiO(2) = 0.11) immediately after surgery or TBI (respectively). DWIs were obtained at 2, 4, and 24 h and at I week post injury, and apparent diffusion coefficient (ADC) maps were constructed. Animals in Groups T and TH showed an early decrease (p < 0.001) in ADC values in the cortex ipsilateral to TBI 4 hr post injury, followed by elevated ADCs I week later (p < 0.05). No significant differences in ADC values were seen between T and TH groups in the ipsilateral cortex. In contrast, the ipsilateral hippocampus for Group TH showed only increasing ADC values. This hyperintensity in the ADC map began at 2 h after TBI, was significant by 24 h (p < 0.05), and reached a maximum at I week. This hyperintensity was not observed in Group T. Histopathology seen in TBI animals corresponded well with the pathology observed with MRI. Midline shifts reflecting edema were only observed in TBI animals with little difference between normoxic (T) and hypoxic animals (TH). In sum, this study demonstrates that the development and extent of brain edema following TBI can be examined in vivo in rats using DWI technology. TBI resulted in an early decrease in ADC values indicating cytotoxic edema in the cortex that was followed at I week by an increase in the ADC that was associated with decreased tissue cellularity. Histopathology corresponded well to the regions of brain injury and edema visualized by T2 and DWI procedures. Overall, the addition of hypoxia to brain injury resulted in a small increase in the magnitude of edema in hippocampus and cortex over that seen with trauma alone.	Univ Calif Davis, Dept Neurol Surg, Davis, CA 94515 USA; Univ Utrecht, Dept Neurol Surg, Utrecht, Netherlands		Berman, RF (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 94515 USA.	rfberman@ucdavis.edu		van Putten, Erik/0000-0002-6839-8559; Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS039090, R01NS045136] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39090, NS45136, NS29995] Funding Source: Medline		Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; ARAKI T, 1989, ACTA NEUROL SCAND, V80, P548, DOI 10.1111/j.1600-0404.1989.tb03925.x; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Barzo P, 1997, ACT NEUR S, V70, P119; BAUGHMAN VL, 1990, ANESTHESIOLOGY, V72, P85, DOI 10.1097/00000542-199001000-00016; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bramlett HM, 1999, J NEUROTRAUM, V16, P1035, DOI 10.1089/neu.1999.16.1035; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Creutzfeldt O.D., 1995, CORTEX CEREBRI PERFO; Dijkhuizen RM, 1998, STROKE, V29, P695, DOI 10.1161/01.STR.29.3.695; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hallam TM, 2004, J NEUROTRAUM, V21, P521, DOI 10.1089/089771504774129865; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; Kawaguchi M, 2000, ANESTHESIOLOGY, V92, P1335, DOI 10.1097/00000542-200005000-00023; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; KUROIWA T, 1994, PATHOL INT, V44, P171, DOI 10.1111/j.1440-1827.1994.tb02590.x; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEBIHAN D, 1991, JMRI-J MAGN RESON IM, V1, P7, DOI 10.1002/jmri.1880010103; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, ACTA NEUROCHIR, P421; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Paczynski RP, 2000, STROKE, V31, P1702, DOI 10.1161/01.STR.31.7.1702; Portella G, 2000, ACT NEUR S, V76, P273; Rowley HA, 1999, NEUROIMAG CLIN N AM, V9, P343; Schaefer PW, 2000, RADIOLOGY, V217, P331, DOI 10.1148/radiology.217.2.r00nv24331; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stroop R, 1998, ACT NEUR S, V71, P303; Swanson L.W., 1998, BRAIN MAPS STRUCTURE, V2; Unterberg AW, 1997, ACT NEUR S, V70, P106; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	53	69	69	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2005	22	8					857	872					16	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	955LH	WOS:000231226900002	16083353				2022-02-06	
J	Satchell, MA; Lai, YC; Kochanek, PM; Wisniewski, SR; Fink, EL; Siedberg, NA; Berger, RP; DeKosky, ST; Adelson, PD; Clark, RSB				Satchell, MA; Lai, YC; Kochanek, PM; Wisniewski, SR; Fink, EL; Siedberg, NA; Berger, RP; DeKosky, ST; Adelson, PD; Clark, RSB			Cytochrome c, a biomarker of apoptosis, is increased in cerebrospinal fluid from infants with inflicted brain injury from child abuse	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						battered child syndrome; caspase; child abuse; programmed cell death; shaken baby syndrome	PROGRAMMED CELL-DEATH; HEAD-INJURY; NEURONAL APOPTOSIS; CASPASE-3; ACTIVATION; RELEASE; CONTRIBUTES; ISCHEMIA; HUMANS; BCL-2	Previous studies suggest that delayed neuronal death occurs in patients with inflicted traumatic brain injury (TBI) from child abuse. It is unknown whether the mode of this delayed neuronal death represents apoptosis or necrosis, a distinction that carries therapeutic ramifications. Cytochrome c, an electron transport chain component, can be released from mitochondria under conditions of cellular stress, whereupon it can initiate and serve as a biomarker of apoptosis. To resolve this issue, cytochrome c concentration was determined in 167 ventricular cerebrospinal fluid (CSF) samples from 67 infants and children with TBI (including 15 patients diagnosed with child abuse) by ELISA. Controls included lumbar CSF from 19 infants and children without trauma or meningitis. A multivariate model adjusted for multiple within-subject observations was used to identify clinical variables associated with CSF cytochrome c. Other apoptosis-related proteins were also examined in a subset of TBI patients. Increased CSF cytochrome c was independently associated with inflicted TBI (P=0.0001) and female gender (P=0.04), but not age, Glasgow coma scale score, or survival. Other apoptosis-related proteins including Fas and caspase-1 were increased in CSF after TBI, but did not independently discriminate between accidental and inflicted TBI. These data suggest that apoptosis, as detected by the presence of cytochrome c in CSF, is uniquely prominent among the subset of TBI patients diagnosed with child abuse. The degree of apoptosis after TBI also appears to be gender-dependent. Development of strategies targeting apoptosis after TBI, particularly in victims of child abuse and in girls, appears justified.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Sch Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Epidemiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurol & Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Neurol Surg, Sch Med, Pittsburgh, PA 15213 USA		Clark, RSB (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Sch Med, 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015; Fink, Ericka/AAU-9792-2021	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758; Fink, Ericka/0000-0002-3683-4571; Wisniewski, Stephen/0000-0002-3877-9860; Lai, Yi-Chen/0000-0002-9450-5506	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, P50 NS30318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318, R01NS038620] Funding Source: NIH RePORTER		Ahlemeyer B, 2002, BRAIN RES, V934, P107, DOI 10.1016/S0006-8993(02)02365-X; Behl C, 2002, NAT REV NEUROSCI, V3, P433, DOI 10.1038/nrn846; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813, DOI 10.1096/fasebj.13.8.813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; Harter L, 2001, J NEUROIMMUNOL, V121, P76, DOI 10.1016/S0165-5728(01)00409-X; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Lai YC, 2004, J NEUROTRAUM, V21, P229, DOI 10.1089/089771504322972022; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Qiu JH, 2002, J NEUROSCI, V22, P3504; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Tatsuta T, 2000, J BIOL CHEM, V275, P14248, DOI 10.1074/jbc.275.19.14248; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang H, 2003, RESPIROLOGY, V8, P17, DOI 10.1046/j.1440-1843.2003.00433.x; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	32	69	73	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2005	25	7					919	927		10.1038/sj.jcbfm.9600088			9	Endocrinology & Metabolism; Hematology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	940CW	WOS:000230122300014	15744250	Bronze			2022-02-06	
J	Selassie, AW; McCarthy, ML; Ferguson, PL; Tian, JM; Langlois, JA				Selassie, AW; McCarthy, ML; Ferguson, PL; Tian, JM; Langlois, JA			Risk of posthospitalization mortality among persons with traumatic brain injury, South Carolina 1999-2001	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							LONG-TERM SURVIVAL; PREEXISTING CONDITIONS; LIFE EXPECTANCY; DEATH; SEVERITY; EPIDEMIOLOGY; DISCHARGE; SYSTEMS; TRENDS	Traumatic brain injury (TBI) negatively impacts long-term survival. However, little is known about the likelihood of death within the first year following hospital discharge. This study examined mortality among a representative sample of 3679 persons within 1 year of being discharged from any of 62 acute care hospitals in South Carolina following TBI and identified the factors associated with early death using a multivariable Cox proportional hazards model. The mortality experience of the cohort was also compared with that of the general population by using standardized mortality ratios for selected causes of death by age, adjusted for race and sex.	Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA; S Carolina Dept Hlth & Environm Control, Div Biostat & Hlth GIS,Publ Hlth Stat & Informat, Charleston, SC USA; Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA		Selassie, AW (corresponding author), Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, 135 Cannon St,POB 250835, Charleston, SC 29425 USA.	selassie@musc.edu			ODCDC CDC HHS [U17/CCU421926] Funding Source: Medline		Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Allison PD, 1995, ESTIMATING COMPARING, V29-59; Anderson PM, 2002, LEUKEMIA, V16, P406; Anderson Robert N, 2003, Natl Vital Stat Rep, V52, P1; Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1; Baguley I, 2000, BRAIN INJURY, V14, P505; BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BUTLER JA, 2001, CENTRAL NERVOUS SYST; *CDCP NAT CTR INJ, 1999, TRAUM BRAIN INJ US; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Committee on Injury Scaling, 1990, ABBR INJ SCAL 1990 R; CONROY C, 1988, NEUROEPIDEMIOLOGY, V7, P13, DOI 10.1159/000110131; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FAHY TJ, 1967, LANCET, V2, P475; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Grossman MD, 2002, J TRAUMA, V52, P242, DOI 10.1097/00005373-200202000-00007; Gubler KD, 1997, ARCH SURG-CHICAGO, V132, P1010; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; KLEINBAUM DG, 1996, EVALUATING PROPORTIO, P133; Kraus J F, 2000, Neurosurg Focus, V8, pe5; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; MACKENZIE EJ, 1984, AM J EMERG MED, V2, P537, DOI 10.1016/0735-6757(84)90081-0; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; McGwin G, 2000, J TRAUMA, V49, P470, DOI 10.1097/00005373-200009000-00014; MORRIS JA, 1990, JAMA-J AM MED ASSOC, V263, P1942, DOI 10.1001/jama.263.14.1942; Mosenthal AC, 2002, J TRAUMA, V52, P907, DOI 10.1097/00005373-200205000-00015; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Mullins RJ, 1999, J TRAUMA, V47, pS59, DOI 10.1097/00005373-199909001-00013; Mullins RJ, 1998, JAMA-J AM MED ASSOC, V279, P1727, DOI 10.1001/jama.279.21.1727; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Olson CJ, 2003, J TRAUMA, V55, P45, DOI 10.1097/01.TA.0000071291.17287.57; Peek-Asa C, 2001, BRAIN INJURY, V15, P801, DOI 10.1080/02699050010025768; Perdue PW, 1998, J TRAUMA, V45, P805, DOI 10.1097/00005373-199810000-00034; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; Sacco WJ, 1999, J TRAUMA, V47, P441, DOI 10.1097/00005373-199909000-00001; SACCO WJ, 1993, J TRAUMA, V35, P538, DOI 10.1097/00005373-199310000-00007; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman DJ., 1995, GUIDELINES SURVEILLA; TIRET L, 1990, INT J EPIDEMIOL, V19, P133, DOI 10.1093/ije/19.1.133; *US CENS BUR, 2001, UNP US POP AG SEX RA; VANDENBROUCKE JP, 1982, AM J EPIDEMIOL, V115, P303, DOI 10.1093/oxfordjournals.aje.a113306; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WEISS GH, 1982, ARCH NEUROL-CHICAGO, V39, P741, DOI 10.1001/archneur.1982.00510240003001; WHO, 2004, INT STAT CLASS DIS R; WOODWARD M, 1999, COX PROPORTIONAL HAZ, P534; 1982, INT CLASSIFICATION D	52	69	69	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					257	269		10.1097/00001199-200505000-00008			13	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500008	15908825				2022-02-06	
J	Cicerone, KD				Cicerone, KD			Participation as an outcome of traumatic brain injury rehabilitation	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; outcomes; rehabilitation	QUALITY-OF-LIFE; COMMUNITY INTEGRATION; SATISFACTION; INDIVIDUALS	Objectives: Participation in meaningful life situations is an important aspect of functioning after traumatic brain injury (TBI). However, to date, few studies have included measures of social participation or community integration as outcome measures after TBI rehabilitation. This paper is a selective review of the literature that examines the effects of TBI rehabilitation on measures of participation or community integration. It also addresses the related questions of clinically significant improvements in community integration, variability in patterns of community functioning, and the relationship of participation and quality of life after TBI. Design: Literature review. Conclusions: A small number of studies suggest that postacute TBI rehabilitation can produce improvements in participation and community integration. However, a considerable amount of variability in rehabilitation outcomes may be apparent. Analysis of clinically significant changes in individual's functioning suggests that rehabilitation may exert its benefits not only by facilitating improvements, but also by preventing declines in community functioning. Subjective well-being and quality of life have generally been ignored as TBI rehabilitation outcomes. There is considerable evidence that participation and subjective well-being represent distinct and dissociable outcomes after TBI which may reflect the importance of patients' preferences and values in evaluating the effectiveness of rehabilitation.	JFK Johnson Rehabil Inst, Dept Phys Med & Rehabil, Edison, NJ USA		Cicerone, KD (corresponding author), 2048 Oak Tree Rd, Edison, NJ 08820 USA.	kcicerone@solarishs.org					ACOUVI P, 2001, 4 WORLD C BRAIN INJ; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Doninger NA, 2003, REHABIL PSYCHOL, V48, P67, DOI 10.1037/0090-5550.48.2.67; EVANS C, 2003, J INT NEUROPSYCH SOC, V9, P253; Goranson TE, 2003, BRAIN INJURY, V17, P759, DOI 10.1080/0269905031000088513; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer J., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI [10.1097/00001199-199308020-00009, DOI 10.1097/00001199-199308020-00009]; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; Powell JM, 2001, ARCH PHYS MED REHAB, V82, P1025, DOI 10.1053/apmr.2001.25082; Sander AM, 2001, J HEAD TRAUMA REHAB, V16, P356, DOI 10.1097/00001199-200108000-00006; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; Seale GS, 2002, BRAIN INJURY, V16, P955, DOI 10.1080/02699050210155258; Smith J, 1998, CANADIAN J REHABILIT, V11, P131; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9	25	69	69	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					494	501		10.1097/00001199-200411000-00006			8	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100006	15602311				2022-02-06	
J	Salman, H; Ghosh, P; Kernie, SG				Salman, H; Ghosh, P; Kernie, SG			Subventricular zone neural stem cells remodel the brain following traumatic injury in adult mice	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical injury; DiO; neural stem cells; subventricular zone; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; ROSTRAL MIGRATORY STREAM; OLFACTORY-BULB; GENERATED NEURONS; PROGENITOR CELLS; BONE-MARROW; NEUROGENESIS; PROLIFERATION; HIPPOCAMPUS; FOREBRAIN	Neural stem cells have recently been shown to contribute to the cellular remodeling that occurs following traumatic brain injury (TBI). Potential sources for these stem cells from within the brain include the subventricular zone of the lateral ventricles and the subgranular zone of the dentate gyrus. Using intraventricular injections of the fluorescent vital dye DiO in mice, we demonstrate that the subventricular zone population of stem cells can be reliably labeled and followed over time. By following these injections with a contralateral controlled cortical injury we demonstrate that cells from the subventricular zone migrate to the most proximally injured cortical areas. Using double-labeling immunohistochemistry with anti-nestin, anti-GFAP, and anti-NeuN antibodies we demonstrate that labeled cells from the subventricular zone contribute primarily to the astroglial scar following injury. We do not observe any contribution to deeper areas of injury including the hippocampus. These data demonstrate that the subventricular zone contributes to brain remodeling following TBI, though neural stem cell sources outside the subventricular zone appear to play reparative roles as well.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Pediat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Kent Waldrep Fdn Ctr Basic Res Nerve Growth & Reg, Dallas, TX 75390 USA		Kernie, SG (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, Dept Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020	Kernie, Steven/0000-0003-1371-0549	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD001470] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD001470, 1K08 HD01470-01] Funding Source: Medline		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 2002, BRAIN RES BULL, V57, P751, DOI 10.1016/S0361-9230(01)00770-5; Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brock SC, 1998, METHODS, V16, P268, DOI 10.1006/meth.1998.0684; Cao QL, 2002, J NEUROSCI RES, V68, P501, DOI 10.1002/jnr.10240; Chen XH, 2003, J NEUROTRAUM, V20, P623, DOI 10.1089/089771503322144545; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Coskun V, 2002, J NEUROSCI RES, V69, P795, DOI 10.1002/jnr.10336; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Demeurisse G, 2000, ACTA NEUROL BELG, V100, P77; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; HINDS JW, 1968, J COMP NEUROL, V134, P305, DOI 10.1002/cne.901340305; HONIG MG, 1989, TRENDS NEUROSCI, V12, P333, DOI 10.1016/0166-2236(89)90040-4; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Jankovski A, 1996, J COMP NEUROL, V371, P376; Kakita A, 2003, J COMP NEUROL, V458, P381, DOI 10.1002/cne.10597; KAPLAN MS, 1977, SCIENCE, V197, P1092, DOI 10.1126/science.887941; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1994, FASEB J, V8, P722, DOI 10.1096/fasebj.8.10.8050671; Markakis EA, 1999, J COMP NEUROL, V406, P449; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Stewart RR, 2002, J NEUROBIOL, V50, P305, DOI 10.1002/neu.10038; TEMPLE S, 1995, NEURON, V15, P249, DOI 10.1016/0896-6273(95)90030-6; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008	46	69	73	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					283	292		10.1089/089771504322972077			10	Critical Care Medicine; Clinical Neurology; Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600006	15115603				2022-02-06	
J	Hooper, SR; Alexander, J; Moore, D; Sasser, HC; Laurent, S; King, J; Bartel, S; Callahan, B				Hooper, SR; Alexander, J; Moore, D; Sasser, HC; Laurent, S; King, J; Bartel, S; Callahan, B			Caregiver reports of common symptoms in children following a traumatic brain injury	NEUROREHABILITATION			English	Article						pediatric traumatic brain injury; TBI symptoms; symptom complaints; TBI follow-up	POSTTRAUMATIC-STRESS-DISORDER; FAMILY-MEMBERS; HEAD-TRAUMA; MILD; PREVALENCE; DEPRESSION; SYMPTOMATOLOGY; ADOLESCENTS; CONCORDANCE; DYSFUNCTION	This study describes the common symptoms in children and adolescents following a traumatic brain injury (TBI) as reported by their primary caregivers. Utilizing data from a large-scale state demonstration project, 681 children who had sustained a TBI were ascertained from both Hospital Emergency Departments (n = 409) and Pediatric Inpatient settings (n = 272). The sample ranged in age from infancy to 18 years, was largely male (59.7%), and had equal numbers of Caucasian and minority patients. Most of the participants experienced a mild TBI (83%), with about 5.1% being moderate and 12% severe. Caregivers described the presence of current symptoms (neurological, neurocognitive, behavioral, school problems) using a series of dichotomous questions regarding their child via a structured telephone interview at 1, 4, and 10 months post-injury. Inpatient children were described as manifesting more symptoms at each of the follow-up time points than their ED counterparts. At 1 month inpatients were described as having more symptoms across all 4 domains. At 4 and 10 months, the inpatients were described as having more neurocognitive symptoms and as not returning to school on a full-time basis, with behavior problems approaching significance at the 10-month point. A large number of individuals from both groups also reported persistent symptoms 10 months post-injury including headaches, attention and memory problems, low frustration tolerance, sleep problems, personality changes, and new school problems. Practical implications of these findings for the ongoing management of these children are discussed.	Univ N Carolina, Sch Med, Clin Ctr Study Dev & Learning, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Phys Med & Rehabil, Chapel Hill, NC USA; E Carolina Univ, Brody Sch Med, Dept Phys Med & Rehabil, Greenville, NC USA; Carolinas HealthCare Syst, R Stuart Dickson Inst Hlth Studies, Charlotte, NC USA; Carolinas Med Ctr, Dept Phys Med & Rehabil, Charlotte, NC 28203 USA; N Carolina State Div Dev Disabil, Mental Hlth Serv, Raleigh, NC USA; N Carolina State Div Dev Disabil, Subst Abuse Serv, Raleigh, NC USA		Hooper, SR (corresponding author), Univ N Carolina, Sch Med, Ctr Dev & Learning, CB 7255, Chapel Hill, NC 27599 USA.	Stephen.hooper@cdl.unc.edu	Hooper, Stephen/X-8171-2019				Alexander J, 2001, N C Med J, V62, P344; Alexander J, 2001, N C Med J, V62, P359; Annoni J M, 1992, Disabil Rehabil, V14, P23; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; *CDCP, 2001, TRAUM BRAIN INJ; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Childers MK, 1998, BRAIN INJURY, V12, P613; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; DISCALA C, 2003, BRAIN INJURY SOU SPR, P8; Douglas JM, 2000, BRAIN INJURY, V14, P71, DOI 10.1080/026990500120943; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; HACKL JM, 1986, ANAESTHESIST, V35, P171; Hart T, 2003, ARCH PHYS MED REHAB, V84, P204, DOI 10.1053/apmr.2003.50019; HARVEY AG, 1993, J INT NEUROPSYCH SOC, V9, P663; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; Hellawell DJ, 2001, DISABIL REHABIL, V23, P300, DOI 10.1080/769979114; Hooper S R, 2001, N C Med J, V62, P350; HOOPER SR, 2003, BRAIN INJURY SOU SPR, P28; Junque C, 1997, BRAIN INJURY, V11, P251, DOI 10.1080/026990597123557; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lash M, 2003, BRAIN INJURY SOU SPR, P20; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Levi RB, 1999, J CLIN CHILD PSYCHOL, V28, P232, DOI 10.1207/s15374424jccp2802_10; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Masson F, 1996, ARCH PEDIATRIE, V3, P651, DOI 10.1016/0929-693X(96)87085-0; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; Max JE, 1998, J AM ACAD CHILD PSY, V37, P841, DOI 10.1097/00004583-199808000-00014; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; McAllister TW, 2002, NEUROREHABILITATION, V17, P357; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McMahon MA, 2001, J HEAD TRAUMA REHAB, V16, P587, DOI 10.1097/00001199-200112000-00006; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Roberts MA, 1996, BRAIN INJURY, V10, P739, DOI 10.1080/026990596124007; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Smith C G, 2001, N C Med J, V62, P328; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; SOSIN DM, 1992, JAMA-J AM MED ASSOC, V268, P791, DOI 10.1001/jama.1992.03490060127048; Thurman DJ., 1995, GUIDELINES SURVEILLA; VERDUYN W H, 1992, Brain Injury, V6, P245, DOI 10.3109/02699059209029666; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026	66	69	69	0	5	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2004	19	3					175	189					15	Clinical Neurology; Rehabilitation	Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	883HU	WOS:000226003000002	15502252				2022-02-06	
J	Rohling, ML; Meyers, JE; Millis, SR				Rohling, ML; Meyers, JE; Millis, SR			Neuropsychological impairment following traumatic brain injury: A dose-response analysis	CLINICAL NEUROPSYCHOLOGIST			English	Article							LINEAR-MODELS; MEMORY; VALIDATION; INDEX	Dikmen, Machamer, Winn, and Temkin (1995) administered the Halstead-Reitan Battery (HRB) to a sample of TBI patients. Similar patients were obtained from the second author (JEM) for two main purposes. First, we wished to determine if there is a dose-response relationship between TBI severity and residual cognitive deficit. Second, are Dikmen et al. results generalizable to other TBI samples? Analyses of the Meyers sample replicated the analyses of Dikmen sample. A significant dose-response relationship between loss of consciousness (LOC) and cognitive impairment was found using effect sizes for the Dikmen sample, as well as using regression-based normative T scores for the Meyers sample. The two methods were highly correlated with one another. Using mean scores for the six LOC-severity groups and the two samples resulted in a correlation coefficient r=.97, p<.0001. Results are presented for clinicians to use when assessing individual patients.	Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; Mercy Rehabil Ctr, Sioux City, IA USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA		Rohling, ML (corresponding author), Univ S Alabama, Dept Psychol, 381 LSCB, Mobile, AL 36688 USA.	mrohling@usouthal.edu					BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; DAWES RM, 1974, PSYCHOL BULL, V81, P95, DOI 10.1037/h0037613; DAWES RM, 1979, AM PSYCHOL, V34, P571, DOI 10.1037/0003-066X.34.7.571; DEFILIPPIS NA, 1991, BOOKLET CATEGORY TES; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DYER FN, 1973, MEM COGNITION, V1, P106, DOI 10.3758/BF03198078; FAITH MS, 1996, DESIGN ANAL SINGLE C; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P201; Heaton RK, 2001, ARCH GEN PSYCHIAT, V58, P24, DOI 10.1001/archpsyc.58.1.24; Heaton RK, 1991, COMPREHENSIVE NORMS; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; KIERNAN RJ, 1976, J CONSULT CLIN PSYCH, V44, P951, DOI 10.1037/0022-006X.44.6.951; Kozel JJ, 1998, ARCH CLIN NEUROPSYCH, V13, P327, DOI 10.1016/S0887-6177(97)00036-X; Larrabee GJ, 1990, NEUROPSYCHOLOGY, V4, P239, DOI 10.1037/0894-4105.4.4.239; Lundin KA, 1999, CLIN NEUROPSYCHOL, V13, P433, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT433; Meyers JE, 2003, ARCH CLIN NEUROPSYCH, V18, P261, DOI 10.1016/S0887-6177(02)00136-1; Meyers JE., 1995, REY COMPLEX FIGURE T; MILBERG WP, 1986, ASSESSMENT NEUROPSYC; Miller LS, 2001, NEUROPSYCHOL REV, V11, P143, DOI 10.1023/A:1016602708066; MILLER LS, 1998, ARCH CLIN NEUR ABSTR, V12, P86; Pilgrim B M, 1999, Appl Neuropsychol, V6, P243, DOI 10.1207/s15324826an0604_7; Reitan R.M., 1993, HALSTEADREITAN NEURO; Reitan RM, 2001, ARCH CLIN NEUROPSYCH, V16, P215; REITAN RM, 1999, WORKSH ANN NAT AC NE; Rohling ML, 2003, PREDICTION IN FORENSIC AND NEUROPSYCHOLOGY, P171; Rohling ML, 2000, ARCH CLIN NEUROPSYCH, V15, P821, DOI 10.1016/S0887-6177(00)80311-X; ROHLING ML, IN PRESS CLIN NEUROP; ROHLING ML, IN PRESS NEUROPSYCHO; ROHLING ML, 1998, J INT NEUROPSYCH SOC, V4, P26; Russell E. W., 1970, ASSESSMENT BRAIN DAM; Spreen O., 1998, COMPENDIUM NEUROPSYC, V2nd ed.); SWEET J, 2000, CLIN NEUROPSYCHOL, V14, P38; Volbrecht ME, 2000, ARCH CLIN NEUROPSYCH, V15, P251, DOI 10.1016/S0887-6177(99)00016-5; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D, 1981, WECHSLER ADULT INTEL; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Wedding D, 1989, Arch Clin Neuropsychol, V4, P233, DOI 10.1016/0887-6177(89)90016-4	41	69	69	0	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	AUG	2003	17	3					289	302		10.1076/clin.17.3.289.18086			14	Psychology, Clinical; Clinical Neurology; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychology; Neurosciences & Neurology	748DP	WOS:000186847100001	14704881				2022-02-06	
J	Chodobski, A; Chung, I; Kozniewska, E; Ivanenko, T; Chang, W; Harrington, JF; Duncan, JA; Szmydynger-Chodobska, J				Chodobski, A; Chung, I; Kozniewska, E; Ivanenko, T; Chang, W; Harrington, JF; Duncan, JA; Szmydynger-Chodobska, J			Early neutrophilic expression of vascular endothelial growth factor after traumatic brain injury	NEUROSCIENCE			English	Article						subarachnoid space; choroid plexus; astrocytes; heparan sulfate proteoglycans; extracellular matrix; rat	NECROSIS-FACTOR-ALPHA; HEPARAN-SULFATE PROTEOGLYCAN; MIDDLE CEREBRAL-ARTERY; BLOOD-RETINAL BARRIER; FACTOR VEGF; DIFFERENTIAL EXPRESSION; EXTRACELLULAR-MATRIX; NEURONAL EXPRESSION; FACTOR FAMILY; UP-REGULATION	The formation of edema after traumatic brain injury (TBI) is in part associated with the disruption of the blood-brain barrier. However, the molecular and cellular mechanisms underlying these phenomena have not been fully understood. One possible factor involved in edema formation is vascular endothelial growth factor (VEGF). This growth factor has previously been demonstrated to increase the blood-brain barrier permeability to the low molecular weight markers and macromolecules. In this study, we analyzed the temporal changes in VEGF expression after TBI in rats. In the intact brain, VEGF was expressed at relatively low levels and was found in the cells located close to the cerebrospinal fluid space. These were the astrocytes located under the ependyma and the pia-glial lining, as well as the epithelial cells of the choroid plexus. In addition, several groups of neurons, including those located in the frontoparietal cortex and in all hippocampal regions, were VEGF-positive. The pattern of VEGF-immunopositive staining of neurons and choroidal epithelium suggested that in these cells, VEGF binds to the cell membrane-associated heparan sulfate proteoglycans. Following TBI, there was an early (within 4 h post-injury) increase in VEGF expression in the traumatized parenchyma associated with neutrophilic invasion. The ipsilateral choroid plexus appeared to play a role in facilitating the migration of neutrophils from blood into the cerebrospinal fluid space, from where many of these cells infiltrated the brain parenchyma. VEGF-immunopositive staining of neutrophils resembled haloes and was found ipsilaterally within the frontoparietal cortex and around the velum interpositum, a part of the subarachnoid space. These haloes likely represent the deposition of neutrophil-derived VEGF within the extracellular matrix, from where this growth factor may be gradually released during an early post-traumatic period. The maximum number of VEGF-secreting neutrophils was observed between 8 h and 1 day after TBI. In addition, from 4 h post-TBI, there was a progressive increase in the number of VEGF-immunoreactive astrocytes in the ipsilateral frontoparietal cortex. The maximum number of astrocytes expressing VEGF was observed 4 days after TBI, and then the levels of astroglial VEGF expression declined gradually. Early invasion of brain parenchyma by VEGF-secreting neutrophils together with a delayed increase in astrocytic synthesis of this growth factor correlate with the biphasic opening of the blood-brain barrier and formation of edema previously observed after TBI. Therefore, these findings suggest that VEGF plays an important role in promoting the formation of post-traumatic brain edema. (C) 2003 IBRO. Published by Elsevier Ltd. All rights reserved.	Brown Univ, Sch Med, Dept Clin Neurosci, Providence, RI 02903 USA; Med Res Ctr Polish Acad Sci, Lab Nucl Med, PL-02106 Warsaw, Poland		Chodobski, A (corresponding author), Brown Univ, Sch Med, Dept Clin Neurosci, Aldrich Bldg,Room 405,593 Eddy St, Providence, RI 02903 USA.	adam_chodobski@brown.edu		Kozniewska, Ewa/0000-0003-0675-1238	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-39921] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039921] Funding Source: NIH RePORTER		ANDERSSON PB, 1992, J EXP MED, V176, P255, DOI 10.1084/jem.176.1.255; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279, DOI 10.1002/jlb.61.3.279; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Chung I, 2003, NEUROSCIENCE, V116, P349, DOI 10.1016/S0306-4522(02)00720-0; Clasper S, 1999, J BIOL CHEM, V274, P24113, DOI 10.1074/jbc.274.34.24113; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Esser S, 1998, J CELL SCI, V111, P1853; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; Gaudry M, 1997, BLOOD, V90, P4153, DOI 10.1182/blood.V90.10.4153; Gengrinovitch S, 1999, J BIOL CHEM, V274, P10816, DOI 10.1074/jbc.274.16.10816; Grunstein J, 2000, MOL CELL BIOL, V20, P7282, DOI 10.1128/MCB.20.19.7282-7291.2000; Hayashi T, 1997, STROKE, V28, P2039, DOI 10.1161/01.STR.28.10.2039; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Iseki K, 2002, GLIA, V39, P1, DOI 10.1002/glia.10078; Issa R, 1999, LAB INVEST, V79, P417; Kaneider NC, 2001, BIOCHEM BIOPH RES CO, V287, P42, DOI 10.1006/bbrc.2001.5534; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Kovacs Z, 1996, STROKE, V27, P1865, DOI 10.1161/01.STR.27.10.1865; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; Lennmyr F, 1998, J NEUROPATH EXP NEUR, V57, P874, DOI 10.1097/00005072-199809000-00009; LITWACK ED, 1994, J NEUROSCI, V14, P3713; Liu W, 1998, J BIOL CHEM, V273, P22825, DOI 10.1074/jbc.273.35.22825; MATZNER Y, 1992, J LEUKOCYTE BIOL, V51, P519, DOI 10.1002/jlb.51.6.519; Mollinedo F, 1997, BIOCHEM J, V327, P917, DOI 10.1042/bj3270917; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Murata T, 1996, LAB INVEST, V74, P819; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Nag S, 2002, J NEUROPATH EXP NEUR, V61, P778, DOI 10.1093/jnen/61.9.778; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Pichiule P, 1999, MOL BRAIN RES, V74, P83, DOI 10.1016/S0169-328X(99)00261-2; Plouet J, 1997, J BIOL CHEM, V272, P13390, DOI 10.1074/jbc.272.20.13390; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Robinson CJ, 2001, J CELL SCI, V114, P853; Rousseau S, 2000, J BIOL CHEM, V275, P10661, DOI 10.1074/jbc.275.14.10661; Ruhrberg C, 2002, GENE DEV, V16, P2684, DOI 10.1101/gad.242002; Scapini P, 1999, J IMMUNOL METHODS, V232, P121, DOI 10.1016/S0022-1759(99)00170-2; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Soares HD, 1995, J NEUROSCI, V15, P8223; STRUGAR JG, 1995, J NEUROSURG, V83, P682, DOI 10.3171/jns.1995.83.4.0682; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; van Bruggen N, 1999, J CLIN INVEST, V104, P1613, DOI 10.1172/JCI8218; Wang W, 2001, AM J PHYSIOL-HEART C, V280, pH434, DOI 10.1152/ajpheart.2001.280.1.H434; Webb NJA, 1998, CYTOKINE, V10, P254, DOI 10.1006/cyto.1997.0297; Whalen MJ, 2000, CRIT CARE MED, V28, P3710, DOI 10.1097/00003246-200011000-00029; Zhang H, 2001, J LEUKOCYTE BIOL, V70, P225	61	69	72	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2003	122	4					853	867		10.1016/j.neuroscience.2003.08.055			15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	751PD	WOS:000187075400001	14643756				2022-02-06	
J	Blanchard, R; Christensen, BK; Strong, SM; Cantor, JM; Kuban, ME; Klassen, P; Dickey, R; Blak, T				Blanchard, R; Christensen, BK; Strong, SM; Cantor, JM; Kuban, ME; Klassen, P; Dickey, R; Blak, T			Retrospective self-reports of childhood accidents causing unconsciousness in phallometrically diagnosed pedophiles	ARCHIVES OF SEXUAL BEHAVIOR			English	Article						childhood accidents; head injury; neuropsychology; pedophilia; phallometry; sex offenders	TRAUMATIC BRAIN INJURY; LEFT-HANDEDNESS; HEAD-INJURY; MENTAL-RETARDATION; SEXUAL ORIENTATION; PREFRONTAL CORTEX; INCREASED RISK; FOLLOW-UP; CHILDREN; AGE	The present study investigated whether head injuries in childhood might increase the risk of pedophilia in males. The subjects were 1206 patients referred to a clinical sexology service for assessment of their erotic preferences. These were classified, on the basis of phallometric test results, as pedophilic (n = 413) or nonpedophilic (n = 793). Information regarding early head injuries, other signs of possible neurodevelopmental problems, and parental histories of psychiatric treatment were collected with self-administered questionnaires. The results showed that childhood accidents that resulted in unconsciousness were associated with pedophilia and with lower levels of intelligence and education. These associations were statistically significant for accidents that occurred before the age of 6, but not for accidents that occurred between the ages of 6 and 12. These results are compatible with the hypothesis that neurodevelopmental perturbations in early childhood may increase the risk of pedophilia. They are also, however, compatible with the alternative explanation that prior neurodevelopmental problems lead to accident-proneness and head injury, on the one hand, and to pedophilia, on the other, and that head injury has no causal influence on pedophilia. A secondary finding was that the pedophiles were more likely to report that their mothers had undergone psychiatric treatment. This finding suggests that pedophilia may be influenced by genetic factors, which are manifested in women as an increased risk of psychiatric problems, and in their sons, as an increased risk of erotic interest in children.	Ctr Addict & Mental Hlth, Law & Mental Hlth Program, Toronto, ON M5T 1R8, Canada; Univ Toronto, Fac Med, Dept Psychiat, Toronto, ON M5S 1A1, Canada; Ctr Addict & Mental Hlth, Schizophrenia & Continuing Care Program, Toronto, ON, Canada		Blanchard, R (corresponding author), Ctr Addict & Mental Hlth, Law & Mental Hlth Program, Clarke Site,250 Coll St, Toronto, ON M5T 1R8, Canada.		Cantor, James M/P-8796-2014				ALMLI CR, 1984, EARLY BRAIN DAMAGE, V1; ANDERSON SA, 1995, NEUROSCIENCE, V67, P7, DOI 10.1016/0306-4522(95)00051-J; Barbaree Howard E., 1997, P175; Barkley Russell A., 1996, P63; Bates E, 2001, BRAIN LANG, V79, P223, DOI 10.1006/brln.2001.2482; BIRO V, 1995, STUD PSYCHOL, V37, P81; Blanchard R, 2001, HORM BEHAV, V40, P105, DOI 10.1006/hbeh.2001.1681; Blanchard R, 1999, ARCH SEX BEHAV, V28, P111, DOI 10.1023/A:1018754004962; Blanchard R, 2002, HORM BEHAV, V41, P321, DOI 10.1006/hbeh.2002.1765; BLANCHARD R, 1989, J NERV MENT DIS, V177, P616, DOI 10.1097/00005053-198910000-00004; Blanchard R, 2001, PSYCHOL ASSESSMENT, V13, P118, DOI 10.1037/1040-3590.13.1.118; Blanchard R, 2001, J BIOSOC SCI, V33, P451, DOI 10.1017/S0021932001004515; BLANCHARD R, 1998, HDB SEXUALITY RELATE, P581; Bogaert AF, 2001, NEUROPSYCHOLOGIA, V39, P465, DOI 10.1016/S0028-3932(00)00134-2; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cantor JM, 2002, ARCH SEX BEHAV, V31, P63, DOI 10.1023/A:1014031201935; CANTOR JM, 2001, DIAGNOSIS PROGNOSIS; CAVINESS VS, 1989, DEV NEUROBIOL, P1; Chapman SB, 2000, J COMMUN DISORD, V33, P333, DOI 10.1016/S0021-9924(00)00029-0; COREN S, 1991, PSYCHOL BULL, V109, P90, DOI 10.1037/0033-2909.109.1.90; COREN S, 1994, EARLY HUM DEV, V40, P23, DOI 10.1016/0378-3782(94)90096-5; DENNIS M, 1994, J DEV BEHAV PEDIATR, V15, P124; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; EARLS CM, 1987, ARCH SEX BEHAV, V16, P493, DOI 10.1007/BF01541713; ELLIS A, 1951, INT J SEXOLOGY, V4, P127; FINGER S, 1984, EARLY BRAIN DAMAGE, V2; Fisch GS, 1996, AM J MED GENET, V64, P356, DOI 10.1002/(SICI)1096-8628(19960809)64:2<356::AID-AJMG24>3.0.CO;2-D; FREUND K, 1967, BEHAV RES THER, V5, P209, DOI 10.1016/0005-7967(67)90036-8; FREUND K, 1989, J CONSULT CLIN PSYCH, V57, P100, DOI 10.1037/0022-006X.57.1.100; FREUND K, 1983, ARCH SEX BEHAV, V12, P369, DOI 10.1007/BF01542881; FREUND K, 1983, J HOMOSEXUAL, V9, P7, DOI 10.1300/J082v09n01_02; FREUND K., 1981, ADULT SEXUAL INTERES, P139; FREUND K, 1998, HDB SEXUALITY RELATE, P454; Freund K., 1991, PSYCHOL ASSESSMENT J, V3, P254, DOI DOI 10.1037/1040-3590.3.2.254; Frosch J, 1939, AM J ORTHOPSYCHIAT, V9, P761, DOI 10.1111/j.1939-0025.1939.tb05646.x; Frydman Marcel, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P169; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GOTTFRIED AW, 1973, PSYCHOL BULL, V80, P231, DOI 10.1037/h0034914; HAMBRIDGE JA, 1994, J FORENSIC SCI, V39, P456; Harris G.T., 1992, PSYCHOL ASSESSMENT, V4, P502, DOI [10.1037/1040-3590.4.4.502, DOI 10.1037/1040-3590.4.4.502]; HAYES A, 1993, PEDIATR CLIN N AM, V40, P523; HENN FA, 1976, AM J PSYCHIAT, V133, P694; Henry P C, 1992, J Neurosci Nurs, V24, P311; HEPPER PG, 1991, NEUROPSYCHOLOGIA, V29, P1107, DOI 10.1016/0028-3932(91)90080-R; Hucker S, 1988, ANN SEX RES, V1, P33, DOI DOI 10.1177/107906328800100104; Jernigan T. L., 1997, NEURODEVELOPMENT ADU, P63; Kennard MA, 1938, J NEUROPHYSIOL, V1, P477, DOI 10.1152/jn.1938.1.6.477; Kieler H, 2001, EPIDEMIOLOGY, V12, P618, DOI 10.1097/00001648-200111000-00007; Kolb B, 2000, DEV NEUROPSYCHOL, V18, P423, DOI 10.1207/S1532694208Kolb; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kozma C, 1998, AM J MED GENET, V81, P269, DOI 10.1002/(SICI)1096-8628(19980508)81:3<269::AID-AJMG12>3.0.CO;2-D; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kuban M, 1999, ARCH SEX BEHAV, V28, P345, DOI 10.1023/A:1018700813140; Langevin R., 1989, ANN SEX RES, V2, P163, DOI DOI 10.1007/BF00851321; LANGEVIN R, 1985, EROTIC PREFERENCE GE, P1; LANGEVIN R, 1988, ANN SEX RES, V1, P401; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LUND JS, 1993, J COMP NEUROL, V328, P282, DOI 10.1002/cne.903280209; LUND JS, 1997, NEURODEVELOPMENT ADU, P3; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARLOW N, 1989, ARCH DIS CHILD, V64, P1713, DOI 10.1136/adc.64.12.1713; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; Neyens LGJ, 1999, EPILEPSY RES, V34, P85, DOI 10.1016/S0920-1211(98)00118-1; Olson HC, 1998, ALCOHOL CLIN EXP RES, V22, P1998, DOI 10.1097/00000374-199812000-00016; OVERGAARD J, 1973, LANCET, V2, P631; PFEFFERBAUM A, 1994, ARCH NEUROL-CHICAGO, V51, P874, DOI 10.1001/archneur.1994.00540210046012; PLANT TM, 1988, FRONT NEUROENDOCRIN, V10, P215; QUINSEY VL, 1980, J CLIN PSYCHOL, V36, P410, DOI 10.1002/jclp.6120360204; RADCLIFFE J, 1994, INT J DEV NEUROSCI, V12, P327, DOI 10.1016/0736-5748(94)90081-7; SAIGAL S, 1992, DEV MED CHILD NEUROL, V34, P425; SCOTT ML, 1984, J FORENSIC SCI, V29, P1114; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Wesseling J, 2001, THROMB HAEMOSTASIS, V85, P609, DOI 10.1055/s-0037-1615641; WILLIAMS CS, 1992, AM J EPIDEMIOL, V136, P277, DOI 10.1093/oxfordjournals.aje.a116493; [No title captured]; [No title captured]	76	69	71	0	20	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0004-0002			ARCH SEX BEHAV	Arch. Sex. Behav.	DEC	2002	31	6					511	526		10.1023/A:1020659331965			16	Psychology, Clinical; Social Sciences, Interdisciplinary	Social Science Citation Index (SSCI)	Psychology; Social Sciences - Other Topics	603CK	WOS:000178541100007	12462478				2022-02-06	
J	Kolakowsky-Hayner, S; Gourley, EV; Kreutzer, JS; Marwitz, JH; Meade, MA; Cifu, DX				Kolakowsky-Hayner, S; Gourley, EV; Kreutzer, JS; Marwitz, JH; Meade, MA; Cifu, DX			Post-injury substance abuse among persons with brain injury and persons with spinal cord injury	BRAIN INJURY			English	Article							ALCOHOL-USE; HEAD-INJURY	Primary objective: To identify the patient population at greatest risk for post-injury adjustment problems, the present study independently examines and compares alcohol and drug use rates in patients with traumatic brain injury (TBI) and patients with spinal cord injury. Research design: The two samples were matched with regard to age, gender and mechanism of injury. The study provides a description of post-injury use rates for each population, and describes similarities and differences between the two groups. Methods and procedures: Participants included 30 consecutive Model Systems spinal cord injury (SCI) patients seen for follow-up neuropsychological testing between October 1996-June 1999. An equivalent number of Model Systems TBI patients were matched from a larger sample comprised of 440 consecutive hospital admissions, that returned for a 1-year follow-up neuropsychological evaluation between February 1989-December 1998. All participants were treated in an urban Level I trauma centre and associated inpatient rehabilitation programmes. Information regarding patient demographics, as well as pre- and post-injury psychiatric, employment, academic, criminal, and medical history was obtained via the General Health and History Questionnaire. Main outcomes and results: With regard to post-injury alcohol use rates, persons with spinal cord injury were more likely to drink on a daily basis. Although not statistically significant, pre- injury drinking rates differed from post-injury rates for both groups. With regard to illicit drug use, persons with TBI differed significantly from persons with SCI. A significant difference was also noted between pre- injury drug use and post-injury drug use for both groups. Conclusions: Persons who drink post-injury are unlikely to be 'light' or social drinkers. Either people choose to abstain completely or appear to use alcohol frequently.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA		Kolakowsky-Hayner, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, 1200 E Broad St,Room 3-102,POB 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387			Bombardier CH, 1998, ARCH PHYS MED REHAB, V79, P1110, DOI 10.1016/S0003-9993(98)90180-0; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P642; CAHALAN D, 1968, Q J STUD ALCOHOL, V29, P130; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Drubach D A, 1993, Md Med J, V42, P989; EDNA T, 1984, ACTA CHIR SCAND, V148, P209; FISHBURNE PM, 1979, NATL SURVEY DRUG ABU; Frisbie J H, 1984, J Am Paraplegia Soc, V7, P71; FULLERTON DT, 1981, ARCH GEN PSYCHIAT, V38, P1369; GALBRAITH S, 1976, BRIT J SURG, V63, P128, DOI 10.1002/bjs.1800630210; GALE JL, 1983, NEUROSURGERY, V12, P487, DOI 10.1227/00006123-198305000-00001; Go Bette K., 1995, P21; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Heinemann A. W., 1989, ALCOHOL HEALTH RES W, V13, P110; HEINEMANN AW, 1990, REHABIL PSYCHOL, V35, P217, DOI 10.1037/h0079065; HEINEMANN AW, 1988, ARCH PHYS MED REHAB, V69, P619; HEINEMANN AW, 1989, REHABIL PSYCHOL, V34, P191, DOI 10.1037//0090-5550.34.3.191; HEINEMANN AW, 1991, ARCH PHYS MED REHAB, V72, P482; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Krause J, 1992, NEUROREHABILITATION, V2, P45; Kreutzer J., 1987, GEN HLTH HIST QUESTI; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; KREUTZER JS, 1995, BRAIN INJURY, V9, P757, DOI 10.3109/02699059509008232; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Marmarou A., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI [10.1097/00001199-199009000-00006, DOI 10.1097/00001199-199009000-00006]; McKinley WO, 1999, AM J PHYS MED REHAB, V78, P306, DOI 10.1097/00002060-199907000-00002; ODONNELL JP, 1981, ALCOHOL HEALTH RES W, V148, P209; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Rimel RW, 1990, REHABILITATION ADULT, P8; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Smith J, 1993, SPINAL NETWORK, P375; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Sparadeo F. R., 1990, J HEAD TRAUMA REHAB, V5, P1, DOI DOI 10.1097/00001199-199009000-00004; TATE DG, 1993, AM J PHYS MED REHAB, V72, P192, DOI 10.1097/00002060-199308000-00004; WILKINSON DA, 1987, NEUROPSYCHOLOGY ALCO, P76; YOUNG ME, 1995, ARCH PHYS MED REHAB, V76, P525, DOI 10.1016/S0003-9993(95)80506-0	39	69	70	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2002	16	7					583	592		10.1080/02699050110119475			10	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Neurosciences & Neurology; Rehabilitation	569RN	WOS:000176616100003	12119077				2022-02-06	
J	Hesdorffer, DC; Ghajar, J; Iacono, L				Hesdorffer, DC; Ghajar, J; Iacono, L			Predictors of compliance with the evidence-based guidelines for traumatic brain injury care: A survey of United States trauma centers	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	5th International Neurotrauma Symposium	OCT 01-05, 2000	GARMISCH-PARTENKIRCHEN, GERMANY			traumatic brain injury; guideline compliance; survey	HEAD-INJURY; CLINICAL-PRACTICE; MAJOR TRAUMA; IMPACT; MANAGEMENT; MORTALITY; OUTCOMES; SYSTEM	Background. In 1995, evidence-based guidelines for the management of severe traumatic brain injury (TBI) were published and disseminated. Information regarding their implementation is limited. Methods: During 1999 to 2000, we contacted all designated U.S. trauma centers caring for adults with severe TBI to determine the degree of guideline compliance and to identify predictors. Results: Of 924 centers identified, 828 participated (90%). Four hundred thirty-three with intensive care units caring for severe TBI were surveyed. Three hundred ninety-five centers transferring patients were excluded. Full guideline compliance was rare (n = 68 [16%]). In multivariate analyses, treatment protocols (odds ratio [OR], 3.6; 95% confidence interval [CI], 1.9-6.6), neurosurgery residency program (OR, 5.0; 95% CI, 2.6-9.8), and state (OR, 2.7; 95% CI, 0.62-12) or American College of Surgeons (OR, 5.1; 95% CI, 1.1-23) designation increased the likelihood of full compliance versus noncompliance. Conclusion: Although evidence-based guidelines were published and disseminated in 1995, implementation is infrequent. Focus must turn to changing physician practice and transport decisions to provide guideline-compliant care and improve patient outcome.	Brain Trauma Fdn, New York, NY 10021 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA; Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Neurosurg, New York, NY USA		Hesdorffer, DC (corresponding author), Brain Trauma Fdn, 523 E 72nd St, New York, NY 10021 USA.	dch5@columbia.edu					*AM MED ASS OFF QU, 1990, HLTH CAR ORG ATTR GU; Brain Trauma Foundation, 2000, GUID PREH MAN TRAUM, P67; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Drobetz H, 2000, ANASTH INTENSIV NOTF, V35, P630, DOI 10.1055/s-2000-7365; EAST TD, 1992, CHEST, V101, P697, DOI 10.1378/chest.101.3.697; GAAB MR, 1994, AENTRALBL NEUROCHIR, V55, P133; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GRACEY DR, 1992, MAYO CLIN PROC, V67, P131, DOI 10.1016/S0025-6196(12)61313-5; Handley M R, 1994, HMO Pract, V8, P75; Hosmer D. W., 1989, APPL LOGISTIC REGRES, P216; Jeevaratnam DR, 1996, BRIT MED J, V312, P944; KAGAN RJ, 1994, AM SURGEON, V60, P394; Kaups KL, 1998, J TRAUMA, V45, P884, DOI 10.1097/00005373-199811000-00007; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Max W, 1991, J HEAD TRAUMA REHAB, V6, P76; Mcilvoy L, 2001, J Neurosci Nurs, V33, P72; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; *NIH, 1994, REP TASK FORC TRAUM; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Palmer S, 2001, J TRAUMA, V50, P657, DOI 10.1097/00005373-200104000-00010; Rosomoff HL, 1996, CRIT CARE MED, V24, pS48; Sampalis JS, 1997, J TRAUMA, V43, P288, DOI 10.1097/00005373-199708000-00014; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spain DA, 1998, J TRAUMA, V45, P101, DOI 10.1097/00005373-199807000-00022; TRASK AL, 1998, J TRAUMA, V45, P1109; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Young JS, 1998, AM SURGEON, V64, P88	33	69	69	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2002	52	6					1202	1209		10.1097/00005373-200206000-00031			8	Critical Care Medicine; Surgery	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine; Surgery	562KJ	WOS:000176195700040	12045655				2022-02-06	
J	Hammoud, DA; Wassennan, BA				Hammoud, DA; Wassennan, BA			Diffuse axonal injuries: pathophysiology and imaging	NEUROIMAGING CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN INJURY; MAGNETIC-RESONANCE SPECTROSCOPY; INFLICTED HEAD-INJURY; FUNCTIONAL MRI; MILD; CT; NEUROPATHOLOGY; REHABILITATION; RECOVERY; FEATURES	Diffuse axonal injury (DAI) is the sequela of shear-strain injury to the brain, and occurs in almost half of serious traumatic brain injuries, both in adults and children. This article discusses the mechanism and pathophysiology of axonal shear injury as well as the clinical presentation and prognostic factors of DAI patients. The different imaging modalities are discussed, with emphasis on both classical and new modalities.	Johns Hopkins Univ, Div Neuroradiol, Sch Med, Baltimore, MD 21287 USA		Wassennan, BA (corresponding author), Johns Hopkins Univ, Div Neuroradiol, Sch Med, 600 N Wolfe St,Phipps B-100, Baltimore, MD 21287 USA.	bwasser@rad.jhu.edu	Hammoud, Dima A/C-2286-2015	Hammoud, Dima/0000-0001-7406-7871			Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Azouvi P, 2000, CURR OPIN NEUROL, V13, P665, DOI 10.1097/00019052-200012000-00009; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Bigler E D, 1999, Appl Neuropsychol, V6, P217, DOI 10.1207/s15324826an0604_4; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cioni G, 2001, NEUROREPORT, V12, P1335, DOI 10.1097/00001756-200105250-00009; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; COTRAN R, 1999, ROBBINS PATHOLOGIC B, P1301; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 2001, MAGNETIC RESONANCE I, P1069; GOETZ CG, 1999, TXB CLIN NEUROLOGY, P1035; Graham DI, 2001, BRAIN, V124, P1261, DOI 10.1093/brain/124.7.1261; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Laatsch L, 1999, BRAIN INJURY, V13, P555, DOI 10.1080/026990599121304; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Nakayama Y, 2000, FORENSIC SCI INT, V113, P245, DOI 10.1016/S0379-0738(00)00217-6; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; PRAYER L, 1993, ACTA RADIOL, V34, P593; TAVERAS J, 1996, NEURORADIOLOGY, P353; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	40	69	79	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1052-5149	1557-9867		NEUROIMAG CLIN N AM	Neuroimaging Clin. N. Am.	MAY	2002	12	2					205	+	PII S1052-5149(02)00011-4	10.1016/S1052-5149(02)00011-4			13	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	609GA	WOS:000178894200005	12391632				2022-02-06	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			Delayed-onset posttraumatic stress disorder: a prospective evaluation	AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY			English	Article						delayed onset; diagnosis; posttraumatic stress disorder	MOTOR-VEHICLE ACCIDENTS; 2-YEAR PROSPECTIVE EVALUATION; TRAUMATIC BRAIN INJURY; PTSD; WAR; PREDICTORS; INTERVIEW; SURVIVORS; SYMPTOMS; VETERANS	Objective: Delayed onset posttraumatic stress disorder (PTSD) refers to PTSD that develops at least 6 months after the traumatic event. This study aimed to index the features of patients who develop delayed-onset PTSD. Method: This study investigated delayed onset PTSD by prospectively assessing 103 motor vehicle accident survivors within 1 month of the motor vehicle accident for acute stress disorder, and subsequently assessing them for PTSD 6 months post-accident, and 2 years post-accident. Patients were initially assessed for symptoms of traumatic stress, anxiety, depression, and resting heart rate. Results: Five patients displayed PTSD 2 years post-trauma without meeting PTSD criteria 6 months posttrauma. Delayed onset cases were characterized by elevated psycho-pathology scores and resting heart rate levels within the initial month and elevated psychopathology 6 months posttrauma. Conclusions: These findings suggest that cases of delayed onset PTSD suffer subsyndromal levels of posttraumatic stress prior to the diagnosis of PTSD. These findings challenge the notion of PTSD developing after a period without symptoms.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia; Univ Oxford, Oxford, England		Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL; BECK AT, 1979, COGNITIVE THERAPY DE; Bryant RA, 2000, J ABNORM PSYCHOL, V109, P341, DOI 10.1037/0021-843X.109.2.341; Bryant RA, 1998, PSYCHOL ASSESSMENT, V10, P215, DOI 10.1037/1040-3590.10.3.215; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Buckley TC, 1996, J ABNORM PSYCHOL, V105, P617, DOI 10.1037/0021-843X.105.4.617; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; EPSTEIN RS, 1993, J TRAUMA STRESS, V6, P451, DOI 10.1007/BF00974316; GREEN BL, 1990, AM J ORTHOPSYCHIAT, V60, P43, DOI 10.1037/h0079168; GREEN MM, 1993, MED J AUSTRALIA, V159, P529, DOI 10.5694/j.1326-5377.1993.tb138006.x; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1998, J CONSULT CLIN PSYCH, V66, P507, DOI 10.1037/0022-006X.66.3.507; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; HERRMANN N, 1994, CAN J PSYCHIAT, V39, P439, DOI 10.1177/070674379403900710; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P30, DOI 10.1097/00005053-198801000-00004; MCFARLANE AC, 1997, PSYCHOBIOLOGY POSTTR, P433; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; PITMAN RK, 1989, BIOL PSYCHIAT, V26, P221, DOI 10.1016/0006-3223(89)90033-4; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; SIMON RI, 1995, POSTTRAUMATIC STRESS; SOLOMON Z, 1989, PSYCHIATRY, V52, P428, DOI 10.1080/00332747.1989.11024467; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; VANDYKE C, 1985, AM J PSYCHIAT, V142, P1070	26	69	69	0	5	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	0004-8674			AUST NZ J PSYCHIAT	Aust. N. Z. J. Psych.	APR	2002	36	2					205	209		10.1046/j.1440-1614.2002.01009.x			5	Psychiatry	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry	554XR	WOS:000175762900007	11982541				2022-02-06	
J	Linstedt, U; Meyer, O; Kropp, P; Berkau, A; Tapp, E; Zenz, M				Linstedt, U; Meyer, O; Kropp, P; Berkau, A; Tapp, E; Zenz, M			Serum concentration of S-100 protein in assessment of cognitive dysfunction after general anesthesia in different types of surgery	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						postoperative cognitive deficit; serum markers; S-100; NSE	NEURON-SPECIFIC ENOLASE; CORONARY-ARTERY BYPASS; FEMORAL-NECK FRACTURES; TRAUMATIC BRAIN INJURY; NEUROBIOCHEMICAL MARKERS; CEREBRAL-ISCHEMIA; ELDERLY PATIENTS; CARDIAC-SURGERY; DAMAGE; BLOOD	Background: S-100 protein serum concentration (S-100) serves as a marker of cerebral ischemia in cardiac surgery head injury and stroke. In these circumstances S-100 corresponds well with the results of neuropsychological tests. The aim of the present study was to investigate the value of S-100 and neuron specific enolase (NSE) in reflecting postoperative cognitive deficit (POCD) after general surgical procedures. Methods: One hundred and twenty patients undergoing vascular, trauma, urological or abdominal surgery were investigated. Serum values of S-100 and NSE were determined preoperatively and 0.5, 4, 18 and 36 h postoperatively. Neuropsychological tests for detecting POCD were performed preoperatively and on day 1, 3, and 6 after the operation. A decline of more than 10% in neuropsychological test results was regarded as POCD. Furthermore, we retrospectively compared the S-100 in patients with and without POCD in different types of surgery. Results: According to our definition, forty-eight patients had POCD (95% confidence interval: 37.5-58.5). These patients showed higher serum concentrations of S-100 (median 024ng/ml; range 0.01-3.3ng/ml) compared with those without POCD (n=69; median 0.14ng/ml; range 0-1.34ng/ml) 30 min post-operatively (P=0.01). Neuron specific enolase was unchanged during the course of the study. Differences of S-100 in patients with and without POCD were found in abdominal and vascular surgery but not in urological surgery. Conclusion: When all patients are pooled, S-100 appears to be suitable in the assessment of incidence, course and outcome of cognitive deficits. We suspect that in some surgical procedures, such as urological surgery, S-100 appears to be of limited value in detecting POCD. Neuron specific enolase did not reflect neuropsychological dysfunction after noncardiac surgery. (C) Acta Anaesthesiologica Scandinavica 46 (2002).	Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Anesthesiol Intens Care Med & Pain Therpay, D-4630 Bochum, Germany; Univ Kiel, Inst Med Psychol, Kiel, Germany; Univ Kiel, Dept Anesthesiol & Intens Care Med, Kiel, Germany		Linstedt, U (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Klin Anaesthesiol Intensiv Med & Schmerztherapie, Schornau 23-25, D-44892 Bochum, Germany.		Kropp, Peter/B-8132-2012				Anderson RE, 1999, ANN THORAC SURG, V67, P1721, DOI 10.1016/S0003-4975(99)00318-5; BERGGREN D, 1987, ANESTH ANALG, V66, P497; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Borowicz LM, 1996, J CARDIOTHOR VASC AN, V10, P105, DOI 10.1016/S1053-0770(96)80185-6; Brickenkamp R, 1994, TEST D2 AUFMERKSAMKE; GODET G, 2001, PROTEIN LEVELS CORRE, V15, P25; Grocott HP, 1998, ANN THORAC SURG, V65, P1645, DOI 10.1016/S0003-4975(98)00276-8; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; Hauschild A, 1999, ONCOLOGY-BASEL, V56, P338, DOI 10.1159/000011989; Herrmann M, 1999, RESTOR NEUROL NEUROS, V14, P109; Johnsson P, 1995, J CARDIOTHOR VASC AN, V9, P694, DOI 10.1016/S1053-0770(05)80231-9; Johnsson P, 1996, J CARDIOTHOR VASC AN, V10, P120, DOI 10.1016/S1053-0770(96)80187-X; Linstedt U, 2000, ANAESTHESIST, V49, P887, DOI 10.1007/s001010070042; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; McKeating EG, 1998, ACT NEUR S, V71, P117; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; NEWMAN S, 1987, CURR PSYCHOL RES REV, V6, P115, DOI 10.1007/BF02686616; OKEEFE ST, 1994, BRIT J ANAESTH, V73, P673, DOI 10.1093/bja/73.5.673; Oswald W. D., 1997, ZAHLEN VERBINDUNGS T; Rasmussen LS, 2000, J CARDIOTHOR VASC AN, V14, P166, DOI 10.1016/S1053-0770(00)90012-0; Rasmussen LS, 1999, ACTA ANAESTH SCAND, V43, P495, DOI 10.1034/j.1399-6576.1999.430502.x; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242, DOI 10.1093/oxfordjournals.bja.a013410; Rasmussen LS, 2001, ACTA ANAESTH SCAND, V45, P275, DOI 10.1034/j.1399-6576.2001.045003275.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Spreen O, 1998, COMPENDIUM NEUROPSYC, P232; URDAL P, 1983, CLIN CHEM, V29, P310; Wechsler D., 1981, ADULT INTELLIGENCE S; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	29	69	87	2	9	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	APR	2002	46	4					384	389		10.1034/j.1399-6576.2002.460409.x			6	Anesthesiology	Science Citation Index Expanded (SCI-EXPANDED)	Anesthesiology	548AV	WOS:000175366500009	11952437				2022-02-06	
J	Kishi, Y; Robinson, RG; Kosier, JT				Kishi, Y; Robinson, RG; Kosier, JT			Suicidal ideation among patients with acute life-threatening physical illness - Patients with stroke, traumatic brain injury, myocardial infarction, and spinal cord injury	PSYCHOSOMATICS			English	Article							PRIMARY-CARE; DEPRESSION; SYMPTOMS; OUTPATIENTS; FREQUENCY; EPILEPSY; DEATH; PLANS; MOOD	Suicide is one of the leading causes of death in the community. The risk of suicide is greater among patients with physical illnesses than among the general population. This study was undertaken to evaluate the clinical characteristics and correlates of suicidal ideation in patients with acute life-threatening physical illnesses and to assess the duration of suicidal ideation. The study included a consecutive series of patients admitted with stroke, traumatic brain injury myocardial infarction, or spinal cord injury (n = 496). Study participants were administered a semistructured psychiatric interview as well as a series of standardized quantitative scales of mood, cognitive function, physical impairment, social ties, and social functioning. Follow-up evaluations of up to 24 months were also carried out. This study found that 36 (7.3%) patients with acute medical illness had clinically, significant suicidal ideation. The suicidal ideation occurred mostly among patients with major depression and sometimes in those with minor depression. About 25% of patients with major depression and acute physical illnesses developed suicidal ideation. After the improvement of depressive disorders, suicidal ideations were ameliorated. These findings suggest that the detection and treatment of depressive disorders is the most important factor in preventing suicide among this patient population.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Chiba Hokusoh Hosp, Nippon Med Sch, Dept Psychiat, Chiba, Japan		Robinson, RG (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 200 Hawkins Dr, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021; Kishi, Yasuhiro/T-4047-2019		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH52879, MH53592] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH053592, R01MH052879] Funding Source: NIH RePORTER		ACHTE KA, 1971, ACTA PSYCHIATR SCA S, V225, P3; American Psychiatric Association American Psychiatric Association American Psychiatric Association, 1994, DIAGN STAT MAN MENT DIAGN STAT MAN MENT, V4th 4th 4th; ASNIS GM, 1993, AM J PSYCHIAT, V150, P108; BROWN JH, 1986, AM J PSYCHIAT, V143, P208; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; DEVIVO MJ, 1991, PARAPLEGIA, V29, P620, DOI 10.1038/sc.1991.91; DEVIVO MJ, 1993, ARCH PHYS MED REHAB, V74, P248; FEDOROFF JP, 1991, AM J PSYCHIAT, V148, P1172; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GUZE SB, 1970, BRIT J PSYCHIAT, V117, P437, DOI 10.1192/bjp.117.539.437; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAWTON K, 1980, J NEUROL NEUROSUR PS, V43, P168, DOI 10.1136/jnnp.43.2.168; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Kishi Y, 1999, PSYCHOSOMATICS, V40, P345, DOI 10.1016/S0033-3182(99)71230-2; Kishi Y, 1996, J NERV MENT DIS, V184, P274, DOI 10.1097/00005053-199605000-00002; Kishi Y, 1996, J NEUROPSYCH CLIN N, V8, P442; Kishi Y, 1996, Int Psychogeriatr, V8, P623, DOI 10.1017/S1041610296002931; LIEBENLUFT E, 1988, PSYCHOSOMATICS, V29, P379; Lish JD, 1996, PSYCHOSOMATICS, V37, P413, DOI 10.1016/S0033-3182(96)71528-1; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MAYOU R, 1988, J PSYCHOSOM RES, V32, P541, DOI 10.1016/0022-3999(88)90038-4; MILES CP, 1977, J NERV MENT DIS, V164, P231, DOI 10.1097/00005053-197704000-00002; MURPHY GE, 1983, ARCH GEN PSYCHIAT, V40, P342; Olfson M, 1996, J GEN INTERN MED, V11, P447, DOI 10.1007/BF02599038; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; ROBINSON RG, 1981, BRAIN LANG, V14, P282, DOI 10.1016/0093-934X(81)90080-8; ROBINSON RG, 1983, COMPR PSYCHIAT, V24, P555, DOI 10.1016/0010-440X(83)90024-X; Rost K, 1998, GEN HOSP PSYCHIAT, V20, P12, DOI 10.1016/S0163-8343(97)00095-9; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; Starr L B, 1982, Soc Work Res Abstr, V18, P28; WELLS KB, 1994, PSYCHOSOMATICS, V35, P279, DOI 10.1016/S0033-3182(94)71776-X; WHITE SJ, 1979, LANCET, V2, P458; Wing J. K., 1974, MEASUREMENT CLASSIFI; ZIMMERMAN M, 1995, J GEN INTERN MED, V10, P573, DOI 10.1007/BF02640368; Zisook S, 1994, Ann Clin Psychiatry, V6, P27, DOI 10.3109/10401239409148836	38	69	70	0	3	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	SEP-OCT	2001	42	5					382	390		10.1176/appi.psy.42.5.382			9	Psychiatry; Psychology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Psychiatry; Psychology	487PU	WOS:000171885100002	11739904				2022-02-06	
J	Veinbergs, I; Mallory, M; Sagara, Y; Masliah, E				Veinbergs, I; Mallory, M; Sagara, Y; Masliah, E			Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						ageing; Alzheimer's disease; antioxidants; gene knock-out; neurodegeneration	LIPOPROTEIN LIPID-PEROXIDATION; CENTRAL-NERVOUS-SYSTEM; CLOSED-HEAD INJURY; E KNOCKOUT MICE; ALZHEIMERS-DISEASE; CHOLINERGIC IMPAIRMENTS; IN-VIVO; APOE; NEURODEGENERATION; ATHEROSCLEROSIS	Recent studies have suggested that altered function of apolipoprotein E might lead to Alzheimer's disease via oxidative stress. In this context, the objective of this study was to determine if antioxidative treatment with vitamin E was neuroprotective in apolipoprotein E-deficient mice. For this purpose, 1-month-old control and apolipoprotein E-deficient mice received dietary vitamin E for 12 months. We showed that, compared to apolipoprotein E-deficient mice who received a regular diet, mice treated with vitamin E displayed a significantly improved behavioural performance in the Morris water maze. This improved performance was associated with preservation of the dendritic structure in vitamin E-treated apolipoprotein E-deficient mice. In addition, whilst untreated apolipoprotein E-deficient mice displayed increased levels of lipid peroxidation and glutathione, vitamin E-treated mice showed near normal levels of both lipid peroxidation and glutathione. These results support the contention that vitamin E prevents the age-related neurodegenerative alterations in apolipoprotein E-deficient mice.	Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA		Masliah, E (corresponding author), Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG5131, AG10869] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R29AG010869] Funding Source: NIH RePORTER		Buttini M, 1999, J NEUROSCI, V19, P4867; delaTorre JC, 1996, VIROLOGY, V220, P508, DOI 10.1006/viro.1996.0340; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Fisher A, 1998, J NEUROCHEM, V70, P1991; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; Gozes I, 1997, J NEUROBIOL, V33, P329, DOI 10.1002/(SICI)1097-4695(199709)33:3<329::AID-NEU10>3.0.CO;2-A; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hayek T, 1998, J CARDIOVASC PHARM, V31, P540, DOI 10.1097/00005344-199804000-00011; HAYEK T, 1994, BIOCHEM BIOPH RES CO, V201, P1567, DOI 10.1006/bbrc.1994.1883; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; IGNATIUS MJ, 1987, SCIENCE, V236, P959, DOI 10.1126/science.3576212; Letters JM, 1999, J LIPID RES, V40, P1104; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Masliah E, 1996, PROG NEUROBIOL, V50, P493, DOI 10.1016/S0301-0082(96)00038-X; Masliah E, 1997, BRAIN RES, V751, P307, DOI 10.1016/S0006-8993(96)01420-5; MASLIAH E, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P405; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MASLIAH E, 1995, APOLIPOPROTEIN E ALZ, P59; Matthews RT, 1996, BRAIN RES, V718, P181, DOI 10.1016/0006-8993(95)01576-0; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEISTER A, 1994, J BIOL CHEM, V269, P9397; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Moghadasian MH, 1999, CIRCULATION, V99, P1733, DOI 10.1161/01.CIR.99.13.1733; Montine TJ, 1996, J NEUROPATH EXP NEUR, V55, P202, DOI 10.1097/00005072-199602000-00009; Montine TJ, 1999, EXP NEUROL, V158, P234, DOI 10.1006/exnr.1999.7067; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; Oitzl MS, 1997, BRAIN RES, V752, P189, DOI 10.1016/S0006-8993(96)01448-5; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Ramassamy C, 1999, FREE RADICAL BIO MED, V27, P544, DOI 10.1016/S0891-5849(99)00102-1; Sagara Y, 1998, J NEUROCHEM, V71, P1002, DOI 10.1046/j.1471-4159.1998.71031002.x; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shaish A, 1999, ARTERIOSCL THROM VAS, V19, P1470, DOI 10.1161/01.ATV.19.6.1470; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tsimikas S, 2000, ARTERIOSCL THROM VAS, V20, P689, DOI 10.1161/01.ATV.20.3.689; Veinbergs I, 1998, NEUROSCI LETT, V249, P71, DOI 10.1016/S0304-3940(98)00399-1; WEST HL, 1994, NEUROSCI LETT, V175, P460; Witting PK, 1999, FASEB J, V13, P667, DOI 10.1096/fasebj.13.6.667	44	69	72	0	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0953-816X			EUR J NEUROSCI	Eur. J. Neurosci.	DEC	2000	12	12					4541	4546		10.1046/j.1460-9568.2000.01308.x			6	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	387FV	WOS:000166113000038	11122365				2022-02-06	
J	Hanten, G; Martin, RC				Hanten, G; Martin, RC			Contributions of phonological and semantic short-term memory to sentence processing: Evidence from two cases of closed head injury in children	JOURNAL OF MEMORY AND LANGUAGE			English	Article						short-term memory; sentence comprehension; sentence repetition; multiple components of STM; language development	WORKING-MEMORY; WORD-LENGTH; GRAMMATICALITY JUDGMENTS; ACOUSTIC SIMILARITY; SPOKEN LANGUAGE; COMPREHENSION; APHASIA; RECALL; SPAN; ACQUISITION	This paper reports the short-term memory and sentence processing performance of two head-injured children who were approximately 10 years of age at the time of test. The two children were found to have similarly reduced memory span on a variety of short-term memory tasks relative to age-matched control children, but differing patterns of performance. One child showed reduced (or absent) effects of phonological variables, and the other showed reduced effects of semantic variables. A dissociation in their performance on sentence processing tasks was also observed, with one child showing preserved comprehension but impaired repetition, and the other child showing the reverse. The results are consistent with previous findings from brain-damaged adults supporting a multiple-components model of short-term memory in which phonological and semantic components play different roles in sentence processing. Contrary to our initial hypothesis, the phonological component did not appear to play a more important role in sentence comprehension for children than for adults. (C) 2000 Acadcmic Press.	Rice Univ, Dept Psychol, Houston, TX 77251 USA		Martin, RC (corresponding author), Rice Univ, Dept Psychol, POB 1892, Houston, TX 77251 USA.	rmartin@rice.edu					Baddeley A, 1998, PSYCHOL REV, V105, P158, DOI 10.1037/0033-295X.105.1.158; Baddeley A, 1993, Memory, V1, P65, DOI 10.1080/09658219308258225; Baddeley A.D., 1986, WORKING MEMORY; BOURASSA DC, 1994, PSYCHON B REV, V1, P122, DOI 10.3758/BF03200768; BUTTERWORTH B, 1986, Q J EXP PSYCHOL-A, V38, P705, DOI 10.1080/14640748608401622; Caplan D, 1999, BEHAV BRAIN SCI, V22, P77; CARAMAZZA A, 1981, BRAIN LANG, V14, P235, DOI 10.1016/0093-934X(81)90078-X; CARPENTER PA, 1981, J VERB LEARN VERB BE, V20, P137, DOI 10.1016/S0022-5371(81)90357-1; COWAN N, 1994, J MEM LANG, V33, P234, DOI 10.1006/jmla.1994.1012; COWAN N, 1991, J EXP CHILD PSYCHOL, V51, P30, DOI 10.1016/0022-0965(91)90076-5; DELL GS, 1990, LANG COGNITIVE PROC, V5, P313, DOI 10.1080/01690969008407066; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DUNN LM, 1980, PEABODY PICTURE VOCA; FREEDMAN M, IN PRESS COGNITIVE N; Gathercole S E, 1994, Memory, V2, P103, DOI 10.1080/09658219408258940; Gathercole SE, 1999, APPL COGNITIVE PSYCH, V13, P65, DOI 10.1002/(SICI)1099-0720(199902)13:1<65::AID-ACP548>3.0.CO;2-O; Gathercole SE, 1997, DEV PSYCHOL, V33, P966, DOI 10.1037/0012-1649.33.6.966; GATHERCOLE SE, 1990, BRIT J PSYCHOL, V81, P439, DOI 10.1111/j.2044-8295.1990.tb02371.x; GILHOOLY KJ, 1980, BEHAV RES METH INSTR, V12, P395, DOI 10.3758/BF03201693; HALL JF, 1954, AM J PSYCHOL, V67, P138, DOI 10.2307/1418080; Hanten G, 1999, DEV NEUROPSYCHOL, V16, P393, DOI 10.1207/S15326942DN1603_23; HENRY LA, 1991, Q J EXP PSYCHOL-A, V43, P35, DOI 10.1080/14640749108400998; HITCH GJ, 1989, MEM COGNITION, V17, P175, DOI 10.3758/BF03197067; HOLCOMB PJ, 1992, DEV NEUROPSYCHOL, V8, P203, DOI 10.1080/87565649209540525; HOLLAND BA, 1986, AM J NEURORADIOL, V7, P201; HULME C, 1989, J EXP CHILD PSYCHOL, V47, P72, DOI 10.1016/0022-0965(89)90063-5; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; HULME C, 1984, DEV PSYCHOL, V20, P650, DOI 10.1037/0012-1649.20.4.650; JESCHENIAK JD, 1994, J EXP PSYCHOL LEARN, V20, P824, DOI 10.1037/0278-7393.20.4.824; Kabrich M, 1996, AM J MENT RETARD, V100, P510; KAIL R, 1994, ACTA PSYCHOL, V86, P199, DOI 10.1016/0001-6918(94)90003-5; Knott R, 1997, COGNITIVE NEUROPSYCH, V14, P1165, DOI 10.1080/026432997381303; Lenneberg E.H., 1967, BIOL FDN LANGUAGE; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Liu H, 1997, APPL PSYCHOLINGUIST, V18, P157, DOI 10.1017/S0142716400009954; MANN VA, 1989, J LEARN DISABIL, V22, P76, DOI 10.1177/002221948902200202; MARSLENWILSON W, 1980, COGNITION, V8, P1, DOI 10.1016/0010-0277(80)90015-3; MARTIN N, 1992, BRAIN LANG, V43, P240, DOI 10.1016/0093-934X(92)90130-7; Martin N, 1997, COGNITIVE NEUROPSYCH, V14, P641; MARTIN N, 1990, BRAIN LANG, V39, P254, DOI 10.1016/0093-934X(90)90014-8; MARTIN R, 1995, PSYCH SOC M LOS ANG; Martin R., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; Martin R. C., 1996, MODELS SHORT TERM ME, P149; MARTIN RC, 1992, COGNITIVE NEUROPSYCH, V9, P509, DOI 10.1080/02643299208252070; MARTIN RC, 1994, J MEM LANG, V33, P83, DOI 10.1006/jmla.1994.1005; MARTIN RC, 1993, MEM COGNITION, V21, P176, DOI 10.3758/BF03202730; MARTIN RC, 1987, BRAIN LANG, V32, P159, DOI 10.1016/0093-934X(87)90122-2; Martin RC, 1999, J MEM LANG, V41, P3, DOI 10.1006/jmla.1999.2637; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; MONTGOMERY JW, 1995, J SPEECH HEAR RES, V38, P187, DOI 10.1044/jshr.3801.187; MORRISON CM, 1992, MEM COGNITION, V20, P705, DOI 10.3758/BF03202720; Nippold M. A., 1988, LATER LANGUAGE DEV; PAIVIO A, 1965, J VERB LEARN VERB BE, V4, P32, DOI 10.1016/S0022-5371(65)80064-0; PATTERSON K, 1994, J COGNITIVE NEUROSCI, V6, P57, DOI 10.1162/jocn.1994.6.1.57; Penney CG, 1999, J EXP PSYCHOL LEARN, V25, P284, DOI 10.1037/0278-7393.25.1.284; POTTER MC, 1990, J MEM LANG, V29, P633, DOI 10.1016/0749-596X(90)90042-X; Quinlan P., 1992, OXFORD PSYCHOLINGUIS; Romani C, 1999, J EXP PSYCHOL GEN, V128, P56, DOI 10.1037/0096-3445.128.1.56; Saffran E. M., 1990, NEUROPSYCHOLOGICAL I, P428; SAFFRAN EM, 1975, BRAIN LANG, V2, P420, DOI 10.1016/S0093-934X(75)80081-2; SAFFRAN EM, 1990, ADV COGNITIVE NEUROP, P137; Scott CherylM., 1988, LATER LANGUAGE DEV A, P49; SHALLICE T, 1990, NEUROPSYCHOLOGICAL I, P131; TEASDALE G, 1974, LANCET, V2, P81; THATCHER RW, 1992, BRAIN COGNITION, V20, P24, DOI 10.1016/0278-2626(92)90060-Y; TYLER LK, 1981, J VERB LEARN VERB BE, V20, P400, DOI 10.1016/S0022-5371(81)90524-7; VALLAR G, 1984, COGNITIVE NEUROPSYCH, V1, P21; WATERS G, 1991, COGNITIVE NEUROPSYCH, V8, P81, DOI 10.1080/02643299108253368; WULFECK B, 1991, BRAIN LANG, V41, P311, DOI 10.1016/0093-934X(91)90158-W; WULFECK BB, 1993, J SPEECH HEAR RES, V36, P1208, DOI 10.1044/jshr.3606.1208	70	69	70	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0749-596X	1096-0821		J MEM LANG	J. Mem. Lang.	AUG	2000	43	2					335	361		10.1006/jmla.2000.2731			27	Linguistics; Psychology; Psychology, Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Linguistics; Psychology	340XE	WOS:000088561000009					2022-02-06	
J	Baguley, I; Slewa-Younan, S; Lazarus, R; Green, A				Baguley, I; Slewa-Younan, S; Lazarus, R; Green, A			Long-term mortality trends in patients with traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; APOLIPOPROTEIN-E; SURVIVAL; MEN	Comparison of long-term mortality rates between patients with traumatic brain injury (TBI) and the general population has not been adequately investigated. This project aimed to obtain information on the long-term mortality rate of patients with TBI. Using a rehabilitation database of a major teaching hospital, the search identified 476 patients, of whom 27 were deceased. This mortality rate (5.7%) was compared with the expected mortality rate for an equivalent population without TBI (1.5%) using Australian Life Table data. It was found chat patients with TBI had a significantly higher mortality rate than the general population (chi(2) = 12.2, p < 0.001). Possible reasons for this finding are discussed.	Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia; Univ Sydney, Fac Med, Camperdown, NSW, Australia		Baguley, I (corresponding author), Westmead Hosp, Brain Injury Rehabil Serv, Westmead, NSW 2145, Australia.	ianb@biru.wsahs.nsw.gov.au	Baguley, Ian J/K-6878-2013; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; lazarus, ross/0000-0003-3939-1961			*AUSTR BUR STAT, 1997, 33020 ABS; FELMINGHAM KL, UNPUB ARCH PHYSICAL; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Graham DI, 1997, BRAIN PATHOL, V7, P1285; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Hall K, 1992, NEUROREHABILITATION, V2, P98, DOI DOI 10.3233/NRE-1992-2410; Hartig W, 1997, BRAIN RES PROTOC, V2, P35, DOI 10.1016/S1385-299X(97)00026-3; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; RISH BL, 1983, J NEUROSURG, V59, P775, DOI 10.3171/jns.1983.59.5.0775; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; *SPSS BAS 9 0, 1999, US GUID; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WALKER AE, 1971, ARCH NEUROL-CHICAGO, V24, P95, DOI 10.1001/archneur.1971.00480320023001; WALKER AE, 1968, HEAD INJURED MEN 15; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124	20	69	71	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2000	14	6					505	512					8	Neurosciences; Rehabilitation	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology; Rehabilitation	325WN	WOS:000087699600002	10887885				2022-02-06	
J	Bagley, LJ; McGowan, JC; Grossman, RI; Sinson, G; Kotapka, M; Lexa, FJ; Berlin, JA; McIntosh, TK				Bagley, LJ; McGowan, JC; Grossman, RI; Sinson, G; Kotapka, M; Lexa, FJ; Berlin, JA; McIntosh, TK			Magnetization transfer imaging of traumatic brain injury	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Article; Proceedings Paper	5th Annual Meeting of ISMRM	APR, 1997	VANCOUVER, CANADA	Int Soc Magnet Resonance Med		magnetization transfer (MT); magnetic resonance (MR); brain injuries	DIFFUSE AXONAL INJURY; HEAD-INJURY; MULTIPLE-SCLEROSIS; HISTOPATHOLOGIC CORRELATION; MICROSCOPIC DISEASE; TRANSFER CONTRAST; MILD; MR; TOMOGRAPHY; DAMAGE	Magnetization transfer imaging (MTI) has been shown to be sensitive for the detection of white matter abnormalities in entities such as multiple sclerosis, progressive multifocal leukencephalopathy, and wallerian degeneration. Our hypothesis was that MTI would detect traumatic white matter abnormalities (TWMA) and provide information additional to that obtainable with routine spin- and gradient-echo imaging, We hypothesized that the presence of TWMA defined by MTI would correlate with outcome following TBI. Twenty-eight victims of head trauma and 15 normal controls underwent magnetic resonance imaging including MTI. Magnetization transfer ratios (MTR) were calculated for areas of shearing injury and for normal-appearing white matter (NAWM) in locations frequently subject to diffuse axonal injury. Abnormal MTRs were detected in NAWM in eight patients. All eight had persistent neurologic deficits, including cognitive deficits, aphasia, and extremity weakness. Seven of the 28 patients had no abnormal findings on neurologic exam at discharge, transfer, or follow-up. None of these patients had an abnormal MTR in NAWM, In the remaining 13 patients, who had persistent neurologic deficits, no regions of abnormal MTR were detected in NAWM, MTI is a sensitive method for the detection of TWMA, Detection of abnormal MTR in NAWM that is prone to axonal injury may predict a poor patient outcome, The presence of normal MTR in NAWM in these areas does not necessarily confer a good outcome, however. (C) 2000 Wiley-Liss, Inc.	Univ Penn, Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA		Bagley, LJ (corresponding author), Univ Penn, Med Ctr, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.	bagley@oasis.rad.upenn.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS08803, NS34353] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, P50NS008803, R29NS034353, R55NS034353] Funding Source: NIH RePORTER		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; Adams JH, 1982, RECENT ADV NEUROPATH, P165; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; CHAMPION HR, 1990, J TRAUMA, V30, P539, DOI 10.1097/00005373-199005000-00003; CLARK JM, 1974, J NEUROL NEUROSUR PS, V37, P463, DOI 10.1136/jnnp.37.4.463; COLLINS JG, 1990, VITAL HLTH STAT, V10, P175; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; FARBER M, 1994, SPORTS ILLUSTRATED, V81, P39; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1993, HEAD INJURY, P137; GROSSMAN RI, 1988, RSNA 74 SCI ASS ANN; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; LOEVNER LA, 1995, RADIOLOGY, V196, P511, DOI 10.1148/radiology.196.2.7617869; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.0.CO;2-6; MITTL RL, 1993, AM J NEURORADIOL, V14, P881; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; SINSON G, 1996, J NEUROSURG, V84, P113; STRICH SJ, 1961, LANCET, V2, P443; vanBuchem MA, 1996, MAGN RESON MED, V36, P632, DOI 10.1002/mrm.1910360420; VANBUCHEM MA, 1996, AJNR, V18, P1287; WILBERGER JE, 1990, NEUROSURGERY, V27, P208, DOI 10.1227/00006123-199008000-00006; WOLFF SD, 1991, RADIOLOGY, V179, P133, DOI 10.1148/radiology.179.1.2006263; WOLFF SD, 1989, MAGNET RESON MED, V10, P135, DOI 10.1002/mrm.1910100113	37	69	75	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1053-1807	1522-2586		J MAGN RESON IMAGING	J. Magn. Reson. Imaging	JAN	2000	11	1					1	8		10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H			8	Radiology, Nuclear Medicine & Medical Imaging	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Radiology, Nuclear Medicine & Medical Imaging	323NT	WOS:000087572400001	10676614	Bronze			2022-02-06	
